
@article{ ISI:000250614100030,
Author = {Zar, Heather J.},
Title = {{Diagnosis of pulmonary tuberculosis in children - what's new?}},
Journal = {{SAMJ SOUTH AFRICAN MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{97}},
Number = {{10}},
Pages = {{983-985}},
Month = {{OCT}},
Abstract = {{The global burden of paediatric tuberculosis (TB) has been
   underappreciated. Control programmes, focused on adult infectious cases,
   have largely based case detection and reporting on sputum smear
   results.(1) However, evidence suggests that in developing countries,
   where most disease occurs, childhood TB constitutes a large proportion
   of the TB caseload, contributing approximately 15 - 20\% of all cases.
   The burden in children and impact on child health has been
   under-recognised, partly because of difficulties in confirming the
   diagnosis. Diagnostic confirmation may be difficult because of many
   factors including nonspecific clinical signs, coexisting malnutrition,
   variable interpretation of chest radiographs, paucibacillary disease,
   difficulty in obtaining specimens for culture and relatively low rates
   of bacteriological confirmation. As a result diagnosis in children has
   relied mainly on clinical case definitions, tuberculin skin testing and
   chest radiography(2) Diagnostic uncertainty has been compounded by the
   HIV epidemic in which chronic lung disease, anergy, coexisiting
   malnutrition and nonspecific clinical and radiological signs make
   definitive diagnosis even more challenging.
   The consequences of undiagnosed or untreated paediatric TB are
   especially serious as children are more likely to develop miliary or
   severe disease. Furthermore cases of childhood TB frequently reflect an
   undiagnosed adult infectious source case; therefore the occurrence of TB
   in children frequently indicates failure of a TB control programme.
   Moreover, definitive diagnosis and microbiological confirmation have
   become increasingly important in the era of multidrug-resistant TB (MDR)
   and extremely extensively drug-resistant TB (XDR).
   This review considers currently available and new diagnostic methods for
   pulmonary TB (PTB). Current methods have relied predominantly on
   clinical case definitions, tuberculin skin testing and chest
   radiography. Newer methods include improved specimens and
   microbiological methods, immune testing, especially gamma-interferon
   assays, phage-based tests, polymerase chain reaction and antigen
   detection.}},
Publisher = {{SA MEDICAL ASSOC}},
Address = {{BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Zar, HJ (Reprint Author), Red Cross Childrens Hosp, Sch Child \& Adolescent Hlth, Cape Town, South Africa.
   Red Cross Childrens Hosp, Sch Child \& Adolescent Hlth, Cape Town, South Africa.
   Univ Cape Town, ZA-7700 Rondebosch, South Africa.}},
ISSN = {{0256-9574}},
Keywords-Plus = {{CHILDHOOD TUBERCULOSIS; METAANALYSIS; ASSAY}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{heather.zar@uct.ac.za}},
Cited-References = {{Boehme C, 2005, T ROY SOC TROP MED H, V99, P893, DOI 10.1016/j.trstmh.2005.04.014.
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0.
   Gennaro ML, 2000, CLIN INFECT DIS, V30, pS243, DOI 10.1086/313868.
   GIE R, 2003, DIAGN ATL INTR TUB C.
   Hesseling AC, 2002, INT J TUBERC LUNG D, V6, P1038.
   Liebeschuetz S, 2004, LANCET, V364, P2196, DOI 10.1016/S0140-6736(04)17592-2.
   Marais BJ, 2007, SAMJ S AFR MED J, V97, P978.
   Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524.
   Nahid Payam, 2006, Proc Am Thorac Soc, V3, P103, DOI 10.1513/pats.200511-119JH.
   Pai M, 2005, J INFECTION, V51, P175, DOI 10.1016/j.jint.2005.05.017.
   Sarmiento OL, 2003, J CLIN MICROBIOL, V41, P3233, DOI 10.1128/JCM.41.7.3233-3240.2003.
   SINGADIA D, 2003, LANCET INFECT DIS, V3, P624.
   Swingler GH, 2005, ARCH DIS CHILD, V90, P1153, DOI 10.1136/adc.2004.062315.
   World Health Organization, 2006, GUID NAT TUB PROGR M.
   Zar HJ, 2005, LANCET, V365, P130, DOI 10.1016/S0140-6736(05)17702-2.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{SAMJ S. Afr. Med. J.}},
Doc-Delivery-Number = {{226UN}},
Unique-ID = {{ISI:000250614100030}},
}

@article{ ISI:000250614100031,
Author = {Goussard, Pierre and Gie, Robert},
Title = {{Airway involvement in pulmonary tuberculosis}},
Journal = {{SAMJ SOUTH AFRICAN MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{97}},
Number = {{10}},
Pages = {{986-988}},
Month = {{OCT}},
Abstract = {{Airway involvement is relatively commonly seen in children with primary
   tuberculosis (TB), but in only a small group of children is the
   compression severe, needing intervention. The incidence of children with
   airway obstruction due to primary TB in the chemotherapeutic era is not
   known. In two recent reports the incidence of complicated lymph node
   disease varied from 8\% to 38\% in children less than 15 years of
   age.(1,2)
   The trachea and the two main bronchi are the airways most often affected
   by the enlarged glands. Upper-airway involvement is rare in children;
   most reports of upper-airway TB have been in adults. However, two forms
   of upper-airway TB have been described in children: laryngeal TB and
   retropharyngeal TB abscess.
   In children other conditions also cause airway compression and it is
   important to include these in the differential diagnosis. External
   airway compression can be caused by congenital malformations, vascular
   compression and enlarged mediastinal lymph nodes. Airway compression can
   also be confused with airway obstruction, with foreign-body inhalation a
   common cause of intraluminal obstruction.}},
Publisher = {{SA MEDICAL ASSOC}},
Address = {{BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Goussard, P (Reprint Author), Univ Stellenbosch, Dept Paediat \& Child Hlth, Desmond Tutu TB Ctr, ZA-7505 Tygerberg, W Cape, South Africa.
   Univ Stellenbosch, Dept Paediat \& Child Hlth, Desmond Tutu TB Ctr, ZA-7505 Tygerberg, W Cape, South Africa.}},
ISSN = {{0256-9574}},
Keywords-Plus = {{NODE-BRONCHIAL TUBERCULOSIS; DOUBLE-BLIND; CHILDHOOD; PREDNISONE;
   CHILDREN; THERAPY; ADJUNCT}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{pgouss@sun.ac.za}},
Cited-References = {{Andronikou S, 2004, PEDIATR RADIOL, V34, P232, DOI 10.1007/s00247-003-1117-0.
   De Villiers Richard V P, 2004, Australas Radiol, V48, P148, DOI 10.1111/j.1440-1673.2004.01276.x.
   Fishman JE, 2000, AM J ROENTGENOL, V174, P43.
   Goussard P, 2004, PEDIATR PULM, V38, P451, DOI 10.1002/ppul.20119.
   KONSTANTINOS A, 1999, ANN THORAC SURG, V68, P1182.
   Marais BJ, 2006, INT J TUBERC LUNG D, V10, P1.
   NEMIR RL, 1967, AM REV RESPIR DIS, V95, P402.
   NEMIR RL, 1963, AM REV RESPIR DIS, V88, P189.
   Theart AC, 2005, INT J TUBERC LUNG D, V9, P1210.}},
Number-of-Cited-References = {{9}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{SAMJ S. Afr. Med. J.}},
Doc-Delivery-Number = {{226UN}},
Unique-ID = {{ISI:000250614100031}},
}

@article{ ISI:000250614100032,
Author = {Jeena, P. M.},
Title = {{The interaction of HIV and tuberculosis in childhood}},
Journal = {{SAMJ SOUTH AFRICAN MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{97}},
Number = {{10}},
Pages = {{989-991}},
Month = {{OCT}},
Abstract = {{The recognition of a case of childhood tuberculosis (TB) is a sentinel
   public event. It reflects a poor adult TB control programme, a marker of
   other diseases, e.g. HIV, provides a reservoir for future cases of TB,
   an opportunity to undertake contact tracing and a need for action in
   child health. Childhood TB accounts for 11\% (884 000 cases) of the
   global burden of TB, with Africa accounting for 27\% of the global cases
   despite having just 11\% of the world's population. South Africa has the
   seventh highest global burden of TB with an incidence of 600/100 000.
   Of the 2.8 million cases of childhood HIV disease, 2.2 million (> 80\%)
   live in sub-Saharan Africa (SSA). There are 665 000 new childhood
   infections and 450 000 deaths (3\%) globally from HIV each year despite
   effective strategies for the prevention of mother-to-child transmission.
   In SSA, only 6\% of children deserving antiretroviral drugs receive
   therapy; consequently HIV disease accounts for 6\% of all deaths in
   children younger than 5 years of age. In South Africa, of the 240 000
   HIV-infected children only 10 - 15\% receive treatment.
   The incidence of TB in HIV-uninfected persons is 656/100 000 person
   years while in HIV-infected persons it is 4 381 /100 000 person years.
   In South Africa, the incidence of both TB and HIV is increasing
   exponentially, with each epidemic fuelling the other (4.3- and 3.5-fold
   increase for TB and HIV respectively). The risk of acquiring TB is 10\%
   per annum in HIV-infected children while for an HIV-uninfected child it
   is 10\% per lifetime. The impact of HIV on TB prevalence is clearly seen
   with the increase in the prevalence of congenital TB, paucibacillary or
   smear-negative TB, extrapulmonary TB, reactivation and reinfection TB
   and immune reconstitution inflammatory syndrome (IRIS).}},
Publisher = {{SA MEDICAL ASSOC}},
Address = {{BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Jeena, PM (Reprint Author), Univ KwaZulu Natal, Dept Paediat \& Child Hlth, Durban, South Africa.
   Univ KwaZulu Natal, Dept Paediat \& Child Hlth, Durban, South Africa.}},
ISSN = {{0256-9574}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{jeena@ukzn.ac.za}},
Cited-References = {{Gray A, 2006, AIDS, V20, P302, DOI 10.1097/01.aids.0000202652.49020.94.
   la Porte CJL, 2004, ANTIMICROB AGENTS CH, V48, P1553, DOI 10.1128/AAC.48.5.1553-1560.2004.
   Michailidis C, 2005, ANTIVIR THER, V10, P417.
   {*}WHO, GUID ANT THER CHILDR.
   WHO, 2007, WKLY EPIDEMIOL REC, V82, P17.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{SAMJ S. Afr. Med. J.}},
Doc-Delivery-Number = {{226UN}},
Unique-ID = {{ISI:000250614100032}},
}

@article{ ISI:000250614100033,
Author = {Donald, Peter R.},
Title = {{The treatment of tuberculosis in childhood}},
Journal = {{SAMJ SOUTH AFRICAN MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{97}},
Number = {{10}},
Pages = {{992-994}},
Month = {{OCT}},
Abstract = {{The treatment of tuberculosis (TB) in children and adults has remained
   unchanged for more than 30 years, and although new drugs are at last
   entering clinical trials it will be 5 - 10 years before their precise
   place in therapy is established. It is therefore necessary to continue
   to use our current drugs with care and prudence and be particularly
   careful about preventing the further development of drug resistance. The
   principles of treatment in adults and children are the same, but there
   is an increasing appreciation that the spectrum of disease seen in
   childhood is different and that children also differ from adults with
   regard to the pharmacokinetics of drugs.}},
Publisher = {{SA MEDICAL ASSOC}},
Address = {{BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Donald, PR (Reprint Author), Univ Stellenbosch, Fac Hlth Sci, Dept Paediat \& Child Hlth, ZA-7505 Tygerberg, W Cape, South Africa.
   Univ Stellenbosch, Fac Hlth Sci, Dept Paediat \& Child Hlth, ZA-7505 Tygerberg, W Cape, South Africa.
   Tygerberg Childrens Hosp, Tygerberg, W Cape, South Africa.}},
ISSN = {{0256-9574}},
Keywords-Plus = {{HUMAN-IMMUNODEFICIENCY-VIRUS; PULMONARY TUBERCULOSIS; CHILDREN;
   CHEMOTHERAPY; THERAPY}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{prd@sun.ac.za}},
Cited-References = {{Al-Dossary FS, 2002, PEDIATR INFECT DIS J, V21, P91, DOI 10.1097/00006454-200202000-00002.
   ANDRIES K, 2005, SCIENCE, V307, P23.
   Donald PR, 2006, INT J TUBERC LUNG D, V10, P1318.
   Donald P R, 2003, Expert Rev Anti Infect Ther, V1, P141, DOI 10.1586/14787210.1.1.141.
   Donald PR, 1998, INT J TUBERC LUNG D, V2, P704.
   Driver CR, 2001, CLIN INFECT DIS, V33, P1762, DOI 10.1086/323784.
   El-Sadr WM, 2001, CLIN INFECT DIS, V32, P623, DOI 10.1086/318706.
   Johnson JL, 2006, INT J TUBERC LUNG D, V10, P605.
   Matsumoto M, 2006, PLOS MED, V3, P2131, DOI 10.1371/journal.pmed.0030466.
   MITCHISON DA, 1979, CHEST, V76, P771, DOI 10.1378/chest.76.6\_Supplement.771.
   O'Brien Richard, 2001, Tuberculosis (Edinburgh), V81, P1.
   REIS FJC, 1990, AM REV RESPIR DIS, V142, P996.
   Schaaf HS, 2005, ARCH DIS CHILD, V90, P614, DOI 10.1136/adc.2004.052175.
   {*}WHO, 2003, WHOCDX2003313.
   World Health Organization, 2006, WHOHTMTB2006371.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{SAMJ S. Afr. Med. J.}},
Doc-Delivery-Number = {{226UN}},
Unique-ID = {{ISI:000250614100033}},
}

@article{ ISI:000250614100034,
Author = {Schaaf, H. Simon},
Title = {{Drug-resistant tuberculosis in children}},
Journal = {{SAMJ SOUTH AFRICAN MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{97}},
Number = {{10}},
Pages = {{995-997}},
Month = {{OCT}},
Abstract = {{Drug-resistant tuberculosis (TB), and especially multidrug-resistant
   (MDR) TB (i.e. resistance to isoniazid and rifampicin with or without
   resistance to other drugs) or extensively drug-resistant (XDR) TB (i.e.
   MDR resistance plus resistance to the fluoroquinolones and one of the
   second-line injectables - kanamycin, amikacin or capreomycin),(1) has
   very important implications for affected children and the TB control
   programme. These children are difficult to manage because of the
   increased adverse effects of the second-line anti-TB drugs and the
   prolonged duration of treatment. Furthermore, they are often diagnosed
   late because the history of a drug-resistant contact was not obtained or
   responded to. Children mainly have paucibacillary disease, which means
   that diagnosis of a child, especially with MDR TB, usually points to
   recent transmission in the community and therefore a failure of the TB
   control programme.}},
Publisher = {{SA MEDICAL ASSOC}},
Address = {{BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Schaaf, HS (Reprint Author), Univ Stellenbosch, Desmond Tutu TB Res Ctr, ZA-7505 Tygerberg, W Cape, South Africa.
   Univ Stellenbosch, Desmond Tutu TB Res Ctr, ZA-7505 Tygerberg, W Cape, South Africa.
   Univ Stellenbosch, Dept Paediat \& Child Hlth, ZA-7505 Tygerberg, W Cape, South Africa.
   Tygerberg Childrens Hosp, Tygerberg, W Cape, South Africa.}},
ISSN = {{0256-9574}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; YOUNG-CHILDREN;
   CONTACT; DISEASE}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{hss@sun.ac.za}},
Cited-References = {{Schaaf HS, 2007, EUR J CLIN MICROBIOL, V26, P203, DOI 10.1007/s10096-007-0257-9.
   Schaaf HS, 2002, PEDIATRICS, V109, P765, DOI 10.1542/peds.109.5.765.
   Schaaf HS, 2006, ACTA PAEDIATR, V95, P523, DOI 10.1080/08035250600675741.
   Schaaf HS, 2003, ARCH DIS CHILD, V88, P1106, DOI 10.1136/adc.88.12.1106.
   Schaaf HS, 2000, PEDIATR INFECT DIS J, V19, P695.
   Schaaf HS, 1999, PEDIATR INFECT DIS J, V18, P494, DOI 10.1097/00006454-199906000-00004.
   SNEAG DB, 2007, S AFR RESP J, V13, P27.
   SNIDER DE, 1985, AM REV RESPIR DIS, V132, P125.
   STEINER M, 1966, NEW ENGL J MED, V274, P755, DOI 10.1056/NEJM196604072741401.
   STEINER P, 1985, AM J DIS CHILD, V139, P780.
   Steiner P., 1993, SEM PEDIAT INFECT DI, V4, P275.
   WHO, 2006, WHOHTMTB2006361.}},
Number-of-Cited-References = {{12}},
Times-Cited = {{14}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{SAMJ S. Afr. Med. J.}},
Doc-Delivery-Number = {{226UN}},
Unique-ID = {{ISI:000250614100034}},
}

@article{ ISI:000250614100035,
Author = {Hawkridge, Tony},
Title = {{Tuberculosis contacts and prophylaxis}},
Journal = {{SAMJ SOUTH AFRICAN MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{97}},
Number = {{10}},
Pages = {{998-1000}},
Month = {{OCT}},
Abstract = {{Every day much energy is expended sorting out the tragedy that is
   childhood tuberculosis (TB). Given the other challenges faced by our
   public health services this is energy we can ill afford. It is unlikely
   that we shall have a more effective TB vaccine available before 2015. In
   the meantime, many cases of severe and complicated paediatric TB could
   be prevented by an effective programme of contact screening and
   chemoprophylaxis. This article looks at the `what, who and why' of TB
   contact investigation and TB chemoprophylaxis, including some special
   cases. We ask why these activities are not happening and what can be
   done about the situation. Lastly, some proposals for improving the
   situation are made.}},
Publisher = {{SA MEDICAL ASSOC}},
Address = {{BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hawkridge, T (Reprint Author), Univ Cape Town, S African TB Vaccine Initiat, Inst Infect Dis \& Mol Med, ZA-7700 Rondebosch, South Africa.
   Univ Cape Town, S African TB Vaccine Initiat, Inst Infect Dis \& Mol Med, ZA-7700 Rondebosch, South Africa.}},
ISSN = {{0256-9574}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{Anthony.Hawkridge@uct.ac.za}},
Cited-References = {{Marais BJ, 2004, INT J TUBERC LUNG D, V8, P278.
   Pediatric Tuberculosis Collaborative GroupTargeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents, 2004, PEDIATRICS, V114, P1175, DOI DOI 10.1542/PEDS.2004-0809.
   South African Department of Health, 2004, S AFR TUB CONTR PROG.
   Schaaf HS, 2007, SAMJ S AFR MED J, V97, P995.
   Smieja MJ, 2004, COCHRANE LIB.
   World Health Organization, 2007, INT J TUBERC LUNG D, V11, P12.}},
Number-of-Cited-References = {{6}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{SAMJ S. Afr. Med. J.}},
Doc-Delivery-Number = {{226UN}},
Unique-ID = {{ISI:000250614100035}},
}

@article{ ISI:000250614100036,
Author = {Hussey, Gregory},
Title = {{Prospects for new tuberculosis vaccines}},
Journal = {{SAMJ SOUTH AFRICAN MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{97}},
Number = {{10}},
Pages = {{1001-1002}},
Month = {{OCT}},
Abstract = {{The world urgently requires a new vaccine to combat the problem of
   tuberculosis (TB). The failure of BCG vaccine, the emergence of
   extensively drug-resistant TB and the increasing global TB-related
   mortality has emphasised the urgent need to develop more effective TB
   vaccines to combat this scourge. The development of new genetic
   technology and the sequencing of the Mycobacterium tuberculosis genome
   in the late nineties have made the rational development of new TB
   vaccines a reality. The ideal TB vaccine should be affordable,
   especially in the poorest countries of the world where it is most
   needed, and should be more cost-effective than BCG vaccine. It should be
   easily administered at or soon after birth, and be safe, immunogenic and
   effective at all ages and in all populations. It is unlikely that a
   single new vaccine candidate will meet all or even most of these
   requirements, and it is likely that more than one new vaccine will be
   needed. TB is a leading opportunistic infection in HIV-positive persons.
   New TB vaccines would therefore have to be safe, immunogenic and
   effective in this at-risk population as well. Recently the WHO has
   recommended that children who are known to be HIV positive, even if they
   are asymptomatic, should not be given BCG vaccine because of the high
   risk of possibly developing disseminated BCG disease.}},
Publisher = {{SA MEDICAL ASSOC}},
Address = {{BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hussey, G (Reprint Author), Univ Cape Town, S African TB Vaccine Initiat, Inst Infect Dis \& Mol Med, ZA-7700 Rondebosch, South Africa.
   Univ Cape Town, S African TB Vaccine Initiat, Inst Infect Dis \& Mol Med, ZA-7700 Rondebosch, South Africa.}},
ISSN = {{0256-9574}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{gregory.hussey@uct.ac.za}},
Cited-References = {{Ginsberg AM, 2002, B WORLD HEALTH ORGAN, V80, P483.
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128.
   {*}NIH, TUB VACC STAT SCI.
   Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419.
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3.
   World Health Organization, 2007, WKLY EPIDEMIOL REC, V82, P193.}},
Number-of-Cited-References = {{6}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{SAMJ S. Afr. Med. J.}},
Doc-Delivery-Number = {{226UN}},
Unique-ID = {{ISI:000250614100036}},
}

@article{ ISI:000249493700006,
Author = {Amoudy, H. A. and Ahmad, S. and Thole, J. E. and Mustafa, A. S.},
Title = {{Demonstration of In vivo expression of a hypothetical open reading frame
   (ORF-14) encoded by the RD1 region of Mycobacterium tuberculosis}},
Journal = {{SCANDINAVIAN JOURNAL OF IMMUNOLOGY}},
Year = {{2007}},
Volume = {{66}},
Number = {{4}},
Pages = {{422-425}},
Month = {{OCT}},
Abstract = {{Previously we identified a novel antigenic open reading frame (ORF),
   designated as ORF-14, on the RD1 region of Mycobacterium tuberculosis
   that was not originally predicted by Mahairas or by annotation of the M.
   tuberculosis H37 Rv genome. Here we show that anti-ORF-14 antibodies
   either from mice immunized with recombinant ORF-14 protein or isolated
   from serum samples from tuberculosis patients, react with a protein in
   culture filtrate but not in cytoplasmic or cell wall fractions from M.
   tuberculosis. Our data indicate that the ORF-14 protein is expressed as
   a secreted protein, representing one more secreted protein antigen not
   previously identified by genomics.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Amoudy, HA (Reprint Author), Kuwait Univ, Fac Med, Dept Microbiol, POB 24923, Safat 13110, Kuwait.
   Kuwait Univ, Fac Med, Dept Microbiol, Safat 13110, Kuwait.
   Univ London Imperial Coll Sci Technol \& Med, Dept Microbiol \& Immunol, London, England.
   Anim Sci Grp, Div Infect Dis, Lelystad, Netherlands.}},
DOI = {{10.1111/j.1365-3083.2007.01961.x}},
ISSN = {{0300-9475}},
Keywords-Plus = {{T-CELL RESPONSES; CALMETTE-GUERIN; GENOME SEQUENCE; ESAT-6 ANTIGEN;
   IDENTIFICATION; PROTEINS; EPITOPES; BCG; IMMUNOGENICITY; COMPILATION}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{hanady@hsc.edu.kw}},
Cited-References = {{Ahmad S, 2004, SCAND J IMMUNOL, V60, P382, DOI 10.1111/j.0300-9475.2004.01490.x.
   Ahmad S, 1999, SCAND J IMMUNOL, V49, P515.
   Amoudy HA, 2006, MED PRIN PRACT, V15, P137, DOI 10.1159/000090919.
   Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520.
   Brodin P, 2006, INFECT IMMUN, V74, P88, DOI 10.1128/IAI.74.1.88-98.2006.
   Camus JC, 2002, MICROBIOL-SGM, V148, P2967.
   CHERAYIL BJ, 1988, J IMMUNOL, V141, P4370.
   Cole ST, 1998, NATURE, V393, P537.
   Daugelat S, 2003, MICROBES INFECT, V5, P1082, DOI 10.1016/S1286-4579(03)00205-3.
   Dobos KM, 1996, J BACTERIOL, V178, P2498.
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0.
   Ewer K, 2006, AM J RESP CRIT CARE, V174, P831, DOI 10.1164/rccm.200511-1783OC.
   Gomez Manuel, 2000, Infection and Immunity, V68, P2323, DOI 10.1128/IAI.68.4.2323-2327.2000.
   Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x.
   Hsu T, 2003, P NATL ACAD SCI USA, V100, P12420, DOI 10.1073/pnas.1635213100.
   Jungblut PR, 2001, INFECT IMMUN, V69, P5905, DOI 10.1128/IAI.69.9.5905-5907.2001.
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081.
   Lewis KN, 2003, J INFECT DIS, V187, P117, DOI 10.1086/345862.
   Mahairas GG, 1996, J BACTERIOL, V178, P1274.
   Mustafa AS, 2005, MED PRIN PRACT, V14, P27, DOI 10.1159/000086182.
   Mustafa A. S., 2001, Current Pharmaceutical Biotechnology, V2, P157, DOI 10.2174/1389201013378707.
   Mustafa AS, 2006, TUBERCULOSIS, V86, P115, DOI 10.1016/j.tube.2005.05.001.
   Mustafa AS, 2005, TUBERCULOSIS, V85, P367, DOI 10.1016/j.tube.2005.08.006.
   Mustafa AS, 2003, SCAND J IMMUNOL, V57, P125, DOI 10.1046/j.1365-3083.2003.01204.x.
   Mustafa AS, 2002, MOL IMMUNOL, V39, P113, DOI 10.1016/S0161-5890(02)00048-2.
   Mustafa AS, 2002, CLIN EXP IMMUNOL, V130, P37, DOI 10.1046/j.1365-2249.2002.01937.x.
   Mustafa AS, 1998, SCAND J IMMUNOL, V48, P535.
   Mustafa AS, 2000, CLIN INFECT DIS, V30, pS201, DOI 10.1086/313862.
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.
   Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859.
   Rosenkrands I, 2000, ELECTROPHORESIS, V21, P935, DOI 10.1002/(SICI)1522-2683(20000301)21:5<935::AID-ELPS935>3.3.CO;2-G.
   WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145.
   Wiker HG, 1999, MICROB PATHOGENESIS, V26, P207, DOI 10.1006/mpat.1998.0267.
   YOUNG DB, 1992, MOL MICROBIOL, V6, P133, DOI 10.1111/j.1365-2958.1992.tb01994.x.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{12}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Scand. J. Immunol.}},
Doc-Delivery-Number = {{210ZI}},
Unique-ID = {{ISI:000249493700006}},
}

@article{ ISI:000249868300014,
Author = {Steingart, Karen R. and Henry, Megan and Laal, Suman and Hopewell,
   Philip C. and Ramsay, Andrew and Menzies, Dick and Cunningham, Jane and
   Weldingh, Karin and Pai, Madhukar},
Title = {{A systematic review of commercial serological antibody detection tests
   for the diagnosis of extrapulmonary tuberculosis}},
Journal = {{THORAX}},
Year = {{2007}},
Volume = {{62}},
Number = {{10}},
Pages = {{911-918}},
Month = {{OCT}},
Abstract = {{Conventional diagnostic tests for tuberculosis have several limitations
   and are often unhelpful in establishing the diagnosis of extrapulmonary
   tuberculosis. Although commercial serological antibody based tests are
   available, their usefulness in the diagnosis of extrapulmonary
   tuberculosis is unknown. A systematic review was conducted to assess the
   accuracy of commercial serological antibody detection tests for the
   diagnosis of extrapulmonary tuberculosis. In a comprehensive search, 21
   studies that reported data on sensitivity and specificity for
   extrapulmonary tuberculosis were identified. These studies evaluated
   seven different commercial tests, with Anda-TB IgG accounting for 48\%
   of the studies. The results showed that (1) all commercial tests
   provided highly variable estimates of sensitivity (range 0.00 - 1.00)
   and specificity (range 0.59 - 1.00) for all extrapulmonary sites
   combined; (2) the Anda-TB IgG kit showed highly variable sensitivity
   (range 0.26 - 1.00) and specificity (range 0.59 - 1.00) for all
   extrapulmonary sites combined; (3) for all tests combined, sensitivity
   estimates for both lymph node tuberculosis (range 0.23 - 1.00) and
   pleural tuberculosis (range 0.26 - 0.59) were poor and inconsistent; and
   (4) there were no data to determine the accuracy of the tests in
   children or in patients with HIV infection, the two groups for which the
   test would be most useful. At present, commercial antibody detection
   tests for extrapulmonary tuberculosis have no role in clinical care or
   case detection.}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Pai, M (Reprint Author), McGill Univ, Dept Epidemiol Biostat \& Occupat Hlth, Montreal, PQ H3A 1A2, Canada.
   McGill Univ, Dept Epidemiol Biostat \& Occupat Hlth, Montreal, PQ H3A 1A2, Canada.
   Montreal Chest Inst, Resp Epidemiol \& Clin Res Unit, Montreal, PQ, Canada.
   Statens Serum Inst, Dept Infect Dis Immunol, DK-2300 Copenhagen S, Denmark.
   WHO, UNICEF, UNDP, World Bank,WHO Special Programme Res \& Training, CH-1211 Geneva, Switzerland.
   NYU, Sch Med, Dept Pathol, New York, NY USA.
   NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.
   Vet Affairs Med Ctr, New York, NY USA.
   Cty Sacramento Dept Hlth \& Human Serv, Sacramento, CA USA.
   Univ Calif San Francisco, Div Pulm \& Crit Care Med, San Francisco Gen Hosp, San Francisco, CA 94143 USA.
   Francis J Curry Natl TB Ctr, San Francisco, CA USA.}},
DOI = {{10.1136/thx.2006.075754}},
ISSN = {{0040-6376}},
Keywords-Plus = {{IMMUNODEFICIENCY-VIRUS-INFECTION; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY
   TUBERCULOSIS; PRECLINICAL TUBERCULOSIS; IMMUNOLOGICAL DIAGNOSIS;
   DEVELOPING-COUNTRIES; ACTIVE TUBERCULOSIS; RAPID DIAGNOSIS; PLEURAL
   FLUID; ANTIGEN}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Author-Email = {{madhukar.pai@mcgill.ca}},
Cited-References = {{Alifano M, 1998, THORAX, V53, P377.
   Banerjee Swati, 2003, Indian J Clin Biochem, V18, P48, DOI 10.1007/BF02867367.
   Banoo S, 2006, NAT REV MICROBIOL, V4, pS21.
   Boehme C, 2005, T ROY SOC TROP MED H, V99, P893, DOI 10.1016/j.trstmh.2005.04.014.
   Bossuyt PM, 2003, ANN INTERN MED, V138, P40.
   Bothamley G H, 1995, Eur Respir J Suppl, V20, p676s.
   CAMINERO JA, 1994, RESPIRATION, V61, P283.
   CAMINERO JA, 1993, RESPIRATION, V60, P58.
   {*}CDCP, 2006, REP TUB US 2005, P64.
   Chan ED, 2000, TUBERCLE LUNG DIS, V80, P131, DOI 10.1054/tuld.2000.0243.
   DANIEL TM, 1990, J LAB CLIN MED, V116, P277.
   DANIEL TM, 1989, REV INFECT DIS, V11, pS471.
   De Milito A, 2004, BLOOD, V103, P2180, DOI 10.1182/blood-2003-07-2375.
   Delogu G, 2006, MICROBES INFECT, V8, P2061, DOI 10.1016/j.micinf.2006.03.015.
   ELLIOTT AM, 1993, TUBERCLE LUNG DIS, V74, P191, DOI 10.1016/0962-8479(93)90010-U.
   Gennaro ML, 2000, CLIN INFECT DIS, V30, pS243, DOI 10.1086/313868.
   GEVAUDAN MJ, 1992, EUR J EPIDEMIOL, V8, P666, DOI 10.1007/BF00145382.
   Golden MP, 2005, AM FAM PHYSICIAN, V72, P1761.
   Hargreaves NJ, 2001, INT J TUBERC LUNG D, V5, P847.
   Hendrickson RC, 2000, J CLIN MICROBIOL, V38, P2354.
   HOPEWELL PC, 2005, MURRAY NADELS TXB RE, P984.
   Hopewell PC, 2006, LANCET INFECT DIS, V6, P710, DOI 10.1016/S1473-3099(06)70628-4.
   Houghton RL, 2002, CLIN DIAGN LAB IMMUN, V9, P883, DOI 10.1128/CDLI.9.4.883-891.2002.
   Iseman MD, 2000, CLIN GUIDE TUBERCULO, P63.
   Iseman MD, 2000, CLIN GUIDE TUBERCULO, P145.
   ISEMAN MD, 2000, CLIN GUIDE TUBERCULO, P207.
   Johnson JL, 1998, INT J TUBERC LUNG D, V2, P397.
   Jones CM, 2005, ANN THORAC SURG, V79, P16, DOI 10.1016/j.athoracsur.2004.09.040.
   Kunter E, 2003, CLIN MICROBIOL INFEC, V9, P212, DOI 10.1046/j.1469-0691.2003.00536.x.
   Laal S, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P71.
   Laal S, 1997, J INFECT DIS, V176, P133, DOI 10.1086/514015.
   Laal S., 2004, TUBERCULOSIS, P185.
   Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061.
   Lijmer JG, 2002, STAT MED, V21, P1525, DOI 10.1002/sim.1185.
   LITTENBERG B, 1993, MED DECIS MAKING, V13, P313, DOI 10.1177/0272989X9301300408.
   Luh K T, 1996, Respirology, V1, P145, DOI 10.1111/j.1440-1843.1996.tb00024.x.
   MARTINEZMAZA O, 1987, J IMMUNOL, V138, P3720.
   McConkey SJ, 2002, INT J TUBERC LUNG D, V6, P246.
   McMurray DN, 2001, TRENDS MOL MED, V7, P135, DOI 10.1016/S1471-4914(00)01901-8.
   MENZIES D, 2004, TOMANS TUBERCULOSIS, P88.
   Monforte AD, 1996, EUR J CLIN MICROBIOL, V15, P453, DOI 10.1007/BF01691311.
   Nagase H, 2001, CLIN IMMUNOL, V100, P250, DOI 10.1006/clim.2001.5054.
   NSANZE H, 1997, CLIN MICROBIOL INFEC, V3, P236, DOI 10.1111/j.1469-0691.1997.tb00603.x.
   Pai M, 2006, EXPERT REV MOL DIAGN, V6, P423, DOI 10.1586/14737159.6.3.423.
   Pai M, 2006, EXPERT REV MOL DIAGN, V6, P509, DOI 10.1586/14737159.6.4.509.
   Pai Madhukar, 2004, ACP J Club, V141, pA11.
   Palomino JC, 2005, EUR RESPIR J, V26, P339, DOI 10.1183/09031936.05.00050305.
   Perkins MD, 2006, LANCET, V367, P942, DOI 10.1016/S0140-6736(06)68386-4.
   Rana FS, 2000, J ACQ IMMUN DEF SYND, V24, P23.
   RICHTER C, 1991, TROP GEOGR MED, V43, P375.
   Samanich K, 2001, INFECT IMMUN, V69, P4600, DOI 10.1128/IAI.69.7.4600-4609.2001.
   SARTAIN MJ, 2006, MOL CELL PROTEOMICS, P2102.
   SHAFER RW, 1991, MEDICINE, V70, P384.
   Shingadia D, 2003, LANCET INFECT DIS, V3, P624, DOI 10.1016/S1473-3099(03)00771-0.
   Singh KK, 2005, CLIN DIAGN LAB IMMUN, V12, P354, DOI 10.1128/CDLI.12.2.354-358.2005.
   Singh KK, 2001, INFECT IMMUN, V69, P4185, DOI 10.1128/IAI.69.6.4185-4191.2001.
   Small PM, 2000, LANCET, V356, P1048, DOI 10.1016/S0140-6736(00)02724-0.
   {*}SPSS INC, 2006, SPSS WIND 14 0 1 366.
   Talaat AM, 2004, P NATL ACAD SCI USA, V101, P4602, DOI 10.1073/pnas.0306023101.
   Talavera Wilfredo, 1994, P113.
   Tatsioni A, 2005, ANN INTERN MED, V142, P1048.
   Tessema TA, 2001, SCAND J INFECT DIS, V33, P279.
   Walsh A, 2004, INT J TUBERC LUNG D, V8, P609.
   Walter SD, 2002, STAT MED, V21, P1237, DOI 10.1002/sim.1099.
   WEIR MR, 1985, AM J MED, V79, P467, DOI 10.1016/0002-9343(85)90034-8.
   Weldingh K, 2005, J CLIN MICROBIOL, V43, P57, DOI 10.1128/JCM.43.1.57-65.2005.
   Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25.
   {*}WHO, 2006, TB EP SURV WORKSH.
   {*}WHO SPEC PROGR RE, 2006, DIAGN TUB GLOB DEM M, P61.
   Zamora Javier, 2006, BMC Med Res Methodol, V6, P31, DOI 10.1186/1471-2288-6-31.}},
Number-of-Cited-References = {{70}},
Times-Cited = {{69}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Thorax}},
Doc-Delivery-Number = {{216HE}},
Unique-ID = {{ISI:000249868300014}},
}

@article{ ISI:000250515700029,
Author = {Salami, A. K. and Katibi, I. A.},
Title = {{Tuberculosis among the health-care workers of the University of Ilorin
   Teaching Hospital}},
Journal = {{TROPICAL DOCTOR}},
Year = {{2007}},
Volume = {{37}},
Number = {{4}},
Pages = {{251}},
Month = {{OCT}},
Publisher = {{ROYAL SOC MEDICINE PRESS LTD}},
Address = {{1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Salami, AK (Reprint Author), Univ Ilorin, Dept Med, PMB 1515, Ilorin, Nigeria.
   Univ Ilorin, Dept Med, Ilorin, Nigeria.}},
DOI = {{10.1258/004947507782332810}},
ISSN = {{0049-4755}},
Research-Areas = {{Public, Environmental \& Occupational Health; Tropical Medicine}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Tropical Medicine}},
Author-Email = {{Salkaz2000@yahoo.com}},
Cited-References = {{Bloom BR, 2002, NEW ENGL J MED, V346, P1434, DOI 10.1056/NEJM200205093461902.
   CRAVEN RB, 1975, ANN INTERN MED, V82, P628.
   MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206.
   PIKE RM, 1979, ANNU REV MICROBIOL, V33, P41, DOI 10.1146/annurev.mi.33.100179.000353.}},
Number-of-Cited-References = {{4}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Trop. Dr.}},
Doc-Delivery-Number = {{225KB}},
Unique-ID = {{ISI:000250515700029}},
}

@article{ ISI:000250920300010,
Author = {Kibiki, Gibson S. and Mulder, Bert and van der Ven, Andre J. A. M. and
   Sam, Noel and Boeree, Martin J. and van der Zanden, Adri and Dolmans,
   Wil M. V.},
Title = {{Laboratory diagnosis of pulmonary tuberculosis in TB and HIV endemic
   settings and the contribution of real time PCR for M-tuberculosis in
   bronchoalveolar lavage fluid}},
Journal = {{TROPICAL MEDICINE \& INTERNATIONAL HEALTH}},
Year = {{2007}},
Volume = {{12}},
Number = {{10}},
Pages = {{1210-1217}},
Month = {{OCT}},
Abstract = {{BACKGROUND Tuberculosis (TB) in Africa is increasing because of the
   human immunodeficiency virus (HIV) epidemic, and in HIV/AIDS patients it
   presents atypically. Pulmonary tuberculosis (PTB) in Africa is mainly
   diagnosed clinically, by chest radiograph or by sputum smear for acid
   fast bacilli (AFB).
   METHODS We evaluated in 120 HIV-infected patients with chest infection
   the diagnostic accuracy of AFB smear of sputum and bronchoalveolar
   lavage (BAL) fluid, sputum Mycobacterium tuberculosis (MTB) culture,
   real-time PCR and MycoDot((R)) serological test, using MTB culture of
   BAL fluid as gold standard. We correlated PCR cycle threshold values
   (C-T) to the culture results. Retrospectively, we evaluated the
   development of active TB in patients with positive PCR but negative
   culture.
   RESULTS Culture of BAL fluid identified 28 patients with PTB. Fifty-six
   patients could not produce adequate sputum. Sputum AFB smear and the
   serotogical test had sensitivities of 66.7\% and 0\%, respectively. PCR
   with C-T 40 was positive in 73 patients, 27 of whom were also TB culture
   positive (96.4\% sensitivity and 52.3\% specificity of PCR). PCR with CT
   32 had sensitivity of 85.7\% and specificity of 90.9\% to diagnose PTB
   in BAL. No patients with positive PCR but negative culture developed
   active TB during 18 months follow-up.
   CONCLUSION In these HIV-infected patients, AFB smear and serology had
   very low sensitivities. PCR of BAL with CT value 32 had improved
   specificity to diagnose active PTB. A prospective follow-up study is
   warranted in TB/HIV endemic settings, applying real time PCR to both
   sputum and BAL.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kibiki, GS (Reprint Author), KCMC, Endoscopy Unit, Dept Internal Med, POB 3010, Moshi, Tanzania.
   KCMC, Endoscopy Unit, Dept Internal Med, Moshi, Tanzania.
   Lab Med Microbiol \& Publ Hlth, Enschede, Netherlands.
   St Radboud Univ Med Ctr, Dept Internal Med, Nijmegen, Netherlands.
   Gelre Hosp, Dept Med Microbiol \& Infect Control, Apeldoorn, Netherlands.}},
DOI = {{10.1111/j.1365-3156.2007.01907.x}},
ISSN = {{1360-2276}},
Keywords = {{branchoalveolar lavage; human immunodeficiency virus/tuberculosis
   co-infection; laboratory diagnosis; real time PCR; sensitivity; smear
   negative}},
Keywords-Plus = {{HUMAN-IMMUNODEFICIENCY-VIRUS; ACID-FAST BACILLI; MYCODOT(TM) TEST;
   SPUTUM SMEARS; INFECTION; EPIDEMIC; TANZANIA; DISEASE; METAANALYSIS;
   PREVALENCE}},
Research-Areas = {{Public, Environmental \& Occupational Health; Tropical Medicine}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Tropical Medicine}},
Author-Email = {{gkibiki@gmail.com}},
ResearcherID-Numbers = {{Boeree, Martin/G-6132-2010
   Ven, A.J.A.M./H-8102-2014}},
Cited-References = {{ABER VR, 1980, TUBERCLE, V61, P123, DOI 10.1016/0041-3879(80)90001-X.
   Aliyu MH, 2003, WIEN KLIN WOCHENSCHR, V115, P685.
   Banda HT, 1998, T ROY SOC TROP MED H, V92, P161, DOI 10.1016/S0035-9203(98)90727-1.
   BATUNGWANAYO J, 1992, AM REV RESPIR DIS, V146, P53.
   Behr MA, 1999, LANCET, V353, P444, DOI 10.1016/S0140-6736(98)03406-0.
   Broccolo F, 2003, J CLIN MICROBIOL, V41, P4565, DOI 10.1128/JCM.41.10.4565-4572.2003.
   Bucher HC, 1999, AIDS, V13, P501, DOI 10.1097/00002030-199903110-00009.
   Cantwell MF, 1996, TUBERCLE LUNG DIS, V77, P220, DOI 10.1016/S0962-8479(96)90004-0.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404.
   Albuquerque SC, 2001, REV SOC BRAS MED TRO, V34, P369.
   DEGARCIA J, 1997, CHEST, V111, P1180.
   FLORA GS, 1990, CHEST, V98, P1056, DOI 10.1378/chest.98.5.1056.
   GORDIN F, 1990, ARCH PATHOL LAB MED, V114, P1025.
   Hargreaves NJ, 2001, INT J TUBERC LUNG D, V5, P847.
   Harries AD, 1998, INT J TUBERC LUNG D, V2, P999.
   Hernandez-Pando R, 2000, LANCET, V356, P2133, DOI 10.1016/S0140-6736(00)03493-0.
   KIM TC, 1984, AM REV RESPIR DIS, V129, P264.
   Kivihya-Ndugga L, 2004, J CLIN MICROBIOL, V42, P1012, DOI 10.1128/JCM.42.3.1012-1015.2004.
   KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M.
   Kowk S., 1989, NATURE, V339, P237.
   LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H.
   {*}MIN HLTH UN REP T, 2003, MAN NAT TUB LEPR PRO, P35.
   Mtei L, 2005, CLIN INFECT DIS, V40, P1500, DOI 10.1086/429825.
   MUELLER A, 2003, TMJ, V3, P27.
   Odhiambo JA, 1999, AM J PUBLIC HEALTH, V89, P1078, DOI 10.2105/AJPH.89.7.1078.
   Ole-Nguyaine S, 2004, ANN TROP MED PARASIT, V98, P171, DOI 10.1179/000349804225003163.
   PARRY CM, 1993, TROP DOCT, V23, P145.
   Ratanasuwan W, 1997, INT J TUBERC LUNG D, V1, P259.
   Sarmiento OL, 2003, J CLIN MICROBIOL, V41, P3233, DOI 10.1128/JCM.41.7.3233-3240.2003.
   Savelkoul PHM, 2006, J MICROBIOL METH, V66, P177, DOI 10.1016/j.mimet.2005.12.003.
   SHELHAMER JH, 1992, ANN INTERN MED, V117, P415.
   Siddiqi K, 2003, LANCET INFECT DIS, V3, P288, DOI 10.1016/S1473-3099(03)00609-1.
   SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503.
   Somi GR, 1999, INT J TUBERC LUNG D, V3, P231.
   TOSSEMA TA, 2001, SCANDINAVIAN J INFEC, V33, P355.
   van Der Zanden A. G. M., 1998, Molecular Pathology, V51, P209.
   Vargas D, 2005, LANCET, V365, P150, DOI 10.1016/S0140-6736(05)17705-8.
   WAYNE LG, 1994, EUR J CLIN MICROBIOL, V13, P908, DOI 10.1007/BF02111491.
   Wilcke JTR, 1998, RESP MED, V92, P493, DOI 10.1016/S0954-6111(98)90297-9.}},
Number-of-Cited-References = {{40}},
Times-Cited = {{23}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Trop. Med. Int. Health}},
Doc-Delivery-Number = {{231BB}},
Unique-ID = {{ISI:000250920300010}},
}

@article{ ISI:000250920300011,
Author = {Mahendradhata, Yodi and Utarini, Adi and Lazuardi, Upiek and Boelaert,
   Marleen and Van der Stuyft, Patrick},
Title = {{Private practitioners and tuberculosis case detection in Jogjakarta,
   Indonesia: actual role and potential}},
Journal = {{TROPICAL MEDICINE \& INTERNATIONAL HEALTH}},
Year = {{2007}},
Volume = {{12}},
Number = {{10}},
Pages = {{1218-1224}},
Month = {{OCT}},
Abstract = {{BACKGROUND Indonesia has a high tuberculosis (TB) prevalence and a large
   private health sector.
   OBJECTIVES To explore the potential of private practitioners (PP) in TB
   control in Jogjakarta by assessing their load of TB suspects and
   case-management practices.
   METHODS We conducted a cross-sectional telephone survey of a random
   sample of 164 PP, weighted to the local proportions of specialists,
   general practitioners (GP), nurses and midwives. We investigated their
   knowledge of directly observed treatment, short-course (DOTS), whether
   they see TB suspects, whether they refer such patients and how they
   possibly diagnose and treat TB.
   RESULTS We sampled 174 PP, of which 164 (94.3\%) completed the
   interview. Most PP (63.4\%) reported to have seen TB suspects in their
   private practice, and 62.8\% were also employed in a DOTS facility.
   Specialists saw on average 18 suspects, GP 11 suspects, and
   nurses-midwives three suspects in a year. Many PP (45.2\%) always relied
   on National Tuberculosis Control Programme (NTP) services for diagnosis.
   Fewer PP (41.5\%) used, by themselves, diagnostic procedures complying
   with the NTP guidelines. The majority (63.6\%) always referred confirmed
   cases for treatment, mainly (71.4\%) to NTP services. Most PP (72.7\%)
   who treated TB patients themselves did not prescribe the NTP standard
   regimen.
   CONCLUSION The study shows that the TB case load per PP is low in
   Jogjakarta, where the NTP already involves public and private hospitals
   besides public health centres. Initiatives to engage all PP might only
   marginally contribute in increasing the TB case detection.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mahendradhata, Y (Reprint Author), Inst Trop Med, Dept Publ Hlth, Epidemiol \& Dis Control Unit, Natl Str 155, B-2000 Antwerp, Belgium.
   Inst Trop Med, Dept Publ Hlth, Epidemiol \& Dis Control Unit, B-2000 Antwerp, Belgium.
   Gadjah Mada Univ, Dept Publ Hlth, Fac Med, Yogyakarta, Indonesia.
   Gadjah Mada Univ, Ctr Hlth Serv Management, Fac Med, Yogyakarta, Indonesia.}},
DOI = {{10.1111/j.1365-3156.2007.01946.x}},
ISSN = {{1360-2276}},
Keywords-Plus = {{TB CONTROL; INDIA; PARTNERSHIP; HEALTH; NEPAL; DOTS}},
Research-Areas = {{Public, Environmental \& Occupational Health; Tropical Medicine}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Tropical Medicine}},
Author-Email = {{yodi\_mahendradhata@yahoo.co.uk}},
ResearcherID-Numbers = {{Boelaert, Marleen/E-2698-2012
   }},
ORCID-Numbers = {{Boelaert, Marleen/0000-0001-8051-6776
   Mahendradhata, Yodi/0000-0002-4522-1785}},
Cited-References = {{Borgdorff MW, 2002, B WORLD HEALTH ORGAN, V80, P501.
   CHAKAYA J, 2005, INT J TUBERC LUNG D, V4, P403.
   Dewan PK, 2006, BRIT MED J, V332, P574, DOI 10.1136/bmj.38738.473252.7C.
   {*}DOH ROI, 2003, NAT GUID TUB CONTR.
   DWIPRAHASTO I, 1992, ANTIBIOTIC UTLIZATIO.
   IDRIS F, 2003, PARTNERSHIP MODEL TB.
   Lambert ML, 2005, TROP MED INT HEALTH, V10, P945, DOI 10.1111/j.1365-3156.2005.01485.x.
   LAMBERT ML, 2005, TROP MED INT HEALTH, V3, P246.
   Lonnroth K, 2004, B WORLD HEALTH ORGAN, V82, P580.
   Mahendradhata Y, 2003, INT J HEALTH PLAN M, V18, pS53, DOI 10.1002/hpm.724.
   Murthy KJR, 2001, INT J TUBERC LUNG D, V5, P354.
   Newell J, 2002, B WORLD HEALTH ORGAN, V80, P836.
   Newell JN, 2006, LANCET, V367, P903, DOI 10.1016/S0140-6736(06)68380-3.
   Newell JN, 2005, INT J TUBERC LUNG D, V9, P1013.
   {*}NIHRD, 2005, TUB PRE SURV IND 200.
   NSUTHI L, 2001, INT J TUBERC LUNG D, V11, P1006.
   Portero JL, 2003, TROP MED INT HEALTH, V8, P329, DOI 10.1046/j.1365-3156.2003.01032.x.
   Tuberculosis Coalition for Technical Assistance (TBCTA), 2006, INT STAND TUB CAR IS.
   Uplekar M, 2001, LANCET, V358, P912, DOI 10.1016/S0140-6736(01)06076-7.
   Uplekar M, 1998, INT J TUBERC LUNG D, V2, P324.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.
   World Health Organization (WHO), 2006, STOP TB STRAT BUILD.
   WHO, 2006, ENG ALL HLTH CAR PRO.
   {*}WHO, 2003, INV PRIV PRACT TUB C.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Trop. Med. Int. Health}},
Doc-Delivery-Number = {{231BB}},
Unique-ID = {{ISI:000250920300011}},
}

@article{ ISI:000248993100021,
Author = {Santucci, Marilina B. and Greco, Emanuela and De Spirito, Marco and
   Arcovito, Giuseppe and De Angelis, Giulia and Cauda, Roberto and
   Fraziano, Maurizio},
Title = {{Sphingosine 1-phosphate promotes antigen processing and presentation to
   CD4+ T cells in Mycobacterium tuberculosis-infected monocytes}},
Journal = {{BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS}},
Year = {{2007}},
Volume = {{361}},
Number = {{3}},
Pages = {{687-693}},
Month = {{SEP 28}},
Abstract = {{Sphingosine 1-phosphate (SIP) has recently been described to induce
   antimycobacterial activity. The present study analyses the role played
   by SIP in antigen presentation of monocytes and in the next activation
   of Mycobacterium tuberculosis (MTB)-specific CD4+ T cell response.
   Results reported herein show that SIP stimulation of MTB-infected
   monocytes (i) inhibits intracellular mycobacterial growth, (ii) enhances
   phagolysosorne maturation and the transit of mycobacteria in MHC class
   II compartments, (iii) increases the frequency of MTB-specific CD4+CD69+
   T cells, expressing the inflammatory homing receptor CCR5, derived from
   tuberculosis patients and PPD+, BCG naive. healthy Subjects, and (iv)
   induces IFN-gamma production in CD4+CD69+CCR5+ T cells derived from PPD+
   healthy individuals, only. Altogether, these results show that S I P
   promotes antigen processing and presentation in monocytes, increases the
   frequency of MTB-specific CD4+ T cells and can regulate IFN-gamma
   production by antigen specific CD4+ T cells in the course of active
   disease. (c) 2007 Elsevier Inc. All rights reserved.}},
Publisher = {{ACADEMIC PRESS INC ELSEVIER SCIENCE}},
Address = {{525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Fraziano, M (Reprint Author), Univ Roma Tor Vergata, Dept Biol, Via Ricerca Sci, I-00133 Rome, Italy.
   Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy.
   Univ Cattolica Sacro Cuore, Inst Phys, I-00168 Rome, Italy.
   Univ Cattolica Sacro Cuore, Dept Infect Dis, I-00168 Rome, Italy.}},
DOI = {{10.1016/j.bbrc.2007.07.087}},
ISSN = {{0006-291X}},
Keywords = {{sphingosine 1-phosphate; Mycobacterium tuberculosis; antigen
   presentation; patients; IFN-gamma; CCR5}},
Keywords-Plus = {{ACTIVE PULMONARY TUBERCULOSIS; SPHINGOSINE 1-PHOSPHATE; IN-VITRO;
   IMMUNOLOGY; MATURATION; PHAGOSOME; INHIBITION; ACTIVATION; RESPONSES;
   BLOOD}},
Research-Areas = {{Biochemistry \& Molecular Biology; Biophysics}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Biophysics}},
Author-Email = {{fraziano@bio.uniroma.2.it}},
ResearcherID-Numbers = {{De Spirito, Marco/C-5386-2008
   Fraziano, Maurizio/F-1425-2013
   }},
ORCID-Numbers = {{De Spirito, Marco/0000-0003-4260-5107
   Fraziano, Maurizio/0000-0002-5643-0769
   CAUDA, Roberto/0000-0002-1498-4229}},
Cited-References = {{Anes E, 2003, NAT CELL BIOL, V5, P793, DOI 10.1038/ncb1036.
   CARRASCOMARIN E, 1994, EUR J IMMUNOL, V24, P2031, DOI 10.1002/eji.1830240915.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Doherty TM, 2006, LANCET, V367, P947, DOI 10.1016/S0140-6736(06)68389-X.
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93.
   Garg SK, 2006, CLIN IMMUNOL, V121, P23, DOI 10.1016/j.clim.2006.06.003.
   Garg SK, 2006, CLIN IMMUNOL, V121, P260, DOI 10.1016/j.clim.2006.09.002.
   Garg SK, 2004, J INFECT DIS, V189, P2129, DOI 10.1086/386286.
   Greco E, 2006, BIOCHEM BIOPH RES CO, V347, P963, DOI 10.1016/j.bbrc.2006.06.186.
   Guyot-Revol V, 2006, AM J RESP CRIT CARE, V173, P803, DOI 10.1164/rccm.200508-1294OC.
   Hladik F, 1999, J IMMUNOL, V163, P2306.
   Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558.
   Kursar M, 2007, J IMMUNOL, V178, P2661.
   Lin PL, 2006, INFECT IMMUN, V74, P3790, DOI 10.1128/IAI.00064-06.
   Malik ZA, 2003, J IMMUNOL, V170, P2811.
   Manca C, 2004, INFECT IMMUN, V72, P5511, DOI 10.1128/IAI.72.9.5511-5514.2004.
   Mills KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/nri1485.
   Mitra DK, 2005, EUR J IMMUNOL, V35, P2367, DOI 10.1002/eji.200525977.
   Murata N, 2000, ANAL BIOCHEM, V282, P115, DOI 10.1006/abio.2000.4580.
   Roberts T, 2007, J INFECT DIS, V195, P870, DOI 10.1086/511277.
   Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650.
   Sadek MI, 1998, AM J RESP CELL MOL, V19, P513.
   Salgame P, 2005, CURR OPIN IMMUNOL, V17, P374, DOI 10.1016/j.coi.2005.06.006.
   Santucci MB, 2004, EUR RESPIR J, V24, P638, DOI 10.1183/09031936.04.00105403.
   Spiegel S, 1996, FASEB J, V10, P1388.
   Tully G, 2005, J IMMUNOL, V174, P2174.
   Ullrich HJ, 2000, J IMMUNOL, V165, P6073.
   Vergne I, 2004, ANNU REV CELL DEV BI, V20, P367, DOI 10.1146/annurev.cellbio.20.010403.114015.
   von Andrian UH, 2000, NEW ENGL J MED, V343, P1020.
   Wang WG, 2004, FASEB J, V18, P1043, DOI 10.1096/fj.04-1555fje.
   Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821.
   Zahrt TC, 2003, MICROBES INFECT, V5, P159, DOI 10.1016/S1286-4579(02)00083-7.}},
Number-of-Cited-References = {{32}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Biochem. Biophys. Res. Commun.}},
Doc-Delivery-Number = {{203SA}},
Unique-ID = {{ISI:000248993100021}},
}

@article{ ISI:000249933600024,
Author = {Vidyarani, M. and Selvaraj, P. and Jawahar, M. S. and Rajeswari, D.
   Nisha and Anbalagan, S. and Narayanan, P. R.},
Title = {{Intracellular granzyme A expression of peripheral blood lymphocyte
   subsets in pulmonary tuberculosis}},
Journal = {{CURRENT SCIENCE}},
Year = {{2007}},
Volume = {{93}},
Number = {{6}},
Pages = {{823-825}},
Month = {{SEP 25}},
Abstract = {{Cell-mediated immunity is a key weapon of host defence against
   tuberculosis (TB). Granzyme A (GzmA), a serine protease, present in the
   granules of cytotoxic cells induces caspase-independent cell death. We
   estimated the proportion of GzmA producing lymphocyte subsets in
   peripheral blood from 59 normal healthy volunteers and 48 pulmonary TB
   (PTB) patients using flow cytometry. When compared with normal healthy
   subjects, we observed a significantly higher percentage of GzmA-positive
   CD56(+) cells (P = 0.01) in PTB patients. However, when the absolute
   number was compared between the two groups, a significantly decreased
   number of GzmA-expressing CD16(+) (P = 0.01) and CD56(+) (P = 0.0001)
   cells was observed in patients and this could be explained by the
   significantly reduced number of total lymphocytes (P = 0.0009) seen in
   the patients. There was no significant difference in the number of
   CD4(+) and CD8(+) GzmA double-positive cells between the two study
   groups. CD56 is a natural killer cell marker and these cells represent
   innate immune response to TB. We report an increased percentage of
   CD56(+) cells expressing GzmA in TB patients, which shows the relevance
   of the GzmA-mediated pathway of apoptosis in immunity against
   Mycobacterium tuberculosis.}},
Publisher = {{CURRENT SCIENCE ASSOC}},
Address = {{C V RAMAN AVENUE, PO BOX 8005, BANGALORE 560 080, INDIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Selvaraj, P (Reprint Author), Tuberculosis Res Ctr, Indian Council Med Res, Mayor VR Ramanathan Rd, Madras 600031, Tamil Nadu, India.
   Tuberculosis Res Ctr, Indian Council Med Res, Madras 600031, Tamil Nadu, India.}},
ISSN = {{0011-3891}},
Keywords = {{cytotoxic cells; granzyme A; peripheral blood; pulmonary tuberculosis}},
Keywords-Plus = {{CELLS; ACTIVATION; INFECTION; CYTOLYSIS}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Author-Email = {{psraj21@hotmail.com}},
Cited-References = {{Beresford PJ, 1999, IMMUNITY, V10, P585, DOI 10.1016/S1074-7613(00)80058-8.
   Carvalho ACC, 2002, THORAX, V57, P357, DOI 10.1136/thorax.57.4.357.
   Cho S, 2000, P NATL ACAD SCI USA, V97, P12210, DOI 10.1073/pnas.210391497.
   Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8.
   Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885.
   Grossman WJ, 2004, BLOOD, V104, P2840, DOI 10.1182/blood-2004-03-0859.
   Jans DA, 1998, J CELL SCI, V111, P2645.
   KOS FJ, 1995, J IMMUNOL, V155, P578.
   Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0.
   PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0.
   RAJESWARI N, 2006, INDIAN J MED RES, V123, P687.
   Sada-Ovalle I, 2006, CLIN IMMUNOL, V121, P314, DOI 10.1016/j.clim.2006.08.011.
   Sower LE, 1996, J IMMUNOL, V156, P2585.
   Stenger S, 1997, SCIENCE, V276, P1684, DOI 10.1126/science.276.5319.1684.
   Zhang D, 2001, P NATL ACAD SCI USA, V98, P5746, DOI 10.1073/pnas.101329598.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Curr. Sci.}},
Doc-Delivery-Number = {{217FK}},
Unique-ID = {{ISI:000249933600024}},
}

@article{ ISI:000249693100013,
Author = {Wong, Chun K. and Wong, Bonnie C. K. and Chan, K. C. Allen and Joynt,
   Gavin M. and Yap, Florence Y. H. Y. and Lam, Christopher W. K. and Lee,
   Nelson and Lee, Shui S. and Cockram, Clive S. and Sung, Joseph J. Y. and
   Chan, Paul K. S. and Lo, Y. M. Dennis and Tang, Julian W.},
Title = {{Cytokine profile in fatal human immunodeficiency virus-tuberculosis
   Epstein-Barr virus-associated Hemophagocytic syndrome}},
Journal = {{ARCHIVES OF INTERNAL MEDICINE}},
Year = {{2007}},
Volume = {{167}},
Number = {{17}},
Pages = {{1901-1903}},
Month = {{SEP 24}},
Publisher = {{AMER MEDICAL ASSOC}},
Address = {{515 N STATE ST, CHICAGO, IL 60610-0946 USA}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Tang, JW (Reprint Author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Microbiol, Shatin, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Microbiol, Shatin, Peoples R China.}},
DOI = {{10.1001/archinte.167.17.1901}},
ISSN = {{0003-9926}},
Keywords-Plus = {{INFECTION}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{julian.tang@cuhk.edu.hk}},
ResearcherID-Numbers = {{Lee, Nelson/B-6418-2008
   Chan, Paul/J-9360-2013
   Wong, Chun Kwok/H-3256-2016
   Lo, Yuk Ming Dennis/D-4468-2011
   Lee, Shui Shan/B-9374-2008
   Joynt, Gavin/C-7606-2009
   Hossain, Sarah /C-7332-2009
   Chan, KC Allen/M-2930-2013}},
ORCID-Numbers = {{Wong, Chun Kwok/0000-0002-5637-8331
   Lo, Yuk Ming Dennis/0000-0001-8746-0293
   Lee, Shui Shan/0000-0003-1448-765X
   Joynt, Gavin/0000-0002-5823-3435
   Hossain, Sarah /0000-0003-1355-0979
   }},
Cited-References = {{Bourgarit A, 2006, AIDS, V20, pF1, DOI 10.1097/01.aids.0000202648.18526.bf.
   De Luca A, 2000, AIDS RES HUM RETROV, V16, P835, DOI 10.1089/08892220050042774.
   Fisman DN, 2000, EMERG INFECT DIS, V6, P601.
   HENTER JI, 1991, BLOOD, V78, P2918.
   Lo YMD, 1999, CANCER RES, V59, P1188.
   Vockerodt M, 2005, INT J CANCER, V114, P598, DOI 10.1002/ijc.20759.}},
Number-of-Cited-References = {{6}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Arch. Intern. Med.}},
Doc-Delivery-Number = {{213UR}},
Unique-ID = {{ISI:000249693100013}},
}

@article{ ISI:000249373300038,
Author = {Noike, Motoyoshi and Ambo, Takanori and Mkuchi, Sayaka and Yamashita,
   Satoshi and Takahashi, Seiji and Kurokawa, Hirofurm and Koyama,
   Tanetoshi},
Title = {{Product chain-length determination mechanism of short-chain
   cis-prenyltransferase from Mycobacterium tuberculosis}},
Journal = {{JOURNAL OF MOLECULAR CATALYSIS B-ENZYMATIC}},
Year = {{2007}},
Volume = {{48}},
Number = {{3-4}},
Pages = {{111-112}},
Month = {{SEP 24}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 980, Japan.}},
ISSN = {{1381-1177}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Chemistry, Physical}},
Author-Email = {{noike@tagen.tohoku.ac.jp}},
ResearcherID-Numbers = {{Kurokawa, Hirofumi/A-7231-2010}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Mol. Catal. B-Enzym.}},
Doc-Delivery-Number = {{209FB}},
Unique-ID = {{ISI:000249373300038}},
}

@article{ ISI:000249727900024,
Author = {Moore, David A. J. and Roper, Martha H.},
Title = {{Diagnosis of smear-negative tuberculosis in people with HIV/AIDS}},
Journal = {{LANCET}},
Year = {{2007}},
Volume = {{370}},
Number = {{9592}},
Pages = {{1033-1034}},
Month = {{SEP 22}},
Publisher = {{LANCET LTD}},
Address = {{84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Moore, DAJ (Reprint Author), Univ London Imperial Coll Sci \& Technol, Fac Med, Dept Infect Dis \& Immun, Hammersmith Campus,DuCane Rd, London W12 0NN, England.
   Univ London Imperial Coll Sci \& Technol, Fac Med, Dept Infect Dis \& Immun, London W12 0NN, England.
   Univ London Imperial Coll Sci \& Technol, Fac Med, Wellcome Ctr Clin Trop Med, London W12 0NN, England.
   Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.}},
DOI = {{10.1016/S0140-6736(07)61474-3}},
ISSN = {{0140-6736}},
Keywords-Plus = {{DRUG-SUSCEPTIBILITY ASSAY; PULMONARY TUBERCULOSIS}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{davidajmoore@msn.com}},
Cited-References = {{Arias M, 2007, CLIN INFECT DIS, V44, P674, DOI 10.1086/511639.
   Getahun H, 2007, LANCET, V369, P2042, DOI 10.1016/S0140-6736(07)60284-0.
   Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524.
   Shiferaw G, 2007, J CLIN MICROBIOL, V45, P1093, DOI 10.1128/JCM.01949-06.
   Vargas D, 2005, LANCET, V365, P150, DOI 10.1016/S0140-6736(05)17705-8.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Lancet}},
Doc-Delivery-Number = {{214HJ}},
Unique-ID = {{ISI:000249727900024}},
}

@article{ ISI:000249455600022,
Author = {Chen, Yaodong and Anderson, David E. and Rajagopalan, Malini and
   Erickson, Harold P.},
Title = {{Assembly dynamics of mycobacterium tuberculosis FtsZ}},
Journal = {{JOURNAL OF BIOLOGICAL CHEMISTRY}},
Year = {{2007}},
Volume = {{282}},
Number = {{38}},
Pages = {{27736-27743}},
Month = {{SEP 21}},
Abstract = {{We have investigated the assembly of FtsZ from Mycobacterium
   tuberculosis (MtbFtsZ). Electron microscopy confirmed the previous
   observation that MtbFtsZ assembled into long, two-stranded filaments at
   PH 6.5. However, we found that assembly at pH 7.2 or 7.7 produced
   predominantly short, one-stranded protofilaments, similar to those of
   Escherichia coli FtsZ (EcFtsZ). Near pH 7, which is close to the pH of
   M. tuberculosis cytoplasm, MtbFtsZ formed a mixture of single- and
   two-stranded filaments. We developed a fluorescence resonance energy
   transfer assay to measure the kinetics of initial assembly and the
   dynamic properties at steady state. Assembly of MtbFtsZ reached a
   plateau after 60-100 s, about 10 times slower than EcFtsZ. The initial
   assembly kinetics were similar at pH 6.5 and 7.7, despite the striking
   difference in the polymer structures. Both were fit with a cooperative
   assembly mechanism involving a weak dimer nucleus, similar to EcFtsZ but
   with slower kinetics. Subunit turnover and GTPase at steady state were
   also about 10 times slower for MtbFtsZ than for EcFtsZ. Specifically,
   the half-time for subunit turnover in vitro at PH 7.7 was 42 s for
   MtbFtsZ compared with 5.5 s for EcFtsZ. Photo-bleaching studies in vivo
   showed a range of turnover half-times with an average of 25 s for
   MtbFtsZ as compared with 9 s for EcFtsZ.}},
Publisher = {{AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Erickson, HP (Reprint Author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
   Univ Texas Hlth Ctr, Tyler, TX 75708 USA.}},
DOI = {{10.1074/jbc.M703788200}},
ISSN = {{0021-9258}},
Keywords-Plus = {{DIVISION PROTEIN FTSZ; BACTERIAL-CELL-DIVISION; ESCHERICHIA-COLI;
   NUCLEOTIDE TURNOVER; FITTING PROGRAMS; SMALL-MOLECULE; IN-VITRO; GTP;
   PROTOFILAMENT; HYDROLYSIS}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{h.erickson@cellbio.duke.edu}},
ResearcherID-Numbers = {{Chen, Yaodong/C-6138-2011}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI48417, AI64502, R01 AI048417, R01 AI048417-06A1, R21
   AI064502]; NIGMS NIH HHS {[}GM66014, R01 GM066014, R01 GM066014-04]}},
Cited-References = {{Anderson DE, 2004, J BACTERIOL, V186, P5775, DOI 10.1128/JB.186.17.5775-5781.2004.
   BARSHOP BA, 1983, ANAL BIOCHEM, V130, P1.
   CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O.
   Chen YD, 2005, J BIOL CHEM, V280, P22549, DOI 10.1074/jbc.M500895200.
   Chen YD, 2005, BIOPHYS J, V88, P505, DOI 10.1529/biophysj.104.044149.
   Dang Q, 1997, TRENDS BIOCHEM SCI, V22, P317, DOI 10.1016/S0968-0004(97)01062-1.
   DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0.
   Dziadek J, 2002, MICROBIOL-SGM, V148, P961.
   Dziadek J, 2003, MICROBIOL-SGM, V149, P1593, DOI 10.1099/mic.0.26023-0.
   Flyvbjerg H, 1996, PHYS REV E, V54, P5538, DOI 10.1103/PhysRevE.54.5538.
   FRIEDEN C, 1994, METHOD ENZYMOL, V240, P311.
   GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X.
   Gonzalez JM, 2003, J BIOL CHEM, V278, P37664, DOI 10.1074/jbc.M305230200.
   Huang Q, 2006, J MED CHEM, V49, P463, DOI 10.1021/jm050920y.
   KASHKET ER, 1982, BIOCHEMISTRY-US, V21, P5534, DOI 10.1021/bi00265a024.
   Leung AKW, 2004, J MOL BIOL, V342, P953, DOI 10.1016/j.jmb.2004.07.061.
   Lu CL, 1999, CELL STRUCT FUNCT, V24, P285, DOI 10.1247/csf.24.285.
   Maddox PS, 2000, NAT CELL BIOL, V2, P36, DOI 10.1038/71357.
   Margalit DN, 2004, P NATL ACAD SCI USA, V101, P11821, DOI 10.1073/pnas.0404439101.
   Mingorance J, 2001, MOL MICROBIOL, V41, P83, DOI 10.1046/j.1365-2958.2001.02498.x.
   Oliva MA, 2004, NAT STRUCT MOL BIOL, V11, P1243, DOI 10.1038/nsmb855.
   PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x.
   Rajagopalan M, 2005, BIOCHEM BIOPH RES CO, V331, P1171, DOI 10.1016/j.bbrc.2005.03.239.
   Rajagopalan M, 2005, FEMS MICROBIOL LETT, V250, P9, DOI 10.1016/j.femsle.2005.06.043.
   Rao M, 2001, MICROBIOL-UK, V147, P1017.
   Redick SD, 2005, J BACTERIOL, V187, P2727, DOI 10.1128/187.8.2727-2736.2005.
   Romberg L, 2004, BIOCHEMISTRY-US, V43, P282, DOI 10.1021/bi035465r.
   Scheffers DJ, 2002, BIOCHEMISTRY-US, V41, P521, DOI 10.1021/bi011370i.
   Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099.
   Tadros M, 2006, FEBS LETT, V580, P4941, DOI 10.1016/j.febslet.2006.07.083.
   THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012.
   Wang J, 2003, J BIOL CHEM, V278, P44424, DOI 10.1074/jbc.M307625200.
   White EL, 2000, J BACTERIOL, V182, P4028, DOI 10.1128/JB.182.14.4028-4034.2000.
   Zhang Y, 2003, J ANTIMICROB CHEMOTH, V52, P56, DOI 10.1093/jac/dkg287.
   ZIMMERLE CT, 1989, BIOCHEM J, V258, P381.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{38}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Biol. Chem.}},
Doc-Delivery-Number = {{210KR}},
Unique-ID = {{ISI:000249455600022}},
}

@article{ ISI:000249501500020,
Author = {Rai, Dinesh and Johar, Monika and Srivastav, Naveen C. and Manning,
   Tracey and Agrawal, B. and Kunimoto, Dennis Y. and Kumar, Rakesh},
Title = {{Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and
   Mycobacterium avium by novel dideoxy nucleosides}},
Journal = {{JOURNAL OF MEDICINAL CHEMISTRY}},
Year = {{2007}},
Volume = {{50}},
Number = {{19}},
Pages = {{4766-4774}},
Month = {{SEP 20}},
Abstract = {{The prevalence of tuberculosis (TB) and mutidrug-resistant tuberculosis
   (MDR-TB) has been increasing, leading to serious infections, high
   mortality, and a global health threat. Here, we report the
   identification of a novel class of dideoxy nucleosides as potent and
   selective inhibitors of Mycobacterium bovis, Mycobacterium tuberculosis,
   and drug-resistant Mycobacterium tuberculosis. A series of 5-acetylenic
   derivatives of 2 `,3 `-dideoxyuridine (3-8) and 3 `-fluoro-2 `,3
   `-dideoxyuridine (22-27) were synthesized and tested for their
   antimycobacterial activity against M. bovis, M. tuberculosis, and M.
   avium. 2 `,3 `-Dideoxyuridine possessing 5-decynyl, 5-dodecynyl,
   5-tridecynyl, and 5-tetradecynyl substituents (4-7) exhibited the
   highest antimycobacterial activity against all three mycobacteria. In
   contrast, in the 3 `-fluoro-2 `,3 `-dideoxyuridine series, a
   5-tetradecynyl analogue (26) displayed the most potent activity against
   these mycobacteria. Among other derivatives,
   5-bromo-2',3'-dideoxycytidine (11), 5-methyl-2 `,3 `-dideoxycytidine
   (12). and 5-chloro-4-thio-2 `,3 `-dideoxyuridine (19) exhibited modest
   inhibition of M. bovis and M. tuberculosis. In the series of dideoxy
   derivatives of adenosine, guanosine, and purines,
   2-amino-6-mercaptoethyl-9-(2,3-dideoxy-beta-D-glyceropentofuranosyl)puri
   ne (32) and
   2-amino-4-fluoro-7-(2,3-dideoxy-beta-D-glyceropentofuranosyl)pyrrolo{[}2
   ,3-d]pyrimidine (35) were the most efficacious against M. bovis and M.
   tuberculosis, and All. avium, respectively.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kumar, R (Reprint Author), Univ Alberta, Dept Lab Med \& Pathol, 1-71 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.
   Univ Alberta, Dept Lab Med \& Pathol, Edmonton, AB T6G 2H7, Canada.
   Univ Alberta, Fac Med \& Dent, Dept Surg, Edmonton, AB T6G 2H7, Canada.
   Univ Alberta, Fac Med \& Dent, Dept Med, Edmonton, AB T6G 2H7, Canada.}},
DOI = {{10.1021/jm070391t}},
ISSN = {{0022-2623}},
EISSN = {{1520-4804}},
Keywords-Plus = {{DRUG-RESISTANT TUBERCULOSIS; ALAMAR BLUE ASSAY; ANTI-HIV ACTIVITY;
   IN-VITRO; ANTITUBERCULOSIS DRUGS; INFECTION; ANALOGS; EPIDEMIOLOGY;
   PREVENTION; DISEASE}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Chemistry, Medicinal}},
Author-Email = {{rakesh.kumar@ualberta.ca}},
Cited-References = {{BALZARINI J, 1989, MOL PHARMACOL, V35, P571.
   Bermudez LE, 2001, ANTIMICROB AGENTS CH, V45, P2210, DOI 10.1128/AAC.45.8.2210-2214.2001.
   Campos-Outcalt D, 2003, J FAM PRACTICE, V52, P792.
   Cohen J, 2006, SCIENCE, V313, P1554.
   Coker RJ, 2004, TROP MED INT HEALTH, V9, P25, DOI 10.1046/j.1365-3156.2003.01156.x.
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698.
   Cole ST, 1998, NATURE, V393, P537.
   Collins LA, 1997, ANTIMICROB AGENTS CH, V41, P1004.
   Falkinham JO, 1996, CLIN MICROBIOL REV, V9, P177.
   Franzblau SG, 1998, J CLIN MICROBIOL, V36, P362.
   Gordin FM, 1996, AM J RESP CRIT CARE, V154, P1478.
   Grassi C, 1997, Expert Opin Investig Drugs, V6, P1211, DOI 10.1517/13543784.6.9.1211.
   Guerrero A, 1997, LANCET, V350, P1738, DOI 10.1016/S0140-6736(97)07567-3.
   Guerrin-Tran E, 2006, EUR J EPIDEMIOL, V21, P783, DOI 10.1007/s10654-006-9069-y.
   HERDEWIJN P, 1989, NUCLEOS NUCLEOT, V8, P65, DOI 10.1080/07328318908054159.
   INDERLIED CB, 1993, CLIN MICROBIOL REV, V6, P266.
   JACOBSON KA, 1995, J MED CHEM, V38, P1720, DOI 10.1021/jm00010a017.
   Johar M, 2005, BIOORGAN MED CHEM, V13, P6663, DOI 10.1016/j.bmc.2005.07.046.
   KIM CH, 1987, J MED CHEM, V30, P862, DOI 10.1021/jm00388a020.
   Kling J., 1999, MODERN DRUG DISC JAN, P32.
   KOEHLER CSW, 2002, MODERN DRUG DISCOVER, P47.
   KOJIMA E, 1991, NUCL ACIDS S SER, V25, P91.
   KRAWCZYK SH, 1995, J MED CHEM, V38, P4115, DOI 10.1021/jm00020a027.
   Lancet Editorial, 2006, LANCET, V368, P964.
   LIN TS, 1987, J MED CHEM, V30, P440, DOI 10.1021/jm00385a033.
   Long R, 2003, CAN MED ASSOC J, V169, P789.
   Maher D., 2005, CLIN CHEST, V26, P168.
   Meier C, 1999, J MED CHEM, V42, P1604, DOI 10.1021/jm981096z.
   MENDEZ AP, 1998, NEW ENGL J MED, V338, P1641.
   Moss AR, 1997, INT J TUBERC LUNG D, V1, P115.
   MURAKAMI K, 1991, J MED CHEM, V34, P1606, DOI 10.1021/jm00109a012.
   Murray JF, 1998, RESPIRATION, V65, P335, DOI 10.1159/000029291.
   NEUGEBAUER JM, 1990, METHOD ENZYMOL, V182, P239.
   Nguyen D, 2003, AM J RESP CRIT CARE, V168, P1353, DOI 10.1164/rccm.200307-910OC.
   PELOQUIN CA, 1994, ANN PHARMACOTHER, V28, P72.
   Pilheu JA, 1998, INT J TUBERC LUNG D, V2, P696.
   Pozniak Anton, 2002, J HIV Ther, V7, P13.
   Rai D, 2005, J MED CHEM, V48, P7012, DOI 10.1021/jm058167w.
   RAMASAMY K, 1990, J MED CHEM, V33, P1220, DOI 10.1021/jm00166a021.
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220.
   ROBINS MJ, 1995, J ORG CHEM, V60, P7902, DOI 10.1021/jo00129a034.
   Rouhi AM, 1999, CHEM ENG NEWS, V77, P52, DOI 10.1021/cen-v077n020.p052.
   Ryan AJ, 2003, J MED CHEM, V46, P3448, DOI 10.1021/jm0340896.
   Schlesinger N, 2005, JCR-J CLIN RHEUMATOL, V11, P17, DOI 10.1097/01.rhu.0000152144.91206.0c.
   Shah NS, 2007, EMERG INFECT DIS, V13, P380.
   SHIRASAKA T, 1990, P NATL ACAD SCI USA, V87, P9426, DOI 10.1073/pnas.87.23.9426.
   Tomioka H, 2006, CURR PHARM DESIGN, V12, P4047, DOI 10.2174/138161206778743646.
   Valadas E, 2005, EUR J RADIOL, V55, P154, DOI 10.1016/j.ejrad.2005.04.013.
   VANAERSCHOT A, 1990, J MED CHEM, V33, P1833, DOI 10.1021/jm00168a046.
   {*}WHO, 2004, HIV TUB MAL.
   {[}Anonymous], 2004, GLOB TUB CONTR SURV.
   Willcox P A, 2000, Curr Opin Pulm Med, V6, P198, DOI 10.1097/00063198-200005000-00006.
   Wrigbt A., 2006, Morbidity and Mortality Weekly Report, V55, P301.
   Kelly M.T., 1998, COMMUNICABLE DIS REP, Patent No. CA 2273436.}},
Number-of-Cited-References = {{54}},
Times-Cited = {{32}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{11}},
Journal-ISO = {{J. Med. Chem.}},
Doc-Delivery-Number = {{211CI}},
Unique-ID = {{ISI:000249501500020}},
}

@article{ ISI:000251169100001,
Author = {Vree, M. and Hoa, N. B. and Sy, D. N. and Co, N. V. and Cobelens, F. G.
   J. and Borgdorff, M. W.},
Title = {{Low tuberculosis notification in mountainous Vietnam is not due to low
   case detection: a cross-sectional survey}},
Journal = {{BMC INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{7}},
Month = {{SEP 19}},
Abstract = {{Background: Studies show that tuberculosis notification declines with
   increasing altitude. This can be due to declining incidence or declining
   case detection. In Vietnam notification rates of new smear-positive
   tuberculosis in the central mountainous provinces (26/100,000
   population) are considerably lower than in Vietnam in general
   (69/100,000 population). In order to clarify whether this is explained
   by low incidence or low case detection, we aimed to assess the
   prevalence of new smear- positive tuberculosis among adults with
   prolonged cough in three mountainous provinces in central Vietnam.
   Methods: A house-to-house survey of persons (>= 15 years) was carried
   out in twelve randomly selected districts in 2003. Three sputum
   specimens were microscopically examined of persons reporting a prolonged
   cough (>= 3 weeks). Case detection was assessed by the ratio between
   notification and prevalence.
   Results: Of 68,946 included persons (95\% response), 1,298 (1.9\% 95\%
   Cl 1.8-2.2) reported a prolonged cough. Of these, eighteen were sputum
   smear-positive of whom two had had anti-tuberculosis treatment. The
   prevalence of new smear-positive tuberculosis was 27/100,000 (95\% Cl
   11-44/100,000) and the notification rate was 44/100,000 among persons >=
   15 years. The estimated case detection rate was 76\%.
   Conclusion: Low tuberculosis notification in this mountainous setting is
   probably a true reflection of low tuberculosis incidence. Possible
   causes for low incidence in mountainous areas include low transmission
   rates or altitude- related differences in pathology.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Vree, M (Reprint Author), KNCV Tuberculosis Fdn, The Hague, Netherlands.
   KNCV Tuberculosis Fdn, The Hague, Netherlands.
   Acad Med Ctr, Ctr Infect \& Immun Amsterdam, Amsterdam, Netherlands.
   Natl Tuberculosis Programme, Hanoi, Vietnam.}},
DOI = {{10.1186/1471-2334-7-109}},
Article-Number = {{109}},
ISSN = {{1471-2334}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; PREVALENCE; ALTITUDE; INFECTION; MORTALITY; PERU}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{vreem@kncvtbc.nl
   nguyenbinhhoatb@yahoo.com
   ngocsyvienlao@yahoo.com
   vienlao@bvlaobp.org
   cobelensf@kncvtbc.nl
   borgdorffm@kncvtbc.nl}},
Cited-References = {{BERG G, 1939, PROGNOSIS OPEN PULMO.
   Borgdorff MW, 2004, EMERG INFECT DIS, V10, P1523.
   BUHL K, 1967, B WORLD HEALTH ORGAN, V37, P907.
   Cohen R, 1996, CHEST, V109, P420, DOI 10.1378/chest.109.2.420.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7.
   {*}GEN STAT OFF UN P, 2001, KET QUA BAO DAN CHO.
   Grosset J., 1993, TUBERCULOSIS COMPREH, P49.
   Hoa NP, 2003, SCAND J PUBLIC HEALT, V31, P59, DOI 10.1080/14034950310015121.
   Horie T, 2007, INT J TUBERC LUNG D, V11, P562.
   Huong NT, 2005, INT J TUBERC LUNG D, V9, P151.
   Mansoer JR, 1999, INT J TUBERC LUNG D, V3, P156.
   {*}MIN HLTH, 2005, HLTH STAT YB 2004, P135.
   Nagelkerke NJD, 2000, INT J TUBERC LUNG D, V4, P314.
   Olender S, 2003, AM J TROP MED HYG, V68, P721.
   Raviglione M, 2001, INT J TUBERC LUNG D, V5, P213.
   RIEDER HL, 1999, EPIDEMIOLOGIC BASIS, V13, P20.
   Saito M, 2006, AM J TROP MED HYG, V75, P49.
   Styblo K., 1991, SELECTED PAPERS, V24.
   Thompson B C, 1943, Br Med J, V2, P721.
   Thorson A, 2004, J CLIN EPIDEMIOL, V57, P398, DOI 10.1016/j.jclinepi.2002.11.001.
   Vargas MH, 2004, INT J TUBERC LUNG D, V8, P1321.
   {*}WHO, 2005, WHO REP GEN.
   DAKLAK PROVINCE.
   KON TUM PROVINCE.
   GIALAI PROVINCE.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{BMC Infect. Dis.}},
Doc-Delivery-Number = {{234MV}},
Unique-ID = {{ISI:000251169100001}},
}

@article{ ISI:000249850300010,
Author = {Hwang, Shen-An and Wilk, Katarzyna M. and Budnicka, Monika and Olsen,
   Margaret and Bangale, Yogesh A. and Hunter, Robert L. and Kruzel, Marian
   L. and Actor, Jeffrey K.},
Title = {{Lactoferrin enhanced efficacy of the BCG vaccine to generate host
   protective responses against challenge with virulent Mycobacterium
   tuberculosis}},
Journal = {{VACCINE}},
Year = {{2007}},
Volume = {{25}},
Number = {{37-38}},
Pages = {{6730-6743}},
Month = {{SEP 17}},
Abstract = {{Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a
   disease with world wide consequences, affecting nearly a third of the
   world's population. The established vaccine for TB, an attenuated strain
   of Mycobacterium bovis Calmette Guerin (BCG), has existed since 1921.
   Lactoferrm, an iron-binding protein found in mucosal secretions and
   granules of neutrophils was hypothesized to be an ideal adjuvant to
   enhance the efficacy of the BCG vaccine, specifically because of
   previous reports of lactoferrin enhancement of IL-12 production from
   macrophages infected with BCG. Different vaccination protocols were
   investigated for generation of host protective responses against MTB
   infection using lactoferrin admixed to the BCG vaccine. Resulting
   effects demonstrate that BCG/lactoferrin increased host protection
   against MTB infection by decreasing organ bacterial load and reducing
   lung histopathology; significant reduction in tissue CFUs and pathology
   were observed post-challenge compared to those seen with BCG alone.
   Addition of lactoferrin to the vaccine led to reduced pathological
   damage upon subsequent infection with virulent MTB, with positive
   results demonstrated when admixed in oil-based vehicle (incomplete
   Freund's adjuvant, IFA) or when given with BCG in saline. The observed
   post-challenge results paralleled increasing production of IFN-gamma and
   IL-6, but only limited changes to proinflammatory mediators TNF-alpha or
   IL-1 beta from BCG-stimulated splenocytes. Overall, these studies
   indicate that lactoferrin is a useful and effective adjuvant to improve
   efficacy of the BCG vaccine, with potential to reduce related tissue
   damage and pulmonary histopathology. (c) 2007 Elsevier Ltd. All rights
   reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Actor, JK (Reprint Author), Univ Texas, Houston Med Sch, Dept Pathol \& Lab Med, Houston, TX 77030 USA.
   Univ Texas, Houston Med Sch, Dept Pathol \& Lab Med, Houston, TX 77030 USA.
   Univ Texas, Houston Med Sch, Program Mol Pathol, Houston, TX 77030 USA.
   Univ Texas, Houston Med Sch, Dept Integrat Biol \& Pharmacol, Houston, TX 77030 USA.}},
DOI = {{10.1016/j.vaccine.2007.07.005}},
ISSN = {{0264-410X}},
Keywords = {{lactoferrin; BCG; tuberculosis; vaccine adjuvant; immunization}},
Keywords-Plus = {{BACILLUS-CALMETTE-GUERIN; INTERFERON-GAMMA; IFN-GAMMA;
   CELL-DIFFERENTIATION; ORGANISM CONTAINMENT; MURINE TUBERCULOSIS;
   GRANULOMA-FORMATION; ORAL LACTOFERRIN; T-CELLS; MICE}},
Research-Areas = {{Immunology; Research \& Experimental Medicine}},
Web-of-Science-Categories  = {{Immunology; Medicine, Research \& Experimental}},
Author-Email = {{Jeffrey.K.Actor@uth.tmc.edu}},
ORCID-Numbers = {{Actor, Jeffrey/0000-0002-9265-7012}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}R41 AI051050, R42 AI051050, R41AI51050-01, R42
   AI051050-02, R42 AI051050-03, R42-AI051050-02, R41 AI051050-01A1]}},
Cited-References = {{Actor JK, 1999, J INTERF CYTOK RES, V19, P1183, DOI 10.1089/107999099313136.
   Actor JK, 2002, INT IMMUNOPHARMACOL, V2, P475, DOI 10.1016/S1567-5769(01)00189-8.
   Actor JK, 2001, SCAND J IMMUNOL, V53, P464, DOI 10.1046/j.1365-3083.2001.00902.x.
   ACTOR JK, 2001, METHODS MOL MED INTE, P83.
   Ami Y, 2005, J VIROL, V79, P12871, DOI 10.1128/JVI.79.20.12871-12879.2005.
   BAGGIOLINI M, 1970, Journal of Experimental Medicine, V131, P559, DOI 10.1084/jem.131.3.559.
   Bao L, 2003, INFECT IMMUN, V71, P1656, DOI 10.1128/IAI.71.4-1656-1661.2003.
   Bastos KRB, 2002, J LEUKOCYTE BIOL, V71, P271.
   Bean AGD, 1999, J IMMUNOL, V162, P3504.
   Behr MA, 2002, LANCET INFECT DIS, V2, P86, DOI 10.1016/S1473-3099(02)00182-2.
   Brennan MJ, 2004, PAHO SCI P, P177.
   Brewer TF, 2000, CLIN INFECT DIS, V31, pS64, DOI 10.1086/314072.
   BROCK J, 1995, IMMUNOL TODAY, V16, P417, DOI 10.1016/0167-5699(95)80016-6.
   Brock JH, 2002, BIOCHEM CELL BIOL, V80, P1, DOI 10.1139/o01-212.
   Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169.
   Chambers MA, 2004, VACCINE, V22, P1063, DOI 10.1016/j.vaccine.2003.05.002.
   COLDITZ GA, 1995, PEDIATRICS, V96, P29.
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243.
   COOPER AM, 1995, IMMUNOLOGY, V84, P423.
   Cooper AM, 2002, J IMMUNOL, V168, P1322.
   Cooper AM, 1997, J EXP MED, V186, P39, DOI 10.1084/jem.186.1.39.
   Debbabi H, 1998, J DAIRY RES, V65, P283, DOI 10.1017/S0022029997002732.
   Doherty TM, 2005, VACCINE, V23, P2109, DOI 10.1016/j.vaccine.2005.01.060.
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93.
   Garcia I, 1997, EUR J IMMUNOL, V27, P3182, DOI 10.1002/eji.1830271215.
   Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995.
   Guidry TV, 2004, J INTERF CYTOK RES, V24, P362, DOI 10.1089/107999004323142222.
   Haile M, 2005, TUBERCULOSIS, V85, P107, DOI 10.1016/j.tube.2004.09.013.
   Haile M, 2004, VACCINE, V22, P1498, DOI 10.1016/j.vacinne.2003.10.016.
   Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986.
   Holscher C, 2001, J IMMUNOL, V167, P6957.
   Horwitz MA, 2000, P NATL ACAD SCI USA, V97, P13853, DOI 10.1073/pnas.250480397.
   Hwang SA, 2005, INT IMMUNOPHARMACOL, V5, P591, DOI 10.1016/j.intimp.2004.11.006.
   Hwang SA, 2007, MED MICROBIOL IMMUN, V196, P171, DOI 10.1007/s00430-007-0041-6.
   IYER S, 1993, EUR J CLIN NUTR, V47, P232.
   Jagannath C, 2000, SCAND J IMMUNOL, V52, P369, DOI 10.1046/j.1365-3083.2000.00770.x.
   Jung YJ, 2005, J EXP MED, V201, P1915, DOI 10.1084/jem.20050265.
   Kaufmann SHE, 2005, TRENDS IMMUNOL, V26, P660, DOI 10.1016/j.it.2005.09.012.
   KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4.
   Kruzel ML, 2002, ARCH IMMUNOL THER EX, V50, P399.
   Logan KE, 2005, VACCINE, V23, P5526, DOI 10.1016/j.vaccine.2005.07.037.
   Maher D, 2005, CLIN CHEST MED, V26, P167, DOI 10.1016/j.ccm.2005.02.009.
   Majlessi L, 2006, INFECT IMMUN, V74, P2128, DOI 10.1128/IAI.74.4.2128-2137.2006.
   McMurray DN, 2003, INT J PARASITOL, V33, P547, DOI 10.1016/S0020-7519(03)00061-4.
   McMurray DN, 2001, TUBERCULOSIS, V81, P141, DOI 10.1054/tube.2000.0265.
   McShane H, 2005, MICROBES INFECT, V7, P962, DOI 10.1016/j.micinf.2005.03.009.
   Nagabhushanam V, 2003, J IMMUNOL, V171, P4750.
   O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0.
   Oettinger T., 1999, Tubercle and Lung Disease, V79, P243, DOI 10.1054/tuld.1999.0206.
   Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859.
   Rao V, 2003, SCAND J IMMUNOL, V58, P449, DOI 10.1046/j.1365-3083.2003.01321.x.
   Salgame P, 2005, CURR OPIN IMMUNOL, V17, P374, DOI 10.1016/j.coi.2005.06.006.
   SANCHEZ L, 1992, ARCH DIS CHILD, V67, P657.
   Saunders BM, 2000, IMMUNOL CELL BIOL, V78, P334, DOI 10.1046/j.1440-1711.2000.00933.x.
   SCHMITT E, 1994, EUR J IMMUNOL, V24, P793, DOI 10.1002/eji.1830240403.
   SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188.
   Shibaki A, 2002, EXP DERMATOL, V11, P126, DOI 10.1034/j.1600-0625.2002.110204.x.
   Singh M, 2003, CURR HIV RES, V1, P309, DOI 10.2174/1570162033485195.
   Sorimachi K, 1997, BIOCHEM MOL BIOL INT, V43, P79.
   Sterne JAC, 1998, INT J TUBERC LUNG D, V2, P200.
   Stills HF, 2005, ILAR J, V46, P280.
   Teraguchi S, 2004, BIOMETALS, V17, P231, DOI 10.1023/B:BIOM.0000027697.83706.32.
   VanHeyningen TK, 1997, J IMMUNOL, V158, P330.
   Vogel FR, 2000, CLIN INFECT DIS, V30, pS266, DOI 10.1086/313883.
   Wakabayashi H, 2006, CLIN VACCINE IMMUNOL, V13, P239, DOI 10.1128/CVI.13.2.239-245.2006.
   Wakabayashi H, 2004, BIOSCI BIOTECH BIOCH, V68, P537, DOI 10.1271/bbb.68.537.
   Wozniak TM, 2006, INFECT IMMUN, V74, P557, DOI 10.1128/IAI.74.1.557-565.2006.
   Zimecki M, 2000, IMMUNOL LETT, V74, P183, DOI 10.1016/S0165-2478(00)00260-1.}},
Number-of-Cited-References = {{68}},
Times-Cited = {{26}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Vaccine}},
Doc-Delivery-Number = {{216AO}},
Unique-ID = {{ISI:000249850300010}},
}

@article{ ISI:000249850300011,
Author = {Yu, Da-Hai and Li, Min and Hu, Xi-Dan and Cai, Hong},
Title = {{A combined DNA vaccine enhances protective immunity against
   Mycobacterium tuberculosis and Brucella abortus in the presence of an
   IL-12 expression vector}},
Journal = {{VACCINE}},
Year = {{2007}},
Volume = {{25}},
Number = {{37-38}},
Pages = {{6744-6754}},
Month = {{SEP 17}},
Abstract = {{We examined the immunogenicity and protective efficacy of a combined DNA
   vaccine that included six genes encoding immunodominant antigens from
   Mycobacterium tuberculosis and Brucella abortus. The IL-12 adjuvant
   system was used for immunization in combination with the combined DNA
   vaccine (DNA-IL-12(+)). Mice immunized with DNA-IL-12(+) had
   significantly reduced CFU counts for M. tuberculosis and B. abortus in
   lung and spleen, respectively (P < 0.001), and DNA-IL-12(+) elicited
   better protection than the combined DNA vaccine alone (DNA-IL- 12(-)) or
   with the positive control groups after challenge with a virulent M.
   tuberculosis strain and B. abortus 2308 infection. The DNA-IL- 12(+)
   group had stronger antigen-specific IFN-gamma ELISPOT activities and
   higher levels of antigen-specific CD4(+) and CD8(+) T cell responses
   than either the DNA-IL-12(-) or positive control groups. Likewise,
   antigen-specific IgG titers were also much higher than in other
   immunized groups. Moreover, DNA-IL-12(+) gave a stronger IgG2a-skewed
   response than did DNA-IL-12(-). In addition, its mean concentrations of
   IFN-gamma and IL-2 were about 2.5- to 4.5-fold higher than those
   observed in the DNA-IL-12(-)-treated Mice, and were significantly higher
   than control groups (P < 0.01 or P < 0.001), whereas IL-4 and IL-10
   secretion were lower. These results suggest that IL-12 acts as an
   adjuvant to enhance protective immunity against M. tuberculosis and B.
   abortus through the induction of stronger Th1-associated immune
   responses. This is the first report to show that a single combined DNA
   vaccine protects animals against two infectious diseases. (c) 2007
   Elsevier Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Cai, H (Reprint Author), Peking Univ, Coll Life Sci, Natl Lab Prot Engn \& Plant Genet Engn, Beijing 100871, Peoples R China.
   Peking Univ, Coll Life Sci, Natl Lab Prot Engn \& Plant Genet Engn, Beijing 100871, Peoples R China.
   Xinjiang Acad Anim Sci, Inst Vet Med, Urumqi 830000, Peoples R China.}},
DOI = {{10.1016/j.vaccine.2007.06.061}},
ISSN = {{0264-410X}},
Keywords = {{mycobacterium tuberculosis; brucella abortus; combined DNA vaccine;
   IL-12 adjuvant; th 1 immune responses; protective immunity}},
Keywords-Plus = {{OUTER-MEMBRANE PROTEIN-31; CONFERS PROTECTION; BALB/C MICE; INFECTION;
   EFFICACY; INTERLEUKIN-12; INNATE; MELITENSIS; STRATEGIES; CHALLENGE}},
Research-Areas = {{Immunology; Research \& Experimental Medicine}},
Web-of-Science-Categories  = {{Immunology; Medicine, Research \& Experimental}},
Author-Email = {{hcai@pku.edu.cn}},
Cited-References = {{Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015.
   Al-Mariri A, 2001, INFECT IMMUN, V69, P4816, DOI 10.1128/IAI.69.8.4816-4822.2001.
   Baek KM, 2003, VACCINE, V21, P3684, DOI 10.1016/S0264-410X(03)00378-5.
   Cai H, 2006, DNA CELL BIOL, V25, P438, DOI 10.1089/dna.2006.25.438.
   Cai H, 2005, VACCINE, V23, P3887, DOI 10.1016/j.vaccine.2005.03.025.
   Cai H, 2005, VACCINE, V23, P4167, DOI 10.1016/j.vaccine.2005.03.024.
   Cai H, 2004, DNA CELL BIOL, V23, P450, DOI 10.1089/1044549041474742.
   Cai SQ, 2005, ACTA OCEANOL SIN, V24, P10.
   Calarota SA, 2004, IMMUNOL REV, V199, P84, DOI 10.1111/j.0105-2896.2004.00150.x.
   Cassataro J, 2005, INFECT IMMUN, V73, P8079, DOI 10.1128/IAI.73.12.8079-8088.2005.
   Cassataro J, 2005, INFECT IMMUN, V73, P6537, DOI 10.1128/IAI.73.10.6537-6546.2005.
   Cooper AM, 1997, J EXP MED, V186, P39, DOI 10.1084/jem.186.1.39.
   Donnelly JJ, 2005, J IMMUNOL, V175, P633.
   Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927.
   Hornef MW, 2002, NAT IMMUNOL, V3, P1033, DOI 10.1038/ni1102-1033.
   Kamath AT, 1999, INFECT IMMUN, V67, P1702.
   Kurar E, 1997, VACCINE, V15, P1851, DOI 10.1016/S0264-410X(97)00140-0.
   Li H, 2006, VACCINE, V24, P1315, DOI 10.1016/j.vaccine.2005.09.025.
   MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243.
   Matsumoto S, 2005, J IMMUNOL, V175, P441.
   MAYFIELD JE, 1988, GENE, V63, P1, DOI 10.1016/0378-1119(88)90540-9.
   Moriyon I, 2004, VET RES, V35, P1, DOI 10.1051/vetres:2003037.
   Munoz-Montesino C, 2004, INFECT IMMUN, V72, P2081, DOI 10.1128/IAI.72.4.2081-2087.2004.
   Palendira U, 2002, INFECT IMMUN, V70, P1949, DOI 10.1128/IAI.70.4.1949-1956.2002.
   Pan Y, 2003, ACTA BIOCH BIOPH SIN, V35, P71.
   Pappas G, 2005, NEW ENGL J MED, V352, P2325, DOI 10.1056/NEJMra050570.
   Pasquali P, 2002, CLIN DIAGN LAB IMMUN, V9, P491, DOI 10.1128/CDLI.9.2.491-492.2002.
   SANGARI FJ, 1994, FEMS MICROBIOL LETT, V121, P337, DOI 10.1016/0378-1097(94)90314-X.
   Shafer-Weaver K, 2003, J TRANSL MED, V1, P14, DOI DOI 10.1186/1479-5876-1-14.
   Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001.
   Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419.
   Tian Xia, 2005, Zhonghua Yi Xue Za Zhi, V85, P1410.
   Triccas JA, 2002, IMMUNOL CELL BIOL, V80, P346, DOI 10.1046/j.1440-1711.2002.01087.x.
   Velikovsky CA, 2002, INFECT IMMUN, V70, P2507, DOI 10.1128/IAI.70.5.2507-2511.2002.
   World Health Organization, 2006, GUID DRINK WAT QUAL, P1.
   Wozniak TM, 2006, INFECT IMMUN, V74, P557, DOI 10.1128/IAI.74.1.557-565.2006.
   YOSHIDA S, 2005, VACCINE.
   Yu DH, 2007, DNA CELL BIOL, V26, P435, DOI 10.1089/dna.2006.0552.
   ZHENG LM, 1991, FASEB J, V5, P79.}},
Number-of-Cited-References = {{39}},
Times-Cited = {{16}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Vaccine}},
Doc-Delivery-Number = {{216AO}},
Unique-ID = {{ISI:000249850300011}},
}

@article{ ISI:000249328600006,
Author = {France, Anne Marie and Cave, M. Donald and Bates, Joseph H. and Foxman,
   Betsy and Chu, Toby and Yang, Zhenhua},
Title = {{What's driving the decline in tuberculosis in arkansas? A molecular
   epidemiologic analysis of tuberculosis trends in a rural, low-incidence
   population, 1997-2003}},
Journal = {{AMERICAN JOURNAL OF EPIDEMIOLOGY}},
Year = {{2007}},
Volume = {{166}},
Number = {{6}},
Pages = {{662-671}},
Month = {{SEP 15}},
Abstract = {{Incident cases of tuberculosis may result from a recently acquired
   Mycobacterium tuberculosis infection or from the reactivation of a
   latent infection acquired in the remote past. The authors used molecular
   fingerprinting data to estimate the relative contributions of recent and
   remotely acquired infection to the yearly incidence of tuberculosis in
   Arkansas, a state with a largely rural population where the incidence of
   tuberculosis declined from 7.9 cases per 100,000 population to 4.7 cases
   per 100,000 between 1997 and 2003. The authors used a time-restricted
   definition of clustering in addition to the standard definition in order
   to increase the specificity of the clustering measure for recent
   transmission. The greatest overall declines were seen in non-Hispanic
   Blacks (from 13.8 cases per 100,000 in 1997 to 6.5 cases per 100,000 in
   2003) and persons aged 65 years or more (from 19.9 cases per 100,000 in
   1997 to 8.5 cases per 100,000 in 2003). In both groups, the incidence of
   nonclustered cases,declined more dramatically than the incidence of
   clustered cases. This suggests that the decline in rates resulted
   primarily from declining rates of disease due to reactivation of past
   infections. Declines in the overall incidence of tuberculosis in a
   population may not necessarily result from declines in active
   transmission.}},
Publisher = {{OXFORD UNIV PRESS INC}},
Address = {{JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Yang, ZH (Reprint Author), Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 109 Observatory St,Room 3542, Ann Arbor, MI 48109 USA.
   Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   Univ Arkansas Med Sci, Coll Med, Dept Neurol \& Dev Sci, Little Rock, AR 72205 USA.
   Cent Arkansas Vet Healthcare Ctr, Little Rock, AR USA.
   Univ Arkansas Med Sci, Coll Publ Hlth, Dept Internal Med, Little Rock, AR USA.
   Univ Arkansas Med Sci, Coll Publ Hlth, Dept Microbiol, Little Rock, AR USA.
   Arkansas Dept Hlth \& Human Serv, Div Hlth, Little Rock, AR USA.}},
DOI = {{10.1093/aje/kwm135}},
ISSN = {{0002-9262}},
Keywords = {{arkansas; cohort effect; DNA fingerprinting; epidemiology; molecular;
   infection control; Mycobacterium tuberculosis; rural health;
   tuberculosis}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; SAN-FRANCISCO; STRAIN; TRANSMISSION;
   NETHERLANDS; STATE}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{zhenhua@umich.edu}},
ORCID-Numbers = {{Foxman, Betsy/0000-0001-6682-238X}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}5 T32 AI049816A, R01-AI151975]}},
Cited-References = {{ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403.
   Borgdorff MW, 2005, EMERG INFECT DIS, V11, P597.
   Braden CR, 1997, J INFECT DIS, V175, P1446.
   Buchanan I., 2004, CALCULATING POISSON.
   Dillaha JA, 2002, EMERG INFECT DIS, V8, P1246.
   Ellis BA, 2002, EMERG INFECT DIS, V8, P1197.
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4.
   Geng E, 2005, JAMA-J AM MED ASSOC, V293, P2740, DOI 10.1001/jama.293.22.2740.
   Jasmer RM, 1999, ANN INTERN MED, V130, P971.
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907.
   Kempf MC, 2005, J CLIN MICROBIOL, V43, P870, DOI 10.1128/JCM.43.2.870-878.2005.
   Nguyen D, 2004, J CLIN MICROBIOL, V42, P2573, DOI 10.1128/JCM.42.6.2573-2580.2004.
   Nguyen D, 2003, J CLIN MICROBIOL, V41, P2878, DOI 10.1128/JCM.41.7.2878-2883.2003.
   SAS Institute Inc, 2003, SAS VERS 9 1.
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402.
   Sutherland I, 1991, Bull Int Union Tuberc Lung Dis, V66, P189.
   Taylor Zachary, 2005, MMWR Recomm Rep, V54, P1.
   {*}US BUR CENS, 2000, CENS 2000 DAT STAT.
   {*}US DEP HHS, 1997, REP TUB US 1996.
   {*}US DEP HHS, 2001, REP TUB US 2000.
   {*}US DEP HHS, 2000, REP TUB US 1999.
   {*}US DEP HHS, 2003, REP TUB US 2002.
   {*}US DEP HHS, 1999, REP TUB US 1998.
   {*}US DEP HHS, 2004, REP TUB US 2003.
   {*}US DEP HHS, 2002, REP TUB US 2001.
   {*}US DEP HHS, 1998, REP TUB US 1997.
   van Soolingen D, 1999, J INFECT DIS, V180, P726, DOI 10.1086/314930.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.
   Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917.
   YANG ZH, 1995, J CLIN MICROBIOL, V33, P2077.
   Yang ZH, 2001, J CLIN MICROBIOL, V39, P1691, DOI 10.1128/JCM.39.5.1691-1695.2001.
   2004, MMWR MORB MORTAL WKL, V53, P556.
   2006, MMWR MORB MORTAL WKL, V55, P305.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{17}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Am. J. Epidemiol.}},
Doc-Delivery-Number = {{208OH}},
Unique-ID = {{ISI:000249328600006}},
}

@article{ ISI:000249537700018,
Author = {Beresford, N. and Patel, S. and Armstrong, Jane and Szoeor, B. and
   Fordham-Skelton, A. P. and Tabernero, L.},
Title = {{MptpB, a virulence factor from Mycobacterium tuberculosis, exhibits
   triple-specificity phosphatase activity (vol 406, pg 13, 2007)}},
Journal = {{BIOCHEMICAL JOURNAL}},
Year = {{2007}},
Volume = {{406}},
Number = {{3}},
Pages = {{527}},
Month = {{SEP 15}},
Publisher = {{PORTLAND PRESS LTD}},
Address = {{THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND}},
Type = {{Correction}},
Language = {{English}},
ISSN = {{0264-6021}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
ResearcherID-Numbers = {{Szoor, Balazs/G-5732-2013}},
ORCID-Numbers = {{Szoor, Balazs/0000-0002-2805-9843}},
Cited-References = {{Beresford N, 2007, BIOCHEM J, V406, P13, DOI 10.1042/BJ20070670.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Biochem. J.}},
Doc-Delivery-Number = {{211QF}},
Unique-ID = {{ISI:000249537700018}},
}

@article{ ISI:000248881600011,
Author = {Spyridis, Nikos P. and Spyridis, Panayotis G. and Gelesme, Anna and
   Sypsa, Vana and Valianatou, Mina and Metsou, Flora and Gourgiotis,
   Dimitris and Tsolia, Maria N.},
Title = {{The effectiveness of a 9-month regimen of isoniazid alone versus 3-and
   4-month regimens of isoniazid plus rifampin for treatment of latent
   tuberculosis infection in children: Results of an 11-year Randomized
   study}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{45}},
Number = {{6}},
Pages = {{715-722}},
Month = {{SEP 15}},
Abstract = {{Background. A 9-month course of isoniazid monotherapy is currently
   recommended for the treatment of latent tuberculosis infection (LTBI)
   and has been shown to be effective in both children and adults. Reduced
   compliance with this regimen has forced physicians to explore shorter
   regimens. The aim of this study was to compare 3- and 4-month
   combination regimens of isoniazid plus rifampin with a 9-month regimen
   of isoniazid monotherapy for the treatment of LTBI in children.
   Methods. This prospective, randomized, controlled study was conducted
   over an 11-year period (1995-2005). In period 1 (1995-1998), 232
   patients received isoniazid therapy for 9 months ( group A), and 238
   patients received isoniazid and rifampin for 4 months (group B). In
   period 2 (1999-2002), 236 patients were treated with isoniazid and
   rifampin for 4 months (group C), and 220 patients received the same
   regimen for 3 months (group D). All patients were observed for >= 3
   years.
   Results. Overall compliance with treatment was good, but patients who
   received isoniazid monotherapy were less compliant than were those who
   received short-course combination therapy (, for group A vs. group Pp.
   011 B; for group C vs. group D). No patient in any group developed
   clinical disease during the follow-up Pp. 510 period. New radiographic
   findings suggestive of possible active disease were more common in
   patients who received isoniazid monotherapy (24\%) than in those treated
   with shorter regimens (11.8\%, 13.6\%, and 11\% for groups B, C, and D,
   respectively; for group A vs. group B; for group C vs. group D). Serious
   drug-related adverse effects were not detected.
   Conclusions. Short-course treatment with isoniazid and rifampin for 3- 4
   months is safe and seems to be superior to a 9-month course of isoniazid
   monotherapy.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tsolia, MN (Reprint Author), Univ Athens, Sch Med, P\&A Kyriakou Childrens Hosp, Dept Pediat 2, GR-11527 Athens, Greece.
   Univ Athens, Sch Med, P\&A Kyriakou Childrens Hosp, TB Clin, GR-11527 Athens, Greece.
   Univ Athens, Sch Med, P\&A Kyriakou Childrens Hosp, Res Lab, GR-11527 Athens, Greece.
   Univ Athens, Sch Med, Dept Hyg \& Epidemiol, GR-11527 Athens, Greece.}},
DOI = {{10.1086/520983}},
ISSN = {{1058-4838}},
Keywords-Plus = {{COST-EFFECTIVENESS ANALYSIS; SHORT-COURSE THERAPY; ANTITUBERCULOSIS
   CHEMOPROPHYLAXIS; PULMONARY TUBERCULOSIS; PREVENTIVE THERAPY;
   UNITED-STATES; FOLLOW-UP; CHEMOTHERAPY; COMPLETION; RESISTANCE}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{matsolia@ath.forthnet.gr}},
ResearcherID-Numbers = {{SYPSA, VANA/A-5082-2008}},
Cited-References = {{American Academy of Pediatrics Pediatric Tuberculosis Collaborative Group, 2004, PEDIATRICS, V114, P1175.
   Arif K, 1998, INT J TUBERC LUNG D, V2, P225.
   BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359.
   Brown Phyllida, 2002, BMJ, V325, P1320, DOI 10.1136/bmj.325.7376.1320.
   Cohn DL, 2000, CLIN INFECT DIS, V31, P120, DOI 10.1086/313891.
   Coly A, 2004, INT J TUBERC LUNG D, V8, P703.
   Comstock GW, 2000, INT J TUBERC LUNG D, V4, P485.
   Cynamon MH, 1999, ANTIMICROB AGENTS CH, V43, P2922.
   DELACOURT C, 1993, ARCH DIS CHILD, V69, P430.
   Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376.
   Edwards DJ, 2007, INT J TUBERC LUNG D, V11, P263.
   Ena J, 2005, CLIN INFECT DIS, V40, P670, DOI 10.1086/427802.
   Falzon D, 2006, INT J TUBERC LUNG D, V10, P954.
   Ferebee S H, 1970, Bibl Tuberc, V26, P28.
   GIRLING DJ, 1992, AM REV RESPIR DIS, V145, P36.
   HSU KHK, 1974, JAMA-J AM MED ASSOC, V229, P528, DOI 10.1001/jama.229.5.528.
   Jasmer RM, 2000, AM J RESP CRIT CARE, V162, P1648.
   Kanavaki S, 2006, INT J TUBERC LUNG D, V10, P559.
   KHAN EA, 1995, EMERG INFECT DIS, V1, P115.
   Khan K, 2002, NEW ENGL J MED, V347, P1850, DOI 10.1056/NEJMsa021099.
   Kucers A, 1987, USE ANTIBIOTICS COMP.
   Levesque JF, 2004, INT J TUBERC LUNG D, V8, P711.
   Marais BJ, 2006, ARCH DIS CHILD, V91, P762, DOI 10.1136/adc.2006.097220.
   Marais BJ, 2006, AM J RESP CRIT CARE, V173, P1078, DOI 10.1164/rccm.200511-1809SO.
   Menzies D, 2004, AM J RESP CRIT CARE, V170, P445, DOI 10.1164/rccm.200404-478OC.
   MENZIES R, 1993, TUBERCLE LUNG DIS, V74, P32, DOI 10.1016/0962-8479(93)90066-7.
   NOLAN CM, 1986, AM REV RESPIR DIS, V133, P431.
   Ormerod LP, 1998, ARCH DIS CHILD, V78, P169.
   Ormerod P, 2000, THORAX, V55, P887.
   Palanduz A, 2003, PEDIATR PULM, V36, P55, DOI 10.1002/ppul.10314.
   Rose DN, 1998, ANN INTERN MED, V129, P779.
   Rothe TB, 1996, TUBERCLE LUNG DIS, V77, P93, DOI 10.1016/S0962-8479(96)90083-0.
   Schaaf HS, 2007, EUR J CLIN MICROBIOL, V26, P203, DOI 10.1007/s10096-007-0257-9.
   Schaaf HS, 2006, ACTA PAEDIATR, V95, P523, DOI 10.1080/08035250600675741.
   Spyridis P, 2001, SCAND J INFECT DIS, V33, P362.
   STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3.
   STARKE JR, 1990, PEDIATR INFECT DIS J, V9, P785, DOI 10.1097/00006454-199011000-00002.
   STARKE JR, 1992, INFECT DIS CLIN N AM, V6, P215.
   Sterling TR, 2006, AM J RESP CRIT CARE, V173, P927, DOI 10.1164/rccm.200510-1563OC.
   THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555.
   van Zyl S, 2006, INT J TUBERC LUNG D, V10, P13.
   Villarino ME, 1997, AM J RESP CRIT CARE, V155, P1735.
   WHO, 1997, TREATM TUB GUID NAT.}},
Number-of-Cited-References = {{43}},
Times-Cited = {{81}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{202DG}},
Unique-ID = {{ISI:000248881600011}},
}

@article{ ISI:000249465600012,
Author = {Rothfuchs, Antonio Gigliotti and Bafica, Andre and Feng, Carl G. and
   Egen, Jackson G. and Williams, David L. and Brown, Gordon D. and Sher,
   Alan},
Title = {{Dectin-1 interaction with mycobacterium tuberculosis leads to enhanced
   IL-12p40 production by splenic dendritic cells}},
Journal = {{JOURNAL OF IMMUNOLOGY}},
Year = {{2007}},
Volume = {{179}},
Number = {{6}},
Pages = {{3463-3471}},
Month = {{SEP 15}},
Abstract = {{Dectin-1 is a fungal pattern recognition receptor that binds to
   beta-glucans and triggers cytokine production by facilitating
   interaction with TLR2 or by directly activating spleen tyrosine kinase
   (Syk). To assess the possible role of Dectin-1 in the innate response to
   mycobacteria, we used an in vitro system in which IL-12p40 production is
   measured in splenic dendritic cells (SpDC) following exposure to live
   Mycobacterium tuberculosis bacilli. Treatment of SpDC with laminarin or
   glucan phosphate, two molecules known to block Dectin-1-dependent
   activity, led to a reduction in M. tuberculosis-induced IL-12p40 as well
   as IL-12p70 production. Moreover, SpDC from Dectin-1(-/-) chimeric mice
   displayed reduced IL-12p40 production in response to mycobacteria when
   compared with Dectin-sufficient DC. Laminarin treatment also inhibited
   mycobacterial-induced IL-12p40 production in DC from TLR2(-/-) mice,
   arguing that Dectin-1 functions independently of TLR2 signaling in this
   system. Importantly, a Dectin-1 fusion protein was found to directly
   bind to live mycobacteria in a laminarin-inhabitable manner indicating
   the presence of ligands for the receptor in the bacterium and laminarin
   pretreatment resulted in reduced association of mycobacteria to SpDC. In
   additional experiments, mycobacterial stimulation was shown to be
   associated with increased phosphorylation of Syk and this response was
   inhibited by laminarin. Furthermore, pharmacologic inhibition of Syk
   reduced the M. tuberculosis-induced IL-12p40 response. Together, these
   findings support a role for Dectin-1 in promoting M.
   tuberculosis-induced IL-12p40 production by DC in which the receptor
   augments bacterial-host cell interaction and enhances the subsequent
   cytokine response through an unknown mechanism involving Syk signaling.}},
Publisher = {{AMER ASSOC IMMUNOLOGISTS}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rothfuchs, AG (Reprint Author), NIAID, Immunobiol Sect, Parasit Dis Lab, NIH, Room 6148,Bldg 50,50 South Dr, Bethesda, MD 20892 USA.
   NIAID, Immunobiol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA.
   Univ Fed Santa Catarina, Dept Microbiol \& Parasitol, Div Immunol, Florianopolis, SC, Brazil.
   E Tennessee State Univ, James H Quillen Coll Med, Dept Surg, Johnson City, TN 37614 USA.
   Univ Cape Town, Inst Infect Dis \& Mol Med, Div Immunol, ZA-7700 Rondebosch, South Africa.}},
ISSN = {{0022-1767}},
Keywords-Plus = {{BETA-GLUCAN RECEPTOR; C-TYPE LECTINS; MACROPHAGE RECEPTORS; PATHOGEN
   RECOGNITION; IMMUNE RECOGNITION; ADAPTIVE IMMUNITY; INNATE IMMUNITY;
   INFECTION; RESPONSES; INDUCTION}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{rothfuchsa@niaid.nih.gov}},
ResearcherID-Numbers = {{brown, gordon/B-4249-2012
   Rothfuchs, Antonio/F-5981-2013
   }},
ORCID-Numbers = {{Rothfuchs, Antonio/0000-0001-6001-7240
   Egen, Jackson/0000-0003-2053-0837}},
Funding-Acknowledgement = {{Intramural NIH HHS}},
Cited-References = {{Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8.
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015.
   Aliberti J, 2002, NAT IMMUNOL, V3, P76, DOI 10.1038/ni745.
   Arellano-Reynoso B, 2005, NAT IMMUNOL, V6, P618, DOI 10.1038/ni1202.
   Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199.
   Bafica A, 2005, J EXP MED, V202, P1715, DOI 10.1081/jem.20051782.
   Bafica A, 2006, J IMMUNOL, V177, P3515.
   Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470.
   Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890.
   Brown GD, 2006, NAT REV IMMUNOL, V6, P33, DOI 10.1038/nri1745.
   Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620.
   Carter RW, 2006, J IMMUNOL, V177, P2276.
   Cooper AM, 1997, J EXP MED, V186, P39, DOI 10.1084/jem.186.1.39.
   Cooper AM, 2007, TRENDS IMMUNOL, V28, P33, DOI 10.1016/j.it.2006.11.002.
   Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2.
   Cywes C, 1997, INFECT IMMUN, V65, P4258.
   Ehlers MRW, 1998, TRENDS MICROBIOL, V6, P328, DOI 10.1016/S0966-842X(98)01301-8.
   Ernst JD, 1998, INFECT IMMUN, V66, P1277.
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93.
   Fulton SA, 1996, INFECT IMMUN, V64, P2523.
   Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787.
   Graham LM, 2006, J IMMUNOL METHODS, V314, P164, DOI 10.1016/j.jim.2006.05.013.
   Grunvald E, 1996, INFECT IMMUN, V64, P2010.
   Hemmi H, 2000, NATURE, V408, P740.
   Herre J, 2004, BLOOD, V104, P4038, DOI 10.1182/blood-2004-03-1140.
   Hetland G, 1998, SCAND J IMMUNOL, V47, P548.
   Holscher C, 2001, J IMMUNOL, V167, P6957.
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112.
   Jang S, 2004, J IMMUNOL, V173, P3392.
   Khader SA, 2005, J IMMUNOL, V175, P788.
   Khader SA, 2006, J EXP MED, V203, P1805, DOI 10.1084/jem.20052545.
   KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P.
   Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028.
   Leifer CA, 2004, J IMMUNOL, V173, P1179.
   McIntosh M, 2005, APPL MICROBIOL BIOT, V68, P163, DOI 10.1007/s00253-005-1959-5.
   Muller A, 1996, J IMMUNOL, V156, P3418.
   Palma AS, 2006, J BIOL CHEM, V281, P5771, DOI 10.1074/jbc.M511461200.
   Pompei L, 2007, J IMMUNOL, V178, P5192.
   Reid DM, 2004, J LEUKOCYTE BIOL, V76, P86, DOI 10.1189/jlb.0104031.
   Robinson MJ, 2006, NAT IMMUNOL, V7, P1258, DOI 10.1038/ni1417.
   Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004.
   Saijo S, 2007, NAT IMMUNOL, V8, P39, DOI 10.1038/ni1425.
   Sanjuan MA, 2006, J CELL BIOL, V172, P1057, DOI 10.1083/jcb.200508058.
   Schardl J, 1996, J PLAST FILM SHEET, V12, P157.
   Tailleux L, 2003, TRENDS MICROBIOL, V11, P259, DOI 10.1016/S0966-842X(03)00102-1.
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3.
   Taylor BJ, 2001, J HIGH ENERGY PHYS.
   Taylor PR, 2004, J IMMUNOL, V172, P1157.
   Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816.
   Thornton BP, 1996, J IMMUNOL, V156, P1235.
   Tian T, 2005, J IMMUNOL, V175, P3268.
   Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001.
   Underhill DM, 2005, BLOOD, V106, P2543, DOI 10.1182/blood-2005-03-1239.
   van de Vosse E, 2006, MICROBES INFECT, V8, P1167, DOI 10.1016/j.micinf.2005.10.032.
   Velasco-Velazquez MA, 2003, MICROB PATHOGENESIS, V35, P125, DOI 10.1016/S0882-4010(03)00099-8.
   von Meyenn F, 2006, IMMUNOBIOLOGY, V211, P557, DOI 10.1016/j.imbio.2006.05.004.
   Yadav M, 2006, BLOOD, V108, P3168, DOI 10.1180/blood-2006-05-024406.}},
Number-of-Cited-References = {{57}},
Times-Cited = {{108}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{J. Immunol.}},
Doc-Delivery-Number = {{210ON}},
Unique-ID = {{ISI:000249465600012}},
}

@article{ ISI:000249304900068,
Author = {Stadthagen, Gustavo and Sambou, Tounkang and Guerin, Marcelo and
   Barilone, Nathalie and Boudou, Frederic and Kordulakova, Jana and
   Charles, Patricia and Alzari, Pedro M. and Lemassu, Anne and Daffe,
   Mamadou and Puzo, Germain and Gicquel, Brigitte and Riviere, Michel and
   Jackson, Mary},
Title = {{Genetic basis for the biosynthesis of methylglucose lipopolysaccharides
   in Mycobacterium tuberculosis}},
Journal = {{JOURNAL OF BIOLOGICAL CHEMISTRY}},
Year = {{2007}},
Volume = {{282}},
Number = {{37}},
Pages = {{27270-27276}},
Month = {{SEP 14}},
Abstract = {{Mycobacteria produce two unusual polymethylated polysaccharides, the
   6-O-methylglucosyl-containing lipopolysaccharides (MGLP) and the
   3-O-methylmannose polysaccharides, which have been shown to regulate
   fatty acid biosynthesis in vitro. A cluster of genes dedicated to the
   synthesis of MGLP was identified in Mycobacterium tuberculosis and
   Mycobacterium smegmatis. Overexpression of the putative
   glycosyltransferase gene Rv3032 in M. smegmatis greatly stimulated MGLP
   production, whereas the targeted disruption of Rv3032 in M. tuberculosis
   and that of the putative methyltransferase gene MSMEG2349 in M.
   smegmatis resulted in a dramatic reduction in the amounts of MGLP
   synthesized and in the accumulation of precursors of these molecules.
   Disruption of Rv3032 also led to a significant decrease in the glycogen
   content of the tubercle bacillus, indicating that the product of this
   gene is likely to be involved in the elongation of more than one
   alpha-(1 -> 4)-glucan in this bacterium. Results thus suggest that
   Rv3032 encodes the alpha-(1 -> 4)- glucosyltransferase responsible for
   the elongation of MGLP, whereas MSMEG2349 encodes the
   O-methyltransferase required for the 6-O-methylation of these compounds.}},
Publisher = {{AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Jackson, M (Reprint Author), Colorado State Univ, Dept Microbiol Immunol\& Pathol, Ft Collins, CO 80523 USA.
   Inst Pasteur, Unite Genet Mycobacterienne, F-75015 Paris, France.
   Inst Pasteur, Unite Biochim Struct, F-75015 Paris, France.
   CNRS, Inst Pharmacol \& Biol Struct, Dept Mecanismes Mol infect Mycobacteriennes, F-31077 Toulouse, France.}},
DOI = {{10.1074/jbc.M702676200}},
ISSN = {{0021-9258}},
EISSN = {{1083-351X}},
Keywords-Plus = {{PALMITOYL-COENZYME-A; METHYLMANNOSE POLYSACCHARIDE; REVISED STRUCTURE;
   SMEGMATIS; ACID; POLYMETHYLPOLYSACCHARIDES; 6-O-METHYL-D-GLUCOSE;
   METHYLTRANSFERASE; IDENTIFICATION; PURIFICATION}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{Mary.Jackson@colostate.edu}},
ResearcherID-Numbers = {{Kordulakova, Jana/I-3887-2014
   Jackson, Mary/D-5345-2017
   }},
ORCID-Numbers = {{Jackson, Mary/0000-0002-9212-0258
   Alzari, Pedro/0000-0002-4233-1903}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}5R01 AI 064798-03, R01 AI064798]}},
Cited-References = {{Berg S, 2007, GLYCOBIOLOGY, V17, p35R, DOI 10.1093/glycob/cwm010.
   Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1.
   BUEDING E, 1964, J BIOL CHEM, V239, P4018.
   Dinadayala P, 2004, J BIOL CHEM, V279, P12369, DOI 10.1074/jbc.M308908200.
   ELBEIN AD, 1973, J BACTERIOL, V113, P863.
   FERGUSON JA, 1970, J BIOL CHEM, V245, P4213.
   FORSBERG LS, 1982, J BIOL CHEM, V257, P3555.
   GRAY GR, 1971, J BIOL CHEM, V246, P6835.
   GRELLERT E, 1972, J BIOL CHEM, V247, P3236.
   HARRIS LS, 1977, J BIOL CHEM, V252, P2470.
   HINDSGAUL O, 1984, BIOCHEMISTRY-US, V23, P577, DOI 10.1021/bi00298a028.
   HUNTER SW, 1986, J BIOL CHEM, V261, P2345.
   Jackson M, 2001, Methods Mol Med, V54, P59, DOI 10.1385/1-59259-147-7:059.
   KAMISANGO K, 1987, J BIOL CHEM, V262, P4580.
   Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200.
   LEE YC, 1964, J BIOL CHEM, V239, P3602.
   LEE YC, 1966, J BIOL CHEM, V241, P1899.
   LEMASSU A, 1994, BIOCHEM J, V297, P351.
   LORNITZO FA, 1968, BIOCHIM BIOPHYS ACTA, V158, P329, DOI 10.1016/0304-4165(68)90286-9.
   MAGGIO JE, 1980, P NATL ACAD SCI-BIOL, V77, P2582, DOI 10.1073/pnas.77.5.2582.
   MAITRA SK, 1977, J BIOL CHEM, V252, P2459.
   MCNEIL M, 1989, METHOD ENZYMOL, V179, P215.
   Murakami T, 2006, J BACTERIOL, V188, P5915, DOI 10.1128/JB.00390-06.
   Newton GL, 2003, J BACTERIOL, V185, P3476, DOI 10.1128/JB.185.11.3476-3479.2003.
   POMMIER MT, 1986, J GEN MICROBIOL, V132, P2433.
   Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625.
   Tatituri RVV, 2007, J BIOL CHEM, V282, P4561, DOI 10.1074/jbc.M608695200.
   Tuffal G, 1998, GLYCOBIOLOGY, V8, P675, DOI 10.1093/glycob/8.7.675.
   TUFFAL G, 1995, EUR J BIOCHEM, V233, P377, DOI 10.1111/j.1432-1033.1995.377\_1.x.
   Tuffal G, 1998, ANAL CHEM, V70, P1853, DOI 10.1021/ac971101r.
   TUNG KK, 1973, J BIOL CHEM, V248, P7126.
   Tzvetkov M, 2003, MICROBIOL-SGM, V149, P1659, DOI 10.1099/mic.0.26205-0.
   WEISMAN LS, 1984, J BIOL CHEM, V259, P3457.
   WEISMAN LS, 1984, J BIOL CHEM, V259, P3464.
   YABUSAKI KK, 1978, P NATL ACAD SCI USA, V75, P691, DOI 10.1073/pnas.75.2.691.
   YABUSAKI KK, 1979, J BIOL CHEM, V254, P2314.
   YABUSAKI KK, 1979, J BIOL CHEM, V254, P7282.
   YAMADA H, 1979, J BIOL CHEM, V254, P1972.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{26}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{J. Biol. Chem.}},
Doc-Delivery-Number = {{208FJ}},
Unique-ID = {{ISI:000249304900068}},
}

@article{ ISI:000249304900075,
Author = {Reddy, Manchi C. M. and Palaninathan, Satheesh K. and Shetty, Nishant D.
   and Owen, Joshua L. and Watson, Misty D. and Sacchettini, James C.},
Title = {{High resolution crystal structures of Mycobacterium tuberculosis
   adenosine kinase - Insights into the mechanism and specificity of this
   novel prokaryotic enzyme}},
Journal = {{JOURNAL OF BIOLOGICAL CHEMISTRY}},
Year = {{2007}},
Volume = {{282}},
Number = {{37}},
Pages = {{27334-27342}},
Month = {{SEP 14}},
Abstract = {{Adenosine kinase (ADK) catalyzes the phosphorylation of adenosine (Ado)
   to adenosine monophosphate (AMP). It is part of the purine salvage
   pathway that has been identified only in eukaryotes, with the single
   exception of Mycobacterium spp. Whereas it is not clear if Mycobacterium
   tuberculosis (Mtb) ADK is essential, it has been shown that the enzyme
   can selectively phosphorylate nucleoside analogs to produce products
   toxic to the cell. We have determined the crystal structure of Mtb ADK
   unliganded as well as ligand (Ado) bound at 1.5- and 1.9-angstrom
   resolution, respectively. The structure of the binary complexes with the
   inhibitor 2-fluoroadenosine (F-Ado) bound and with the adenosine
   5'-(beta,gamma- methylene) triphosphate (AMPPCP) (non-hydrolyzable ATP
   analog) bound were also solved at 1.9- A resolution. These four
   structures indicate that Mtb ADK is a dimer formed by an extended beta
   sheet. The active site of the unliganded ADK is in an open conformation,
   and upon Ado binding a lid domain of the protein undergoes a large
   conformation change to close the active site. In the closed
   conformation, the lid forms direct interactions with the substrate and
   residues of the active site. Interestingly, AMP-PCP binding alone was
   not sufficient to produce the closed state of the enzyme. The binding
   mode of F-Ado was characterized to illustrate the role of additional
   non-bonding interactions in Mtb ADK compared with human ADK.}},
Publisher = {{AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Sacchettini, JC (Reprint Author), Texas A\&M Univ, Dept Biochem \& Biophys, College Stn, TX 77843 USA.
   Texas A\&M Univ, Dept Biochem \& Biophys, College Stn, TX 77843 USA.}},
DOI = {{10.1074/jbc.M703290200}},
ISSN = {{0021-9258}},
Keywords-Plus = {{PENTAVALENT IONS DEPENDENCY; ESCHERICHIA-COLI RIBOKINASE; ANGSTROM
   RESOLUTION; TOXOPLASMA-GONDII; METABOLISM; SUBSTRATE; SEQUENCE; BINDING;
   2-METHYLADENOSINE; IDENTIFICATION}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{sacchett@tamu.edu}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}P01 AI 68135]}},
Cited-References = {{Barrow EW, 2003, J ANTIMICROB CHEMOTH, V52, P801, DOI 10.1093/jac/dkg444.
   Basso LA, 1998, J INFECT DIS, V178, P769.
   Basso LA, 2001, BIOCHEMISTRY-US, V40, P8196, DOI 10.1021/bi010584x.
   BORK P, 1993, PROTEIN SCI, V2, P31.
   BROCKMAN RW, 1980, CANCER RES, V40, P3610.
   Chen CK, 2002, MICROBIOL-SGM, V148, P289.
   CHRISTOPHER JA, 1998, CTR MACROMOLECULAR D.
   Cole ST, 1998, NATURE, V393, P537.
   Collaborative Computational Project Number 4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112.
   Cook WJ, 2000, PROTEIN SCI, V9, P704.
   Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0.
   Duncan K, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P297.
   Hao WH, 1996, BIOCHEM MOL BIOL INT, V38, P889.
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211.
   Kantardjieff KA, 2002, ACTA CRYSTALLOGR D, V58, P735, DOI 10.1107/S0O907444901019588.
   LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351.
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944.
   Long MC, 2007, J ANTIMICROB CHEMOTH, V59, P118, DOI 10.1093/jac/dkl448.
   Long MC, 2006, BIOCHEM PHARMACOL, V71, P1671, DOI 10.1016/j.bcp.2006.03.006.
   Long MC, 2003, J BACTERIOL, V185, P6548, DOI 10.1128/JB.185.22.6548-6555.2003.
   Maj MC, 2002, BIOCHEMISTRY-US, V41, P4059, DOI 10.1021/bi0119161.
   Mathews II, 1998, BIOCHEMISTRY-US, V37, P15607, DOI 10.1021/bi9815445.
   McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094.
   MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396.
   MILLER RL, 1979, J BIOL CHEM, V254, P2346.
   Ogata CM, 1998, NAT STRUCT BIOL, V5, P638, DOI 10.1038/1330.
   Ohshima N, 2004, J MOL BIOL, V340, P477, DOI 10.1016/j.jmb.2004.04.074.
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X.
   Park BK, 2001, ANNU REV PHARMACOL, V41, P443, DOI 10.1146/annurev.pharmtox.41.1.443.
   Parker WB, 2004, TUBERCULOSIS, V84, P327, DOI 10.1016/j.tube.2004.02.004.
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084.
   PITTILLO R F, 1964, Antimicrob Agents Chemother (Bethesda), V10, P474.
   Schumacher MA, 2000, J MOL BIOL, V296, P549, DOI 10.1006/jmbi.1999.3474.
   SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3.
   Sigrell JA, 1997, PROTEIN SCI, V6, P2474.
   Sigrell JA, 1998, STRUCTURE, V6, P183, DOI 10.1016/S0969-2126(98)00020-3.
   Sigrell JA, 1999, J MOL BIOL, V290, P1009, DOI 10.1006/jmbi.1999.2938.
   Spychala J, 1996, P NATL ACAD SCI USA, V93, P1232, DOI 10.1073/pnas.93.3.1232.
   Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956.
   Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839.
   Wayne LG, 1996, INFECT IMMUN, V64, P2062.
   World Health Organization, 1993, WORLD HEALTH FORUM, V14, P438.
   WU LF, 1991, J BACTERIOL, V173, P3117.
   Zhang Y, 2004, STRUCTURE, V12, P1809, DOI 10.1016/j.str.2004.07.020.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{23}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{J. Biol. Chem.}},
Doc-Delivery-Number = {{208FJ}},
Unique-ID = {{ISI:000249304900075}},
}

@article{ ISI:000249645000019,
Author = {Srikantiah, Padmini and Walusimbi, Maria N. and Kayanja, H. Kose and
   Mayanja-Kizza, Harriet and Mugerwa, Roy D. and Lin, Royce and
   Charlebois, Edwin D. and Boom, W. Henry and Whalen, Christopher C. and
   Havlir, Diane V.},
Title = {{Early virological response of zidovudine/larnivudine/abacavir for
   patients co-infected with HIV and tuberculosis in Uganda}},
Journal = {{AIDS}},
Year = {{2007}},
Volume = {{21}},
Number = {{14}},
Pages = {{1972-1974}},
Month = {{SEP 12}},
Abstract = {{Triple nucleoside reverse transcriptase inhibitors are recommended as an
   alternative regimen for HIV-infected patients undergoing tuberculosis
   treatment in resource-limited settings. Few data exist on the efficacy
   of such regimens in tuberculosis patients. In 34
   tuberculosis/HIV-co-infected patients treated with
   zidovudine/lamivudine/abacavir, 76\% achieved HIV RNA less than 50
   copies/ml at 24 weeks. No cases of hypersensitivity or immune
   reconstitution syndrome were observed. These data support the continuing
   evaluation of nucleoside-based antiretroviral regimens as an alternative
   treatment for this population.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Srikantiah, P (Reprint Author), Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA 94080 USA.
   Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA 94080 USA.
   Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA.
   Makerere Univ, Sch Med, Mulago Hosp, CWRU Res Collaborat, Kampala, Uganda.
   Case Western Reserve Univ, Sch Med, Tuberculosis Res Unit, Cleveland, OH USA.}},
DOI = {{10.1097/QAD.0b013e32823ecf6e}},
ISSN = {{0269-9370}},
Keywords-Plus = {{ACTIVE ANTIRETROVIRAL THERAPY; 24-WEEK EFFICACY; RIFAMPICIN; NEVIRAPINE}},
Research-Areas = {{Immunology; Infectious Diseases; Virology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Virology}},
Funding-Acknowledgement = {{FIC NIH HHS {[}D43 TW000011]; NIAID NIH HHS {[}R01 AI032414]}},
Cited-References = {{Bisson GP, 2006, AIDS, V20, P1613, DOI 10.1097/01.aids.0000238407.00874.dc.
   Friedland G, 2006, J ANTIMICROB CHEMOTH, V58, P1299, DOI 10.1093/jac/dkl399.
   Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772.
   Jack C, 2004, JAIDS-J ACQ IMM DEF, V36, P929, DOI 10.1097/00126334-200408010-00006.
   Lugada ES, 2004, CLIN DIAGN LAB IMMUN, V11, P29, DOI 10.1128/CDLI.11.1.29-34.2004.
   Manosuthi W, 2006, CLIN INFECT DIS, V43, P253, DOI 10.1086/505210.
   Manosuthi W, 2005, AIDS, V19, P1481, DOI 10.1097/01.aids.0000183630.27665.30.
   Moore DM, 2006, JAIDS-J ACQ IMM DEF, V43, P436, DOI 10.1097/01.qai.0000243105.80393.42.
   MUNDERI P, 2006, 13 C RETR OPP INF DE.
   Ribera E, 2001, J ACQ IMMUN DEF SYND, V28, P450.
   Sungkanuparph S, 2006, J INFECTION, V52, P188, DOI 10.1016/j.jinf.2005.05.010.
   US FDA, 2005, FDA PUBL HLTH ADV NE.}},
Number-of-Cited-References = {{12}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Aids}},
Doc-Delivery-Number = {{213DA}},
Unique-ID = {{ISI:000249645000019}},
}

@article{ ISI:000249645000022,
Author = {Tamburini, Jerome and Grimaldi, David and Chiche, Jean-Daniel and
   Bricaire, Francois and Bossi, Philippe},
Title = {{Cytokine pattern in Kaposi's sarcoma associated with immune restoration
   disease in HIV and tuberculosis co-infected patients}},
Journal = {{AIDS}},
Year = {{2007}},
Volume = {{21}},
Number = {{14}},
Pages = {{1980-1983}},
Month = {{SEP 12}},
Abstract = {{We analysed the evolution of different cytokines (IL-4, IL-6, tumour
   necrosis factor alpha and vascular endothelial growth factor; VEGF)
   involved in the development of Kaposi's sarcoma in two patients in whom
   HIV infection presented with disseminated Mycobacterium tuberculosis
   infection. They simultaneously developed tuberculosis-associated immune
   restoration disease and Kaposi's sarcoma shortly after the initiation of
   HAART. Analysis of VEGF and pro-inflammatory cytokines led us to
   hypothesize that Kaposi's sarcoma could be promoted by the tuberculosis
   immune response.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tamburini, J (Reprint Author), Grp Hosp Pitie Salpetriere, Dept Infect Dis, F-75634 Paris, France.
   Grp Hosp Pitie Salpetriere, Dept Infect Dis, F-75634 Paris, France.
   INSERM, Inst Cochin, Dept Cell Biol, U567, Paris, France.}},
DOI = {{10.1097/QAD.0b013e3282efa62c}},
ISSN = {{0269-9370}},
Keywords-Plus = {{RECONSTITUTION INFLAMMATORY SYNDROME}},
Research-Areas = {{Immunology; Infectious Diseases; Virology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Virology}},
Cited-References = {{Alatas F, 2004, CHEST, V125, P2156, DOI 10.1378/chest.125.6.2156.
   Barete S, 2000, ARCH DERMATOL, V136, P1452, DOI 10.1001/archderm.136.12.1452.
   Boshoff C, 2002, NAT REV CANCER, V2, P373, DOI 10.1038/nrc797.
   Bower M, 2005, J CLIN ONCOL, V23, P5224, DOI 10.1200/JCO.2005.14.597.
   Ferrari N, 2003, CLIN CANCER RES, V9, P6020.
   Hsieh SM, 1999, AIDS, V13, P935, DOI 10.1097/00002030-199905280-00009.
   Jacobson LP, 1999, J ACQ IMMUN DEF SYND, V21, P34.
   Shelburne SA, 2005, AIDS, V19, P399, DOI 10.1097/01.aids.0000161769.06158.8a.
   Stebbing J, 2003, ANN ONCOL, V14, P1660, DOI 10.1093/annonc/mdg461.
   Stone S F, 2002, HIV Med, V3, P21, DOI 10.1046/j.1464-2662.2001.00096.x.}},
Number-of-Cited-References = {{10}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Aids}},
Doc-Delivery-Number = {{213DA}},
Unique-ID = {{ISI:000249645000022}},
}

@article{ ISI:000207455600027,
Author = {Verkhedkar, Ketki D. and Raman, Karthik and Chandra, Nagasuma R. and
   Vishveshwara, Saraswathi},
Title = {{Metabolome Based Reaction Graphs of M-tuberculosis and M-leprae: A
   Comparative Network Analysis}},
Journal = {{PLOS ONE}},
Year = {{2007}},
Volume = {{2}},
Number = {{9}},
Month = {{SEP 12}},
Abstract = {{Background. Several types of networks, such as transcriptional,
   metabolic or protein-protein interaction networks of various organisms
   have been constructed, that have provided a variety of insights into
   metabolism and regulation. Here, we seek to exploit the reaction-based
   networks of three organisms for comparative genomics. We use concepts
   from spectral graph theory to systematically determine how differences
   in basic metabolism of organisms are reflected at the systems level and
   in the overall topological structures of their metabolic networks.
   Methodology/Principal Findings. Metabolome-based reaction networks of
   Mycobacterium tuberculosis, Mycobacterium leprae and Escherichia coli
   have been constructed based on the KEGG LIGAND database, followed by
   graph spectral analysis of the network to identify hubs as well as the
   sub-clustering of reactions. The shortest and alternate paths in the
   reaction networks have also been examined. Sub-cluster profiling
   demonstrates that reactions of the mycolic acid pathway in mycobacteria
   form a tightly connected sub-cluster. Identification of hubs reveals
   reactions involving glutamate to be central to mycobacterial metabolism,
   and pyruvate to be at the centre of the E. coli metabolome. The analysis
   of shortest paths between reactions has revealed several paths that are
   shorter than well established pathways. Conclusions. We conclude that
   severe downsizing of the leprae genome has not significantly altered the
   global structure of its reaction network but has reduced the total
   number of alternate paths between its reactions while keeping the
   shortest paths between them intact. The hubs in the mycobacterial
   networks that are absent in the human metabolome can be explored as
   potential drug targets. This work demonstrates the usefulness of
   constructing metabolome based networks of organisms and the feasibility
   of their analyses through graph spectral methods. The insights obtained
   from such studies provide a broad overview of the similarities and
   differences between organisms, taking comparative genomics studies to a
   higher dimension.}},
Publisher = {{PUBLIC LIBRARY SCIENCE}},
Address = {{185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Vishveshwara, S (Reprint Author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.
   Verkhedkar, Ketki D.; Vishveshwara, Saraswathi, Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.
   Raman, Karthik; Chandra, Nagasuma R., Indian Inst Sci, Bioinformat Ctr, Supercomp Educ \& Res Ctr, Bangalore 560012, Karnataka, India.}},
DOI = {{10.1371/journal.pone.0000881}},
Article-Number = {{e881}},
ISSN = {{1932-6203}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Author-Email = {{sv@mbu.iisc.ernet.in}},
ORCID-Numbers = {{Raman, Karthik/0000-0002-9311-7093}},
Funding-Acknowledgement = {{computational genomics initiative at IISc; Department of Biotechnology,
   India; Indian Government agency}},
Funding-Text = {{Funding: Support was obtained from the computational genomics initiative
   at IISc, funded by Department of Biotechnology, India. This support was
   an academic research grant from an Indian Government agency, and no
   financial claims are associated with it.}},
Cited-References = {{Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019.
   Barabasi AL, 2002, LINKED NEW SCI NETWO.
   Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3.
   Becker SA, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180/5/8.
   Bilke S, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.036106.
   Brinda KV, 2005, BIOPHYS J, V89, P4159, DOI 10.1529/biophysj.105.064485.
   Bu DB, 2003, NUCLEIC ACIDS RES, V31, P2443, DOI 10.1093/nar/gkg340.
   Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006.
   Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528.
   Eisenberg E, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.138701.
   FELIX L, 2007, BIOMOL ENG IN PRESS, DOI DOI 10.1016/J.BIOENG.2007.02.008.
   Fell DA, 2000, NAT BIOTECHNOL, V18, P1121, DOI 10.1038/81025.
   FLOYD RW, 1962, COMMUN ACM, V5, P345, DOI 10.1145/367766.368168.
   Gansner ER, 2000, SOFTWARE PRACT EXPER, V30, P1203, DOI 10.1002/1097-024X(200009)30:11<1203::AID-SPE338>3.3.CO;2-E.
   Goto S, 2002, NUCLEIC ACIDS RES, V30, P402, DOI 10.1093/nar/30.1.402.
   GROSS J, 1999, DISCRETE MATH ITS AP.
   Guimera R, 2005, NATURE, V433, P895, DOI 10.1038/nature03288.
   HALL KM, 1970, MANAGE SCI, V17, P219, DOI 10.1287/mnsc.17.3.219.
   Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555.
   Holme P, 2003, BIOINFORMATICS, V19, P532, DOI 10.1093/bioinformatics/btg033.
   Jeong H, 2000, NATURE, V407, P651.
   Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138.
   Kanna N, 1999, J MOL BIOL, V292, P441, DOI 10.1006/jmbi.1999.3058.
   KETTNER C, 2007, IN SILICO BIOL, V7.
   KIM TY, 2007, BIOTECHNOLO IN PRESS, DOI DOI 10.1002/BIT.21433.
   Krishnadev O, 2005, PROTEINS, V61, P152, DOI 10.1002/prot.20532.
   Kunin V, 2004, MOL BIOL EVOL, V21, P1171, DOI 10.1093/molbev/msh085.
   Liang Z, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-457.
   Luscombe NM, 2004, NATURE, V431, P308, DOI 10.1038/nature02782.
   Ma HW, 2003, BIOINFORMATICS, V19, P270, DOI 10.1093/bioinformatics/19.2.270.
   Ma HW, 2003, BIOINFORMATICS, V19, P1423, DOI 10.1093/bioinformatics/btg177.
   Papin JA, 2004, TRENDS BIOCHEM SCI, V29, P641, DOI 10.1016/j.tibs.2004.10.001.
   PARK D, 2004, BIOINFORMATICS, V21, P3234.
   Park J, 2001, Genome Inform, V12, P135.
   Patra SM, 2000, BIOPHYS CHEM, V84, P13, DOI 10.1016/S0301-4622(99)00134-9.
   Rahman SA, 2006, BIOINFORMATICS, V22, P1767, DOI 10.1093/bioinformatics/btl181.
   Raman K, 2005, PLOS COMPUT BIOL, V1, P349, DOI 10.1371/journal.pcbi.0010046.
   Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374.
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x.
   Sen TZ, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-355.
   Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881.
   Sistla RK, 2005, PROTEINS, V59, P616, DOI 10.1002/prot.20444.
   Takayama K, 2005, CLIN MICROBIOL REV, V18, P81, DOI 10.1128/CMR.18.1.81-101.2005.
   Uetz P, 2000, NATURE, V403, P623.
   van Helden J, 2002, E SCHERING RES FDN W, V38, P245.
   Vishveshwara S., 2002, J THEOR COMPUT CHEM, V1, P187, DOI DOI 10.1142/S0219633602000117.
   Wagner A, 2001, P ROY SOC B-BIOL SCI, V268, P1803.
   Wolf YI, 2002, BIOESSAYS, V24, P105, DOI 10.1002/bies.10059.
   Wuchty S, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-8.
   Zhao J, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-386.}},
Number-of-Cited-References = {{50}},
Times-Cited = {{23}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{PLoS One}},
Doc-Delivery-Number = {{V10HR}},
Unique-ID = {{ISI:000207455600027}},
}

@article{ ISI:000249513000017,
Author = {Sacco, Emmanuelle and Covarrubias, Adrian Suarez and O'Hare, Helen M.
   and Carroll, Paul and Eynard, Nathalie and Jones, T. Alwyn and Parish,
   Tanya and Daffe, Marnadou and Baeckbro, Kristina and Quemard, Annaik},
Title = {{The missing piece of the type II fatty acid synthase system from
   Mycobacterium tuberculosis}},
Journal = {{PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA}},
Year = {{2007}},
Volume = {{104}},
Number = {{37}},
Pages = {{14628-14633}},
Month = {{SEP 11}},
Abstract = {{The Mycobacterium tuberculosis fatty acid synthase type II (FAS-II)
   system has the unique property of producing unusually long-chain fatty
   acids involved in the biosynthesis of mycolic acids, key molecules of
   the tubercle bacillus. The enzyme(s) responsible for dehydration of
   (3R)-hydroxyacyl-ACP during the elongation cycles of the mycobacterial
   FAS-II remained unknown. This step is classically catalyzed by FabZ- and
   FabA-type enzymes in bacteria, but no such proteins are present in
   mycobacteria. Bioinformatic analyses and an essentiality study allowed
   the identification of a candidate protein cluster, Rv0635-M636-110637.
   Its expression in recombinant Escherichia coli strains leads to the
   formation of two heterodimers, Rv0635-Rv0636 (HadAB) and Rv0636-Rv0637
   (HadBC), which also occurs in Mycobacterium smegmatis, as shown by
   split-Trp assays. Both heterodimers exhibit the enzymatic properties
   expected for mycobacterial FAS-II dehydratases: a marked specificity for
   both long-chain ( >=C-12) and ACP-linked substrates. Furthermore, they
   function as 3-hydroxyacyl clehydratases when coupled with MabA and InhA
   enzymes from the M. tuberculosis FAS-II system. HadAB and HadBC are the
   long-sought (3R)-hydroxyacyl-ACP dehydratases. The correlation between
   the substrate specificities of these enzymes, the organization of the
   orthologous gene cluster in different Corynebacterineae, and the
   structure of their mycolic acids suggests distinct roles for both
   heterodimers during the elongation process. This work describes
   bacterial monofunctional (3R)-hydroxyacyl-ACP clehydratases belonging to
   the hydratase 2 family. Their original structure and the fact that they
   are essential for M. tuberculosis survival make these enzymes very good
   candidates for the development of antimycobacterial drugs.}},
Publisher = {{NATL ACAD SCIENCES}},
Address = {{2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Queemard, A (Reprint Author), CNRS, Inst Pharmacol \& Biol Struct, 205 Route Narbonne, F-31077 Toulouse, France.
   CNRS, Inst Pharmacol \& Biol Struct, Dept Mec Mol Infect Mycobacter, F-31077 Toulouse, France.
   Uppsala Univ, Ctr Biomed, Dept Cell \& Mol Biol, SE-75124 Uppsala, Sweden.
   Ecole Polytech Fed Lausanne, Inst Chem Sci \& Engn, CH-1015 Lausanne, Switzerland.
   Ctr Infect Dis, Inst Cell \& Mol Biol, London E1 2AT, England.}},
DOI = {{10.1073/pnas.0704132104}},
ISSN = {{0027-8424}},
Keywords = {{(3R)-hydroxyacyl-ACP dehydratase; hydratase 2; mycolic acid
   biosynthesis; fatty acid elongation; hot dog fold}},
Keywords-Plus = {{ACYL CARRIER PROTEIN; CONSERVED HYPOTHETICAL PROTEIN; ENZYMATIC
   CHARACTERIZATION; ESCHERICHIA-COLI; MYCOLIC ACIDS; CELL-LYSIS;
   BIOSYNTHESIS; SMEGMATIS; KASB; HYDRATASE}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Author-Email = {{annaik.quemard@ipbs.fr}},
ResearcherID-Numbers = {{O'Hare, Helen/G-1528-2012}},
ORCID-Numbers = {{O'Hare, Helen/0000-0002-8666-7433}},
Cited-References = {{Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3.
   Bhatt A, 2005, J BACTERIOL, V187, P7596, DOI 10.1128/JB.187.22.7596-7606.2005.
   Bhatt A, 2007, P NATL ACAD SCI USA, V104, P5157, DOI 10.1073/pnas.0608654104.
   Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1.
   Castell A, 2005, PROTEIN SCI, V14, P1850, DOI 10.1110/ps.051442305.
   Dubnau E, 2000, MOL MICROBIOL, V36, P630, DOI 10.1046/j.1365-2958.2000.01882.x.
   Gao LY, 2003, MOL MICROBIOL, V49, P1547, DOI 10.1046/j.1365-2958.2003.03667.x.
   Hisano T, 2003, J BIOL CHEM, V278, P617, DOI 10.1074/jbc.M.205484200.
   Johansson P, 2006, PROTEIN SCI, V15, P2300, DOI 10.1110/ps.062309306.
   JOSHI AK, 1993, J BIOL CHEM, V268, P22508.
   Kastaniotis AJ, 2004, MOL MICROBIOL, V53, P1407, DOI 10.1111/j.1365-2958.2004.04191.x.
   Koski MK, 2004, J BIOL CHEM, V279, P24666, DOI 10.1074/jbc.M400293200.
   Kremer L, 2002, BIOCHEM J, V364, P423, DOI 10.1042/BJ20011628.
   Marrakchi H, 2002, MICROBIOL-SGM, V148, P951.
   Parish T, 2000, MICROBIOL-UK, V146, P1969.
   Parish T, 2007, J BACTERIOL, V189, P3721, DOI 10.1128/JB.01740-06.
   Qin YM, 2000, J BIOL CHEM, V275, P4965, DOI 10.1074/jbc.275.7.4965.
   QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004.
   ROCK CO, 1979, J BIOL CHEM, V254, P7123.
   Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2.
   Sacco E, 2007, BBA-PROTEINS PROTEOM, V1774, P303, DOI 10.1016/j.bbapap.2006.11.016.
   Schaeffer ML, 2001, J BIOL CHEM, V276, P47029, DOI 10.1074/jbc.M108903200.
   Tafelmeyer P, 2004, CHEM BIOL, V11, P681, DOI 10.1016/j.chembiol.2004.02.026.
   Vilcheze C, 2000, J BACTERIOL, V182, P4059, DOI 10.1128/JB.182.14.4059-4067.2000.
   World Health Organization, 2004, 3 WHO.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{74}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{11}},
Journal-ISO = {{Proc. Natl. Acad. Sci. U. S. A.}},
Doc-Delivery-Number = {{211GT}},
Unique-ID = {{ISI:000249513000017}},
}

@article{ ISI:000249274100016,
Author = {Selvaraj, M. and Roy, S. and Singh, N. S. and Sangeetha, R. and
   Varshney, U. and Vijayan, M.},
Title = {{Structural plasticity and enzyme action: Crystal structures of
   Mycobacterium tuberculosis peptidyl-tRNA hydrolase}},
Journal = {{JOURNAL OF MOLECULAR BIOLOGY}},
Year = {{2007}},
Volume = {{372}},
Number = {{1}},
Pages = {{186-193}},
Month = {{SEP 7}},
Abstract = {{Peptidyl-tRNA hydrolase cleaves the ester bond between tRNA and the
   attached peptide in peptidyl-tRNA in order to avoid the toxicity
   resulting from its accumulation and to free the tRNA available for
   further rounds in protein synthesis. The structure of the enzyme from
   Mycobacteritan tuberculosis has been determined in three crystal forms.
   This structure and the structure of the enzyme frorn Escherichia coli in
   its crystal differ substantially on account of the binding of the C
   terminus of the E. coli enzyme to the peptide-binding site of a
   neighboring molecule in the crystal. A detailed examination of this
   difference led to an elucidation of the plasticity of the binding site
   of the enzyme. The peptide-binding site of the enzyme is a cleft between
   the body, of the molecule and a polypepticle Y stretch involving a loop
   and a helix. This stretch is in the open conformation when the enzyme is
   in the free state as in the crystals of M. tuberculosis peptidyl-tRNA
   hydrolase. Furthermore, there is no physical continuity between the tRNA
   and the peptide-binding sites. The molecule in the E. coli crystal
   mimics the peptide-bound enzyme molecule. The peptide stretch referred
   to earlier now closes on the bound peptide. Concurrently, a channel
   connecting the tRNA and the peptide-binding site opens primarily through
   the concerted movement of two residues. Thus, the crystal structure of
   M. tuberculosis peptidyl-tRNA hydrolase when compared with the crystal
   structure of the E. coli enzyme, leads to a model of structural changes
   associated with enzyme action on the basis of the plasticity of the
   molecule. (c) 2007 Elsevier Ltd. All rights reserved.}},
Publisher = {{ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD}},
Address = {{24-28 OVAL RD, LONDON NW1 7DX, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Vijayan, M (Reprint Author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.
   Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.
   Indian Inst Sci, Microbiol \& Cell Biol Lab, Bangalore 560012, Karnataka, India.}},
DOI = {{10.1016/j.jmb.2007.06.053}},
ISSN = {{0022-2836}},
Keywords = {{protein synthesis; peptide-binding site; tRNA-binding site; open and
   closed conformation; mobility of active site}},
Keywords-Plus = {{BOVINE BETA-LACTOGLOBULIN; X-RAY-ANALYSIS; ESCHERICHIA-COLI;
   PROTEIN-SYNTHESIS; ANGSTROM RESOLUTION; TANFORD TRANSITION; BINDING
   PROTEIN; SITE; RECA; IDENTIFICATION}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{mv@mbu.iisc.emet.in}},
ResearcherID-Numbers = {{Varshney, Umesh/A-8062-2009}},
Cited-References = {{ATHERLY AG, 1978, NATURE, V275, P769, DOI 10.1038/275769a0.
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254.
   Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500.
   Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729.
   Collaborative Computational Project Number 4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112.
   CUZIN F, 1967, P NATL ACAD SCI USA, V58, P2079, DOI 10.1073/pnas.58.5.2079.
   Das G, 2006, MICROBIOL-SGM, V152, P2191, DOI 10.1099/mic.0.29024-0.
   Das S, 2006, ACTA CRYSTALLOGR D, V62, P628, DOI 10.1107/S0907444906012728.
   Datta S, 2003, J BACTERIOL, V185, P4280, DOI 10.1128/JB.185.14.4280-4284.2003.
   Datta S, 2000, NUCLEIC ACIDS RES, V28, P4964, DOI 10.1093/nar/28.24.4964.
   de Pereda JM, 2004, J BIOL CHEM, V279, P8111, DOI 10.1074/jbc.M311449200.
   DEGROOT N, 1969, BIOCHIM BIOPHYS ACTA, V186, P286, DOI 10.1016/0005-2787(69)90006-9.
   DUTKA S, 1993, NUCLEIC ACIDS RES, V21, P4025, DOI 10.1093/nar/21.17.4025.
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158.
   Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412.
   Fromant M, 2005, BIOCHEMISTRY-US, V44, P4294, DOI 10.1021/bi047711k.
   Fromant M, 1999, BIOCHEMISTRY-US, V38, P4982, DOI 10.1021/bi982657r.
   GARCIAVILLEGAS MR, 1991, EMBO J, V10, P3549.
   Goodall JJ, 2004, BIOCHEMISTRY-US, V43, P4583, DOI 10.1021/bi0302200.
   Kossel H., 1968, J MOL BIOL, V273, P389.
   Krishna R, 2006, NUCLEIC ACIDS RES, V34, P2186, DOI 10.1093/nar/gkl107.
   LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351.
   Liang J, 1998, PROTEIN SCI, V7, P1884.
   Maniatis T, 1982, MOL CLONING LAB MANU.
   MENNINGER JR, 1976, J BIOL CHEM, V251, P3392.
   Oliveira KMG, 2001, EUR J BIOCHEM, V268, P477, DOI 10.1046/j.1432-1327.2001.01918.x.
   Ostheimer GJ, 2005, J MOL BIOL, V345, P51, DOI 10.1016/j.jmb.2004.10.032.
   Powers R, 2005, PROTEIN SCI, V14, P2849, DOI 10.1110/ps.051666705.
   Qin BY, 1998, BIOCHEMISTRY-US, V37, P14014, DOI 10.1021/bi981016t.
   Roy S, 2004, J MOL BIOL, V339, P1103, DOI 10.1016/j.jmb.2004.04.042.
   Ruzheinikov SN, 2004, J MOL BIOL, V339, P265, DOI 10.1016/j.jmb.2004.03.043.
   Saikrishnan K, 2005, J MOL BIOL, V345, P29, DOI 10.1016/j.jmb.2004.10.034.
   Saikrishnan K, 2003, J MOL BIOL, V331, P385, DOI 10.1016/S0022-2836(03)00729-0.
   Schmitt E, 1997, EMBO J, V16, P4760, DOI 10.1093/emboj/16.15.4760.
   Selvaraj M, 2006, ACTA CRYSTALLOGR F, V62, P913, DOI 10.1107/S1744309106031125.
   SHILOACH J, 1975, FEBS LETT, V57, P130, DOI 10.1016/0014-5793(75)80700-9.
   Singh NS, 2004, NUCLEIC ACIDS RES, V32, P6028, DOI 10.1093/nar/gkh924.
   Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{43}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{J. Mol. Biol.}},
Doc-Delivery-Number = {{207TN}},
Unique-ID = {{ISI:000249274100016}},
}

@article{ ISI:000250030800001,
Author = {Stevenson, Catherine R. and Forouhi, Nita G. and Roglic, Gojka and
   Williams, Brian G. and Lauer, Jeremy A. and Dye, Chirstopher and Unwin,
   Nigel},
Title = {{Diabetes and tuberculosis: the impact of the diabetes epidemic on
   tuberculosis incidence}},
Journal = {{BMC PUBLIC HEALTH}},
Year = {{2007}},
Volume = {{7}},
Month = {{SEP 6}},
Abstract = {{Background: Tuberculosis ( TB) remains a major cause of mortality in
   developing countries, and in these countries diabetes prevalence is
   increasing rapidly. Diabetes increases the risk of TB. Our aim was to
   assess the potential impact of diabetes as a risk factor for incident
   pulmonary tuberculosis, using India as an example.
   Methods: We constructed an epidemiological model using data on
   tuberculosis incidence, diabetes prevalence, population structure, and
   relative risk of tuberculosis associated with diabetes. We evaluated the
   contribution made by diabetes to both tuberculosis incidence, and to the
   difference between tuberculosis incidence in urban and rural areas.
   Results: In India in 2000 there were an estimated 20.7 million adults
   with diabetes, and 900,000 incident adult cases of pulmonary
   tuberculosis. Our calculations suggest that diabetes accounts for 14.8\%
   ( uncertainty range 7.1\% to 23.8\%) of pulmonary tuberculosis and
   20.2\% ( 8.3\% to 41.9\%) of smear- positive ( i. e. infectious)
   tuberculosis. We estimate that the increased diabetes prevalence in
   urban areas is associated with a 15.2\% greater smear- positive
   tuberculosis incidence in urban than rural areas - over a fifth of the
   estimated total difference.
   Conclusion: Diabetes makes a substantial contribution to the burden of
   incident tuberculosis in India, and the association is particularly
   strong for the infectious form of tuberculosis. The current diabetes
   epidemic may lead to a resurgence of tuberculosis in endemic regions,
   especially in urban areas. This potentially carries a risk of global
   spread with serious implications for tuberculosis control and the
   achievement of the United Nations Millennium Development Goals.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Unwin, N (Reprint Author), Univ Newcastle Upon Tyne, Inst Hlth \& Soc, Newcastle Upon Tyne NE1 7RU, Tyne \& Wear, England.
   Univ Newcastle Upon Tyne, Inst Hlth \& Soc, Newcastle Upon Tyne NE1 7RU, Tyne \& Wear, England.
   MRC, Epidemiol Unit, Cambridge, England.
   WHO, Dept Chron Dis \& Hlth Promot, CH-1211 Geneva, Switzerland.}},
DOI = {{10.1186/1471-2458-7-234}},
Article-Number = {{234}},
ISSN = {{1471-2458}},
Keywords-Plus = {{IMPAIRED GLUCOSE-TOLERANCE; TEMPORAL-CHANGES; SOUTHERN INDIA;
   PREVALENCE; POPULATION; BURDEN; RISK}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{n.c.unwin@ncl.ac.uk
   nf250@medschl.cam.ac.uk
   roglicg@who.int
   williamsbg@who.int
   lauerj@who.int
   dyec@who.int
   n.c.unwin@ncl.ac.uk}},
ORCID-Numbers = {{Forouhi, Nita/0000-0002-5041-248X}},
Funding-Acknowledgement = {{Medical Research Council {[}MC\_U106179471]}},
Cited-References = {{Alisjahbana B, 2006, INT J TUBERC LUNG D, V10, P696.
   ALISJAHBANA B, 2007, IN PRESS CLIN INFECT.
   {*}CDCP, 2003, REP TUB US 2003.
   Chadha VK, 2005, INT J TUBERC LUNG D, V9, P116.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Department of Health, 2004, STOPP TUB ENGL ACT P.
   Dixon B, 2007, LANCET INFECT DIS, V7, P444, DOI 10.1016/S1473-3099(07)70144-5.
   Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767.
   Ezung Thungchanbemo, 2002, J Indian Med Assoc, V100, P378.
   GOPI PG, 2006, J TUBERCULOSIS LUNG, V10, P115.
   Gothi D, 2004, POSTGRAD MED J, V80, P97, DOI 10.1136/pmj.2003.008185.
   Gupta A, 2003, DIABETES RES CLIN PR, V61, P69, DOI 10.1016/S0168-8227(03)00085-8.
   Hopewell PC, 2006, LANCET INFECT DIS, V6, P710, DOI 10.1016/S1473-3099(06)70628-4.
   Tuberculosis Coalition for Technical Assistance, 2006, TUB COAL TECHN ASS.
   Kim SJ, 1995, TUBERCLE LUNG DIS, V76, P529, DOI 10.1016/0962-8479(95)90529-4.
   Last J.M., 2001, DICT EPIDEMIOLOGY.
   LUNTZ G, 1954, Lancet, V266, P973.
   Mohan V, 2001, DIABETIC MED, V18, P280, DOI 10.1046/j.1464-5491.2001.00421.x.
   MURRAY CJ, 1993, DIS CONTROL PRIORITI.
   Nolan CM, 2005, AM J RESP CRIT CARE, V172, P1169, DOI 10.1164/rccm.2508001.
   Ponce-De-Leon A, 2004, DIABETES CARE, V27, P1584, DOI 10.2337/diacare.27.7.1584.
   Ramachandran A, 2004, DIABETOLOGIA, V47, P860, DOI 10.1007/s00125-004-1387-6.
   Ramachandran A, 2002, DIABETES RES CLIN PR, V58, P55, DOI 10.1016/S0168-8227(02)00125-0.
   Ramachandran A, 2001, DIABETOLOGIA, V44, P1094, DOI 10.1007/s001250100627.
   Raviglione MC, 2006, LANCET, V367, P952, DOI 10.1016/S0140-6736(06)68392-X.
   Sadikot SM, 2004, DIABETES RES CLIN PR, V66, P301, DOI 10.1016/j.diabres.2004.04.008.
   Sharma SK, 2004, INDIAN J MED RES, V120, P316.
   Shetty N, 2006, INT J TUBERC LUNG D, V10, P80.
   STEVENSON CR, 2007, IN PRESS CHRONIC ILL.
   Styblo K., 1985, B INT UNION TUBERC, V60, P117.
   UN, 2006, WORLD POP PROSP.
   World Health Organization, 2006, GLOB TB DAT.
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{139}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{17}},
Journal-ISO = {{BMC Public Health}},
Doc-Delivery-Number = {{218QU}},
Unique-ID = {{ISI:000250030800001}},
}

@article{ ISI:000207455500010,
Author = {Miranda, Abraham and Morgan, Meade and Jamal, Leda and Laserson, Kayla
   and Barreira, Draurio and Silva, Guida and Santos, Joseney and Wells,
   Charles and Paine, Patricia and Garrett, Denise},
Title = {{Impact of Antiretroviral Therapy on the Incidence of Tuberculosis: The
   Brazilian Experience, 1995-2001}},
Journal = {{PLOS ONE}},
Year = {{2007}},
Volume = {{2}},
Number = {{9}},
Month = {{SEP 5}},
Abstract = {{Background. The human immunodeficiency virus (HIV) fuels tuberculosis
   (TB) epidemics. In controlled clinical trials, antiretroviral therapy
   (ART) reduces TB incidence in HIV-infected patients. In this study we
   determine if, under programmatic conditions, Brazil's policy of
   universal ART access has impacted TB incidence among HIV-infected
   patients. Methods. We abstracted clinical information from records of
   HIV-infected patients managed in the public sector in 11 Brazilian
   states between 1/1/1995 and 12/31/2001. Case ascertainment (TB and HIV)
   utilized guidelines (with added stringency) published by Brazil's
   Ministry of Health. We determined TB incidence and hazards ratio (HR)
   for ART-naive and ART-treated {[}including highly active ART (HAART)]
   patients employing Cox proportional hazards analysis. Results.
   Information from 463 HIV-infected patients met study criteria. The
   median age of the study population was 34 years, 70\% were male, and
   mean follow-up to primary endpoints-TB, death, and last clinic visit-was
   330, 1059, and 1125 days, respectively. Of the 463 patients, 76 (16\%)
   remained ART-naive. Of the patients who never received HAART (n = 157)
   81 were treated with ART non-HAART. Of the patients who received any ART
   (n = 387), 306 were treated with HAART (includes those patients who
   later switched from ART non-HAART to HAART). Tuberculosis developed in
   39/463 (8\%) patients. Compared to HAART- and ART non-HAART-treated
   patient groups, TB incidence was 10- (p<0.001) and 2.5-fold (p = 0.03)
   higher in ART-naive patients, respectively. The median baseline absolute
   CD4+ T-lymphocyte count for patients who developed TB was not
   significantly different from that of patients who remained TB free. In
   multivariate analysis, the incidence of TB was statistically
   significantly lower in HAART- treated {[}HR 0.2; 95\% (CI 0.1, 0.6);
   p<0.01] compared to ART naive patients. A baseline CD4+ T-lymphocyte
   count <200 cells/mm(3) {[}HR 2.5; (95\% CI 1.2, 5.4); p<0.01], prior
   hospitalization {[}HR 4.2; (95\% CI 2.0, 8.8); p<0.001], prior
   incarceration {[}HR 4.1; 95\% CI 1.6, 10.3); p<0.01], and a positive
   tuberculin skin test {[}HR 3.1; (95\% CI 1.1, 9.0); p = 0.04] were
   independently and positively associated with incident TB. Conclusion. In
   this population-based study we demonstrate an 80\% reduction in incident
   TB, under programmatic conditions, in HAART- treated HIV-infected
   patients compared to ART-naive patients.}},
Publisher = {{PUBLIC LIBRARY SCIENCE}},
Address = {{185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Miranda, A (Reprint Author), US Ctr Dis Control \& Prevent, Global AIDS Program, Atlanta, GA USA.
   Miranda, Abraham; Morgan, Meade; Laserson, Kayla, US Ctr Dis Control \& Prevent, Global AIDS Program, Atlanta, GA USA.
   Miranda, Abraham; Wells, Charles, US Ctr Dis Control \& Prevent, Div TB Eliminat, Atlanta, GA USA.
   Jamal, Leda, State Sao Paulo Dept Hlth, Ctr Referencia \& Treinamento DST AIDS, STD AIDS Program State Sao Paulo, Sao Paulo, Brazil.
   Laserson, Kayla, US Ctr Dis Control \& Prevent, Off Director, Off Global Hlth Coordinator, Atlanta, GA USA.
   Barreira, Draurio, Brazil Minist Hlth, Programa Nacl DST AIDS, Brasilia, DF, Brazil.
   Silva, Guida; Santos, Joseney; Paine, Patricia; Garrett, Denise, Brazil Minist Hlth, Programa Nacl Controle TB, Brasilia, DF, Brazil.
   Garrett, Denise, Int Union TB \& Lung Dis, Paris, France.}},
DOI = {{10.1371/journal.pone.0000826}},
Article-Number = {{e826}},
ISSN = {{1932-6203}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Author-Email = {{aci5@cdc.gov
   garrettdo@yahoo.com}},
Funding-Acknowledgement = {{The US Agency for International Development (USAID)}},
Funding-Text = {{The US Agency for International Development (USAID) provided financial
   support for this project but had no role in the design or conduct of the
   study, in the collection, analysis, or interpretation of the data, nor
   in the preparation, review, or approval of the manuscript.}},
Cited-References = {{Badri M, 2002, INT J TUBERC LUNG D, V6, P231.
   Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3.
   Bleed D, 2000, Curr Opin Pulm Med, V6, P174, DOI 10.1097/00063198-200005000-00002.
   Bucher HC, 1999, AIDS, V13, P501, DOI 10.1097/00002030-199903110-00009.
   Carmody ER, 2003, TROP MED INT HEALTH, V8, P378, DOI 10.1046/j.1365-3156.2003.01046.x.
   Chintu C, 2004, LANCET, V364, P1865, DOI 10.1016/S0140-6736(04)17442-4.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Corbett EL, 2002, CLIN INFECT DIS, V34, P1251, DOI 10.1086/339540.
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404.
   Dheda K, 2004, J INFECT DIS, V190, P1670, DOI 10.1086/424676.
   DIPERRI G, 1989, LANCET, V2, P1502.
   ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502.
   Fitzgerald DW, 2000, LANCET, V356, P1470, DOI 10.1016/S0140-6736(00)02870-1.
   Girardi E, 2001, J ACQ IMMUN DEF SYND, V26, P326.
   Girardi E, 2000, AIDS, V14, P1985, DOI 10.1097/00002030-200009080-00015.
   GODREYFAUSSETT P, 2003, TUBERCULOSIS, V83, P68.
   Grant A D, 1997, AIDS, V11 Suppl B, pS43.
   Chaisson R. E, 2000, TUBERCULOSIS COMPREH, P525.
   Hung CC, 2003, AIDS, V17, P2615, DOI 10.1097/01.aids.0000088220.77946.19.
   Jones JL, 2000, INT J TUBERC LUNG D, V4, P1026.
   JORDA R, 2002, BRIT MED J, V325, P757.
   Lawn SD, 2005, AIDS, V19, P1113, DOI 10.1097/01.aids.0000176211.08581.5a.
   Levi GC, 2002, AIDS, V16, P2373, DOI 10.1097/00002030-200212060-00001.
   Lienhardt C, 1997, INT J TUBERC LUNG D, V1, P196.
   Lipman M, 2006, CURR OPIN INFECT DIS, V19, P20, DOI 10.1097/01.qco.0000200543.80712.01.
   Maher D, 2005, INT J TUBERC LUNG D, V9, P17.
   {*}MIN SAUD BRAS PRO, 2006, REC TER ANT AD AD IN.
   {*}MIN SAUD BRAS SEC, 2002, MAN TECN CONTR TUB C.
   Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2.
   MUKADI Y, 1993, LANCET, V342, P143, DOI 10.1016/0140-6736(93)91346-N.
   NUNN P, 1992, AM REV RESPIR DIS, V146, P849.
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301.
   Raviglione M C, 1997, AIDS, V11 Suppl B, pS115.
   Santoro-Lopes G, 2002, CLIN INFECT DIS, V34, P543, DOI 10.1086/338641.
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901.
   Shelburne SA, 2005, AIDS, V19, P399, DOI 10.1097/01.aids.0000161769.06158.8a.
   Sonnenberg P, 2001, LANCET, V358, P1687, DOI 10.1016/S0140-6736(01)06712-5.
   WHO, 2006, TUB INF CONTR ER EXP.
   World Health Organization, 2002, WHOCDSTB2002296.
   {*}WHO, 1995, WHOHTMTB2004336, P27.
   {*}WHO, 2002, WHOHTMTB2004330.
   WHO, 1999, WKLY EPIDEMIOL REC, V74, P385.
   World Health Organization, 1990, WKLY EPIDEMIOL REC, V65, P221.
   WHO, 2007, WHOHTMTB2007376.
   World Health Organization, 2002, SCAL ANT THER RES LT.
   {*}WHO, 2004, 3 5 PROGR REP.
   Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0.
   Williams BG, 2003, SCIENCE, V301, P1535, DOI 10.1126/science.1086845.
   Wolday D, 2003, Int J Tuberc Lung Dis, V7, P110.}},
Number-of-Cited-References = {{49}},
Times-Cited = {{43}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{PLoS One}},
Doc-Delivery-Number = {{V10HQ}},
Unique-ID = {{ISI:000207455500010}},
}

@article{ ISI:000250033400001,
Author = {Pathak, Divya and Chakravorty, Soumitesh and Hanif, Mahmud and Tyagi,
   Jaya Sivaswami},
Title = {{Lysis of tubercle bacilli in fresh and stored sputum specimens:
   implications for diagnosing tuberculosis in stored and paucibacillary
   specimens by PCR}},
Journal = {{BMC MICROBIOLOGY}},
Year = {{2007}},
Volume = {{7}},
Month = {{SEP 4}},
Abstract = {{Background: Nucleic acid amplification techniques are being used
   increasingly in diagnosing tuberculosis. In developing countries
   clinical samples are often stored for subsequent analysis since
   molecular tests are conducted at only a limited number of laboratories.
   This study was conducted to assess the speed at which mycobacteria
   undergo autolysis and free DNA is detected in the supernatant during
   low-temperature storage.
   Results: Eighty-seven smear positive sputa from tuberculosis patients
   were analysed immediately and after storage at -20 degrees C. Timelines
   of 1 and 2 months were selected to assess the maximum extent of DNA loss
   that occurred during storage. All samples remained PCR- and
   smear-positive at 1 month and only 1 sample turned negative after 2
   months. Bacterial lysis in the specimens was demonstrated by PCR
   analysis of supernatant fractions; 53\% of the freshly analysed samples
   contained mycobacterial DNA in supernatants. PCR positivity increased
   significantly during storage ( to 69\% and 77\% after 1 and 2 months of
   storage, respectively, P < 0.0001). Storage-associated bacterial lysis
   was accompanied by a decrease in smear grade status in 28 of 87 samples
   ( P < 0.0001 after 2 months of storage) and a significant
   storage-associated reduction in bacterial numbers in the remaining
   samples.
   Conclusion: We conclude that ( i) freshly isolated sputum contains both
   intact and lysed mycobacteria, (ii) lysis increased during storage and
   (iii) supernatant fractions routinely discarded during sample processing
   contain mycobacterial DNA. We propose that supernatant is a valuable
   sample for PCR for both fresh and stored specimens, particularly those
   with a low bacterial load in addition to conventional sediment.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tyagi, JS (Reprint Author), All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, India.
   All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, India.
   New Delhi TB Ctr, New Delhi 110002, India.
   Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.
   Univ Med \& Dent New Jersey, Dept Med, Div Infect Dis, Ruy V Lourenco Ctr Study Emerging \& Reemerging Pa, Newark, NJ 07103 USA.}},
DOI = {{10.1186/1471-2180-7-83}},
Article-Number = {{83}},
ISSN = {{1471-2180}},
Keywords-Plus = {{POLYMERASE-CHAIN-REACTION; MYCOBACTERIUM-TUBERCULOSIS; SMEAR MICROSCOPY;
   PULMONARY TUBERCULOSIS; CULTURE; DNA; METHODOLOGY}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{divya7pathak@rediffmail.com
   chakraso@umdnj.edu
   hanifmahmud@hotmail.com
   jstyagi@aiims.ac.in}},
Cited-References = {{Banda HT, 2000, INT J TUBERC LUNG D, V4, P272.
   CARTER MJ, 1993, NUCLEIC ACIDS RES, V21, P1044, DOI 10.1093/nar/21.4.1044.
   Catanzaro A, 1997, AM J RESP CRIT CARE, V155, P1804.
   Chakravorty S, 2005, J CLIN MICROBIOL, V43, P2703, DOI 10.1128/JCM.6.2703-2708.2004.
   Chakravorty S, 2005, J CLIN MICROBIOL, V43, P2697, DOI 10.1128/JCM.43.6.2697-2702.2005.
   Chakravorty S, 2005, J CLIN MICROBIOL, V43, P4357, DOI 10.1128/JCM.43.9.4357-4362.2005.
   EISENACH KD, 1990, J INFECT DIS, V161, P977.
   NOORDHOEK GT, 1994, J CLIN MICROBIOL, V32, P277.
   Portillo-Gomez L, 2000, INT J TUBERC LUNG D, V4, P361.
   Selvakumar N, 2002, J CLIN MICROBIOL, V40, P3017, DOI 10.1128/JCM.40.8.3017-3020.2002.
   Singh KK, 2000, J CLIN PATHOL, V53, P355, DOI 10.1136/jcp.53.5.355.
   Traore I, 1981, Czech Med, V4, P203.
   YAJCO DM, 1995, J CLIN MICROBIOL, V33, P1944.}},
Number-of-Cited-References = {{13}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{BMC Microbiol.}},
Doc-Delivery-Number = {{218RU}},
Unique-ID = {{ISI:000250033400001}},
}

@article{ ISI:000249225000015,
Author = {Scott-Browne, James P. and Shafiani, Shahin and Tucker-Heard, Glady's
   and Ishida-Tsubota, Kumiko and Fontenot, Jason D. and Rudensky,
   Alexander Y. and Bevan, Michael J. and Urdahl, Kevin B.},
Title = {{Expansion and function of Foxp3-expressing T regulatory cells during
   tuberculosis}},
Journal = {{JOURNAL OF EXPERIMENTAL MEDICINE}},
Year = {{2007}},
Volume = {{204}},
Number = {{9}},
Pages = {{2159-2169}},
Month = {{SEP 3}},
Abstract = {{Mycobacterium tuberculosis ( Mtb) frequently establishes persistent
   infections that may be facilitated by mechanisms that dampen immunity. T
   regulatory ( T reg) cells, a subset of CD4(+) T cells that are essential
   for preventing autoimmunity, can also suppress antimicrobial immune
   responses. We use Foxp3-GFP mice to track the activity of T reg cells
   after aerosol infection with Mtb. We report that during tuberculosis, T
   reg cells proliferate in the pulmonary lymph nodes ( pLNs), change their
   cell surface phenotype, and accumulate in the pLNs and lung at a rate
   parallel to the accumulation of effector T cells. In the Mtb -infected
   lung, T reg cells accumulate in high numbers in all sites where CD4(+) T
   cells are found, including perivascular/ peribronchiolar regions and
   within lymphoid aggregates of granulomas. To determine the role of T reg
   cells in the immune response to tuberculosis, we generated mixed bone
   marrow chimeric mice in which all cells capable of expressing Foxp3
   expressed Thy1.1. When T reg cells were depleted by administration of
   anti-Thy1.1 before aerosol infection with Mtb, we observed similar to 1
   log less of colony-forming units of Mtb in the lungs. Thus, after
   aerosol infection, T reg cells proliferate and accumulate at sites of
   infection, and have the capacity to suppress immune responses that
   contribute to the control of Mtb.}},
Publisher = {{ROCKEFELLER UNIV PRESS}},
Address = {{1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Urdahl, KB (Reprint Author), Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
   Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
   Univ Washington, Dept Immunol, Seattle, WA 98195 USA.
   Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA.}},
DOI = {{10.1084/jem.20062105}},
ISSN = {{0022-1007}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; HELICOBACTER-PYLORI; DENDRITIC CELLS;
   CALMETTE-GUERIN; DC-SIGN; CYTOKINE PRODUCTION; IMMUNE-RESPONSES; BCG
   VACCINATION; INFECTED MICE; CUTTING EDGE}},
Research-Areas = {{Immunology; Research \& Experimental Medicine}},
Web-of-Science-Categories  = {{Immunology; Medicine, Research \& Experimental}},
Author-Email = {{kurdah@u.washington.edu}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}K08 AI055889, AI 055889-01, AI 19335, R01 AI019335]}},
Cited-References = {{Adams VC, 2004, EUR J IMMUNOL, V34, P631, DOI 10.1002/eji.200324659.
   Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211.
   ARMBRUSTER C, 1990, J INFECT DIS, V162, P1216.
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444.
   Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181.
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152.
   Bevan MJ, 2000, CURR BIOL, V10, pR338, DOI 10.1016/S0960-9822(00)00461-9.
   Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784.
   Caparros E, 2006, BLOOD, V107, P3950, DOI 10.1182/blood-2005-03-1252.
   Chan K, 2002, P NATL ACAD SCI USA, V99, P3920, DOI 10.1073/pnas.002024599.
   Chen XC, 2007, CLIN IMMUNOL, V123, P50, DOI 10.1016/j.clim.2006.11.009.
   Chiang CY, 2005, LANCET INFECT DIS, V5, P629, DOI 10.1016/S1473-3099(05)70240-1.
   Cosma CL, 2004, NAT IMMUNOL, V5, P828, DOI 10.1038/ni1091.
   Cosma CL, 2003, ANNU REV MICROBIOL, V57, P641, DOI 10.1146/annurev.micro.57.030502.091033.
   Couper KN, 2007, J IMMUNOL, V178, P4136.
   de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035.
   de Heer HJ, 2005, SEMIN IMMUNOL, V17, P295, DOI 10.1016/j.smim.2005.05.002.
   Flynn JL, 2005, TRENDS MICROBIOL, V13, P98, DOI 10.1016/j.tim.2005.01.005.
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93.
   Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016.
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904.
   Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229.
   Gonzalez-Juarrero M, 2001, INFECT IMMUN, V69, P1722, DOI 10.1128/IAI.69.3.1722-1728.2001.
   Guyot-Revol V, 2006, AM J RESP CRIT CARE, V173, P803, DOI 10.1164/rccm.200508-1294OC.
   Herman AE, 2004, J EXP MED, V199, P1479, DOI 10.1084/jem.20040179.
   Horwitz MA, 2005, INFECT IMMUN, V73, P4676, DOI 10.1128/IAI.73.8.4676-4683.2005.
   Hsu T, 2003, P NATL ACAD SCI USA, V100, P12420, DOI 10.1073/pnas.1635213100.
   Joetham A, 2007, J IMMUNOL, V178, P1433.
   Jung YJ, 2005, J EXP MED, V201, P1915, DOI 10.1084/jem.20050265.
   Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166.
   Kocks JR, 2007, J EXP MED, V204, P723, DOI 10.1084/jem.20061424.
   Kohm AP, 2006, J IMMUNOL, V176, P3301.
   Kursar M, 2002, J EXP MED, V196, P1585, DOI 10.1084/jem.20011347.
   Kursar M, 2007, J IMMUNOL, V178, P2661.
   Lazarevic V, 2005, J IMMUNOL, V175, P1107.
   Lewis KN, 2003, J INFECT DIS, V187, P117, DOI 10.1086/345862.
   Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506.
   Lundgren A, 2005, INFECT IMMUN, V73, P523, DOI 10.1128/IAI.73.1.523-531.2005.
   Lundgren A, 2003, INFECT IMMUN, V71, P1755, DOI 10.1128/IAI.71.4.1755-1762.2003.
   Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276.
   Martin C, 2006, VACCINE, V24, P3408, DOI 10.1016/j.vaccine.2006.03.017.
   Mendez S, 2004, J EXP MED, V200, P201, DOI 10.1084/jem.20040298.
   North RJ, 2004, ANNU REV IMMUNOL, V22, P599, DOI 10.1146/annurev.immunol.22.012703.104635.
   Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019.
   Quinn KM, 2006, IMMUNOL CELL BIOL, V84, P467, DOI 10.1111/j.1440-1711.2006.01460.x.
   Raghavan S, 2004, SCAND J IMMUNOL, V60, P82, DOI 10.1111/j.0300-9475.2004.01447.x.
   Raghavan S, 2003, CLIN EXP IMMUNOL, V132, P393, DOI 10.1046/j.1365-2249.2003.02177.x.
   Ribeiro-Rodrigues R, 2006, CLIN EXP IMMUNOL, V144, P25, DOI 10.1111/j.1365-2249.2006.03027.x.
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122.
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178.
   Saunders BM, 2007, IMMUNOL CELL BIOL, V85, P103, DOI 10.1038/sj.icb.7100027.
   SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245.
   Suffia IJ, 2006, J EXP MED, V203, P777, DOI 10.1084/jem.20052056.
   Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468.
   Ulrichs T, 2006, J PATHOL, V208, P261, DOI 10.1002/path.1906.
   Urdahl KB, 2003, J IMMUNOL, V170, P1987.}},
Number-of-Cited-References = {{56}},
Times-Cited = {{222}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{J. Exp. Med.}},
Doc-Delivery-Number = {{207AW}},
Unique-ID = {{ISI:000249225000015}},
}

@article{ ISI:000254256600008,
Author = {Chiu, Chiung-Zuan and Shyu, Kou-Gi},
Title = {{Deep vein thrombosis associated with marked hyperhomocysteinemia and
   active pulmonary tuberculosis}},
Journal = {{ACTA CARDIOLOGICA SINICA}},
Year = {{2007}},
Volume = {{23}},
Number = {{3}},
Pages = {{186-190}},
Month = {{SEP}},
Abstract = {{We report a 32-year-old male patient presented with acute deep vein
   thrombosis of his right leg after recent onset of active pulmonary
   tuberculosis. Marked hyperhomocysteinemia (> 50 umol/L), folic acid
   deficiency, and abnormal coagulation profiles (elevations of fibrinogen
   and fibrinogen degradation product) were noted after a series of
   work-ups. After treatment with low-molecular-weight heparin, deep vein
   thrombosis improved. Serum homocysteine level returned to normal after
   folic acid and vitamin B 12 supplementation for 2 months. After therapy
   with four-combined anti-tuberculosis drugs for 9 months, the pulmonary
   tuberculosis subsided. In the present case report, the cause of
   hyperhomocysteinemia may be related to folic acid deficiency and chronic
   renal insufficiency.}},
Publisher = {{TAIWAN SOC CARDIOLOGY}},
Address = {{7F NO 27 MIN-CHUAN W RD, TAIPEI, 104, TAIWAN}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Shyu, KG (Reprint Author), Shin Kong Wu Ho Su Mem Hosp, Div Cardiol, Dept Internal Med, 95,Wen Chang Rd, Taipei, Taiwan.
   Chiu, Chiung-Zuan; Shyu, Kou-Gi, Shin Kong Wu Ho Su Mem Hosp, Div Cardiol, Dept Internal Med, Taipei, Taiwan.
   Chiu, Chiung-Zuan; Shyu, Kou-Gi, Fu Jen Catholic Univ, Sch Med, Taipei, Taiwan.
   Shyu, Kou-Gi, Taipei Med Univ, Grad Inst Med Sci, Taipei, Taiwan.}},
ISSN = {{1011-6842}},
Keywords = {{deep vein thrombosis; hyperhomocysteinemia; pulmonary tuberculosis;
   folic acid deficiency; hypercoagulable state}},
Keywords-Plus = {{DISEASE PATIENTS; HOMOCYSTEINE; THERAPY}},
Research-Areas = {{Cardiovascular System \& Cardiology}},
Web-of-Science-Categories  = {{Cardiac \& Cardiovascular Systems}},
Author-Email = {{juice243@hotmail.com}},
Cited-References = {{Austen SK, 2003, CLIN NEPHROL, V60, P375.
   BRATTSTROM LE, 1985, METABOLISM, V34, P1073, DOI 10.1016/0026-0495(85)90082-4.
   Cetin O, 2006, CLIN NEPHROL, V65, P97.
   CHAUVEAU P, 1993, KIDNEY INT S, V41, pS72.
   FRANKEN DG, 1994, ARTERIOSCLER THROMB, V14, P465.
   GOWIE RL, 1989, LANCET, V2, P1397.
   GULDENER CV, 2000, SEMINARS THROMBOSIS, V26, P313.
   HEIJER MD, 1998, ARTERIOSCLER THROMB, V18, P356.
   Kaul S, 2006, J AM COLL CARDIOL, V48, P914, DOI 10.1016/j.jacc.2006.04.086.
   NAURATH HJ, 1995, LANCET, V346, P85, DOI 10.1016/S0140-6736(95)92113-3.
   Nerbass FB, 2006, J AM DIET ASSOC, V106, P267, DOI 10.1016/j.jada.2005.10.035.
   VANDENBERG M, 1994, J VASC SURG, V20, P933.
   WHITE NW, 1989, LANCET, V2, P434.
   WICKEN DE, 1979, EUR J CLIN INVEST, V9, P301.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Acta Cardiol. Sin.}},
Doc-Delivery-Number = {{278AU}},
Unique-ID = {{ISI:000254256600008}},
}

@article{ ISI:000249759900178,
Author = {Nunes, I. K. da C. and De Simone, C. A. and Silva, R. S. F. and Pinto,
   A. V. and Goulart, M. O. F.},
Title = {{14b-chloro-4a-methoxy-3,3-dimethyl-2,3,4a,14b-tetrahydro-1H-benzo{[}a]py
   rano{[}2,3-c] phenazine: a new active structural type against
   Mycobacterium tuberculosis}},
Journal = {{ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE}},
Year = {{2007}},
Volume = {{63}},
Number = {{9}},
Pages = {{O3686-U1945}},
Month = {{SEP}},
Abstract = {{The title compound, C22H21ClN2O2, obtained from the reaction of the
   phenazine of beta-lapachone with trichloroisocyanuric acid, showed a
   minimum inhibitory concentration of 6.25 ng ml(-1) in tuberculostatic
   assays against Mycobacterium tuberculosis and established a new
   structural type with potential interest in medicinal chemistry. The
   dihydropyran ring adopts a pure chair conformation, while the ring fused
   to it has a half-chair conformation. The two substituents, OMe and Cl,
   are in axial positions, due to anomeric effects towards the methoxy
   derivative.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Nunes, IKD (Reprint Author), Univ Fed Alagoas, Inst Quim \& Biotecnol, BR-57072970 Maceio, AL, Brazil.
   Univ Fed Alagoas, Inst Quim \& Biotecnol, BR-57072970 Maceio, AL, Brazil.
   Univ Fed Rio de Janeiro, Nucleo Pesquisas Produtos Nat, BR-21944971 Rio De Janeiro, Brazil.}},
DOI = {{10.1107/S1600536807033259}},
ISSN = {{1600-5368}},
Keywords-Plus = {{IN-VITRO; X-RAY; MICROORGANISMS; SAPHENAMYCIN; DIFFRACTION; METABOLITES;
   ANALOGS}},
Research-Areas = {{Crystallography}},
Web-of-Science-Categories  = {{Crystallography}},
Author-Email = {{isabellekarinecn@yahoo.com.br}},
Cited-References = {{Agrawal YK, 2007, J SCI IND RES INDIA, V66, P191.
   ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1.
   BAHNMULLER U, 1988, J ANTIBIOT, V41, P1552.
   CREMER D, 1975, J AM CHEM SOC, V97, P1354, DOI 10.1021/ja00839a011.
   de Andrade-Neto VF, 2004, BIOORG MED CHEM LETT, V14, P1145, DOI 10.1016/j.bmcl.2003.12.069.
   Emoto T, 2000, TETRAHEDRON LETT, V41, P355, DOI 10.1016/S0040-4039(99)02061-4.
   Farrugia L. J., 1997, J APPL CRYSTALLOGR, V30, P565, DOI DOI 10.1107/S0021889897003117.
   Farrugia L. J., 1999, J APPL CRYSTALLOGR, V32, P837, DOI DOI 10.1107/S0021889899006020.
   Franzblau SG, 1998, J CLIN MICROBIOL, V36, P362.
   GEIGER A, 1988, J ANTIBIOT, V41, P1542.
   Janin YL, 2007, BIOORGAN MED CHEM, V15, P2479, DOI 10.1016/j.bmc.2007.01.030.
   Laursen JB, 2002, BIOORG MED CHEM LETT, V12, P171, DOI 10.1016/S0960-894X(01)00692-8.
   MACKGATHO ME, 2000, DRUG DEVELOP RES, V50, P195.
   Nonius, 2000, COLLECT.
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X.
   REWCASTLE GW, 1987, J MED CHEM, V30, P843, DOI 10.1021/jm00388a017.
   Sheldrick G. M., 1997, SHELXS97 SHELXL97.
   van Rensburg CEJ, 2000, CHEMOTHERAPY, V46, P43, DOI 10.1159/000007255.
   Wang WY, 2000, BIOORG MED CHEM LETT, V10, P1151, DOI 10.1016/S0960-894X(00)00217-1.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Acta Crystallogr. Sect. E.-Struct Rep. Online}},
Doc-Delivery-Number = {{214TB}},
Unique-ID = {{ISI:000249759900178}},
}

@article{ ISI:000249591900012,
Author = {Oezkara, Sevgiye Kacar and Turan, Gupse and Basyigit, Ilknur},
Title = {{Clinicopathologic significance of eosinophilic pleural effusions in a
   population with a high prevalence of tuberculosis and cancer}},
Journal = {{ACTA CYTOLOGICA}},
Year = {{2007}},
Volume = {{51}},
Number = {{5}},
Pages = {{773-781}},
Month = {{SEP-OCT}},
Abstract = {{Objective
   To reveal the diagnostic and prognostic significance of eosinophilic
   pleural effusions (EPEs) and assess their clinical implications.
   Study Design
   Seventy EPEs front 60 patients among 697 consecutive pleural effusions
   were investigated from in 1996-2005 at Kocaeli University Hospital,
   Kocaeli, Turkey. Koss and Light's criteria were applied in the analysis,
   which comprised macroscopic, cytopathologic, biochemical and
   microbiologic examinations
   Results
   Overall, cancerous underlying conditions were diagnosed in 22 patients
   (13 malignant and 9 paramalignant), 36.7\% of EPFs. Benign causes were
   found in 43.3\% (2 6 of 60) of the patients. Twelve pleural effusions
   (20.0\%) were idiopathic. The comparison of pleural fluid and peripheral
   blood findings disclosed no significant difference among the various
   subgroups.
   Conclusion
   EPE could be associated with inflammatory, benign, cancerous and
   paramalignant conditions. A closer search for a definite causes is
   warranted in the setting of EPEs, especially in populations with a high
   prevalence of tuberculosis and malignancy, such as in Kocaeli, Turkey,
   an industrial city in a developing countty.}},
Publisher = {{SCI PRINTERS \& PUBL INC}},
Address = {{PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ozkara, SK (Reprint Author), Mustafa Pasa Mah Bagdat Cad 0712 Sol 19-6, TR-41400 Gebze, Turkey.
   Kocaeli Univ, Fac Med, Dept Pathol, Kocaeli, Turkey.
   Kocaeli Univ, Fac Med, Dept Chest Dis, Kocaeli, Turkey.}},
DOI = {{10.1159/000325841}},
ISSN = {{0001-5547}},
Keywords = {{effusion; pleural effusion eosinophilic; pleura}},
Keywords-Plus = {{DIAGNOSTIC UTILITY; FLUID EOSINOPHILIA; CELLS}},
Research-Areas = {{Pathology}},
Web-of-Science-Categories  = {{Pathology}},
Author-Email = {{emrecan1999@yahoo.com}},
Cited-References = {{ADELMAN M, 1984, AM J MED, V77, P915, DOI 10.1016/0002-9343(84)90542-4.
   CURRAN WS, 1963, ARCH INTERN MED, V3, P809.
   Ilgazli A, 2004, ARCH MED RES, V35, P435, DOI 10.1016/j.arcmed.2004.05.008.
   Kalomenidis I, 2004, CURR OPIN PULM MED, V10, P289, DOI 10.1097/01.mcp.0000127902.37822.13.
   Kalomenidis Ioannis, 2003, Curr Opin Pulm Med, V9, P254, DOI 10.1097/00063198-200307000-00002.
   Katayama H, 2002, AM J RESP CELL MOL, V26, P398.
   KOBAYASHI TK, 1980, ACTA CYTOL, V24, P84.
   KUHN M, 1989, CHEST, V96, P992, DOI 10.1378/chest.96.5.992.
   Light RW, 1997, EUR RESPIR J, V10, P476, DOI 10.1183/09031936.97.10020476.
   MAREL M, 1995, CHEST, V107, P1598, DOI 10.1378/chest.107.6.1598.
   Martinez-Garcia MA, 2000, EUR RESPIR J, V15, P166, DOI 10.1034/j.1399-3003.2000.15a30.x.
   MATTHAI SM, 2003, DIAGN CYTOPATHOL, P2896.
   Mohamed KH, 2002, CHEST, V122, P576, DOI 10.1378/chest.122.2.576.
   Rubins JB, 1996, CHEST, V110, P1271, DOI 10.1378/chest.110.5.1271.
   SPRIGGS AI, 1989, CURRENT HISTOPATHOLO, V14, P38.
   VERESS JF, 1979, ACTA CYTOL, V23, P40.
   WYSENBEEK AJ, 1985, RESPIRATION, V48, P73.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Acta Cytol.}},
Doc-Delivery-Number = {{212JF}},
Unique-ID = {{ISI:000249591900012}},
}

@article{ ISI:000249397800478,
Author = {Fyock, Christopher and Adrain, Alyn},
Title = {{A case of ileocecal tuberculosis found on screening colonoscopy}},
Journal = {{AMERICAN JOURNAL OF GASTROENTEROLOGY}},
Year = {{2007}},
Volume = {{102}},
Number = {{2}},
Meeting = {{480}},
Pages = {{S291-S292}},
Month = {{SEP}},
Note = {{72nd Annual Scientific Meeting of the
   American-College-of-Gastroenterology, Philadelphia, PA, OCT 12-17, 2007}},
Organization = {{Amer Coll Gastroengerol}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Brown Univ, Rhode Isl Hosp, Sch Med, Providence, RI 02903 USA.
   Gastroenterol Associates, Providence, RI USA.}},
ISSN = {{0002-9270}},
Research-Areas = {{Gastroenterology \& Hepatology}},
Web-of-Science-Categories  = {{Gastroenterology \& Hepatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Am. J. Gastroenterol.}},
Doc-Delivery-Number = {{209OL}},
Unique-ID = {{ISI:000249397800478}},
}

@article{ ISI:000249397800552,
Author = {Hyun, Jae Geun and Goldstein, Eric S. and Sylla, Patricia and Bub, David},
Title = {{Intestinal tuberculosis masquerading as Crohn's disease}},
Journal = {{AMERICAN JOURNAL OF GASTROENTEROLOGY}},
Year = {{2007}},
Volume = {{102}},
Number = {{2}},
Meeting = {{554}},
Pages = {{S320-S321}},
Month = {{SEP}},
Note = {{72nd Annual Scientific Meeting of the
   American-College-of-Gastroenterology, Philadelphia, PA, OCT 12-17, 2007}},
Organization = {{Amer Coll Gastroengerol}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Mt Sinai Med Ctr, New York, NY 10029 USA.}},
ISSN = {{0002-9270}},
Research-Areas = {{Gastroenterology \& Hepatology}},
Web-of-Science-Categories  = {{Gastroenterology \& Hepatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Am. J. Gastroenterol.}},
Doc-Delivery-Number = {{209OL}},
Unique-ID = {{ISI:000249397800552}},
}

@article{ ISI:000249397800668,
Author = {Somnay, Kaumudi and Belova, Natalya},
Title = {{EUS with trucut biopsy for diagnosis of intra-abdominal tuberculosis}},
Journal = {{AMERICAN JOURNAL OF GASTROENTEROLOGY}},
Year = {{2007}},
Volume = {{102}},
Number = {{2}},
Meeting = {{678}},
Pages = {{S364}},
Month = {{SEP}},
Note = {{72nd Annual Scientific Meeting of the
   American-College-of-Gastroenterology, Philadelphia, PA, OCT 12-17, 2007}},
Organization = {{Amer Coll Gastroengerol}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{New York Hosp Queens, Dept Gastroenterol, Flushing, NY USA.}},
ISSN = {{0002-9270}},
Research-Areas = {{Gastroenterology \& Hepatology}},
Web-of-Science-Categories  = {{Gastroenterology \& Hepatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Am. J. Gastroenterol.}},
Doc-Delivery-Number = {{209OL}},
Unique-ID = {{ISI:000249397800668}},
}

@article{ ISI:000249312200027,
Author = {Olson, Douglas P. and Day, Cheryl L. and Magula, Nombulelo P. and Sahid,
   Faieza and Moosa, Mahomed-Yunus S.},
Title = {{Case report: Cutaneous extensively drug-resistant tuberculosis}},
Journal = {{AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE}},
Year = {{2007}},
Volume = {{77}},
Number = {{3}},
Pages = {{551-554}},
Month = {{SEP}},
Abstract = {{A 48-year-old immunocompetent man without known exposure to tuberculosis
   had a > 10-year history of recurrent skin lesions. Cutaneous
   tuberculosis without any current or past history of pulmonary
   tuberculosis was diagnosed. Culture of biopsy specimens showed the
   organism to be resistant to multiple first-line and second-line agents.
   The patient had a broad, vigorous CD4-specific immune response against
   multiple tuberculosis antigens. This case is the first report of
   cutaneous extensively drug-resistant tuberculosis.}},
Publisher = {{AMER SOC TROP MED \& HYGIENE}},
Address = {{8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Olson, DP (Reprint Author), Yale Univ, Sch Med, 26131 Town Walk Dr, Hamden, CT 06518 USA.
   Univ KwaZulu Natal, Dept Infect Dis, Div Med, Durban, South Africa.
   Univ KwaZulu Natal, HIV Pathogenesis Programme, Durban, South Africa.
   George Washington Univ, Sch Med, Washington, DC USA.
   Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Boston, MA USA.}},
ISSN = {{0002-9637}},
Research-Areas = {{Public, Environmental \& Occupational Health; Tropical Medicine}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Tropical Medicine}},
Author-Email = {{douglas.olson@yale.edu}},
ResearcherID-Numbers = {{Day, Cheryl/J-9844-2012}},
Cited-References = {{Barbagallo Joseph, 2002, Am J Clin Dermatol, V3, P319, DOI 10.2165/00128071-200203050-00004.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   Friedman PC, 2005, J AM ACAD DERMATOL, V53, pS154, DOI 10.1016/j.jaad.2005.01.110.
   Ginsburg AS, 2003, CLIN INFECT DIS, V37, P1448, DOI 10.1086/379328.
   Golden MP, 2005, AM FAM PHYSICIAN, V72, P1761.
   Gopinathan R, 2001, Indian J Med Microbiol, V19, P193.
   Ho C. K., 2006, Hong Kong Medical Journal, V12, P272.
   Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400.
   Ramam M, 2005, INT J DERMATOL, V44, P121, DOI 10.1111/j.1365-4632.2005.02063.x.
   Ramesh V, 2001, PEDIATR DERMATOL, V18, P393, DOI 10.1046/j.1525-1470.2001.01962.x.
   {*}S AFR NAT TUB CON, 2004, S AFR NAT TUB CONT P.
   {*}US CDCP, 2006, MMWR-MORBID MORTAL W, V55, P301.
   World Health Organisation (WHO), 2006, WHO GLOB TASK FORC O.
   {[}Anonymous], 1975, TUBERCLE, V56, P269.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Am. J. Trop. Med. Hyg.}},
Doc-Delivery-Number = {{208IE}},
Unique-ID = {{ISI:000249312200027}},
}

@article{ ISI:000250890400003,
Author = {Huang, Tsi-Shu and Liu, Yung-Ching and Tu, Hui-Zin and Sy, Cheng-Len and
   Chen, Yao-Shen and Chen, Bao-Chen},
Title = {{Rapid purity check method for susceptibility testing of M-tuberculosis
   complex with the MGIT 960 system}},
Journal = {{ANNALS OF CLINICAL AND LABORATORY SCIENCE}},
Year = {{2007}},
Volume = {{37}},
Number = {{4}},
Pages = {{323-329}},
Month = {{FAL}},
Abstract = {{The Bactec MGIT 960 system is a rapid and reliable automated method for
   drug susceptibility testing of Mycobacterium tuberculosis complex (MTBC)
   that yields a high percentage of agreement with the standard method. The
   microscopic cord morphology of M. tuberculosis in liquid medium is
   characteristic, and readily differentiates MTBC from nontuberculous
   mycobacteria (NTM). The goals of this study were to describe the
   microscopic and macroscopic growth morphology of MTBC in
   antimicrobial-containing MGIT tubes and to evaluate the usefulness of
   the growth appearance during purity checking. The macroscopic cotton
   wool-like appearance of MTBC isolates in isoniazid (INH), streptomycin
   (SM), rifampin (RMP), and ethambutol (EMB)-containing tubes was observed
   in 97, 90, 93, and 71\% of the isolates, respectively. The percentage of
   typical cord, loose, or frayed rope microscopic features in smears
   prepared from MTBC-positive cultures of INH, SM, RMP, and EMB-containing
   tubes was 96, 86, 97, and 71\%, respectively. The sensitivity of the
   macroscopic morphology for predicting the purity of drug-containing MGIT
   tubes was 93\%, while the microscopic morphology predicted the purity
   with a sensitivity rate of 92\%. We found that simply examining the
   macroscopic morphology of the antimicrobial-containing MGIT tubes of
   drug-resistant MTBC isolates is useful in preventing false resistant
   results of susceptibility testing by the MGIT 960 system.}},
Publisher = {{ASSOC CLINICAL SCIENTISTS}},
Address = {{PO BOX 1287, MIDDLEBURY, VT 05753 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Liu, YC (Reprint Author), Kaohsiung Vet Gen Hosp, Infect Dis Sect, 386 Ta Chung 1st Rd, Kaohsiung, Taiwan.
   Kaohsiung Vet Gen Hosp, Infect Dis Sect, Kaohsiung, Taiwan.
   Kaohsiung Vet Gen Hosp, Microbiol Sect, Kaohsiung, Taiwan.
   Fooyin Inst Technol, Dept Med Technol, Kaohsiung, Taiwan.
   Natl Yang Ming Univ, Dept Internal Med, Kaohsiung, Taiwan.
   Natl Kaohsiung Normal Univ, Grad Inst Environm Educ, Kaohsiung, Taiwan.}},
ISSN = {{0091-7370}},
Keywords = {{M. tuberculosis complex; MGIT; antimicrobial susceptibility testing}},
Keywords-Plus = {{GROWTH INDICATOR TUBE; RESTRICTION ENZYME ANALYSIS;
   POLYMERASE-CHAIN-REACTION; PRESUMPTIVE IDENTIFICATION; RESPIRATORY
   SPECIMENS; 1ST-LINE DRUGS}},
Research-Areas = {{Medical Laboratory Technology}},
Web-of-Science-Categories  = {{Medical Laboratory Technology}},
Author-Email = {{tshuang@vghks.gov.tw}},
Cited-References = {{Ardito F, 2000, New Microbiol, V23, P151.
   Bergmann JS, 1998, J CLIN MICROBIOL, V36, P2766.
   Brunello F, 2000, J CLIN MICROBIOL, V38, P872.
   Diaz-Infantes MS, 2000, J CLIN MICROBIOL, V38, P1988.
   Furuhata Yukie, 2004, Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi, V15, P7.
   Goloubeva V, 2001, J CLIN MICROBIOL, V39, P1501, DOI 10.1128/JCM.39.4.1501-1505.2001.
   Huang TS, 2002, ANN CLIN LAB SCI, V32, P142.
   Huang TS, 1996, J FORMOS MED ASSOC, V95, P530.
   KILBURN JO, 1981, ANTIMICROB AGENTS CH, V20, P401.
   Macondo EA, 2000, CLIN MICROBIOL INFEC, V6, P363.
   McCarter YS, 1998, J CLIN MICROBIOL, V36, P2769.
   Palaci M, 1996, J CLIN MICROBIOL, V34, P762.
   Palomino JC, 1999, INT J TUBERC LUNG D, V3, P344.
   Rusch-Gerdes S, 1999, J CLIN MICROBIOL, V37, P45.
   TELENTI A, 1993, J CLIN MICROBIOL, V31, P175.
   Tu HZ, 2003, ANN CLIN LAB SCI, V33, P179.
   Wang SX, 2004, J MED MICROBIOL, V53, P57, DOI 10.1099/jmm.0.05454-0.
   YING Z, 2005, TUBERCULOSIS TUBERCL, V8, P115.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Clin. Lab. Sci.}},
Doc-Delivery-Number = {{230QG}},
Unique-ID = {{ISI:000250890400003}},
}

@article{ ISI:000250796100015,
Author = {Chong, Yap Yew and Kodati, Shyam and Kosmin, A.},
Title = {{Ocular tuberculosis}},
Journal = {{ANNALS OF OPHTHALMOLOGY}},
Year = {{2007}},
Volume = {{39}},
Number = {{3}},
Pages = {{243-245}},
Month = {{FAL}},
Abstract = {{We present an article on asymptomatic tuberculous choroiditis on
   screening. Discussions also include the manifestations, relevant
   investigations and management of ocular tuberculosis. Clinicians should
   be aware of these findings when treating such patients.}},
Publisher = {{HUMANA PRESS INC}},
Address = {{999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Chong, YY (Reprint Author), Watford Dist Gen Hosp, Dept Ophthalmol, Watford, England.
   Watford Dist Gen Hosp, Dept Ophthalmol, Watford, England.}},
DOI = {{10.1007/s12009-007-0033-6}},
ISSN = {{1530-4086}},
Research-Areas = {{Ophthalmology}},
Web-of-Science-Categories  = {{Ophthalmology}},
Author-Email = {{eyapyc@gmail.com}},
Cited-References = {{Bodaghi B, 2000, Curr Opin Ophthalmol, V11, P443, DOI 10.1097/00055735-200012000-00010.
   Cunningham ET, 2001, BRIT J OPHTHALMOL, V85, P127, DOI 10.1136/bjo.85.2.127.
   Demirci H, 2004, SURV OPHTHALMOL, V49, P78, DOI 10.1016/j.survophthal.2003.10.009.
   DONAHUE HC, 1967, AM J OPHTHALMOL, V64, P742.
   ROSE MR, 1990, REV BIOL RES AGING, V4, P3.
   SEN DK, 1977, J PEDIATR OPHTHALMOL, V14, P25.
   Sheu SJ, 2001, OPHTHALMOLOGY, V108, P1580, DOI 10.1016/S0161-6420(01)00693-5.
   SHIONO T, 1990, BRIT J OPHTHALMOL, V74, P317, DOI 10.1136/bjo.74.5.317.}},
Number-of-Cited-References = {{8}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Ophthalmol.}},
Doc-Delivery-Number = {{229II}},
Unique-ID = {{ISI:000250796100015}},
}

@article{ ISI:000248982400052,
Author = {Bertin, Francois and Labrousse, Louis and Gazaille, Virgile and Vincent,
   Francois and Guerlin, Antoine and Laskar, Marc},
Title = {{New modality of collapse therapy for pulmonary tuberculosis sequels:
   Tissue expander}},
Journal = {{ANNALS OF THORACIC SURGERY}},
Year = {{2007}},
Volume = {{84}},
Number = {{3}},
Pages = {{1023-1025}},
Month = {{SEP}},
Abstract = {{Classical collapse therapy with extrapleural Lucite balls placement used
   for tuberculosis sequelae is associated with long term complications,
   such as migration of the foreign body. We report a new modality of
   collapse therapy for tuberculosis cavitation which may avoid this
   complication and which uses percutaneous tissue expanders. Postoperative
   course was uneventful and mid term follow-up confirmed the functional
   improvement without recurrence of the infection. This new modality of
   post-tuberculosis collapse therapy may allow treatment with fewer
   physical and physiologic sequelae of the residual cavities, and should
   reduce long term complications such as migration.}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bertin, F (Reprint Author), Univ Limoges, Ctr Hosp, Dept Thorac \& Cardiovasc Surg \& Angiol, 2 Ave Martin Luther King, F-87042 Limoges, France.
   Univ Limoges, Ctr Hosp, Dept Thorac \& Cardiovasc Surg \& Angiol, F-87042 Limoges, France.
   Univ Limoges, Ctr Hosp, Dept Pulm Dis, F-87042 Limoges, France.}},
DOI = {{10.1016/j.athoracsur.2007.04.013}},
ISSN = {{0003-4975}},
Keywords-Plus = {{PNEUMONECTOMY SYNDROME; SURGICAL-CORRECTION; LATE COMPLICATIONS;
   PLOMBAGE; IMPLANTS}},
Research-Areas = {{Cardiovascular System \& Cardiology; Respiratory System; Surgery}},
Web-of-Science-Categories  = {{Cardiac \& Cardiovascular Systems; Respiratory System; Surgery}},
Author-Email = {{francois.bertin@chu-limoges.fr}},
ORCID-Numbers = {{Vincent, Francois/0000-0001-5159-4417}},
Cited-References = {{Barker W L, 1994, Chest Surg Clin N Am, V4, P593.
   DOWNEY RJ, 1994, J THORAC CARDIOV SUR, V107, P953.
   HOROWITZ MD, 1992, ANN THORAC SURG, V53, P803.
   Massard G, 1997, ANN THORAC SURG, V64, P220, DOI 10.1016/S0003-4975(97)00344-5.
   MATTURRI L, 1992, PLAST RECONSTR SURG, V90, P636, DOI 10.1097/00006534-199210000-00013.
   SHEPHERD MP, 1985, THORAX, V40, P328, DOI 10.1136/thx.40.5.328.
   WASSERMAN K, 1979, CHEST, V75, P78, DOI 10.1378/chest.75.1.78.
   Weissberg D, 2001, CHEST, V120, P847, DOI 10.1378/chest.120.3.847.}},
Number-of-Cited-References = {{8}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Ann. Thorac. Surg.}},
Doc-Delivery-Number = {{203NX}},
Unique-ID = {{ISI:000248982400052}},
}

@article{ ISI:000249175400043,
Author = {Lenaerts, Anne J. and Hoff, Donald and Aly, Sahar and Ehlers, Stefan and
   Andries, Koen and Cantarero, Luis and Orme, Ian M. and Basaraba, Randall
   J.},
Title = {{Location of persisting mycobacteria in a guinea pig model of
   tuberculosis revealed by R207910}},
Journal = {{ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}},
Year = {{2007}},
Volume = {{51}},
Number = {{9}},
Pages = {{3338-3345}},
Month = {{SEP}},
Abstract = {{The lengthy chemotherapy of tuberculosis reflects the ability of a small
   subpopulation of Mycobarterium tuberculosis bacteria to persist in
   infected individuals. To date, the exact location of these persisting
   bacteria is not known. Lung lesions in guinea pigs infected with M.
   tuberculosis have striking similarities, such as necrosis,
   mineralization, and hypoxia, to natural infections in humans. Guinea
   pigs develop necrotic primary lesions after aerosol infection that
   differ in their morphology compared to secondary lesions resulting from
   hematogenous dissemination. In infected guinea pigs conventional therapy
   for tuberculosis during 6 weeks reduced the bacterial load by 1.7 logs
   in the lungs and, although this completely reversed lung inflammation
   associated with secondary lesions, the primary granulomas remained
   largely unaffected. Treatment of animals with the experimental drug
   R207910 (TMC207) for 6 weeks was highly effective with almost complete
   eradication of the bacteria throughout both the primary and the
   secondary lesions. Most importantly, the few remnants of acid-fast
   bacilli remaining after R207910 treatment were to be found
   extracellular, in a microenvironment of residual primary lesion necrosis
   with incomplete dystrophic calcification. This zone of the primary
   granuloma is hypoxic and is morphologically similar to what has been
   described for human lung lesions. These results show that this acellular
   rim may, therefore, be a primary location of persisting bacilli
   withstanding drug treatment.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Lenaerts, AJ (Reprint Author), Colorado State Univ, Dept Microbiol Immunol \& Pathol, Ft Collins, CO 80523 USA.
   Colorado State Univ, Dept Microbiol Immunol \& Pathol, Ft Collins, CO 80523 USA.
   Res Ctr Borstel, D-23845 Borstel, Germany.
   Johson \& Johnson Pharmaceut Res \& Dev, B-2340 Beerse, Belgium.
   Mycos Res, Loveland, CO 80538 USA.}},
DOI = {{10.1128/AAC.00276-07}},
ISSN = {{0066-4804}},
Keywords-Plus = {{NITROIMIDAZOPYRAN PA-824; MURINE TUBERCULOSIS; BIOFILM FORMATION;
   OXYGEN-TENSION; DISEASE-MODEL; INFECTED MICE; IN-VITRO; GRANULOMAS;
   TISSUE; AVIUM}},
Research-Areas = {{Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Microbiology; Pharmacology \& Pharmacy}},
Author-Email = {{lenaerts@colostate.edu}},
ResearcherID-Numbers = {{Ehlers, Stefan/B-4075-2010
   Lenaerts, Anne/F-1353-2017}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}R01 AI054697, AI054697, AI070456, N01 AI95385,
   N01AI95385, U01 AI070456]}},
Cited-References = {{Aly S, 2006, J PATHOL, V210, P298, DOI 10.1002/path.2055.
   Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753.
   Arteel GE, 1998, EUR J BIOCHEM, V253, P743, DOI 10.1046/j.1432-1327.1998.2530743.x.
   ARTEEL GE, 1995, BRIT J CANCER, V72, P889, DOI 10.1038/bjc.1995.429.
   Basaraba RJ, 2006, INFECT IMMUN, V74, P5397, DOI 10.1128/IAI.00332-06.
   BASARABA RJ, 2006, INFECT IMMUN, V86, P386.
   Bishal WR, 2000, LANCET, V356, P2113, DOI 10.1016/S0140-6736(00)03485-1.
   Boshoff HIM, 2005, NAT REV MICROBIOL, V3, P70, DOI 10.1038/nrmicro1065.
   Brandt L, 2004, INFECT IMMUN, V72, P6622, DOI 10.1128/IAI.72.11.6622-6632.2004.
   Carter G, 2003, J MED MICROBIOL, V52, P747, DOI 10.1099/jmm.0.05224-0.
   Cho SH, 2007, ANTIMICROB AGENTS CH, V51, P1380, DOI 10.1128/AAC.00055-06.
   Dannenberg Arthur M. Jr., 1994, P459.
   Fenhalls G, 2002, J MICROBIOL METH, V51, P197, DOI 10.1016/S0167-7012(02)00076-3.
   Gomez JE, 2004, TUBERCULOSIS, V84, P29, DOI 10.1016/j.tube.2003.08.003.
   Gruppo V, 2006, ANTIMICROB AGENTS CH, V50, P1245, DOI 10.1128/AAC.50.4.1245-1250.2006.
   Hernandez-Pando R, 2000, LANCET, V356, P2133, DOI 10.1016/S0140-6736(00)03493-0.
   Ibrahim M, 2007, ANTIMICROB AGENTS CH, V51, P1011, DOI 10.1128/AAC.00898-06.
   Johnson CM, 2005, ANTIMICROB AGENTS CH, V49, P4335, DOI 10.1128/AAC.49.10.4335-4338.2005.
   Karakousis PC, 2004, J EXP MED, V200, P647, DOI 10.1084/jem.20040646.
   Lamichhane G, 2005, INFECT IMMUN, V73, P2533, DOI 10.1128/IAI.73.4.2533-2540.2005.
   Lenaerts AJ, 2005, ANTIMICROB AGENTS CH, V49, P2294, DOI 10.1285/AAC.49.6.294-2301.2005.
   Lounis N, 2006, ANTIMICROB AGENTS CH, V50, P3543, DOI 10.1128/AAC.00766-06.
   McMurray DN, 2003, TUBERCULOSIS, V83, P131, DOI 10.1016/S1472-9792(02)00079-3.
   McMurray DN, 2001, TRENDS MOL MED, V7, P135, DOI 10.1016/S1471-4914(00)01901-8.
   McMurray DN, 1996, CURR TOP MICROBIOL, V215, P157.
   Munoz-Elias EJ, 2005, INFECT IMMUN, V73, P546, DOI 10.1128/IAI.73.1.546-551.2005.
   Neyrolles O, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000043.
   Nuermberger EL, 2004, AM J RESP CRIT CARE, V169, P421, DOI 10.1164/rccm.200310-1380OC.
   Ojha A, 2005, CELL, V123, P861, DOI 10.1016/j.cell.2005.09.012.
   Orme IM, 2005, VACCINE, V23, P2105, DOI 10.1016/j.vaccine.2005.01.062.
   Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5.
   Rose L, 2004, MICROBES INFECT, V6, P965, DOI 10.1016/j.micinf.2004.05.011.
   SMITH DW, 1991, TUBERCLE, V72, P223, DOI 10.1016/0041-3879(91)90013-I.
   Somoskovi A, 2001, CHEST, V120, P250, DOI 10.1378/chest.120.1.250.
   Stover CK, 2000, NATURE, V405, P962, DOI 10.1038/35016103.
   Suarez S, 2001, PHARMACEUT RES, V18, P1315, DOI 10.1023/A:1013094112861.
   Teng R, 2003, FEMS MICROBIOL LETT, V227, P171, DOI 10.1016/S0378-1097(03)00584-6.
   Tsai MC, 2006, CELL MICROBIOL, V8, P218, DOI 10.1111/j.1462-5822.2005.00612.x.
   Turner OC, 2003, GRANULOMATOUS INFECTIONS AND INFLAMMATIONS: CELLULAR AND MOLECULAR MECHANISMS, P65.
   Tyagi S, 2005, ANTIMICROB AGENTS CH, V49, P2289, DOI 10.1128/AAC.49.6.2289-2293.2005.
   Ulrichs T, 2006, J PATHOL, V208, P261, DOI 10.1002/path.1906.
   Ulrichs T, 2005, J PATHOL, V205, P633, DOI 10.1002/path.1728.
   Wayne LG, 1996, INFECT IMMUN, V64, P2062.
   {*}WHO, 2006, WHOHTMTB2006375.
   Yamazaki Y, 2006, APPL ENVIRON MICROB, V72, P819, DOI 10.1128/AEM.72.1.819-825.2006.
   Yamazaki Y, 2006, CELL MICROBIOL, V8, P806, DOI 10.1111/j.1462-5822.2005.00667.x.
   Zambrano MM, 2005, CELL, V123, P762, DOI 10.1016/j.cell.2005.11.011.}},
Number-of-Cited-References = {{47}},
Times-Cited = {{139}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{Antimicrob. Agents Chemother.}},
Doc-Delivery-Number = {{206HV}},
Unique-ID = {{ISI:000249175400043}},
}

@article{ ISI:000250010100002,
Author = {Tang, Kang-lai and Li, Qi-hong and Chen, Guang-xin and Guo, Lin and Dai,
   Gang and Yang, Liu},
Title = {{Arthroscopically assisted ankle fusion in patients with end-stage
   tuberculosis}},
Journal = {{ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY}},
Year = {{2007}},
Volume = {{23}},
Number = {{9}},
Pages = {{919-922}},
Month = {{SEP}},
Abstract = {{Purpose: Our purpose was to evaluate the clinical outcomes of
   arthroscopically assisted ankle fusion in patients with end-stage
   tuberculosis. Methods: Ten patients, all with end-stage tuberculosis,
   were operated on by arthroscopically assisted ankle fusion, and a
   half-ring sulcated external fixator was used. Partial weight-bearing was
   started on the fourth day. The clinical results were assessed with the
   American Orthopaedic Foot \& Ankle Society score. Ankle fusion was
   proved by radiographs. Results: At the mean follow-up of 23 months, all
   fusions were healed; the mean time to radiologic healing was 14.5 weeks.
   The final American Orthopaedic Foot \& Ankle Society score was 66
   points. Conclusions: Arthroscopically assisted debridement and ankle
   arthrodesis with an external fixator provided a very satisfactory rate
   of ankle fusion in 10 patients who had no recurrences or other
   complications. Level of Evidence: Level IV, therapeutic case series.}},
Publisher = {{W B SAUNDERS CO-ELSEVIER INC}},
Address = {{1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tang, KL (Reprint Author), Third Mil Med Univ, Dept Orthopaed, Ctr Joint Surg, SW Hosp, Gaotanyan St 30, Chongqing 400038, Peoples R China.
   Third Mil Med Univ, Dept Orthopaed, Ctr Joint Surg, SW Hosp, Chongqing 400038, Peoples R China.}},
DOI = {{10.1016/j.arthro.2007.04.004}},
ISSN = {{0749-8063}},
Keywords = {{arthroscopy; external fixation; ankle; tuberculosis; arthrodesis}},
Keywords-Plus = {{ARTHRODESIS; JOINT}},
Research-Areas = {{Orthopedics; Surgery}},
Web-of-Science-Categories  = {{Orthopedics; Surgery}},
Author-Email = {{tangkanglai@hotmail.com}},
Cited-References = {{Cai Daozhang, 1998, Zhonghua Jiehe He Huxi Zazhi, V21, P276.
   Cameron SE, 2000, ARTHROSCOPY, V16, P21, DOI 10.1016/S0749-8063(00)90123-3.
   Dhillon MS, 2002, CLIN ORTHOP RELAT R, P107.
   Ferkel RD, 2005, FOOT ANKLE INT, V26, P275.
   Fitzgibbons T C, 1999, Instr Course Lect, V48, P243.
   Glick JM, 1996, ARTHROSCOPY, V12, P428, DOI 10.1016/S0749-8063(96)90036-5.
   Karladani AH, 2004, ACTA ORTHOP SCAND, V75, P471.
   MYERSON MS, 1991, CLIN ORTHOP RELAT R, P84.
   O'Brien TS, 1999, FOOT ANKLE INT, V20, P368.
   Sequeira W, 2000, Am J Ther, V7, P393, DOI 10.1097/00045391-200007060-00009.
   Titov AG, 2004, KNEE, V11, P57, DOI 10.1016/S0968-0160(03)00035-8.
   Titov AG, 2004, ARCH PATHOL LAB MED, V128, P205.
   Tuli SM, 2002, CLIN ORTHOP RELAT R, P11.
   Winson IG, 2005, J BONE JOINT SURG BR, V87B, P343, DOI 10.1302/0301-620X.87B3.15756.
   Zvijac JE, 2002, ARTHROSCOPY, V18, P70, DOI 10.1053/jars.2002.29923.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Arthroscopy}},
Doc-Delivery-Number = {{218IV}},
Unique-ID = {{ISI:000250010100002}},
}

@article{ ISI:000249805000015,
Author = {Avilov, K. K. and Romanyukha, A. A.},
Title = {{Mathematical modeling of tuberculosis propagation and patient detection}},
Journal = {{AUTOMATION AND REMOTE CONTROL}},
Year = {{2007}},
Volume = {{68}},
Number = {{9}},
Pages = {{1604-1617}},
Month = {{SEP}},
Abstract = {{A mathematical model of the spread of tuberculosis taking into account
   the impact of the antituberculosis programs was considered. The
   singularity of the proposed model lies in making explicit discrimination
   between the detected and overlooked patients and taking into account
   their migration. Studies demonstrated insufficiency of the standard
   accounting form of the regional Russian antituberculosis institutions.
   Proposed was a submodel enabling objective estimation of the patient
   detection system on the basis of individualized database. These
   estimates corroborated the assumption of a substantial nonuniformity of
   the Russian regions in terms of tuberculosis morbidity and efficiency of
   patient detection. For example, the rates of patient detection can
   differ by the factor of five through six. The model can be used to
   forecast the tuberculosis morbidity and efficiency of the
   antituberculosis programs.}},
Publisher = {{MAIK NAUKA/INTERPERIODICA/SPRINGER}},
Address = {{233 SPRING ST, NEW YORK, NY 10013-1578 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Avilov, KK (Reprint Author), Russian Acad Sci, Inst Numer Math, Moscow, Russia.
   Russian Acad Sci, Inst Numer Math, Moscow, Russia.}},
DOI = {{10.1134/S0005117907090159}},
ISSN = {{0005-1179}},
Keywords-Plus = {{RISKS}},
Research-Areas = {{Automation \& Control Systems; Instruments \& Instrumentation}},
Web-of-Science-Categories  = {{Automation \& Control Systems; Instruments \& Instrumentation}},
ResearcherID-Numbers = {{Avilov, Konstantin/H-3606-2016}},
ORCID-Numbers = {{Avilov, Konstantin/0000-0003-1711-5659}},
Cited-References = {{AVILOV KK, 2006, SB TEZ 1 MEZHD K MAT, P140.
   AVILOV KK, 2006, SB TEZ YUB NAUCH PRA.
   AVILOV KK, 2006, SB TEZ VSER K STUD M, P5.
   Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7.
   Murray CJL, 1998, P NATL ACAD SCI USA, V95, P13881, DOI 10.1073/pnas.95.23.13881.
   MURRAY CJL, 1998, HARVARD CTR POPULATI.
   National Tuberculosis Institute Bangalore, 1974, B WORLD HEALTH ORGAN, V51, P473.
   Perelman MI, 2004, RUSS J NUMER ANAL M, V19, P305, DOI 10.1163/1569398041974905.
   SUTHERLAND I, 1982, TUBERCLE, V63, P255, DOI 10.1016/S0041-3879(82)80013-5.
   Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917.
   Vynnycky E, 2000, AM J EPIDEMIOL, V152, P247, DOI 10.1093/aje/152.3.247.
   WAALER HANS, 1962, AMER JOUR PUBL HEALTH, V52, P1002, DOI 10.2105/AJPH.52.6.1002.
   WAALER HT, 1969, B WORLD HEALTH ORGAN, V41, P75.
   WAALER HT, 1968, AM REV RESPIR DIS, V98, P591.
   2004, REGIONY ROSSII OSNOV.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Autom. Remote Control}},
Doc-Delivery-Number = {{215JQ}},
Unique-ID = {{ISI:000249805000015}},
}

@article{ ISI:000249151700012,
Author = {Carta, Antonio and Palomba, Michele and Paglietti, Giuseppe and
   Molicotti, Paola and Paglietti, Bianca and Cannas, Sara and Zanetti,
   Stefania},
Title = {{{[}1,2,3]triazolo{[}4,5-h]quinolones. A new class of potent
   antitubercular agents against multidrug resistant Mycobacterium
   tuberculosis strains}},
Journal = {{BIOORGANIC \& MEDICINAL CHEMISTRY LETTERS}},
Year = {{2007}},
Volume = {{17}},
Number = {{17}},
Pages = {{4791-4794}},
Month = {{SEP 1}},
Abstract = {{In this preliminary study we report the activity of
   3-methyl-9-substituted-6-oxo-6,9-dihydro-3H-{[}1,2,3]-triazolo
   {[}4,5-h]quinolone-earboxylic acids and their esters as a new class of
   antiinfective agents against MDR Mycobacterium tuberculosis. In
   antitubercular screening against H37Rv and 11 clinically isolated
   strains of M. tuberculosis several derivatives (1o,3a,c,i,j,p) showed
   MIC90 in the range 0.5-3.2 mu g/mL. 3c showed no cytotoxicity and proved
   to be the most potent derivative exhibiting MIC90 = 0.5 mu g/mL against
   all M. tuberculosis strains and infected human macrophages (J774-A1)
   tested. (c) 2007 Elsevier Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Carta, A (Reprint Author), Univ Sassari, Dipartimento Farmacochim Tossicol, Via Muroni 23-a, I-07100 Sassari, Italy.
   Univ Sassari, Dipartimento Farmacochim Tossicol, I-07100 Sassari, Italy.
   Univ Sassari, Dipartimento Sci Biomed, I-07100 Sassari, Italy.}},
DOI = {{10.1016/j.bmcl.2007.06.064}},
ISSN = {{0960-894X}},
Keywords = {{triazolo{[}4,5-h]quinolones; MDR M. tuberculosis; in vitro
   antitubercular activity}},
Keywords-Plus = {{IN-VITRO; ANTIMICROBIAL EVALUATION; URINARY-TRACT; ANTIMYCOBACTERIAL;
   ACIDS; CIPROFLOXACIN; 1,4-DIOXIDES}},
Research-Areas = {{Pharmacology \& Pharmacy; Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Chemistry, Organic}},
Author-Email = {{acarta@uniss.it}},
ORCID-Numbers = {{PAGLIETTI, Bianca/0000-0002-2568-0642}},
Cited-References = {{ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403.
   Carta A, 2004, EUR J MED CHEM, V39, P195, DOI 10.1016/j.ejmech.2003.11.008.
   Carta A, 2002, EUR J MED CHEM, V37, P355, DOI 10.1016/S0223-5234(02)01346-6.
   Carta A, 2001, HETEROCYCLES, V55, P1133.
   Ginsburg AS, 2003, LANCET INFECT DIS, V3, P432, DOI 10.1016/S1473-3099(03)00671-6.
   HEWER CL, 1949, BRIT MED J, V2, P1521.
   Lalloo UG, 2006, CURR OPIN PULM MED, V12, P179, DOI 10.1097/01.mcp.0000219266.27439.52.
   Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8.
   Milata V, 2001, ADV HETEROCYCL CHEM, V78, P189, DOI 10.1016/S0065-2725(01)78004-X.
   {*}NCCLS, 1995, ANT SUSC TEST MYC TU.
   NUVOLE A, 1989, FARMACO, V44, P619.
   Palaci M, 1996, J CLIN MICROBIOL, V34, P762.
   Sanna P, 2002, FARMACO, V57, P79, DOI 10.1016/S0014-827X(01)01174-0.
   SANNA P, 1992, FARMACO, V47, P1001.
   SANNA P, 1989, FARMACO, V44, P609.
   Sanna P, 2000, EUR J MED CHEM, V35, P535, DOI 10.1016/S0223-5234(00)00144-6.
   Shandil RK, 2007, ANTIMICROB AGENTS CH, V51, P576, DOI 10.1128/AAC.00414-06.
   SRIAM D, 2006, J GEN APPL MICROBIOL, V52, P195.
   Sriram D, 2005, BIOORGAN MED CHEM, V13, P5774, DOI 10.1016/j.bmc.2005.05.063.
   Styblo K, 1982, Indian J Chest Dis Allied Sci, V24, P101.
   WHALEN C, 1995, AM RESP CRIT CARE ME, V51, P129.
   {*}WHO, 2002, GLOB TUB CONTR REP.
   {*}XDRTB, 2006, LANCET, V368, P964.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{21}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Bioorg. Med. Chem. Lett.}},
Doc-Delivery-Number = {{205YS}},
Unique-ID = {{ISI:000249151700012}},
}

@article{ ISI:000250059700014,
Author = {Gelmanova, I. Y. and Keshavjee, S. and Golubchikova, V. T. and Berezina,
   V. I. and Strelis, A. K. and Yanova, G. V. and Atwood, S. and Murray, M.},
Title = {{Barriers to successful tuberculosis treatment in Tomsk, Russian
   Federation: non-adherence, default and the acquisition of multidrug
   resistance}},
Journal = {{BULLETIN OF THE WORLD HEALTH ORGANIZATION}},
Year = {{2007}},
Volume = {{85}},
Number = {{9}},
Pages = {{703-711}},
Month = {{SEP}},
Abstract = {{Objective To identify barriers to successful tuberculosis (TB) treatment
   in Tomsk, Siberia, by analysing individual and programmatic risk factors
   for non-adherence, default and the acquisition of multidrug resistance
   in a TB treatment cohort in the Russian Federation.
   Methods We conducted a retrospective cohort study of consecutively
   enrolled, newly detected, smear and/or culture-positive adult TB
   patients initiating therapy in a DOTS programme in Tomsk between 1
   January and 31 December 2001.
   Findings Substance abuse was strongly associated with non-adherence
   {[}adjusted odds ratio (OR): 7.3; 95\% confidence interval (0):
   2.89-18.46] and with default (adjusted OR: 11.2; 95\% CI: 2.55-49.17).
   Although non-adherence was associated with poor treatment outcomes (OR:
   2.4; 95\% CI: 1.1-5.5), it was not associated with the acquisition of
   multi-drug resistance during the course of therapy. Patients who began
   treatment in the hospital setting or who were hospitalized later during
   their treatment course had a substantially higher risk of developing
   multidrug-resistant TB than those who were treated as outpatients
   (adjusted HRs: 6.34; 95\% Cl: 1.35-29.72 and 6.26; 95\% CI: 1.02-38.35
   respectively).
   Conclusion In this cohort of Russian TB patients, substance abuse was a
   strong predictor of non-adherence and default. DOTS programmes may
   benefit from incorporating measures to diagnose and treat alcohol misuse
   within the medical management of patients undergoing TB therapy.
   Multidrug-resistant TB occurred among adherent patients who had been
   hospitalized in-the course of their therapy. This raises the possibility
   that treatment for drug-sensitive disease unmasked a pre-existing
   population of drug-resistant organisms, or that these patients were
   reinfected with a drug-resistant strain of TB.}},
Publisher = {{WORLD HEALTH ORGANIZATION}},
Address = {{MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Murray, M (Reprint Author), Harvard Univ, Sch Publ Hlth, Div Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Div Epidemiol, Boston, MA 02115 USA.
   Partners Hlth Russia, Moscow, Russia.
   Brigham \& Womens Hosp, Div Social Med \& Hlth Inequalities, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Social Med, Program Infect Dis \& Social Change, Boston, MA USA.
   Partners Hlth, Boston, MA USA.
   Tomsk Oblast Tuberculosis Serv, Tomsk, Russia.
   Siberia State Med Univ, Tomsk, Russia.}},
DOI = {{10.2471/BLT.06.038331}},
ISSN = {{0042-9686}},
Keywords-Plus = {{DIRECTLY OBSERVED THERAPY; PULMONARY TUBERCULOSIS; ST-PETERSBURG;
   TREATMENT COMPLETION; NOSOCOMIAL OUTBREAK; DRUG-RESISTANCE;
   PRIMARY-CARE; REINFECTION; RISK; NONCOMPLIANCE}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{mmurray@hsph.harvard.edu}},
ORCID-Numbers = {{Yanova, Galina/0000-0003-2222-6281}},
Cited-References = {{Bertholet N, 2005, ARCH INTERN MED, V165, P986, DOI 10.1001/archinte.165.9.986.
   Burman WJ, 1997, CHEST, V111, P1168, DOI 10.1378/chest.111.5.1168.
   Cayla JA, 2004, INT J TUBERC LUNG D, V8, P458.
   Chaulk CP, 1998, JAMA-J AM MED ASSOC, V279, P943, DOI 10.1001/jama.279.12.943.
   CORCORAN R, 1986, IRISH MED J, V79, P87.
   Diel R, 2003, INT J TUBERC LUNG D, V7, P124.
   FERRER X, 1991, Boletin de la Oficina Sanitaria Panamericana, V111, P423.
   Fry RS, 2005, INT J TUBERC LUNG D, V9, P1027.
   Goldstein MG, 2004, AM J PREV MED, V27, P61, DOI 10.1016/j.amepre.2004.04.023.
   KOKJENSEN A, 1970, SCAND J RESPIR DIS, V51, P42.
   Krupitsky EM, 2006, EUR ADDICT RES, V12, P12, DOI 10.1159/000088578.
   Kruuner A, 2001, J CLIN MICROBIOL, V39, P3339, DOI 10.1128/JCM.39.9.3339-3345.2001.
   Mathew TA, 2006, INT J TUBERC LUNG D, V10, P857.
   Narvskaya O, 2002, EUR J CLIN MICROBIOL, V21, P596, DOI 10.1007/s10096-002-0775-4.
   PablosMendez A, 1997, AM J MED, V102, P164.
   Raviglione MC, 2002, LANCET, V359, P775, DOI 10.1016/S0140-6736(02)07880-7.
   Rivero A, 2001, CLIN INFECT DIS, V32, P159, DOI 10.1086/317547.
   Salami A K, 2003, West Afr J Med, V22, P114.
   Santha T, 2002, INT J TUBERC LUNG D, V6, P780.
   SCHLUGER N, 1995, AM J RESP CRIT CARE, V151, P1486.
   Seung KJ, 2004, CLIN INFECT DIS, V39, P1321, DOI 10.1086/425005.
   Shilova MV, 2001, PHILOS T ROY SOC B, V356, P1069.
   Toungoussova OS, 2006, TUBERCULOSIS, V86, P1, DOI 10.1016/j.tube.2005.04.001.
   van Rie A, 2005, AM J RESP CRIT CARE, V172, P636, DOI 10.1164/rccm.200503-449OC.
   Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602.
   Veen J, 1998, EUR RESPIR J, V12, P505, DOI 10.1183/09031936.98.12020505.
   Verver S, 2005, AM J RESP CRIT CARE, V171, P1430, DOI 10.1164/rccm.200409-1200OC.
   Whitlock EP, 2004, BEHAV COUNSELING INT.
   Willenbring ML, 2005, AIDS, V19, pS227, DOI 10.1097/01.aids.0000192094.84624.c2.
   {[}Anonymous], 2003, TREATMENT TUBERCULOS.
   2005, GLOBAL TUBERCULOSIS.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{67}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Bull. World Health Organ.}},
Doc-Delivery-Number = {{219BM}},
Unique-ID = {{ISI:000250059700014}},
}

@article{ ISI:000250059700017,
Author = {Odermatt, Peter and Nanthaphone, Sayphone and Barennes, Hubert and
   Chanthavysouk, Khamsay and Tran, Duc-Si and Kosanouvong, Bounsou and
   Keola, Siamphay and Mathouchanh, Phetsamone and Choumlivong, Khamloune
   and Keoluangkhot, Valy and Niranh, Phoumindr and Nanthanavone, Sixomxay
   and Phrommala, Souraxay and Degremont, Antoine and Strobel, Michel},
Title = {{Improving tuberculosis case detection rate with a lay informant
   questionnaire: an experience from the Lao People's Democratic Republic}},
Journal = {{BULLETIN OF THE WORLD HEALTH ORGANIZATION}},
Year = {{2007}},
Volume = {{85}},
Number = {{9}},
Pages = {{727-731}},
Month = {{SEP}},
Abstract = {{Problem In many countries, the tuberculosis (TB) annual case detection
   rate is below the target of 70\%. In the Lao People's Democratic
   Republic in 2005, it did not exceed 55\%.
   Approach The DOTS strategy promotes passive case detection of TB. In
   order to increase the detection rate, we validated a questionnaire
   targeting lay informants at village level to notify patients with
   chronic cough and assessed the relevance for TB case-finding. A
   three-item questionnaire was sent through the district health
   departments to all villages in six districts in six provinces. The
   village headmen were asked to notify chronic cough patients. Answers
   were validated in a door-to-door survey (20 villages/district). In a
   sub-sample (four villages/district) all confirmed patients were screened
   for TB and paragonimiasis.
   Local setting Attapeu, Luang Namtha, Luang Prabang, Saravane, Savanakhet
   and Vientiane provinces in the Lao People's Democratic Republic.
   Relevant changes Lay informant questionnaires sent from district health
   offices to villages are cost-effective and foster interaction between
   the health services and remote and underserved communities. Although the
   correct detection of patients is highly dependent on direct respondents,
   a substantial number of new TB and paragonimiasis cases were
   consistently diagnosed in chronic cough patients.
   Lessons learned Out of 456 questionnaires, 295 were returned (65\%).
   Return rates were highly variable between districts (48-87\%),
   questionnaires' sensitivity (56-98\%), positive predictive value
   (34-88\%) and correlation between number of notified and confirmed
   patients (r.0.26-0.78). In sub-sampled villages (13541 population) 19
   (5.1\%) TB and 26 (7.0\%) paragonimiasis cases were detected in 374
   chronic cough patients. This quick questionnaire approach proved
   motivating for district authorities and village key informants, although
   no incentives were provided. The highly operator-dependent approach
   yielded a consistent detection rate of TB and paragonimiasis cases. This
   approach brings health services and populations in need in close
   contact, which is particularly crucial in remote and underserved areas.}},
Publisher = {{WORLD HEALTH ORGANIZATION}},
Address = {{MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Odermatt, P (Reprint Author), Swiss Trop Inst, Dept Publ Hlth \& Epidemiol, POB 4002, Basel, Switzerland.
   Swiss Trop Inst, Dept Publ Hlth \& Epidemiol, Basel, Switzerland.
   Inst Francophonie Pour Med Trop, Viangchan, Laos.
   Natl Univ Laos, Fac Med Sci, Viangchan, Laos.
   Minist Hlth, Natl Publ Hlth Inst, Viangchan, Laos.}},
DOI = {{10.2471/BLT.06.038539}},
ISSN = {{0042-9686}},
Keywords-Plus = {{PREVALENCE; BURDEN; HIV}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{peter.odermatt@unibas.ch}},
ResearcherID-Numbers = {{Barennes, hubert/E-9728-2011}},
Cited-References = {{Arnadottir T, 2001, INT J TUBERC LUNG D, V5, P391.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Currie CSM, 2003, AIDS, V17, P2501, DOI 10.1097/00002030-200311210-00013.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   Golub JE, 2005, INT J TUBERC LUNG D, V9, P1183.
   Lengeler C, 2002, B WORLD HEALTH ORGAN, V80, P235.
   Murray CJL, 1998, INT J TUBERC LUNG D, V2, pS9.
   NSANZUMUHIRE H, 1977, TUBERCLE, V58, P117, DOI 10.1016/0041-3879(77)90012-5.
   ODERMATT P, 2007, IN PRESS ACTA TROPIC.
   Strobel M, 2005, MED MALADIES INFECT, V35, P476, DOI 10.1016/j.medmal.2005.08.002.
   TRAN DS, 2004, SE ASIAN J TROP MED, V35, P323.
   2006, TUBERCULOSIS CONTROL.}},
Number-of-Cited-References = {{12}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Bull. World Health Organ.}},
Doc-Delivery-Number = {{219BM}},
Unique-ID = {{ISI:000250059700017}},
}

@article{ ISI:000254288800001,
Author = {Long, Richard and Ellis, Edward},
Title = {{Introducing the sixth edition of the Canadian Tuberculosis Standards}},
Journal = {{CANADIAN JOURNAL OF INFECTIOUS DISEASES \& MEDICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{18}},
Number = {{5}},
Pages = {{283-284}},
Month = {{SEP-OCT}},
Publisher = {{PULSUS GROUP INC}},
Address = {{2902 S SHERIDAN WAY, OAKVILLE, ONTARIO L6J 7L6, CANADA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Long, R (Reprint Author), Aberhart Hosp, TB Program Evaluat \& Res Unit, Room 8325,11402 Univ Ave, Edmonton, AB T6G 2J3, Canada.
   Long, Richard, TB Committee Canadian Thorac Soc Canadian Lung As, Ottawa, ON, Canada.
   Ellis, Edward, Publ Hlth Agcy Canada, TB Prevent \& Control Program, Ottawa, ON, Canada.}},
ISSN = {{1712-9532}},
Research-Areas = {{Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology}},
Author-Email = {{richard.long@ualberta.ca}},
Cited-References = {{GROSS PA, 1994, CLIN INFECT DIS, V18, P421.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Can. J. Infect. Dis. Med. Microbiol.}},
Doc-Delivery-Number = {{278LZ}},
Unique-ID = {{ISI:000254288800001}},
}

@article{ ISI:000254288800003,
Author = {Alexander, Paul E. and De, Prithwish},
Title = {{The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV
   coinfection, multidrug-resistant TB and the resulting public health
   threat from extensively drug-resistant TB, globally and in Canada}},
Journal = {{CANADIAN JOURNAL OF INFECTIOUS DISEASES \& MEDICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{18}},
Number = {{5}},
Pages = {{289-291}},
Month = {{SEP-OCT}},
Abstract = {{Resistance to anti- tuberculosis (TB) drugs continues to present a major
   challenge to global public health. Resistance usually develops due to
   inadequate TB management, including improper use of medications,
   improper treatment regimens and failure to complete the treatment
   course. This may be due to an erratic supply or a lack of access to
   treatment, as well as to patient noncompliance. However, the emergence
   and transmission of drug-resistant TB, including the recently detected
   extensively drug resistant TB (XDR-TB), is driven, in part, by the
   synergistic relationship between TB and HIV (TB/HIV coinfection). There
   is evidence that persons infected with HIV are more likely to experience
   XDR-TB. XDR-TB is virtually untreatable with available TB medications.
   XDR-TB presents a grave global public health threat, particularly in
   high HIV prevalence settings. The present commentary discusses the
   Current status of XDR-TB and draws attention to the urgency in
   addressing this problem, for both the global and Canadian public health
   networks. XDR-TB and the apparent XDR-TB and HIV association warrants
   further study.}},
Publisher = {{PULSUS GROUP INC}},
Address = {{2902 S SHERIDAN WAY, OAKVILLE, ONTARIO L6J 7L6, CANADA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Alexander, PE (Reprint Author), 890 Sheppard Ave W,U-504, Toronto, ON M3H 6B9, Canada.
   Alexander, Paul E., Hlth Canada, S Asian Assoc Reg Cooperat Canada, Toronto, ON, Canada.
   De, Prithwish, McGill Univ, Dept Epidemiol \& Biostat, Montreal, PQ, Canada.}},
ISSN = {{1712-9532}},
Keywords = {{coinfection; drug resistance; HIV; MDR-TB; TB/HIV; tuberculosis; XDR-TB}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; HIV; OUTBREAK; DISEASE; IMPACT}},
Research-Areas = {{Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology}},
Author-Email = {{elias98\_99@yahoo.com}},
Cited-References = {{BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   Campos PE, 2003, EMERG INFECT DIS, V9, P1571.
   Cantwell MF, 1997, INT J TUBERC LUNG D, V1, P205.
   Centers for Disease Control and Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P301.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Cosivi O, 1998, EMERG INFECT DIS, V4, P59.
   Dahle UR, 2006, BRIT MED J, V333, P705, DOI 10.1136/bmj.333.7570.705.
   Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Goletti D, 1996, J IMMUNOL, V157, P1271.
   Masjedi MR, 2006, CLIN INFECT DIS, V43, P841, DOI 10.1086/507542.
   Narain JP, 2002, TUBERCULOSIS EPIDEMI.
   Punnotok J, 2000, INT J TUBERC LUNG D, V4, P537.
   Raviglione M C, 1997, AIDS, V11 Suppl B, pS115.
   Raviglione MC, 2007, NEW ENGL J MED, V356, P656, DOI 10.1056/NEJMp068273.
   Toossi Z, 2003, J INFECT DIS, V188, P1146, DOI 10.1086/378676.
   {*}UNAIDS UNAIDS WHO, 2007, AIDS EP UPD.
   UNAIDS/WHO-Joint United Nations Programme on HIV/AIDS, 2002, AIDS EP UPD.
   {*}WHO, 2007, EM XDR TB WHO CONC E.
   {*}WHO, 2007, TUB TB XDR TB EXT DR.
   {[}Anonymous], 2007, AIDS EP UPD.
   Yang H, 2005, INT J TUBERC LUNG D, V9, P288.
   Zachariah R, 2005, INT J TUBERC LUNG D, V9, P238.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Can. J. Infect. Dis. Med. Microbiol.}},
Doc-Delivery-Number = {{278LZ}},
Unique-ID = {{ISI:000254288800003}},
}

@article{ ISI:000254272800002,
Author = {Long, Richard and Ellis, Edward},
Title = {{Introducing the sixth edition of the Canadian Tuberculosis Standards}},
Journal = {{CANADIAN RESPIRATORY JOURNAL}},
Year = {{2007}},
Volume = {{14}},
Number = {{6}},
Pages = {{327-328}},
Month = {{SEP}},
Publisher = {{PULSUS GROUP INC}},
Address = {{2902 S SHERIDAN WAY, OAKVILLE, ONTARIO L6J 7L6, CANADA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Long, R (Reprint Author), Aberhart Hosp, TB Program Evaluat, Room 8325,11402 Univ Ave, Edmonton, AB T6G 2J3, Canada.
   Long, Richard, Canadian Lung Assoc, Canadian Thorac Soc, TB Comm, Ottawa, ON, Canada.
   Ellis, Edward, Publ Hlth Agcy Canada, TB Prevent \& Control Program, Ottawa, ON, Canada.}},
ISSN = {{1198-2241}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Author-Email = {{richard.long@ualberta.ca}},
Cited-References = {{GROSS PA, 1994, CLIN INFECT DIS, V18, P421.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Can. Respir. J.}},
Doc-Delivery-Number = {{278GK}},
Unique-ID = {{ISI:000254272800002}},
}

@article{ ISI:000249742100035,
Author = {Guerra, Renata L. and Hooper, Nancy M. and Baker, James F. and Alborz,
   Roya and Armstrong, Derek T. and Maltas, Gina and Kiehlbauch, Julia A.
   and Dorman, Susan E.},
Title = {{Use of the amplified Mycobacterium tuberculosis direct test in a public
   health laboratory - Test performance and impact on clinical care}},
Journal = {{CHEST}},
Year = {{2007}},
Volume = {{132}},
Number = {{3}},
Pages = {{946-951}},
Month = {{SEP}},
Abstract = {{Background: The Amplified Mycobacterium tuberculosis Direct Test (MTD;
   Gen-Probe; San Diego, CA) is a nucleic-acid amplification test for rapid
   pulmonary tuberculosis (PTB) diagnosis. In a routine public health
   setting, test accuracy and impact on clinical decisions are unknown.
   Methods: Retrospectively, we evaluated MTD accuracy and impact on
   clinical decisions in a public health setting. To estimate MTD accuracy,
   mycobacterial culture was used as the ``gold standard.{''} To evaluate
   MTD impact on clinical decisions, concordance of clinician presumptive
   diagnosis (at time of MTD and smear availability) and definitive
   diagnosis, and duration of nonindicated tuberculosis therapy were
   determined for smear-positive PTB suspects in a period of MTD
   availability (MTD group) and a prior period of MTD nonavailability
   (non-MTD group). Results: A total of 1,151 respiratory specimens from
   638 PTB suspects were analyzed. MTD sensitivity, specificity, positive
   predictive value, and negative predictive value were 91.7\%, 98.7\%,
   96.7\%, and 96.5\% overall, respectively; and 98.7\%, 97.8\%, 98.7\%,
   and 97.8\% for smear-positive patients; and 62.2\%, 98.9\%, 85.2\%, and
   96.1\% for smear-negative patients. In the MTD group, concordance
   between definitive and clinician presumptive diagnoses was 78\% (95\%
   confidence interval {[}CI], 64 to 88\%), similar to that for the non-MTD
   group (79\%; 95\% CI, 68.4 to 89.6\%). However, concordance between
   definitive diagnosis and the MTD test was 98\% (95\% CL 94.1 to 100\%).
   Median duration of nonindicated tuberculosis treatment was 6 days for
   the MTD group vs 31 days for the non-MTD group (p = 0.002). Conclusion:
   In this public health setting, MTD was accurate and rapidly detected
   more than half of the smear-negative PTB cases. For smear-positive PTB
   suspects, MTD had excellent concordance with definitive diagnosis, but
   clinicians often inappropriately initiated TB therapy despite a negative
   MTD result.}},
Publisher = {{AMER COLL CHEST PHYSICIANS}},
Address = {{3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Dorman, SE (Reprint Author), Johns Hopkins Univ, Sch Med, Room 1M-06,1550 Orleans St, Baltimore, MD 21231 USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD 21231 USA.
   Maryland Dept Hlth \& Mental Hyg, Baltimore, MD 21201 USA.}},
DOI = {{10.1378/chest.06-2959}},
ISSN = {{0012-3692}},
Keywords = {{Mycobacterium tuberculosis direct test; diagnosis; respiratory
   specimens; tuberculosis; amplified}},
Keywords-Plus = {{NONTUBERCULOUS MYCOBACTERIA; RAPID DIAGNOSIS; SPECIMENS}},
Research-Areas = {{General \& Internal Medicine; Respiratory System}},
Web-of-Science-Categories  = {{Critical Care Medicine; Respiratory System}},
Author-Email = {{dsusan1@jhmi.edu}},
ORCID-Numbers = {{Guerra, Renata/0000-0002-7507-6435}},
Funding-Acknowledgement = {{FIC NIH HHS {[}D43 TW05574-01, U2R TW006883]; NIAID NIH HHS
   {[}K23AI51528, U19AI45432]}},
Cited-References = {{American Thoracic Society, 1997, AM J RESP CRIT CARE, V156, pS1.
   Bergmann JS, 1999, J CLIN MICROBIOL, V37, P1419.
   Catanzaro A, 2000, JAMA-J AM MED ASSOC, V283, P639, DOI 10.1001/jama.283.5.639.
   Catanzaro A, 1997, AM J RESP CRIT CARE, V155, P1804.
   Coll P, 2003, INT J TUBERC LUNG D, V7, P886.
   Gamboa F, 1998, J CLIN MICROBIOL, V36, P684.
   Kent PT, 1985, PUBLIC HLTH MYCOBACT.
   Lim TK, 2003, CHEST, V124, P902, DOI 10.1378/chest.124.3.902.
   Marras TK, 2002, CLIN CHEST MED, V23, P553, DOI 10.1016/S0272-5231(02)00019-9.
   Murray P. R., 1999, MANUAL CLIN MICROBIO.
   Sloutsky A, 2004, J CLIN MICROBIOL, V42, P1547, DOI 10.1128/JCM.42.4.1547-1551.2004.
   Somoskovi A, 2000, J CLIN MICROBIOL, V38, P2743.
   Woods GL, 2001, ARCH PATHOL LAB MED, V125, P122.
   Wright PW, 1998, J CLIN MICROBIOL, V36, P1046.
   GEN PROBE AMPLIFIED.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{34}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Chest}},
Doc-Delivery-Number = {{214MN}},
Unique-ID = {{ISI:000249742100035}},
}

@article{ ISI:000249742100037,
Author = {Kang, Young Ae and Lee, Hye Won and Hwang, Seung Sik and Um, Sang-Won
   and Han, Sung Koo and Shim, Young-Soo and Yim, Jae-Joon},
Title = {{Usefulness of whole-blood interferon-gamma assay and interferon-gamma
   enzyme-linked immunospot assay in the diagnosis of active pulmonary
   tuberculosis}},
Journal = {{CHEST}},
Year = {{2007}},
Volume = {{132}},
Number = {{3}},
Pages = {{959-965}},
Month = {{SEP}},
Abstract = {{Purpose: The aim of this study was to evaluate the usefulness of the
   whole-blood interferon-gamma assay (enzyme-linked immunosorbent assay
   {[}ELISA]) and interferon-gamma enzyme-linked immuno-spot assay
   (ELISPOT) based on early secretory antigenic target 6 and culture
   filtrate protein 10 in the diagnosis of active pulmonary tuberculosis
   (TB) in routine clinical practice. Method: We conducted a prospective
   study enrolling 144 participants with suspected pulmonary TB in a
   tertiary referral hospital in Seoul, South Korea, to investigate the
   diagnostic sensitivity, specificity, positive predictive value (PPV),
   and negative predictive value (NPV) of these tests. Clinical assessment,
   tuberculin skin test (TST), whole-blood interferon-gamma ELISA
   (Quanti-FERON-TB Gold {[}QFT-G]; Cellestis Ltd; Victoria, Australia),
   and an ELISPOT assay (T SPOT.TB; Oxford Immunotec; Oxford, UK) were
   performed. Test results were compared with the final confirmed
   diagnoses. Results: Active pulmonary TB was diagnosed in 67 of 144
   participants (47\%). Sensitivities of QFT-G and T SPOT.TB for active
   pulmonary TB were 89\% (95\% confidence interval {[}CI], 79 to 96\%) and
   92\% (95\% Cl, 83 to 97\%), respectively; and specificities were 49\%
   (95\% Cl, 37 to 61\%) and 47\% (95\% Cl, 36 to 59\%). NPVs of QFT-G
   (84\%; 95\% CI, 69 to 93\%) and T SPOT.TB (S7\%; 95\% CI, 73 to 96\%)
   were higher than that of TST (64\%; 95\% CI, 51 to 76\%) {[}p = 0.001
   and p < 0.001, respectively]. Conclusion: High NPVs of QFT-G and T
   SPOT.TB for the diagnosis of active TB suggest the supplementary role of
   these tests for the diagnostic exclusion of active TB, although the low
   PPV limits their usefulness in routine clinical practice in South Korea,
   where the prevalence of latent TB infection is considerable.}},
Publisher = {{AMER COLL CHEST PHYSICIANS}},
Address = {{3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Yim, JJ (Reprint Author), Seoul Natl Univ, Coll Med, Dept Internal Med, Div Pulm \& Crit Care Med, 28 Yongon Dong, Seoul 110744, South Korea.
   Seoul Natl Univ, Coll Med, Dept Internal Med, Div Pulm \& Crit Care Med, Seoul 110744, South Korea.
   Seoul Natl Univ, Coll Med, Lung Inst, Seoul 110744, South Korea.
   Natl Canc Ctr, Natl Canc Control Res Inst, Goyang, South Korea.}},
DOI = {{10.1378/chest.06-2805}},
ISSN = {{0012-3692}},
Keywords = {{culture filtrate protein 10; diagnosis; early secretory antigenic target
   6; interferon-gamma; tuberculosis}},
Keywords-Plus = {{CELL-BASED ASSAY; MYCOBACTERIUM-TUBERCULOSIS; SKIN-TEST; T-CELLS;
   CLINICAL-PRACTICE; INFECTION; CHILDREN; ENUMERATION; PREVALENCE;
   ANTIGENS}},
Research-Areas = {{General \& Internal Medicine; Respiratory System}},
Web-of-Science-Categories  = {{Critical Care Medicine; Respiratory System}},
Author-Email = {{yimjj@snu.ac.kr}},
ResearcherID-Numbers = {{Yim, Jae Joon/J-2783-2012
   Han, Sung Koo/J-5706-2012}},
Cited-References = {{ABER VR, 1980, TUBERCLE, V61, P123, DOI 10.1016/0041-3879(80)90001-X.
   American Thoracic Society, 2000, AM J RESP CRIT CARE, V161, pS221.
   AMERICAN THORACIC SOCIETY, 2000, AM J RESP CRIT CARE, V161, P1376, DOI {[}DOI 10.1164/AJRCCM.161.4.16141, 10.1164/ajrccm.161.4.16141].
   Brock Iinger, 2004, American Journal of Respiratory and Critical Care Medicine, V170, P65, DOI 10.1164/rccm.200402-232OC.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Dewan PK, 2007, CLIN INFECT DIS, V44, P69, DOI 10.1086/509928.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9.
   Ferrara G, 2005, AM J RESP CRIT CARE, V172, P631, DOI 10.1164/rccm.200502-196OC.
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6.
   Fleiss JL, 2004, STAT METHODS RATES P, P598, DOI DOI 10.1002/0471445428.CH18.
   Fourie PB, 1998, INT J TUBERC LUNG D, V2, P116.
   Hong YP, 1998, INT J TUBERC LUNG D, V2, P27.
   Houwert KAF, 1998, EUR RESPIR J, V11, P1116, DOI 10.1183/09031936.98.11051116.
   Kang YA, 2005, JAMA-J AM MED ASSOC, V293, P2756, DOI 10.1001/jama.293.22.2756.
   Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824.
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081.
   Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1.
   Lee JY, 2006, EUR RESPIR J, V28, P24, DOI 10.1183/09031936.06.00016906.
   Liebeschuetz S, 2004, LANCET, V364, P2196, DOI 10.1016/S0140-6736(04)17592-2.
   MANCHIN D, 1997, SAMPLE SIZE TABLES C.
   Mazurek Gerald H., 2005, Morbidity and Mortality Weekly Report, V54, P49.
   Meier T, 2005, EUR J CLIN MICROBIOL, V24, P529, DOI 10.1007/s10096-005-1377-8.
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC.
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.
   Piana F, 2006, AM J RESP CRIT CARE, V173, P130.
   Ravn P, 2005, CLIN DIAGN LAB IMMUN, V12, P491, DOI 10.1128/CDLI.12.4.491-496.2005.
   Richeldi L, 2004, ANN INTERN MED, V140, P709.
   Richeldi L, 2006, AM J RESP CRIT CARE, V174, P736, DOI 10.1164/rccm.200509-1516PP.
   Sant'Anna CC, 2006, INT J TUBERC LUNG D, V10, P463.
   Siddiqi K, 2003, LANCET INFECT DIS, V3, P288, DOI 10.1016/S1473-3099(03)00609-1.
   SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.
   World Health Organization, TUB.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{98}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Chest}},
Doc-Delivery-Number = {{214MN}},
Unique-ID = {{ISI:000249742100037}},
}

@article{ ISI:000248978200021,
Author = {dos Santos, Jr., R. Rodrigues and Sartori, A. and Bonato, V. L. Deperon
   and Castelo, A. A. M. Coelho and Vilella, C. A. and Zollner, R. L. and
   Silva, C. Lopes},
Title = {{Immune modulation induced by tuberculosis DNA vaccine protects non-obese
   diabetic mice from diabetes progression}},
Journal = {{CLINICAL AND EXPERIMENTAL IMMUNOLOGY}},
Year = {{2007}},
Volume = {{149}},
Number = {{3}},
Pages = {{570-578}},
Month = {{SEP}},
Abstract = {{We have described previously the prophylactic and therapeutic effect of
   a DNA vaccine encoding the Mycobacterium leprae 65 kDa heat shock
   protein (DNA-HSP65) in experimental murine tuberculosis. However, the
   high homology of this protein to the corresponding mammalian 60 kDa heat
   shock protein (Hsp60), together with the CpG motifs in the plasmid
   vector, could trigger or exacerbate the development of autoimmune
   diseases. The non-obese diabetic (NOD) mouse develops insulin-dependent
   diabetes mellitus (IDDM) spontaneously as a consequence of an autoimmune
   process that leads to destruction of the insulin-producing beta cells of
   the pancreas. IDDM is characterized by increased T helper 1 (Th1) cell
   responses toward several autoantigens, including Hsp60, glutamic acid
   decarboxylase and insulin. In the present study, we evaluated the
   potential of DNA-HSP65 injection to modulate diabetes in NOD mice. Our
   results show that DNA-HSP65 or DNA empty vector had no diabetogenic
   effect and actually protected NOD mice against the development of severe
   diabetes. However, this effect was more pronounced in DNA-HSP65-injected
   mice. The protective effect of DNA-HSP65 injection was associated with a
   clear shift in the cellular infiltration pattern in the pancreas. This
   change included reduction of CD4(+) and CD8(+) T cells infiltration,
   appearance of CD25(+) cells influx and an increased staining for
   interleukin (IL)-10 in the islets. These results show that DNA-HSP65 can
   protect NOD mice against diabetes and can therefore be considered in the
   development of new immunotherapeutic strategies.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Silva, CL (Reprint Author), Fac Med Ribeirao Preto, Dept Bioquim \& Imunol, Ave Bandeirantes 3900,Campus USP, BR-14049900 Ribeirao Preto, SP, Brazil.
   Fac Med Ribeirao Preto, Dept Bioquim \& Imunol, BR-14049900 Ribeirao Preto, SP, Brazil.
   UNESP, Inst Biociencias, Botucatu, SP, Brazil.
   Univ Estadual Campinas, Fac Ciencias Med, Dept Clin Med, Lab Imunol Clin, Campinas, SP, Brazil.}},
DOI = {{10.1111/j.1365-2249.2007.03433.x}},
ISSN = {{0009-9104}},
Keywords = {{cytokines; diabetes; DNA vaccine; heat shock protein (Hsp65)}},
Keywords-Plus = {{HEAT-SHOCK-PROTEIN; PREVENTS AUTOIMMUNE-DISEASE; IMMUNOREGULATORY
   T-CELLS; NOD MICE; MYCOBACTERIUM-TUBERCULOSIS; EFFECTOR FUNCTION;
   PLASMID DNA; IFN-GAMMA; IMMUNIZATION; ARTHRITIS}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{clsilva@fmrp.usp.br}},
ResearcherID-Numbers = {{Coelho Castelo, Arlete/C-8530-2012
   Sartori, Alexandrina /B-2951-2013
   Silva, Celio/C-4639-2012}},
Cited-References = {{Ablamunits V, 1998, J AUTOIMMUN, V11, P73, DOI 10.1006/jaut.1997.0177.
   Afek A, 2000, J AUTOIMMUN, V14, P115, DOI 10.1006/jaut.1999.0351.
   Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995.
   Birk OS, 1996, J AUTOIMMUN, V9, P159, DOI 10.1006/jaut.1996.0019.
   Bonato VLD, 1998, INFECT IMMUN, V66, P169.
   Bonato VLD, 2004, IMMUNOLOGY, V113, P130, DOI 10.1046/j.1365-2567.2004.01931.x.
   Bras A, 1996, IMMUNOLOGY, V89, P20, DOI 10.1046/j.1365-2567.1996.d01-717.x.
   Coon B, 1999, J CLIN INVEST, V104, P189, DOI 10.1172/JCI7209.
   DANIELI MG, 1992, CLIN IMMUNOL IMMUNOP, V64, P121, DOI 10.1016/0090-1229(92)90189-U.
   DiLorenzo TP, 2005, IMMUNOL REV, V204, P250, DOI 10.1111/j.0105-2896.2005.00244.x.
   ELIAS D, 1991, P NATL ACAD SCI USA, V88, P3088, DOI 10.1073/pnas.88.8.3088.
   Elias D, 1997, DIABETES, V46, P758, DOI 10.2337/diabetes.46.5.758.
   ELIAS D, 1995, DIABETES, V44, P1132, DOI 10.2337/diabetes.44.9.1132.
   Feige U, 1996, EXS, V77, P359.
   Goudy KS, 2005, INT REV IMMUNOL, V24, P307, DOI 10.1080/08830180500379721.
   Gupta M M, 1991, J Assoc Physicians India, V39, P540.
   Gurunathan S, 2000, CURR OPIN IMMUNOL, V12, P442, DOI 10.1016/S0952-7915(00)00118-7.
   Hassett DE, 2000, J VIROL, V74, P2620, DOI 10.1128/JVI.74.6.2620-2627.2000.
   Homann D, 1999, IMMUNITY, V11, P463, DOI 10.1016/S1074-7613(00)80121-1.
   Jaeschke A, 2005, P NATL ACAD SCI USA, V102, P6931, DOI 10.1073/pnas.0502143102.
   Kallmann BA, 1999, DIABETOLOGIA, V42, P1080, DOI 10.1007/s001250051274.
   Keren P, 2000, DIABETES, V49, P1064, DOI 10.2337/diabetes.49.6.1064.
   Krause I, 1999, J AUTOIMMUN, V13, P49, DOI 10.1006/jaut.1999.0292.
   LOWRIE DB, 1994, VACCINE, V12, P1537, DOI 10.1016/0264-410X(94)90080-9.
   Lowrie DB, 1997, VACCINE, V15, P834, DOI 10.1016/S0264-410X(97)00073-X.
   Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326.
   Pavin E. J., 1994, BRAZILIAN ARCHIVES E, V38, P105.
   Portaro FCV, 2002, BIOCHEMISTRY-US, V41, P7400, DOI 10.1021/bi0119991.
   Quintana FJ, 2000, J IMMUNOL, V165, P6148.
   Quintana FJ, 2002, J IMMUNOL, V169, P6030.
   Ruiz PJ, 1999, J IMMUNOL, V162, P3336.
   Santos-Junior RR, 2005, HUM GENE THER, V16, P1338, DOI 10.1089/hum.2005.16.1338.
   Silva CL, 1999, IMMUNOLOGY, V97, P573.
   Silva CL, 2000, INFECT IMMUN, V68, P3269, DOI 10.1128/IAI.68.6.3269-3274.2000.
   Silva CL, 1996, INFECT IMMUN, V64, P2400.
   SILVA CL, 2004, VACINAS GENICAS CAPI, P463.
   Stevenson FK, 1999, SEMIN HEMATOL, V36, P38.
   Suri-Payer E, 1998, J IMMUNOL, V160, P1212.
   Syrengelas AD, 1996, NAT MED, V2, P1038, DOI 10.1038/nm0996-1038.
   Takahashi T, 2003, CURR MOL MED, V3, P693, DOI 10.2174/1566524033479429.
   Tanaka S, 1999, J IMMUNOL, V163, P5560.
   Thompson SJ, 1998, J IMMUNOL, V160, P4628.
   Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287.
   Thornton AM, 2000, J IMMUNOL, V164, P183.
   Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X.
   Ulmer JB, 1998, J VIROL, V72, P5648.
   van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593.
   VANEDEN W, 1991, IMMUNOL REV, V121, P5.
   Ventura-Oliveira D, 2002, BRAZ J MED BIOL RES, V35, P1347, DOI 10.1590/S0100-879X2002001100013.
   Waisman A, 1996, NAT MED, V2, P899, DOI 10.1038/nm0896-899.
   Walter U, 2003, DIABETOLOGIA, V46, P1106, DOI 10.1007/s00125-003-1164-y.}},
Number-of-Cited-References = {{51}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Clin. Exp. Immunol.}},
Doc-Delivery-Number = {{203MH}},
Unique-ID = {{ISI:000248978200021}},
}

@article{ ISI:000249488400013,
Author = {Lyashchenko, Konstantin P. and Greenwald, Rena and Esfandiari, Javan and
   Greenwald, David and Nacy, Carol A. and Gibson, Susan and Didier, Peter
   J. and Washington, Marc and Szczerba, Peter and Motzel, Sherri and
   Handt, Larry and Pollock, John M. and McNair, James and Andersen, Peter
   and Langermans, Jan A. M. and Verreck, Frank and Ervin, Sean and Ervin,
   Frank and McCombs, Candace},
Title = {{Prima TB STAT-PAK assay, a novel, rapid lateral-flow test for
   tuberculosis in nonhuman primates}},
Journal = {{CLINICAL AND VACCINE IMMUNOLOGY}},
Year = {{2007}},
Volume = {{14}},
Number = {{9}},
Pages = {{1158-1164}},
Month = {{SEP}},
Abstract = {{Tuberculosis (TB) is the most important zoonotic bacterial disease in
   nonhuman primates (NHP). The current diagnostic method, the intradermal
   palpebral tuberculin test, has serious shortcomings. We characterized
   antibody responses in NHP against Mycobacterium tuberculosis to identify
   inummodominant antigens and develop a rapid serodiagnostic test for TB.
   A total of 422 NHP were evaluated, including 243 rhesus (Macaca
   mulatta), 46 cynomolgus (Macaca fascicularis), and 133 African green
   (Cercopithecus aethiops sabaeus) monkeys at five collaborative centers.
   Of those, 50 monkeys of the three species were experimentally inoculated
   with M. tuberculosis. Antibody responses were monitored every 2 to 4
   weeks for up to 8 months postinfection by MultiAntigen Print ImmunoAssay
   with a panel of 12 recombinant antigens. All of the infected monkeys
   produced antibodies at various levels and with different antigen
   recognition patterns. ESAT-6 and MPB83 were the most frequently
   recognized proteins during infection. A combination of selected antigens
   which detected antibodies in all of the infected monkeys was designed to
   develop the PrimaTB STAT-PAK assay by lateral-flow technology.
   Serological evaluation demonstrated high diagnostic sensitivity (90\%)
   and specificity (99\%). The highest rate of TB detection was achieved
   when the skin test was combined with the PrimaTB STAT-PAK kit. This
   novel immunoassay provides a simple, rapid, and accurate test for TB in
   NHP.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Lyashchenko, KP (Reprint Author), Chembio Diagnost Syst Inc, 3661 Horseblock Rd, Medford, NY 11763 USA.
   Chembio Diagnost Syst Inc, Medford, NY 11763 USA.
   Sequella Inc, Rockville, MD USA.
   Univ S Alabama, Mobile, AL 36688 USA.
   Tulane Natl Res Primate Ctr, Covington, LA USA.
   Merck Res Labs, West Point, PA USA.
   Vet Sci Div, Belfast, Antrim, North Ireland.
   Statens Serum Inst, DK-2300 Copenhagen, Denmark.
   Anim Sci Grp Wageningen UR, Lelystad, Netherlands.
   Biomed Primate Res Ctr, Rijswijk, Netherlands.
   Behav Sci Fdn Labs, Basseterre, St Kitts, Dominica.}},
DOI = {{10.1128/CVI.00230-07}},
ISSN = {{1556-6811}},
Keywords-Plus = {{VIRULENT MYCOBACTERIUM-TUBERCULOSIS; MACACA-MULATTA; ANTIGEN
   RECOGNITION; ANTIBODY-RESPONSES; SERUM ANTIBODIES; SKIN REACTIVITY;
   CALMETTE-GUERIN; RHESUS-MONKEYS; DIAGNOSIS; BOVIS}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{kiyashchenko@chembio.com}},
Funding-Acknowledgement = {{NCRR NIH HHS {[}R44 RR019845, RR019845]}},
Cited-References = {{Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2.
   BARAM P, 1971, LAB ANIM SCI, V21, P727.
   Brusasca PN, 2003, COMPARATIVE MED, V53, P165.
   CHAPARAS SD, 1975, AM REV RESPIR DIS, V112, P43.
   CORCORAN KD, 1991, LAB ANIM SCI, V41, P57.
   CORCORAN KD, 1991, J MED PRIMATOL, V20, P404.
   CUPUANO SV, 2003, INFECT IMMUN, V71, P5831.
   DeMarcus TA, 1999, J INFECT DIS, V179, pS281, DOI 10.1086/514279.
   FIFE EH, 1970, LAB ANIM CARE, V20, P969.
   FLEISCHMAN RW, 1982, J AM VET MED ASSOC, V181, P1358.
   Flynn JL, 2003, TUBERCULOSIS, V83, P116, DOI 10.1016/S1472-9792(02)00059-8.
   FOX JG, 1982, J MED PRIMATOL, V11, P380.
   Garcia MA, 2004, COMPARATIVE MED, V54, P578.
   Garcia MA, 2004, COMPARATIVE MED, V54, P86.
   GOODWIN BT, 1988, LAB ANIM SCI, V38, P20.
   Greenwald R, 2003, DIAGN MICR INFEC DIS, V46, P197, DOI 10.1016/S0732-8893(03)00046-4.
   Holmberg C A, 1982, Vet Pathol Suppl, V7, P9.
   Houghton RL, 2002, CLIN DIAGN LAB IMMUN, V9, P883, DOI 10.1128/CDLI.9.4.883-891.2002.
   JACKSON RK, 1989, LAB ANIM SCI, V39, P425.
   Kanaujia GV, 2003, COMPARATIVE MED, V53, P602.
   Lyashchenko K, 2004, INFECT IMMUN, V72, P2462, DOI 10.1128/IAI.72.5.2462-2467.2004.
   Lyashchenko KP, 2006, CLIN VACCINE IMMUNOL, V13, P722, DOI 10.1128/CVI.00133-06.
   Lyashchenko KP, 2000, J IMMUNOL METHODS, V242, P91, DOI 10.1016/S0022-1759(00)00241-6.
   MAHFOUZ O M, 1980, Tubercle, V61, P1, DOI 10.1016/0041-3879(80)90053-7.
   MCLAUGHLIN RM, 1976, LAB ANIM SCI, V26, P44.
   Michel AL, 1998, J S AFR VET ASSOC, V69, P64.
   MUSCOPLAT CC, 1975, AM J VET RES, V36, P699.
   Okuda Y, 2004, J CLIN MICROBIOL, V42, P1136, DOI 10.1128/JCM.42.3.1136-1141.2004.
   Perkins MD, 2003, CHEST, V123, P107, DOI 10.1378/chest.123.1.107.
   Steingart KR, 2007, PLOS MED, V4, P1041, DOI 10.1371/journal.pmed.0040202.
   TAURASO NM, 1973, LAB ANIM SCI, V23, P201.
   Vervenne RAW, 2004, VET IMMUNOL IMMUNOP, V100, P61, DOI 10.1016/j.vetimm.2004.03.003.
   Walsh GP, 1996, NAT MED, V2, P430, DOI 10.1038/nm0496-430.
   Waters WR, 2004, CLIN DIAGN LAB IMMUN, V11, P849, DOI 10.1128/CDLI.11.5.849-855.2004.
   ZUMPE D, 1980, LAB ANIM SCI, V30, P237.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{44}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Clin. Vaccine Immunol.}},
Doc-Delivery-Number = {{210XH}},
Unique-ID = {{ISI:000249488400013}},
}

@article{ ISI:000249488400026,
Author = {Franken, Willeke P. J. and Koster, Ben F. P. J. and Bossink, Ailko W. J.
   and Thijsen, Steven F. T. and Bouwman, John J. M. and van Dissel, Jaap
   T. and Arend, Sandra M.},
Title = {{Follow-up study of tuberculosis-exposed supermarket customers with
   negative tuberculin skin test results in association with positive gamma
   interferon release assay results}},
Journal = {{CLINICAL AND VACCINE IMMUNOLOGY}},
Year = {{2007}},
Volume = {{14}},
Number = {{9}},
Pages = {{1239-1241}},
Month = {{SEP}},
Abstract = {{We report a follow-up study of 29 subjects with negative tuberculin skin
   test (TST) results in association with positive gamma interferon release
   assay (IGRA) results, mainly due to responses to CFP-10 in the T-SPOT.TB
   assay, during a contact investigation. One year later, 12/29 subjects
   (41\%) had converted to positive TST results in association with
   negative IGRA results.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Franken, WPJ (Reprint Author), Leiden Univ, Med Ctr, Dept Infect Dis, C5-P 37,POB 9600, NL-2300 RC Leiden, Netherlands.
   Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands.
   Municipal Hlth Author, Dept TB Control, Utrecht, Netherlands.
   Diakonessen Hosp, Dept Med Microbiol \& Immunol, Utrecht, Netherlands.
   Diakonessen Hosp, Dept Pulmonol, Heart Lung Ctr Utrecht, Utrecht, Netherlands.}},
DOI = {{10.1128/CVI.00185-07}},
ISSN = {{1556-6811}},
Keywords-Plus = {{ENZYME-LINKED IMMUNOSPOT; T-CELL RESPONSES; MYCOBACTERIUM-TUBERCULOSIS;
   BLOOD-TESTS; INFECTION; DIAGNOSIS; ESAT-6}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{w.p.j.franken@lumc.nl}},
Cited-References = {{Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2.
   Arend SM, 2007, AM J RESP CRIT CARE, V175, P618, DOI 10.1164/rccm.200608-1099OC.
   Bennekov T, 2006, EUR J IMMUNOL, V36, P3346, DOI 10.1002/eji.2006361281.
   Chee CBE, 2007, AM J RESP CRIT CARE, V175, P282, DOI 10.1164/rccm.200608-1109OC.
   Connell T, 2006, CLIN INFECT DIS, V42, pE82, DOI 10.1086/503910.
   Dheda K, 2005, AIDS, V19, P2038, DOI 10.1097/01.aids.0000191923.08938.5b.
   Ewer K, 2006, AM J RESP CRIT CARE, V174, P831, DOI 10.1164/rccm.200511-1783OC.
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6.
   Fox A, 2007, T ROY SOC TROP MED H, V101, P691, DOI 10.1016/j.trstmh.2007.03.001.
   Granger C, 2006, EUR RESPIR J, V28, P1283, DOI 10.1183/09031936.00107506.
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362.
   Lalvani A, 2005, LANCET INFECT DIS, V5, P322, DOI 10.1016/S1473-3099(05)70118-3.
   Lee JY, 2006, EUR RESPIR J, V28, P24, DOI 10.1183/09031936.06.00016906.
   Nardell EA, 2006, AM J RESP CRIT CARE, V174, P734, DOI 10.1164/rccm.200607-923ED.
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.
   Pai M, 2005, Indian J Med Microbiol, V23, P151.
   Pai M, 2006, AM J RESP CRIT CARE, V174, P349, DOI 10.1164/rccm.200604-472OC.
   Piana F, 2006, EUR RESPIR J, V28, P31, DOI 10.1183/09031936.06.00110205.
   Richeldi L, 2004, AM J RESP CRIT CARE, V170, P288, DOI 10.1164/rccm.200403-307OC.
   Rothel James S, 2005, Expert Rev Anti Infect Ther, V3, P981, DOI 10.1586/14787210.3.6.981.
   Shams H, 2005, AM J RESP CRIT CARE, V172, P1161, DOI 10.1164/rccm.200505-748OC.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{16}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Clin. Vaccine Immunol.}},
Doc-Delivery-Number = {{210XH}},
Unique-ID = {{ISI:000249488400026}},
}

@article{ ISI:000249642400015,
Author = {Aberra, Faten N. and Stettler, Nicolas and Brensinger, Colleen and
   Lichtenstein, Gary R. and Lewis, James D.},
Title = {{Risk for active tuberculosis in inflammatory bowel disease patients}},
Journal = {{CLINICAL GASTROENTEROLOGY AND HEPATOLOGY}},
Year = {{2007}},
Volume = {{5}},
Number = {{9}},
Pages = {{1070-1075}},
Month = {{SEP}},
Abstract = {{Background \& Aims: The primary aim of this study was to determine the
   incidence of active tuberculosis in an inflammatory bowel disease
   population compared with the general population before the availability
   of infliximab. Methods: We performed a retrospective cohort study with
   the General Practice Research Database from January 1988 October 1997.
   Ulcerative colitis and Crohn's disease subjects with a minimum of 1 year
   of follow-up were matched to randomly selected subjects from the
   remaining population on year of birth ( 5 years), sex, and primary care
   practice at ratio of 1:4. Active tuberculosis was determined by
   tuberculosis diagnostic codes. The incidence of active tuberculosis in
   the inflammatory bowel disease population and the relative risk for
   active tuberculosis in inflammatory bowel disease population compared
   with the general population were calculated. Multivariate logistic
   regression analysis was performed to adjust for confounders. Results:
   There were 16,213 inflammatory bowel disease subjects and 66,512 control
   subjects. The annual incidence of active tuberculosis was 20/100,000 in
   inflammatory bowel disease subjects compared with 9/100,000 in control
   subjects, yielding an unadjusted relative risk for active tuberculosis
   of 2.36 (95\% confidence interval, 1.17-4.74). Adjusting for
   confounders, corticosteroid use and smoking, the odds ratio of
   inflammatory bowel disease for active tuberculosis was 1.88 (95\%
   confidence interval, 0.68-5.20). Conclusions: During the pre-infliximab
   era, inflammatory bowel disease subjects appeared to be at higher risk
   for active tuberculosis than the general population, with
   immunosuppressant medications likely the main reason for this increased
   risk.}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Aberra, FN (Reprint Author), Univ Penn, Div Gastroenterol, 3400 Spruce St, Philadelphia, PA 19104 USA.
   Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA.
   Childrens Hosp Philadelphia, Div Gastroenterol Hepatol \& Nutr, Philadelphia, PA 19104 USA.
   Univ Penn, Ctr Clin Epidemiol \& Biostat, Philadelphia, PA 19104 USA.}},
DOI = {{10.1016/j.cgh.2007.04.007}},
ISSN = {{1542-3565}},
Keywords-Plus = {{PRACTICE RESEARCH DATABASE; CROHNS-DISEASE; CORTICOSTEROID-THERAPY;
   INFECTION; SMOKING; COHORT; UK}},
Research-Areas = {{Gastroenterology \& Hepatology}},
Web-of-Science-Categories  = {{Gastroenterology \& Hepatology}},
Author-Email = {{faten.aberra@uphs.upenn.edu}},
ResearcherID-Numbers = {{Research Datalink, Clinical Practice/H-2477-2013
   CPRD, CPRD/B-9594-2017}},
Cited-References = {{ALLEN MB, 1991, BRIT MED J, V303, P871.
   BAHR GM, 1988, CLIN EXP IMMUNOL, V72, P26.
   BATEMAN E, 1991, AM REV RESPIR DIS, V142, pA54.
   Cline JC, 1997, ANN PHARMACOTHER, V31, P775.
   Danese S, 2004, AUTOIMMUN REV, V3, P394, DOI 10.1016/j.autrev.2004.03.002.
   Duffield JS, 1996, THORAX, V51, P140, DOI 10.1136/thx.51.2.140.
   Faubion WA, 2001, GASTROENTEROLOGY, V121, P255, DOI 10.1053/gast.2001.26279.
   GUIDETTI GS, 1991, J CLIN GASTROENTEROL, V13, P593.
   Gupta G, 2005, GASTROENTEROLOGY, V129, P819, DOI 10.1053/j.gastro.2005.06.022.
   {*}HLTH PROT AG UK, 2006, ANN REP TUB CAS TUB.
   JICK H, 1991, BRIT MED J, V302, P766.
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110.
   Kolappan C, 2002, THORAX, V57, P964, DOI 10.1136/thorax.57.11.964.
   Kumar N, 1994, Trop Gastroenterol, V15, P219.
   LEWIS J, 2004, AGREEMENT GPRD SMOKI.
   Lewis JD, 2002, PHARMACOEPIDEM DR S, V11, P211, DOI 10.1002/pds.698.
   Lewis JD, 2001, GASTROENTEROLOGY, V121, P1080, DOI 10.1053/gast.2001.28703.
   Lewis JD, 2005, PHARMACOEPIDEM DR S, V14, P443, DOI 10.1002/pds.1115.
   Lewis JD, 2001, GASTROENTEROLOGY, V120, pA269.
   LIS Y, 1995, J CLIN EPIDEMIOL, V48, P431, DOI 10.1016/0895-4356(94)00137-F.
   Mandell GL, 2000, PRINCIPLES PRACTICE.
   Maurya V, 2002, INT J TUBERC LUNG D, V6, P942.
   MUNKHOLM P, 1995, SCAND J GASTROENTERO, V30, P699, DOI 10.3109/00365529509096316.
   MUNKHOLM P, 1994, GUT, V35, P360, DOI 10.1136/gut.35.3.360.
   Puiatti P, 1990, G Ital Dermatol Venereol, V125, P445.
   Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419.
   ROSE A, 2002, THORAX, V56, P173.
   SAHN SA, 1976, BRIT J DIS CHEST, V70, P195, DOI 10.1016/0007-0971(76)90029-2.
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901.
   Silverstein MD, 1999, GASTROENTEROLOGY, V117, P49, DOI 10.1016/S0016-5085(99)70549-4.
   Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586.
   Van Staa TP, 2003, GASTROENTEROLOGY, V125, P1591, DOI 10.1053/S0016-5085(03)01519-1.
   van Wijngaarden P, 2001, SCAND J GASTROENTERO, V36, P1004.
   WHO, 2000, OB PREV MAN GLOB EP.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{32}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Clin. Gastroenterol. Hepatol.}},
Doc-Delivery-Number = {{213CB}},
Unique-ID = {{ISI:000249642400015}},
}

@article{ ISI:000248557000017,
Author = {Hoff, Soren T. and Abebe, Markos and Ravn, Pernille and Range, Nyagosya
   and Malenganisho, Wabyahe and Rodriques, Denise S. and Kallas, Esper G.
   and Soborg, Christian and Doherty, T. Mark and Andersen, Peter and
   Weldingh, Karin},
Title = {{Evaluation of Mycobacterium tuberculosis-specific antibody responses in
   populations with different levels of exposure from Tanzania, Ethiopia,
   Brazil, and Denmark}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{45}},
Number = {{5}},
Pages = {{575-582}},
Month = {{SEP 1}},
Abstract = {{Background. New, simple, and better-performing diagnostic tools are
   needed for the diagnosis of tuberculosis (TB). Much effort has been
   invested in developing an antibody-based test for TB, but to date, no
   such test has performed with sufficient sensitivity and specificity. A
   key question remaining is the extent to which the disappointing
   performance of current tests is associated with a high background
   prevalence of latent TB.
   Methods. We compared Mycobacterium tuberculosis-specific ESAT-6 and
   CFP-10 antibody responses in a total of 565 human serum samples from M.
   tuberculosis-uninfected donors and donors with latent infection, as well
   as samples from patients with active TB. Our study included samples from
   4 countries, representing environments with low, intermediate, and high
   TB incidences.
   Results. We demonstrated significant increases in antibody levels in
   latently infected contacts, compared with M. tuberculosis-uninfected
   individuals, and in patients with active TB disease, compared with
   latently infected contacts. Furthermore, we found a striking increase in
   the magnitude of the antibody responses in samples obtained from
   infected Ethiopian individuals (with and without disease), compared with
   Danish and Brazilian infected individuals; this was presumably the
   result of higher exposure levels.
   Conclusions. Our study confirms the presence of ESAT-6 and CFP-10
   antibodies in patients with TB, and we demonstrate that significant
   antibody responses are not restricted to active TB disease but can
   reflect latent infection, particularly in areas with high levels of
   exposure to M. tuberculosis. This finding is important for the
   understanding of the poor discriminatory power of current serodiagnostic
   tests in regions of endemicity, and it may have major implications on
   the future development of serologic tests.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hoff, ST (Reprint Author), Statens Serum Inst, Dept Infect Dis Immunol, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
   Statens Serum Inst, Dept Infect Dis Immunol, DK-2300 Copenhagen S, Denmark.
   Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark.
   Hvidovre Univ Hosp, Dept Infect Dis, Copenhagen, Denmark.
   Armauer Hansen Res Inst, Addis Ababa, Ethiopia.
   Univ Fed Sao Paulo, Sao Paulo, Brazil.
   Clemente Ferreira Inst, Sao Paulo, Brazil.}},
DOI = {{10.1086/520662}},
ISSN = {{1058-4838}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; ACTIVE TUBERCULOSIS; SEROLOGICAL MARKERS;
   HUMORAL RESPONSE; CELL EPITOPES; T-CELLS; DIAGNOSIS; INFECTION;
   ANTIGENS; ESAT-6}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{Sho@ssi.dk}},
ResearcherID-Numbers = {{Kallas, Esper/C-9539-2012}},
Cited-References = {{Al Zahrani K, 2000, AM J RESP CRIT CARE, V162, P1323.
   Aseffa A, 2005, LEPROSY REV, V76, P147.
   Azzurri A, 2006, INT J IMMUNOPATH PH, V19, P199.
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195.
   Brock I, 2004, J CLIN MICROBIOL, V42, P2379, DOI 10.1128/JCM.42.6.2379-2387.2004.
   Brusasca PN, 2001, SCAND J IMMUNOL, V54, P448, DOI 10.1046/j.1365-3083.2001.00975.x.
   Cardoso FLL, 2002, INFECT IMMUN, V70, P6707, DOI 10.1128/IAI.70.12.6707-6714.2002.
   Conde MB, 2004, CLIN DIAGN LAB IMMUN, V11, P94, DOI 10.1128/CDLI.11.1.94-97.2004.
   Davidow A, 2005, INFECT IMMUN, V73, P6846, DOI 10.1128/IAI.73.10.6846-6851.2005.
   Demissie A, 2004, J IMMUNOL, V172, P6938.
   DINNES J, 2007, HEALTH TECHNOL ASSES, V4, pE202.
   Gennaro ML, 2000, CLIN INFECT DIS, V30, pS243, DOI 10.1086/313868.
   Gounder C, 2002, J CLIN MICROBIOL, V40, P1989, DOI 10.1128/JCM.40.6.1989-1993.2002.
   Greenaway C, 2005, INT J TUBERC LUNG D, V9, P1112.
   Haile Y, 2002, MICROBIOL-SGM, V148, P3881.
   Harboe M, 1998, INFECT IMMUN, V66, P717.
   HILL PG, 2001, SCAND J IMMUNOL, V54, P448.
   Houghton RL, 2002, CLIN DIAGN LAB IMMUN, V9, P883, DOI 10.1128/CDLI.9.4.883-891.2002.
   Kassa-Kelembho E, 2006, CLIN VACCINE IMMUNOL, V13, P702, DOI 10.1128/CDLI.00194-05.
   Keeler Emmett, 2006, Nature, V444 Suppl 1, P49, DOI 10.1038/nature05446.
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081.
   Maekura R, 2003, J CLIN MICROBIOL, V41, P1322, DOI 10.1128/JCM.41.3.1322-1325.2003.
   McConkey SJ, 2002, INT J TUBERC LUNG D, V6, P246.
   Mukhopadhyay A, 2006, INT J TUBERC LUNG D, V10, P620.
   Okuda Y, 2004, J CLIN MICROBIOL, V42, P1136, DOI 10.1128/JCM.42.3.1136-1141.2004.
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.
   Perkins MD, 2003, CHEST, V123, P107, DOI 10.1378/chest.123.1.107.
   Range N, 2005, TROP MED INT HEALTH, V10, P826, DOI 10.1111/j.1365-3156.2005.01463.x.
   Ravn P, 2005, CLIN DIAGN LAB IMMUN, V12, P491, DOI 10.1128/CDLI.12.4.491-496.2005.
   Rogerson BJ, 2006, IMMUNOLOGY, V118, P195, DOI 10.1111/j.1365-2567.2006.02355.x.
   ROTHEL JS, 2005, ANTI INFECT THER, V3, P981.
   Silva VMC, 2003, INT J TUBERC LUNG D, V7, P478.
   Singh KK, 2005, INFECT IMMUN, V73, P5004, DOI 10.1128/IAI.73.8.5004-501.4.2005.
   Singh KK, 2005, CLIN DIAGN LAB IMMUN, V12, P354, DOI 10.1128/CDLI.12.2.354-358.2005.
   SORENSEN AL, 1995, INFECT IMMUN, V63, P1710.
   Steingart KR, 2007, PLOS MED, V4, P1041, DOI 10.1371/journal.pmed.0040202.
   Talbot EA, 2004, CLIN INFECT DIS, V39, pE1, DOI 10.1086/421388.
   Tiwari RP, 2005, CLIN DIAGN LAB IMMUN, V12, P465, DOI 10.1128/CDLI.12.3.465-473.2005.
   Weldingh K, 2005, J CLIN MICROBIOL, V43, P57, DOI 10.1128/JCM.43.1.57-65.2005.
   {*}WHO, 2004, GLOB TUB CONTR REP.}},
Number-of-Cited-References = {{40}},
Times-Cited = {{36}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{197LM}},
Unique-ID = {{ISI:000248557000017}},
}

@article{ ISI:000248959000011,
Author = {Shimamoto, Hiroaki and Hamada, Kenichiro and Higuchi, Ichiro and
   Tsujihata, Masao and Nonomura, Norio and Tomita, Yasuhiko and Okuyama,
   Akihiko and Aozasa, Katsuyuki and Hatazawa, Jun},
Title = {{Abdominal tuberculosis: Peritoneal involvement shown by F-18 FDG PET}},
Journal = {{CLINICAL NUCLEAR MEDICINE}},
Year = {{2007}},
Volume = {{32}},
Number = {{9}},
Pages = {{716-718}},
Month = {{SEP}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Shimamoto, H (Reprint Author), Osaka Univ, Grad Sch Med, Dept Nucl Med \& Tracer Kinet, Osaka, Japan.
   Osaka Univ, Grad Sch Med, Dept Nucl Med \& Tracer Kinet, Osaka, Japan.
   Osaka Univ, Grad Sch Med, Dept Urol, Osaka, Japan.
   Osaka Univ, Grad Sch Med, Dept Pathol, Osaka, Japan.}},
DOI = {{10.1097/RLU.0b013e318123f813}},
ISSN = {{0363-9762}},
Keywords = {{FDG-PET; tuberculous peritoneum; peritoneal carcinomatosis}},
Keywords-Plus = {{TOMOGRAPHY; TUMORS}},
Research-Areas = {{Radiology, Nuclear Medicine \& Medical Imaging}},
Web-of-Science-Categories  = {{Radiology, Nuclear Medicine \& Medical Imaging}},
Author-Email = {{h-shima@tracer.med.osaka-u.ac.jp}},
ResearcherID-Numbers = {{Hatazawa, Jun/D-2336-2009}},
Cited-References = {{Akhan O, 2002, EUR RADIOL, V12, P312, DOI 10.1007/s003300100994.
   HA KH, 1996, AM J ROENTGENOL, V167, P743.
   Jadvar H, 1997, AM J ROENTGENOL, V168, P1455.
   Jeffry L, 2003, BJOG-INT J OBSTET GY, V110, P1129, DOI 10.1111/j.1471-0528.2003.03070.x.
   Lodge MA, 1999, EUR J NUCL MED, V26, P22, DOI 10.1007/s002590050355.
   MACGREGOR RR, 1993, SEMIN ROENTGENOL, V28, P101, DOI 10.1016/S0037-198X(05)80099-9.
   Paustian FF, 1964, GASTROENTEROLOGY, V11, P311.
   Pereira JM, 2005, EUR J RADIOL, V55, P173, DOI 10.1016/j.ejrad.2005.04.015.
   SARMA MP, 2004, INDIAN J MED RES, V120, P354.
   Schulte M, 1999, EUR J NUCL MED, V26, P599, DOI 10.1007/s002590050427.
   Schulte M, 2000, J NUCL MED, V41, P1695.
   Sinan T, 2002, BMC MED IMAGING, V2, P3, DOI 10.1186/1471-2342-2-3.
   Suri S, 1999, BRIT J RADIOL, V72, P92.
   Yoshioka T, 2003, J NUCL MED, V44, P690.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{16}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Clin. Nucl. Med.}},
Doc-Delivery-Number = {{203EX}},
Unique-ID = {{ISI:000248959000011}},
}

@article{ ISI:000248959000012,
Author = {Fernandez, Philippe and Guyot, Martine and Lazaro, Estibaliz and
   Viallard, Jean-Francois and Allard, Michele and Ducassou, Dominique},
Title = {{Systemic tuberculosis presenting as an epiglottic mass detected on F-18
   FDG PET/CT}},
Journal = {{CLINICAL NUCLEAR MEDICINE}},
Year = {{2007}},
Volume = {{32}},
Number = {{9}},
Pages = {{719-724}},
Month = {{SEP}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Fernandez, P (Reprint Author), CHU Bordeaux, Hop Pellegrin, Nucl Med Serv, F-33076 Bordeaux, France.
   CHU Bordeaux, Hop Pellegrin, Nucl Med Serv, F-33076 Bordeaux, France.
   Univ Bordeaux 2, F-33076 Bordeaux, France.
   CHU Bordeaux, Hop Haut Leveque, Serv Med Interne \& Malad Infectieuses, F-33600 Pessac, France.}},
DOI = {{10.1097/RLU.0b013e318123f7fb}},
ISSN = {{0363-9762}},
Research-Areas = {{Radiology, Nuclear Medicine \& Medical Imaging}},
Web-of-Science-Categories  = {{Radiology, Nuclear Medicine \& Medical Imaging}},
Author-Email = {{philippe.femandez@u-bordeaux2.fr}},
ResearcherID-Numbers = {{ALLARD, Michele/D-8538-2014}},
Cited-References = {{ALTAWFIQ JA, 2007, MED SCI MONITOR, V27, P13.
   Chen YK, 2004, CLIN NUCL MED, V29, P124, DOI 10.1097/01.rlu.0000109300.89514.35.
   Galli J, 2002, AM J OTOLARYNG, V23, P237, DOI 10.1053/ajot.2002.123441.
   Krecicki T, 2004, LANCET INFECT DIS, V4, P57, DOI 10.1016/S1473-3099(03)00863-6.
   Sanabe Naoya, 2002, J Hepatobiliary Pancreat Surg, V9, P515, DOI 10.1007/s005340200065.
   Sheahan P, 2005, HEAD NECK-J SCI SPEC, V27, P28, DOI 10.1002/hed.20110.
   Unal M, 2006, MT SINAI J MED, V73, P806.
   Yang CM, 2003, ANN NUCL MED, V17, P407, DOI 10.1007/BF03006610.}},
Number-of-Cited-References = {{8}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Clin. Nucl. Med.}},
Doc-Delivery-Number = {{203EX}},
Unique-ID = {{ISI:000248959000012}},
}

@article{ ISI:000250540300012,
Author = {Une, Yumi and Mori, Tooru},
Title = {{Tuberculosis as a zoonosis from a veterinary perspective}},
Journal = {{COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{30}},
Number = {{5-6}},
Pages = {{415-425}},
Month = {{SEP}},
Abstract = {{Tuberculosis is an important disease among many zoonoses, because both
   Mycobacterium tuberculosis and Mycobacterium bovis, which are the major
   causes of tuberculosis, are highly pathogenic, infect many animal
   species and thus are likely to be the source of infection in humans. In
   particular, monkeys are highly susceptible to these bacteria and are
   important spreaders. Recently, two outbreaks of M. tuberculosis occurred
   in four different kinds of monkeys and humans were also infected with
   the disease in Japan. In zoos, tuberculosis was reported not only in
   monkeys, but also in several different kinds of animals, including
   elephants. Pets such as dogs and cats are believed to be generally less
   susceptible to M. tuberculosis, but in this article we introduce a case
   of infection from man to dog by close contact. Japan is one of the few
   countries that have been able to control M. bovis infection. In other
   countries, however, cases of bovine tuberculosis and human M. bovis
   infection have been reported, and thus further attention is still
   required in the future. (C) 2007 Elsevier Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article}},
Language = {{French}},
Affiliation = {{Une, Y (Reprint Author), Azabu Univ, Sch Vet Med, Lab Vet Pathol, 1-17-71 Fuchinobe, Kanagawa 2298501, Japan.
   Azabu Univ, Sch Vet Med, Lab Vet Pathol, Kanagawa 2298501, Japan.
   Japan Anti TB Assoc, Res Inst TB, Tokyo 2048533, Japan.}},
DOI = {{10.1016/j.cimid.2007.05.002}},
ISSN = {{0147-9571}},
Keywords = {{zoonosis; Mycobacterium tuberculosis; Mycobacterium bovis; monkey;
   elephant; dog}},
Keywords-Plus = {{CAPTIVE ASIAN ELEPHANTS; MYCOBACTERIUM-TUBERCULOSIS; INFECTION; CANINE;
   ZOO; TRANSMISSION; EPIDEMIOLOGY; POPULATIONS}},
Research-Areas = {{Immunology; Microbiology; Veterinary Sciences}},
Web-of-Science-Categories  = {{Immunology; Microbiology; Veterinary Sciences}},
Author-Email = {{une@azabu-u.ac.jp}},
ORCID-Numbers = {{Une, Yumi/0000-0002-2112-1894}},
Cited-References = {{CHIBA T, 1993, PATHOLOGY ZOO ANIMAL.
   Corner LAL, 2006, VET MICROBIOL, V112, P303, DOI 10.1016/j.vetmic.2005.11.015.
   Davis M, 2001, Appl Occup Environ Hyg, V16, P350, DOI 10.1080/10473220120327.
   Erwin PC, 2004, EMERG INFECT DIS, V10, P2258.
   Greene CE, 1998, INFECT DIS DOG CAT, P313.
   Isaza R., 2003, ZOO WILD ANIMAL MED, P689.
   LAIR RC, 2005, ELEPHANT CARE MANUAL.
   Lewerin SS, 2005, VET REC, V156, P171.
   LIU S, 1980, J AM VET MED ASSOC, V177, P164.
   Michalak K, 1998, EMERG INFECT DIS, V4, P283.
   Mikota SK, 2001, J ZOO WILDLIFE MED, V32, P1.
   Montali RJ, 2001, REV SCI TECH OIE, V20, P291.
   Oh P, 2002, EMERG INFECT DIS, V8, P1290.
   ORLANDO FL, 2005, EL TUB RES WORKSH, P1.
   Ruiz PR, 2002, CLIN INFECT DIS, V35, P212.
   SNIDER WR, 1971, AM REV RESPIR DIS, V104, P877.
   THOEN CO, 1994, TUBERCULOSIS PATHOGE, P158.
   {*}USDA APHIS, 2000, GUID CONTR TUB EL.
   vanSoolingen D, 1997, INT J SYST BACTERIOL, V47, P1236.
   World Health Organization, 2005, WHO GLOB TUB CONTR S.
   Williams BG, 2005, P NATL ACAD SCI USA, V102, P9619, DOI 10.1073/pnas.0501615102.
   YAMAMOTO S, 1954, J VET MED SCI, V16, P187.
   Yoshikawa Yasuhiro, 2006, Kekkaku, V81, P613.
   2006, INFECTIOUS AGENTS SU, V27, P255.
   2006, INFECTIOUS AGENTS SU, V26, P213.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{29}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{17}},
Journal-ISO = {{Comp. Immunol. Microbiol. Infect. Dis.}},
Doc-Delivery-Number = {{225TK}},
Unique-ID = {{ISI:000250540300012}},
}

@article{ ISI:000257191200012,
Author = {Fradet, Vincent and Gaudreau, Christian E. and Perrotte, Paul and Cote,
   Jean and Paquin, Jean-Marie},
Title = {{Management of hepatic granulomatous tuberculosis complicating
   intravesical BCG for superficial bladder cancer}},
Journal = {{CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL}},
Year = {{2007}},
Volume = {{1}},
Number = {{3}},
Pages = {{269-272}},
Month = {{SEP}},
Abstract = {{Intravesical bacille Calmette-Guerin (BCG) therapy is the most effective
   treatment for high-risk superficial bladder cancer. Severe systemic
   complications are rare, but may occur in approximately 1\% of cases. We
   report a severe complication of intravesical BCG: a disseminated
   Mycobacterium bovis infection with biopsy-proven granulomatous hepatitis
   in a patient with bladder cancer. We also elaborate on the different
   management alternatives.}},
Publisher = {{CANADIAN MEDICAL ASSOC}},
Address = {{1867 ALTA VISTA DR, OTTAWA, ON KIG 3Y6, CANADA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Fradet, V (Reprint Author), Clin Urol Berger, 416-1000 Chemin, Ste Foy, PQ G1S 2L6, Canada.
   Fradet, Vincent; Perrotte, Paul; Paquin, Jean-Marie, Univ Montreal, Hop St Luc, Dept Urol Surg, Ctr Hosp, Montreal, PQ, Canada.
   Gaudreau, Christian E., Univ Montreal, Hop St Luc, Dept Microbiol, Ctr Hosp, Montreal, PQ, Canada.
   Cote, Jean, Univ Montreal, Hop St Luc, Dept Pathol, Ctr Hosp, Montreal, PQ, Canada.}},
ISSN = {{1911-6470}},
Keywords-Plus = {{BACILLUS-CALMETTE-GUERIN; THERAPY; IMMUNOTHERAPY; INSTILLATION;
   INFECTION; SAFETY; TUMORS}},
Research-Areas = {{Urology \& Nephrology}},
Web-of-Science-Categories  = {{Urology \& Nephrology}},
Author-Email = {{vincent.fradet@videotron.ca}},
Cited-References = {{Al-Bhlal L, 2000, AM J CLIN PATHOL, V113, P703.
   Alexandroff AB, 1999, LANCET, V353, P1689, DOI 10.1016/S0140-6736(98)07422-4.
   Aljada IS, 1999, J CLIN MICROBIOL, V37, P2106.
   Debois H, 2001, PROG UROL, V11, P458.
   Durek C, 2001, J UROLOGY, V165, P1765, DOI 10.1016/S0022-5347(05)66410-5.
   Durek C, 2000, EUR UROL, V37, P21, DOI 10.1159/000052378.
   Elkabani M, 2000, Cancer Control, V7, P476.
   Fendler JP, 2002, PROG UROL, V12, P309.
   Gottke MU, 2000, CAN J GASTROENTEROL, V14, P333.
   Grange J M, 1998, Commun Dis Public Health, V1, P84.
   Huang TC, 2000, ANN PHARMACOTHER, V34, P529.
   Kamat A M, 2001, Curr Urol Rep, V2, P62, DOI 10.1007/s11934-001-0027-7.
   Kamphuis JT, 2001, NETH J MED, V58, P71, DOI 10.1016/S0300-2977(00)00098-X.
   LAMM DL, 1992, J UROLOGY, V147, P596.
   LAMM DL, 1986, J UROLOGY, V135, P272.
   Lamm DL, 2000, CLIN INFECT DIS, V31, P86.
   Mangiarotti B, 2002, J UROLOGY, V168, P1094, DOI 10.1097/01.ju.0000024783.27150.43.
   MORALES A, 1976, J UROLOGY, V116, P180.
   Saint F, 2001, PROG UROL, V11, P647.
   Saint F, 2001, UROLOGY, V57, P883, DOI 10.1016/S0090-4295(00)01117-1.
   Su WJ, 2001, INT J TUBERC LUNG D, V5, P380.
   Vegt PDJ, 1997, J UROLOGY, V157, P1246, DOI 10.1016/S0022-5347(01)64936-X.}},
Number-of-Cited-References = {{22}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{CUAJ-Can. Urol. Assoc. J.}},
Doc-Delivery-Number = {{319UZ}},
Unique-ID = {{ISI:000257191200012}},
}

@article{ ISI:000249955400008,
Author = {Kumar, Alok and Upadhyay, Sanjay and Kumari, Geeta},
Title = {{Clinical presentation, treatment outcome and survival among the HIV
   infected children with culture confirmed tuberculosis}},
Journal = {{CURRENT HIV RESEARCH}},
Year = {{2007}},
Volume = {{5}},
Number = {{5}},
Pages = {{499-504}},
Month = {{SEP}},
Abstract = {{Background: We studied the clinical presentation, diagnosis, treatment
   outcome and survival in children with HIV and Tuberculosis (TB)
   co-infection.
   Methods: All HIV infected children with symptoms or signs consistent
   with tuberculosis were screened. We studied 24 cases of culture
   confirmed TB from among a cohort of 213 HIV infected children. All these
   children were on HAART for their HIV infection. Information on TB was
   collected by retrospective chart review of these children.
   Results: In a cohort of 213 children with vertically transmitted HIV
   infection, a total of 76 (36\%) children suspected to have tuberculosis
   based on their clinical presentation together with either a positive
   Mantoux test or AFB positivity and treated for TB. Twenty four children
   had culture positive TB. The median age at diagnosis of TB was 16
   months. Over half of these children had some immunodeficiency. Common
   presentations were fever (87\%), history of contact with an open case of
   TB (79\%), cough for more than 2 weeks (75\%), malnutrition (71\%),
   hepatosplenomegaly (71\%), chronic diarrhea (67\%) and generalized
   lymphadenopathy (58\%). Mantoux test result was positive in 12 (50\%)
   patients. Chest roentgenograms were abnormal in all the children, with
   hilar and/or Para tracheal node (62\%) and lobar or segmental
   opacification (57\%). Twenty one (87\%) children had pulmonary TB at the
   time of their diagnosis. One or more sites of Extrapulmonary TB were
   confinned in 10 (41\%) patients. After six months of ATT, the cure rate
   was 64\%. Three patients had documented drug-resistant. Five children
   (20\%) died.
   Conclusion: TB is a common co-infection in HIV infected children and
   children often present with un-resolving pneumonia. It carries
   significant mortality despite the HAART and adequate anti-tuberculosis
   treatment in these children.}},
Publisher = {{BENTHAM SCIENCE PUBL LTD}},
Address = {{EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kumar, A (Reprint Author), Univ W Indies, Queen Elizabeth Hosp, Sch Clin Med \& Res, Martindales Rd, St Michael, Barbados.
   Univ W Indies, Queen Elizabeth Hosp, Sch Clin Med \& Res, St Michael, Barbados.
   Naz Fdn, New Delhi, India.}},
DOI = {{10.2174/157016207781662434}},
ISSN = {{1570-162X}},
Keywords = {{tuberculosis; HIV infection; treatment outcome; children}},
Keywords-Plus = {{COTE-DIVOIRE; IMPACT; ABIDJAN; COHORT}},
Research-Areas = {{Immunology; Infectious Diseases; Virology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Virology}},
Author-Email = {{alokkumar.uwichill@gmail.com}},
Cited-References = {{Bai S Sushama, 2002, Indian Pediatr, V39, P458.
   BARLTROP D, 1992, TXB PAEDIATR, P1257.
   Bwire R, 1999, E AFR MED J, V76, P307.
   Chadha V K, 2003, J Indian Med Assoc, V101, P144.
   Chan SP, 1996, PEDIATR INFECT DIS J, V15, P443, DOI 10.1097/00006454-199605000-00012.
   Deivanayagam C N, 2002, Indian J Chest Dis Allied Sci, V44, P237.
   Elenga N, 2005, PEDIATR INFECT DIS J, V24, P1077, DOI 10.1097/01.inf.0000190008.91534.b7.
   Espinal MA, 1996, J ACQ IMMUN DEF SYND, V13, P155.
   FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406.
   HANSON CA, 1989, SEMINAR RESP INFECTI, V4, P82.
   Hesseling AC, 2005, ARCH DIS CHILD, V90, P1171, DOI 10.1136/adc.2004.070466.
   Hongthiamthong Prachum, 1994, Journal of the Medical Association of Thailand, V77, P520.
   HSIEH SM, 1996, J FORMOS MED ASSOC, V95, P823.
   {*}IND NACO, 2005, HIV AIDS EP SURV EST.
   Jeena PM, 2002, INT J TUBERC LUNG D, V6, P672.
   KHOURI YF, 1992, PEDIATR INFECT DIS J, V11, P950.
   Mukadi YD, 1997, AIDS, V11, P1151, DOI 10.1097/00002030-199709000-00011.
   Palme IB, 2002, PEDIATR INFECT DIS J, V21, P1053, DOI 10.1097/01.inf.0000036090.75121.f3.
   Puri S, 2007, INDIAN J PEDIATR, V74, P47, DOI 10.1007/s12098-007-0026-x.
   Sawhney Mps, 2006, Med J Armed Forces India, V62, P104, DOI 10.1016/S0377-1237(06)80047-X.
   Schaaf HS, 1998, PEDIATR INFECT DIS J, V17, P599, DOI 10.1097/00006454-199807000-00005.
   Soeters M, 2005, SAMJ S AFR MED J, V95, P602.
   World Health Organization, 2006, GLOB HLTH ATL.
   World Helath Organisation, 2005, INT WHO CLIN STAG HI.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Curr. HIV Res.}},
Doc-Delivery-Number = {{217NU}},
Unique-ID = {{ISI:000249955400008}},
}

@article{ ISI:000249148500014,
Author = {Chan, Pei-Chun and Huang, Li-Min and Wu, Yi-Chun and Yang, Hsiang-Lin
   and Chang, I-Shou and Lu, Chun-Yi and Lee, Ping-Ing and Lee, Chin-Yun
   and Chang, Luan-Yin},
Title = {{Tuberculosis in children and adolescents, Taiwan, 1996-2003}},
Journal = {{EMERGING INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{13}},
Number = {{9}},
Pages = {{1361-1363}},
Month = {{SEP}},
Abstract = {{Analysis of data from Taiwan's National Tuberculosis (TB) Registry
   showed that incidence of TB in persons <20 years of age was 9.61/100,000
   person-years, biphasic, and age-relevant, with a major peak in persons
   slightly >12 years. Aboriginal children were 8.1-17.4x more likely to
   have TB than non-Aboriginal children.}},
Publisher = {{CENTER DISEASE CONTROL}},
Address = {{ATLANTA, GA 30333 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Chang, LY (Reprint Author), Natl Taiwan Univ Hosp, Dept Pediat, Coll Med, 7 Chung Shan S Rd, Taipei 100, Taiwan.
   Natl Taiwan Univ Hosp, Dept Pediat, Coll Med, Taipei 100, Taiwan.
   Ctr Dis Control, Taipei, Taiwan.
   Natl Hlth Res Inst, Miaoli, Taiwan.}},
ISSN = {{1080-6040}},
Research-Areas = {{Immunology; Infectious Diseases}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases}},
Author-Email = {{ly7077@tpts6.seed.net.tw}},
ResearcherID-Numbers = {{Chang, I-Shou/D-2084-2010
   }},
ORCID-Numbers = {{LEE, CHIN-YUN/0000-0002-3938-377X
   Chang, Luan-Yin/0000-0003-2632-1956
   LU, CHUN-YI/0000-0002-5240-2808
   Huang, Li-Min/0000-0002-9291-260X
   Lee, Ping-Ing/0000-0002-7299-2825}},
Cited-References = {{{*}CDC, 2001, STRAT TUB CONTR TUB.
   Chiang CY, 2002, INT J TUBERC LUNG D, V6, P974.
   Howie S, 2005, ARCH DIS CHILD, V90, P1157, DOI 10.1136/ADC.2005.066415.
   Hsu YH, 2006, J FORMOS MED ASSOC, V105, P363.
   Lin T M, 1981, Taiwan Yi Xue Hui Za Zhi, V80, P359.
   {*}MIN INT TAIW, 2004, STAT ANN REP MIN INT.
   Nelson LJ, 2004, PEDIATRICS, V114, P333, DOI 10.1542/peds.114.2.333.
   Yang ZH, 2004, CLIN INFECT DIS, V38, P199, DOI 10.1086/380644.
   Yu MC, 2004, J FORMOS MED ASSOC, V103, P817.}},
Number-of-Cited-References = {{9}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Emerg. Infect. Dis}},
Doc-Delivery-Number = {{205XM}},
Unique-ID = {{ISI:000249148500014}},
}

@article{ ISI:000249148500038,
Author = {Mondal, Rajesh and Jain, Amita},
Title = {{Extensively drug-resistant Mycobacterium tuberculosis, India}},
Journal = {{EMERGING INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{13}},
Number = {{9}},
Pages = {{1429-1431}},
Month = {{SEP}},
Publisher = {{CENTER DISEASE CONTROL}},
Address = {{ATLANTA, GA 30333 USA}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Jain, A (Reprint Author), King Georges Med Univ, Grad Dept Microbiol, Lucknow 226003, Uttar Pradesh, India.
   King Georges Med Univ, Grad Dept Microbiol, Lucknow 226003, Uttar Pradesh, India.}},
ISSN = {{1080-6040}},
Research-Areas = {{Immunology; Infectious Diseases}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases}},
Author-Email = {{amita602002@yahoo.com}},
Cited-References = {{CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21.
   Gupta R, 2002, TROP MED INT HEALTH, V7, P970, DOI 10.1046/j.1365-3156.2002.00960.x.
   Kim SJ, 2004, INT J TUBERC LUNG D, V8, P1157.
   Prammananan T, 2005, INT J TUBERC LUNG D, V9, P216.
   Prasad R., 2005, INDIAN J TUBERC, V52, P121.
   Shah NS, 2007, EMERG INFECT DIS, V13, P380.
   Singh JA, 2007, PLOS MED, V4, P19, DOI 10.1371/journal.pmed.0040050.
   {*}WHO, WHOCDSTB2001288.
   World Health Organization, 2005, WHOHTMTB2005349.
   World Health Organization, 2006, WHOHTMTB2006362.}},
Number-of-Cited-References = {{10}},
Times-Cited = {{30}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Emerg. Infect. Dis}},
Doc-Delivery-Number = {{205XM}},
Unique-ID = {{ISI:000249148500038}},
}

@article{ ISI:000249018300399,
Author = {Magheswari, U. and Johnson, P. and Ramaswamy, P. and Balakrishnan, K.
   and Jenny, A. and Bates, M.},
Title = {{Exposure to biomass fuel smoke and tuberculosis - A case-control study
   in India}},
Journal = {{EPIDEMIOLOGY}},
Year = {{2007}},
Volume = {{18}},
Number = {{5, S}},
Pages = {{S122}},
Month = {{SEP}},
Note = {{19th Annual Conference of the
   International-Society-for-Environmental-Epidemiology, Mexico City,
   MEXICO, SEP 05-09, 2007}},
Organization = {{Int Soc Environm Epidemiol}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Univ Calif Berkeley, Berkeley, CA 94720 USA.}},
ISSN = {{1044-3983}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Number-of-Cited-References = {{0}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Epidemiology}},
Doc-Delivery-Number = {{204BQ}},
Unique-ID = {{ISI:000249018300399}},
}

@article{ ISI:000249908100002,
Author = {Drakonakis, George E. and Bouros, Demosthenes},
Title = {{References to tuberculosis in Greek popular music (Rebetico)}},
Journal = {{EUROPEAN JOURNAL OF INTERNAL MEDICINE}},
Year = {{2007}},
Volume = {{18}},
Number = {{5}},
Pages = {{357-358}},
Month = {{SEP}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Drakonakis, GE (Reprint Author), Ainou 91, GR-68100 Alexandroupolis, Greece.
   Sitia Hosp, Healthcare Ctr, Dept Pneumol, Sitia, Greece.
   Univ Thrace, Univ Hosp Alexandroupolis, Alexandroupolis, Greece.}},
DOI = {{10.1016/j.ejim.2007.02.008}},
ISSN = {{0953-6205}},
Keywords = {{tuberculosis; phthisis; Rebetico; popular music}},
Keywords-Plus = {{COMPLEX}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{drakonakis@gmail.com}},
ORCID-Numbers = {{BOUROS, DEMOSTHENES/0000-0002-0685-0765}},
Cited-References = {{BOUROS D, 1995, RESPIRATION, V62, P336.
   CONSTANTINIDIS TC, 2000, PNEUMON, V13, P73.
   Das R K, 2000, J Indian Med Assoc, V98, P112.
   DRAKONAKIS GE, 2004, IATRIKI, V85, P317.
   {*}HELL UN TUB RESP, 1994, REP GREEK MED S TUB.
   Horsburgh CR, 2000, CLIN INFECT DIS, V31, P633, DOI 10.1086/314007.
   Huard RC, 2003, J CLIN MICROBIOL, V41, P1637, DOI 10.1128/JCM.41.4.1637-1650.2003.
   Kanavaki S, 2006, INT J TUBERC LUNG D, V10, P559.
   KOCH R, 1882, BERL KLIN WOCHENSCHR, V1, P15.
   Warren RM, 2006, INT J TUBERC LUNG D, V10, P818.
   1982, ZENTRALBL BAKTERIOL, V251, P287.
   1997, AM J RESP CRIT CARE, V156, pS1.}},
Number-of-Cited-References = {{12}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Eur. J. Intern. Med.}},
Doc-Delivery-Number = {{216VW}},
Unique-ID = {{ISI:000249908100002}},
}

@article{ ISI:000248187100012,
Author = {Pascual-Vaca, Diego and Lopez-Cerero, Lorena and Vilar, Neus and
   Herrera, Alberto and Romero, Joaquin and Alejo, Angel and
   Gonzalez-Hachero, Jose},
Title = {{Perianal involvement and inguinal adenitis as unusual presentation of
   tuberculosis}},
Journal = {{EUROPEAN JOURNAL OF PEDIATRICS}},
Year = {{2007}},
Volume = {{166}},
Number = {{9}},
Pages = {{967-968}},
Month = {{SEP}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING STREET, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Lopez-Cerero, L (Reprint Author), Univ Hosp Virgen Macarena, Dept Microbiol, Ave Dr Fedriani 3, Seville 41009, Spain.
   Univ Hosp Virgen Macarena, Dept Microbiol, Seville 41009, Spain.
   Univ Hosp Virgen Macarena, Paediat Unit, Seville 41009, Spain.
   Univ Hosp Virgen Macarena, Dermatol Unit, Seville 41009, Spain.}},
DOI = {{10.1007/s00431-006-0324-8}},
ISSN = {{0340-6199}},
Keywords = {{childhood; tuberculous lymphadenitis; anal and inguinal tuberculosis}},
Keywords-Plus = {{DIAGNOSIS}},
Research-Areas = {{Pediatrics}},
Web-of-Science-Categories  = {{Pediatrics}},
Author-Email = {{lorenalc@terra.es}},
ORCID-Numbers = {{Lopez Cerero, Lorena/0000-0001-8950-4384}},
Cited-References = {{Carrol E D, 2001, Paediatr Respir Rev, V2, P113, DOI 10.1053/prrv.2000.0118.
   Esteban J, 2004, CLIN MICROBIOL INFEC, V10, P335, DOI 10.1111/j.1198-743X.2004.00817.x.
   Honig E, 2000, BRIT J DERMATOL, V142, P186, DOI 10.1046/j.1365-2133.2000.03272.x.
   Neu N, 1999, PEDIATR INFECT DIS J, V18, P122, DOI 10.1097/00006454-199902000-00008.
   Polesky A, 2005, MEDICINE, V84, P350, DOI 10.1097/01.md.0000189090.52626.7a.
   Sultan S, 2002, DIS COLON RECTUM, V45, P407, DOI 10.1007/s10350-004-6191-3.}},
Number-of-Cited-References = {{6}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Eur. J. Pediatr.}},
Doc-Delivery-Number = {{192FV}},
Unique-ID = {{ISI:000248187100012}},
}

@article{ ISI:000249509700017,
Author = {Ritchie, S. R. and Harrison, A. C. and Vaughan, R. H. and Calder, L. and
   Morris, A. J.},
Title = {{New recommendations for duration of respiratory isolation based on time
   to detect Mycobacterium tuberculosis in liquid culture}},
Journal = {{EUROPEAN RESPIRATORY JOURNAL}},
Year = {{2007}},
Volume = {{30}},
Number = {{3}},
Pages = {{501-507}},
Month = {{SEP}},
Abstract = {{It was hypothesised that the time to detect Mycobacterium, tuberculosis
   in liquid culture of sputum from patients with pulmonary tuberculosis
   may be a better indicator for the duration of respiratory isolation than
   sputum smear status.
   Pre-treatment and during-treatment sputum acid-fast bacilli (AFB) smear
   and culture results were reviewed in 284 patients with pulmonary
   tuberculosis. The time to detect M. tuberculosis in liquid culture
   (TTD-TB) was the number of days from inoculation of the Mycobacterial
   Growth Indicator Tube to culture detection and visualisation of AFB.
   The median (interquartile range) TTD-TB for smear group 0 (no bacilli
   seen) was 14 (1220) days. This value was used as the standard at which
   release from isolation could be permitted. In smear group 4 (>9 AFB per
   high-power field (hpf) in sputum specimens before treatment) patients,
   the TTD-TB exceeded 14 days after a median of 25 days of treatment.
   The current authors recommend that patients in smear groups 1 and 2 (1-9
   AFB per 100 hpf and 1-9 AFB per 10 hpf in sputum specimens before
   treatment, respectively) receive treatment in respiratory isolation for
   7 days, provided the risk of drug resistance is low. Smear group 3 (19
   AFB per hpf) and 4 patients should receive treatment in respiratory
   isolation for 14 and 25 days, respectively. These criteria would have
   reduced the duration of respiratory isolation by 1,516 days in the 143
   study participants with sputum smear-positive pulmonary tuberculosis.
   Provided clinical and radiographical criteria are satisfactory, use of
   the time to detect Mycobacterium tuberculosis in liquid culture could
   enable the duration of respiratory isolation to be predicted from the
   pre-treatment sputum smear grade. The recommendations enable isolation
   to end well before sputum becomes smear negative, with considerable
   benefits to patients and healthcare providers.}},
Publisher = {{EUROPEAN RESPIRATORY SOC JOURNALS LTD}},
Address = {{146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ritchie, SR (Reprint Author), Auckland City Hosp, Dept Infect Dis, Green Lane Resp Serv, Auckland, New Zealand.
   Auckland City Hosp, Dept Infect Dis, Green Lane Resp Serv, Auckland, New Zealand.
   LabPLUS, Dept Microbiol, Auckland, New Zealand.
   Auckland Reg Publ Hlth Serv, Auckland, New Zealand.}},
DOI = {{10.1183/09031936.00131406}},
ISSN = {{0903-1936}},
Keywords = {{infectivity; pulmonary tuberculosis; respiratory isolation; time to
   detect tuberculosis in liquid culture; transmission; treatment}},
Keywords-Plus = {{ACID-FAST BACILLI; PULMONARY TUBERCULOSIS; SPUTUM SMEARS; INFECTIVITY;
   CHEMOTHERAPY; TRANSMISSION; DRUGS}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Author-Email = {{sritchie@adhb.govt.nz}},
ORCID-Numbers = {{Ritchie, Stephen/0000-0001-5001-8899}},
Cited-References = {{Al-Moamary MS, 1999, CHEST, V116, P726, DOI 10.1378/chest.116.3.726.
   Behr MA, 1999, LANCET, V353, P444, DOI 10.1016/S0140-6736(98)03406-0.
   DAVIES BH, 1980, THORAX, V35, P481, DOI 10.1136/thx.35.7.481.
   Epstein MD, 1998, CHEST, V113, P379, DOI 10.1378/chest.113.2.379.
   GUNNELS JJ, 1974, AM REV RESPIR DIS, V109, P323.
   HOBBY GL, 1973, ANTIMICROB AGENTS CH, V4, P94.
   Iseman MD, 1997, CLIN INFECT DIS, V25, P671, DOI 10.1086/513774.
   Jenssen HK, 2005, INDIANA U MATH J, V54, P1, DOI 10.1512/iumj.2005.54.2685.
   JINDANI A, 1980, AM REV RESPIR DIS, V121, P939.
   Jindani A, 2003, AM J RESP CRIT CARE, V167, P1348, DOI 10.1164/rccm.200210-1125OC.
   KAMAT SR, 1966, B WORLD HEALTH ORGAN, V34, P517.
   LIIPPO KK, 1993, AM REV RESPIR DIS, V148, P235.
   Long R, 2003, INFECT CONT HOSP EP, V24, P831, DOI 10.1086/502145.
   Marks SM, 2000, AM J RESP CRIT CARE, V162, P2033.
   Mixides G, 2005, CHEST, V128, P108, DOI 10.1378/chest.128.1.108.
   Ormerod P, 1998, THORAX, V53, P536.
   PATERSON A, 2003, NZ MINISTRY HLTH GUI.
   PFYFFER FE, 2003, MANUAL CLIN MICROBIO, P532.
   Sepkowitz KA, 1996, CLIN INFECT DIS, V23, P954.
   SHAW JB, 1954, AM REV TUBERC PULM, V69, P724.
   Taylor Zachary, 2005, MMWR Recomm Rep, V54, P1.
   WINTERS RE, 1994, CLIN INFECT DIS, V19, P309.
   YEAGER H, 1967, AM REV RESPIR DIS, V95, P998.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Eur. Resp. J.}},
Doc-Delivery-Number = {{211FM}},
Unique-ID = {{ISI:000249509700017}},
}

@article{ ISI:000248960400012,
Author = {Carroll, Paul and Brown, Amanda C. and Hartridge, Anna R. and Parish,
   Tanya},
Title = {{Expression of Mycobacterium tuberculosis Rv1991c using an
   arabinose-inducible promoter demonstrates its role as a toxin}},
Journal = {{FEMS MICROBIOLOGY LETTERS}},
Year = {{2007}},
Volume = {{274}},
Number = {{1}},
Pages = {{73-82}},
Month = {{SEP}},
Abstract = {{Conditional gene expression systems are useful tools for studying the
   role of essential or toxic gene products in bacterial systems. There is
   a paucity of such systems available for use in the mycobacteria. The
   utility of the Escherichia coli arabinose-inducible system was looked
   into, since it is tightly controlled in response to the presence of
   arabinose and glucose. It was demonstrated that the P-BAD promoter can
   be used to express heterologous genes in Mycobacterium smegmatis.
   Expression of a lacZ reporter gene demonstrated that promoter activity
   was inducible in response to the presence of glucose, but only on solid
   medium. This system was utilized to study the functional consequences of
   expressing one member of a putative toxin-antitoxin pair (Rv1991c).
   Rv1991c has homology with a number of bacterial toxins, including ChpK,
   MazF and PemK. A potential antitoxin gene has been identified, adjacent
   to Rv1991c in the genome, which was coexpressed with the toxin.
   Expression of the toxin alone inhibited the growth of E. coli, whereas
   coexpression with the antitoxin did not. Expression of Rv1991c also led
   to a marked reduction of cell viability in M. smegmatis, confirming its
   role as a potent toxin.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Parish, T (Reprint Author), Barts \& London Queen Marys Sch Med \& Dent, Ctr Infect Dis, Barts \& London, Inst Cell \& Mol Sci, Blizard Bldg,4 Newark St, London E1 2AT, England.
   Barts \& London Queen Marys Sch Med \& Dent, Ctr Infect Dis, Barts \& London, Inst Cell \& Mol Sci, London E1 2AT, England.}},
DOI = {{10.1111/j.1574-6968.2007.00842.x}},
ISSN = {{0378-1097}},
Keywords = {{mycobacteria; conditional gene expression; P-BAD; toxin-antitoxin}},
Keywords-Plus = {{MESSENGER-RNA INTERFERASE; ESCHERICHIA-COLI; GENE-EXPRESSION; SHUTTLE
   VECTORS; INSTABILITY; SMEGMATIS; PLASMID; PROTEIN; SYSTEM; PURIFICATION}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{t.parish@qmul.ac.uk}},
Funding-Acknowledgement = {{Wellcome Trust {[}063894]}},
Cited-References = {{Al-Zarouni M, 2002, TUBERCULOSIS, V82, P283, DOI 10.1054/tube.2002.0374.
   Anilkumar G, 1998, GENE, V214, P7, DOI 10.1016/S0378-1119(98)00248-0.
   Arcus VL, 2005, TRENDS MICROBIOL, V13, P360, DOI 10.1016/j.tim.2005.06.008.
   Bai GC, 2005, J BACTERIOL, V187, P7795, DOI 10.1128/JB.187.22.7795-7804.2005.
   Bateman BT, 2001, INFECT IMMUN, V69, P7851, DOI 10.1128/IAI.69.12.7851-7857.2001.
   Blokpoel MCJ, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni023.
   Brown AC, 2006, PLASMID, V55, P81, DOI 10.1016/j.plasmid.2005.06.005.
   Carroll P, 2005, APPL ENVIRON MICROB, V71, P3077, DOI 10.1128/AEM.71.6.3077-3084.2005.
   Chawla M, 1999, PLASMID, V41, P135, DOI 10.1006/plas.1998.1384.
   Christensen SK, 2001, P NATL ACAD SCI USA, V98, P14328, DOI 10.1073/pnas.251327898.
   Cole ST, 1998, NATURE, V393, P537.
   De Smet KAL, 1999, MICROBIOL-UK, V145, P3177.
   DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21.
   Dussurget O, 1999, J BACTERIOL, V181, P3402.
   Ehrt S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni013.
   Eichenbaum Z, 1998, APPL ENVIRON MICROB, V64, P2763.
   ELVIN CM, 1990, GENE, V87, P123, DOI 10.1016/0378-1119(90)90503-J.
   GEISSENDORFER M, 1990, APPL MICROBIOL BIOT, V33, P657.
   GUZMAN LM, 1995, J BACTERIOL, V177, P4121.
   Herai S, 2004, P NATL ACAD SCI USA, V101, P14031, DOI 10.1073/pnas.0406058101.
   Herrmann JL, 1996, EMBO J, V15, P3547.
   JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi\_17020205.x.
   KOCHANOWSKI R, 2006, SO PROTEIN EXPR PURI, V50, P25.
   LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111.
   LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274.
   Machowski EE, 2000, GENE, V253, P67, DOI 10.1016/S0378-1119(00)00238-9.
   MAHENTHIRALINGAM E, 1993, J GEN MICROBIOL, V139, P575.
   Marianovsky I, 2001, J BIOL CHEM, V276, P5975, DOI 10.1074/jbc.M008832200.
   Miles AA, 1938, J HYG-CAMBRIDGE, V38, P732.
   Miller J. H., 1972, EXPT MOL GENETICS.
   Pandey DP, 2005, NUCLEIC ACIDS RES, V33, P966, DOI 10.1093/nar/gki201.
   Parish T, 2005, TUBERCULOSIS, V85, P197, DOI 10.1016/j.tube.2005.01.002.
   Parish T, 1998, METH MOL B, V101, P129, DOI 10.1385/0-89603-471-2:129.
   Pedersen K, 2002, MOL MICROBIOL, V45, P501, DOI 10.1046/j.1365-2958.2002.03027.x.
   RAUZIER J, 1988, GENE, V71, P315, DOI 10.1016/0378-1119(88)90048-0.
   Schleif R, 2000, TRENDS GENET, V16, P559, DOI 10.1016/S0168-9525(00)02153-3.
   Siegele DA, 1997, P NATL ACAD SCI USA, V94, P8168, DOI 10.1073/pnas.94.15.8168.
   Springer B, 2001, INT J MED MICROBIOL, V290, P669.
   Strahilevitz J, 2006, PROTEIN EXPRES PURIF, V47, P10, DOI 10.1016/j.pep.2005.08.009.
   Suzuki M, 2005, MOL CELL, V18, P253, DOI 10.1016/j.molcel.2005.03.011.
   Szweda P, 2005, J BIOTECHNOL, V117, P203, DOI 10.1016/j.jbiotec.2005.01.012.
   TIMM JL, 1994, J BACTERIOL, V176, P6749.
   Triccas JA, 1998, FEMS MICROBIOL LETT, V167, P151, DOI 10.1111/j.1574-6968.1998.tb13221.x.
   Vazquez-Laslop N, 2006, J BACTERIOL, V188, P3494, DOI 10.1128/JB.188.10.3494-3497.2006.
   Zhang JJ, 2003, J BIOL CHEM, V278, P32300, DOI 10.1074/jbc.M304767200.
   Zhang YL, 2005, J BIOL CHEM, V280, P26080, DOI 10.1074/jbc.M502050200.
   Zhang YL, 2005, J BIOL CHEM, V280, P3143, DOI 10.1074/jbc.M411811200.
   Zhu L, 2006, J BIOL CHEM, V281, P18638, DOI 10.1074/jbc.M512693200.}},
Number-of-Cited-References = {{48}},
Times-Cited = {{17}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{FEMS Microbiol. Lett.}},
Doc-Delivery-Number = {{203FL}},
Unique-ID = {{ISI:000248960400012}},
}

@article{ ISI:000249277300002,
Author = {Olesen, R. and Wejse, C. and Velez, D. R. and Bisseye, C. and Sodemann,
   M. and Aaby, P. and Rabna, P. and Worwui, A. and Chapman, H. and Diatta,
   M. and Adegbola, Ra and Hill, Pc and Ostergaard, L. and Williams, S. M.
   and Sirugo, G.},
Title = {{DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants
   associate with pulmonary tuberculosis risk in West Africans}},
Journal = {{GENES AND IMMUNITY}},
Year = {{2007}},
Volume = {{8}},
Number = {{6}},
Pages = {{456-467}},
Month = {{SEP}},
Abstract = {{We investigated the role of DC-SIGN ( CD209), long pentraxin 3 ( PTX3)
   and vitamin D receptor ( VDR) gene single nucleotide polymorphisms (
   SNPs) in susceptibility to pulmonary tuberculosis ( TB) in 321 TB cases
   and 347 healthy controls from Guinea-Bissau. Five additional,
   functionally relevant SNPs within toll-like receptors ( TLRs) 2, 4 and 9
   were typed but found, when polymorphic, not to affect host vulnerability
   to pulmonary TB. We did not replicate an association between SNPs in the
   DC-SIGN promoter and TB. However, we found that two polymorphisms, one
   in DC-SIGN and one in VDR, were associated in a nonadditive model with
   disease risk when analyzed in combination with ethnicity ( P = 0.03 for
   DC- SIGN and P = 0.003 for VDR). In addition, PTX3 haplotype frequencies
   significantly differed in cases compared to controls and a protective
   effect was found in association with a specific haplotype ( OR 0.78,
   95\% Cl 0.63-0.98). Our findings support previous data showing that VDR
   SNPs modulate the risk for TB in West Africans and suggest that
   variation within DC- SIGN and PTX3 also affect the disease outcome.}},
Publisher = {{NATURE PUBLISHING GROUP}},
Address = {{MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Sirugo, G (Reprint Author), MRC Labs, POB 273, Banjul, Gambia.
   MRC Labs, Banjul, Gambia.
   Aarhus Univ Hosp, Dept Infect Dis, Skejby, Denmark.
   Danish Epidemiol Sci Ctr, Bandin Hlth Project, Bissau, Guinea Bissau.
   State Serum Inst, Bissau, Guinea Bissau.
   Vanderbilt Univ, Dept Cardiovasc Med, Ctr Human Genet Res, Nashville, TN USA.}},
DOI = {{10.1038/sj.gene.6364410}},
ISSN = {{1466-4879}},
Keywords = {{tuberculosis; genetic susceptibility; DC-SIGN; pentraxin 3; vitamin D
   receptor; epistasis}},
Keywords-Plus = {{SINGLE-NUCLEOTIDE POLYMORPHISMS; TOLL-LIKE RECEPTORS; WALL COMPONENT
   LIPOARABINOMANNAN; HUMAN DENDRITIC CELLS; MYCOBACTERIUM-TUBERCULOSIS;
   SUSCEPTIBILITY; DISEASE; EXPRESSION; HYPERTENSION; INFLAMMATION}},
Research-Areas = {{Genetics \& Heredity; Immunology}},
Web-of-Science-Categories  = {{Genetics \& Heredity; Immunology}},
Author-Email = {{gsirugo@mrc.gm}},
ResearcherID-Numbers = {{Williams, Scott/B-9491-2012
   Velez Edwards, Digna/C-1090-2012
   Wejse, Christian/C-8468-2014
   }},
ORCID-Numbers = {{Wejse, Christian/0000-0002-2534-2942
   Olesen, Rikke/0000-0002-5157-080X}},
Funding-Acknowledgement = {{Medical Research Council {[}MC\_U190071468]}},
Cited-References = {{AABY P, 1983, J INFECT DIS, V147, P693.
   Abel B, 2002, J IMMUNOL, V169, P3155.
   Arbour NC, 2000, NAT GENET, V25, P187.
   Azzurri A, 2005, MICROBES INFECT, V7, P1, DOI 10.1016/j.micinf.2004.09.004.
   Bafica A, 2005, J EXP MED, V202, P1715, DOI 10.1081/jem.20051782.
   BARREIRO LB, 2006, PLOS MED, V3, DOI UNSP 0230-0235.
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457.
   Ben-Ali M, 2004, CLIN DIAGN LAB IMMUN, V11, P625, DOI 10.1128/CDLI.11.3.625-626.2004.
   Bornman L, 2004, J INFECT DIS, V190, P1631, DOI 10.1086/424462.
   Brassat D, 2006, GENES IMMUN, V7, P310, DOI 10.1038/sj.gene.6364299.
   Cho YM, 2004, DIABETOLOGIA, V47, P549, DOI 10.1007/s00125-003-1321-3.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Ducati RG, 2006, MEM I OSWALDO CRUZ, V101, P697, DOI 10.1590/S0074-02762006000700001.
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424.
   Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756.
   Gomez LM, 2006, HUM IMMUNOL, V67, P808, DOI 10.1016/j.humimm.2006.07.003.
   Gustafson P, 2004, INT J EPIDEMIOL, V33, P163, DOI 10.1093/ije/dyh026.
   Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869.
   HARRIES A, 2004, TB HIV CLIN MANUAL, P105.
   Hill AVS, 2006, ANNU REV GENET, V40, P469, DOI 10.1146/annurev.genet.40.110405.090546.
   JAKULIN A, 2003, 7 EUR C PRINC PRACT, P229.
   JAKULIN A, 2003, 9 C ART INT MED EUR, P229.
   Lazarus R, 2003, GENOMICS, V81, P85, DOI 10.1016/S0888-7543(02)00022-8.
   Liu KJ, 2005, BIOINFORMATICS, V21, P2128, DOI 10.1093/bioinformatics/bti282.
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933.
   Means TK, 1999, J IMMUNOL, V163, P3920.
   Means TK, 2001, J IMMUNOL, V166, P4074.
   Moore JH, 2006, J THEOR BIOL, V241, P252, DOI 10.1016/j.jtbi.2005.11.036.
   Newport MJ, 2004, TUBERCULOSIS, V84, P347, DOI 10.1016/j.tube.2004.02.001.
   Ogus AC, 2004, EUR RESPIR J, V23, P219, DOI 10.1183/09031936.03.00061703.
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085.
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276.
   Sakuntabhai A, 2005, NAT GENET, V37, P507, DOI 10.1038/ng1550.
   Sanada H, 2006, CLIN CHEM, V52, P352, DOI 10.1373/clinchem.2005.059139.
   Schroder NW, 2005, LANCET INFECT DIS, V5, P156, DOI 10.1016/S1473-3099(05)70023-2.
   Sirugo G, 2004, NAT GENET, V36, P785, DOI 10.1038/ng0804-785.
   Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468.
   Tsai CT, 2004, CIRCULATION, V109, P1640, DOI 10.1161/01.CIR.0000124487.36586.26.
   Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000.
   Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459.
   Vouret-Craviari V, 1997, CYTOKINE, V9, P992, DOI 10.1006/cyto.1997.0242.
   VouretCraviari V, 1997, INFECT IMMUN, V65, P1345.
   Williams SM, 2004, HUM HERED, V57, P28, DOI 10.1159/000077387.
   Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{107}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Genes Immun.}},
Doc-Delivery-Number = {{207UT}},
Unique-ID = {{ISI:000249277300002}},
}

@article{ ISI:000249277300004,
Author = {Chu, S-F and Tam, C. M. and Wong, H. S. and Kam, K. M. and Lau, Y. L.
   and Chiang, A. K. S.},
Title = {{Association between RANTES functional polymorphisms and tuberculosis in
   Hong kong chinese}},
Journal = {{GENES AND IMMUNITY}},
Year = {{2007}},
Volume = {{8}},
Number = {{6}},
Pages = {{475-479}},
Month = {{SEP}},
Abstract = {{Chemokines play a major role in leukocyte recruitment during the
   formation of tuberculous granulomas. We studied the association between
   genetic polymorphisms of three chemokines, monocyte chemoattractant
   protein-1 ( MCP-1), RANTES ( regulated on activation, normal T cell
   expressed and secreted) and macrophage inflammatory protein-1 alpha (
   MIP-1 alpha), and tuberculosis ( TB). The distribution of five
   functionally significant single-nucleotide polymorphisms ( SNPs),
   MCP-1-2518A/ G, RANTES-403G/ A,-28C/ G and In1.1T/ C as well as MIP-1
   alpha + 459C/ T was not found to be different between patients with TB
   and healthy control subjects of the Hong Kong Chinese population.
   However, differences in linkage disequilibrium ( LD) of the SNPs of
   RANTES and in distribution of the haplotypes of RANTES between patients
   with TB and healthy controls ( P<0.0001) were found. Two risk haplotypes
   of RANTES, A-C-T and G-C-C, at positions -403, -28 and In1.1,
   respectively, were identified. Furthermore, combining the genotypes of
   RANTES -403 and In1.1, two diplotypes GA/ TT ( P<0.001) and GG/ TC (
   P<0.0001) showed strong association with TB. Our findings support the
   association between RANTES functional polymorphisms and TB.}},
Publisher = {{NATURE PUBLISHING GROUP}},
Address = {{MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Chiang, A (Reprint Author), Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Dept Pediat \& Adolescent Med, Rm107,New Clin Bldg, Pokfulam, Hong Kong, Peoples R China.
   Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Dept Pediat \& Adolescent Med, Pokfulam, Hong Kong, Peoples R China.
   Dept Hlth, TB \& Chest Serv, Pokfulam, Hong Kong, Peoples R China.
   Publ Hlth Lab Ctr, Dept Hlth, TB Lab, Pokfulam, Hong Kong, Peoples R China.}},
DOI = {{10.1038/sj.gene.6364412}},
ISSN = {{1466-4879}},
Keywords = {{chemokines; RANTES; tuberculosis; genetic susceptibility}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; PROMOTER POLYMORPHISM; DISEASE PROGRESSION;
   CHEMOKINE RANTES; BETA-CHEMOKINES; SUSCEPTIBILITY; INFECTION;
   EXPRESSION; GRANULOMAS; INHIBIT}},
Research-Areas = {{Genetics \& Heredity; Immunology}},
Web-of-Science-Categories  = {{Genetics \& Heredity; Immunology}},
Author-Email = {{chiangak@hkucc.hku.hk}},
ResearcherID-Numbers = {{Kam, Kai Man/K-4546-2012
   Lau, Yu Lung/C-4322-2009
   }},
ORCID-Numbers = {{Kam, Kai Man/0000-0003-0579-0307
   Chiang, Alan/0000-0002-1089-5325}},
Cited-References = {{An P, 2002, P NATL ACAD SCI USA, V99, P10002, DOI 10.1073/pnas.142313799.
   Appay V, 2001, TRENDS IMMUNOL, V22, P83, DOI 10.1016/S1471-4906(00)01812-3.
   Blackwell JM, 1997, PHILOS T ROY SOC B, V352, P1331.
   Chensue SW, 1999, J IMMUNOL, V163, P165.
   Co DO, 2004, CLIN IMMUNOL, V113, P130, DOI 10.1016/j.clim.2004.08.012.
   Flores-Villanueva PO, 2005, J EXP MED, V202, P1649, DOI 10.1084/jem20050216.
   Gonzalez E, 2001, P NATL ACAD SCI USA, V98, P5199, DOI 10.1073/pnas.091056898.
   Jamieson SE, 2004, GENES IMMUN, V5, P46, DOI 10.1038/sj.gene.6364029.
   Kallmann FJ, 1943, AM REV TUBERC, V47, P549.
   Kurashima K, 1997, AM J RESP CRIT CARE, V155, P1474.
   Lima MF, 1997, CELL MOL BIOL, V43, P1067.
   Liu HL, 1999, P NATL ACAD SCI USA, V96, P4581, DOI 10.1073/pnas.96.8.4581.
   McDermott DH, 2000, AIDS, V14, P2671, DOI 10.1097/00002030-200012010-00006.
   Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6.
   Nickel RG, 2000, J IMMUNOL, V164, P1612.
   Rovin BH, 1999, BIOCHEM BIOPH RES CO, V259, P344, DOI 10.1006/bbrc.1999.0796.
   Sadek MI, 1998, AM J RESP CELL MOL, V19, P513.
   Saukkonen JJ, 2002, INFECT IMMUN, V70, P1684, DOI 10.1128/IAI.70.4.1684-1693.2002.
   Szalai C, 2001, ATHEROSCLEROSIS, V158, P233, DOI 10.1016/S0021-9150(01)00423-3.
   Taub DD, 1996, J IMMUNOL, V156, P2095.
   Tso HW, 2005, GENES IMMUN, V6, P358, DOI 10.1038/sj.gene.6364189.
   Tso HW, 2004, J INFECT DIS, V190, P913, DOI 10.1086/422693.
   Ulrichs T, 2004, J PATHOL, V204, P217, DOI 10.1002/path.1628.
   {[}World Health Organization Office WPR], 2000, REG STRAT PLAN STOP.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{41}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Genes Immun.}},
Doc-Delivery-Number = {{207UT}},
Unique-ID = {{ISI:000249277300004}},
}

@article{ ISI:000249925800006,
Author = {Karim, Fazlul and Islam, Md. Akramul and Chowdhury, Amr and Johansson,
   Eva and Diwan, Vinod K.},
Title = {{Gender differences in delays in diagnosis and treatment of tuberculosis}},
Journal = {{HEALTH POLICY AND PLANNING}},
Year = {{2007}},
Volume = {{22}},
Number = {{5}},
Pages = {{329-334}},
Month = {{SEP}},
Abstract = {{Objective To assess the gender variations in delay from symptom onset to
   help seeking, diagnosis and treatment of tuberculosis (TB) using DOTS at
   community level, in 10 subdistricts of Bangladesh with 2.5 million
   people under a non-governmental organization's (Building Resources
   Across Communities, or BRAC) DOTS programme for TB control.
   Design A cross-sectional survey of 1000 newly diagnosed pulmonary TB
   patients (500 women and 500 men).
   Findings Women, in comparison with men, had significantly longer mean
   and median delays in total delay (63.2 and 61.0 days vs. 60.3 and 53
   days, respectively), total diagnostic delay (61.2, 60.0 vs. 58.5, 52.0
   days), patient's delay ( 51.9, 50.0 vs. 48.7, 42.0 days) and treatment
   delay (2.0, 1.0 vs. 1.9, 1.0 day). Patient's mean and median delays were
   longer than the health system delay. However, patient gender showed
   strong association with total delay, total diagnostic delay and
   patient's delay. Older age of women was significantly associated with
   longer patient and treatment delay categories, respectively.
   Conclusion Compared with men, women experienced longer delays at various
   stages of the clinical process of help seeking for TB. This warrants
   appropriate measures to improve the situation.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Karim, F (Reprint Author), Karolinska Inst, Dept Publ Hlth Sci, Div Int Hlth, Nobels Vag 9, SE-17177 Stockholm, Sweden.
   Karolinska Inst, Dept Publ Hlth Sci, Div Int Hlth, SE-17177 Stockholm, Sweden.
   BRAC, Res \& Evaluat Div, Dhaka, Bangladesh.
   BRAC, BRAC Hlth Programme, Dhaka, Bangladesh.}},
DOI = {{10.1093/heapol/czm026}},
ISSN = {{0268-1080}},
Keywords = {{delay; gender; DOTS; tuberculosis; service provider; Bangladesh}},
Keywords-Plus = {{SEEKING BEHAVIOR; COST}},
Research-Areas = {{Health Care Sciences \& Services}},
Web-of-Science-Categories  = {{Health Care Sciences \& Services; Health Policy \& Services}},
Author-Email = {{f\_karim124@yahoo.com}},
Cited-References = {{{*}BANGL BUR STAT, 2004, STAT POCK BOOK BANGL.
   CAMINERO JA, 1995, TUBERCLE LUNG DIS, V76, P387, DOI 10.1016/0962-8479(95)90003-9.
   DALE MN, 2001, TROP MED INT HEALTH, V6, P256.
   Diwan VK, 1999, LANCET, V353, P1000, DOI 10.1016/S0140-6736(99)01318-5.
   Franco J, 1996, MED CLIN-BARCELONA, V107, P453.
   Gibson N, 1998, INT J TUBERC LUNG D, V2, P726.
   Hudelson P, 1996, TUBERCLE LUNG DIS, V77, P391, DOI 10.1016/S0962-8479(96)90110-0.
   Jaramillo E, 1998, TROP MED INT HEALTH, V3, P138, DOI 10.1046/j.1365-3156.1998.00202.x.
   Lawn SD, 1997, INT J TUBERC LUNG D, V1, P485.
   Long NH, 1999, INT J TUBERC LUNG D, V3, P388.
   Pirkis JE, 1996, TUBERCLE LUNG DIS, V77, P401, DOI 10.1016/S0962-8479(96)90111-2.
   Yamasaki-Nakagawa M, 2001, INT J TUBERC LUNG D, V5, P24.}},
Number-of-Cited-References = {{12}},
Times-Cited = {{42}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Health Policy Plan.}},
Doc-Delivery-Number = {{217CK}},
Unique-ID = {{ISI:000249925800006}},
}

@article{ ISI:000249843400016,
Author = {Harris, James and De Haro, Sergio A. and Master, Sharon S. and Keane,
   Joseph and Roberts, Esteban A. and Delgado, Monica and Deretic, Vojo},
Title = {{T helper 2 Cytokines inhibit autophagic control of intracellular
   Mycobacterium tuberculosis}},
Journal = {{IMMUNITY}},
Year = {{2007}},
Volume = {{27}},
Number = {{3}},
Pages = {{505-517}},
Month = {{SEP}},
Abstract = {{Autophagy is a recently recognized immune effector mechanism against
   intracellular pathogens. The role of autophagy in innate immunity has
   been well established, but the extent of its regulation by the adaptive
   immune response is less well understood. The T helper 1 (Th1) cell
   cytokine IFN-gamma induces autophagy in macrophages to eliminate
   Mycobacterium tuberculosis. Here, we report that Th2 cytokines affect
   autophagy in macrophages and their ability to control intracellular M.
   tuberculosis. IL-4 and IL-13 abrogated autophagy and autophagymediated
   killing of intracellular mycobacteria in murine and human macrophages.
   Inhibition of starvation-induced autophagy by IL-4 and IL-13 was
   dependent on Akt signaling, whereas the inhibition of IFN-gamma-induced
   autophagy was Akt independent and signal transducer and activator of
   transcription 6 (STAT6) dependent. These findings establish a mechanism
   through which Th1-Th2 polarization differentially affects the immune
   control of intracellular pathogens.}},
Publisher = {{CELL PRESS}},
Address = {{600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Deretic, V (Reprint Author), Univ New Mexico, Sch Med, Dept Mol Genet \& Microbiol, Ctr Hlth Sci, 915 Camino Salud NE, Albuquerque, NM 87131 USA.
   Univ New Mexico, Sch Med, Dept Mol Genet \& Microbiol, Ctr Hlth Sci, Albuquerque, NM 87131 USA.
   St James Hosp, Dublin 8, Ireland.
   Univ Dublin Trinity Coll, Dublin 8, Ireland.
   Univ New Mexico, Dept Cell Biol \& Physiol, Albuquerque, NM 87131 USA.}},
DOI = {{10.1016/j.immuni.2007.07.022}},
ISSN = {{1074-7613}},
Keywords-Plus = {{CELL-DEATH; IFN-GAMMA; T-CELLS; ALTERNATIVE ACTIVATION;
   TOXOPLASMA-GONDII; ADAPTIVE IMMUNITY; IL-13 RECEPTOR; MACROPHAGES;
   INDUCTION; APOPTOSIS}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{vderetic@salud.unm.edu}},
ResearcherID-Numbers = {{De Haro, Sergio/B-1047-2009
   }},
ORCID-Numbers = {{Keane, Joseph/0000-0001-5313-385X
   Deretic, Vojo/0000-0002-3624-5208
   Harris, James/0000-0002-5634-9637}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI042999, AI045148, AI045148S1, AI069345]}},
Cited-References = {{Andrade RM, 2006, J CLIN INVEST, V116, P2366, DOI 10.1172/JCI28796.
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200.
   Aspord C, 2007, J EXP MED, V204, P1037, DOI 10.1084/jem.20061120.
   Baliko Z, 1998, FEMS IMMUNOL MED MIC, V22, P199, DOI 10.1111/j.1574-695X.1998.tb01207.x.
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3.
   Birmingham CL, 2006, J BIOL CHEM, V281, P11374, DOI 10.1074/jbc.M509157200.
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002.
   Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x.
   Bloom BR, 1998, NEW ENGL J MED, V338, P677, DOI 10.1056/NEJM199803053381008.
   Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918.
   Chensue SW, 1997, J IMMUNOL, V159, P3565.
   Chua J, 2004, J BIOL CHEM, V279, P36982, DOI 10.1074/jbc.M405082200.
   Dengjel J, 2005, P NATL ACAD SCI USA, V102, P7922, DOI 10.1073/pnas.0501190102.
   Deretic V, 2005, TRENDS IMMUNOL, V26, P523, DOI 10.1016/j.it.2005.08.003.
   Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200.
   Dlugovitzky D, 1997, FEMS IMMUNOL MED MIC, V18, P203, DOI 10.1016/S0928-8244(97)00040-0.
   Donaldson DD, 1998, J IMMUNOL, V161, P2317.
   Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332.
   Fratazzi C, 1999, J LEUKOCYTE BIOL, V66, P763.
   Freeman S, 2006, J INTERF CYTOK RES, V26, P27, DOI 10.1089/jir.2006.26.27.
   Gingras AC, 2001, GENE DEV, V15, P2852.
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978.
   Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038.
   HUANG SK, 1995, J IMMUNOL, V155, P2688.
   Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094.
   Jo EK, 2003, CURR OPIN INFECT DIS, V16, P205, DOI 10.1097/01.qco.0000073768.11390.a3.
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720.
   Kahnert A, 2006, EUR J IMMUNOL, V36, P631, DOI 10.1002/eji.200535496.
   Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673.
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029.
   Kyei GB, 2006, EMBO J, V25, P5250, DOI 10.1038/sj.emboj.7601407.
   Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005.
   LEVINE B, 2007, IN PRESS NAT REV IMM.
   Liang XH, 1999, NATURE, V402, P672.
   Ling YM, 2006, J EXP MED, V203, P2063, DOI 10.1084/jem.20061318.
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046.
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689.
   Manca C, 2004, INFECT IMMUN, V72, P5511, DOI 10.1128/IAI.72.9.5511-5514.2004.
   Mazzarella G, 2003, CLIN EXP IMMUNOL, V132, P283, DOI 10.1046/j.1365-2249.2003.02121.x.
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704.
   Montaner LJ, 1999, J IMMUNOL, V162, P4606.
   Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701.
   Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036.
   Orvedahl A, 2007, CELL HOST MICROBE, V1, P23, DOI 10.1016/j.chom.2006.12.001.
   Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904.
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002.
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992.
   Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200.
   Roberts EA, 2006, J CELL BIOL, V174, P923, DOI 10.1083/jcb.200603026.
   Schmid D, 2006, J MOL MED-JMM, V84, P194, DOI 10.1007/s00109-005-0014-4.
   SCHMIDT D, 2006, IMMUNITY, V26, P79.
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993.
   Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577.
   Sun YJ, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-105.
   Taha RA, 1997, AM J RESP CRIT CARE, V155, P1135.
   van Crevel R, 2000, J INFECT DIS, V181, P1194, DOI 10.1086/315325.
   Vergne I, 2004, ANNU REV CELL DEV BI, V20, P367, DOI 10.1146/annurev.cellbio.20.010403.114015.
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016.
   Wurster AL, 2002, J BIOL CHEM, V277, P27169, DOI 10.1074/jbc.M201207200.
   Zhang JG, 1997, J BIOL CHEM, V272, P9474.
   Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909.}},
Number-of-Cited-References = {{61}},
Times-Cited = {{251}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{Immunity}},
Doc-Delivery-Number = {{215XX}},
Unique-ID = {{ISI:000249843400016}},
}

@article{ ISI:000250452400009,
Author = {Martins, Marta and Viveiros, Miguel and Kristiansen, Jette E. and
   Molnar, Joseph and Amaral, Leonard},
Title = {{The curative activity of thioridazine on mice infected with
   Mycobacterium tuberculosis}},
Journal = {{IN VIVO}},
Year = {{2007}},
Volume = {{21}},
Number = {{5}},
Pages = {{771-775}},
Month = {{SEP-OCT}},
Abstract = {{Background: The aim of the study was to evaluate the effectiveness of
   thioridazine (TZ) at different dose levels on mice that had been
   infected intraperitoneally (i.p.) with a high dose of the Mycobacterium
   tuberculosis ATCC H3 7Rv strain. Subjects and Methods: Groups of five
   female BALB/C mice were infected i.p. with 106 colony forming units/mL.
   After thirty days, treatment with TZ was initiated, except for the
   control group. Mice were treated with TZ at equivalent concentrations to
   that used in the humans (1200 mg/day), ranging from 0.05 to 0.5 mg/day.
   Results: The results demonstrated that a daily dose of 0.5 mg/day of TZ
   reduced the number of colony forming units retrieved from the lungs of
   infected mice within one month. Conclusion: By the end of 300 days of
   therapy, although mycobacteria were still retained, their presence, in
   comparison to that of the control was 8 orders of magnitude lower.}},
Publisher = {{INT INST ANTICANCER RESEARCH}},
Address = {{EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Amaral, L (Reprint Author), UPMM, Unit Mycobacteriol, Inst Higiene \& Med Trop, Rua Junqueira 96, P-1349008 Lisbon, Portugal.
   UPMM, Unit Mycobacteriol, Inst Higiene \& Med Trop, P-1349008 Lisbon, Portugal.
   Sonderborg So Danish Univ, Dept Clin Microbiol, DK-6400 Sonderborg, Denmark.
   Univ Szeged, Dept Med Microbiol, H-6720 Szeged, Hungary.}},
ISSN = {{0258-851X}},
Keywords = {{pulmonary tuberculosis; mouse; Mycobacterium tuberculosis; thioridazine
   therapy}},
Keywords-Plus = {{MULTIDRUG-RESISTANT TUBERCULOSIS; IN-VITRO ACTIVITY;
   CELLULAR-DISTRIBUTION; POTENTIAL MANAGEMENT; PSYCHOTROPIC-DRUGS;
   NON-ANTIBIOTICS; PHENOTHIAZINES; THERAPY; ANTIDEPRESSANTS;
   CHLORPROMAZINE}},
Research-Areas = {{Research \& Experimental Medicine}},
Web-of-Science-Categories  = {{Medicine, Research \& Experimental}},
Author-Email = {{lamaral@ihmt.uni.pt}},
ResearcherID-Numbers = {{Viveiros, Miguel/A-7326-2008
   MARTINS, MARTA/I-3015-2012
   molnar,  joseph/D-4375-2013
   santos, sofia/I-1637-2012
   Amaral, Leonard/I-2112-2012}},
ORCID-Numbers = {{Viveiros, Miguel/0000-0001-9676-6251
   Amaral, Leonard/0000-0003-3127-1295}},
Cited-References = {{Amaral L, 2006, CURR DRUG TARGETS, V7, P887, DOI 10.2174/138945006777709539.
   Amaral L, 2004, IN VIVO, V18, P725.
   AMARAL L, 1992, J ANTIMICROB CHEMOTH, V30, P556, DOI 10.1093/jac/30.4.556.
   Amaral L, 1996, J ANTIMICROB CHEMOTH, V38, P1049, DOI 10.1093/jac/38.6.1049.
   Amaral L, 2000, INT J ANTIMICROB AG, V14, P173, DOI 10.1016/S0924-8579(99)00153-3.
   Amaral L, 2001, TROP MED INT HEALTH, V6, P1016, DOI 10.1046/j.1365-3156.2001.00804.x.
   Amaral L, 2001, J ANTIMICROB CHEMOTH, V47, P505, DOI 10.1093/jac/47.5.505.
   Amaral L, 2001, INT J ANTIMICROB AG, V18, P411, DOI 10.1016/S0924-8579(01)00432-0.
   Amaral L, 2007, J ANTIMICROB CHEMOTH, V59, P1237, DOI 10.1093/jac/dkl500.
   Bettencourt MV, 2000, INT J ANTIMICROB AG, V16, P69, DOI 10.1016/S0924-8579(00)00199-0.
   Centers for Disease Control and Prevention (CDC), 2005, MMWR-MORBID MORTAL W, V54, P1.
   {*}CDCP, 2005, MMWR-MORBID MORTAL W, V55, P305.
   CROWLE AJ, 1992, CHEMOTHERAPY, V38, P410.
   Daniel WA, 1999, TOXICOL APPL PHARM, V158, P115, DOI 10.1006/taap.1999.8688.
   Daniel WA, 1997, PHARMACOL TOXICOL, V80, P62.
   Daniel WA, 1997, PHARMACOL TOXICOL, V81, P259.
   Daniel WA, 1999, EUR NEUROPSYCHOPHARM, V9, P483, DOI 10.1016/S0924-977X(99)00034-6.
   Daniel WA, 2001, BRIT J PHARMACOL, V134, P807, DOI 10.1038/sj.bjp.0704319.
   KRISTIANSEN JE, 1986, ACTA PATH MICRO IM B, V94, P393.
   Kristiansen JE, 1997, J ANTIMICROB CHEMOTH, V40, P319, DOI 10.1093/jac/40.3.319.
   Martins M, 2007, INT J ANTIMICROB AG, V29, P338, DOI 10.1016/j.ijantimicag.2006.10.013.
   MOLNAR J, 1977, ZBL BAKT-INT J MED M, V239, P521.
   Ordway D, 2003, ANTIMICROB AGENTS CH, V47, P917, DOI 10.1128/AAC.47.3.917-922.2003.
   Ordway D. J., 2005, American Journal of Immunology, V1, P42.
   Russell DG, 2007, NAT REV MICROBIOL, V5, P39, DOI 10.1038/nrmicro1538.
   {*}US DEP HHS, 2000, HLTH PEOPL 2000 2010.
   Viveiros M, 2005, J CLIN MICROBIOL, V43, P4880, DOI 10.1128/JCM.43.9.4880-4884.2005.
   Viveiros M, 2005, IN VIVO, V19, P733.
   Viveiros M, 2002, ANTIMICROB AGENTS CH, V46, P2804, DOI 10.1128/AAC.46.9.2804-2810.2002.
   Viveiros M, 2001, INT J ANTIMICROB AG, V17, P225, DOI 10.1016/S0924-8579(00)00343-5.
   Weinstein EA, 2005, P NATL ACAD SCI USA, V102, P4548, DOI 10.1073/pnas.0500469102.
   {*}WHO, 2005, GLOB TUB CONTR SURV, P247.
   Xie ZF, 2005, ANTIMICROB AGENTS CH, V49, P4778, DOI 10.1128/AAC.49.11.4778-4780.2005.
   Yano T, 2006, J BIOL CHEM, V281, P11456, DOI 10.1074/jbc.M508844200.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{47}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{In Vivo}},
Doc-Delivery-Number = {{224MZ}},
Unique-ID = {{ISI:000250452400009}},
}

@article{ ISI:000251946600003,
Author = {Vijayan, V. K.},
Title = {{Miliary tuberculosis \& its sequelae - Commentary}},
Journal = {{INDIAN JOURNAL OF MEDICAL RESEARCH}},
Year = {{2007}},
Volume = {{126}},
Number = {{3}},
Pages = {{176-178}},
Month = {{SEP}},
Publisher = {{INDIAN COUNCIL MEDICAL RES}},
Address = {{PO BOX 4911 ANSARI NAGAR, NEW DELHI 110029, INDIA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Vijayan, VK (Reprint Author), Univ Delhi, Vallabhbhai Patel Chest Inst, Delhi 110007, India.
   Univ Delhi, Vallabhbhai Patel Chest Inst, Delhi 110007, India.}},
ISSN = {{0971-5916}},
Keywords-Plus = {{PULMONARY-FUNCTION; LUNG; DISEASE}},
Research-Areas = {{Immunology; General \& Internal Medicine; Research \& Experimental
   Medicine}},
Web-of-Science-Categories  = {{Immunology; Medicine, General \& Internal; Medicine, Research \&
   Experimental}},
Author-Email = {{vijayanvk@hotmail.com}},
Cited-References = {{Chetta A, 2004, RESPIRATION, V71, P209, DOI 10.1159/000077416.
   Escobedo-Jaimes L, 2003, INT J TUBERC LUNG D, V7, P580.
   HNZIDO E, 2000, THORAX, V55, P32.
   Iwanaga Tomoaki, 2006, Kekkaku, V81, P407.
   Kim JY, 2003, INT J TUBERC LUNG D, V7, P359.
   Loebinger MR, 2007, CHEST, V132, P279, DOI 10.1378/chest.06-2751.
   Long R, 1998, CHEST, V113, P933, DOI 10.1378/chest.113.4.933.
   Ohi M, 1990, Kekkaku, V65, P847.
   Pasipanodya JG, 2007, CHEST, V131, P1817, DOI 10.1378/chest.06-2949.
   Pipavath SNJ, 2007, INDIAN J MED RES, V126, P193.
   Shao CZ, 2003, CHINESE MED J-PEKING, V116, P1717.
   Sharma SK, 2006, INDIAN J MED RES, V124, P411.
   Sharma S K, 1996, Australas Radiol, V40, P113, DOI 10.1111/j.1440-1673.1996.tb00363.x.
   SHARMA SK, 1992, AM REV RESPIR DIS, V145, P1167.
   Sharma SK, 2005, LANCET INFECT DIS, V5, P415, DOI 10.1016/S1473-3099(05)70163-8.
   Strang JIG, 2004, QJM-INT J MED, V97, P525, DOI 10.1093/qjmed/hch086.
   Tamura A, 1998, Kekkaku, V73, P619.
   Vijayan V K, 1990, Indian J Chest Dis Allied Sci, V32, P49.
   Vijayan V K, 2000, J Indian Med Assoc, V98, P107.
   Wilcox PA, 1989, RESP MED, V83, P195.
   Zhang Y, 2004, FRONT BIOSCI, V9, P1136, DOI 10.2741/1291.
   Zompatori M, 2004, RESPIRATION, V71, P4, DOI 10.1159/000075642.}},
Number-of-Cited-References = {{22}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Indian J. Med. Res.}},
Doc-Delivery-Number = {{245PD}},
Unique-ID = {{ISI:000251946600003}},
}

@article{ ISI:000251946600006,
Author = {Pipavath, S. N. J. and Sharma, S. K. and Sinha, S. and Mukhopadhyay, S.
   and Gulati, M. S.},
Title = {{High resolution CT (HRCT) in miliary tuberculosis (MTB) of the lung:
   Correlation with pulmonary function tests \& gas exchange parameters in
   north Indian patients}},
Journal = {{INDIAN JOURNAL OF MEDICAL RESEARCH}},
Year = {{2007}},
Volume = {{126}},
Number = {{3}},
Pages = {{193-198}},
Month = {{SEP}},
Abstract = {{Background \& objectives: High resolution computed tomography (HRCT)
   scans are known to be helpful in early diagnosis and management of
   patients with miliary tuberculosis (MTB). We made an attempt in this
   study to identify patterns of pulmonary MTB on HRCT and to correlate the
   HRCT disease extent with pulmonary function tests (PFT) and gas exchange
   analysis (GEA).
   Methods: A total of 16 non-HIV patients with MTB underwent HRCT of the
   chest, PFT and GEA. All the investigations in these patients were
   completed within 20 days of presentation. Evidence of TB was diagnosed
   by biopsy from lymph nodes (3/16), organ biopsy {[}skin, liver, bone
   marrow and lung (transbronchial) (6/16)]. In one patient fundoscopy
   revealed choroid tubercles. In 6 patients, diagnosis was confirmed by
   clinical/radiological improvement following anti-tuberculosis therapy.
   Radiological patterns of involvement on HRCT of the lungs were studied
   and disease extent was estimated in each case by consensus between two
   radiologists using specially devised visual scoring system. Disease
   extent was correlated with PFT and GEA. Spearman rank correlation was
   used for statistical analysis.
   Results: Findings on HRCT in MTB included miliary nodularity (16/16),
   alveolar lesions such as ground glass attenuation and/or consolidation
   (5/16), lymphadenopathy (8/16), peribronchovascular interstitial
   thickening (1/16), emphysema (1/16), pleural pathology (2/16), and
   pericardial effusion (2/16). A significant correlation was noted between
   disease extent score and forced vital capacity (FVC) (r = -0.76;
   P=0.003), forced expiratory volume in one second (FEV1)(r = -0.74; P =
   0.005), total lung capacity (TLC) (r = -0.66; P = 0.037), oxygen
   saturation in arterial blood (SaO(2)) (r = -0.69, P = 0.01), diffusion
   capacity of the lung (DLco) (r = -0.8; P = 0.02). Interpretation \&
   conclusion: Our findings showed that HRCT reliably diagnosed NITB, and
   thus could help in predicting derangement of pulmonary function tests
   and GEA in these patients.}},
Publisher = {{INDIAN COUNCIL MEDICAL RES}},
Address = {{PO BOX 4911 ANSARI NAGAR, NEW DELHI 110029, INDIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Sharma, SK (Reprint Author), All India Inst Med Sci, Div Pulm Crit Care \& Sleep Med, Ansari Nagar, New Delhi 110029, India.
   Sharma, S. K., All India Inst Med Sci, Div Pulm Crit Care \& Sleep Med, New Delhi 110029, India.
   Sharma, S. K.; Sinha, S., All India Inst Med Sci, Dept Med, New Delhi 110029, India.
   Pipavath, S. N. J.; Mukhopadhyay, S.; Gulati, M. S., All India Inst Med Sci, Dept Radiodiag, New Delhi 110029, India.}},
ISSN = {{0971-5916}},
Keywords = {{miliary tuberculosis; gas exchange analysis; high resolution computed;
   pulmonary function tests}},
Keywords-Plus = {{APPEARANCE; DISEASE}},
Research-Areas = {{Immunology; General \& Internal Medicine; Research \& Experimental
   Medicine}},
Web-of-Science-Categories  = {{Immunology; Medicine, General \& Internal; Medicine, Research \&
   Experimental}},
Author-Email = {{sksharma@aiims.ac.in}},
Cited-References = {{BROMBERG PA, 1963, ADV TUBERC RES, V12, P1.
   Fujita J, 2006, INT J TUBERC LUNG D, V10, P222.
   Hong SH, 1998, J COMPUT ASSIST TOMO, V22, P220, DOI 10.1097/00004728-199803000-00011.
   MULLER NL, 1989, RADIOLOGY, V171, P613.
   OH YW, 1994, J COMPUT ASSIST TOMO, V18, P862, DOI 10.1097/00004728-199411000-00003.
   PENNER C, 1995, AM J RESP CRIT CARE, V151, P867.
   Rich AR, 1951, PATHOGENESIS TUBERCU.
   Sharma SK, 2006, INDIAN J MED RES, V124, P411.
   Sharma S K, 1996, Australas Radiol, V40, P113, DOI 10.1111/j.1440-1673.1996.tb00363.x.
   Sharma SK, 2006, INT J TUBERC LUNG D, V10, P429.
   SHARMA SK, 1995, QJM-MON J ASSOC PHYS, V88, P29.
   Voloudaki AE, 1999, ACTA RADIOL, V40, P451.}},
Number-of-Cited-References = {{12}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Indian J. Med. Res.}},
Doc-Delivery-Number = {{245PD}},
Unique-ID = {{ISI:000251946600006}},
}

@article{ ISI:000251602200009,
Author = {Krishnamurthy, Sriram and Yadav, Sangeeta},
Title = {{Immune thrombocytopenic purpura as a presentation of childhood
   tuberculosis}},
Journal = {{INDIAN JOURNAL OF PEDIATRICS}},
Year = {{2007}},
Volume = {{74}},
Number = {{9}},
Pages = {{853-855}},
Month = {{SEP}},
Abstract = {{Immune thrombocytopenic purpura as a presentation of childhood
   tuberculosis is a rare event and occasional reports are described in the
   pediatric literature. We describe a 8-yr-old girl with mediastinal
   tubercular lymphadenitis-induced immune thrombocytopenia, who was
   successfully treated with anti-tubercular drugs. We also review the
   published reports. Tuberculosis should be considered a cause of immune
   thrombocytopenia in areas where tuberculosis is highly endemic.}},
Publisher = {{ALL INDIA INST MEDICAL SCIENCES}},
Address = {{ANSARI NAGAR, NEW DELHI 110 029, INDIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Yadav, S (Reprint Author), Maulana Azad Med Coll, Dept Pediat, New Delhi 110002, India.
   Krishnamurthy, Sriram; Yadav, Sangeeta, Maulana Azad Med Coll, Dept Pediat, New Delhi 110002, India.
   Krishnamurthy, Sriram; Yadav, Sangeeta, Associated Lok Nayak Hosp, New Delhi 110002, India.}},
DOI = {{10.1007/s12098-007-0152-5}},
ISSN = {{0019-5456}},
Keywords = {{immune thrombocytopenic purpura; mediastinal tubercular lymphadenitis}},
Research-Areas = {{Pediatrics}},
Web-of-Science-Categories  = {{Pediatrics}},
Cited-References = {{AlMajed SA, 1995, ACTA HAEMATOL-BASEL, V94, P135.
   BAKHSHI M, 2003, INDIAN J PEDIATR, V70, P993.
   BOOTS RJ, 1992, THORAX, V47, P396, DOI 10.1136/thx.47.5.396.
   CHIA YC, 1979, BRIT J CLIN PRACT, V33, P55.
   COCKCROFT DW, 1976, CAN MED ASSOC J, V115, P871.
   Ghobrial MW, 2001, AM J HEMATOL, V67, P139, DOI 10.1002/ajh.1093.
   HernandezMaraver D, 1996, ACTA HAEMATOL-BASEL, V96, P266.
   JURAK SS, 1983, CLIN PEDIATR, V22, P318, DOI 10.1177/000992288302200416.
   Kabra S K, 2004, Indian Pediatr, V41, P927.
   LEVY M, 1964, CAN MED ASSOC J, V90, P373.
   Montgomery RR, 2004, NELSON TXB PEDIAT, P1651.
   MUNCK A, 1990, AM REV RESPIR DIS, V141, P2.
   Ozkalemkas Fahir, 2004, Ann Clin Microbiol Antimicrob, V3, P16, DOI 10.1186/1476-0711-3-16.
   Paolo WF, 2004, LANCET INFECT DIS, V4, P287, DOI 10.1016/S1473-3099(04)01004-7.
   Pavithran K, 1993, Indian J Med Sci, V47, P239.
   Singh S P, 1986, J Indian Med Assoc, V84, P247.
   SPENDINI P, 2002, HAEMATOLOGIA, V87, DOI UNSP ELT09.
   Talbot S, 1998, AUST NZ J MED, V28, P465, DOI 10.1111/j.1445-5994.1998.tb02084.x.
   Tongyoo Surat, 2003, J Med Assoc Thai, V86, P976.
   Tsuro K, 2006, INTERNAL MED, V45, P739, DOI 10.2169/internalmedicine.45.1639.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Indian J. Pediatr.}},
Doc-Delivery-Number = {{240QN}},
Unique-ID = {{ISI:000251602200009}},
}

@article{ ISI:000250072200009,
Author = {David, Suzana and Ribeiro, Diana Raposo and Antunes, Abilio and
   Portugal, Clara and Sancho, Luisa and de Sousa, Jose Germano},
Title = {{Contribution of spoligotyping to the characterization of the population
   structure of Mycobacterium tuberculosis isolates in Portugal}},
Journal = {{INFECTION GENETICS AND EVOLUTION}},
Year = {{2007}},
Volume = {{7}},
Number = {{5}},
Pages = {{609-617}},
Month = {{SEP}},
Abstract = {{Tuberculosis is a major health problem in Portugal. To begin
   characterizing the population structure of Mycobacterium tuberculosis,
   spoligotyping was used for the systematic typing, through consecutive
   sampling, of patient isolates from the Amadora-Sintra area of Greater
   Lisbon. Distribution amongst major spoligotype families, including the
   Latin American Mediterranean (LAM), T, Haarlem and Beijing, was compared
   to that of the international spoligotype database SpolDB4 and to the
   European countries of traditional Portuguese immigration represented in
   SpolDB4. Spoligotypes from 665 isolates were analyzed and 97 shared
   international types (SITs) identified. In SpolDB4 Portugal is
   represented by part of the spoligotypes from this study explaining the
   reduced number of unidentified patterns. The importance of the LAM
   family, and especially of LAM I and LAM9 sub-families that alone
   represented 38\% of all the isolates in this study as compared to 8\%
   relative to the European sub group, led us to believe that at least in
   this respect the population structure was closer to that of Africa and
   South America than to Europe. Spoligotypes characteristic of Portugal or
   Portuguese related settings were identified. These included SIT244 a T I
   sub-family predominant in Portugal and Bangladesh, SIT64 a LAM 6
   sub-family common to Portugal and Brazil, and SIT1106 a LAM 9
   sub-family. These studies were the first in Portugal stressing the
   importance of monitoring the population structure of M. tuberculosis
   isolates, an important step towards gaining an understanding of
   tuberculosis and the dynamics of this disease. (C) 2007 Elsevier B.V.
   All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{David, S (Reprint Author), Ctr TB \& Micobacterias, Inst Nacl Saude Dr Ricardo Jorge Delegacao, Oporto, Portugal.
   Ctr TB \& Micobacterias, Inst Nacl Saude Dr Ricardo Jorge Delegacao, Oporto, Portugal.
   Univ Nova Lisboa, Inst Higiene \& Med Trop, Unidad Ensino \& Invest, P-1200 Lisbon, Portugal.
   Univ Nova Lisboa, Inst Higiene \& Med Trop, UEI Clin \& Doencas, P-1200 Lisbon, Portugal.
   Hosp Fernando Fonseca, Serv Patol Clin, Amadora, Portugal.}},
DOI = {{10.1016/j.meegid.2007.05.007}},
ISSN = {{1567-1348}},
Keywords = {{Mycobacterium tuberculosis; spoligotyping; Portugal}},
Keywords-Plus = {{GLOBAL DISTRIBUTION; VARIABLE-NUMBER; DRUG-RESISTANT; EPIDEMIOLOGY;
   FAMILY; STRAINS; POLYMORPHISM; DATABASE}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{sdavid@ibmc.up.pt}},
ORCID-Numbers = {{David, Susana/0000-0001-6483-8660}},
Cited-References = {{Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6.
   Brudey K, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-23.
   Cowan LS, 2005, J CLIN MICROBIOL, V43, P688, DOI 10.1128/JCM.43.2.688-695.2005.
   DAVID S, 2006, REV PORT PNEUMOLOGIA, V9, P513.
   David Suzana, 2004, Rev Port Pneumol, V10, P195.
   Garcia de Viedma D, 2005, J CLIN MICROBIOL, V43, P1797, DOI DOI 10.1128/JCM.43.4.1797-1806.2005.
   Douglas JT, 2003, J CLIN MICROBIOL, V41, P2723, DOI 10.1128/JCM.41.6.2723-2726.2003.
   Drobniewski F, 2005, JAMA-J AM MED ASSOC, V293, P2726, DOI 10.1001/jama.293.22.2726.
   Filliol I, 2003, J CLIN MICROBIOL, V41, P1963, DOI 10.1128/JCM.41.5.1963.1970.2003.
   Filliol I, 2000, J CLIN MICROBIOL, V38, P2520.
   Filliol I, 2002, EMERG INFECT DIS, V8, P1347.
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907.
   McHugh TD, 2005, TUBERCULOSIS, V85, P127, DOI 10.1016/j.tube.2004.06.002.
   Niobe-Eyangoh SN, 2004, J CLIN MICROBIOL, V42, P5029, DOI 10.1128/JCM.42.11.5029-5035.2004.
   Oelemann MC, 2007, J CLIN MICROBIOL, V45, P691, DOI 10.1128/JCM.01393-06.
   Portugal I, 1999, INT J TUBERC LUNG D, V3, P207.
   Sola C, 2001, EMERG INFECT DIS, V7, P390.
   Sola C, 2003, INFECT GENET EVOL, V3, P125, DOI 10.1016/S1567-1348(03)00011-X.
   Sun YJ, 2004, J CLIN MICROBIOL, V42, P5058, DOI 10.1128/JCM.42.11.5058-5064.2004.
   VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Infect. Genet. Evol.}},
Doc-Delivery-Number = {{219GH}},
Unique-ID = {{ISI:000250072200009}},
}

@article{ ISI:000250072200012,
Author = {Koedmoen, Csaba and Niemann, Stefan and Gutierrez, M. Cristina and Sola,
   Christophe and Rastogi, Nalin and Lukacs, Judit and Somoskoevi, Akos},
Title = {{Molecular clues of a microepidemy among homeless tuberculosis patients
   in Budapest due to a new and local Mycobacterium tuberculosis clade}},
Journal = {{INFECTION GENETICS AND EVOLUTION}},
Year = {{2007}},
Volume = {{7}},
Number = {{5}},
Pages = {{632-635}},
Month = {{SEP}},
Abstract = {{In Budapest, the capital of Hungary, one of the most important
   tuberculosis related risk factor is homelessness. The aim of this
   retrospective study was the genetic characterization of Mycobacterium
   tuberculosis strains isolated from 66 homeless tuberculosis patients by
   spoligotyping and mycobacterial interspersed repetitive unit (MIRU)
   typing. The study identified a local microepidemy in the district with
   the highest tuberculosis incidence of Budapest. Further genetic
   characterization has shown that the microepidemy was due to a locally
   emerged Budapest-specific lineage of M. tuberculosis. These data may
   serve as a reference to better monitor and understand the patterns and
   transmission dynamics of tuberculosis in this at-risk population and is
   the first report on genetic diversity of M. tuberculosis in today's
   Hungarians. The findings also indicate that tuberculosis control and
   prevention steps among the homeless need to be strengthened. (C) 2007
   Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Somoskovi, A (Reprint Author), Semmelweis Univ, Sch Med, Dept Resp Med, Budapest, Hungary.
   Semmelweis Univ, Sch Med, Dept Resp Med, Budapest, Hungary.
   Natl Publ Hlth \& Med Off Serv, Miskolc, Hungary.
   Forschungszentrum, Natl Reference Ctr Mycobacteria, Borstel, Germany.
   Inst Pasteur, Lab Reference Mycobacteries, Paris, France.
   Inst Pasteur, Unite TB \& Mycobacteries, Pointe a Pitre, Guadeloupe.}},
DOI = {{10.1016/j.meegid.2007.06.003}},
ISSN = {{1567-1348}},
Keywords = {{Mycobacterium tuberculosis; spoligotyping; mycobacterial interspersed
   repetitive unit; Budapest-specific lineage; microepidemy; homeless}},
Keywords-Plus = {{EPIDEMIOLOGY; POLYMORPHISM; STRAINS; DNA; RECOMMENDATIONS;
   IDENTIFICATION; HUNGARY; GERMANY}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{somoskovi@pulm.sote.hu}},
ResearcherID-Numbers = {{Niemann, Stefan/C-9327-2011
   Gutierrez, Cristina/B-5597-2012
   }},
ORCID-Numbers = {{Gutierrez, Cristina/0000-0002-5567-5908
   Rastogi, Nalin/0000-0002-7199-7747
   SOLA, Christophe Noel/0000-0003-4672-2140}},
Cited-References = {{Brudey K, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-23.
   Day NPJ, 2001, SCIENCE, V292, P114, DOI 10.1126/science.1056495.
   Garcia de Viedma D, 2005, J CLIN MICROBIOL, V43, P1797, DOI DOI 10.1128/JCM.43.4.1797-1806.2005.
   Diel R, 2002, J CLIN MICROBIOL, V40, P532, DOI 10.1128/JCM.40.2.532-539.2002.
   Filliol I, 2003, J CLIN MICROBIOL, V41, P1963, DOI 10.1128/JCM.41.5.1963.1970.2003.
   Filliol I, 2006, J BACTERIOL, V188, P759, DOI 10.1128/JB.188.2.759-772.2006.
   Fletcher HA, 2003, MICROBIOL-SGM, V149, P143, DOI 10.1099/mic.0.25961-0.
   Gutacker MM, 2006, J INFECT DIS, V193, P121, DOI 10.1086/498574.
   Gutierrez MC, 1998, J CLIN MICROBIOL, V36, P486.
   JONAS J, 2004, ANN REP HUNG MED CAR.
   KENT PT, 1985, PUBL HLTH MYCOBACTER.
   Kremer K, 1999, J CLIN MICROBIOL, V37, P2607.
   Li J, 2003, INT J TUBERC LUNG D, V7, pS397.
   Lukacs J, 2004, J CLIN MICROBIOL, V42, P5931, DOI 10.1128/JCM.42.12.5931-5934.2004.
   MCGRATH JW, 1988, AM J PHYS ANTHROPOL, V77, P483, DOI 10.1002/ajpa.1330770409.
   Mester J, 2002, INT J TUBERC LUNG D, V6, P966.
   Niemann S, 1997, J CLIN MICROBIOL, V35, P3015.
   PATAKI G, 2003, ANN REP HUNG MED CAR.
   Rindi L, 2004, J MICROBIOL METH, V59, P283, DOI 10.1016/j.mimet.2004.06.012.
   Somoskovi A, 2000, J CLIN MICROBIOL, V38, P2743.
   Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869.
   Supply P, 2001, J CLIN MICROBIOL, V39, P3563, DOI 10.1128/JCM.39.10.3563-3571.2001.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Infect. Genet. Evol.}},
Doc-Delivery-Number = {{219GH}},
Unique-ID = {{ISI:000250072200012}},
}

@article{ ISI:000250072200013,
Author = {Tazi, Loubna and Reintjes, Ralf and Banuls, Anne-Laure},
Title = {{Tuberculosis transmission in a high incidence area: A retrospective
   molecular epidemiological study of Mycobacterium tuberculosis in
   Casablanca, Morocco}},
Journal = {{INFECTION GENETICS AND EVOLUTION}},
Year = {{2007}},
Volume = {{7}},
Number = {{5}},
Pages = {{636-644}},
Month = {{SEP}},
Abstract = {{Like in most developing countries, tuberculosis represents a major
   public health problem in Morocco. This paper describes the first study
   combining molecular and conventional epidemiology of tuberculosis in
   Casablanca, the economic capital of this country. Molecular
   fingerprinting of the genomic DNA recovered from cultures of sputum of
   150 patients was performed by MIRU-VNTR. This molecular marker revealed
   that 53.1 \% of the total cases were clustered. These cases were
   classified into 23 clusters ranging in size from 2 to 13 patients,
   suggesting a rate of 37\% of recent transmission in the sample under
   study. In a multivariate analysis, there were no independent predictors
   of clustering. However, the clinical form was associated with drug
   resistance (odds ratio = 9.9; P value = 0.0006). The phylogenetic
   analysis showed that the heterogeneity found in this population includes
   also the members from a same patient family, and that the 2 majoritary
   families distributed in Casablanca were the Latin American-Mediterranean
   (LAM) and Haarlem families. All the results of this work allow to
   understand better the tuberculosis transmission in Casablanca, and
   suggest that different clones of M. tuberculosis seem to circulate in
   this city, and that the reactivation of latent infections would be
   mainly responsible for the endemic situation of this disease. These
   findings indicate also that the transmission of TB in Morocco is not
   optimally controlled, and that efforts for control strategies should be
   sustained in all developing countries where the incidence of TB is high
   and still raising. (C) 2007 Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tazi, L (Reprint Author), Brigham Young Univ, Dept Biol, 679 Widtsoe Bldg, Provo, UT 84602 USA.
   Brigham Young Univ, Dept Biol, Provo, UT 84602 USA.
   Ctr IRD, CNRS, UMR, IRD 2724, F-34394 Montpellier, France.
   Hamburg Univ Appl Sci, D-21033 Hamburg, Germany.
   Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland.}},
DOI = {{10.1016/j.meegid.2007.06.005}},
ISSN = {{1567-1348}},
Keywords = {{tuberculosis; molecular epidemiology; Morocco; MIRU-VNTR}},
Keywords-Plus = {{INTERSPERSED REPETITIVE UNITS; FRAGMENT-LENGTH-POLYMORPHISM; GLOBAL
   EPIDEMIOLOGY; GENETIC DIVERSITY; POPULATION; STRAINS; COMPLEX; IS6110;
   MORTALITY; HAMBURG}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{lt247@byu.edu}},
ORCID-Numbers = {{Banuls, Anne-Laure/0000-0002-2106-8667}},
Cited-References = {{Barnes PF, 2003, NEW ENGL J MED, V349, P1149, DOI 10.1056/NEJMra021964.
   Bauer J, 1998, J CLIN MICROBIOL, V36, P305.
   Bennett DE, 2002, EMERG INFECT DIS, V8, P1224.
   Bishai WR, 1998, JAMA-J AM MED ASSOC, V280, P1679, DOI 10.1001/jama.280.19.1679.
   Brudey K, 2006, J CLIN MICROBIOL, V44, P183, DOI 10.1128/JCM.44.1.183-191.2006.
   Calusni ALR, 2003, MEM I OSWALDO CRUZ, V98, P655, DOI 10.1590/S0074-02762003000500012.
   CANETTI G, 1963, Rev Tuberc Pneumol (Paris), V27, P217.
   CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q.
   Chevenet F, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-439.
   Cowan LS, 2002, J CLIN MICROBIOL, V40, P1592, DOI 10.1128/JCM.40.5.1592-1602.2002.
   DEAN AG, 2002, EPI INFO 2002 DATABA.
   Diel R, 2004, J CLIN MICROBIOL, V42, P2952, DOI 10.1128/JCM.42.7.2952-2960.2004.
   Diel R, 2002, J CLIN MICROBIOL, V40, P532, DOI 10.1128/JCM.40.2.532-539.2002.
   Diraa O, 2005, INT J TUBERC LUNG D, V9, P1294.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   Easterbrook PJ, 2004, J CLIN MICROBIOL, V42, P4536, DOI 10.1128/JCM.42.10.4536-4544.2004.
   EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552.
   El Baghdadi J, 1997, B SOC PATHOL EXOT, V90, P303.
   ElBaghdadi J, 1997, B SOC PATHOL EXOT, V90, P156.
   Elharti E, 2002, East Mediterr Health J, V8, P819.
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4.
   Gilks CF, 1997, AIDS, V11, P911, DOI 10.1097/00002030-199707000-00011.
   Grange JM, 2002, J R SOC PROMO HEALTH, V122, P78, DOI 10.1177/146642400212200206.
   Gutierrez MC, 1998, J CLIN MICROBIOL, V36, P486.
   Hosmer DW, 1989, APPL LOGISTIC REGRES.
   Kempf MC, 2005, J CLIN MICROBIOL, V43, P870, DOI 10.1128/JCM.43.2.870-878.2005.
   Kodmon C, 2006, J CLIN MICROBIOL, V44, P4258, DOI 10.1128/JCM.01254-06.
   Kremer K, 1999, J CLIN MICROBIOL, V37, P2607.
   Laraqui CH, 2001, INT J TUBERC LUNG D, V5, P939.
   LOIEZ C, 2006, CLIN INFECT DIS, V42, P86.
   Mazars E, 2001, P NATL ACAD SCI USA, V98, P1901, DOI 10.1073/pnas.98.4.1901.
   McNabb SJN, 2002, EMERG INFECT DIS, V8, P1314.
   Murray M, 2002, B WORLD HEALTH ORGAN, V80, P477.
   OTTMANI S, 1998, B EPIDEMIOLOGIQUE, V35, P2.
   Owusu-Dabo Ellis, 2006, Emerg Infect Dis, V12, P1171.
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220.
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406.
   Savine E, 2002, J CLIN MICROBIOL, V40, P4561, DOI 10.1128/JCM.40.12.4561-4566.2002.
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402.
   Sun YJ, 2004, J CLIN MICROBIOL, V42, P1986, DOI 10.1128/JCM.42.5.1986-1993.2004.
   Supply P, 2000, MOL MICROBIOL, V36, P762, DOI 10.1046/j.1365-2958.2000.01905.x.
   Supply P, 2003, MOL MICROBIOL, V47, P529, DOI 10.1046/j.1365-2958.2003.03315.x.
   Supply P, 2001, J CLIN MICROBIOL, V39, P3563, DOI 10.1128/JCM.39.10.3563-3571.2001.
   Supply P, 2006, J CLIN MICROBIOL, V44, P4498, DOI 10.1128/JCM.01392-06.
   Tazi L, 2004, J CLIN MICROBIOL, V42, P461, DOI 10.1128/JCM.42.1.461-466.2004.
   van Deutekom H, 2005, J CLIN MICROBIOL, V43, P4473, DOI 10.1128/JCM.43.9.4473-4479.2005.
   VANSOOLINGEN D, 1994, METHOD ENZYMOL, V235, P196.
   Verver S, 2004, INT J EPIDEMIOL, V33, P351, DOI 10.1093/ije/dyh021.
   Verver S, 2004, LANCET, V363, P212, DOI 10.1016/S0140-6736(03)15332-9.
   Wilkinson D, 1997, TROP MED INT HEALTH, V2, P747, DOI 10.1046/j.1365-3156.1997.d01-386.x.}},
Number-of-Cited-References = {{50}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Infect. Genet. Evol.}},
Doc-Delivery-Number = {{219GH}},
Unique-ID = {{ISI:000250072200013}},
}

@article{ ISI:000258299200007,
Author = {Shieh, Ying-Hua and Chang, Juei-Chin},
Title = {{Medical evacuation from Vietnam of an elderly with tuberculosis
   spondylitis}},
Journal = {{INTERNATIONAL JOURNAL OF GERONTOLOGY}},
Year = {{2007}},
Volume = {{1}},
Number = {{3}},
Pages = {{138-140}},
Month = {{SEP}},
Abstract = {{Despite the growth in economy in Vietnam, the infrastructure of
   dependable medical care is still lacking. Therefore, aeromedical
   evacuation of patients to other countries for further medical
   interventions has become an important medical service in the region. We
   report a case where an elderly man who was aeromedically evacuated from
   Ho Chi Minh City, Vietnam-to Taipei Medical University-Municipal Wan
   Fang Hospital in Taipei, Taiwan. The patient developed a sudden onset of
   quadriplegia because of an epidural abscess at the cervical spine C6-C7.
   Antituberculous medication was prescribed for suspected tuberculous
   spondylitis, because his cerebral spinal fluid showed elevated white
   blood cells with a predominance of lymphocytes, and mildly elevated
   total protein. However, whole body tumor scan (Ga-67 mCi) and whole body
   bone scan (Tc-99m methylene diphosphonate, 25 mCi) did not reveal any
   specific results. Surgical intervention was arranged because of cervical
   spine instability and the need for a diagnostic biopsy. Adenocarcinoma
   of the prostate was found incidentally and was treated with bilateral
   orchiectomy and radiation therapy. This was the first medical evacuation
   by the Family Medical Practice group in Ho Chi Minh City, Vietnam to
   Taiwan.}},
Publisher = {{ELSEVIER SINGAPORE PTE LTD}},
Address = {{3 KILLINEY ROAD 08-01, WINSLAND HOUSE 1, SINGAPORE, 239519, SINGAPORE}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Chang, JC (Reprint Author), Taipei Med Univ, Municipal Wan Fang Hosp, Dept Family Med, 111,Sect 3,Hsing Long Rd, Taipei 116, Taiwan.
   Shieh, Ying-Hua; Chang, Juei-Chin, Taipei Med Univ, Municipal Wan Fang Hosp, Dept Family Med, Taipei 116, Taiwan.}},
DOI = {{10.1016/S1873-9598(08)70036-X}},
ISSN = {{1873-9598}},
Keywords = {{aeromedical evacuation; tuberculous spondylitis}},
Keywords-Plus = {{AIR-TRAVEL}},
Research-Areas = {{Geriatrics \& Gerontology}},
Web-of-Science-Categories  = {{Geriatrics \& Gerontology}},
Author-Email = {{B8701146@tmu.edu.tw}},
Cited-References = {{Alothman A, 2001, Spine (Phila Pa 1976), V26, pE565, DOI 10.1097/00007632-200112150-00020.
   Blumberg Henry M, 2003, Am J Respir Crit Care Med, V167, P603.
   Cesarone MR, 2002, ANGIOLOGY, V53, P1, DOI 10.1177/000331970205300101.
   Lam DM, 2003, AVIAT SPACE ENVIR MD, V74, P863.
   Moon MS, 1997, SPINE, V22, P1791, DOI 10.1097/00007632-199708010-00022.
   Ormerod P, 1998, THORAX, V53, P536.
   Possick SE, 2004, J TRAVEL MED, V11, P243.
   Teichman PG, 2007, NEW ENGL J MED, V356, P262, DOI 10.1056/NEJMra063651.
   WHO, 2005, INT TRAV HLTH.
   Wilde H, 2003, J TRAVEL MED, V10, P315.
   {[}Anonymous], 1982, J BONE JOINT SURG BR, V64, P393.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Int. J. Gerontol.}},
Doc-Delivery-Number = {{335OF}},
Unique-ID = {{ISI:000258299200007}},
}

@article{ ISI:000249273200011,
Author = {Park, Seung-Kyu and Cho, Sungae and Lee, In-Hee and Jeon, Doo-Soo and
   Hong, Sung-Hee and Smego, Jr., Raymond A. and Cho, Sang-Nae},
Title = {{Subcutaneously administered interferon-gamma for the treatment of
   multidrug-resistant pulmonary tuberculosis}},
Journal = {{INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{11}},
Number = {{5}},
Pages = {{434-440}},
Month = {{SEP}},
Abstract = {{Objective: We evaluated the clinical and laboratory effects of
   subcutaneously administered interferon-gamma (IFN-gamma) in the
   treatment of chronic and advanced multidrug-resistant tuberculosis
   (MDR-TB).
   Design: Eight patients with sputum smear and culture persistently
   positive MDR-TB were subcutaneously administered 2 million international
   units of recombinant human IFN-gamma three times a week for 24 weeks (72
   doses total) between December 2002 and May 2003. Subjects also received
   a customized drug regimen containing second- and third-time
   antituberculosis agents based upon drug susceptibility testing and
   previous treatment history.
   Results: Body weight remained stable or slightly decreased in all
   subjects during the study period, and none displayed radiographic
   improvement on serial chest computed tomography scanning. Sputum smears
   and cultures remained positive for all patients, and there was no
   increase in the mean time to yield a positive culture (from 16.5 +/- 6.4
   to 11.8 +/- 4.9 days). There was no enhancement of cell-mediated immune
   responses in terms of production of IFN-gamma or IL-10, or of
   composition of lymphocytes among peripheral blood mononuclear cells. In
   four patients, therapy was discontinued because of adverse reactions.
   Conclusion: In patients with chronic and advanced MDR-TB, subcutaneous
   IFN-gamma treatment did not result in improvement in clinical,
   radiologic, microbiologic, or immunologic parameters. (C) 2007
   International Society for Infectious Diseases. Published by Elsevier
   Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Natl Masan Tuberculosis Hosp, Dept Chest Surg, Masan, South Korea.
   Natl Masan Tuberculosis Hosp, Clin Res Ctr, Masan, South Korea.
   Yonsei Univ, Coll Med, Dept Microbiol, Seoul, South Korea.
   NIH, NIAID, Tuberculosis Res Sect, Rockville, MD USA.}},
DOI = {{10.1016/j.ijid.2006.12.004}},
ISSN = {{1201-9712}},
Keywords = {{tuberculosis; multidrug-resistant TB; interferon-gamma; subcutaneous
   injection}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; RESPONSES; MACROPHAGES; EXPRESSION; ALPHA;
   IMMUNOTHERAPY; CHEMOTHERAPY; CYTOKINES; THERAPY; CELLS}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{rsmego@hsc.wvu.edu}},
Cited-References = {{Al-Attiyah R, 2003, FEMS IMMUNOL MED MIC, V38, P249, DOI 10.1016/S0928-8244(03)00166-4.
   Condos R, 1998, AM J RESP CRIT CARE, V157, P729.
   Condos R, 1997, LANCET, V349, P1513, DOI 10.1016/S0140-6736(96)12273-X.
   Condos R, 2004, CHEST, V125, P2146, DOI 10.1378/chest.125.6.2146.
   Condos R, 2003, INFECT IMMUN, V71, P2058, DOI 10.1128/IAI.71.4.2058-2064.2003.
   De La Barrera S, 2004, CLIN EXP IMMUNOL, V138, P128, DOI 10.1111/j.1365-2249.2004.02577.x.
   Dieli F, 2000, SCAND J IMMUNOL, V52, P96.
   Ellner JJ, 2000, CLIN INFECT DIS, V30, pS279, DOI 10.1086/313874.
   Giosue S, 1998, AM J RESP CRIT CARE, V158, P1156.
   Giosue S, 2000, EUR CYTOKINE NETW, V11, P99.
   Gong JH, 1996, INFECT IMMUN, V64, P913.
   Hirsch CS, 1999, J INFECT DIS, V180, P2069, DOI 10.1086/315114.
   Hirsch CS, 1999, J INFECT DIS, V179, P945, DOI 10.1086/314667.
   Holland S M, 2001, Semin Respir Infect, V16, P47.
   Jo EK, 2003, CURR OPIN INFECT DIS, V16, P205, DOI 10.1097/01.qco.0000073768.11390.a3.
   Kawakami Kazuyoshi, 2003, Journal of Infection and Chemotherapy, V9, P201, DOI 10.1007/s10156-003-0263-5.
   Koh WJ, 2004, J KOREAN MED SCI, V19, P167.
   MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6.
   Murray HW, 1996, INTENS CARE MED, V22, P456.
   NATHAN CF, 1984, J EXP MED, V160, P600, DOI 10.1084/jem.160.2.600.
   Palmero D, 1999, INT J TUBERC LUNG D, V3, P214.
   Raju B, 2004, INFECT IMMUN, V72, P1275, DOI 10.1128/IAI.72.3.1275-1283.2004.
   Ribeiro-Rodrigues R, 2006, CLIN EXP IMMUNOL, V144, P25, DOI 10.1111/j.1365-2249.2006.03027.x.
   Ribeiro-Rodrigues R, 2002, CLIN DIAGN LAB IMMUN, V9, P818, DOI 10.1128/CDLI.9.4.818-823.2002.
   ROM WN, 1995, SCHWEIZ MED WSCHR, V125, P2178.
   SANCHEZ FO, 1994, INFECT IMMUN, V62, P5673.
   Schraufnagel DE, 1999, INT J TUBERC LUNG D, V3, P651.
   Suarez-Mendez R, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-44.
   Toossi Z, 1998, CYTOKINES CELL MOL T, V4, P105.
   Tsao TCY, 2002, INT J TUBERC LUNG D, V6, P720.
   Verbon A, 1999, CLIN EXP IMMUNOL, V115, P110.
   VILCEK J, 1994, INT ARCH ALLERGY IMM, V104, P311.
   Wallis RS, 2005, CLIN INFECT DIS, V41, P201, DOI 10.1086/430914.
   ZHANG M, 1995, INFECT IMMUN, V63, P3231.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{12}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Int. J. Infect. Dis.}},
Doc-Delivery-Number = {{207TE}},
Unique-ID = {{ISI:000249273200011}},
}

@article{ ISI:000249273200018,
Author = {Tuon, Felipe Francisco and Siqueira, Andre M. and Litvoc, Marcelo
   Nobrega and Lopes, Marta Hetoisa},
Title = {{Tuberculosis and tracheal bronchus}},
Journal = {{INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{11}},
Number = {{5}},
Pages = {{467-468}},
Month = {{SEP}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Tuon, FF (Reprint Author), Univ Sao Paulo, Sch Med, Hosp Clin, Dept Infect Dis, Ave Dr Eneas Carvalho Aguiar 255,4 Andar Sala 402, BR-05403010 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Hosp Clin, Dept Infect Dis, BR-05403010 Sao Paulo, Brazil.}},
DOI = {{10.1016/i.ijid.2006.11.002}},
ISSN = {{1201-9712}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{ffbt@pop.com.br}},
ResearcherID-Numbers = {{Lopes, Marta/J-3285-2012
   Siqueira, Andre/G-1340-2010}},
ORCID-Numbers = {{Siqueira, Andre/0000-0003-2208-0294}},
Cited-References = {{Berrocal Teresa, 2004, Radiographics, V24, pe17, DOI 10.1148/rg.e17.
   Borgdorff MW, 2002, B WORLD HEALTH ORGAN, V80, P217.
   GIE RP, 1995, S AFR MED J, V85, P658.
   Harzallah L, 2003, Rev Pneumol Clin, V59, P45.
   LIFSHITS NA, 1974, GRUDN KHIR, V3, P101.
   Wong Kin-sun, 2005, Indian Journal of Pediatrics, V72, P537, DOI 10.1007/BF02724437.}},
Number-of-Cited-References = {{6}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Infect. Dis.}},
Doc-Delivery-Number = {{207TE}},
Unique-ID = {{ISI:000249273200018}},
}

@article{ ISI:000250104800007,
Author = {Bogli-Stuber, K. and Lechenne, B. and Hilty, A. and Bodmer, T.},
Title = {{Evaluation of the GenoType((R)) MTBDRplus assay for the direct detection
   of isoniazid- and rifampicin-resistant mycobacterium tuberculosis}},
Journal = {{INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{297}},
Number = {{43}},
Pages = {{5-6}},
Month = {{SEP}},
Note = {{59th Annual Meeting of the
   Deutschen-Gesellschaft-fur-Hygiene-und-Mikrobiologie, Gottingen,
   GERMANY, SEP 30-OCT 04, 2007}},
Organization = {{Deutsch Gesell Hygiene Mikrobiolog}},
Publisher = {{ELSEVIER GMBH, URBAN \& FISCHER VERLAG}},
Address = {{OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Bogli-Stuber, K.; Lechenne, B.; Hilty, A.; Bodmer, T., Univ Bern, Inst Infect Dis, Bern, Switzerland.}},
ISSN = {{1438-4221}},
Research-Areas = {{Microbiology; Virology}},
Web-of-Science-Categories  = {{Microbiology; Virology}},
ResearcherID-Numbers = {{Kummer, Juerg/B-3322-2011}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Med. Microbiol.}},
Doc-Delivery-Number = {{219SK}},
Unique-ID = {{ISI:000250104800007}},
}

@article{ ISI:000250104800071,
Author = {Russell, D.},
Title = {{Mycobacterium tuberculosis: Life and death in the phagosome}},
Journal = {{INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{297}},
Number = {{43}},
Pages = {{29}},
Month = {{SEP}},
Note = {{59th Annual Meeting of the
   Deutschen-Gesellschaft-fur-Hygiene-und-Mikrobiologie, Gottingen,
   GERMANY, SEP 30-OCT 04, 2007}},
Organization = {{Deutsch Gesell Hygiene Mikrobiolog}},
Publisher = {{ELSEVIER GMBH, URBAN \& FISCHER VERLAG}},
Address = {{OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Russell, D., Cornell Univ, Ithaca, NY 14853 USA.}},
ISSN = {{1438-4221}},
Research-Areas = {{Microbiology; Virology}},
Web-of-Science-Categories  = {{Microbiology; Virology}},
ResearcherID-Numbers = {{Russell, David/D-4533-2009}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Int. J. Med. Microbiol.}},
Doc-Delivery-Number = {{219SK}},
Unique-ID = {{ISI:000250104800071}},
}

@article{ ISI:000250104800190,
Author = {Behnck-Knoblau, S. and Goldenberg, O. and Steinhoff, U.},
Title = {{Oral continuous exposure to environmental mycobacteria renders germfree
   but not conventional mice susceptible to M. tuberculosis infection}},
Journal = {{INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{297}},
Number = {{43}},
Pages = {{73-74}},
Month = {{SEP}},
Note = {{59th Annual Meeting of the
   Deutschen-Gesellschaft-fur-Hygiene-und-Mikrobiologie, Gottingen,
   GERMANY, SEP 30-OCT 04, 2007}},
Organization = {{Deutsch Gesell Hygiene Mikrobiolog}},
Publisher = {{ELSEVIER GMBH, URBAN \& FISCHER VERLAG}},
Address = {{OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Behnck-Knoblau, S.; Steinhoff, U., MPI Infekt Biol, Berlin, Germany.
   Goldenberg, O., Transgenom Ltd, Berlin, Germany.}},
ISSN = {{1438-4221}},
Research-Areas = {{Microbiology; Virology}},
Web-of-Science-Categories  = {{Microbiology; Virology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Med. Microbiol.}},
Doc-Delivery-Number = {{219SK}},
Unique-ID = {{ISI:000250104800190}},
}

@article{ ISI:000250104800398,
Author = {Niemann, S. and Weniger, T. and Harmsen, D. and Supply, P.},
Title = {{Mycobacteria MIRU-VNTRplus: Online database for identification of M.
   tuberculosis complex isolates based on MIRU, SPOLIGO, and regions of
   difference data}},
Journal = {{INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{297}},
Number = {{43}},
Pages = {{149}},
Month = {{SEP}},
Note = {{59th Annual Meeting of the
   Deutschen-Gesellschaft-fur-Hygiene-und-Mikrobiologie, Gottingen,
   GERMANY, SEP 30-OCT 04, 2007}},
Organization = {{Deutsch Gesell Hygiene Mikrobiolog}},
Publisher = {{ELSEVIER GMBH, URBAN \& FISCHER VERLAG}},
Address = {{OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Niemann, S., Natl Ref Ctr Mycobacteria, Res Ctr Borstel, Borstel, Germany.
   Weniger, T.; Harmsen, D., Univ Hosp Muenster, Dept Periodontol, Munster, Germany.
   Supply, P., Inst Pasteur, F-59019 Lille, France.}},
ISSN = {{1438-4221}},
Research-Areas = {{Microbiology; Virology}},
Web-of-Science-Categories  = {{Microbiology; Virology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Med. Microbiol.}},
Doc-Delivery-Number = {{219SK}},
Unique-ID = {{ISI:000250104800398}},
}

@article{ ISI:000249138900001,
Author = {Donald, Peter R.},
Title = {{Low serum concentrations of anti-tuberculosis agents: do they matter?}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{9}},
Pages = {{937}},
Month = {{SEP}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Donald, PR (Reprint Author), Univ Stellenbosch, Fac Hlth Sci, ZA-7505 Tygerberg, South Africa.
   Univ Stellenbosch, Fac Hlth Sci, ZA-7505 Tygerberg, South Africa.}},
ISSN = {{1027-3719}},
Keywords-Plus = {{EARLY BACTERICIDAL ACTIVITY; TUBERCULOSIS; ETHAMBUTOL; CHILDREN}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{prd@sun.ac.za}},
Cited-References = {{Donald PR, 2004, CLIN INFECT DIS, V39, P1425, DOI 10.1086/424999.
   Graham SM, 2006, ANTIMICROB AGENTS CH, V50, P407, DOI 10.1128/AAC.50.2.407-413.2006.
   Johnson JL, 2006, INT J TUBERC LUNG D, V10, P605.
   Peloquin CA, 2002, DRUGS, V62, P2169, DOI 10.2165/00003495-200262150-00001.
   Peloquin CA, 2001, CLIN INFECT DIS, V33, P584, DOI 10.1086/322706.
   Thee S, 2007, INT J TUBERC LUNG D, V11, P965.
   Um SW, 2007, INT J TUBERC LUNG D, V11, P972.
   Zhu M, 2004, INT J TUBERC LUNG D, V8, P1360.}},
Number-of-Cited-References = {{8}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{205UA}},
Unique-ID = {{ISI:000249138900001}},
}

@article{ ISI:000249138900004,
Author = {Gilpin, C. and Kim, S. J. and Lumb, R. and Rieder, H. L. and Van Deun,
   A. and Working Grp Sputum Microscopy},
Title = {{Critical appraisal of current recommendations and practices for
   tuberculosis sputum smear microscopy}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{9}},
Pages = {{946-952}},
Month = {{SEP}},
Abstract = {{This report is the consensus-based, agreed position of the participants
   in a workshop for experts in sputum smear microscopy organised in August
   2005 by the International Union Against Tuberculosis and Lung Disease
   (The Union), and as such reflects their views, but not necessarily those
   of their respective organisations.
   The group reviewed current practices in sputum smear microscopy for
   tuberculosis (TB) and suggests considering certain changes in standard
   guidelines for the sputum collection strategy and the definition of
   sputum smear-positive TB. The Ziehl-Neelsen staining guidelines need to
   incorporate a wider error margin for widespread application under field
   conditions. Quality assurance is of utmost importance, and needs more
   commitment from SUMMARY National Tuberculosis Programmes and other
   health authorities. In particular, allocation of sufficient resources
   for rechecking and integration of laboratory supervision must be
   ensured. Countries must make better investments in the purchase of high
   quality microscopes and laboratory supplies. To address the human
   resource crisis, personnel without specific laboratory schooling can, in
   principle, be trained to respond to immediate needs for TB diagnostic
   microscopy services. Periodic reporting on acid-fast smear examinations
   is highly desirable for regular monitoring and a more balanced provision
   of supplies.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Van Deun, A (Reprint Author), Inst Trop Med, Mycobacteriol Unit, Natl Str 155, B-2000 Antwerp, Belgium.
   Int Union Against TB \& Lung Dis, Paris, France.}},
ISSN = {{1027-3719}},
Keywords-Plus = {{ACID-FAST BACILLI; ISOLATED POSITIVE CULTURES; HIGH HIV PREVALENCE;
   SCANTY AFB SMEARS; PULMONARY TUBERCULOSIS; QUALITY-CONTROL;
   CARBOL-FUCHSIN; ZIEHL-NEELSEN; MYCOBACTERIUM-TUBERCULOSIS; BACTERIOLOGY}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{avandeun@iuatld.org}},
Cited-References = {{ABER VR, 1980, TUBERCLE, V61, P123, DOI 10.1016/0041-3879(80)90001-X.
   AMLOAMARY MS, 1999, CHEST, V116, P726.
   Angeby KAK, 2004, INT J TUBERC LUNG D, V8, P806.
   Angra P, 2003, J CLIN MICROBIOL, V41, P3459, DOI 10.1128/JCM.41.7.3459.2003.
   Archibald LK, 1998, CLIN INFECT DIS, V26, P290, DOI 10.1086/516297.
   Aziz M A, 2002, EXTERNAL QUALITY ASS.
   Behr MA, 1999, LANCET, V353, P444, DOI 10.1016/S0140-6736(98)03406-0.
   BISHOP P J, 1970, Tubercle, V51, P196, DOI 10.1016/0041-3879(70)90073-5.
   Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1.
   Crampin AC, 2001, INT J TUBERC LUNG D, V5, P994.
   Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376.
   Enarson D, 2000, MANAGEMENT TUBERCULO.
   Fujiki A, 2002, INT J TUBERC LUNG D, V6, P39.
   GITHUI W, 1992, TUBERCLE LUNG DIS, V73, P203, DOI 10.1016/0962-8479(92)90087-Z.
   Gopi PG, 2004, INT J TUBERC LUNG D, V8, P824.
   GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90.
   HARADA K, 1976, MICROSC ACTA, V78, P21.
   {[}International Union Against Tuberculosis and Lung Diseases IUALTD], 2000, TECHN GUID SPUT EX T.
   Johnson JL, 1998, INT J TUBERC LUNG D, V2, P397.
   Karstaedt AS, 1998, INT J TUBERC LUNG D, V2, P312.
   Kim SJ, 2007, INT J TUBERC LUNG D, V11, P138.
   KIM TC, 1984, AM REV RESPIR DIS, V129, P264.
   Lawson L, 2005, INT J TUBERC LUNG D, V9, P933.
   Lumb R, 2006, INT J TUBERC LUNG D, V10, P227.
   Lumb R, 2005, LAB DIAGNOSIS TUBERC.
   Mabaera B, 2006, INT J TUBERC LUNG D, V10, P1030.
   Martinez A, 2005, INT J TUBERC LUNG D, V9, P301.
   Martinez M, 2006, J CLIN MICROBIOL, V44, P2967, DOI 10.1128/JCM.00754-06.
   Mitchison D A, 1968, Bull Int Union Tuberc, V41, P139.
   MITCHISON DA, 1980, TUBERCLE, V61, P135, DOI 10.1016/0041-3879(80)90002-1.
   Munyati SS, 2005, CLIN INFECT DIS, V40, P1818, DOI 10.1086/429912.
   Narasimhan V, 2004, LANCET, V363, P1469, DOI 10.1016/S0140-6736(04)16108-4.
   Nyirenda TE, 1998, INT J TUBERC LUNG D, V2, P690.
   PARAMASIVAN CN, 1983, TUBERCLE, V64, P119, DOI 10.1016/0041-3879(83)90036-3.
   Perkins MD, 2006, INT J TUBERC LUNG D, V10, P1.
   Steingart K, 2006, LANCET INFECT DIS, V6, P570, DOI 10.1016/S1473-3099(06)70578-3.
   Ramsay A, 2006, INT J TUBERC LUNG D, V10, P256.
   Rieder HL, 1996, TUBERCLE LUNG DIS, V77, P124, DOI 10.1016/S0962-8479(96)90026-X.
   Rieder HL, 1997, INT J TUBERC LUNG D, V1, P339.
   Rieder HL, 2007, PRIORITIES TUBERCULO.
   Rohit Sarin, 2001, Indian Journal of Tuberculosis, V48, P13.
   Selvakumar N, 2005, J CLIN MICROBIOL, V43, P913, DOI 10.1128/JCM.43.2.913-915.2005.
   Selvakumar N, 2005, INT J TUBERC LUNG D, V9, P226.
   Selvakumar N, 2002, J CLIN MICROBIOL, V40, P3041, DOI 10.1128/JCM.40.8.3041-3043.2002.
   SHAW JB, 1954, AM REV TUBERC PULM, V69, P724.
   Smithwick R.W., 1976, LAB MANUAL ACID FAST.
   Telzak EE, 1997, CLIN INFECT DIS, V25, P666, DOI 10.1086/513772.
   TOMAN K, 2004, CASE DETECTION TREAT.
   Van Deun A, 2002, INT J TUBERC LUNG D, V6, P222.
   Van Deun A, 2005, INT J TUBERC LUNG D, V9, P1127.
   Van Deun A, 2005, INT J TUBERC LUNG D, V9, P700.
   Van Deun A, 2004, INT J TUBERC LUNG D, V8, P816.
   Van Deun A, 1998, INT J TUBERC LUNG D, V2, P756.
   Walker D, 2000, INT J TUBERC LUNG D, V4, P246.
   {*}WHO, 2002, WHOCDSTB2002301.
   World Health Organization, 2003, WHOCDSTB2003313.
   {*}WHO, 1998, TUBERCULOSIS HDB.
   World Health Organization, 2003, QUAL ASS SPUT MICR D.
   World Health Organization, 1998, WHOTB98258.
   YEGIAN D., 1943, American Review of Tuberculosis and Pulmonary Diseases, V48, P54.}},
Number-of-Cited-References = {{60}},
Times-Cited = {{20}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{205UA}},
Unique-ID = {{ISI:000249138900004}},
}

@article{ ISI:000249138900006,
Author = {Mabaera, B. and Lauritsen, J. M. and Katamba, A. and Laticevschi, D. and
   Naranbat, N. and Rieder, H. L.},
Title = {{Sputum smear-positive tuberculosis: empiric evidence challenges the need
   for confirmatory smears}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{9}},
Pages = {{959-964}},
Month = {{SEP}},
Abstract = {{OBJECTIVE: To determine the frequency of single scanty or positive
   sputum smear results and its impact on the surveillance definition of
   sputum smear-positive tuberculosis (TB).
   SETTING: Moldova, Mongolia, Uganda and Zimbabwe.
   METHODS: A representative sample of laboratories was selected in each
   country. Data were double-entered and discordances resolved by
   rechecking the register.
   RESULTS: The dataset comprised 128808 examinees with valid information
   from 23 laboratories in Moldova, all 31 in Mongolia, 30 in Uganda and 23
   in Zimbabwe, each covering at least one calendar year. The reason for
   the examination was diagnostic for 89362, of which 15.2\% (n = 13 577)
   were defined as laboratory cases with at least one bacillus on at least
   one examination. Cases were confirmed by another examination in 72.6\%
   (n = 9861). Of the 9014 cases who had a full set of three examinations,
   confirmation was obtained in 92.4\% (n = 8325).
   CONCLUSION: One quarter of laboratory cases had no confirmatory result,
   almost entirely attributable to not examining another specimen. The
   current definition of sputum smear-positive TB requires two positive
   smears or one positive smear result plus more complex confirmatory
   evidence. Accepting a single positive examination as sufficient for the
   definition would greatly increase the sensitivity of the surveillance
   definition without sacrificing its specificity.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rieder, HL (Reprint Author), Int Union Against TB \& Lung Dis, Dept TB Control \& Prevent, F-75006 Paris, France.
   Int Union Against TB \& Lung Dis, Dept TB Control \& Prevent, F-75006 Paris, France.
   Univ Zimbabwe, Harare, Zimbabwe.
   Univ So Denmark, Odense, Denmark.
   EpiData Assoc, Odense, Denmark.
   Kampala City Council, Dept Publ Hlth, Kampala, Uganda.
   TB AIDS Project Coordinat Unit, Kishinev, Moldova.
   Global Fund Fight AIDS TB \& Malaria, Geneva, Switzerland.}},
ISSN = {{1027-3719}},
Keywords = {{tuberculosis; microscopy; diagnosis; surveillance; case definition}},
Keywords-Plus = {{QUALITY-ASSURANCE; EFFICIENCY; LABORATORIES; DIAGNOSIS; SYSTEM}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{TBRieder@tbrieder.org}},
Cited-References = {{ABER VR, 1980, TUBERCLE, V61, P123, DOI 10.1016/0041-3879(80)90001-X.
   Addo KK, 2006, INT J TUBERC LUNG D, V10, P812.
   AZIZ MA, 2002, EXPERNAL QUALITY ASS.
   Basra D, 2006, East Afr Med J, V83, P306.
   Enarson D, 2000, MANAGEMENT TUBERCULO.
   Harries AD, 2001, B WORLD HEALTH ORGAN, V79, P329.
   {[}International Union Against Tuberculosis and Lung Diseases IUALTD], 2000, TECHN GUID SPUT EX T.
   Katamba A, 2007, INT J TUBERC LUNG D, V11, P659.
   KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M.
   Mabaera B, 2006, INT J TUBERC LUNG D, V10, P1030.
   Martinez-Guarneros A, 2003, INT J TUBERC LUNG D, V7, P516.
   MENG, 2004, INT J HLTH PLANN MGM, V19, pS45.
   Paramasivan CN, 2003, INT J TUBERC LUNG D, V7, P522.
   Raviglione M, 2001, INT J TUBERC LUNG D, V5, P213.
   Rieder HL, 2005, INT J TUBERC LUNG D, V9, P384.
   Rouillon A, 1991, Bull Int Union Tuberc Lung Dis, V66, P159.
   Selvakumar N, 2005, J CLIN MICROBIOL, V43, P913, DOI 10.1128/JCM.43.2.913-915.2005.
   Toman K, 2004, TOMANS TUBERCULOSIS.
   Van Deun A, 2004, INT J TUBERC LUNG D, V8, P816.
   {*}WHO, 1993, TREATM TUB GUID LIN.
   World Health Organization, 2005, WHOHTMTB2005349.
   World Health Organization, 1998, WHOTB98258.
   World Health Organization, 2003, TREATM TUB GUID NAT.
   World Health Organization, 2006, WHOHTMTB2006362.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{11}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{205UA}},
Unique-ID = {{ISI:000249138900006}},
}

@article{ ISI:000249138900007,
Author = {Thee, S. and Detjen, A. and Quarcoo, D. and Wahn, U. and Magdorf, K.},
Title = {{Ethambutol in paediatric tuberculosis: aspects of ethambutol serum
   concentration, efficacy and toxicity in children}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{9}},
Pages = {{965-971}},
Month = {{SEP}},
Abstract = {{SETTING: Ethambutol (EMB) is used as a fourth drug in paediatric
   anti-tuberculosis treatment. In current recommendations the dosage of
   EMB is calculated per kg body weight.
   OBJECTIVE: To present two studies investigating an appropriate EMB
   dosage in children, and observational data on its toxicity and efficacy.
   DESIGN: EMB serum levels in children of different age groups were
   determined after single oral administration of EMB alone as well as
   after EMB combined with rifampicin, and optimal dosages were
   established. The efficacy and toxicity of these EMB dosages were
   examined retrospectively.
   RESULTS: EMB serum levels were lower than those expected in adults
   receiving a similar oral dose, due to different pharmacokinctics and
   pharmacodynamics in childhood. Thereafter, children were treated with
   EMB doses calculated by body surface (867mg/m(2)). Ocular toxicity
   occurred in 0.7\% of cases and relapses in 0.8\%.
   CONCLUSION: Current recommended EMB dosages in childhood tuberculosis
   lead to subtlierapeutic serum levels. It appears to be more valid to
   calculate the EMB dosage on the basis of body surface rather than body
   weight, leading to higher dosages especially in younger children. With
   these dosages, therapeutic serum levels are reached in all age groups,
   leading to a high efficacy of anti-tuberculosis treatment without
   increased ocular toxicity.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Magdorf, K (Reprint Author), Helios Klinikum Emil Behring, Kinderabt, Standort Campus Benjamin Franklin,Hindenburgdamm, D-12200 Berlin, Germany.
   Chest Hosp Heckeshorn, Helios Klinikum Emil Bahring, Dept Paediat Pneumol \& Immuol Allergy, Berlin, Germany.
   Univ Med Berlin, Charite, Dept Paediat Pneumol \& Immunol, Berlin, Germany.}},
ISSN = {{1027-3719}},
Keywords = {{anti-tuberculosis agents; drug therapy pharmacokinetics; ethambutol;
   children}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; OCULAR TOXICITY; CHEMOTHERAPY; CHILDHOOD;
   RECOMMENDATIONS; MANAGEMENT; DOSAGE}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{klaus.magdorf@charite.de}},
Cited-References = {{American Thoracic Society/Centers for Disease Control and Prevention/Infectious Disease Society of America, 2003, AM J RESP CRIT CARE, V167, P603.
   BARTMANN K, 1961, Beitr Klin Tuberk Spezif Tuberkuloseforsch, V124, P310, DOI 10.1007/BF02144642.
   BENDERT K, 1974, MED KLIN, V69, P1808.
   BRUCKSCHEN EG, 1976, MYAMBUTOL EXPERIMENT, P90.
   BRYSKIER A, 2005, ANTIMICROBIAL AGENTS, P1103.
   CHAN ED, 2004, TUBERCULOSIS, P776.
   CHATTERJEE VKK, 1986, BRIT J DIS CHEST, V80, P288, DOI 10.1016/0007-0971(86)90066-5.
   DARBYSHIRE JH, 1989, ARCH DIS CHILD, V64, P1004.
   Donald PR, 2006, INT J TUBERC LUNG D, V10, P1318.
   DONOMAE I, 1966, ANN NY ACAD SCI, V135, P849, DOI 10.1111/j.1749-6632.1966.tb45528.x.
   DOST F H, 1962, Monatsschr Kinderheilkd, V110, P259.
   DOSTER B, 1973, AM REV RESPIR DIS, V107, P177.
   Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706.
   Graham SM, 2006, ANTIMICROB AGENTS CH, V50, P407, DOI 10.1128/AAC.50.2.407-413.2006.
   {*}HO, 2006, WHOHTMTB2006365.
   HUSSELS H, 1971, PNEUMONOLOGIE, V145, P392, DOI 10.1007/BF02095059.
   HUSSELS H, 1973, PNEUMONOLOGIE, V149, P31, DOI 10.1007/BF02179950.
   Hussels H J, 1969, Med Lab (Stuttg), V22, P195.
   LEIBOLD JE, 1966, ANN NY ACAD SCI, V135, P904, DOI 10.1111/j.1749-6632.1966.tb45532.x.
   LESTER W, 1980, PULMONARY DIS DISORD, P1305.
   Lewis ML, 1999, ANTIMICROBIAL, P643.
   Mankodi N A, 1970, Indian Pediatr, V7, P202.
   Ormerod P, 1998, THORAX, V53, P536.
   OTTO HS, 1981, PRAX KLIN PNEUMOL, V35, P588.
   PELOQUIN CA, 2003, CLIN TUBERCULOSIS, P176.
   Peloquin CA, 1992, DRUG THER, V22, P31.
   PYLE MM, 1966, ANN NY ACAD SCI, V135, P835, DOI 10.1111/j.1749-6632.1966.tb45526.x.
   Radenbach K L, 1973, Bull Int Union Tuberc, V48, P106.
   Scialfa A, 1969, Ann Ottalmol Clin Ocul, V95, P857.
   SETH V, 1991, Indian Pediatrics, V28, P713.
   STWOE CD, 1999, PAEDIAT DRUGS, V1, P299.
   Trebucq A, 1997, INT J TUBERC LUNG D, V1, P12.
   VIANEN WV, 2005, ANTIMICROB AGENTS CH, V49, DOI UNSP 238798.
   von HARNACK G, 1960, Med Klin, V55, P1094.
   Zhu M, 2004, INT J TUBERC LUNG D, V8, P1360.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{21}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{205UA}},
Unique-ID = {{ISI:000249138900007}},
}

@article{ ISI:000249138900008,
Author = {Um, S-W. and Lee, S. W. and Kwon, S. Y. and Yoon, H. I. and Park, K. U.
   and Song, J. and Lee, C-T. and Lee, J-H.},
Title = {{Low serum concentrations of anti-tuberculosis drugs and determinants of
   their serum levels}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{9}},
Pages = {{972-978}},
Month = {{SEP}},
Abstract = {{SETTING: Low serum concentrations of anti-tuberculosis drugs have
   occasionally been associated with treatment failure.
   OBJECTIVE: To determine the prevalence of low serum concentrations of
   anti-tuberculosis drugs and to identify the determinants of drug
   concentrations.
   DESIGN: Venous blood was obtained 2 h after drug ingestion, and serum
   levels of isoniazid (INH), rifampicin (RMP), etharnbutol (EMB),
   pyrazinamide (PZA), acetyl INH and 25-desacetyl RMP were analysed using
   liquid chromatography-tandem mass spectrometry (LC-MS/MS). Patients with
   human immunodeficiency virus co-infection and gastrointestinal disease
   or diarrhoea were excluded.
   RESULTS: Among 69 enrolled TB patients, the prevalence of a low 2 h
   serum concentration of at least one anti-tuberculosis drug was 46.4\%.
   Prevalences of a low SUMMARY concentration of INH, RMP, EMB or PZA were
   15.2\%, 23.5\%, 22.4\% and 4.5\%, respectively. By multivariate linear
   regression analysis, the serum concentrations of INH, RMP and PZA were
   positively associated with dose per kg of body weight (P < 0.05).
   Moreover, INH concentration was associated with acetyl INH/INH ratio
   (beta = -8.588, P < 0.001) and EMB concentration was associated with
   calculated creatininc clearance (beta = -0.025, P < 0.001).
   CONCLUSION: Low concentrations of anti-tuberculosis drugs are common,
   and although the clinical significance of low concentrations remains
   uncertain, it may be necessary to optimise drug doses by therapeutic
   drug monitoring, especially in patients with an inadequate clinical
   response to chemotherapy.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Lee, JH (Reprint Author), Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Div Resp \& Crit Care Med, 300 Gumi Dong, Songnam 46370, Gyeonggi Do, South Korea.
   Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Div Resp \& Crit Care Med, Songnam 46370, Gyeonggi Do, South Korea.
   Seoul Natl Univ, Coll Med, Dept Internal Med \& Lung Inst, Seoul, South Korea.
   Seoul Natl Univ, Bundang Hosp, Dept Lab Med, Gyeonggi Do, South Korea.}},
ISSN = {{1027-3719}},
Keywords = {{tuberculosis; drug; monitoring}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; FASTING CONDITIONS; ANTIMYCOBACTERIAL DRUGS;
   PLASMA-CONCENTRATIONS; PHARMACOKINETICS; RIFAMPIN; ANTACIDS; FOOD;
   PYRAZINAMIDE; HIV}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{jhlee7@snubh.org}},
ResearcherID-Numbers = {{Park, Kyoung Un/J-5473-2012}},
Cited-References = {{Blumberg Henry M, 2003, Am J Respir Crit Care Med, V167, P603.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   Gilljam M, 1999, EUR RESPIR J, V14, P347, DOI 10.1034/j.1399-3003.1999.14b18.x.
   Gurumurthy P, 2004, ANTIMICROB AGENTS CH, V48, P4473, DOI 10.1128/AAC.48.11.4473-4475.2004.
   HOLDINESS MR, 1984, CLIN PHARMACOKINET, V9, P511, DOI 10.2165/00003088-198409060-00003.
   Hong YP, 1998, INT J TUBERC LUNG D, V2, P365.
   Kimerling ME, 1998, CHEST, V113, P1178, DOI 10.1378/chest.113.5.1178.
   McIlleron H, 2006, ANTIMICROB AGENTS CH, V50, P1170, DOI 10.1128/AAC.50.4.1170-1177.2006.
   Mehta JB, 2001, CHEST, V120, P1520, DOI 10.1378/chest.120.5.1520.
   MITCHISON DA, 1993, AM REV RESPIR DIS, V147, P1062.
   Morehead RS, 2000, SOUTHERN MED J, V93, P507.
   PELOQUIN CA, 1993, MED CLIN N AM, V77, P1253.
   Peloquin CA, 2002, DRUGS, V62, P2169, DOI 10.2165/00003495-200262150-00001.
   Peloquin CA, 1997, ANTIMICROB AGENTS CH, V41, P2670.
   Peloquin CA, 1999, INT J TUBERC LUNG D, V3, P703.
   Peloquin CA, 1999, CHEST, V115, P12, DOI 10.1378/chest.115.1.12.
   Peloquin CA, 1999, ANTIMICROB AGENTS CH, V43, P568.
   Peloquin CA, 1998, PHARMACOTHERAPY, V18, P1205.
   Ray J, 2003, INTERN MED J, V33, P229, DOI 10.1046/j.1445-5994.2003.00390.x.
   Sahai J, 1997, ANN INTERN MED, V127, P289.
   Song SH, 2007, RAPID COMMUN MASS SP, V21, P1331, DOI 10.1002/rcm.2961.
   Tappero JW, 2005, CLIN INFECT DIS, V41, P461, DOI 10.1086/431984.
   van Crevel R, 2002, INT J TUBERC LUNG D, V6, P497.
   WEBER WW, 1985, PHARMACOL REV, V37, P25.
   Weiner M, 2005, CLIN INFECT DIS, V40, P1481, DOI 10.1086/429321.
   Weiner M, 2003, AM J RESP CRIT CARE, V167, P1341, DOI 10.1164/rccm.200208-951OC.
   WHO, 2007, WHOHTMTB2007376.
   Woo J, 1995, J MED, V26, P279.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{36}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{205UA}},
Unique-ID = {{ISI:000249138900008}},
}

@article{ ISI:000249138900009,
Author = {Toeruen, T. and Tahaoglu, K. and Oezmen, I. and Sevim, T. and Atac, G.
   and Kir, A. and Guengoer, G. and Boeluekbasi, Y. and Maden, E.},
Title = {{The role of surgery and fluoroquinolones in the treatment of
   multidrug-resistant tuberculosis}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{9}},
Pages = {{979-985}},
Month = {{SEP}},
Abstract = {{SETTING: Although modern tuberculosis treatment relies on chemotherapy,
   surgery is accepted as adjuvant treatment for multidrug-resistant
   tuberculosis (MDR-TB).
   OBJECTIVE: To evaluate the effect of resectional surgery and
   fluoroquinolones on long-term treatment success and survival in a large
   group of MDR-TB cases.
   DESIGN: A total of 252 patients with MDR-TB were included in this
   retrospective cohort study. Multiple logistic regression was used to
   determine independent predictive factors for long-term treatment
   success, and survival analyses were done based on different treatment
   approaches with or without surgery.
   R E S U LT S: The mean age of the study cohort was 37.9 +/- 12.5 years;
   204 (80\%) were males. Long-term treatment success was associated with
   resistance to fewer drugs, female sex, younger age and limited disease.
   Sixty-six patients (26.2\%) had undergone resectional surgery after 2-16
   months of treatment. The highest long-term treatment success and
   survival rates were achieved in patients who both received
   fluoroquinolones and underwent surgery (P = 0.001 vs. other groups).
   CONCLUSION: Although the treatment success rate was higher in patients
   treated with surgery and fluoroquinolones compared to other groups, an
   additional significant benefit from surgery could not be demonstrated.
   Larger scale studies are needed to clarify this issue.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Torun, T (Reprint Author), SB Sureyyapasa Gogus Kalp Damar Hastaliklari Egit, Gogus 2 Klinigi, Istanbul, Turkey.
   Sureyyapasa Ctr Chest \& Thorac Surg, Dept Pulm Dis, Istanbul, Turkey.
   Sureyyapasa Ctr Chest \& Thorac Surg, Dept Thorac Surg, Istanbul, Turkey.}},
ISSN = {{1027-3719}},
Keywords = {{tuberculosis; multidrug resistance; surgery; fluoroquinolone}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; RIFAMPIN}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{tulaytorun@superonline.com}},
ORCID-Numbers = {{Gungor, Gokay/0000-0003-2294-489X}},
Cited-References = {{Chan ED, 2004, AM J RESP CRIT CARE, V169, P1103, DOI 10.1164/rccm.200308-11590C.
   Farmer P, 2001, NEW ENGL J MED, V345, P208, DOI 10.1056/NEJM200107193450310.
   GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802.
   Gosling RD, 2003, AM J RESP CRIT CARE, V168, P1342, DOI 10.1164/rccm.200305-682OC.
   Griffith DE, 2004, AM J RESP CRIT CARE, V169, P1082, DOI 10.1164/rccm.2403003.
   Kir A, 2006, J THORAC CARDIOV SUR, V131, P693, DOI 10.1016/j.jtcvs.2005.09.033.
   Leimane V, 2005, LANCET, V365, P318.
   Loddenkemper R, 2002, EUR RESP J S36, V20, P66.
   Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928.
   Mukherjee JS, 2004, LANCET, V363, P474, DOI 10.1016/S0140-6736(04)15496-2.
   Park SK, 1998, INT J TUBERC LUNG D, V2, P877.
   Pomerantz BJ, 2001, J THORAC CARDIOV SUR, V121, P448, DOI 10.1067/mtc.2001.112339.
   Tahaoglu K, 2001, NEW ENGL J MED, V345, P170, DOI 10.1056/NEJM200107193450303.
   TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404.
   Torun T, 2005, INT J TUBERC LUNG D, V9, P1373.
   WHO, 2006, WHOHTMTB2006361.
   Yew WW, 2000, CHEST, V117, P744, DOI 10.1378/chest.117.3.744.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{29}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{205UA}},
Unique-ID = {{ISI:000249138900009}},
}

@article{ ISI:000249138900010,
Author = {Giampaglia, C. M. S. and Martins, M. C. and Vieira, G. B. de Oliveira
   and Vinhas, S. A. and Telles, M. A. da Silva and Palaci, M. and Marsico,
   A. G. and Hadad, D. J. and Mello, F. C. Q. and Fonseca, L. de Souza and
   Kritski, A.},
Title = {{Multicentre evaluation of an automated BACTEC 960 system for
   susceptibility testing of Mycobacterium tuberculosis}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{9}},
Pages = {{986-991}},
Month = {{SEP}},
Abstract = {{SETTING: Three mycobacteria reference laboratories in the south-eastern
   part of Brazil.
   OBJECTIVE: To evaluate the automated Mycobacteria Growth Indicator Tube
   (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis.
   DESIGN: Performance of the automated BACTEC MGIT 960 (M960) system for
   testing M. tuberculosis susceptibility to streptomycin (SM), isoniazid
   (INH), rifampicin (RMP) and ethambutol (EMB) was evaluated with 95
   clinical isolates and compared to the results of the radiometric BACTEC
   460TB (B460) system, the proportion method (PM), and the resistance
   ratio method (RRM). judicial susceptibility profiles of 88 isolates were
   defined based on two or more concordant results among B460, PM and RRM,
   and used as a reference for comparison with M960 results.
   RESULTS: Agreement rates between M960 and conventional methods were
   95.2\% with B460, 96.6\% with the PM and 93.4\% with the RRM. The lowest
   agreement rates were obtained for SM with the RRM and for EMB with B460.
   When comparing M960 with judicial susceptibility profiles, the agreement
   rate was 97.9\%. The agreement rates obtained for INH and RMP were
   99.2\% and for SM and EMB they were 96.2\% and 96.9\%, respectively. The
   mean time to reporting the M960 results was 6.9 days.
   CONCLUSION: M960 offers great improvements when compared to the
   proportion and resistance ratio methods and would benefit patient
   treatment.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Giampaglia, CMS (Reprint Author), Inst Adolfo Lurz, Mycobacteria Dept, Av Dr Arnaldo 351, Sao Paulo, Brazil.
   Inst Adolfo Lurz, Mycobacteria Dept, Sao Paulo, Brazil.
   Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   Univ Espirito Santa, Vitoria, Espirito Santo, Brazil.}},
ISSN = {{1027-3719}},
Keywords = {{Mycobacterium tuberculosis; susceptibility; MGIT 960; proportion method;
   resistance ratio method; BACTEC 460}},
Keywords-Plus = {{GROWTH INDICATOR TUBE; MULTIDRUG-RESISTANT TUBERCULOSIS; MGIT-960
   SYSTEM; ANTITUBERCULOUS DRUGS; 1ST-LINE DRUGS; ETHAMBUTOL; PROPORTION;
   COMPLEX; EMBB}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{hrgiampa@uol.com.br}},
ResearcherID-Numbers = {{Mello, Fernanda /I-2957-2013}},
Cited-References = {{Adjers-Koskela K, 2003, J CLIN MICROBIOL, V41, P1235, DOI 10.1128/JCM.41.3.1235-1239.2003.
   Alcaide F, 1997, ANTIMICROB AGENTS CH, V41, P2270.
   Ardito F, 2001, J CLIN MICROBIOL, V39, P4440, DOI 10.1128/JCM.39.12.4440-4444.2001.
   {*}B DICK CO, 1994, BBL MGIT PROD DET MY.
   Berner P., 2002, J CLIN MICROBIOL, V40, P150.
   Collins C. H., 1997, TUBERCULOSIS BACTERI.
   Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767.
   {*}FUND NACL SAUD, 1994, MAN BACT TUB.
   Johansen IS, 2004, DIAGN MICR INFEC DIS, V50, P103, DOI 10.1016/j.diagmicrobio.2004.04.001.
   Kent PT, 1985, PUBLIC HLTH MYCOBACT.
   Kontos F, 2004, J MICROBIOL METH, V56, P291, DOI 10.1016/j.mimet.2003.10.015.
   Laszlo A, 2002, INT J TUBERC LUNG D, V6, P748.
   Macondo EA, 2000, B SOC PATHOL EXOT, V93, P97.
   Madison B, 2002, J CLIN MICROBIOL, V40, P3976, DOI 10.1128/JCM.40.11.3976-3979.2002.
   Marttila HJ, 2003, EUR J CLIN MICROBIOL, V22, P757, DOI 10.1007/s10096-003-1030-3.
   Brasil, IND MORB FAT RISC.
   Mukherjee JS, 2004, LANCET, V363, P474, DOI 10.1016/S0140-6736(04)15496-2.
   Palaci M, 1996, J CLIN MICROBIOL, V34, P762.
   Piersimoni C, 2006, J CLIN MICROBIOL, V44, P20, DOI 10.1128/JCM.44.1.20-28.2006.
   Rusch-Gerdes S, 1999, J CLIN MICROBIOL, V37, P45.
   Scarparo C, 2004, J CLIN MICROBIOL, V42, P1109, DOI 10.1128/JCM.42.3.1109-1114.2004.
   SIDDIQI SH, 1996, 460 BACTEC.
   Sreevatsan S, 1997, ANTIMICROB AGENTS CH, V41, P1677.
   Tortoli E, 2002, J CLIN MICROBIOL, V40, P607, DOI 10.1128/JCM.40.2.607-610.2002.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{17}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{205UA}},
Unique-ID = {{ISI:000249138900010}},
}

@article{ ISI:000249138900011,
Author = {Farge, D. and Porcher, R. and Antoun, F. and Fain, O. and Keshtmand, H.
   and Rocher, G. and Mallet, H.-P. and Rambeloarisoa, J. and Gerber, F.
   and De Castro, N. and Che, D. and Coulombier, D. and Zaleskis, R. and
   Herrmann, J-L. and Dye, C. and TB-INFO Association},
Title = {{Tuberculosis in European cities: establishment of a patient monitoring
   system over 10 years in Paris, France}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{9}},
Pages = {{992-998}},
Month = {{SEP}},
Abstract = {{BACKGROUND: Tuberculosis (TB) is a persistent public health problem in
   European cities. France has been unable to report on treatment outcomes
   until now, and it is not known whether the World Health Organization
   (WHO) target cure rate of 85\% has been met.
   METHODS: All patients placed under treatment in four hospitals and five
   out-patient Social Medical Centres in Paris were followed up between
   1996 and 2005. Patient monitoring and evaluation were performed using a
   new software programme, TB-INFO.
   RESULTS: In a cohort of 1127 patients, 76\% had pulmonary TB, of whom
   39\% were smear-positive, 81\% were foreign-born and 9.3\% were human
   immunodeficiency virus positive. At the end of the follow-up, 16\% were
   cured and 54\% had completed treatment. Among the 1118
   non-multidrug-resistant patients, these percentages were 17\% and 46\%,
   respectively, for smear-positive pulmonary patients. Some patients died
   (1.9\%) or failed treatment (0.1\%), but,many more defaulted (20.5\%) as
   they interrupted treatment (1.5 \%), were lost to follow-up (19.5\%) or
   were transferred out (7.9\%).
   CONCLUSIONS: This 10-year follow-up of TB patients, managed with TB-INFO
   software, shows that a patient monitoring system can be implemented in
   France, providing essential information. Treatment success in this
   cohort of patients was far below the WHO target.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Farge, D (Reprint Author), Hop St Louis, AP HP, Serv Med Interne \& Pathol Vasc, 1 Ave Claude Vellefaux, F-75010 Paris, France.
   Hop St Louis, AP HP, Serv Med Interne \& Pathol Vasc, F-75010 Paris, France.
   INSERM, U697, F-75010 Paris, France.
   Hop St Louis, Dept Biostat \& Informat Med, Paris, France.
   Direct Act Sociale Enfance \& Sante, Paris, France.
   Hop Jean Verdier, Serv Med Interne, Bondy, France.
   Ctr Hosp Carnelle, St Martin Terte, France.
   Hop St Louis, Serv Pneumol, Paris, France.
   Hop St Louis, Serv Maladies Infect, Paris, France.
   Inst Natl Veille Sanitaire, St Maurice, France.
   European Ctr Dis Prevent \& Control, Stockholm, Sweden.
   WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark.
   Hop Raymond Poincare, Microbiol Serv, Garches, France.
   WHO, Stop TB Dept, CH-1211 Geneva, Switzerland.}},
ISSN = {{1027-3719}},
Keywords = {{patient cohort monitoring; treatment outcomes; TB-INFO software; WHO
   target}},
Keywords-Plus = {{SURVEILLANCE}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{dominique.farge-bancel@sls.aphp.fr}},
ORCID-Numbers = {{Herrmann, Jean-Louis/0000-0003-2347-6418}},
Cited-References = {{Antoine D, 2007, BEH, V11, P85.
   Antoun F, 2005, B EPIDEMIOL HEBD, V17-18, P70.
   BAYOLHONNET G, 2001, B EPIDEMIOL HEBD, V41, P199.
   Cailhol J, 2005, INT J TUBERC LUNG D, V9, P803.
   de Colombani P, 2004, EUR RESPIR J, V24, P493, DOI 10.1183/09031936.04.00064504.
   Falzon D, 2006, Euro Surveill, V11, P20.
   FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406.
   Grange JM, 2002, J R SOC PROMO HEALTH, V122, P78, DOI 10.1177/146642400212200206.
   {*}HLTH PROT AG, 2007, TUB CAS REP ENGL WAL.
   MARJANOVIC Z, 2002, EUR J INTERN MED, V13, P180, DOI 10.1016/S0953-6205(02)00013-4.
   Raviglione M, 2001, INT J TUBERC LUNG D, V5, P213.
   Raviglione MC, 2003, TUBERCULOSIS, V83, P4, DOI 10.1016/S1472-9792(02)00071-9.
   Robert J, 2003, EUR RESPIR J, V22, P833, DOI 10.1183/09031936.03.00014103.
   Schwoebel V, 2000, EUR RESPIR J, V16, P364, DOI 10.1034/j.1399-3003.2000.16b28.x.
   SHELDON CD, 1992, THORAX, V47, P1015, DOI 10.1136/thx.47.12.1015.
   Valin N, 2005, INT J TUBERC LUNG D, V9, P528.
   vanDeutekom H, 1997, CLIN INFECT DIS, V25, P1071, DOI 10.1086/516072.
   Veen J, 1998, EUR RESPIR J, V12, P505, DOI 10.1183/09031936.98.12020505.
   Vranken R, 2002, INT J TUBERC LUNG D, V6, P111.
   {*}WHO, 2002, DOTS EXP PLAN STOP T.
   {*}WHO, 2007, WHOHTMTB2006362.
   {[}Anonymous], 2006, J OFFICIEL REPUBLIQU.}},
Number-of-Cited-References = {{22}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{205UA}},
Unique-ID = {{ISI:000249138900011}},
}

@article{ ISI:000249138900012,
Author = {Kolappan, C. and Gopi, P. G. and Subramani, R. and Narayanan, P. R.},
Title = {{Selected biological and behavioural risk factors associated with
   pulmonary tuberculosis}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{9}},
Pages = {{999-1003}},
Month = {{SEP}},
Abstract = {{OBJECTIVES: To measure the independent association of risk factors age,
   sex, smoking and alcoholism with pulmonary tuberculosis (TB) in terms of
   prevalence odds ratio (POR).
   METHOD: A community-based cross-sectional survey was conducted from June
   2001 to December 2003. A total of 93 945 individuals aged >= 15 years
   selected from a random sample of villages in a district from South India
   were screened for pulmonary TB by chest symptoms and chest X-ray (MMR).
   Two sputum samples were collected (one spot and one early morning) from
   patients with chest symptoms and those with abnormal X-rays for
   examination by microscopy for acid-fast bacilli and by culture for
   Mycobacterium tuberculosis. Bacillary cases are bacteriologically
   positive cases diagnosed by either spu turn smear or culture
   examination. In addition, data on exposure to tobacco smoking and
   alcohol consumption were collected from the male population only. All
   females were considered non-smokers and non-alcoholics.
   RESULTS: A total of 429 bacteriologically positive cases were detected
   during the survey. The adjusted PORs (with 95\%CI) for age, sex, smoking
   and alcoholism were 3.3 (2.7-4.1), 2.5 (1.9-3.3), 2.1 (1.7-2.7) and 1.5
   (1.22.0), respectively.
   CONCLUSION: Risk factors such as age, sex, smoking and alcoholism are
   independently associated with pulmonary TB. Risk factors age and sex
   show a stronger association than smoking and alcoholism.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Narayanan, PR (Reprint Author), Indian Council Med Res, TB Res Ctr, Mayor V R Ramanathan Rd, Madras 600031, Tamil Nadu, India.
   Indian Council Med Res, TB Res Ctr, Madras 600031, Tamil Nadu, India.}},
ISSN = {{1027-3719}},
Keywords = {{pulmonary TB; risk factors; alcoholism; smoking; prevalence odds ratio}},
Keywords-Plus = {{SOUTH-INDIA; PREVALENCE; COMMUNITY; SMOKING}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{prnarayanan@trcchennai.in}},
Cited-References = {{ACAIDE J, 1996, TUBERCLE LUNG DIS, V77, P112.
   BUSKIN SE, 1994, AM J PUBLIC HEALTH, V84, P1750, DOI 10.2105/AJPH.84.11.1750.
   Cutolo M, 2004, LUPUS, V13, P635, DOI 10.1191/0961203304lu1094oa.
   Gopi PG, 2003, INT J TUBERC LUNG D, V7, P1154.
   Gustafson P, 2004, INT J EPIDEMIOL, V33, P163, DOI 10.1093/ije/dyh026.
   Jacobson JM, 1992, ALCOHOL HEALTH RES W, V16, P39.
   Kolappan C, 2002, THORAX, V57, P964, DOI 10.1136/thorax.57.11.964.
   Leung CC, 2003, INT J TUBERC LUNG D, V7, P980.
   Markovic Ljiljana, 2004, Srp Arh Celok Lek, V132, P187.
   MEYERSTEINBRENNER H, 2005, ENV PROTECT EU, V2, P433.
   Narayanan S, 2004, INDIAN J MED RES, V120, P233.
   Pearce N, 2004, ENVIRON HEALTH PERSP, V112, P1047, DOI 10.1289/ehp.6927.
   PRAKASH G, 1996, TOB CONTROL, V5, P14.
   Radhakrishna S, 2001, INT J TUBERC LUNG D, V5, P142.
   Sopori ML, 1998, ADV EXP MED BIOL, V437, P279.
   Tekkel M, 2002, INT J TUBERC LUNG D, V6, P887.
   Tocque K, 2001, EUR RESPIR J, V18, P959, DOI 10.1183/09031936.01.00211701.
   {*}TUB RES CTR, 1980, IND J MED RES S, V12, P1.
   YU GP, 1988, TUBERCLE, V69, P105, DOI 10.1016/0041-3879(88)90072-4.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{21}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{205UA}},
Unique-ID = {{ISI:000249138900012}},
}

@article{ ISI:000249138900014,
Author = {Cain, K. R. and Kanara, N. and Laserson, K. F. and Vannarith, C. and
   Sameourn, K. and Samnang, K. and Qualls, M. L. and Wells, C. D. and
   Varma, J. K.},
Title = {{The epidemiology of HIV-associated tuberculosis in rural Cambodia}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{9}},
Pages = {{1008-1013}},
Month = {{SEP}},
Abstract = {{SETTING: Banteay Meanchey Province, Cambodia.
   OBJECTIVE: The World Health Organization recommends human
   immunodeficiency virus (HIV) testing for all tuberculosis (TB) patients
   and TB screening for all HIV-infected persons in countries with a TB-HIV
   syndemic. We sought to determine whether evidence supports implementing
   these recommendations in South-East Asia.
   DESIGN: We conducted a cross-sectional survey and retrospective cohort
   study of patients newly diagnosed with HIV or TB from October 2003 to
   February 2005 to identify risk factors for HIV infection and TB, and for
   death during TB treatment.
   RESULTS: HIV infection was diagnosed in 216/574 (38\%) TB patients. TB
   disease was found in 124/450 (24\%) HIV-Infected persons. No sub-groups
   of patients had a low risk of HIV infection or TB. Of 180 TB patients
   with HIV infection and a recorded treatment outcome, 49 (27\%) died
   compared to 17/357 (5\%) without HIV infection (relative risk {[}RR]
   5.2, 95\% confidence interval {[}CI] 3.1-8.7). HIV-infected TB patients
   with smear-negative pulmonary disease died less frequently than those
   with smear-positive pulmonary disease (RR 0.39, 95\%Cl 0.16-0.93).
   CONCLUSIONS: No sub-groups of patients had low risk for HIV infection or
   TB, and mortality among HIVinfected TB patients was high. These data
   justify using the WHO global TB-HIV recommendations in South-East Asia.
   Urgent interventions are needed to reduce the high mortality rate in
   HIV-infected TB patients.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Cain, KR (Reprint Author), Ctr Dis Control \& Prevent, Div TB Eliminat, 1600 Clifton Rd,MS E 10, Atlanta, GA 30333 USA.
   Ctr Dis Control \& Prevent, Div TB Eliminat, Atlanta, GA 30333 USA.
   Ctr Dis Control \& Prevent, Off Workforce \& Career Dev, Epidem Intellignce Serv, Atlanta, GA USA.
   Cambodia Minist Hlth, Banteay Meanchey Prov Hlth Dept, Prov AIDS Off, Sisiphon, Cambodia.
   US CDC Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand.}},
ISSN = {{1027-3719}},
Keywords = {{tuberculosis; HIV; epidemiology; mortality; Cambodia}},
Keywords-Plus = {{NEGATIVE PULMONARY TUBERCULOSIS; CHI-MINH CITY; PREVALENCE; OUTCOMES;
   MALAWI}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{kcain@cdc.gov}},
Cited-References = {{Breiman L., 1984, CLASSIFICATION REGRE.
   {*}CDCP, 2007, SPOTL SYND.
   Centers for Disease Control Prevention, 2005, MMWR-MORBID MORTAL W, V54, P1177.
   Freudenberg N, 2006, AM J PUBLIC HEALTH, V96, P424, DOI 10.2105/AJPH.2005.063511.
   Hargreaves NJ, 2001, INT J TUBERC LUNG D, V5, P847.
   Harries AD, 2001, INT J TUBERC LUNG D, V5, P1000.
   {*}JOINT UN PROGR HI, 2005, AIDS EP UPD.
   Kang'ombe CT, 2004, INT J TUBERC LUNG D, V8, P829.
   MANOSUTHI W, 2006, AIDS, V43, P42.
   {*}MIN HLTH, 2002, REP HIV SENT SURV CA.
   Mukadi YD, 2001, AIDS, V15, P143, DOI 10.1097/00002030-200101260-00002.
   Quy HT, 2006, INT J TUBERC LUNG D, V10, P45.
   Quy HT, 2002, AIDS, V16, P931, DOI 10.1097/00002030-200204120-00016.
   SHAH N, 2006, RISK FACTORS SMEAR N.
   Siddiqi K, 2003, LANCET INFECT DIS, V3, P288, DOI 10.1016/S1473-3099(03)00609-1.
   Singer M, 2003, MED ANTHROPOL Q, V17, P423, DOI 10.1525/maq.2003.17.4.423.
   SMITH RL, 1994, CHEST, V106, P684, DOI 10.1378/chest.106.3.684.
   World Health Organization, 2003, WHOCDSTB2003313.
   WHO, 2005, TB HIV RES PRIOR RES.
   World Health Organization, 2004, WHOHTMTB2004330.
   World Health Organization, 2005, WHOHTMTB2005349.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{29}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{205UA}},
Unique-ID = {{ISI:000249138900014}},
}

@article{ ISI:000249138900015,
Author = {Moran-Mendoza, O. and Marion, S. A. and Elwood, K. and Patrick, D. M.
   and FitzGeraidt, J. M.},
Title = {{Tuberculin skin test size and risk of tuberculosis development: a large
   population-based study in contacts}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{9}},
Pages = {{1014-1020}},
Month = {{SEP}},
Abstract = {{SETTING: Contacts of tuberculosis (TB) cases identified from eight
   Provincial databases in British Columbia, Canada, between 1990 and 2000.
   OBJECTIVE: To assess the risk of developing TB based on tuberculin skin
   test (TST) sizes in contacts of TB cases who did not receive treatment
   for latent TB infection.
   DESIGN: Retrospective, population-based cohort study with a 12-year
   follow-up.
   RESULTS: Among 26 542 contacts, 180 individuals developed TB (TB rate
   678/100 000). Household contacts with a TST size 0-4 mm had a TB rate of
   1014/100 000, those with 5-9 mm a TB rate of 2162/100 000 and those with
   10-14 mm a rate of 4478/100000. Children aged 0-10 years with 0-4 mm had
   a TB rate of 806/100000, those with 5-9 mm, a TB rate of 55561100000 and
   those with 10-14 mm a rate of 42 424/100000. Immunosuppressed contacts
   with TST sizes 0-4 mm had a TB rate of 630/100000, those with 5-9 mm a
   TB rate of 1923/ 100000, and those with 10-14 mm a rate of 1770/ 100000.
   CONCLUSIONS: TB rates were high for all TST sizes in household contacts,
   0-10 year old contacts and immuno-suppressed contacts. These contacts
   may benefit from treatment for latent TB infection, regardless of the
   size of their TST.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Moran-Mendoza, O (Reprint Author), Univ Autonoma San Luis Potosi, Fac Med, Dept Clin Epidemiol, Av Venusitano Carranza 2405, Col Filtros 78210, SLP, Mexico.
   Univ Autonoma San Luis Potosi, Fac Med, Dept Clin Epidemiol, Col Filtros 78210, SLP, Mexico.
   Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.}},
ISSN = {{1027-3719}},
Keywords = {{tuberculosis risk; latent tuberculosis infection; tuberculin skin test}},
Keywords-Plus = {{BCG VACCINATION; UNITED-STATES; TRIAL; PREVENTION; VACCINES; REFUGEES;
   CHILDREN}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{omoran@uaslp.mx}},
Cited-References = {{American Thoracic Society, 2000, AM J RESP CRIT CARE, V161, pS221.
   BAILY DVJ, 1979, INDIAN J MED RES, V70, P349.
   BATES BH, 1996, AM J RESP CRIT CARE, V154, P251.
   {*}CAN LUNG ASS, 2000, CAN TUB STAND.
   {*}CAN TUB RESP DIS, 1972, CAN TUB STAND.
   Centers for Disease Control and Prevention, 1999, MMWR-MORBID MORTAL W, V48, P1.
   Chee CBE, 2001, AM J RESP CRIT CARE, V164, P958.
   COMSTOCK GW, 1974, AM REV RESPIR DIS, V110, P572.
   COMSTOCK GW, 1976, PUBLIC HEALTH REP, V91, P276.
   COMSTOCK GW, 1974, AM J PUBLIC HEALTH, V64, P283, DOI 10.2105/AJPH.64.3.283.
   COMSTOCK GW, 1966, AM REV RESPIR DIS, V93, P171.
   COMSTOCK GW, 1967, AM REV RESPIR DIS, V95, P935.
   CORPE RF, 1965, AM REV RESPIR DIS, V91, P297.
   Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376.
   Ferebee S H, 1970, ADV TUBERC RES, V17, P28.
   FINE PEM, 1994, LANCET, V344, P1245, DOI 10.1016/S0140-6736(94)90748-X.
   Hennekens C. H., 1987, EPIDEMIOLOGY MED.
   HORWITZ O, 1969, B WORLD HEALTH ORGAN, V41, P95.
   Hosmer DW, 1999, APPL SURVIVAL ANAL R, P196.
   MacIntyre CR, 1998, INT J TUBERC LUNG D, V2, P56.
   MacIntyre CR, 1999, INT J TUBERC LUNG D, V3, P287.
   Marks GB, 2000, AM J RESP CRIT CARE, V162, P1851.
   Mazurek Gerald H, 2003, MMWR Recomm Rep, V52, P15.
   Meier T, 2005, EUR J CLIN MICROBIOL, V24, P529, DOI 10.1007/s10096-005-1377-8.
   Nolan CM, 2005, AM J RESP CRIT CARE, V172, P1169, DOI 10.1164/rccm.2508001.
   Ormerod P, 2000, THORAX, V55, P887.
   Radhakrishna S, 2003, Int J Tuberc Lung Dis, V7, P1083.
   Small PM, 2001, NEW ENGL J MED, V345, P189, DOI 10.1056/NEJM200107193450307.
   THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{27}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{205UA}},
Unique-ID = {{ISI:000249138900015}},
}

@article{ ISI:000249138900016,
Author = {Mori, T. and Harada, N. and Higuchi, K. and Sekiya, Y. and Uchimura, K.
   and Shimao, T.},
Title = {{Waning of the specific interferon-gamma response after years of
   tuberculosis infection}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{9}},
Pages = {{1021-1025}},
Month = {{SEP}},
Abstract = {{HYPOTHESIS: Memory T-cell responses to specific antigens wane over time
   in subjects with tuberculosis (TB) infection.
   SETTING: Accumulated evidence indicates that Quanti-FERON (R)-TB Gold
   (QFT-G), a specific whole-blood interferon-gamma (IFN-gamma) based
   assay, can detect recent TB infections with superior sensitivity and
   specificity.
   OBJECTIVE: We applied this technique to the adult population of a
   Japanese community to determine its epidemiological usefulness.
   METHOD: A total of 1559 subjects attending periodic health screening
   volunteered to participate in the study.
   RESULTS: The QFT-G positive rates were 3.1\% for those aged 40-49 years,
   5.9\% for those aged 50-59 and 9.8\% for those aged 60-69. The expected
   infection prevalence estimated by the authors from a series of studies
   was 11.1\%, 29.6\% and 53.1\% for those aged 40-49, 50-59 and 60-69
   years, respectively. This wide gap between the expected and observed
   positivity suggests that the IFN-gamma response waned substantially with
   time after infection. Those with X-rays; suggestive of old TB lesions
   exhibited positivity rates well below 100\%.
   CONCLUSION: The specific IFN-gamma response may wane considerably with
   time after infection. Longitudinal studies are required to investigate
   long-term dynamics of cell-mediated immunity in infected donors.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mori, T (Reprint Author), Natl Inst Infect Dis, Leprosy Res Ctr, Tokyo 1890002, Japan.
   Natl Inst Infect Dis, Leprosy Res Ctr, Tokyo 1890002, Japan.
   Japan Anti TB Assoc, Res Inst TB, Tokyo, Japan.
   Kitasato Univ, Kitasato Inst Life Sci, Immunoregulat Lab, Tokyo, Japan.}},
ISSN = {{1027-3719}},
Keywords = {{tuberculosis infection; interferon-gamma; diagnostic; epidemiology;
   tuberculin skin test}},
Keywords-Plus = {{T-CELL RESPONSES; MYCOBACTERIUM-TUBERCULOSIS; BLOOD-TEST; ASSAY;
   DIAGNOSIS; ANTIGENS; REVERSION; THERAPY}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{t-mori@nih.go.jp}},
Cited-References = {{Aiken AM, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-66.
   AOKI M, 2006, KEKKAKU, V81, P277.
   Brock Iinger, 2004, American Journal of Respiratory and Critical Care Medicine, V170, P65, DOI 10.1164/rccm.200402-232OC.
   Carrara S, 2004, CLIN INFECT DIS, V38, P754, DOI 10.1086/381754.
   Chee CBE, 2007, AM J RESP CRIT CARE, V175, P282, DOI 10.1164/rccm.200608-1109OC.
   Dheda K, 2005, CURR OPIN PULM MED, V11, P195, DOI 10.1097/01.mcp.0000158726.13159.5e.
   Diel R, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-77.
   Ewer K, 2006, AM J RESP CRIT CARE, V174, P831, DOI 10.1164/rccm.200511-1783OC.
   Funayama Kazushi, 2005, Kekkaku, V80, P527.
   {*}GOV OK, 1973, TUB PREV SURV REP.
   GRZYBOWSKI S, 1964, AM REV RESPIR DIS, V90, P707.
   Harada Nobuyuki, 2004, Kekkaku, V79, P637.
   Harada N, 2006, INFECT CONT HOSP EP, V27, P442, DOI 10.1086/504358.
   HIGUCHI K, 2007, IN PRESS RESPIROLOGY.
   HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P46.
   Kang YA, 2005, JAMA-J AM MED ASSOC, V293, P2756, DOI 10.1001/jama.293.22.2756.
   Menzies D, 1999, AM J RESP CRIT CARE, V159, P15.
   {*}MIN HLTH LAB WELF, 2004, STAT TUB 2004.
   Mori T, 2000, EMERG INFECT DIS, V6, P566.
   MORI T, 1971, Kekkaku, V46, P357.
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC.
   MORI T, 1988, KEKKAKU, V63, P339.
   Nicol MP, 2005, CLIN INFECT DIS, V40, P1301, DOI 10.1086/429245.
   Pathan AA, 2001, J IMMUNOL, V167, P5217.
   Ravn P, 2005, CLIN DIAGN LAB IMMUN, V12, P491, DOI 10.1128/CDLI.12.4.491-496.2005.
   STYBLO K, 1969, Bulletin of the International Union Against Tuberculosis, V42, P5.
   Suzuki K, 2004, KEKKAKU, V79, P200.
   Yamauchi Y., 1999, KEKKAKU, V74, P819.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{46}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{205UA}},
Unique-ID = {{ISI:000249138900016}},
}

@article{ ISI:000249138900019,
Author = {Haar, C. H. and Cobelens, F. G. J. and Kalisvaart, N. A. and van Gerven,
   P. J. H. J. and van der Havet, J. J.},
Title = {{HIV-related mortality among tuberculosis patients in the Netherlands,
   1993-2001}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{9}},
Pages = {{1038-1041}},
Month = {{SEP}},
Abstract = {{Human immunodeficiency virus (HIV) infection in tuberculosis (TB)
   patients in the Netherlands during the period 1993-2001 was associated
   with an increased risk of death (adjusted odds ratio 4.71, P < 0.002).
   Age and sex-standardised mortality rates among HIV-infected TB patients
   decreased significantly over time, from 22.9\% in 1993-1995 to 11.8\% in
   1999-2001 (P < 0.001). No such change was observed for HIV-negative
   patients. The decrease in mortality is likely due to the more widespread
   use of highly active antiretroviral therapy (HAART).}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Cobelens, FGJ (Reprint Author), KNCV TB Fdn, Pk St 17, NL-2514 JD The Hague, Netherlands.
   KNCV TB Fdn, NL-2514 JD The Hague, Netherlands.
   Municipal Hlth Serv, Groningen, Netherlands.
   Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.}},
ISSN = {{1027-3719}},
Keywords = {{human immunodeficiency virus; low prevalence; mortality; the
   Netherlands; tuberculosis}},
Keywords-Plus = {{ACTIVE ANTIRETROVIRAL THERAPY}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{cobelensf@kncvtbc.nl}},
Cited-References = {{Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3.
   Churchyard GJ, 2000, INT J TUBERC LUNG D, V4, P705.
   Dheda K, 2004, J INFECT DIS, V190, P1670, DOI 10.1086/424676.
   Haar CH, 2006, INT J TUBERC LUNG D, V10, P768.
   Lawn S D, 1999, West Afr J Med, V18, P270.
   Rieder H. L., 1999, EPIDEMIOLOGIC BASIS.
   WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129.}},
Number-of-Cited-References = {{7}},
Times-Cited = {{14}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{205UA}},
Unique-ID = {{ISI:000249138900019}},
}

@article{ ISI:000249138900020,
Author = {Muniyandi, M. and Ramachandran, R. and Gopi, R. G. and Chandrasekaran,
   V. and Subramani, R. and Sadacharam, K. and Kumaran, R. and Santha, T.
   and Wares, F. and Narayanan, R. R.},
Title = {{The prevalence of tuberculosis in different economic strata: a community
   survey from South India}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{9}},
Pages = {{1042-1045}},
Month = {{SEP}},
Abstract = {{A cross-sectional socio-economic survey to assess the standard of living
   index (SLI) of a rural population in South India was undertaken along
   with a tuberculosis (TB) prevalence survey during 2004-2006. Of 32 780
   households, the SLI was low, medium and high in 22\%, 36\% and 42\%, and
   TB prevalence was 343, 169 and 92 per 100 000 population, respectively,
   a significant decrease in trend (P < 0.001); 57\% of the TB patients had
   SUMMARY a low SLI and the prevalence of TB was higher amongst the
   landless (P < 0.001), those living below the poverty line (P < 0.01) and
   in katcha houses (P < 0.001), suggesting that TB disproportionately
   affects those with a low SLI.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Narayanan, RR (Reprint Author), Indian Council Med Res, TB Res Ctr, Mayor V R Ramanathan Rd, Madras 600031, Tamil Nadu, India.
   Indian Council Med Res, TB Res Ctr, Madras 600031, Tamil Nadu, India.
   WHO, New Delhi, India.}},
ISSN = {{1027-3719}},
Keywords = {{tuberculosis programme; prevalence; poverty; economic strata; standard
   of living index}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{prnarayanan@trcchennai.in}},
Cited-References = {{Central TB Division, 2006, RNTCP STAT REP.
   GLEWWE P, 1993, 132 LIV STAND MEAS S.
   Gopi PG, 2003, INT J TUBERC LUNG D, V7, P1154.
   International Institute for Population Sciences and ORC-Macro, 2000, NAT FAM HLTH SURV NF.
   Marmot M, 2002, HEALTH AFFAIR, V21, P31, DOI 10.1377/hlthaff.21.2.31.
   MUNIYANDI M, 2004, J TUBERC LUNG DIS HI, V1, P14.
   SPENCE DPS, 1993, BRIT MED J, V307, P759.
   Subramani R, 2007, INT J EPIDEMIOL, V36, P387, DOI 10.1093/ije/dyl216.
   Subramanian SV, 2006, PLOS MED, V3, P1794, DOI 10.1371/journal.pmed.0030421.
   {*}WORLD BANK, 1995, WORLD BANKS STRAT RE, P42.
   {*}WORLD HLTH ORG, 2005, WHOHTMTB2005352, P12.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{24}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{205UA}},
Unique-ID = {{ISI:000249138900020}},
}

@article{ ISI:000249214000055,
Author = {Canbakan, Basol and Ergun, Ihsan and Ekmekci, Yakup and Ates, Kenan and
   Karatan, Oktay},
Title = {{Pulmonary and peritoneal tuberculosis in a CAPD patient}},
Journal = {{INTERNATIONAL UROLOGY AND NEPHROLOGY}},
Year = {{2007}},
Volume = {{39}},
Number = {{3}},
Pages = {{975-978}},
Month = {{SEP}},
Abstract = {{Patients with chronic renal failure have an increased incidence of
   tuberculosis due to decreased cellular immunity. More than half of the
   tuberculosis infection in these patients presented with extrapulmonary
   involvement. Tuberculous peritonitis is an important problem in patients
   undergoing continuous ambulatory peritoneal dialysis (CAPD).
   Simultaneous pulmonary and peritoneal tuberculosis is a very rare
   condition. We describe a 39-year-old man with culture negative CAPD
   peritonitis. In spite of conventional antimicrobial therapy the patient
   had persistent fever, weight loss, and night sweats. Approximately after
   one month from starting treatment, both sputum specimen and peritoneal
   fluid were positive for mycobacterium. Quadruple therapy for
   tuberculosis has been started. The response to treatment was promptly.
   He is still on treatment for six months and receiving CAPD. Tuberculous
   peritonitis should always be considered when patients on CAPD develop
   culture negative peritonitis treated with conventional antibiotics
   without improvement. In addition, the existence of extraperitoneal
   tuberculosis, especially pulmonary disease must be investigated.}},
Publisher = {{SPRINGER}},
Address = {{VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ergun, I (Reprint Author), Ankara Univ, Sch Med, Dept Nephrol, Ibni Sina Hosp, TR-06100 Ankara, Turkey.
   Ankara Univ, Sch Med, Dept Nephrol, Ibni Sina Hosp, TR-06100 Ankara, Turkey.}},
DOI = {{10.1007/s11255-006-9135-0}},
ISSN = {{0301-1623}},
Keywords-Plus = {{DIALYSIS; FEATURES}},
Research-Areas = {{Urology \& Nephrology}},
Web-of-Science-Categories  = {{Urology \& Nephrology}},
Author-Email = {{ihsanerg@yahoo.com}},
Cited-References = {{Al-Heresh A. M., 1997, International Urology and Nephrology, V29, P107, DOI 10.1007/BF02551425.
   DEMIR K, 2001, EUR J GASTROEN HEPAT, V13, P377.
   Fang HC, 2004, INT J TUBERC LUNG D, V8, P92.
   Karayaylali I, 2003, RENAL FAILURE, V25, P819, DOI 10.1081/JDI-120024296.
   Lui SL, 2001, AM J KIDNEY DIS, V38, P1055, DOI 10.1053/ajkd.2001.28599.
   Quantrill SJ, 2001, NEPHROL DIAL TRANSPL, V16, P1024, DOI 10.1093/ndt/16.5.1024.
   Rapoport J, 1999, NEPHRON, V81, P375, DOI 10.1159/000045319.
   Sahin Garip, 2004, Ann Clin Microbiol Antimicrob, V3, P19, DOI 10.1186/1476-0711-3-19.
   Sanai FM, 2005, ALIMENT PHARM THERAP, V22, P685, DOI 10.1111/j.1365-2036.2005.02645.x.
   Smith I, 2003, CLIN MICROBIOL REV, V16, P463, DOI 10.1128/CMR.16.3.463-496.2003.
   Talwani R, 2000, CLIN INFECT DIS, V31, P70, DOI 10.1086/313919.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Int. Urol. Nephrol.}},
Doc-Delivery-Number = {{206WQ}},
Unique-ID = {{ISI:000249214000055}},
}

@article{ ISI:000253453400018,
Author = {Malone, A. and McConkey, S. and Dorman, A. and Lavin, P. and Gopthanian,
   D. and Conlon, P.},
Title = {{Mycobacterium tuberculosis in a renal transplant transmitted from the
   donor}},
Journal = {{IRISH JOURNAL OF MEDICAL SCIENCE}},
Year = {{2007}},
Volume = {{176}},
Number = {{3}},
Pages = {{233-235}},
Month = {{SEP}},
Abstract = {{Background Disease caused by Mycobacterium tuberculosis (MTB) is a
   well-recognised complication of renal transplantation worldwide due to
   immunosuppression. It is more common in developing countries. Infection
   isolated to a renal allograft is rare and infection transmitted by the
   allograft is also very rare.
   Aim To describe the first reported case of MTB in a renal transplant
   transmitted from the donor in Ireland and review the literature.
   Results A 53-year-old male 29 months after allogenic renal transplant
   for adult polycystic kidney disease with no other risk factors for MTB
   presented with deteriorating renal function. Pathological examination of
   a renal biopsy specimen showed caseating granulomata. MTB was confirmed
   by culture of early morning urine.
   Conclusions MTB isolated to a renal transplant is rare in the developed
   world. Such an infection should always be considered as our donor pool
   becomes increasingly more travelled particularly to endemic areas. The
   new interferon gamma release assays (IGRA) may be a viable alternative
   screening method to the tuberculin skin test (TST).}},
Publisher = {{SPRINGER LONDON LTD}},
Address = {{ASHBOURNE HOUSE, THE GUILDWAY, OLD PORTSMOUTH ROAD, ARTINGTON GU3 1LP,
   GUILDFORD, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Malone, A (Reprint Author), Beaumont Hosp, Dept Med, Dublin 9, Ireland.
   Malone, A.; Lavin, P.; Gopthanian, D.; Conlon, P., Beaumont Hosp, Dept Med, Dublin 9, Ireland.
   McConkey, S., RCSI, Dept Int Hlth \& Trop Med, Dublin, Ireland.
   Dorman, A., Beaumont Hosp, Dept Renal Histopathol, Dublin, Ireland.}},
DOI = {{10.1007/s11845-007-0048-4}},
ISSN = {{0021-1265}},
Keywords = {{adult polycystic kidney disease; cadaveric renal transplant; caseating
   granuloma; immunosuppression; Mycobacterium tuberculosis; renal biopsy}},
Keywords-Plus = {{RECIPIENTS; INFECTION}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{78.andrew@gmail.com}},
ResearcherID-Numbers = {{McConkey, Samuel/E-7307-2012
   }},
ORCID-Numbers = {{McConkey, Samuel/0000-0001-9085-7793}},
Cited-References = {{Atasever A, 2005, NEPHROL DIAL TRANSPL, V20, P797, DOI 10.1093/ndt/gfh691.
   Basiri A, 2005, TRANSPLANT P, V37, P3041, DOI 10.1016/transproceed.2005.07.041.
   Douie W J, 2000, Transpl Infect Dis, V2, P44, DOI 10.1034/j.1399-3062.2000.020109.x.
   Graham JC, 2001, J INFECTION, V43, P251, DOI 10.1053/jinf.2000.0879.
   Klote MM, 2004, AM J TRANSPLANT, V4, P1523, DOI 10.1111/j.1600-6143.2004.00545.x.
   Singh N, 1998, CLIN INFECT DIS, V27, P1266, DOI 10.1086/514993.
   SPENCE RK, 1983, ARCH SURG-CHICAGO, V118, P356.
   van den Toorn LM, 2003, CURR OPIN PULM MED, V9, P15, DOI 10.1097/00063198-200301000-00003.
   {*}WHO, 2003, WHO TB EP PROF.
   NEPHROL DIAL TRAN S4, V17, P39.}},
Number-of-Cited-References = {{10}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Irish J. Med. Sci.}},
Doc-Delivery-Number = {{266QZ}},
Unique-ID = {{ISI:000253453400018}},
}

@article{ ISI:000249201900019,
Author = {Lawn, Stephen D. and Wood, Robin},
Title = {{Optimum time to initiate antiretroviral therapy in patients with
   HIV-associated tuberculosis - There may be more than one right answer}},
Journal = {{JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES}},
Year = {{2007}},
Volume = {{46}},
Number = {{1}},
Pages = {{121-123}},
Month = {{SEP 1}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Lawn, SD (Reprint Author), Univ Cape Town, Fac Hlth Sci, Inst Infect Dis \& Mol Med, Desmond Tutu HIV Ctr, Cape Town, South Africa.
   Univ Cape Town, Fac Hlth Sci, Inst Infect Dis \& Mol Med, Desmond Tutu HIV Ctr, Cape Town, South Africa.
   London Sch Hyg \& Trop Med, Clin Res Unit, London WC1, England.}},
ISSN = {{1525-4135}},
Keywords-Plus = {{IMMUNE RECONSTITUTION DISEASE; SOUTH-AFRICA; TREATMENT SERVICE; EARLY
   MORTALITY; RISK-FACTORS; PROGRAM; IMPACT; COUNTRIES; OUTCOMES; ERA}},
Research-Areas = {{Immunology; Infectious Diseases}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases}},
ResearcherID-Numbers = {{Wood, Robin/G-8509-2011}},
Cited-References = {{Braitstein P, 2006, LANCET, V367, P817.
   BURMAN W, 2005, 43 ANN M INF DIS SOC.
   Burman WJ, 2001, AM J RESP CRIT CARE, V164, P7.
   Colebunders R, 2006, INT J TUBERC LUNG D, V10, P946.
   de Jong BC, 2004, ANNU REV MED, V55, P283, DOI 10.1146/annurev.med.55.091902.103753.
   Dean GL, 2002, AIDS, V16, P75, DOI 10.1097/00002030-200201040-00010.
   Lawn SD, 2005, LANCET INFECT DIS, V5, P361, DOI 10.1016/S1473-3099(05)70140-7.
   Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1.
   LAWN SD, 2007, 13 C RESTR OPP INF C.
   Lawn SD, 2007, SAMJ S AFR MED J, V97, P412.
   Lawn SD, 2007, AIDS, V21, P335, DOI 10.1097/QAD.0b013e328011efac.
   Lawn SD, 2006, J INFECT DIS, V194, P1467, DOI 10.1086/508549.
   Lawn SD, 2006, CLIN INFECT DIS, V43, P770, DOI 10.1086/507095.
   Lawn SD, 2006, AIDS, V20, P1605, DOI 10.1097/01.aids.0000238406.93249.cd.
   Schiffer JT, 2007, JAIDS-J ACQ IMM DEF, V44, P229, DOI 10.1097/QAI.0b013e31802e2975.
   Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782.
   Zachariah R, 2006, AIDS, V20, P2355, DOI 10.1097/QAD.0b013e32801086b0.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{JAIDS}},
Doc-Delivery-Number = {{206RZ}},
Unique-ID = {{ISI:000249201900019}},
}

@article{ ISI:000249201900020,
Author = {Schiffer, Joshua T. and Sterling, Timothy R.},
Title = {{Optimum time to initiate antiretroviral therapy in patients with
   HIV-associated tuberculosis - There may be more than one right answer -
   Reply}},
Journal = {{JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES}},
Year = {{2007}},
Volume = {{46}},
Number = {{1}},
Pages = {{123}},
Month = {{SEP 1}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Schiffer, JT (Reprint Author), Univ Washington, Dept Med, Div Infect Dis, Seattle, WA 98195 USA.
   Univ Washington, Dept Med, Div Infect Dis, Seattle, WA 98195 USA.
   Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
   Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, Nashville, TN USA.
   Vanderbilt Univ, Med Ctr, Dept Med, Ctr Hlth Serv Res, Nashville, TN USA.}},
ISSN = {{1525-4135}},
Keywords-Plus = {{IMMUNE RECONSTITUTION DISEASE}},
Research-Areas = {{Immunology; Infectious Diseases}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases}},
Cited-References = {{BRESS JN, 2007, AM J MED, V120, P461.
   BURMAN W, 2005, 43 ANN M INF DIS SOC.
   Lawn SD, 2005, LANCET INFECT DIS, V5, P361, DOI 10.1016/S1473-3099(05)70140-7.
   Lawn SD, 2007, AIDS, V21, P335, DOI 10.1097/QAD.0b013e328011efac.
   Schiffer JT, 2007, JAIDS-J ACQ IMM DEF, V44, P229, DOI 10.1097/QAI.0b013e31802e2975.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{JAIDS}},
Doc-Delivery-Number = {{206RZ}},
Unique-ID = {{ISI:000249201900020}},
}

@article{ ISI:000250116000011,
Author = {Berkia, I. and El Kharras, A. and Darbi, A. and Chaouir, S. and Amil, T.
   and Benameur, M. and Bassou, D.},
Title = {{Primary tuberculosis of the mandible: a case report}},
Journal = {{JOURNAL DE RADIOLOGIE}},
Year = {{2007}},
Volume = {{88}},
Number = {{9, 1}},
Pages = {{1193-1195}},
Month = {{SEP}},
Publisher = {{MASSON EDITEUR}},
Address = {{21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{El Kharras, A (Reprint Author), A El Kharras, ALEM, Im A7,Appt 15 Almenzeh, Rabat, Morocco.
   A El Kharras, ALEM, Rabat, Morocco.
   Hop Miltaire Instruct Mohamed, Serv Imargie Med, Rabat, Morocco.}},
DOI = {{10.1016/S0221-0363(07)89933-1}},
ISSN = {{0221-0363}},
Keywords = {{mandible; osteomyelitis; tuberculosis; radiology}},
Keywords-Plus = {{OSTEOMYELITIS; CHILD}},
Research-Areas = {{Radiology, Nuclear Medicine \& Medical Imaging}},
Web-of-Science-Categories  = {{Radiology, Nuclear Medicine \& Medical Imaging}},
Author-Email = {{aelkharras@yahoo.fr}},
Cited-References = {{Bhatt A P, 2001, Int J Paediatr Dent, V11, P304, DOI 10.1046/j.1365-263X.2001.00276.x.
   Boussel L, 2002, J RADIOL, V83, P1025.
   Chan ED, 2002, BRIT MED J, V325, P1282, DOI 10.1136/bmj.325.7375.1282.
   Chateil JF, 2005, J RADIOL, V86, P453, DOI 10.1016/S0221-0363(05)81388-5.
   Chaudhary S, 2004, ORAL SURG ORAL MED O, V97, P603, DOI 10.1016/j.tripleo.2003.10.032.
   Dimitrakopoulos I, 2005, J ORAL MAXIL SURG, V63, P1227, DOI 10.1016/j.joms.2005.04.009.
   DIMITRAKOPOULOS I, 1991, ORAL SURG ORAL MED O, V72, P712, DOI 10.1016/0030-4220(91)90017-7.
   Erasmus JH, 1998, J ORAL MAXIL SURG, V56, P1355, DOI 10.1016/S0278-2391(98)90623-1.
   FUKUDA J, 1992, ORAL SURG ORAL MED O, V73, P278, DOI 10.1016/0030-4220(92)90120-F.
   HENEY C, 1988, PEDIATR INFECT DIS J, V7, P74, DOI 10.1097/00006454-198801000-00021.
   Imamura M, 2004, PEDIATR INT, V46, P736, DOI 10.1111/j.1442-200x.2004.01992.x.
   Kothari P, 1998, J LARYNGOL OTOL, V112, P585.
   Lee K C, 1995, Ear Nose Throat J, V74, P395.
   Mooney R, 1998, BRIT J RADIOL, V71, P852.
   N'Golet A, 2007, REV STOMATOL CHIR, V108, P65, DOI 10.1016/j.stomax.2005.11.002.
   Paradisi F, 1999, BEST PRACT RES CL RH, V13, P163, DOI 10.1053/berh.1999.0012.
   Wang MNH, 1999, J PEDIATR ORTHOPED, V19, P151, DOI 10.1097/00004694-199903000-00003.
   WOOD R E, 1987, Pediatric Dentistry, V9, P317.
   Wu Hang, 1998, Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, V85, P243, DOI 10.1016/S1079-2104(98)90001-4.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Radiol.}},
Doc-Delivery-Number = {{219VJ}},
Unique-ID = {{ISI:000250116000011}},
}

@article{ ISI:000250312000011,
Author = {Veeser, Peggy Ingram and Smith, Phillip Karl and Handy, Barry and
   Martin, Sharon R.},
Title = {{Tuberculosis screening on a health science campus: Use of QuantiFERON-TB
   gold test for students and employees}},
Journal = {{JOURNAL OF AMERICAN COLLEGE HEALTH}},
Year = {{2007}},
Volume = {{56}},
Number = {{2}},
Pages = {{175-180}},
Month = {{SEP-OCT}},
Abstract = {{Detecting and managing Mycobacterium tuberculosis (TB) infection in a
   health-science center population is a clinical dilemma. Tuberculin skin
   tests are still the preferred method for detecting present or past
   infection of TB. The authors discuss the performance of whole blood
   interferon gamma release assay test commercially known as QuantiFERON-TB
   Gold Test (QFT-G) as an additional tool for a TB surveillance program
   for the students and employees at an academic medical center. QFT-G was
   successfully implemented as a confirmatory test for screening of TB
   infection.}},
Publisher = {{HELDREF PUBLICATIONS}},
Address = {{1319 EIGHTEENTH ST NW, WASHINGTON, DC 20036-1802 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Veeser, PI (Reprint Author), Univ Tennessee, Ctr Hlth Sci, Univ Hlth Serv, Memphis, TN 38163 USA.
   Univ Tennessee, Ctr Hlth Sci, Univ Hlth Serv, Memphis, TN 38163 USA.}},
DOI = {{10.3200/JACH.56.2.175-180}},
ISSN = {{0744-8481}},
Keywords = {{college health; health science students; QuantiFERON-TB Gold; TB
   screening}},
Keywords-Plus = {{INTERFERON-GAMMA ASSAY; MYCOBACTERIUM-TUBERCULOSIS; SKIN-TEST;
   INFECTION; DIAGNOSIS}},
Research-Areas = {{Education \& Educational Research; Public, Environmental \& Occupational
   Health}},
Web-of-Science-Categories  = {{Education \& Educational Research; Public, Environmental \& Occupational
   Health}},
Author-Email = {{pveeser@utmem.edu}},
Cited-References = {{ATKIN S, 2003, EMERG MED.
   Britton WJ, 2005, TUBERCULOSIS, V85, P137, DOI 10.1016/j.tube.2004.06.003.
   Centers for Disease Control and Prevention, 2005, MMWR MORB MORTAL WKL, V54.
   {*}CDCP, QUANTIFERONTB GOLD T.
   {*}CTR MED MED SERV, 2003, EXTR SUMM SYST BESS.
   Dewan PK, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-47.
   Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376.
   Ferrara G, 2005, AM J RESP CRIT CARE, V172, P631, DOI 10.1164/rccm.200502-196OC.
   Fietta A, 2003, AM J INFECT CONTROL, V31, P347, DOI 10.1067/mic.2003.40.
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968.
   Kang YA, 2005, JAMA-J AM MED ASSOC, V293, P2756, DOI 10.1001/jama.293.22.2756.
   Mazurek Gerald H., 2005, Morbidity and Mortality Weekly Report, V54, P49.
   Mazurek Gerald H, 2003, MMWR Recomm Rep, V52, P15.
   Mazurek GH, 2001, JAMA-J AM MED ASSOC, V286, P1740, DOI 10.1001/jama.286.14.1740.
   MITCHELL D, 2006, BUSINESS CASE ANAL Q.
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC.
   Taggart EW, 2004, CLIN DIAGN LAB IMMUN, V11, P1089, DOI 10.1128/CDLI.11.6.1089-1093.2004.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{J. Am. Coll. Health}},
Doc-Delivery-Number = {{222QM}},
Unique-ID = {{ISI:000250312000011}},
}

@article{ ISI:000249882200030,
Author = {Aragon, Lina Marcela and Garrigo, Montserrat and Moreno, Carmen and
   Espanol, Montserrat and Coll, Pere},
Title = {{Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB
   PZA for testing Mycobacterium tuberculosis susceptibility to
   pyrazinamide}},
Journal = {{JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY}},
Year = {{2007}},
Volume = {{60}},
Number = {{3}},
Pages = {{655-657}},
Month = {{SEP}},
Abstract = {{Objectives: To compare the performance of the BacT/ALERT PZA kit
   (BioMerieux, Marcy l'Etoile, France) with the radiometric BACTEC 460TB
   PZA test (Becton-Dickinson method) for testing Mycobacterium
   tuberculosis susceptibility to pyrazinamide.
   Methods: A total of 50 M. tuberculosis strains were tested. Thirty of
   these strains had been previously considered pyrazinamide-susceptible
   and 20 pyrazinamide-resistant by BACTEC 460TB.
   Results: Final overall agreement was 100\%. Time needed for the
   susceptibility test was 6.69 days for the BacT/ALERT PZA kit versus 8.07
   days for the BACTEC 460TB PZA test.
   Conclusions: BacT/ALERT PZA test is an excellent alternative to BACTEC
   460TB for pyrazinamide susceptibility testing.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{Rumanian}},
Affiliation = {{Coll, P (Reprint Author), Hosp Santa Creu \& Sant Pau, Microbiol Serv, Av St Antoni Ma Claret,167, E-08025 Barcelona, Spain.
   Hosp Santa Creu \& Sant Pau, Microbiol Serv, E-08025 Barcelona, Spain.
   Univ Autonoma Barcelona, Dept Genet \& Microbiol, E-08193 Cerdanyola del Valles, Spain.}},
DOI = {{10.1093/jac/dkm252}},
ISSN = {{0305-7453}},
Keywords = {{susceptibility testing; resistance; tuberculosis}},
Keywords-Plus = {{MB/BACT SYSTEM}},
Research-Areas = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Author-Email = {{pcoll@santpau.es}},
ResearcherID-Numbers = {{Coll, Pere/A-1959-2009}},
Cited-References = {{Barco P, 2006, J ANTIMICROB CHEMOTH, V58, P930, DOI 10.1093/jac/dkl363.
   Barreto AMW, 2003, MEM I OSWALDO CRUZ, V98, P827, DOI 10.1590/S0074-02762003000600020.
   Bemer P, 2004, J CLIN MICROBIOL, V42, P1030, DOI 10.1128/JCM.42.3.1030-1034.2004.
   {*}NAT COMM CLIN LAB, 2004, M24A NCCLS.
   Siddiqi SH, 1995, BACTEC 460 TB SYSTEM.
   SINGH P, 2006, J CLIN MICROBIOL, V45, P76.
   SOMOSKOVI A, 2006, J CLIN MICROBIOL, V45, P595.
   Zhang Y, 2003, INT J TUBERC LUNG D, V7, P6.}},
Number-of-Cited-References = {{8}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Antimicrob. Chemother.}},
Doc-Delivery-Number = {{216MN}},
Unique-ID = {{ISI:000249882200030}},
}

@article{ ISI:000249041100015,
Author = {Pang, Xiuhua and Howard, Susan T.},
Title = {{Regulation of the alpha-crystallin gene acr2 by the MprAB two-component
   system of Mycobacterium tuberculosis}},
Journal = {{JOURNAL OF BACTERIOLOGY}},
Year = {{2007}},
Volume = {{189}},
Number = {{17}},
Pages = {{6213-6221}},
Month = {{SEP}},
Abstract = {{Coordinated regulation of molecular chaperones is an important feature
   of the bacterial stress response. The small molecular chaperone gene
   acr2 of Mycobacterium tuberculosis is activated by exposure to several
   stresses, including heat and the detergent sodium dodecyl sulfate (SDS).
   In this study, we show that acr2 is directly regulated by the MprAB
   two-component system, and that MprAB has both positive and negative
   effects on acr2 expression. mRNA analyses showed that acr2 expression
   levels were lower under SDS stress and control conditions but higher
   under heat shock in an mprAB deletion mutant than they were in the
   parental strain. Parental expression patterns were restored in an
   mprAB-complemented strain. Western blotting using an anti-Acr2 antibody
   showed that Acr2 protein synthesis correlated with mRNA levels. Primer
   extension identified one transcriptional start point (TSP) for acr2 in
   all three strains under control and stress conditions. Electrophoresis
   mobility shift assays revealed multiple MprA binding sites in the acr2
   promoter, including one downstream and three upstream of the acr2 TSP,
   with one overlapping the binding sites predicted for SigE, SigH, and
   HspR. DNA footprinting confirmed that MprA protected large sections of
   the acr2 promoter region. Expression of several housekeeping genes under
   SDS stress also was evaluated, revealing the upregulation of large
   molecular chaperone genes and, unexpectedly, sigA, with slightly lower
   sigA mRNA levels detected in the mprAB deletion mutant than in the wild
   type. In contrast to Acr2, SigA protein synthesis did not correlate with
   mRNA expression. Overall, the data indicated that MprA has complex
   interactions with the acr2 promoter and indirect effects on major
   housekeeping genes.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Howard, ST (Reprint Author), Univ Texas Hlth Ctr, CPIDC, Dept Microbiol \& Immunol, BMR D617,11937 US Highway 271, Tyler, TX 75708 USA.
   Univ Texas Hlth Ctr, CPIDC, Dept Microbiol \& Immunol, Tyler, TX 75708 USA.}},
DOI = {{10.1128/JB.00492-07}},
ISSN = {{0021-9193}},
EISSN = {{1098-5530}},
Keywords-Plus = {{HEAT-SHOCK PROTEINS; SIGNAL-TRANSDUCTION SYSTEM; RIBOSOME-ASSOCIATED
   PROTEIN; ENVELOPE-STRESS-RESPONSE; BACILLUS-CALMETTE-GUERIN;
   SIGMA-FACTOR; STREPTOMYCES-COELICOLOR; HYPOXIC RESPONSE; FUNCTIONAL
   SIMILARITIES; CELL-ENVELOPE}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{susan.howard@uthct.edu}},
ORCID-Numbers = {{Howard, Susan/0000-0003-1376-5451}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}R21 AI063229, R21 AI063229-01]}},
Cited-References = {{Alba BM, 2004, MOL MICROBIOL, V52, P613, DOI 10.1111/j.1365-2958.2003.03982.x.
   Beggs ML, 1996, GENE, V174, P285, DOI 10.1016/0378-1119(96)00037-6.
   BUCCA G, 1995, MOL MICROBIOL, V17, P663, DOI 10.1111/j.1365-2958.1995.mmi\_17040663.x.
   Bucca G, 1997, J BACTERIOL, V179, P5999.
   Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161.
   Chang ZY, 1996, J BIOL CHEM, V271, P7218.
   Cole ST, 1998, NATURE, V393, P537.
   Dannenberg Arthur M. Jr., 1994, P459.
   Fernandes ND, 1999, J BACTERIOL, V181, P4266.
   Florczyk MA, 2003, INFECT IMMUN, V71, P5332, DOI 10.1128/IAI.71.9.5332-5343.2003.
   Gomez M, 1998, MOL MICROBIOL, V29, P617, DOI 10.1046/j.1365-2958.1998.00960.x.
   Gomez M, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P111.
   He HJ, 2006, J BACTERIOL, V188, P2134, DOI 10.1128/JB.188.6.2134-2143.2006.
   He HJ, 2005, J BACTERIOL, V187, P202, DOI 10.1128/JB.187.1.202-212.2005.
   Hong HJ, 2002, MOL MICROBIOL, V44, P1199, DOI 10.1046/j.1365-2958.2002.02960.x.
   HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449.
   Howard ST, 2000, MICROBES INFECT, V2, P1845, DOI 10.1016/S1286-4579(00)01338-1.
   Hu Yanmin, 1999, Journal of Bacteriology, V181, P469.
   Hu YM, 2006, INFECT IMMUN, V74, P861, DOI 10.1128/IAI.74.2.861-868.2006.
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0.
   Manganelli R, 2002, MOL MICROBIOL, V45, P365, DOI 10.1046/j.1365-2958.2002.03005.x.
   Manganelli R, 1999, MOL MICROBIOL, V31, P715, DOI 10.1046/j.1365-2958.1999.01212.x.
   Manganelli R, 2001, MOL MICROBIOL, V41, P423, DOI 10.1046/j.1365-2958.2001.02525.x.
   Mascher T, 2004, ANTIMICROB AGENTS CH, V48, P2888, DOI 10.1128/AAC.48.8.2888-2896.2004.
   MECSAS J, 1993, GENE DEV, V7, P2618, DOI 10.1101/gad.7.12b.2618.
   MERCK KB, 1993, J BIOL CHEM, V268, P1046.
   Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002.
   O'Toole R, 2003, J BACTERIOL, V185, P1543, DOI 10.1128/JB.185.5.1543-1554.2003.
   Ohara N, 1997, J BACTERIOL, V179, P6495.
   Pang XH, 2007, MICROBIOL-SGM, V153, P1229, DOI 10.1099/mic.0.29281-0.
   Park HD, 2003, MOL MICROBIOL, V48, P833, DOI 10.1046/j.1365-2958.2003.03474.x.
   Qamra R, 2005, TUBERCULOSIS, V85, P385, DOI 10.1016/j.tube.2005.08.014.
   Raman S, 2001, J BACTERIOL, V183, P6119, DOI 10.1128/JB.183.20.6119-6125.2001.
   Rison SCG, 2005, MYCOBACTERIUM MOL MI.
   Roberts DM, 2004, J BIOL CHEM, V279, P23082, DOI 10.1074/jbc.M401230200.
   Ruiz N, 2005, CURR OPIN MICROBIOL, V8, P122, DOI 10.1016/j.mib.2005.02.013.
   Samten B, 2003, J IMMUNOL, V170, P3180.
   Samten B, 2002, J IMMUNOL, V168, P3520.
   Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846.
   Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498.
   Solano-Serena F, 2000, APPL ENVIRON MICROB, V66, P2392, DOI 10.1128/AEM.66.6.2392-2399.2000.
   Stewart GR, 2005, MOL MICROBIOL, V55, P1127, DOI 10.1111/j.1365-2958.2004.04450.x.
   Stewart GR, 2002, MICROBIOL-SGM, V148, P3129.
   Stewart GR, 2001, NAT MED, V7, P732, DOI 10.1038/89113.
   STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054.
   Sun RG, 2004, MOL MICROBIOL, V52, P25, DOI 10.1111/j.1365-2958.2003.03958.x.
   Tabira Y, 2000, MICROB PATHOGENESIS, V29, P213, DOI 10.1006/mpat.2000.0384.
   Talaat AM, 2004, P NATL ACAD SCI USA, V101, P4602, DOI 10.1073/pnas.0306023101.
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498.
   Valdez MM, 2002, EUR J BIOCHEM, V269, P1806, DOI 10.1046/j.1432-1033.2002.02812.x.
   VERBON A, 1992, J BACTERIOL, V174, P1352.
   Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205.
   Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4.
   Walters SB, 2006, MOL MICROBIOL, V60, P312, DOI 10.1111/j.1365-2958.2006.05102.x.
   Wilkinson KA, 2005, J IMMUNOL, V174, P4237.
   Wu QL, 1997, J BACTERIOL, V179, P2922.
   Wu SP, 2004, MOL MICROBIOL, V51, P1551, DOI 10.1111/j.1365-2958.2003.03922.x.
   Yuan Ying, 1996, Journal of Bacteriology, V178, P4484.
   Zahrt TC, 2003, INFECT IMMUN, V71, P6962, DOI 10.1128/IAI.71.12.6962-6970.2003.
   Zahrt TC, 2001, P NATL ACAD SCI USA, V98, P12706, DOI 10.1073/pnas.221272198.}},
Number-of-Cited-References = {{60}},
Times-Cited = {{21}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Bacteriol.}},
Doc-Delivery-Number = {{204JY}},
Unique-ID = {{ISI:000249041100015}},
}

@article{ ISI:000249041100018,
Author = {de Mendonqa, Jordana Dutra and Ely, Fernanda and Palma, Mario Sergio and
   Frazzon, Jeverson and Basso, Luiz Augusto and Santos, Digenes Santiago},
Title = {{Functional characterization by genetic complementation of aroB-Encoded
   dehydroquinate synthase from Mycobactetium tuberculosis H37Rv and its
   heterologous expression and purification}},
Journal = {{JOURNAL OF BACTERIOLOGY}},
Year = {{2007}},
Volume = {{189}},
Number = {{17}},
Pages = {{6246-6252}},
Month = {{SEP}},
Abstract = {{The recent recrudescence of Mycobacterium tuberculosis infection and the
   emergence of multidrug-resistant strains have created an urgent need for
   new therapeutics against tuberculosis. The enzymes of the shikimate
   pathway are attractive drug targets because this route is absent in
   mammals and, in M. tuberculosis, it is essential for pathogen viability.
   This pathway leads to the biosynthesis of aromatic compounds, including
   aromatic amino acids, and it is found in plants, fungi, bacteria, and
   apicomplexan parasites. The aroB-encoded enzyme dehydroquinate synthase
   is the second enzyme of this pathway, and it catalyzes the cyclization
   of 3-deoxy-D-arabino-heptulosonate-7-phosphate in 3-dehydroquinate. Here
   we describe the PCR amplification and cloning of the aroB gene and the
   overexpression and purification of its product, dehydroquinate synthase,
   to homogeneity. In order to probe where the recombinant dehydroquinate
   synthase was active, genetic complementation studies were performed. The
   Escherichia coli AB2847 mutant was used to demonstrate that the plasmid
   construction was able to repair the mutants, allowing them to grow in
   minimal medium devoid of aromatic compound supplementation. In addition,
   homogeneous recombinant M. tuberculosis dehydroquinate synthase was
   active in the absence of other enzymes, showing that it is homomeric.
   These results will support the structural studies with M. tuberculosis
   dehydroquinate synthase that are essential for the rational design of
   antimycobacterial agents.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Santos, DS (Reprint Author), Pontificia Univ Catoloica do Rio Grande do Sul, Ctr Pesquisas Biol Mol \& Func, Av Ipiranga 6681,Tecn Predio 92A, BR-90619900 Porto Alegre, RS, Brazil.
   Pontificia Univ Catoloica do Rio Grande do Sul, Ctr Pesquisas Biol Mol \& Func, BR-90619900 Porto Alegre, RS, Brazil.
   Univ Estadual Paulista, Inst Biociencias, Dept Biol, Ctr Estudos Insetos Sociais,Lab Biol Estrutural \&, BR-13506900 Sao Paulo, Brazil.
   Univ Fed Rio Grande do Sul, Ctr Biotechnol, BR-91501970 Porto Alegre, RS, Brazil.}},
DOI = {{10.1128/JB.00425-07}},
ISSN = {{0021-9193}},
EISSN = {{1098-5530}},
Keywords-Plus = {{PURINE NUCLEOSIDE PHOSPHORYLASE; SHIKIMATE PATHWAY; 3-DEHYDROQUINATE
   SYNTHASE; INORGANIC-PHOSPHATE; ESCHERICHIA-COLI; ENZYME; CLONING;
   PROTEIN; OVEREXPRESSION; CATIONS}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{diogenes@pucrs.br}},
ResearcherID-Numbers = {{Santos, Diogenes/A-6647-2008
   Frazzon, Jeverson/L-6402-2013
   Palma, Mario/E-7800-2012
   Ely, Fernanda/C-9676-2017}},
ORCID-Numbers = {{Santos, Diogenes/0000-0003-4971-463X
   Palma, Mario/0000-0002-7363-8211
   Ely, Fernanda/0000-0002-2866-5704}},
Cited-References = {{Basso LA, 2005, MEM I OSWALDO CRUZ, V100, P575, DOI 10.1590/S0074-02762005000600001.
   Basso LA, 2005, MED CHEM REV ONLINE, V2, P393, DOI 10.2174/156720305774330458.
   BENDER SL, 1989, BIOCHEMISTRY-US, V28, P7555, DOI 10.1021/bi00445a009.
   BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615.
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999.
   Centers for Disease Control and Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P301.
   Chapman T, 2005, NATURE, V434, P795, DOI 10.1038/434795b.
   Chassaigne H, 1998, ANALYST, V123, P2125, DOI 10.1039/a804713h.
   Cole ST, 1998, NATURE, V393, P537.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   DAVIS BD, 1950, J BACTERIOL, V60, P17.
   Dorman SE, 2007, NAT MED, V13, P295, DOI 10.1038/nm0307-295.
   Ducati RG, 2007, CURR DRUG TARGETS, V8, P423, DOI 10.2174/138945007780059004.
   Ducati RG, 2006, MEM I OSWALDO CRUZ, V101, P697, DOI 10.1590/S0074-02762006000700001.
   DUNCAN K, 1987, BIOCHEM J, V246, P375.
   FROST JW, 1984, BIOCHEMISTRY-US, V23, P4470, DOI 10.1021/bi00314a036.
   GAERTNER FH, 1977, BIOCHEM BIOPH RES CO, V75, P259, DOI 10.1016/0006-291X(77)91037-3.
   GARBE T, 1991, MOL GEN GENET, V228, P385.
   Grossman TH, 1998, GENE, V209, P95, DOI 10.1016/S0378-1119(98)00020-1.
   HASAN N, 1978, J BIOL CHEM, V253, P4999.
   HAWKINS AR, 1993, J GEN MICROBIOL, V139, P2891.
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0.
   LAMBERT JM, 1985, BIOCHEM J, V226, P817.
   Magalhaes MLB, 2002, PROTEIN EXPRES PURIF, V26, P59, DOI 10.1016/S1046-5928(02)00509-0.
   Moore JD, 1998, J AM CHEM SOC, V120, P7105, DOI 10.1021/ja974220x.
   Nichols CE, 2004, J MOL BIOL, V343, P533, DOI 10.1016/j.jmb.2004.08.039.
   Nixon AE, 1998, ANAL BIOCHEM, V265, P299, DOI 10.1006/abio.1998.2916.
   Oliveira JS, 2001, PROTEIN EXPRES PURIF, V22, P430, DOI 10.1006/prep.2001.1457.
   Oliveira JS, 2003, PROTEIN EXPRES PURIF, V28, P287, DOI 10.1016/S1046-5928(02)00708-8.
   Parish T, 2002, MICROBIOL-SGM, V148, P3069.
   POMP D, 1991, BIOTECHNIQUES, V10, P58.
   Rizzi C, 2005, PROTEIN EXPRES PURIF, V40, P23, DOI 10.1016/j.pep.2004.06.040.
   Silva RG, 2003, PROTEIN EXPRES PURIF, V27, P158, DOI 10.1016/S1046-5928(02)00602-2.
   SRINIVASAN PR, 1963, J BIOL CHEM, V238, P3176.
   VANDENHOMBERGH JPTW, 1992, BIOCHEM J, V284, P861.
   Vincentelli R, 2003, ACCOUNTS CHEM RES, V36, P165, DOI 10.1021/ar010130s.
   WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.
   WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266.}},
Number-of-Cited-References = {{39}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{J. Bacteriol.}},
Doc-Delivery-Number = {{204JY}},
Unique-ID = {{ISI:000249041100018}},
}

@article{ ISI:000249506900008,
Author = {Sekiguchi, Jun-Ichiro and Nakamura, Tomohiko and Miyoshi-Akiyama, Tohru
   and Kirikae, Fumiko and Kobayashi, Intetsu and Augustynowicz-Kopec, Ewa
   and Zwolska, Zofia and Morita, Koji and Suetake, Toshinori and Yoshida,
   Hiroshi and Kato, Seiya and Mori, Toru and Kirikae, Teruo},
Title = {{Development and evaluation of a line probe assay for rapid
   identification of pncA mutations in pyrazinamide-resistant Mycobacterium
   tuberculosis strains}},
Journal = {{JOURNAL OF CLINICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{45}},
Number = {{9}},
Pages = {{2802-2807}},
Month = {{SEP}},
Abstract = {{Resistance of Mycobacterium tuberculosis to pyrazinamide (PZA) derives
   mainly from mutations in the pnc,4 gene. We developed a reverse
   hybridization-based line probe assay with oligonucleotide probes
   designed to detect mutations in pnc,4. The detection of PZA resistance
   was evaluated in 258 clinical isolates of M. tuberculosis. The
   sensitivity and specificity of PZA resistance obtained by this new assay
   were both 100\%, consistent with the results of conventional PZA
   susceptibility testing. This assay can be used with sputa from
   tuberculosis patients. It appears to be reliable and widely applicable
   and, given its simplicity and rapid performance, will be a valuable tool
   for diagnostic use.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kirikae, T (Reprint Author), Int Med Ctr Japan, Dept Infect Dis, Res Inst, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.
   Int Med Ctr Japan, Dept Infect Dis, Res Inst, Shinjuku Ku, Tokyo 1628655, Japan.
   Nipro Corp, Res \& Dev Lab, Dept 3, Shiga 5250055, Japan.
   Mitsubishi Chem Med Corp, Itabashi Ku, Tokyo 1748555, Japan.
   Natl Res Inst TB \& Lung Dis, PL-01138 Warsaw, Poland.
   Kyorin Univ, Sch Hlth Sci, Dept Microbiol, Tokyo 1928508, Japan.
   Japan Anti TB Assoc, Res Inst TB, Tokyo 2048533, Japan.
   Natl Inst Infect Dis, Leprosy Res Ctr, Tokyo 1890002, Japan.}},
DOI = {{10.1128/JCM.00352-07}},
ISSN = {{0095-1137}},
Keywords-Plus = {{SUSCEPTIBILITY; RIFAMPIN; SYSTEM}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{tkirikae@ri.imcj.go.jp}},
Cited-References = {{Beenhouwer H, 1995, TUBERCLE LUNG DIS, V76, P425.
   Bemer P, 2004, J CLIN MICROBIOL, V42, P1030, DOI 10.1128/JCM.42.3.1030-1034.2004.
   BENJAMIN BD, 2004, NUCLEIC ACIDS RES, V32, pE176.
   BUMJOON K, 2001, J CLIN MICROBIOL, V39, P2610.
   Clinical and Laboratory Standards Institute, 2000, Document M24-T2.
   HEIFETS L, 1992, AM REV RESPIR DIS, V145, P1223.
   KONNO K, 1967, AM REV RESPIR DIS, V95, P461.
   Marttila HJ, 1999, SCAND J INFECT DIS, V31, P269.
   MCDERMOTT W, 1954, AM REV TUBERC PULM, V70, P748.
   MITCHISON DA, 1985, TUBERCLE, V66, P219, DOI 10.1016/0041-3879(85)90040-6.
   Morlock GP, 2000, ANTIMICROB AGENTS CH, V44, P2291, DOI 10.1128/AAC.44.9.2291-2295.2000.
   Otsuka Y, 2004, J CLIN MICROBIOL, V42, P3538, DOI 10.1128/JCM.42.8.3538-3548.2004.
   Pfyffer GE, 2002, J CLIN MICROBIOL, V40, P1670, DOI 10.1128/JCM.40.5.1670-1674.2002.
   Rossau R, 1997, ANTIMICROB AGENTS CH, V41, P2093.
   SALFINGER M, 1994, EUR J CLIN MICROBIOL, V13, P961, DOI 10.1007/BF02111498.
   Scorpio A, 1996, NAT MED, V2, P662, DOI 10.1038/nm0696-662.
   Scorpio A, 1997, ANTIMICROB AGENTS CH, V41, P540.
   Sekiguchi J, 2007, J CLIN MICROBIOL, V45, P179, DOI 10.1128/JCM.00750-06.
   SNIDER DE, 1982, AM REV RESPIR DIS, V125, P265.
   WAYNE LG, 1974, AM REV RESPIR DIS, V109, P147.
   Zhang Y, 2003, INT J TUBERC LUNG D, V7, P6.
   Zhang Y, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P235.}},
Number-of-Cited-References = {{22}},
Times-Cited = {{33}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{J. Clin. Microbiol.}},
Doc-Delivery-Number = {{211EK}},
Unique-ID = {{ISI:000249506900008}},
}

@article{ ISI:000249506900055,
Author = {Soudani, Alya and Hadjfredj, Sondess and Zribi, Meriem and Masmoudi,
   Afef and Messaoud, Taieb and Tiouri, Hanene and Fendri, Chedlia},
Title = {{Characterization of tunisian Mycobacterium tuberculosis
   rifampin-resistant clinical isolates}},
Journal = {{JOURNAL OF CLINICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{45}},
Number = {{9}},
Pages = {{3095-3097}},
Month = {{SEP}},
Abstract = {{Analysis of the gene encoding the P-subunit of Mycobacterium
   tuberculosis RNA polymerase (rpoB) has demonstrated a small region that
   harbors the mutations most frequently associated with rifampin
   resistance. In this study, we determined the occurrence of rifampin
   resistance in 544 Tunisian clinical M. tuberculosis strains isolated in
   a university hospital between 2004 and 2006 by using the
   standard-proportion agar method, the INNO-LiPA Rif.TB assay, and DNA
   sequencing.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Soudani, A (Reprint Author), Rabta Univ Hosp, Bacteriol Lab, 1007 E1 Jabbary, Tunis, Tunisia.
   Rabta Univ Hosp, Bacteriol Lab, Tunis, Tunisia.
   Childrens Hosp, Biochem \& Mol Lab, Tunis, Tunisia.
   Rabta Univ Hosp, Infect Dis Unit, Tunis, Tunisia.}},
DOI = {{10.1128/JCM.00643-07}},
ISSN = {{0095-1137}},
Keywords-Plus = {{LINE PROBE ASSAY; STRAND CONFORMATION POLYMORPHISM;
   POLYMERASE-CHAIN-REACTION; NEW-YORK-CITY; RPOB GENE; DRUG-RESISTANCE;
   RAPID DETECTION; MOLECULAR CHARACTERIZATION; MUTATIONS; STRAINS}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{alya\_soudani@yahoo.fr}},
Cited-References = {{Bobadilla-del-Valle M, 2001, EMERG INFECT DIS, V7, P1010.
   CANETTI G, 1963, B WORLD HEALTH ORGAN, V29, P565.
   CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21.
   Cooksey RC, 1997, J CLIN MICROBIOL, V35, P1281.
   DEBEENHOUWER H, 1995, TUBERCLE LUNG DIS, V76, P425, DOI 10.1016/0962-8479(95)90009-8.
   FELMLEE TA, 1995, J CLIN MICROBIOL, V33, P1617.
   Hirano K, 1999, J CLIN MICROBIOL, V37, P2663.
   Hwang HY, 2003, J MED MICROBIOL, V52, P239, DOI 10.1099/jmm.0.05045-0.
   KAPUR V, 1994, J CLIN MICROBIOL, V32, P1095.
   Mani C, 2001, J CLIN MICROBIOL, V39, P2987, DOI 10.1128/JCM.39.8.2987-2990.2001.
   Matsiota-Bernard P, 1998, J CLIN MICROBIOL, V36, P20.
   {*}MIN PUBL HLTH, 2004, DIRE SOINS SANT BAS.
   Mitchison DA, 1998, INT J TUBERC LUNG D, V2, P10.
   Ohno H, 1996, ANTIMICROB AGENTS CH, V40, P1053.
   Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301.
   Ramaswamy SV, 2004, J MED MICROBIOL, V53, P107, DOI 10.1099/jmm.0.05343-0.
   Rattan A, 1998, EMERG INFECT DIS, V4, P195.
   Ridzon R, 1998, AM J RESP CRIT CARE, V157, P1881.
   Rossau R, 1997, ANTIMICROB AGENTS CH, V41, P2093.
   Sajduda A, 2004, J CLIN MICROBIOL, V42, P2425, DOI 10.1128/JCM.42.6.2425-2431.2004.
   Saribas Z, 2003, J CLIN MICROBIOL, V41, P816, DOI 10.1128/JCM.41.2.816-818.2003.
   Siddiqi N, 2002, ANTIMICROB AGENTS CH, V46, P443, DOI 10.1128/AAC.46.2.443-450.2002.
   TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F.
   TELENTI A, 1993, ANTIMICROB AGENTS CH, V37, P2054.
   Toungoussova OS, 2004, EUR J CLIN MICROBIOL, V23, P174, DOI 10.1007/s10096-003-1080-6.
   Tracevska T, 2002, J CLIN MICROBIOL, V40, P3789, DOI 10.1128/JCM.40.10.3789-3792.2002.
   Traore H, 2000, INT J TUBERC LUNG D, V4, P481.
   WILLIAMS DL, 1994, ANTIMICROB AGENTS CH, V38, P2380.
   Yue J, 2003, J CLIN MICROBIOL, V41, P2209, DOI 10.1128/JCM.41.5.2209-2212.2003.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Clin. Microbiol.}},
Doc-Delivery-Number = {{211EK}},
Unique-ID = {{ISI:000249506900055}},
}

@article{ ISI:000249506900060,
Author = {Quezada, Cindy Maria and Kamanzi, Eliane and Mukamutara, Julienne and De
   Rijk, Pim and Rigouts, Leen and Portaels, Francoise and Ben Amor, Yanis},
Title = {{Implementation validation performed in Rwanda to determine whether the
   INNO-LiPA Rif.TB, line probe assay can be used for detection of
   multidrug-resistant Mycobacterium tuberculosis in low-resource countries}},
Journal = {{JOURNAL OF CLINICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{45}},
Number = {{9}},
Pages = {{3111-3114}},
Month = {{SEP}},
Abstract = {{We validated the implementation of the INNO-LiPA Rif.TB line probe
   assay, a diagnostic test for rapid detection of multidrug-resistant
   tuberculosis (MDR-TB), in Rwanda. No substantial difference was found
   between results obtained in Rwanda and results obtained in Belgium with
   the same samples. This rapid diagnostic test for MDR-TB can therefore be
   reliably implemented in a resource-poor setting.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ben Amor, Y (Reprint Author), Columbia Univ, Earth Inst, Hogan Hall B-19,Mail Code 3277,2910 Broadway, New York, NY 10025 USA.
   Columbia Univ, Earth Inst, New York, NY 10025 USA.
   Rockefeller Univ, Lab Struct Microbiol, New York, NY 10021 USA.
   Univ Hosp Butare, Butare, Rwanda.
   Inst Trop Med, Dept Microbiol, Mycobacteriol Unit, B-2000 Antwerp, Belgium.}},
DOI = {{10.1128/JCM.00590-07}},
ISSN = {{0095-1137}},
Keywords-Plus = {{RIFAMPICIN RESISTANCE; CLINICAL SPECIMENS; RAPID DETECTION; MDR-TB;
   PROGRAMS; COMPLEX}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{yba2101@columbia.edu}},
Cited-References = {{Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469.
   Brodie D, 2005, CLIN CHEST MED, V26, P247, DOI 10.1016/j.ccm.2005.02.012.
   Cirillo D. M., 2004, New Microbiologica, V27, P221.
   DEBEENHOUWER H, 1995, TUBERCLE LUNG DIS, V76, P425, DOI 10.1016/0962-8479(95)90009-8.
   Dye C, 2001, P ROY SOC B-BIOL SCI, V268, P45, DOI 10.1098/rspb.2000.1328.
   Farmer P, 1998, INT J TUBERC LUNG D, V2, P869.
   {*}FIND DIAGN, 2006, FIND HAIN LIF AGR FA.
   Gamboa F, 1998, EUR J CLIN MICROBIOL, V17, P189, DOI 10.1007/BF01691116.
   Gupta R, 2002, TROP MED INT HEALTH, V7, P970, DOI 10.1046/j.1365-3156.2002.00960.x.
   Gupta R, 2001, INT J TUBERC LUNG D, V5, P1078.
   Johansen IS, 2003, J CLIN MICROBIOL, V41, P4454, DOI 10.1128/JCM.41.9.4454-4456.2003.
   Kim JY, 2003, TUBERCULOSIS, V83, P59, DOI 10.1016/S1472-9792(02)00078-1.
   KOCHI A, 1993, RES MICROBIOL, V144, P104, DOI 10.1016/0923-2508(93)90023-U.
   Morgan M, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-62.
   Mukherjee JS, 2004, LANCET, V363, P474, DOI 10.1016/S0140-6736(04)15496-2.
   MUSSER JM, 1995, CLIN MICROBIOL REV, V8, P496.
   PORTAELS F, 2006, REICHMAN HERSHFIEL B, P823.
   Rossau R, 1997, ANTIMICROB AGENTS CH, V41, P2093.
   Shah NS, 2007, EMERG INFECT DIS, V13, P380.
   Stop TB, 2006, GLOB PLAN STOP TB 20.
   Traore H, 2000, INT J TUBERC LUNG D, V4, P481.
   Traore H, 2006, J CLIN MICROBIOL, V44, P4384, DOI 10.1128/JCM.01332-06.
   Umubyeyi AN, 2007, INT J TUBERC LUNG D, V11, P189.
   World Health Organization, 2003, TREATM TUB GUID NAT.
   World Health Organization, 2004, 3 WHO.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{18}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Clin. Microbiol.}},
Doc-Delivery-Number = {{211EK}},
Unique-ID = {{ISI:000249506900060}},
}

@article{ ISI:000249506900076,
Author = {Streicher, E. M. and Victor, T. C. and van der Spuy, G. and Sola, C. and
   Rastogi, N. and van Helden, P. D. and Warren, R. M.},
Title = {{Spoligotype signatures in the Mycobacterium tuberculosis complex (vol
   45, pg 237, 2007)}},
Journal = {{JOURNAL OF CLINICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{45}},
Number = {{9}},
Pages = {{3149}},
Month = {{SEP}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Correction}},
Language = {{English}},
Affiliation = {{Streicher, EM (Reprint Author), Univ Stellenbosch, DST INRF Ctr Excellence Biomed TB Res, Div Mol Biol \& Human Genet, Fac Hlth Sci, ZA-7505 Tygerberg, South Africa.
   Univ Stellenbosch, DST INRF Ctr Excellence Biomed TB Res, Div Mol Biol \& Human Genet, Fac Hlth Sci, ZA-7505 Tygerberg, South Africa.
   Inst Pasteur, Pointe a Pitre, Guadeloupe.}},
DOI = {{10.1128/JCM.01389-07}},
ISSN = {{0095-1137}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
ORCID-Numbers = {{Streicher, Elizabeth/0000-0003-3901-1981}},
Cited-References = {{Streicher EM, 2007, J CLIN MICROBIOL, V45, P237, DOI 10.1128/JCM.01429-06.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Clin. Microbiol.}},
Doc-Delivery-Number = {{211EK}},
Unique-ID = {{ISI:000249506900076}},
}

@article{ ISI:000248814800005,
Author = {Ailinger, Rita L. and Black, Pat and Nguyen, Nga and Lasus, Howard},
Title = {{Predictors of adherence to latent tuberculosis infection therapy in
   Latino immigrants}},
Journal = {{JOURNAL OF COMMUNITY HEALTH NURSING}},
Year = {{2007}},
Volume = {{24}},
Number = {{3}},
Pages = {{191-198}},
Month = {{FAL}},
Abstract = {{Adherence to Latent Tuberculosis Infection (LTBI) therapy is a
   continuing community problem. The purpose of this study was to examine
   the predictors of adherence to LTBI therapy in Latino immigrants at a
   public health clinic. A descriptive study was conducted to examine 153
   randomly selected records from a population of Latino immigrant clients
   who had received a recommendation for 9 months of lsoniazid (INH)
   therapy. Most of the clients were women (64\%), the mean age was 26.1,
   and the mean time in the U.S. was 4.58 years. The majority came from El
   Salvador, Bolivia, or Guatemala. Adherence dropped off in a linear
   fashion from month 1 (84\%) to month 8 (34\%). None of the demographic
   factors predicted adherence. Implications for community health nursing
   are discussed.}},
Publisher = {{LAWRENCE ERLBAUM ASSOC INC-TAYLOR \& FRANCIS}},
Address = {{325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ailinger, RL (Reprint Author), Georgetown Univ, Sch Nursing \& Hlth Studies, 3700 Reservoir Rd NW, Washington, DC 20057 USA.
   Georgetown Univ, Sch Nursing \& Hlth Studies, Washington, DC 20057 USA.
   George Mason Univ, Nursing Doctoral Program, Fairfax, VA 22030 USA.
   Tuberculosis Control Program, Arlington, VA USA.
   George Mason Univ, Univ Lib, Fairfax, VA 22030 USA.}},
ISSN = {{0737-0016}},
Keywords-Plus = {{UNITED-STATES; ADOLESCENTS}},
Research-Areas = {{Nursing}},
Web-of-Science-Categories  = {{Nursing}},
Author-Email = {{rla22@Georgetown.edu}},
Funding-Acknowledgement = {{NINR NIH HHS {[}R15 NR009438-01]}},
Cited-References = {{Ailinger RL, 2006, PUBLIC HEALTH NURS, V23, P307, DOI 10.1111/j.1525-1446.2006.00566.x.
   Berg J, 2004, PATIENT EDUC COUNS, V52, P31, DOI 10.1016/S0738-3991(02)00268-9.
   Blumberg EJ, 2005, J CLIN EPIDEMIOL, V58, P645, DOI 10.1016/j.jclinepi.2004.11.022.
   {*}CDCP, 2005, REP TB CAS RAC ETHN.
   {*}CDCP, 2005, TARG TUB TEST TREATM.
   Horsburgh CR, 2004, NEW ENGL J MED, V350, P2060, DOI 10.1056/NEJMsa031667.
   Hovell MF, 2003, AM J PUBLIC HEALTH, V93, P1871, DOI 10.2105/AJPH.93.11.1871.
   LoBue PA, 2003, AM J RESP CRIT CARE, V168, P443, DOI 10.1164/rccm.200303-390OC.
   Morisky DE, 2003, EVAL HEALTH PROF, V26, P43, DOI 10.1177/0163278702250080.
   Salabarria-Pena Yamir, 2001, Ethnicity and Disease, V11, P661.
   Sterling TR, 2006, AM J RESP CRIT CARE, V173, P927, DOI 10.1164/rccm.200510-1563OC.
   {*}US CENS BUR, 2004, HISP US.
   Villarruel AM, 2006, J MULTICULTURAL NURS, V12, P4.}},
Number-of-Cited-References = {{13}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Community Health Nurs.}},
Doc-Delivery-Number = {{201ER}},
Unique-ID = {{ISI:000248814800005}},
}

@article{ ISI:000250581200003,
Author = {Singh, Nidhi and Avery, Mitchell A. and McCurdy, Christopher R.},
Title = {{Toward Mycobacterium tuberculosis DXR inhibitor design: homology
   modeling and molecular dynamics simulations}},
Journal = {{JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN}},
Year = {{2007}},
Volume = {{21}},
Number = {{9}},
Pages = {{511-522}},
Month = {{SEP}},
Abstract = {{Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate
   reductoisomerase (MtDXR) is a potential target for antitubercular
   chemotherapy. In the absence of its crystallographic structure, our aim
   was to develop a structural model of MtDXR. This will allow us to gain
   early insight into the structure and function of the enzyme and its
   likely binding to ligands and cofactors and thus, facilitate structure-
   based inhibitor design. To achieve this goal, initial models of MtDXR
   were generated using MODELER. The best quality model was refined using a
   series of minimizations and molecular dynamics simulations. A protein -
   ligand complex was also developed from the initial homology model of the
   target protein by including information about the known ligand as
   spatial restraints and optimizing the mutual interactions between the
   ligand and the binding site. The final model was evaluated on the basis
   of its ability to explain several sitedirected mutagenesis data.
   Furthermore, a comparison of the homology model with the X-ray structure
   published in the final stages of the project shows excellent agreement
   and validates the approach. The knowledge gained from the current study
   should prove useful in the design and development of inhibitors as
   potential novel therapeutic agents against tuberculosis by either de
   novo drug design or virtual screening of large chemical databases.}},
Publisher = {{SPRINGER}},
Address = {{VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{McCurdy, CR (Reprint Author), Univ Mississippi, Dept Med Chem, Lab Appl Drug Design \& Synth, University, MS 38677 USA.
   Univ Mississippi, Dept Med Chem, Lab Appl Drug Design \& Synth, University, MS 38677 USA.
   Univ Mississippi, Natl Ctr Nat Prod Res, University, MS 38677 USA.
   Univ Mississippi, Dept Chem \& Biochem, University, MS 38677 USA.
   Univ Mississippi, Sch Pharm, Dept Pharmacol, University, MS 38677 USA.}},
DOI = {{10.1007/s10822-007-9132-0}},
ISSN = {{0920-654X}},
Keywords = {{Mycobacterium tuberculosis; 1-Deoxy-D-xylulose 5-phosphate r
   eductoisomerase; ruberculosis; homology modeling; molecular dynamics;
   drug design}},
Keywords-Plus = {{1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE; NON-MEVALONATE PATHWAY;
   ISOPENTENYL DIPHOSPHATE BIOSYNTHESIS; ISOPRENOID BIOSYNTHESIS;
   CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; NONMEVALONATE PATHWAY; TERPENOID
   BIOSYNTHESIS; STRUCTURAL GENOMICS; DRUG DESIGN}},
Research-Areas = {{Biochemistry \& Molecular Biology; Biophysics; Computer Science}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Biophysics; Computer Science,
   Interdisciplinary Applications}},
Author-Email = {{cmccurdy@olemiss.edu}},
Funding-Acknowledgement = {{PHS HHS {[}U50/CCU423310-02]}},
Cited-References = {{Argyrou A, 2004, BIOCHEMISTRY-US, V43, P4375, DOI 10.1021/bi049974k.
   Baker D, 2001, SCIENCE, V294, P93, DOI 10.1126/science.1065659.
   Bellamacina CR, 1996, FASEB J, V10, P1257.
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235.
   BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055.
   Blundell TL, 1996, NATURE, V384, P23.
   BOCHAR DA, 1999, COMPREHENSIVE NATURA, P1544.
   BRICKMANN J, 1997, MOLCAD MOLECULAR COM.
   BROERS STJ, 1994, THESIS EIDGENO SSICH.
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211.
   Burley SK, 2000, NAT STRUCT BIOL, V7, P932, DOI 10.1038/80697.
   Cole ST, 1998, NOVART FDN SYMP, V217, P160, DOI 10.1002/0470846526.ch12.
   Cole ST, 1998, NATURE, V393, P537.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Dhiman RK, 2005, J BACTERIOL, V187, P8395, DOI 10.1128/JB.187.24.8395-8402.2005.
   Fiser A, 2000, PROTEIN SCI, V9, P1753.
   HEIDEN W, 1993, J COMPUT AID MOL DES, V7, P503, DOI 10.1007/BF00124359.
   HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915.
   Henriksson LM, 2006, ACTA CRYSTALLOGR D, V62, P807, DOI 10.1107/S0907444906019196.
   HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2.
   Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573.
   Kaufmann SHE, 2005, NAT MED, V11, pS33, DOI 10.1038/nm1221.
   Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100.
   Krieger Elmar, 2003, Methods Biochem Anal, V44, P509.
   Kroemer RT, 1996, PROTEIN ENG, V9, P493, DOI 10.1093/protein/9.6.493.
   Kuzuyama T, 2000, J BIOL CHEM, V275, P19928, DOI 10.1074/jbc.M001820200.
   Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P7913, DOI 10.1016/S0040-4039(98)01755-9.
   Lange BM, 1999, P NATL ACAD SCI USA, V96, P13714, DOI 10.1073/pnas.96.24.13714.
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944.
   Lee KW, 2004, PROTEINS, V54, P693, DOI 10.1002/prot.10300.
   Lell B, 2003, ANTIMICROB AGENTS CH, V47, P735, DOI 10.1128/AAC.47.2.735-738.2003.
   Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105.
   Mac Sweeney A, 2005, J MOL BIOL, V345, P115, DOI 10.1016/j.jmb.2004.10.030.
   Mahapatra S, 2005, J BACTERIOL, V187, P2747, DOI 10.1128/JB.187.8.2747-2757.2005.
   Mikusova K, 1996, J BIOL CHEM, V271, P7820.
   Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95.
   Missinou MA, 2002, LANCET, V360, P1941, DOI 10.1016/S0140-6736(02)11860-5.
   Mueller C, 2000, BIOCHEM SOC T, V28, P792, DOI 10.1042/0300-5127:0280792.
   Perlman DC, 1997, AIDS, V11, P1473, DOI 10.1097/00002030-199712000-00011.
   Proteau PJ, 2004, BIOORG CHEM, V32, P483, DOI 10.1016/j.bioorg.2004.08.004.
   QURESHI AA, 1981, BIOSYNTHESIS ISOPREN, P47.
   Rattan A, 1998, EMERG INFECT DIS, V4, P195.
   Reuter K, 2002, J BIOL CHEM, V277, P5378, DOI 10.1074/jbc.M109500200.
   Ricagno S, 2004, BBA-PROTEINS PROTEOM, V1698, P37, DOI 10.1016/j.bbapap.2003.10.006.
   Rodriguez-Concepcion M, 2000, FEBS LETT, V473, P328, DOI 10.1016/S0014-5793(00)01552-0.
   ROHMER M, 1993, BIOCHEM J, V295, P517.
   ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413.
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626.
   SCHWARZ MK, 1994, THESIS EIDGENO SSICH.
   Schwender J, 1996, BIOCHEM J, V316, P73.
   Singh N, 2006, J CHEM INF MODEL, V46, P1360, DOI 10.1021/ci050523w.
   Singh Sandeep Kumar, 2004, J Vet Sci, V5, P331.
   Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857.
   Steinbacher S, 2003, J BIOL CHEM, V278, P18401, DOI 10.1074/jbc.M300993200.
   Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879.
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673.
   WHITTLE PJ, 1994, ANNU REV BIOPH BIOM, V23, P349, DOI 10.1146/annurev.bb.23.060194.002025.
   {*}WHO, 2006, FACT SHEET TUB.
   WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328.
   Yajima S, 2004, J AM CHEM SOC, V126, P10824, DOI 10.1021/ja040126m.
   Yajima S, 2002, J BIOCHEM, V131, P313.
   2005, INSIGHT2 MOL MODELIN.}},
Number-of-Cited-References = {{62}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{J. Comput.-Aided Mol. Des.}},
Doc-Delivery-Number = {{226HX}},
Unique-ID = {{ISI:000250581200003}},
}

@article{ ISI:000249811200008,
Author = {Olmstead, Alan L. and Rhode, Paul W.},
Title = {{Not on my farm! Resistance to bovine tuberculosis eradication in the
   United States}},
Journal = {{JOURNAL OF ECONOMIC HISTORY}},
Year = {{2007}},
Volume = {{67}},
Number = {{3}},
Pages = {{768-809}},
Month = {{SEP}},
Abstract = {{The active opposition to technical change has frequently impeded
   economic growth. This article examines the widespread resistance to
   government-led campaigns to use new tuberculin testing technologies to
   eradicate bovine tuberculosis in the United States. We explore three
   issues: the political economy of opposition; the role of earlier
   scientific controversies in the discourse; and the techniques used by
   the opponents. Over time, the protests shifted from challenging the
   scientific merits of the testing technology to more nuts-and-bolts
   distributional and administrative issues.}},
Publisher = {{CAMBRIDGE UNIV PRESS}},
Address = {{32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Olmstead, AL (Reprint Author), Univ Calif Davis, Inst Govt, Davis, CA 95616 USA.
   Univ Calif Davis, Inst Govt, Davis, CA 95616 USA.
   Univ Arizona, Tucson, AZ 85721 USA.}},
ISSN = {{0022-0507}},
Research-Areas = {{Business \& Economics; History; Social Sciences - Other Topics}},
Web-of-Science-Categories  = {{Economics; History; History Of Social Sciences}},
Cited-References = {{Alesina A, 2005, J ECON LIT, V43, P762, DOI 10.1257/002205105774431243.
   ARBURUA JM, 1966, NARRATIVE VET PROFES.
   ARCHIE D, 1959, IOWAN            APR, P28.
   ARCHIE D, 1959, IOWAN            APR, P52.
   Bauer M.W., 2002, BIOTECHNOLOGY MAKING.
   BOHME FG, 1956, CALIFORNIA HIST SOC, V35, P235.
   BOYD AG, 1931, CALIFORNIA DEP AGR B, V20, P491.
   {*}BUR MARK AN, 1926, RAD MARK DAIR FARM S.
   Choate Jean, 2002, DISPUTED GROUND FARM.
   CRAIG E, 1933, J ASSEMBLY 2, P3016.
   DAVENPORT W, 1932, COLLIERS        0227, P10.
   DAVENPORT W, 1932, COLLIERS        0227, P46.
   DILEVA FD, 1953, ANN IOWA, V32, P81.
   Dormandy T, 2001, WHITE DEATH HIST TUB.
   DUCKWORTH CU, 1939, CALIFORNIA DEP AGR B, V28, P629.
   DUCKWORTH CU, 1936, CALIFORNIA DEP AGR B, V25, P411.
   DUCKWORTH CU, 1935, CALIFORNIA DEP AGR B, V24, P365.
   DUCKWORTH CU, 1937, CALIFORNIA DEP AGR B, V26, P359.
   DUCKWORTH CU, 1938, CALIFORNIA DEP AGR B, V27, P487.
   DUCKWORTH CU, 1938, P 42 ANN M US LIV ST, P227.
   DUCKWORTH CU, 1939, CALIFORNIA DEP AGR B, V28, P42.
   DUFLO E, 2007, IN PRESS Q J EC, V122.
   DynCorp International, WASHINGTON POST.
   {*}FED RAD COMM, 1931, 5 FED RAD COMM.
   Fowler G., 2002, BORDER RADIO QUACKS.
   GLASS C, PAPERS U VIRGINIA SP.
   Graves Alvin Ray, 2004, PORTUGUESE CALIFORNI.
   HICKMAN RW, 1911, US DEP AGR YB 1910, P231.
   Houck Ulysses Grant, 1924, BUREAU ANIMAL IND US.
   HUGHES JRT, 1991, GOVT HABIT REDUX EC.
   {*}IA DEP AGR, 1929, LAWS REL BOV TUB ER.
   {*}INT CONS POL SOC, 1970, INT CONS POL SOC RES, V3.
   IRANZO S, 2003, EXOTIC PESTS DIS BIO, pCH5.
   IVERSON JP, 1930, CALIFORNIA DEP AGR B, V19, P673.
   IVERSON JP, 1925, CALIFORNIA DEP AGR B, V14, P215.
   IVERSON JP, 1923, CALIFORNIA DEP AGR B, V12, P382.
   JACKLEY JG, 1921, CALIFORNIA DEP AGR B, V10, P660.
   Johnston Robert D., 2003, RADICAL MIDDLE CLASS.
   KANTHACK E, 1908, PUBLIC HLTH      MAY, P119.
   Kaufman M, 1967, Bull Hist Med, V41, P463.
   KOCH R, 1901, AM VET REV, V25, P441.
   KRAMER D, 1956, WILD JACKASSES AM FA.
   Davis L. M., 1923, USDA YB 1922, P281.
   Libecap G. D., 1989, CONTRACTING PROPERTY.
   MCCANN AW, 1918, THIS FAMISHING WORLD.
   MCDONALD ME, 1932, CAL FRUIT GROW FARM, P22.
   MELVIN AD, 1910, 25 ANN REPORT BUREAU.
   Miller Gale, 1989, PERSPECTIVES SOCIAL, V1, P1.
   MILLHAUSER S, 1983, GRAND STREET, V2, P128, DOI 10.2307/25006539.
   MOHLER JR, 1931, USDA MISCELLANEOUS P, V59.
   MOKYR J, 2002, GIFTS ATHENA HIST OR.
   MYERS JA, 1970, TUBERCULOSIS HALF CE.
   Myers J.A., 1969, BOVINE TUBERCULOSIS.
   Myers J.A., 1940, MANS GREATEST VICTOR.
   {*}NAT RES COUNC US, 1994, LIV DIS ER EV COOP S.
   Nelkin D, 1984, CONTROVERSY POLITICS.
   Olmstead AL, 2004, J ECON HIST, V64, P929.
   OLMSTEAD AL, 1994, AGR HIST, V68, P35.
   Olmstead AL, 2004, J ECON HIST, V64, P734.
   Orland B, 2003, FOOD HIST, V1, P179.
   ORMSBY GJ, PAPERS IOWA STATE U.
   Ossian LL, 2006, AGR HIST, V80, P296, DOI 10.1525/ah.2006.80.3.296.
   PALMER JE, 1938, C GLASS UNRECONSTRUC.
   Parente S. L., 2000, BARRIERS RICHES.
   PEGRAM TR, 1991, AGR HIST, V65, P36.
   PETERS A, 1908, T 6 INT C TUB 2, V4, P884.
   RENO M, PAPERS U IOWA SPECIA.
   REYNOLDS MH, 1909, AM VET REV       JAN, P454.
   ROSEN CM, 2006, IN PRESS ENTERPRISE.
   Rosenberg M, 1985, OIL PETROCHEM POLLUT, V2, P155, DOI 10.1016/S0143-7127(85)90178-4.
   Ruggles S., 2004, INTEGRATED PUBLIC US.
   Ryan B, 1948, RURAL SOCIOL, V13, P273.
   SALMON DE, 1906, US BUREAU ANIMAL IND, V38.
   Salmon D. E., 1901, US BUREAU ANIMAL IND.
   Hopkins Andrew W., 1957, HIST DAIRY JOURNALIS.
   Shover John L., 1965, CORNBELT REBELLION F.
   Smith Howard R., 1958, CONQUEST BOVINE TUBE.
   Smith Rixey, 1939, C GLASS BIOGRAPHY.
   STONEHILL PC, 1995, BARRELFUL MEMORIES S.
   SWEET FT, 1930, T COMMONWEALTH CLUB, V25, P326.
   Teller ME, 1988, TUBERCULOSIS MOVEMEN.
   TOBEY JA, 1947, LEGAL ASPECTS MILK S.
   {*}US BUR AGR EC, 1938, LIV FARMS JAN 1 1867.
   {*}US BUR AN IND, REC CENTR CORR 1913.
   {*}US BUR AN IND, STAT BOV TUB ER AR B.
   {*}US BUR AN IND, 1916, SPEC REP DIS CATTL.
   {*}US BUR AN IND, ANN REP.
   {*}US BUR AN IND, SERV REG ANN.
   US Census Bureau, 1976, HIST STAT US.
   {*}US FED COMM COMM, REC CORR REL APPL BR.
   {*}USDA, CROPS MARK.
   {*}USDA, 1933, YB AGR 1933.
   WALL JF, 1983, ANN IOWA, V47, P116.
   WHITE G, PAPERS U IOWA LIB SP.
   WHITE RA, 1975, M RENO FARMERS UNION.
   WIGHT AE, 1943, USDA YB 1942, P237.
   WINSTON A, 1934, THROTTLE FACT STORY.
   WISER V, 1986, J NAL ASS, V11.
   WOLFE JG, 1968, J BROADCASTING, V12, P389.
   CALIFORNIA CULTIVATO.
   1931, TIPTON ADVERTIS 0924.
   {[}Anonymous], MODESTO BEE.
   1932, CHICAGO TRIBUNE 1012.
   {[}Anonymous], PACIFIC RURAL PRESS.
   MIDWEST FREE PRESS.
   WALLACES FARMER.
   {[}Anonymous], SACRAMENTO BEE.
   {[}Anonymous], TRUTH TELLER.
   1996, IOWA STATER      MAY.
   HOARDS DAIRYMAN.
   {[}Anonymous], NY TIMES.
   1930, RURAL NEW YORKE 0531.
   1901, BREEDERS GAZETT 1002.
   FARMERS NATL WEEKLY.
   TULARE DAILY ADV REG.
   1931, MOINES REGISTER 0922.
   1931, NATION, V133, P349.
   1930, CALIFORNIA DAIR 1101.
   1934, SACRAMENTO UNIO 0315.
   1931, DAVENPORT DEMOC 0309.
   HANFORD DAILY SENTIN.
   DAVENPORT DAILY TIME.
   {[}Anonymous], LOS ANGELES TIMES.
   {[}Anonymous], SAN FRANCISCO CHRONI.
   1922, J AM MED ASS, V79, P395.
   {[}Anonymous], FRESNO BEE.}},
Number-of-Cited-References = {{126}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{J. Econ. Hist.}},
Doc-Delivery-Number = {{215LZ}},
Unique-ID = {{ISI:000249811200008}},
}

@article{ ISI:000248991800052,
Author = {Garlanda, Cecilia and Di Liberto, Diana and Vecchi, Annunciata and La
   Manna, Marco P. and Buracchi, Chiara and Caccamo, Nadia and Salerno,
   Alfredo and Dieli, Francesco and Mantovani, Alberto},
Title = {{Damping excessive inflammation and tissue damage in Mycobacterium
   tuberculosis infection by toll IL-1 receptor 8/Single Ig IL-1-related
   receptor, a negative regulator of IL-1/TLR signaling}},
Journal = {{JOURNAL OF IMMUNOLOGY}},
Year = {{2007}},
Volume = {{179}},
Number = {{5}},
Pages = {{3119-3125}},
Month = {{SEP 1}},
Abstract = {{Toll IL-IR Mingle Ig IL-1-related receptor (TIR8,1SIGIRR) is a member of
   the IL-111 family, expressed by epithelial tissues and immature
   dendritic cells, and is regarded as a negative regulator of TLR/IL-lR
   signaling. Tir8-deficient mice were rapidly killed by intranasal
   administration of low doses of Mycobacterium tuberculosis, despite
   controlling efficiently the number of viable bacilli in different
   organs. Tir8(-1-) -infected mice showed an increased number of
   neutrophils and macrophages in the lungs; however, mycobacteria-specific
   CD4 and CD8 T cells were similar in Tir(-/-) and Tir8(+/+) mice.
   Exaggerated mortality of Tir8-1- mice was due to massive liver necrosis
   and was accompanied by increased levels of IL-1,6 and TNF-a in lung
   mononuclear cells and serum, as well as by increased production of
   IIL-113 and TNF-a by M. tuberculosis-infected dendritic cells in vitro.
   Accordingly, blocking JIL-1 beta and TNF-a with a mix of anti-cytokine
   Abs, significantly prolonged survival of Tir8(-/-) mice. Thus,
   TIR8/SIGIRR plays a key role in damping inflammation and tissue damage
   inM. tuberculosis infection.}},
Publisher = {{AMER ASSOC IMMUNOLOGISTS}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Dieli, F (Reprint Author), Univ Palermo, Dipartimento Biopatol \& Metodol Biomed, Corso Tukory 211, I-90134 Palermo, Italy.
   Univ Palermo, Dipartimento Biopatol \& Metodol Biomed, I-90134 Palermo, Italy.
   Ist Ricovero \& Cura Carattere Scientif, Ist Clin Humanitas, Rozzano, Italy.
   Univ Milan, Ist Patol Gen, Milan, Italy.}},
ISSN = {{0022-1767}},
Keywords-Plus = {{TUMOR-NECROSIS-FACTOR; INDUCED FULMINANT-HEPATITIS;
   BACILLUS-CALMETTE-GUERIN; TOLL-LIKE RECEPTORS; DELTA-T-CELLS;
   GRANULOMA-FORMATION; FACTOR-ALPHA; TNF-ALPHA; IMMUNE-RESPONSE; MICE}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{dieli@unipa.it}},
ResearcherID-Numbers = {{Garlanda, Cecilia/K-4601-2016
   Carloni, Massimiliano/I-7721-2014
   }},
ORCID-Numbers = {{Garlanda, Cecilia/0000-0002-1510-7703
   Carloni, Massimiliano/0000-0003-3019-8612
   Mantovani, Alberto/0000-0001-5578-236X
   CACCAMO, Nadia Rosalia/0000-0002-1018-5710}},
Funding-Acknowledgement = {{Telethon {[}GGP05095]}},
Cited-References = {{ADAMS LB, 1995, J INFECT DIS, V171, P400.
   Algood HMS, 2005, CLIN INFECT DIS, V41, pS189.
   Bean AGD, 1999, J IMMUNOL, V162, P3504.
   Bekker LG, 2000, INFECT IMMUN, V68, P6954, DOI 10.1128/IAI.68.12.6954-6961.2000.
   BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505.
   Bulut Y, 2001, J IMMUNOL, V167, P987.
   CHENSUE SW, 1992, AM J PATHOL, V140, P269.
   DENIS M, 1994, INFECT IMMUN, V62, P457.
   Dieli F, 2004, EUR J IMMUNOL, V34, P3227, DOI 10.1002/eji.200425368.
   Dieli F, 2003, J IMMUNOL, V171, P1961.
   Dieli F, 2003, J IMMUNOL, V170, P463.
   Dinarello CA, 1996, BLOOD, V87, P2095.
   Fenton MJ, 1996, INFECT IMMUN, V64, P683.
   FERLUGA J, 1981, AM J PATHOL, V105, P82.
   FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2.
   FUJIOKA N, 1995, J LEUKOCYTE BIOL, V58, P90.
   Garlanda C, 2004, P NATL ACAD SCI USA, V101, P3522, DOI 10.1073/pnas.0303860101.
   GARLANDA CF, 2007, IN PRESS CANC RES.
   Hajjar AM, 2001, J IMMUNOL, V166, P15.
   Jovanovic DV, 1998, J IMMUNOL, V160, P3513.
   Juffermans NP, 2000, J INFECT DIS, V182, P902, DOI 10.1086/315771.
   KASAHARA K, 1988, AM J PATHOL, V130, P629.
   Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558.
   KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4.
   Lazarevic V, 2003, IMMUNITY, V19, P823, DOI 10.1016/S1074-7613(03)00324-8.
   Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630.
   Mantovani A, 2004, J LEUKOCYTE BIOL, V75, P738, DOI 10.1189/jlb.1003473.
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015.
   NAGAKAWA J, 1990, GASTROENTEROLOGY, V99, P758.
   North RJ, 2004, ANNU REV IMMUNOL, V22, P599, DOI 10.1146/annurev.immunol.22.012703.104635.
   NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171.
   Orme IM, 1998, TRENDS MICROBIOL, V6, P94, DOI 10.1016/S0966-842X(98)01209-8.
   Perera PY, 1998, INFECT IMMUN, V66, P2562.
   Polentarutti N., 2003, EUR CYTOKINE NETW, V14, P1.
   Qin JZ, 2005, J BIOL CHEM, V280, P25233, DOI 10.1074/jbc.M501363200.
   Roach DR, 2001, J EXP MED, V193, P239, DOI 10.1084/jem.193.2.239.
   Ryffel B, 2005, TUBERCULOSIS, V85, P395, DOI 10.1016/j.tube.2005.08.021.
   Sedgwick JD, 2000, IMMUNOL TODAY, V21, P110, DOI 10.1016/S0167-5699(99)01573-X.
   Sireci G, 2007, J LEUKOCYTE BIOL, V81, P607, DOI 10.1189/jlb.0506298.
   Sugawara I, 2001, MICROBIOL IMMUNOL, V45, P743.
   Tazi KA, 2006, J HEPATOL, V45, P280, DOI 10.1016/j.jhep.2006.02.013.
   Thomassen E, 1999, CYTOKINE, V11, P389, DOI 10.1006/cyto.1998.0452.
   Tsuji H, 1997, INFECT IMMUN, V65, P1892.
   Wald D, 2003, NAT IMMUNOL, V4, P920, DOI 10.1038/ni968.
   Xiao H, 2007, IMMUNITY, V26, P461, DOI 10.1016/j.immuni.2007.02.012.
   Yamada H, 2000, LAB INVEST, V80, P759.
   Yao HW, 2005, INFLAMM RES, V54, P471, DOI 10.1007/s00011-005-1381-6.}},
Number-of-Cited-References = {{47}},
Times-Cited = {{67}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{J. Immunol.}},
Doc-Delivery-Number = {{203RN}},
Unique-ID = {{ISI:000248991800052}},
}

@article{ ISI:000248991800060,
Author = {Kincaid, Eleanor Z. and Wolf, Andrea J. and Desvignes, Ludovic and
   Mahapatra, Sebabrata and Crick, Dean C. and Brennan, Patrick J. and
   Pavelka, Jr., Martin S. and Ernst, Joel D.},
Title = {{Codominance of TLR2-dependent and TLR2-independent modulation of MHC
   class II in Mycobacterium tuberculosis infection in vivo}},
Journal = {{JOURNAL OF IMMUNOLOGY}},
Year = {{2007}},
Volume = {{179}},
Number = {{5}},
Pages = {{3187-3195}},
Month = {{SEP 1}},
Abstract = {{Mycobacterium tuberculosis is an exceptionally successful human
   pathogen. A major component of this success is the ability of the
   bacteria to infect immunocompetent individuals and to evade eradication
   by an adaptive immune response that includes production of the
   macrophage-activating cytokine, IFN-gamma. Although IFN-gamma is
   essential for arrest of progressive tuberculosis, it is insufficient for
   efficacious macrophage killing of the bacteria, which may be due to the
   ability of M. tuberculosis to inhibit selected macrophage responses to
   IFN-gamma. In vitro studies have determined that mycobacterial
   lipoproteins and other components of the M. tuberculosis cell envelope,
   acting as agonists for TLR2, inhibit IFN-gamma induction of MHC class
   11. In addition, M. tuberculosis peptidoglycan and IL-6 secreted by
   infected macrophages inhibit IFN-gamma,y induction of MHC class 11 in a
   TLR2-independent manner. To determine whether TLR2-dependent inhibition
   of macrophage responses to IFN-gamma,y is quantitatively dominant over
   the TLR2-independent mechanisms in vivo, we prepared mixed bone marrow
   chimeric mice in which the hemopoietic compartment was reconstituted
   with a mixture of TLR+/+ and TLR2(-/-) cells. When the chimeric mice
   were infected with M. tuberculosis, the expression of MHC class 11 on
   TLR2{''}' and TLR2(-/-) macrophages from the lungs of individual
   infected chimeric mice was indistinguishable. These results indicate
   that TLR2-dependent and -independent mechanisms of inhibition of
   responses to IFN-,y are equivalent in vivo, and that M. tuberculosis
   uses multiple pathways to abrogate the action of an important effector
   of adaptive immunity.}},
Publisher = {{AMER ASSOC IMMUNOLOGISTS}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ernst, JD (Reprint Author), NYU, Sch Med, Smilow Res Ctr, Dept Med,Div Infect Dis, Room 901,550 1st Ave, New York, NY 10016 USA.
   NYU, Sch Med, Smilow Res Ctr, Dept Med,Div Infect Dis, New York, NY 10016 USA.
   Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA.
   Colorado State Univ, Dept Microbiol \& Immunol Pathol, Ft Collins, CO 80523 USA.
   Univ Rochester, Dept Microbiol \& Immunol, Rochester, NY 14642 USA.
   NYU, Dept Pathol, New York, NY 10016 USA.
   NYU, Dept Pathol, New York, NY 10016 USA.}},
ISSN = {{0022-1767}},
Keywords-Plus = {{TOLL-LIKE RECEPTOR-2; INHIBITS MACROPHAGE RESPONSES; IFN-GAMMA;
   DENDRITIC CELLS; INTERFERON-GAMMA; NITRIC-OXIDE; INTRACELLULAR
   MULTIPLICATION; TRANSCRIPTIONAL RESPONSES; LEGIONELLA-PNEUMOPHILA;
   ALVEOLAR MACROPHAGES}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{joel.ernst@tned.nyu.edu}},
ResearcherID-Numbers = {{Crick, Dean/H-8251-2017}},
ORCID-Numbers = {{Crick, Dean/0000-0001-9281-7058}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI 018357, AI 046097, AI 049151, AI 051242, AI 059667,
   AI 47311]}},
Cited-References = {{Arko-Mensah J, 2007, SCAND J IMMUNOL, V65, P148, DOI 10.1111/j.1365-3083.2006.01888.x.
   Banaiee N, 2006, J IMMUNOL, V176, P3019.
   BARNES PF, 1989, J IMMUNOL, V142, P1114.
   BARNES PF, 1990, J IMMUNOL, V145, P149.
   BARNES PF, 1993, INFECT IMMUN, V61, P3482.
   BHARDWAJ N, 1986, J IMMUNOL, V137, P2662.
   Bulut Y, 2005, J BIOL CHEM, V280, P20961, DOI 10.1074/jbc.M411379200.
   CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111.
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243.
   DOUVAS GS, 1985, INFECT IMMUN, V50, P1.
   DRAPER P, 1976, INT J LEPROSY, V44, P95.
   DRAPER P, 1987, J GEN MICROBIOL, V133, P1187.
   Drennan MB, 2004, AM J PATHOL, V164, P49, DOI 10.1016/S0002-9440(10)63095-7.
   Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123.
   Fenhalls G, 2002, IMMUNOLOGY, V105, P325, DOI 10.1046/j.1365-2567.2002.01378.x.
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93.
   Fortune SM, 2004, J IMMUNOL, V172, P6272.
   Fulton SA, 2004, INFECT IMMUN, V72, P2101, DOI 10.1128/IAI.72.2.2101-2110.2004.
   Gehring AJ, 2003, INFECT IMMUN, V71, P4487, DOI 10.1128/IAI.71.8.4487-4497.2003.
   Gehring AJ, 2004, J IMMUNOL, V173, P2660.
   Gonzalez-Juarrero M, 2003, J IMMUNOL, V171, P3128.
   Gonzalez-Juarrero M, 2001, INFECT IMMUN, V69, P1127, DOI 10.1128/IAI.69.2.1127-1133.2001.
   HASH JH, 1967, J BIOL CHEM, V242, P5586.
   Henderson RA, 1997, J IMMUNOL, V159, P635.
   Hertz CJ, 2001, J IMMUNOL, V166, P2444.
   Jakubzick C, 2006, J IMMUNOL, V176, P3578.
   Jung YJ, 2002, J EXP MED, V196, P991, DOI 10.1084/jem.20021186.
   Kincaid EZ, 2003, J IMMUNOL, V171, P2042.
   KOTANI S, 1970, BIKEN J, V13, P249.
   Lafuse WP, 2006, J INTERF CYTOK RES, V26, P548, DOI 10.1089/jir.2006.26.548.
   Landsman L, 2007, J IMMUNOL, V178, P2000.
   Mahapatra S, 2005, J BACTERIOL, V187, P2341, DOI 10.1128/JB.187.7.2341-2347.2005.
   Means TK, 1999, J IMMUNOL, V163, P3920.
   Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200.
   Mogues T, 2001, J EXP MED, V193, P271, DOI 10.1084/jem.193.3.271.
   MURRAY HW, 1983, J CLIN INVEST, V72, P1506, DOI 10.1172/JCI111107.
   MURRAY HW, 1991, INFECT IMMUN, V59, P4684.
   Nagabhushanam V, 2003, J IMMUNOL, V171, P4750.
   NASH TW, 1988, J IMMUNOL, V140, P3978.
   NATHAN CF, 1984, J EXP MED, V160, P600, DOI 10.1084/jem.160.2.600.
   Noss EH, 2000, CELL IMMUNOL, V201, P63, DOI 10.1006/cimm.2000.1633.
   Noss EH, 2001, J IMMUNOL, V167, P910.
   Pai RK, 2003, J IMMUNOL, V171, P175.
   Peters W, 2004, J IMMUNOL, V172, P7647.
   Pierre P, 1997, NATURE, V388, P787.
   Raymond JB, 2005, J BIOL CHEM, V280, P326, DOI 10.1074/jbc.M411006200.
   Reiling N, 2002, J IMMUNOL, V169, P3480.
   Robertson HE, 1933, AM J PATHOL, V9, P711.
   Shi LB, 2003, P NATL ACAD SCI USA, V100, P241, DOI 10.1073/pnas.0136863100.
   SICHER SC, 1995, J IMMUNOL, V155, P5826.
   Sugawara I, 2003, MICROBIOL IMMUNOL, V47, P327.
   Ting LM, 1999, J IMMUNOL, V163, P3898.
   Uehori J, 2003, INFECT IMMUN, V71, P4238, DOI 10.1128/IAI.71.8.4238-4249.2003.
   Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459.
   WOLF A, 2007, J IMMUNOL, V16, P2509.
   Yao YX, 2006, J IMMUNOL, V177, P70.
   Young KD, 1996, J BACTERIOL, V178, P3962.}},
Number-of-Cited-References = {{57}},
Times-Cited = {{37}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{J. Immunol.}},
Doc-Delivery-Number = {{203RN}},
Unique-ID = {{ISI:000248991800060}},
}

@article{ ISI:000249791600015,
Author = {Ozekinci, T. and Ozbek, E. and Celik, Y.},
Title = {{Comparison of tuberculin skin test and a specific T-cell-based test,
   T-Spot (TM).TB, for the diagnosis of latent tuberculosis infection}},
Journal = {{JOURNAL OF INTERNATIONAL MEDICAL RESEARCH}},
Year = {{2007}},
Volume = {{35}},
Number = {{5}},
Pages = {{696-703}},
Month = {{SEP-OCT}},
Abstract = {{There is substantial evidence that the detection of T cells specific for
   the proteins ESAT-6 and CFP-10 using the ex vivo enzyme-linked
   immunospot technique is a marked improvement on the existing tuberculin
   skin test (TST). This new technique, which
   detects,gamma-interferon-producing T cells, is now available as the
   commercial assay, T-Spot (TM).TB. We compared the T-Spot (TM).TB test
   with the TST for the diagnosis of latent tuberculosis infection (LTBI)
   in different groups of subjects. Significant accordance (85.7\%) between
   the tests was found in subjects with active lung tuberculosis and in
   tuberculosis clinic and laboratory personnel (63.6\%) but accordance was
   lowest and not significant amongst house contacts of tuberculosis
   patients (53.6\%). We conclude that, in countries where vaccination is
   routinely performed, the T-Spot (TM).TB test is a useful diagnostic test
   for LTBI in highrisk groups when carried out either together with the
   TST and/or to confirm the TST result.}},
Publisher = {{CAMBRIDGE MED PUBL}},
Address = {{WICKER HOUSE, HIGH ST, WORTHING BN11 1DJ, W SUSSEX, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ozekinci, T (Reprint Author), Univ Dicle, Dept Microbiol, Fac Med, TR-21280 Diyarbakir, Turkey.
   Univ Dicle, Dept Microbiol, Fac Med, TR-21280 Diyarbakir, Turkey.
   Univ Dicle, Dept Biostat, Fac Med, TR-21280 Diyarbakir, Turkey.}},
ISSN = {{0300-0605}},
Keywords = {{latent tuberculosis; interferon-gamma; tuberculin skin test; T-Spot
   (TM).TB}},
Keywords-Plus = {{LINKED IMMUNOSPOT ASSAY; MYCOBACTERIUM-TUBERCULOSIS; RAPID DETECTION;
   ENUMERATION; CHILDREN}},
Research-Areas = {{Research \& Experimental Medicine; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Medicine, Research \& Experimental; Pharmacology \& Pharmacy}},
Author-Email = {{tunozek@dicle.edu.tr}},
Cited-References = {{Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2.
   Barnes PF, 2004, AM J RESP CRIT CARE, V170, P5, DOI 10.1164/rccm.2404004.
   Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520.
   Broekmans JF, 2002, EUR RESPIR J, V19, P765, DOI 10.1183/09031936.02.00261402.
   Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008.
   Diel R, 2006, EUR RESPIR J, V28, P16, DOI 10.1183/09031936.06.00107005.
   Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002.
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9.
   Hill PC, 2006, PEDIATRICS, V117, P1542, DOI 10.1542/peds.2005-2095.
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968.
   Jasmer RM, 2002, NEW ENGL J MED, V347, P1860, DOI 10.1056/NEJMcp021045.
   Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824.
   Lee JY, 2006, EUR RESPIR J, V28, P24, DOI 10.1183/09031936.06.00016906.
   Liebeschuetz S, 2004, LANCET, V364, P2196, DOI 10.1016/S0140-6736(04)17592-2.
   Meier T, 2005, EUR J CLIN MICROBIOL, V24, P529, DOI 10.1007/s10096-005-1377-8.
   Ozkara S, 2003, TURKIYE TUBERKULOZUN.
   Pai M, 2005, Indian J Med Microbiol, V23, P151.
   {*}WHO, WHO REP 2006 GLOB TU.
   Wrighton-Smith P, 2006, EUR RESPIR J, V28, P45, DOI 10.1183/09031936.06.00005906.
   Zellweger JP, 2005, INT J TUBERC LUNG D, V9, P1242.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{16}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{J. Int. Med. Res.}},
Doc-Delivery-Number = {{215ER}},
Unique-ID = {{ISI:000249791600015}},
}

@article{ ISI:000247325900029,
Author = {Nucci, M. C. and Leach, P. G. L.},
Title = {{Lie integrable cases of the simplified multistrain/two-stream model for
   tuberculosis and dengue fever}},
Journal = {{JOURNAL OF MATHEMATICAL ANALYSIS AND APPLICATIONS}},
Year = {{2007}},
Volume = {{333}},
Number = {{1}},
Pages = {{430-449}},
Month = {{SEP 1}},
Abstract = {{We apply the techniques of Lie's symmetry analysis to a caricature of
   the simplified multistrain model of Castillo-Chavez and Feng {[}C.
   Castillo-Chavez, Z. Feng, To treat or not to treat: The case of
   tuberculosis, J. Math. Biol. 35 (1997) 629-656] for the transmission of
   tuberculosis and the coupled two-stream vector-based model of Feng and
   Velasco-Hernandez {[}Z. Feng, JX Velasco-Hernandez, Competitive
   exclusion in a vector-host model for the dengue fever, J. Math. Biol. 35
   (1997) 523-544] to identify the combinations of parameters which lead to
   the existence of nontrivial symmetries. In particular we identify those
   combinations which lead to the possibility of the linearization of the
   system and provide the corresponding solutions. Many instances of
   additional symmetry are analyzed. (c) 2007 Elsevier Inc. All rights
   reserved.}},
Publisher = {{ACADEMIC PRESS INC ELSEVIER SCIENCE}},
Address = {{525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Nucci, MC (Reprint Author), Univ Perugia, Dipartimento Matemat \& Informat, I-06123 Perugia, Italy.
   Univ Perugia, Dipartimento Matemat \& Informat, I-06123 Perugia, Italy.
   Univ KwaZulu Natal, Sch Math Sci, ZA-4000 Durban, South Africa.}},
DOI = {{10.1016/j.jmaa.2007.02.061}},
ISSN = {{0022-247X}},
Keywords = {{Lie group analysis; mathematical epidemiology}},
Keywords-Plus = {{CONFIGURATIONAL INVARIANTS}},
Research-Areas = {{Mathematics}},
Web-of-Science-Categories  = {{Mathematics, Applied; Mathematics}},
Author-Email = {{nucci@unipg.it
   leachp@ukzn.ac.za}},
ResearcherID-Numbers = {{Nucci, Maria Clara/B-3588-2012}},
ORCID-Numbers = {{Nucci, Maria Clara/0000-0003-1453-0988}},
Cited-References = {{Bianchi L., 1918, LEZIONI TEORIA GRUPP.
   CastilloChavez C, 1997, J MATH BIOL, V35, P629, DOI 10.1007/s002850050069.
   Edwards M, 2006, J NONLINEAR MATH PHY, V13, P211, DOI 10.2991/jnmp.2006.13.2.6.
   Ermakov V. P., 1880, U IZV KIEV 3, V9, P1, DOI doi:10.2298/AADM0802123E.
   Feng ZL, 1997, J MATH BIOL, V35, P523, DOI 10.1007/s002850050064.
   HALL LS, 1983, PHYSICA D, V8, P90, DOI 10.1016/0167-2789(83)90312-3.
   IBRAGIMOV NH, 1994, LIE GROUPS THEIR APP, V1, P49.
   Ince E., 1927, ORDINARY DIFFERENTIA.
   Lie S., 1912, VORLESUNGEN DIFFEREN.
   NUCCI MC, 1990, 062090051 GEORG I TE.
   NUCCI MC, 1996, CRC HDB LIE GROUP AN, V3.
   PINNEY E, 1950, P AM MATH SOC, V1, P681, DOI 10.2307/2032300.
   SARLET W, 1985, PHYSICA D, V17, P87, DOI 10.1016/0167-2789(85)90136-8.
   Soh CW, 2004, J NONLINEAR MATH PHY, V11, P13, DOI 10.2991/jnmp.2004.11.1.3.
   Torrisi V, 2001, CONT MATH, V285, P11.
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Math. Anal. Appl.}},
Doc-Delivery-Number = {{179YG}},
Unique-ID = {{ISI:000247325900029}},
}

@article{ ISI:000249703000003,
Author = {El-Shazly, Sherief and Ahmad, Suhail and Mustafa, Abu S. and Al-Attiyah,
   Raja and Krajci, Dimitrolos},
Title = {{Internalization by HeLa cells of latex beads coated with mammalian cell
   entry (Mce) proteins encoded by the mce3 operon of Mycobacterium
   tuberculosis}},
Journal = {{JOURNAL OF MEDICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{56}},
Number = {{9}},
Pages = {{1145-1151}},
Month = {{SEP}},
Abstract = {{The mammalian cell entry (Mce) operon 3 (mce3) is one of four homologous
   mce operons of Mycobacterium tuberculosis, encoding six (Mce3A-F)
   invasin-like membrane-associated proteins. Previous studies have shown
   that recombinant expression of Mce1A encoded by the mce1 operon in
   Escherichia coli allows this non-pathogenic bacterium to invade and
   survive inside macrophages, and latex beads coated with Mce1A are
   internalized by non-phagocytic HeLa cells. However, the role of other
   mce1 operon proteins (Mce1B-F) and proteins encoded by the operons
   mce2-4 in facilitating the internalization of M. tuberculosis in
   mammalian cells has not been studied. This study was carried out to
   determine whether Mce proteins encoded by the mce3 operon also
   facilitated the internalization of latex beads by HeLa cells.
   Recombinant pure Mce3A and lipoprotein LprM (Mce3E) were expressed and
   purified from E coli cells. Mce1A expressed as a fusion protein with
   glutathione S-transferase (GST-Mce1A) and GST alone, purified similarly
   from E coli cells, were used as control proteins. Fluorescent latex
   beads coated with purified proteins were used to study their uptake by
   HeLa cells using fluorescence microscopy, flow cytometry and electron
   microscopy. Fluorescence microscopy and flow cytometry showed an
   association of HeLa cells with beads coated with both Mce3A and LprM,
   whilst GST-Mce1A and GST yielded the expected results. Transmission
   electron microscopy confirmed the uptake of beads coated with Mce3A or
   LprM by HeLa. cells. The data showed that Mce3A encoded by the mce3
   operon facilitated the uptake and internalization of latex beads by HeLa
   cells. The data also showed, for the first time, the role of another Mce
   protein (LprM/Mce3E) in facilitating the interaction and internalization
   of M. tuberculosis by mammalian cells.}},
Publisher = {{SOC GENERAL MICROBIOLOGY}},
Address = {{MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ahmad, S (Reprint Author), Kuwait Univ, Fac Med, Dept Microbiol, Kuwait, Kuwait.
   Kuwait Univ, Fac Med, Dept Microbiol, Kuwait, Kuwait.
   Kuwait Univ, Fac Med, Dept Anat, Kuwait, Kuwait.}},
DOI = {{10.1099/jmm.0.47095-0}},
ISSN = {{0022-2615}},
Keywords-Plus = {{ESCHERICHIA-COLI; MACROPHAGES; SURVIVAL; GENOME; DNA; LIPOARABINOMANNAN;
   PHAGOCYTOSIS; MECHANISMS; EXPRESSION; INFECTION}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{suliail\_ah@hsc.edu.kw}},
Cited-References = {{Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593.
   Ahmad S, 2005, SCAND J IMMUNOL, V62, P16, DOI 10.1111/j.1365-3083.2005.01639.x.
   Ahmad S, 2004, SCAND J IMMUNOL, V60, P382, DOI 10.1111/j.0300-9475.2004.01490.x.
   Ahmad S, 2003, PROTEIN EXPRES PURIF, V29, P167, DOI 10.1016/S1046-5928(03)00052-4.
   Ahmad S, 1999, SCAND J IMMUNOL, V50, P510.
   ARRUDA S, 1993, SCIENCE, V261, P1454, DOI 10.1126/science.8367727.
   Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520.
   Bermudez LE, 1996, INFECT IMMUN, V64, P1400.
   Casali N, 2002, INFECT IMMUN, V70, P6846, DOI 10.1128/IAI.70.12.6846-6852.2002.
   Chitale S, 2001, CELL MICROBIOL, V3, P247, DOI 10.1046/j.1462-5822.2001.00110.x.
   Cole ST, 1998, NATURE, V393, P537.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Das AK, 2003, BIOCHEM BIOPH RES CO, V302, P442, DOI 10.1016/S0006-291X(03)00116-5.
   El-Etr SH, 2001, FRONT BIOSCI, V6, pD737, DOI 10.2741/sahar.
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4.
   Garcia-Perez BE, 2003, MICROB PATHOGENESIS, V35, P49, DOI 10.1016/S0882-4010(03)00089-5.
   Glickman MS, 2001, CELL, V104, P477, DOI 10.1016/S0092-8674(01)00236-7.
   Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x.
   Harboe M, 1999, SCAND J IMMUNOL, V50, P519.
   Hernandez-Pando R, 2000, LANCET, V356, P2133, DOI 10.1016/S0140-6736(00)03493-0.
   Hingley-Wilson SM, 2003, NAT IMMUNOL, V4, P949, DOI 10.1038/ni981.
   Kang PB, 2005, J EXP MED, V202, P987, DOI 10.1084/jem.20051239.
   Krajci D, 2000, EUR J CELL BIOL, V79, P365, DOI 10.1078/S0171-9335(04)70041-2.
   Lu SW, 2006, ANAL BIOCHEM, V353, P7, DOI 10.1016/j.ab.2006.01.044.
   Mehta PK, 2006, MICROB PATHOGENESIS, V41, P119, DOI 10.1016/j.micpath.2006.05.002.
   Mitra D, 2005, TUBERCULOSIS, V85, P337, DOI 10.1016/j.tube.2005.08.010.
   Nguyen L, 2005, TRENDS CELL BIOL, V15, P269, DOI 10.1016/j.tcb.2005.03.009.
   Reddy VM, 2002, TUBERCULOSIS, V82, P31, DOI 10.1054/tube.2001.0320.
   Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034.
   SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070.
   SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920.
   Zumarraga M, 1999, MICROBIOL-UK, V145, P893.}},
Number-of-Cited-References = {{32}},
Times-Cited = {{25}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{J. Med. Microbiol.}},
Doc-Delivery-Number = {{213YK}},
Unique-ID = {{ISI:000249703000003}},
}

@article{ ISI:000249703000014,
Author = {Han, Hui and Wang, Fang and Xiao, Yong and Ren, Yi and Chao, Yanjie and
   Guo, Aizhen and Ye, Lingxiang},
Title = {{Utility of mycobacterial interspersed repetitive unit typing for
   differentiating Mycobacterium tuberculosis isolates in Wuhan, China}},
Journal = {{JOURNAL OF MEDICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{56}},
Number = {{9}},
Pages = {{1219-1223}},
Month = {{SEP}},
Abstract = {{Mycobacterial interspersed repetitive unit (MIRU) typing has been found
   to allow rapid, reliable, high-throughput genotyping of Mycobacterium
   tuberculosis, and may represent a feasible approach to study M.
   tuberculosis molecular epidemiology. To evaluate the use of MIRU typing
   in discriminating M. tuberculosis strains, isolates from 105 patients in
   Wuhan City, China, were genotyped by this method as compared to
   spoligotyping. MIRU typing identified 55 types that defined 21 clusters
   and 34 unique isolates. The discriminatory power was high
   {[}Hunter-Gaston discriminatory index (HGDI), 0.97]. Spoligotyping
   showed that 86 (81.9\%) of 105 isolates belonged to the Beijing family
   genotype. For Beijing family and non-Beijing strains, the discriminatory
   power of MIRU was high (HGDI, 0.95 and 0.98, respectively). Among the
   alleles of the MIRU loci for the Beijing family, only locus 26 was
   highly discriminative, but for non-Beijing strains, loci 10, 16 and 26
   were highly discriminative. MIRU typing is a simple and fast method
   which may be used for preliminary screening of M. tuberculosis isolates
   in China.}},
Publisher = {{SOC GENERAL MICROBIOLOGY}},
Address = {{MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ye, LX (Reprint Author), Huazhong Univ Sci \& Technol, Sch Publ Hlth, Dept Epidemiol, Wuhan 430030, Peoples R China.
   Huazhong Univ Sci \& Technol, Sch Publ Hlth, Dept Epidemiol, Wuhan 430030, Peoples R China.
   Huazhong Univ Sci \& Technol, Sch Publ Hlth, Dept Social Med, Wuhan 430030, Peoples R China.
   Wuhan Tuberculosis Prevent \& Treatment Hosp, Wuhan 430030, Peoples R China.
   Huazhong Agr Univ, Natl Key Lab Agr Microbiol, Wuhan 430070, Peoples R China.
   China CDC, Natl Ctr Women \& Childrens Hlth, Beijing 100013, Peoples R China.}},
DOI = {{10.1099/jmm.0.47005-0}},
ISSN = {{0022-2615}},
Keywords-Plus = {{NUMBER-TANDEM REPEAT; BEIJING-FAMILY STRAINS; DISCRIMINATORY POWER;
   COMPLEX STRAINS; EPIDEMIOLOGY; DIVERSITY; MARKERS; REPRODUCIBILITY;
   RECOMMENDATIONS; METHODOLOGY}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{yelx2004@163.com}},
ResearcherID-Numbers = {{Chao, Yanjie/J-1931-2014}},
ORCID-Numbers = {{Chao, Yanjie/0000-0002-5735-7954}},
Cited-References = {{Barlow REL, 2001, J CLIN MICROBIOL, V39, P2453, DOI 10.1128/JCM.39.7.2453-2457.2001.
   Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6.
   Cowan LS, 2002, J CLIN MICROBIOL, V40, P1592, DOI 10.1128/JCM.40.5.1592-1602.2002.
   Dale JW, 2001, INT J TUBERC LUNG D, V5, P216.
   Glynn JR, 2002, EMERG INFECT DIS, V8, P843.
   Graur D, 2000, FUNDAMENTALS MOL EVO, P58.
   HUNTER PR, 1988, J CLIN MICROBIOL, V26, P2465.
   Kam KM, 2005, J CLIN MICROBIOL, V43, P306, DOI 10.1128/JCM.43.1.306-313.2005.
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907.
   Kanduma E, 2003, J APPL MICROBIOL, V94, P781, DOI 10.1046/j.1365-2672.2003.01918.x.
   Kremer K, 2005, J CLIN MICROBIOL, V43, P5628, DOI 10.1128/JCM.43.11.5628-5638.2005.
   Kremer K, 2004, J CLIN MICROBIOL, V42, P4040, DOI 10.1128/JCM.42.9.4040-4049.2004.
   Kremer K, 1999, J CLIN MICROBIOL, V37, P2607.
   Kwara A, 2003, J CLIN MICROBIOL, V41, P2683, DOI 10.1128/JCM.41.6.2683-2685.2003.
   Mazars E, 2001, P NATL ACAD SCI USA, V98, P1901, DOI 10.1073/pnas.98.4.1901.
   Mokrousov I, 2003, EUR J CLIN MICROBIOL, V22, P342, DOI 10.1007/s10096-003-0944-0.
   Mokrousov I, 2004, J CLIN MICROBIOL, V42, P2438, DOI 10.1128/JCM.42.6.2438-2444.2004.
   Nikolayevskyy V, 2006, EMERG INFECT DIS, V12, P1406.
   Sola C, 2003, INFECT GENET EVOL, V3, P125, DOI 10.1016/S1567-1348(03)00011-X.
   Sun YJ, 2004, J CLIN MICROBIOL, V42, P1986, DOI 10.1128/JCM.42.5.1986-1993.2004.
   Supply P, 2000, MOL MICROBIOL, V36, P762, DOI 10.1046/j.1365-2958.2000.01905.x.
   Supply P, 2003, MOL MICROBIOL, V47, P529, DOI 10.1046/j.1365-2958.2003.03315.x.
   Supply P, 2001, J CLIN MICROBIOL, V39, P3563, DOI 10.1128/JCM.39.10.3563-3571.2001.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.
   VANSOOLINGEN D, 1995, J CLIN MICROBIOL, V33, P3234.
   Warren R, 1996, J CLIN MICROBIOL, V34, P2219.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{22}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{J. Med. Microbiol.}},
Doc-Delivery-Number = {{213YK}},
Unique-ID = {{ISI:000249703000014}},
}

@article{ ISI:000249573800002,
Author = {Ikryannikova, Larisa N. and Afanas'ev, Maxim V. and Akopian, Tat'yana A.
   and Il'ina, Elena N. and Kuz'min, Aleksey V. and Larionova, Elena E. and
   Smirnova, Tat'yana G. and Chernousova, Larisa N. and Govorun, Vadim M.},
Title = {{Mass-spectrometry based minisequencing method for the rapid detection of
   drug resistance in Mycobacterium tuberculosis}},
Journal = {{JOURNAL OF MICROBIOLOGICAL METHODS}},
Year = {{2007}},
Volume = {{70}},
Number = {{3}},
Pages = {{395-405}},
Month = {{SEP}},
Abstract = {{A MALDI TOF MS based minisequencing method has been developed and
   applied for the analysis of rifampin (RIF)- and isoniazid (INH)resistant
   M. tuberculosis strains. Eight genetic markers of RIF
   resistance-nucleotide polymorphisms located in RRDR of rpoB gene, and
   three of INH resistance including codon 315 of katG gene and -8 and -15
   positions of the promoter region of fabG1-inhA operon were worked out.
   Based on the analysis of 100 M tuberculosis strains collected from the
   Moscow region in 1997-2005 we deduced that 91\% of RIF-resistant and
   94\% of INH-resistant strains can be identified using the technique
   suggested. The approach is rapid, reliable and allows to reveal the drug
   resistance of M. tuberculosis strains within 12 h after sample
   isolation. (C) 2007 Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ikryannikova, LN (Reprint Author), Minist Publ Hlth Russian Federat, Res Inst Phys Chem Med, Malaya Pirogovskaya 1a, Moscow 119992, Russia.
   Minist Publ Hlth Russian Federat, Res Inst Phys Chem Med, Moscow 119992, Russia.
   Russian Acad Med Sci, Cent TB Res Inst, Moscow, Russia.}},
DOI = {{10.1016/j.inimet.2007.05.015}},
ISSN = {{0167-7012}},
Keywords = {{drug resistance; MALDI-TOF mass-spectrometry; minisequencing;
   Mycobacterium tuberculosis}},
Keywords-Plus = {{SINGLE NUCLEOTIDE POLYMORPHISMS; MOLECULAR CHARACTERIZATION; RIFAMPIN
   RESISTANCE; ISONIAZID RESISTANCE; RPOB MUTATIONS; GENE-MUTATIONS;
   COMPLEX; ASSAY; IDENTIFICATION; HYBRIDIZATION}},
Research-Areas = {{Biochemistry \& Molecular Biology; Microbiology}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Microbiology}},
Author-Email = {{larisa@kgc.msu.ru}},
ResearcherID-Numbers = {{Ilina, Elena/N-8190-2015}},
ORCID-Numbers = {{Ilina, Elena/0000-0003-0130-5079}},
Cited-References = {{Baker LV, 2005, ANTIMICROB AGENTS CH, V49, P1455, DOI 10.1128/AAC.49.4.1455-1464.2005.
   Bakonyte D, 2003, ANTIMICROB AGENTS CH, V47, P2009, DOI 10.1128/AAC.47.6.2009-2011.2003.
   Bartfai Z, 2001, J CLIN MICROBIOL, V39, P3736, DOI 10.1128/JCM.39.10.3736-3739.2001.
   Blondal T, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng156.
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495.
   Cardoso RF, 2004, ANTIMICROB AGENTS CH, V48, P3373, DOI 10.1128/AAC.48.9.3373-3381.2004.
   Cavusoglu C, 2002, J CLIN MICROBIOL, V40, P4435, DOI 10.1128/JCM.40.12.4435-4438.2002.
   Espasa M, 2005, J ANTIMICROB CHEMOTH, V55, P860, DOI 10.1093/jac/dki132.
   Espinal MA, 2003, TUBERCULOSIS, V83, P44, DOI 10.1016/S1472-9792(02)00058-6.
   Fan XY, 2003, J CLIN MICROBIOL, V41, P993, DOI 10.1128/JCM.41.3.993-997.2003.
   Gillespie SH, 2002, ANTIMICROB AGENTS CH, V46, P267, DOI 10.1128/AAC.46.2.267-274.2002.
   Gryadunov D, 2005, CLIN MICROBIOL INFEC, V11, P531, DOI 10.1111/j.1469-0691.2005.01183.x.
   Haff LA, 1997, GENOME RES, V7, P378.
   HERERA L, 2003, INT J ANTIMICROB AG, V21, P403.
   Ilina EN, 2005, J CLIN MICROBIOL, V43, P2810, DOI 10.1128/JCM.43.6.2810-2815.2005.
   Kim BJ, 2004, J CLIN MICROBIOL, V42, P1308, DOI 10.1128/JCM.42.3.1308-1312.2004.
   Lavender C, 2005, ANTIMICROB AGENTS CH, V49, P4068, DOI 10.1128/AAC.49.10.4068-4074.2005.
   Lin SYG, 2004, J CLIN MICROBIOL, V42, P4204, DOI 10.1128/JCM.42.9.4204-4208.2004.
   Liu YP, 2000, J CLIN MICROBIOL, V38, P3656.
   Maher D, 2005, CLIN CHEST MED, V26, P167, DOI 10.1016/j.ccm.2005.02.009.
   Marttila HJ, 1998, ANTIMICROB AGENTS CH, V42, P2443.
   McCammon MT, 2005, ANTIMICROB AGENTS CH, V49, P2200, DOI 10.1128/AAC.49.6.2200-2209.2005.
   Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002.
   Ramaswamy SV, 2003, ANTIMICROB AGENTS CH, V47, P1241, DOI 10.1128/AAC.47.4.1241-1250.2003.
   Rossau R, 1997, ANTIMICROB AGENTS CH, V41, P2093.
   Sharma SK, 2004, INDIAN J MED RES, V120, P354.
   Tang X, 2005, J MICROBIOL METH, V63, P318, DOI 10.1016/j.mimet.2005.04.026.
   Tracevska T, 2002, J CLIN MICROBIOL, V40, P3789, DOI 10.1128/JCM.40.10.3789-3792.2002.
   Van Der Zanden AGM, 2003, J CLIN MICROBIOL, V41, P1101, DOI 10.1128/JCM.41.3.1101-1108.2003.
   van Doorn HR, 2003, J CLIN MICROBIOL, V41, P4630, DOI 10.1128/JCM.41.10.4630-4635.2003.
   VERESHCHAGIN VA, 2005, NEISSERIA GONORHOEAE, V39, P806.
   Wade MM, 2004, FRONT BIOSCI, V9, P975, DOI 10.2741/1289.
   WHO, 1998, LAB SERV TUB CONTR 3.
   World Health Organization, 2003, GUID SURV DRUG RES T.
   Yue J, 2003, J CLIN MICROBIOL, V41, P2209, DOI 10.1128/JCM.41.5.2209-2212.2003.
   2003, DECREE MINISTRY PUBL.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{J. Microbiol. Methods}},
Doc-Delivery-Number = {{212DM}},
Unique-ID = {{ISI:000249573800002}},
}

@article{ ISI:000249660200014,
Author = {Anderson, Charlotte and Abubakar, Ibrahim and Maguire, Helen and
   Sonnenberg, Pam},
Title = {{Survey of tuberculosis incidents in hospital healthcare workers, England
   and Wales, 2005}},
Journal = {{JOURNAL OF PUBLIC HEALTH}},
Year = {{2007}},
Volume = {{29}},
Number = {{3}},
Pages = {{292-297}},
Month = {{SEP}},
Abstract = {{Background Tuberculosis (TB) incidence has increased in England and
   Wales since 1987, with much of the increase in migrants from high TB
   incidence countries. The National Health Service increasingly depends on
   healthcare workers (HCWs) trained abroad, often from areas of high TB
   incidence. A retrospective survey of TB incidents in hospital-based HCWs
   was carried out to describe their frequency, distribution and
   characteristics.
   Methods Reports of HCWs with TB in hospitals were identified among
   routine surveillance of TB incidents. Additional data on these and
   reports of further incidents fitting the study definition were obtained
   by contacting local and regional Health Protection Units.
   Results At least 105 incidents of TB in hospital-based HCWs occurred in
   England and Wales in 2005. Most involved HCWs from high incidence
   countries, and most cases had pre-employment occupational health
   screening. We found no evidence of onward transmission within hospitals.
   Conclusions Pre-employment screening for active disease may not be
   enough to prevent the occurrence of these incidents. A high index of
   suspicion among HCWs with TB symptoms is needed. Detection of latent
   infection with interferon gamma release assays, and the use of
   preventive treatment, should be evaluated.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Abubakar, I (Reprint Author), Ctr Infect, Dept Resp Dis, Hlth Protect Agcy, Colindale NW9 5EQ, England.
   Ctr Infect, Dept Resp Dis, Hlth Protect Agcy, Colindale NW9 5EQ, England.
   London Reg Epidemiol, Hlth Protect Agcy, London, England.
   UCL, Ctr Sex Hlth \& HIV Res, London, England.}},
DOI = {{10.1093/pubmed/fdm042}},
ISSN = {{1741-3842}},
Keywords = {{tuberculosis; healthcare workers; hospitals}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{ibrahim.abubak@hpa.org.uk}},
ORCID-Numbers = {{Abubakar, Ibrahim/0000-0002-0370-1430
   Sonnenberg, Pam/0000-0002-1067-1583}},
Cited-References = {{Aiken LH, 2004, HEALTH AFFAIR, V23, P69, DOI 10.1377/hlthaff.23.3.69.
   Bach Stephen, 2003, 209 INT LAB OFF.
   Department of Health, 2004, STOPP TUB ENGL ACT P.
   {*}GEN MED COUNC, 2004, GEN MED COUNC ANN RE.
   Health Protection Agency, 2006, FOC TUB ANN SURV REP.
   Joshi R, 2006, PLOS MED, V3, P2376, DOI 10.1371/journal.pmed.0030494.
   {*}NAT I HLTH CLIN E, 2006, TUB.
   World Health Organization, 2006, WHOHTMTB2006362.}},
Number-of-Cited-References = {{8}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{J. Public Health}},
Doc-Delivery-Number = {{213IN}},
Unique-ID = {{ISI:000249660200014}},
}

@article{ ISI:000249472500005,
Author = {Dias, Marcio Vinicius Bertacine and Vasconcelos, Igor Bordin and Prado,
   Adriane Michele Xavier and Fadel, Valmir and Basso, Luiz Augusto and De
   Azevedo, Jr., Walter Filgueira and Santos, Diogenes Santiago},
Title = {{Crystallographic studies on the binding of isonicotinyl-NAD adduct to
   wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from
   Mycobacterium tuberculosis}},
Journal = {{JOURNAL OF STRUCTURAL BIOLOGY}},
Year = {{2007}},
Volume = {{159}},
Number = {{3}},
Pages = {{369-380}},
Month = {{SEP}},
Abstract = {{The resumption of tuberculosis led to an increased need to understand
   the molecular mechanisms of drug action and drug resistance, which
   should provide significant insight into the development of newer
   compounds. Isoniazid (INH), the most prescribed drug to treat TB,
   inhibits an NADH-dependent enoyl-acyl carrier protein reductase (InhA)
   that provides precursors of mycolic acids, which are components of the
   mycobacterial cell wall. InhA is the major target of the mode of action
   of isoniazid. INH is a pro-drug that needs activation to form the
   inhibitory INH-NAD adduct. Missense mutations in the inhA structural
   gene have been identified in clinical isolates of Mycobacterium
   tuberculosis resistant to INH. To understand the mechanism of resistance
   to INH, we have solved the structure of two InhA mutants (121V and
   S94A), identified in INH-resistant clinical isolates, and compare them
   to INH-sensitive WT InhA structure in complex with the INH-NAD adduct.
   We also solved the structure of unliganded INH-resistant S94A protein,
   which is the first report on apo form of InhA. The salient features of
   these structures are discussed and should provide structural information
   to improve our understanding of the mechanism of action of, and
   resistance to, INH in M. tuberculosis. The unliganded structure of InhA
   allows identification of conformational changes upon ligand binding and
   should help structure-based drug design of more potent antimycobacterial
   agents. (c) 2007 Elsevier Inc. All rights reserved.}},
Publisher = {{ACADEMIC PRESS INC ELSEVIER SCIENCE}},
Address = {{525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{De Azevedo, WF (Reprint Author), Pontificia Univ Catolica Rio de Janeiro, Fac Biociencias, Av Ipiranga 6681, BR-90619900 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio de Janeiro, Fac Biociencias, BR-90619900 Porto Alegre, RS, Brazil.
   UNESP, Dept Fis, Programa Posgrad Biofis Mol, BR-15054000 Sao Jose Do Rio Preto, SP, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Inst Pesquisas Biomed, Ctr Pesquisa Biol Mol \& Func, Porto Alegre, RS, Brazil.}},
DOI = {{10.1016/j.jsb.2007.04.009}},
ISSN = {{1047-8477}},
Keywords = {{mycobacterium tuberculosis; InhA; crystal structure; isoniazid; drug
   resistance; Enoyl-ACP reductase}},
Keywords-Plus = {{ENOYL-ACP REDUCTASE; ENZYMATIC CHARACTERIZATION; MACROMOLECULAR
   STRUCTURES; CRYSTAL-STRUCTURE; DRUG-RESISTANCE; MDR-TB; INHA;
   ETHIONAMIDE; TARGET; MECHANISM}},
Research-Areas = {{Biochemistry \& Molecular Biology; Biophysics; Cell Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Biophysics; Cell Biology}},
Author-Email = {{walter.junior@pucrs.br
   diogenes@pucrs.br}},
ResearcherID-Numbers = {{Santos, Diogenes/A-6647-2008
   Fadel, Valmir/D-5321-2014}},
ORCID-Numbers = {{Santos, Diogenes/0000-0003-4971-463X
   Fadel, Valmir/0000-0001-6368-8955}},
Cited-References = {{BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673.
   Basso LA, 1998, J INFECT DIS, V178, P769.
   Basso LA, 1998, ADV EXP MED BIOL, V456, P115.
   Basso LA, 1996, J AM CHEM SOC, V118, P11301, DOI 10.1021/ja962035y.
   Basso LA, 2005, MED CHEM REV ONLINE, V2, P393, DOI 10.2174/156720305774330458.
   BERNSTEIN J, 1952, AM REV TUBERC PULM, V65, P357.
   Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215.
   Centers for Disease Control and Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P301.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   De Lano W.L., 2004, PYMOL MOL GRAPHICS S.
   DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450.
   Espinal MA, 2003, TUBERCULOSIS, V83, P44, DOI 10.1016/S1472-9792(02)00058-6.
   Glickman MS, 2001, CELL, V104, P477, DOI 10.1016/S0092-8674(01)00236-7.
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505.
   JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038.
   JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063.
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4.
   Kremer L, 2003, J BIOL CHEM, V278, P20547, DOI 10.1074/jbc.M302435200.
   Kuo MR, 2003, J BIOL CHEM, V278, P20851, DOI 10.1074/jbc.M211968200.
   Larsen MH, 2002, MOL MICROBIOL, V46, P453, DOI 10.1046/j.1365-2958.2002.03162.x.
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944.
   Lei BF, 2000, J BIOL CHEM, V275, P2520, DOI 10.1074/jbc.275.4.2520.
   McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094.
   MIDDLEBROOK G, 1953, SCIENCE, V118, P297, DOI 10.1126/science.118.3063.297.
   MITCHISON DA, 1985, TUBERCLE, V66, P219, DOI 10.1016/0041-3879(85)90040-6.
   Morlock GP, 2003, ANTIMICROB AGENTS CH, V47, P3799, DOI 10.1128/AAC.47.12.3799-3805.2003.
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255.
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597.
   Oliveira JS, 2007, CURR DRUG TARGETS, V8, P399, DOI 10.2174/138945007780058942.
   Oliveira JS, 2006, J MOL BIOL, V359, P646, DOI 10.1016/j.jmb.2006.03.055.
   Ormerod LP, 2005, BRIT MED BULL, V73-74, P17, DOI 10.1093/bmb/ldh047.
   Pablos-Mendez A, 2002, B WORLD HEALTH ORGAN, V80, P489.
   Parikh S, 1999, BIOCHEMISTRY-US, V38, P13623, DOI 10.1021/bi990529c.
   Polikarpov I, 1998, J SYNCHROTRON RADIAT, V5, P72, DOI 10.1107/S0909049597014684.
   QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004.
   Rawat R, 2003, P NATL ACAD SCI USA, V100, P13881, DOI 10.1073/pnas.2235848100.
   Rozwarski DA, 1999, J BIOL CHEM, V274, P15582, DOI 10.1074/jbc.274.22.15582.
   Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98.
   Schroeder E. K., 2002, Current Pharmaceutical Biotechnology, V3, P197, DOI 10.2174/1389201023378328.
   Uchoa HB, 2004, BIOCHEM BIOPH RES CO, V325, P1481, DOI 10.1016/j.bbrc.2004.10.192.
   Veyron-Churlet R, 2004, MOL MICROBIOL, V54, P1161, DOI 10.1111/j.1365-2958.2004.04334.x.
   Vilcheze C, 2005, ANTIMICROB AGENTS CH, V49, P708, DOI 10.1128/AAC.49.2.708-720.2005.
   Vilcheze C, 2006, NAT MED, V12, P1027, DOI 10.1038/nm1466.
   Zabinski RF, 1997, J AM CHEM SOC, V119, P2331, DOI 10.1021/ja9639731.
   {[}Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760.
   2006, WKLY EPIDEMIOL REC, V21, P386.}},
Number-of-Cited-References = {{46}},
Times-Cited = {{32}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{J. Struct. Biol.}},
Doc-Delivery-Number = {{210RE}},
Unique-ID = {{ISI:000249472500005}},
}

@article{ ISI:000249616000034,
Author = {Sykes, Jane E. and Cannon, Allison B. and Norris, Aimee J. and Byrne,
   Barbara A. and Affolter, Timothy and O'Malley, Michael A. and Wisner,
   Erik R.},
Title = {{Mycobacterium tuberculosis complex infection in a dog}},
Journal = {{JOURNAL OF VETERINARY INTERNAL MEDICINE}},
Year = {{2007}},
Volume = {{21}},
Number = {{5}},
Pages = {{1108-1112}},
Month = {{SEP-OCT}},
Publisher = {{AMER COLL VETERINARY INTERNAL MEDICINE}},
Address = {{1997 WADSWORTH BOULEVARD, STE A, LAKEWOOD, CO 80214-5293 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Sykes, JE (Reprint Author), Univ Calif Davis, Dept Med \& Epidemiol, 2108 Tupper Hall, Davis, CA 95616 USA.
   Univ Calif Davis, Dept Med \& Epidemiol, Davis, CA 95616 USA.
   Univ Calif Davis, Dept Pathol Microbiol \& Immunol, Davis, CA 95616 USA.
   Vet Med Teaching Hosp, Davis, CA USA.
   Univ Calif Davis, Employee Hlth Serv, Davis, CA 95616 USA.}},
DOI = {{10.1892/0891-6640(2007)21{[}1108:MTCIIA]2.0.CO;2}},
ISSN = {{0891-6640}},
Keywords-Plus = {{MACAW ARA-CHLOROPTERA; TRANSMISSION}},
Research-Areas = {{Veterinary Sciences}},
Web-of-Science-Categories  = {{Veterinary Sciences}},
Author-Email = {{jesykes@ucdavis.edu}},
Cited-References = {{Andreu J, 2004, EUR J RADIOL, V51, P139, DOI 10.1016/j.ejrad.2004.03.009.
   Deforges L, 2004, VET MICROBIOL, V103, P249, DOI 10.1016/j.vetmic.2004.06.016.
   Desmond E, 2004, EMERG INFECT DIS, V10, P921.
   Ellis MD, 2006, VET REC, V159, P46.
   FOSTER ES, 1986, J AM VET MED ASSOC, V188, P1188.
   Glynn JR, 2002, EMERG INFECT DIS, V8, P843.
   Gori A, 2005, EMERG INFECT DIS, V11, P1242.
   HAAS DW, 2000, MANDELL DOUGLAS BENN, P2580.
   Hackendahl NC, 2004, JAVMA-J AM VET MED A, V225, P1573, DOI 10.2460/javma.2004.225.1573.
   Hoop RK, 2002, AVIAN DIS, V46, P502, DOI 10.1637/0005-2086(2002)046{[}0502:MTIIAC]2.0.CO;2.
   LIU S, 1980, J AM VET MED ASSOC, V177, P164.
   Oelemann MC, 2007, J CLIN MICROBIOL, V45, P691, DOI 10.1128/JCM.01393-06.
   Sola C, 2001, EMERG INFECT DIS, V7, P390.
   Steinmetz HW, 2006, AVIAN DIS, V50, P641, DOI 10.1637/7609-041906R.1.
   Tell LA, 2003, AVIAN DIS, V47, P1406, DOI 10.1637/7063.
   VILLAR D, 1995, VET HUM TOXICOL, V37, P473.
   Vincent V., 2003, MANUAL CLIN MICROBIO, P560.
   Washko RM, 1998, J CLIN MICROBIOL, V36, P1101.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Vet. Intern. Med.}},
Doc-Delivery-Number = {{212SB}},
Unique-ID = {{ISI:000249616000034}},
}

@article{ ISI:000248923700053,
Author = {Im, Eung-Jun and Saubi, Narcis and Virgili, Goretti and Sander, Clare
   and Teoh, Denise and Gatell, Jose M. and McShane, Helen and Joseph, Joan
   and Hanke, Tomas},
Title = {{Vaccine platform for prevention of tuberculosis and mother-to-child
   transmission of human immunodeficiency virus type 1 through
   breastfeeding}},
Journal = {{JOURNAL OF VIROLOGY}},
Year = {{2007}},
Volume = {{81}},
Number = {{17}},
Pages = {{9408-9418}},
Month = {{SEP}},
Abstract = {{Most children in Africa receive their vaccine against tuberculosis at
   birth. Those infants born to human immunodeficiency virus type 1
   (HIV-1)-positive mothers are at high risk of acquiring HIV-1 infection
   through breastfeeding in the first weeks of their lives. Thus, the
   development of a vaccine which would protect newborns against both of
   these major global killers is a logical yet highly scientifically,
   ethically, and practically challenging aim. Here, a recombinant lysine
   auxotroph of Mycobacterium bovis bacillus Calmette-Guerin (BCG), a BCG
   strain that is safer than those currently used and expresses an African
   HIV-1 clade-derived immunogen, was generated and shown to be stable and
   to induce durable, high-quality HIV-1-specific CD4+-and CD8(+)-T-cell
   responses. Furthermore, when the recombinant BCG vaccine was used in a
   priming-boosting regimen with heterologous components, the
   HIV-1-specific responses provided protection against surrogate virus
   challenge, and the recombinant BCG vaccine alone protected against
   aerosol challenge with M. tuberculosis. Thus, inserting an HIV-1-derived
   immunogen into the scheduled BCG vaccine delivered at or soon after
   birth may prime HIV-1-specific responses, which can be boosted by
   natural exposure to HIV-1 in the breast milk and/or by a heterologous
   vaccine such as recombinant modified vaccinia virus Ankara delivering
   the same immunogen, and decrease mother-to-child transmission of HIV-1
   during breastfeeding.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hanke, T (Reprint Author), Univ Oxford, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DU, England.
   Univ Oxford, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DU, England.
   Univ Barcelona, Catalan HIV Vaccine Res \& Dev Ctr, August Pi I Sunyer Biomed Res Inst, Hosp Clin,Infect Dis Dept,AIDS Res Unit,Sch Med, E-08036 Barcelona, Spain.
   Churchill Hosp, Ctr Clin Vaccinol \& Trop Med, Oxford OX3 7LJ, England.}},
DOI = {{10.1128/JVI.00707-07}},
ISSN = {{0022-538X}},
Keywords-Plus = {{BACILLUS-CALMETTE-GUERIN; LYME-DISEASE VACCINE; EXPRESSING HIV-1 GAG; A
   OSPA LIPOPROTEIN; IMMUNE-RESPONSE; CELL RESPONSES; LYMPHOCYTE RESPONSES;
   PROTECTIVE IMMUNITY; DNA VACCINATION; BOOST REGIMEN}},
Research-Areas = {{Virology}},
Web-of-Science-Categories  = {{Virology}},
Author-Email = {{tomas.hanke@imm.ox.ac.uk}},
Funding-Acknowledgement = {{Medical Research Council {[}MC\_U137884179]; Wellcome Trust {[}076943]}},
Cited-References = {{Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394.
   Alter G, 2004, J IMMUNOL METHODS, V294, P15, DOI 10.1016/j.jim.2004.08.008.
   Ami Y, 2005, J VIROL, V79, P12871, DOI 10.1128/JVI.79.20.12871-12879.2005.
   Andersson SGE, 1996, MICROBIOL-UK, V142, P915.
   Andre S, 1998, J VIROL, V72, P1497.
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233.
   Buseyne F, 1998, AIDS RES HUM RETROV, V14, P1435, DOI 10.1089/aid.1998.14.1435.
   CAYABYAB MJ, 2006, ENV J VIROL, V80, P1645, DOI DOI 10.1128/JVI.80.4.1645-1652.2006.
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698.
   Dennehy M, 2005, VACCINE, V23, P1209, DOI 10.1016/j.vaccine.2004.08.039.
   Dorrell L, 2006, J VIROL, V80, P4705, DOI 10.1128/JVI.80.10.4705-4716.2006.
   Dorrell L, 2005, AIDS, V19, P1321, DOI 10.1097/01.aids.0000180104.65640.16.
   Edelman R, 1999, VACCINE, V17, P904, DOI 10.1016/S0264-410X(98)00276-X.
   GHEORGHIU M, 1988, J BIOL STAND, V16, P15, DOI 10.1016/0092-1157(88)90025-X.
   Goonetilleke N, 2006, J VIROL, V80, P4717, DOI 10.1128/JVI.80.10.4717-4728.2006.
   Goulder PJR, 2001, BRIT MED BULL, V58, P89, DOI 10.1093/bmb/58.1.89.
   Hanke T, 2000, NAT MED, V6, P951, DOI 10.1038/79626.
   Hanke T, 2007, J GEN VIROL, V88, P1, DOI 10.1099/vir.0.82493-0.
   Hermans IF, 2004, J IMMUNOL METHODS, V285, P25, DOI 10.1016/j.jim.2003.10.017.
   Horwitz MA, 2003, INFECT IMMUN, V71, P1672, DOI 10.1128/IAI.71.4.1672-1679.2003.
   Hussey GD, 2002, IMMUNOLOGY, V105, P314, DOI 10.1046/j.1365-2567.2002.01366.x.
   IM EJ, 2007, AIDS RES HUM RETROV, V33, P857.
   Joseph J, 2006, EXPERT REV VACCINES, V5, P827, DOI 10.1586/14760584.5.6.827.
   Larke N, 2005, J VIROL, V79, P14822, DOI 10.1128/JVI.79.23.14822-14833.2005.
   Larke N, 2007, EUR J IMMUNOL, V37, P566, DOI 10.1002/eji.200636711.
   Lotte A, 1984, Adv Tuberc Res, V21, P107.
   LUZURIAGA K, 1995, J IMMUNOL, V154, P433.
   Marchant A, 1999, J IMMUNOL, V163, P2249.
   Marchant A, 2005, CLIN EXP IMMUNOL, V141, P10, DOI 10.111/j.1365.2249.2005.02799.x.
   Marchant A, 2000, CURR OPIN INFECT DIS, V13, P241.
   Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI200317470.
   Mbori-Ngacha D, 2001, JAMA-J AM MED ASSOC, V286, P2413, DOI 10.1001/jama.286.19.2413.
   McMichael AJ, 2006, ANNU REV IMMUNOL, V24, P227, DOI 10.1146/annurev.immunol.24.021605.090605.
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128.
   Moss WJ, 2003, B WORLD HEALTH ORGAN, V81, P61.
   Neyrolles O, 2001, J IMMUNOL, V166, P447.
   Ondondo BO, 2006, EUR J IMMUNOL, V36, P2585, DOI 10.1002/eji.200636508.
   Ota MOC, 2002, J IMMUNOL, V168, P919.
   Pavelka MS, 1999, J BACTERIOL, V181, P4780.
   Phillpotts RJ, 1997, EPIDEMIOL INFECT, V118, P71, DOI 10.1017/S0950268896007157.
   Pikora CA, 1997, J EXP MED, V185, P1153, DOI 10.1084/jem.185.7.1153.
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220.
   Rousseau CM, 2003, J INFECT DIS, V187, P741, DOI 10.1086/374273.
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397.
   Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7.
   Slyker JA, 2005, VACCINE, V23, P4711, DOI 10.1016/j.vaccine.2005.01.145.
   STOVER CK, 1993, J EXP MED, V178, P197, DOI 10.1084/jem.178.1.197.
   TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105.
   Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1.
   {*}WHO, 2001, WEEKLY EPIDEMIOLOGIC, V76, P33.
   YASUTOMI Y, 1993, J IMMUNOL, V150, P3101.
   Young D, 2006, CELL, V124, P683, DOI 10.1016/j.cell.2006.02.013.
   Yu JS, 2006, CLIN VACCINE IMMUNOL, V13, P1204, DOI 10.1128/CVI.00195-06.}},
Number-of-Cited-References = {{53}},
Times-Cited = {{29}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Virol.}},
Doc-Delivery-Number = {{202SL}},
Unique-ID = {{ISI:000248923700053}},
}

@article{ ISI:000249091700009,
Author = {Nelson, Roxanne},
Title = {{New approaches needed for tuberculosis drug compliance}},
Journal = {{LANCET INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{7}},
Number = {{9}},
Pages = {{574}},
Month = {{SEP}},
Publisher = {{LANCET LTD}},
Address = {{84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND}},
Type = {{News Item}},
Language = {{English}},
DOI = {{10.1016/S1473-3099(07)70197-4}},
ISSN = {{1473-3099}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Lancet Infect. Dis.}},
Doc-Delivery-Number = {{205CV}},
Unique-ID = {{ISI:000249091700009}},
}

@article{ ISI:000249642800007,
Author = {Stefanie Deppenmeier and Andrea Schieszler and Ingo Nolte and Irmgard
   Moser and Marion Hewicker-Trautwein},
Title = {{Pulmonary tuberculosis caused by Mycobacterium tuberculosis in golden
   retriever}},
Journal = {{MAGYAR ALLATORVOSOK LAPJA}},
Year = {{2007}},
Volume = {{129}},
Number = {{9}},
Pages = {{549-552}},
Month = {{SEP}},
Publisher = {{MEZOGAZDA KIADO KFT}},
Address = {{PO BOX 16, 1631 BUDAPEST, HUNGARY}},
Type = {{Article}},
Language = {{Hungarian}},
Affiliation = {{Deppenmeier, S (Reprint Author), Free Univ Berlin, Inst Tierpathol, D-1000 Berlin, Germany.
   Free Univ Berlin, Inst Tierpathol, D-1000 Berlin, Germany.}},
ISSN = {{0025-004X}},
Research-Areas = {{Veterinary Sciences}},
Web-of-Science-Categories  = {{Veterinary Sciences}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Magy. Allatorv. Lapja}},
Doc-Delivery-Number = {{213CF}},
Unique-ID = {{ISI:000249642800007}},
}

@article{ ISI:000250007400018,
Author = {Mascia Lopes, Flavia Cristine and Polesi Placeres, Marisa Campos and
   Jordao Junior, Cleso Mendonca and Higuchi, Celio Takashi and Rinaldo,
   Daniel and Vilegas, Wagner and Fujimura Leite, Clarice Queico and
   Carlos, Iracilda Zeppone},
Title = {{Immunological and microbiological activity of Davilla elliptica St.
   Hill. (Dilleniaceae) against Mycobacterium tuberculosis}},
Journal = {{MEMORIAS DO INSTITUTO OSWALDO CRUZ}},
Year = {{2007}},
Volume = {{102}},
Number = {{6}},
Pages = {{769-772}},
Month = {{SEP}},
Abstract = {{Mycobacterium tuberculosis is responsible for over 8 million cases of
   tuberculosis (TB) annually. Natural products may play important roles in
   the chemotherapy of TB. The immunological activity of Davilla elliptica
   chloroform extract (DECE) was evaluated in vitro by the determination of
   hydrogen peroxide (H2O2), nitric oxide ( NO), and tumor necrosis
   factor-alpha (TNF-alpha) release in peritoneal macrophages cultures.
   DECE was also tested for its antimycobacterial activity against M.
   tuberculosis using the microplate alamar blue assay. DECE ( 50, 150, 250
   mu g/ml) stimulated the production of H2O2 (from 1,79 +/- 0,23 to 7,27
   +/- 2,54; 15,02 +/- 2,86; 20,5 +/- 2,1 nmols) (means +/- SD), NO ( from
   2,64 +/- 1,02 to 25,59 +/- 2,29; 26,68 +/- 2,41; 29,45 +/- 5,87 mu mols)
   ( means +/- SD) and TNF-alpha ( from 2,44 +/- 1,46 to 30,37 +/- 8,13;
   38,68 +/- 1,59; 41,6 +/- 0,90 units/ml) (means +/- SD) in a
   dose-dependent manner and also showed a promising antimycobacterial
   activity with a minimum inhibitory concentration of 62,5 mu g/ml. This
   plant may have therapeutic potential in the immunological and
   microbiological control of TB.}},
Publisher = {{FUNDACO OSWALDO CRUZ}},
Address = {{AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Carlos, IZ (Reprint Author), UNESP, Dept Anal Clin, P Expedicionarios Brasil 1601, BR-14801902 Araraquara, SP, Brazil.
   UNESP, Dept Anal Clin, BR-14801902 Araraquara, SP, Brazil.
   UNESP, Dept Ciencias Biol, BR-14801902 Araraquara, SP, Brazil.
   UNESP, Dept Quim Organ, BR-14801902 Araraquara, SP, Brazil.}},
DOI = {{10.1590/S0074-02762007005000086}},
ISSN = {{0074-0276}},
EISSN = {{1678-8060}},
Keywords = {{Davilla elliptica; antimycobacterial activity; immunological activity}},
Keywords-Plus = {{NECROSIS-FACTOR-ALPHA; TUMOR; MACROPHAGES; SYSTEM; ASSAY}},
Research-Areas = {{Parasitology; Tropical Medicine}},
Web-of-Science-Categories  = {{Parasitology; Tropical Medicine}},
Author-Email = {{carlosiz@fcfar.unesp.br}},
ResearcherID-Numbers = {{Leite, Clarice/D-9492-2012
   Vilegas, Wagner/D-3170-2012
   Rinaldo, Daniel/G-2852-2012
   Carlos, Iracilda Zeppone/I-8567-2012}},
ORCID-Numbers = {{Vilegas, Wagner/0000-0003-3032-2556
   Rinaldo, Daniel/0000-0001-5363-6481
   }},
Cited-References = {{ADAMS LB, 1995, J INFECT DIS, V171, P400.
   Akihisa T, 2005, BIOL PHARM BULL, V28, P158, DOI 10.1248/bpb.28.158.
   CARLOS IZ, 1994, MYCOPATHOLOGIA, V127, P189, DOI 10.1007/BF01102920.
   Collins LA, 1997, ANTIMICROB AGENTS CH, V41, P1004.
   Ehlers S, 2003, ANN RHEUM DIS, V62, P37.
   FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2.
   Gaemperli A, 2006, Z RHEUMATOL, V65, P24, DOI 10.1007/s00393-005-0018-z.
   GOW AJ, 1999, NITRIC OXIDE INFECT, P175.
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X.
   Hughes R, 2003, APPL ENVIRON MICROB, V69, P2563, DOI 10.1128/AEM.69.5.2563.2567.2003.
   Kwon O. Jung, 1997, Journal of Korean Medical Science, V12, P481.
   Linares E, 2001, FREE RADICAL BIO MED, V30, P1234, DOI 10.1016/S0891-5849(01)00516-0.
   McKinney JD, 2000, NAT MED, V6, P1330, DOI 10.1038/82142.
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4.
   Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841.
   Okunade AL, 2004, PHYTOCHEMISTRY, V65, P1017, DOI 10.1016/j.phytochem.2004.02.013.
   PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1.
   Raja A, 2004, INDIAN J MED RES, V120, P213.
   Raupach B, 2001, CURR OPIN IMMUNOL, V13, P417, DOI 10.1016/S0952-7915(00)00236-3.
   Rodrigues V. E. G., 2001, Ciencia e Agrotecnologia, V25, P102.
   Swamy R, 1988, INDIAN J TUBERC, V35, P3.
   WALKER L, 1981, NATURE, V293, P69, DOI 10.1038/293069a0.}},
Number-of-Cited-References = {{22}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Mem. Inst. Oswaldo Cruz}},
Doc-Delivery-Number = {{218HU}},
Unique-ID = {{ISI:000250007400018}},
}

@article{ ISI:000250948900006,
Author = {Lima, Patricia and Sidders, Ben and Morici, Lisa and Reader, Rachel and
   Senaratne, Ryan and Casali, Nicola and Riley, Lee W.},
Title = {{Enhanced mortality despite control of lung infection in mice
   aerogenically infected with a Mycobacterium tuberculosis mce1 operon
   mutant}},
Journal = {{MICROBES AND INFECTION}},
Year = {{2007}},
Volume = {{9}},
Number = {{11}},
Pages = {{1285-1290}},
Month = {{SEP}},
Abstract = {{Mycobacterium tuberculosis causes a variety of host clinical outcomes.
   We previously showed that M. tuberculosis disrupted in an operon called
   nice] proliferates unchecked in BALB/c mouse lungs. The observed outcome
   could be attributed either to the mutant bacteria] burden or to the host
   immunopathologic response. To differentiate these possibilities, we
   studied the outcomes of infection in a mouse strain (C57BL/6) less
   susceptible to M. tuberculosis than BALB/c. We found that the mutant
   infection reached a plateau in the lungs at a rate similar to that of
   the wild type. All mice infected with the mutant, but only half of the
   groups of mice infected with the wild type or complemented strain, died
   by 40 weeks (p < 0.05). At 12-21 weeks of infection, histological
   examination of the lungs of mice infected with the mutant showed a
   diffuse pattern of lymphocyte infiltration, while that of mice infected
   with the other strains exhibited a nodular cellular infiltration
   pattern. Surprisingly, the number of bacilli recovered from the lungs
   was similar in all three groups. These observations suggest that rather
   than the bacterial burden, products of the mce 1 operon may directly or
   indirectly modulate the host immune response that is protective to both
   the tubercle bacilli and the host. (C) 2007 Elsevier Masson SAS. All
   rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Riley, LW (Reprint Author), Univ London Royal Vet Coll, Dept Pathol \& Infect Dis, 32 Belgrave Sq, London, England.
   Tulane Univ, Hlth Sci Ctr, Dept Microbiol \& Immunol, New Orleans, LA USA.
   Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, Berkeley, CA 94720 USA.
   Univ Calif Davis, Sch Vet Med, Comparat Pathol Dis, Davis, CA 95616 USA.}},
DOI = {{10.1016/j.micinf.2007.05.020}},
ISSN = {{1286-4579}},
Keywords = {{Mycobacterium tuberculosis; mce1 operon; latent tuberculosis infection;
   C57BL/6 mouse}},
Keywords-Plus = {{PROGRESSIVE PRIMARY TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; MCE1
   OPERON; VIRULENCE}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{lwriley@berkeley.edu}},
ORCID-Numbers = {{Sidders, Ben/0000-0003-2733-3078}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}R01 AI035266, R01 AI035266-10]}},
Cited-References = {{Casali N, 2006, J BACTERIOL, V188, P441, DOI 10.1128/JB.188.2.441-449.2006.
   Casali N, 2002, INFECT IMMUN, V70, P6846, DOI 10.1128/IAI.70.12.6846-6852.2002.
   Casali N, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-60.
   Chitale S, 2001, CELL MICROBIOL, V3, P247, DOI 10.1046/j.1462-5822.2001.00110.x.
   Cole ST, 1998, NATURE, V393, P537.
   Gioffre A, 2005, MICROBES INFECT, V7, P325, DOI 10.1016/j.micinf.2004.11.007.
   Harboe M, 2002, SCAND J IMMUNOL, V56, P580, DOI 10.1046/j.1365-3083.2002.01172.x.
   Joshi SM, 2006, P NATL ACAD SCI USA, V103, P11760, DOI 10.1073/pnas.0603179103.
   Mustafa T, 2000, SCAND J IMMUNOL, V51, P548.
   Mustafa T, 1999, SCAND J IMMUNOL, V50, P127.
   Nuermberger EL, 2004, INFECT IMMUN, V72, P1065, DOI 10.1128/IAI.72.2.1065-1071.2004.
   Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5.
   Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100.
   Scott HM, 2002, INFECT IMMUN, V70, P5946, DOI 10.1128/IAI.70.11.5946-5954.2002.
   Shimono N, 2003, P NATL ACAD SCI USA, V100, P15918, DOI 10.1073/pnas.2433882100.
   Tekaia F., 1999, Tubercle and Lung Disease, V79, P329, DOI 10.1054/tuld.1999.0220.
   Uchida Y, 2007, CELL MICROBIOL, V9, P1275, DOI 10.1111/j.1462-5822.2006.00870.x.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{14}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Microbes Infect.}},
Doc-Delivery-Number = {{231LS}},
Unique-ID = {{ISI:000250948900006}},
}

@article{ ISI:000250948900011,
Author = {Hougardy, Jean-Michel and Verscheure, Virginie and Locht, Camille and
   Mascart, Franqoise and Mascart, Francoise},
Title = {{In vitro expansion of CD4(+)CD25(high)FOXP3(+)CD127(low/-) regulatory T
   cells from peripheral blood lymphocytes of healthy Mycobacterium
   tuberculosis-infected humans}},
Journal = {{MICROBES AND INFECTION}},
Year = {{2007}},
Volume = {{9}},
Number = {{11}},
Pages = {{1325-1332}},
Month = {{SEP}},
Abstract = {{CD4(+)CD25(high)FOXP3(+) regulatory T (Treg) cells have recently been
   found at elevated levels in the peripheral blood of tuberculosis
   patients, compared to Mycobacterium tuberculosis latently infected
   (LTB1) healthy individuals and non-infected controls. Here, we show that
   CD4(+)CD25(high)FOXP3(+) T lymphocytes can be expanded in vitro from
   peripheral blood mononuclear cells (PBMC) of LTBI individuals, but not
   of uninfected controls by incubating them with BCG in the presence of
   TGF-beta. These expanded cells from the PBMC of LTBI subjects expressed
   CTLA-4, GITR and OX-40, but were CD127(low/-) and have therefore the
   phenotype of Treg cells. In addition, they inhibited in a dose-dependant
   manner the proliferation of freshly isolated mononuclear cells in
   response to polyclonal stimulation, indicating that they are functional
   Treg lymphocytes. In contrast, incubation of the PBMC with BCG alone
   preferentially induced activated CD4(+) T cells, expressing CD25 and/or
   CD69 and secreting IFN-gamma. These results show that
   CD4(+)CD25(high)FOXP3(+) Treg cells can be expanded or induced in the
   peripheral blood of LTBI individuals in conditions known to predispose
   to progression towards active tuberculosis and may therefore play an
   important role in the pathogenesis of the disease. (C) 2007 Elsevier
   Masson SAS. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mascart, F (Reprint Author), Hop Erasme, Immunol Clin, 808 route de Lennik, B-1070 Brussels, Belgium.
   Hop Erasme, Immunol Clin, B-1070 Brussels, Belgium.
   Univ Libre Bruxelles, Lab Vaccinol \& Mucosal Immun, Brussels, Belgium.
   INSERM, F-59045 Lille, France.
   Inst Pasteur, F-59019 Lille, France.}},
DOI = {{10.1016/j.micinf.2007.06.004}},
ISSN = {{1286-4579}},
Keywords = {{Tuberculosis; human regulatory T cells; FOXP3; CD127}},
Keywords-Plus = {{HEPARIN-BINDING HEMAGGLUTININ; IMMUNOLOGICAL SELF-TOLERANCE;
   GROWTH-FACTOR-BETA; IMMUNE-RESPONSES; ACTIVE TUBERCULOSIS; ANTIGEN;
   FOXP3; EXPRESSION; INDUCTION; DISEASES}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{fmascart@ulb.ac.be}},
ORCID-Numbers = {{Hougardy, Jean-Michel/0000-0002-7769-5360}},
Cited-References = {{Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816.
   Baecher-Allan C, 2001, J IMMUNOL, V167, P1245.
   Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918.
   Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047.
   Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152.
   Demissie A, 2006, CLIN VACCINE IMMUNOL, V13, P179, DOI 10.1128/CVI.13.2.179-186.2006.
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0.
   Fine PEM, 1996, LANCET, V348, P17.
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9.
   Flores L, 2004, DIABETIC MED, V21, P818, DOI 10.1111/j.1464-5491.2004.01242.x.
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93.
   Guyot-Revol V, 2006, AM J RESP CRIT CARE, V173, P803, DOI 10.1164/rccm.200508-1294OC.
   Hirsch CS, 1996, P NATL ACAD SCI USA, V93, P3193, DOI 10.1073/pnas.93.8.3193.
   Hougardy JM, 2007, AM J RESP CRIT CARE, V176, P409, DOI 10.1164/rccm.200701-084OC.
   HUYGEN K, 1988, SCAND J IMMUNOL, V27, P187, DOI 10.1111/j.1365-3083.1988.tb02338.x.
   Itoh M, 1999, J IMMUNOL, V162, P5317.
   Jagirdar J, 1996, AM J RESP CRIT CARE, V154, P1076.
   Jiang H, 2006, NEW ENGL J MED, V354, P1166, DOI 10.1056/NEJMra055446.
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772.
   Mascart F, 2003, J IMMUNOL, V170, P1504.
   Masungi C, 2002, J INFECT DIS, V185, P513, DOI 10.1086/338833.
   MCHUGH RS, 2002, IMMUNITY, V16, P303.
   Mills KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/nri1485.
   Ribeiro-Rodrigues R, 2006, CLIN EXP IMMUNOL, V144, P25, DOI 10.1111/j.1365-2249.2006.03027.x.
   Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303.
   Temmerman S, 2004, NAT MED, V10, P935, DOI 10.1038/nm1090.
   Turner J, 2000, INFECT IMMUN, V68, P1706, DOI 10.1128/IAI.68.3.1706-1709.2000.
   Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441.
   Yamamoto T, 1996, KIDNEY INT, V49, P461, DOI 10.1038/ki.1996.65.
   Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{33}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Microbes Infect.}},
Doc-Delivery-Number = {{231LS}},
Unique-ID = {{ISI:000250948900011}},
}

@article{ ISI:000250013400031,
Author = {Lynett, Jennifer and Stokes, Richard W.},
Title = {{Selection of transposon mutants of Mycobacterium tuberculosis with
   increased macrophage infectivity identifies fadD23 to be involved in
   sulfolipid production and association with macrophages}},
Journal = {{MICROBIOLOGY-SGM}},
Year = {{2007}},
Volume = {{153}},
Number = {{9}},
Pages = {{3133-3140}},
Month = {{SEP}},
Abstract = {{Alterations to the composition or architecture of the mycobacterial cell
   envelope can affect the macrophage infectivity of the bacillus. To
   further characterize the mycobacterial gene products that modulate the
   interaction with host cells, we employed transposon mutagenesis and
   screened for mutants that demonstrated an enhanced binding affinity
   toward macrophages. After successive rounds of mutant selection and
   enrichment, a total of five mutants were isolated that harboured gene
   disruptions within loci involved in lipid synthetic pathways as well as
   genes coding for putative hypothetical proteins. One mutant in
   particular, with a disruption in the Rv3826 gene (fadD23), was
   repeatedly isolated during library screening. Analysis of the cell
   envelope constituents of the Tn:: fadD23 strain revealed a lack of
   sulfolipid production which was restored following complementation with
   the wild-type gene.}},
Publisher = {{SOC GENERAL MICROBIOLOGY}},
Address = {{MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Stokes, RW (Reprint Author), Univ British Columbia, Dept Microbiol \& Immunol, Vancouver, BC V5Z 4H4, Canada.
   Univ British Columbia, Dept Microbiol \& Immunol, Vancouver, BC V5Z 4H4, Canada.
   Univ British Columbia, Dept Paediat, Vancouver, BC V5Z 4H4, Canada.
   British Columbia Childrens Hosp, Div Infect \& Immunol Dis, Vancouver, BC V5Z 4H4, Canada.}},
DOI = {{10.1099/mic.0.2007/007864-0}},
ISSN = {{1350-0872}},
Keywords-Plus = {{CELL-WALL; FATTY-ACIDS; MDR-TB; VIRULENCE; BIOSYNTHESIS; H37RV; MICE;
   GLYCOPEPTIDOLIPIDS; ACYLTRANSFERASE; PHAGOCYTOSIS}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{rstokes@interchange.ubc.ca}},
Cited-References = {{Bardarov S, 1997, P NATL ACAD SCI USA, V94, P10961, DOI 10.1073/pnas.94.20.10961.
   Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI 10.1093/nar/gkh121.
   Belisle JT, 1998, METH MOL B, V101, P31, DOI 10.1385/0-89603-471-2:31.
   Besra GS, 1998, METH MOL B, V101, P91, DOI 10.1385/0-89603-471-2:91.
   Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x.
   Cole ST, 1998, NATURE, V393, P537.
   Converse SE, 2003, P NATL ACAD SCI USA, V100, P6121, DOI 10.1073/pnas.1030024100.
   Cox JS, 1999, NATURE, V402, P79.
   Lorenzo G., 2005, J INFECT DIS, V192, P2059, DOI DOI 10.1086/498245.PUBMED:16288368.
   Dobson G., 1985, CHEM METHODS BACTERI, P237.
   Domenech P, 2004, J BIOL CHEM, V279, P21257, DOI 10.1074/jbc.M400324200.
   Dubey VS, 2002, MOL MICROBIOL, V45, P1451, DOI 10.1046/j.1365-2958.2002.03119.x.
   Dullaghan EM, 2002, MICROBIOL-SGM, V148, P3111.
   El-Etr SH, 2001, FRONT BIOSCI, V6, pD737, DOI 10.2741/sahar.
   Ernst JD, 1998, INFECT IMMUN, V66, P1277.
   Espinal MA, 2003, TUBERCULOSIS, V83, P44, DOI 10.1016/S1472-9792(02)00058-6.
   Etienne G, 2002, MICROBIOL-SGM, V148, P3089.
   Hisert KB, 2004, INFECT IMMUN, V72, P5315, DOI 10.1128/IAI.72.9.5315-5321.2004.
   Jain M, 2007, P NATL ACAD SCI USA, V104, P5133, DOI 10.1073/pnas.0610634104.
   McAdam RA, 2002, MICROBIOL-SGM, V148, P2975.
   Nunn P, 2005, NAT REV IMMUNOL, V5, P819, DOI 10.1038/nri1704.
   Ormerod LP, 2005, BRIT MED BULL, V73-74, P17, DOI 10.1093/bmb/ldh047.
   RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997.
   Raviglione MC, 2003, TUBERCULOSIS, V83, P4, DOI 10.1016/S1472-9792(02)00071-9.
   Rousseau C, 2003, CELL MICROBIOL, V5, P405, DOI 10.1046/j.1462-5822.2003.00289.x.
   Sambrook J., 1989, MOL CLONING LAB MANU.
   Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100.
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x.
   Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200.
   SMITH RJ, 1981, INFLAMMATION, V5, P177, DOI 10.1007/BF00914442.
   Soto CY, 2000, FEMS MICROBIOL LETT, V187, P103, DOI 10.1111/j.1574-6968.2000.tb09144.x.
   STEWART GR, 2005, PLOS PATHOG, V2, P269.
   STOKES RW, 1986, INFECT IMMUN, V54, P811.
   Stokes RW, 2004, INFECT IMMUN, V72, P5676, DOI 10.1128/IAI.72.10.5676-5686.2004.
   Stokes RW, 1999, CELL IMMUNOL, V197, P1, DOI 10.1006/cimm.1999.1554.
   STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0.
   TAKAYAMA K, 1975, J LIPID RES, V16, P308.
   Trivedi OA, 2004, NATURE, V428, P441, DOI 10.1038/nature02384.
   Villeneuve C, 2003, J BIOL CHEM, V278, P51291, DOI 10.1074/jbc.M306554200.
   VUORIO R, 1994, FEBS LETT, V337, P289, DOI 10.1016/0014-5793(94)80211-4.
   Waddell SJ, 2005, LETT APPL MICROBIOL, V40, P201, DOI 10.1111/j.1472-765X.2005.01659.x.
   Wenzel CQ, 2005, MOL MICROBIOL, V57, P1288, DOI 10.1111/j.1365-2958.2005.04767.x.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{19}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Microbiology-(UK)}},
Doc-Delivery-Number = {{218KC}},
Unique-ID = {{ISI:000250013400031}},
}

@article{ ISI:000249425600013,
Author = {Mishra, Arun K. and Alderwick, Luke J. and Rittmann, Doris and Tatituri,
   Raju V. V. and Nigou, Jerome and Gilleron, Martine and Eggeling, Lothar
   and Besra, Gurdyal S.},
Title = {{Identification of an alpha(1 -> 6) mannopyranosyltransferase (MptA),
   involved in Corynebacterium glutamicum lipomanann biosynthesis, and
   identification of its orthologue in Mycobacterium tuberculosis}},
Journal = {{MOLECULAR MICROBIOLOGY}},
Year = {{2007}},
Volume = {{65}},
Number = {{6}},
Pages = {{1503-1517}},
Month = {{SEP}},
Abstract = {{Corynebacterium glutamicum and Mycobacterium tuberculosis share a
   similar cell wall architecture, and the availability of their genome
   sequences has enabled the utilization of C. glutamicum as a model for
   the identification and study of, otherwise essential, mycobacterial
   genes involved in lipomannan (LM) and lipoarabinomannan (LAM)
   biosynthesis. We selected the putative glycosyltransferase-Rv2174 from
   M. tuberculosis and deleted its orthologue NCgl2093 from C. glutamicum.
   This resulted in the formation of a novel truncated lipomannan (Cg-t-LM)
   and a complete ablation of LM/LAM biosynthesis. Purification and
   characterization of Cg-t-LM revealed an overall decrease in molecular
   mass, a reduction of alpha(1 -> 6) and alpha(1 -> 2) glycosidic linkages
   illustrating a reduced degree of branching compared with wild-type LM.
   The deletion mutant's biochemical phenotype was fully complemented by
   either NCgl2093 or Rv2174. Furthermore, the use of a synthetic
   neoglycolipid acceptor in an in vitro cell-free assay utilizing the
   sugar donor beta-D-mannopyranosyl-1-monophosphoryl-decaprenol together
   with the neoglycolipid acceptor alpha-D-Manp-(1 ->
   6)-alpha-D-Manp-O-C(8) as a substrate, confirmed NCgl2093 and Rv2174 as
   an alpha(1 -> 6) mannopyranosyltransferase (MptA), involved in the
   latter stages of the biosynthesis of the alpha(1 -> 6) mannan core of
   LM. Altogether, these studies have identified a new mannosyltransferase,
   MptA, and they shed further light on the biosynthesis of LM/LAM in
   Corynebacterianeae.}},
Publisher = {{WILEY-BLACKWELL}},
Address = {{COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Besra, GS (Reprint Author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.
   Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.
   Res Ctr Juelich, Inst Biotechnol, D-52425 Julich, Germany.
   CNRS, UMR, Inst Pharmacol \& Biol Struct, F-5089 Toulouse, France.}},
DOI = {{10.1111/j.1365-2958.2007.05884.x}},
ISSN = {{0950-382X}},
Keywords-Plus = {{BOMBARDMENT MASS-SPECTROMETRY; WALL ARABINAN BIOSYNTHESIS; MYCOLIC ACID
   BIOSYNTHESIS; MYO-INOSITOL ANCHOR; CELL-WALL; PHOSPHATIDYLINOSITOL
   MANNOSIDES; MONOPHOSPHOMANNOSE SYNTHASE; NONREDUCING TERMINI; EMB
   PROTEINS; LIPOARABINOMANNAN}},
Research-Areas = {{Biochemistry \& Molecular Biology; Microbiology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Microbiology}},
Author-Email = {{g.besra@bham.ac.uk}},
ORCID-Numbers = {{GILLERON, Martine/0000-0002-2581-3302}},
Funding-Acknowledgement = {{Medical Research Council {[}G0200510]; Wellcome Trust {[}081569/2/06/2]}},
Cited-References = {{ADAMS LB, 1993, INFECT IMMUN, V61, P4173.
   Alderwick LJ, 2006, J BIOL CHEM, V281, P15653, DOI 10.1074/jbc.M600045200.
   Alderwick LJ, 2005, J BIOL CHEM, V280, P32362, DOI 10.1074/jbc.M506339200.
   Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI 10.1093/nar/gkh121.
   Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420.
   Berg S, 2005, J BIOL CHEM, V280, P5651, DOI 10.1074/jbc.M411418200.
   Berg S, 2007, GLYCOBIOLOGY, V17, p35R, DOI 10.1093/glycob/cwm010.
   Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460.
   BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015.
   Besra GS, 1997, BIOCHEM SOC T, V25, P845.
   Bhatt A, 2005, J BACTERIOL, V187, P7596, DOI 10.1128/JB.187.22.7596-7606.2005.
   BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055.
   BRENNAN P, 1967, J BIOL CHEM, V242, P3046.
   BRENNAN P, 1968, J BIOL CHEM, V243, P2975.
   Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6.
   BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333.
   Brown JR, 2001, BIOORGAN MED CHEM, V9, P815, DOI 10.1016/S0968-0896(00)00300-X.
   CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497.
   Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113.
   COYLE MB, 1990, CLIN MICROBIOL REV, V3, P227.
   DAFFE M, 1990, J BIOL CHEM, V265, P6734.
   Dinadayala P, 2006, J BIOL CHEM, V281, P20027, DOI 10.1074/jbc.M603395200.
   Dover LG, 2004, FEMS MICROBIOL REV, V28, P225, DOI 10.1016/j.femsre.2003.10.001.
   Eggeling L., 2005, HDB CORYNEBACTERIUM.
   Escuyer VE, 2001, J BIOL CHEM, V276, P48854, DOI 10.1074/jbc.M102272200.
   Gande R, 2004, J BIOL CHEM, V279, P44847, DOI 10.1074/jbc.M408648200.
   Gibson KJC, 2003, J BIOL CHEM, V278, P40842, DOI 10.1074/jbc.M307988200.
   Gill KK, 2000, SEMIN HEMATOL, V37, P275, DOI 10.1016/S0037-1963(00)90106-9.
   Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438.
   Gilleron M, 1997, J BIOL CHEM, V272, P117.
   Guerardel Y, 2002, J BIOL CHEM, V277, P30635, DOI 10.1074/jbc.M204398200.
   Gurcha SS, 2002, BIOCHEM J, V365, P441, DOI 10.1042/BJ20020107.
   HILL DL, 1966, J BIOL CHEM, V241, P895.
   HUNTER SW, 1986, J BIOL CHEM, V261, P2345.
   JAGER W, 1992, J BACTERIOL, V174, P5462.
   Kaur D, 2006, P NATL ACAD SCI USA, V103, P13664, DOI 10.1073/pnas.0603049103.
   KHOO KH, 1995, J BIOL CHEM, V270, P12380.
   Knutson KL, 1998, J BIOL CHEM, V273, P645, DOI 10.1074/jbc.273.1.645.
   Kordulakova J, 2003, J BIOL CHEM, V278, P36285, DOI 10.1074/jbc.M303639200.
   Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200.
   Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437.
   LEOPOLD K, 1993, ANAL BIOCHEM, V208, P57, DOI 10.1006/abio.1993.1008.
   Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103.
   Ludwiczak P, 2002, MICROBIOL-SGM, V148, P3029.
   Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200.
   MCNEIL M, 1990, J BIOL CHEM, V265, P18200.
   MCNEIL M, 1991, J BIOL CHEM, V266, P13217.
   Mills JA, 2004, J BIOL CHEM, V279, P43540, DOI 10.1074/jbc.M407782200.
   Minnikin DE, 2002, CHEM BIOL, V9, P545, DOI 10.1016/S1074-5521(02)00142-4.
   Morita YS, 2006, J BIOL CHEM, V281, P25143, DOI 10.1074/jbc.M604214200.
   Morita YS, 2004, BIOCHEM J, V378, P589, DOI 10.1042/BJ20031372.
   Movahedzadeh F, 2004, MOL MICROBIOL, V51, P1003, DOI 10.1046/j.1365-2958.2003.03900.x.
   Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0.
   Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094.
   Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8.
   Sahm H, 2000, BIOL CHEM, V381, P899, DOI 10.1515/BC.2000.111.
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x.
   Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625.
   SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7.
   SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070.
   Seidel M, 2007, J BIOL CHEM, V282, P14729, DOI 10.1074/jbc.M700271200.
   Seidel M, 2007, GLYCOBIOLOGY, V17, P210, DOI 10.1093/glycob/cw1066.
   Stackebrandt E, 1997, INT J SYST BACTERIOL, V47, P479.
   Tatituri RVV, 2007, J BIOL CHEM, V282, P4561, DOI 10.1074/jbc.M608695200.
   Zhang N, 2003, MOL MICROBIOL, V50, P69, DOI 10.1046/j.1365-2958.2003.03681.x.}},
Number-of-Cited-References = {{65}},
Times-Cited = {{45}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Mol. Microbiol.}},
Doc-Delivery-Number = {{209ZD}},
Unique-ID = {{ISI:000249425600013}},
}

@article{ ISI:000249325500008,
Author = {Ahmad, Zahoor and Sharma, Sadhna and Khuller, Gopal K.},
Title = {{Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole
   antifungal and antitubercular drugs against murine tuberculosis}},
Journal = {{NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE}},
Year = {{2007}},
Volume = {{3}},
Number = {{3}},
Pages = {{239-243}},
Month = {{SEP}},
Abstract = {{The present study was designed to evaluate the chemotherapeutic
   potential of alginate nanoparticle-encapsulated econazole and
   antitubercular drugs (ATDs) against murine tuberculosis. Alginate
   nanoparticles encapsulating econazole and ATDs were prepared by the
   cation-induced controlled gelification of alginate and were
   characterized. Drugs were analyzed by high-performance liquid
   chromatography. All the ATDs were detected above minimum inhibitory
   concentrations for as long as 15 days and econazole until the day 8 in
   organs (lungs, liver, and spleen) after administration of encapsulated
   drugs, whereas free drugs remained detectable for only 12 to 24 hours.
   Eight doses of alginate nanoparticle-encapsulated econazole or 112 doses
   of free econazole reduced bacterial burden by more than 90\% in the
   lungs and spleen of mice infected with Myeobacterium tuberculosis.
   Econazole (free or encapsulated) could replace rifampicin and isoniazid
   during chemotherapy of murine tuberculosis. Alginate nanoparticles
   reduced the dosing frequency of azoles and ATDs by 15-fold. Alginate
   nanoparticles are the ideal carriers of azole and antitubercular drugs,
   which can reduce dosing frequency of azoles as well as ATDs for the
   better management of tuberculosis. (C) 2007 Published by Elsevier Inc.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Khuller, GK (Reprint Author), Postgrad Inst Med Educ \& Res, Dept Biochem, Sector 12, Chandigarh 160012, India.
   Postgrad Inst Med Educ \& Res, Dept Biochem, Chandigarh 160012, India.
   Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD USA.}},
DOI = {{10.1016/j.nano.2007.05.001}},
ISSN = {{1549-9634}},
EISSN = {{1549-9642}},
Keywords = {{nanoparticles; chemotherapy; econazole; bioavailability}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; RELEASE; CYTOCHROME-P450; MICROPARTICLES;
   DELIVERY}},
Research-Areas = {{Science \& Technology - Other Topics; Research \& Experimental Medicine}},
Web-of-Science-Categories  = {{Nanoscience \& Nanotechnology; Medicine, Research \& Experimental}},
Author-Email = {{gkkhuller@yahoo.co.in}},
Cited-References = {{Chickering DE, 1997, J CONTROL RELEASE, V48, P35, DOI 10.1016/S0168-3659(97)00054-0.
   Cui JH, 2001, DRUG DEV IND PHARM, V27, P309, DOI 10.1081/DDC-100103730.
   Gonzalez-Rodriguez ML, 2002, INT J PHARM, V232, P225, DOI 10.1016/S0378-5173(01)00915-2.
   Guardiola-Diaz HM, 2001, BIOCHEM PHARMACOL, V61, P1463, DOI 10.1016/S0006-2952(01)00571-8.
   HOSTETLER JS, 1992, ANTIMICROB AGENTS CH, V36, P477.
   Joseph I, 1995, INT J PHARMACEUT, V126, P161, DOI 10.1016/0378-5173(95)00173-5.
   Lannuccelli V., 1996, INT J PHARMACEUT, V143, P195, DOI 10.1016/S0378-5173(96)04703-5.
   Leys D, 2003, J BIOL CHEM, V278, P5141, DOI 10.1074/jbc.M209928200.
   Pandey R, 2006, DRUG DELIV, V13, P287, DOI 10.1080/10717540500398076.
   Pandey R, 2005, INT J PHARM, V301, P268, DOI 10.1016/j.ijpharm.2005.05.027.
   Pandey R, 2003, TUBERCULOSIS, V83, P373, DOI 10.1016/j.tube.2003.07.001.
   RAJAONARIVONY M, 1993, J PHARM SCI, V82, P912, DOI 10.1002/jps.2600820909.
   RATTAN A, 2000, TUBERCULOSIS, P113.
   Takka S, 1999, J MICROENCAPSUL, V16, P275.
   Whitehead L, 2000, INT J PHARM, V210, P45, DOI 10.1016/S0378-5173(00)00567-6.
   Zahoor A., 2005, FEMS MICROBIOL LETT, V251, P19.
   Zahoor A., 2006, J NANOSCIENCE, V1, P81.
   ZAHOOR A, 2006, FEMS MICROBIOL LETT, V261, P181.
   Zahoor A., 2006, FEMS MICROBIOL LETT, V258, P200.
   ZAHOOR A, 2006, INT J ANTIMICROB AG, V27, P420.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{40}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{14}},
Journal-ISO = {{Nanomed.-Nanotechnol. Biol. Med.}},
Doc-Delivery-Number = {{208NG}},
Unique-ID = {{ISI:000249325500008}},
}

@article{ ISI:000249138000011,
Author = {Lange, Christoph and Hellmich, Bernhard and Ernst, Martin and Ehlers,
   Stefan},
Title = {{Rapid immunodiagnosis of tuberculosis in a woman receiving anti-TNF
   therapy}},
Journal = {{NATURE CLINICAL PRACTICE RHEUMATOLOGY}},
Year = {{2007}},
Volume = {{3}},
Number = {{9}},
Pages = {{528-534}},
Month = {{SEP}},
Abstract = {{Background A 63-year-old German woman with a 24-year history of Crohn's
   disease and associated polyarthralgias presented with severe malaise,
   dyspnea, fever, night sweats, dry cough and an extensive right-sided
   pleural effusion. The patient had begun treatment with bi-weekly
   subcutaneous injections of adalimumab 5 weeks earlier.
   Investigations Physical examination, chest X-ray, transthoracic
   ultrasonography, pleural tap and drainage, bacterial and cytological
   analyses of pleural fluid, bronchoscopy, microscopy and bacteriological
   culture of pleural exudates and bronchoalveolar lavage fluid, thoracic
   CT, thoracoscopy, histopathology of pleural biopsy, tuberculin skin
   test, nucleic acid amplification of mycobacterial RNA and DNA in the
   pleural fluid specimens and the parietal pleural biopsy, microscopy of
   sputum samples, ESAT-6-specific and CFP-10-specific nterferon-gamma
   enzyme-linked immunospot assay on peripheral blood and pleural exudate
   mononuclear cells.
   Diagnosis Pulmonary and pleural tuberculosis.
   Management Cessation of adalimumab treatment. Initiation of quadruple
   antibiotic therapy with isoniazid, rifampin, ethambutol and
   pyrazinamide. Prednisolone administered to reduce the pleural effusion.}},
Publisher = {{NATURE PUBLISHING GROUP}},
Address = {{75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ehlers, S (Reprint Author), Res Ctr Borstel, Div Mol Infect Biol, Parkallee 22, D-23845 Borstel, Germany.
   Res Ctr Borstel, Div Mol Infect Biol, D-23845 Borstel, Germany.}},
DOI = {{10.1038/ncptheum0571}},
ISSN = {{1745-8382}},
Keywords = {{adalimumab; ELISPOT; pleural tuberculosis; TNF-targeted; therapy;
   tuberculin skin test}},
Keywords-Plus = {{TUMOR-NECROSIS-FACTOR; ALPHA TREATMENT; BLOOD-TEST; T-CELLS; INFECTION;
   DIAGNOSIS; RECOMMENDATIONS; REACTIVATION; DISEASE; ASSAYS}},
Research-Areas = {{Rheumatology; Social Issues}},
Web-of-Science-Categories  = {{Rheumatology; Social Issues}},
Author-Email = {{sehlers@fz-borstel.de}},
ResearcherID-Numbers = {{Ehlers, Stefan/B-4075-2010
   Lange, Christoph/J-6289-2012}},
Cited-References = {{American Thoracic Society, 2000, MMWR RECOMM REP, V49, P1.
   Carmona L, 2005, ARTHRITIS RHEUM, V52, P1766, DOI 10.1002/art.21043.
   Chan J, 2004, CLIN IMMUNOL, V110, P2, DOI 10.1016/S1521-6616(03)00210-9.
   Diel R, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-77.
   Diel R, 2006, EUR RESPIR J, V28, P16, DOI 10.1183/09031936.06.00107005.
   Gooding Sarah, 2007, J Infect, V54, pe169, DOI 10.1016/j.jinf.2006.11.002.
   Jafari C, 2006, AM J RESP CRIT CARE, V174, P1048, DOI 10.1164/rccm.200604-465OC.
   Lee JY, 2006, EUR RESPIR J, V28, P24, DOI 10.1183/09031936.06.00016906.
   Liebeschuetz S, 2004, LANCET, V364, P2196, DOI 10.1016/S0140-6736(04)17592-2.
   Malipeddi AS, 2007, LANCET, V369, P162, DOI 10.1016/S0140-6736(07)60078-6.
   Mow WS, 2004, CLIN GASTROENTEROL H, V2, P309, DOI 10.1053/S1542-3565(04)00060-6.
   Ormerod LP, 2005, THORAX, V60, P800, DOI 10.1136/thx.2005.046797.
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.
   Ravn P, 2004, SCAND J INFECT DIS, V36, P499, DOI 10.1080/00365540410015222.
   Richeldi L, 2006, LEUKEMIA, V20, P379, DOI 10.1038/sj.leu.2404053.
   Richeldi L, 2004, ANN INTERN MED, V140, P709.
   Sichletidis L, 2006, INT J TUBERC LUNG D, V10, P1127.
   WALLROTH C, 1941, Z JAGDKUNDE, V3, P1.
   Wilkinson KA, 2005, CLIN INFECT DIS, V40, P184, DOI 10.1086/426139.
   Winthrop KL, 2006, NAT CLIN PRACT RHEUM, V2, P602, DOI 10.1038/ncprheum0336.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{16}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Nat. Clin. Pract. Rheumatol.}},
Doc-Delivery-Number = {{205TR}},
Unique-ID = {{ISI:000249138000011}},
}

@article{ ISI:000249291800025,
Author = {Kim, Yong Min and Kim, Ah Young and Park, Yong Ho and Kim, Dong Hyun and
   Rha, Ki-Sang},
Title = {{Eight cases of nasal tuberculosis}},
Journal = {{OTOLARYNGOLOGY-HEAD AND NECK SURGERY}},
Year = {{2007}},
Volume = {{137}},
Number = {{3}},
Pages = {{500-504}},
Month = {{SEP}},
Abstract = {{OBJECTIVE: To elucidate the clinical characteristics of nasal
   tuberculosis and to discuss its diagnostic difficulties.
   STUDY DESIGN: Retrospective clinical analysis.
   RESULTS: A total of eight patients presented with nasal tuberculosis
   during the study period (from January 1989 through December 2006). Six
   were female and two were male. The patient age varied from 17 to 51
   years, with a mean of 31 years. The most commonly involved site was the
   nasal septum (7 of 8). Perforation of the nasal septum was observed in
   three cases. Sinus invasion was observed in two cases and required sinus
   surgery. Six of the cases were a result of primary infections, while two
   were secondary disease manifestations. All patients were treated with
   antituberculosis medications, with subsequent improvement with regard to
   clinical symptoms and physical signs.
   CONCLUSIONS: We present the largest number of nasal tuberculosis cases
   reported in the medical literature from a single institute. Diagnosing
   nasal tuberculosis requires a high index of suspicion and occasionally
   the use of experimental drug treatment options. (c) 2007 American
   Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights
   reserved.}},
Publisher = {{MOSBY-ELSEVIER}},
Address = {{360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rha, KS (Reprint Author), Chungnam Natl Univ Hosp, Dept Otolaryngol Head \& Neck Surg, 640 Daesa Dong, Taejon 301721, South Korea.
   Chungnam Natl Univ, Dept Otolaryngol Head \& Neck Surg, Taejon, South Korea.}},
DOI = {{10.1016/j.otohns.2007.04.009}},
ISSN = {{0194-5998}},
Keywords-Plus = {{NOSE; DIAGNOSIS; ENTITY; EAR}},
Research-Areas = {{Otorhinolaryngology; Surgery}},
Web-of-Science-Categories  = {{Otorhinolaryngology; Surgery}},
Author-Email = {{ksrha@cnu.ac.kr}},
Cited-References = {{Al-Serhani AM, 2001, LARYNGOSCOPE, V111, P2012, DOI 10.1097/00005537-200111000-00027.
   Butt AA, 1997, AM J MED SCI, V313, P332, DOI 10.1097/00000441-199706000-00003.
   CHAMBERLAIN WB, 1922, ANN RHINOLOGY LARYNG, V31, P423.
   CHODOSH PL, 1970, LARYNGOSCOPE, V80, P679, DOI 10.1288/00005537-197005000-00001.
   CLARRIDGE JE, 1993, J CLIN MICROBIOL, V31, P2049.
   Friedmann I, 1971, J Laryngol Otol, V85, P631.
   GOGUEN LA, 1995, OTOLARYNG HEAD NECK, V113, P131, DOI 10.1016/S0194-5998(95)70156-7.
   Havens FZ, 1931, ARCHIV OTOLARYNGOL, V14, P181.
   JOHNSON IJM, 1995, J LARYNGOL OTOL, V109, P326.
   MCKIBBEN BG, 1956, ARCHIV OTOLARYNGOL, V63, P286.
   MESSERVY M, 1951, J LARYNGOL OTOL, V65, P177.
   Nalini B, 2006, AM J OTOLARYNG, V27, P39, DOI 10.1016/j.amjoto.2005.07.005.
   PAGE JR, 1974, J LARYNGOL OTOL, V88, P579, DOI 10.1017/S0022215100079111.
   PUST RE, 1992, SOUTHERN MED J, V85, P584.
   SHARAN R, 1981, PRACTITIONER, V225, P1506.
   Sharma SC, 2003, INT J PEDIATR OTORHI, V67, P399, DOI 10.1016/S0165-5876(02)00381-6.
   SLUTSKER L, 1993, CLIN INFECT DIS, V16, P513.
   WALDMAN SR, 1981, LARYNGOSCOPE, V91, P11.
   WEIR N, 1997, SCOTT BROWNS OTOLARY, P4.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Otolaryngol. Head Neck Surg.}},
Doc-Delivery-Number = {{208AI}},
Unique-ID = {{ISI:000249291800025}},
}

@article{ ISI:000250114000011,
Author = {Suessmuth, Sandra and Bange, Franz-Christoph and Gappa, Monika},
Title = {{Multidrug resistant tuberculosis in a 6 year old child}},
Journal = {{PAEDIATRIC RESPIRATORY REVIEWS}},
Year = {{2007}},
Volume = {{8}},
Number = {{3}},
Pages = {{265-268}},
Month = {{SEP}},
Abstract = {{The case is reported of a 6 year old girl whose mother had multidrug
   resistant tuberculosis (MDR TB). The diagnostic algorithm and the pros
   and cons of treatment of MDR TB in a child are discussed. (C) 2007
   Elsevier Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Gappa, M (Reprint Author), Hannover Med Sch, Dept Paediat Pulm, D-3000 Hannover, Germany.
   Hannover Med Sch, Dept Paediat Pulm, D-3000 Hannover, Germany.
   Hannover Med Sch, Dept Neonatol, D-3000 Hannover, Germany.
   Hannover Med Sch, Dept Med Microbiol, D-3000 Hannover, Germany.
   Hannover Med Sch, Dept Hosp Epidemiol, D-3000 Hannover, Germany.}},
DOI = {{10.1016/j.prrv.2007.07.006}},
ISSN = {{1526-0542}},
Keywords = {{multidrug resistant; tuberculosis; child}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; YOUNG-CHILDREN;
   INFECTION; DIAGNOSIS; ASSAY}},
Research-Areas = {{Pediatrics; Respiratory System}},
Web-of-Science-Categories  = {{Pediatrics; Respiratory System}},
Author-Email = {{Gappa.Monika@mh-hannover.de}},
Cited-References = {{Connell TG, 2006, THORAX, V61, P616, DOI 10.1136/thx.2005.048033.
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9.
   Hesseling AC, 2002, INT J TUBERC LUNG D, V6, P1038.
   HSU KHK, 1984, JAMA-J AM MED ASSOC, V251, P1283, DOI 10.1001/jama.251.10.1283.
   Marais BJ, 2006, AM J RESP CRIT CARE, V173, P1078, DOI 10.1164/rccm.200511-1809SO.
   Marais BJ, 2004, INT J TUBERC LUNG D, V8, P392.
   Pediatric Tuberculosis Collaborative GroupTargeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents, 2004, PEDIATRICS, V114, P1175, DOI DOI 10.1542/PEDS.2004-0809.
   Schaaf HS, 2007, EUR J CLIN MICROBIOL, V26, P203, DOI 10.1007/s10096-007-0257-9.
   Schaaf HS, 2002, PEDIATRICS, V109, P765, DOI 10.1542/peds.109.5.765.
   Schaaf HS, 2003, ARCH DIS CHILD, V88, P1106, DOI 10.1136/adc.88.12.1106.
   Schaaf HS, 2000, INT J TUBERC LUNG D, V4, P1149.
   Singh M, 2000, Indian Pediatr, V37, P947.
   van Helden Paul D, 2006, Expert Rev Anti Infect Ther, V4, P759, DOI 10.1586/14787210.4.5.759.
   Wallgren A, 1935, AM J DIS CHILD, V49, P1105.
   {*}WHO, 2006, 20062361 WHO HTM TB.
   World Health Organization, 2003, WHOCDSTB2003313.
   {*}WHO, 2006, WHOHTMTB20062362.
   Zar HJ, 2005, LANCET, V365, P130, DOI 10.1016/S0140-6736(05)17702-2.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Paediatr. Respir. Rev.}},
Doc-Delivery-Number = {{219UP}},
Unique-ID = {{ISI:000250114000011}},
}

@article{ ISI:000247977300705,
Author = {Derakhshan, D. and Jalaeian, H. and Derakhshan, A. and Sabet, B. and
   Fallahzadeh, M.},
Title = {{Tuberculosis in Iranian pediatric kidney transplant recipients}},
Journal = {{PEDIATRIC NEPHROLOGY}},
Year = {{2007}},
Volume = {{22}},
Number = {{9}},
Pages = {{1581}},
Month = {{SEP}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING STREET, NEW YORK, NY 10013 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Nemazee Hosp, Shiraz Nephro Urol Res Ctr, Shiraz, Iran.
   Nemazee Hosp, Shiraz Organ Transplantat Ctr, Shiraz, Iran.}},
ISSN = {{0931-041X}},
Research-Areas = {{Pediatrics; Urology \& Nephrology}},
Web-of-Science-Categories  = {{Pediatrics; Urology \& Nephrology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Pediatr. Nephrol.}},
Doc-Delivery-Number = {{189GL}},
Unique-ID = {{ISI:000247977300705}},
}

@article{ ISI:000249232000066,
Author = {Mandalakas, Anna M. and Kirchner, H. Lester and Iverson, Sandra and
   Chesney, Mary and Spencer, Mary Jo and Sidler, Angela and Johnson, Dana},
Title = {{Predictors of Mycobacterium tuberculosis infection in international
   adoptees}},
Journal = {{PEDIATRICS}},
Year = {{2007}},
Volume = {{120}},
Number = {{3}},
Pages = {{E610-E616}},
Month = {{SEP}},
Abstract = {{OBJECTIVE. The objective of this study was to measure the factors that
   are associated with Mycobacterium tuberculosis infection in
   international adoptees.
   METHODS. A retrospective chart review was conducted on 880 international
   adoptees who presented to the International Adoption Clinic at the
   University of Minnesota between 1986 and 2001. Five tuberculin units of
   purified protein derivative were placed intradermally on the left
   forearm. The largest diameter of induration was measured in millimeters
   between 48 and 72 hours. Nutritional status was assessed using
   anthropometric measures at initial screening. Data on age, birth
   country, and year of adoption were assessed.
   RESULTS. Adoptees ( mean age: 26 months; range: 1-200 months; 62\%
   female) came from 33 birth countries. Twenty-eight percent and 5\% had
   evidence of chronic and acute malnutrition, respectively. Twelve percent
   had evidence of M tuberculosis infection. The odds of M tuberculosis
   infection increased 7\% for each subsequent year during the period
   studied, increased 142\% with each additional year of age for children
   <= 24 months of age at baseline screening, and increased 15\% with each
   additional year of age for children > 24 months of age at the time of
   evaluation. Tuberculin skin test induration response was not associated
   with nutritional status or birth region.
   CONCLUSIONS. Our study demonstrated a high prevalence of M tuberculosis
   infection and malnutrition in internationally adopted children, placing
   them at considerable risk for progression to tuberculosis disease. These
   findings also support current guidelines recommending completion of
   tuberculin screening immediately after adoption.}},
Publisher = {{AMER ACAD PEDIATRICS}},
Address = {{141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mandalakas, AM (Reprint Author), 11100 Euclid Ave, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA.
   Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA.}},
DOI = {{10.1542/peds.2006-2817}},
ISSN = {{0031-4005}},
Keywords = {{tuberculin test; malnutrition; tuberculosis; adoption; immigrants;
   pediatrics}},
Keywords-Plus = {{CALMETTE-GUERIN VACCINATION; CHILDHOOD TUBERCULOSIS; MEDICAL EVALUATION;
   BCG VACCINATION; EASTERN-EUROPE; SKIN-TEST; T-CELLS; CHILDREN;
   PREVALENCE; MALNUTRITION}},
Research-Areas = {{Pediatrics}},
Web-of-Science-Categories  = {{Pediatrics}},
Author-Email = {{amm13@po.cwru.edu}},
Cited-References = {{Albers LH, 1997, JAMA-J AM MED ASSOC, V278, P922, DOI 10.1001/jama.278.11.922.
   {*}AM AC PED, 2006, RED BOOK 2006 REP CO, P678.
   Aronson J, 2000, PEDIATR ANN, V29, P218.
   BOELAERT M, 1995, NUTR GUIDELINES.
   {*}CDCP, CDC GROWTH CHARTS US.
   Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008.
   CHILHOOD TB, 2006, GUIDANCE NATL TUBERC.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Curtis AB, 1999, NEW ENGL J MED, V341, P1491, DOI 10.1056/NEJM199911113412002.
   Daunhauer LA, 2005, OTJR-OCCUP PART HEAL, V25, P33.
   Faber S, 2000, PEDIATR ANN, V29, P242.
   Hesseling AC, 2002, INT J TUBERC LUNG D, V6, P1038.
   Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030.
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362.
   Hostetter M K, 1999, Adv Pediatr Infect Dis, V14, P147.
   HOSTETTER MK, 1991, NEW ENGL J MED, V325, P479, DOI 10.1056/NEJM199108153250706.
   Jenista JA, 2000, PEDIATR ANN, V29, P208.
   JENISTA JA, 1993, CURR OPIN INFECT DIS, V6, P576, DOI 10.1097/00001432-199308000-00016.
   Johnson Dana E., 1996, Pediatric Research, V39, p135A.
   Johnson D., 1996, PEDIATR RES, V39, p134A.
   Johnson DE, 2000, PEDIATR ANN, V29, P234.
   JOHNSON DE, 1992, JAMA-J AM MED ASSOC, V268, P3446, DOI 10.1001/jama.268.24.3446.
   KARALLIEDDE S, 1987, TUBERCLE, V68, P33, DOI 10.1016/0041-3879(87)90005-5.
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081.
   LLOYD AVC, 1968, BRIT MED J, V3, P529.
   MANDALAKAS A, 2006, KENDIGS DISORDERS RE, P507, DOI 10.1016/B978-0-7216-3695-5.50038-9.
   MANDALAKAS A, 2006, HIST CROSS CULTURAL, P331.
   Marais BJ, 2004, INT J TUBERC LUNG D, V8, P392.
   MENZIES R, 1992, AM REV RESPIR DIS, V145, P621.
   MENZIES R, 1992, AM REV RESPIR DIS, V146, P752.
   Miller LC, 2000, PEDIATR ANN, V29, P224.
   Nelson LJ, 2004, INT J TUBERC LUNG D, V8, P636.
   Pai M, 2005, AM J RESP CRIT CARE, V172, P519, DOI 10.1164/rccm.2506003.
   PLACEK PJ, 1999, ADOPTION FACTBOOK 3, P24.
   Saiman L, 2001, PEDIATRICS, V108, P608, DOI 10.1542/peds.108.3.608.
   Singh M, 2005, ARCH DIS CHILD, V90, P624, DOI 10.1136/adc.2003.044255.
   SINHA DP, 1976, LANCET, V2, P531.
   STARKE JR, 2006, AAP NEWS, V27, P14.
   Tissot F, 2005, CLIN INFECT DIS, V40, P211, DOI 10.1086/426434.
   {*}US DEP STAT, 2003, IMM VIS ISS ORPH COM.
   {*}WHO, 2005, COMM DIS SEV FOOD SH.
   World Health Organization (WHO), 2005, WHO CHILD GROWTH STA.
   WHO Multicentre Growth Reference Study Group, 2006, ACTA PAEDIATR, V450, P76, DOI DOI 10.1080/08035320500495548.
   WHO Working Group, 1986, B WORLD HEALTH ORGAN, V64, P929.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Pediatrics}},
Doc-Delivery-Number = {{207DO}},
Unique-ID = {{ISI:000249232000066}},
}

@article{ ISI:000250035200001,
Author = {Gale, George A. and Kirtikara, Kanyawim and Pittayakhajonwut, Pattama
   and Sivichai, Somsak and Thebtaranonth, Yodhathai and Thongpanchang,
   Chawanee and Vichai, Vanicha},
Title = {{In search of cyclooxygenase inhibitors, anti-Mycobacterium tuberculosis
   and anti-malarial drugs from Thai flora and microbes}},
Journal = {{PHARMACOLOGY \& THERAPEUTICS}},
Year = {{2007}},
Volume = {{115}},
Number = {{3}},
Pages = {{307-351}},
Month = {{SEP}},
Abstract = {{Malaria continues to be a major infectious disease of the developing
   world and the problem is compounded not only by the emergence of drug
   resistant strains but also from a lack of a vaccine. The situation for
   tuberculosis (TB) infection is equally problematic. Once considered a
   ``treatable{''} disease for which eradication was predicted, TB has
   re-emerged as highly lethal, multi-drug resistant strains after the
   outbreak of AIDS. Worldwide, the disease causes millions of deaths
   annually. Similarly, treatments for chronic inflammatory diseases such
   as arthritis have been impeded due to the potentially lethal side
   effects of the new and widely prescribed non-steroidal anti-inflammatory
   compounds.
   Thais have utilized bioresources from plants and some microorganisms for
   medicine for thousands of years. Because of the need for new drugs to
   fight malaria and TB, with radically different chemical structures and
   mode of actions other than existing drugs, efforts have been directed
   towards searching for new drugs from bioresources. This is also true for
   anti-inflammatories. Although Thailand is considered species-rich, only
   a small number of potential bioresources has been investigated.
   This article briefly describes the pathogenesis of 2 infectious
   diseases, malaria and TB, and modem medicines employed in chemotherapy.
   Diversities of Thai flora and fungi and their chemical constituents with
   antagonistic properties against these 2 diseases are described in
   detail. Similarly, anti-inflammatory compounds, mostly cyclooxygenase
   (COX) inhibitors, are also described herein to demonstrate the potential
   of Thai bioresources to provide a wide array of compounds for treatment
   of diseases of a different nature. (c) 2007 Elsevier Inc. All rights
   reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Kirtikara, K (Reprint Author), Natl Ctr Genet Engn \& Biotechnol BIOTEC, 113 Thailand Sci Pk,Paholyothin Rd,Klong 1, Klongluang 12120, Patumtani, Thailand.
   Natl Ctr Genet Engn \& Biotechnol BIOTEC, Klongluang 12120, Patumtani, Thailand.
   King Mongkuts Univ Technol Thonburi, Sch Bioresources \& Technol, Conservat Ecol Program, Bangkok 10150, Thailand.}},
DOI = {{10.1016/j.pharmthera.2007.03.016}},
ISSN = {{0163-7258}},
Keywords = {{malaria; tuberculosis; cyclooxygenase; inflammation; fungi; bioactive
   compounds; Thailand}},
Keywords-Plus = {{NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FUNGUS VERTICILLIUM-HEMIPTERIGENUM;
   CORDYCEPS-PSEUDOMILITARIS BCC-1620; QUINOLINE-CONTAINING ANTIMALARIALS;
   PRECURSOR-DIRECTED BIOSYNTHESIS; PAECILOMYCES-TENUIPES BCC-1614;
   PLASMODIUM-FALCIPARUM MALARIA; RANDOMIZED CONTROLLED-TRIAL;
   PROSTAGLANDIN H-2 SYNTHASE; HIRSUTELLA-NIVEA BCC-2594}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Author-Email = {{kanyawim@biotec.or.th}},
ResearcherID-Numbers = {{Kirtikara, Kanyawim/D-1595-2011
   vichai, vanicha/F-2122-2011}},
Cited-References = {{Apisantiyakom S, 2004, CHEM BIODIVERS, V1, P1694, DOI 10.1002/cbdv.200490127.
   Atherton C, 2004, CLIN GASTROENTEROL H, V2, P113, DOI 10.1053/S1542-3565(03)00318-5.
   Awtry EH, 2000, CIRCULATION, V101, P1206.
   Baird JK, 2005, NEW ENGL J MED, V352, P1565, DOI 10.1056/NEJMra043207.
   Ballou LR, 2000, P NATL ACAD SCI USA, V97, P10272, DOI 10.1073/pnas.180319297.
   Bamba H, 1998, BIOCHEM BIOPH RES CO, V245, P567, DOI 10.1006/bbrc.1998.8436.
   Bensen WG, 1999, MAYO CLIN PROC, V74, P1095.
   Bhisutthibhan J, 1998, J BIOL CHEM, V273, P16192, DOI 10.1074/jbc.273.26.16192.
   Biagini GA, 2003, TRENDS PARASITOL, V19, P479, DOI 10.1016/j.pt.2003.09.011.
   Bias P, 2004, AM J GASTROENTEROL, V99, P611, DOI 10.1111/j.1572-0241.2004.04133.x.
   BLACK ML, 1963, J MED CHEM, V6, P145, DOI 10.1021/jm00338a014.
   Blanco FJ, 2003, ANN RHEUM DIS, V62, P262.
   BLOLAND PB, 2001, WHOCDRCSRDRS200144.
   Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103.
   BOMBARDIERI S, 1981, BRIT J PHARMACOL, V73, P893.
   Boonlaksiri C, 2000, PHYTOCHEMISTRY, V54, P415, DOI 10.1016/S0031-9422(00)00074-1.
   Boonphong S, 2001, PLANTA MED, V67, P279, DOI 10.1055/s-2001-11997.
   Borstnik K, 2002, INT J PARASITOL, V32, P1661, DOI 10.1016/S0020-7519(02)00195-9.
   Bosetti F, 2004, J NEUROCHEM, V91, P1389, DOI 10.1111/j.1471-4159.2004.02829.x.
   BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208.
   Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493.
   Brockman A, 2000, T ROY SOC TROP MED H, V94, P537, DOI 10.1016/S0035-9203(00)90080-4.
   BRODIE MJ, 1980, LIFE SCI, V27, P603, DOI 10.1016/0024-3205(80)90310-0.
   Brooks PM, 2006, CLIN RHEUMATOL, V25, P778, DOI 10.1007/s10067-006-0240-3.
   Byarugaba DK, 2004, INT J ANTIMICROB AG, V24, P105, DOI 10.1016/j.ijantimicag.2004.02.015.
   Cao C, 1998, Brain Res Mol Brain Res, V56, P45.
   Carvalho JCT, 1996, PLANTA MED, V62, P402, DOI 10.1055/s-2006-957925.
   Chan K., 2002, J MACHINE LEARNING R, V3, P99.
   Chang CH, 1996, AM J CHINESE MED, V24, P139, DOI 10.1142/S0192415X96000189.
   Chanphen R, 1998, J NAT PROD, V61, P1146, DOI 10.1021/np980041x.
   Chinworrungsee M, 2004, J NAT PROD, V67, P689, DOI 10.1021/np0304870.
   Chinworrungsee M, 2001, BIOORG MED CHEM LETT, V11, P1965, DOI 10.1016/S0960-894X(01)00327-4.
   Chinworrubgsee M, 2002, J CHEM SOC P1, V22, P2473.
   Chivian E, 2001, CAN MED ASSOC J, V164, P66.
   Choi SH, 2006, J NEUROCHEM, V98, P801, DOI 10.1111/j.1471-4159.2006.03926.x.
   Chumkaew P, 2003, J NAT PROD, V66, P540, DOI 10.1021/np0204489.
   CLAESON P, 1993, PLANTA MED, V59, P451, DOI 10.1055/s-2006-959730.
   Claeson P, 1996, PLANTA MED, V62, P236, DOI 10.1055/s-2006-957867.
   Collins LA, 1997, ANTIMICROB AGENTS CH, V41, P1004.
   Collins WE, 2005, CLIN MICROBIOL REV, V18, P570, DOI 10.1128/CMR.18.3.570-581.2005.
   Corbett EL, 2006, LANCET, V367, P926, DOI 10.1016/S0140-6736(06)68383-9.
   COWMAN AF, 1994, P NATL ACAD SCI USA, V91, P1143, DOI 10.1073/pnas.91.3.1143.
   DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710.
   Dettrakul S, 2003, BIOORG MED CHEM LETT, V13, P1253, DOI 10.1016/S0960-894X(03)00111-2.
   DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485.
   Di Perri G, 2004, J ANTIMICROB CHEMOTH, V54, P593, DOI 10.1093/jac/dkh377.
   DICKINSON JM, 1981, AM REV RESPIR DIS, V123, P367.
   DIROSA M, 1971, J PATHOL, V104, P15, DOI 10.1002/path.1711040103.
   DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0.
   Dover LG, 2004, FEMS MICROBIOL REV, V28, P225, DOI 10.1016/j.femsre.2003.10.001.
   Eckstein-Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813.
   Emery P, 1999, LANCET, V354, P2106, DOI 10.1016/S0140-6736(99)02332-6.
   England S, 1996, J PHYSIOL-LONDON, V495, P429.
   Espinal MA, 2003, TUBERCULOSIS, V83, P44, DOI 10.1016/S1472-9792(02)00058-6.
   Famin O, 2002, BIOCHEM PHARMACOL, V63, P393, DOI 10.1016/S0006-2952(01)00878-4.
   Famin O, 1999, BIOCHEM PHARMACOL, V58, P59, DOI 10.1016/S0006-2952(99)00059-3.
   Ferreira MU, 2004, CLIN DIAGN LAB IMMUN, V11, P987, DOI 10.1128/CDLI.11.6.987-995.2004.
   FERREIRA SH, 1972, NATURE-NEW BIOL, V240, P200.
   Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132.
   FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288.
   Foley M, 1998, PHARMACOL THERAPEUT, V79, P55, DOI 10.1016/S0163-7258(98)00012-6.
   FOOTE SJ, 1990, P NATL ACAD SCI USA, V87, P3014, DOI 10.1073/pnas.87.8.3014.
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871.
   Furberg CD, 2005, CIRCULATION, V111, P249, DOI 10.1161/01.CIR.0000155081.76164.17.
   Gardiner DL, 2005, POSTGRAD MED J, V81, P505, DOI 10.1136/pgmj.2004.030304.
   Gierse JK, 1999, BIOCHEM J, V339, P607, DOI 10.1042/0264-6021:3390607.
   Ginsburg H, 1999, PARASITOL TODAY, V15, P357, DOI 10.1016/S0169-4758(99)01502-1.
   GINSBURG H, 1987, BIOCHEM PHARMACOL, V36, P1567, DOI 10.1016/0006-2952(87)90038-4.
   Ginsburg H, 2005, ACTA TROP, V96, P16, DOI 10.1016/j.actatropica.2005.06.021.
   GINSBURG H, 1992, BIOCHEM PHARMACOL, V43, P63, DOI 10.1016/0006-2952(92)90662-3.
   GOETZL EJ, 1995, FASEB J, V9, P1051.
   Gogtay NJ, 2000, ANN TROP MED PARASIT, V94, P519.
   Gomez JE, 2004, TUBERCULOSIS, V84, P29, DOI 10.1016/j.tube.2003.08.003.
   GORMAN C, 1971, WORLD ARCHAEOL, V2, P300.
   Graham SM, 1998, ARCH DIS CHILD, V79, P274.
   GRAHAM M., 1994, NATL PARKS THAILAND.
   Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3.
   Gregson A, 2005, PHARMACOL REV, V57, P117, DOI 10.1124/pr.57.1.4.
   Hammond P.M., 1990, P197.
   HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620.
   HARVEY RJ, 1982, REV INFECT DIS, V4, P255.
   Hawkey C, 1998, BRIT J RHEUMATOL, V37, P937.
   HAWKSWORTH DL, 2002, MYCOL RES, V106, P386.
   Haynes RK, 2001, CURR OPIN INFECT DIS, V14, P719.
   HAYNES RK, 1999, TETRAHEDRON LETT, V40, P15.
   Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8.
   Heywood VH, 1995, GLOBAL BIODIVERSITY.
   HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384.
   HONG YL, 1994, MOL BIOCHEM PARASIT, V63, P121, DOI 10.1016/0166-6851(94)90014-0.
   HUDSON N, 1993, GUT, V34, P742, DOI 10.1136/gut.34.6.742.
   Hunt RH, 2003, AM J GASTROENTEROL, V98, P1725, DOI 10.1016/S0002-9270(03)00449-0.
   Hunter Richard G., 2003, Current Drug Targets - CNS and Neurological Disorders, V2, P201, DOI 10.2174/1568007033482896.
   HYDE JE, 1990, PHARMACOL THERAPEUT, V48, P45, DOI 10.1016/0163-7258(90)90017-V.
   Hyde KD, 1998, BIODIVERS CONSERV, V7, P1147, DOI 10.1023/A:1008823515157.
   ICHIHARA Y, 1992, PLANTA MED, V58, P549, DOI 10.1055/s-2006-961547.
   Intahphuak S, 2004, J ETHNOPHARMACOL, V90, P69, DOI 10.1016/j.jep.2003.09.026.
   Isaka M, 2000, PLANTA MED, V66, P473, DOI 10.1055/s-2000-8588.
   Isaka M, 2005, J NAT PROD, V68, P1680, DOI 10.1021/np050246n.
   Isaka M, 2005, ACCOUNTS CHEM RES, V38, P813, DOI 10.1021/ar040247r.
   Isaka M, 2005, J NAT PROD, V68, P945, DOI 10.1021/np058028h.
   Isaka M, 2005, TETRAHEDRON, V61, P5577, DOI 10.1016/j.tet.2005.03.099.
   Isaka M, 2005, ORG LETT, V7, P2257, DOI 10.1021/ol0507266.
   Isaka M, 2002, ANTIMICROB AGENTS CH, V46, P1112, DOI 10.1128/AAC.46.4.1112-1113.2002.
   Isaka M, 2002, J ORG CHEM, V67, P1561, DOI 10.1021/jo010930g.
   Isaka M, 2001, J NAT PROD, V64, P1015, DOI 10.1021/np010006h.
   Isaka M, 2001, J ORG CHEM, V66, P4803, DOI 10.1021/jo0100906.
   Isaka M, 2001, J ANTIBIOT, V54, P36.
   Isaka M, 1999, J NAT PROD, V62, P329, DOI 10.1021/np980323x.
   Isaka M, 2006, ORG LETT, V8, P2815, DOI 10.1021/ol060926x.
   Iskander MN, 2002, PLANT FOOD HUM NUTR, V57, P233, DOI 10.1023/A:1021851230890.
   Jaturapat A, 2001, J ANTIBIOT, V54, P29.
   Jones E.B.G., 2004, THAI FUNGAL DIVERSIT, P7.
   KAIN KC, 1994, J INFECT DIS, V170, P258.
   Kain KC, 2001, CLIN INFECT DIS, V33, P226, DOI 10.1086/321817.
   Kala CP, 2005, CONSERV BIOL, V19, P368, DOI 10.1111/j.1523-1739.2005.00602.x.
   KAMCHONWONGPAISAN S, 1995, TETRAHEDRON LETT, V36, P1821, DOI 10.1016/0040-4039(95)00152-3.
   Kanokmedhakul S, 2003, PLANTA MED, V69, P568, DOI 10.1055/s-2003-40639.
   Kanokmedhakul S, 2003, J NAT PROD, V66, P616, DOI 10.1021/np020498d.
   Kanokmedhakul S, 2002, PLANTA MED, V68, P834, DOI 10.1055/s-2002-34415.
   Kirchgatter K, 2005, AN ACAD BRAS CIENC, V77, P455, DOI 10.1590/S0001-37652005000300008.
   Kirk PM, 2001, AINSWORTH BISBYS DIC.
   Kirtikara K, 1998, J EXP MED, V187, P517, DOI 10.1084/jem.187.4.517.
   Kittakoop P, 2004, HELV CHIM ACTA, V87, P175, DOI 10.1002/hlca.200490006.
   Kittakoop P, 2000, PHYTOCHEMISTRY, V55, P349, DOI 10.1016/S0031-9422(00)00318-6.
   Kittakoop P, 1999, PHYTOCHEMISTRY, V52, P453, DOI 10.1016/S0031-9422(99)00272-1.
   Kittakoop P, 2001, J NAT PROD, V64, P385, DOI 10.1021/np0004404.
   KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571.
   Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485.
   KONNO K, 1973, AM REV RESPIR DIS, V107, P1006.
   KUJUBU DA, 1992, J BIOL CHEM, V267, P7991.
   KULMACZ RJ, 1985, J BIOL CHEM, V260, P2572.
   Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0.
   Lanes SF, 2000, PHARMACOEPIDEM DR S, V9, P113, DOI 10.1002/(SICI)1099-1557(200003/04)9:2<113::AID-PDS478>3.0.CO;2-2.
   Lang T, 2003, LANCET INFECT DIS, V3, P162, DOI 10.1016/S1473-3099(03)00547-4.
   LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4.
   LARSEN K, 1984, LEGUMINOSAE CAESALPI, V4.
   LARSEN K, 1996, MYRSINACEAE, V6.
   Lastra-Gonzalez G, 2005, EXPERT OPIN PHARMACO, V6, P2209, DOI 10.1517/14656566.6.13.2209.
   Laupattarakasem P, 2004, PLANTA MED, V70, P496, DOI 10.1055/s-2004-827147.
   Lety MA, 1997, ANTIMICROB AGENTS CH, V41, P2629.
   Li RW, 2004, PHYTOTHER RES, V18, P78, DOI 10.1002/ptr.1373.
   Li RW, 2003, J ETHNOPHARMACOL, V85, P61, DOI 10.1016/S0378-8741(02)00339-2.
   Limmatvapirat C, 2004, PLANTA MED, V70, P276, DOI 10.1055/s-2004-818924.
   Liu JH, 1998, PLANTA MED, V64, P525, DOI 10.1055/s-2006-957507.
   Lodge DL, 1996, ECOL STU AN, V122, P69.
   LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637.
   Loria P, 1999, BIOCHEM J, V339, P363, DOI 10.1042/0264-6021:3390363.
   Luxemburger C, 1998, T ROY SOC TROP MED H, V92, P668, DOI 10.1016/S0035-9203(98)90807-0.
   Mackinnon MJ, 2004, PHILOS T R SOC B, V359, P965, DOI 10.1098/rstb.2003.1414.
   Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5.
   Martel-Pelletier J, 2003, ANN RHEUM DIS, V62, P501, DOI 10.1136/ard.62.6.501.
   MAXWELL JF, 2007, VEGETATION VASCULAR, V5.
   McCammon MT, 2005, ANTIMICROB AGENTS CH, V49, P2210, DOI 10.1128/AAC.49.6.2210-2217.2005.
   Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607.
   MESHNICK SR, 1991, MOL BIOCHEM PARASIT, V49, P181, DOI 10.1016/0166-6851(91)90062-B.
   MESHNICK SR, 1993, ANTIMICROB AGENTS CH, V37, P1108.
   MOCKENHAUPT FP, 1995, PARASITOL TODAY, V11, P248, DOI 10.1016/0169-4758(95)80201-0.
   Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954.
   Mukherjee JS, 2004, LANCET, V363, P474, DOI 10.1016/S0140-6736(04)15496-2.
   Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501.
   Newton P, 1999, ANNU REV MED, V50, P179.
   Nilanonta C, 2003, TETRAHEDRON, V59, P1015, DOI 10.1016/S0040-4020(02)01631-9.
   Nilanonta C, 2003, J ANTIBIOT, V56, P647.
   Nilanonta C, 2002, TETRAHEDRON, V58, P3355, DOI 10.1016/S0040-4020(02)00294-6.
   Nilanonta C, 2000, PLANTA MED, V66, P756, DOI 10.1055/s-2000-9776.
   O'Neill PM, 1998, PHARMACOL THERAPEUT, V77, P29, DOI 10.1016/S0163-7258(97)00084-3.
   {*}OEPP, 2002, NAT REP IMPL CONV BI.
   Olliaro PL, 2001, TRENDS PARASITOL, V17, P122, DOI 10.1016/S1471-4922(00)01838-9.
   Onyebujoh P, 2005, B WORLD HEALTH ORGAN, V83, P857.
   OUELLET M, 1995, BIOCHEM J, V306, P247.
   Paitayatat S, 1997, J MED CHEM, V40, P633, DOI 10.1021/jm960767v.
   Panthong A, 2004, J ETHNOPHARMACOL, V91, P237, DOI 10.1016/j.jep.2003.12.025.
   Panthong A, 2003, J ETHNOPHARMACOL, V85, P151, DOI 10.1016/S0378-8741(02)00368-9.
   Paramasivan CN, 2004, INDIAN J MED RES, V120, P377.
   Pauli GF, 2005, LIFE SCI, V78, P485, DOI 10.1016/j/lfs.2005.09.004.
   Pavelka K, 2003, RHEUMATOLOGY, V42, P1207, DOI 10.1093/rheumatology/keg359.
   Perez S, 2005, J ETHNOPHARMACOL, V102, P1, DOI 10.1016/j.jep.2005.06.047.
   PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/pnas.87.8.3018.
   Petras JM, 2000, ANAT EMBRYOL, V201, P383, DOI 10.1007/s004290050326.
   Pittayakhajonwut P, 2002, PLANTA MED, V68, P1017, DOI 10.1055/s-2002-35653.
   Plowe CV, 1997, J INFECT DIS, V176, P1590.
   Pongprayoon U, 1996, PHYTOTHER RES, V10, P534.
   POSNER GH, 1995, J MED CHEM, V38, P2273, DOI 10.1021/jm00013a001.
   PRAYOONRAT P, 2005, BIODIVERSITY MED WEE.
   Price RN, 2000, EXPERT OPIN INV DRUG, V9, P1815, DOI 10.1517/13543784.9.8.1815.
   Promsawan N, 2003, PLANTA MED, V69, P776, DOI 10.1055/s-2003-42782.
   Puntumchai A, 2004, J NAT PROD, V67, P485, DOI 10.1021/np030429e.
   Ralph SA, 2001, DRUG RESIST UPDATE, V4, P145, DOI 10.1054/drup.2001.0205.
   Ridley RG, 2002, P NATL ACAD SCI USA, V99, P13362, DOI 10.1073/pnas.232483699.
   Ridley RG, 2002, NATURE, V415, P686, DOI 10.1038/415686a.
   Rios MY, 2006, J NAT PROD, V69, P887, DOI 10.1021/np0504311.
   Robert A, 1998, CHEM SOC REV, V27, P273, DOI 10.1039/a827273z.
   ROCHANAKIJ S, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P66.
   Rordorf C, 2003, ALIMENT PHARM THERAP, V18, P533, DOI 10.1046/j.0269-2813.2003.01691.x.
   ROTH GJ, 1975, P NATL ACAD SCI USA, V72, P3073, DOI 10.1073/pnas.72.8.3073.
   Rukachaisirikul T, 2004, J ETHNOPHARMACOL, V93, P173, DOI 10.1016/j.jep.2004.01.022.
   Rukachaisirikul T, 2002, PLANTA MED, V68, P853, DOI 10.1055/s-2002-34410.
   Rukachaisirikul V, 2006, J NAT PROD, V69, P305, DOI 10.1021/np050433l.
   Rukachaisirikul V, 2005, J NAT PROD, V68, P1674, DOI 10.1021/np0502286.
   Rukachaisirikul V, 2004, J NAT PROD, V67, P1953, DOI 10.1021/np0401415.
   Rukachaisirikul V, 2006, J NAT PROD, V69, P980, DOI 10.1021/np060164e.
   Sahr F, 2001, ANN TROP MED PARASIT, V95, P445, DOI 10.1080/00034980120072284.
   SALOM IL, 1984, J CLIN PHARMACOL, V24, P240.
   SANTISUK T, 2001, FLORA THAILAND ALI 3, V7.
   Sawadjoon S, 2004, PLANTA MED, V70, P1085, DOI 10.1055/s-2004-832652.
   Sawadjoon S, 2002, J ORG CHEM, V67, P5470, DOI 10.1021/jo020045d.
   Schuster FL, 2002, CLIN MICROBIOL REV, V15, P355, DOI 10.1128/CMR.15.3.355-364.2002.
   Seephonkai P, 2002, PLANTA MED, V68, P45, DOI 10.1055/s-2002-20055.
   Seephonkai P, 2001, J ANTIBIOT, V54, P751.
   Seephonkai P, 2006, ORG LETT, V8, P3073, DOI 10.1021/ol061046l.
   Selinsky BS, 2001, BIOCHEMISTRY-US, V40, P5172, DOI 10.1021/bi010045s.
   Sharma SK, 2004, INDIAN J MED RES, V120, P354.
   Sharma SK, 2005, LANCET INFECT DIS, V5, P415, DOI 10.1016/S1473-3099(05)70163-8.
   Sikes DH, 2002, EUR J GASTROEN HEPAT, V14, P1101, DOI 10.1097/00042737-200210000-00011.
   Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247.
   SIMPSON DA, 1998, CYPERACEAE, V6.
   Singh V, 2002, TROP MED INT HEALTH, V7, P693, DOI 10.1046/j.1365-3156.2002.00909.x.
   SIPPEL A, 1968, BIOCHIM BIOPHYS ACTA, V157, P218, DOI 10.1016/0005-2787(68)90286-4.
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107.
   Smith WL, 1996, J BIOL CHEM, V271, P33157.
   SMITINAND T, 2005, AIZOACEAE ARALIDIA 1, V9.
   SMITINAND T, 1981, ACTINIDIACEAE APOSTA, V2.
   SMITINAND T, 1990, SCROPHULARIACEAE 2, V5.
   Solomon DH, 2004, HYPERTENSION, V44, P140, DOI 10.1161/01.HYP.0000136134.31846.83.
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405.
   Sridhar C, 2005, PHYTOCHEMISTRY, V66, P1707, DOI 10.1016/j.phytochem.2005.05.008.
   Sridhar C, 2004, J NAT PROD, V67, P2012, DOI 10.1021/np040117r.
   Suksamrarn A, 2005, CHEM PHARM BULL, V53, P1327, DOI 10.1248/cpb.53.1327.
   Suksamrarn A, 2003, ARCH PHARM RES, V26, P816, DOI 10.1007/BF02980026.
   Suksamrarn A, 2003, J ETHNOPHARMACOL, V88, P275, DOI 10.1016/S0378-8741(03)00261-7.
   Suksamrarn A, 2002, PLANTA MED, V68, P72, DOI 10.1055/s-2002-20048.
   Suksamrarn A, 2004, ARCH PHARM RES, V27, P507, DOI 10.1007/BF02980123.
   Suksamrarn S, 2006, CHEM PHARM BULL, V54, P535, DOI 10.1248/cpb.54.535.
   Suksamrarn S, 2003, CHEM PHARM BULL, V51, P857, DOI 10.1248/cpb.51.857.
   Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219.
   Sunthitikawinsakul A, 2003, PLANTA MED, V69, P155, DOI 10.1055/s-2003-37716.
   TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493.
   TANARIYA P, 1995, T ROY SOC TROP MED H, V89, P426, DOI 10.1016/0035-9203(95)90039-X.
   THEBTARANONTH C, 1995, PHYTOCHEMISTRY, V40, P125, DOI 10.1016/0031-9422(95)00260-E.
   Thongtan J, 2003, J NAT PROD, V66, P868, DOI 10.1021/np030067a.
   TRIGLIA T, 1994, P NATL ACAD SCI USA, V91, P7149, DOI 10.1073/pnas.91.15.7149.
   Triglia T, 1999, DRUG RESIST UPDATE, V2, P15, DOI 10.1054/drup.1998.0060.
   Tuchinda P, 2002, PHYTOCHEMISTRY, V59, P169, DOI 10.1016/S0031-9422(01)00451-4.
   Tuntiwachwuttikul P, 2006, CHEM PHARM BULL, V54, P149, DOI 10.1248/cpb.54.149.
   Tuntiwachwuttikul P, 2006, CHEM PHARM BULL, V54, P44, DOI 10.1248/cpb.54.44.
   Tuntiwachwuttikul P, 2003, CHEM PHARM BULL, V51, P1423, DOI 10.1248/cpb.51.1423.
   Uhlemann AC, 2005, MOLECULAR APPROACHES TO MALARIA, P429.
   Ushikubi F, 1998, NATURE, V395, P281.
   VANDERJAGT DL, 1987, BIOCHEM PHARMACOL, V36, P3285.
   VANE JR, 1971, NATURE-NEW BIOL, V231, P232.
   VANWELZEN PC, 2005, FLORA THAILAND EUPHO.
   Vongvanich N, 2002, J NAT PROD, V65, P1346, DOI 10.1021/np020055+.
   Vongvilai P, 2004, HELV CHIM ACTA, V87, P2066, DOI 10.1002/hlca.200490185.
   Walker MC, 2001, BIOCHEM J, V357, P709, DOI 10.1042/0264-6021:3570709.
   Wallace JL, 1998, J CLIN GASTROENTEROL, V27, pS28, DOI 10.1097/00004836-199800001-00006.
   Wallace JL, 2001, EXP BIOL MED, V226, P1003.
   Wallace JL, 1996, FASEB J, V10, P731.
   Wallace JL, 2000, GASTROENTEROLOGY, V119, P512, DOI 10.1053/gast.2000.9304.
   Wang P, 1997, MOL MICROBIOL, V23, P979, DOI 10.1046/j.1365-2958.1997.2821646.x.
   Weatherall David J, 2002, Hematology Am Soc Hematol Educ Program, P35.
   Wei BL, 2001, PLANTA MED, V67, P745.
   WEMSDORFER WH, 1990, MED TROP-MARSEILLE, V50, P119.
   WERNSDORFER WH, 1991, PARASITOL TODAY, V7, P297, DOI 10.1016/0169-4758(91)90262-M.
   WERNSDORFER WH, 1994, ACTA TROP, V56, P143, DOI 10.1016/0001-706X(94)90060-4.
   Whitby M, 1997, J ANTIMICROB CHEMOTH, V40, P749, DOI 10.1093/jac/40.6.749.
   White NJ, 1998, BRIT MED BULL, V54, P703.
   {[}Anonymous], 2003, 134 WHO.
   WHO Global Tuberculosis Program, 1992, TUB PROGR REV IND.
   Wiesner J, 2003, ANGEW CHEM INT EDIT, V42, P5274, DOI 10.1002/anie.200200569.
   WILLIAMS K, 2004, BOT DIVERSITY BIOGEO.
   WILLIS AL, 1969, J PHARM PHARMACOL, V21, P126.
   Winstanley P, 2001, TROP MED INT HEALTH, V6, P952, DOI 10.1046/j.1365-3156.2001.00751.x.
   WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328.
   Wongsrichanalai C, 2002, LANCET INFECT DIS, V2, P209, DOI 10.1016/S1473-3099(02)00239-6.
   Wongsrichanalai Chansuda, 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P41.
   WONGYAI S, 2005, COUNTRY REPORT THAIL.
   Woodrow CJ, 2005, POSTGRAD MED J, V81, P71, DOI 10.1136/pgmj.2004.028399.
   Wu WM, 1996, CHEM COMMUN, P2213, DOI 10.1039/cc9960002213.
   YAYON A, 1985, P NATL ACAD SCI USA, V82, P2784, DOI 10.1073/pnas.82.9.2784.
   Yenjai C, 2004, FITOTERAPIA, V75, P89, DOI 10.1016/j.fitote.2003.08.017.
   Yenjai C, 2000, PLANTA MED, V66, P277, DOI 10.1055/s-2000-8558.
   Yeung S, 2004, AM J TROP MED HYG, V71, P179.
   Zhang K, 2002, SCIENCE, V296, P545, DOI 10.1126/science.1068274.
   Zhang Y, 2003, J ANTIMICROB CHEMOTH, V52, P790, DOI 10.1093/jac/dkg446.
   Zhang Y, 2003, INT J TUBERC LUNG D, V7, P6.
   Zhang Y, 1999, J BACTERIOL, V181, P2044.}},
Number-of-Cited-References = {{286}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{11}},
Journal-ISO = {{Pharmacol. Ther.}},
Doc-Delivery-Number = {{218SM}},
Unique-ID = {{ISI:000250035200001}},
}

@article{ ISI:000249768100022,
Author = {Hotez, Peter J. and Molyneux, David H. and Fenwick, Alan and Ottesen,
   Eric and Sachs, Sonia Ehrlich and Sachs, Jeffrey D.},
Title = {{Incorporating a rapid-impact package for neglected tropical diseases
   with programs for HIV/AIDS, tuberculosis, and malaria (vol 3, pg e102,
   2006)}},
Journal = {{PLOS MEDICINE}},
Year = {{2007}},
Volume = {{4}},
Number = {{9}},
Pages = {{1553}},
Month = {{SEP}},
Publisher = {{PUBLIC LIBRARY SCIENCE}},
Address = {{185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA}},
Type = {{Correction}},
Language = {{English}},
DOI = {{10.1371/journal.pmed.0040277}},
Article-Number = {{e277}},
ISSN = {{1549-1277}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
ORCID-Numbers = {{Hotez, Peter/0000-0001-8770-1042}},
Cited-References = {{Hotez PJ, 2006, PLOS MED, V3, P576, DOI 10.1371/journal.pmed.0030102.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{10}},
Journal-ISO = {{PLos Med.}},
Doc-Delivery-Number = {{214WE}},
Unique-ID = {{ISI:000249768100022}},
}

@article{ ISI:000249768300007,
Author = {Lewinsohn, Deborah A. and Winata, Ervina and Swarbrick, Gwendolyn M. and
   Tanner, Katie E. and Cook, Matthew S. and Null, Megan D. and Cansler,
   Meghan E. and Sette, Alessandro and Sidney, John and Lewinsohn, David M.},
Title = {{Immunodominant tuberculosis CD8 antigens preferentially restricted by
   HLA-B}},
Journal = {{PLOS PATHOGENS}},
Year = {{2007}},
Volume = {{3}},
Number = {{9}},
Pages = {{1240-1249}},
Month = {{SEP}},
Abstract = {{CD8(+) T cells are essential for host defense to intracellular bacterial
   pathogens such as Mycobacterium tuberculosis (Mtb), Salmonella species,
   and Listeria monocytogenes, yet the repertoire and dominance pattern of
   human CD8 antigens for these pathogens remains poorly characterized.
   Tuberculosis ( TB), the disease caused by Mtb infection, remains one of
   the leading causes of infectious morbidity and mortality worldwide and
   is the most frequent opportunistic infection in individuals with
   HIV/AIDS. Therefore, we undertook this study to define immunodominant
   CD8 Mtb antigens. First, using IFN-gamma ELISPOT and synthetic peptide
   arrays as a source of antigen, we measured ex vivo frequencies of CD8(+)
   T cells recognizing known immunodominant CD4(+) T cell antigens in
   persons with latent tuberculosis infection. In addition, limiting
   dilution was used to generate panels of Mtb-specific T cell clones.
   Using the peptide arrays, we identified the antigenic specificity of the
   majority of T cell clones, defining several new epitopes. In all cases,
   peptide representing the minimal epitope bound to the major
   histocompatibility complex (MHC)-restricting allele with high affinity,
   and in all but one case the restricting allele was an HLA-B allele.
   Furthermore, individuals from whom the T cell clone was isolated
   harbored high ex vivo frequency CD8(+) T cell responses specific for the
   epitope, and in individuals tested, the epitope represented the single
   immunodominant response within the CD8 antigen. We conclude that
   Mtb-specific CD8(+) T cells are found in high frequency in infected
   individuals and are restricted predominantly by HLA-B alleles, and that
   synthetic peptide arrays can be used to define epitope specificities
   without prior bias as to MHC binding affinity. These findings provide an
   improved understanding of immunodominance in humans and may contribute
   to a development of an effective TB vaccine and improved
   immunodiagnostics.}},
Publisher = {{PUBLIC LIBRARY SCIENCE}},
Address = {{185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Lewinsohn, DM (Reprint Author), Oregon Hlth \& Sci Univ, Dept Pediat, Portland, OR 97201 USA.
   Oregon Hlth \& Sci Univ, Dept Pediat, Portland, OR 97201 USA.
   Oregon Hlth \& Sci Univ, Dept Mol Microbiol \& Immunol, Portland, OR 97201 USA.
   Oregon Hlth \& Sci Univ, Div Pulm \& Crit Care Med, Portland, OR 97201 USA.
   Portland VA Med Ctr, Portland, OR USA.
   La Jolla Inst Allergy \& Immunol, San Diego, CA USA.}},
DOI = {{10.1371/journal.ppat.0030127}},
Article-Number = {{e127}},
ISSN = {{1553-7366}},
Keywords-Plus = {{MYCOBACTERIUM-BOVIS BCG; T-CELL RESPONSES; 19-KDA LIPOPROTEIN;
   INFECTED-CELLS; MICE; IDENTIFICATION; COMPLEX; RESISTANCE; EXPRESSION;
   CLONING}},
Research-Areas = {{Microbiology; Parasitology; Virology}},
Web-of-Science-Categories  = {{Microbiology; Parasitology; Virology}},
Author-Email = {{lewinsod@ohsu.edu}},
ResearcherID-Numbers = {{Yehorov, Bohdan/Q-1365-2015
   Lewinsohn, David/I-4936-2013}},
ORCID-Numbers = {{Yehorov, Bohdan/0000-0001-7526-0315
   Lewinsohn, David/0000-0001-9906-9494}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}R01 AI048090, R01 AI054474, R01AI054474, R01AI48090];
   PHS HHS {[}N01-A1-400081]}},
Cited-References = {{Alderson MR, 2000, J EXP MED, V191, P551, DOI 10.1084/jem.191.3.551.
   Beckman EM, 1996, J IMMUNOL, V157, P2795.
   Behar SM, 1999, J EXP MED, V189, P1973, DOI 10.1084/jem.189.12.1973.
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195.
   BORREMANS M, 1989, INFECT IMMUN, V57, P3123.
   Caccamo N, 2002, J INFECT DIS, V186, P991, DOI 10.1086/344174.
   Charo J, 2001, EUR J IMMUNOL, V31, P3602, DOI 10.1002/1521-4141(200112)31:12<3602::AID-IMMU3602>3.0.CO;2-L.
   Coler RN, 1998, J IMMUNOL, V161, P2356.
   COLLINS ME, 1990, J GEN MICROBIOL, V136, P1429.
   Crubezy E, 1998, CR ACAD SCI III-VIE, V321, P941, DOI 10.1016/S0764-4469(99)80009-2.
   Dillon DC, 2000, J CLIN MICROBIOL, V38, P3285.
   Dillon DC, 1999, INFECT IMMUN, V67, P2941.
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93.
   FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013.
   Fulton SA, 2004, INFECT IMMUN, V72, P2101, DOI 10.1128/IAI.72.2.2101-2110.2004.
   Gehring AJ, 2003, INFECT IMMUN, V71, P4487, DOI 10.1128/IAI.71.8.4487-4497.2003.
   Geluk A, 2000, J IMMUNOL, V165, P6463.
   Heinzel AS, 2002, J EXP MED, V196, P1473, DOI 10.1084/jem.20020609.
   Kamath AB, 2004, J EXP MED, V200, P1479, DOI 10.1084/jem.20041690.
   Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113.
   Klein MR, 2002, INFECT IMMUN, V70, P981, DOI 10.1128/IAI.70.2.981-984.2002.
   Klein MR, 2001, J INFECT DIS, V183, P928, DOI 10.1086/319267.
   Klenerman P, 2005, NAT IMMUNOL, V6, P873, DOI 10.1038/ni1241.
   LADEL CH, 1995, EUR J IMMUNOL, V25, P377, DOI 10.1002/eji.1830250211.
   Lalvani Ajit, 1998, Proceedings of the National Academy of Sciences of the United States of America, V95, P270, DOI 10.1073/pnas.95.1.270.
   Lam KS, 1997, ANTI-CANCER DRUG DES, V12, P145.
   Lewinsohn DA, 2003, AM J RESP CRIT CARE, V168, P1346, DOI 10.1164/rccm.200306-837OC.
   Lewinsohn DA, 2002, AM J RESP CRIT CARE, V166, P843, DOI 10.1164/rccm.2110094.
   Lewinsohn DM, 2006, MICROBES INFECT, V8, P2587, DOI 10.1016/j.micinf.2006.07.007.
   Lewinsohn DM, 2000, J IMMUNOL, V165, P925.
   Lewinsohn DM, 1998, J EXP MED, V187, P1633, DOI 10.1084/jem.187.10.1633.
   Lewinsohn DM, 2001, J IMMUNOL, V166, P439.
   Louise R, 2001, Scand J Infect Dis, V33, P643.
   Mogues T, 2001, J EXP MED, V193, P271, DOI 10.1084/jem.193.3.271.
   Mohagheghpour N, 1998, J IMMUNOL, V161, P2400.
   Moody DB, 2000, NATURE, V404, P884, DOI 10.1038/35009119.
   MULLER I, 1987, INFECT IMMUN, V55, P2037.
   North RJ, 2004, ANNU REV IMMUNOL, V22, P599, DOI 10.1146/annurev.immunol.22.012703.104635.
   Noss EH, 2001, J IMMUNOL, V167, P910.
   Oldstone M B, 1994, Curr Top Microbiol Immunol, V189, P1.
   ORME IM, 1987, TUBERCLE, V68, P277, DOI 10.1016/0041-3879(87)90068-7.
   Peters B, 2006, PLOS COMPUT BIOL, V2, P574, DOI 10.1371/journal.pcbi.0020065.
   Reed S, 2005, MICROBES INFECT, V7, P922, DOI 10.1016/j.micinf.2005.03.011.
   Rolph MS, 2001, EUR J IMMUNOL, V31, P1944, DOI 10.1002/1521-4141(200106)31:6<1944::AID-IMMU1944>3.0.CO;2-R.
   ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83.
   Rosat JP, 1999, J IMMUNOL, V162, P366.
   Rosenkrands I, 2000, ELECTROPHORESIS, V21, P3740, DOI 10.1002/1522-2683(200011)21:17<3740::AID-ELPS3740>3.3.CO;2-V.
   SALO WL, 1994, P NATL ACAD SCI USA, V91, P2091, DOI 10.1073/pnas.91.6.2091.
   Sette Alessandro, 2005, Immunity, V22, P155, DOI 10.1016/j.immuni.2005.01.009.
   SIDNEY J, 1999, CURRENT PROTOCOLS IM.
   SILVA CL, 1994, IMMUNOLOGY, V83, P341.
   SORENSEN AL, 1995, INFECT IMMUN, V63, P1710.
   Sousa AO, 2000, P NATL ACAD SCI USA, V97, P4204, DOI 10.1073/pnas.97.8.4204.
   Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882.
   Tobian AAR, 2003, J IMMUNOL, V171, P1413.
   Turner J, 1996, IMMUNOLOGY, V87, P339, DOI 10.1046/j.1365-2567.1996.512590.x.
   Urdahl KB, 2003, J IMMUNOL, V170, P1987.
   Gey Van Pittius NC, 2001, GENOME BIOL, V2.
   {*}WHO, 2007, WHO REP 2007.
   World Health Organization, 2006, GLOB PLAN STOP TB 20.
   Wong P, 2003, ANNU REV IMMUNOL, V21, P29, DOI 10.1146/annurev.immunol.21.120601.141114.
   Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51.}},
Number-of-Cited-References = {{62}},
Times-Cited = {{80}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{PLoS Pathog.}},
Doc-Delivery-Number = {{214WG}},
Unique-ID = {{ISI:000249768300007}},
}

@article{ ISI:000249903900010,
Author = {Xolalpa, Wendy and Vallecillo, Antonio J. and Lara, Martha and
   Mendoza-Hernandez, Guillermo and Comini, Marcelo and Spalle, Ralf and
   Singh, Mahavir and Espitia, Clara},
Title = {{Identification of novel bacterial plasminogen-binding proteins in the
   human pathogen Mycobacterium tuberculosis}},
Journal = {{PROTEOMICS}},
Year = {{2007}},
Volume = {{7}},
Number = {{18}},
Pages = {{3332-3341}},
Month = {{SEP}},
Abstract = {{Binding and activation of human plasminogen (Plg) to generate the
   proteolytic enzyme plasmin (Plm) have been associated with the invasive
   potential of certain bacteria. In this work, proteomic analysis together
   with ligand blotting assays identified several major Plg-binding spots
   in Mycobacterium tuberculosis soluble extracts (SEs) and culture
   filtrate proteins. The identity of 15 different proteins was deduced by
   N-terminal and/or MS and corresponded to DnaK, GroES, GlnA1, Ag85
   complex, Mpt51, Mpt64, PrcB, MetK, SahH, Lpd, Icl, Fba, and EF-Tu.
   Binding of Plg to recombinant M. tuberculosis DnaK, GlnA1, and Ag85B was
   further confirmed by ELISA and ligand blotting assays. The binding was
   inhibited by F-aminocaproic acid, indicating that the interaction
   involved lysine residues. Plg bound to recombinant mycobacterial
   proteins was activated to Plm by tissue-type Plg activator. In contrast
   with recombinant proteins, M. tuberculosis SE enhanced several times the
   Plg activation mediated by the activator. Interestingly, GlnA1 was able
   to bind the extracellular matrix (ECM) protein fibronectin. Together
   these results show that M. tuberculosis posses several Plg receptors
   suggesting that bound Plg to bacteria surface, can be activated to Plm,
   endowing bacteria with the ability to break down ECM and basal membranes
   proteins contributing to tissue injury in tuberculosis.}},
Publisher = {{WILEY-V C H VERLAG GMBH}},
Address = {{PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Espitia, C (Reprint Author), Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Immunol, Apartado Postal 70-228, Mexico City 04510, DF, Mexico.
   Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Immunol, Mexico City 04510, DF, Mexico.
   Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Mexico City 04510, DF, Mexico.
   German Res Ctr Biotechnol, Braunschweig, Germany.
   LIONEX Diagnost \& Therapeut GmbH, Braunschweig, Germany.}},
DOI = {{10.1002/pmic.200600876}},
ISSN = {{1615-9853}},
Keywords = {{2-DE; ligand blotting; Mycobacterium tuberculosisl; plasminogen
   receptors}},
Keywords-Plus = {{GROUP-A STREPTOCOCCI; ESCHERICHIA-COLI; EXTRACELLULAR PROTEINS;
   SALMONELLA-ENTERICA; BASEMENT-MEMBRANES; ENZYMATIC-ACTIVITY; PROTEOME
   ANALYSIS; SURFACE PROTEIN; BOVIS BCG; ACTIVATION}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Biochemistry \& Molecular Biology}},
Author-Email = {{espitia@biomedicas.unam.mx}},
Cited-References = {{ABOUZEID C, 1988, INFECT IMMUN, V56, P3046.
   ANDERSEN AB, 1991, SCAND J IMMUNOL, V34, P365, DOI 10.1111/j.1365-3083.1991.tb01558.x.
   Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497.
   Bartow RA, 1997, TUBERCLE LUNG DIS, V78, P185, DOI 10.1016/S0962-8479(97)90025-3.
   Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420.
   BERGE A, 1993, J BIOL CHEM, V268, P25417.
   CHAPMAN HA, 1984, BIOCHEM J, V222, P721.
   Crowe JD, 2003, MOL MICROBIOL, V47, P1637, DOI 10.1046/j.1365-2958.2003.03390.x.
   Dallo SF, 1996, INFECT IMMUN, V64, P2595.
   Darwin KH, 2003, SCIENCE, V302, P1963, DOI 10.1126/science.1091176.
   Derbise A, 2004, INFECT IMMUN, V72, P94, DOI 10.1128/IAI.72.1.94-105.2004.
   EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x.
   ESPITIA C, 1992, CLIN EXP IMMUNOL, V87, P362.
   FUCHS H, 1994, P NATL ACAD SCI USA, V91, P12594, DOI 10.1073/pnas.91.26.12594.
   HARTH G, 1994, P NATL ACAD SCI USA, V91, P9342, DOI 10.1073/pnas.91.20.9342.
   HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530.
   Jonsson K, 2004, P NATL ACAD SCI USA, V101, P1852, DOI 10.1073/pnas.0307329101.
   Kinter M., 2000, PROTEIN SEQUENCING I, P147.
   Korhonen TK, 1997, ADV EXP MED BIOL, V412, P185.
   KORHONEN TK, 1992, FEMS MICROBIOL LETT, V100, P307, DOI 10.1111/j.1574-6968.1992.tb05720.x.
   Kukkonen M, 1998, INFECT IMMUN, V66, P4965.
   KUKKONEN M, 1993, MOL MICROBIOL, V7, P229, DOI 10.1111/j.1365-2958.1993.tb01114.x.
   KUUSELA P, 1992, INFECT IMMUN, V60, P196.
   LAHTEENMAKI K, 1993, FEMS MICROBIOL LETT, V106, P309, DOI 10.1016/0378-1097(93)90420-7.
   Lahteenmaki K, 2000, METHODS, V21, P125, DOI 10.1006/meth.2000.0983.
   Lahteenmaki K, 2005, TRENDS MICROBIOL, V13, P79, DOI 10.1016/j.tim.2004.12.003.
   Lahteenmaki K, 2001, FEMS MICROBIOL REV, V25, P531, DOI 10.1111/j.1574-6976.2001.tb00590.x.
   Lijnen HR, 2002, BIOCHEMISTRY-MOSCOW+, V67, P92, DOI 10.1023/A:1013908332232.
   Lottenberg Richard, 1994, Trends in Microbiology, V2, P20, DOI 10.1016/0966-842X(94)90340-9.
   Marques MAM, 1998, INFECT IMMUN, V66, P2625.
   Mattow J, 2003, ELECTROPHORESIS, V24, P3405, DOI 10.1002/elps.200305601.
   Mawuenyega KG, 2005, MOL BIOL CELL, V16, P396.
   Meghji S, 1997, J EXP MED, V186, P1241, DOI 10.1084/jem.186.8.1241.
   Monroy V, 2000, INFECT IMMUN, V68, P4327, DOI 10.1128/IAI.68.7.4327-4330.2000.
   Mosesson MW, 2005, J THROMB HAEMOST, V3, P1894, DOI 10.1111/j.1538-7836.2005.01365.x.
   Munoz-Elias EJ, 2005, NAT MED, V11, P638, DOI 10.1038/nm1252.
   Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503.
   Pancholi V, 2003, INT J MED MICROBIOL, V293, P391, DOI 10.1078/1438-4221-00283.
   PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415.
   PLOW EF, 1995, FASEB J, V9, P939.
   Raynaud C, 1998, MICROBIOL-UK, V144, P577.
   Rosenkrands I, 2000, ELECTROPHORESIS, V21, P3740, DOI 10.1002/1522-2683(200011)21:17<3740::AID-ELPS3740>3.3.CO;2-V.
   Rosenkrands I, 2002, J BACTERIOL, V184, P3485, DOI 10.1128/JB.184.13.3485-3491.2002.
   Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100.
   Seifert KN, 2003, CAN J MICROBIOL, V49, P350, DOI 10.1139/W03-042.
   Sjostrom I, 1997, BBA-BIOMEMBRANES, V1324, P182, DOI 10.1016/S0005-2736(96)00218-0.
   Syrovets T, 2004, CELL MOL LIFE SCI, V61, P873, DOI 10.1007/s00018-003-3348-5.
   YOUNG DB, 1991, INFECT IMMUN, V59, P3086.}},
Number-of-Cited-References = {{48}},
Times-Cited = {{74}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{Proteomics}},
Doc-Delivery-Number = {{216UG}},
Unique-ID = {{ISI:000249903900010}},
}

@article{ ISI:000249269300008,
Author = {Khieu, K. and Ito, K. and Hamajima, N.},
Title = {{Experience in tuberculosis treatment through directly observed therapy
   short course in health centres and communities in Cambodia}},
Journal = {{PUBLIC HEALTH}},
Year = {{2007}},
Volume = {{121}},
Number = {{9}},
Pages = {{696-699}},
Month = {{SEP}},
Publisher = {{W B SAUNDERS CO LTD}},
Address = {{32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Khieu, K (Reprint Author), Nagoya Univ, Grad Sch Med, Young Leader Program, Nagoya, Aichi, Japan.
   Nagoya Univ, Grad Sch Med, Young Leader Program, Nagoya, Aichi, Japan.}},
DOI = {{10.1016/j.puhe.2007.02.012}},
ISSN = {{0033-3506}},
Keywords-Plus = {{RANDOMIZED CONTROLLED-TRIAL; DOTS}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{kimleekh@yahoo.com}},
ResearcherID-Numbers = {{Hamajima, Nobuyuki/I-7237-2014}},
Cited-References = {{Chowdhury AMR, 1997, LANCET, V350, P169, DOI 10.1016/S0140-6736(96)11311-8.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   DAILY F, 2004, BANT MEAN KAMP SVAY.
   {*}MIN HLTH, 2004, GUID COMM DOTS IMPL.
   Newell JN, 2006, LANCET, V367, P903, DOI 10.1016/S0140-6736(06)68380-3.
   Nyangulu DS, 1997, LANCET, V350, P1284, DOI 10.1016/S0140-6736(97)05023-X.
   Walley JD, 2001, LANCET, V357, P664, DOI 10.1016/S0140-6736(00)04129-5.
   Xianyi C, 2002, B WORLD HEALTH ORGAN, V80, P430.}},
Number-of-Cited-References = {{8}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Public Health}},
Doc-Delivery-Number = {{207RR}},
Unique-ID = {{ISI:000249269300008}},
}

@article{ ISI:000248561400018,
Author = {Cummings, Kristin J.},
Title = {{Tuberculosis control: Challenges of an ancient and ongoing epidemic}},
Journal = {{PUBLIC HEALTH REPORTS}},
Year = {{2007}},
Volume = {{122}},
Number = {{5}},
Pages = {{683-692}},
Month = {{SEP-OCT}},
Publisher = {{ASSOC SCHOOLS PUBLIC HEALTH}},
Address = {{1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Cummings, KJ (Reprint Author), NIOSH, Div Resp Dis Studies, 1095 Willowdale Rd,MS 2800, Morgantown, WV 26505 USA.
   Stanford Univ, Dept Med, Internal Med Residency Program, Sch Med, Stanford, CA 94305 USA.}},
ISSN = {{0033-3549}},
Keywords-Plus = {{MULTIDRUG-RESISTANT TUBERCULOSIS; HUMAN-IMMUNODEFICIENCY-VIRUS;
   NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS;
   UNITED-STATES; PREVENTIVE THERAPY; PUBLIC-HEALTH; HIV-INFECTION;
   REFUGEES}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{cvx5@cdc.gov}},
Cited-References = {{ALLAN WGL, 1982, TUBERCLE, V63, P89.
   American Thoracic Society, 2000, AM J RESP CRIT CARE, V161, pS221.
   American Thoracic Society Centre for Disease Control and Infectious Diseases Society of America, 2003, MMWR RECOMM REP, V52, P1.
   American Thoracic Society, 1967, AM REV RESPIR DIS, V96, P558.
   Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753.
   ARONSON JD, 1958, ARCH INTERN MED, V101, P881.
   Barnes PF, 2006, AM J RESP CRIT CARE, V174, P731, DOI 10.1164/rccm.200607-907ED.
   Binkin NJ, 1996, CLIN INFECT DIS, V23, P1226.
   Bucher HC, 1999, AIDS, V13, P501, DOI 10.1097/00002030-199903110-00009.
   CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535.
   {*}CDC, 2002, MMWR-MORBID MORTAL W, V51, P101.
   Chan ED, 2004, AM J RESP CRIT CARE, V169, P1103, DOI 10.1164/rccm.200308-11590C.
   CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945.
   COMSTOCK GW, 1994, CONTROL CLIN TRIALS, V15, P247, DOI 10.1016/0197-2456(94)90042-6.
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404.
   DANIEL TM, 1997, CAPTAIN DEATH STORY, P217.
   Dasgupta K, 2005, EUR RESPIR J, V25, P1107, DOI 10.1183/09031936.05.00074004.
   De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457.
   DeRiemer K, 1998, ARCH INTERN MED, V158, P753, DOI 10.1001/archinte.158.7.753.
   DOSTER B, 1973, AM REV RESPIR DIS, V107, P177.
   Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   Ferebee S H, 1970, Bibl Tuberc, V26, P28.
   Fortun J, 2005, J ANTIMICROB CHEMOTH, V56, P180, DOI 10.1093/jac/dki148.
   Fox W, 1999, INT J TUBERC LUNG D, V3, pS231.
   FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801.
   Friedrich MJ, 2005, JAMA-J AM MED ASSOC, V293, P2703, DOI 10.1001/jama.293.22.2703.
   Fruth U, 2004, INT J TUBERC LUNG D, V8, P151.
   GARIBALDI RA, 1972, AM REV RESPIR DIS, V106, P357.
   Golding LA, 2004, ACSMS HEALTH FIT J, V8, P7, DOI 10.1097/00135124-200411000-00006.
   Granich RM, 2005, JAMA-J AM MED ASSOC, V293, P2732, DOI 10.1001/jama.293.22.2732.
   Grant AD, 2005, JAMA-J AM MED ASSOC, V293, P2719, DOI 10.1001/jama.293.22.2719.
   GROSSET J, 1978, Bulletin of the International Union Against Tuberculosis, V53, P5.
   Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861.
   Hadzibegovic DS, 2005, INT J TUBERC LUNG D, V9, P409.
   Hiransuthikul N, 2005, INT J TUBERC LUNG D, V9, P270.
   Iseman M D, 2002, Eur Respir J Suppl, V36, p87s.
   Kambashi B, 2001, INT J TUBERC LUNG D, V5, P364.
   Kim JY, 2003, TUBERCULOSIS, V83, P59, DOI 10.1016/S1472-9792(02)00078-1.
   Lehmann J, 1946, LANCET, V1, P15, DOI DOI 10.1016/S0140-6736(46)91185-3.
   Lenaerts AJ, 2005, ANTIMICROB AGENTS CH, V49, P2294, DOI 10.1285/AAC.49.6.294-2301.2005.
   LINCOLN EM, 1954, AM REV TUBERC PULM, V69, P682.
   Mazurek Gerald H., 2005, Morbidity and Mortality Weekly Report, V54, P49.
   McNabb SJN, 2002, EMERG INFECT DIS, V8, P1314.
   McShane H, 2005, TUBERCULOSIS, V85, P47, DOI 10.1016/j.tube.2004.09.015.
   Medical Research Council, 1950, BRIT MED J, V2, P1073.
   Medical Research Council, 1948, BMJ-BRIT MED J, V2, P769, DOI DOI 10.1136/BMJ.2.4582.769.
   Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928.
   Moore DF, 2005, DIAGN MICR INFEC DIS, V52, P247, DOI 10.1016/j.diagmicrobio.2005.02.014.
   Moore M, 1997, JAMA-J AM MED ASSOC, V278, P833, DOI 10.1001/jama.278.10.833.
   Munsiff SS, 2006, CLIN INFECT DIS, V43, P1468, DOI 10.1086/508278.
   Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6.
   Navin TR, 2002, EMERG INFECT DIS, V8, P1187.
   Noordhoek GT, 2004, CLIN MICROBIOL INFEC, V10, P295, DOI 10.1111/j.1198-743X.2004.00825.x.
   Northrup JM, 2002, EMERG INFECT DIS, V8, P1264.
   O'Brien RJ, 2005, CLIN CHEST MED, V26, P327, DOI 10.1016/j.ccm.2005.02.013.
   PablosMendez A, 1997, AM J MED, V102, P164.
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.
   {[}Anonymous], 1998, MMWR RECOMM REP, V47, P1.
   Schatz A, 1944, P SOC EXP BIOL MED, V57, P244.
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901.
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402.
   {[}Anonymous], 2003, INT J TUBERC LUNG D, V7, P410.
   Tuberculosis Chemotherapy Centre Madras, 1959, B WORLD HEALTH ORGAN, V21, P51.
   Wells CD, 1997, AM J RESP CRIT CARE, V156, P573.
   WENDEL KA, 2002, CLIN CARE, V14, P9.
   World Health Organization, 2003, WHOCDSTB2003313.
   {[}Anonymous], 2000, WHOCDSTB2000278.
   {*}WHO, 2000, 53 WORLD HLTH ASS ST.
   {[}Anonymous], 2007, TUBERCULOSIS.
   World Health Organization, 2002, WHOCDSTB2002297.
   ZAZA S, 1995, J INFECT DIS, V172, P1542.
   2006, MMWR MORB MORTAL WKL, V55, P11763.}},
Number-of-Cited-References = {{73}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Public Health Rep.}},
Doc-Delivery-Number = {{197NB}},
Unique-ID = {{ISI:000248561400018}},
}

@article{ ISI:000249393200002,
Author = {Burrill, Joshua and Williams, Christopher J. and Bain, Gillian and
   Conder, Gabriel and Hine, Andrew L. and Misra, Rakesh R.},
Title = {{Tuberculosis: a radiologic review}},
Journal = {{RADIOGRAPHICS}},
Year = {{2007}},
Volume = {{27}},
Number = {{5}},
Month = {{SEP-OCT}},
Note = {{91st Scientific Assembly and Annual Meeting of the
   Radiological-Society-of-North-America, Chicago, IL, NOV 27-DEC 02, 2005}},
Organization = {{Radiol Soc N Amer}},
Abstract = {{Tuberculosis has shown a resurgence in nonendemic populations in recent
   years, a phenomenon that has been attributed to factors such as
   increased migration and the human immunodeficiency virus epidemic.
   Although the thorax is most frequently involved, tuberculosis may
   involve any of a number of organ systems ( eg, the respiratory, cardiac,
   central nervous, musculoskeletal, gastrointestinal, and genitourinary
   systems), and timely diagnosis of the disease is paramount, since
   delayed treatment is associated with severe morbidity. Unfortunately, a
   history of infection with or exposure to tuberculosis may or may not be
   present, and evidence of active tuberculosis is present in less than
   50\% of cases. A negative tuberculin skin test does not in itself
   exclude infection. Furthermore, the clinical and radiologic features of
   tuberculosis may mimic those of many other diseases. Therefore, although
   in many cases biopsy or culture specimens are required to make the
   definitive diagnosis, it is imperative that radiologists and clinicians
   understand the typical distribution, patterns, and imaging
   manifestations of tuberculosis. (c) RSNA, 2007}},
Publisher = {{RADIOLOGICAL SOC NORTH AMERICA}},
Address = {{820 JORIE BLVD, OAK BROOK, IL 60523 USA}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Misra, RR (Reprint Author), Cent Middlesex Hosp, Dept Radiol, London NW10 7NS, England.
   Cent Middlesex Hosp, Dept Radiol, London NW10 7NS, England.
   Wycombe Gen Hosp, Dept Radiol, High Wycombe HP11 2TT, Bucks, England.}},
DOI = {{10.1148/rg.275065176}},
Article-Number = {{1255}},
ISSN = {{0271-5333}},
Keywords-Plus = {{NERVOUS-SYSTEM TUBERCULOSIS; HIV-INFECTED PATIENTS; HEALTH-CARE WORKERS;
   PULMONARY TUBERCULOSIS; COMPUTED-TOMOGRAPHY; ABDOMINAL TUBERCULOSIS;
   EXTRAPULMONARY TUBERCULOSIS; SKELETAL TUBERCULOSIS; EMISSION-TOMOGRAPHY;
   JOINT TUBERCULOSIS}},
Research-Areas = {{Radiology, Nuclear Medicine \& Medical Imaging}},
Web-of-Science-Categories  = {{Radiology, Nuclear Medicine \& Medical Imaging}},
Author-Email = {{mail@misraonline.co.uk}},
Cited-References = {{Andreu J, 2004, EUR J RADIOL, V51, P139, DOI 10.1016/j.ejrad.2004.03.009.
   BERNEY S, 1972, AM J MED, V53, P36, DOI 10.1016/0002-9343(72)90113-1.
   CHAPMAN M, 1979, SEMIN ROENTGENOL, V14, P266, DOI 10.1016/0037-198X(79)90024-5.
   Cherian G, 2004, POSTGRAD MED J, V80, P262, DOI 10.1136/pgmj.2003.013664.
   Curvo-Semedo L, 2005, EUR J RADIOL, V55, P158, DOI 10.1016/j.ejrad.2005.04.014.
   DAVIDSON PT, 1970, AM J MED, V48, P77, DOI 10.1016/0002-9343(70)90101-4.
   DECASTRO CC, 1995, RADIOL CLIN N AM, V33, P753.
   DENTON T, 1993, CLIN RADIOL, V47, P409, DOI 10.1016/S0009-9260(05)81062-1.
   Djuretic T, 2002, THORAX, V57, P477, DOI 10.1136/thorax.57.6.477.
   Engin G, 2000, RADIOGRAPHICS, V20, P471.
   FRAMPTON MW, 1992, ANN INTERN MED, V117, P312.
   GEE GT, 1992, AM J ROENTGENOL, V159, P1075.
   Goo JM, 2000, RADIOLOGY, V216, P117.
   Granich R, 1999, GUIDELINES PREVENTIO.
   Hara T, 2003, CHEST, V124, P893, DOI 10.1378/chest.124.3.893.
   HAYGOOD TM, 1994, RADIOGRAPHICS, V14, P561.
   Ho CL, 2004, ANN ACAD MED SINGAP, V33, P155.
   HOFFMAN EB, 1993, J BONE JOINT SURG BR, V75, P233.
   JAIN R, 1993, CLIN RADIOL, V47, P196, DOI 10.1016/S0009-9260(05)81162-6.
   Jenssen HK, 2005, INDIANA U MATH J, V54, P1, DOI 10.1512/iumj.2005.54.2685.
   JINKINS JR, 1995, RADIOL CLIN N AM, V33, P771.
   Kostakoglu L, 2003, RADIOGRAPHICS, V23, P315, DOI 10.1148/rg.232025705.
   KUKREJ N, 2002, AM J TRANSPLANT, V2, P1025.
   Lam KY, 2001, CLIN ENDOCRINOL, V54, P633, DOI 10.1046/j.1365-2265.2001.01266.x.
   LEDER RA, 1995, RADIOL CLIN N AM, V33, P691.
   LIFESO RM, 1985, J BONE JOINT SURG AM, V67A, P1405.
   Lin WY, 1998, CLIN NUCL MED, V23, P743, DOI 10.1097/00003072-199811000-00004.
   Lin WY, 1999, NUKLEARMED, V38, P199.
   LISBONA R, 1993, J NUCL MED, V34, P853.
   Lolge S, 2003, CLIN RADIOL, V58, P545, DOI 10.1016/S0009-9260(03)00120-X.
   Maher D, 2005, CLIN CHEST MED, V26, P167, DOI 10.1016/j.ccm.2005.02.009.
   MARTINI M, 1988, ORTHOPEDICS, V11, P861.
   MCADAMS HP, 1995, RADIOL CLIN N AM, V33, P655.
   Menzies D, 2000, ANN INTERN MED, V133, P779.
   MODIC MT, 1985, RADIOLOGY, V157, P157.
   Morgado C, 2005, EUR J RADIOL, V55, P188, DOI 10.1016/j.ejrad.2005.04.017.
   MUNOZ P, 1995, CLIN INFECT DIS, V21, P398.
   NAIMURRAHMAN, 1980, J BONE JOINT SURG BR, V62, P162.
   National Collaborating Centre for Chronic Conditions, 2006, TUB CLIN DIAGN MAN T.
   NEWTON P, 1982, ANN RHEUM DIS, V41, P1, DOI 10.1136/ard.41.1.1.
   Nunn P, 2005, NAT REV IMMUNOL, V5, P819, DOI 10.1038/nri1704.
   OMARI B, 1989, CHEST, V95, P145, DOI 10.1378/chest.95.1.145.
   Ormerod P, 2000, THORAX, V55, P887.
   Palmieri F, 2002, INFECTION, V30, P68, DOI 10.1007/s15010-002-2062-9.
   PITMAN AG, 2002, BRIT J RADIOL, V75, P1144.
   RESNICK D, 2002, DIAGNOSIS BONE JOINT, P2524.
   Rodriguez E, 2001, J COMPUT ASSIST TOMO, V25, P577, DOI 10.1097/00004728-200107000-00012.
   Rose AMC, 2002, J PUBLIC HEALTH MED, V24, P136, DOI 10.1093/pubmed/24.2.136.
   Rose AMC, 2001, THORAX, V56, P173, DOI 10.1136/thorax.56.3.173.
   Schneider E, 2005, CLIN CHEST MED, V26, P183, DOI 10.1016/j.ccm.2005.02.007.
   Sharma A, 1997, AM J ROENTGENOL, V168, P807.
   SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503.
   SUCHET IB, 1992, J COMPUT ASSIST TOMO, V16, P391, DOI 10.1097/00004728-199205000-00010.
   Sugawara Y, 1998, EUR J NUCL MED, V25, P1238, DOI 10.1007/s002590050290.
   Suri S, 1999, BRIT J RADIOL, V72, P92.
   Teo DTW, 2004, ANN ACAD MED SINGAP, V33, P95.
   Wang LJ, 1997, J COMPUT ASSIST TOMO, V21, P254, DOI 10.1097/00004728-199703000-00016.
   Wang Y X, 1998, J Belge Radiol, V81, P226.
   WEAVER P, 1984, SKELETAL RADIOL, V12, P178.
   Whiteman MLH, 1997, NEUROIMAG CLIN N AM, V7, P199.
   WOODRING JH, 1986, AM J ROENTGENOL, V146, P497.
   Zissin R, 2001, ISRAEL MED ASSOC J, V3, P414.
   Zissin R, 2001, ABDOM IMAGING, V26, P533, DOI 10.1007/s002610000201.}},
Number-of-Cited-References = {{63}},
Times-Cited = {{109}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Radiographics}},
Doc-Delivery-Number = {{209MS}},
Unique-ID = {{ISI:000249393200002}},
}

@article{ ISI:000249339600010,
Author = {Lebrato, J. Canora and Garcia, A. Hernando and Perez, B. Frutos and
   Aroca, J. Jaqueti and Gaviria, A. Zapatero},
Title = {{Disseminated granulomatous disease: sarcoidosis or tuberculosis?}},
Journal = {{REVISTA CLINICA ESPANOLA}},
Year = {{2007}},
Volume = {{207}},
Number = {{8}},
Pages = {{408-410}},
Month = {{SEP}},
Publisher = {{EDICIONES DOYMA S A}},
Address = {{TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Lebrato, JC (Reprint Author), Hosp Fuenlabrada, Med Interna Serv, Madrid, Spain.
   Hosp Fuenlabrada, Med Interna Serv, Madrid, Spain.
   Hosp Fuenlabrada, Serv Radiodiagnost, Madrid, Spain.
   Hosp Fuenlabrada, Microbiol Serv, Madrid, Spain.}},
ISSN = {{0014-2565}},
EISSN = {{1578-1860}},
Keywords-Plus = {{NEUROSARCOIDOSIS; MANAGEMENT; DIAGNOSIS}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{Almeida A, 2005, EUR J RADIOL, V55, P193, DOI 10.1016/j.ejrad.2005.04.018.
   Cormican L, 2006, POSTGRAD MED J, V82, P46, DOI 10.1136/pgmj.2005.032862.
   Kellinghaus C, 2004, EUR NEUROL, V51, P84, DOI 10.1159/000076534.
   Sharma OP, 1997, CHEST, V112, P220, DOI 10.1378/chest.112.1.220.
   Spencer TS, 2005, SEMIN ARTHRITIS RHEU, V34, P649, DOI 10.1016/j.semarthrit.2004.07.011.
   Wasay M, 2003, J NEUROIMAGING, V13, P240, DOI 10.1177/1051228403254654.
   Zajicek JP, 1999, QJM-INT J MED, V92, P103, DOI 10.1093/qjmed/92.2.103.}},
Number-of-Cited-References = {{7}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Rev. Clin. Esp.}},
Doc-Delivery-Number = {{208SN}},
Unique-ID = {{ISI:000249339600010}},
}

@article{ ISI:000253378500002,
Author = {Barreira, Draurio and Grangeiro, Alexandre},
Title = {{Evaluation of tuberculosis control strategies in Brazil}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Editorial Material}},
Language = {{Portuguese}},
Affiliation = {{Barreira, D (Reprint Author), SCS, Programa Nacl Controle TB, Quadra 4,Bloco A 3 Andar, BR-70304000 Brasilia, DF, Brazil.
   Barreira, Draurio, Programa Nacl Controle TB, Secretaria Vigilancia Saude, Minist Saude, Brasilia, DF, Brazil.
   Grangeiro, Alexandre, Nucl Invest Condicoes Vide \& Situa Saude, Inst Saude, Secretaria Estado Saude Sao Paulo, Sao Paulo, SP, Brazil.}},
ISSN = {{0034-8910}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{draurio.barreira@saude.gov.br}},
Cited-References = {{Ducati RG, 2006, MEM I OSWALDO CRUZ, V101, P697, DOI 10.1590/S0074-02762006000700001.
   {*}GLOB FUND FIGHT A, 2007, TUB MAL PARTN IMP RE.
   {*}I PESQ EC APL, 2004, OBJ DES MIL REL NAC.
   Brasil, 2006, DIR OP PACT PEL VID.
   {*}MIN SAUD SECR VIG, 2005, SAUD BRAS AN SIT SAU.
   {*}MIN SAUD SECR VIG, 2004, PROGR NAC CONTR TUB.
   {[}Anonymous], PLAN ESTR REG CONTR.
   Ruffino-Netto Antonio, 2002, Rev Soc Bras Med Trop, V35, P51, DOI 10.1590/S0037-86822002000100010.
   {*}UN, 2001, ROAD MAP IMPL UN MIL.
   {*}UN INF CTR, 2000, DECL MIL NAC UN.
   VANDRAMINI SHF, 2007, REV LAT-AM ENFERM, V15, P171.
   World Health Organization, 2002, WHOCDSTB2002296.
   World Health Organization, 2001, WHOCDSTB2001287.
   World Health Organization, 2005, WHOHTMTB2005349.
   {*}WHO, 2000, MIN C 22 24 MARCH 20.
   WHO, 2007, WHOHTMTB2007376.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500002}},
}

@article{ ISI:000253378500010,
Author = {Bierrenbach, Ana Luiza and Stevens, Antony Peter and Ferreira Gomes,
   Adriana Bacelar and Noronha, Elza Ferreira and Glatt, Ruth and Carvalho,
   Carolina Novaes and Gregorio de Oliveira, Jr., Joao and Marinho de
   Souza, Maria de Fatima},
Title = {{Impact on tuberculosis incidence rates of removal of repeat notification
   records}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Abstract = {{OBJECTIVE: To evaluate the impact on tuberculosis (TB) incidence rates
   of removal of improper duplicate records from the notification system.
   METHODS: Data from the Sistema de Informacao de Agravos de Notificacao
   (Brazilian Information System for Tuberculosis Notification) from 2000
   to 2004 were analyzed. Repeat records were identified through
   probabilistic record linkage and classified into six mutually exclusive
   categories and then kept, combined or removed from database.
   RESULTS: Of all TB records, 73.7\% had no duplicate, 18.9\% were
   duplicate, 4.7\% were triplicate, and 2.7\% were quadruplicate or more.
   Of all repeat records, 47.3\% were classified as transfer in/out; 23.6\%
   return after default, 16.4\% true duplicates, 10\% relapse, 2.5\%
   inconclusive and 0.2\% had missing data. These proportions were
   different in Brazilian states. Removal of improper duplicate records
   reduced TB incidence rate per 100.000 inhabitants by 6.1\% in the year
   2000 (from 44 to 41.3), 8.3\% in 2001 (from 44.5 to 40.8), 9.4\% in 2002
   (from 45.8 to 41.5), 9.2\% in 2003 (from 46.9 to 42.6) and 8.4\% in 2004
   (from 45.4 to 41.6).
   CONCLUSIONS: The study results indicate that the observed tuberculosis
   incidence rates represent estimates that would be closer to the actual
   rates than those obtained from the raw database at state and country
   level. The use of record linkage approach should be promoted for better
   quality of notification system data.}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bierrenbach, AL (Reprint Author), Esplanada Minist, Bloco G,Edificio Sede,10 Andar,Sala 150, BR-70058900 Brasilia, DF, Brazil.
   Bierrenbach, Ana Luiza; Stevens, Antony Peter; Ferreira Gomes, Adriana Bacelar; Glatt, Ruth; Carvalho, Carolina Novaes; Gregorio de Oliveira, Joao, Jr.; Marinho de Souza, Maria de Fatima, Minist Saude, Secretaria Vigilancia Saude, Brasilia, DF, Brazil.
   Noronha, Elza Ferreira, Univ Brasilia, Fac Med, Brasilia, DF, Brazil.}},
ISSN = {{0034-8910}},
Keywords = {{tuberculosis, epidemiology; disease notification; diseases registries;
   data sources; information systems; Brazil}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{ana.bierrenbach@saude.gov.br}},
ResearcherID-Numbers = {{Bierrenbach, Ana/F-3185-2014}},
ORCID-Numbers = {{Bierrenbach, Ana/0000-0002-6837-0636}},
Cited-References = {{Camargo K R Jr, 2000, Cad Saude Publica, V16, P439, DOI 10.1590/S0102-311X2000000200014.
   FELLEGI IP, 1969, J AM STAT ASSOC, V64, P1183, DOI 10.2307/2286061.
   Laguardia J., 2004, EPIDEMIOL SERV SAUDE, V13, P135.}},
Number-of-Cited-References = {{3}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500010}},
}

@article{ ISI:000253378500005,
Author = {Bierrenbach, Ana Luiza and Ferreira Gomes, Adriana Bacelar and Noronha,
   Elza Ferreira and Marinho de Souza, Maria de Fatima},
Title = {{Tuberculosis incidence and cure rates, Brazil, 2000-2004}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Abstract = {{OBJECTIVE: To describe the geographical distribution of tuberculosis
   incidence rates based on a set of epidemiological and operational
   indicators from information system database.
   METHODS: Data from the Sistema de Informacao de Agravos de Notificacao
   (Brazilian Information System for Tuberculosis Notification) were
   collected after removal of improper repeat records and record linkage.
   Tuberculosis incidence rates were estimated according to geographical
   unit, age group, sex, clinical manifestation and treatment schedule and
   standardized for population age group distribution based on 2000
   Population Census.
   RESULTS: In 2004, in Brazil, tuberculosis incidence rate was 41 per
   100,000 inhabitants and 74,540 new cases were notified. Of these, 52.8\%
   were pulmonary tuberculosis with positive bacilloscopy, 24.1\% were
   under supervised treatment, 63.5\% were from state capitals or
   metropolitan areas, and 54.9\% were cured cases (complete treatment).
   After records with missing outcome data were excluded, cure rates were
   72.4\% for new cases, 47\% for new HIV-positive cases, 64.9\% for
   relapses, 64.5\% for transfers in/out, and 40\% for returns after
   default. Cure rate for new cases under supervised treatment was 77.1\%.
   A higher proportion of records with missing outcome information was seen
   in recent years.
   CONCLUSIONS: Different incidence rates and treatment outcomes were found
   in different Brazilian states. To reach the 85\% cure goal for new cases
   and to increase cure in HIV-positive and defaults cases additional
   efforts are needed by the Brazilian National Tuberculosis Program,
   including scaling up the Directly Observed Therapy Strategy.}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bierrenbach, AL (Reprint Author), Esplanda Minist, Bloco G,Edif Sede 10 Andar,Sala 150, BR-70058900 Brasilia, DF, Brazil.
   Noronha, Elza Ferreira, Univ Brasilia, Fac Med, Brasilia, DF, Brazil.
   Bierrenbach, Ana Luiza; Ferreira Gomes, Adriana Bacelar; Marinho de Souza, Maria de Fatima, Minist Saude, Secretaria Vigilancia Saude, Brasilia, DF, Brazil.}},
ISSN = {{0034-8910}},
Keywords = {{tuberculosis, epidemiology; incidence; diseases registries;
   epidemiology, descriptive; Brazil}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{ana.bierrenbach@saude.gov.br}},
Cited-References = {{BIERRENBACH AL, 2007, REV SAUDE PUBLICA S1, V41.
   Chaimowicz F, 2001, REV SAUDE PUBL, V35, P81, DOI 10.1590/S0034-89102001000100012.
   {*}COOR NAC PNEUM SA, 1993, BOL PNEUMOL SANIT, P1.
   {*}CTR REF PROF HEL, 2005, BOL PNEUMOL SANIT, V13, P133.
   Façanha Mônica Cardoso, 2005, Rev. bras. epidemiol., V8, P25.
   Souza WV, 2005, REV SAUDE PUBL, V39, P82, DOI 10.1590/s0034-89102005000100011.
   World Health Organization, 2005, WHOHTMTB2005349.}},
Number-of-Cited-References = {{7}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500005}},
}

@article{ ISI:000253378500004,
Author = {Bierrenbach, Ana Luiza and Duartei, Elisabeth Carmen and Ferreira Gomes,
   Adriana Bacelar and Marinho de Souza, Maria de Fatima},
Title = {{Mortality trends due to tuberculosis in Brazil, 1980-2004}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Abstract = {{OBJECTIVE: To analyze the current profile and trends of tuberculosis
   mortality in Brazil between 1980 and 2004.
   METHODS: Descriptive study of tuberculosis as underlying or associate
   cause of death based on secondary data from the Brazilian Mortality
   Information System.
   RESULTS: An irregular reduction in the number of tuberculosis deaths and
   mortality rates along the study period, from 5.8 in 1980 to 2.3 per
   100,000 inhabitants in 2004, was seen. An accelerated reduction in
   mortality trend was seen until 1985 mostly in the states of Rio de
   Janeiro and Sao Paulo. There was a trend towards mortality occurring in
   older ages. In 2004, 4,981 tuberculosis cases were notified as
   underlying cause of death in Brazil but it would increase by 50\% if
   tuberculosis as associate cause and tuberculosis sequelae as underlying
   cause of death were added. In 2004, the highest mortality rates were
   found in the states of Pernambuco (5.4) and Rio de Janeiro (5.0) and in
   state capitals such as Recife (7.7) and Belem (5.8).
   CONCLUSIONS: Given the well-known association between tuberculosis and
   Aids, the impact of AIDS epidemic indirectly reflects on the mortality
   trends of tuberculosis.}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bierrenbach, AL (Reprint Author), Esplanda Minist, Bloco G,Edifico Sede,10 Andar,Sala 150, BR-70058900 Brasilia, DF, Brazil.
   Duartei, Elisabeth Carmen, Univ Brasilia, Fac Med, Dept Med Sociol, Brasilia, DF, Brazil.
   Bierrenbach, Ana Luiza; Ferreira Gomes, Adriana Bacelar; Marinho de Souza, Maria de Fatima, Minist Saude, Secretaria Vigilancia Saude, Brasilia, DF, Brazil.}},
ISSN = {{0034-8910}},
Keywords = {{tuberculosis, mortality; tuberculosis, epidemiology; mortality
   registries; mortality, trends; brazil}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; BURDEN}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{ana.bierrenbach@saude.gov.br}},
ResearcherID-Numbers = {{Bierrenbach, Ana/F-3185-2014}},
ORCID-Numbers = {{Bierrenbach, Ana/0000-0002-6837-0636}},
Cited-References = {{ANTUNES JLF, 2000, CIENC SAUDE COLETIVA, V5, P367, DOI 10.1590/S1413-81232000000200010.
   BARNES PF, 1988, J INFECT DIS, V158, P366.
   BRAGA JU, 1999, INT J TUBERC LUNG S1, V3, pS121.
   Buchalla CM, 1996, REV SAUDE PUBL, V30, P479.
   Campos HS, 2000, B PNEUM SAN, V8, P7.
   Chaimowicz F, 2001, REV SAUDE PUBL, V35, P81, DOI 10.1590/S0034-89102001000100012.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Franco Rosana, 2003, Braz J Infect Dis, V7, P166, DOI 10.1590/S1413-86702003000200011.
   HUMPHRIES MJ, 1984, BRIT J DIS CHEST, V78, P149, DOI 10.1016/S0007-0971(84)80096-0.
   Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9.
   LUNA JAC, 1992, NEUMOLOGIA, V1, P15.
   {*}MIN SAUD, 2005, BOL PNEUMOL SANIT, V13, P133.
   Oliveira Helenice Bosco de, 2004, Rev Saude Publica, V38, P503, DOI 10.1590/S0034-89102004000400004.
   Rede Interagencial de Informacoes para a Saude, 2002, IND BAS SAUD BRAS CO.
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154.
   RUFFINONETTO A, 1995, REV SAUDE PUBL, V29, P279, DOI 10.1590/S0034-89101995000400004.
   Santo AH, 2003, REV SAUDE PUBL, V37, P714, DOI {[}10.1590/S0034-89102003000600005, 10.1590/s0034-89102003000600005].}},
Number-of-Cited-References = {{17}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500004}},
}

@article{ ISI:000253378500011,
Author = {Braga, Jose Ueleres},
Title = {{Tuberculosis surveillance and health information system in Brazil,
   2001-2003}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Abstract = {{OBJECTIVE: To assess the quality of tuberculosis surveillance in Brazil.
   METHODS: Local data from 2001 to 2003 were assessed according to the
   quality of detection and follow-up of the cases in the region, the
   quality of the information produced by the notification system, and the
   load of morbidity of tuberculosis. Cities were classified into four
   groups, according to tuberculosis epidemiologic stage and the quality of
   tuberculosis surveillance.
   RESULTS: In the study period, about 8\% of the Brazilian cities
   presented over 10\% of the cases of tuberculosis notified by the health
   care services of another city. In about 950 cities, the frequency of
   patients with pulmonary tuberculosis undergoing sputum examination was
   lower than 90\%. In the North region, Amazonas, Para and Amapa presented
   more cities classified in the groups of poor tuberculosis surveillance.
   In the Northeast, Pernambuco, Ceara and Bahia presented the poorest
   surveillance. The South and Midwest regions presented greater number of
   cities with better tuberculosis surveillance.
   CONCLUSIONS: One third of the Brazilian cities present poor tuberculosis
   surveillance. This picture is not homogeneous in Brazil, and the regions
   with highest tuberculosis incidence have a great number of cities with
   apparently insufficient control measures.}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Braga, JU (Reprint Author), R Belisario Tavora 653,Apto 202 Laranjeiras, BR-22245070 Rio De Janeiro, RJ, Brazil.
   Braga, Jose Ueleres, Univ Estado Rio de Janeiro, Inst Social Med, Dept Epidemiol, Rio De Janeiro, RJ, Brazil.}},
ISSN = {{0034-8910}},
Keywords = {{tuberculosis, epidemiology; morbidity; diseases registries; registries;
   data source; Brazil}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{ueleres@pq.cnpq.br}},
Cited-References = {{ASSUNCAO RM, 1998, CAD SAUDE PUBLICA, V14, P712.
   Bailey TC, 1995, INTERACTIVE SPATIAL.
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220.
   RUFFINONETTO A, 1999, INFORME EPIDEMIOLOGI, V8, P35.}},
Number-of-Cited-References = {{4}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500011}},
}

@article{ ISI:000253378500006,
Author = {Dalcolmo, Margareth Pretti and de Noronha Andrade, Monica Kramer and
   Piconi, Pedro Dornelles},
Title = {{Multiresistant tuberculosis in Brazil: history and control}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Abstract = {{The article aimed at assessing multidrug-resistant tuberculosis control
   in Brazil, based on the experiences of reference institutions, and the
   most relevant studies carried out to determine local and national
   resistance rates. Control measures and the current situation of
   treatment and diagnoses after the implementation of the national
   guidelines, which were revised in 2004, are considered. The first
   national survey on resistance to anti-tuberculosis drugs was performed
   in the middle of last decade. From its outcomes, a regimen to treat all
   cases of multidrug-resistant tuberculosis was validated and adopted.
   Government measures enabled the implementation of a surveillance system,
   whose outcomes are also commented.}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO,
   BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Dalcolmo, MP (Reprint Author), Estrada Curicica Jacarepagua 2000, BR-22710552 Rio De Janeiro, RJ, Brazil.
   Dalcolmo, Margareth Pretti, Ctr Referencia Helio Fraga, Minist Saude, Rio De Janeiro, RJ, Brazil.
   de Noronha Andrade, Monica Kramer, Univ Fed Rio de Janeiro, Fac Med, Rio De Janeiro, RJ, Brazil.
   Piconi, Pedro Dornelles, Hosp Sanatorio Partenon, Secretaria Estado Saude Rio Grande Sul, Porto Alegre, RS, Brazil.}},
ISSN = {{0034-8910}},
Keywords = {{tuberculosis, multidrug-resistant, prevention \& control; tuberculosis,
   multidrug-resistant, history; evaluation of results of therapeutic
   interventions; epidemiologic surveillance; national health programs;
   Brazil}},
Keywords-Plus = {{DRUG-RESISTANT TUBERCULOSIS; SHORT-COURSE CHEMOTHERAPY;
   MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{margareth.dalcolmo@saude.gov.br}},
Cited-References = {{BATES JH, 1995, AM J RESP CRIT CARE, V151, P942.
   BRAGA JU, 1993, INT J TUBERC LUNG S1, V3, P121.
   CANETTI G, 1963, Rev Tuberc Pneumol (Paris), V27, P217.
   {*}CDCP, 2007, MMWR MORBMORTAL WKLY, V56, P250.
   Chan ED, 2004, AM J RESP CRIT CARE, V169, P1103, DOI 10.1164/rccm.200308-11590C.
   Cole Stewart T., 1994, Trends in Microbiology, V2, P411, DOI 10.1016/0966-842X(94)90621-1.
   Dalcolmo MP, 1999, J PNEUMOL, V25, P70.
   DEMELO FAF, 1996, J PNEUMOL, V22, P3.
   DEMELO FAF, 1993, J PNEUMOL, V19, P73.
   Filho AC, 2004, J BRAS PNEUMOL S1, V30, pS57.
   FILHO GG, 1993, J PNEUMOL, V19, P4.
   FOX W, 1972, Bulletin of the International Union Against Tuberculosis, V47, P49.
   FOX W, 1975, AM REV RESPIR DIS, V111, P325.
   Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229.
   Fujiwara PI, 1997, ARCH INTERN MED, V157, P531, DOI 10.1001/archinte.157.5.531.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Caminero Luna JA, 2003, GUIA TUBERCULOSIS ME.
   Migliori GB, 2007, EUR RESPIR J, V29, P423, DOI 10.1183/09031936.00001307.
   Mitchison DA, 2005, EUR RESPIR J, V25, P376, DOI 10.1183/09031936.05.00075704.
   Mitchison DA, 2004, SEM RESP CRIT CARE M, V25, P307, DOI 10.1055/s-2004-829503.
   MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423.
   PICON PD, 1993, TUBERCULOSE EDPDEMIO, P504.
   Shah NS, 2007, EMERG INFECT DIS, V13, P380.
   Silva MSN, 2003, J CLIN MICROBIOL, V41, P4471, DOI 10.1128/JCM.41.9.4471-4474.2003.
   Telenti A, 1997, CLIN CHEST MED, V18, P55, DOI 10.1016/S0272-5231(05)70355-5.
   WHO, 2006, GUID PROGR MAN DRUG.
   ZANG Y, 1994, J ANTIMICROB CHEMOTH, V34, P313.}},
Number-of-Cited-References = {{27}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500006}},
}

@article{ ISI:000253378500015,
Author = {dos Santos Filho, Ezio Tavora and dos Santos Gomes, Zaiera Machado},
Title = {{Strategies for tuberculosis control in Brazil: networking and civil
   society participation}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Abstract = {{Although no significant changes in the tuberculosis indicators have been
   registered in Brazil in recent years, there is a clear shift in the
   political scenario regarding the manner this disease has been tackled,
   with the appearance of civil society standing out. Considerations about
   the conditions that contributed to its emergence are made, such as the
   origin, composition, actions, partners and perspectives on social
   mobilization. Due to initiatives for tuberculosis control on an
   international level and attempts to encourage social mobilization on
   state and municipal levels, the Brazilian federal government began to
   engage in a more consistent and coherent policy, also including civil
   society in its actions. In spite of being an actor acknowledged by the
   public power and considered strategic for the success of tuberculosis
   control actions, community participation requires incentives and
   constant support from other sectors.}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{dos Santos, ET (Reprint Author), R Correa Dutra,149 Sala 102, BR-22210050 Rio De Janeiro, RJ, Brazil.
   dos Santos Filho, Ezio Tavora; dos Santos Gomes, Zaiera Machado, Fundo Global Contra Aids, Mecan Coordenador Pais Brasil Para, Rio De Janeiro, RJ, Brazil.}},
ISSN = {{0034-8910}},
Keywords = {{tuberculosis, prevention \& control; consumer participation;
   participative planning; health public policy; Brazil}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{tbhiv@eziocon.net}},
Cited-References = {{FILHO ETS, 2006, POLITICA TB BRASIL P.
   {*}MIN SAUD SECR POL, 1999, PLAN NAC CONTR TUB.
   NACIMENTO DR, 2002, FUNDACAO ATAULPHO PA, P30.
   {*}ORG MUND SAL, 1994, OMSTB94179.
   {*}ORG MUND SAL, 1991, 44 AS MUND SAL MAY 6.
   RUFFINONETTO A, 2006, TUBERCULOSE IMPLANTA.
   SILVA CL, 2005, RELATORIO ATIVIDADES, P1.
   {*}STOP TB PARTN, 2000, AMST DECL STOP TB AM.
   {*}STOP TB PARTN, 2001, WASH COMM STOP TB.
   {*}WHO, 2001, 5 EL DOTS DOTS REM H.}},
Number-of-Cited-References = {{10}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500015}},
}

@article{ ISI:000253378500013,
Author = {Ferreira Goncalves, Maria Jacirema and Fernandes Penna, Maria Lucia},
Title = {{Tuberculosis morbidity and effectiveness of the control programin
   Brazilian municipalities, 2001-2003}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Note = {{Seminar on the Assessment of Strategies for the Control of Tuberculosis,
   Sao Paulo, BRAZIL, SEP, 2006}},
Abstract = {{OBJECTIVE: To analyze Brazilian municipalities according to morbidity
   and effectiveness of epidemiological inspection control of tuberculosis
   and AIDS.
   METHODS: Exploratory analysis of two non-hierarchical data clusters of
   epidemiological inspection data on tuberculosis and AIDS, and
   operational indicators of the Programa Nacional de Controle de
   Tuberculose ( National Tuberculosis Control Program), from 2001 to 2003.
   The distribution was stratified in metropolitan areas and priority
   municipalities, according to the size of the population. The association
   between morbidity clusters and effectiveness was evaluated by the
   Chi-square test, with analysis of residues in order to identify
   significant associations.
   RESULTS: Out of the five morbidity clusters, the concerning
   epidemiological situation occurs in municipalities with high incidence
   of Aids, with high or low incidence of tuberculosis, prevailing in the
   Southeast and South of Brazil and larger cities. Out of the six program
   effectiveness clusters, moderate and average effectiveness are
   significantly associated to priority municipalities, in metropolitan
   areas with more than 80 thousand inhabitants. Clusters with average and
   poor effectiveness represent 10\% of municipalities with elevated
   treatment drop out and low rates of cure. The ``no data{''} cluster is
   associated with the very low incidence of tuberculosis and AIDS cluster.
   CONCLUSIONS: The findings reflect inadequacy of inspection concerning
   the epidemiological reality in Brazil: precarious social factors
   associated with tuberculosis and AIDS and insufficient effectiveness of
   the control program.}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Goncalves, MJF (Reprint Author), Univ Fed Amazonas, Escola Enfermagem manus, R Teresina,495 Adrianopolis, BR-69057070 Manaus, Amazonas, Brazil.
   Ferreira Goncalves, Maria Jacirema, Univ Fed Amazonas, Escola Enfermagem manus, BR-69057070 Manaus, Amazonas, Brazil.
   Fernandes Penna, Maria Lucia, Univ Estado Rio de Janeiro, Inst Social Med, Rio De Janeiro, RJ, Brazil.}},
ISSN = {{0034-8910}},
Keywords = {{tuberculosis, epidemiology; program evaluation; health status
   indicators; epidemiologic surveillance; Brazil}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{jaciremagoncalves@ufam.edu.br}},
ResearcherID-Numbers = {{Goncalves, Maria Jacirema/B-7018-2009}},
ORCID-Numbers = {{Goncalves, Maria Jacirema/0000-0002-8460-8501}},
Cited-References = {{Carvalho MS, 1997, CAD SAUDE PUBLICA, V13, P635.
   Contandriopoulos AP, 2000, REV EPIDEMIOL SANTE, V48, P517.
   Costa J. S. D., 1998, CAD SAUDE PUBLICA, V14, P409.
   Donabedian A, 2005, MILBANK Q, V83, P691, DOI 10.1111/j.1468-0009.2005.00397.x.
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4.
   HAIR JF, 1995, MULTIVARIATE DATA AN.
   JKPENNNA MLF, 1988, CAD IMS, V2, P117.
   Lillebaek T, 2002, EMERG INFECT DIS, V8, P679.
   Menezes A, 1998, REV BRAS EPIDEMIOL, V1, P50, DOI 10.1590/S1415-790X1998000100006.
   Mota Fabio Frias, 2003, Cad Saude Publica, V19, P915, DOI 10.1590/S0102-311X2003000400014.
   Murray CJL, 1998, P NATL ACAD SCI USA, V95, P13881, DOI 10.1073/pnas.95.23.13881.
   Natal S, 1999, B PNEUMOL SANIT, V7, P65.
   Oliveira H B, 2000, Rev Saude Publica, V34, P437.
   PENNA MLF, 1987, CAD IMS, V1, P68.
   Pereira JCR, 2004, ANAL DADOS QUALITATI.
   PIO A, 1998, WHOTB98253.
   Raviglione MC, 1997, LANCET, V350, P624, DOI 10.1016/S0140-6736(97)04146-9.
   Raviglione MC, 2002, LANCET, V359, P775, DOI 10.1016/S0140-6736(02)07880-7.
   Ruffino-Netto Antonio, 2002, Rev Soc Bras Med Trop, V35, P51, DOI 10.1590/S0037-86822002000100010.
   RUFFINONETTO A, 1999, BOL PNEUMOL SANIT, V7, P7.
   Schonlau Matthias, 2002, STATA J, V2, P391.
   Toledo ACD, 2000, MEM I OSWALDO CRUZ, V95, P437.
   VENDRAMINI SHF, 2002, B PNEUMOL SANIT, V10, P2.
   World Health Organization, 2006, GLOB PLAN STOP TB 20.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500013}},
}

@article{ ISI:000253378500017,
Author = {Galesi, Vera Maria Neder},
Title = {{Data on tuberculosis in the state of Sao Paulo, Brazil}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Letter}},
Language = {{Portuguese}},
Affiliation = {{Galesi, VMN (Reprint Author), TB Estado Sao Paulo, Coordenadora Programa Controle, Sao Paulo, Brazil.
   TB Estado Sao Paulo, Coordenadora Programa Controle, Sao Paulo, Brazil.}},
ISSN = {{0034-8910}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500017}},
}

@article{ ISI:000253378500008,
Author = {Hijjar, Miguel Aiub and Gerhardt, Germano and Teixeira, Gilmario M. and
   Procopio, Maria Jose},
Title = {{Retrospect of tuberculosis control in Brazil}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Abstract = {{The aim of the study was to look back on the course of action involving
   measures of tuberculosis control in Brazil since the end of the 19th
   century, covering the history of social struggles and pointing out
   institutions and people that have dedicated themselves to looking for
   solutions to these issues. The Brazilian response to tuberculosis
   started in society with the Ligas Contra a Tuberculose (Leagues Against
   Tuberculosis), promoting scientific advances, such as the BCG
   vaccination, which begun in 1927. From the public power, the Inspetoria
   de Profilaxia da TB (TB Prophylaxis Inspection Service - 1920), the
   Servico Nacional de Tuberculose (National Service of Tuberculosis -
   1940), and the Campanha Nacional Contra a Tuberculose (National Campaign
   Against Tuberculosis - 1946), coordinated national policies such as
   chemotherapy, beginning with the discovery of streptomycin in 1944. The
   emergence of bacterial resistance led to the development of several
   therapeutic schemes. The Scheme 1 (rifampycin, hydrazide and
   pyrazinamid), which was the main one in 1979 and is still used nowadays,
   had a great epidemiological effect. The WHO declared TB a public health
   emergency in 1993. In response, Brazil developed some strategies; the
   first one was the Plano Emergencial para Controle da Tuberculose
   (Emergency Plan for Tuberculosis Control - 1994), prioritizing 230
   municipalities. The current prospects are an effective municipalization
   of actions and their greater integration with the Programas de Agentes
   Comunitarios e Sa de da Familia (Humanitarian Agents and Family Health
   Programs).}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hijjar, MA (Reprint Author), Estrada Curic Jacarepagua 2000, SVS MS, Ctr Referencia Prof Helio Fraga, BR-22710550 Rio De Janeiro, RJ, Brazil.
   Hijjar, Miguel Aiub; Teixeira, Gilmario M.; Procopio, Maria Jose, Estrada Curic Jacarepagua 2000, SVS MS, Ctr Referencia Prof Helio Fraga, BR-22710550 Rio De Janeiro, RJ, Brazil.
   Gerhardt, Germano, Fundacao Ataulpho Paiva, Rio De Janeiro, RJ, Brazil.}},
ISSN = {{0034-8910}},
Keywords = {{tuberculosis, history; tuberculosis, prevention \& control; national
   health programs; health programs and plans; Brazil}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{miguel.hijjar@saude.gov.br}},
Cited-References = {{{*}CAMP NAC CONTR TU, 1966, REV SREV NAC TUBERC, V10, P467.
   {*}CAMP NAC CONTR TU, 1960, REV SERV NAC TUBERC, V4, P289.
   CHATKIN JM, 1979, REV DIV NAC PNEUM SA, V23, P79.
   {*}COM TECN CAMP NAC, 1972, REV DIV NAC TUBERC, V16, P64.
   CRUZ O, 1948, REV BRAS TUB, V16, P118.
   Poppe de Figeuiredo F, 1974, B INT UNION TUBERC, V49, P382.
   FIGUEIREDO FHP, 1964, REV SRV NAC TUBERC, V8, P191.
   FRAGA H, 1961, CONTRIBUICAO ESTUDO.
   FRAGA H, 1979, PYRAZINAMIDE 25 ANS.
   FRAGA H, 1980, MED HOJE, V6, P444.
   FRAGA H, 1958, REV SERV NAC TUBERC, V3, P459.
   GERHARD G, 1982, INT J TUBERC LUNG D, V57, P87.
   GERHARDT G, 1979, 3 SEM REG SOBR TUB Q.
   Reichman L.B., 2000, TUBERCULOSIS COMPREH.
   RIBEIRO L, 1985, FUNDACAO ATAULFO PAI.
   RODRIGUES BA, 1979, FUNDAMENTOS ADMINIST.
   SANTOS IB, 1963, VIDA OBRA MANOEL ABR.
   Toman K, 1979, TUBERCULOSIS CASE FI.
   Tuberculosis Chemotherapy Centre Madras, 1959, B WORLD HEALTH ORGAN, V21, P51.
   {*}WHO, 1964, WHO TECHN RKEP SER, V290.
   {*}WHO, 1957, WHO TECH REP SER, V57, P1.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500008}},
}

@article{ ISI:000253378500014,
Author = {Jamal, Leda Fatima and Moherdaui, Fabio},
Title = {{Tuberculosis and HIV infection in Brazil: magnitude of the problem and
   strategies for control}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Note = {{Seminar on the Assessment of Strategies for the Control of Tuberculosis,
   Sao Paulo, BRAZIL, SEP, 2006}},
Abstract = {{The aim of the article was to propose, based on an analysis of the
   current scenario and of the interaction between tuberculosis and AIDS,
   strategies to minimize the epidemiological impact of one disease over
   the other in Brazil. The manner by which health policies aimed at
   controlling the HIV/AIDS epidemic is analyzed - such as access to
   antiretroviral drugs and campaigns for the early detection of HIV
   infection and for encouraging adherence to treatment - and their impact
   on the achievement of goals related to controlling tuberculosis. The
   implementation of measures for preventing the onset of tuberculosis in
   HIV-infected individuals, early detection of tuberculosis disease, and
   ensuring treatment adherence, is discussed. It is commented upon the
   role that Brazil may assume in the global effort to develop a
   therapeutic arsenal and the need for integrated work between the fields
   of tuberculosis and HIV/AIDS.}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Jamal, LF (Reprint Author), Ctr Referencia \& Treinamento DST Aids, Assessoria Persquisa, Coordenadoria Controle Doencas, Secreteria Estado Saude Sao Paulo, R Santa Cruz,81-10 Andar,Vila Mariana, BR-04121000 Sao Paulo, SP, Brazil.
   Jamal, Leda Fatima, Ctr Referencia \& Treinamento DST Aids, Assessoria Persquisa, Coordenadoria Controle Doencas, Secreteria Estado Saude Sao Paulo, BR-04121000 Sao Paulo, SP, Brazil.
   Moherdaui, Fabio, Programa Nacl TB, Secretaria Vigilancia Saude, Minist Saude, Brasilia, DF, Brazil.}},
ISSN = {{0034-8910}},
Keywords = {{tuberculosis, epidemiology; tuberculosis, prevention \& control;
   antibiotics, antitubercular, supply \& distribution; comorbidity; HIV
   infections, epidemiology; HIV infections, prevention \& control;
   anti-HIV agents, supply \& distribution; Brazil}},
Keywords-Plus = {{ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS;
   SOUTH-AFRICA; COHORT; PAULO; DEATH; STATE; RISK}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Cited-References = {{ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143.
   Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3.
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404.
   FILHO AC, 2004, J BRAS PNEUMOL S1, V30, P57.
   Grant AD, 2005, JAMA-J AM MED ASSOC, V293, P2719, DOI 10.1001/jama.293.22.2719.
   Murray J F, 1991, Bull Int Union Tuberc Lung Dis, V66, P21.
   Nunn P, 2005, NAT REV IMMUNOL, V5, P819, DOI 10.1038/nri1704.
   Santo AH, 2003, REV SAUDE PUBL, V37, P714, DOI {[}10.1590/S0034-89102003000600005, 10.1590/s0034-89102003000600005].
   Santo AH, 2000, REV SAUDE PUBL, V34, P581, DOI 10.1590/S0034-89102000000600004.
   Santoro-Lopes G, 2002, CLIN INFECT DIS, V34, P543, DOI 10.1086/338641.}},
Number-of-Cited-References = {{10}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500014}},
}

@article{ ISI:000253378500003,
Author = {Kritski, Afranio Lineu and Villa, Tereza Scatena and Trajman, Anete and
   Lapa e Silva, Jose Roberto and Medronho, Roberto A. and Ruffino-Netto,
   Antonio},
Title = {{Two decades of research on tuberculosis in Brazil: state of the art of
   scientific publications}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Abstract = {{The trends of scientific articles about tuberculosis in Brazil published
   between 1986 and 2006 were analyzed. This analysis included Capes
   database-indexed dissertations and theses and papers indexed in Medline
   and SciELO. Papers containing the word ``tuberculosis{''} and authors
   affiliated to Brazilian institutions were included in the assessment.
   The analysis showed initially case report and review publications, and
   later it shifted to original articles on science, technology and
   innovation. These changes may reflect the strengthening of scientific
   research activities and new attitudes regarding tuberculosis research
   objectives in academic institutions in recent years. Although many
   theses used qualitative methodology, few qualitative publications were
   found, possibly because of the quantitative orientation of many
   journals. Qualitative versus quantitative research and education versus
   research-oriented publications are discussed, together with public
   policies and strategies to include research as a tool to control
   diseases. The use of the same methodology is suggested to assess the
   trends in research on other neglected diseases.}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kritski, AL (Reprint Author), UFRJ, Hosp Univ Clementino Fraga Filho, Fac Med, Programa Acad TB,Ilha Fdn, 40 Andar,UPT,Av Prof Jose Rodolpho Rocco S-N, BR-21941 Rio De Janeiro, Brazil.
   Kritski, Afranio Lineu; Lapa e Silva, Jose Roberto, Univ Fed Rio de Janeiro, Fac Med, Programa Acad TB, Rio De Janeiro, Brazil.
   Villa, Tereza Scatena, Univ Sao Paulo, Escola Enfermagem Ribeiro Preto, BR-14049 Ribeirao Preto, SP, Brazil.
   Trajman, Anete, Univ Gama Filho, Curso Med, Rio De Janeiro, Brazil.
   Ruffino-Netto, Antonio, USP, Fac Med Ribeirao Preto, Ribeirao Preto, SP, Brazil.}},
ISSN = {{0034-8910}},
Keywords = {{tuberculosis; academic dissertations {[}publication type]; research;
   trends; qualitative research; publications for science diffusion;
   education, public health professional}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{kritskia@gmail.com}},
ResearcherID-Numbers = {{Medronho, Roberto/B-6196-2013}},
ORCID-Numbers = {{Medronho, Roberto/0000-0003-4073-3930}},
Cited-References = {{Centers for Disease Control and Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P301.
   Maher D, 2006, INT J TUBERC LUNG D, V10, P240.
   Raviglione MC, 2007, NEW ENGL J MED, V356, P656, DOI 10.1056/NEJMp068273.
   WHO, 2007, WHOHTMTB2007376.
   WHO, 1994, TB GLOB EM WHO REP T.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500003}},
}

@article{ ISI:000253378500009,
Author = {Pereira, Susan M. and Souza Dantas, Odimariles Maria and Ximenes,
   Ricardo and Barreto, Mauricio L.},
Title = {{BCG vaccine against tuberculosis: its protective effect and vaccination
   policies}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Note = {{Seminar on the Assessment of Strategies for the Control of Tuberculosis,
   Sao Paulo, BRAZIL, SEP, 2006}},
Abstract = {{OBJECTIVE: The BCG vaccine has been in use since 1921, but still arouses
   controversy and uncertainties. The objective was to analyze the
   protective effect of the BCG vaccine in its first and second doses and
   the accompanying vaccination policies.
   METHODS: A systematic review of the literature in both English and
   Spanish was carried out, covering the period 1948 to 2006, using the
   PubMed database. The main search terms used included BCG vaccine, BCG
   efficacy, BCG and tuberculosis. The studies were grouped by design, with
   the main results from the clinic tests, case-control studies and
   meta-analyses presented separately.
   RESULTS: The protective effect of the first dose of the BCG vaccine
   against tuberculosis in its miliary and meningeal forms is high.
   However, the results vary in relation to the pulmonary form of the
   disease, with some indicating zero effect and others levels of nearly
   80\%. Research is being carried out to develop new vaccines that could
   substitute the BCG or be used as a booster.
   CONCLUSIONS: There are evidences that the protective effect of the BCG
   vaccine does not increase with a second dose. In spite of its
   limitations and the expectation that a new tuberculosis vaccine will be
   developed in the future, the BCG vaccine remains an important tool in
   controlling the harmful effects of tuberculosis, particularly in
   countries with medium or high incidence levels of the disease.}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Pereira, SM (Reprint Author), Univ Fed Bahia, Inst Saude Coletiva, Rua Basilio Gama S-N,Campus Univ Canela, BR-40110040 Salvador, BA, Brazil.
   Pereira, Susan M.; Barreto, Mauricio L., Univ Fed Bahia, Inst Saude Coletiva, BR-40110040 Salvador, BA, Brazil.
   Souza Dantas, Odimariles Maria; Ximenes, Ricardo, Univ Fed Pernambuco, Ctr Ciencias Saude, Recife, PE, Brazil.}},
ISSN = {{0034-8910}},
Keywords = {{tuberculosis, prevention \& control; BCG vaccine, supply \&
   distribution; BCG vaccine, history; immunization programs; review
   {[}publication type]}},
Keywords-Plus = {{CALMETTE-GUERIN VACCINE; HUMAN-IMMUNODEFICIENCY-VIRUS; CONTROLLED TRIAL;
   CLINICAL-TRIALS; EFFICACY; CHILDREN; MENINGITIS; REVACCINATION;
   PREVENTION; BRAZIL}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{susanmp@ufba.br}},
Cited-References = {{Arbelaez MP, 2000, INT J EPIDEMIOL, V29, P1085, DOI 10.1093/ije/29.6.1085.
   ARONSON JD, 1948, AM REV TUBERC PULM, V58, P255.
   Aronson NE, 2004, JAMA-J AM MED ASSOC, V291, P2086, DOI 10.1001/jama.291.17.2086.
   BARRETO MB, 2005, INT J TUBERC LUNG D, V10, P1171.
   BHAT GJ, 1993, J TROP PEDIATRICS, V39, P219.
   Brennan MJ, 2005, TUBERCULOSIS, V85, P7, DOI 10.1016/j.tube.2004.09.001.
   CAMARGOS PAM, 1988, INT J EPIDEMIOL, V17, P193, DOI 10.1093/ije/17.1.193.
   COLDITZ GA, 1995, PEDIATRICS, V96, P29.
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P98.
   COLLINS DM, 1987, J GEN MICROBIOL, V133, P1431.
   COMSTOCK GW, 1972, SCAND J RESPIR DIS, V53, P207.
   COSTA MCN, 1991, B OFICINA SANIT PANA, V110, P26.
   Dantas OMS, 2006, INT J TUBERC LUNG D, V10, P536.
   Deeks SL, 2005, PEDIATR INFECT DIS J, V24, P538, DOI 10.1097/01.inf.0000164769.22033.2c.
   Dourado I, 2003, INT J TUBERC LUNG D, V7, P399.
   Fine PEM, 1996, LANCET, V348, P17.
   Fine PEM, 1998, VACCINE, V16, P1923, DOI 10.1016/S0264-410X(98)00124-8.
   GRANGE JM, 1983, TUBERCLE, V64, P129, DOI 10.1016/0041-3879(83)90038-7.
   Grant AD, 1998, BRIT MED BULL, V54, P369.
   HART PD, 1977, BRIT MED J, V2, P293.
   Hesseling AC, 2006, CLIN INFECT DIS, V42, P548, DOI 10.1086/499953.
   Hewinson RG, 2005, TUBERCULOSIS, V85, P1, DOI 10.1016/j.tube.2004.10.002.
   Ibango HB, 2006, LANCET INFECT DIS, V6, P522, DOI 10.1016/S1473-3099(06)70552-7.
   Infuso A, 2006, Euro Surveill, V11, P6.
   Lotte A, 1988, Bull Int Union Tuberc Lung Dis, V63, P47.
   Lugosi L, 1987, Bull Int Union Tuberc Lung Dis, V62, P15.
   Medical Research Council, 1972, B WORLD HEALTH ORGAN, V46, P371.
   MICELI I, 1988, INT J EPIDEMIOL, V17, P629, DOI 10.1093/ije/17.3.629.
   MILSTIEN JB, 1990, B WORLD HEALTH ORGAN, V68, P93.
   Moss WJ, 2003, B WORLD HEALTH ORGAN, V81, P61.
   Orme IM, 2006, TUBERCULOSIS, V86, P68, DOI 10.1016/j.tube.2005.07.002.
   Rodrigues LC, 2005, LANCET, V366, P1290, DOI 10.1016/S0140-6736(05)67145-0.
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154.
   Romanus V, 2006, Euro Surveill, V11, P14.
   ROSENTHAL S, 1961, PEDIATRICS, V28, P622.
   SEPULVEDA RL, 1992, TUBERCLE LUNG DIS, V73, P372, DOI 10.1016/0962-8479(92)90043-J.
   SOYSAL A, 2005, LANCET, V366, P1433.
   SPRINGETT VH, 1994, TUBERCLE LUNG DIS, V75, P227, DOI 10.1016/0962-8479(94)90013-2.
   STARKE JR, 2004, VACCINES, P456.
   Sterne JAC, 1998, INT J TUBERC LUNG D, V2, P200.
   Tala-Heikkila MM, 1998, AM J RESP CRIT CARE, V157, P1324.
   TENDAM HG, 1982, TUBERCLE, V63, P225.
   Tocque K, 1998, INT J TUBERC LUNG D, V2, P213.
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.
   {*}WHO, 2003, WEEKLY EPIDEMIOLOGIC, V78, P277.
   WHO, 1995, WKLY EPIDEMIOL REC, V70, P229.
   {[}Anonymous], 2006, WHO VACC PREV DIS MO.
   WILSON ME, 1995, CLIN INFECT DIS, V20, P982.
   WUNSCH V, 1990, B WORLD HEALTH ORGAN, V68, P69.
   {[}Anonymous], 1980, INDIAN J MED RES S, V72, P1.}},
Number-of-Cited-References = {{51}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500009}},
}

@article{ ISI:000253378500007,
Author = {Porto, Angela},
Title = {{Social representations of tuberculosis: stigma and prejudice}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Note = {{Seminar on the Assessment of Strategies for the Control of Tuberculosis,
   Sao Paulo, BRAZIL, SEP, 2006}},
Abstract = {{Social representations of tuberculosis are analyzed at the turn of the
   20(th) century, focusing on aspects associated to feelings and
   contradictory manifestations awakened by the disease. The romanticized
   pattern of experience of this disease was replaced by a more
   naturalistic vision, though the stigmas and prejudices are reinforced.
   To this day it is possible to detect some aspects about the way of
   perceiving tuberculosis, which marked its presence in the past. The
   persistence of the stigmatization of tuberculosis and of the people who
   suffer from it consists in a serious obstacle to the disease's control
   nowadays.}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Porto, A (Reprint Author), Casa Oswaldo Cruz Fiocruz, Fundacao Oswaldo Cruz, Av Brasil,4036 Sala 404, BR-21040361 Rio De Janeiro, RJ, Brazil.
   Casa Oswaldo Cruz Fiocruz, Fundacao Oswaldo Cruz, BR-21040361 Rio De Janeiro, RJ, Brazil.}},
ISSN = {{0034-8910}},
Keywords = {{tuberculosis, history; prejudice; social medicine; social representation
   of disease; stigma; literature}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{aporto@fiocruz.br}},
Cited-References = {{BANDEIRA M, 1958, POESIA PROSA, V1.
   BANDEIRA M, 1966, ANDORINHA ANDORINHA.
   BARBOSA FA, 1988, MANUEL BANDEIRA 100.
   Duarte LFD, 1986, VIDA NERVOSA NAS CLA.
   DUBOS R, 1992, WHITE PLAGEUE TUBERC.
   ESTIGMA GE, 1978, NOTAS SOBRE MANIPULA.
   FAUCAULT M, 1979, HIST SEXUALIDADE, V1.
   Filho Claudio Bertolli, 2001, HIST SOCIAL TUBERCUL.
   GONCALVES H, 2002, PESTE BRANCA ESTUDO.
   MANN T, 1986, MONTANHA MAGICA.
   MONTENEGRO TH, 1971, TUBERCULOSE LIT NOTA.
   NETO HMC, 1924, VIDA MUNDANA.
   NOGUEIRA O, 1949, REV DIDAT CIENT, P159.
   NUNES B, 1985, ORG ROMANTISMO.
   Porto A, 1995, HIST CIENC SAUDE MAN, V1, P129.
   PRAZ M, 1996, CARNE MORTE DIABO LI.
   RICHARD L, 1982, MAG LITT, V186, P49.
   Sontag S, 1984, DOENCA COMO METAFORA.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500007}},
}

@article{ ISI:000253378500001,
Author = {Rodrigues, Laura and Barreto, Mauricio and Kramer, Monica and Barata,
   Rita De C. Barradas},
Title = {{Brazilian response to tuberculosis: context, challenges and perspectives}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Editorial Material}},
Language = {{English}},
ISSN = {{0034-8910}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Number-of-Cited-References = {{0}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500001}},
}

@article{ ISI:000253378500016,
Author = {Sant'Anna, Clemax Couto and Hijjar, Miguel Aiub},
Title = {{Recent contribution of the World Health Organization to control
   childhood tuberculosis}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Abstract = {{The article comments the pioneer and recent publication of the World
   Health Organization called ``Guidance for National Tuberculosis
   Programmes on the Management of Childhood Tuberculosis in Children{''},
   aiming at spreading interesting aspects on the practice of health
   professionals. A parallel between Latin America and the African
   continent is established, concerning the co-infection TB-HIV and
   childhood tuberculosis.}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Sant'Anna, CC (Reprint Author), R Sa Ferreira 159 Ap 405 Copacabana, BR-22071100 Rio De Janeiro, RJ, Brazil.
   Sant'Anna, Clemax Couto, Univ Fed Rio de Janeiro, Fac Med, Dept Pediat, Rio De Janeiro, RJ, Brazil.
   Hijjar, Miguel Aiub, Ctr Referencia Prof Helio Fraga, Secretaria Vigilancia Saude, Minist Saude, Rio De Janeiro, RJ, Brazil.}},
ISSN = {{0034-8910}},
Keywords = {{tuberculosis, prevention \& control; HIV infections.; AIDS-related
   opportunistic infections; child health (public health); national health
   programs; World Health Organization}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{clemax@vetor.com.br}},
Cited-References = {{Corrigan D. L., 2007, BREATHE, V3, P351.
   Edwards DJ, 2007, INT J TUBERC LUNG D, V11, P263.
   HIJJAR MA, 2006, VER HOSP PEDRO ERNES, V5, P15.
   Hijjar MA, 2005, PULMAO RJ, V14, P310.
   Nelson LJ, 2004, INT J TUBERC LUNG D, V8, P636.
   Sant'Anna CC, 2006, INT J TUBERC LUNG D, V10, P463.
   Sant'Anna Clemax Couto, 2004, Braz J Infect Dis, V8, P305, DOI 10.1590/S1413-86702004000400006.
   Sant'Anna Clemax Couto, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P103, DOI 10.1590/S0036-46652003000200010.
   {*}STOP TB PARTN CHI, 2006, INT J TUBERC LUND DI, V10, P1091.
   World Health Organization, 2006, WHOHTMTB2006371.
   WHO, 2007, WHOHTMTB2007376.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500016}},
}

@article{ ISI:000253378500012,
Author = {Santos, Joseney},
Title = {{Brazilian response to tuberculosis control}},
Journal = {{REVISTA DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{41}},
Number = {{1}},
Month = {{SEP}},
Abstract = {{Tuberculosis remains a public health problem in Brazil. In 2003,
   controlling tuberculosis was highlighted as a priority among health
   public policies. The article reports the Brazilian response to this
   challenge, describing the main strategies of the National Control Plan
   for 2003 to 2006. Among its main results are: expansion of strategic
   coverage of the supervised treatment, increase in the percentage of
   cure, decrease in the number of patients' treatment default, and of the
   incidence rate.}},
Publisher = {{REVISTA DE SAUDE PUBLICA}},
Address = {{FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Santos, J (Reprint Author), PNCT, Minist Saude, SCS Quadra 4,Bloco A,Ed Principal 30 Andar, BR-70304000 Brasilia, DF, Brazil.
   PNCT, Minist Saude, BR-70304000 Brasilia, DF, Brazil.}},
ISSN = {{0034-8910}},
Keywords = {{tuberculosis, epidemiology; tuberculosis, prevention \& control;
   tuberculosis, therapy; health priorities; health programs and plans;
   Brazil}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{joseney.santos@gmail.com}},
Cited-References = {{{*}COORD NAC PNEUM S, 1996, BOL PNEUMOL SANIT, V4, P7.
   Ruffino-Netto A., 2001, INF EPIDEMIOL SUS, V10, P129.
   {*}WHO, 1999, WHAT IS DOTS GUID UN.
   {*}WHO, 2000, MIN C TUB SUST DEV M.}},
Number-of-Cited-References = {{4}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Rev. Saude Publica}},
Doc-Delivery-Number = {{265RL}},
Unique-ID = {{ISI:000253378500012}},
}

@article{ ISI:000253847900008,
Author = {Sperli Geraides Santos, Maria de Lourdes and Figueiredo Vendramini,
   Silvia Helena and Gazetta, Claudia Eli and Cruz Oliveira, Sonia
   Aparecida and Scatena Villa, Tereza Cristina},
Title = {{Poverty: socioeconomic characterization at tuberculosis}},
Journal = {{REVISTA LATINO-AMERICANA DE ENFERMAGEM}},
Year = {{2007}},
Volume = {{15}},
Number = {{SI}},
Pages = {{762-767}},
Month = {{SEP-OCT}},
Abstract = {{This study aimed to evaluate the epidemiological status of Tuberculosis
   regarding to the socioeconomic characteristics of Sao Jose do Rio Preto
   between 1998 and 2004. Indexes estimated for 432 urban census tracts
   from the demographic census of 2000, sorted systematically according to
   the values of socioeconomic factors and grouped into quartiles were
   taken into account. The socioeconomic characterization was outlined
   based on Schooling, Income, and Number of Residents. The incidence rates
   were considered for 1998, 1999, 2003, and 2004. The socioeconomic factor
   accounted for 87\% of the total variation. The disease prevalence is
   higher in the poorest areas. The incidence rate and the risk of being
   infected by TB in the poorest areas declined in 2003 and 2004. The
   results confirm that TB is determined by the population's living
   conditions in the city studied. It strengthens the relevance of
   under-standing the TB conditional social factors to transform the
   worrisome scenario in which this population is inserted.}},
Publisher = {{UNIV SAO PAOLO}},
Address = {{AV PADUA DIAS 11, C P 9, PIRACICABA, SP 13418-900, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Santos, MDSG (Reprint Author), Inter Units Program, Sao Jose Do Rio Preto, Brazil.
   Sperli Geraides Santos, Maria de Lourdes, Inter Units Program, Sao Jose Do Rio Preto, Brazil.
   Sperli Geraides Santos, Maria de Lourdes; Figueiredo Vendramini, Silvia Helena; Gazetta, Claudia Eli; Cruz Oliveira, Sonia Aparecida, Med Sch Sao Jose, Sao Jose Do Rio Preto, Brazil.
   Scatena Villa, Tereza Cristina, Univ Sao Paulo, Coll Nursing, WHO Collaborating Ctr Nursing Res Dev, BR-14049 Ribeirao Preto, Brazil.}},
DOI = {{10.1590/S0104-11692007000700008}},
ISSN = {{0104-1169}},
Keywords = {{poverty; tuberculosis; social conditions}},
Research-Areas = {{Nursing}},
Web-of-Science-Categories  = {{Nursing}},
Author-Email = {{mlsperli@gmail.com
   silviave@eerp.usp.br
   claudiagazetta@yahoo.com.br
   soniaoliveira@famerp.br
   tite@eerp.usp.br}},
ResearcherID-Numbers = {{Scatena Villa, Tereza Cristina/K-7891-2013}},
ORCID-Numbers = {{Scatena Villa, Tereza Cristina/0000-0001-8927-2624}},
Cited-References = {{Costa J. S. D., 1998, CAD SAUDE PUBLICA, V14, P409.
   {*}DATASUS, BRAS MIN SAUD INF SA.
   DORIOPRETO SJ, 2004, BOL EPIDEMIOL.
   FONSECA MG, 2000, CAD SAUDE PUBLICA S1, V16, pS77.
   {*}FUND SIST EST AN, GOV EST SAO PAUL IND.
   {*}MAPINFO CORP, 2002, MAPINFO 7 0.
   {*}ORG MUND SAL, 2006, AL ALT TUB ORG MUND.
   {*}PNUD, 2003, INF SOBR DES HUM OBJ.
   SANTOS ET, 2006, POLITICA TB BRASIL P.
   Vendramini Silvia H. F., 2005, J. bras. pneumol., V31, P237, DOI 10.1590/S1806-37132005000300010.
   Vendramini SHF, 2006, INT J TUBERC LUNG D, V10, P1231.
   VENDRAMINI SHF, 2005, THESIS ECOLA ENFERMA.
   VENDRAMINI SHF, 2007, ENFERMAGEM, V15, P171.
   Weiss KB, 1998, AM J RESP CRIT CARE, V157, P1011.
   {*}WHO, ADD POV TB CONTR OPT.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{14}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Rev. Latino-Am. Enfermagem}},
Doc-Delivery-Number = {{272GM}},
Unique-ID = {{ISI:000253847900008}},
}

@article{ ISI:000259158000009,
Author = {Hino, Paula and da Costa-Junior, Moacyr Lobo and Sassaki, Cinthia Midori
   and Oliveira, Mayra Fernanda and Scatena Villa, Tereza Cristina and dos
   Santos, Claudia Benedita},
Title = {{Time series of tuberculosis mortality in Brazil (1980-2001)}},
Journal = {{REVISTA LATINO-AMERICANA DE ENFERMAGEM}},
Year = {{2007}},
Volume = {{15}},
Number = {{5}},
Pages = {{936-941}},
Month = {{SEP-OCT}},
Abstract = {{This descriptive study aimed to describe Tuberculosis-related mortality
   in Brazil between 1980 and 2001, through time series analysis of data
   from the DATASUS related to cases in which Tuberculosis was the basic
   cause of death. The mortality rates were calculated per 100,000
   inhabitants according to gender and age. We found a decrease in
   Tuberculosis mortality of approximately 42\% for men and 54\% for women
   across the period analyzed. The International Classification of Diseases
   was used: ICD-9, for the period of 1980 to 1995; ICD-10 for 1996 to
   2001. Deaths are related to late diagnosis, which is a problem of
   organization of the primary health care, as neither prevention actions
   nor case detections by active search for respiratory symptoms were
   incorporated into the health professionals' practice which contributes
   to higher death rates in more vulnerable groups.}},
Publisher = {{UNIV SAO PAULO, ESCOLA DE ENFERMAGEM DE RIBEIRAO PRETO}},
Address = {{AV BANDEIRANTES, 3900, RIBEIRAO PRETO, SP, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hino, P (Reprint Author), Univ Sao Paulo, Sch Nursing, WHO, Collaborating Ctr Nursing Res Dev, BR-14049 Ribeirao Preto, Brazil.
   Hino, Paula; da Costa-Junior, Moacyr Lobo; Sassaki, Cinthia Midori; Oliveira, Mayra Fernanda; Scatena Villa, Tereza Cristina; dos Santos, Claudia Benedita, Univ Sao Paulo, Sch Nursing, WHO, Collaborating Ctr Nursing Res Dev, BR-14049 Ribeirao Preto, Brazil.}},
DOI = {{10.1590/S0104-11692007000500009}},
ISSN = {{0104-1169}},
Keywords = {{tuberculosis; mortality; health services}},
Keywords-Plus = {{COUNTRIES}},
Research-Areas = {{Nursing}},
Web-of-Science-Categories  = {{Nursing}},
Author-Email = {{paulahino@yahoo.com.br
   moacyr@eerp.usp.br
   midsas@eerp.usp.br
   tite@eerp.usp.br
   cbsantos@eerp.usp.br}},
ResearcherID-Numbers = {{santos, claudia /E-9710-2012
   Scatena Villa, Tereza Cristina/K-7891-2013}},
ORCID-Numbers = {{Scatena Villa, Tereza Cristina/0000-0001-8927-2624}},
Cited-References = {{Antunes J L, 1999, Cad Saude Publica, V15, P463, DOI 10.1590/S0102-311X1999000300003.
   Caldeira AP, 2005, REV SAUDE PUBL, V39, P67, DOI {[}10.1590/S0034-89102005000100009, 10.1590/s0034-89102005000100009].
   Chaimowicz F, 2001, REV SAUDE PUBL, V35, P81, DOI 10.1590/S0034-89102001000100012.
   Harries AD, 2001, LANCET, V357, P1519, DOI 10.1016/S0140-6736(00)04639-0.
   HINO S, 2005, REV LAT-AM ENFERM, V13, P27.
   KUSANO MSE, 2002, B PNEUMOL SANITARIA, V10, P55.
   Lienhardt C, 2004, TROP MED INT HEALTH, V9, P833, DOI 10.1111/j.1365-3156.2004.01273.x.
   Brasil, 2004, SIST INF AGR NOT.
   {*}MIN SAUD BR, 1999, PLAN NAC CONTR TUB.
   Ministerio da Saude (BR), 2002, CONTR TUB PROP INT E.
   MISHIMA EO, 2001, B PNEUMOLOGIA SANITA, V9, P5.
   Mota Fabio Frias, 2003, Cad Saude Publica, V19, P915, DOI 10.1590/S0102-311X2003000400014.
   Muniz JN, 2002, B PNEUMOL SANITARIA, V10, P49.
   Ruffino-Netto Antonio, 2002, Rev Soc Bras Med Trop, V35, P51, DOI 10.1590/S0037-86822002000100010.
   Selig Lia, 2004, J. bras. pneumol., V30, P417, DOI 10.1590/S1806-37132004000400006.
   Suarez PG, 2001, J INFECT DIS, V184, P473, DOI 10.1086/322777.
   {*}WHO, 2005, WHO REP, V349, P11.
   2005, EUROTRIALS INFORM.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Rev. Latino-Am. Enfermagem}},
Doc-Delivery-Number = {{347RF}},
Unique-ID = {{ISI:000259158000009}},
}

@article{ ISI:000254653200008,
Author = {Saint-Blancard, R. and Harket, A. and Defuentes, G. and de Fonclare, A.
   L. and Bonnichon, A. and de Revel, T. and Berets, O. and Margery, J.},
Title = {{Primary pleural lymphoma: a late complication of pleural decortication
   for tuberculosis: two cases in western countries}},
Journal = {{REVUE DE PNEUMOLOGIE CLINIQUE}},
Year = {{2007}},
Volume = {{63}},
Number = {{4}},
Pages = {{277-281}},
Month = {{SEP}},
Abstract = {{Pleural lymphomas after a long standing pyothorax due to pleuropulmonary
   tuberculosis are now well identified, but rarely observed in Europe. We
   report two new cases in a non-immunocompromised patients. The two cases
   occurred 54-55years following artificial pneumothorax for pulmonary
   tuberculosis, The patients presented with a localized pleural tumor
   mass. Histology revealed high-grade lymphomas, diffuse large B-cell
   lymphoma and anaplastic lymphoma. Serology for Epstein-Barr virus was
   positive. Pleural lymphomas are an established complication of
   artificial pneumothorax. Epstein-Barr virus is known to play a crucial
   role in the pathogenis, but despite the large number of artificial
   pneumothorax operations, these lymphomas remain rare, suggesting
   additional oncogenic factors.}},
Publisher = {{ELSEVIER}},
Address = {{685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Saint-Blancard, R (Reprint Author), Hop Instruct Armees Percy, Serv Anat Pathol, 101 Ave Henri Barbusse, F-92141 Clamart, France.
   Saint-Blancard, R.; Harket, A., Hop Instruct Armees Percy, Serv Anat Pathol, F-92141 Clamart, France.
   Defuentes, G.; de Fonclare, A. L.; Berets, O., Hop Instruct Armees Percy, Serv Med Interne, F-92141 Clamart, France.
   Bonnichon, A.; Margery, J., Hop Instruct Armees Percy, Serv Pneumol, F-92141 Clamart, France.
   de Revel, T., Hop Instruct Armees Percy, Hematol Serv, F-92141 Clamart, France.}},
ISSN = {{0761-8417}},
Keywords = {{pleural lymphoma; pyothorax-associated lymphoma; Epstein-Barr virus;
   tuberculosis}},
Keywords-Plus = {{PYOTHORAX-ASSOCIATED LYMPHOMA; B-CELLS; EXPRESSION; DISEASE; ENTITY; PAL}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Author-Email = {{psbpercy@yahoo.fr}},
Cited-References = {{Androulaki A, 2004, HISTOPATHOLOGY, V44, P69, DOI 10.1111/j.1365-2559.2004.01737.x.
   AOZASA K, 1993, JPN J CANCER RES, V84, P55.
   Banks PM, 2004, WHO CLASSIFICATION T, P137.
   Biasoli I, 2005, HISTOPATHOLOGY, V46, P328, DOI 10.1111/j.1365-2559.2005.02099.x.
   Jaffe ES, 1996, AM J CLIN PATHOL, V105, P141.
   Jardin F, 1999, REV MED INTERNE, V20, P985, DOI 10.1016/S0248-8663(00)87079-4.
   Lavole A, 2001, REV MAL RESPIR, V18, P72.
   Mori N, 1996, AM J SURG PATHOL, V20, P760, DOI 10.1097/00000478-199606000-00015.
   Nakatsuka S, 2002, J CLIN ONCOL, V20, P4255, DOI 10.1200/JCO.2002.09.021.
   Nishiu M, 2004, CANCER SCI, V95, P828, DOI 10.1111/j.1349-7006.2004.tb02189.x.
   Petitjean B, 2002, AM J SURG PATHOL, V26, P724, DOI 10.1097/01.PAS.0000015151.82934.6F.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Rev. Pneumol. Clin.}},
Doc-Delivery-Number = {{283RC}},
Unique-ID = {{ISI:000254653200008}},
}

@article{ ISI:000249815900007,
Author = {Toure, N. O. and Kane, Y. Dia and Diatta, A. and Diop, S. Ba and Niang,
   A. and Ndiaye, E. M. and Thiam, K. and MBaye, F. B. R. and Badiane, M.
   and Hane, A. A.},
Title = {{Tuberculosis and diabetes}},
Journal = {{REVUE DES MALADIES RESPIRATOIRES}},
Year = {{2007}},
Volume = {{24}},
Number = {{7}},
Pages = {{869-875}},
Month = {{SEP}},
Abstract = {{Introduction We performed a retrospective case control study for the
   period between 1st January 1999 and 31st August 2004, comparing the
   radiological appearances of tuberculosis in 100 diabetics to those in
   patients matched for age and sex, with pulmonary TB alone presenting to
   The Chest clinic of the National Hospital of Fann.
   Methods and results Diabetes was present in 4.7\% of the 2116 patients
   hospitalized for pulmonary tuberculosis during the period of study and
   occurred more commonly in men (60\%) with an average age of 51 years
   (73\%). 82\% had type 11, non-insulin dependent diabetes. The various
   types of radiological lesions classically described in tuberculosis were
   found in nearly identical proportions in the two groups of patients,
   with parenchymal shadowing the most frequent appearance in both
   diabetics (N = 86) and controls (N = 88). Cavitation occurred
   significantly less frequently in diabetics (72\%) than controls (88\%)
   (p = 0.04). Where radiological abnormalities were bilateral, they were
   worse on the left in the diabetics (27\% versus 15\% in controls). There
   was a trend for basal lesions to occur more frequently in diabetics
   (15\%) than controls (3\%) (p = 0.06).
   Conclusion Mortality was higher in diabetics (18\%) than controls (6\%),
   with death generally occurring within the first 24 hours of
   hospitalization.}},
Publisher = {{MASSON EDITEUR}},
Address = {{21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE}},
Type = {{Article}},
Language = {{French}},
Affiliation = {{Toure, NO (Reprint Author), BP 12 566, Dakar, Senegal.
   CHN Fann, Serv Pneumol, Dakar, Senegal.
   CHN Fann, Serv Radiol Gen, Dakar, Senegal.}},
DOI = {{10.1019/200720025}},
ISSN = {{0761-8425}},
Keywords = {{tuberculosis; diabetes; thoracic radiography}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; MELLITUS}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Author-Email = {{nattouba@hotmail.com}},
Cited-References = {{AITKHALED N, 1997, REV MAL RESP, V14.
   AlWabel AH, 1997, E AFR MED J, V74, P62.
   Bacakoglu F, 2001, RESPIRATION, V68, P595, DOI 10.1159/000050578.
   BRUN J, 1965, REV DIABET5E, V13, P65.
   DIEDHIOU A, 1998, THESE MED, V13.
   Ezung Thungchanbemo, 2002, J Indian Med Assoc, V100, P378.
   FOSSATI C, 1969, DIABETE, V71, P261.
   GENTILINI M, 1993, MED TROPICALE FLAMMA, P309.
   GIRON J, 1991, ENCY MED CHIR, V10.
   GOLLI V, 1974, BORDEAUX MED, V7, P285.
   HARIES A, 1996, WHOTB96200.
   MBOUSSA K, 2003, REV PNEUMOL CLIN, V59, P39.
   Perez-Guzman C, 1999, CHEST, V116, P961, DOI 10.1378/chest.116.4.961.
   Perez-Guzman C, 2001, INT J TUBERC LUNG D, V5, P455.
   Restrepo BI, 2006, EPIDEMIO INFECT, V25, P1.
   SANO O, 1996, THESE MED DAKAR, P15.
   SARR AL, 1993, THESE MED DAKAR, P49.
   Sidibe E, 2000, ANN MED INTERNE, V151, P624.
   Sidibe E H, 2000, Rev Pneumol Clin, V56, P217.
   Skodric-Trifunovic Vesna, 2004, Med Pregl, V57 Suppl 1, P59.
   SY MR, 1993, THESE MED DAKAR, V33.
   2001, PROGRAMME NATL LUTTE.}},
Number-of-Cited-References = {{22}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Rev. Mal. Respir.}},
Doc-Delivery-Number = {{215NI}},
Unique-ID = {{ISI:000249815900007}},
}

@article{ ISI:000250125900027,
Author = {Albert, H. and Trollip, A. P. and Seaman, T. and Abrahams, C. and Mole,
   R. J. and Jordaan, A. and Victor, T. and Hoosain, E.},
Title = {{Evaluation of a rapid screening test for rifampicin resistance in
   re-treatment tuberculosis patients in the Eastern Cape}},
Journal = {{SAMJ SOUTH AFRICAN MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{97}},
Number = {{9}},
Pages = {{858-863}},
Month = {{SEP}},
Abstract = {{Background and objectives. Patients with multidrug-resistant (MDR)
   tuberculosis (TB) are at high risk of treatment failure. It is
   anticipated that early identification of MDR-TB and appropriate
   treatment will improve patient outcome and disease control. We evaluated
   the rapid detection of rifampicin resistance in previously treated TB
   patients, directly from acid-fast bacilli (AFB)-positive sputum using a
   phage-based test, FASTPlaque-Response (Biotec Laboratories Ltd, Ipswich,
   UK). The ability of rifampicin resistance to predict MDR-TB was also
   determined.
   Design. A prospective study was done comparing performance of the rapid
   phage test with conventional culture and drug susceptibility testing
   (DST) in AFB-positive TB patients. Setting. Five primary health clinics
   and one TB referral centre in the Port Elizabeth Metropolitan area,
   Eastern Cape. Outcome measures. Sensitivity, specificity and overall
   accuracy of the phage test were determined compared with gold standard
   culture and DST. Discrepant results were resolved by molecular detection
   of mutations conferring rifampicin resistance. The proportion of
   rifampicin-resistant strains that were MDR was also determined.
   Results. Previously treated patients were at a high risk of MDR-TB
   (35.7\%). Sensitivity, specificity and overall accuracy of
   FASTPlaque-Response for rifampicin resistance determination were 95.4\%
   (95\% confidence interval (CI): 91.0-99.8\%), 97.2\% (95\% CI:
   94.5-99.9\%) and 96.5\% (95\% CI: 94.1-98.9\%) respectively compared
   with conventional DST (unresolved), calculated for specimens that had
   both FASTPlaque-Response and conventional DST results available.
   FASTPlaque-Response results were available in 2 days instead of 28-85
   days with conventional DST. However, only 70.6\% of FASTPlaque-Response
   results were interpretable compared with 86.3\% of conventional DST
   results. The majority (95.5\%) of rifampicin-resistant strains were
   MDR-TB.
   Conclusions. Rapid detection of rifampicin resistance using
   FASTPlaque-Response could contribute to improved management of patients
   at risk of MDR-TB, such as previously treated patients. However,
   improvement in control of specimen-related contamination is needed to
   ensure that a higher proportion of FASTPlaque-Response results are
   interpretable. Where indicated, early modification of therapy could
   improve patient, prognosis and reduce disease transmission.}},
Publisher = {{SA MEDICAL ASSOC}},
Address = {{BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Albert, H (Reprint Author), Fdn Innovat New Diagnost, Cape Town, South Africa.
   Fdn Innovat New Diagnost, Cape Town, South Africa.
   Univ Cape Town, Dept Clin Pharmacol, ZA-7925 Cape Town, South Africa.
   Univ Stellenbosch, Dept Med Biochem, Med Res Council Ctr Mol \& Cellular Biol, Tygerberg, South Africa.
   Nelson Mandela Metropolitan Municipality, Port Elizabeth, South Africa.}},
ISSN = {{0256-9574}},
Keywords-Plus = {{BACTERIOPHAGE-BASED METHOD; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY
   TUBERCULOSIS; SPECIMENS}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{alberth@mweb.co.za}},
Cited-References = {{Albert H, 2004, INT J TUBERC LUNG D, V8, P1114.
   Albert H, 2002, INT J TUBERC LUNG D, V6, P529.
   Albert H, 2001, INT J TUBERC LUNG D, V5, P906.
   BAMFORD L, 2004, S AFRICAN HLTH REV.
   {*}BIOT LAB LTD, 2003, FASTPL PLAQ RESP PRO.
   {*}DEP HLTH, 1996, S AFR TUB CONTR PROG.
   {*}DOH, 2004, DOTS PLUS STAND MAN.
   Enarson D, 2000, MANAGEMENT TUBERCULO.
   Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537.
   Farmer P, 1998, INT J TUBERC LUNG D, V2, P869.
   Kent PT, 1985, PUBLIC HLTH MYCOBACT.
   KISA P, 2003, INT J TUBERC LUNG D, V7, P284.
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310.
   Marei AM, 2003, J MED MICROBIOL, V52, P331, DOI 10.1099/jmm.0.05091-0.
   MOLE RJ, 2005, INT J TUBERC LUNG S1, V9, pS271.
   Muzaffar R, 2002, INT J TUBERC LUNG D, V6, P635.
   Pachas AMC, 2004, INT J TUBERC LUNG D, V8, P52.
   Teixeira L, 2001, INT J TUBERC LUNG D, V5, P321.
   Victor T. C., 1999, Tubercle and Lung Disease, V79, P343, DOI 10.1054/tuld.1999.0222.
   World Health Organization, 2004, GLOB TUB CONTR.
   {*}WHO, 2004, 3 WHOIUATLD.
   WILSON D, 2003, 1 S AFR AIDS C DURB.
   Wilson SM, 1997, NAT MED, V3, P465, DOI 10.1038/nm0497-465.
   WILSON SM, 1997, Patent No. 97022713.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{SAMJ S. Afr. Med. J.}},
Doc-Delivery-Number = {{219ZE}},
Unique-ID = {{ISI:000250125900027}},
}

@article{ ISI:000249669600012,
Author = {Lee, Ing-Kit and Liu, Jien-Wei},
Title = {{Osteomyelitis concurrently caused by Staphylococcus aureus and
   Mycobacterium tuberculosis}},
Journal = {{SOUTHERN MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{100}},
Number = {{9}},
Pages = {{903-905}},
Month = {{SEP}},
Abstract = {{We report the case of a 59-year-old woman who presented with fever and a
   cutaneous ulcer on her left ankle. In addition to Staphylococcus aureus
   growth from a blood culture, S aureus and Mycobacterium tuberculosis
   were both isolated from tissue specimens. This case highlights that
   osteomyelitis may be concurrently caused by S aureus and M tuberculosis.
   In a patient whose osteomyelitis due to S aureus responds poorly to
   clinical therapy, clinicians should suspect coexisting tuberculosis,
   especially in areas where tuberculosis is endemic.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Liu, JW (Reprint Author), Chang Gung Univ, Chang Gung Mem Hosp, Div Infect Dis,Dept Internal Med, Coll Med,Kaohsiung Med Ctr, 123 Ta Pei Rd, Kaohsiung 833, Hsien, Taiwan.
   Chang Gung Univ, Chang Gung Mem Hosp, Div Infect Dis,Dept Internal Med, Coll Med,Kaohsiung Med Ctr, Kaohsiung 833, Hsien, Taiwan.}},
ISSN = {{0038-4348}},
Keywords = {{Staphylococcus aureus; Mycobacterium tuberculosis; osteomyelitis; dual
   infection}},
Keywords-Plus = {{CEFAZOLIN}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{88b0@adm.cgmh.org.tw}},
Cited-References = {{BoachieAdjei O, 1996, ORTHOP CLIN N AM, V27, P95.
   Carlson B. E., 2000, TRAUMA VIOLENCE ABUS, V1, P321, DOI DOI 10.1177/1524838000001004002.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Dooley KE, 2002, CLIN INFECT DIS, V34, P1607, DOI 10.1086/340618.
   HAAS DW, 2000, MANDELL DOUGLAS BENN, P2576.
   KURZ RW, 1986, J ANTIMICROB CHEMOTH, V18, P772, DOI 10.1093/jac/18.6.772.
   Mandal S, 2002, J INFECTION, V44, P143, DOI 10.1053/jinf.2001.0952.
   Sharma SK, 2004, INDIAN J MED RES, V120, P316.
   Tsai MS, 2003, INT J TUBERC LUNG D, V7, P690.
   TURK JL, 1996, OXFORD TXB PATBOLOGY, P394.
   Watts HG, 1996, J BONE JOINT SURG AM, V78A, P288.
   Yilmaz O, 1999, VET HUM TOXICOL, V41, P222.}},
Number-of-Cited-References = {{12}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{South.Med.J.}},
Doc-Delivery-Number = {{213LT}},
Unique-ID = {{ISI:000249669600012}},
}

@article{ ISI:000249227700009,
Author = {Zwang, Julien and Garenne, Michel and Kahn, Kathleen and Collinson, Mark
   and Tollman, Stephen M.},
Title = {{Trends in mortality from pulmonary tuberculosis and HIV/AIDS
   co-infection in rural South Africa (Agincourt)}},
Journal = {{TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE}},
Year = {{2007}},
Volume = {{101}},
Number = {{9}},
Pages = {{893-898}},
Month = {{SEP}},
Abstract = {{This study investigates trends and age-and-sex patterns of mortality in
   pulmonary tuberculosis (PTB) and PTB/HIV co-infection in a rural
   population of South Africa. The PTB/HIV mortality emerged in 1994, and
   has been rising ever since (men: P=0.001; women: P=0.020, test for
   trend). In the last 2 years, for both sexes combined, 63\% (95\% Cl
   51-74\%) of PTB deaths were attributable to HIV/AIDS. PTB/HIV death rate
   was higher in men than in women for all ages combined (RRMH =2.48, 95\%
   Cl 1.53-4.04, P < 0.001). PTB/HIV death rate was also higher younger
   individuals (< 25 years) compared with PTB without HIV/AIDS (P= 0.033),
   and the median age at death from PTB/HIV in women (28 years) was lower
   than in men (38 years, P=0.002). While mortality from PTB without HIV
   remained constant over time, HIV/AIDS explained the rise in PTB
   mortality. In the last 3 years, the HlV/AlDS epidemic has caused the
   number of persons dying of PTB to increase by +117\%, with the mortality
   excess being higher in women (+164\%) than in men (+103\%, P=0.001).
   Combined PTB and HIV programme activities need to be reinforced to
   respond to the increase in PTB mortality, particularly in women. (c)
   2007 Royal Society of Tropical. Medicine and Hygiene. Published by
   Elsevier Ltd. All rights reserved.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Zwang, J (Reprint Author), Univ Paris 06, ISD IRD, Inst Biomed Cordeliers, 15 Rue Ecole Med, F-75270 Paris 06, France.
   Univ Paris 06, ISD IRD, Inst Biomed Cordeliers, 15 Rue Ecole Med, F-75270 Paris 06, France.
   Inst Pasteur, Unite Epidemiol Malad Emergentes, Paris, France.
   Directeur Rech, IRD, F-75015 Paris, France.
   Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, MRC Wits Rural Publ Hlth \& Hlth Res Inst Agincour, ZA-2193 Johannesburg, South Africa.}},
DOI = {{10.1016/j.trstmh.2007.04.023}},
ISSN = {{0035-9203}},
EISSN = {{1878-3503}},
Keywords = {{tuberculosis; HIV; AIDS; sex distribution; mortality; South Africa}},
Keywords-Plus = {{DEATH; HIV; EPIDEMIC; HEALTH; IMPACT; AREA}},
Research-Areas = {{Public, Environmental \& Occupational Health; Tropical Medicine}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Tropical Medicine}},
Author-Email = {{jzwang@bhdc.jussieu.fr}},
ResearcherID-Numbers = {{GARENNE, Michel/A-7712-2013}},
ORCID-Numbers = {{GARENNE, Michel/0000-0001-6073-7803}},
Funding-Acknowledgement = {{Wellcome Trust {[}062886/Z/00/Z, 069683, 069683/Z/02/Z]}},
Cited-References = {{BRADSHAW D, 1992, S AFR MED J, V82, P237.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Corbett EL, 2003, J INFECT DIS, V188, P1156, DOI 10.1086/378519.
   Dorrington R., 2001, IMPACT HIV AIDS ADUL.
   Garenne M, 1990, MEASUREMENT ANAL MOR, P123.
   GARENNE M, 1998, J TROP PEDIATRICS, V46, P183.
   Hosegood V, 2004, AIDS, V18, P663, DOI 10.1097/01.aids.0000111463.61782.aa.
   Kahn K, 1999, TROP MED INT HEALTH, V4, P433, DOI 10.1046/j.1365-3156.1999.00415.x.
   Kahn K, 2000, TROP MED INT HEALTH, V5, P824, DOI 10.1046/j.1365-3156.2000.00638.x.
   KAHN K, 2006, NEW SERIES UMEA U, V1056.
   {*}N MAND FDN, 2005, S AFR NAT HIV PREV H.
   Pronyk PM, 2004, INT J TUBERC LUNG D, V8, P796.
   RIEDER HL, 1999, BAS EP LUTT ANT.
   Setel PW, 2006, TROP MED INT HEALTH, V11, P681, DOI 10.1111/j.1365-3156.2006.01603.x.
   Sonnenberg P, 2004, AIDS, V18, P657, DOI 10.1097/01.aids.0000111404.02002ce.
   Tollman SM, 1999, S AFR MED J, V89, P858.
   Tollman SM, 1995, AGINCOURT DEMOGRAPHI.
   World Health Organization, 2004, WHOHTMTB2004330.
   {*}WHO, 2005, GLOB TUB CONTR COUNT.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{20}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{9}},
Journal-ISO = {{Trans. Roy. Soc. Trop. Med. Hyg.}},
Doc-Delivery-Number = {{207BX}},
Unique-ID = {{ISI:000249227700009}},
}

@article{ ISI:000249397600489,
Author = {Najarian, R. M. and Mohammed, M. T. and Read, S. and Uhl, L. and Haspel,
   R. L.},
Title = {{Reduced expression of kell blood group antigens with Kp(b) autoantibody
   formation in the setting of disseminated tuberculosis}},
Journal = {{TRANSFUSION}},
Year = {{2007}},
Volume = {{47}},
Number = {{3, S}},
Pages = {{166A}},
Month = {{SEP}},
Note = {{60th Annual Meeting of the American-Association-of-Blood-Banks, Anaheim,
   CA, OCT 20-23, 2007}},
Organization = {{Amer Assoc Blood Banks}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
   Amer Red Cross, Dedham, MA USA.}},
ISSN = {{0041-1132}},
Research-Areas = {{Hematology}},
Web-of-Science-Categories  = {{Hematology}},
Author-Email = {{rnajaria@bidmc.harvard.edu}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Transfusion}},
Doc-Delivery-Number = {{209OJ}},
Unique-ID = {{ISI:000249397600489}},
}

@article{ ISI:000249249200009,
Author = {Place, S. and Knoop, C. and Remmelink, M. and Baldassarre, S. and Van
   Vooren, J.-P. and Jacobs, F. and Mascart, F. and Estenne, M.},
Title = {{Paradoxical worsening of tuberculosis in a heart-lung transplant
   recipient}},
Journal = {{TRANSPLANT INFECTIOUS DISEASE}},
Year = {{2007}},
Volume = {{9}},
Number = {{3}},
Pages = {{219-224}},
Month = {{SEP}},
Abstract = {{We report on a heart-lung transplant recipient who presented with
   pulmonary tuberculosis (TB) 2.5 months aftertransplantation and then
   developed a paradoxical reaction after 4 months of adequate anti-TB
   treatment. She eventually recovered with anti-TB and high-dose steroid
   treatments.
   Methods. Using sequential bronchoalveolar lavages, we assessed the
   inflammatory response in the lung and investigated the alveolar immune
   response against a Mycobacterium tuberculosis antigen.
   Results. The paradoxical reaction was characterized by a massive
   infiltration of the alveolar space by M. tuberculosis antigen-specific
   CD4(+) Tcells and by the presence of a CD4(-)CD8(-) T lymphocyte
   subpopulation bearing phenotypic markers (CD16(+)/56(+)) classically
   associated with NK cells.
   Conclusion. This case report illustrates that even solid organ
   transplant recipients receiving intense triple-drug immune suppression
   may be able to develop a paradoxical reaction duringTB treatment.
   Transplant physicians should be aware of this phenomenon in order to
   differentiate it from treatment failure.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Estenne, M (Reprint Author), Erasme Univ Hosp, 808 Route Lennik, B-1070 Brussels, Belgium.
   Free Univ Brussels, Erasme Univ Hosp, Dept Chest Med, Brussels, Belgium.
   Free Univ Brussels, Erasme Univ Hosp, Dept Pathol, Brussels, Belgium.
   Free Univ Brussels, Erasme Univ Hosp, Treatment Immunodeficiency Dept, Brussels, Belgium.
   Free Univ Brussels, Erasme Univ Hosp, Dept Infect Dis, Brussels, Belgium.
   Free Univ Brussels, Erasme Univ Hosp, Lab Vaccinol \& Mucosal Immun, Brussels, Belgium.}},
DOI = {{10.1111/j.1399-3062.2006.00194.x}},
ISSN = {{1398-2273}},
Keywords = {{lung transplantation; paradoxical response; tuberculosis}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; PERIPHERAL-BLOOD;
   T-LYMPHOCYTES; THERAPY; CELLS}},
Research-Areas = {{Immunology; Infectious Diseases; Transplantation}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Transplantation}},
Author-Email = {{mestenne@ulb.ac.be}},
Cited-References = {{Asano T, 2000, TRANSPLANT P, V32, P1960, DOI 10.1016/S0041-1345(00)01512-8.
   Barry SM, 2003, J INFECT DIS, V187, P243, DOI 10.1086/346112.
   Bravo C, 2005, TRANSPLANTATION, V79, P59, DOI 10.1097/01.TP.0000147784.53188.DC.
   Breen RAM, 2004, THORAX, V59, P704, DOI 10.1136/thx.2003.019224.
   Burman WJ, 2000, CLIN INFECT DIS, V31, P1390, DOI 10.1086/317504.
   Cheng VCC, 2002, EUR J CLIN MICROBIOL, V21, P803, DOI 10.1007/s10096-002-0821-2.
   Condos R, 1998, AM J RESP CRIT CARE, V157, P729.
   De la Barrera SS, 2003, CLIN EXP IMMUNOL, V132, P450, DOI 10.1046/j.1365-2249.2003.02176.x.
   John George T, 2002, Semin Respir Infect, V17, P274, DOI 10.1053/srin.2002.36445.
   Lee J, 2003, J HEART LUNG TRANSPL, V22, P1168, DOI 10.1016/S1053-2498(02)01189-0.
   Narita M, 1998, AM J RESP CRIT CARE, V158, P157.
   Raja A, 2004, INDIAN J MED RES, V120, P213.
   Roman A, 2000, J HEART LUNG TRANSPL, V19, P903, DOI 10.1016/S1053-2498(00)00163-7.
   Singh N, 1998, CLIN INFECT DIS, V27, P1266, DOI 10.1086/514993.
   Slebos DJ, 2002, AM J RESP CRIT CARE, V165, P501, DOI 10.1164/rccm.2107035.
   Tsao TCY, 2002, CHEST, V122, P1285, DOI 10.1378/chest.122.4.1285.
   Urdaneta E, 1998, SCAND J IMMUNOL, V47, P496.
   Vankayalapati R, 2004, J IMMUNOL, V172, P130.
   VILCEK J, 1986, J CLIN IMMUNOL, V6, P146, DOI 10.1007/BF00918747.
   Winthrop KL, 2004, AM J TRANSPLANT, V4, P1529, DOI 10.1111/j.1600-6143.2004.00536.x.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Transpl. Infect. Dis.}},
Doc-Delivery-Number = {{207KE}},
Unique-ID = {{ISI:000249249200009}},
}

@article{ ISI:000249954000916,
Author = {Helal, Imed and Ezzeddine, Abderrahim and Ben Hamida, Fethi and Ben
   Abdallah, Taieb and Kheder, Adel},
Title = {{Tuberculosis infection in renal transplant patients}},
Journal = {{TRANSPLANT INTERNATIONAL}},
Year = {{2007}},
Volume = {{20}},
Number = {{2}},
Pages = {{231}},
Month = {{SEP}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Helal, Imed; Ezzeddine, Abderrahim; Ben Hamida, Fethi; Ben Abdallah, Taieb; Kheder, Adel, Hop Charles Nicolle, Tunis, Tunisia.}},
ISSN = {{0934-0874}},
Research-Areas = {{Surgery; Transplantation}},
Web-of-Science-Categories  = {{Surgery; Transplantation}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Transpl. Int.}},
Doc-Delivery-Number = {{217NG}},
Unique-ID = {{ISI:000249954000916}},
}

@article{ ISI:000249678700001,
Author = {McEvoy, Christopher R. E. and Falmer, Alecia A. and Gey van Pittius,
   Nicolaas C. and Victor, Thomas C. and van Helden, Paul D. and Warren,
   Robin M.},
Title = {{The role of IS6110 in the evolution of Mycobacterium tuberculosis}},
Journal = {{TUBERCULOSIS}},
Year = {{2007}},
Volume = {{87}},
Number = {{5}},
Pages = {{393-404}},
Month = {{SEP}},
Abstract = {{Members of the Mycobacterium tuberculosis complex contain the
   transposable element IS6110 which, due to its high numerical and
   positional polymorphism, has become a widely used marker in
   epidemiological studies. Here, we review the evidence that IS6110 is not
   simply a passive or `junk' DNA sequence, but that, through its
   transposable activity, it is able to generate genotypic variation that
   translates into strain-specific phenotypic variation. We also speculate
   on the role that this variation has played in the evolution of M.
   tuberculosis and conclude that the presence of a moderate IS6110 copy
   number within the genome may provide the pathogen with a selective
   advantage that has aided its virulence. (c) 2007 Elsevier Ltd. All
   rights reserved.}},
Publisher = {{CHURCHILL LIVINGSTONE}},
Address = {{JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{McEvoy, CRE (Reprint Author), Univ Stellenbosch, Fac Hlth Sci, MRC, Ctr Cellular \& Mol Biol DST NRF Ctr EBTR Div MBHG, ZA-7505 Tygerberg, South Africa.
   Univ Stellenbosch, Fac Hlth Sci, MRC, Ctr Cellular \& Mol Biol DST NRF Ctr EBTR Div MBHG, ZA-7505 Tygerberg, South Africa.}},
DOI = {{10.1016/j.tube.2007.05.010}},
ISSN = {{1472-9792}},
Keywords = {{Mycobacterium tuberculosis; IS6110; transposon; evolution}},
Keywords-Plus = {{IS6110-MEDIATED DELETION POLYMORPHISM; COMPLETE GENOME SEQUENCE;
   INSERTION-SEQUENCE; NUCLEOTIDE POLYMORPHISMS; TRANSPOSON MUTAGENESIS;
   TRANSLATIONAL CONTROL; GLOBAL DISSEMINATION; PREFERENTIAL LOCUS; BEIJING
   GENOTYPE; COMPLEX STRAINS}},
Research-Areas = {{Immunology; Microbiology; Respiratory System}},
Web-of-Science-Categories  = {{Immunology; Microbiology; Respiratory System}},
Author-Email = {{cmcevoy@sun.ac.za}},
ResearcherID-Numbers = {{Gey van Pittius, Nicolaas/D-3434-2015}},
ORCID-Numbers = {{Gey van Pittius, Nicolaas/0000-0002-8807-4105}},
Cited-References = {{Abebe F, 2006, CLIN EXP IMMUNOL, V145, P389, DOI 10.1111/j.1365-2249.2006.03162.x.
   Alland D, 2003, J BACTERIOL, V185, P3392, DOI 10.1128/JB.185.11.3392-3399.2003.
   Andersson DI, 1999, CURR OPIN MICROBIOL, V2, P489, DOI 10.1016/S1369-5274(99)00005-3.
   Anh DD, 2000, EMERG INFECT DIS, V6, P302.
   Baker L, 2004, EMERG INFECT DIS, V10, P1568.
   Banu S, 2002, MOL MICROBIOL, V44, P9, DOI 10.1046/j.1365-2958.2002.02813.x.
   Beggs ML, 2000, J CLIN MICROBIOL, V38, P2923.
   Biemont C, 2006, NATURE, V443, P521, DOI 10.1038/443521a.
   Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6.
   BODDINGHAUS B, 1990, J CLIN MICROBIOL, V28, P1751.
   Brisse S, 2006, PLOS PATHOG, V2, P812, DOI 10.1371/journal.ppat.0020095.
   Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299.
   Brugger K, 2004, BIOCHEM SOC T, V32, P179, DOI 10.1042/BST0320179.
   CAVE MD, 1994, J CLIN MICROBIOL, V32, P262.
   Chacon-Salinas R, 2005, CLIN EXP IMMUNOL, V140, P443, DOI 10.1111/j.1365-2249.2005.02797.x.
   Cole ST, 1998, NATURE, V393, P537.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Dale J W, 1995, Eur Respir J Suppl, V20, p633s.
   Dale JW, 1997, TUBERCLE LUNG DIS, V78, P225, DOI 10.1016/S0962-8479(97)90002-2.
   Dale JW, 2003, J BACTERIOL, V185, P2555, DOI 10.1128/JB.185.8.2555-2562.2003.
   de Boer AS, 1999, J INFECT DIS, V180, P1238, DOI 10.1086/314979.
   de Boer AS, 2000, J CLIN MICROBIOL, V38, P4478.
   Dormans J, 2004, CLIN EXP IMMUNOL, V137, P460, DOI 10.1111/j.1365-2249.2004.02551.x.
   Duval-Valentin G, 2001, EMBO J, V20, P5802, DOI 10.1093/emboj/20.20.5802.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   ESCOUBAS JM, 1991, EMBO J, V10, P705.
   Fang Z, 1999, J BACTERIOL, V181, P1014.
   Fang Z, 1998, J BACTERIOL, V180, P2102.
   Fang Z, 1999, J BACTERIOL, V181, P1021.
   Fang ZG, 1997, J CLIN MICROBIOL, V35, P479.
   Filliol I, 2006, J BACTERIOL, V188, P759, DOI 10.1128/JB.188.2.759-772.2006.
   Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002.
   Fomukong N, 1997, Tuber Lung Dis, V78, P109.
   Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100.
   Ghanekar K, 1999, MOL MICROBIOL, V33, P982, DOI 10.1046/j.1365-2958.1999.01539.x.
   Glynn JR, 2002, EMERG INFECT DIS, V8, P843.
   Glynn JR, 2004, J INFECT DIS, V190, P1158, DOI 10.1086/423144.
   Gordon SV, 1999, MICROBIOL-UK, V145, P881.
   Gutacker MM, 2006, J INFECT DIS, V193, P121, DOI 10.1086/498574.
   Gutacker MM, 2002, GENETICS, V162, P1533.
   Gutierrez MC, 2005, PLOS PATHOG, V1, P55, DOI 10.1371/journal.ppat.0010005.
   Haas M, 2002, J BACTERIOL, V184, P5833, DOI 10.1128/JB.184.21.5833-5841.2002.
   Hanekom M, 2007, J CLIN MICROBIOL, V45, P1483, DOI 10.1128/JCM.02191-06.
   HERMANS PWM, 1991, INFECT IMMUN, V59, P2695.
   Ho TBL, 2000, YEAST, V17, P272, DOI 10.1002/1097-0061(200012)17:4<272::AID-YEA48>3.0.CO;2-2.
   Hughes AL, 2002, EMERG INFECT DIS, V8, P1342.
   Kato-Maeda M, 2001, GENOME RES, V11, P547, DOI 10.1101/gr.166401.
   Kurepina N. E., 1998, Tubercle and Lung Disease, V79, P31, DOI 10.1054/tuld.1998.0003.
   Lemaitre N, 1999, ANTIMICROB AGENTS CH, V43, P1761.
   Liu XM, 2006, J BACTERIOL, V188, P8169, DOI 10.1128/JB.01062-06.
   MA C, 1990, EMBO J, V9, P1267.
   Manca C, 2004, INFECT IMMUN, V72, P5511, DOI 10.1128/IAI.72.9.5511-5514.2004.
   Matsumoto T, 2005, TUBERCULOSIS, V85, P207, DOI 10.1016/j.tube.2005.02.001.
   Maus CE, 2005, ANTIMICROB AGENTS CH, V49, P571, DOI 10.1128/AAC.49.2.571-577.2005.
   McAdam RA, 2002, MICROBIOL-SGM, V148, P2975.
   MCADAM RA, 1995, INFECT IMMUN, V63, P1004.
   Mokrousov I, 2005, GENOME RES, V15, P1357, DOI 10.1101/gr.3840605.
   Nagy Z, 2004, RES MICROBIOL, V155, P387, DOI 10.1016/j.resmic.2004.01.008.
   Niemann S, 1999, J CLIN MICROBIOL, V37, P3078.
   Parkhill J, 2003, NAT GENET, V35, P32, DOI 10.1038/ng1227.
   Perez E, 2001, MOL MICROBIOL, V41, P179, DOI 10.1046/j.1365-2958.2001.02500.x.
   POLARD P, 1991, J MOL BIOL, V222, P465, DOI 10.1016/0022-2836(91)90490-W.
   Quy HTW, 2003, INT J TUBERC LUNG D, V7, P631.
   Raynaud C, 2002, MOL MICROBIOL, V45, P203, DOI 10.1046/j.1365-2958.2002.03009.x.
   Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837.
   Rengarajan J, 2004, MOL MICROBIOL, V53, P275, DOI 10.1111/j.1365-2958.2004.04120.x.
   Safi H, 2004, MOL MICROBIOL, V52, P999, DOI 10.1111/j.1365-2958.2004.04037.x.
   Sampson S. L., 1999, Tubercle and Lung Disease, V79, P349, DOI 10.1054/tuld.1999.0218.
   Sampson SL, 2004, J CLIN MICROBIOL, V42, P895, DOI 10.1128/JCM.42.2.895-898.2004.
   Sampson SL, 2003, J BACTERIOL, V185, P2856, DOI 10.1128/JB.185.9.2856-2866.2003.
   Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100.
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x.
   Sassetti CM, 2001, P NATL ACAD SCI USA, V98, P12712, DOI 10.1073/pnas.231275498.
   SEKINE Y, 1994, J MOL BIOL, V235, P1406, DOI 10.1006/jmbi.1994.1097.
   Sekine Y, 1997, GENES CELLS, V2, P547, DOI 10.1046/j.1365-2443.1997.1440342.x.
   Smith NH, 2006, J THEOR BIOL, V239, P220, DOI 10.1016/j.jtbi.2005.08.036.
   Smith NH, 2006, PLOS PATHOG, V2, P809, DOI 10.1371/journal.ppat.0020098.
   Soto CY, 2004, J CLIN MICROBIOL, V42, P212, DOI 10.1128/JCM.42.1.212-219.2004.
   Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869.
   STEAD WW, 1995, AM J RESP CRIT CARE, V151, P1267.
   Tanaka MM, 2004, MOL BIOL EVOL, V21, P2195, DOI 10.1093/molbev/msh234.
   Tanaka MM, 2000, P NATL ACAD SCI USA, V97, P3532, DOI 10.1073/pnas.060564997.
   Tavakoli NP, 2001, EMBO J, V20, P2923, DOI 10.1093/emboj/20.11.2923.
   THIERRY D, 1990, J CLIN MICROBIOL, V28, P2668.
   Tsolaki AG, 2004, P NATL ACAD SCI USA, V101, P4865, DOI 10.1073/pnas.0305634101.
   Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.
   VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578.
   Vera-Cabrera L, 2001, J CLIN MICROBIOL, V39, P3499, DOI 10.1128/JCM.39.10.3499-3504.2001.
   Victor TC, 2007, INT J TUBERC LUNG D, V11, P195.
   Wall S, 1999, MICROBIOL-UK, V145, P3169.
   Warren RM, 2000, MOL MICROBIOL, V37, P1405, DOI 10.1046/j.1365-2958.2000.02090.x.
   Warren RM, 2002, J CLIN MICROBIOL, V40, P1277, DOI 10.1128/JCM.40.4.1277-1282.2002.
   Warren RM, 2002, J CLIN MICROBIOL, V40, P1705, DOI 10.1128/JCM.40.5.1705-1708.2002.
   Yang ZH, 2005, AM J RESP CRIT CARE, V171, P1436, DOI 10.1164/rccm.200408-1147OC.
   Yeh RW, 1998, J INFECT DIS, V177, P1107.
   Yesilkaya H, 2005, J BACTERIOL, V187, P6726, DOI 10.1128/JB.187.19.6726-6732.2005.
   Zhang M, 1999, J INFECT DIS, V179, P1213, DOI 10.1086/314738.
   {[}Anonymous], 2006, MMWR MORB MORTAL WKL, V55, P301.}},
Number-of-Cited-References = {{99}},
Times-Cited = {{73}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{Tuberculosis}},
Doc-Delivery-Number = {{213PD}},
Unique-ID = {{ISI:000249678700001}},
}

@article{ ISI:000249678700002,
Author = {Rodgers, J. D. and Connery, N. L. and McNair, J. and Welsh, M. D. and
   Skuce, R. A. and Bryson, D. G. and McMurray, D. N. and Pollock, J. M.},
Title = {{Experimental exposure of cattle to a precise aerosolised challenge of
   Mycobacterium bovis: A novel model to study bovine tuberculosis}},
Journal = {{TUBERCULOSIS}},
Year = {{2007}},
Volume = {{87}},
Number = {{5}},
Pages = {{405-414}},
Month = {{SEP}},
Abstract = {{Non-aerosol models of bovine tuberculosis are limited in reproducibility
   and relevance to natural cases seen in farmed animals. Therefore, there
   is a need for aerosol models of infection in cattle that can reproduce
   bovine tuberculosis as seen in natural cases of the disease.
   This manuscript describes a cattle tuberculosis model based on the
   inhalation of a precisely defined dose of Mycobacterium bovis in aerosol
   form, and defines those sites of M. bovis deposition following aerosol
   inhalation. The dissemination of bacilli and the resultant pathological
   change following infection is also described. Cattle aged 4-5 months,
   were infected with approximately 104 colony forming units (CFU), using a
   Madison chamber that had been modified to deliver aerosols to calves. In
   Experiment 1, calves were examined for gross pathology at post mortem
   (PM) examination at 93 and 132 days post-infection (PI), respectively.
   In Experiment 2, pairs of calves were examined for gross pathology at PM
   examination at 1 day PI and 7 days PI, respectively. At PM examination,
   samples were taken for bacteriology. Retrospective counts showed that
   the calves inhaled between 3 x 10(4) and 8 x 10(4) CFU of M. bovis. In
   Experiment 1, pathology indicative of tuberculosis and detection of M.
   bovis by qualitative bacteriology was found throughout the lower
   respiratory tract (LRT). In Experiment 2, pathology was only observed in
   a single site of one calf at day 7 PI. Samples positive for M. bovis by
   bacteriology were predominantly in the LRT The numbers of M. bovis CFU
   recovered and the distributions of positive sites were greater at day 7
   PI than day 1 PI.
   This study describes an aerosol exposure method that can deliver a
   defined dose of M. bovis almost exclusively to the LRT The distribution
   of M. bovis and lesions indicative of tuberculosis suggests this aerosol
   method replicates the primary mode of tuberculosis transmission in
   cattle. (c) 2007 Elsevier Ltd. All rights reserved.}},
Publisher = {{CHURCHILL LIVINGSTONE}},
Address = {{JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{McNair, J (Reprint Author), Vet Sci Div, Stormont,Stoney Rd, Belfast, Antrim, North Ireland.
   Vet Sci Div, Belfast, Antrim, North Ireland.
   Queens Univ Belfast, Dept Vet Sci, Belfast, Antrim, North Ireland.
   Texas A\&M Univ, Dept Med Microbiol \& Immunol, College Stn, TX USA.}},
DOI = {{10.1016/j.tube.2007.04.003}},
ISSN = {{1472-9792}},
Keywords = {{Mycobacterium bovis; bovine tuberculosis; aerosol infection model;
   pathogenesis}},
Keywords-Plus = {{GUINEA-PIGS; INFECTION; PATHOGENESIS; EXCRETION; INOCULATION;
   ENUMERATION; LESIONS; LUNG}},
Research-Areas = {{Immunology; Microbiology; Respiratory System}},
Web-of-Science-Categories  = {{Immunology; Microbiology; Respiratory System}},
Author-Email = {{jim.mcnair@afbini.gov.uk}},
ResearcherID-Numbers = {{Rodgers, John/C-5571-2011}},
Cited-References = {{ANDERSEN AA, 1958, J BACTERIOL, V76, P471.
   Buddle BM, 2005, TUBERCULOSIS, V85, P19, DOI 10.1016/j.tube.2004.09.003.
   BUDDLE BM, 1994, NEW ZEAL VET J, V42, P167, DOI 10.1080/00480169.1994.35814.
   Cassidy JP, 1998, J COMP PATHOL, V119, P27, DOI 10.1016/S0021-9975(98)80069-8.
   Chackerian AA, 2002, INFECT IMMUN, V70, P4501, DOI 10.1128/IAI.70.8.4501-4509.2002.
   Chambers MA, 2001, VET MICROBIOL, V80, P213, DOI 10.1016/S0378-1135(00)00378-3.
   Cox C. S., 1987, AEROBIOLOGICAL PATHW.
   Dannenberg Arthur M. Jr., 1994, P149.
   DUNN PL, 1995, INFECT IMMUN, V63, P3428.
   Fitzgerald SD, 2003, J WILDLIFE DIS, V39, P418.
   Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100.
   GUSSMAN RA, 1984, AM IND HYG ASSOC J, V45, P8.
   MCILROY SG, 1986, VET REC, V118, P718.
   McMurray David N., 1994, P135.
   McMurray DN, 2003, TUBERCULOSIS, V83, P131, DOI 10.1016/S1472-9792(02)00079-3.
   NEILL SD, 1994, VET MICROBIOL, V40, P41, DOI 10.1016/0378-1135(94)90045-0.
   NEILL SD, 1988, VET REC, V123, P340.
   Neill SD, 2001, TUBERCULOSIS, V81, P79, DOI 10.1054/tube.2000.0279.
   NEILL SD, 1991, VET MICROBIOL, V28, P103, DOI 10.1016/0378-1135(91)90102-L.
   Orme Ian M., 1994, P113.
   Palmer MV, 2003, J WILDLIFE DIS, V39, P817.
   Palmer MV, 2002, TUBERCULOSIS, V82, P275, DOI 10.1054/tube.2002.0341.
   Palmer MV, 1999, AM J VET RES, V60, P310.
   Pollock JM, 2006, VET MICROBIOL, V112, P141, DOI 10.1016/j.vetmic.2005.11.032.
   POLLOCK JM, 1995, SCAND J IMMUNOL, V41, P85, DOI 10.1111/j.1365-3083.1995.tb03537.x.
   Skuce RA, 2005, VET REC, V157, P501.
   van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000.
   WIEGESHAUS EH, 1970, AM REV RESPIR DIS, V102, P422.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{10}},
Journal-ISO = {{Tuberculosis}},
Doc-Delivery-Number = {{213PD}},
Unique-ID = {{ISI:000249678700002}},
}

@article{ ISI:000249678700005,
Author = {Menendez, M. Carmen and Buxton, Roger S. and Evans, Jason T. and
   Gascoyne-Binzi, Deborah and Barlow, Rachael E. L. and Hinds, Jason and
   Hawkey, Peter M. and Closton, M. Joseph},
Title = {{Genome analysis shows a common evolutionary origin for the dominant
   strains of Mycobacterium tuberculosis in a UK South Asian community}},
Journal = {{TUBERCULOSIS}},
Year = {{2007}},
Volume = {{87}},
Number = {{5}},
Pages = {{426-436}},
Month = {{SEP}},
Abstract = {{We have investigated the Mycobacterium tuberculosis strain types present
   in the South Asian population of the UK, in which tuberculosis is
   particularly prevalent. In contrast to the widespread Beijing strains
   which have the variable number tandem repeats (VNTR) profile 42435,
   isolates with the VNTR profile 42235, jointly with 02335 or 42234
   profiles, appear more frequently in tuberculosis patients of South Asian
   ethnic origin (SA-strains) in the UK than in any other ethnic group.
   Using microarray-based comparative genomics to distinguish total or
   partially deteted genes, we found that three of the common deleted
   regions in the SA-strains were identical to some deteted genes in the
   strain CH, which caused an outbreak among South Asian patients in
   Leicester in 2001 but were different from genomic deletions found in
   Beijing/W strains. Analysis of some of the deleted regions reveated
   differences in comparison to the strain CH including the polymorphism in
   some of the PE/PPE and Esat-6 genes, which may be responsible for the
   diversity of antigenic variation or differences in the activation of the
   host immune response. Interrupted genes or the replacement by insertion
   elements was confirmed in some of the deleted genomic regions. Our
   results are consistent with the hypothesis that the SA-strains may
   present common features, implying a common origin for this group of
   strains. (c) 2007 Elsevier Ltd. All rights reserved.}},
Publisher = {{CHURCHILL LIVINGSTONE}},
Address = {{JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Buxton, RS (Reprint Author), Natl Inst Med Res, MRC, Div Mycobacterial Res, Ridgeway,Mill Hill, London NW7 1AA, England.
   Natl Inst Med Res, MRC, Div Mycobacterial Res, London NW7 1AA, England.
   Univ Birmingham, Sch Med, Div Immun \& Infect, Birmingham B15 2TT, W Midlands, England.
   Gen Infirm, Dept Microbiol, Leeds LS1 3EX, W Yorkshire, England.
   Univ London St Georges Hosp, Div Cellular \& Mol Med, Bacterial Microarray Grp, London SW17 0RE, England.
   Birmingham Heartlands Hosp, Hlth Protect Agcy, W Midlands Lab, Birmingham B9 5SS, W Midlands, England.
   Univ Autonoma Madrid, Fac Med, Dept Prevent Med, E-28029 Madrid, Spain.}},
DOI = {{10.1016/j.tube.2007.05.017}},
ISSN = {{1472-9792}},
Keywords = {{Mycobacterium tuberculosis; PE/PPE; polymorphism; VNTR 42235; South
   Asian community}},
Keywords-Plus = {{ESAT-6 GENE FAMILY; PE-PGRS PROTEINS; COMPLEX; VIRULENCE; DELETIONS;
   EXPRESSION; DIVERSITY; SEQUENCE; ANTIGENS; LINEAGE}},
Research-Areas = {{Immunology; Microbiology; Respiratory System}},
Web-of-Science-Categories  = {{Immunology; Microbiology; Respiratory System}},
Author-Email = {{rbuxton@nimr.mrc.ac.uk}},
Funding-Acknowledgement = {{Medical Research Council {[}MC\_U117585867, U.1175.02.002.00013
   (85867)]; Wellcome Trust {[}062511]}},
Cited-References = {{Alland D, 2007, J CLIN MICROBIOL, V45, P39, DOI 10.1128/JCM.02483-05.
   Banu S, 2002, MOL MICROBIOL, V44, P9, DOI 10.1046/j.1365-2958.2002.02813.x.
   Brennan MJ, 2001, INFECT IMMUN, V69, P7326, DOI 10.1128/IAI.69.12.7326-7333.2001.
   Brosch R, 1999, INFECT IMMUN, V67, P5768.
   Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299.
   Cole ST, 1998, NATURE, V393, P537.
   Cosma CL, 2003, ANNU REV MICROBIOL, V57, P641, DOI 10.1146/annurev.micro.57.030502.091033.
   DAVIS EO, 1991, J BACTERIOL, V173, P5653.
   Espitia C, 1999, MICROBIOL-UK, V145, P3487.
   Frota CC, 2004, MICROBIOL-SGM, V150, P1519, DOI 10.1099/mic.0.26660-0.
   Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103.
   Garcia-Pelayo MC, 2004, TUBERCULOSIS, V84, P159, DOI 10.1016/j.tube.2003.12.002.
   Gascoyne-Binzi DM, 2002, INT J TUBERC LUNG D, V6, P492.
   Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x.
   Gutierrez MC, 2006, EMERG INFECT DIS, V12, P1367.
   Hirsh AE, 2004, P NATL ACAD SCI USA, V101, P4871, DOI 10.1073/pnas.0305627101.
   Ho TBL, 2000, YEAST, V17, P272, DOI 10.1002/1097-0061(200012)17:4<272::AID-YEA48>3.0.CO;2-2.
   Hogarth PJ, 2005, VACCINE, V23, P2557, DOI 10.1016/j.vaccine.2004.11.030.
   Kremer K, 1999, J CLIN MICROBIOL, V37, P2607.
   Lightbody KL, 2004, FEMS MICROBIOL LETT, V238, P255, DOI 10.1016/j.femsle.2004.07.043.
   Marmiesse M, 2004, MICROBIOL-SGM, V150, P483, DOI 10.1099/mic.0.26662-0.
   Mokrousov I, 2002, RES MICROBIOL, V153, P629, DOI 10.1016/S0923-2508(02)01374-8.
   Musser JM, 2000, GENETICS, V155, P7.
   Newton SM, 2006, P NATL ACAD SCI USA, V103, P15594, DOI 10.1073/pnas.0604283103.
   Ormerod LP, 1998, THORAX, V53, P176.
   Rajakumar K, 2004, J CLIN MICROBIOL, V42, P1890, DOI 10.1128/JCM.42.5.1890-1896.2004.
   Raynaud C, 2002, MOL MICROBIOL, V45, P203, DOI 10.1046/j.1365-2958.2002.03009.x.
   Safi H, 2004, MOL MICROBIOL, V52, P999, DOI 10.1111/j.1365-2958.2004.04037.x.
   Sampson SL, 2001, TUBERCULOSIS, V81, P305, DOI 10.1054/tube.2001.0304.
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x.
   Shamputa IC, 2004, J CLIN MICROBIOL, V42, P5528, DOI 10.1128/JCM.42.12.5528-5536.2004.
   Skeiky YAW, 2000, J IMMUNOL, V165, P7140.
   Skjot RLV, 2002, INFECT IMMUN, V70, P5446, DOI 10.1128/IAI.70.10.5446-5453.2002.
   Soini H, 2000, J CLIN MICROBIOL, V38, P669.
   Sola C, 2003, INFECT GENET EVOL, V3, P125, DOI 10.1016/S1567-1348(03)00011-X.
   Soto CY, 2004, J CLIN MICROBIOL, V42, P212, DOI 10.1128/JCM.42.1.212-219.2004.
   Stewart GR, 2002, MICROBIOL-SGM, V148, P3129.
   Tekaia F., 1999, Tubercle and Lung Disease, V79, P329, DOI 10.1054/tuld.1999.0220.
   Tsolaki AG, 2005, J CLIN MICROBIOL, V43, P3185, DOI 10.1128/JCM.43.7.3185-3191.2005.
   Tsolaki AG, 2004, P NATL ACAD SCI USA, V101, P4865, DOI 10.1073/pnas.0305634101.
   VANSOOLINGEN D, 1994, METHOD ENZYMOL, V235, P196.
   Vera-Cabrera L, 2001, J CLIN MICROBIOL, V39, P3499, DOI 10.1128/JCM.39.10.3499-3504.2001.
   World Health Organization, TUB.
   Yesilkaya H, 2006, TUBERCULOSIS, V86, P357, DOI 10.1016/j.tube.2005.08.019.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{Tuberculosis}},
Doc-Delivery-Number = {{213PD}},
Unique-ID = {{ISI:000249678700005}},
}

@article{ ISI:000249678700007,
Author = {Chen, Jing and Tsolaki, Anthony G. and Shen, Xin and Jiang, Xi and Mei,
   Jim and Gao, Qian},
Title = {{Deletion-targeted multiplex PCR (DTM-PCR) for identification of
   Beijing/W genotypes of Mycobacterium tuberculosis}},
Journal = {{TUBERCULOSIS}},
Year = {{2007}},
Volume = {{87}},
Number = {{5}},
Pages = {{446-449}},
Month = {{SEP}},
Abstract = {{Beijing/W strains of Mycobacterium tuberculosis cause the vast majority
   of tuberculosis cases in Shanghai, China. Such highly prevalent strains
   are considered as hypervirulent and are often associated with multi-drug
   resistance, treatment failure and HIV status. We present a reliable and
   fast detection method to identify these Beijing/W strains, which can be
   applied to screening large numbers of samples at low cost. Using this
   Deletion-Targeted Multiplex PCR (DTM-PCR) method for detecting these
   strains, we obtained 100\% sensitivity and specificity. (c) 2007
   Elsevier Ltd. All rights reserved.}},
Publisher = {{CHURCHILL LIVINGSTONE}},
Address = {{JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Gao, Q (Reprint Author), Fudan Univ, Coll Med, Key Lab Med Mol Virol, 138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.
   Fudan Univ, Coll Med, Key Lab Med Mol Virol, Shanghai 200032, Peoples R China.
   Fudan Univ, Inst Med Microbiol, Shanghai 200032, Peoples R China.
   Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China.
   Shanghai Municipal Ctr Dis Control \& Prevent, Dept TB Control, Shanghai 200336, Peoples R China.
   Fudan Univ, Sch Life Sci, Genet Inst, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
   Brunel Univ, Sch Hlth Sci \& Social Care, London UB8 3PH, England.}},
DOI = {{10.1016/j.tube.2007.05.014}},
ISSN = {{1472-9792}},
Keywords = {{Mycobacterium tuberculosis; Beijing/W genotype; DTM-PCR}},
Keywords-Plus = {{REAL-TIME PCR; GENOMIC DELETIONS; RAPID DETECTION; STRAINS; LINEAGE}},
Research-Areas = {{Immunology; Microbiology; Respiratory System}},
Web-of-Science-Categories  = {{Immunology; Microbiology; Respiratory System}},
Author-Email = {{qgao99@yahoo.com}},
Cited-References = {{Aldous WK, 2005, J CLIN MICROBIOL, V43, P2471, DOI 10.1128/JCM.43.5.2471-2473.2005.
   Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6.
   Chin PJ, 2007, J CLIN MICROBIOL, V45, P1022, DOI 10.1128/JCM.02036-06.
   Doig C, 2002, J CLIN PATHOL, V55, P778, DOI 10.1136/jcp.55.10.778.
   Glynn JR, 2002, EMERG INFECT DIS, V8, P843.
   Glynn JR, 2006, EMERG INFECT DIS, V12, P736.
   Hillemann D, 2006, J CLIN MICROBIOL, V44, P302, DOI 10.1128/JCM.44.2.302-306.2006.
   Kremer K, 2004, J CLIN MICROBIOL, V42, P4040, DOI 10.1128/JCM.42.9.4040-4049.2004.
   Li Wei-min, 2003, Zhonghua Liu Xing Bing Xue Za Zhi, V24, P381.
   Li WM, 2005, INT J TUBERC LUNG D, V9, P1314.
   Mokrousov I, 2006, J CLIN MICROBIOL, V44, P2851, DOI 10.1128/JCM.00705-06.
   Rao KR, 2006, J CLIN MICROBIOL, V44, P274, DOI 10.1128/JCM.44.1.274-277.2006.
   Shen Guo-miao, 2005, Zhonghua Jiehe He Huxi Zazhi, V28, P292.
   Tsolaki AG, 2005, J CLIN MICROBIOL, V43, P3185, DOI 10.1128/JCM.43.7.3185-3191.2005.
   Tsolaki AG, 2004, P NATL ACAD SCI USA, V101, P4865, DOI 10.1073/pnas.0305634101.
   VANSOOLINGEN D, 1995, J CLIN MICROBIOL, V33, P3234.
   YOKOYAMA E, 2007, INFECT GENET EVOL.
   Zhang M, 1999, J INFECT DIS, V179, P1213, DOI 10.1086/314738.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{41}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Tuberculosis}},
Doc-Delivery-Number = {{213PD}},
Unique-ID = {{ISI:000249678700007}},
}

@article{ ISI:000249678700008,
Author = {Robertson, Dina and Carroll, Paul and Parish, Tanya},
Title = {{Rapid recombination screening to test gene essentiality demonstrates
   that pyrH is essential in Mycobacterium tuberculosis}},
Journal = {{TUBERCULOSIS}},
Year = {{2007}},
Volume = {{87}},
Number = {{5}},
Pages = {{450-458}},
Month = {{SEP}},
Abstract = {{The availability of the complete genome of Mycobacterium tuberculosis
   affords the possibility of screening genes for essentiality under
   defined conditions. We tested a rapid recombination method for screening
   and confirmation of gene essentiality which would be more amenable to
   higher throughput applications. Non-replicating vectors carrying the
   internal portion of a gene were used as recombination substrates. Such
   vectors would lead to inactivation of the target gene in a single
   recombination step. For non-essential genes, recombinants can be
   obtained; for essential genes, no recombinants can be obtained, thus
   providing a rapid screening method to determine essentiality in a
   targeted manner. The incorporation of a promoter in the vector allowed
   us to establish the essentiality of a single gene in an operon. We
   confirmed this method worked with several essential (proC, glnE, mtrB,
   trpD) and one non-essential (tlyA) gene. In addition, we used the method
   to demonstrate that the pyrH gene is essential. (c) 2007 Elsevier Ltd.
   All rights reserved.}},
Publisher = {{CHURCHILL LIVINGSTONE}},
Address = {{JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Parish, T (Reprint Author), Ctr Infect Dis, Inst Cell \& Mol Sci, Barts \& London, Blizard Bldg, London E1 2AT, England.
   Ctr Infect Dis, Inst Cell \& Mol Sci, Barts \& London, London E1 2AT, England.}},
DOI = {{10.1016/j.tube.2007.05.015}},
ISSN = {{1472-9792}},
Keywords = {{essential genes; homologous recombination; mycobacteria}},
Keywords-Plus = {{COMPLETE GENOME SEQUENCE; ILLEGITIMATE RECOMBINATION; MUTANTS;
   IDENTIFICATION; REPLACEMENT; MUTAGENESIS; VIRULENCE; GROWTH; SYSTEM;
   BOVIS}},
Research-Areas = {{Immunology; Microbiology; Respiratory System}},
Web-of-Science-Categories  = {{Immunology; Microbiology; Respiratory System}},
Author-Email = {{t.parish@qmul.ac.uk}},
Cited-References = {{Bardarov S, 1997, P NATL ACAD SCI USA, V94, P10961, DOI 10.1073/pnas.94.20.10961.
   Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006.
   Cole ST, 1998, NATURE, V393, P537.
   Collins DM, 2002, MICROBIOL-SGM, V148, P3019.
   Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100.
   Hinds J, 1999, MICROBIOL-UK, V145, P519.
   KALPANA GV, 1991, P NATL ACAD SCI USA, V88, P5433, DOI 10.1073/pnas.88.12.5433.
   McAdam RA, 2002, MICROBIOL-SGM, V148, P2975.
   Movahedzadeh F, 2004, MOL MICROBIOL, V51, P1003, DOI 10.1046/j.1365-2958.2003.03900.x.
   Musser JM, 2001, EMERG INFECT DIS, V7, P486.
   Parish T, 2000, J BACTERIOL, V182, P5715, DOI 10.1128/JB.182.20.5715-5720.2000.
   Parish T, 2000, MICROBIOL-UK, V146, P1969.
   Parish T, 2002, MICROBIOL-SGM, V148, P3069.
   Parish T, 1999, MICROBIOL-UK, V145, P3497.
   Pashley CA, 2006, MICROBIOL-SGM, V152, P2727, DOI 10.1099/mic.0.28942-0.
   Pelicic V, 1996, MOL MICROBIOL, V20, P919, DOI 10.1111/j.1365-2958.1996.tb02533.x.
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x.
   Sassetti CM, 2001, P NATL ACAD SCI USA, V98, P12712, DOI 10.1073/pnas.231275498.
   Zahrt TC, 2000, J BACTERIOL, V182, P3832, DOI 10.1128/JB.182.13.3832-3838.2000.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Tuberculosis}},
Doc-Delivery-Number = {{213PD}},
Unique-ID = {{ISI:000249678700008}},
}

@article{ ISI:000249678700009,
Author = {Hofmeyr, Ann and Lau, W. F. Eddie and Slavin, Monica A.},
Title = {{Mycobacterium tuberculosis infection in patients with cancer, the role
   of 18-fluorodeoxyglucose positron emission tomography for diagnosis and
   monitoring treatment response}},
Journal = {{TUBERCULOSIS}},
Year = {{2007}},
Volume = {{87}},
Number = {{5}},
Pages = {{459-463}},
Month = {{SEP}},
Abstract = {{Active tuberculosis (TB) infection including asymptomatic and
   extrapulmonary disease may be detected with 18-fluorodeoxyglucose
   positron emission tomography/computed tomography (FDG-PET/CT). This
   report highlights the promising role of FDG-PET/CT for evaluation of TB
   in high-risk, immunocompromised patients with cancer. PET/CT performed
   for cancer evaluation may detect asymptomatic infection and guide
   definitive diagnosis. It may also be a useful tool in the assessment of
   latent TB, to exclude active disease prior to treatment. PET/CT has
   potential for monitoring response to anti-tuberculosis treatment.
   Metabolic response may indicate clinical response and guide duration of
   anti-microbial therapy. Crown Copyright (c) 2007 Published by Elsevier
   Ltd. All rights reserved.}},
Publisher = {{CHURCHILL LIVINGSTONE}},
Address = {{JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hofmeyr, A (Reprint Author), Dept Microbiol \& Infect Dis, Sydney S W Pathol Serv, Locked Bag 7090, Liverpool, NSW 1871, Australia.
   Peter MacCallum Canc Ctr, Dept Infect Dis, Melbourne, Vic, Australia.
   Peter MacCallum Canc Ctr, Ctr Mol Imaging, Melbourne, Vic, Australia.
   Univ Melbourne, Dept Med Radiol, Melbourne, Vic, Australia.
   Royal Melbourne Hosp, Ctr Clin Res Excellence Infect Dis, Melbourne, Vic, Australia.}},
DOI = {{10.1016/j.tube.2007.05.013}},
ISSN = {{1472-9792}},
Keywords = {{tuberculosis; treatment; malignancy; positron emission tomography;
   interferon-gamma}},
Keywords-Plus = {{FDG PET; LUNG-CANCER; F-18-FLUORODEOXYGLUCOSE; MANAGEMENT; F-18-FDG}},
Research-Areas = {{Immunology; Microbiology; Respiratory System}},
Web-of-Science-Categories  = {{Immunology; Microbiology; Respiratory System}},
Author-Email = {{Ann.hofmeyr@sswahs.nsw.gov.au}},
ORCID-Numbers = {{Slavin, Monica/0000-0002-8443-314X}},
Cited-References = {{Bakheet SMB, 1998, CLIN NUCL MED, V23, P739, DOI 10.1097/00003072-199811000-00003.
   Blockmans D, 2001, CLIN INFECT DIS, V32, P191, DOI 10.1086/318480.
   Buck AK, 2003, J NUCL MED, V44, P1426.
   Chen YK, 2004, CLIN NUCL MED, V29, P124, DOI 10.1097/01.rlu.0000109300.89514.35.
   El-Haddad G, 2004, SEMIN NUCL MED, V34, P313, DOI 10.1053/j.semnuclmed.2004.06.006.
   Ferrara G, 2005, AM J RESP CRIT CARE, V172, P631, DOI 10.1164/rccm.200502-196OC.
   Goo JM, 2000, RADIOLOGY, V216, P117.
   Hara T, 2003, CHEST, V124, P893, DOI 10.1378/chest.124.3.893.
   Horsburgh CR, 2004, NEW ENGL J MED, V350, P2060, DOI 10.1056/NEJMsa031667.
   HOT A, 2006, P 46 INT C ANT AG CH, P414.
   KUBOTA R, 1994, J NUCL MED, V35, P104.
   Lau WFE, 2005, MED J AUSTRALIA, V182, P172.
   Low SY, 2006, RESPIROLOGY, V11, P84, DOI 10.1111/j.1440-1843.2006.00789.x.
   Mahfouz T, 2005, J CLIN ONCOL, V23, P7857, DOI 10.1200/JCO.2004.00.8581.
   Miceli M, 2004, J CLIN ONCOL, V22, P1949, DOI 10.1200/JCO.2004.10.160.
   Pai M, 2005, AM J RESP CRIT CARE, V172, P519, DOI 10.1164/rccm.2506003.
   Piana F, 2006, EUR RESPIR J, V28, P31, DOI 10.1183/09031936.06.00110205.
   Yago Y, 2005, ANN NUCL MED, V19, P515, DOI 10.1007/BF02985581.
   {[}Anonymous], 2000, AM J RESP CRIT CARE, V161, pS221.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{36}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Tuberculosis}},
Doc-Delivery-Number = {{213PD}},
Unique-ID = {{ISI:000249678700009}},
}

@article{ ISI:000250733500003,
Author = {Minnett, Valerie and Poutanen, Mary-Anne},
Title = {{Swatting flies for health: Children and tuberculosis in early
   twentieth-century Montreal (Montreal Daily Star, Swat the fly)}},
Journal = {{URBAN HISTORY REVIEW-REVUE D HISTOIRE URBAINE}},
Year = {{2007}},
Volume = {{36}},
Number = {{1}},
Pages = {{32-44}},
Month = {{FAL}},
Abstract = {{Responding to an appeal by city physicians and health reformers to
   destroy a prodigious disease carrier, the housefly, the Montreal Daily
   Star launched an island-wide contest in july 1912, offering prizes to
   children who collected the most dead flies. Nearly a thousand children,
   largely from working-class families, participated in a three-week-long
   ``Swat the Fly{''} competition. Engaging Montreal children in this
   contest underscores a popular idea at the time that the best way to
   improve public health and combat the ignorance of a generation was to
   arm a new one with knowledge. While historians recognize that children's
   participation in campaigns to promote public health measures was pivotal
   to their success, youngsters are often rendered as passive recipients of
   reformers' efforts. We argue the contrary: children were active agents
   in public health crusades both as consumers and as advocates.}},
Publisher = {{URBAN HISTORY REVIEW/REVUE D HISTOIRE URBAINE}},
Address = {{BOX 507, STATION Q, TORONTO, ONTARIO M4T 2M5, CANADA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Minnett, V (Reprint Author), Carleton Univ, Ottawa, ON K1S 5B6, Canada.
   Carleton Univ, Ottawa, ON K1S 5B6, Canada.
   Concordia Univ, Montreal, PQ, Canada.
   McGill Univ, Montreal, PQ H3A 2T5, Canada.}},
ISSN = {{0703-0428}},
Research-Areas = {{History}},
Web-of-Science-Categories  = {{History}},
Cited-References = {{AMES HB, 1972, CITY BELOW HILL SOCI, P80.
   ATHERTON WH, 1914, BIOGRAPHICAL, V3.
   BIDEAU A, 1997, DEADLY DISCRIMINATIO, P216.
   COMMACHIO CR, 1993, NATIONS BUILT BABIES.
   COPP, ANATOMY POVERTY, P100.
   FREDERICK V, 2005, INSECT LIFE SHORT AC, P166.
   GAGEN E, 2001, HIST GEOGRAPHY, V29, P60.
   GLEASON M, 1960, J CAN STUD, P112.
   HEWITT CG, 1912, HOUSE FLES HOW THEY.
   LEWIS N, 1939, PHYS PERFECTION SPIR.
   LINTEAU P, 2000, HIST MONTREAL DEPUIS, P318.
   MCCUAIG, WEARINESS FEVER.
   MCCUAIG K, 1999, WEARINESS FEVER FRET, P16.
   McIntosh Robert G., 2000, BOYS PITS CHILD LABO, P10.
   OLSON SH, 1980, BUILDING AM CITY, P268.
   OPP J, 2002, J CANADIAN HIST ASS, V13, P83.
   Prout Alan, 1997, CONSTRUCTING RECONST, P8.
   ROGERS N, 1989, B HIST MED, V63, P599.
   ROOKE PT, 1982, CHILDREN ENGLISH CAN, P135.
   ROSNER D, 1995, HIVES SICKNESS PUBLI, P1.
   SHORTT SED, 1981, GROWING UP CHILDHOOD, P361.
   TARR JA, 1996, SEARCH ULTIMATE SINK, P323.
   TOMES N, 1997, MORALITY HLTH, P272.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Urban Hist. Rev.-Rev. Hist. Urbaine}},
Doc-Delivery-Number = {{228MH}},
Unique-ID = {{ISI:000250733500003}},
}

@article{ ISI:000249687900016,
Author = {Dinser, R. and Fousse, M. and Sester, U. and Albrecht, K. and Singh, M.
   and Koehler, H. and Mueller-Ladner, U. and Sester, M.},
Title = {{Screening of latent tuberculosis before TNF-alpha inhibition by means of
   a flow-cytometric Interferon-gamma-release assay}},
Journal = {{ZEITSCHRIFT FUR RHEUMATOLOGIE}},
Year = {{2007}},
Volume = {{66}},
Number = {{1}},
Pages = {{9}},
Month = {{SEP}},
Publisher = {{SPRINGER HEIDELBERG}},
Address = {{TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY}},
Type = {{Meeting Abstract}},
Language = {{German}},
Affiliation = {{Univ Giessen, Kerckhoff Klin, Giessen, Germany.
   Univ Klin Saarlandes, Homburg, Germany.
   Helmholtz Zentrum Infektionskranheiten, Braunschweig, Germany.}},
ISSN = {{0340-1855}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Z. Rheumatol.}},
Doc-Delivery-Number = {{213SR}},
Unique-ID = {{ISI:000249687900016}},
}

@article{ ISI:000249687900155,
Author = {Merwald, H. and Welcker, M. and Topka, H. and Piper, B. and Moertlbauer,
   H. and Vallbracht, I.},
Title = {{Intracerebral miliar tuberculosis in patients with sarcoidosis after
   TNF-alpha treatment}},
Journal = {{ZEITSCHRIFT FUR RHEUMATOLOGIE}},
Year = {{2007}},
Volume = {{66}},
Number = {{1}},
Pages = {{55}},
Month = {{SEP}},
Publisher = {{SPRINGER HEIDELBERG}},
Address = {{TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY}},
Type = {{Meeting Abstract}},
Language = {{German}},
Affiliation = {{KH Munchen Bogenhausen, Klin Neurol, Munich, Germany.
   KH Munchen Bogenhausen, Klin Rheumatol \& Klin Immunol, Munich, Germany.
   Rheumatol Praxis, Munich, Germany.}},
ISSN = {{0340-1855}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Z. Rheumatol.}},
Doc-Delivery-Number = {{213SR}},
Unique-ID = {{ISI:000249687900155}},
}

@article{ ISI:000250677800001,
Author = {Wahyuni, Chatarina U. and Budiono and Rahariyani, Lutfia Dwi and
   Sulistyowati, Muji and Rachmawati, Tety and Djuwari and Yuliwati, Sri
   and van der Werf, Marieke J.},
Title = {{Obstacles for optimal tuberculosis case detection in primary health
   centers (PHC) in Sidoarjo district, East Java, Indonesia}},
Journal = {{BMC HEALTH SERVICES RESEARCH}},
Year = {{2007}},
Volume = {{7}},
Month = {{AUG 30}},
Abstract = {{Background: Pulmonary tuberculosis (TB) is a major health problem
   worldwide. Detection of the most infectious cases of tuberculosis -
   sputum smear-positive pulmonary cases - by passive case finding is an
   essential component of TB control. The district of Sidoarjo in East Java
   reported a low case detection rate (CDR) of 14\% in 2003. We evaluated
   the diagnostic process for TB in primary health care centers (PHC) in
   Sidoarjo district to assess whether problems in identification of TB
   suspects or in diagnosing TB patients can explain the low CDR.
   Methods: We performed interviews with the staff (general nurse, TB
   worker, laboratory technician, and head of health center) of the 25 PHCs
   of Sidoarjo district to obtain information about the knowledge of TB,
   health education practices, and availability of support services for TB
   diagnosis. The quality of the laboratory diagnosis was examined by
   providing 10 slides with a known result to the laboratory technicians
   for re-examination.
   Results: Eighty percent of the nurses and 84\% of the TB workers knew
   that cough > 3 weeks can be a symptom of TB. Only 40\% of the nurses
   knew the cause of TB, few could mention complications of TB and none
   could mention the duration of infectiousness after start of treatment.
   Knowledge of TB workers was much better. Information about how to
   produce a good sputum sample was provided to TB suspects by 76\% of the
   nurses and 84\% of the TB workers. Only few provided all information.
   Fifty-five percent of the 11 laboratory technicians correctly identified
   all positive slides as positive and 45\% correctly identified 100\% of
   the negative slides as negative. All TB workers, one general nurses and
   32\% of the laboratory technicians had received specific training in TB
   control. There has been no shortage of TB forms and laboratory materials
   in 96\% of the PHCs.
   Conclusion: The quality of the diagnostic process for TB at PHC in
   Sidoarjo district should be improved on all levels. Training in TB
   control of all general nurses and the laboratory technicians that have
   not received training would be a good first step to enhance diagnosis of
   TB and to improve the case detection rate.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{van der Werf, MJ (Reprint Author), KNCV TB Fdn, The Hague, Netherlands.
   KNCV TB Fdn, The Hague, Netherlands.
   Univ Amsterdam, Acad Med Ctr, CINIMA, NL-1012 WX Amsterdam, Netherlands.
   Dist Hlth Off Sidoarjo, E Java, Indonesia.
   Dist Hlth Off Lamongan, E Java, Indonesia.
   Ctr Res \& Dev Hlth Syst \& Policy, Surabaya, Indonesia.
   Airlangga Univ, Sch Publ Hlth, Dept Hlth Promot \& Behav, Surabaya, Indonesia.
   Inst Hlth Polytech, Surabaya, Indonesia.
   Airlangga Univ, Fac Med, Surabaya, Indonesia.
   Airlangga Univ, Sch Publ Hlth, Dept Epidemiol, Surabaya, Indonesia.}},
DOI = {{10.1186/1472-6963-7-135}},
Article-Number = {{135}},
ISSN = {{1472-6963}},
Keywords-Plus = {{PREVALENCE; DIAGNOSIS}},
Research-Areas = {{Health Care Sciences \& Services}},
Web-of-Science-Categories  = {{Health Care Sciences \& Services}},
Author-Email = {{vanderwerfm@kncvtbc.nl}},
Cited-References = {{Alisjahbana B, 2005, INT J TUBERC LUNG D, V9, P814.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   FRIEDEN T, 2004, TUMANS TUBERCULOSIS.
   Fujiki A, 2002, INT J TUBERC LUNG D, V6, P39.
   Hashim D S, 2003, East Mediterr Health J, V9, P718.
   Hoa NP, 2005, HEALTH POLICY, V72, P1, DOI 10.1016/j.healthpol.2004.02.013.
   Mundy CJF, 2002, INT J TUBERC LUNG D, V6, P47.
   RATGONO A, 2005, PROGRAM PENANGULANGA.
   Singla N, 1998, INT J TUBERC LUNG D, V2, P1005.
   Soemantri S, 2007, INT J TUBERC LUNG D, V11, P398.
   World Health Organization, 1994, WHO TUB PROGR FRAM E.
   World Health Organization, 2006, WHOHTMTB2006362.}},
Number-of-Cited-References = {{12}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{BMC Health Serv. Res.}},
Doc-Delivery-Number = {{227SJ}},
Unique-ID = {{ISI:000250677800001}},
}

@article{ ISI:000207455400020,
Author = {Hotta, Katsuyuki and Ogura, Toshio and Nishii, Kenji and Kodani,
   Tsuyoshi and Onishi, Masaru and Shimizu, Yukito and Kanehiro, Arihiko
   and Kiura, Katsuyuki and Tanimoto, Mitsune and Tobe, Kazuo},
Title = {{Whole Blood Interferon-Gamma Assay for Baseline Tuberculosis Screening
   among Japanese Healthcare Students}},
Journal = {{PLOS ONE}},
Year = {{2007}},
Volume = {{2}},
Number = {{8}},
Month = {{AUG 29}},
Abstract = {{Background. The whole blood interferon-gamma assay (QuantiFERON-TB-2G;
   QFT) has not been fully evaluated as a baseline tuberculosis screening
   test in Japanese healthcare students commencing clinical contact. The
   aim of this study was to compare the results from the QFT with those
   from the tuberculin skin test (TST) in a population deemed to be at a
   low risk for infection with Mycobacterium tuberculosis.
   Methodology/Principal Findings. Healthcare students recruited at Okayama
   University received both the TST and the QFT to assess the level of
   agreement between these two tests. The interleukin-10 levels before and
   after exposure to M tuberculosis-specific antigens (early-secreted
   antigenic target 6-kDa protein {[}ESAT-6] and culture filtrate protein
   10 {[}CFP-10]) were also measured. Of the 536 healthcare students, most
   of whom had been vaccinated with bacillus-Calmette-Guerin (BCG), 207
   (56\%) were enrolled in this study. The agreement between the QFT and
   the TST results was poor, with positive result rates of 1.4\% vs.
   27.5\%, respectively. A multivariate analysis also revealed that the
   induration diameter of the TST was not affected by the interferon-gamma
   concentration after exposure to either of the antigens but was
   influenced by the number of BCG needle scars (p = 0.046). The whole
   blood interleukin-10 assay revealed that after antigen exposure, the
   median increases in interleukin-10 concentration was higher in the
   subgroup with the small increase in interferon-gamma concentration than
   in the subgroup with the large increase in interferon-gamma
   concentration (0.3 vs. 0 pg/mL; p = 0.004). Conclusions/Significance. As
   a baseline screening test for low-risk Japanese healthcare students at
   their course entry, QFT yielded quite discordant results, compared with
   the TST, probably because of the low specificity of the TST results in
   the BCG-vaccinated population. We also found, for the first time, that
   the change in the interleukin-10 level after exposure to specific
   antigens was inversely associated with that in the interferon-gamma
   level in a low-risk population.}},
Publisher = {{PUBLIC LIBRARY SCIENCE}},
Address = {{185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hotta, K (Reprint Author), Okayama Univ, Hlth \& Environm Ctr, Okayama, Japan.
   Hotta, Katsuyuki; Ogura, Toshio; Onishi, Masaru; Shimizu, Yukito; Tobe, Kazuo, Okayama Univ, Hlth \& Environm Ctr, Okayama, Japan.
   Nishii, Kenji; Kodani, Tsuyoshi, Okayama Inst Hlth \& Prevent, Dept Resp Med, Okayama, Japan.
   Kanehiro, Arihiko; Kiura, Katsuyuki; Tanimoto, Mitsune, Okayama Univ Hosp, Dept Resp Med, Okayama, Japan.}},
DOI = {{10.1371/journal.pone.0000803}},
Article-Number = {{e803}},
ISSN = {{1932-6203}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Author-Email = {{khotta@md.okayama-u.ac.jp}},
ResearcherID-Numbers = {{KANEHIRO, Arihiko/B-1926-2011}},
Funding-Acknowledgement = {{Ministry of Education, Culture, Sports, Science and Technology of Japan
   {[}18790397]}},
Funding-Text = {{This work was partly supported by a Grant-in-Aid for Young Scientists (
   B) ( No. 18790397) from the Ministry of Education, Culture, Sports,
   Science and Technology of Japan.}},
Cited-References = {{Aliberti J, 2005, PROSTAG LEUKOTR ESS, V73, P283, DOI 10.1016/j.plefa.2005.05.018.
   Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192.
   FIORENTINO DF, 1991, J IMMUNOL, V147, P3815.
   Graham M, 2006, MED J AUSTRALIA, V185, P324.
   Guyot-Revol V, 2006, AM J RESP CRIT CARE, V173, P803, DOI 10.1164/rccm.200508-1294OC.
   Harada N, 2006, INFECT CONT HOSP EP, V27, P442, DOI 10.1086/504358.
   Johnson PDR, 1999, CLIN DIAGN LAB IMMUN, V6, P934.
   Joshi R, 2006, PLOS MED, V3, P2376, DOI 10.1371/journal.pmed.0030494.
   Menzies D, 2007, INT J TUBERC LUNG D, V11, P593.
   Menzies D, 2007, ANN INTERN MED, V146, P340.
   Minion FC, 2003, INFECT IMMUN, V71, P2239, DOI 10.1128/IAI.71.4.2239-2243.2003.
   Mori T, 2000, EMERG INFECT DIS, V6, P566.
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC.
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.
   Pai M, 2007, LANCET INFECT DIS, V7, P428, DOI 10.1016/S1473-3099(07)70086-5.
   Pai M, 2007, PLOS MED, V4, P980, DOI 10.1371/journal.pmed.0040208.
   Pai M, 2006, AM J RESP CRIT CARE, V174, P349, DOI 10.1164/rccm.200604-472OC.
   Trajkovic V, 2002, INFECT IMMUN, V70, P6558, DOI 10.1128/IAI.70.12.6558-6566.2002.
   {*}WHO, WHO GLOB TB CONTR 20.
   YAMAUCHI Y, 1994, KEKKAKU, V74, P819.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{16}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{PLoS One}},
Doc-Delivery-Number = {{V10HP}},
Unique-ID = {{ISI:000207455400020}},
}

@article{ ISI:000207455400022,
Author = {Joshi, Rajnish and Patil, Samir and Kalantri, Shriprakash and
   Schwartzman, Kevin and Menzies, Dick and Pai, Madhukar},
Title = {{Prevalence of Abnormal Radiological Findings in Health Care Workers with
   Latent Tuberculosis Infection and Correlations with T Cell Immune
   Response}},
Journal = {{PLOS ONE}},
Year = {{2007}},
Volume = {{2}},
Number = {{8}},
Month = {{AUG 29}},
Abstract = {{Background. More than half of all health care workers (HCWs) in high
   TB-incidence, low and middle income countries are latently infected with
   tuberculosis (TB). We determined radiological lesions in a cohort of
   HCWs with latent TB infection (LTBI) in India, and determined their
   association with demographic, occupational and T-cell immune response
   variables. Methodology. We obtained chest radiographs of HCWs who had
   undergone tuberculin skin test (TST) and QuantiFERON-TB Gold In Tube
   (QFT), an interferon-gamma release assay, in a previous cross-sectional
   study, and were diagnosed to have LTBI because they were positive by
   either TST or QFT, but had no evidence of clinical disease. Two
   observers independently interpreted these radiographs using a
   standardized data form and any discordance between them resolved by a
   third observer. The radiological diagnostic categories (normal,
   suggestive of inactive TB, and suggestive of active TB) were compared
   with results of TST, QFT assay, demographic, and occupational
   covariates. Results. A total of 330 HCWs with positive TST or QFT
   underwent standard chest radiography. Of these 330, 113 radiographs
   (34.2\%) were finally classified as normal, 206 (62.4\%) had lesions
   suggestive of inactive TB, and 11 (3.4\%) had features suggestive of
   active TB. The mean TST indurations and interferon-gamma levels in the
   HCWs in these three categories were not significantly different. None of
   the demographic or occupational covariates was associated with
   prevalence of inactive TB lesions on chest radiography.
   Conclusion/Significance. In a high TB incidence setting, nearly
   two-thirds of HCWs with latent TB infection had abnormal radiographic
   findings, and these findings had no clear correlation with T cell immune
   responses. Further studies are needed to verify these findings and to
   identify the causes and prognosis of radiologic abnormalities in health
   care workers.}},
Publisher = {{PUBLIC LIBRARY SCIENCE}},
Address = {{185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Pai, M (Reprint Author), McGill Univ, Montreal Chest Inst, Resp Epidemiol \& Clin Res Unit, Montreal, PQ, Canada.
   Schwartzman, Kevin; Menzies, Dick; Pai, Madhukar, McGill Univ, Montreal Chest Inst, Resp Epidemiol \& Clin Res Unit, Montreal, PQ, Canada.
   Schwartzman, Kevin; Menzies, Dick; Pai, Madhukar, McGill Univ, Dept Epidemiol Biostat \& Occupat Hlth, Montreal, PQ, Canada.
   Patil, Samir, Parmanand D Hinduja Hosp, Bombay, Maharashtra, India.
   Patil, Samir, Med Res Ctr, Bombay, Maharashtra, India.
   Joshi, Rajnish; Kalantri, Shriprakash, Mahatma Gandhi Inst Med Sci, Dept Med, Sevagram, Maharashtra, India.
   Joshi, Rajnish, Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA.}},
DOI = {{10.1371/journal.pone.0000805}},
Article-Number = {{e805}},
ISSN = {{1932-6203}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Author-Email = {{madhukar.pai@mcgill.ca}},
ORCID-Numbers = {{Patil, Samir/0000-0003-3898-3594}},
Funding-Acknowledgement = {{Canadian Institutes of Health Research (CIHR) {[}MOP-81362]; Fogarty
   AIDS International Training Program {[}AITRP] {[}1-D43-TW00003-17];
   Fonds de la Recherche en Sante du Quebec (FRSQ); CIHR New Investigator
   Career Award}},
Funding-Text = {{This study was supported in part by a grant from the Canadian Institutes
   of Health Research (CIHR), grant MOP-81362. RJ is a recipient of a
   training fellowship from the Fogarty AIDS International Training Program
   {[}AITRP] (grant 1-D43-TW00003-17), USA. KS is the recipient of a
   Chercheur-Boursier Clinicien career award from the Fonds de la Recherche
   en Sante du Quebec (FRSQ). DM is the recipient of a Chercheur National
   career award from the FRSQ. MP is a recipient of a CIHR New Investigator
   Career Award. The CIHR, Fogarty AITRP and FRSQ had no role in the
   design, conduct or review of this manuscript.}},
Cited-References = {{Al Zahrani K, 2000, AM J RESP CRIT CARE, V162, P1419.
   Andreu J, 2004, EUR J RADIOL, V51, P139, DOI 10.1016/j.ejrad.2004.03.009.
   Balabanova Y, 2005, BRIT MED J, V331, P379, DOI 10.1136/bmj.331.7513.379.
   BLUM RN, 1993, CHEST, V103, P1670, DOI 10.1378/chest.103.6.1670.
   BOON SD, 2005, INT J TUBERC LUNG D, V9, P1088.
   COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131.
   DALEY CL, 2003, RADIOGRAPHIC MANIFES.
   DANNENBERG AM, 1982, AM REV RESPIR DIS, V125, P25.
   DeRiemer K, 1998, ARCH INTERN MED, V158, P753, DOI 10.1001/archinte.158.7.753.
   Geng E, 2005, JAMA-J AM MED ASSOC, V293, P2740, DOI 10.1001/jama.293.22.2740.
   GOTHI GD, 1982, INDIAN J TUBERC, V29, P134.
   Graham S, 2002, INT J TUBERC LUNG D, V6, P137.
   HAQUE AK, 1990, J THORAC IMAG, V5.
   Hopewell PC, 2006, LANCET INFECT DIS, V6, P710, DOI 10.1016/S1473-3099(06)70628-4.
   HORWITZ O, 1976, PUBLIC HEALTH REP, V91, P146.
   International Labour Office (ILO), 2002, OCC SAF HLTH SER, V22.
   Jenssen HK, 2005, INDIANA U MATH J, V54, P1, DOI 10.1512/iumj.2005.54.2685.
   Joshi R, 2006, PLOS MED, V3, P2376, DOI 10.1371/journal.pmed.0030494.
   LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92.
   LoBue PA, 2004, CHEST, V126, P1777, DOI 10.1378/chest.126.6.1777.
   Magkanas E, 2005, INT J TUBERC LUNG D, V9, P865.
   Maloney SA, 2006, ARCH INTERN MED, V166, P234, DOI 10.1001/archinte.166.2.234.
   Marais BJ, 2004, INT J TUBERC LUNG D, V8, P392.
   MCADAMS HP, 1995, RADIOL CLIN N AM, V33, P655.
   Menzies D, 2007, INT J TUBERC LUNG D, V11, P593.
   Mullan F, 2005, NEW ENGL J MED, V353, P1810, DOI 10.1056/NEJMsa050004.
   Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746.
   Pai M, 2007, INFECTION, V35, P98, DOI 10.1007/s15010-007-6114-z.
   Pai M, 2007, LANCET INFECT DIS, V7, P428, DOI 10.1016/S1473-3099(07)70086-5.
   Pai M, 2007, PLOS MED, V4, P980, DOI 10.1371/journal.pmed.0040208.
   Pai Madhukar, 2006, J Occup Med Toxicol, V1, P7, DOI 10.1186/1745-6673-1-7.
   Pai M, 2006, EMERG INFECT DIS, V12, P1311.
   Pai M, 2006, AM J RESP CRIT CARE, V174, P349, DOI 10.1164/rccm.200604-472OC.
   Pai M, 2006, EXPERT REV MOL DIAGN, V6, P413, DOI 10.1586/14737159.6.3.413.
   PANG SC, 2000, INT J TUBERC LUNG D, V4, P432.
   REICHMAN LB, 1974, HEALTH SERV REP, V89, P177, DOI 10.2307/4595006.
   Reider HL, 1999, EPIDEMIOLOGICAL BASI.
   Richards B, 2005, INT J TUBERC LUNG D, V9, P858.
   SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638.
   Schwartzman K, 2000, AM J RESP CRIT CARE, V161, P780.
   Seah GT, 2000, J INFECT DIS, V181, P385, DOI 10.1086/315200.
   Sodhi A, 1997, CLIN INFECT DIS, V25, P617, DOI 10.1086/513769.
   STEINBRUCK P, 1972, B INT UNION TUBERC, V47.
   Wilcke JTR, 1998, INT J TUBERC LUNG D, V2, P219.
   Zellweger JP, 2006, INT J TUBERC LUNG D, V10, P1123.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{23}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{PLoS One}},
Doc-Delivery-Number = {{V10HP}},
Unique-ID = {{ISI:000207455400022}},
}

@article{ ISI:000248886500008,
Author = {Yukl, Erik T. and Ioanoviciu, Alexandra and de Montellano, Paul R. Ortiz
   and Moenne-Loccoz, Pierre},
Title = {{Interdomain interactions within the two-component heme-based sensor DevS
   from Mycobacterium tuberculosis}},
Journal = {{BIOCHEMISTRY}},
Year = {{2007}},
Volume = {{46}},
Number = {{34}},
Pages = {{9728-9736}},
Month = {{AUG 28}},
Abstract = {{DevS is the sensor of the DevS-DevR two-component regulatory system of
   Mycobacterium tuberculosis. This system is thought to be responsible for
   initiating entrance of this bacterium into the nonreplicating persistent
   state in response to NO and anaerobiosis. DevS is modular in nature and
   consists of two N-terminal GAF domains and C-terminal histidine kinase
   and ATPase domains. The first GAF domain (GAF A) binds heme, and this
   cofactor is thought to be responsible for sensing environmental stimuli,
   but the function of the second GAF domain (GAF B) is unknown. Here we
   report the RR characterization of full-length DevS (FL DevS) as well as
   truncated proteins consisting of the single GAF A domain (GAF A DevS)
   and both GAF domains (GAF A/B) in both oxidation states and bound to the
   exogenous ligands CO, NO, and O(2). The results indicate that the GAF B
   domain increases the specificity with which the distal heme pocket of
   the GAF A domain interacts with CO and NO as opposed to O(2).
   Specifically, while two comparable populations of CO and NO adducts are
   observed in GAF A DevS, only one of these two conformers is present in
   significant concentration in the GAF A/B and FL DevS proteins. In
   contrast, hydrogen bond interactions at the bound oxygen in the oxy
   complexes are conserved in all DevS constructs. The comparison of the
   data obtained with the O(2) complexes with those of the CO and NO
   complexes suggests a model for ligand discrimination which relies on a
   specific hydrogen-bonding network with bound O(2). It also suggests that
   interactions between the two GAF domains are responsible for
   transduction of structural changes at the heme domain that accompany
   ligand binding/dissociation to modulate activity at the kinase domain.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Moenne-Loccoz, P (Reprint Author), Oregon Hlth \& Sci Univ, Dept Environm \& Biomol Syst, OGI Sch Sci \& Engn, 20000 NW Walker rd, Beaverton, OR 97006 USA.
   Oregon Hlth \& Sci Univ, Dept Environm \& Biomol Syst, OGI Sch Sci \& Engn, Beaverton, OR 97006 USA.
   Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA.}},
DOI = {{10.1021/bi7008695}},
ISSN = {{0006-2960}},
Keywords-Plus = {{RESONANCE RAMAN-SPECTROSCOPY; IRON COORDINATION STRUCTURES; NITRIC-OXIDE
   ADDUCTS; OXYGEN SENSOR; BACILLUS-SUBTILIS; LIGAND-BINDING;
   NONREPLICATING PERSISTENCE; ALPHA-CRYSTALLIN; HYPOXIC RESPONSE; PROTEIN
   HEMAT}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{ploccoz@ebs.ogi.edu}},
ORCID-Numbers = {{Yukl, Erik/0000-0001-6519-6938
   MOENNE-LOCCOZ, PIERRE/0000-0002-7684-7617}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI074824]; NIGMS NIH HHS {[}P01 GM56531, GM74785]}},
Cited-References = {{Anderton CL, 1997, BBA-PROTEIN STRUCT M, V1338, P107, DOI 10.1016/S0167-4838(96)00194-X.
   Aono S, 2002, J BIOL CHEM, V277, P13528, DOI 10.1074/jbc.M112256200.
   Choi HS, 2002, AM J RESP CRIT CARE, V166, P178, DOI 10.1164/rccm.2201023.
   Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223.
   Coyle CM, 2003, BIOCHEMISTRY-US, V42, P4896, DOI 10.1021/bi026395b.
   Cunningham AF, 1998, J BACTERIOL, V180, P801.
   Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d.
   Dasgupta N, 2000, TUBERCLE LUNG DIS, V80, P141, DOI 10.1054/tuld.2000.0240.
   Dick T, 2001, J ANTIMICROB CHEMOTH, V47, P117, DOI 10.1093/jac/47.1.117.
   HU SZ, 1991, J AM CHEM SOC, V113, P9760, DOI 10.1021/ja00026a008.
   Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e.
   Ioanoviciu A, 2007, BIOCHEMISTRY-US, V46, P4250, DOI 10.1021/bi602422p.
   Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242.
   LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021.
   LING JH, 1994, BBA-BIOENERGETICS, V1188, P417, DOI 10.1016/0005-2728(94)90063-9.
   LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230.
   Miyatake H, 1999, J BIOL CHEM, V274, P23176, DOI 10.1074/jbc.274.33.23176.
   Ohta T, 2004, J AM CHEM SOC, V126, P15000, DOI 10.1021/ja046896f.
   Park HJ, 2004, BIOCHEMISTRY-US, V43, P2738, DOI 10.1021/bi035980p.
   RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019.
   Roberts DM, 2004, J BIOL CHEM, V279, P23082, DOI 10.1074/jbc.M401230200.
   Sardiwal S, 2005, J MOL BIOL, V353, P929, DOI 10.1016/j.jmb.2005.09.011.
   Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498.
   Sousa EHS, 2007, PROTEIN SCI, V16, P1708, DOI 10.1110/ps.072897707.
   Spiro T. G., 1988, BIOL APPLICATIONS RA, VIII, P1.
   TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013.
   Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457.
   Tomita T, 1999, J PHYS CHEM B, V103, P7044, DOI 10.1021/jp991106n.
   Tomita T, 2002, BIOCHEMISTRY-US, V41, P4819, DOI 10.1021/bi0158831.
   TSUBAKI M, 1982, BIOCHEMISTRY-US, V21, P1132, DOI 10.1021/bi00535a004.
   Unno M, 2004, J BIOL CHEM, V279, P21055, DOI 10.1074/jbc.M400491200.
   VANWART HE, 1985, J BIOL CHEM, V260, P8372.
   Vogel KM, 1999, J AM CHEM SOC, V121, P9915, DOI 10.1021/ja990042r.
   Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205.
   Wayne LG, 1996, INFECT IMMUN, V64, P2062.
   Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139.
   {*}WHO, 2007, FACT SHEET TB.
   Yoshimura H, 2006, BIOCHEMISTRY-US, V45, P8301, DOI 10.1021/bi060315c.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{22}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Biochemistry}},
Doc-Delivery-Number = {{202FD}},
Unique-ID = {{ISI:000248886500008}},
}

@article{ ISI:000250534800001,
Author = {Lawn, Stephen D. and Bangani, Nonzwakazi and Vogt, Monica and Bekker,
   Linda-Gail and Badri, Motasim and Ntobongwana, Marjorie and Dockrell,
   Hazel M. and Wilkinson, Robert J. and Wood, Robin},
Title = {{Utility of interferon-gamma ELISPOT assay responses in highly
   tuberculosis-exposed patients with advanced HIV infection in South
   Africa}},
Journal = {{BMC INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{7}},
Month = {{AUG 28}},
Abstract = {{Background: Interferon-gamma (IFN-gamma)ELISPOT assays incorporating
   Mycobacterium tuberculosis-specific antigens are useful in the diagnosis
   of tuberculosis (TB) or latent infection. However, their utility in
   patients with advanced HIV is unknown. We studied determinants of
   ELISPOT responses among patients with advanced HIV infection (but
   without active TB) living in a South African community with very high TB
   notification rates.
   Methods: IFN-gamma responses to ESAT-6 and CFP-10 in overnight ELISPOT
   assays and in 7-day whole blood assays (WBA) were compared in
   HIV-infected patients (HIV+, n = 40) and healthy HIV-negative controls
   (HIV-, n = 30) without active TB. Tuberculin skin tests (TSTs) were also
   done.
   Results: ELISPOTs, WBAs and TSTs were each positive in > 70\% of HIV-
   controls, reflecting very high community exposure to M. tuberculosis.
   Among HIV+ patients, quantitative WBA responses and TSTs (but not the
   proportion of positive ELISPOT responses) were significantly impaired in
   those with CD4 cell counts < 100 cells/mu l compared to those with
   higher counts. In contrast, ELISPOT responses (but not WBA or TST) were
   strongly related to history of TB treatment; a much lower proportion of
   HIV+ patients who had recently completed treatment for TB (n = 19) had
   positive responses compared to those who had not been treated (11\%
   versus 62\%, respectively; P < 0.001). Multivariate analysis confirmed
   that ELISPOT responses had a strong inverse association with a history
   of recent TB treatment (adjusted OR = 0.06, 95\% CI = 0.10-0.40, P <
   0.01) and that they were independent of CD4 cell count and viral load.
   Among HIV+ individuals who had not received TB treatment both the
   magnitude and proportion of positive ELISPOT responses (but not TST or
   WBA) were similar to those of HIV-negative controls.
   Conclusion: The proportion of positive ELISPOT responses in patients
   with advanced HIV infection was independent of CD4 cell count but had a
   strong inverse association with history of TB treatment. This concurs
   with the previously documented low TB risk among patients in this cohort
   with a history of recent treatment for TB. These data suggest ELISPOT
   assays may be useful for patient assessment and as an
   immuno-epidemiological research tool among patients with advanced HIV
   and warrant larger scale prospective evaluation.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Lawn, SD (Reprint Author), Univ Cape Town, Fac Hlth Sci, Inst Infect Dis \& Mol Med, Desmond Tutu HIV Ctr, ZA-7700 Rondebosch, South Africa.
   Univ Cape Town, Fac Hlth Sci, Inst Infect Dis \& Mol Med, Desmond Tutu HIV Ctr, ZA-7700 Rondebosch, South Africa.
   London Sch Hyg \& Trop Med, Dept Infect \& Trop Dis, Climat Res Unit, London WC1, England.
   London Sch Hyg \& Trop Med, Dept Infect \& Trop Dis, Immunol Unit, London WC1, England.
   Univ Cape Town, Inst Infect Dis \& Mol Med, ZA-7700 Rondebosch, South Africa.
   Univ Cape Town, Dept Med, ZA-7700 Rondebosch, South Africa.
   Univ London Imperial Coll Sci Technol \& Med, Div Med, Wellcome Trust Res Clin Trop Med, London SW7 2AZ, England.}},
DOI = {{10.1186/1471-2334-7-99}},
Article-Number = {{99}},
ISSN = {{1471-2334}},
Keywords-Plus = {{CELL-BASED ASSAY; MYCOBACTERIUM-BOVIS BCG; T-CELLS; SKIN-TEST; TREATMENT
   SERVICE; RAPID DETECTION; IFN-GAMMA; INDIVIDUALS; COMMUNITY; PROGRAM}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{stevelawn@yahoo.co.uk
   nbangani@curie.uct.ac.za
   monica.vogt@hiv-research.org.za
   linda-gail.bekker@hiv-research.org.za
   motasim.badri@hiv-research.org.za
   marjorie.ntobongwana@hiv-research.org.za
   hazel.dockrell@lshtm.ac.uk
   r.j.wilkinson@imperial.ac.uk
   robin.wood@hiv-research.org.za}},
ResearcherID-Numbers = {{Wood, Robin/G-8509-2011}},
Funding-Acknowledgement = {{Medical Research Council {[}MC\_U117588499]; NIAID NIH HHS
   {[}1U19AI53217-01, R01 AI058736, U19 AI053217]; PHS HHS {[}R01
   A1058736-01A1]; Wellcome Trust {[}072070, 074641]}},
Cited-References = {{Aiken AM, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-66.
   Bekker LG, 2006, SAMJ S AFR MED J, V96, P315.
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195.
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8.
   Black GF, 2001, INT J TUBERC LUNG D, V5, P664.
   Carrara S, 2004, CLIN INFECT DIS, V38, P754, DOI 10.1086/381754.
   Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008.
   Elliott AM, 2004, T ROY SOC TROP MED H, V98, P660, DOI 10.1016/j.trstmh.2004.01.007.
   ELLIOTT J, 2007, 14 C RETR OPP INF FE.
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9.
   Goletti D, 2006, J INFECT DIS, V194, P984, DOI 10.1086/507427.
   Harboe M, 1996, INFECT IMMUN, V64, P16.
   Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030.
   {*}HLTH SYST TRUST, 2004, CONTR CTTB PROGR REP.
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778.
   Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824.
   Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1.
   Lawn SD, 2006, CLIN INFECT DIS, V42, P1040, DOI 10.1086/501018.
   Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1.
   Lawn SD, 2006, CLIN INFECT DIS, V43, P770, DOI 10.1086/507095.
   Lawn SD, 2006, AIDS, V20, P1605, DOI 10.1097/01.aids.0000238406.93249.cd.
   Liebeschuetz S, 2004, LANCET, V364, P2196, DOI 10.1016/S0140-6736(04)17592-2.
   Luetkemeyer AF, 2007, AM J RESP CRIT CARE, V175, P737, DOI 10.1164/rccm.200608-1088OC.
   MILLER SB, 1992, VIROLOGY, V191, P973, DOI 10.1016/0042-6822(92)90275-T.
   Nunn P, 2005, NAT REV IMMUNOL, V5, P819, DOI 10.1038/nri1704.
   OYAIZU N, 1990, P NATL ACAD SCI USA, V87, P2379, DOI 10.1073/pnas.87.6.2379.
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.
   Pathan AA, 2001, J IMMUNOL, V167, P5217.
   Rangaka MX, 2007, CLIN INFECT DIS, V44, P1639, DOI 10.1086/518234.
   Rangaka MX, 2007, AM J RESP CRIT CARE, V175, P514, DOI 10.1164/rccm.200610-1439OC.
   SORENSEN AL, 1995, INFECT IMMUN, V63, P1710.
   Vordermeier HM, 2002, INFECT IMMUN, V70, P3026, DOI 10.1128/IAI.70.6.3026-3032.2002.
   {*}WHO, 2005, WHO DECL TB EM AFR C.
   Wilkinson KA, 2005, CLIN INFECT DIS, V40, P184, DOI 10.1086/426139.
   Wood R, 2007, AM J RESP CRIT CARE, V175, P87, DOI 10.1164/rccm.200606-759OC.
   Wu-Hsieh BA, 2001, CLIN INFECT DIS, V33, P1336, DOI 10.1086/323044.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{48}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{BMC Infect. Dis.}},
Doc-Delivery-Number = {{225RK}},
Unique-ID = {{ISI:000250534800001}},
}

@article{ ISI:000250502200001,
Author = {Jackson, Marguerite and Harrity, Shawn and Hoffman, Helene and
   Catanzaro, Antonino},
Title = {{A survey of health professions students for knowledge, attitudes, and
   confidence about tuberculosis, 2005}},
Journal = {{BMC PUBLIC HEALTH}},
Year = {{2007}},
Volume = {{7}},
Month = {{AUG 28}},
Abstract = {{Background: In 2003 the NIH perceived a need to strengthen teaching
   about tuberculosis ( TB) to health professions students. The National
   Tuberculosis Curriculum Consortium ( NTCC) was funded to meet this need.
   The purpose of this study was to survey students enrolled in NTCC
   schools prior to NTCC-developed educational materials being made
   available to faculty.
   Methods: A self-administered survey for students in NTCC schools to
   establish a baseline level of knowledge, attitudes, and confidence about
   tuberculosis.
   Results: 1480/ 2965 ( 50\%) students in 28 programs in 20 NTCC schools
   completed the survey. If public health students are eliminated from
   totals ( only 61 respondents of 765 public health students), the overall
   response proportion for the seven clinically-related disciplines was
   64.5\%. The majority (74\%) were in schools of medicine ( MD/DO),
   undergraduate nursing (BSN), and pharmacy (PharmD); others were in
   programs for physician assistants (PA), advanced practice nursing
   (NP/APN), respiratory therapy (RT), clinical laboratory sciences
   (MT/CLS), and public health (MPH). Almost 90\% had attended at least one
   lecture about TB. Although 91.4\% knew TB was transmitted via aerosols,
   about one-third did not know the method for administering tuberculin, or
   that Bacillus Calmette-Guerin ( BCG) vaccine was not a contraindication
   to TB skin testing. Fewer than two-thirds knew that about 10\% of people
   in the U. S. A. who have latent tuberculosis infection (LTBI) and a
   normal immune system will develop TB disease, or that BCG is not part of
   the routine vaccination program in the U. S. A. because it complicates
   surveillance for new TB infection.
   Conclusion: There is room for improvement in knowledge, attitudes, and
   confidence about TB by health professions students surveyed. The
   NTCC-developed educational products may be used by faculty to improve
   student performance to be assessed with future surveys.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Jackson, M (Reprint Author), Univ Calif San Diego, Sch Med, NTCC, San Diego, CA 92103 USA.
   Univ Calif San Diego, Sch Med, NTCC, San Diego, CA 92103 USA.}},
DOI = {{10.1186/1471-2458-7-219}},
Article-Number = {{219}},
ISSN = {{1471-2458}},
Keywords-Plus = {{NEW-YORK-CITY; NONPHYSICIAN CLINICIAN; MEDICAL-STUDENTS; UNITED-STATES;
   CARE WORKERS; PREVENTION; INFECTION; ERRORS; MODEL}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{majackson@ucsd.edu
   sharrity@ucsd.edu
   hhoffman@ucsd.edu
   acatanzaro@ucsd.edu}},
Funding-Acknowledgement = {{NHLBI NIH HHS {[}N01-HR-36157 2003-08, N01HR36157]}},
Cited-References = {{Bai Li-qiong, 2003, Zhonghua Jiehe He Huxi Zazhi, V26, P458.
   {*}CDCP, 2000, 996206 CDCP DIV TUB.
   Centers for Disease Control Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P305.
   {*}CDCP, 2000, 005763 DIV TUB EL.
   Cook S, 2003, INFECT CONT HOSP EP, V24, P807, DOI 10.1086/502141.
   Cooper RA, 1998, JAMA-J AM MED ASSOC, V280, P795, DOI 10.1001/jama.280.9.795.
   Cooper Richard, 2004, J Health Serv Res Policy, V9 Suppl 1, P39, DOI 10.1258/135581904322724121.
   Druss BG, 2003, NEW ENGL J MED, V348, P130, DOI 10.1056/NEJMsa020993.
   Durbin CG, 2006, CRIT CARE MED, V34, pS12, DOI 10.1097/01.CCM.0000199985.72497.D1.
   Emili J, 2001, MED EDUC, V35, P530, DOI 10.1046/j.1365-2923.2001.00918.x.
   FAIR BS, 2006, INT J NURS ED SCHOLA.
   Harrity S, 2007, INT J TUBERC LUNG D, V11, P270.
   Jensen PA, 2005, INT J TUBERC LUNG D, V9, P825.
   KEHRLI S, 2006, HR MAG, V51, P113.
   Kilicaslan Z, 2003, INT J TUBERC LUNG D, V7, P159.
   Kurane Shuji, 2003, Kekkaku, V78, P573.
   Louther J, 1997, AM J RESP CRIT CARE, V156, P201.
   Manangan LP, 2000, CHEST, V117, P620, DOI 10.1378/chest.117.3.620.
   McCray E, 1997, CLIN CHEST MED, V18, P99, DOI 10.1016/S0272-5231(05)70359-2.
   NELSON ME, 1995, AM J PREV MED, V11, P48.
   Niveau G, 2006, PUBLIC HEALTH, V120, P33, DOI 10.1016/j.puhe.2005.03.017.
   Prensky M., 2001, DIGITAL NATIVES DIGI, V9, P5.
   Rao SN, 2000, CHEST, V117, P734, DOI 10.1378/chest.117.3.734.
   Teixeira EG, 2005, INT J TUBERC LUNG D, V9, P841.
   {*}WHO, 1998, WHO WORKSH ROM IT 29.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{11}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{BMC Public Health}},
Doc-Delivery-Number = {{225FJ}},
Unique-ID = {{ISI:000250502200001}},
}

@article{ ISI:000251136700001,
Author = {Brown, Alistair K. and Meng, Guoyu and Ghadbane, Hemza and Scott, David
   J. and Dover, Lynn G. and Nigou, Jerome and Besra, Gurdyal S. and
   Futterer, Klaus},
Title = {{Dimerization of inositol monophosphatase Mycobacterium tuberculosis SuhB
   is not constitutive, but induced by binding of the activator Mg2+}},
Journal = {{BMC STRUCTURAL BIOLOGY}},
Year = {{2007}},
Volume = {{7}},
Month = {{AUG 28}},
Abstract = {{Background: The cell wall of Mycobacterium tuberculosis contains a wide
   range of phosphatidyl inositol-based glycolipids that play critical
   structural roles and, in part, govern pathogen-host interactions.
   Synthesis of phosphatidyl inositol is dependent on free myo-inositol,
   generated through dephosphorylation of myo-inositol-I-phosphate by
   inositol monophosphatase (IMPase). Human IMPase, the putative target of
   lithium therapy, has been studied extensively, but the function of four
   IMPase-like genes in M. tuberculosis is unclear.
   Results: We determined the crystal structure, to 2.6 angstrom
   resolution, of the IMPase M. tuberculosis SuhB in the apo form, and
   analysed self-assembly by analytical ultracentrifugation. Contrary to
   the paradigm of constitutive dimerization of IMPases, SuhB is
   predominantly monomeric in the absence of the physiological activator
   Mg2+, in spite of a conserved fold and apparent dimerization in the
   crystal. However, Mg2+ concentrations that result in enzymatic
   activation of SuhB decisively promote dimerization, with the inhibitor
   Li+ amplifying the effect of Mg2+, but failing to induce dimerization on
   its own.
   Conclusion: The correlation of Mg2+-driven enzymatic activity with
   dimerization suggests that catalytic activity is linked to the dimer
   form. Current models of lithium inhibition of IMPases posit that Li+
   competes for one of three catalytic Mg2+ sites in the active site,
   stabilized by a mobile loop at the dimer interface. Our data suggest
   that Mg2+/Li+-induced ordering of this loop may promote dimerization by
   expanding the dimer interface of SuhB. The dynamic nature of the
   monomer-dimer equilibrium may also explain the extended concentration
   range over which Mg2+ maintains SuhB activity.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Besra, GS (Reprint Author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.
   Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.
   Univ Nottingham, Sch Biosci, Natl Ctr Macromol Hydrodynamics, Sutton LE12 5RD, Surrey, England.
   Inst Pharmacol Biol Struct, Ctr Natl Res Sci Unit Mix Res, Dept Mol Mechanism Mycobac Infect, F-5089 Toulouse, France.
   Univ London Birkbeck Coll, Sch Crystall, London WC1E 7HX, England.}},
DOI = {{10.1186/1472-6807-7-55}},
Article-Number = {{55}},
ISSN = {{1471-2237}},
Keywords-Plus = {{MYOINOSITOL MONOPHOSPHATASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI;
   THERMOTOGA-MARITIMA; LITHIUM-THERAPY; GENE-PRODUCT; BOVINE BRAIN;
   ENZYME; PROTEIN; FRUCTOSE-1,6-BISPHOSPHATASE}},
Research-Areas = {{Biophysics}},
Web-of-Science-Categories  = {{Biophysics}},
Author-Email = {{a.k.brown.1@bham.ac.uk
   ubcg54l@mail.cryst.bbk.ac.uk
   HXG597@bham.ac.uk
   dj.scott@nottingham.ac.uk
   L.G.Dover@bham.ac.uk
   jerome.nigou@ipbs.fr
   G.Besra@bham.ac.uk
   K.Futterer@bham.ac.uk}},
ResearcherID-Numbers = {{Dover, Lynn/F-3021-2010
   }},
ORCID-Numbers = {{Dover, Lynn/0000-0002-4776-2665
   Besra, Gurdyal/0000-0002-5605-0395
   Scott, David/0000-0002-6726-2078}},
Funding-Acknowledgement = {{Medical Research Council {[}G0500590]}},
Cited-References = {{Albert A, 2000, J MOL BIOL, V295, P927, DOI 10.1006/jmbi.1999.3408.
   ALLISON JH, 1971, NATURE-NEW BIOL, V233, P267.
   Arai R, 2007, PROTEINS, V67, P732, DOI 10.1002/prot.21299.
   BONE R, 1994, BIOCHEMISTRY-US, V33, P9460, DOI 10.1021/bi00198a011.
   BONE R, 1994, BIOCHEMISTRY-US, V33, P9468, DOI 10.1021/bi00198a012.
   BONE R, 2005, P NATL ACAD SCI USA, V61, P545.
   BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333.
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254.
   CCP4 (Collaborative Computational Project Number 4), 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112.
   Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113.
   CHEN IW, 1966, J BIOL CHEM, V241, P2194.
   Chen LJ, 2000, BIOCHEMISTRY-US, V39, P4145, DOI 10.1021/bi992424f.
   Chen LJ, 1999, APPL ENVIRON MICROB, V65, P4559.
   Chen LJ, 1998, APPL ENVIRON MICROB, V64, P2609.
   Cole ST, 1998, NATURE, V393, P537.
   Ganzhorn AJ, 1996, BIOCHEMISTRY-US, V35, P10957, DOI 10.1021/bi9603837.
   GANZHORN AJ, 1990, BIOCHEMISTRY-US, V29, P6065, DOI 10.1021/bi00477a026.
   Gill R, 2005, ACTA CRYSTALLOGR D, V61, P545, DOI 10.1107/S0907444905004038.
   Gille C, 2001, BIOINFORMATICS, V17, P377, DOI 10.1093/bioinformatics/17.4.377.
   Gu XL, 2006, BIOCHEM BIOPH RES CO, V339, P897, DOI 10.1016/j.bbrc.2005.11.088.
   HALLCHER LM, 1980, J BIOL CHEM, V255, P896.
   Hines JK, 2006, J BIOL CHEM, V281, P18386, DOI 10.1074/jbc.M602553200.
   HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044.
   Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200.
   Johnson KA, 2001, BIOCHEMISTRY-US, V40, P618, DOI 10.1021/bi0016422.
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224.
   KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243.
   Krissinel E, 2007, J MOL BIOL.
   KWON OS, 1993, J BIOL CHEM, V268, P7912.
   Miller DJ, 2007, MINI-REV MED CHEM, V7, P107, DOI 10.2174/138955707779802624.
   Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399.
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255.
   NIGOU A, 2002, BIOCHEM J, V361, P385.
   Nigou J, 2002, BIOCHEMISTRY-US, V41, P4392, DOI 10.1021/bi0160056.
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X.
   Patel S, 2002, J MOL BIOL, V315, P677, DOI 10.1006/jmbi.2001.5271.
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x.
   Saudek V, 1996, EUR J BIOCHEM, V240, P288.
   Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6.
   Schuck P, 2000, BIOPHYS J, V78, P1606.
   Schwede T, 2000, RES MICROBIOL, V151, P107, DOI 10.1016/S0923-2508(00)00121-2.
   Stec B, 2000, NAT STRUCT BIOL, V7, P1046, DOI 10.1038/80968.
   Stieglitz KA, 2002, J BIOL CHEM, V277, P22863, DOI 10.1074/jbc.M201042200.
   Stieglitz KA, 2007, FEBS J, V274, P2461, DOI 10.1111/j.1742-4658.2007.05779.x.
   STRASSER F, 1995, BIOCHEM J, V307, P585.
   Strohmeier GR, 1999, MICROBES INFECT, V1, P709, DOI 10.1016/S1286-4579(99)80072-0.
   Vercellone A, 1998, FRONT BIOSCI-LANDMRK, V3, pE149.
   YORK JD, 1995, P NATL ACAD SCI USA, V92, P5149, DOI 10.1073/pnas.92.11.5149.
   ZHANG YP, 1993, BIOCHEM BIOPH RES CO, V190, P1080, DOI 10.1006/bbrc.1993.1159.}},
Number-of-Cited-References = {{49}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{BMC Struct. Biol.}},
Doc-Delivery-Number = {{234BW}},
Unique-ID = {{ISI:000251136700001}},
}

@article{ ISI:000248933000037,
Author = {Dunford, Adrian J. and McLean, Kirsty J. and Sabri, Muna and Seward,
   Harriet E. and Heyes, Derren J. and Scrutton, Nigel S. and Munro, Andrew
   W.},
Title = {{Rapid P450 heme iron reduction by laser photoexcitation of Mycobacterium
   tuberculosis CYP121 and CYP51B1 - Analysis of CO complexation reactions
   and reversibility of the P450/P420 equilibrium}},
Journal = {{JOURNAL OF BIOLOGICAL CHEMISTRY}},
Year = {{2007}},
Volume = {{282}},
Number = {{34}},
Pages = {{24816-24824}},
Month = {{AUG 24}},
Abstract = {{We demonstrate that photoexcitation of NAD(P) H reduces heme iron of
   Mycobacterium tuberculosis P450s CYP121 and CYP51B1 on the microsecond
   time scale. Rates of formation for the ferrous-carbonmonoxy (Fe-II-CO)
   complex were determined across a range of coenzyme/CO concentrations.
   CYP121 reaction transients were biphasic. A hyperbolic dependence on CO
   concentration was observed, consistent with the presence of a CO binding
   site in ferric CYP121. CYP51B1 absorption transients for Fe-II-CO
   complex formation were monophasic. The reaction rate was second order
   with respect to {[}CO], suggesting the absence of a CO-binding site in
   ferric CYP51B1. In the absence of CO, heme iron reduction by
   photoexcited NAD(P)H is fast (similar to 10,000-11,000 s(-1)) with both
   P450s. For CYP121, transients revealed initial production of the
   thiolate-coordinated (P450) complex (absorbance maximum at 448 nm),
   followed by a slower phase reporting partial conversion to the
   thiol-coordinated P420 species (at 420 nm). The slow phase amplitude
   increased at lower pH values, consistent with heme cysteinate
   protonation underlying the transition. Thus, CO binding occurs to the
   thiolate-coordinated ferrous form prior to cysteinate protonation. For
   CYP51B1, slow conversions of both the ferrous/Fe-II-CO forms to species
   with spectral maxima at 423/421.5 nm occurred following photoexcitation
   in the absence/presence of CO. This reflected conversion from ferrous
   thiolate-to thiol-coordinated forms in both cases, indicating
   instability of the thiolate-coordinated ferrous CYP51B1. CYP121 Fe-II-CO
   complex pH titrations revealed reversible spectral transitions between
   P450 and P420 forms. Our data provide strong evidence for P420 formation
   linked to reversible heme thiolate protonation, and demonstrate key
   differences in heme chemistry and CO binding for CYP121 and CYP51B1.}},
Publisher = {{AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Munro, AW (Reprint Author), Univ Manchester, Fac Life Sci, Manchester Interdisciplinary Biocentre, 131 Princess St, Manchester M1 7DN, Lancs, England.
   Univ Manchester, Fac Life Sci, Manchester Interdisciplinary Biocentre, Manchester M1 7DN, Lancs, England.
   Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England.}},
DOI = {{10.1074/jbc.M702958200}},
ISSN = {{0021-9258}},
Keywords-Plus = {{FLAVOCYTOCHROME P-450 BM3; STEROL 14-ALPHA-DEMETHYLASE; SPECTROSCOPIC
   CHARACTERIZATION; AZOLE ANTIFUNGALS; CRYSTAL-STRUCTURE; CYTOCHROME-P450;
   BINDING; PURIFICATION; INHIBITORS; REVEALS}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{Andrew.Munro@manchester.ac.uk}},
Funding-Acknowledgement = {{Biotechnology and Biological Sciences Research Council {[}C19757/2]}},
Cited-References = {{Ahmad Z, 2006, FEMS MICROBIOL LETT, V261, P181, DOI 10.1111/j.1574-6968.2006.00350.x.
   Aoyama Y, 1998, J BIOCHEM-TOKYO, V124, P694.
   Bellamine A, 1999, P NATL ACAD SCI USA, V96, P8937, DOI 10.1073/pnas.96.16.8937.
   Cargill R., 1990, CARBON MONOXIDE, V43, P5.
   Cole ST, 1998, NATURE, V393, P537.
   CZOCHRALSKA B, 1983, CHEM PHYS LETT, V101, P297, DOI 10.1016/0009-2614(83)87016-X.
   Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s.
   Estabrook RW, 2003, DRUG METAB DISPOS, V31, P1461, DOI 10.1124/dmd.31.12.1461.
   GIRVAN HM, 2007, J AM CHEM SOC, V129, P6447.
   Guardiola-Diaz HM, 2001, BIOCHEM PHARMACOL, V61, P1463, DOI 10.1016/S0006-2952(01)00571-8.
   Jackson CJ, 2000, FEMS MICROBIOL LETT, V192, P159, DOI 10.1016/S0378-1097(00)00425-0.
   Lepesheva GI, 2004, MOL CELL ENDOCRINOL, V215, P165, DOI 10.1016/j.mce.2003.11.016.
   Leys D, 2003, J BIOL CHEM, V278, P5141, DOI 10.1074/jbc.M209928200.
   Matsuura K, 2005, J BIOL CHEM, V280, P9088, DOI 10.1074/jbc.M413042200.
   McLean KJ, 2002, MICROBIOL-SGM, V148, P2937.
   McLean KJ, 2006, BIOCHEMISTRY-US, V45, P8427, DOI 10.1021/bi0601609.
   McLean KJ, 2002, J INORG BIOCHEM, V91, P527, DOI 10.1016/S0162-0134(02)00479-8.
   MILES JS, 1992, BIOCHEM J, V288, P503.
   Munro AW, 1996, BBA-PROTEIN STRUCT M, V1296, P127, DOI 10.1016/0167-4838(96)00061-1.
   Ogura H, 2004, BIOCHEMISTRY-US, V43, P14712, DOI 10.1021/bi048980d.
   OMURA T, 1964, J BIOL CHEM, V239, P2370.
   ORII Y, 1993, BIOCHEMISTRY-US, V32, P11910, DOI 10.1021/bi00095a021.
   Perera R, 2003, P NATL ACAD SCI USA, V100, P3641, DOI 10.1073/pnas.0737142100.
   Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898.
   Podust LM, 2004, STRUCTURE, V12, P1937, DOI 10.1016/j.str.2004.08.009.
   Seward HE, 2006, J BIOL CHEM, V281, P39437, DOI 10.1074/jbc.M607665200.
   SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078.
   Waterman MR, 2005, BIOCHEM BIOPH RES CO, V338, P418, DOI 10.1016/j.bbrc.2005.08.118.
   {*}WHO, 2007, 104 WHO.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{24}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{J. Biol. Chem.}},
Doc-Delivery-Number = {{202VU}},
Unique-ID = {{ISI:000248933000037}},
}

@article{ ISI:000248809000018,
Author = {Li, Zexuan and Huang, Yishu and Ge, Jing and Fan, Hang and Zhou,
   Xiaohong and Li, Shentao and Bartlam, Mark and Wang, Honghai and Rao,
   Zihe},
Title = {{The crystal structure of MCAT from Mycobacterium tuberculosis reveals
   three new catalytic models}},
Journal = {{JOURNAL OF MOLECULAR BIOLOGY}},
Year = {{2007}},
Volume = {{371}},
Number = {{4}},
Pages = {{1075-1083}},
Month = {{AUG 24}},
Abstract = {{The malonyl coenzyme A (CoA)-acyl carrier protein (ACP) transacylase
   (MCAT) plays a key role in cell wall biosynthesis in Mycobacteriurn
   tuberculosis and other bacteria. The M. tuberculosis MCAT (MtMCAT) is
   encoded by the FabD gene and catalyzes the transacylation of malonate
   from 2 malonyl-CoA to holo-ACP. Malonyl-ACP is the substrate in fatty
   acid biosynthesis and is a by-product of the transacylation reaction.
   This ability for fatty acid biosynthesis enables M. tuberculosis to
   survive in hostile environments, and thus understanding the mechanism of
   biosynthesis is important for the design of new anti-tuberculosis drugs.
   The 2.3 angstrom crystal structure of MtMCAT reported here shows that
   its catalytic mechanism differs from those of ScMCAT and EcMCAT, whose
   structures have previously been determined. In MtMCAT, the
   C-beta-O-gamma bond of Ser91 turns upwards, resulting in a different
   orientation and thus an overall change of the active pocket compared to
   other known MCAT enzymes. We identify three new nucleophilic attack
   chains from the MtMCAT structure: His90- Ser91, Asn155-Wat6-Ser91 and
   Asn155-His90-Ser91. Enzyme activity assays show that His90A, Asn155A and
   His90A-Asn155A mutants all have substantially reduced MCAT activity,
   indicating that M. tuberculosis MCAT supports a unique means of proton
   transfer. Furthermore, His194 can-not form part of a His-Ser catalytic
   dyad and only stabilizes the substrate. This new discovery should
   provide a deeper insight into the catalytic mechanisms of MCATs. (c)
   2007 Elsevier Ltd. All rights reserved.}},
Publisher = {{ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD}},
Address = {{24-28 OVAL RD, LONDON NW1 7DX, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Wang, HH (Reprint Author), Tsing Hua Univ, Tsinghua Nankai IBP Res Grp Struct Biol, Beijing 100084, Peoples R China.
   Tsing Hua Univ, Tsinghua Nankai IBP Res Grp Struct Biol, Beijing 100084, Peoples R China.
   Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.
   Fudan Univ, Sch Life Sci, Inst Genet, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
   Fudan Univ, Sch Life Sci, Sch Microbiol \& Microbial Engn, Shanghai 200433, Peoples R China.
   Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China.
   Capital Med Univ, Beijing 100069, Peoples R China.}},
DOI = {{10.1016/j.jmb.2007.06.004}},
ISSN = {{0022-2836}},
Keywords = {{malonyl-CoA : ACP transacylase; crystal structure; nucleophilic attack;
   fatty acids biosynthesis; Mycobacterium tuberculosis}},
Keywords-Plus = {{ACYL CARRIER PROTEIN; FATTY-ACID SYNTHASE; COA-ACPM TRANSACYLASE;
   MALONYL-COA; STREPTOMYCES-COELICOLOR; SIGNAL PEPTIDASE; ACTIVE-SITE;
   BIOSYNTHESIS; INHIBITOR; TARGET}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{hhwang@fudan.edu.cn
   raozh@xtal.tsinghua.edu.cn}},
ResearcherID-Numbers = {{li, zexuan/F-4186-2012
   }},
ORCID-Numbers = {{Bartlam, Mark/0000-0001-5173-5080
   zhou, xiaohong/0000-0003-0519-2550}},
Cited-References = {{Arthur CJ, 2005, BIOCHEMISTRY-US, V44, P15414, DOI 10.1021/bi051499i.
   BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673.
   BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333.
   BUNGER AT, 1998, ACTA CRYSTALLOGR D, V54, P905.
   Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305.
   Cole ST, 1998, NATURE, V393, P537.
   DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450.
   Dreier J, 2001, BIOCHEMISTRY-US, V40, P12407, DOI 10.1021/bi011108+.
   Fersht A., 1999, STRUCTURE MECHANISM.
   Huang YS, 2006, PROTEIN EXPRES PURIF, V45, P393, DOI 10.1016/j.pep.2005.07.003.
   JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430.
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224.
   Keatinge-Clay AT, 2003, STRUCTURE, V11, P147, DOI 10.1016/S0969-2126(03)00004-2.
   Kim Y, 2002, J BIOL CHEM, V277, P2823, DOI 10.1074/jbc.M108888200.
   Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200.
   Kremer L, 2001, J BIOL CHEM, V276, P27967, DOI 10.1074/jbc.M103687200.
   Liu WZ, 2006, FEBS LETT, V580, P697, DOI 10.1016/j.febslet.2005.12.085.
   Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95.
   Molnos J, 2003, ANAL BIOCHEM, V319, P171, DOI 10.1016/S0003-2697(03)00327-0.
   Oefner C, 2006, ACTA CRYSTALLOGR D, V62, P613, DOI 10.1107/S090744490609474.
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X.
   Paetzel M, 1998, NATURE, V396, P186.
   QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004.
   SERRE L, 1995, J BIOL CHEM, V270, P12961.
   Slayden RA, 2000, MOL MICROBIOL, V38, P514, DOI 10.1046/j.1365-2958.2000.02145.x.
   Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813.
   SUMMERS RG, 1995, BIOCHEMISTRY-US, V34, P9389, DOI 10.1021/bi00029a015.
   Tjalsma H, 2000, J BIOL CHEM, V275, P25102, DOI 10.1074/jbc.M002676200.
   Wang YC, 2006, NATURE, V444, P179, DOI 10.1038/nature05255.
   WEI YY, 1995, NAT STRUCT BIOL, V2, P218, DOI 10.1038/nsb0395-218.
   White SW, 2005, ANNU REV BIOCHEM, V74, P791, DOI 10.1146/annurev.biochem.74.082803.133524.
   Zhang Y, 2002, CURR DRUG TARGETS, V3, P131, DOI 10.2174/1389450024605391.
   ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{J. Mol. Biol.}},
Doc-Delivery-Number = {{201CL}},
Unique-ID = {{ISI:000248809000018}},
}

@article{ ISI:000248990700017,
Author = {Colijn, Caroline and Cohen, Ted and Murray, Megan},
Title = {{Emergent heterogeneity in declining tuberculosis epidemics}},
Journal = {{JOURNAL OF THEORETICAL BIOLOGY}},
Year = {{2007}},
Volume = {{247}},
Number = {{4}},
Pages = {{765-774}},
Month = {{AUG 21}},
Abstract = {{Tuberculosis is a disease of global importance: over 2 million deaths
   are attributed to this infectious disease each year. Even in areas where
   tuberculosis is in decline, there are sporadic outbreaks which are often
   attributed either to increased host susceptibility or increased strain
   transmissibility and virulence. Using two mathematical models, we
   explore the role of the contact structure of the population, and find
   that in declining epidemics, localized outbreaks may occur as a result
   of contact heterogeneity even in the absence of host or strain
   variability. We discuss the implications of this finding for
   tuberculosis control in low incidence settings. (c) 2007 Published by
   Elsevier Ltd.}},
Publisher = {{ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD}},
Address = {{24-28 OVAL RD, LONDON NW1 7DX, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Colijn, C (Reprint Author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA.
   Brigham \& Womens Hosp, Dept Social Med \& Hlth Inequal, Boston, MA 02115 USA.
   Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA.}},
DOI = {{10.1016/j.jtbi.2007.04.015}},
ISSN = {{0022-5193}},
Keywords = {{epidemiology; networks; mathematical model; delay model; reinfection}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; REINFECTION; INFECTION; MODEL; TRANSMISSION;
   POPULATIONS; NETWORKS; CONTACT; DISEASE}},
Research-Areas = {{Life Sciences \& Biomedicine - Other Topics; Mathematical \&
   Computational Biology}},
Web-of-Science-Categories  = {{Biology; Mathematical \& Computational Biology}},
Author-Email = {{ccolijn@hsph.harvard.edu}},
ResearcherID-Numbers = {{Cohen, Ted/G-8101-2011}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}K08 AI055985, K08 AI055985-05]}},
Cited-References = {{BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815.
   Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497.
   Cohen T, 2006, P NATL ACAD SCI USA, V103, P7042, DOI 10.1073/pnas.0600349103.
   Cohen T, 2004, NAT MED, V10, P1117, DOI 10.1038/nm1110.
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0.
   Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7.
   Edmunds W J, 2006, Emerg Themes Epidemiol, V3, P10, DOI 10.1186/1742-7622-3-10.
   ENGELBORGHS K, 2002, T MATH SOFTWARE, P1.
   ENGELBORGHS K, 2001, J THEOR BIOL.
   Feng Z., 2001, J DYN DIFFER EQU, V13, P425, DOI 10.1023/A:1016688209771.
   Feng ZL, 2000, THEOR POPUL BIOL, V57, P235, DOI 10.1006/tpbi.2000.1451.
   Gomes MGM, 2004, P ROY SOC B-BIOL SCI, V271, P617, DOI 10.1098/rspb.2003.2606.
   GUPTA S, 1995, P ROY SOC B-BIOL SCI, V261, P271, DOI 10.1098/rspb.1995.0147.
   HORWITZ O, 1969, AM REV RESPIR DIS, V99, P183.
   May RM, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.066112.
   MEYERS L, 2003, EMERG INFECT DIS, V9, P205.
   Murphy BM, 2002, MATH BIOSCI, V180, P161, DOI 10.1016/S0025-5564(02)00133-5.
   Pastor-Satorras R, 2001, PHYS REV LETT, V86, P3200, DOI 10.1103/PhysRevLett.86.3200.
   Read JM, 2003, P ROY SOC B-BIOL SCI, V270, P699, DOI 10.1098/rspb.2002.2305.
   Salpeter EE, 1998, AM J EPIDEMIOL, V147, P398.
   Schinazi RB, 1999, J STAT PHYS, V97, P409, DOI 10.1023/A:1004635606196.
   SINGER B, 2004, MATH BIOSCI ENG, V1.
   SOHEN T, 2007, R SOC INTERFACES, V4, P523.
   SPRINGETT V H, 1971, Tubercle, V52, P73, DOI 10.1016/0041-3879(71)90015-8.
   Styblo K, 1969, Bull Int Union Tuberc, V42, P1.
   Styblo K., 1991, EPIDEMIOLOGY TUBERCU.
   SUTHERLAND I, 1976, Bulletin of the International Union Against Tuberculosis, V51, P171.
   Sutherland I, 1976, Adv Tuberc Res, V19, P1.
   SUTHERLAND I, 1982, TUBERCLE, V63, P255, DOI 10.1016/S0041-3879(82)80013-5.
   Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001.
   Vynnycky E, 1999, INT J EPIDEMIOL, V28, P327, DOI 10.1093/ije/28.2.327.
   Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917.
   {*}WHO K, 2006, GLOB TUB CONTR SURV.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{12}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{J. Theor. Biol.}},
Doc-Delivery-Number = {{203RC}},
Unique-ID = {{ISI:000248990700017}},
}

@article{ ISI:000207593900765,
Author = {Kiessling, Laura L.},
Title = {{BIOL 149-Understanding carbohydrate biosynthetic pathways in
   Mycobacterium tuberculosis}},
Journal = {{ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY}},
Year = {{2007}},
Volume = {{234}},
Meeting = {{149-BIOL}},
Month = {{AUG 19}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Kiessling, Laura L., Univ Wisconsin, Dept Chem \& Biochem, Madison, WI 53706 USA.}},
ISSN = {{0065-7727}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary}},
Author-Email = {{kiessling@chem.wisc.edu}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Abstr. Pap. Am. Chem. Soc.}},
Doc-Delivery-Number = {{V12IW}},
Unique-ID = {{ISI:000207593900765}},
}

@article{ ISI:000207593901507,
Author = {Lowary, Todd L.},
Title = {{Synthetic and biochemical investigations related to cell wall
   polysaccharides from Mycobacterium tuberculosis}},
Journal = {{ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY}},
Year = {{2007}},
Volume = {{234}},
Meeting = {{11-CARB}},
Month = {{AUG 19}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Lowary, Todd L., Univ Alberta, Dept Chem, Gunning Lemieux Chem Ctr, Edmonton, AB T6G 2G2, Canada.
   Lowary, Todd L., Univ Alberta, Alberta Ingenu Ctr Carbohydrate Sci, Gunning Lemieux Chem Ctr, Edmonton, AB T6G 2G2, Canada.}},
ISSN = {{0065-7727}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary}},
Author-Email = {{tlowary@ualberta.ca}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Abstr. Pap. Am. Chem. Soc.}},
Doc-Delivery-Number = {{V12IW}},
Unique-ID = {{ISI:000207593901507}},
}

@article{ ISI:000207593907735,
Author = {Roberts, Justin P. and Kriger, Inna and Sun, Qingan and McKee, Eric and
   Ioerger, Thomas R. and Freundlich, Joel S. and Sacchettini, James C.},
Title = {{MEDI 204-Structure-based design, synthesis, and biological evaluation of
   novel inhibitors of Mycobacterium tuberculosis malate synthase}},
Journal = {{ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY}},
Year = {{2007}},
Volume = {{234}},
Meeting = {{204-MEDI}},
Month = {{AUG 19}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Roberts, Justin P.; Freundlich, Joel S., Princeton Univ, Dept Chem, Frick Chem Lab, Princeton, NJ 08544 USA.
   Kriger, Inna; Sun, Qingan; Sacchettini, James C., Texas A\&M Univ, Dept Biochem \& Biophys, College Stn, TX 77843 USA.
   McKee, Eric; Ioerger, Thomas R., Texas A\&M Univ, Dept Comp Sci, College Stn, TX 77843 USA.}},
ISSN = {{0065-7727}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary}},
Author-Email = {{jprobert@Princeton.EDU
   joelf@princeton.edu}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Abstr. Pap. Am. Chem. Soc.}},
Doc-Delivery-Number = {{V12IW}},
Unique-ID = {{ISI:000207593907735}},
}

@article{ ISI:000207593907810,
Author = {Sullivan, Todd J. and am Ende, Christopher and Truglio, James J. and
   Johnson, Francis and Lenaerts, Ann and Slayden, Richard A. and Kisker,
   Caroline and Tonge, Peter J.},
Title = {{MEDI 203-High affinity InhA inhibitors with activity against
   drug-resistant strains of Mycobacterium tuberculosis}},
Journal = {{ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY}},
Year = {{2007}},
Volume = {{234}},
Meeting = {{203-MEDI}},
Month = {{AUG 19}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Truglio, James J., SUNY Stony Brook, Dept Pharmacol Sci, Struct Biol Ctr, Stony Brook, NY 11794 USA.
   Johnson, Francis, SUNY Stony Brook, Dept Pharmacol Sci \& Chem, Stony Brook, NY 11794 USA.
   Lenaerts, Ann; Slayden, Richard A., Colorado State Univ, Dept Microbiol Immunol \& Pathol, Ft Collins, CO 80523 USA.
   Kisker, Caroline, Univ Wurzburg, Inst Biol Struct, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany.
   Tonge, Peter J., SUNY Stony Brook, Dept Chem, Inst Chem Biol \& Drug Discovery, Stony Brook, NY 11794 USA.}},
ISSN = {{0065-7727}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary}},
Author-Email = {{francis@pharm.sunysb.edu
   richard.slayden@colostate.edu}},
ResearcherID-Numbers = {{Slayden, Richard/O-8626-2016}},
ORCID-Numbers = {{Slayden, Richard/0000-0001-6857-7277}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Abstr. Pap. Am. Chem. Soc.}},
Doc-Delivery-Number = {{V12IW}},
Unique-ID = {{ISI:000207593907810}},
}

@article{ ISI:000207593900666,
Author = {Thomson, Joshua G. and Ramos, Julian N. and O'Handley, Suzanne F.},
Title = {{BIOL 82-Rv2985 diadenosine polyphosphatase from M. tuberculosis, an
   ``invasion{''} enzyme homolog and potential novel antibiotic target}},
Journal = {{ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY}},
Year = {{2007}},
Volume = {{234}},
Meeting = {{82-BIOL}},
Month = {{AUG 19}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Thomson, Joshua G.; Ramos, Julian N.; O'Handley, Suzanne F., Rochester Inst Technol, Dept Chem, Rochester, NY 14623 USA.}},
ISSN = {{0065-7727}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary}},
Author-Email = {{sfosch@rit.edu}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Abstr. Pap. Am. Chem. Soc.}},
Doc-Delivery-Number = {{V12IW}},
Unique-ID = {{ISI:000207593900666}},
}

@article{ ISI:000207593900615,
Author = {Yang, Xinxin and Dubnau, Eugenie and Smith, Issar and Sampson, Nicole S.},
Title = {{BIOL 134-RV1106c from Mycobacterium tuberculosis is a 3
   beta-hydroxysteroid dehydrogenase}},
Journal = {{ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY}},
Year = {{2007}},
Volume = {{234}},
Meeting = {{134-BIOL}},
Month = {{AUG 19}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Yang, Xinxin; Sampson, Nicole S., SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.
   Dubnau, Eugenie; Smith, Issar, Publ Hlth Res Inst, Newark, NJ 07103 USA.}},
ISSN = {{0065-7727}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary}},
Author-Email = {{xinyang@ic.sunysb.edu
   nicole.sampson@stonybrook.edu}},
ResearcherID-Numbers = {{Sampson, Nicole/C-4598-2014
   Zhou, Xin/H-1242-2014}},
ORCID-Numbers = {{Sampson, Nicole/0000-0002-2835-7760
   }},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Abstr. Pap. Am. Chem. Soc.}},
Doc-Delivery-Number = {{V12IW}},
Unique-ID = {{ISI:000207593900615}},
}

@article{ ISI:000248820900022,
Author = {Agarwal, Ritesh and Srinivas, Rajagopala and Gupta, Dheeraj},
Title = {{Disseminated tuberculosis after anti-TNF alpha treatment}},
Journal = {{LANCET}},
Year = {{2007}},
Volume = {{370}},
Number = {{9587}},
Pages = {{564}},
Month = {{AUG 18}},
Publisher = {{LANCET LTD}},
Address = {{84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Agarwal, R (Reprint Author), Postgrad Inst Med Educ \& Res, Dept Pulm Med, Sector 12, Chandigarh 160012, India.
   Postgrad Inst Med Educ \& Res, Dept Pulm Med, Chandigarh 160012, India.}},
DOI = {{10.1016/S0140-6736(07)61288-4}},
ISSN = {{0140-6736}},
Keywords-Plus = {{GRANULOMAS; THERAPY}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{ritesh@indiachest.org}},
ORCID-Numbers = {{Agarwal, Ritesh/0000-0003-2547-7668}},
Cited-References = {{Asakawa H, 2001, J GASTROENTEROL, V36, P190.
   Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275.
   JARMAN PR, 1995, BRIT MED J, V310, P517.
   Malipeddi AS, 2007, LANCET, V369, P162, DOI 10.1016/S0140-6736(07)60078-6.
   Vavricka SR, 2003, THORAX, V58, P278, DOI 10.1136/thorax.58.3.278.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Lancet}},
Doc-Delivery-Number = {{201HA}},
Unique-ID = {{ISI:000248820900022}},
}

@article{ ISI:000248820900023,
Author = {Iizuka, Masahiro and Watanabe, Sumio},
Title = {{Disseminated tuberculosis after anti-TNF alpha treatment}},
Journal = {{LANCET}},
Year = {{2007}},
Volume = {{370}},
Number = {{9587}},
Pages = {{564}},
Month = {{AUG 18}},
Publisher = {{LANCET LTD}},
Address = {{84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Iizuka, M (Reprint Author), Akita Univ, Sch Med, Dept Internal Med, Akita 0108543, Japan.
   Akita Univ, Sch Med, Dept Internal Med, Akita 0108543, Japan.
   Juntendo Univ, Sch Med, Dept Internal Med, Juntendo, Japan.}},
DOI = {{10.1016/S0140-6736(07)61289-6}},
ISSN = {{0140-6736}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{maiizuka@doc.med.akita-u.ac.jp}},
Cited-References = {{Fonseca Joao Eurico, 2006, Acta Reumatol Port, V31, P247.
   Malipeddi AS, 2007, LANCET, V369, P162, DOI 10.1016/S0140-6736(07)60078-6.
   Okubo Hikaru, 2005, Mod Rheumatol, V15, P62.
   Stas P, 2006, ACTA GASTRO-ENT BELG, V69, P217.}},
Number-of-Cited-References = {{4}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Lancet}},
Doc-Delivery-Number = {{201HA}},
Unique-ID = {{ISI:000248820900023}},
}

@article{ ISI:000248820900024,
Author = {Malipeddi, Aruna and Kallarackal, George},
Title = {{Disseminated tuberculosis after anti-TNF alpha treatment - Reply}},
Journal = {{LANCET}},
Year = {{2007}},
Volume = {{370}},
Number = {{9587}},
Pages = {{565}},
Month = {{AUG 18}},
Publisher = {{LANCET LTD}},
Address = {{84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Malipeddi, A (Reprint Author), Gen Hosp Kettering, Dept Rheumatol, Kettering NN16 8UZ, England.
   Gen Hosp Kettering, Dept Rheumatol, Kettering NN16 8UZ, England.}},
DOI = {{10.1016/S0140-6736(07)61290-2}},
ISSN = {{0140-6736}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{arunam@doctors.org.uk}},
Cited-References = {{Ormerod LP, 2005, THORAX, V60, P800, DOI 10.1136/thx.2005.046797.
   Vavricka SR, 2003, THORAX, V58, P278, DOI 10.1136/thorax.58.3.278.}},
Number-of-Cited-References = {{2}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Lancet}},
Doc-Delivery-Number = {{201HA}},
Unique-ID = {{ISI:000248820900024}},
}

@article{ ISI:000249693000018,
Author = {Flueckiger, B. and Otto, P. and Ackermann, C. and Traichl, B. and von
   Kempis, J.},
Title = {{Ankylosing spondylitis complicated by abdominal tuberculosis, under
   treatment with infliximab}},
Journal = {{SWISS MEDICAL WEEKLY}},
Year = {{2007}},
Volume = {{137}},
Number = {{159}},
Meeting = {{17}},
Pages = {{11S}},
Month = {{AUG 18}},
Publisher = {{E M H SWISS MEDICAL PUBLISHERS LTD}},
Address = {{FARNSBURGERSTR 8, CH-4132 MUTTENZ, SWITZERLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{KSSG, St Gallen, Switzerland.}},
ISSN = {{1424-7860}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{BRAUN, 2003, ARTHRITIS RHEUM, V48.
   KEANE, 2001, N ENGL J MED, P345.
   VLACHAKI, 2005, RESP MED, P99.}},
Number-of-Cited-References = {{3}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Swiss Med. Wkly.}},
Doc-Delivery-Number = {{213UQ}},
Unique-ID = {{ISI:000249693000018}},
}

@article{ ISI:000250534700001,
Author = {Lala, Sanjay and Dheda, Keertan and Chang, Jung-Su and Huggett, Jim F.
   and Kim, Louise U. and Johnson, Margaret A. and Rook, Graham A. W. and
   Keshav, Satish and Zumla, Alimuddin},
Title = {{The pathogen recognition sensor, NOD2, is variably expressed in patients
   with pulmonary tuberculosis}},
Journal = {{BMC INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{7}},
Month = {{AUG 16}},
Abstract = {{Background: NOD2, an intracellular pathogen recognition sensor,
   modulates innate defences to muropeptides derived from various bacterial
   species, including Mycobacterium tuberculosis (MTB). Experimentally,
   NOD2 attenuates two key putative mycobactericidal mechanisms. TNF-alpha
   synthesis is markedly reduced in MTB-antigen stimulated-mononuclear
   cells expressing mutant NOD2 proteins. NOD2 agonists also induce
   resistance to apoptosis, and may thus facilitate the survival of MTB in
   infected macrophages. To further define a role for NOD2 in disease
   pathogenesis, we analysed NOD2 transcriptional responses in pulmonary
   leucocytes and mononuclear cells harvested from patients with pulmonary
   tuberculosis (PTB).
   Methods: We analysed NOD2 mRNA expression by real-time polymerase
   chain-reaction in alveolar lavage cells obtained from 15 patients with
   pulmonary tuberculosis and their matched controls. We compared NOD2
   transcriptional responses, in peripheral leucocytes, before and after
   anti-tuberculous treatment in 10 patients. In vitro, we measured NOD2
   mRNA levels in MTB-antigen stimulated-mononuclear cells.
   Results: No significant differences in NOD2 transcriptional responses
   were detected in patients and controls. In some patients, however, NOD2
   expression was markedly increased and correlated with toll-like-receptor
   2 and 4 expression. In whole blood, NOD2 mRNA levels increased
   significantly after completion of anti-tuberculosis treatment. NOD2
   expression levels did not change significantly in mononuclear cells
   stimulated with mycobacterial antigens in vitro.
   Conclusion: There are no characteristic NOD2 transcriptional responses
   in PTB. Nonetheless, the increased levels of NOD2 expression in some
   patients with severe tuberculosis, and the increases in expression
   levels within peripheral leucocytes following treatment merit further
   studies in selected patient and control populations.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Dheda, K (Reprint Author), Royal Free Hosp NHS Trust, Ctr Infect Dis \& Int Hlth, London, England.
   Royal Free Hosp NHS Trust, Ctr Infect Dis \& Int Hlth, London, England.
   Royal Free Hosp NHS Trust, Ctr Gastroenterol, London, England.
   Univ Cape Town, Div Pulm, Dept Med, Lung Infect \& Immun Unit, ZA-7700 Rondebosch, South Africa.
   Royal Free Hosp NHS Trust, Dept Thorac \& HIV Med, London, England.}},
DOI = {{10.1186/1471-2334-7-96}},
Article-Number = {{96}},
ISSN = {{1471-2334}},
Keywords-Plus = {{INTESTINAL EPITHELIAL-CELLS; TOLL-LIKE RECEPTORS;
   MYCOBACTERIUM-TUBERCULOSIS; CROHNS-DISEASE; IN-VITRO; KAPPA-B;
   INFECTION; SUSCEPTIBILITY; GENE; IL-4-DELTA-2}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{lala@mweb.co.za
   keertandheda@yahoo.co.uk
   susanchangtw@yahoo.com
   huggett@ucl.ac.uk
   l.kim@ucl.ac.uk
   Margaret.Johnson@royalfree.nhs.uk
   g.rook@ucl.ac.uk
   satish.keshav@royalfree.nhs.uk
   a.i.zumla@googlemail.com}},
ORCID-Numbers = {{Huggett, Jim/0000-0002-0945-1911
   Rook, Graham/0000-0002-8041-8110
   Zumla, Alimuddin/0000-0002-5111-5735}},
Funding-Acknowledgement = {{Medical Research Council {[}G0200231]}},
Cited-References = {{Al-Attiyah R, 2003, FEMS IMMUNOL MED MIC, V38, P249, DOI 10.1016/S0928-8244(03)00166-4.
   Chang JS, 2006, J IMMUNOL, V176, P3010.
   Demissie A, 2004, J IMMUNOL, V172, P6938.
   Dheda K, 2004, BIOTECHNIQUES, V37, P112.
   Dheda K, 2005, AIDS, V19, P2038, DOI 10.1097/01.aids.0000191923.08938.5b.
   Dheda K, 2005, J INFECT DIS, V192, P1201, DOI 10.1086/444545.
   Dheda K, 2005, AM J RESP CRIT CARE, V172, P501, DOI 10.1164/rccm.200502-278OC.
   Dheda K, 2005, ANAL BIOCHEM, V344, P141, DOI 10.1016/j.ab.2005.05.022.
   Dheda K, 2005, CURR OPIN PULM MED, V11, P195, DOI 10.1097/01.mcp.0000158726.13159.5e.
   Dheda K, 2004, BIOTECHNIQUES, V37, P116.
   Dheda K, 2004, BIOTECHNIQUES, V37, P116.
   Doherty TM, 2004, J CLIN INVEST, V114, P1699, DOI 10.1172/JCI200423867.
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9.
   Ferwerda G, 2005, PLOS PATHOG, V1, P279, DOI 10.1371/journal.ppat.0010034.
   Fletcher HA, 2004, IMMUNOLOGY, V112, P669, DOI 10.1111/j.1365-2567.2004.01922.x.
   Fremond CM, 2004, J CLIN INVEST, V114, P1790, DOI 10.1172/JCI200421027.
   Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200.
   Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200.
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107.
   Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200.
   Kart L, 2003, MEDIAT INFLAMM, V12, P9, DOI 10.1080/0962935031000096926.
   Lala S, 2003, GASTROENTEROLOGY, V125, P47, DOI 10.1016/S0016-5085(03)00661-9.
   LEUNG E, 2006, MOL IMMUNOL, V44, P284.
   Loeuillet C, 2006, J IMMUNOL, V177, P6245.
   Mazzarella G, 2003, CLIN EXP IMMUNOL, V132, P283, DOI 10.1046/j.1365-2249.2003.02121.x.
   North RJ, 2004, ANNU REV IMMUNOL, V22, P599, DOI 10.1146/annurev.immunol.22.012703.104635.
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114.
   Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200.
   Opitz B, 2004, J BIOL CHEM, V279, P36426, DOI 10.1074/jbc.M403861200.
   Ribeiro-Rodrigues R, 2002, CLIN DIAGN LAB IMMUN, V9, P818, DOI 10.1128/CDLI.9.4.818-823.2002.
   Rosenstiel P, 2003, GASTROENTEROLOGY, V124, P1001, DOI 10.1053/gast.2003.50157.
   Stockton JC, 2004, FEMS IMMUNOL MED MIC, V41, P157, DOI 10.1016/j.femsim.2004.02.004.
   Strober W, 2006, NAT REV IMMUNOL, V6, P9, DOI 10.1038/nri1747.
   Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092.
   Zarember KA, 2002, J IMMUNOL, V168, P554.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{BMC Infect. Dis.}},
Doc-Delivery-Number = {{225RJ}},
Unique-ID = {{ISI:000250534700001}},
}

@article{ ISI:000250090600001,
Author = {Baral, Sushil C. and Karki, Deepak K. and Newell, James N.},
Title = {{Causes of stigma and discrimination associated with tuberculosis in
   Nepal: a qualitative study}},
Journal = {{BMC PUBLIC HEALTH}},
Year = {{2007}},
Volume = {{7}},
Month = {{AUG 16}},
Abstract = {{Background: Tuberculosis ( TB) is a major cause of death. The condition
   is highly stigmatised, with considerable discrimination towards
   sufferers. Although there have been several studies assessing the extent
   of such discrimination, there is little published research explicitly
   investigating the causes of the stigma and discrimination associated
   with TB. The objectives of our research were therefore to take the first
   steps towards determining the causes of discrimination associated with
   TB.
   Methods: Data collection was performed in Kathmandu, Nepal. Thirty four
   in- depth interviews were performed with TB patients, family members of
   patients, and members of the community.
   Results: Causes of self- discrimination identified included fear of
   transmitting TB, and avoiding gossip and potential discrimination.
   Causes of discrimination by members of the general public included: fear
   of a perceived risk of infection; perceived links between TB and other
   causes of discrimination, particularly poverty and low caste; perceived
   links between TB and disreputable behaviour; and perceptions that TB was
   a divine punishment. Furthermore, some patients felt they were
   discriminated against by health workers
   Conclusion: A comprehensive package of interventions, tailored to the
   local context, will be needed to address the multiple causes of
   discrimination identified: basic population- wide health education is
   unlikely to be effective.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Newell, JN (Reprint Author), Univ Leeds, Leeds Inst Hlth Sci, Nuffield Ctr Int Hlth \& Dev, Charles Thackrah Bldg,101 Clarendon Rd, Leeds LS2 9LJ, W Yorkshire, England.
   Univ Leeds, Leeds Inst Hlth Sci, Nuffield Ctr Int Hlth \& Dev, Leeds LS2 9LJ, W Yorkshire, England.
   Hlth Res \& Social Dev Forum, Kathmandu, Nepal.
   Natl Med AIDS \& STD Control, Minist Hlth \& Populat, Kathmandu, Nepal.}},
DOI = {{10.1186/1471-2458-7-211}},
Article-Number = {{211}},
ISSN = {{1471-2458}},
Keywords-Plus = {{SOCIAL STIGMA; VIETNAM; ATTITUDES}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{sushilb@mos.com.np
   dekarki@wlink.com.np
   j.n.newell@leeds.ac.uk}},
Cited-References = {{AUER C, 2003, THESIS BASEL U.
   Awofeso N, 1998, TROP DOCT, V28, P185.
   Cambanis A, 2005, TROP MED INT HEALTH, V10, P330, DOI 10.1111/j.1365-3156.2005.01393.x.
   Chapple A, 2004, BRIT MED J, V328, P1470, DOI 10.1136/bmj.38111.639734.7C.
   Crandall CS, 1997, J APPL SOC PSYCHOL, V27, P95, DOI 10.1111/j.1559-1816.1997.tb00625.x.
   Eastwood SV, 2004, INT J TUBERC LUNG D, V8, P70.
   Goffman E., 1963, STIGMA NOTES MANAGEM.
   Heijnders ML, 2004, INT J LEPROSY, V72, P437, DOI 10.1489/1544-581X(2004)72<437:TDOSIL>2.0.CO;2.
   Health and Development Networks, 2006, HIV REL STIGM DISCR.
   {*}HLTH DEV NETW, 2004, SELF STIGM HIV AIDS.
   {*}HLTH DEV NETW, 2006, LIV OUTS.
   Health and Development Networks, 2001, ADV ACT STIGM HIV AI.
   Hoa NR, 2004, INT J TUBERC LUNG D, V8, P603.
   Hurtig AK, 1999, INT J TUBERC LUNG D, V3, P553.
   {*}INT COUNC NURS, TB STIGM PRES.
   Johansson E, 1999, INT J TUBERC LUNG D, V3, P862.
   Joint United Nations Programme on HIV/AIDS, 2005, INT HIV PREV UNAIDS.
   Khan A, 2000, SOC SCI MED, V50, P247, DOI 10.1016/S0277-9536(99)00279-8.
   Lawn SD, 2000, INT J TUBERC LUNG D, V4, P1190.
   Link BG, 2001, ANNU REV SOCIOL, V27, P363, DOI 10.1146/annurev.soc.27.1.363.
   Long NH, 2001, HEALTH POLICY, V58, P69, DOI 10.1016/S0168-8510(01)00143-9.
   Macq J, 2006, Psychol Health Med, V11, P346, DOI 10.1080/13548500600595277.
   Macq J, 2005, HEALTH POLICY, V74, P205, DOI 10.1016/j.healthpol.2005.01.003.
   {*}PUBL HLTH WATCH, 2006, CIV SOC PERSP TB POL.
   Rajeswari R, 2005, SOC SCI MED, V60, P1845, DOI 10.1016/j.socscimed.2004.08.024.
   Rieder HL, 1999, EPIDEMIOLOGICAL BASI.
   ROUILLON A, 1976, TUBERCLE, V57, P275.
   Smith I., 2004, TOMANS TUBERCULOSIS, P233.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.
   {*}WHO, 2001, MENT HLTH NEW UND NE.
   World Health Organisation, 2006, STOP TB STRAT.
   World Health Organization, 2006, GLOB PLAN STOP TB 20.}},
Number-of-Cited-References = {{32}},
Times-Cited = {{58}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{14}},
Journal-ISO = {{BMC Public Health}},
Doc-Delivery-Number = {{219MZ}},
Unique-ID = {{ISI:000250090600001}},
}

@article{ ISI:000249441100001,
Author = {Vree, Marleen and Huong, Nguyen T. and Duong, Bui D. and Co, Nguyen V.
   and Sy, Dinh N. and Cobelens, Frank G. and Borgdorff, Martien W.},
Title = {{High mortality during tuberculosis treatment does not indicate long
   diagnostic delays in Vietnam: a cohort study}},
Journal = {{BMC PUBLIC HEALTH}},
Year = {{2007}},
Volume = {{7}},
Month = {{AUG 16}},
Abstract = {{Background: Delay in tuberculosis diagnosis and treatment initiation may
   increase disease severity and mortality. In evaluations of tuberculosis
   control programmes high fatality rates during tuberculosis treatment,
   are used as an indicator of long delays in low HIV-prevalence settings.
   However, data for this presumed association between delay and fatality
   are lacking. We assessed the association between diagnostic delay and
   mortality of new smear-positive pulmonary tuberculosis patients in
   Vietnam.
   Methods: Follow-up of a patient cohort included in a survey of
   diagnostic delay in 70 randomly selected districts. Data on diagnosis
   and treatment were extracted from routine registers. Patients who had
   died during the course of treatment were compared to those with reported
   cure, completed treatment or failure ( survivors).
   Results: Complete data were available for 1881/2093 (89.9\%) patients,
   of whom 82 (4.4\%) had died. Fatality was 4.5\% for patients with <= 4
   weeks delay, 5.0\% for 5- <= 8 weeks delay (aOR 1.11, 95\% CI 0.67-1.84)
   and 3.2\% for > 9 weeks delay ( aOR 0.69, 95\% CI 0.37-1.30). Fatality
   tended to decline with increasing delay but this was not significant.
   Fatality was not associated with median diagnostic delay at district
   level ( Spearman's rho = -0.08, P = 0.5).
   Conclusion: Diagnostic delay is not associated with treatment mortality
   in Vietnam at individual nor district level, suggesting that high case
   fatality should not be used as an indicator of long diagnostic delay in
   national tuberculosis programmes.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Vree, M (Reprint Author), KNCV TB Fdn, Res Unit, PO Box 146, NL-2501 CC The Hague, Netherlands.
   KNCV TB Fdn, Res Unit, NL-2501 CC The Hague, Netherlands.
   Acad Med Ctr, Ctr Infect \& Immun Amsterdam, Amsterdam, Netherlands.
   Natl TB Programme Vietnam, Hanoi, Vietnam.}},
DOI = {{10.1186/1471-2458-7-210}},
Article-Number = {{210}},
ISSN = {{1471-2458}},
Keywords-Plus = {{SEEKING BEHAVIOR; CONTROL PROGRAM; OUTCOMES; CITY}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{vreem@kncvtbc.nl
   nthuong139@gmail.com
   bdduong06@gmail.com
   sonlinh\_2001@yahoo.com
   ngocsyvienlao@yahoo.com
   cobelensf@kncvtbc.nl
   borgdorff@kncvtbc.nl}},
Cited-References = {{Barker RD, 2006, INT J TUBERC LUNG D, V10, P670.
   CROFTON J, 1999, PULMONARY TUBERCULOS.
   Enarson D, 2000, MANAGEMENT TUBERCULO.
   FIELDER JF, 2002, INT J TUBERC LUNG D, V6, P114.
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4.
   Garcia-Garcia MD, 2002, EMERG INFECT DIS, V8, P1327.
   Greenaway C, 2002, AM J RESP CRIT CARE, V165, P927, DOI 10.1164/rccm.2107040.
   Harries A, 2004, TOMANS TUBERCULOSIS.
   Huong NT, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-110.
   Huong NT, 2005, INT J TUBERC LUNG D, V9, P151.
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414.
   Laszlo A, 2000, TECHNICAL GUIDE SPUT.
   LUELMO F, 2004, TOMANS TUBERCULOSIS, V39.
   Nguyen TNL, 1999, INT J TUBERC LUNG D, V3, P483.
   Ouedraogo M, 2006, INT J TUBERC LUNG D, V10, P184.
   PablosMendez A, 1996, JAMA-J AM MED ASSOC, V276, P1223, DOI 10.1001/jama.276.15.1223.
   Quy HT, 2006, INT J TUBERC LUNG D, V10, P45.
   Raviglione M, 2001, INT J TUBERC LUNG D, V5, P213.
   Rojpibulstit M, 2006, INT J TUBERC LUNG D, V10, P422.
   Singla Rupak, 2005, Indian J Chest Dis Allied Sci, V47, P19.
   STYBLO K, SELECTED PAPERS EPID, V24.
   Toman K, 2004, TOMANS TUBERCULOSIS.
   {*}UNAIDS UNICEF WHO, 2006, EP FACT SHEET HIV AI.
   van der Werf MJ, 2006, INT J TUBERC LUNG D, V10, P390.
   {*}VIETN MIN HLTH, 2005, VIETN MIN HLTH, P135.
   Vree M, 2007, INT J TUBERC LUNG D, V11, P392.
   Vree M, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-134.
   {[}WHO World Health Organization], 1998, LAB SERV TUB CONTR 2.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.
   World Health Organization (WHO), 2005, GLOB TUB CONTR SURV.
   {*}WHO, 2005, TB EPID SURV WORKSH.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{BMC Public Health}},
Doc-Delivery-Number = {{210FC}},
Unique-ID = {{ISI:000249441100001}},
}

@article{ ISI:000247491000006,
Author = {Oloya, J. and Muma, J. B. and Opuda-Asibo, J. and Djonne, B. and
   Kazwala, R. and Skjerve, E.},
Title = {{Risk factors for herd-level bovine-tuberculosis seropositivity in
   transhumant cattle in Uganda}},
Journal = {{PREVENTIVE VETERINARY MEDICINE}},
Year = {{2007}},
Volume = {{80}},
Number = {{4}},
Pages = {{318-329}},
Month = {{AUG 16}},
Abstract = {{We investigated the prevalence and risk factors to positive herd-level
   tuberculin reactivity between October 2003 to May 2004 to bovine
   tuberculosis (BTB) in the four transhumant districts of Uganda: three
   districts (Karamoja region) of nomadic transhumance cattle rearing (30
   superherds and 1522 cattle), and one district (Nakasongola) of
   fixed-transhumance (7 herds and 342 cattle). We used the comparative
   intradermal skin-test, sampled 50 animals per superherd/herd, and
   considered herd positive if there was at least one reactor. Of the 30
   superherds under nomadic transhumance, 60\% (95\% CI 41.4, 79) were
   tuberculin-test positive; of the 7 fixed herds, 14.3\% (95\% CI -20.7,
   49.2) were tuberculin test positive. The true herd prevalence was
   estimated at 46.6\%. Many risk factors were collinear. The final
   multivariable logistic-regression model included: recent introductions
   from market (OR = 3.4; 95\% CI 1.1, 10.3), drinking water form mud holes
   during dry season (OR = 49; 95\% CI 9.1, 262), and the presence of
   monkeys (OR = 0.08; 95\% CI 0.0, 0.6) or warthogs (OR = 0.1; 95\% CI
   0.0, 0.3). No association was found between herd size or number of herd
   contacts with reactors; it was probably masked by the effect of high
   between-herd interactions. Provision of water from mud holes in dry
   river beds and introductions of new animals are risk factors that might
   be targeted to control BTB in transhumance areas. (c) 2007 Elsevier B.V.
   All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Skjerve, E (Reprint Author), Norwegian Sch Vet Sci, Dept Food Safety \& Infect Biol, POB 8146, N-0033 Oslo, Norway.
   Norwegian Sch Vet Sci, Dept Food Safety \& Infect Biol, N-0033 Oslo, Norway.
   Makerere Univ, Dept Vet Publ Hlth \& Prevent Med, Kampala, Uganda.
   Natl Vet Inst, N-0032 Oslo, Norway.
   Univ Zambia, Sch Vet Med, Dept Dis Control, Lusaka, Zambia.
   Sokoine Univ Agr, Morogoro, Tanzania.}},
DOI = {{10.1016/j.prevetmed.2007.03.004}},
ISSN = {{0167-5877}},
Keywords = {{bovine tuberculosis; nomadic; transhumance; risk factors; epidemiology;
   Uganda}},
Keywords-Plus = {{MYCOBACTERIUM-BOVIS; ENVIRONMENTAL-FACTORS; EPIDEMIOLOGY; TRANSMISSION;
   TANZANIA; INFECTIONS; ANIMALS; FARMS; WATER; ZONE}},
Research-Areas = {{Veterinary Sciences}},
Web-of-Science-Categories  = {{Veterinary Sciences}},
Author-Email = {{Eystein.Skjerve@veths.no}},
Cited-References = {{ACEN F, 1991, THESIS MAKERERE U.
   Biet F, 2005, VET RES, V36, P411, DOI 10.1051/vetres:2005001.
   COSIVI O, 1995, REV SCI TECH OIE, V14, P733.
   Cosivi O, 1998, EMERG INFECT DIS, V4, P59.
   Costello E, 1998, VET J, V155, P245, DOI 10.1016/S1090-0233(05)80019-X.
   DABORN CJ, 1993, BRIT VET J, V149, P405.
   Dailloux M, 1999, WATER RES, V33, P2219, DOI 10.1016/S0043-1354(98)00466-7.
   DOHOO I, 2003, VET EPIDEMIOLOGIC RE, P33.
   FARIES FC, 1997, TEXAS AGR EXTENSION, P6.
   Faye B., 2005, PREV VET MED, V67, p267 , DOI DOI 10.1016/J.PREVETMED.2004.11.002.
   Greiner M, 2000, PREV VET MED, V45, P3, DOI 10.1016/S0167-5877(00)00114-8.
   GRIFFIN JM, 1993, PREV VET MED, V17, P145, DOI 10.1016/0167-5877(93)90025-O.
   Iivanainen E, 1999, J APPL MICROBIOL, V86, P673, DOI 10.1046/j.1365-2672.1999.00711.x.
   Jiwa SFH, 1997, VET RES COMMUN, V21, P533, DOI 10.1023/A:1005900929479.
   Kaneene JB, 2002, J AM VET MED ASSOC, V221, P837, DOI 10.2460/javma.2002.221.837.
   Kazwala RR, 2001, VET RES COMMUN, V25, P609, DOI 10.1023/A:1012757011524.
   KELSEY LJ, 1996, METHOD OBSERVATIONAL, P244.
   Menzies FD, 2000, VET J, V160, P92.
   Mfinanga SG, 2003, INT J TUBERC LUNG D, V7, P695.
   Michel AL, 2006, VET MICROBIOL, V112, P91, DOI 10.1016/j.vetmic.2005.11.035.
   MONAGHAN ML, 1994, VET MICROBIOL, V40, P111, DOI 10.1016/0378-1135(94)90050-7.
   MORRIS RS, 1994, VET MICROBIOL, V40, P153, DOI 10.1016/0378-1135(94)90053-1.
   NEILL SD, 1989, VET REC, V124, P269.
   Oloya J, 2006, TROP ANIM HEALTH PRO, V38, P275, DOI 10.1007/s11250-006-4322-7.
   Omer MK, 2001, TROP ANIM HEALTH PRO, V33, P295, DOI 10.1023/A:1010531802372.
   OREILLY LM, 1995, TUBERCLE LUNG DIS, V76, P1, DOI 10.1016/0962-8479(95)90591-X.
   ORGAN BWH, 1994, B WORLD HLTH ORG, V72, P851.
   Parra A, 2003, VET MICROBIOL, V97, P123, DOI 10.1016/j.vetmic.2003.08.007.
   Phillips CJC, 2003, RES VET SCI, V74, P1, DOI 10.1016/S0034-5288(02)00145-5.
   Schmitt SM, 2002, ANN NY ACAD SCI, V969, P262.
   Sheffield RE, 1997, T ASAE, V40, P595.
   Shirima GM, 2003, PREV VET MED, V57, P167, DOI 10.1016/S0167-5877(02)00214-3.
   Simpson VR, 2002, VET J, V163, P128, DOI 10.1053/tvjl.2001.0662.
   2004, SECTOR SITUATION ANA.
   1990, ANN ABATTOIR SLAUGHT.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{25}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Prev. Vet. Med.}},
Doc-Delivery-Number = {{182FR}},
Unique-ID = {{ISI:000247491000006}},
}

@article{ ISI:000249107300001,
Author = {Traynor, Kate},
Title = {{Tuberculosis control poses global challenges}},
Journal = {{AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY}},
Year = {{2007}},
Volume = {{64}},
Number = {{16}},
Pages = {{1672+}},
Month = {{AUG 15}},
Publisher = {{AMER SOC HEALTH-SYSTEM PHARMACISTS}},
Address = {{7272 WISCONSIN AVE, BETHESDA, MD 20814 USA}},
Type = {{News Item}},
Language = {{English}},
DOI = {{10.2146/news070072}},
ISSN = {{1079-2082}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Am. J. Health-Syst. Pharm.}},
Doc-Delivery-Number = {{205IN}},
Unique-ID = {{ISI:000249107300001}},
}

@article{ ISI:000248682100016,
Author = {Hougardy, Jean-Michel and Place, Sammy and Hildebrand, Marc and Drowart,
   Annie and Debrie, Anne-Sophie and Locht, Camille and Mascart, Francoise},
Title = {{Regulatory T cells depress immune responses to protective antigens in
   active tuberculosis}},
Journal = {{AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE}},
Year = {{2007}},
Volume = {{176}},
Number = {{4}},
Pages = {{409-416}},
Month = {{AUG 15}},
Abstract = {{Rationale: Tuberculosis (TB) remains a leading cause of death, and the
   role of T-cell responses to control Mycobacterium tuberculosis
   infections is well recognized. Patients with latent TB infection develop
   strong IFN-gamma responses to the protective antigen heparin-binding
   hemagglutinin (HBHA), whereas patients with active TB do not.
   Objectives: We investigated the mechanism of this difference and
   evaluated the possible involvement of regulatory T (Treg) cells and/or
   cytokines in the low HBHA T-cell responses of patients with active TB.
   Methods: The impact of anti-transforming growth factor (TGF)-beta and
   anti-IL-10 antibodies and of Treg cell depletion on the HBHA-induced
   IFN-gamma secretion was analyzed, and the Treg cell phenotype was
   characterized by flow cytometry.
   Measurements and Main Results: Although the addition of anti-TGF-beta or
   anti-IL-10 antibodies had no effect on the HBHA-induced IFN-gamma
   secretion in patients with active TB, depletion of CD4(+)CD25(high)
   FOXP3(+) T lymphocytes resulted in the induction by HBHA of IFN-gamma
   concentrations that reached levels similar to those obtained for latent
   TB infection. No effect was noted on the early-secreted antigen target-6
   or candidin T-cell responses.
   Conclusions: Specific CD4(+)CD25(high)FOXP3(+) T cells depress the
   T-cell-mediated immune responses to the protective mycobacterial antigen
   HBHA during active TB in humans.}},
Publisher = {{AMER THORACIC SOC}},
Address = {{1740 BROADWAY, NEW YORK, NY 10019-4374 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mascart, F (Reprint Author), Univ Libre Bruxelles, Immunobiol Clin, Hop Erasme, 808 Route Lennik, B-1070 Brussels, Belgium.
   Univ Libre Bruxelles, Immunobiol Clin, Hop Erasme, B-1070 Brussels, Belgium.
   Univ Libre Bruxelles, Dept Infect Dis, Hop St Pierre, Brussels, Belgium.
   Univ Libre Bruxelles, Chest Dept, Hop Brugmann, Brussels, Belgium.
   Inst Pasteur, F-59019 Lille, France.
   INSERM U629, Lille, France.
   Hop Erasme, Lab Vaccinol \& Mucosal Immun, B-1070 Brussels, Belgium.}},
DOI = {{10.1164/rccm.200701-084OC}},
ISSN = {{1073-449X}},
Keywords = {{tuberculosis; regulatory T cells; heparin-binding hemagglutinin}},
Keywords-Plus = {{HEPARIN-BINDING HEMAGGLUTININ; MYCOBACTERIUM-TUBERCULOSIS;
   EXTRAPULMONARY DISSEMINATION; DISEASE; FOXP3; INDIVIDUALS; SUPPRESSION;
   MODULATION; MECHANISMS; ADHESIN}},
Research-Areas = {{General \& Internal Medicine; Respiratory System}},
Web-of-Science-Categories  = {{Critical Care Medicine; Respiratory System}},
Author-Email = {{fmascart@ulb.ac.be}},
ORCID-Numbers = {{Hougardy, Jean-Michel/0000-0002-7769-5360}},
Cited-References = {{Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918.
   Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   {*}FARES, DIAGN INF TUB LAT.
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93.
   Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016.
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904.
   Gazzola L, 2006, AM J RESP CRIT CARE, V174, P356.
   Guyot-Revol V, 2006, AM J RESP CRIT CARE, V173, P803, DOI 10.1164/rccm.200508-1294OC.
   Hirsch CS, 1999, J INFECT DIS, V180, P2069, DOI 10.1086/315114.
   Hirsch CS, 1996, P NATL ACAD SCI USA, V93, P3193, DOI 10.1073/pnas.93.8.3193.
   HOUGARDY JM, 2006, 6 ANN C FED CLIN IMM.
   HOUGARDY JM, 2006, 16 EUR C IMM PAR SEP.
   HUYGEN K, 1988, SCAND J IMMUNOL, V27, P187, DOI 10.1111/j.1365-3083.1988.tb02338.x.
   Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893.
   Jafari C, 2006, AM J RESP CRIT CARE, V174, P1048, DOI 10.1164/rccm.200604-465OC.
   Jiang H, 2006, NEW ENGL J MED, V354, P1166, DOI 10.1056/NEJMra055446.
   Kinter AL, 2004, J EXP MED, V200, P331, DOI 10.1084/jem.20032069.
   Locht C, 2006, TUBERCULOSIS, V86, P303, DOI 10.1016/j.tube.2006.01.016.
   Masungi C, 2002, J INFECT DIS, V185, P513, DOI 10.1086/338833.
   Menozzi FD, 1996, J EXP MED, V184, P993, DOI 10.1084/jem.184.3.993.
   Menozzi FD, 1998, P NATL ACAD SCI USA, V95, P12625, DOI 10.1073/pnas.95.21.12625.
   Mills KHG, 2004, SEMIN IMMUNOL, V16, P107, DOI 10.1016/j.smim.2003.12.006.
   Parra M, 2004, INFECT IMMUN, V72, P6799, DOI 10.1128/IAI.72.12.6799-6805.2004.
   Pethe K, 2002, P NATL ACAD SCI USA, V99, P10759, DOI 10.1073/pnas.162246899.
   Pethe K, 2001, NATURE, V412, P190, DOI 10.1038/35084083.
   PLACE S, 2004, 12 INT C IMM 4 ANN C.
   Ribeiro-Rodrigues R, 2006, CLIN EXP IMMUNOL, V144, P25, DOI 10.1111/j.1365-2249.2006.03027.x.
   Taams LS, 2002, EUR J IMMUNOL, V32, P1621, DOI 10.1002/1521-4141(200206)32:6<1621::AID-IMMU1621>3.0.CO;2-Q.
   Temmerman S, 2004, NAT MED, V10, P935, DOI 10.1038/nm1090.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{115}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Am. J. Respir. Crit. Care Med.}},
Doc-Delivery-Number = {{199FR}},
Unique-ID = {{ISI:000248682100016}},
}

@article{ ISI:000248870000009,
Author = {Lepesheva, Galina I. and Seliskar, Matej and Knutson, Charles G. and
   Stourman, Nina V. and Rozman, Damjana and Waterman, Michael R.},
Title = {{Conformational dynamics in the F/G segment of CYP51 from Mycobacterium
   tuberculosis monitored by FRET}},
Journal = {{ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS}},
Year = {{2007}},
Volume = {{464}},
Number = {{2}},
Pages = {{221-227}},
Month = {{AUG 15}},
Abstract = {{A cysteine was introduced into the FG-loop (P187C) of CYP51 from
   Mycobacterium tuberculosis (MT) for selective labeling with BODIPY and
   fluorescence energy transfer (FRET) analysis. Forster radius for the
   BODIPY-heme pair was calculated assuming that the distance between the
   heme and Cysl87 in solution corresponds to that in the crystal structure
   of ligand free MTCYP51. Interaction of MTCYP51 with azole inhibitors
   ketoconazole and fluconazole or the substrate analog estriol did not
   influence the fluorescence, but titration with the substrate lanosterol
   quenched BODIPY emission, the effect being proportional to the portion
   of substrate bound MTCYP51. The detected changes correspond to similar
   to 10 angstrom decrease in the calculated distance between BODIPY-Cysl87
   and the heme. The results confirm (1) functional importance of
   conformational motions in the MTCYP51 F/G segment and (2) applicability
   of FRET to monitor them in solution. (c) 2007 Elsevier Inc. All rights
   reserved.}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Waterman, MR (Reprint Author), Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA.
   Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA.
   Univ Ljubljana, Fac Med, Inst Biochem, Ctr Funct Genom \& Biochips, Ljubljana 1000, Slovenia.}},
DOI = {{10.1016/j.abb.2007.05.017}},
ISSN = {{0003-9861}},
Keywords = {{cytochrome P450; sterol 14 alpha-demethylase; ligand binding;
   conformational changes; FRET}},
Keywords-Plus = {{RESONANCE ENERGY-TRANSFER; MAMMALIAN CYTOCHROME P4502C5; SUBSTRATE
   RECOGNITION SITES; CRYSTAL-STRUCTURE; STEROL 14-ALPHA-DEMETHYLASE;
   THERMOPHILIC CYTOCHROME-P450; 14-ALPHA-STEROL DEMETHYLASE;
   SULFOLOBUS-SOLFATARICUS; ANGSTROM RESOLUTION; FLUORESCENT-PROBE}},
Research-Areas = {{Biochemistry \& Molecular Biology; Biophysics}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Biophysics}},
Author-Email = {{michael.waterman@vanderbilt.edu}},
ORCID-Numbers = {{Rozman, Damjana/0000-0002-6501-2163}},
Funding-Acknowledgement = {{NIEHS NIH HHS {[}P30 ES000267, ES 00267-32]; NIGMS NIH HHS {[}R01
   GM067871-03, R01 GM067871-01A1, GM0030910-23, R01 GM030910, R01
   GM067871-05, R01 GM067871-04, R01 GM067871-02, GM067871, R01 GM067871]}},
Cited-References = {{Anderluh G, 2003, J BIOL CHEM, V278, P21860, DOI 10.1074/jbc.M300411200.
   BERNHARDT R, 1983, BIOCHIM BIOPHYS ACTA, V745, P140, DOI 10.1016/0167-4838(83)90042-0.
   Chiang CW, 2006, J MOL BIOL, V364, P266, DOI 10.1016/j.jmb.2006.09.039.
   Clodfelter KH, 2006, BIOCHEMISTRY-US, V45, P9393, DOI 10.1021/bi060343v.
   Corry B, 2005, BIOPHYS J, V89, pL49, DOI 10.1529/biophysj.105.072009.
   Croney JC, 2003, FEBS LETT, V550, P175, DOI 10.1016/S0014-5793(03)00870-6.
   Davydov DR, 2005, BIOPHYS J, V89, P418, DOI 10.1529/biophysj.104.058479.
   Dunn AR, 2001, P NATL ACAD SCI USA, V98, P12420, DOI 10.1073/pnas.221297998.
   GOTOH O, 1992, J BIOL CHEM, V267, P83.
   Hammes GG, 2002, BIOCHEMISTRY-US, V41, P8221, DOI 10.1021/bi0260839.
   Heyduk T, 2002, CURR OPIN BIOTECH, V13, P292, DOI 10.1016/S0958-1669(02)00332-4.
   Hudecek J, 2007, BBA-GEN SUBJECTS, V1770, P413, DOI 10.1016/j.bbagen.2006.10.008.
   Kajihara D, 2006, NAT METHODS, V3, P923, DOI 10.1038/NMETH945.
   Lakowicz J. R., 1983, PRINCIPLES FLUORESCE.
   Lepesheva GI, 2007, BBA-GEN SUBJECTS, V1770, P467, DOI 10.1016/j.bbagen.2006.07.018.
   Lepesheva GI, 2006, J BIOL CHEM, V281, P3577, DOI 10.1074/jbc.M510317200.
   Lepesheva GI, 2003, BIOCHEMISTRY-US, V42, P9091, DOI 10.1021/bi034663f.
   Lepesheva GI, 2004, BIOCHEMISTRY-US, V43, P10789, DOI 10.1021/bi048967t.
   Lepesheva GI, 2001, J BIOL CHEM, V276, P28413, DOI 10.1074/jbc.M102767200.
   Lepesheva GI, 1999, BBA-PROTEIN STRUCT M, V1434, P31, DOI 10.1016/S0167-4838(99)00156-9.
   Li HY, 2004, CURR TOP MED CHEM, V4, P1789, DOI 10.2174/1568026043387205.
   Marme N, 2003, BIOCONJUGATE CHEM, V14, P1133, DOI 10.1021/bc0341324.
   Meharenna YT, 2004, BIOCHEMISTRY-US, V43, P9487, DOI 10.1021/bi049293p.
   Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8.
   Otyepka M, 2007, BBA-GEN SUBJECTS, V1770, P376, DOI 10.1016/j.bbagen.2006.09.013.
   Park SY, 2002, J INORG BIOCHEM, V91, P491, DOI 10.1016/S0162-0134(02)00446-4.
   Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898.
   Podust LM, 2001, J INORG BIOCHEM, V87, P227, DOI 10.1016/S0162-0134(01)00388-9.
   Podust LM, 2004, STRUCTURE, V12, P1937, DOI 10.1016/j.str.2004.08.009.
   Poulos TL, 2003, P NATL ACAD SCI USA, V100, P13121, DOI 10.1073/pnas.2336095100.
   Pylypenko O, 2004, ANNU REV BIOCHEM, V73, P991, DOI 10.1146/annurev.biochem.73.011303.073711.
   Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200.
   Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200.
   Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948.
   Smirnova IN, 2006, BIOCHEMISTRY-US, V45, P15279, DOI 10.1021/bi061632m.
   Tsalkova TN, 2007, BIOCHEMISTRY-US, V46, P106, DOI 10.1021/bi061944p.
   Wester MR, 2004, J BIOL CHEM, V279, P35630, DOI 10.1074/jbc.M405427200.
   Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi0345561.
   Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922.
   Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862.
   Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736.
   Xiao M, 2003, NAT STRUCT BIOL, V10, P402, DOI 10.1038/nsb916.
   Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200.
   Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200.
   Zhao B, 2006, BIOCHEMISTRY-US, V45, P7493, DOI 10.1021/bi060193o.
   Zhao YH, 2006, J BIOL CHEM, V281, P5973, DOI 10.1074/jbc.M511464200.}},
Number-of-Cited-References = {{46}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Arch. Biochem. Biophys.}},
Doc-Delivery-Number = {{201ZB}},
Unique-ID = {{ISI:000248870000009}},
}

@article{ ISI:000248870000010,
Author = {McLean, Kirsty J. and Dunford, Adrian J. and Neeli, Rajasekhar and
   Driscoll, Max D. and Munro, Andrew W.},
Title = {{Structure, function and drug targeting in Mycobacterium tuberculosis
   cytochrome P450 systems}},
Journal = {{ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS}},
Year = {{2007}},
Volume = {{464}},
Number = {{2}},
Pages = {{228-240}},
Month = {{AUG 15}},
Abstract = {{The human pathogen Mycobacterium tuberculosis has made a dramatic
   resurgence in recent years. Drug resistant and multidrug resistant
   strains are prevalent, and novel antibiotic strategies are desperately
   needed to counter Mtb's global spread. The M. tuberculosis genome
   sequence revealed an unexpectedly high number of cytochrome P450 (P450)
   enzymes (20), and parallel studies indicated that P450-inhibiting azole
   drugs had potent anti-mycobacterial activity. This article reviews
   current knowledge or structure/function of P450s and redox partner
   systems in M. tuberculosis. Recent research has highlighted potential
   drug target Mtb P450s and provided evidence for roles of selected P450
   isoforms in host lipid and sterol/steroid transformations. Structural
   analysis of key Mtb P450s has provided fundamental information on the
   nature of the heme binding site, P450 interactions with azole drugs, the
   biochemical nature of cytochrome P420, and novel mutational adaptations
   by which azole binding to P450s may be diminished to facilitate azole
   resistance. (c) 2007 Elsevier Inc. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Munro, AW (Reprint Author), Univ Manchester, Fac Life Sci, Manchester Interdisciplinary Bioctr, 131 Princess St, Manchester M1 7DN, Lancs, England.
   Univ Manchester, Fac Life Sci, Manchester Interdisciplinary Bioctr, Manchester M1 7DN, Lancs, England.}},
DOI = {{10.1016/j.abb.2007.03.026}},
ISSN = {{0003-9861}},
Keywords = {{tuberculosis; cytochrome P450; azole drugs; CYP121; CYP51; FprA;
   ferredoxins; cholesterol; lipids}},
Keywords-Plus = {{COMPLETE GENOME SEQUENCE; STEROL 14-ALPHA-DEMETHYLASE; ADRENODOXIN
   REDUCTASE; CRYSTAL-STRUCTURE; FERREDOXIN REDUCTASE;
   CATALYTIC-PROPERTIES; AZOLE ANTIFUNGALS; ESCHERICHIA-COLI;
   CANDIDA-ALBICANS; P450 SYSTEMS}},
Research-Areas = {{Biochemistry \& Molecular Biology; Biophysics}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Biophysics}},
Author-Email = {{Andrew.Munro@Manchester.ac.uk}},
Funding-Acknowledgement = {{Biotechnology and Biological Sciences Research Council {[}BBS/B/06288/2,
   C19757/2]}},
Cited-References = {{Adler JJ, 1996, TUBERCULOSIS, P129.
   Ahmad Z, 2005, FEMS MICROBIOL LETT, V251, P19, DOI 10.1016/j.femsle.2005.07.022.
   Ahmad Z, 2006, FEMS MICROBIOL LETT, V261, P181, DOI 10.1111/j.1574-6968.2006.00350.x.
   Aoyama Y, 1998, J BIOCHEM-TOKYO, V124, P694.
   Bak S, 1997, PLANT J, V11, P191, DOI 10.1046/j.1365-313X.1997.11020191.x.
   Bellamine A, 1999, P NATL ACAD SCI USA, V96, P8937, DOI 10.1073/pnas.96.16.8937.
   Bellamine A, 2004, J LIPID RES, V45, P2000, DOI 10.1194/jlr.M400239-JLR200.
   Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a.
   Berger BJ, 2003, BMC MICROBIOL, V3, DOI 10.1186/1471-2180-3-12.
   BESRA GS, 1993, BIOCHEMISTRY-US, V32, P12705, DOI 10.1021/bi00210a020.
   Betts JC, 2003, ANTIMICROB AGENTS CH, V47, P2903, DOI 10.1128/AAC.47.9.2903-2913.2003.
   Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453.
   Bossi RT, 2002, BIOCHEMISTRY-US, V41, P8807, DOI 10.1021/bi025858a.
   Brodin P, 2004, TRENDS MICROBIOL, V12, P500, DOI 10.1016/j.tim.2004.09.007.
   Burguiere A, 2005, MICROBIOL-SGM, V151, P2087, DOI 10.1099/mic.0.27938-0.
   Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0.
   Cole ST, 1998, NATURE, V396, P190, DOI 10.1038/24206.
   Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006.
   Duncan K, 2004, CURR OPIN MICROBIOL, V7, P460, DOI 10.1016/j.mib.2004.08.011.
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0.
   Ekroos M, 2006, P NATL ACAD SCI USA, V103, P13682, DOI 10.1073/pnas.0603236103.
   Etienne G, 2002, MICROBIOL-SGM, V148, P3089.
   Fischer F, 2002, EUR J BIOCHEM, V269, P3005, DOI 10.1046/j.1432-1033.2002.02989.x.
   Fisher MA, 2002, J BACTERIOL, V184, P4025, DOI 10.1128/JB.184.14.4025-4032.2002.
   Gamieldien J, 2002, TRENDS GENET, V18, P5, DOI 10.1016/S0168-9525(01)02529-X.
   Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100.
   Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647.
   Girvan HM, 2004, J BIOL CHEM, V279, P23274, DOI 10.1074/jbc.M401716200.
   Gradmann C, 2006, MICROBES INFECT, V8, P294, DOI 10.1016/j.micinf2005.06.004.
   Hanoulle X, 2006, J ANTIMICROB CHEMOTH, V58, P768, DOI 10.1093/jac/dkl332.
   Harries AD, 2006, ANN TROP MED PARASIT, V100, P415, DOI 10.1179/136485906X91477.
   Hishiki T, 2000, J BIOCHEM-TOKYO, V128, P965.
   Kendall SL, 2004, TRENDS MICROBIOL, V12, P537, DOI 10.1016/j.tim.2004.10.005.
   Lamb DC, 2000, ANTIMICROB AGENTS CH, V44, P63.
   Lepesheva GI, 2006, BIOCHEM SOC T, V34, P1161.
   Lepesheva GI, 2003, BIOCHEMISTRY-US, V42, P9091, DOI 10.1021/bi034663f.
   Lepesheva GI, 2001, J BIOL CHEM, V276, P28413, DOI 10.1074/jbc.M102767200.
   Leys D, 2003, J BIOL CHEM, V278, P5141, DOI 10.1074/jbc.M209928200.
   Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140.
   Li J, 2001, J BIOL CHEM, V276, P1503, DOI 10.1074/jbc.M007198200.
   Marichal P, 1999, MICROBIOL-SGM, V145, P2701.
   McLean KJ, 2006, BIOCHEM SOC T, V34, P1178.
   McLean KJ, 2002, MICROBIOL-SGM, V148, P2937.
   McLean KJ, 2006, BIOCHEMISTRY-US, V45, P8427, DOI 10.1021/bi0601609.
   McLean KJ, 2003, BIOCHEM J, V372, P317, DOI 10.1042/BJ20021692.
   McLean KJ, 2006, TRENDS MICROBIOL, V14, P220, DOI 10.1016/j.tim.2006.03.002.
   McLean KJ, 2002, J INORG BIOCHEM, V91, P527, DOI 10.1016/S0162-0134(02)00479-8.
   MCLEAN KM, UNPUB.
   Munro AW, 2007, BBA-GEN SUBJECTS, V1770, P345, DOI 10.1016/j.bbagen.2006.08.018.
   Muskett FW, 1996, J MOL BIOL, V258, P172, DOI 10.1006/jmbi.1996.0241.
   Nagano S, 2005, J BIOL CHEM, V280, P31659, DOI 10.1074/jbc.M505261200.
   Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352.
   Obata S, 2006, INT J ANTIMICROB AG, V27, P32, DOI 10.1016/j.ijantimicag.2005.09.015.
   Odds FC, 2003, TRENDS MICROBIOL, V11, P272, DOI 10.1016/S0966-842X(03)00117-3.
   Ogura H, 2004, BIOCHEMISTRY-US, V43, P14712, DOI 10.1021/bi048980d.
   Pennati A, 2006, BIOCHEMISTRY-US, V45, P8712, DOI 10.1021/bi060369m.
   Perera R, 2003, P NATL ACAD SCI USA, V100, P3641, DOI 10.1073/pnas.0737142100.
   Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898.
   Podust LM, 2004, STRUCTURE, V12, P1937, DOI 10.1016/j.str.2004.08.009.
   Poulos TL, 2005, BIOCHEM BIOPH RES CO, V338, P337, DOI 10.1016/j.bbrc.2005.07.204.
   Recchi C, 2003, J BIOL CHEM, V278, P33763, DOI 10.1074/jbc.M305963200.
   Rozman D, 1996, GENOMICS, V38, P371, DOI 10.1006/geno.1996.0640.
   Ruckert C, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-121.
   Russell DG, 2007, NAT REV MICROBIOL, V5, P39, DOI 10.1038/nrmicro1538.
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x.
   Seward HE, 2006, J BIOL CHEM, V281, P39437, DOI 10.1074/jbc.M607665200.
   Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498.
   Sherman DR, 2001, P NATL ACAD SCI USA, V98, P15393.
   Stewart GR, 2002, MICROBIOL-SGM, V148, P3129.
   Timmins GS, 2006, MOL MICROBIOL, V62, P1220, DOI 10.1111/j.1365-2958.2006.05467.x.
   Van der Geize R, 2007, P NATL ACAD SCI USA, V104, P1947, DOI 10.1073/pnas.0605728104.
   Vannelli TA, 2002, J BIOL CHEM, V277, P12824, DOI 10.1074/jbc.M110751200.
   Waterman MR, 2005, BIOCHEM BIOPH RES CO, V338, P418, DOI 10.1016/j.bbrc.2005.08.118.
   Ying Z, 2005, ANNU REV PHARMACOL, V45, P529, DOI 10.1146/annurev.pharmtox.45.120403.100120.
   Zanno A, 2005, BBA-BIOENERGETICS, V1707, P157, DOI 10.1016/j.bbabio.2004.11.010.
   Zhang Y, 2003, J ANTIMICROB CHEMOTH, V52, P790, DOI 10.1093/jac/dkg446.
   Zhang Y, 2003, INT J TUBERC LUNG D, V7, P6.
   Zhao XB, 2006, BIOCHEMISTRY-US, V45, P4131, DOI 10.1021/bi051967o.
   Ziegler GA, 1999, J MOL BIOL, V289, P981, DOI 10.1006/jmbi.1999.2807.
   D NELSONS CYTOCHROME.}},
Number-of-Cited-References = {{80}},
Times-Cited = {{40}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{16}},
Journal-ISO = {{Arch. Biochem. Biophys.}},
Doc-Delivery-Number = {{201ZB}},
Unique-ID = {{ISI:000248870000010}},
}

@article{ ISI:000248172700027,
Author = {Pathak, Ashish K. and Pathaka, Vibha and Seitz, Lainne and Gurcha,
   Sudagar S. and Besra, Gurdyal S. and Riordan, James M. and Reynolds,
   Robert C.},
Title = {{Disaccharide analogs as probes for glycosyltransferases in Mycobacterium
   tuberculosis}},
Journal = {{BIOORGANIC \& MEDICINAL CHEMISTRY}},
Year = {{2007}},
Volume = {{15}},
Number = {{16}},
Pages = {{5629-5650}},
Month = {{AUG 15}},
Abstract = {{Glycosyltransferases (GTs) play a crucial role in mycobacterial cell
   wall biosynthesis and are necessary for the survival of mycobacteria.
   Hence, these enzymes are potential new drug targets for the treatment of
   tuberculosis (TB), especially multiple drug-resistant TB (MDR-TB).
   Herein, we report the efficient syntheses of Araf(alpha 1 -> 5)Araf,
   Ga1f(beta 1 -> 5)Galf and Galf(beta 1 -> 6)Galf disaccharides possessing
   a 5-N,N-dimethylaminonaphthalene-l-sulfonamidoethyl (dansyl) unit that
   were prepared as fluorescent disaccharide acceptors for arabinosyl- and
   galactosyl-transferases, respectively. Such analogs may offer advantages
   relative to radiolabeled acceptors or donors for studying the enzymes
   and for assay development and compound screening. Additionally, analogs
   possessing a 5-azidonaphthalene-1-sulfonamidoethyl unit were prepared as
   photoaffinity probes for then-potential utility in studying active site
   labeling of the GTs (arabinosyl and galactosyl) in MYcobacterium
   tuberculosis (MTB). Beyond their preparation, initial biological testing
   and kinetic analysis of these disaccharides as acceptors toward
   glycosyltransferases are also presented. (C) 2007 Elsevier Ltd. All
   rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Reynolds, RC (Reprint Author), So Res Inst, Drug Discovery Div, PO Box 55305, Birmingham, AL 35255 USA.
   So Res Inst, Drug Discovery Div, Birmingham, AL 35255 USA.
   Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.
   Western Illinois Univ, Dept Chem, Macomb, IL 61455 USA.}},
DOI = {{10.1016/j.bmc.2007.04.012}},
ISSN = {{0968-0896}},
Keywords = {{arabinofuranose; galactofuranose; fluorescent probe; photoaffinity
   probe; glycosyltransferases.; arabinosyltransferases;
   galactosyltransferases; tuberculosis}},
Keywords-Plus = {{DRUG-RESISTANT TUBERCULOSIS; CELL-WALL; ARABINOSYLTRANSFERASE ACTIVITY;
   ARABINOFURANOSYL DISACCHARIDE; MOLECULAR-MECHANISMS;
   TRANSFERASE-ACTIVITY; MASS-SPECTROMETRY; BIOSYNTHESIS; ARABINOGALACTAN;
   INFECTION}},
Research-Areas = {{Biochemistry \& Molecular Biology; Pharmacology \& Pharmacy; Chemistry}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic}},
Author-Email = {{reynolds@ocsri.org}},
ORCID-Numbers = {{Pathak, Ashish/0000-0003-0143-7979
   Besra, Gurdyal/0000-0002-5605-0395}},
Funding-Acknowledgement = {{Medical Research Council {[}G0500590]; NCI NIH HHS {[}CA-13148, P30
   CA013148]; NIAID NIH HHS {[}R01 AI045317, R01 AI045317-04, R01AI45317];
   Wellcome Trust}},
Cited-References = {{ABOUZEID C, 1982, EUR J BIOCHEM, V128, P363.
   BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359.
   Bayley H, 1977, Methods Enzymol, V46, P69.
   BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015.
   Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215.
   BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333.
   CHITTENDEN GJ, 1972, CARBOHYD RES, V25, P35, DOI 10.1016/S0008-6215(00)82743-3.
   CORY PP, 1968, J AM CHEM SOC, P1643.
   CYR N, 1979, CAN J CHEM, V57, P2504, DOI 10.1139/v79-399.
   D'Souza FW, 1998, J ORG CHEM, V63, P9037, DOI 10.1021/jo9815406.
   DAFFE M, 1990, J BIOL CHEM, V265, P6734.
   de Jong BC, 2004, ANNU REV MED, V55, P283, DOI 10.1146/annurev.med.55.091902.103753.
   EBERLE AN, 1985, METHOD ENZYMOL, V109, P129.
   GREENE TW, 1999, PROTECTIVE GROUPS OR, P86.
   GUTHRIE RD, 1968, CHEM IND-LONDON, P547.
   HAZUM E, 1983, METHOD ENZYMOL, V103, P58.
   KAM BL, 1979, CARBOHYD RES, V69, P135, DOI 10.1016/S0008-6215(00)85758-4.
   Lee RE, 1996, CURR TOP MICROBIOL, V215, P1.
   Lee RE, 1997, GLYCOBIOLOGY, V7, P1121, DOI 10.1093/glycob/7.8.1121.
   Long R, 2000, CAN MED ASSOC J, V163, P425.
   MAUCH H, 1993, ZBL HYG UMWELTMED, V194, P152.
   Mikusova K, 2000, J BIOL CHEM, V275, P33890, DOI 10.1074/jbc.M006875200.
   Mikusova K, 2006, J BACTERIOL, V188, P6592, DOI 10.1128/JB.00489-06.
   MIZUTANI K, 1989, CARBOHYD RES, V185, P27, DOI 10.1016/0008-6215(89)84018-2.
   MURAMOTO K, 1984, AGR BIOL CHEM TOKYO, V48, P2695.
   Pathak A K, 2001, Carbohydr Lett, V4, P117.
   Pathak AK, 1998, TETRAHEDRON LETT, V39, P1497, DOI 10.1016/S0040-4039(98)00051-3.
   Pathak AK, 2004, CARBOHYD RES, V339, P683, DOI 10.1016/j.carres.2003.10.031.
   Pathak AK, 2002, BIOORGAN MED CHEM, V10, P923, DOI 10.1016/S0968-0896(01)00343-1.
   Pathak AK, 2002, BIOORG MED CHEM LETT, V12, P2749, DOI 10.1016/S0960-894X(02)00536-X.
   Pathak AK, 1999, BIOORGAN MED CHEM, V7, P2407, DOI 10.1016/S0968-0896(99)00199-6.
   Pathak AK, 2001, TETRAHEDRON LETT, V42, P979, DOI 10.1016/S0040-4039(00)02161-4.
   Pathak AK, 2001, BIOORGAN MED CHEM, V9, P3129, DOI 10.1016/S0968-0896(01)00179-1.
   Pathak AK, 2001, BIOORGAN MED CHEM, V9, P3145, DOI 10.1016/S0968-0896(01)00180-8.
   Rattan A, 1998, EMERG INFECT DIS, V4, P195.
   Raviglione MC, 2000, SCOT MED J, V45, P52.
   Reynolds RC, 1999, CARBOHYD RES, V317, P164, DOI 10.1016/S0008-6215(99)00069-5.
   Rose NL, 2006, J AM CHEM SOC, V128, P6721, DOI 10.1021/ja058254d.
   SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P47.
   Van Scoy RE, 1999, MAYO CLIN PROC, V74, P1038.
   Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219.}},
Number-of-Cited-References = {{41}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Bioorg. Med. Chem.}},
Doc-Delivery-Number = {{192AI}},
Unique-ID = {{ISI:000248172700027}},
}

@article{ ISI:000248877800025,
Author = {Pathak, Ashish K. and Pathak, Vibha and Riordan, James R. and Suling,
   William J. and Gurcha, Sudagar S. and Besra, Gurdyal S. and Reynolds,
   Robert C.},
Title = {{Synthesis of symmetrical C- and pseudo-symmetrical O-linked disaccharide
   analogs for arabinosyltransferase inhibitory activity in Mycobacterium
   tuberculosis}},
Journal = {{BIOORGANIC \& MEDICINAL CHEMISTRY LETTERS}},
Year = {{2007}},
Volume = {{17}},
Number = {{16}},
Pages = {{4527-4530}},
Month = {{AUG 15}},
Abstract = {{Herein we report the Synthesis of symmetrical C-linked and
   pseudo-symmetrical O-linked disaccharides structurally related to Araf
   motifs present in the cell wall of MTB. Their activity in a
   competition-based arabinosyltransferase assay using {[}C-14]-DPA as the
   glycosyl donor is also presented. In addition, in vitro inhibitory
   activity for the disaccharides was determined in a colorimetric broth
   microdilution assay system against MTB H37Ra and Mycobacterium avium.
   (c) 2007 Elsevier Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Reynolds, RC (Reprint Author), So Res Inst, Drug Discovery Div, POB 55305, Birmingham, AL 35255 USA.
   So Res Inst, Drug Discovery Div, Birmingham, AL 35255 USA.
   Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.}},
DOI = {{10.1016/j.bmcl.2007.05.099}},
ISSN = {{0960-894X}},
Keywords = {{tuberculosis; glycosyltransferases; inhibitors; disaccharides}},
Keywords-Plus = {{CELL-WALL; ARABINOFURANOSYL DISACCHARIDE; POTENTIAL INHIBITORS; MOTIF;
   OLIGOSACCHARIDES; BIOSYNTHESIS; ETHAMBUTOL; PROBE; ASSAY}},
Research-Areas = {{Pharmacology \& Pharmacy; Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Chemistry, Organic}},
Author-Email = {{reynolds@sri.org}},
ORCID-Numbers = {{Pathak, Ashish/0000-0003-0143-7979
   Besra, Gurdyal/0000-0002-5605-0395}},
Funding-Acknowledgement = {{Medical Research Council {[}G0500590]; NIAID NIH HHS {[}R01AI45317, R01
   AI045317, R01 AI045317-04]; Wellcome Trust}},
Cited-References = {{Aslam T, 2005, TETRAHEDRON LETT, V46, P3249, DOI 10.1016/j.tetlet.20005.03.017.
   Basso LA, 1998, ADV EXP MED BIOL, V456, P115.
   BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333.
   Chang GX, 2006, TETRAHEDRON LETT, V47, P4561, DOI 10.1016/j.tetlet.2006.05.008.
   Cociorva OM, 2004, CARBOHYD RES, V339, P853, DOI 10.1016/j.carres.2003.12.015.
   COLLINS FM, 1993, CRIT REV MICROBIOL, V19, P1, DOI 10.3109/10408419309113520.
   DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213.
   Dondoni A, 2003, TETRAHEDRON LETT, V44, P4067, DOI 10.1016/S0040-4039(03)00844-X.
   Dondoni A, 1997, J ORG CHEM, V62, P8114, DOI 10.1021/jo971177n.
   Gurjar MK, 2002, TETRAHEDRON LETT, V43, P7577, DOI 10.1016/S0040-4039(02)01760-4.
   LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002.
   Lee RE, 1997, GLYCOBIOLOGY, V7, P1121, DOI 10.1093/glycob/7.8.1121.
   Lowary TL, 2002, J CARBOHYD CHEM, V21, P691, DOI 10.1081/CAR-120016487.
   Pathak A K, 2001, Carbohydr Lett, V4, P117.
   Pathak AK, 2003, TETRAHEDRON, V59, P10239, DOI 10.1016/j.tet.2003.10.054.
   Pathak AK, 2002, BIOORG MED CHEM LETT, V12, P2749, DOI 10.1016/S0960-894X(02)00536-X.
   Pathak AK, 2001, TETRAHEDRON LETT, V42, P979, DOI 10.1016/S0040-4039(00)02161-4.
   Pathak AK, 2001, BIOORGAN MED CHEM, V9, P3145, DOI 10.1016/S0968-0896(01)00180-8.
   Reynolds RC, 1999, CARBOHYD RES, V317, P164, DOI 10.1016/S0008-6215(99)00069-5.
   Sanchez S, 2000, TETRAHEDRON LETT, V41, P7447, DOI 10.1016/S0040-4039(00)01273-9.
   Suling WJ, 1998, J ANTIMICROB CHEMOTH, V42, P811, DOI 10.1093/jac/42.6.811.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Bioorg. Med. Chem. Lett.}},
Doc-Delivery-Number = {{202BX}},
Unique-ID = {{ISI:000248877800025}},
}

@article{ ISI:000248877800036,
Author = {Bonnac, Laurent and Gao, Guang-Yao and Chen, Liqiang and Felczak,
   Krzysztof and Bennett, Eric M. and Xu, Hua and Kim, TaeSoo and Liu, Nina
   and Oh, HyeWon and Tonge, Peter J. and Pankiewicz, Krzysztof W.},
Title = {{Synthesis of 4-phenoxybenzamide adenine dinucleotide as NAD analogue
   with inhibitory activity against enoyl-ACP reductase (InhA) of
   Mycobacterium tuberculosis}},
Journal = {{BIOORGANIC \& MEDICINAL CHEMISTRY LETTERS}},
Year = {{2007}},
Volume = {{17}},
Number = {{16}},
Pages = {{4588-4591}},
Month = {{AUG 15}},
Abstract = {{The chemical synthesis of 4-phenoxybenzamide adenine dinucleotide (3), a
   NAD analogue which mimics isoniazid-NAD adduct and inhibits
   Mycobacterium tuberculosis NAD-dependent enoyl-ACP reductase (InhA), is
   reported. The 4-phenoxy benzamide riboside (1) has been prepared as a
   key intermediate, converted into its 5 `-mononucleotide (2), and coupled
   with AMP imidazolide to give the desired NAD analogue 3. It inhibits
   InhA with IC50 = 27 mu M. (c) 2007 Elsevier Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Pankiewicz, KW (Reprint Author), Univ Minnesota, Ctr Drug Design, Minneapolis, MN 55455 USA.
   Univ Minnesota, Ctr Drug Design, Minneapolis, MN 55455 USA.
   SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.}},
DOI = {{10.1016/j.bmcl.2007.05.084}},
ISSN = {{0960-894X}},
Keywords = {{M. tuberculosis; enoyl-ACP reductase (InhA); NAD analogues; isoniazid;
   fragment-based drug discovery}},
Keywords-Plus = {{CATALASE-PEROXIDASE; CHEMICAL-SYNTHESIS; ISONIAZID TARGET;
   DRUG-RESISTANCE; PROTEIN; ADDUCTS; BINDING; AGENTS; KATG; IDENTIFICATION}},
Research-Areas = {{Pharmacology \& Pharmacy; Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Chemistry, Organic}},
Author-Email = {{panki001@umn.edu}},
ResearcherID-Numbers = {{Tonge, Peter/A-7443-2009
   Liu, Nina/G-2837-2013}},
Cited-References = {{Argyrou A, 2006, NAT STRUCT MOL BIOL, V13, P408, DOI 10.1038/nsmb1089.
   Aziz MA, 2006, LANCET, V368, P2142, DOI 10.1016/S0140-6736(06)69863-2.
   Basso LA, 1998, J INFECT DIS, V178, P769.
   Bonnac L, 2007, BIOORG MED CHEM LETT, V17, P1512, DOI 10.1016/j.bmcl.2007.01.012.
   Broussy S, 2005, J ORG CHEM, V70, P10502, DOI 10.1021/jo051901z.
   Broussy S, 2003, CHEM-EUR J, V9, P2034, DOI 10.1002/chem.200204637.
   Choi KH, 2000, J BIOL CHEM, V275, P28201.
   Delaine T, 2007, J ORG CHEM, V72, P675, DOI 10.1021/jo062100e.
   DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450.
   Ducasse-Cabanot S, 2004, ANTIMICROB AGENTS CH, V48, P242, DOI 10.1128/AAC.48.1.242-249.2004.
   Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200.
   Kristensen JL, 2003, J ORG CHEM, V68, P4091, DOI 10.1021/jo0300340.
   KUO MR, 2003, J BIOL CHEM, V26, P26.
   Lei BF, 2000, J BIOL CHEM, V275, P2520, DOI 10.1074/jbc.275.4.2520.
   Merchant KJ, 2000, TETRAHEDRON LETT, V41, P3747, DOI 10.1016/S0040-4039(00)00482-2.
   Morlock GP, 2003, ANTIMICROB AGENTS CH, V47, P3799, DOI 10.1128/AAC.47.12.3799-3805.2003.
   Nguyen M, 2002, ANTIMICROB AGENTS CH, V46, P2137, DOI 10.1128/AAC.46.7.2137-2144.2002.
   Nguyen M, 2001, CHEMBIOCHEM, V2, P877, DOI 10.1002/1439-7633(20011203)2:12<877::AID-CBIC877>3.0.CO;2-V.
   Ormerod LP, 2005, BRIT MED BULL, V73-74, P17, DOI 10.1093/bmb/ldh047.
   Pankiewicz KW, 2004, CURR MED CHEM, V11, P887, DOI 10.2174/0929867043455648.
   Pankiewicz KW, 2002, J MED CHEM, V45, P703, DOI 10.1021/jm0104116.
   Pankiewicz KW, 1997, J MED CHEM, V40, P1287, DOI 10.1021/jm960641y.
   Pasqualoto KFM, 2004, J MED CHEM, V47, P3755, DOI 10.1021/jm049913k.
   Raviglione MC, 2007, NEW ENGL J MED, V356, P656, DOI 10.1056/NEJMp068273.
   Rawat R, 2003, P NATL ACAD SCI USA, V100, P13881, DOI 10.1073/pnas.2235848100.
   Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98.
   Schaeffer ML, 2001, J BIOL CHEM, V276, P47029, DOI 10.1074/jbc.M108903200.
   Wei CJ, 2003, ANTIMICROB AGENTS CH, V47, P670, DOI 10.1128/AAC.47.2.670-675.2003.
   Zatorski A, 1996, J MED CHEM, V39, P2422, DOI 10.1021/jm9601415.
   Zhao XB, 2007, BIOCHEMISTRY-US, V46, P3161, DOI 10.1021/bi062218p.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{14}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{Bioorg. Med. Chem. Lett.}},
Doc-Delivery-Number = {{202BX}},
Unique-ID = {{ISI:000248877800036}},
}

@article{ ISI:000248079500004,
Author = {Alisjahbana, Bachti and Sahiratmadja, Edhyana and Nelwan, Erni J. and
   Purwa, Anugrah Maya and Ahmad, Yana and Ottenhoff, Tom H. M. and Nelwan,
   Ronald H. H. and Parwati, Ida and van der Meer, Jos W. M. and van
   Crevel, Reinout},
Title = {{The effect of type 2 diabetes mellitus on the presentation and treatment
   response of pulmonary tuberculosis}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{45}},
Number = {{4}},
Pages = {{428-435}},
Month = {{AUG 15}},
Abstract = {{Background. Diabetes mellitus (DM) is a known risk factor for
   tuberculosis (TB), and with the increasing prevalence of type 2 DM in
   less developed regions, many patients with TB will have concomitant DM.
   Presently, little is known about the effect of DM on the clinical
   presentation and treatment outcome of TB.
   Methods. In an urban setting in Indonesia, 737 patients with pulmonary
   TB were screened for DM and were followed up prospectively during TB
   treatment. Clinical characteristics and outcome were compared between
   patients with TB who had DM and patients with TB who did not have DM.
   Results. DM was diagnosed in 14.8\% of patients with TB and was
   associated with older age and a greater body weight. On presentation,
   diabetic patients with TB had more symptoms but had no evidence of
   more-severe TB. After 2 months, results of sputum microscopic
   examination was more often positive in diabetic patients (18.1\% vs.
   10.0\%). After 6 months, 22.2\% of cultured sputum specimens from
   diabetic patients were positive for Mycobacterium tuberculosis (adjusted
   odds ratio, 7.65; p = .004).
   Conclusion. DM seems to have a negative effect on the outcome of TB
   treatment. The underlying mechanisms for the different response to
   treatment in diabetic patients with TB must be explored. Screening for
   DM and subsequent glycemic control may improve the outcome of TB
   treatment.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{van Crevel, R (Reprint Author), Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, PO Box 9101, NL-6500 HB Nijmegen, Netherlands.
   Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands.
   Padjadjaran State Univ, Fac Med, Dept Clin Pathol, Bandung, Indonesia.
   Univ Indonesia, Fac Med, Eijkman Inst Mol Biol, Jakarta, Indonesia.
   Univ Indonesia, Fac Med, Infect Dis Working Grp, Jakarta, Indonesia.
   Leiden Univ, Fac Med, Dept Immunohematol \& Blood Transfus, Leiden, Netherlands.
   Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands.}},
DOI = {{10.1086/519841}},
ISSN = {{1058-4838}},
Keywords-Plus = {{RISK-FACTORS; PREVALENCE}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{r.vancrevel@aig.umcn.nl}},
ResearcherID-Numbers = {{van Crevel, reinout/A-6636-2010
   van der Meer, Jos/C-8521-2013}},
ORCID-Numbers = {{van der Meer, Jos/0000-0001-5120-3690}},
Cited-References = {{Alisjahbana B, 2006, INT J TUBERC LUNG D, V10, P696.
   American Diabetes A, 2006, DIABETES CARE S1, V29, pS43.
   Bacakoglu F, 2001, RESPIRATION, V68, P595, DOI 10.1159/000050578.
   BOUCOT KR, 1952, AM REV TUBERC PULM, V65, P1.
   Coker R, 2006, BRIT MED J, V332, P85, DOI 10.1136/bmj.38684.687940.80.
   FALK A, 1979, DIAGNOSTIC STANDARDS, P67.
   FIRSOVA VA, 2000, PROBL TUBERK, V4, P17.
   HENDY HH, 1983, BR J DIS CHEST, V77, P87.
   Jayaram R, 2003, ANTIMICROB AGENTS CH, V47, P2118, DOI 10.1128/AAC.47.7.2118-2124.2003.
   Jindani A, 2004, LANCET, V364, P1244, DOI 10.1016/S0140-6736(04)17141-9.
   Kim SJ, 1995, TUBERCLE LUNG DIS, V76, P529, DOI 10.1016/0962-8479(95)90529-4.
   LUNTZ GRWN, 1957, BRIT MED J, V1, P1082.
   Mboussa J, 2003, Rev Pneumol Clin, V59, P39.
   MOR V, 1984, CANCER, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W.
   MORRIS JT, 1992, CHEST, V102, P539, DOI 10.1378/chest.102.2.539.
   Mos-Antkowiak R, 1991, Pneumonol Alergol Pol, V59, P43.
   MUGUSI F, 1990, TUBERCLE, V71, P271, DOI 10.1016/0041-3879(90)90040-F.
   Nijland HMJ, 2006, CLIN INFECT DIS, V43, P848, DOI 10.1086/507543.
   NISSAPATORN V, 2005, ASIAN J TROP MED S4, V36, P213.
   Peloquin CA, 2002, DRUGS, V62, P2169, DOI 10.2165/00003495-200262150-00001.
   Ponce-De-Leon A, 2004, DIABETES CARE, V27, P1584, DOI 10.2337/diacare.27.7.1584.
   Restrepo BI, 2007, EPIDEMIOL INFECT, V135, P483, DOI 10.1017/S0950268806006935.
   Root HF, 1934, NEW ENGL J MED, V210, P1, DOI 10.1056/NEJM193401042100101.
   Shaikh MA, 2003, SAUDI MED J, V24, P278.
   Shetty N, 2006, INT J TUBERC LUNG D, V10, P80.
   Singla R, 2006, INT J TUBERC LUNG D, V10, P74.
   UMUT S, 1994, CHEST, V106, P326.
   VANKLINGEREN B, IN PRESS J CLIN MICR.
   Wang JY, 2005, INT J TUBERC LUNG D, V9, P777.
   WEAVER RA, 1974, AM REV RESPIR DIS, V109, P162.
   World Health Organization, 2006, TREATM TUB GUID NAT.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{118}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{190SK}},
Unique-ID = {{ISI:000248079500004}},
}

@article{ ISI:000248079500005,
Author = {Restrepo, Blanca I.},
Title = {{Convergence of the tuberculosis and diabetes epidemics: Renewal of old
   acquaintances}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{45}},
Number = {{4}},
Pages = {{436-438}},
Month = {{AUG 15}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Restrepo, BI (Reprint Author), Univ Texas, Sch Publ Hlth, Hlth Sci Ctr, Univ Texas Brownsville, SPH Bldg, 80 Ft Brown, Brownsville, TX 78520 USA.
   Univ Texas, Sch Publ Hlth, Hlth Sci Ctr, Brownsville, TX 78520 USA.}},
DOI = {{10.1086/519939}},
ISSN = {{1058-4838}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; RISK-FACTORS; MELLITUS; ASSOCIATION; PREVALENCE;
   BORDER}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{Blanca.I.Restrepo@utb.edu}},
Funding-Acknowledgement = {{NCRR NIH HHS {[}M01 RR002558, M01-RR 02558, UL1 RR024148]; NIMHD NIH HHS
   {[}P20 MD000170-05, MD000170, P20 MD000170]; PHS HHS {[}R21 A1056207]}},
Cited-References = {{Alisjahbana B, 2006, INT J TUBERC LUNG D, V10, P696.
   Alisjahbana B, 2007, CLIN INFECT DIS, V45, P428, DOI 10.1086/519841.
   Bacakoglu F, 2001, RESPIRATION, V68, P595, DOI 10.1159/000050578.
   Banyai AL, 1931, AM REV TUBERC, V24, P650.
   Bashar M, 2001, CHEST, V120, P1514, DOI 10.1378/chest.120.5.1514.
   BLADE NM, 2006, INT J TUBERC LUNG D, V10, P1036.
   BOUCOT KR, 1952, AM REV TUBERC PULM, V65, P1.
   {*}CDCP, 2002, DIAB DIS DEAD RIS.
   Centers for Disease Control and Prevention, 2000, MMWR-MORBID MORTAL W, V49, P1.
   Coker R, 2006, BRIT MED J, V332, P85, DOI 10.1136/bmj.38684.687940.80.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Guler M, 2007, INT J CLIN PRACT, V61, P231, DOI 10.1111/j.1742-1241.2006.01131.x.
   Hill PC, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-156.
   Nijland HMJ, 2006, CLIN INFECT DIS, V43, P848, DOI 10.1086/507543.
   Oscarsson N, 1958, ACTA MED SCAND S335, V160, P23.
   Oursler KK, 2002, CLIN INFECT DIS, V34, P752, DOI 10.1086/338784.
   PablosMendez A, 1997, AM J PUBLIC HEALTH, V87, P574, DOI 10.2105/AJPH.87.4.574.
   Perez A, 2006, AM J TROP MED HYG, V74, P604.
   Perez-Guzman C, 2000, AM J RESP CRIT CARE, V162, P1738.
   Ponce-De-Leon A, 2004, DIABETES CARE, V27, P1584, DOI 10.2337/diacare.27.7.1584.
   Prentice AM, 2006, INT J EPIDEMIOL, V35, P93, DOI 10.1093/ije/dyi272.
   Restrepo BI, 2007, EPIDEMIOL INFECT, V135, P483, DOI 10.1017/S0950268806006935.
   Root HF, 1934, NEW ENGL J MED, V210, P1, DOI 10.1056/NEJM193401042100101.
   Ruder Kate, 2007, Diabetes Forecast, V60, P50.
   Shetty N, 2006, INT J TUBERC LUNG D, V10, P80.
   Singla R, 2006, INT J TUBERC LUNG D, V10, P74.
   World Health Organization (WHO), 2005, GLOB TUB CONTR SURV.
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047.
   2004, WKLY EPIDEMIOL REC, V79, P125.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{37}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{190SK}},
Unique-ID = {{ISI:000248079500005}},
}

@article{ ISI:000248959200006,
Author = {Liu, Philip T. and Stenger, Steffen and Tang, Dominic H. and Modlin,
   Robert L.},
Title = {{Cutting edge: Vitamin D-mediated human antimicrobial activity against
   Mycobacterium tuberculosis is dependent on the induction of cathelicidin}},
Journal = {{JOURNAL OF IMMUNOLOGY}},
Year = {{2007}},
Volume = {{179}},
Number = {{4}},
Pages = {{2060-2063}},
Month = {{AUG 15}},
Abstract = {{Host defense against intracellular pathogens depends upon innate and
   adaptive antimicrobial effector pathways. TLR2/1-activation of monocytes
   leads to the vitamin D-dependent production of cathelicidin and, at the
   same time, an antimicrobial activity against intracellular Mycobacterium
   tuberculosis. To determine whether induction of cathelicidin was
   required for the vitamin D-triggered antimicrobial activity, the human
   monocytic cell line THP-1 was infected with M. tuberculosis H37Ra and
   then activated with the active vitamin D hormone 1,25-dihydroxyvitamin
   D(3) (1,25D(3)). 1,25D3 stimulation resulted in antimicrobial activity
   against intracellular M. tuberculosis and expression of cathelicidin
   mRNA and protein. Using small interfering RNA (siRNA) specific for
   cathelicidin, 1,25D(3)-induced cathelicidin mRNA and protein expressions
   were efflciently knocked down, whereas a nonspecific siRNA control had
   little effect. Finally, 1,25D3-induced antimicrobial activity was
   completely inhibited in the presence of siRNA against cathelicidin,
   instead leading to enhanced intracellular growth of mycobacteria. These
   data demonstrate that cathelicidin is required for the
   1,25D(3)-triggered antimicrobial activity against intracellular M.
   tuberculosis.}},
Publisher = {{AMER ASSOC IMMUNOLOGISTS}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Modlin, RL (Reprint Author), Univ Calif Los Angeles, Div Dermatol, Ctr Hlth Sci, 52-121,10833 Le Contre Ave, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, Div Dermatol, Ctr Hlth Sci, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
   Univ Ulm, Inst Med Microbiol \& Hyg, Ulm, Germany.}},
ISSN = {{0022-1767}},
Keywords-Plus = {{TACO GENE-TRANSCRIPTION; HUMAN MACROPHAGES; MONOCYTES; PROTEIN}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{rmodlin@mednet.ucla.edu}},
ResearcherID-Numbers = {{Liu, Philip/C-2524-2009
   Liu, Philip/C-9638-2011
   }},
ORCID-Numbers = {{Modlin, Robert/0000-0003-4720-031X}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}2-T32-AI-07323, K22 AI085025, R01 AI22553, R01
   AI47868]; NIAMS NIH HHS {[}R01 AR40312]}},
Cited-References = {{Anand PK, 2005, FEMS MICROBIOL LETT, V250, P137, DOI 10.1016/j.femsle.2005.06.056.
   Anand PK, 2003, BIOCHEM BIOPH RES CO, V310, P876, DOI 10.1016/j.bbrc.2003.09.087.
   CROWLE AJ, 1987, INFECT IMMUN, V55, P2945.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Garcia VE, 1997, J IMMUNOL, V159, P1328.
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933.
   Martineau AR, 2007, J STEROID BIOCHEM, V103, P793, DOI 10.1016/j.jsbmb.2006.12.052.
   Martineau AR, 2007, J IMMUNOL, V178, P7190.
   MARTINEAU AR, 2007, IN PRESS AM J RESP C.
   Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a.
   Nozaki Y, 1997, INFECT IMMUN, V65, P3644.
   Rajavelu P, 2007, MICROBIOL IMMUNOL, V51, P201.
   ROOK GAW, 1986, IMMUNOLOGY, V57, P159.
   Sly LM, 2001, J BIOL CHEM, V276, P35482, DOI 10.1074/jbc.M102876200.
   Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544.
   Wang TT, 2004, J IMMUNOL, V173, P2909.
   WEINBERG JB, 1995, BLOOD, V86, P1184.
   Zahrt TC, 2001, P NATL ACAD SCI USA, V98, P12706, DOI 10.1073/pnas.221272198.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{384}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{25}},
Journal-ISO = {{J. Immunol.}},
Doc-Delivery-Number = {{203EZ}},
Unique-ID = {{ISI:000248959200006}},
}

@article{ ISI:000248959200056,
Author = {Wolf, Andrea J. and Linas, Beth and Trevejo-Nunez, Giraldina J. and
   Kincaid, Eleanor and Tamura, Toshiki and Takatsu, Kiyoshi and Ernst,
   Joel D.},
Title = {{Mycobacterium tuberculosis infects dendritic cells with high frequency
   and impairs their function in vivo}},
Journal = {{JOURNAL OF IMMUNOLOGY}},
Year = {{2007}},
Volume = {{179}},
Number = {{4}},
Pages = {{2509-2519}},
Month = {{AUG 15}},
Abstract = {{Mycobacterium tuberculosis (Mtb) is thought to reside in macrophages,
   although infected dendritic cells (DCs) have been observed. Thus,
   although cellular associations have been made, global characterization
   of the cells harboring Mtb is lacking. We have performed temporal and
   quantitative characterization of the cells harboring Mtb following
   aerosol infection of mice by using GFP-expressing bacteria and flow
   cytometry. We discovered that Mtb infects phagocytic cells of diverse
   phenotypes, that the predominant infected cell populations change with
   time, and that myeloid DCs are the major cell population infected with
   Mtb in the lungs and lymph nodes. We also found that the bacteria in the
   lung-draining lymph node are transported there from the lungs by a
   CCL19/21-dependent mechanism and that the transport of bacteria to the
   lymph node is a transient phenomenon despite chronic infection. In
   addition, we found that the lymph node cell subsets that are most
   efficacious in stimulating Mtb-specific, TCR-transgenic CD4(+) T
   lymphocytes are not infected with the bacteria and are scarce or absent
   from the lungs of infected mice. Finally, we found that the lung cell
   populations that are infected with Mtb at high frequency are relatively
   ineffective at stimulating Ag-specitic CD4(+) T lymphocytes, and we have
   obtained evidence that live Mtb can inhibit MHC class 11 Ag presentation
   without a decrease in the surface expression of MHC class II. These
   results indicate that Mtb targets DC migration and Ag presentation in
   vivo to promote persistent infection.}},
Publisher = {{AMER ASSOC IMMUNOLOGISTS}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Takatsu, K (Reprint Author), NYU, Sch Med, Div Infect Dis, Smilow Res Ctr,Dept Med, Room 901,550 1st Ave, New York, NY 10016 USA.
   NYU, Sch Med, Div Infect Dis, Smilow Res Ctr,Dept Med, New York, NY 10016 USA.
   Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA.
   Natl Inst Infect Dis, Leprosy Res Ctr, Dept Microbiol, Tokyo, Japan.
   Univ Tokyo, Inst Med Sci, Dept Microbiol \& Immunol, Div Immunol, Tokyo, Japan.
   NYU, Sch Med, Dept Pathol, New York, NY 10016 USA.
   NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.}},
ISSN = {{0022-1767}},
Keywords-Plus = {{CD4(+) T-CELLS; PULMONARY TUBERCULOSIS; LYMPH-NODES; INTERFERON-GAMMA;
   IFN-GAMMA; RECEPTOR; CHEMOKINE; MONOCYTE; IMMUNITY; VITRO}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{takatsuk@ims.u-tokyo.ac.jp
   joel.ernst@med.nyu.edu}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}R01-AI051242]}},
Cited-References = {{Bonecini-Almeida MG, 1998, J IMMUNOL, V160, P4490.
   Buettner M, 2005, J IMMUNOL, V174, P4203.
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243.
   Cowley SC, 2003, J IMMUNOL, V171, P4689.
   Cunningham RS, 1925, B JOHNS HOPKINS HOSP, V37, P231.
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249.
   Gonzalez-Juarrero M, 2003, J IMMUNOL, V171, P3128.
   Hanekom WA, 2003, J INFECT DIS, V188, P257, DOI 10.1086/376451.
   Henri S, 2001, J IMMUNOL, V167, P741.
   Hertz CJ, 2001, J IMMUNOL, V166, P2444.
   Humphreys IR, 2006, MICROBES INFECT, V8, P1339, DOI 10.1016/j.micinf.2005.12.023.
   Jakubzick C, 2006, J IMMUNOL, V176, P3578.
   Jiao XN, 2002, J IMMUNOL, V168, P1294.
   Landsman L, 2007, J IMMUNOL, V178, P2000.
   Legge KL, 2003, IMMUNITY, V18, P265, DOI 10.1016/S1074-7613(03)00023-2.
   Lezzi G., 2006, J IMMUNOL, V177, P1250.
   Medeiros MA, 2002, MICROBIOL-SGM, V148, P1999.
   Mogues T, 2001, J EXP MED, V193, P271, DOI 10.1084/jem.193.3.271.
   Nakano H, 2001, J IMMUNOL, V166, P361.
   North RJ, 2004, ANNU REV IMMUNOL, V22, P599, DOI 10.1146/annurev.immunol.22.012703.104635.
   Opie EL, 1927, ARCH PATHOL LAB MED, V4, P1.
   Perlman DC, 1997, CLIN INFECT DIS, V25, P242, DOI 10.1086/514546.
   Peters W, 2004, J IMMUNOL, V172, P7647.
   Peters W, 2001, P NATL ACAD SCI USA, V98, P7958, DOI 10.1073/pnas.131207398.
   Robertson HE, 1933, AM J PATHOL, V9, P711.
   Scott HM, 2002, INFECT IMMUN, V70, P5946, DOI 10.1128/IAI.70.11.5946-5954.2002.
   Shafer RW, 1996, AIDS, V10, P269, DOI 10.1097/00002030-199603000-00005.
   Silver RF, 1998, J IMMUNOL, V160, P2408.
   Somoskovi A, 2000, IMMUNOBIOLOGY, V201, P450.
   Sonnenberg P, 2005, J INFECT DIS, V191, P150, DOI 10.1086/426827.
   Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468.
   Tamura T, 2004, INT IMMUNOL, V16, P1691, DOI 10.1093/intimm/dxh170.
   Tian T, 2005, J IMMUNOL, V175, P3268.
   Vremec D, 1997, J IMMUNOL, V159, P565.
   WANG C, 1917, LANCET, V2, P417.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{259}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{9}},
Journal-ISO = {{J. Immunol.}},
Doc-Delivery-Number = {{203EZ}},
Unique-ID = {{ISI:000248959200056}},
}

@article{ ISI:000248959200058,
Author = {Ordway, Diane and Palanisamy, Gopinath and Henao-Tamayo, Marcela and
   Smith, Erin E. and Shanley, Crystal and Orme, Ian M. and Basaraba,
   Randall J.},
Title = {{The cellular immune response to Mycobacterium tuberculosis infection in
   the guinea pig}},
Journal = {{JOURNAL OF IMMUNOLOGY}},
Year = {{2007}},
Volume = {{179}},
Number = {{4}},
Pages = {{2532-2541}},
Month = {{AUG 15}},
Abstract = {{Pulmonary tuberculosis in guinea pigs is an extremely useful model for
   drug and vaccine testing due to the fact that its pathological disease
   process is similar to that present in humans. Progress in this field has
   been hindered because the tools necessary to undertake a complete
   immunological analysis of the guinea. pig cellular immune response
   against Mycobacterium tuberculosis have been lacking. In this study, we
   combined a new flow cytometric gating strategy with immunohistochemistry
   to track T cells, B cells, and the MIL4 Ab, which detects both guinea
   pig heterophils (neutrophils) and eosinophils, to provide the first
   documentation of the kinetics of influx and positioning of these cell
   populations. The results show that the responding T cells are mostly CD4
   cells and that after day 30 of the infection numbers of these cells in
   the lungs drops dramatically. These appear to be replaced by a steady
   increase in B cells and granulocytes which was associated with worsening
   lung pathology. These data reveal new information about the cellular
   phenotypes which mediate protective immunity or host immunopathogenesis
   during M. tuberculosis infection in this key animal model.}},
Publisher = {{AMER ASSOC IMMUNOLOGISTS}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ordway, D (Reprint Author), Colorado State Univ, Dept Microbiol Immunol \& Pathol, Mycobacteria Res Labs, Ft Collins, CO 80523 USA.
   Colorado State Univ, Dept Microbiol Immunol \& Pathol, Mycobacteria Res Labs, Ft Collins, CO 80523 USA.}},
ISSN = {{0022-1767}},
EISSN = {{1550-6606}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; PERIPHERAL-BLOOD; MICE; LYMPHOCYTES; VACCINES;
   DISEASE; ANTIGEN; IMMUNOPATHOGENESIS; IDENTIFICATION; PATHOGENESIS}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{D.Ordway-Rodtiguez@colostate.edu}},
ResearcherID-Numbers = {{Palanisamy, Gopinath/A-4467-2013
   Henao-Tamayo, Marcela/D-8189-2017
   Ordway, Diane/H-9732-2017}},
ORCID-Numbers = {{Henao-Tamayo, Marcela/0000-0002-4249-9650
   Ordway, Diane/0000-0003-0003-326X}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI-054697]}},
Cited-References = {{Ahlstrom-Emanuelsson CA, 2004, EUR RESPIR J, V24, P750, DOI 10.1183/09031936.04.00133603.
   Basaraba RJ, 2006, INFECT IMMUN, V74, P5397, DOI 10.1128/IAI.00332-06.
   Basaraba RJ, 2006, VACCINE, V24, P280, DOI 10.1016/j.vaccine.2005.07.103.
   Black GF, 2003, CLIN DIAGN LAB IMMUN, V10, P602, DOI 10.1112//CDLI.10.4.602-611.2003.
   BURGER R, 1983, J IMMUNOL, V131, P1350.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Dannenberg AM, 2006, PATHOGENESIS OF HUMAN PULMONARY TUBERCULOSIS: INSIGHTS FROM THE RABBIT MODEL, P1.
   Duncan K, 2003, TUBERCULOSIS, V83, P201, DOI 10.1016/S1472-9792(02)00076-8.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   Fine P, 2005, BRIT MED J, V331, P647, DOI 10.1136/bmj.331.7518.647.
   Fine PEM, 1998, VACCINE, V16, P1923, DOI 10.1016/S0264-410X(98)00124-8.
   Flynn JL, 2006, MICROBES INFECT, V8, P1179, DOI 10.1016/j.micinf.2005.10.033.
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93.
   Gonzalez-Juarrero M, 2001, INFECT IMMUN, V69, P1722, DOI 10.1128/IAI.69.3.1722-1728.2001.
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978.
   HART IJ, 1992, IMMUNOLOGY, V77, P377.
   HAVERSON K, 1994, J IMMUNOL METHODS, V170, P233, DOI 10.1016/0022-1759(94)90398-0.
   Hiromatsu K, 2002, IMMUNOLOGY, V106, P159, DOI 10.1046/j.1365-2567.2002.01422.x.
   Johnson CM, 1997, TUBERCLE LUNG DIS, V78, P257, DOI 10.1016/S0962-8479(97)90006-X.
   Johnson CM, 2005, ANTIMICROB AGENTS CH, V49, P4335, DOI 10.1128/AAC.49.10.4335-4338.2005.
   Junqueira-Kipnis AP, 2004, INFECT IMMUN, V72, P570, DOI 10.1128/IAI.72.1.570-575.2004.
   Kahnert A, 2007, J INFECT DIS, V195, P46, DOI 10.1086/508894.
   Kochi A, 2001, B WORLD HEALTH ORGAN, V79, P71.
   KRAAL G, 1986, EUR J IMMUNOL, V16, P1515, DOI 10.1002/eji.1830161208.
   Kraft SL, 2004, INFECT IMMUN, V72, P5963, DOI 10.1128/IAI.72.10.5963-5971.2004.
   MacKenzie JR, 2001, J IMMUNOL, V167, P3146.
   McMurray DN, 2005, TUBERCULOSIS, V85, P295, DOI 10.1016/j.tube.2005.08.012.
   Ordway D, 2006, J IMMUNOL, V176, P4931.
   Ordway D, 2007, J IMMUNOL, V179, P522.
   Orme IM, 2006, TUBERCULOSIS, V86, P68, DOI 10.1016/j.tube.2005.07.002.
   Orme IM, 2005, TUBERCULOSIS, V85, P13, DOI 10.1016/j.tube.2004.08.001.
   Orme IM, 1998, TRENDS MICROBIOL, V6, P94, DOI 10.1016/S0966-842X(98)01209-8.
   Rhoades ER, 1997, TUBERCLE LUNG DIS, V78, P57, DOI 10.1016/S0962-8479(97)90016-2.
   Rook GAW, 1996, ANNU REV MICROBIOL, V50, P259, DOI 10.1146/annurev.micro.50.1.259.
   SMITH DW, 1977, AM J PATHOL, V89, P273.
   SMITH DW, 1989, REV INFECT DIS, V11, pS385.
   Takizawa M, 2006, J IMMUNOL METHODS, V311, P47, DOI 10.1016/j.jim.2006.01.010.
   Takizawa M, 2004, EXP ANIM TOKYO, V53, P321, DOI 10.1538/expanim.53.321.
   TAN BTG, 1985, HYBRIDOMA, V4, P115, DOI 10.1089/hyb.1985.4.115.
   Turner OC, 2003, INFECT IMMUN, V71, P864, DOI 10.1128/IAI.71.2.864-871.2003.
   Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6.}},
Number-of-Cited-References = {{41}},
Times-Cited = {{65}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{J. Immunol.}},
Doc-Delivery-Number = {{203EZ}},
Unique-ID = {{ISI:000248959200058}},
}

@article{ ISI:000248037300025,
Author = {Davies, Geraint Rhys and Phillips, Patrick P. J. and Nunn, Andrew J.},
Title = {{Biomarkers and surrogate end points in clinical trials of tuberculosis
   treatment}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{4}},
Pages = {{648-649}},
Month = {{AUG 15}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Davies, GR (Reprint Author), Univ Liverpool, Dept Pharmacol \& Therapeut, POB 147, Liverpool L69 3BX, Merseyside, England.
   Univ Liverpool, Dept Pharmacol \& Therapeut, Liverpool L69 3BX, Merseyside, England.
   MRC, Clin Trials Unit, London, England.}},
DOI = {{10.1086/519744}},
ISSN = {{0022-1899}},
Keywords-Plus = {{CD4 CELL COUNT; METAANALYSIS; RNA}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{gerrydavies@doctors.org.uk}},
ORCID-Numbers = {{Phillips, Patrick/0000-0002-6336-7024}},
Cited-References = {{ABER V R, 1978, Bulletin of the International Union Against Tuberculosis, V53, P260.
   Aboulker JP, 1999, AIDS, V13, P565.
   Babiker A, 2000, AIDS RES HUM RETROV, V16, P1123.
   Baker Stuart G, 2003, BMC Med Res Methodol, V3, P16, DOI 10.1186/1471-2288-3-16.
   Hughes MD, 1998, AIDS, V12, P1823, DOI 10.1097/00002030-199814000-00014.
   Mistry R, 2007, J INFECT DIS, V195, P357, DOI 10.1086/510397.
   MITCHISON DA, 1996, SOC APPL BACTERIOL S, V25, pS73.
   Molenberghs G, 2004, STAT METHODS MED RES, V13, P177.}},
Number-of-Cited-References = {{8}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190DD}},
Unique-ID = {{ISI:000248037300025}},
}

@article{ ISI:000248037300026,
Author = {Walzl, Gerhard and Mistry, Rohit and Dockrell, Hazel M. and van Helden,
   Paul D. and Cliff, Jacqueline M.},
Title = {{Biomarkers and surrogate end points in clinical trials of tuberculosis
   treatment - Reply to Davies et al.}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{4}},
Pages = {{649-650}},
Month = {{AUG 15}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Cliff, JM (Reprint Author), Univ London London Sch Hyg \& Trop Med, Dept Infect \& Trop Dis, Keppel St, London WC1E 7HT, England.
   Univ London London Sch Hyg \& Trop Med, Dept Infect \& Trop Dis, London WC1E 7HT, England.
   Univ Stellenbosch, Fac Hlth Sci, Dept Med Biochem, ZA-7505 Tygerberg, South Africa.}},
DOI = {{10.1086/519746}},
ISSN = {{0022-1899}},
Keywords-Plus = {{GAMMA PRODUCTION}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{jackie.cliff@lshtm.ac.uk}},
ORCID-Numbers = {{Walzl, Gerhard/0000-0003-2487-125X}},
Cited-References = {{Brahmbhatt S, 2006, CLIN EXP IMMUNOL, V146, P243, DOI 10.1111/j.1365-2249.2006.03211.x.
   Davies GR, 2007, J INFECT DIS, V196, P648, DOI 10.1086/519744.
   Jo EK, 2003, CURR OPIN INFECT DIS, V16, P205, DOI 10.1097/01.qco.0000073768.11390.a3.
   Roberts T, 2007, J INFECT DIS, V195, P870, DOI 10.1086/511277.
   Turner J, 2000, TUBERCLE LUNG DIS, V80, P161, DOI 10.1054/tuld.2000.0241.
   Veenstra H, 2006, CLIN EXP IMMUNOL, V145, P252, DOI 10.1111/j.1365-2249.2006.03144.x.}},
Number-of-Cited-References = {{6}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190DD}},
Unique-ID = {{ISI:000248037300026}},
}

@article{ ISI:000248045700014,
Author = {Bartlett, John G.},
Title = {{Tuberculosis and HIV infection: Partners in human tragedy}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{1}},
Pages = {{S124-S125}},
Month = {{AUG 15}},
Publisher = {{OXFORD UNIV PRESS INC}},
Address = {{JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bartlett, JG (Reprint Author), Johns Hopkins Univ, Sch Med, 1830 E Monument St,Rm 447, Baltimore, MD 21218 USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.}},
DOI = {{10.1086/518668}},
ISSN = {{1537-6613}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{jb@jhmi.edu}},
Cited-References = {{Aziz MA, 2006, LANCET, V368, P2142, DOI 10.1016/S0140-6736(06)69863-2.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Kaufmann SHE, 2005, NEW ENGL J MED, V353, P2423, DOI 10.1056/NEJMp058131.
   Leimane V, 2005, LANCET, V365, P318.
   Munsiff SS, 2003, J INFECT DIS, V188, P356, DOI 10.1086/376837.
   Nunn P, 2007, J INFECT DIS, V196, pS5, DOI 10.1086/518660.
   Raviglione MC, 2007, NEW ENGL J MED, V356, P656, DOI 10.1056/NEJMp068273.
   SCHWALBE N, 2006, TB ALLIANCE NEW 0909.
   SMITH DG, 1947, J BACTERIOL, V54, P253.
   Spigelman MK, 2007, J INFECT DIS, V196, pS28, DOI 10.1086/518663.
   {*}UN WHO, 2006, JOINT UN PROGR HIV A.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.}},
Number-of-Cited-References = {{13}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190GC}},
Unique-ID = {{ISI:000248045700014}},
}

@article{ ISI:000248045700007,
Author = {Blanc, Francois-Xavier and Havlir, Diane V. and Onyebujoh, Philip C. and
   Thim, Sok and Goldfeld, Anne E. and Delfraissy, Jean-Francois},
Title = {{Treatment strategies for HIV-infected patients with tuberculosis:
   Ongoing and planned clinical trials}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{1}},
Pages = {{S46-S51}},
Month = {{AUG 15}},
Abstract = {{Currently, there are limited data to guide the management of highly
   active antiretroviral therapy (HAART) for human immunodeficiency virus
   type 1 (HIV-1)-infected patients with active tuberculosis (TB), the
   leading cause of death among individuals with acquired immunodeficiency
   syndrome (AIDS) in resource-limited areas. Four trials to take place in
   Southeast Asian, African, and South American countries will address the
   unresolved question of the optimal timing for initiation of HAART in
   patients with AIDS and TB: (1) Cambodian Early versus Late Introduction
   of Antiretrovirals (CAMELIA {[}ANRS 1295/NIH-CIPRA KH001]), (2) Adult
   AIDS Clinical Trials Group A5221, (3) START, and (4) a trial sponsored
   by the World Health Organization/Special Programme for Research and
   Training in Tropical Diseases. Two other clinical questions regarding
   patients with TB and HIV-1 coinfection are also undergoing evaluation:
   (1) the benefits of short-term HAART when CD4 cell counts are 1350
   cells/mm3 (PART {[}NIH 1 R01 AI051219-01A2]) and (2) the efficacy of a
   once-daily HAART regimen in treatment-naive patients (BKVIR {[}ANRS
   129]). Here, we present an overview of these ongoing or planned clinical
   studies, which are supported by international agencies.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Blanc, FX (Reprint Author), Univ Paris 11, CHU Bicetre, AP HP, Serv Med Interne, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.
   Univ Paris 11, CHU Bicetre, AP HP, Serv Med Interne, F-94275 Le Kremlin Bicetre, France.
   Univ Paris 11, CHU Bicetre, AP HP, Agence Natl Rech Sida \& Hepatites Virales, F-94275 Le Kremlin Bicetre, France.
   Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94143 USA.
   Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA.
   WHO, United Nat Childrens Fund, United Nat Dev Programme, Worl Bank,Special Programme Res \& Training Trop D, CH-1211 Geneva, Switzerland.
   Cambodian Hlth Comm, Phnom Penh, Cambodia.}},
DOI = {{10.1086/518658}},
ISSN = {{0022-1899}},
Keywords-Plus = {{ACTIVE ANTIRETROVIRAL THERAPY; MANAGEMENT; SETTINGS; CAMBODIA; ADULTS}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{xavier.blanc@bct.aphp.fr}},
ResearcherID-Numbers = {{Blanc, Francois-Xavier/D-7425-2015}},
Cited-References = {{Blumberg Henry M, 2003, Am J Respir Crit Care Med, V167, P603.
   Blumberg HM, 2005, JAMA-J AM MED ASSOC, V293, P2776, DOI 10.1001/jama.293.22.2776.
   de Jong BC, 2004, ANNU REV MED, V55, P283, DOI 10.1146/annurev.med.55.091902.103753.
   DeAngelis CD, 2004, JAMA-J AM MED ASSOC, V292, P1363, DOI 10.1001/jama.292.11.1363.
   Delgado JC, 2004, INT J TUBERC LUNG D, V8, P982.
   Di Perri Giovanni, 2005, Expert Opin Drug Saf, V4, P821, DOI 10.1517/14740338.4.5.821.
   Fujiwara PI, 2005, INT J TUBERC LUNG D, V9, P946.
   Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827.
   Harries AD, 2006, LANCET, V367, P944, DOI 10.1016/S0140-6736(06)68387-6.
   Jack C, 2004, JAIDS-J ACQ IMM DEF, V36, P929, DOI 10.1097/00126334-200408010-00006.
   Kwara A, 2005, INT J TUBERC LUNG D, V9, P248.
   Lawn SD, 2005, LANCET INFECT DIS, V5, P361, DOI 10.1016/S1473-3099(05)70140-7.
   Lipman M, 2006, CURR OPIN INFECT DIS, V19, P20, DOI 10.1097/01.qco.0000200543.80712.01.
   McIlleron H, 2007, J INFECT DIS, V196, pS63, DOI 10.1086/518655.
   Mofenson Lynne M., 2004, Morbidity and Mortality Weekly Report, V53, P1.
   Onyebujoh P, 2005, B WORLD HEALTH ORGAN, V83, P857.
   Ranjbar S, 2004, J IMMUNOL, V172, P1953.
   Thim S, 2004, JAMA-J AM MED ASSOC, V292, P566, DOI 10.1001/jama.292.5.566-c.
   {*}WHO, 2004, SCAL ANT THER RES LI.
   World Health Organization, 2006, WHOHTMTB2006362.
   2003, REV MAL RESP, V20.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{36}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190GC}},
Unique-ID = {{ISI:000248045700007}},
}

@article{ ISI:000248045700012,
Author = {Bock, Naomi N. and Jensen, Paul A. and Miller, Bess and Nardell, Edward},
Title = {{Tuberculosis infection control in resource-limited settings in the era
   of expanding HIV care and treatment}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{1}},
Pages = {{S108-S113}},
Month = {{AUG 15}},
Abstract = {{The opportunities for human immunodefiency virus (HIV) care and
   treatment created by new treatment initiatives promoting universal
   access are also creating unprecedented opportunities for persons with
   HIV-associated immunosuppression to be exposed to patients with
   infectious tuberculosis ( TB) within health care facilities, with the
   attendant risks of acquiring TB infection and developing TB disease.
   Infection control measures can reduce the risk of Mycobacterium
   tuberculosis transmission even in settings with limited resources, on
   the basis of a 3-level hierarchy of controls, including administrative
   or work practice, environmental controls, and respiratory protection.
   Further research is needed to define the most efficient interventions.
   The importance of preventing transmission of M. tuberculosis in the era
   of expanding HIV care and treatment in resource-limited settings must be
   recognized and addressed.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bock, NN (Reprint Author), Ctr Dis Control, 1600 Clifton Rd,Mail Stop E-04, Atlanta, GA 30333 USA.
   Ctr Dis Control \& Prevent, Global Programme AIDS, Atlanta, GA USA.
   Ctr Dis Control \& Prevent, Div TB Eliminat, Atlanta, GA USA.
   Harvard Univ, Sch Med, Brigham \& Womens Hosp, Div Soc Med \& Hlth Inequal, Cambridge, MA 02138 USA.
   Partners Hlth, Boston, MA USA.}},
DOI = {{10.1086/518661}},
ISSN = {{0022-1899}},
Keywords-Plus = {{RESISTANT MYCOBACTERIUM-TUBERCULOSIS; SOUTH-AFRICA; TRANSMISSION;
   OUTBREAK; WORKERS; REINFECTION; RISK}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{neb2@cdc.gov}},
Cited-References = {{Aita J, 1996, MEDICINA-BUENOS AIRE, V56, P48.
   BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   BOUVET E, 1991, B EPIDEMIOLOGIQUE HE, V45, P196.
   Brahdy L, 1941, AM J PUBLIC HEALTH N, V31, P1040, DOI 10.2105/AJPH.31.10.1040.
   Burgess AL, 2001, AIDS, V15, P1875, DOI 10.1097/00002030-200109280-00018.
   BUVE A, 1994, AIDS, V8, P396.
   Centers for Disease Control and Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P301.
   Coetzee D, 2004, TROP MED INT HEALTH, V9, pA11, DOI 10.1111/j.1365-3156.2004.01259.x.
   DALAL S, 2006, 16 INT AIDS C.
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404.
   Do AN, 1999, INT J TUBERC LUNG D, V3, P377.
   DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   Fitzpatrick LK, 2002, INT J TUBERC LUNG D, V6, P550.
   Harries AD, 1997, PHARMACOL THERAPEUT, V73, P1, DOI 10.1016/S0163-7258(96)00115-5.
   Harries AD, 1997, B WORLD HEALTH ORGAN, V75, P477.
   Harries AD, 1999, T ROY SOC TROP MED H, V93, P32, DOI 10.1016/S0035-9203(99)90170-0.
   Heimbeck J, 1928, ARCH INTERN MED, V41, P336.
   Israel HL, 1941, JAMA-J AM MED ASSOC, V117, P839, DOI 10.1001/jama.1941.02820360021007..
   Jenssen HK, 2005, INDIANA U MATH J, V54, P1, DOI 10.1512/iumj.2005.54.2685.
   MOLL A, 2006, 13 C RETR OPP INF AL.
   MOORE D, 2006, 13 C RETR OPP INF AL.
   Nachega J, 2003, AIDS, V17, P1398, DOI 10.1097/01.aids.0000060408.18106.d9.
   Raviglione M C, 1997, AIDS, V11 Suppl B, pS115.
   Seyler C, 2005, AM J RESP CRIT CARE, V172, P123, DOI 10.1164/rccm.200410-1342OC.
   SIDIBE K, 1997, INT J TUBERC LUNG S, V1, pS103.
   SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011.
   Sonnenberg P, 2001, LANCET, V358, P1687, DOI 10.1016/S0140-6736(01)06712-5.
   World Health Organization, 1999, GUID PREV TUB HLTH C.
   World health organization, GLOB PLAN STOP TB 20.
   {*}WHO, 2006, PROGR GLOB ACC HIV A.
   Geneva: World Health Organization, 2004, WHOHTMTB2004336.
   World Health Organization/Centres for Disease Control and Prevention, 2006, TUB INF CONTR ER EXP.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{85}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190GC}},
Unique-ID = {{ISI:000248045700012}},
}

@article{ ISI:000248045700008,
Author = {Churchyard, Gavin J. and Scano, Fabio and Grant, Alison D. and Chaisson,
   Richard E.},
Title = {{Tuberculosis preventive therapy in the era of HIV infection: Overview
   and research priorities}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{1}},
Pages = {{S52-S62}},
Month = {{AUG 15}},
Abstract = {{The recognition of tuberculosis ( TB) as a major cause of morbidity and
   mortality among human immunodeficiency virus (HIV)-infected persons has
   led to renewed interest in TB preventive therapy and its incorporation
   into the essential package of health care for these individuals. Despite
   convincing data regarding its efficacy, TB preventive therapy has not
   been widely implemented. Further work is needed to determine how to
   overcome the barriers to the implementation of such therapy, including
   how best to exclude the presence of active TB before providing
   preventive therapy. Such issues as the optimal duration of preventive
   therapy for and the role of TB preventive therapy in the treatment of
   individuals receiving antiretroviral therapy remain to be defined.
   Ongoing research will help to determine how best to use this
   intervention in the care of HIV-infected persons and in the control of
   TB on a wider basis.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Churchyard, GJ (Reprint Author), Aurum Inst Hlth Res, POB 61587, ZA-2107 Gauteng, South Africa.
   Aurum Inst Hlth Res, ZA-2107 Gauteng, South Africa.
   Univ KwaZulu Natal, CAPRISA, Natal, RN, Brazil.
   Univ London London Sch Hyg \& Trop Med, London WC1E 7HT, England.
   WHO, Stop TB Dept, CH-1211 Geneva, Switzerland.
   Johns Hopkins Univ, Ctr TB Res, Baltimore, MD 21218 USA.}},
DOI = {{10.1086/518662}},
ISSN = {{0022-1899}},
Keywords-Plus = {{ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS;
   RANDOMIZED-TRIAL; SOUTH-AFRICA; ISONIAZID PROPHYLAXIS; LATENT
   TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; RECURRENT TUBERCULOSIS;
   MATERNAL MORTALITY; COST-EFFECTIVENESS}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{gchurchyard@auruminstitute.org}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI16137, 1 U19 AI51794]}},
Cited-References = {{Ahmed Y, 1999, INT J TUBERC LUNG D, V3, P675.
   Alfaro EM, 2000, MED CLIN-BARCELONA, V115, P161.
   Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3.
   Balcells ME, 2006, EMERG INFECT DIS, V12, P744.
   Bell JC, 1999, AIDS, V13, P1549, DOI 10.1097/00002030-199908200-00016.
   BOULLE A, 2005, 2 S AFR AIDS C DURB.
   Bucher HC, 1999, AIDS, V13, P501, DOI 10.1097/00002030-199903110-00009.
   Chaisson RE, 2001, AM J MED, V110, P610, DOI 10.1016/S0002-9343(01)00695-7.
   Charalambous S, 2004, AIDS CARE, V16, P47, DOI 10.1080/09540120310001633967.
   CHURCHYARD G, 2005, HIV AIDS S AFRICA.
   Churchyard GJ, 2003, AIDS, V17, P2063, DOI 10.1097/01.aids.0000076319.42412.70.
   COMSTOCK GW, 1979, AM REV RESPIR DIS, V119, P827.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   CORBETT EL, 2002, 14 INT AIDS C BARC.
   Currie CSM, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-130.
   Day JH, 2006, INT J TUBERC LUNG D, V10, P523.
   Day JH, 2004, J INFECT DIS, V190, P1677, DOI 10.1086/424851.
   de Pinho AMF, 2001, AIDS, V15, P2129, DOI 10.1097/00002030-200111090-00008.
   Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767.
   Fitzgerald DW, 2000, LANCET, V356, P1470, DOI 10.1016/S0140-6736(00)02870-1.
   Fitzgerald DW, 2001, J ACQ IMMUN DEF SYND, V28, P305.
   Foster S, 1997, AIDS, V11, P919, DOI 10.1097/00002030-199707000-00012.
   FRANKS AL, 1989, PUBLIC HEALTH REP, V104, P151.
   Girardi E, 2000, AIDS, V14, P1985, DOI 10.1097/00002030-200009080-00015.
   Goletti D, 1996, J IMMUNOL, V157, P1271.
   GOLUB JE, 2006, 16 INT AIDS C TOR.
   Gordin F, 2000, JAMA-J AM MED ASSOC, V283, P1445, DOI 10.1001/jama.283.11.1445.
   Gordin FM, 2004, CLIN INFECT DIS, V39, P561, DOI 10.1086/422724.
   Gordin FM, 1997, NEW ENGL J MED, V337, P315, DOI 10.1056/NEJM199707313370505.
   GRANT A, 2005, 3 IAS C HIV PATH TRE.
   Grant AD, 2005, JAMA-J AM MED ASSOC, V293, P2719, DOI 10.1001/jama.293.22.2719.
   Haller L, 1999, CHEMOTHERAPY, V45, P452, DOI 10.1159/000007239.
   Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X.
   Hawken MP, 1997, AIDS, V11, P875, DOI 10.1097/00002030-199707000-00006.
   Horsburgh CR, 2004, NEW ENGL J MED, V350, P2060, DOI 10.1056/NEJMsa031667.
   HORWITZ O, 1966, B WORLD HEALTH ORGAN, V35, P509.
   Johnson JL, 2001, AIDS, V15, P2137, DOI 10.1097/00002030-200111090-00009.
   Jones JL, 2000, INT J TUBERC LUNG D, V4, P1026.
   Khan M, 2001, AIDS, V15, P1857, DOI 10.1097/00002030-200109280-00016.
   KUMARANAYAKE L, 2002, 15 INT C AIDS BANGK.
   Lexau CA, 2005, JAMA-J AM MED ASSOC, V294, P2043, DOI 10.1001/jama.294.16.2043.
   MacIntyre CR, 2000, PREV MED, V30, P425, DOI 10.1006/pmed.2000.0654.
   Manabe YC, 2000, NAT MED, V6, P1327, DOI 10.1038/82139.
   MASOBE P, 1995, S AFR MED J, V85, P75.
   Millard PS, 1996, WESTERN J MED, V164, P486.
   MITCHELL JR, 1976, ANN INTERN MED, V84, P181.
   Morris L, 2003, J INFECT DIS, V187, P1967, DOI 10.1086/375346.
   MOTSAMAI OI, 2005, INT J TUBERC LUNG S1, V9, pS28.
   Mwinga A, 1998, AIDS, V12, P2447, DOI 10.1097/00002030-199818000-00014.
   Nolan CM, 1999, JAMA-J AM MED ASSOC, V281, P1014, DOI 10.1001/jama.281.11.1014.
   OBRIEN RJ, 1995, AIDS, V9, P665, DOI 10.1097/00002030-199507000-00001.
   PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6.
   Perkins MD, 2007, J INFECT DIS, V196, pS15, DOI 10.1086/518656.
   PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204.
   Quigley MA, 2001, AIDS, V15, P215, DOI 10.1097/00002030-200101260-00011.
   Rivero A, 2003, ENFERM INFEC MICR CL, V21, P287, DOI 10.1157/13048575.
   Rose DN, 1998, ANN INTERN MED, V129, P779.
   Rowe KA, 2005, INT J TUBERC LUNG D, V9, P263.
   SALPETER SR, 1993, WESTERN J MED, V159, P560.
   Santoro-Lopes G, 2002, CLIN INFECT DIS, V34, P543, DOI 10.1086/338641.
   SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101.
   Sonnenberg P, 2001, LANCET, V358, P1687, DOI 10.1016/S0140-6736(01)06712-5.
   Stout JE, 2003, AM J RESP CRIT CARE, V167, P824, DOI 10.1164/rccm.200209-998OC.
   Toossi Z, 2001, CLIN EXP IMMUNOL, V123, P233, DOI 10.1046/j.1365-2249.2001.01401.x.
   URASSA E, 1994, E AFR MED J, V71, P226.
   Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602.
   Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201.
   {*}WHO, 2005, WHOHIV200503.
   World Health Organization, 2004, WHOHTMTB2004330.
   WHO, 1999, WKLY EPIDEMIOL REC, V74, P385.
   World Health Organisation, 2004, WHOHTMTB2004329.
   Geneva: World Health Organization, 2004, WHOHTMTB2004336.
   World Health Organization, 2006, WHOHTMTB2006362.
   World Health Organization, 2005, WHOHTMTB2005355, P355.
   Stop TB Partnership World Health Organization, 2006, WHOHTMSTB200635.
   Wilkinson D, 1998, BRIT MED J, V317, P625.
   Wilkinson D, 2000, COCHRANE DB SYST REV.
   Woldehanna S, 2004, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD000171.PUB2.
   ZAR Z, 2004, EJIAS, V1.
   2001, JAMA, V286, P1445.
   {[}Anonymous], 2003, MMWR MORB MORTAL WKL, V52, P735.
   {[}Anonymous], 2000, AM J RESP CRIT CARE, V161, pS221.}},
Number-of-Cited-References = {{82}},
Times-Cited = {{45}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190GC}},
Unique-ID = {{ISI:000248045700008}},
}

@article{ ISI:000248045700001,
Author = {Friedland, Gerald and Churchyard, Gavin J. and Nardell, Edward},
Title = {{Tuberculosis and HIV coinfection: Current state of knowledge and
   research priorities}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{1}},
Pages = {{S1-S3}},
Month = {{AUG 15}},
Publisher = {{OXFORD UNIV PRESS INC}},
Address = {{JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Friedland, G (Reprint Author), Yale Univ, Sch Med, AIDS Program, Sect Infect Dis,Dept Internal Med, 135 Coll St,Ste 323, New Haven, CT 06510 USA.
   Yale Univ, Sch Med, AIDS Program, Sect Infect Dis,Dept Internal Med, New Haven, CT 06510 USA.
   Yale Univ, Sch Med, AIDS Program, Sect Infect Dis,Dept Epidemiol, New Haven, CT 06510 USA.
   Yale Univ, Sch Med, AIDS Program, Sect Infect Dis,Dept Publ Hlth, New Haven, CT 06510 USA.
   Harvard Univ, Sch Med, Brigham \& Womens Hosp, Div Social Med \& Hlth Inequalities, Cambridge, MA 02138 USA.
   Partners Hlth, Boston, MA USA.
   Univ KwaZulu Natal, Ctr AIDS Programme Res S Africa, CAPRISA, Durban, South Africa.
   London Sch Hyg \& Trop Med, London WC1, England.}},
DOI = {{10.1086/1518667}},
ISSN = {{1537-6613}},
Keywords-Plus = {{INFECTION; ERA; CHALLENGES; THERAPY}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{Gerald.friedland@yale.edu}},
Cited-References = {{Bartlett JG, 2007, J INFECT DIS, V196, pS124, DOI 10.1086/518668.
   Blanc FX, 2007, J INFECT DIS, V196, pS46, DOI 10.1086/518658.
   Bock NN, 2007, J INFECT DIS, V196, pS108, DOI 10.1086/518661.
   Churchyard GJ, 2007, J INFECT DIS, V196, pS52, DOI 10.1086/518662.
   Corbett EL, 2006, LANCET, V367, P926, DOI 10.1016/S0140-6736(06)68383-9.
   Friedland G, 2007, J INFECT DIS, V196, pS114, DOI 10.1086/518664.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   {*}JOINT UN PROG RHI, 2006, UNAIDS0519E.
   Marais BJ, 2007, J INFECT DIS, V196, pS76, DOI 10.1086/518659.
   McIlleron H, 2007, J INFECT DIS, V196, pS63, DOI 10.1086/518655.
   Nunn P, 2007, J INFECT DIS, V196, pS5, DOI 10.1086/518660.
   Onyebujoh PC, 2007, J INFECT DIS, V196, pS35, DOI 10.1086/518657.
   Perkins MD, 2007, J INFECT DIS, V196, pS15, DOI 10.1086/518656.
   Spigelman MK, 2007, J INFECT DIS, V196, pS28, DOI 10.1086/518663.
   Wells CD, 2007, J INFECT DIS, V196, pS86, DOI 10.1086/518665.
   {*}WHO, 2004, STOP TB DEPT HIV AID.
   World Health Organization, 2006, WHOHTMTB2006362.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{26}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190GC}},
Unique-ID = {{ISI:000248045700001}},
}

@article{ ISI:000248045700013,
Author = {Friedland, Gerald and Harries, Anthony and Coetzee, David},
Title = {{Implementation issues in tuberculosis/HIV program collaboration and
   integration: 3 case studies}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{1}},
Pages = {{S114-S123}},
Month = {{AUG 15}},
Abstract = {{The many interactions between tuberculosis (TB) and human
   immunodeficiency virus (HIV) infection influence the design and
   implementation of programs to address the needs of patients living with
   or at risk for both diseases. Collaboration between national TB and HIV
   programs and some degree of integration of services at a local level
   have been advocated by the World Health Organization and other
   international bodies and are recognized as essential in areas where the
   2 diseases are prevalent. However, in most settings, strategies to
   accomplish this are only beginning to reach the field where their impact
   will be made and the expectation of improving the outcome of both
   diseases realized. In this article, 3 such strategies, offering varying
   degrees of collaboration and integration, are described, 1 at a national
   level in Malawi and 2 at local sites in South Africa. These
   geographically and programmatically distinct experiences in TB/HIV
   service integration are instructive, illustrate common themes, and show
   that the strategy can be successful, but they also show that
   programmatic, medical, staffing, resource, and scale-up challenges
   remain. In addition, they indicate that, although broad program
   principles of TB/HIV service integration are essential, program designs
   and components may vary by country and even within countries, as a
   result of differing TB and HIV disease prevalences, resources, levels of
   expertise, and differences in program settings (urban vs. rural and/or
   primary vs. district vs. specialty site). Large national programs can
   successfully provide rapid, uniform and widespread change and
   implementation but also must negotiate the subtleties of intricacies of
   TB/HIV interactions, which confound a uniform ``one size fits all{''}
   public health approach. Conversely, smaller demonstration projects, even
   with successful outcomes, must grapple with issues related to
   generalization of findings, wider implementation, and scale up, to
   benefit larger populations of those in need.}},
Publisher = {{OXFORD UNIV PRESS INC}},
Address = {{JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Friedland, G (Reprint Author), Yale Univ, Sch Med, AIDS Program, 135 Coll St,Ste 323, New Haven, CT 06510 USA.
   Yale Univ, Sch Med, Dept Internal Med, Infect Dis Sect,AIDS Program, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Dept Epidemiol, Infect Dis Sect,AIDS Program, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Dept Publ Hlth, Infect Dis Sect,AIDS Program, New Haven, CT 06520 USA.
   Minist Hlth, Clin HIV Unit, Lilongwe, Malawi.
   Malawi Country Off, Family Hlth Int, Lilongwe, Malawi.
   London Sch Hyg \& Trop Med, London WC1, England.
   Univ Cape Town, Fac Hlth Sci, Sch Publ Hlth \& Family Med, Infect Dis Epidemiol Unit, ZA-7700 Rondebosch, South Africa.}},
DOI = {{10.1086/518664}},
ISSN = {{1537-6613}},
Keywords-Plus = {{ANTIRETROVIRAL THERAPY; POSITIVE TUBERCULOSIS; COTRIMOXAZOLE
   PROPHYLAXIS; HIV-INFECTION; MALAWI; AFRICA; MORTALITY; SETTINGS;
   DISTRICT}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{Gerald.friedland@yale.edu}},
Cited-References = {{Aaron L, 2004, CLIN MICROBIOL INFEC, V10, P388, DOI 10.1111/j.1469-0691.2004.00758.x.
   Abdool-Karim Salim S, 2004, AIDS, V18, P975.
   Bock NN, 2007, J INFECT DIS, V196, pS108, DOI 10.1086/518661.
   Boeree MJ, 2005, TROP MED INT HEALTH, V10, P723, DOI 10.1111/j.1365-3156.2005.01433.x.
   BOULLE A, 2004, 15 INT AIDS C BANGK.
   {*}CAPRISA DIV AIDS, 2004, START START TUB ANT.
   CHIMZIZI R, 2005, REPORT COUNTRY WIDE.
   Chintu C, 2004, LANCET, V364, P1865, DOI 10.1016/S0140-6736(04)17442-4.
   Coetzee D, 2004, TROP MED INT HEALTH, V9, pSA11.
   {*}DEP HLTH S AFR, 2003, DEP HLTH OP PLAN COM.
   Friedland G, 2006, J ANTIMICROB CHEMOTH, V58, P1299, DOI 10.1093/jac/dkl399.
   GANDHI N, 2005, 3 INT AIDS SOC C HIV.
   GANDHI N, 2006, 16 INT AIDS C TOR CA.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Harries AD, 2004, T ROY SOC TROP MED H, V98, P695, DOI 10.1016/j.trstmh.2004.05.002.
   Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9.
   Jack C, 2004, JAIDS-J ACQ IMM DEF, V36, P929, DOI 10.1097/00126334-200408010-00006.
   Kwanjana JK, 2001, MALAWI MED J, V13, P7.
   LAURENT C, 2003, LANCET, V362, P2083.
   Libamba E, 2005, INT J TUBERC LUNG D, V9, P1062.
   Malawi Ministry of Health, 2003, TREATM AIDS GUID US.
   Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5.
   {*}MIN HLTH POP, 2002, MAN NAT TUB CONTR PR.
   {*}MIN HLTH POP PRET, S AFR TUB CONTR PROG.
   Mukherjee J, 2004, LANCET, V363, P1071, DOI 10.1016/S0140-6736(04)15846-7.
   Mwaungulu FBD, 2004, B WORLD HEALTH ORGAN, V82, P354.
   National AIDS Commission, 2003, NAT EST HIV AIDS MAL.
   Nyirenda TE, 2004, INT J TUBERC LUNG D, V8, P1089.
   Pozniak AL, 2005, HIV MED, V6, P62, DOI 10.1111/j.1468-1293.2005.00293.x.
   SALANIPONI F, 1999, WHOCDSCPCTB99268 COM.
   Stewart R, 2005, S AFRICAN HLTH REV 2.
   Tobin MJ, 2003, AM J RESP CRIT CARE, V167, P306, DOI 10.1164/rccm.2212006.
   Wells CD, 2007, J INFECT DIS, V196, pS86, DOI 10.1086/518665.
   World Health Organization, 2003, WHOCDSTB2003313.
   {*}WHO, 2006, SCALING ANTIRETROVIR.
   {*}WHO, 2004, GLOB TUB CONTR COUNT.
   World Health Organization, 2004, WHOHTMTB2004330.
   {*}WHO, 2000, JOINT UN PROGR HIV A.
   World Health Organisation, 2004, WHOHTMHIV20041.
   {*}WHO, 2005, WHOCDS2005295.
   Wilkinson D, 1997, S AFR MED J, V87, P447.
   Zachariah R, 2005, INT J TUBERC LUNG D, V9, P238.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{51}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190GC}},
Unique-ID = {{ISI:000248045700013}},
}

@article{ ISI:000248045700002,
Author = {Hoxie, James A. and Miller, Veronica and Walker, Bruce},
Title = {{Tuberculosis and HIV coinfection: Genesis of the supplement and
   sponsors' contribution}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{1}},
Pages = {{S4}},
Month = {{AUG 15}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Miller, V (Reprint Author), George Washington Univ, Forum Collaborat HIV Res, 2021 K St NW,Ste 800, Washington, DC 20006 USA.
   George Washington Univ, Forum Collaborat HIV Res, Washington, DC 20006 USA.
   Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
   Univ Penn, Penn Ctr AIDS Res, Philadelphia, PA 19104 USA.
   Harvard Ctr AIDS Res, Cambridge, MA USA.
   Harvard Univ, Dept Med, Cambridge, MA 02138 USA.}},
DOI = {{10.1086/518666}},
ISSN = {{0022-1899}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{vmiller@gwu.edu}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190GC}},
Unique-ID = {{ISI:000248045700002}},
}

@article{ ISI:000248045700010,
Author = {Marais, B. J. and Graham, S. M. and Cotton, M. F. and Beyers, N.},
Title = {{Diagnostic and management challenges for childhood tuberculosis in the
   era of HIV}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{1}},
Pages = {{S76-S85}},
Month = {{AUG 15}},
Abstract = {{The diagnosis and management of childhood tuberculosis (TB) pose
   substantial challenges in the era of the human immunodeficiency virus
   (HIV) epidemic. The highest TB incidences and HIV infection prevalences
   are recorded in sub-Saharan Africa, and, as a consequence, children in
   this region bear the greatest burden of TB/HIV infection. The tuberculin
   skin test (TST), which is the standard marker of Mycobacterium
   tuberculosis infection in immunocompetent children, has poor sensitivity
   when used in HIV-infected children. Novel T cell assays may offer higher
   sensitivity and specificity than the TST, but these tests still fail to
   make the crucial distinction between latent M. tuberculosis infection
   and active disease and are limited by cost considerations. Symptom-based
   diagnostic approaches are less helpful in HIV-infected children, because
   of the difficulty of differentiating TB-related symptoms from those
   caused by other HIV-associated conditions. Knowing the HIV infection
   status of all children with suspected TB is helpful because it improves
   clinical management. HIV-infected children are at increased risk of
   developing active disease after TB exposure/infection, which justifies
   the use of isoniazid preventive therapy once active TB has been
   excluded. The higher mortality and relapse rates noted among
   HIV-infected children with active TB who are receiving standard TB
   treatment highlight the need for further research to define optimal
   treatment regimens. HIV-infected children should also receive
   appropriate supportive care, including cotrimoxazole prophylaxis, and
   antiretroviral therapy, if indicated. Despite the difficulties
   experienced in resource-limited countries, the management of children
   with TB/HIV infection could be vastly improved by better implementation
   of readily available interventions.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Marais, BJ (Reprint Author), Univ Stellenbosch, Fac Hlth Sci, Dept Paediat \& Child Hlth, PO Box 19063, ZA-7505 Tygerberg, South Africa.
   Univ Stellenbosch, Fac Hlth Sci, Desmund Tutu TB Ctr, Cape Town, South Africa.
   Univ Stellenbosch, Fac Hlth Sci, Ukwanda Ctr Rural Hlth, Cape Town, South Africa.
   Univ Malawi, Coll Med, Malawi Livepool Wellcome Trust Programme Tro, Blantyre, Malawi.
   Univ Malawi, Coll Med, Dept Paediat, Blantyre, Malawi.}},
DOI = {{10.1086/518659}},
ISSN = {{0022-1899}},
Keywords-Plus = {{HUMAN-IMMUNODEFICIENCY-VIRUS; CULTURE-CONFIRMED TUBERCULOSIS; IMMUNE
   RECONSTITUTION SYNDROME; ACTIVE ANTIRETROVIRAL THERAPY; RANDOMIZED
   CONTROLLED-TRIAL; VACCINE-INDUCED DISEASE; PRE-CHEMOTHERAPY ERA;
   CELL-BASED ASSAY; PULMONARY TUBERCULOSIS; INFECTED CHILDREN}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{bjmarais@sun.ac.za}},
Cited-References = {{Ahmed Y, 1999, INT J TUBERC LUNG D, V3, P675.
   BARR RG, 1994, TUBERCLE LUNG DIS, V75, P251, DOI 10.1016/0962-8479(94)90129-5.
   Blumberg Henry M, 2003, Am J Respir Crit Care Med, V167, P603.
   Blumberg HM, 2005, JAMA-J AM MED ASSOC, V293, P2776, DOI 10.1001/jama.293.22.2776.
   Breen RAM, 2005, AIDS, V19, P1201, DOI 10.1097/01.aids.0000176221.33237.67.
   Breton G, 2004, CLIN INFECT DIS, V39, P1709, DOI 10.1086/425742.
   Brocklehurst P, 1998, BRIT J OBSTET GYNAEC, V105, P836, DOI 10.1111/j.1471-0528.1998.tb10227.x.
   BUITJELS PCAM, 2005, J CLIN MICROBIOL, V43, P6020.
   Recommendations to prevent and control iron deficiency in the United States, 1998, MMWR-MORBID MORTAL W, V47, P1.
   Chintu C, 2004, LANCET, V364, P1865, DOI 10.1016/S0140-6736(04)17442-4.
   Chintu C, 2002, LANCET, V360, P985, DOI 10.1016/S0140-6736(02)11082-8.
   Chow F, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-67.
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698.
   Coovadia HM, 1998, INT J TUBERC LUNG D, V2, P844.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Corbett EL, 2004, AM J RESP CRIT CARE, V170, P673, DOI 10.1164/rccm.200405-590OC.
   COTTON M, 2006, 16 INT AIDS C TOR.
   Curtis AB, 1999, NEW ENGL J MED, V341, P1491, DOI 10.1056/NEJM199911113412002.
   Day JH, 2004, J INFECT DIS, V190, P1677, DOI 10.1086/424851.
   Dheda K, 2005, AIDS, V19, P2038, DOI 10.1097/01.aids.0000191923.08938.5b.
   Donald PR, 2006, INT J TUBERC LUNG D, V10, P1318.
   Donald PR, 2005, J INFECTION, V50, P193, DOI 10.1016/j.jinf.2004.02.010.
   Donald PR, 2002, CURR OPIN PULM MED, V8, P178, DOI 10.1097/00063198-200205000-00005.
   Du Toit G, 2002, INT J TUBERC LUNG D, V6, P814.
   Eamranond P, 2001, INT J TUBERC LUNG D, V5, P594.
   Egwaga SM, 2003, TUBERCULOSIS, V83, P66, DOI 10.1016/S1472-9792(02)00057-4.
   Elenga N, 2005, PEDIATR INFECT DIS J, V24, P1077, DOI 10.1097/01.inf.0000190008.91534.b7.
   Elenga N, 2004, Arch Pediatr, V11, P864, DOI 10.1016/j.arcped.2004.03.031.
   Ena J, 2005, CLIN INFECT DIS, V40, P670, DOI 10.1086/427802.
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9.
   Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192.
   Fine PE, 1999, ISSUES RELATING USE.
   Fine PEM, 2001, SCAND J INFECT DIS, V33, P243, DOI 10.1080/003655401300077144.
   Franchi LM, 1998, LANCET, V352, P1681, DOI 10.1016/S0140-6736(05)61454-7.
   Gerstoft J, 2003, AIDS, V17, P2045, DOI 10.1097/01.aids.0000076358.20434.0d.
   Graham SM, 2006, ANTIMICROB AGENTS CH, V50, P407, DOI 10.1128/AAC.50.2.407-413.2006.
   Graham SM, 2005, INT J TUBERC LUNG D, V9, P592.
   Graham SM, 2001, INT J TUBERC LUNG D, V5, P12.
   Grange J, 1999, J ROY SOC MED, V92, P105.
   Harries AD, 2002, INT J TUBERC LUNG D, V6, P424.
   Harries AD, 2001, LANCET, V357, P1519, DOI 10.1016/S0140-6736(00)04639-0.
   Harries AD, 1997, INT J TUBERC LUNG D, V1, P346.
   Hesseling AC, 2006, CLIN INFECT DIS, V42, P548, DOI 10.1086/499953.
   Hesseling AC, 2005, ARCH DIS CHILD, V90, P1171, DOI 10.1136/adc.2004.070466.
   Hesseling AC, 2003, CLIN INFECT DIS, V37, P1226, DOI 10.1086/378298.
   Hesseling AC, 2002, INT J TUBERC LUNG D, V6, P1038.
   Hesseling AC, 2007, VACCINE, V25, P14, DOI 10.1016/j.vaccine.2006.07.020.
   HUSSEY G, 1991, PEDIATR INFECT DIS J, V10, P832, DOI 10.1097/00006454-199111000-00008.
   Ikeogu MO, 1997, ARCH DIS CHILD, V76, P124.
   JANA N, 1994, INT J GYNECOL OBSTET, V44, P119, DOI 10.1016/0020-7292(94)90064-7.
   Jeena PM, 1998, AIDS, V12, P1185, DOI 10.1097/00002030-199810000-00011.
   Jeena PM, 2002, INT J TUBERC LUNG D, V6, P672.
   Jindani A, 2004, LANCET, V364, P1244, DOI 10.1016/S0140-6736(04)17141-9.
   Kenyon TA, 2002, INT J TUBERC LUNG D, V6, P843.
   Khan M, 2001, AIDS, V15, P1857, DOI 10.1097/00002030-200109280-00016.
   Kiwanuka J, 2001, ANN TROP PAEDIATR, V21, P5, DOI 10.1080/02724930020028849.
   la Porte CJL, 2004, ANTIMICROB AGENTS CH, V48, P1553, DOI 10.1128/AAC.48.5.1553-1560.2004.
   Liebeschuetz S, 2004, LANCET, V364, P2196, DOI 10.1016/S0140-6736(04)17592-2.
   Lucas SB, 1996, BRIT MED J, V312, P335.
   Madhi SA, 2000, INT J TUBERC LUNG D, V4, P448.
   Madhi SA, 2000, CLIN INFECT DIS, V31, P170, DOI 10.1086/313925.
   Madhi SA, 1999, PEDIATR INFECT DIS J, V18, P800, DOI 10.1097/00006454-199909000-00011.
   MAJOKO F, 1997, CENT AFR J MED, V47, P199.
   Marais BJ, 2006, ARCH DIS CHILD, V91, P762, DOI 10.1136/adc.2006.097220.
   Marais BJ, 2006, PEDIATRICS, V118, pE1350, DOI 10.1542/peds.2006-0519.
   Marais BJ, 2006, INT J TUBERC LUNG D, V10, P732.
   Marais BJ, 2005, INT J TUBERC LUNG D, V9, P1305.
   Marais BJ, 2006, AM J RESP CRIT CARE, V173, P1078, DOI 10.1164/rccm.200511-1809SO.
   Marais BJ, 2006, INT J TUBERC LUNG D, V10, P259.
   Marais BJ, 2006, CLIN INFECT DIS, V42, pE69, DOI 10.1086/502652.
   Marais BJ, 2006, PEDIATR INFECT DIS J, V25, P237, DOI 10.1097/01.inf.0000202140.76368.74.
   Marais BJ, 2005, ARCH DIS CHILD, V90, P1166, DOI 10.1136/adc.2004.060640.
   Marais BJ, 2005, ARCH DIS CHILD, V90, P1162, DOI 10.1136/adc.2004.070797.
   Marais BJ, 2005, ANN TROP PAEDIATR, V25, P79, DOI 10.1179/146532805X45665.
   Marais BJ, 2005, PEDIATR INFECT DIS J, V24, P743, DOI 10.1097/01.inf.0000173305.04212.09.
   Marais BJ, 2004, INT J TUBERC LUNG D, V8, P278.
   Marais BJ, 2004, INT J TUBERC LUNG D, V8, P392.
   MARGONO F, 1994, OBSTET GYNECOL, V83, P911.
   Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5.
   Miguez-Burbano MJ, 2006, INT J INFECT DIS, V10, P47, DOI 10.1016/j.ijid.2004.11.005.
   MSANMANGA GI, 1997, NEW ENGL J MED, V337, P849.
   Narita M, 1998, AM J RESP CRIT CARE, V158, P157.
   Nelson LJ, 2004, INT J TUBERC LUNG D, V8, P636.
   Nyirenda M, 2006, INT J TUBERC LUNG D, V10, P585.
   Ormerod LP, 1998, ARCH DIS CHILD, V78, P169.
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.
   Palme IB, 2002, PEDIATR INFECT DIS J, V21, P1053, DOI 10.1097/01.inf.0000036090.75121.f3.
   PEREZ MS, 2002, SEMIN RESP INFECT, V17, P33.
   PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204.
   Pillay T, 2001, SAMJ S AFR MED J, V91, P983.
   Pillay T, 2001, PEDIATR INFECT DIS J, V20, P404, DOI 10.1097/00006454-200104000-00007.
   Puthanakit T, 2006, PEDIATR INFECT DIS J, V25, P53, DOI 10.1097/01.inf.0000195618.55453.9a.
   Saez-Llorens X, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.1.e4.
   Schaaf HS, 2006, ACTA PAEDIATR, V95, P523, DOI 10.1080/08035250600675741.
   Schaaf HS, 2005, PEDIATR INFECT DIS J, V24, P685, DOI 10.1097/01.inf.0000172933.22481.36.
   Schaaf HS, 2005, ARCH DIS CHILD, V90, P614, DOI 10.1136/adc.2004.052175.
   Schaaf HS, 2003, INT J TUBERC LUNG D, V7, P426.
   Schluger NW, 2002, CHEST, V122, P597, DOI 10.1378/chest.122.2.597.
   Smieja MJ, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001363.
   Starke JR, 2003, TUBERCULOSIS, V83, P208, DOI 10.1016/S1472-9792(02)00088-4.
   THEART AC, 2005, INT J TUBERC LUNG D, V9, P1305.
   van Rheenen P, 2002, TROP MED INT HEALTH, V7, P435, DOI 10.1046/j.1365-3156.2002.00882.x.
   van Zyl S, 2006, INT J TUBERC LUNG D, V10, P13.
   Vargas D, 2005, LANCET, V365, P150, DOI 10.1016/S0140-6736(05)17705-8.
   Verver S, 2004, LANCET, V363, P212, DOI 10.1016/S0140-6736(03)15332-9.
   von Reyn CF, 2006, CLIN INFECT DIS, V42, P559, DOI 10.1086/499959.
   Wagner D, 2004, INFECTION, V32, P257, DOI 10.1007/s15010-004-4001-4.
   Weismuller MM, 2002, INT J TUBERC LUNG D, V6, P432.
   {*}WHO, 2004, 2004339 WHOHTMTB.
   {*}WHO, 2006, WHOHTMTB2006371 L.
   WHO, 2006, GUID COTRIM PROPH HI.
   Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0.
   Zachariah R, 2003, AIDS, V17, P1053, DOI 10.1097/01.aids.0000060355.78202.b7.
   Zar HJ, 2007, BRIT MED J, V334, P136, DOI 10.1136/bmj.39000.486400.55.
   Zar HJ, 2005, LANCET, V365, P130, DOI 10.1016/S0140-6736(05)17702-2.
   Zar HJ, 2001, ACTA PAEDIATR, V90, P119.
   Zhou DJ, 1999, J IMMUNOL, V162, P2204.}},
Number-of-Cited-References = {{117}},
Times-Cited = {{96}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190GC}},
Unique-ID = {{ISI:000248045700010}},
}

@article{ ISI:000248045700009,
Author = {McIlleron, Helen and Meintjes, Graeme and Burman, William J. and
   Maartens, Gary},
Title = {{Complications of antiretroviral therapy in patients with tuberculosis:
   Drug interactions, toxicity, and immune reconstitution inflammatory
   syndrome}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{1}},
Pages = {{S63-S75}},
Month = {{AUG 15}},
Abstract = {{Access to antiretroviral therapy is rapidly expanding in
   resource-limited settings, where tuberculosis is the most common
   opportunistic infection. Coadministration of antitubercular and
   antiretroviral agents is, therefore, occurring commonly, and it is
   associated with 3 major complications. First, induction of cytochrome
   P450 enzymes and P-glycoprotein by rifampin results in reduced
   concentrations of nonnucleoside reversetranscriptase inhibitors and,
   particularly, protease inhibitors. This potentially results in the loss
   of antiviral efficacy and the development of viral resistance. Replacing
   rifampin with rifabutin, which does not significantly affect the
   concentrations of antiretroviral agents, is advocated but is currently
   unaffordable in resource- limited settings. Second, overlapping
   toxicities of antitubercular and antiretroviral agents occur frequently,
   necessitating discontinuation of therapy and increasing the risk of
   nonadherence. Third, immunopathological reactions, termed ``the immune
   reconstitution inflammatory syndrome,{''} occur frequently when
   antiretroviral therapy is initiated in patients with tuberculosis. These
   complexities of coadministration of antitubercular and antiretroviral
   agents are reviewed, and research priorities are highlighted.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Maartens, G (Reprint Author), Univ Cape Town, Hlth Sci Fac, Div Clin Pharmacol, Anzio Rd,Observ 7925, ZA-7925 Cape Town, South Africa.
   Univ Cape Town, Hlth Sci Fac, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa.
   Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa.
   Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Denver, CO 80202 USA.}},
DOI = {{10.1086/518655}},
ISSN = {{0022-1899}},
Keywords-Plus = {{HIV-INFECTED PATIENTS; HUMAN-IMMUNODEFICIENCY-VIRUS; ACQUIRED RIFAMYCIN
   RESISTANCE; EFAVIRENZ-CONTAINING REGIMENS; MYCOBACTERIUM-TUBERCULOSIS;
   ANTITUBERCULOSIS DRUGS; PULMONARY TUBERCULOSIS; PLASMA-CONCENTRATIONS;
   VIROLOGICAL RESPONSE; ACTIVE TUBERCULOSIS}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{gary@curie.uct.ac.za}},
ResearcherID-Numbers = {{Maartens, Gary/F-3836-2014
   }},
ORCID-Numbers = {{Maartens, Gary/0000-0003-3080-6606
   McIlleron, Helen/0000-0002-0982-6226}},
Cited-References = {{ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7.
   ALMOND L, 2005, 6 INT WORKSH CLIN PH, P15.
   AUTAR RS, 2005, 6 INT WORKSH CLIN PH, P15.
   BAALWA J, 2005, 36 INT UN TUB LUNG D.
   Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3.
   BENEDEK IH, 1998, 12 WORLD AIDS C GEN.
   Bonfanti P, 2000, J ACQ IMMUN DEF SYND, V23, P236.
   Borin MT, 1997, CLIN PHARMACOL THER, V61, P544, DOI 10.1016/S0009-9236(97)90134-X.
   Boyd MA, 2003, J CLIN PHARMACOL, V43, P1382, DOI 10.1188/009120003259220.
   Breen RAM, 2005, AIDS, V19, P1201, DOI 10.1097/01.aids.0000176221.33237.67.
   Breen RAM, 2004, THORAX, V59, P704, DOI 10.1136/thx.2003.019224.
   Brennan-Benson P, 2005, AIDS, V19, P1541, DOI 10.1097/01.aids.0000183519.45137.a6.
   Breton G, 2004, CLIN INFECT DIS, V39, P1709, DOI 10.1086/425742.
   Brundage RC, 2004, ANTIMICROB AGENTS CH, V48, P979, DOI 10.1128/AAC.48.3.979-984.2004.
   BURGER D, 2005, 12 C RETR OPP INF BO.
   BURGER DM, 1993, ANTIMICROB AGENTS CH, V37, P1426.
   Burman W, 2006, AM J RESP CRIT CARE, V173, P350, DOI 10.1164/rccm.200503-417OC.
   BURMAN W, 2004, 42 ANN M INF DIS SOC, P201.
   Burman WJ, 2001, CLIN PHARMACOKINET, V40, P327, DOI 10.2165/00003088-200140050-00002.
   Centers for Disease Control and Prevention, UPD GUID US RIF TREA.
   CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570.
   Cheng VCC, 2002, EUR J CLIN MICROBIOL, V21, P803, DOI 10.1007/s10096-002-0821-2.
   COHEN K, 2005, 39 C S AFR PHARM SOC, P22.
   COHEN K, 2005, 3 IAS C HIV PATH TRE.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Crump JA, 1998, CLIN INFECT DIS, V26, P1008, DOI 10.1086/517636.
   de Requena DG, 2005, ANTIMICROB AGENTS CH, V49, P3966, DOI 10.1128/AAC.49.9.3966-3969.2005.
   de Vries-Sluijs TEMS, 2003, CLIN PHARMACOKINET, V42, P599, DOI 10.2165/00003088-200342060-00009.
   Dean GL, 2002, AIDS, V16, P75, DOI 10.1097/00002030-200201040-00010.
   Dumon C, 2000, THER DRUG MONIT, V22, P402, DOI 10.1097/00007691-200008000-00007.
   Dworkin MS, 2005, JAIDS-J ACQ IMM DEF, V39, P464, DOI 10.1097/01.qai.0000152400.36723.85.
   Fishman JE, 2000, AM J ROENTGENOL, V174, P43.
   French MA, 2004, AIDS, V18, P1615, DOI 10.1097/01.aids.0000131375.21070.06.
   Ghosal A, 2005, XENOBIOTICA, V35, P405, DOI 10.1080/00498250500136569.
   Girardi E, 2000, AIDS, V14, P1985, DOI 10.1097/00002030-200009080-00015.
   GRANGE S, 2005, 6 INT WORKSH CLIN PH, V27.
   Guex AC, 2002, DIS COLON RECTUM, V45, P977, DOI 10.1097/01.DCR.0000019508.53744.FB.
   Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772.
   Gurumurthy P, 2004, ANTIMICROB AGENTS CH, V48, P4473, DOI 10.1128/AAC.48.11.4473-4475.2004.
   Haas DW, 2004, AIDS, V18, P2391.
   Hirsch HH, 2004, CLIN INFECT DIS, V38, P1159, DOI 10.1086/383034.
   HOETELMANS RMW, 1998, 12 WORLD AIDS GEN.
   Jack C, 2004, JAIDS-J ACQ IMM DEF, V36, P929, DOI 10.1097/00126334-200408010-00006.
   JACK C, 2005, 12 C RETR OPP INF BO.
   Jehle AW, 2004, CLIN INFECT DIS, V38, pE32, DOI 10.1086/381441.
   John M, 1998, MED J AUSTRALIA, V169, P473.
   Jones JL, 2000, INT J TUBERC LUNG D, V4, P1026.
   Kappelhoff BS, 2005, ANTIVIR THER, V10, P145.
   Kappelhoff BS, 2004, CLIN PHARMACOKINET, V43, P845, DOI 10.2165/00003088-200443130-00002.
   Kirk O, 2000, AM J RESP CRIT CARE, V162, P865.
   Kumar S, 2003, J PHARMACOL EXP THER, V304, P1161, DOI 10.1124/jpet.102.045096.
   Kumarasamy N, 2004, JAIDS-J ACQ IMM DEF, V37, P1574, DOI 10.1097/00126334-200412150-00007.
   la Porte CJL, 2004, ANTIMICROB AGENTS CH, V48, P1553, DOI 10.1128/AAC.48.5.1553-1560.2004.
   Lawn SD, 2005, LANCET INFECT DIS, V5, P361, DOI 10.1016/S1473-3099(05)70140-7.
   Lawn SD, 2005, AIDS, V19, P1113, DOI 10.1097/01.aids.0000176211.08581.5a.
   Li JH, 2005, CLIN INFECT DIS, V41, P83, DOI 10.1086/430377.
   Lopez-Cortes LF, 2002, CLIN PHARMACOKINET, V41, P681.
   Losso MH, 2004, ANTIVIR THER, V9, P1031.
   Manosuthi W, 2005, AIDS, V19, P1481, DOI 10.1097/01.aids.0000183630.27665.30.
   Marzolini C, 2001, AIDS, V15, P71, DOI 10.1097/00002030-200101050-00011.
   Masquelier B, 2002, ANTIMICROB AGENTS CH, V46, P2926, DOI 10.1128/AAC.46.9.2926-2932.2002.
   McIlleron H, 2006, ANTIMICROB AGENTS CH, V50, P1170, DOI 10.1128/AAC.50.4.1170-1177.2006.
   Michailidis C, 2005, ANTIVIR THER, V10, P417.
   Moreno S, 2001, AIDS, V15, P1185, DOI 10.1097/00002030-200106150-00018.
   MUIRHEAD G, 2005, 6 INT WORKSH CLIN PH, V21.
   Murray J, 1999, AM J RESP CRIT CARE, V159, P733.
   Narita M, 1998, AM J RESP CRIT CARE, V158, P157.
   Navas E, 2002, ARCH INTERN MED, V162, P97, DOI 10.1001/archinte.162.1.97.
   Olalla J, 2002, INT J TUBERC LUNG D, V6, P71.
   Oliva J, 2003, AIDS, V17, P637, DOI 10.1097/01.aids.0000050845.71999.24.
   Patel A, 2004, JAIDS-J ACQ IMM DEF, V37, P1166, DOI 10.1097/01.qai.0000135956.96166.f0.
   Pedral-Sampaio Diana B, 2004, Braz J Infect Dis, V8, P211, DOI 10.1590/S1413-86702004000300004.
   PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204.
   Pfister M, 2003, ANTIMICROB AGENTS CH, V47, P130, DOI 10.1128/AAC.47.1.130-137.2003.
   Rae JM, 2001, J PHARMACOL EXP THER, V299, P849.
   RAMACHANDRAN G, 2006, J ACQ IMMUN DEF SYND, V41, P1.
   Ribera E, 2005, JAIDS-J ACQ IMM DEF, V40, P317, DOI 10.1097/01.qai.0000182629.74336.4d.
   Ribera E, 2001, J ACQ IMMUN DEF SYND, V28, P450.
   Rolla V, 2005, 3 IAS C HIV PATH TRE.
   Sahai J, 1997, ANN INTERN MED, V127, P289.
   Sanne I, 2005, J INFECT DIS, V191, P825, DOI 10.1086/428093.
   Santoro-Lopes G, 2002, CLIN INFECT DIS, V34, P543, DOI 10.1086/338641.
   Shelburne SA, 2005, AIDS, V19, P399, DOI 10.1097/01.aids.0000161769.06158.8a.
   SORIANO E, 1988, AIDS, V2, P429.
   Sungkanuparph S, 2006, J INFECTION, V52, P188, DOI 10.1016/j.jinf.2005.05.010.
   Tsuchiya K, 2004, BIOCHEM BIOPH RES CO, V319, P1322, DOI 10.1016/j.bbrc.2004.05.116.
   Veldkamp AI, 2001, AIDS, V15, P1089, DOI 10.1097/00002030-200106150-00003.
   Vernon A, 1999, LANCET, V353, P1843, DOI 10.1016/S0140-6736(98)11467-8.
   Weiner M, 2005, CLIN INFECT DIS, V40, P1481, DOI 10.1086/429321.
   Weiner M, 2003, AM J RESP CRIT CARE, V167, P1341, DOI 10.1164/rccm.200208-951OC.
   Wendel KA, 2001, CHEST, V120, P193, DOI 10.1378/chest.120.1.193.
   {*}WHO, 2004, SCAL ANT THER RES LI.
   Wood R, 2000, J ACQ IMMUN DEF SYND, V23, P75.
   Yee D, 2003, AM J RESP CRIT CARE, V167, P1472, DOI 10.1164/rccm.200206-626OC.
   Zhu M, 2004, INT J TUBERC LUNG D, V8, P1360.}},
Number-of-Cited-References = {{95}},
Times-Cited = {{109}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190GC}},
Unique-ID = {{ISI:000248045700009}},
}

@article{ ISI:000248045700003,
Author = {Nunn, Paul and Reid, Alasdair and De Cock, Kevin M.},
Title = {{Tuberculosis and HIV infection: The global setting}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{1}},
Pages = {{S5-S14}},
Month = {{AUG 15}},
Abstract = {{Tuberculosis (TB) and human immunodeficiency virus (HIV) infection make
   each other's control significantly more difficult. Coordination in
   addressing this ``cursed duet{''} is insufficient at both global and
   national levels. However, global policy for TB/HIV coordination has been
   set, and there is consensus around this policy from both the TB and HIV
   control communities. The policy aims to provide all necessary care for
   the prevention and management of HIV-associated TB, but its
   implementation is hindered by real technical difficulties and shortages
   of resources. All major global-level institutions involved in HIV care
   and prevention must include TB control as part of their corporate
   policy. Country-level decision makers need to work together to expand
   both TB and HIV services, and civil society and community
   representatives need to hold those responsible accountable for their
   delivery. The TB and HIV communities should join forces to address the
   health-sector weaknesses that confront them both.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Nunn, P (Reprint Author), WHO, Stop TB Dept, Org Mondiale Sante, CH-1211 Geneva, Switzerland.
   WHO, Stop TB Dept, Org Mondiale Sante, CH-1211 Geneva, Switzerland.
   WHO, HIV AIDS Dept, CH-1211 Geneva, Switzerland.
   Joint United Nat Programme HIV AIDS, Geneva, Switzerland.}},
DOI = {{10.1086/518660}},
ISSN = {{0022-1899}},
Keywords-Plus = {{HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; NEW-YORK-CITY;
   HUMAN-RESOURCES; ANTIRETROVIRAL TREATMENT; COUNTRIES; MORTALITY; IMPACT;
   KENYA; ERA}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{nunnp@who.int}},
Cited-References = {{Aylward RB, 2005, B WORLD HEALTH ORGAN, V83, P268.
   Bosman MCJ, 2000, INT J TUBERC LUNG D, V4, P606.
   BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745.
   Cantwell MF, 1997, INT J TUBERC LUNG D, V1, P205.
   Centers for Disease Control and Prevention, 1993, MMWR-MORBID MORTAL W, V42, P696.
   Chen XY, 2004, LANCET, V364, P417.
   Chin DP, 1996, CLIN CHEST MED, V17, P697, DOI 10.1016/S0272-5231(05)70340-3.
   Coetzee D, 2004, TROP MED INT HEALTH, V9, pA11, DOI 10.1111/j.1365-3156.2004.01259.x.
   {*}COMM AFR, 2005, COMM INT REP COMM AF.
   CONWAY S, 2006, PUBLIC PRIVATE HIV P.
   Corbett EL, 2006, LANCET, V367, P926, DOI 10.1016/S0140-6736(06)68383-9.
   De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457.
   ELLIOTT AM, 1995, T ROY SOC TROP MED H, V89, P78, DOI 10.1016/0035-9203(95)90668-1.
   Elzinga G, 2002, B WORLD HEALTH ORGAN, V80, P469.
   Farmer P, 1998, INT J TUBERC LUNG D, V2, P869.
   FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406.
   {*}G8, 2005, CHAIRS SUMM GLEN SUM.
   Harries AD, 2005, INT J TUBERC LUNG D, V9, P128.
   Harries AD, 1998, TROP DOCT, V28, P243.
   Harries AD, 1998, INT J TUBERC LUNG D, V2, P914.
   HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z.
   Jack C, 2004, JAIDS-J ACQ IMM DEF, V36, P929, DOI 10.1097/00126334-200408010-00006.
   Joint United Nations Programme on HIV/AIDS, 2006, AIDS EP UPD DEC 2006.
   {*}JOINT UN PROGR HI, UNAIDS WHO POL STAT.
   {*}JOINT UN PROGRHIV, 2004, REP GLOB AIDS EP.
   KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M.
   Lonnroth K, 2004, B WORLD HEALTH ORGAN, V82, P580.
   LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005.
   Maher D, 1999, INT J TUBERC LUNG D, V3, P762.
   MANN J, 1986, JAMA-J AM MED ASSOC, V256, P346.
   MARAIS H, 2002, REPORT GLOBAL HIV AI.
   MITCHISON DA, 1980, J ROY COLL PHYS LOND, V14, P91.
   MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7.
   MURRAY CJL, 1990, LANCET, V335, P1043, DOI 10.1016/0140-6736(90)91114-P.
   Narasimhan V, 2004, LANCET, V363, P1469, DOI 10.1016/S0140-6736(04)16108-4.
   NUNN P, 1992, AM REV RESPIR DIS, V146, P849.
   Nunn P, 2005, NAT REV IMMUNOL, V5, P819, DOI 10.1038/nri1704.
   NUNN P, 1991, LANCET, V337, P627.
   NUNN P, 1993, TUBERCLE LUNG DIS, V74, P273, DOI 10.1016/0962-8479(93)90054-2.
   OTTMANI S, 1998, DELM B EPIDEMIOLOGIQ, V35, P2.
   PIOT P, 1984, LANCET, V2, P65.
   PITCHENIK AE, 1983, ANN INTERN MED, V98, P112.
   Raviglione MC, 2006, LANCET, V367, P952, DOI 10.1016/S0140-6736(06)68392-X.
   Rigoli F, 2003, HUM RESOUR HEALTH, V1, P1.
   RILEY DK, 1996, ANN INTERN MED, V124, P45.
   STYBLO K, 1989, REV INFECT DIS, V11, pS339.
   Styblo K., 1991, EPIDEMIOLOGY TUBERCU.
   Suarez PG, 2001, J INFECT DIS, V184, P473, DOI 10.1086/322777.
   {*}UN, 2001, 26 SPEC SESS US GEN.
   UNAIDS (Joint United Nations Programme on HIV/AIDS), 2004, AIDS EP UPD DEC 2004.
   WALLACE D, 1995, LANCET, V346, P1162.
   Weil DEC, 2000, INT J TUBERC LUNG D, V4, P597.
   {*}WHO, 2006, STOP TB PARTN ACT LI.
   {[}WHO World Health Organization], 1998, LAB SERV TUB CONTR 2.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.
   {*}WHO, 2004, GUID MON EV COLL TB.
   {*}WHO, 2006, PROGR GLOB ACC HIV A.
   World Health Organization, 2004, WHOHTMTB2004330.
   {*}WHO, 2004, SCAL UP PREV TREATM.
   WHO, 2003, TREAT 3 MILL 2005 MA.
   World Health Organization (WHO), 2005, GLOB TUB CONTR SURV.
   World Health Organization (WHO), 2004, REP LESS LEARNT WORK.
   {*}WORLD BANK, 2004, ASS ONG ASS AFR MAP.
   The World Bank, 1993, WORLD DEV REP 1993 I.
   Zachariah R, 2005, INT J TUBERC LUNG D, V9, P238.}},
Number-of-Cited-References = {{65}},
Times-Cited = {{40}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190GC}},
Unique-ID = {{ISI:000248045700003}},
}

@article{ ISI:000248045700006,
Author = {Onyebujoh, Philip Chukwuka and Ribeiro, Isabela and Whalen, Christopher
   Curtis},
Title = {{Treatment options for HIV-associated tuberculosis}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{1}},
Pages = {{S35-S45}},
Month = {{AUG 15}},
Abstract = {{The vicious interaction between the human immunodeficiency virus (HIV)
   infection and tuberculosis (TB) pandemics poses special challenges to
   national control programs and individual physicians. Although
   recommendations for the treatment of TB in HIV-infected patients do not
   significantly differ from those for HIV-uninfected patients, the
   appropriate management of HIV-associated TB is complicated by health
   system issues, diagnostic difficulties, adherence concerns, overlapping
   adverse-effect profiles and drug interactions, and the occurrence of
   paradoxical reactions after the initiation of effective antiretroviral
   therapy. In this article, recommended treatment strategies and novel
   approaches to the management of HIV-associated TB are reviewed,
   including adjuvant treatment and options for treatment simplification. A
   focused research agenda is proposed in the context of the limitations of
   the current knowledge framework.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Onyebujoh, PC (Reprint Author), UNDP, United Nat Childrens Fund, WHO Special Programme Res \& Training Trop Dis, Ctr Casai, Geneva, Switzerland.
   UNDP, United Nat Childrens Fund, WHO Special Programme Res \& Training Trop Dis, Ctr Casai, Geneva, Switzerland.
   Case Western Reserve Univ, Dept Epidemiol \& Biostat, TB Res Unit, Cleveland, OH 44106 USA.}},
DOI = {{10.1086/518657}},
ISSN = {{0022-1899}},
Keywords-Plus = {{HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; SOCIETY-USA
   PANEL; DIAGNOSED PULMONARY TUBERCULOSIS; ACQUIRED RIFAMYCIN RESISTANCE;
   RANDOMIZED CONTROLLED-TRIAL; IN-VIVO ACTIVITIES;
   MYCOBACTERIUM-TUBERCULOSIS; UPDATED RECOMMENDATIONS; INFECTED PATIENTS}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{onyebujohp@who.int}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}R01 AI051219-01A2, R01 AI051219]}},
Cited-References = {{Alvirez-Freites EJ, 2002, ANTIMICROB AGENTS CH, V46, P1022, DOI 10.1128/AAC.46.4.1022-1025.2002.
   American Thoracic Society/Centers for Disease Control and Prevention/Infectious Disease Society of America, 2003, AM J RESP CRIT CARE, V167, P603.
   Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008.
   Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015.
   Bartlett JA, 2001, AIDS, V15, P1369, DOI 10.1097/00002030-200107270-00006.
   Bekker LG, 2000, J INFECT DIS, V181, P954, DOI 10.1086/315328.
   Blanc FX, 2007, J INFECT DIS, V196, pS46, DOI 10.1086/518658.
   Blaschke TF, 1996, CLIN INFECT DIS, V22, pS15, DOI 10.1093/clinids/22.Supplement\_1.S15.
   Breen RAM, 2004, THORAX, V59, P704, DOI 10.1136/thx.2003.019224.
   BURMAN V, 2003, 10 C RETR OPP INF BO, P106.
   Burman WJ, 2006, AM J RESP CRIT CARE, V174, P331, DOI 10.1164/rccm.200603-360OC.
   Burman WJ, 2005, CLIN CHEST MED, V26, P283, DOI 10.1016/j.ccm.2005.02.002.
   Burman WJ, 2001, CLIN PHARMACOKINET, V40, P327, DOI 10.2165/00003088-200140050-00002.
   Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381.
   Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78.
   Chimzizi R, 2004, INT J TUBERC LUNG D, V8, P579.
   DEAN GL, 2002, AIDS, V16, P1569.
   Dheda K, 2004, J INFECT DIS, V190, P1670, DOI 10.1086/424676.
   Dybul Mark, 2002, MMWR Recomm Rep, V51, P1.
   East and Central African/British Medical Research Council, 1986, TUBERCLE, V67, P5.
   East and Central African/British Medical Research Council Fifth Collaborative Study, 1983, TUBERCLE, V64, P153.
   Ehlers Stefan, 2005, J Rheumatol Suppl, V74, P35.
   El-Sadr WM, 2001, CLIN INFECT DIS, V32, P623, DOI 10.1086/318706.
   Falzon D, 2005, INT J TUBERC LUNG D, V9, P1224.
   Fischl M, 2001, 8 C RETR OPP INF CHI.
   Friedland G, 2007, J INFECT DIS, V196, pS114, DOI 10.1086/518664.
   Grimwade K, 2005, AIDS, V19, P163, DOI 10.1097/00002030-200501280-00008.
   Gross R, 2001, AIDS, V15, P2109, DOI 10.1097/00002030-200111090-00006.
   Harries AD, 2001, LANCET, V357, P1519, DOI 10.1016/S0140-6736(00)04639-0.
   Imperiali FG, 2001, CLIN EXP IMMUNOL, V123, P435, DOI 10.1046/j.1365-2249.2001.01481.x.
   IRLAM JH, 2005, COCHRANE DATABASE SY.
   Jack C, 2004, JAIDS-J ACQ IMM DEF, V36, P929, DOI 10.1097/00126334-200408010-00006.
   Ji BH, 1998, ANTIMICROB AGENTS CH, V42, P2066.
   Jindani A, 2004, LANCET, V364, P1244, DOI 10.1016/S0140-6736(04)17141-9.
   Keane J, 2005, RHEUMATOLOGY, V44, P714, DOI 10.1093/rheumatology/keh567.
   Kitaura H, 2001, APMIS, V109, P533, DOI 10.1111/j.1600-0463.2001.apm090707.x.
   Korenromp EL, 2003, CLIN INFECT DIS, V37, P101, DOI 10.1086/375220.
   Lawn SD, 2006, AIDS, V20, P1605, DOI 10.1097/01.aids.0000238406.93249.cd.
   Li JH, 2005, CLIN INFECT DIS, V41, P83, DOI 10.1086/430377.
   Lurie MN, 2004, LANCET INFECT DIS, V4, P137, DOI 10.1016/S1473-3099(04)00936-3.
   Mayanja-Kizza H, 2005, J INFECT DIS, V191, P856, DOI 10.1086/427995.
   McIlleron H, 2007, J INFECT DIS, V196, pS63, DOI 10.1086/518655.
   Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5.
   Mitchison DA, 2000, INT J TUBERC LUNG D, V4, P796.
   MITCHISON DA, 1985, TUBERCLE, V66, P219, DOI 10.1016/0041-3879(85)90040-6.
   Mitty JA, 2002, CLIN INFECT DIS, V34, P984, DOI 10.1086/339447.
   MWANUNGULU FB, 2004, B WORLD HEALTH ORGAN, V82, P354.
   Nettles RE, 2004, CLIN INFECT DIS, V38, P731, DOI 10.1086/381675.
   Nuermberger EL, 2004, AM J RESP CRIT CARE, V169, P421, DOI 10.1164/rccm.200310-1380OC.
   Okwera A, 2006, INT J TUBERC LUNG D, V10, P39.
   Onyebujoh P, 2005, B WORLD HEALTH ORGAN, V83, P857.
   Onyebujoh PC, 1999, LANCET, V354, P116.
   {*}PAN CLIM PRACT TR, 2006, GUID US ANT AG HIV 1.
   {*}PAN CLIN PRACT RT, 2003, GUID US ANT AG HIV 1.
   Panel on Clinical Practices for Treatment of HIV Infection, 2001, HIV CLIN TRIALS, V2, P227.
   POZNIAK AL, 2005, BHIVA TREATMENT GUID.
   RUSTOMJEE R, 2005, INT J TUBERC LUNG D, V9, pS23.
   Semba RD, 2005, NUTRITION, V21, P25, DOI 10.1016/j.nut.2004.10.004.
   Singapore Tuberculosis Service British Medical Research Council, 1981, TUBERCLE, V62, P95.
   Singh N, 1999, CLIN INFECT DIS, V29, P824, DOI 10.1086/520443.
   Smego RA, 2003, INT J TUBERC LUNG D, V7, P208.
   Spradling P, 2002, CLIN INFECT DIS, V35, P1106, DOI 10.1086/343047.
   {*}STOP TB PARTN, 2007, GLOB PLAN STOP TB 20.
   {*}STOP TB PARTN WHO, 2004, WHOHTMHIV20041.
   Sungkanuparph S, 2006, J INFECTION, V52, P188, DOI 10.1016/j.jinf.2005.05.010.
   Tuberculosis Research Centre (Indian Council of Medical Research) Chennai, 2002, INDIAN J TUBERC, V49, P27.
   {*}UNAIDS WHO, 2000, PAT SIT HIV AIDS REL.
   Vernon A, 1999, LANCET, V353, P1843, DOI 10.1016/S0140-6736(98)11467-8.
   Volmink J, 2000, COCHRANE DATABASE SY.
   Wallis RS, 1996, J INFECT DIS, V174, P727.
   Wallis RS, 2004, AIDS, V18, P257, DOI 10.1097/01.aids.0000104367.21567.d8.
   Weber A, 2001, BIOPHARM DRUG DISPOS, V22, P157, DOI 10.1002/bdd.268.
   Weiner M, 2005, CLIN INFECT DIS, V41, P1343, DOI 10.1086/496980.
   Weiner M, 2005, CLIN INFECT DIS, V40, P1481, DOI 10.1086/429321.
   World Health Organization, 2003, WHOCDSTB2003313.
   WHO, 2005, TB HIV RES PRIOR RES.
   {*}WHO, 2004, SCAL UP ANT THER RES.
   World Health Organization, 2002, SCAL UP ANT THER RES.
   World Health Organization, 2002, WHOCDSTB2002297.
   World Health Organization, 2006, ANT THER HIV INF AD.
   Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0.
   Wood E, 2004, JAIDS-J ACQ IMM DEF, V35, P261, DOI 10.1097/00126334-200403010-00006.
   Wood E, 2003, ANN INTERN MED, V139, P810.
   Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222.
   {[}Anonymous], 1980, TUBERCLE, V61, P59.
   {[}Anonymous], 1976, AM REV RESP DIS, V114, P471.}},
Number-of-Cited-References = {{86}},
Times-Cited = {{27}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190GC}},
Unique-ID = {{ISI:000248045700006}},
}

@article{ ISI:000248045700004,
Author = {Perkins, Mark D. and Cunningham, Jane},
Title = {{Facing the crisis: Improving the diagnosis of tuberculosis in the HIV
   era}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{1}},
Pages = {{S15-S27}},
Month = {{AUG 15}},
Abstract = {{Although the human immunodeficiency virus (HIV) infection pandemic has
   had a catastrophic impact on tuberculosis (TB) control efforts,
   especially in sub-Saharan Africa, most of the fundamental concepts
   reflected in the directly observed treatment, short course (DOTS)
   strategy still hold true in the HIV era. What has changed, and
   dramatically, is the importance of speedy and accurate TB diagnosis and
   the difficulty of achieving this. The disproportionate amount of
   smear-negative disease in sub-Saharan Africa, which shoulders two-thirds
   of the global burden of HIV infection and acquired immunodeficiency
   syndrome, has greatly complicated TB case detection and disease control.
   Now, 15 years after TB rates began to soar in countries where HIV
   infection is prevalent, we have learned that the conventional
   approach-passively waiting for patients with advanced symptomatic
   disease to make their way to microscopy centers for diagnosis-has
   disastrous consequences. Without better diagnostic tools for TB and
   effective strategies for their implementation, transmission will not be
   interrupted, mortality will not be checked, and TB will not be
   controlled in areas where HIV infection is prevalent. Fortunately, a
   number of technical opportunities exist for the creation of improved
   diagnostic tests. Developing and exploiting such tests to support TB
   control in HIV-infected populations is an urgent priority. A substantial
   public sector effort is under way to work in partnership with the
   biotechnology industry to accelerate progress toward that goal. In this
   article, we will define the need for better TB tests and describe
   technologies being developed to meet that need.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Perkins, MD (Reprint Author), Fdn Innovat New Diagnost, 71 Ave Louis Casal,POB 93, CH-1216 Cointrin, Switzerland.
   Fdn Innovat New Diagnost, CH-1216 Cointrin, Switzerland.
   WHO, United Nat Dev Programme, United Nat Childrens Fund, World Bank,Special Programme Res \& Training Trop, CH-1211 Geneva, Switzerland.}},
DOI = {{10.1086/518656}},
ISSN = {{0022-1899}},
Keywords-Plus = {{NEGATIVE PULMONARY TUBERCULOSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; GENOTYPE
   MTBDR ASSAY; MULTIDRUG-RESISTANT TUBERCULOSIS; BACTEC MGIT-960 SYSTEM;
   LUCIFERASE REPORTER MYCOBACTERIOPHAGES; MEDIATED ISOTHERMAL
   AMPLIFICATION; BACTERIOPHAGE-BASED METHOD; DRUG-SUSCEPTIBILITY ASSAY;
   LOWENSTEIN-JENSEN MEDIUM}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{mark.perkins@finddiagnostics.org}},
Cited-References = {{Abe C, 1999, J CLIN MICROBIOL, V37, P3693.
   Albay A, 2003, DIAGN MICR INFEC DIS, V46, P211, DOI 10.1016/S0732-8893(03)00048-8.
   Albert H, 2002, INT J TUBERC LUNG D, V6, P523.
   Albert H, 2002, INT J TUBERC LUNG D, V6, P529.
   ALBERT H, 2004, INT J TUBERC LUNG D, V8, P111.
   Alcaide F, 2003, J CLIN MICROBIOL, V41, P2867, DOI 10.1128/JCM.41.7.2867-2871.2003.
   Angeby KAK, 2000, INT J TUBERC LUNG D, V4, P684.
   Angeby KAK, 2003, CLIN MICROBIOL INFEC, V9, P1148, DOI 10.1046/j.1469-0691.2003.00783.x.
   Angeby KAK, 2002, J CLIN MICROBIOL, V40, P553, DOI 10.1128/JCM.40.2.553-555.2002.
   Ansari NA, 2002, INT J TUBERC LUNG D, V6, P55.
   Anthony RM, 2006, INT J TUBERC LUNG D, V10, P1060.
   Apers L, 2004, INT J TUBERC LUNG D, V8, P945.
   Apers L, 2003, INT J TUBERC LUNG D, V7, P376.
   ARAJ GF, 1993, DIAGN MICR INFEC DIS, V17, P119, DOI 10.1016/0732-8893(93)90022-Y.
   Arias-Bouda LMP, 2000, J CLIN MICROBIOL, V38, P2278.
   Banaiee N, 2003, J MED MICROBIOL, V52, P557, DOI 10.1099/jmm.0.05149-0.
   Banaiee N, 2001, J CLIN MICROBIOL, V39, P3883, DOI 10.1128/JCM.39.11.3883-3888.2001.
   BANCHUIN N, 1990, ASIAN PAC J ALLERGY, V8, P5.
   Baylan O, 2004, INT J TUBERC LUNG D, V8, P772.
   Bemer P, 2002, J CLIN MICROBIOL, V40, P150, DOI 10.1128/JCM.40.1.150-154.2002.
   Bentley-Hibbert SI, 1999, INFECT IMMUN, V67, P581.
   Boehme C, 2005, T ROY SOC TROP MED H, V99, P893, DOI 10.1016/j.trstmh.2005.04.014.
   Boehme CC, 2007, J CLIN MICROBIOL, V45, P1936, DOI 10.1128/JCM.02352-06.
   Botezatu I, 2000, CLIN CHEM, V46, P1078.
   Bruchfeld J, 2002, SCAND J INFECT DIS, V34, P331, DOI 10.1080/00365540110080025.
   Bruchfeld J, 2000, T ROY SOC TROP MED H, V94, P677, DOI 10.1016/S0035-9203(00)90230-X.
   Buijtels PCAM, 2005, J CLIN MICROBIOL, V43, P6020, DOI 10.1128/JCM.43.12.6020-6026.2005.
   Butt T, 2004, INT J TUBERC LUNG D, V8, P899.
   Campos PE, 2003, EMERG INFECT DIS, V9, P1571.
   Cavusoglu C, 2006, J CLIN MICROBIOL, V44, P2338, DOI 10.1128/JCM.00425-06.
   Chanteau S, 2000, INT J TUBERC LUNG D, V4, P377.
   Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008.
   Chien HP, 2000, INT J TUBERC LUNG D, V4, P866.
   CHO S-N, 1990, Yonsei Medical Journal, V31, P333.
   Choudhry V, 2002, EUR J CLIN MICROBIOL, V21, P1, DOI 10.1007/s10096-001-0651-7.
   COLE RA, 2005, 36 WORLD C LUNG HLTH.
   Colebunders R, 2000, INT J TUBERC LUNG D, V4, P97.
   Crampin AC, 2001, INT J TUBERC LUNG D, V5, P994.
   Cunningham J, 2006, DIAGNOSTICS TUBERCUL.
   Cunningham J A, 2004, INT J TUBERC LUNG S1, V8, pS178.
   da Silva PA, 2006, CLIN MICROBIOL INFEC, V12, P293, DOI 10.1111/j.1469-0691.2005.01355.x.
   Deisingh AK, 2004, INT J FOOD SCI TECH, V39, P587, DOI 10.1111/j.1365-2621.2004.00821.x.
   Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002.
   ELLIOTT AM, 1993, J TROP MED HYG, V96, P1.
   ELLIOTT AM, 1993, TUBERCLE LUNG DIS, V74, P191, DOI 10.1016/0962-8479(93)90010-U.
   Elliott AM, 1999, INT J TUBERC LUNG D, V3, P239.
   Farnia P, 2004, J CLIN MICROBIOL, V42, P3324, DOI 10.1128/JCM.42.7.3324-3325.2004.
   Farnia P, 2002, J CLIN MICROBIOL, V40, P508, DOI 10.1128/JCM.40.2.508-511.2002.
   Fend R, 2006, J CLIN MICROBIOL, V44, P2039, DOI 10.1128/JCM.01591-05.
   Fend R, 2005, J CLIN MICROBIOL, V43, P1745, DOI 10.1128/JCM.43.4.1745-1751.2005.
   Friend JH, 2005, TROP DOCT, V35, P93, DOI 10.1258/0049475054037165.
   Gamboa F, 1998, EUR J CLIN MICROBIOL, V17, P189, DOI 10.1007/BF01691116.
   Getahun H, 2007, LANCET, V369, P2042, DOI 10.1016/S0140-6736(07)60284-0.
   Gil-Setas A, 2004, CLIN MICROBIOL INFEC, V10, P224, DOI 10.1111/j.1198-743X.2004.00733.x.
   GOLETTI D, 2005, 35 WORLD C LUNG HLTH.
   Goloubeva V, 2001, J CLIN MICROBIOL, V39, P1501, DOI 10.1128/JCM.39.4.1501-1505.2001.
   Gutierrez EB, 2002, PATHOL RES PRACT, V198, P339, DOI 10.1078/0344-0338-00264.
   Hagemann P. K. H., 1938, MUNCHENER MED WOCHEN SCHR, V85, P1066.
   Hamasur B, 2001, J MICROBIOL METH, V45, P41, DOI 10.1016/S0167-7012(01)00239-1.
   Hargreaves NJ, 2001, INT J TUBERC LUNG D, V5, P847.
   Harries AD, 2003, INT J TUBERC LUNG D, V7, P953.
   Harries AD, 2001, INT J TUBERC LUNG D, V5, P1000.
   Harries AD, 1998, T ROY SOC TROP MED H, V92, P123, DOI 10.1016/S0035-9203(98)90985-3.
   Hasegawa N, 2002, J CLIN MICROBIOL, V40, P908, DOI 10.1128/JCM.40.3.908-912.2002.
   HELB D, 2005, TUB INT HOST PATH BI.
   Hillemann D, 2005, INT J TUBERC LUNG D, V9, P1409.
   Hillemann D, 2005, J CLIN MICROBIOL, V43, P3699, DOI 10.1128/JCM.43.8.3699-3703.2005.
   Hirano K, 2004, J CLIN MICROBIOL, V42, P390, DOI 10.1128/JCM.42.1.390-392.2004.
   Huggett JF, 2003, INT J BIOCHEM CELL B, V35, P1407, DOI 10.1016/S1357-2725(03)00102-X.
   Iwamoto T, 2003, J CLIN MICROBIOL, V41, P2616, DOI 10.1128/JCM.41.6.2616-2622.2003.
   JACOBS WR, 1993, SCIENCE, V260, P819, DOI 10.1126/science.8484123.
   Kalantri S, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-59.
   KERTCHER JA, 1978, AM REV RESPIR DIS, V117, P631.
   KIEHN TE, 1993, CLIN INFECT DIS, V17, pS447.
   Klautau Giselle Burlamaqui, 2005, Braz J Infect Dis, V9, P464, DOI 10.1590/S1413-86702005000600004.
   KOCAGOZ T, 2000, AM SOC MICR GEN M WA.
   Kontos F, 2004, J MICROBIOL METH, V56, P291, DOI 10.1016/j.mimet.2003.10.015.
   Laal S, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P71.
   Laal S, 1997, J INFECT DIS, V176, P133, DOI 10.1086/514015.
   Landowski CP, 2001, J CLIN MICROBIOL, V39, P2418, DOI 10.1128/JCM.39.7.2418-2424.2001.
   Lanjewar D N, 2001, HIV Med, V2, P266, DOI 10.1046/j.1468-1293.2001.00079.x.
   Lawson L, 2005, INT J TUBERC LUNG D, V9, P933.
   Lee JJ, 2003, INT J TUBERC LUNG D, V7, P569.
   Lee M P, 2000, Respirology, V5, P423, DOI 10.1046/j.1440-1843.2000.00287.x.
   Liam CK, 1997, INT J TUBERC LUNG D, V1, P326.
   LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005.
   Madebo T, 1999, MED GEN MED, pE6.
   Marei AM, 2003, J MED MICROBIOL, V52, P331, DOI 10.1099/jmm.0.05091-0.
   Marttila HJ, 1999, SCAND J INFECT DIS, V31, P269.
   McKee M., 2003, GIANT RATS SNIFF OUT.
   Mejia GI, 1999, INT J TUBERC LUNG D, V3, P138.
   Mesfin MM, 2005, ETHIOP J HEALTH DEV, V19, P13.
   Miotto P, 2006, J CLIN MICROBIOL, V44, P2485, DOI 10.1128/JCM.00083-06.
   MOLL A, 2006, 13 C RETR OPP INF DE.
   Monforte AD, 1996, EUR J CLIN MICROBIOL, V15, P453, DOI 10.1007/BF01691311.
   Moore DAJ, 2004, J CLIN MICROBIOL, V42, P4432, DOI 10.1128/JCM.42.10.4432-4437.2004.
   Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524.
   MORGAN MA, 1983, J CLIN MICROBIOL, V18, P384.
   Murray JF, 2005, INT J TUBERC LUNG D, V9, P826.
   Muzaffar R, 2002, INT J TUBERC LUNG D, V6, P635.
   NELSON AM, 1993, AIDS, V7, P1241, DOI 10.1097/00002030-199309000-00014.
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.
   Pai M, 2005, J INFECTION, V51, P175, DOI 10.1016/j.jint.2005.05.017.
   Pai M, 2007, CLIN INFECT DIS, V44, P74, DOI 10.1086/509927.
   Pavlou AK, 2000, CLIN CHEM LAB MED, V38, P99, DOI 10.1515/CCLM.2000.016.
   Perkins MD, 2003, CHEST, V123, P107, DOI 10.1378/chest.123.1.107.
   PHILLIPS M, 2006, TUBERCULOSIS EDINB, V87, P44.
   Piersimoni C, 2003, J CLIN MICROBIOL, V41, P5355, DOI 10.1128/JCM.41.12.5355-5365.2003.
   PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393.
   Poprawski D, 2000, Southeast Asian J Trop Med Public Health, V31 Suppl 1, P140.
   Pottumarthy S, 2000, J CLIN MICROBIOL, V38, P2227.
   Pronyk PM, 2004, INT J TUBERC LUNG D, V8, P796.
   Steingart K, 2006, LANCET INFECT DIS, V6, P570, DOI 10.1016/S1473-3099(06)70578-3.
   RADHAKRISHNAN VV, 1991, J APPL BACTERIOL, V71, P428, DOI 10.1111/j.1365-2672.1991.tb03812.x.
   Ramsay A, 2006, INT J TUBERC LUNG D, V10, P256.
   Rana FS, 2000, J ACQ IMMUN DEF SYND, V24, P23.
   RICHARDS OSCAR W., 1941, AMER REV TUBERC, V44, P255.
   Ritacco V, 1997, J INFECT DIS, V176, P637.
   ROBERTS GD, 1983, J CLIN MICROBIOL, V18, P689.
   Rohner P, 1997, J CLIN MICROBIOL, V35, P3127.
   Rossau R, 1997, ANTIMICROB AGENTS CH, V41, P2093.
   SADA E, 1992, J CLIN MICROBIOL, V30, P2415.
   SALFINGER M, 1994, EUR J CLIN MICROBIOL, V13, P961, DOI 10.1007/BF02111498.
   Scarparo C, 2004, J CLIN MICROBIOL, V42, P1109, DOI 10.1128/JCM.42.3.1109-1114.2004.
   Scarparo C, 2002, DIAGN MICR INFEC DIS, V44, P157, DOI 10.1016/S0732-8893(02)00437-6.
   Scott CP, 2002, J CLIN MICROBIOL, V40, P3219, DOI 10.1128/JCM.40.9.3219-3222.2002.
   Selvakumar N, 2002, J CLIN MICROBIOL, V40, P3017, DOI 10.1128/JCM.40.8.3017-3020.2002.
   Siddiqi K, 2003, LANCET INFECT DIS, V3, P288, DOI 10.1016/S1473-3099(03)00609-1.
   Smith H, 1998, TRENDS MICROBIOL, V6, P239, DOI 10.1016/S0966-842X(98)01250-5.
   SMITHWICK RW, 1981, J CLIN MICROBIOL, V13, P1109.
   Somi GR, 1999, INT J TUBERC LUNG D, V3, P231.
   Somoskovi A, 2006, J CLIN MICROBIOL, V44, P4459, DOI 10.1128/JCM.01506-06.
   Squire SB, 2005, INT J TUBERC LUNG D, V9, P25.
   Steingart KR, 2006, LANCET INFECT DIS, V6, P664, DOI 10.1016/S1473-3099(06)70602-8.
   Suffys P, 2000, INT J TUBERC LUNG D, V4, P179.
   Sumi MG, 2002, CLIN DIAGN LAB IMMUN, V9, P344, DOI 10.1128/CDLI.9.2.344-437.2002.
   Talbot EA, 2004, CLIN INFECT DIS, V39, pE1, DOI 10.1086/421388.
   Tessema TA, 2002, SCAND J INFECT DIS, V34, P167, DOI 10.1080/00365540110077254.
   Tessema TA, 2002, SCAND J INFECT DIS, V34, P97, DOI 10.1080/00365540110077263.
   Tessema TA, 2001, SCAND J INFECT DIS, V33, P279.
   THYBO S, 1995, TUBERCLE LUNG DIS, V76, P149, DOI 10.1016/0962-8479(95)90558-8.
   Tortoli E, 2002, J CLIN MICROBIOL, V40, P607, DOI 10.1128/JCM.40.2.607-610.2002.
   Tortoli E, 1998, J CLIN MICROBIOL, V36, P1378.
   Wallis RS, 1998, J INFECT DIS, V178, P1115, DOI 10.1086/515701.
   Watterson SA, 1998, J CLIN MICROBIOL, V36, P1969.
   Weldingh K, 2005, J CLIN MICROBIOL, V43, P57, DOI 10.1128/JCM.43.1.57-65.2005.
   {[}Anonymous], 2004, GLOB TUB CONTR SURV.
   World Health Organization, 2000, 2 WHO.
   Williams-Bouyer N, 2000, J CLIN MICROBIOL, V38, P4167.
   Wilson D, 2006, INT J TUBERC LUNG D, V10, P31.
   Wilson SM, 1997, NAT MED, V3, P465, DOI 10.1038/nm0497-465.
   Wright PW, 1998, J CLIN MICROBIOL, V36, P1046.}},
Number-of-Cited-References = {{152}},
Times-Cited = {{169}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190GC}},
Unique-ID = {{ISI:000248045700004}},
}

@article{ ISI:000248045700005,
Author = {Spigelman, Melvin K.},
Title = {{New tuberculosis therapeutics: A growing pipeline}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{1}},
Pages = {{S28-S34}},
Month = {{AUG 15}},
Abstract = {{Novel chemotherapeutic drugs are needed to improve tuberculosis (TB)
   control, especially in the developing world. Given the magnitude of the
   problem and the resources available in countries that have the highest
   burden of disease, the present standards of care for the treatment of
   drug-susceptible TB, drug-resistant TB, TB/human immunodeficiency virus
   (HIV) coinfection, and latent TB infection are all unsatisfactory.
   Because no truly novel compounds for the treatment of TB have been
   discovered in the past 40 years, the recent enhanced activity in the
   research and development of new TB drugs is extremely encouraging. Seven
   compounds are presently in clinical development specifically for the
   treatment of TB. Other known antibiotic compound families are being
   investigated preclinically, in an attempt to identify new antimicrobial
   drugs with specific antituberculous activity. In addition, novel targets
   have been identified and are the subject of efforts to validate their
   potential usefulness in the treatment of TB.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Spigelman, MK (Reprint Author), Global Alliance TB Drug Dev, 80 Broad St,31st Fl, Beijing 100044, Peoples R China.
   Global Alliance TB Drug Dev, Beijing 100044, Peoples R China.}},
DOI = {{10.1086/518663}},
ISSN = {{0022-1899}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; BACTERICIDAL
   ACTIVITY; MURINE TUBERCULOSIS; IN-VITRO; MOXIFLOXACIN; GATIFLOXACIN;
   RIFAPENTINE; REGIMENS; PA-824}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{spigelman@tballiance.org}},
Cited-References = {{Alvirez-Freites EJ, 2002, ANTIMICROB AGENTS CH, V46, P1022, DOI 10.1128/AAC.46.4.1022-1025.2002.
   American Thoracic Society/Centers for Disease Control and Prevention/Infectious Disease Society of America, 2003, AM J RESP CRIT CARE, V167, P603.
   Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753.
   Arora S.K., 2004, 44 INT C ANT AG CHEM, P212.
   Benator D, 2002, LANCET, V360, P528.
   British Medical Journal, 1950, BR MED J, V2, P1073.
   BURMAN WJ, 2005, 45 INT C ANT AG CHEM, P203.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Deidda D, 1998, ANTIMICROB AGENTS CH, V42, P3035.
   Fung-Tomc J, 2000, J ANTIMICROB CHEMOTH, V45, P437, DOI 10.1093/jac/45.4.437.
   Ginsberg A, 2006, TUBERCULOSIS COMPREH, P1135.
   Gosling RD, 2003, AM J RESP CRIT CARE, V168, P1342, DOI 10.1164/rccm.200305-682OC.
   HASHIZUME H, 2005, 45 INT C ANT AG CHEM, P204.
   Hu YM, 2003, ANTIMICROB AGENTS CH, V47, P653, DOI 10.1128/AAC.47.2.653-657.2003.
   HUITRIC EG, 2005, 45 INT C ANT AG CHEM, P208.
   Jia Lee, 2005, British Journal of Pharmacology, V144, P80, DOI 10.1038/sj.bjp.0705984.
   KAWASAKI M, 2005, 45 INT C ANT AG CHEM, P204.
   Lee RE, 2003, J COMB CHEM, V5, P172, DOI 10.1021/cc020071p.
   LIENHARDT C, 2005, 45 INT S ANT AG CHEM, P205.
   Lounis N, 2001, ANTIMICROB AGENTS CH, V45, P3482, DOI 10.1128/AAC.45.12.3482-3486.2001.
   Manjunatha UH, 2006, P NATL ACAD SCI USA, V103, P431, DOI 10.1073/pnas.0508392103.
   MATSUMOTO M, 2005, 45 INT C ANT AG CHEM, P204.
   Mitchison D A, 1996, Soc Appl Bacteriol Symp Ser, V25, p72S.
   Mitchison DA, 2004, FRONT BIOSCI, V9, P1059, DOI 10.2741/1293.
   MITCHISON DA, 1993, AM REV RESPIR DIS, V147, P1062.
   Miyazaki E, 1999, ANTIMICROB AGENTS CH, V43, P85.
   Nuermberger EL, 2004, AM J RESP CRIT CARE, V170, P1131, DOI 10.1164/rccm.200407-885SOC.
   Pletz MWR, 2004, ANTIMICROB AGENTS CH, V48, P780, DOI 10.1128/AAC.48.3.780-782.2004.
   Sinha R. K., 2004, 44 INT C ANT AG CHEM, P212.
   SPIGELMAN MK, 2005, 45 INT C ANT AG CHEM, P115.
   Stover CK, 2000, NATURE, V405, P962, DOI 10.1038/35016103.
   TSUBOUCHI H, 2005, 45 INT C ANT AG CHEM, P207.
   Tuberculosis Research Centre (Indian Council of Medical Research) Chennai, 2002, INDIAN J TUBERC, V49, P27.
   Tyagi S, 2005, ANTIMICROB AGENTS CH, V49, P2289, DOI 10.1128/AAC.49.6.2289-2293.2005.
   World Health Organization (WHO), 1997, WHOGTB97225.
   Yoshimatsu T, 2002, ANTIMICROB AGENTS CH, V46, P1875, DOI 10.1128/AAC.46.6.1875-1879.2002.
   ZHU M, 2005, 45 INT C ANT AG CHEM, P14.}},
Number-of-Cited-References = {{37}},
Times-Cited = {{100}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{9}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190GC}},
Unique-ID = {{ISI:000248045700005}},
}

@article{ ISI:000248045700011,
Author = {Wells, Charles D. and Cegielski, J. Peter and Nelson, Lisa J. and
   Laserson, Kayla F. and Holtz, Timothy H. and Finlay, Alyssa and Castro,
   Kenneth G. and Weyer, Karin},
Title = {{HIV infection and multidrug-resistant tuberculosis - The perfect storm}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{1}},
Pages = {{S86-S107}},
Month = {{AUG 15}},
Abstract = {{Background. Multidrug-resistant (MDR) tuberculosis (TB) has emerged as a
   global epidemic, with similar to 425,000 new cases estimated to occur
   annually. The global human immunodeficiency virus (HIV) infection
   epidemic has caused explosive increases in TB incidence and may be
   contributing to increases in MDR-TB prevalence.
   Methods. We reviewed published studies and available surveillance data
   evaluating links between HIV infection and MDR-TB to quantify
   convergence of these 2 epidemics, evaluate the consequences, and
   determine essential steps to address these epidemics.
   Results. Institutional outbreaks of MDR-TB have primarily affected
   HIV-infected persons. Delayed diagnosis, inadequate initial treatment,
   and prolonged infectiousness led to extraordinary attack rates and
   case-fatality rates among HIV-infected persons. Whether this sequence
   occurs in communities is less clear. MDR-TB appears not to cause
   infection or disease more readily than drug-susceptible TB in
   HIV-infected persons. HIV infection may lead to malabsorption of anti-TB
   drugs and acquired rifamycin resistance. HIV-infected patients with
   MDR-TB have unacceptably high mortality; both antiretroviral and
   antimycobacterial treatment are necessary. Simultaneous treatment
   requires 6-10 different drugs. In HIV-prevalent countries, TB programs
   struggle with increased caseloads, which increase the risk of acquired
   MDR-TB. Surveillance data suggest that HIV infection and MDR-TB may
   converge in several countries.
   Conclusions. Institutional outbreaks, overwhelmed public health
   programs, and complex clinical management issues may contribute to the
   convergence of the MDR-TB and HIV infection epidemics. To forestall
   disastrous consequences, infection control, rapid case detection,
   effective treatment, and expanded program capacity are needed urgently.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Wells, CD (Reprint Author), Ctr Dis Control \& Prevent, Natl Ctr HIV STD \& TB Prevent, Div TB Eliminat, Int Res \& Program Branch, 1600 Clifton Rd, Atlanta, GA 30333 USA.
   Ctr Dis Control \& Prevent, Natl Ctr HIV STD \& TB Prevent, Div TB Eliminat, Int Res \& Program Branch, Atlanta, GA 30333 USA.
   CDC, Global Programme AIDS, Maputo, Mozambique.
   CDC, Res Ctr, Kenya Med Res Inst, Kisumu, Kenya.
   MRC, Pretoria, South Africa.}},
DOI = {{10.1086/518665}},
ISSN = {{0022-1899}},
Keywords-Plus = {{ANTITUBERCULOSIS-DRUG-RESISTANCE; IMMUNODEFICIENCY-VIRUS-INFECTION;
   NEW-YORK-CITY; ISONIAZID PREVENTIVE THERAPY; HEALTH-CARE WORKERS;
   MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; RISK-FACTORS;
   SOUTH-AFRICA; ANTIRETROVIRAL THERAPY}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{cdwells6@bellsouth.net}},
Cited-References = {{Aceijas C, 2004, AIDS, V18, P2295, DOI 10.1097/00002030-200411190-00010.
   Aerts A, 2000, INT J TUBERC LUNG D, V4, P1104.
   Alcaide F, 2003, J CLIN MICROBIOL, V41, P2867, DOI 10.1128/JCM.41.7.2867-2871.2003.
   Almeida D, 2003, CLIN INFECT DIS, V36, pE152, DOI 10.1086/374931.
   ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143.
   Aragon LM, 2006, J ANTIMICROB CHEMOTH, V57, P825, DOI 10.1093/jac/dkl058.
   Balabanova Ia M, 2005, Probl Tuberk Bolezn Legk, P25.
   Balabanova Y, 2005, EUR J CLIN MICROBIOL, V24, P136, DOI 10.1007/s10096-004-1268-4.
   Bass E, 2005, LANCET, V365, P2077, DOI 10.1016/S0140-6736(05)66717-7.
   Becerra MC, 2005, PUBLIC HEALTH REP, V120, P271.
   Beyrer C, 2003, JAIDS-J ACQ IMM DEF, V32, P311, DOI 10.1097/00126334-200303010-00011.
   Biava M., 2006, Infectious Disorders - Drug Targets, V6, P159, DOI 10.2174/187152606784112173.
   BLOMBERG B, 2001, B WORLD HEALTH ORGAN, V79, P1.
   Burman WJ, 2001, CLIN PHARMACOKINET, V40, P327, DOI 10.2165/00003088-200140050-00002.
   Caminero JA, 2006, INT J TUBERC LUNG D, V10, P829.
   CAVALCANTE SC, 2006, INT J TUBERC LUNG S, V10, pS15.
   CAVALIERI SJ, 1995, ANTIMICROB AGENTS CH, V39, P1542.
   Centers for Disease Control and Prevention (CDC), 2005, MMWR-MORBID MORTAL W, V54, P1.
   Centers for Disease Control and Prevention, 1993, MMWR-MORBID MORTAL W, V42, P427.
   Centers for Disease Control and Prevention (CDC), 2003, MMWR-MORBID MORTAL W, V52, P250.
   Centers for Disease Control and Prevention, 1991, MMWR-MORBID MORTAL W, V40, P585.
   Centers for Disease Control and Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P301.
   Chadha VK, 2005, INT J TUBERC LUNG D, V9, P1072.
   Chaisson RE, 1999, INT J TUBERC LUNG D, V3, P1.
   Chan ED, 2004, AM J RESP CRIT CARE, V169, P1103, DOI 10.1164/rccm.200308-11590C.
   Chanda Dorothy, 2006, Online J Issues Nurs, V11, P4.
   Chum HJ, 1996, AIDS, V10, P299, DOI 10.1097/00002030-199603000-00009.
   Churchyard GJ, 2000, INT J TUBERC LUNG D, V4, P433.
   Cohen T, 2006, P NATL ACAD SCI USA, V103, P7042, DOI 10.1073/pnas.0600349103.
   CORONADO VG, 1993, J INFECT DIS, V168, P1052.
   Damle BD, 2002, ANTIMICROB AGENTS CH, V46, P385, DOI 10.1128/AAC.46.2.385-391.2002.
   Day JH, 2006, INT J TUBERC LUNG D, V10, P523.
   Day JH, 2004, J INFECT DIS, V190, P1677, DOI 10.1086/424851.
   De Cock KM, 2005, AM J RESP CRIT CARE, V172, P3, DOI 10.1164/rccm.2504003.
   Deivanayagam C N, 2002, Indian J Chest Dis Allied Sci, V44, P237.
   de Melo FA, 2003, REV SOC BRAS MED TRO, V36, P27.
   Demissie M, 2001, SCAND J INFECT DIS, V33, P914.
   Dewan P, 2005, INT J TUBERC LUNG D, V9, P170.
   DIOUF A, 2006, 16 INT AIDS C TOR.
   Dowdy DW, 2006, AIDS, V20, P751, DOI 10.1097/01.aids.0000216376.07185.cc.
   Drobniewski F, 2005, JAMA-J AM MED ASSOC, V293, P2726, DOI 10.1001/jama.293.22.2726.
   Drobniewski FA, 2004, INT J STD AIDS, V15, P641, DOI 10.1258/0956462041944303.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   Espinal MA, 2001, INT J TUBERC LUNG D, V5, P887.
   ESPINAL MA, 2000, JAMA-J AM MED ASSOC, V283, P2575.
   European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis, 2006, EMERG INFECT DIS, V12, P736.
   Feachem RGA, 2006, LANCET, V368, P537, DOI 10.1016/S0140-6736(06)69163-0.
   FINLAY A, 2006, INT J TUBERC LUNG S, V10, P153.
   FINLAY AF, 2004, INF DIS SOC AM 2004, V155.
   Fraser A, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005435.pub2.
   Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229.
   Garmaise David, 2004, Can HIV AIDS Policy Law Rev, V9, P20.
   Ghandi NR, 2006, LANCET, V368, P1554.
   Githui WA, 2004, INT J TUBERC LUNG D, V8, P352.
   GITHUI WA, 2006, INT J TUBERC LUNG S1, V10, pS186.
   Godfrey-Faussett P, 2000, LANCET, V356, P1066, DOI 10.1016/S0140-6736(00)02730-6.
   Gupta R, 2002, TROP MED INT HEALTH, V7, P970, DOI 10.1046/j.1365-3156.2002.00960.x.
   Gurumurthy P, 2004, ANTIMICROB AGENTS CH, V48, P4473, DOI 10.1128/AAC.48.11.4473-4475.2004.
   Harries AD, 2004, T ROY SOC TROP MED H, V98, P695, DOI 10.1016/j.trstmh.2004.05.002.
   Holtz TH, 2006, INT J TUBERC LUNG D, V10, P649.
   Hopewell PC, 2006, LANCET INFECT DIS, V6, P710, DOI 10.1016/S1473-3099(06)70628-4.
   Huong NT, 2006, INT J TUBERC LUNG D, V10, P963.
   Huong NT, 2006, J INFECT DIS, V194, P1226, DOI 10.1086/507906.
   Jenny-Avital Elizabeth R, 2002, AIDS Clin Care, V14, P72.
   Joseph P, 2006, AIDS, V20, P415, DOI 10.1097/01.aids.0000206505.09159.9a.
   Kamwi R, 2006, LANCET, V367, P1978, DOI 10.1016/S0140-6736(06)68879-X.
   Kayanja HK, 2005, INT J TUBERC LUNG D, V9, P686.
   Kazionny B, 2001, LANCET, V358, P1513, DOI 10.1016/S0140-6736(01)06574-6.
   Kelly JA, 2003, INT J STD AIDS, V14, P361, DOI 10.1258/095646203765371231.
   Kenyon TA, 1999, INT J TUBERC LUNG D, V3, P4.
   Kiepiela P, 2000, TUBERCLE LUNG DIS, V80, P47, DOI 10.1054/tuld.1999.0231.
   Knupp CA, 1997, BIOPHARM DRUG DISPOS, V18, P65.
   Kruuner A, 2001, INT J TUBERC LUNG D, V5, P170.
   Kumaresan J, 2004, INT J TUBERC LUNG D, V8, P130.
   Lan NTN, 2003, EMERG INFECT DIS, V9, P1633.
   Laserson KF, 2001, INT J TUBERC LUNG D, V5, P448.
   Leimane V, 2005, LANCET, V365, P318.
   Li Guoming, 2002, Zhonghua Jiehe He Huxi Zazhi, V25, P723.
   Li Qun, 2000, Zhonghua Jiehe He Huxi Zazhi, V23, P718.
   Lobato MN, 2006, PUBLIC HEALTH REP, V121, P108.
   Lutfey M, 1996, AM J RESP CRIT CARE, V153, P837.
   Mac-Arthur A, 2001, INT J TUBERC LUNG D, V5, P894.
   Maniar Janak K, 2006, Indian J Dermatol Venereol Leprol, V72, P276.
   Mannheimer SB, 1997, INT J TUBERC LUNG D, V1, P319.
   March F, 1997, CLIN INFECT DIS, V25, P1044, DOI 10.1086/516065.
   Masjedi MR, 2006, CLIN INFECT DIS, V43, P841, DOI 10.1086/507542.
   Maslin JR, 2005, JAIDS-J ACQ IMM DEF, V39, P129.
   Mitchison DA, 1998, INT J TUBERC LUNG D, V2, P10.
   Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928.
   Montaner LJG, 1999, B ACAD NAT MED PARIS, V183, P1085.
   Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524.
   Morehead RS, 2000, SOUTHERN MED J, V93, P507.
   Moro ML, 1998, AIDS, V12, P1095, DOI 10.1097/00002030-199809000-00017.
   Morozova I, 2003, Int J Tuberc Lung Dis, V7, P903.
   MOROZOVA I, 2006, 16 INT AIDS C TOR, V78.
   Mosimaneotsile B, 2003, LANCET, V362, P1551, DOI 10.1016/S0140-6736(03)14745-9.
   MOTSAMAI OI, 2005, INT J TUBERC LUNG S1, V9, pS28.
   Moulding TS, 2004, INT J TUBERC LUNG D, V8, P743.
   Moyle GJ, 1998, DRUG SAFETY, V19, P481, DOI 10.2165/00002018-199819060-00005.
   Mugisha B, 2006, INT J TUBERC LUNG D, V10, P761.
   Munsiff SS, 1997, CLIN INFECT DIS, V25, P1465, DOI 10.1086/516146.
   Murray JF, 2005, INT J TUBERC LUNG D, V9, P826.
   Murugasu-Oei B, 2000, J ANTIMICROB CHEMOTH, V46, P917, DOI 10.1093/jac/46.6.917.
   {*}NAT AIDS CONTR OR, 2004, ANN REP 2002 2004.
   Nathanson E, 2006, EMERG INFECT DIS, V12, P1389.
   Nattrass N, 2006, JAIDS-J ACQ IMM DEF, V43, P618.
   Nelson LJ, 2005, LANCET, V366, P488, DOI 10.1016/S0140-6736(05)67062-6.
   Nguyen Tran Hien, 2004, AIDS Educ Prev, V16, P137.
   Nunes EA, 2005, INT J TUBERC LUNG D, V9, P494.
   NYAMANDE K, 2006, BR J RADIOL     0927.
   Nyangulu DS, 1997, LANCET, V350, P1284, DOI 10.1016/S0140-6736(97)05023-X.
   Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301.
   PABLOSMENDEZ A, 2000, MULTIDRUG RESISTANT, P59.
   Paramasivan CN, 2004, INDIAN J MED RES, V120, P377.
   Park MM, 1996, AM J RESP CRIT CARE, V153, P317.
   Peloquin CA, 1996, ANN PHARMACOTHER, V30, P919.
   Pereira M, 2005, INDIAN J MED RES, V121, P235.
   Podlekareva D, 2006, J INFECT DIS, V194, P633, DOI 10.1086/506366.
   Quy HT, 2006, INT J TUBERC LUNG D, V10, P160.
   Rajbhandary SS, 2004, INT J TUBERC LUNG D, V8, P1012.
   Reichler MR, 2003, INT J TUBERC LUNG D, V7, pS325.
   Reid A, 2006, LANCET INFECT DIS, V6, P483, DOI 10.1016/S1473-3099(06)70549-7.
   {*}REP BOTS MIN HLTH, 2006, REP EV NAT TUB PROGR.
   Ridzon R, 1998, AM J RESP CRIT CARE, V157, P1881.
   Ritacco V, 1997, J INFECT DIS, V176, P637.
   Ruddy M, 2005, THORAX, V60, P130, DOI 10.1136/thx.2004.026922.
   Rullan JV, 1996, EMERG INFECT DIS, V2, P125.
   SAHAI J, 1993, CLIN PHARMACOL THER, V53, P292.
   Schleicher GK, 2003, INT J TUBERC LUNG D, V7, P1207.
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901.
   SEUNG KJ, 2005, CLIN INFECT DIS, V40, P1549.
   Seyler C, 2005, AM J RESP CRIT CARE, V172, P123, DOI 10.1164/rccm.200410-1342OC.
   Shah N. S., 2007, Morbidity and Mortality Weekly Report, V56, P250.
   Shin SS, 2006, INT J TUBERC LUNG D, V10, P402.
   Skenders G, 2005, EMERG INFECT DIS, V11, P1461.
   SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601.
   Sonnenberg P, 2004, AIDS, V18, P657, DOI 10.1097/01.aids.0000111404.02002ce.
   Spigelman M, 2006, LANCET, V367, P945, DOI 10.1016/S0140-6736(06)68388-8.
   {[}Anonymous], 2003, INT J TUBERC LUNG D, V7, P410.
   STROUD LA, 1995, INFECT CONT HOSP EP, V16, P141.
   Swaminathan S, 2005, INT J TUBERC LUNG D, V9, P896.
   Taburet AM, 1996, CLIN PHARMACOKINET, V30, P385.
   Talbot EA, 2004, CLIN INFECT DIS, V39, pE1, DOI 10.1086/421388.
   Talbot EA, 2003, INT J TUBERC LUNG D, V7, P710.
   Tappero JW, 2005, CLIN INFECT DIS, V41, P461, DOI 10.1086/431984.
   Telles MAS, 2005, INT J TUBERC LUNG D, V9, P970.
   Ti T, 2006, INT J TUBERC LUNG D, V10, P1111.
   Toungoussova OS, 2006, TUBERCULOSIS, V86, P1, DOI 10.1016/j.tube.2005.04.001.
   Toungoussova OS, 2005, EUR J CLIN MICROBIOL, V24, P202, DOI 10.1007/s10096-005-1284-z.
   {*}UNAIDS, 2006, JOINT UN PROGR HIV A.
   VALWAY SE, 1994, J INFECT DIS, V170, P151.
   van der Merwe K, 2006, JAIDS-J ACQ IMM DEF, V43, P577.
   van der Werf MJ, 2006, EMERG INFECT DIS, V12, P766.
   Vernon A, 1999, LANCET, V353, P1843, DOI 10.1016/S0140-6736(98)11467-8.
   WAISMAN JL, 2006, ENFERM INFEC MICR CL, V24, P69.
   Wang GB, 2002, RESPIROLOGY, V7, P67, DOI 10.1046/j.1440-1843.2002.00368.x.
   Warndorff DK, 2000, INT J TUBERC LUNG D, V4, P752.
   WEYER K, 2003, SURVEY TUBERCULOSIS.
   WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129.
   White VLC, 2000, THORAX, V55, P962, DOI 10.1136/thorax.55.11.962.
   World Health Organization, 2006, WKLY EPIDEMIOL REC, V81, P408.
   {*}WHO, 2006, WHOHTMTB2006343.
   World Health Organization, 2006, WKLY EPIDEMIOL REC, V81, P386.
   World Health Organization, 2003, WHOCDSTB2003313.
   World Health Organization, 1999, TUB INF CONTR ER EXP.
   {*}WHO, EP FACT SHEETS HIV A.
   World Health Organization, 2004, WHOHTMTB2004330.
   World Health Organization, 2004, WHOHTMTB2004343.
   WHO, 2006, WHOHTMTB2006361.
   World Health Organization, 2006, WHOHTMTB2006364.
   World Health Organization, 2006, WKLY EPIDEMIOL REC, V81, P430.
   World Health Organisation, 2004, WHOHTMHIV20041.
   Williams BG, 2005, P NATL ACAD SCI USA, V102, P9619, DOI 10.1073/pnas.0501615102.
   {*}WORK GROUP S AFR, 2002, S AFR MED J, V92, P647.
   Yew WW, 2000, CHEST, V117, P744, DOI 10.1378/chest.117.3.744.
   Zhang LQ, 2004, J VIROL, V78, P13591, DOI 10.1128/JVI-78.24.13591-13599.2004.
   Zhang WD, 2006, INT J INFECT DIS, V10, P475, DOI 10.1016/j.ijid.2006.04.009.
   Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877.
   {[}Anonymous], 1994, TUBER LUNG DIS, V75, P180.
   {[}Anonymous], 2006, LANCET INFECT DIS, V6, P679.}},
Number-of-Cited-References = {{180}},
Times-Cited = {{251}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{35}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{190GC}},
Unique-ID = {{ISI:000248045700011}},
}

@article{ ISI:000249056000019,
Author = {More, S. J. and Clegg, T. A. and McGrath, G. and Collins, J. D. and
   Corner, L. A. L. and Gormley, E.},
Title = {{Does reactive badger culling lead to an increase in tuberculosis in
   cattle?}},
Journal = {{VETERINARY RECORD}},
Year = {{2007}},
Volume = {{161}},
Number = {{6}},
Pages = {{208-209}},
Month = {{AUG 11}},
Abstract = {{The conclusion from the randomised badger culling trial was that
   localised badger culling not only fails to control but can actually
   increase the incidence of bovine tuberculosis in cattle. Professor Simon
   More and colleagues from University College Dublin question that
   conclusion, arguing that the data do not provide sufficient evidence to
   rule out alternative hypotheses.}},
Publisher = {{BRITISH VETERINARY ASSOC}},
Address = {{7 MANSFIELD ST, LONDON W1M 0AT, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{More, SJ (Reprint Author), Univ Coll Dublin, Ctr Vet Epidemiol \& Risk Anal, Sch Agr Food Sci \& Vet Med, Dublin 4, Ireland.
   Univ Coll Dublin, Ctr Vet Epidemiol \& Risk Anal, Sch Agr Food Sci \& Vet Med, Dublin 4, Ireland.
   Univ Coll Dublin, Badger Vaccine Res Lab, Sch Agr Food Sci \& Vet Med, Dublin 4, Ireland.}},
ISSN = {{0042-4900}},
Keywords-Plus = {{MELES-MELES; BOVINE TUBERCULOSIS; MYCOBACTERIUM-BOVIS; IMPACT; IRELAND;
   TRANSMISSION; TB}},
Research-Areas = {{Veterinary Sciences}},
Web-of-Science-Categories  = {{Veterinary Sciences}},
ORCID-Numbers = {{More, Simon/0000-0002-4270-0385
   Clegg, Tracy/0000-0003-0549-3062}},
Cited-References = {{Costello E, 2006, VET REC, V159, P619.
   Donnelly CA, 2006, NATURE, V439, P843, DOI 10.1038/nature04454.
   Donnelly CA, 2003, NATURE, V426, P834, DOI 10.1038/nature02192.
   Donnelly CA, 2007, INT J INFECT DIS, V11, P300, DOI 10.1016/j.ijid.2007.04.001.
   Ferguson NM, 2001, NATURE, V413, P542, DOI 10.1038/35097116.
   Godfray HCJ, 2004, INDEPENDENT SCI REV.
   Griffin JM, 2005, PREV VET MED, V67, P237, DOI 10.1016/j.prevetmed.2004.10.009.
   {*}ISG, 2007, BOV SCI EV.
   Krebs JR, 1998, SCIENCE, V279, P817, DOI 10.1126/science.279.5352.817.
   Le Fevre A. M, 2005, IMPACT LOCALISED REA.
   MacDonald DW, 2006, BIOL CONSERV, V131, P268, DOI 10.1016/j.biocon.2006.05.006.
   OCorryCrowe G, 1996, BIOL ENVIRON, V96B, P147.
   Rogers MR, 1998, SCHOOL PSYCHOL QUART, V13, P265, DOI 10.1037/h0088985.
   Swinton J, 1997, PHILOS T ROY SOC B, V352, P619.
   Tuyttens FAM, 2000, J ANIM ECOL, V69, P567, DOI 10.1046/j.1365-2656.2000.00419.x.
   Tuyttens FAM, 2000, J ANIM ECOL, V69, P815, DOI 10.1046/j.1365-2656.2000.00437.x.
   Woodroffe R, 2006, P NATL ACAD SCI USA, V103, P14713, DOI 10.1073/pnas.0606251103.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{18}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{22}},
Journal-ISO = {{Vet. Rec.}},
Doc-Delivery-Number = {{204PH}},
Unique-ID = {{ISI:000249056000019}},
}

@article{ ISI:000248577500048,
Author = {Schnell, Robert and Oehlmann, Wulf and Singh, Mahavir and Schneider,
   Gunter},
Title = {{Structural insights into catalysis and inhibition of O-acetylserine
   sulfhydrylase from Mycobacterium tuberculosis - Crystal structures of
   the enzyme alpha-aminoacrylate intermediate and an enzyme-inhibitor
   complex}},
Journal = {{JOURNAL OF BIOLOGICAL CHEMISTRY}},
Year = {{2007}},
Volume = {{282}},
Number = {{32}},
Pages = {{23473-23481}},
Month = {{AUG 10}},
Abstract = {{Cysteine biosynthetic genes are up-regulated in the persistent phase of
   Mycobacterium tuberculosis, and the corresponding enzymes are therefore
   of interest as potential targets for novel anti-bacterial agents. cysK1
   is one of these genes and has been annotated as coding for an
   O-acetylserine sulfhydrylase. Recombinant CysK1 is a pyridoxal phosphate
   (PLP)-dependent enzyme that catalyzes the conversion of O-acetylserine
   to cysteine. The crystal structure of the enzyme was determined to 1.8
   angstrom resolution. CysK1 belongs to the family of fold type II PLP
   enzymes and is similar in structure to other O-acetylserine
   sulfhydrylases. We were able to trap the alpha-aminoacrylate reaction
   intermediate and determine its structure by cryocrystallography.
   Formation of the amino acrylate complex is accompanied by a domain
   rotation resulting in active site closure. The aminoacrylate moiety is
   bound in the active site via the covalent linkage to the PLP cofactor
   and by hydrogen bonds of its carboxyl group to several enzyme residues.
   The catalytic lysine residue is positioned such that it can protonate
   the C alpha-carbon atom of the aminoacrylate only from the si-face,
   resulting in the formation of L-cysteine. CysK1 is competitively
   inhibited by a four-residue peptide derived from the C-terminal of
   serine acetyl transferase. The crystallographic analysis reveals that
   the peptide binds to the enzyme active site, suggesting that CysK1 forms
   an bi-enzyme complex with serine acetyl transferase, in a similar manner
   to other bacterial and plant O-acetylserine sulfhydrylases. The
   structure of the enzyme-peptide complex provides a framework for the
   design of strong binding inhibitors.}},
Publisher = {{AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Schneider, G (Reprint Author), Karolinska Inst, Dept Med Biochem \& Biophys, S-17177 Stockholm, Sweden.
   Karolinska Inst, Dept Med Biochem \& Biophys, S-17177 Stockholm, Sweden.
   LIONEX GmbH, D-38124 Braunschweig, Germany.
   Helmholtz Ctr Infect Res, D-38124 Braunschweig, Germany.}},
DOI = {{10.1074/jbc.M703518200}},
ISSN = {{0021-9258}},
Keywords-Plus = {{SERINE ACETYLTRANSFERASE; SALMONELLA-TYPHIMURIUM; TRYPTOPHAN SYNTHASE;
   3-DIMENSIONAL STRUCTURE; INTERNAL ALDIMINE; ESCHERICHIA-COLI;
   GENE-EXPRESSION; AMINO ACIDS; MECHANISM; CYSTEINE}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{Gunter.Schneider@ki.se}},
ORCID-Numbers = {{Schneider, Gunter/0000-0003-0622-5713}},
Cited-References = {{Bonner ER, 2005, J BIOL CHEM, V280, P38803, DOI 10.1074/jbc.M505313200.
   Bornemann C, 1997, BIOCHEM J, V325, P623.
   Burkhard P, 1999, J MOL BIOL, V291, P941, DOI 10.1006/jmbi.1999.3002.
   Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037.
   Claus MT, 2005, BIOCHEMISTRY-US, V44, P8620, DOI 10.1021/bi050485+.
   Collaborative Computational Project Number 4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112.
   Cornish-Bowden A., 2004, FUNDAMENTALS ENZYME.
   Droux M, 1998, EUR J BIOCHEM, V255, P235, DOI 10.1046/j.1432-1327.1998.2550235.x.
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158.
   Ericsson UB, 2006, ANAL BIOCHEM, V357, P289, DOI 10.1016/j.ab.2006.07.027.
   Francois JA, 2006, PLANT CELL, V18, P3647, DOI 10.1105/tpc.106.047316.
   GAITONDE MK, 1967, BIOCHEM J, V104, P627.
   Gallagher DT, 1998, STRUCT FOLD DES, V6, P465, DOI 10.1016/S0969-2126(98)00048-3.
   GRISHIN NV, 1995, PROTEIN SCI, V4, P1291.
   Hampshire T, 2004, TUBERCULOSIS, V84, P228, DOI 10.1016/j.tube.2003.12.010.
   Huang B, 2005, J BACTERIOL, V187, P3201, DOI 10.1128/JB.187-9.3201-3205.2005.
   Hwang CC, 1996, BIOCHEMISTRY-US, V35, P6358, DOI 10.1021/bi9602472.
   HYDE CC, 1988, J BIOL CHEM, V263, P17857.
   Karsten WE, 2002, METHOD ENZYMOL, V354, P223.
   Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282.
   LU ZC, 1993, J BIOL CHEM, V268, P8727.
   Maier THP, 2003, NAT BIOTECHNOL, V21, P422, DOI 10.1038/nbt807.
   Manganelli R, 2002, MOL MICROBIOL, V45, P365, DOI 10.1046/j.1365-2958.2002.03005.x.
   McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074.
   Mino K, 2000, BIOSCI BIOTECH BIOCH, V64, P1874, DOI 10.1271/bbb.64.1874.
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255.
   NAKAMURA T, 1984, J BACTERIOL, V158, P1122.
   Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270.
   Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987.
   Pinto R, 2004, MICROBIOL-SGM, V150, P1681, DOI 10.1099/mic.0.26894-0.
   Rabeh WM, 2005, BIOCHEMISTRY-US, V44, P5541, DOI 10.1021/bi047479i.
   Rabeh WM, 2004, J BIOL CHEM, V279, P26803, DOI 10.1074/jbc.R400001200.
   READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622.
   Rege VD, 1996, BIOCHEMISTRY-US, V35, P13485, DOI 10.1021/bi961517j.
   Rhee KY, 2005, P NATL ACAD SCI USA, V102, P467, DOI 10.1073/pnas.0406133102.
   SCHNACKERZ KD, 1979, BIOCHEMISTRY-US, V18, P3557, DOI 10.1021/bi00583a019.
   Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846.
   Schneider G, 2000, STRUCTURE, V8, P1.
   Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957.
   TAI CH, 1995, BIOCHEMISTRY-US, V34, P12311, DOI 10.1021/bi00038a027.
   Tai CH, 2001, ACCOUNTS CHEM RES, V34, P49, DOI 10.1021/ar990169l.
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673.
   Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766.
   Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139.
   Wooff E, 2002, MOL MICROBIOL, V43, P653, DOI 10.1046/j.1365-2958.2002.02771.x.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{54}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Biol. Chem.}},
Doc-Delivery-Number = {{197ST}},
Unique-ID = {{ISI:000248577500048}},
}

@article{ ISI:000249689300001,
Author = {Ali, Asho and Hasan, Zahra and Tanveer, Mahnaz and Siddiqui, Amna R. and
   Ghebremichael, Solomon and Kallenius, Gunilla and Hasan, Rumina},
Title = {{Characterization of Mycobacterium tuberculosis Central Asian Strain I
   using mycobacterial interspersed repetitive unit genotyping}},
Journal = {{BMC MICROBIOLOGY}},
Year = {{2007}},
Volume = {{7}},
Month = {{AUG 9}},
Abstract = {{Background: The Central Asian StrainI (CASI) genogroup of Mycobacterium
   tuberculosis (MTB) is the most prevalent in Pakistan, India and
   Bangladesh. Mycobacterial interspersed repetitive units variable number
   tandem repeat (MIRU-VNTR) typing is a reliable and reproducible method
   for differentiation of MTB isolates. However, information of its utility
   in determining the diversity of CASI strain is limited. We performed
   standard 12 loci based MIRU-VNTR typing on previously spoligotyped CASI
   strains and ` unique' strains in order to evaluate its discriminatory
   power for these isolates.
   Methods: Twelve loci based MIRU-VNTR typing was used to type178 CASI and
   189 ` unique' MTB strains. The discriminatory index for each of the loci
   was calculated using the Hunter Gaston Discriminatory Index (HGDI). A
   subset of these strains (n = 78) were typed using IS6110 restriction
   fragment length polymorphism (RFLP). MIRU-VNTR profiles were studied
   together with their drug susceptibility patterns.
   Results: A total of 349 MIRU patterns were obtained for the 367 strains
   tested. The CASI strains were subdivided into 160 distinct patterns; 15
   clusters of 2 strains each, 1 cluster of four strains and 144 unique
   patterns. Using HGDI, seven MIRU loci, (numbers 26, 31, 27, 16, 10, 39,
   and 40) were found to be `` highly discriminatory{''} (DI: = 0.6), four
   MIRU loci (numbers 20, 24, 23, and 4) were `` moderately
   discriminatory{''} (DI: 0.3 -0.59), and one locus (number 2) was ``
   poorly discriminatory{''} (DI< 0.3). Loci 26 and 31 were the most
   discriminatory for the CASI isolates. Amongst ` unique' strains in
   addition to loci 26, 31, 27, 16, 10, 39, and 40, locus 23 was highly
   discriminatory, while no locus was poorly discriminating. DI values for
   loci 4, 10 and 26 were significantly lower (P-value <.01) in CASI
   strains than in ` unique' strains. The association between CASI strains
   and MDR was not found to be significant (p value = 0.21).
   Conclusion: We propose that MIRU typing could be used to estimate the
   phylogenetic relatedness amongst prevalent CASI strains, for which MIRU
   loci 26, 31, 16, 10, 27, 39 and 40 were found to be the most
   discriminatory.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hasan, R (Reprint Author), Aga Khan Univ, Dept Pathol \& Microbiol, Stadium Rd,PO Box 3500, Karachi, Pakistan.
   Aga Khan Univ, Dept Pathol \& Microbiol, Karachi, Pakistan.
   Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan.
   Swedish Inst Infectious Dis Control, Dept Bacteriol, Stockholm, Sweden.
   Karolinska Inst, Microbiol \& Tumor Cell Biol, Stockholm, Sweden.}},
DOI = {{10.1186/1471-2180-7-76}},
Article-Number = {{76}},
ISSN = {{1471-2180}},
Keywords-Plus = {{FRAGMENT-LENGTH-POLYMORPHISM; MOLECULAR EPIDEMIOLOGY; GENETIC DIVERSITY;
   BEIJING GENOTYPE; COPY NUMBERS; HONG-KONG; IDENTIFICATION; FAMILY;
   IS6110; PREDOMINANCE}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{asho.ali@aku.edu
   zahra.hasan@aku.edu
   mahnaz.tanveer@aku.edu
   rehana.siddiqui@aku.edu
   solomon.ghebremichael@smi.ki.se
   gunilla.kallenius@smi.ki.se
   rumina.hasan@aku.edu}},
ResearcherID-Numbers = {{Hasan, Rumina/F-4420-2015
   Hasan, Zahra/F-5111-2015
   }},
ORCID-Numbers = {{Kallenius, Gunilla/0000-0002-8921-0551}},
Cited-References = {{Agerton TB, 1999, CLIN INFECT DIS, V29, P85, DOI 10.1086/520187.
   Anh DD, 2000, EMERG INFECT DIS, V6, P302.
   Banu S, 2004, J CLIN MICROBIOL, V42, P674, DOI 10.1128/JCM.42.2.674-682.2004.
   Bhanu NV, 2002, TUBERCULOSIS, V82, P105, DOI 10.1054/tube.332.
   Bifani PJ, 1999, JAMA-J AM MED ASSOC, V282, P2321, DOI 10.1001/jama.282.24.2321.
   Blackwood KS, 2004, J CLIN MICROBIOL, V42, P5001, DOI 10.1128/JCM.42.11.5001-5006.2004.
   BODDINGHAUS B, 1990, J CLIN MICROBIOL, V28, P1751.
   Butt T., 2004, JPMA Journal of the Pakistan Medical Association, V54, P469.
   Chan MY, 2001, EPIDEMIOL INFECT, V127, P169.
   Chin PJ, 2007, J CLIN MICROBIOL, V45, P1022, DOI 10.1128/JCM.02036-06.
   Cowan LS, 2002, J CLIN MICROBIOL, V40, P1592, DOI 10.1128/JCM.40.5.1592-1602.2002.
   Dale JW, 1999, J CLIN MICROBIOL, V37, P1265.
   DEEPAK A, 2005, CID, V40, P881.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706.
   Filliol I, 2003, J CLIN MICROBIOL, V41, P1963, DOI 10.1128/JCM.41.5.1963.1970.2003.
   Gascoyne-Binzi DM, 2002, INT J TUBERC LUNG D, V6, P492.
   Glynn JR, 2002, EMERG INFECT DIS, V8, P843.
   Gutacker MM, 2006, J INFECT DIS, V193, P121, DOI 10.1086/498574.
   Gutierrez MC, 2006, EMERG INFECT DIS, V12, P1367.
   Hasan Z, 2006, J CLIN MICROBIOL, V44, P1763, DOI 10.1128/JCM.44.5.1763-1768.2006.
   Hirsh AE, 2004, P NATL ACAD SCI USA, V101, P4871, DOI 10.1073/pnas.0305627101.
   Honore-Bouakline S, 2003, J CLIN MICROBIOL, V41, P2323, DOI 10.1128/JCM.41.6.2323-2329.2003.
   HUNTER PR, 1988, J CLIN MICROBIOL, V26, P2465.
   Irfan Seema, 2006, J Pak Med Assoc, V56, P397.
   Jou R, 2005, J CLIN MICROBIOL, V43, P1390, DOI 10.1128/JCM.43.3.1390-1394.2005.
   Kovalev SY, 2005, INT J TUBERC LUNG D, V9, P746.
   Kremer K, 2005, J CLIN MICROBIOL, V43, P314, DOI 10.1128/JCM.43.1.314-320.2005.
   Li Q, 2002, INFECT IMMUN, V70, P6489, DOI 10.1128/IAI.70.11.6489-6493.2002.
   Mazars E, 2001, P NATL ACAD SCI USA, V98, P1901, DOI 10.1073/pnas.98.4.1901.
   Mokrousov I, 2004, J CLIN MICROBIOL, V42, P2438, DOI 10.1128/JCM.42.6.2438-2444.2004.
   Mokrousov I, 2002, RES MICROBIOL, V153, P629, DOI 10.1016/S0923-2508(02)01374-8.
   {*}NAT COMM CLIN LAB, 1995, ANT SUSC TEST MYC TU.
   NIKOLAYEVSKYY V, 2006, EID, V12.
   Prodinger WM, 2001, EMERG INFECT DIS, V7, P483.
   Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837.
   Sharma SK, 2004, INDIAN J MED RES, V120, P354.
   Soini H, 2000, J CLIN MICROBIOL, V38, P669.
   Sola C, 1999, EMERG INFECT DIS, V5, P404.
   Sola C, 2003, INFECT GENET EVOL, V3, P125, DOI 10.1016/S1567-1348(03)00011-X.
   Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869.
   Sun YJ, 2004, J CLIN MICROBIOL, V42, P5058, DOI 10.1128/JCM.42.11.5058-5064.2004.
   Sun YJ, 2004, J CLIN MICROBIOL, V42, P1986, DOI 10.1128/JCM.42.5.1986-1993.2004.
   Supply P, 2000, MOL MICROBIOL, V36, P762, DOI 10.1046/j.1365-2958.2000.01905.x.
   Supply P, 2003, MOL MICROBIOL, V47, P529, DOI 10.1046/j.1365-2958.2003.03315.x.
   Supply P, 2001, J CLIN MICROBIOL, V39, P3563, DOI 10.1128/JCM.39.10.3563-3571.2001.
   Supply P, 2006, J CLIN MICROBIOL, V44, P4498, DOI 10.1128/JCM.01392-06.
   Tazi L, 2004, J CLIN MICROBIOL, V42, P461, DOI 10.1128/JCM.42.1.461-466.2004.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.
   Warren RM, 2004, J CLIN MICROBIOL, V42, P5774, DOI 10.1128/JCM.42.12.5774-5782.2004.
   WAYNE LG, 1966, AM J CLIN PATHOL, V45, P769.
   WHO, 2003, WKLY EPIDEMIOL REC, V78, P122.
   Yang ZH, 1998, J CLIN MICROBIOL, V36, P1003.}},
Number-of-Cited-References = {{53}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{BMC Microbiol.}},
Doc-Delivery-Number = {{213TF}},
Unique-ID = {{ISI:000249689300001}},
}

@article{ ISI:000249689000001,
Author = {Candia, Norma and Lopez, Beatriz and Zozio, Thierry and Carrivale,
   Marcela and Diaz, Chyntia and Russomando, Graciela and de Romero, Nilda
   J. and Jara, Juan C. and Barrera, Lucia and Rastogi, Nalin and Ritacco,
   Viviana},
Title = {{First insight into Mycobacterium tuberculosis genetic diversity in
   Paraguay}},
Journal = {{BMC MICROBIOLOGY}},
Year = {{2007}},
Volume = {{7}},
Month = {{AUG 8}},
Abstract = {{Background: We present a picture of the biodiversity of Mycobacterium
   tuberculosis in Paraguay, an inland South American country harboring 5
   million inhabitants with a tuberculosis notification rate of 38/100,000.
   Results: A total of 220 strains collected throughout the country in 2003
   were classified by spoligotyping into 79 different patterns.
   Spoligopatterns of 173 strains matched 51 shared international types
   (SITs) already present in an updated version of SpoIDB4, the global
   spoligotype database at Pasteur Institute, Guadeloupe. Our study
   contributed to the database 13 new SITs and 15 orphan spoligopatterns.
   Frequencies of major M. tuberculosis spoligotype lineages in our sample
   were as follows: Latin-American \& Mediterranean (LAM) 52.3\%, Haarlem
   18.2\%, S clade 9.5\%, T superfamily 8.6\%, X clade 0.9\% and Beijing
   clade 0.5\%. Concordant clustering by IS6110 restriction fragment length
   polymorphism (RFLP) and spoligotyping identified transmission in
   specific settings such as the Tacumbu jail in Asuncion and aboriginal
   communities in the Chaco. LAM genotypes were ubiquitous and predominated
   among both RFLP clusters and new patterns, suggesting ongoing
   transmission and adaptative evolution in Paraguay. We describe a new and
   successfully evolving clone of the Haarlem 3 sub-lineage, SIT2643, which
   is thus far restricted to Paraguay. We confirmed its clonality by RFLP
   and mycobacterial interspersed repetitive unit (MIRU) typing; we named
   it ``Tacumbu{''} after the jail where it was found to be spreading.
   One-fifth of the spoligopatterns in our study are rarely or never seen
   outside Paraguay and one-tenth do not fit within any of the major
   phylogenetic clades in SpoIDB4.
   Conclusion: Lineages currently thriving in Paraguay may reflect local
   host-pathogen adaptation of strains introduced during past migrations
   from Europe.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Candia, N (Reprint Author), Univ Nacl Asuncion, Dept Mol Biol, Inst Invest Ciencias Salud, Asuncion, Paraguay.
   Univ Nacl Asuncion, Dept Mol Biol, Inst Invest Ciencias Salud, Asuncion, Paraguay.
   ANLIS CArlos G Malbran, Inst NAcl Enfermedades Infecciosas, Serv Microbacterias, Buenos Aires, DF, Argentina.
   Inst Pasteur Guadeloupe, Unite Tuberculose Mycobacterias, Guadeloupe, France.
   Programa Nacl Control Tuberculosis, Asuncion, Paraguay.}},
DOI = {{10.1186/1471-2180-7-75}},
Article-Number = {{75}},
ISSN = {{1471-2180}},
Keywords-Plus = {{MOLECULAR EPIDEMIOLOGY; COMPLEX STRAINS; DISCRIMINATORY POWER; GLOBAL
   EPIDEMIOLOGY; REPRODUCIBILITY; RECOMMENDATIONS; POLYMORPHISM; REGION}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{nccandia@yahoo.es
   bealopez@anlis.gov.ar
   tzozio@pasteur-guadeloupe.fr
   carrivale\_marcela@yahoo.es
   cdacosta79@yahoo.com
   grusso@rieder.net.py
   tuberculosispy@hotmail.com
   pnct\_py@hotmail.com
   lbarrera@anlis.gov.ar
   nrastogi@pasteur-guadeloupe.fr
   vritacco@anlis.gov.ar}},
ORCID-Numbers = {{Rastogi, Nalin/0000-0002-7199-7747
   Ritacco, Viviana/0000-0003-1217-0229}},
Cited-References = {{Aristimuno L, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-90.
   Borsuk S, 2005, MICROBES INFECT, V7, P1338, DOI 10.1016/j.micinf.2005.05.009.
   Brudey K, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-23.
   {*}DIR GEN EST, 2004, ENC CENS ATL CENS PA.
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0.
   Filliol I, 2003, J CLIN MICROBIOL, V41, P1963, DOI 10.1128/JCM.41.5.1963.1970.2003.
   Filliol I, 2006, J BACTERIOL, V188, P759, DOI 10.1128/JB.188.2.759-772.2006.
   Filliol I, 2002, RES MICROBIOL, V153, P81, DOI 10.1016/S0923-2508(01)01292-X.
   Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103.
   Heersma HF, 1998, METH MOL B, V101, P395, DOI 10.1385/0-89603-471-2:395.
   Hudelson P, 1996, TUBERCLE LUNG DIS, V77, P391, DOI 10.1016/S0962-8479(96)90110-0.
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907.
   Kremer K, 2005, J CLIN MICROBIOL, V43, P5628, DOI 10.1128/JCM.43.11.5628-5638.2005.
   Kremer K, 1999, J CLIN MICROBIOL, V37, P2607.
   Mancilla EM, 2006, REV CHIL INFECTOL, V23, P220.
   Mazars E, 2001, P NATL ACAD SCI USA, V98, P1901, DOI 10.1073/pnas.98.4.1901.
   Murray M, 2002, EMERG INFECT DIS, V8, P363.
   Murray M, 2002, B WORLD HEALTH ORGAN, V80, P477.
   Sola Christophe, 2005, Infection Genetics and Evolution, V5, P145, DOI 10.1016/j.meegid.2004.08.003.
   Streicher EM, 2007, J CLIN MICROBIOL, V45, P237, DOI 10.1128/JCM.01429-06.
   Supply P, 2000, MOL MICROBIOL, V36, P762, DOI 10.1046/j.1365-2958.2000.01905.x.
   Supply P, 2001, J CLIN MICROBIOL, V39, P3563, DOI 10.1128/JCM.39.10.3563-3571.2001.
   Supply P, 2006, J CLIN MICROBIOL, V44, P4498, DOI 10.1128/JCM.01392-06.
   van Crevel R, 2004, Ned Tijdschr Geneeskd, V148, P425.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.
   VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578.
   Warren RM, 2002, J CLIN MICROBIOL, V40, P4457, DOI 10.1128/JCM.40.12.4457-4465.2002.
   World Health Organization, 2003, WHOTB2003320.
   World Health Organization, 2005, WHOHTMTB2005349.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{35}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{BMC Microbiol.}},
Doc-Delivery-Number = {{213TC}},
Unique-ID = {{ISI:000249689000001}},
}

@article{ ISI:000248484400025,
Author = {Argyrou, Argyrides and Vetting, Matthew W. and Blanchard, John S.},
Title = {{New insight into the mechanism of action of and resistance to isoniazid:
   Interaction of Mycobacterium tuberculosis enoyl-ACP reductase with
   INH-NADP}},
Journal = {{JOURNAL OF THE AMERICAN CHEMICAL SOCIETY}},
Year = {{2007}},
Volume = {{129}},
Number = {{31}},
Pages = {{9582+}},
Month = {{AUG 8}},
Abstract = {{The Mycobacterium tuberculosis inhA-encoded enoyl-ACP reductase is
   inhibited by isonicotinoylated-NADP (INH-NADP) with a K-i of 130 nM. The
   crystal structure of the InhA:INH-NADP complex was solved. The structure
   revealed that it is the acyclic 4S isomer of INH-NADP that binds to the
   enzyme in a conformation similar to the InhA:INH-NAD complex solved
   previously. The in vivo implications of the mechanism of action of and
   resistance to isoniazid resulting from the dual ability of InhA to bind
   to INH-NAD and INH-NADP with high affinity are discussed.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Blanchard, JS (Reprint Author), Bristol Myers Squibb Pharmaceut Co, Res \& Dev, Dept Chem Enzymol, POB 5400, Princeton, NJ 08543 USA.
   Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA.}},
DOI = {{10.1021/ja073160k}},
ISSN = {{0002-7863}},
Keywords-Plus = {{TARGET; ETHIONAMIDE; SMEGMATIS; PROTEIN; GENE}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary}},
Author-Email = {{blanchar@aecom.yu.edu}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}R01 AI033696, AI33696, R01 AI033696-15]}},
Cited-References = {{Argyrou A, 2006, NAT STRUCT MOL BIOL, V13, P408, DOI 10.1038/nsmb1089.
   Argyrou A, 2006, BIOCHEMISTRY-US, V45, P13947, DOI 10.1021/bi061874m.
   BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673.
   BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055.
   Larsen MH, 2002, MOL MICROBIOL, V46, P453, DOI 10.1046/j.1365-2958.2002.03162.x.
   Nguyen M, 2002, ANTIMICROB AGENTS CH, V46, P2137, DOI 10.1128/AAC.46.7.2137-2144.2002.
   Nguyen M, 2001, CHEMBIOCHEM, V2, P877, DOI 10.1002/1439-7633(20011203)2:12<877::AID-CBIC877>3.0.CO;2-V.
   QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004.
   Rawat R, 2003, P NATL ACAD SCI USA, V100, P13881, DOI 10.1073/pnas.2235848100.
   Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98.
   Vilcheze C, 2000, J BACTERIOL, V182, P4059, DOI 10.1128/JB.182.14.4059-4067.2000.
   Walsh C., 2003, ANTIBIOTICS ACTION O.
   ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0.
   Zhao XB, 2006, BIOCHEMISTRY-US, V45, P4131, DOI 10.1021/bi051967o.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{19}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{25}},
Journal-ISO = {{J. Am. Chem. Soc.}},
Doc-Delivery-Number = {{196LW}},
Unique-ID = {{ISI:000248484400025}},
}

@article{ ISI:000248484400040,
Author = {Soellner, Matthew B. and Rawls, Katherine A. and Grundner, Christoph and
   Alber, Tom and Ellman, Jonathan A.},
Title = {{Fragment-based substrate activity screening method for the
   identification of potent inhibitors of the Mycobacterium tuberculosis
   phosphatase PtpB}},
Journal = {{JOURNAL OF THE AMERICAN CHEMICAL SOCIETY}},
Year = {{2007}},
Volume = {{129}},
Number = {{31}},
Pages = {{9613+}},
Month = {{AUG 8}},
Abstract = {{A new substrate-based fragment approach for the identification of novel
   PTP inhibitors is presented. This method was applied to Mycobacterium
   tuberculosis PtpB, a promising new target for the treatment of
   tuberculosis. This resulted in the development of the most potent PtpB
   inhibitor reported to date (0.22 mu M) with low molecular weight and
   good selectivity against a panel of other protein tyrosine phosphatases.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ellman, JA (Reprint Author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.
   Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.
   Univ Calif Berkeley, Dept Mol \& Cell Biol, Berkeley, CA 94720 USA.}},
DOI = {{10.1021/ja0727520}},
ISSN = {{0002-7863}},
Keywords-Plus = {{PROTEIN-TYROSINE-PHOSPHATASE; NON-PEPTIDYL INHIBITORS; RAPID
   IDENTIFICATION; 1B INHIBITORS; CATHEPSIN-S; DISCOVERY; DESIGN; MIMETICS}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary}},
Author-Email = {{jellman@berkeley.edu}},
ResearcherID-Numbers = {{Ellman, Jonathan/C-7732-2013}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI068135]; NIGMS NIH HHS {[}GM54051]}},
Cited-References = {{Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753.
   Carr RAE, 2005, DRUG DISCOV TODAY, V10, P987, DOI 10.1016/S1359-6446(05)03511-7.
   Combs AP, 2005, J MED CHEM, V48, P6544, DOI 10.1021/jm.0504555.
   Erlanson DA, 2004, J MED CHEM, V47, P3463, DOI 10.1021/jm040031v.
   Feng BY, 2006, NAT PROTOC, V1, P550, DOI 10.1038/nprot.2006.77.
   Greenstein AE, 2005, J MOL MICROB BIOTECH, V9, P167, DOI 10.1159/000089645.
   Grundner C, 2007, STRUCTURE, V15, P499, DOI 10.1016/j.str.2007.03.003.
   Hajduk PJ, 2007, NAT REV DRUG DISCOV, V6, P211, DOI 10.1038/nrd2220.
   Hajduk PJ, 2000, J MED CHEM, V43, P3443, DOI 10.1021/jm000164q.
   Horton DA, 2003, CHEM REV, V103, P893, DOI 10.1021/cr020033s.
   Hu X, 2006, BIOORG MED CHEM LETT, V16, P6321, DOI 10.1016/j.bmcl.2006.09.010.
   Inagaki H, 2007, J MED CHEM, V50, P2693, DOI 10.1021/jm070111+.
   King EJ, 1939, BIOCHEM J, V33, P1182.
   Kotoris CC, 1998, BIOORG MED CHEM LETT, V8, P3275, DOI 10.1016/S0960-894X(98)00598-8.
   Koul A, 2000, J BACTERIOL, V182, P5425, DOI 10.1128/JB.182.19.5425-5432.2000.
   Liu G, 2003, J MED CHEM, V46, P4232, DOI 10.1021/jm034122o.
   Mader MM, 1997, CHEM REV, V97, P1281, DOI 10.1021/cr960435y.
   McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y.
   Montalibet J, 2005, METHODS, V35, P2, DOI 10.1016/j.ymeth.2004.07.002.
   Montserat J, 1996, J BIOL CHEM, V271, P7868.
   Moretto AF, 2006, BIOORGAN MED CHEM, V14, P2162, DOI 10.1016/j.bmc.2005.11.005.
   Noren-Muller A, 2006, P NATL ACAD SCI USA, V103, P10606, DOI 10.1073/pnas.0601490103.
   Patterson AW, 2006, J MED CHEM, V49, P6298, DOI 10.1021/jm.060701s.
   Rye CS, 2005, CURR MED CHEM, V12, P3127, DOI 10.2174/092986705774933452.
   Salisbury CM, 2006, CHEMBIOCHEM, V7, P1034, DOI 10.1002/cbic.200600081.
   Singh R, 2005, TUBERCULOSIS, V85, P325, DOI 10.1016/j.tube.2005.08.015.
   Singh R, 2003, MOL MICROBIOL, V50, P751, DOI 10.1046/j.1365-2958.2003.03712.x.
   Taylor SD, 1998, BIOORGAN MED CHEM, V6, P1457, DOI 10.1016/S0968-0896(98)00075-3.
   WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884.
   Wood WJL, 2005, J AM CHEM SOC, V127, P15521, DOI 10.1021/ja0547230.
   Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{75}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{J. Am. Chem. Soc.}},
Doc-Delivery-Number = {{196LW}},
Unique-ID = {{ISI:000248484400040}},
}

@article{ ISI:000248439000016,
Author = {Yang, Xinxin and Dubnau, Eugenie and Smith, Issar and Sampson, Nicole S.},
Title = {{Rv1106c from Mycobacterium tuberculosis is a 3 beta-hydroxysteroid
   dehydrogenase}},
Journal = {{BIOCHEMISTRY}},
Year = {{2007}},
Volume = {{46}},
Number = {{31}},
Pages = {{9058-9067}},
Month = {{AUG 7}},
Abstract = {{New approaches are required to combat Mycobacterium tuberculosis (Mtb),
   especially the multi-drug resistant and extremely drug resistant
   organisms (MDR-TB and XDR-TB). There are many reports that mycobacteria
   oxidize 3 beta-hydroxysterols to 3-ketosteroids, but the enzymes
   responsible for this activity have not been identified in mycobacterial
   species. In this work, the Rv1106c gene that is annotated as a 3
   beta-hydroxysteroid dehydrogenase in Mtb has been cloned and
   heterologously expressed. The purified enzyme was kinetically
   characterized and found to have a pH optimum between 8.5 and 9.5. The
   enzyme, which is a member of the short chain dehydrogenase superfamily,
   uses NAD(+) as a cofactor and oxidizes cholesterol, pregnenolone, and
   dehydroepiandrosterone to their respective 3-keto-4-ene products. The
   enzyme forms a ternary complex with NAD(+) binding before the sterol.
   The enzyme shows no substrate preference for dehydroepiandrosterone
   versus pregnenolone with second-order rate constants (k(cat)/K-m) of 3.2
   +/- 0.4 and 3.9 +/- 0.9 mu M-1 min(-1), respectively, at pH 8.5, 150 mM
   NaCl, 30 mM MgCl2, and saturating NAD(+). Trilostane is a competitive
   inhibitor of dehydroepiandrosterone with a K-i of 197 +/- 8 mu M. The
   expression of the 3 beta-hydroxysteroid dehydrogenase in Mtb is
   intracellular. Disruption of the 3 beta-hydroxysteroid dehydrogenase
   gene in Mtb abrogates mycobacterial cholesterol oxidation activity.
   These data are consistent with the Rv1106c gene being the one
   responsible for 3 beta-hydroxysterol oxidation in Mtb.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Sampson, NS (Reprint Author), SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.
   SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.
   Univ Med \& Dent New Jersey, Publ Hlth Res Inst Ctr, New Jersey Med Sch, Newark, NJ 07103 USA.}},
DOI = {{10.1021/bi700688x}},
ISSN = {{0006-2960}},
Keywords-Plus = {{PLANT DIHYDROFLAVONOL REDUCTASE; COMPLETE GENOME SEQUENCE; CHOLESTEROL
   OXIDASE; SUBSTRATE-SPECIFICITY; VACCINIA VIRUS; HUMAN TYPE-1; GENE;
   CLONING; STREPTOMYCES; DEGRADATION}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{nicole.sampson@stonybrook.edu}},
ResearcherID-Numbers = {{Sampson, Nicole/C-4598-2014
   Yang, Xinxin/O-1705-2014
   Zhou, Xin/H-1242-2014}},
ORCID-Numbers = {{Sampson, Nicole/0000-0002-2835-7760
   Yang, Xinxin/0000-0002-5162-5030
   }},
Funding-Acknowledgement = {{NCRR NIH HHS {[}S10 RR021008-010001, RR021008, S10 RR021008, S10
   RR021008-01]; NIAID NIH HHS {[}AI065251, AI065987, HHSN266200400091C,
   R21 AI065261, R21 AI065261-01A1]; PHS HHS {[}HHSN266200400091C]}},
Cited-References = {{Av-Gay Y, 2000, CAN J MICROBIOL, V46, P826, DOI 10.1139/cjm-46-9-826.
   BAKER ME, 1992, FEBS LETT, V301, P89, DOI 10.1016/0014-5793(92)80216-4.
   BAKER ME, 1992, J STEROID BIOCHEM, V41, P301, DOI 10.1016/0960-0760(92)90355-M.
   BAKER ME, 1990, BIOCHEM J, V269, P558.
   Bendtsen JD, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-58.
   Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028.
   Byarugaba DK, 2004, INT J ANTIMICROB AG, V24, P105, DOI 10.1016/j.ijantimicag.2004.02.015.
   Camus JC, 2002, MICROBIOL-SGM, V148, P2967.
   Changsen C, 2003, ANTIMICROB AGENTS CH, V47, P3682, DOI 10.1128/AAC.47.12.3682-3687.2003.
   Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500.
   Cohen J, 2006, SCIENCE, V313, P1554.
   Cole ST, 1998, NATURE, V393, P537.
   Eiglmeier K, 2001, LEPROSY REV, V72, P462.
   Elalami A, 1999, WORLD J MICROB BIOT, V15, P579, DOI 10.1023/A:1008958008333.
   Ermolaeva MD, 2001, NUCLEIC ACIDS RES, V29, P1216, DOI 10.1093/nar/29.5.1216.
   Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100.
   HORINOUCHI S, 1991, APPL ENVIRON MICROB, V57, P1386.
   Jackson CJ, 2003, BIOCHEM BIOPH RES CO, V301, P558, DOI 10.1016/S0006-291X(02)03078-4.
   JACOBS WR, 1991, METHOD ENZYMOL, V204, P537.
   JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003.
   Kishi K, 2000, BIOSCI BIOTECH BIOCH, V64, P1352, DOI 10.1271/bbb.64.1352.
   KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M.
   Lamb DC, 1998, FEBS LETT, V437, P142, DOI 10.1016/S0014-5793(98)01218-6.
   Lamichhane G, 2003, P NATL ACAD SCI USA, V100, P7213, DOI 10.1073/pnas.1231432100.
   Lancet Editorial, 2006, LANCET, V368, P964.
   MacLachlan J, 2000, J STEROID BIOCHEM, V72, P169, DOI 10.1016/S0960-0760(00)00044-3.
   Marris E, 2006, NATURE, V443, P131, DOI 10.1038/443131b.
   MUROOKA Y, 1986, APPL ENVIRON MICROB, V52, P1382.
   Mwinga A, 2004, TROP MED INT HEALTH, V9, P827, DOI 10.1111/j.1365-3156.2004.01274.x.
   POTTS GO, 1978, STEROIDS, V32, P257, DOI 10.1016/0039-128X(78)90010-7.
   Ramakrishnan L, 2000, SCIENCE, V288, P1436, DOI 10.1126/science.288.5470.1436.
   Rattan A, 1998, EMERG INFECT DIS, V4, P195.
   Raviglione MC, 2007, NEW ENGL J MED, V356, P656, DOI 10.1056/NEJMp068273.
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220.
   Reading PC, 2003, J EXP MED, V197, P1269, DOI 10.1084/jem.20022201.
   Rosenkrands I, 2000, ELECTROPHORESIS, V21, P3740, DOI 10.1002/1522-2683(200011)21:17<3740::AID-ELPS3740>3.3.CO;2-V.
   Rosenkrands I, 2000, ELECTROPHORESIS, V21, P935, DOI 10.1002/(SICI)1522-2683(20000301)21:5<935::AID-ELPS935>3.3.CO;2-G.
   Sampson NS, 1997, J AM CHEM SOC, V119, P855, DOI 10.1021/ja962258o.
   Sampson NS, 1998, BIOCHEMISTRY-US, V37, P5770, DOI 10.1021/bi973067g.
   Simard J, 2005, ENDOCR REV, V26, P525, DOI 10.1210/er.2002-0050.
   SMITH AG, 1977, BIOCHEM J, V167, P121.
   Sojo M, 1997, APPL MICROBIOL BIOT, V47, P583.
   STADTMAN TC, 1955, METHOD ENZYMOL, V1, P678, DOI 10.1016/0076-6879(55)01118-X.
   Tak JD, 1942, ANTON LEEUW INT J G, V8, P32, DOI 10.1007/BF02272764.
   Thomas JL, 2003, J BIOL CHEM, V278, P35483, DOI 10.1074/jbc.M304752200.
   Thomas JL, 2002, J BIOL CHEM, V277, P42795, DOI 10.1074/jbc.M208537200.
   Turfitt GE, 1944, BIOCHEM J, V38, P492.
   Van der Geize R, 2007, P NATL ACAD SCI USA, V104, P1947, DOI 10.1073/pnas.0605728104.
   Wu CH, 2003, NUCLEIC ACIDS RES, V31, P345, DOI 10.1093/nar/gkg040.}},
Number-of-Cited-References = {{49}},
Times-Cited = {{60}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Biochemistry}},
Doc-Delivery-Number = {{195VA}},
Unique-ID = {{ISI:000248439000016}},
}

@article{ ISI:000249134300012,
Author = {Jia Zhong-wei and Li Xiao-wen and Feng Dan and Cao Wu-chun},
Title = {{Transmission models of tuberculosis in heterogeneous population}},
Journal = {{CHINESE MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{120}},
Number = {{15}},
Pages = {{1360-1365}},
Month = {{AUG 5}},
Abstract = {{Objective To review the transmission models of tuberculosis in
   heterogeneous population.
   Data sources The data used in this review were adopted mainly from the
   studies of models of tuberculosis reported from 1995 to 2006.
   Study selection Relevant literature on transmission models of
   tuberculosis in heterogeneous populations are referenced.
   Results Casual/random factors and genetic factors are the main reasons
   for epidemics of tuberculosis in recent years. Mass public transport is
   playing the primary role in casually close contact which can facilitate
   the transmission of tuberculosis. Genetic susceptibility not only varies
   endemic prevalence levels, but also drastically alters the effects of
   treatment for tuberculosis patients. Detailed studies further exhibit
   that casual contact and genetic factor are responsible for over
   30\%-40\% of the total new cases in recent years. The prevalence of
   tuberculosis could double (from 33\% to 60\%) if a genetically
   susceptible phenotype is present in only 30\% of the population. And
   some challenges have emerged along with these exciting results.
   Conclusions Casual/random contact, public transport and genetic
   susceptibility are responsible for most new tuberculosis cases and a
   wide variation in endemic tuberculosis levels between regions. Hence,
   the transmission model of tuberculosis in a heterogeneous population can
   provide more clues to underlying mechanism of tuberculosis transmission
   than in a homogeneous population. However, many challenges remain for us
   in understanding transmission of disease.}},
Publisher = {{CHINESE MEDICAL ASSOC}},
Address = {{42 DONGSI XIDAJIE, BEIJING 100710, PEOPLES R CHINA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Cao, WC (Reprint Author), Beijing Inst Microbiol \& Epidemiol, State Key Lab Pathogen \& Biosecurity, Beijing 100071, Peoples R China.
   Beijing Inst Microbiol \& Epidemiol, State Key Lab Pathogen \& Biosecurity, Beijing 100071, Peoples R China.
   Beijing Univ Posts \& Telecommunicat, InformatEineering, Beijing 100876, Peoples R China.}},
ISSN = {{0366-6999}},
Keywords = {{tuberculosis; transmission; basic reproductive number; mathematical
   mode; heterogeneous}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; CONTROL STRATEGIES; DYNAMICS; IMPACT;
   SUSCEPTIBILITY; INFECTION; EPIDEMICS}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{caowc@nic.bmi.ac.cn}},
Cited-References = {{Aparicio JP, 2000, J THEOR BIOL, V206, P327, DOI 10.1006/jtbi.2000.2129.
   Bellamy R, 2000, CLIN SCI, V98, P245, DOI 10.1042/CS19990228.
   Berezovsky F, 2005, MATH BIOSCI ENG, V2, P133.
   Bjune G, 2005, NORSK EPIDEMIOLOGI, V15, P133.
   BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815.
   Blower SM, 2004, NAT MED, V10, P1111, DOI 10.1038/nm1102.
   Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497.
   BRAND D, 1999, TUBERCULOSIS SPREADS.
   Brewer TF, 2004, J EPIDEMIOL COMMUN H, V58, P822, DOI 10.1136/jech.2003.008664.
   Castillo-Chavez C, 2004, MATH BIOSCI ENG, V1, P361.
   CastilloChavez C, 1997, J MATH BIOL, V35, P629, DOI 10.1007/s002850050069.
   Dubaniewicz A, 2003, THORAX, V58, P890, DOI 10.1136/thorax.58.10.890.
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0.
   Dye C, 2000, P NATL ACAD SCI USA, V97, P8180, DOI 10.1073/pnas.140102797.
   Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7.
   Dye C, 2000, INT J EPIDEMIOL, V29, P558, DOI 10.1093/ije/29.3.558.
   Feng ZL, 2000, THEOR POPUL BIOL, V57, P235, DOI 10.1006/tpbi.2000.1451.
   Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501.
   Kwiatkowski D, 2000, BRIT MED J, V321, P1061, DOI 10.1136/bmj.321.7268.1061.
   LINCOLN E, 1995, ADV TUBERC RES, V14, P157.
   McCluskey C. C., 2004, J DYN DIFFER EQU, V16, P139, DOI 10.1023/B:JODY.0000041283.66784.3e.
   MCFARLAND JW, 1993, LANCET, V342, P112, DOI 10.1016/0140-6736(93)91311-9.
   Munch Z, 2003, INT J TUBERC LUNG D, V7, P271.
   Murphy BM, 2003, J THEOR BIOL, V223, P391, DOI 10.1016/S0022-5193(03)00038-9.
   Murphy BM, 2002, MATH BIOSCI, V180, P161, DOI 10.1016/S0025-5564(02)00133-5.
   Murray CJL, 1998, P NATL ACAD SCI USA, V95, P13881, DOI 10.1073/pnas.95.23.13881.
   Piccolo C, 2005, MATH COMPUT MODEL, V42, P291, DOI 10.1016/j.mcm.2005.01.030.
   RAFFALLI J, 1965, BIBL TUBERC, V21, P157.
   SALOMON JA, 2005, PLOS MED, V3, pE273.
   Schinazi RB, 2002, THEOR POPUL BIOL, V61, P163, DOI 10.1006/tpbi.2001.1567.
   Song BJ, 2002, MATH BIOSCI, V180, P187, DOI 10.1016/S0025-5564(02)00112-8.
   WAALER HANS, 1962, AMER JOUR PUBL HEALTH, V52, P1002, DOI 10.2105/AJPH.52.6.1002.
   WANG HG, 2006, J MED COLL PLA, V28, P859.
   {*}WHO, 1999, LANCET, V353, P305.
   World Health Organization, 2004, CHANG HIST.
   {*}WHO, 2001, GLOB TUB.
   Wolleswinkel-van den Bosch JH, 2002, INT J TUBERC LUNG D, V6, P130.
   Ziv E, 2001, AM J EPIDEMIOL, V153, P381, DOI 10.1093/aje/153.4.381.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{11}},
Journal-ISO = {{Chin. Med. J.}},
Doc-Delivery-Number = {{205SG}},
Unique-ID = {{ISI:000249134300012}},
}

@article{ ISI:000249134300017,
Author = {Gao Xue-lian and Gyaneshwar, Rajat},
Title = {{An unusual presentation of tuberculosis in pregnancy}},
Journal = {{CHINESE MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{120}},
Number = {{15}},
Pages = {{1378-1380}},
Month = {{AUG 5}},
Publisher = {{CHINESE MEDICAL ASSOC}},
Address = {{42 DONGSI XIDAJIE, BEIJING 100710, PEOPLES R CHINA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Gao, XL (Reprint Author), Peking Univ, First Hosp, Dept Gynecol \& Obstet, Beijing 100034, Peoples R China.
   Peking Univ, First Hosp, Dept Gynecol \& Obstet, Beijing 100034, Peoples R China.
   Peking Univ, First Hosp, Liverpool Hlth Serv, Beijing 100034, Peoples R China.}},
ISSN = {{0366-6999}},
Keywords = {{tuberculosis; pregnancy; extrapulmonary}},
Keywords-Plus = {{WOMEN}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{xuelian.gao2006@yahoo.com.cn}},
Cited-References = {{{*}DEP HUM SERV, 2003, CONTR PREV TB GUID H.
   Doveren RFC, 1998, NETH J MED, V52, P100, DOI 10.1016/S0300-2977(98)00004-7.
   Jana N, 1999, NEW ENGL J MED, V341, P645, DOI 10.1056/NEJM199908263410903.
   Llewelyn M, 2000, THORAX, V55, P129, DOI 10.1136/thorax.55.2.129.
   MARGONO F, 1993, JAMA-J AM MED ASSOC, V270, P1293.
   RUAN HL, 2003, J JIANGHAN U NAT SCI, V31, P54.
   WANG ZI, 1996, BAOTOU MED, V20, P187.
   Watts HG, 1996, J BONE JOINT SURG AM, V78A, P288.
   XU Y, 2003, J RARE, V10, P59.
   YU HX, 2004, J PRACT MED TECH, V11, P2469.
   ZHANG BJ, 1995, TIANJIN MED, V23, P422.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Chin. Med. J.}},
Doc-Delivery-Number = {{205SG}},
Unique-ID = {{ISI:000249134300017}},
}

@article{ ISI:000249441200001,
Author = {Karakousis, Petros C. and Sifakis, Frangiscos G. and De Oca, Ruben
   Montes and Amorosa, Valerianna C. and Page, Kathleen R. and Manabe,
   Yukari C. and Campbell, James D.},
Title = {{U. S. medical resident familiarity with national tuberculosis guidelines}},
Journal = {{BMC INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{7}},
Month = {{AUG 2}},
Abstract = {{Background: The ability of medical residents training at U. S. urban
   medical centers to diagnose and manage tuberculosis cases has important
   public health implications. We assessed medical resident knowledge about
   tuberculosis diagnosis and early management based on American Thoracic
   Society guidelines.
   Methods: A 20-question tuberculosis knowledge survey was administered to
   131 medical residents during a single routinely scheduled teaching
   conference at four different urban medical centers in Baltimore and
   Philadelphia. Survey questions were divided into 5 different subject
   categories. Data was collected pertaining to institution, year of
   residency training, and self-reported number of patients managed for
   tuberculosis within the previous year. The Kruskal-Wallis test was used
   to detect differences in median percent of questions answered correctly
   based on these variables.
   Results: The median percent of survey questions answered correctly for
   all participating residents was 55\%. Medical resident knowledge about
   tuberculosis did not improve with increasing postgraduate year of
   training or greater number of patients managed for tuberculosis within
   the previous year. Common areas of knowledge deficiency included the
   diagnosis and management of latent tuberculosis infection ( median
   percent correct, 40.7\%), as well as the interpretation of negative
   acid-fast sputum smear samples.
   Conclusion: Many medical residents lack adequate knowledge of
   recommended guidelines for the management of tuberculosis. Since
   experience during training influences future practice pattterns,
   education of medical residents on guidelines for detection and early
   management of tuberculosis may be important for future improvements in
   national tuberculosis control strategies.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Karakousis, PC (Reprint Author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
   Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
   Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA.}},
DOI = {{10.1186/1471-2334-7-89}},
Article-Number = {{89}},
ISSN = {{1471-2334}},
Keywords-Plus = {{CALMETTE-GUERIN VACCINATION; MYCOBACTERIUM-TUBERCULOSIS; INNER-CITY;
   REACTIVITY; KNOWLEDGE; TRANSMISSION; INFECTION; DIAGNOSIS; IMPACT;
   ADULTS}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{petros@jhmi.edu
   fsifakis@jhsph.edu
   montesd@jhsph.edu
   amorosav@comcast.net
   kpage2@jhmi.edu
   ymanabe@jhmi.edu
   Jcampbel@medicine.umaryland.edu}},
Cited-References = {{Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2.
   Arend SM, 2007, AM J RESP CRIT CARE, V175, P618, DOI 10.1164/rccm.200608-1099OC.
   {[}Anonymous], 2000, AM J RESP CRIT CARE, V161, pS221.
   Behr MA, 1999, LANCET, V353, P444, DOI 10.1016/S0140-6736(98)03406-0.
   Blumberg Henry M, 2003, Am J Respir Crit Care Med, V167, P603.
   Blumberg HM, 2005, JAMA-J AM MED ASSOC, V293, P2776, DOI 10.1001/jama.293.22.2776.
   Cantwell MF, 1998, AM J RESP CRIT CARE, V157, P1016.
   {*}CDC, 2005, REP TUB US 2004, P72.
   Coppola AG, 2004, AM J GASTROENTEROL, V99, P1720, DOI 10.1111/j.1572-0241.2004.10370.x.
   Craft DW, 2000, J CLIN MICROBIOL, V38, P4285.
   Curtis AB, 1999, NEW ENGL J MED, V341, P1491, DOI 10.1056/NEJM199911113412002.
   DeRiemer K, 1999, INT J TUBERC LUNG D, V3, P488.
   Doyle R, 2005, SCI AM, V293, P25.
   Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376.
   Fitz Gerald JD, 2003, ACAD MED, V78, P84, DOI 10.1097/00001888-200301000-00015.
   Fitzpatrick LK, 2001, CLIN INFECT DIS, V33, P1801, DOI 10.1086/323671.
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110.
   Khan JA, 2005, TROP DOCT, V35, P144, DOI 10.1258/0049475054620770.
   KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N.
   Luetkemeyer AF, 2007, AM J RESP CRIT CARE, V175, P737, DOI 10.1164/rccm.200608-1088OC.
   MCGOWAN JE, 1995, J HOSP INFECT, V30, P282, DOI 10.1016/0195-6701(95)90031-4.
   Menzies D, 2000, CLIN INFECT DIS, V31, pS71, DOI 10.1086/314075.
   MENZIES R, 1992, AM REV RESPIR DIS, V145, P621.
   Mortimer JE, 1997, J PAIN SYMPTOM MANAG, V14, P21, DOI 10.1016/S0885-3924(97)00002-X.
   Rao VK, 1999, ANN INTERN MED, V130, P404.
   Saad J A, 1994, Fam Med, V26, P250.
   Sisson Stephen D, 2006, J Clin Hypertens (Greenwich), V8, P344, DOI 10.1111/j.1524-6175.2006.05335.x.
   Sotir MJ, 1999, CLIN INFECT DIS, V29, P1138, DOI 10.1086/313453.
   Taylor Zachary, 2005, MMWR Recomm Rep, V54, P1.
   Wiest FC, 2002, JAMA-J AM MED ASSOC, V288, P2609, DOI 10.1001/jama.288.20.2609.
   Yeh YP, 2005, T ROY SOC TROP MED H, V99, P509, DOI 10.1016/j.trstmh.2005.03.001.
   {[}Anonymous], 2003, MMWR MORB MORTAL WKL, V52, P735.
   2004, MMWR MORB MORTAL WKL, V53, P209.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{BMC Infect. Dis.}},
Doc-Delivery-Number = {{210FD}},
Unique-ID = {{ISI:000249441200001}},
}

@article{ ISI:000248436300001,
Author = {Parmet, Wendy E.},
Title = {{Legal power and legal rights - Isolation and quarantine in the case of
   drug-resistant tuberculosis}},
Journal = {{NEW ENGLAND JOURNAL OF MEDICINE}},
Year = {{2007}},
Volume = {{357}},
Number = {{5}},
Pages = {{433-435}},
Month = {{AUG 2}},
Publisher = {{MASSACHUSETTS MEDICAL SOC}},
Address = {{WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Parmet, WE (Reprint Author), Northeastern Univ, Sch Law, Boston, MA 02115 USA.
   Northeastern Univ, Sch Law, Boston, MA 02115 USA.}},
DOI = {{10.1056/NEJMp078133}},
ISSN = {{0028-4793}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{DiGiovanni C, 2004, BIOSECUR BIOTERROR, V2, P265, DOI 10.1089/bsp.2004.2.265.
   Gasner MR, 1999, NEW ENGL J MED, V340, P359, DOI 10.1056/NEJM199902043400506.
   NEUMANN J, 2007, LOS ANGELES TIM 0607, pA12.
   2005, FED REG         1130, V70, P71892.}},
Number-of-Cited-References = {{4}},
Times-Cited = {{20}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{N. Engl. J. Med.}},
Doc-Delivery-Number = {{195UB}},
Unique-ID = {{ISI:000248436300001}},
}

@article{ ISI:000248315900014,
Author = {ter Horst, Bjorn and Feringa, Ben L. and Minnaard, Adriaan J.},
Title = {{Catalytic asymmetric synthesis of phthioceranic acid, a
   heptamethyl-branched acid from Mycobacterium tuberculosis}},
Journal = {{ORGANIC LETTERS}},
Year = {{2007}},
Volume = {{9}},
Number = {{16}},
Pages = {{3013-3015}},
Month = {{AUG 2}},
Abstract = {{The first total synthesis of phthioceranic acid (1) has been achieved by
   an iterative catalytic asymmetric 1,4-addition protocol. This method
   provides a robust and high-yielding route for the preparation of
   1,3-oligomethyl (deoxypropionate) arrays. After the desired number of
   methyl groups has been introduced, these arrays can be further
   functionalized at both ends to polymethyl-substituted lipids such as
   phthioceranic acid, a heptamethyl-branched fatty acid from the virulence
   factor Sulfolipid-I (2), found in Mycobacterium tuberculosis.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Feringa, BL (Reprint Author), Univ Groningen, Dept Organ \& Mol Inorgan Chem, Stratingh Inst Chem, Nijenborg 4, NL-9747 AG Groningen, Netherlands.
   Univ Groningen, Dept Organ \& Mol Inorgan Chem, Stratingh Inst Chem, NL-9747 AG Groningen, Netherlands.}},
DOI = {{10.1021/ol071078o}},
ISSN = {{1523-7060}},
Keywords-Plus = {{ENANTIOSELECTIVE CONJUGATE ADDITION; SULFOLIPID-I; GRIGNARD-REAGENTS;
   STRAIN H37RV; T-CELLS; BIOSYNTHESIS; EFFICIENT; CARBOALUMINATION;
   BORRELIDIN; IONOMYCIN}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Organic}},
Author-Email = {{b.l.feringa@rug.nl
   a.j.minnaard@rug.nl}},
ResearcherID-Numbers = {{Minnaard, Adriaan/E-9547-2014
   Feringa, Ben/C-1665-2013}},
Cited-References = {{Bhatt K, 2007, MICROBIOL-SGM, V153, P513, DOI 10.1099/mic.0.2006/003103-0.
   Converse SE, 2003, P NATL ACAD SCI USA, V100, P6121, DOI 10.1073/pnas.1030024100.
   Cooksey JP, 2006, ORG BIOMOL CHEM, V4, P3325, DOI 10.1039/b606262h.
   Cox JS, 1999, NATURE, V402, P79.
   DAFFE M, 1989, J GEN MICROBIOL, V135, P2759.
   De Libero G, 2005, NAT REV IMMUNOL, V5, P485, DOI 10.1038/nri1631.
   Des Mazery Renaud, 2005, J Am Chem Soc, V127, P9966, DOI 10.1021/ja053020f.
   Dubey VS, 2002, MOL MICROBIOL, V45, P1451, DOI 10.1046/j.1365-2958.2002.03119.x.
   Duffey MO, 2003, J AM CHEM SOC, V125, P1458, DOI 10.1021/ja028941u.
   EVANS DA, 1990, J AM CHEM SOC, V112, P5290, DOI 10.1021/ja00169a042.
   Feringa BL, 2004, P NATL ACAD SCI USA, V101, P5834, DOI 10.1073/pnas.0308008101.
   Fernandes ND, 1998, J BIOL CHEM, V273, P2823, DOI 10.1074/jbc.273.5.2823.
   Gilleron M, 2004, J EXP MED, V199, P649, DOI 10.1084/jem.20031097.
   GOREN MB, 1970, BIOCHIM BIOPHYS ACTA, V210, P116, DOI 10.1016/0005-2760(70)90067-6.
   GOREN MB, 1970, BIOCHIM BIOPHYS ACTA, V210, P127, DOI 10.1016/0005-2760(70)90068-8.
   GOREN MB, 1976, BIOCHEMISTRY-US, V15, P2728, DOI 10.1021/bi00658a003.
   GOREN MB, 1971, BIOCHEMISTRY-US, V10, P72, DOI 10.1021/bi00777a012.
   Liang B, 2006, J AM CHEM SOC, V128, P2770, DOI 10.1021/ja0530974.
   LINDSTEAD RP, 1950, J CHEM SOC, P333.
   Lopez F, 2007, ACCOUNTS CHEM RES, V40, P179, DOI 10.1021/ar0501976.
   Minnikin DE, 2002, CHEM BIOL, V9, P545, DOI 10.1016/S1074-5521(02)00142-4.
   Mougous JD, 2004, NAT STRUCT MOL BIOL, V11, P721, DOI 10.1038/nsmb802.
   Nagamitsu T, 2007, J ORG CHEM, V72, P2744, DOI 10.1021/jo062089i.
   Negishi E, 2004, P NATL ACAD SCI USA, V101, P5782, DOI 10.1073/pnas.0307514101.
   Novak T, 2005, J AM CHEM SOC, V127, P2838, DOI 10.1021/ja043534z.
   Pasqualoto KFM, 2001, CURR DRUG TARGETS, V2, P427, DOI 10.2174/1389450013348227.
   RATLEDGE C, 1988, MICROBIAL LIPIDS, V1, P248.
   RATLEDTE C, 1982, BIOL MYCOBACTERIA PH, V1, pCH4.
   Schelle MW, 2006, CHEMBIOCHEM, V7, P1516, DOI 10.1002/cbic.200600224.
   Schetter B, 2006, ANGEW CHEM INT EDIT, V45, P7506, DOI 10.1002/anie.200602780.
   Schuppan J, 2004, CHEM COMMUN, P792, DOI 10.1039/b315871c.
   Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200.
   ter Horst B, 2007, CHEM COMMUN, P489, DOI 10.1039/b612593j.
   Tripathi RP, 2005, MED RES REV, V25, P93, DOI 10.1002/med.20017.
   Williams DR, 2004, J ORG CHEM, V69, P5374, DOI 10.1021/jo049567e.
   YOUMANS GP, 1979, TUBERCULOSIS, pCH4.
   Zhang Ying, 2005, Annu Rev Pharmacol Toxicol, V45, P529, DOI 10.1146/annurev.pharmtox.45.120403.100120.
   Zhou JG, 2007, ORG LETT, V9, P1391, DOI 10.1021/ol070298z.
   Zhou JG, 2007, ANGEW CHEM INT EDIT, V46, P1129, DOI 10.1002/anie.200603635.}},
Number-of-Cited-References = {{39}},
Times-Cited = {{45}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{9}},
Journal-ISO = {{Org. Lett.}},
Doc-Delivery-Number = {{194AI}},
Unique-ID = {{ISI:000248315900014}},
}

@article{ ISI:000249310000009,
Author = {Li, Yuan and Yang, Zhi-Gang and Guo, Ying-Kun and Min, Peng-Qiu and Yu,
   Jian-Qun and Ma, En-Sen and Hu, Jian},
Title = {{Distribution and characteristics of hematogenous disseminated
   tuberculosis within the abdomen on contrast-enhanced CT}},
Journal = {{ABDOMINAL IMAGING}},
Year = {{2007}},
Volume = {{32}},
Number = {{4}},
Pages = {{484-488}},
Month = {{AUG}},
Abstract = {{Background: The incidence of abdominal tuberculous lymphadenopathy never
   appears low. In addition to infecting the abdominal lymph nodes through
   the digestive tract, the tuberculosis bacteria can also infect the
   abdominal lymph nodes and extra-nodal organs through hematogenous
   dissemination. This study investigated contrast-enhanced CT features and
   anatomic locations of hematogenous disseminated tuberculosis involving
   abdominal organs.
   Methods: Thirteen patients with documented hematogenous disseminated
   tuberculosis involving abdominal organs were recruited.
   Contrast-enhanced CT scanning was carried out in the abdomen of all
   patients. CT images were retrospectively analyzed for the size,
   attenuation, enhancement patterns, and anatomic distribution of the foci
   in infected lymph node, liver, spleen, and kidney.
   Results: Hematogenous disseminated tuberculosis dominantly affected
   lymph nodes in the hepatoduodenal ligament (84.6\%), the portacaval
   space (84.6\%), the root of the mesentery (84.6\%), the peripancreatic
   region (84.6\%), the periceliac region (76.9\%), the hepatogastric
   ligament (69.2\%), and the upper and lower paraaortic region (both were
   69.2\%). Out of the 13 cases studied, 12 (92.3\%) had lymphadenopathy
   with peripheral enhancement accompanied by multilocular appearance; 10
   (76.9\%) had homogeneous hepatomegaly; 13 (100\%) had inhomogeneous
   splenomegaly accompanied by scattered low-density lesions with
   peripheral enhancement; and 8 (61.5\%) had low-density lesions in the
   kidney with peripheral enhancement.
   Conclusion: Anatomically, peritoneal and retroperitoneal lymph nodes are
   most susceptible to hematogenous disseminated tuberculosis. The
   hepatomegaly manifested to be homogeneous in most cases while the
   splenomegaly is of frequently inhomogeneous attenuation. All these
   characteristics are closely related to the infection routes and
   pathologic features of abdominal hematogenous disseminated tuberculosis.}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING STREET, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Yang, ZG (Reprint Author), W China Hosp, Dept Radiol, 37 Guo Xue Xiang, Chengdu 610041, Peoples R China.
   W China Hosp, Dept Radiol, Chengdu 610041, Peoples R China.
   W China Hosp, Natl Key Lab Biotherapy Ctr, Chengdu 610041, Peoples R China.
   Wuhan Univ, Sch Stomatol, Wuhan 430072, Peoples R China.}},
DOI = {{10.1007/s00261-006-9144-6}},
ISSN = {{0942-8925}},
Keywords = {{abdomen; tuberculosis; lymph node; CT}},
Keywords-Plus = {{ABDOMINAL LYMPH-NODES; AIDS}},
Research-Areas = {{Gastroenterology \& Hepatology; Radiology, Nuclear Medicine \& Medical
   Imaging}},
Web-of-Science-Categories  = {{Gastroenterology \& Hepatology; Radiology, Nuclear Medicine \& Medical
   Imaging}},
Author-Email = {{yangzg1117@yahoo.com.cn}},
Cited-References = {{DORFMAN RE, 1991, RADIOLOGY, V180, P319.
   Fan ZM, 1998, J GASTROENTEROL, V33, P285, DOI 10.1007/s005350050085.
   GOODMAN PC, 1995, RADIOL CLIN N AM, V33, P707.
   Griffith RC, 1990, ANDERSONS PATHOLOGY, P1429.
   HULINICK DH, 1985, RADIOLOGY, V157, P199.
   Jadvar H, 1997, AM J ROENTGENOL, V168, P1455.
   KOBZIK L, 1999, ROBBINS PATHOLOGIC B, P697.
   LEDER RA, 1995, RADIOL CLIN N AM, V33, P691.
   POMBO F, 1994, J COMPUT ASSIST TOMO, V18, P59, DOI 10.1097/00004728-199401000-00013.
   POMBO F, 1992, CLIN RADIOL, V46, P13, DOI 10.1016/S0009-9260(05)80026-1.
   RABUSHKA LS, 1994, RADIOGRAPHICS, V14, P307.
   RADIN DR, 1991, AM J ROENTGENOL, V156, P487.
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220.
   Yang ZG, 1999, AM J ROENTGENOL, V172, P619.
   Yang Zhigang, 1997, Nippon Acta Radiologica, V57, P567.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Abdom. Imaging}},
Doc-Delivery-Number = {{208HI}},
Unique-ID = {{ISI:000249310000009}},
}

@article{ ISI:000249649000026,
Author = {Girgin, S. and Gedik, E. and Bueyuekbayram, H.},
Title = {{Asymptomatic thyroid tuberculosis in a multinodular goitre patient: A
   case report}},
Journal = {{ACTA CHIRURGICA BELGICA}},
Year = {{2007}},
Volume = {{107}},
Number = {{4}},
Pages = {{457-459}},
Month = {{AUG}},
Abstract = {{Thyroid tuberculosis is a very rare disease of the thyroid gland. In
   recent years, the incidence of extra-pulmonary tuberculosis has been
   showing a progressive increase. We present the case of a 41 -year old
   female patient, operated for an asymptomatic multinodular goiter, and
   who had a histopathological diagnosis of thyroid tuberculosis. Thyroid
   tuberculosis should be kept in mind in the differential diagnosis of
   thyroid nodules, even in patients with no history and no symptom of
   tuberculosis disease.}},
Publisher = {{ACTA MEDICAL BELGICA}},
Address = {{AVENUE CIRCULAIRE 138 A, B-1180 BRUSSELS, BELGIUM}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Girgin, S (Reprint Author), Univ Dicle, Sch Med, Dept Gen Surg, TUR-21280 Diyarbakir, Turkey.
   Univ Dicle, Sch Med, Dept Gen Surg, TUR-21280 Diyarbakir, Turkey.
   Univ Dicle, Sch Med, Dept Pathol, Diyarbakir, Turkey.}},
ISSN = {{0001-5458}},
Keywords = {{tuberculosis; thyroid gland; goiter}},
Keywords-Plus = {{GLAND}},
Research-Areas = {{Surgery}},
Web-of-Science-Categories  = {{Surgery}},
Author-Email = {{sgirgin@dicle.edu.tr}},
Cited-References = {{Bulbuloglu E, 2006, WORLD J SURG, V30, P149, DOI 10.1007/s00268-005-0139-1.
   El Malki HO, 2002, ANN CHIR, V127, P385, DOI 10.1016/S0003-3944(02)00777-0.
   EMERY P, 1980, J LARYNGOL OTOL, V94, P553, DOI 10.1017/S0022215100089246.
   Johnson AG, 1973, BRIT J SURG, V60, P667.
   KIERTIBURANAKUL S, 2002, SCAND J INFECT DIS, V35, P68.
   Orlandi F, 1999, HORM RES, V52, P291, DOI 10.1159/000023498.
   Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301.
   Parmar Hemant, 2002, Australas Radiol, V46, P186, DOI 10.1046/j.1440-1673.2001.01033.x.
   Rankin FW, 1932, ANN SURG, V96, P625, DOI 10.1097/00000658-193210000-00013.
   SLAVIN RE, 1980, MEDICINE, V59, P352.}},
Number-of-Cited-References = {{10}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Acta Chir. Belg.}},
Doc-Delivery-Number = {{213EM}},
Unique-ID = {{ISI:000249649000026}},
}

@article{ ISI:000249871900001,
Author = {Anneken, K. and Schilling, M. and Evers, S. and Kloska, S. and Husstedt,
   I.-W. and Schaebitz, W.-R.},
Title = {{Cerebral tuberculosis in HIV infection - Review and case series}},
Journal = {{AKTUELLE NEUROLOGIE}},
Year = {{2007}},
Volume = {{34}},
Number = {{6}},
Pages = {{331-336}},
Month = {{AUG}},
Abstract = {{Background Tuberculosis is the most frequent infectious disease causing
   death worldwide. The main risk factor is an HIV infection. CNS
   involvement occurs in 5-20\% of HIV infected patients with tuberculosis.
   Material and Methods We investigated all cases of CNS tuberculosis in
   HIV infection treated in a German university hospital from 1998 to 2006.
   Clinical symptoms, differential diagnosis, diagnostic and therapeutic
   standards of cerebral tuberculosis, including specific aspects in HIV
   infection, are discussed.
   Results The incidence of CNS tuberculosis in HIV infected patients was
   1.5\%. All patients were transiently treated in an ICU. Related to all
   HIV infected patients admitted to an ICU, the incidence of CNS
   tuberculosis was 10 \%.
   Conclusions Tuberculosis is an important differential diagnosis in HIV
   infected patients with focal and diffuse brain lesions. Due to the HIV
   associated immunodeficiency syndrome, atypical diagnostic results are
   seen frequently. Extensive diagnostic investigations should be
   performed, including biopsy and search for extra cerebral manifestation.
   An antituberculous treatment is indicated even in cases suspicious of
   cerebral tuberculosis. HAART reduces the mortality risk significantly.}},
Publisher = {{GEORG THIEME VERLAG KG}},
Address = {{RUDIGERSTR 14, D-70469 STUTTGART, GERMANY}},
Type = {{Article}},
Language = {{German}},
Affiliation = {{Husstedt, IW (Reprint Author), Univ Klinikum Munster, Neurol Klin \& Poliklin, Albert-Schweitzer-Str 33, D-48149 Munster, Germany.
   Univ Klinikum Munster, Neurol Klin \& Poliklin, D-48149 Munster, Germany.
   Univ Klinikum Munster, Inst Klin Radiol, Munster, Germany.}},
DOI = {{10.1055/s-2007-970897}},
ISSN = {{0302-4350}},
Keywords = {{cerebral tuberculosis; HlV/AlDS; diagnosis; therapy}},
Keywords-Plus = {{HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM;
   MYCOBACTERIUM-TUBERCULOSIS; BRAIN-ABSCESS; AIDS; MENINGITIS; DIAGNOSIS}},
Research-Areas = {{Neurosciences \& Neurology}},
Web-of-Science-Categories  = {{Clinical Neurology}},
Author-Email = {{husstedt@uni-muenster.de}},
Cited-References = {{ARENDT G, 2005, LEITHLINIEN DTSCH GE, P368.
   Berger J. R., 2005, The neurology of AIDS, P485.
   Char G, 2000, W INDIAN MED J, V49, P70.
   Corti ME, 2005, INT J INFECT DIS, V9, P225, DOI 10.1016/j.ijid.2004.10.002.
   CORTI ME, 2000, ENFERM INFEC MICR CL, V4, P192.
   DAVIDSON PT, 1992, DRUGS, V43, P651, DOI 10.2165/00003495-199243050-00003.
   Dheda K, 2004, J INFECT DIS, V190, P1670, DOI 10.1086/424676.
   Helbok R, 2006, NEUROEPIDEMIOLOGY, V26, P37, DOI 10.1159/000089236.
   HIBBELER B, 2005, DTSCH ARZTEBLATT, P102.
   HOFFMANN C, 2004, HIVNET2004I, P341.
   Kammer-Suhr B, 2003, NERVENARZT, V74, P677, DOI 10.1007/s00115-003-1531-4.
   PRANGE H, 2001, INFEKITONSERKRNAKUNG, P313.
   Rosenkranz T, 2002, DEUT MED WOCHENSCHR, V127, P1479, DOI 10.1055/s-2002-32671.
   Sanchez-Portocarrero J, 1999, INFECTION, V27, P313, DOI 10.1007/s150100050035.
   SHELLER JR, 1986, NEUROL CLIN, V4, P143.
   SLUTSKER L, 1993, CLIN INFECT DIS, V16, P513.
   SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503.
   THEUER CP, 1990, J INFECT DIS, V162, P8.
   Thwaites GE, 2007, LANCET NEUROL, V6, P230, DOI 10.1016/S1474-4422(07)70034-0.
   van der Sande MAB, 2004, AIDS, V18, P1933, DOI 10.1097/00002030-200409240-00009.
   Vidal JE, 2005, INT J INFECT DIS, V9, P201, DOI 10.1016/j.ijid.2004.06.010.
   Vidal José E., 2003, Rev. Inst. Med. trop. S. Paulo, V45, P111, DOI 10.1590/S0036-46652003000200013.
   WHITEMAN M, 1995, AM J NEURORADIOL, V16, P1319.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Aktuelle Neurol.}},
Doc-Delivery-Number = {{216IO}},
Unique-ID = {{ISI:000249871900001}},
}

@article{ ISI:000248628400011,
Author = {Kettunen, Christine M. and Sunmonu, Yisa and Hodgkinson, Anna L. and
   Verzurno, Marv and Belding-Braun, Katie and Vaccariello, Pam and Nappi,
   Linda},
Title = {{Contact investigation of a case of active tuberculosis in the community}},
Journal = {{AMERICAN JOURNAL OF INFECTION CONTROL}},
Year = {{2007}},
Volume = {{35}},
Number = {{6}},
Pages = {{421-424}},
Month = {{AUG}},
Abstract = {{Background: Ashtabula County, Ohio, has been a low-risk county for
   tuberculosis (TB) based on the Centers for Disease Control and
   Prevention guidelines. The Ashtabula County TB clinic is provided
   through the Ashtabula County Health Department. over the past 10 years.
   there has been an annual average of one to 2 active cases of TB seen and
   treated at the county TB clinic.
   Contact investigation: In 2005, over a period of 3 months there were 6
   cases of active TB identified in Ashtabula County Contact investigation
   and follow-up were complicated by the fact that the suspected source
   case likely had active disease for more than 4 years and had some
   medical procedures performed at health care facilities in another county
   This person was unaware of having TB and was identified through contact
   investigation by the county health department staff and sent for
   testing. The investigation was complicated further because the index
   case did not reveal contact with the suspected source case, although
   this was confirmed later through investigation. Contact investigation
   involved Ashtabula County and notification of other counties in Ohio.
   The Ohio Department of Health also was notified.
   Discussion: Following identification of each case of active TB, contacts
   were identified through interviews with the clients, physicians, and
   health care facilities where clients were treated, Initially in
   Ashtabula County, 97 people were reviewed for follow-up, and 87 people
   were skin tested for TB. There were 7 conversions.
   Conclusion: Although the overall incidence of TB has declined in the
   United States, increased awareness of TB, appropriate diagnostic
   work-up, treatment. and control measures among health care professionals
   in low-incidence areas is increasingly important. Contact investigation
   of a case of TB requires diligence and effective communication.}},
Publisher = {{MOSBY-ELSEVIER}},
Address = {{360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kettunen, CM (Reprint Author), CIC, Ashtabula Cty Hlth Dept, 12 W Jefferson St, Jefferson, OH 44047 USA.
   CIC, Ashtabula Cty Hlth Dept, Jefferson, OH 44047 USA.
   Ashtabula Cty Hlth Dept, Jefferson, OH USA.
   Ashtabula Cty Med Ctr, Ashtabula, OH USA.}},
DOI = {{10.1016/j.ajic.2006.08.008}},
ISSN = {{0196-6553}},
Keywords-Plus = {{DIRECTLY OBSERVED THERAPY; PULMONARY TUBERCULOSIS; PUBLIC-HEALTH;
   GUIDELINES}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Author-Email = {{ctredway@odh.ohio.gov}},
Cited-References = {{American Thoracic Society, 2000, MMWR RECOMM REP, V49, P1.
   American Thoracic Society Centre for Disease Control and Infectious Diseases Society of America, 2003, MMWR RECOMM REP, V52, P1.
   BOCK NN, 1998, CLIN INFECT DIS, V27, P1121.
   Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1.
   Centers for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P1.
   Centers for Disease Control and Prevention (CDC), 2005, MMWR-MORBID MORTAL W, V54, P1.
   Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P1.
   {*}CDCP, 2000, CORE CURRICULUM TUBE.
   Chaulk CP, 1998, JAMA-J AM MED ASSOC, V279, P943, DOI 10.1001/jama.279.12.943.
   CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945.
   ETKIND SC, 1993, MED CLIN N AM, V77, P1303.
   Hafner R, 1997, AM J RESP CRIT CARE, V156, P918.
   Horsburgh CR, 2000, CLIN INFECT DIS, V31, P633, DOI 10.1086/314007.
   SIMONE PM, 1999, TUBERCULOSIS NONTUBE, P130.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Am. J. Infect. Control}},
Doc-Delivery-Number = {{198LA}},
Unique-ID = {{ISI:000248628400011}},
}

@article{ ISI:000248522100019,
Author = {Breen, Ronan A. M. and Dunleavy, Anne and Lipman, Marc C. I.},
Title = {{Rapid diagnosis of smear-negative tuberculosis by bronchoalveolar lavage
   enzyme-linked immunospot}},
Journal = {{AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE}},
Year = {{2007}},
Volume = {{176}},
Number = {{3}},
Pages = {{316-317}},
Month = {{AUG 1}},
Publisher = {{AMER THORACIC SOC}},
Address = {{1740 BROADWAY, NEW YORK, NY 10019-4374 USA}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Breen, RAM (Reprint Author), UCL Royal Free \& Univ Coll Med Sch, London, England.
   UCL Royal Free \& Univ Coll Med Sch, London, England.}},
ISSN = {{1073-449X}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; RESPONSES; LUNG}},
Research-Areas = {{General \& Internal Medicine; Respiratory System}},
Web-of-Science-Categories  = {{Critical Care Medicine; Respiratory System}},
Cited-References = {{Breen RAM, 2006, AIDS, V20, P1330, DOI 10.1097/01.aids.0000232243.51286.32.
   Burman William J, 2003, Semin Respir Infect, V18, P263.
   Jafari C, 2006, AM J RESP CRIT CARE, V174, P1048, DOI 10.1164/rccm.200604-465OC.
   Schoch OD, 2007, AM J RESP CRIT CARE, V175, P80, DOI 10.1164/rccm.200608-1092OC.
   Schwander SK, 2000, J IMMUNOL, V165, P1479.
   Silver RF, 2003, AM J RESP CELL MOL, V29, P117, DOI 10.1165/rcmb.4840.}},
Number-of-Cited-References = {{6}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Am. J. Respir. Crit. Care Med.}},
Doc-Delivery-Number = {{196ZL}},
Unique-ID = {{ISI:000248522100019}},
}

@article{ ISI:000248522100020,
Author = {Lange, Christoph and Jafari, Claudia and Lalvani, Ajit},
Title = {{Rapid diagnosis of smear-negative tuberculosis by bronchoalveolar lavage
   enzyme-linked immunospot}},
Journal = {{AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE}},
Year = {{2007}},
Volume = {{176}},
Number = {{3}},
Pages = {{317}},
Month = {{AUG 1}},
Publisher = {{AMER THORACIC SOC}},
Address = {{1740 BROADWAY, NEW YORK, NY 10019-4374 USA}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Lange, C (Reprint Author), Res Ctr Borstel, Borstel, Germany.
   Res Ctr Borstel, Borstel, Germany.
   Imperial Coll Sch Med, London, England.}},
ISSN = {{1073-449X}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; RESPONSES}},
Research-Areas = {{General \& Internal Medicine; Respiratory System}},
Web-of-Science-Categories  = {{Critical Care Medicine; Respiratory System}},
ResearcherID-Numbers = {{Lange, Christoph/J-6289-2012}},
Cited-References = {{Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008.
   Jafari C, 2006, AM J RESP CRIT CARE, V174, P1048, DOI 10.1164/rccm.200604-465OC.
   Liebeschuetz S, 2004, LANCET, V364, P2196, DOI 10.1016/S0140-6736(04)17592-2.
   Schwander SK, 2000, J IMMUNOL, V165, P1479.
   Silver RF, 2003, AM J RESP CELL MOL, V29, P117, DOI 10.1165/rcmb.4840.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Am. J. Respir. Crit. Care Med.}},
Doc-Delivery-Number = {{196ZL}},
Unique-ID = {{ISI:000248522100020}},
}

@article{ ISI:000249133500004,
Author = {Hsu, Meng-Shiuan and Wang, Jiun-Ling and Ko, Wen-Je and Lee, Po-Huang
   and Chou, Nai-Kwan and Wang, Shoei-Shen and Chu, Shu-Hsun and Chang,
   Shan-Chwen},
Title = {{Clinical features and outcome of tuberculosis in solid organ transplant
   recipients}},
Journal = {{AMERICAN JOURNAL OF THE MEDICAL SCIENCES}},
Year = {{2007}},
Volume = {{334}},
Number = {{2}},
Pages = {{106-110}},
Month = {{AUG}},
Abstract = {{Background: Taiwan is an area with moderate to high incidence of
   Mycobacterium tuberculosis infection. The risk of M tuberculosis
   infection in transplantation recipients is considered to he significant.
   Our aim in this study was to investigate the clinical spectrums of M
   tuberculosis-infected transplantation recipients in a southeast Asian
   country, Taiwan. Methods: We retrospectively analyzed the demographic
   data, clinical features, treatment, and outcome of M tuberculosis
   infection in kidney, heart, and liver transplant recipients from May
   1996 to April 2005 at the National Taiwan University Hospital. Results:
   Fifteen patients who had received solid organ transplantation developed
   tuberculosis (kidney = 6, heart = 7, liver = 2). The median duration
   from transplantation to diagnosis of tuberculosis was 31 months. The
   cumulative incidence of post-transplantation tuberculosis was 2.0\%
   (15/760), ie, similar to 3 times that of the general population. Ten
   patients (66.7\%) had pulmonary tuberculosis, 1 (6.7\%) had
   extrapulmonary tuberculosis, and 4 (26.7\%) had disseminated
   tuberculosis. Nine patients completed the anti-tuberculosis treatment;
   the median treatment duration was 12 months (pulmonary: 9 months;
   extrapulmonary: 13.5 months). No treatment failure was noted in patients
   receiving the complete treatment course. The graft failure and mortality
   rates of post-transplantation tuberculosis were 13.3\% each (2/15). The
   tuberculosis-associated mortality rate was 6.7\% (1/15). Conclusions:
   Cumulative incidence of tuberculosis was slightly higher in transplant
   recipients than in the general population in Taiwan. Conventional
   4-combined anti-tuberculosis regimen for 12 months can treat the
   potentially fatal infection successfully in post-transplantation
   tuberculosis patients without recurrence.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Chang, SC (Reprint Author), Natl Taiwan Univ Hosp, Dept Internal Med, Div Infect Dis, 7 Chung Shan S Rd, Taipei 100, Taiwan.
   Natl Taiwan Univ Hosp, Dept Internal Med, Div Infect Dis, Taipei 100, Taiwan.
   Far Eastern Mem Hosp, Taipei, Taiwan.
   Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan.}},
DOI = {{10.1097/MAJ.0b013e31812f5a4e}},
ISSN = {{0002-9629}},
Keywords = {{solid organ transplantation; tuberculosis; post-transplantation
   tuberculosis}},
Keywords-Plus = {{INFECTION; CYCLOSPORINE; LIVER}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{changsc@ntu.edu.tw}},
ORCID-Numbers = {{Chou, Nai-Kuan/0000-0001-5494-7708
   CHANG, SHAN-CHWEN/0000-0001-6505-4139
   Chu, Shu-Hsun/0000-0001-9652-3604
   Wang, Shoei-Shen/0000-0003-3201-4143
   LEE, PO-HUANG/0000-0001-5831-035X}},
Cited-References = {{Aguado JM, 1997, TRANSPLANTATION, V63, P1278, DOI 10.1097/00007890-199705150-00015.
   ALSULAIMAN MH, 1990, TRANSPLANTATION, V50, P597, DOI 10.1097/00007890-199010000-00014.
   American Thoracic Society/Centers for Disease Control and Prevention/Infectious Disease Society of America, 2003, AM J RESP CRIT CARE, V167, P603.
   Cavusoglu C, 2002, CLIN TRANSPLANT, V16, P257, DOI 10.1034/j.1399-0012.2002.01098.x.
   DELANEY V, 1993, TRANSPLANT P, V25, P2288.
   European best practice guidelines for renal transplantation (expert group), 2002, NEPHROL DIAL TRAN S4, V17, P39.
   HERREROS J, 1991, TRANSPLANTE, V2, P40.
   Korner MM, 1997, CHEST, V111, P365, DOI 10.1378/chest.111.2.365.
   Meyers BR, 2000, TRANSPLANTATION, V69, P64, DOI 10.1097/00007890-200001150-00013.
   MODRY DL, 1985, TRANSPLANTATION, V39, P313.
   Munoz P, 2005, CLIN INFECT DIS, V40, P581, DOI 10.1086/427692.
   Sayiner A, 1999, TRANSPLANTATION, V68, P1268, DOI 10.1097/00007890-199911150-00009.
   Singh N, 1998, CLIN INFECT DIS, V27, P1266, DOI 10.1086/514993.
   WU YJ, 2005, TAIWAN MED J, V48, P38.
   YEE GC, 1990, CLIN PHARMACOKINET, V19, P319, DOI 10.2165/00003088-199019040-00004.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{30}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Am. J. Med. Sci.}},
Doc-Delivery-Number = {{205RY}},
Unique-ID = {{ISI:000249133500004}},
}

@article{ ISI:000248523700022,
Author = {Garcia-Contreras, L. and Fiegel, J. and Telko, M. J. and Elbert, K. and
   Hawi, A. and Thomas, A. and VerBerkmoes, J. and Germishuizen, W. A. and
   Fourie, P. B. and Hickey, A. J. and Edwards, D.},
Title = {{Inhaled large porous particles of capreomycin for treatment of
   tuberculosis in a guinea pig model}},
Journal = {{ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}},
Year = {{2007}},
Volume = {{51}},
Number = {{8}},
Pages = {{2830-2836}},
Month = {{AUG}},
Abstract = {{Capreomycin is used for the treatment of multidrug-resistant
   tuberculosis (MDR-TB), but it is limited therapeutically by its severe
   side effects. The objectives of the present studies were (i) to design
   low-density porous capreomycin sulfate particles for efficient pulmonary
   delivery to improve local and systemic drug bioavailability and capacity
   to reduce the bacillary load in the lungs in a manner similar to that
   achieved with intramuscular injections; (ii) to determine
   pharmacokinetic parameters after pulmonary administration of these
   capreomycin particles; and (iii) to evaluate the efficacy of these
   particles in treating animals in a small-aerosol-inoculum guinea pig
   model of TB. Capreomycin particles were manufactured by spray drying and
   characterized in terms of size and drug content. Pharmacokinetic
   parameters were determined by noncompartmental methods with healthy
   guinea pigs after administration of capreomycin particles by
   insufflation. The efficacy of the particles was evaluated by
   histopathological analysis and in terms of wet organ weight and
   bacterial burden in TB-infected animals. Lungs of animals receiving a
   14.5-mg/kg dose of capreomycin particles showed significantly lower wet
   weights and smaller bacterial burdens than those of animals receiving
   any other treatment. These results were supported by histopathological
   analysis. The feasibility of inhaling capreomycin in a novel powder
   form, with the ultimate objective of the treatment of MDR-TB, is
   demonstrated by pharmacokinetic and pharmacodynamic studies with guinea
   pigs. If applied to humans with MDR-TB, such a therapeutic approach
   might simplify drug delivery by eliminating injections and might reduce
   adverse effects through lowering the dose.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hickey, AJ (Reprint Author), Harvard Univ, 322 Pierce Hall,29 Oxford St, Cambridge, MA 02138 USA.
   Harvard Univ, Cambridge, MA 02138 USA.
   Univ N Carolina, Chapel Hill, NC 27599 USA.
   Med Need, Cambridge, MA 02138 USA.}},
DOI = {{10.1128/AAC.01164-06}},
ISSN = {{0066-4804}},
Keywords-Plus = {{RESPIRABLE PLGA MICROSPHERES; PULMONARY TUBERCULOSIS; RIFAMPICIN;
   DELIVERY}},
Research-Areas = {{Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Microbiology; Pharmacology \& Pharmacy}},
Author-Email = {{ahickey@unc.edu
   dedwards@seas.harvard.edu}},
Funding-Acknowledgement = {{PHS HHS {[}5 U01 61336-02]}},
Cited-References = {{Ansel H. C., 1999, PHARM DOSAGE FORMS D.
   Bastian I, 1999, DRUGS, V58, P633, DOI 10.2165/00003495-199958040-00005.
   BLACK HR, 1966, ANN NY ACAD SCI, V135, P974, DOI 10.1111/j.1749-6632.1966.tb45538.x.
   Centers for Disease Control and Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P301.
   CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945.
   DEMIDOV SV, 1991, PROBL TUBERK, V12, P52.
   DEVI TI, 1988, INDIAN J CLIN BIOCH, V3, P37.
   DONOMAE I, 1966, ANN NY ACAD SCI, V135, P1011, DOI 10.1111/j.1749-6632.1966.tb45543.x.
   Drandarska I, 2005, INT IMMUNOPHARMACOL, V5, P795, DOI 10.1016/j.intimp.2004.12.008.
   Edwards DA, 1997, SCIENCE, V276, P1868, DOI 10.1126/science.276.5320.1868.
   FRANCIS J, 2004, DRUG RESISTANT TUBER.
   Garcia-Contreras L, 2006, J ANTIMICROB CHEMOTH, V58, P980, DOI 10.1093/jac/dkl369.
   Garcia-Contreras L., 2002, RESP DRUG DELIVERY, P699.
   GARFIELD JW, 1966, ANN NY ACAD SCI, V135, P1039, DOI 10.1111/j.1749-6632.1966.tb45544.x.
   Gonda I., 1992, PHARM INHALATION AER, V54, P61.
   Gyselen A, 1965, Tubercle, V46, P243, DOI 10.1016/S0041-3879(65)80017-4.
   Hinds W. C., 1998, AEROSOL TECHNOLOGY P.
   JIANG S, 2005, ZHONGHUA WEISHENGWUX, V24, P373.
   LECONTE P, 1994, ANTIMICROB AGENTS CH, V38, P2695.
   Lee SH, 2003, INT J ANTIMICROB AG, V22, P81, DOI 10.1016/s0924-8579(03)00124-9.
   LEHMANN CR, 1988, AM REV RESPIR DIS, V138, P1312.
   McMurray David N., 1994, P135.
   NIH, 2003, AER DEL MTB CHEM PIT.
   NIU X, 1998, ZHONGGUO YAOKE DAXUE, V29, P142.
   NIVEN RW, 1996, LUNG BIOL HEALTH DIS, V94, P273.
   O'Hara P, 2000, PHARMACEUT RES, V17, P955, DOI 10.1023/A:1007527204887.
   O'Brien RJ, 1993, TUBERCULOSIS COMPREH, P207.
   ORGANICK AB, 1968, DIS CHEST, V53, P560.
   Rossi C, 2004, J PHARMACEUT BIOMED, V36, P249, DOI 10.1016/j.jpba.2004.06.015.
   SCHEUCH F, 1999, J AEROSOL MED, V12, P138.
   Smith SJ, 1996, INHALATION AEROSOLS, P233.
   Suarez S, 2001, J ANTIMICROB CHEMOTH, V48, P431, DOI 10.1093/jac/48.3.431.
   Suarez S, 2001, PHARMACEUT RES, V18, P1315, DOI 10.1023/A:1013094112861.
   Tsapis N, 2003, TUBERCULOSIS, V83, P379, DOI 10.1016/j.tube.2003.08.016.
   World Health Organization, 2004, 3 WHO.
   WIEGESHAUS EH, 1970, AM REV RESPIR DIS, V102, P422.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{77}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{16}},
Journal-ISO = {{Antimicrob. Agents Chemother.}},
Doc-Delivery-Number = {{196ZZ}},
Unique-ID = {{ISI:000248523700022}},
}

@article{ ISI:000248523700048,
Author = {Diacon, A. H. and Patientia, R. F. and Venter, A. and van Helden, P. D.
   and Smith, P. J. and McIlleron, H. and Maritz, J. S. and Donald, P. R.},
Title = {{Early bactericidal activity of high-dose rifampin in patients with
   pulmonary tuberculosis evidenced by positive sputum smears}},
Journal = {{ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}},
Year = {{2007}},
Volume = {{51}},
Number = {{8}},
Pages = {{2994-2996}},
Month = {{AUG}},
Abstract = {{We studied the early bactericidal activity of twice the standard dose of
   rifampin in subjects with pulmonary tuberculosis evidenced by positive
   smears. The observed mean 2-day activity was almost double that reported
   at the standard dose. Further studies are warranted to establish whether
   higher rifampin doses might assist in shortening tuberculosis treatment.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Diacon, AH (Reprint Author), Univ Stellenbosch, Fac Hlth Sci, Dept Internal Med, POB 19063, ZA-7505 Tygerberg, South Africa.
   Univ Stellenbosch, Fac Hlth Sci, Dept Internal Med, ZA-7505 Tygerberg, South Africa.
   Univ Stellenbosch, Fac Hlth Sci, Dept Mol Biol \& Human Genet, ZA-7505 Tygerberg, South Africa.
   Univ Stellenbosch, Fac Hlth Sci, MRC, Ctr Mol \& Cellular Biol,DST,NRF,Ctr Excellence Bi, ZA-7505 Tygerberg, South Africa.
   Univ Stellenbosch, Fac Hlth Sci, Dept Paediat \& Child Hlth, ZA-7505 Tygerberg, South Africa.
   Univ Cape Town, Div Clin Pharmacol, ZA-7700 Rondebosch, South Africa.
   S African Med Council, Biostat Unit, Cape Town, South Africa.
   Karl Bremer Hosp, Tiervlei Trial Ctr, Bellville, South Africa.}},
DOI = {{10.1128/AAC.01474-06}},
ISSN = {{0066-4804}},
Keywords-Plus = {{VIABLE COUNTS; RIFABUTIN; DRUGS}},
Research-Areas = {{Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Microbiology; Pharmacology \& Pharmacy}},
Author-Email = {{ahd@sun.ac.za}},
ORCID-Numbers = {{McIlleron, Helen/0000-0002-0982-6226}},
Cited-References = {{Acocella G., 1983, REV INFECT DIS S, V5, pS428.
   BERTRAND A, 1994, PRESSE MED, V23, P1128.
   CHAN SL, 1992, TUBERCLE LUNG DIS, V73, P33, DOI 10.1016/0962-8479(92)90077-W.
   Grosset J., 1983, REV INFECT DIS S, V5, P440.
   JEANES CWL, 1972, CAN MED ASSOC J, V106, P884.
   JINDANI A, 1980, AM REV RESPIR DIS, V121, P939.
   KREIS B, 1976, Bulletin of the International Union Against Tuberculosis, V51, P71.
   LEES A W, 1970, British Journal of Diseases of the Chest, V64, P90, DOI 10.1016/S0007-0971(70)80034-1.
   Lesobre R, 1969, Rev Tuberc Pneumol (Paris), V33, P393.
   LONG MW, 1979, AM REV RESPIR DIS, V119, P879.
   Mitchison DA, 2000, INT J TUBERC LUNG D, V4, P796.
   Peloquin C, 2003, INT J TUBERC LUNG D, V7, P3.
   Peloquin CA, 2002, DRUGS, V62, P2169, DOI 10.2165/00003495-200262150-00001.
   Saukkonen JJ, 2006, AM J RESP CRIT CARE, V174, P935, DOI 10.1164/rccm.200510-1666ST.
   Sirgel FA, 2005, AM J RESP CRIT CARE, V172, P128, DOI 10.1164/rccm.200411-1557OC.
   SIRGEL FA, 1993, J ANTIMICROB CHEMOTH, V32, P867, DOI 10.1093/jac/32.6.867.
   Sirgel FA, 2000, J ANTIMICROB CHEMOTH, V45, P859, DOI 10.1093/jac/45.6.859.
   van Crevel R, 2002, INT J TUBERC LUNG D, V6, P497.
   VERBIST L, 1968, AM REV RESPIR DIS, V98, P923.
   Weiner M, 2005, CLIN INFECT DIS, V40, P1481, DOI 10.1086/429321.
   World Health Organization, 2003, TREATM TUB GUID NAT.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{101}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Antimicrob. Agents Chemother.}},
Doc-Delivery-Number = {{196ZZ}},
Unique-ID = {{ISI:000248523700048}},
}

@article{ ISI:000248214500011,
Author = {Owens, S. and Abdel-Rahman, I. E. and Balyejusa, S. and Musoke, P. and
   Cooke, R. P. D. and Parry, C. M. and Coulter, J. B. S.},
Title = {{Nasopharyngeal aspiration for diagnosis of pulmonary tuberculosis}},
Journal = {{ARCHIVES OF DISEASE IN CHILDHOOD}},
Year = {{2007}},
Volume = {{92}},
Number = {{8}},
Pages = {{693-696}},
Month = {{AUG}},
Abstract = {{Background: Confirmation of pulmonary tuberculosis (PTB) in young
   children is difficult as they seldom expectorate sputum.
   Aim: To compare sputa obtained by nasopharyngeal aspiration and by
   sputum induction for staining and culture of Mycobacterium tuberculosis.
   Patients and methods: Patients from Mulago Hospital, Kampala with
   symptoms suggestive of PTB were considered for inclusion in the study.
   Those with a positive tuberculin test and/ or a chest radiograph
   compatible with tuberculosis were recruited. Infection with human
   immunodeficiency virus (HIV) was confirmed by duplicate enzyme-labelled
   immunosorbent assay or in children,15 months by polymerase chain
   reaction (PCR). Direct PCR was undertaken on 82 nasopharyngeal
   aspirates.
   Results: Of 438 patients referred, 94 were recruited over a period of 5
   months. Median (range) age was 48 (4-144) months. Of 63 patients tested,
   69.8\% were infected with HIV. Paired and uncontaminated culture results
   were available for 88 patients and smear results for 94 patients.
   Nasopharyngeal aspirates were smear-positive in 8.5\% and
   culture-positive in 23.9\%. Induced sputa were smear-positive in 9.6\%
   and culture positive in 21.6\%. Overall, 10.6\% were smear-positive,
   25.5\% were culture-positive and 26.6\% had smear and/or culture
   confirmed tuberculosis. Direct PCR on nasopharyngeal aspirates had a
   sensitivity of 62\% and specificity of 98\% for confirmation of
   culture-positive tuberculosis.
   Conclusions: Nasopharyngeal aspiration is a useful, safe and
   low-technology method for confirmation of PTB and, like sputum
   induction, can be undertaken in outpatient clinics.}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Coulter, JBS (Reprint Author), Univ Liverpool Liverpool Sch Trop Med, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.
   Univ Liverpool Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   Makerere Univ, Dept Paediat \& Child Hlth, Kampala, Uganda.
   Univ Liverpool, Dept Med Microbiol, Liverpool L69 3BX, Merseyside, England.}},
DOI = {{10.1136/adc.2007.108308}},
ISSN = {{0003-9888}},
Keywords-Plus = {{CHILDHOOD TUBERCULOSIS; SPUTUM INDUCTION; MYCOBACTERIUM-TUBERCULOSIS;
   CLINICAL-FEATURES; CHILDREN; INFANTS; MALAWI}},
Research-Areas = {{Pediatrics}},
Web-of-Science-Categories  = {{Pediatrics}},
Author-Email = {{coulters@fulwood11.wanadoo.co.uk}},
Cited-References = {{Franchi LM, 1998, LANCET, V352, P1681, DOI 10.1016/S0140-6736(05)61454-7.
   Garay JE, 1997, TROP DOCT, V27, P139.
   Graham SM, 2004, INT J TUBERC LUNG D, V8, P648.
   Iriso R, 2005, INT J TUBERC LUNG D, V9, P716.
   Kiwanuka J, 2001, ANN TROP PAEDIATR, V21, P5, DOI 10.1080/02724930020028849.
   LAVEN GT, 1977, AM REV RESPIR DIS, V115, P743.
   Lloyd A V, 1968, East Afr Med J, V45, P140.
   MILLER RF, 1991, J INFECTION, V23, P5, DOI 10.1016/0163-4453(91)93953-A.
   Montenegro SH, 2003, CLIN INFECT DIS, V36, P16, DOI 10.1086/344900.
   NELSON M, 1990, LANCET, V335, P112, DOI 10.1016/0140-6736(90)90580-X.
   Pomputius WF, 1997, PEDIATR INFECT DIS J, V16, P222, DOI 10.1097/00006454-199702000-00011.
   SCHAAF HS, 1995, PEDIATR INFECT DIS J, V14, P189, DOI 10.1097/00006454-199503000-00004.
   Shata AMA, 1996, ARCH DIS CHILD, V74, P535.
   STARKE JR, 1989, PEDIATRICS, V84, P28.
   Thakur A, 1999, ANN TROP PAEDIATR, V19, P333, DOI 10.1080/02724939992167.
   VALLEJO JG, 1994, PEDIATRICS, V94, P1.
   Weismuller MM, 2002, INT J TUBERC LUNG D, V6, P432.
   Zar HJ, 2005, LANCET, V365, P130, DOI 10.1016/S0140-6736(05)17702-2.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{33}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Arch. Dis. Child.}},
Doc-Delivery-Number = {{192PO}},
Unique-ID = {{ISI:000248214500011}},
}

@article{ ISI:000248214500021,
Author = {Walls, Tony and Shingadia, Delane},
Title = {{The epidemiology of tuberculosis in Europe}},
Journal = {{ARCHIVES OF DISEASE IN CHILDHOOD}},
Year = {{2007}},
Volume = {{92}},
Number = {{8}},
Pages = {{726-729}},
Month = {{AUG}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Shingadia, D (Reprint Author), Great Ormond St Hosp Sick Children, Great Ormond St, London WC1N 3JH, England.}},
DOI = {{10.1136/adc.2006.102889}},
ISSN = {{0003-9888}},
Keywords-Plus = {{RESISTANT TUBERCULOSIS; MOLECULAR EPIDEMIOLOGY; CHILDHOOD TUBERCULOSIS;
   RESURGENCE; CHILDREN; LONDON; IMPACT}},
Research-Areas = {{Pediatrics}},
Web-of-Science-Categories  = {{Pediatrics}},
Author-Email = {{shingd@gosh.nhs.uk}},
Cited-References = {{Antoine D, 2006, Euro Surveill, V11, P25.
   Atkinson P, 2002, ARCH DIS CHILD, V86, P264, DOI 10.1136/adc.86.4.264.
   Balasegaram S, 2003, ARCH DIS CHILD, V88, P772, DOI 10.1136/adc.88.9.772.
   Cantwell MF, 1997, INT J TUBERC LUNG D, V1, P205.
   Chemtob D, 2006, ISRAEL MED ASSOC J, V8, P21.
   Dahle UR, 2001, J CLIN MICROBIOL, V39, P1802, DOI 10.1128/JCM.39.5.1802-1807.2001.
   Djuretic T, 2002, THORAX, V57, P477, DOI 10.1136/thorax.57.6.477.
   Eriksson M, 1997, SCAND J INFECT DIS, V29, P569, DOI 10.3109/00365549709035896.
   EuroTB WHO Collaborating Centre for the Surveillance of Tuberculosis in Europe \& Royal Netherlands Tuberculosis Association (KNCV), SURV TUB EUR REP TUB.
   FALZON D, 2004, EUROSURVEILLANCE WEE, P8.
   Gilad J, 2000, CHEST, V117, P738, DOI 10.1378/chest.117.3.738.
   Hershfield E., 1991, B INT UNION TUBERC L, V66, P61.
   {*}HLTH PROT AUTH, CAS TUB RIS STEEPL D.
   Maguire H, 2002, THORAX, V57, P617, DOI 10.1136/thorax.57.7.617.
   Miller F., 1963, TUBERCULOSIS CHILDRE.
   Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6.
   Raviglione MC, 2006, LANCET, V367, P952, DOI 10.1016/S0140-6736(06)68392-X.
   Rosenfeldt V, 1998, SCAND J INFECT DIS, V30, P53.
   Schaaf HS, 2000, INT J TUBERC LUNG D, V4, P1149.
   Shilova MV, 2001, PHILOS T ROY SOC B, V356, P1069.
   TEO S, 2005, BPSU ANN REPORT 2004, P39.
   Thomas P, 2000, PEDIATR INFECT DIS J, V19, P700.
   TIEXEIRA L, 2001, INT J TUBERC LUNG D, V5, P321.
   WALLS T, 2004, CURR PAEDIAT, V14, P258, DOI 10.1016/j.cupe.2004.02.009.
   World Health Organization, 2007, GLOB TUB CONTR SURV.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{36}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Arch. Dis. Child.}},
Doc-Delivery-Number = {{192PO}},
Unique-ID = {{ISI:000248214500021}},
}

@article{ ISI:000248629900011,
Author = {Bigbee, Carolyn L. and Gonchoroff, Daryl G. and Vratsanos, George and
   Nadler, Steven G. and Haggerty, Helen G. and Flynn, JoAnne L.},
Title = {{Abatacept treatment does not exacerbate chronic Mycobacterium
   tuberculosis infection in mice}},
Journal = {{ARTHRITIS AND RHEUMATISM}},
Year = {{2007}},
Volume = {{56}},
Number = {{8}},
Pages = {{2557-2565}},
Month = {{AUG}},
Abstract = {{Objective. Treatment of rheumatoid arthritis and other autoimmune
   disorders with anti-tumor necrosis factor (anti-TNF) agents is
   associated with an increased risk of reactivation of latent
   Mycobacterium tuberculosis. While the mechanism of action of abatacept
   is fundamentally different from that of anti-TNF therapies, its effect
   on the protective response to latent tuberculosis is not known. We
   undertook this study to determine the effect of abatacept treatment in a
   murine model of chronic M tuberculosis infection.
   Methods. Chronic M tuberculosis infection was established in C57BL/6
   mice. Four months- after infection, mice were treated for up to 16 weeks
   with abatacept, anti-murine TNF antibody, or vehicle. The primary end
   point was survival; body weight, bacterial load, histologic features,
   interferon-gamma (IFN gamma) production by T cells, and cellular
   infiltration were also assessed.
   Results. Abatacept- and vehicle-treated groups both maintained control
   of M tuberculosis infection, with 100\% survival after 16 weeks of
   treatment. These 2 groups had no significant differences in body weight,
   no clinically relevant differences in bacterial load in the lungs, lymph
   nodes, or spleen, and no differences in the mean percentage of total or
   activated T cells, macro- phages, neutrophils, or B cells, or in IFN
   gamma production in the lung or lymph nodes. In contrast, 100\%
   mortality was seen in the anti-TNF antibody-treated group by week 9,
   with significant body weight loss and increased bacterial load in the
   lungs, lymph nodes, and spleen. Furthermore, the anti-TNF
   antibody-treated group had increased pathology consistent with the
   exacerbation of M tuberculosis infection.
   Conclusion. Abatacept did not impair the ability of mice to control a
   chronic M tuberculosis infection. In contrast, mice treated with
   anti-TNF therapy showed increased pathology and bacterial load, with
   100\% mortality by week 9. The clinical significance of these findings
   has not yet been determined.}},
Publisher = {{WILEY-LISS}},
Address = {{DIV JOHN WILEY \& SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Flynn, JL (Reprint Author), Univ Pittsburgh, Sch Med, W1157 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Sch Med, Pittsburgh, PA 15261 USA.
   Bristol Myers Squibb Co, Syracuse, NY USA.
   Bristol Myers Squibb Co, Princeton, NJ USA.}},
DOI = {{10.1002/art.22750}},
ISSN = {{0004-3591}},
Keywords-Plus = {{TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; RHEUMATOID-ARTHRITIS;
   INTERFERON-GAMMA; TYPE-1 CYTOKINES; IMMUNE-RESPONSE; T-CELLS; CTLA4IG;
   MACROPHAGES; ANTAGONISTS}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Author-Email = {{joanne@pitt.edu}},
Cited-References = {{Algood HMS, 2004, J IMMUNOL, V172, P6846.
   Bean AGD, 1999, J IMMUNOL, V162, P3504.
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243.
   Criscione LG, 2002, CURR OPIN RHEUMATOL, V14, P204, DOI 10.1097/00002281-200205000-00002.
   DENIS M, 1991, J LEUKOCYTE BIOL, V49, P380.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   Ehlers S., 2005, CLIN INFECT DIS, V41, P199.
   Ehlers Stefan, 2005, J Rheumatol Suppl, V74, P35.
   FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604.
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249.
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93.
   FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2.
   Gardam MA, 2003, LANCET INFECT DIS, V3, P148, DOI 10.1016/S1473-3099(03)00545-0.
   Genovese MC, 2005, NEW ENGL J MED, V353, P1114, DOI 10.1056/NEJMoa050524.
   Gomez-Reino JJ, 2003, ARTHRITIS RHEUM, V48, P2122, DOI 10.1002/art.11137.
   Harris JR, 2000, EUR UROL, V37, P24, DOI 10.1159/000052389.
   HAVELL EA, 1989, J IMMUNOL, V143, P2894.
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110.
   Kremer JM, 2005, ARTHRITIS RHEUM, V52, P2263, DOI 10.1002/art.21201.
   Lazarevic V, 2003, IMMUNITY, V19, P823, DOI 10.1016/S1074-7613(03)00324-8.
   LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143.
   LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561.
   LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399.
   Mohan AK, 2004, CLIN INFECT DIS, V39, P295, DOI 10.1086/421494.
   Mohan VP, 2001, INFECT IMMUN, V69, P1847, DOI 10.1128/IAI.69.3.1847-1855.2001.
   ORME IM, 1993, J IMMUNOL, V151, P518.
   Ottenhoff THM, 1998, IMMUNOL TODAY, V19, P491, DOI 10.1016/S0167-5699(98)01321-8.
   PEARSON TC, 1994, TRANSPLANTATION, V57, P1701, DOI 10.1097/00007890-199457120-00002.
   Peggs KS, 2005, BRIT J HAEMATOL, V130, P809, DOI 10.1111/j.1365-2141.2005.05627.x.
   Saunders BM, 2000, IMMUNOL CELL BIOL, V78, P334, DOI 10.1046/j.1440-1711.2000.00933.x.
   Scott HM, 2002, INFECT IMMUN, V70, P5946, DOI 10.1128/IAI.70.11.5946-5954.2002.
   Serbina NV, 1999, INFECT IMMUN, V67, P3980.
   TEPPER MA, 1994, TRANSPLANT P, V26, P3151.
   WALLACE PM, 1994, TRANSPLANTATION, V58, P602, DOI 10.1097/00007890-199409150-00013.
   Wallis RS, 2004, CLIN INFECT DIS, V38, P1261, DOI 10.1086/383317.
   Weisman Michael H, 2002, J Rheumatol Suppl, V65, P33.
   Winthrop KL, 2005, ARTHRITIS RHEUM, V52, P2968, DOI 10.1002/art.21382.}},
Number-of-Cited-References = {{37}},
Times-Cited = {{32}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Arthritis Rheum.}},
Doc-Delivery-Number = {{198LP}},
Unique-ID = {{ISI:000248629900011}},
}

@article{ ISI:000249053300012,
Author = {Green, J. A. and Friedland, J. S.},
Title = {{Astrocyte-leucocyte interactions and the mechanisms regulating matrix
   degradation in CNS tuberculosis}},
Journal = {{BIOCHEMICAL SOCIETY TRANSACTIONS}},
Year = {{2007}},
Volume = {{35}},
Number = {{4}},
Pages = {{686-688}},
Month = {{AUG}},
Abstract = {{The CNS (central nervous system) has a unique pattern of immune response
   to infection. TB (tuberculosis) of the CNS is devastating with
   widespread tissue destruction. In TB, astrocyte-leucocyte interactions
   are key in regulating MMP (matrix metalloproteinase) activity and are
   regulated by complex signalling pathways. A synergistic interaction
   between interferon gamma and monocyte-derived mediators drives
   high-level astrocyte MMP-9 secretion; this and other networking effects
   are inhibited by steroids. Better understanding of regulatory mechanisms
   may identify potential switch points that could be future therapeutic
   targets.}},
Publisher = {{PORTLAND PRESS LTD}},
Address = {{THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Friedland, JS (Reprint Author), Univ London Imperial Coll Sci Technol \& Med, Dept Infect Dis \& Immun, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.
   Univ London Imperial Coll Sci Technol \& Med, Dept Infect Dis \& Immun, London W12 0NN, England.}},
ISSN = {{0300-5127}},
Keywords = {{astrocyte; central nervous system; glial cell; metalloproteinase;
   monocyte; tuberculosis (TB)}},
Keywords-Plus = {{NERVOUS-SYSTEM TUBERCULOSIS; IN-VITRO; MMP-9 SECRETION; HOST-DEFENSE;
   METALLOPROTEINASES; MENINGITIS; EXPRESSION; CHEMOKINE; NETWORKS;
   MULTIPLE}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{j.friedland@imperial.ac.uk}},
Funding-Acknowledgement = {{Medical Research Council {[}G0500385]}},
Cited-References = {{Bottcher T, 2003, NEUROSCI LETT, V338, P201, DOI 10.1016/S0304-3940(02)01406-4.
   Elkington PTG, 2005, J IMMUNOL, V175, P5333.
   Gjertsson I, 2005, MICROB PATHOGENESIS, V38, P97, DOI 10.1016/j.micpath.2004.12.005.
   Greenlee KJ, 2007, PHYSIOL REV, V87, P69, DOI 10.1152/physrev.00022.2006.
   Harris JE, 2007, FASEB J, V21, P356, DOI 10.1096/fj.06-6925com.
   Harris JE, 2007, J LEUKOCYTE BIOL, V81, P548, DOI 10.1189/jlb.0806512.
   Harris JE, 2007, J IMMUNOL, V178, P1199.
   Leib SL, 2000, INFECT IMMUN, V68, P615, DOI 10.1128/IAI.68.2.615-620.2000.
   Okada S, 1997, AM J RESP CELL MOL, V17, P519.
   Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418.
   Price NM, 2003, J IMMUNOL, V171, P5579.
   Price NM, 2001, J IMMUNOL, V166, P4223.
   Rosenberg GA, 2005, LANCET, V365, P1291, DOI 10.1016/S0140-6736(05)61008-2.
   Thwaites GE, 2004, NEW ENGL J MED, V351, P1741, DOI 10.1056/NEJMoa040573.
   Thwaites GE, 2003, J INFECT DIS, V188, P1105, DOI 10.1086/378642.
   Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113.
   Yushchenko M, 2000, J NEUROIMMUNOL, V110, P244, DOI 10.1016/S0165-5728(00)00339-8.
   Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127.
   Zozulya AL, 2007, J IMMUNOL, V178, P520.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Biochem. Soc. Trans.}},
Doc-Delivery-Number = {{204OG}},
Unique-ID = {{ISI:000249053300012}},
}

@article{ ISI:000248710100007,
Author = {Kemp, Julia R. and Mann, Gillian and Simwaka, Bertha Nhlema and
   Salaniponi, Felix M. L. and Squire, Stephen Bertel},
Title = {{Can Malawi's poor afford free tuberculosis services? Patient and
   household costs associated with a tuberculosis diagnosis in Lilongwe}},
Journal = {{BULLETIN OF THE WORLD HEALTH ORGANIZATION}},
Year = {{2007}},
Volume = {{85}},
Number = {{8}},
Pages = {{580-585}},
Month = {{AUG}},
Abstract = {{Objective To assess the relative costs of accessing a TB diagnosis for
   the poor and for women in urban Lilongwe, Malawi, a setting where public
   health services are accessible within 6 kilometres and provided free of
   charge.
   Methods Patient and household direct and opportunity costs were assessed
   from a survey of 179 TB patients, systematically sampled from all public
   and mission health facilities in Lilongwe. Poverty status was determined
   from the 1998 Malawi Integrated Household Survey (MIHS).
   Findings On average, patients spent US\$ 13 (MK 996 or 18 days' income)
   and lost 22 days from work while accessing a TB diagnosis. For non-poor
   patients, the total costs amounted to 129\% of total monthly income, or
   184\% after food expenditures. For the poor, this cost rose to 248\% of
   monthly income or 574\% after food. When a woman or when the poor are
   sick, the opportunity costs faced by their households are greater.
   Conclusion Patient and household costs of TB diagnosis are prohibitively
   high even where services are provided free of charge. In scaling up TB
   services to reach the Millennium Development Goals, there is an urgent
   need to identify strategies for diagnosing TB that are cost-effective
   for the poor and their households.}},
Publisher = {{WORLD HEALTH ORGANIZATION}},
Address = {{MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England.}},
DOI = {{10.2471/BLT.06.033167}},
ISSN = {{0042-9686}},
Keywords-Plus = {{CARE FACILITY INVOLVEMENT; PULMONARY TUBERCULOSIS; INCREASED COMMUNITY;
   ECONOMIC-IMPACT; RURAL UGANDA; HEALTH; ETHIOPIA; DISTRICT}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{jkemp@africa-onlin.net}},
Cited-References = {{BRAINE T, 2006, B WORLD HEALTH ORGAN, V84, P593.
   Cambanis A, 2006, INT J TUBERC LUNG D, V10, P230.
   Dye C, 2003, TUBERCULOSIS, V83, P35, DOI 10.1016/S1472-9792(02)00056-2.
   Floyd K, 2003, INT J TUBERC LUNG D, V7, pS29.
   FLOYD K, 1997, BRIT MED J, V315, P1395.
   GIBSON N, 1998, INT J TUBERC LUNG, V2, P929.
   Gwatkin DR, 2005, LANCET, V365, P813.
   Gwatkin DR, 2003, LANCET, V361, P540, DOI 10.1016/S0140-6736(03)12558-5.
   Kamolratanakul P, 1999, INT J TUBERC LUNG D, V3, P596.
   Kemp J, 1996, T R SOC TROP MED HYG, V90, P472.
   Kemp J., 2001, INT J TUBERC LUNG D, V5, pS166.
   Moalosi G, 2003, INT J TUBERC LUNG D, V7, pS80.
   {*}NAT EC COUNC, 2000, POV PROF MAL.
   Needham DM, 1998, INT J TUBERC LUNG D, V2, P811.
   Nganda B, 2003, INT J TUBERC LUNG D, V7, pS14.
   NHLEMA BM, 2002, SYSTEMATIC ANAL TB P.
   Okello D, 2003, INT J TUBERC LUNG D, V7, pS72.
   Rajeswari R, 1999, INT J TUBERC LUNG D, V3, P869.
   Rieder HL, 1999, EPIDEMIOLOGICAL BASI.
   SAUNDERSON PR, 1995, SOC SCI MED, V40, P1203, DOI 10.1016/0277-9536(94)00240-T.
   Simwaka BN, 2007, INT J TUBERC LUNG D, V11, P65.
   Sinanovic E, 2003, INT J TUBERC LUNG D, V7, P556.
   Squire SB, 2005, INT J TUBERC LUNG D, V9, P25.
   SQUIRE SB, 2001, INT J TUBERC LUNG D, V5, pS172.
   STOP TB, 2003, BACKGROUND DOCUMENT.
   Wandwalo Eliud, 2005, Cost Eff Resour Alloc, V3, P6, DOI 10.1186/1478-7547-3-6.
   Wilkinson D, 1997, S AFR MED J, V87, P451.
   WILLETTS A, 2003, INT J TUBERC LUNG S2, V7, pS294.
   Wyss K, 2001, TROP MED INT HEALTH, V6, P60, DOI 10.1046/j.1365-3156.2001.00677.x.
   Yassin MA, 2003, INT J TUBERC LUNG D, V7, P678.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{64}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Bull. World Health Organ.}},
Doc-Delivery-Number = {{199QK}},
Unique-ID = {{ISI:000248710100007}},
}

@article{ ISI:000248710100009,
Author = {Sebhatu, Mineab and Om, Bahlbi and Seyoum, Melles and Kassim, Nuredin
   and Negash, Tesfazion and Tesfazion, Andeberhan and Borgdorff, Martien
   W. and van der Werf, Marieke J.},
Title = {{Determining the burden of tuberculosis in Eritrea: a new approach}},
Journal = {{BULLETIN OF THE WORLD HEALTH ORGANIZATION}},
Year = {{2007}},
Volume = {{85}},
Number = {{8}},
Pages = {{593-599}},
Month = {{AUG}},
Abstract = {{Objective To obtain an estimate of the prevalence of new cases of
   smear-positive tuberculosis in Eritrea using a new low-cost approach.
   Methods The study was designed to include a sample of 35 000 people
   divided between 40 clusters.The clusters were selected by sampling
   proportional to population size. In each cluster, census data were
   obtained from eligible individuals. Individuals aged 15 years or more
   were questioned about cough and its duration and smoking and were asked
   to provide two samples of sputum (spot and morning) for examination by
   fluorescence microscopy.
   Findings A total of 38 032 individuals were included in the study. Of
   the 19 197 individuals aged 15 years or more, 18 152 (94.6\%) provided
   at least one sample of sputum. Fifteen individuals fulfilled the case
   definition, providing a prevalence of new cases of smear-positive
   tuberculosis of 90 per 100 000 (95\% confidence interval, Cl, 35-145 per
   100 000) individuals aged 15 years or more and 50 per 100 000 (95\% Cl,
   19-80 per 100 000) in the total population.
   Conclusion The estimated prevalence of new cases of smear-positive
   tuberculosis obtained from our study is considefably lower than the
   estimate published by the World Health Organization. The new methodology
   for surveys to determine the prevalence of tuberculosis that we used is
   feasible in the field. This methodology should be validated in other
   countries and compared with other}},
Publisher = {{WORLD HEALTH ORGANIZATION}},
Address = {{MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{van der Werf, MJ (Reprint Author), KNCV TB Fdn, The Hague, Netherlands.
   KNCV TB Fdn, The Hague, Netherlands.
   Natl HIV AIDS \& TB Control Div, Minist Hlth, Asmera, Eritrea.
   Natl Hlth Lab, Minist Hlth, Asmera, Eritrea.
   Univ Amsterdam, CINIMA, Amsterdam, Netherlands.}},
DOI = {{10.2471/BLT.06.038604}},
ISSN = {{0042-9686}},
Keywords-Plus = {{SPUTUM SMEAR MICROSCOPY; PULMONARY TUBERCULOSIS; PREVALENCE SURVEY;
   FLUORESCENCE MICROSCOPY; SOUTH-INDIA; X-RAY; DIAGNOSIS; COMMUNITY; YIELD}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{vanderwerfm@kncvtbc.n1}},
Cited-References = {{BENNETT S, 1991, World Health Statistics Quarterly, V44, P98.
   Datta M, 2000, INDIAN J TUBERC, V47, P147.
   den Boon S, 2006, INT J TUBERC LUNG D, V10, P876.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   FOURIE PB, 1981, S AFR MED J, V60, P64.
   GATNER EMS, 1980, TUBERCLE, V61, P27, DOI 10.1016/0041-3879(80)90056-2.
   GITHUI W, 1993, E AFR MED J, V70, P263.
   Gopi PG, 2006, INT J TUBERC LUNG D, V10, P343.
   Gopi PG, 2004, INT J TUBERC LUNG D, V8, P824.
   Gopi PG, 2003, INT J TUBERC LUNG D, V7, P1154.
   GOTHI GD, 1976, INDIAN J MED RES, V64, P1150.
   Hong YP, 1998, INT J TUBERC LUNG D, V2, P27.
   Ipuge YAI, 1996, T ROY SOC TROP MED H, V90, P258, DOI 10.1016/S0035-9203(96)90239-4.
   Kivihya-Ndugga LEA, 2003, INT J TUBERC LUNG D, V7, P1163.
   Lemeshow S, 1985, World Health Stat Q, V38, P65.
   Steingart K, 2006, LANCET INFECT DIS, V6, P570, DOI 10.1016/S1473-3099(06)70578-3.
   ROELSGAARD E., 1964, BULL WORLD HEALTH ORGAN, V30, P459.
   Tupasi TE, 1999, INT J TUBERC LUNG D, V3, P471.
   United Nations, MILL DEV GOALS IND.
   United Nations Population Division, 2005, WORLD POP PROSP 2004.
   {*}US CENS BUR, 2006, IDB POP PYR DAT INT.
   Van Deun A, 2002, INT J TUBERC LUNG D, V6, P222.
   VANDERWERF MJ, IN PRESS TROP MED IN.
   Walker D, 2000, INT J TUBERC LUNG D, V4, P246.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.
   Wu ZL, 2000, INT J TUBERC LUNG D, V4, P1086.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{14}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Bull. World Health Organ.}},
Doc-Delivery-Number = {{199QK}},
Unique-ID = {{ISI:000248710100009}},
}

@article{ ISI:000248710100014,
Author = {Hill, Peter S. and Eang, Mao Tan},
Title = {{Resistance and renewal: health sector reform and Cambodia's national
   tuberculosis programme}},
Journal = {{BULLETIN OF THE WORLD HEALTH ORGANIZATION}},
Year = {{2007}},
Volume = {{85}},
Number = {{8}},
Pages = {{631-636}},
Month = {{AUG}},
Abstract = {{Following the destruction of Cambodia's, health infrastructure during
   the Khmer Rouge period (1975-1979) and the subsequent decade of United
   Nations sanctions, international development assistance has focused on
   reconstructing the country's health system. The recognition of
   Cambodia's heavy burden of tuberculosis (TB) and the lapse of TB control
   strategies during the transition to democracy prompted the national
   tuberculosis programme's relaunch in the mid-1990s as WHO-backed health
   sector reforms were introduced. This paper examines the conflicts that
   arose between health reforms and T13 control programmes due to their
   different operating paradigms. It also discusses how these tensions were
   resolved during introduction of the DOTS strategy for TB treatment.}},
Publisher = {{WORLD HEALTH ORGANIZATION}},
Address = {{MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hill, PS (Reprint Author), Univ Queensland, Sch Populat Hlth, Herston Rd, Herston, Qld 4029, Australia.
   Univ Queensland, Sch Populat Hlth, Herston, Qld 4029, Australia.
   Natl Ctr TB \& Leprosy Control, CENAT, Phnom Penh, Cambodia.}},
DOI = {{10.2471/BLT.06.036822}},
ISSN = {{0042-9686}},
Keywords-Plus = {{COUNTRIES; SERVICES}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{peter.hill@sph.uq.edu.au}},
ResearcherID-Numbers = {{Hill, Peter/F-2768-2010}},
ORCID-Numbers = {{Hill, Peter/0000-0001-7091-5108}},
Cited-References = {{APTED M, 2000, INT S TB HIV CAMBODI, P15.
   BENSON C, 1993, CHANGING ROLE NGOS P, V2, P70.
   Bosman MCJ, 2000, INT J TUBERC LUNG D, V4, P606.
   Desbarats Jacqueline, 1995, PROLIFIC SURVIVORS P.
   {*}GLOB FUND FIGHT A, 2007, CAMB GLOB FUND GRANT.
   GODGREY M, 2000, TECHNICAL ASSISTANCE, P16.
   Hanson C, 2000, INT J TUBERC LUNG D, V4, P627.
   HENG MB, 1995, BRIT MED J, V311, P435.
   Jeppsson A, 2002, SOC SCI MED, V55, P2053, DOI 10.1016/S0277-9536(01)00345-8.
   {*}JOINT HLTH SECT R, 2001, JOINT HLTH SECT REV, P8.
   Lanjouw S, 1999, HEALTH POLICY PLANN, V14, P229, DOI 10.1093/heapol/14.3.229.
   {*}MIN HLTH, 1995, GUID STRENGTH DISTR.
   {*}MIN HLTH, 2002, REV HLTH COV PLAN IS.
   {*}MIN HLTH, 2000, EFF HLTH RED STRAT U.
   {*}MON SANT, 1994, PROGR NATL TUB, V8.
   {*}NAT CTR TUB LEPR, 2005, REP NATL TB PREV SUR, P40.
   {*}NAT CTR TUB LEPR, 2006, RUB REP 2005.
   {[}Anonymous], 2001, NAT EN POL, P11.
   Norval PY, 1998, INT J TUBERC LUNG D, V2, P44.
   Ruffino-Netto A, 2001, Rev Panam Salud Publica, V9, P306, DOI 10.1590/S1020-49892001000500004.
   UNGER JP, 1995, INT J HEALTH PLAN M, V10, P113, DOI 10.1002/hpm.4740100205.
   UNGER JP, 1992, B WORLD HEALTH ORGAN, V70, P487.
   Van Lerberghe W, 1990, ROLE HOSP DISTRICT D.
   VOLKMARANDRE J, 1986, YEARS HORROR DAYS HO, P273.
   {*}WHO, 2003, WHOCDSTB2003316, P66.
   Wilkinson D, 1999, INT J TUBERC LUNG D, V3, P938.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{14}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Bull. World Health Organ.}},
Doc-Delivery-Number = {{199QK}},
Unique-ID = {{ISI:000248710100014}},
}

@article{ ISI:000248710100015,
Author = {Coninx, Rudi},
Title = {{Tuberculosis in complex emergencies}},
Journal = {{BULLETIN OF THE WORLD HEALTH ORGANIZATION}},
Year = {{2007}},
Volume = {{85}},
Number = {{8}},
Pages = {{637-640}},
Month = {{AUG}},
Abstract = {{This paper describes the key factors and remaining challenges for
   tuberculosis (TB) control programmes in complex emergencies. A complex
   emergency is ``a humanitarian crisis in a country, region or society
   where there is total or considerable breakdown of authority resulting
   from internal or external conflict and which requires an international
   response that goes beyond the mandate or capacity of any single agency
   and/or the ongoing United Nations country programme.{''} Some 200
   million people are believed to live in countries affected by complex
   emergencies; almost all of these are developing countries that also bear
   the main burden of TB. The effects of complex emergencies impact on TB
   control programmes, interfering with the goals of identifying and curing
   TB patients and possibly leading to the emergence of MDR-TB. There are
   many detailed descriptions of aid interventions during complex
   emergencies; yet TB control programmes are absent from most of these
   reports. If TB is neglected, it may quickly result in increased
   morbidity and mortality, as was demonstrated in Bosnia and Herzegovina
   and in Somalia. TB is a major disease in complex emergencies and
   requires an appropriate public health response. While there is no manual
   to cover complex emergencies, the interagency manual for TB control in
   refugee and displaced populations provides valuable guidance. These
   programmes con-tribute to the body of evidence needed to compile such a
   manual, and should ensure that the experiences of TB control in complex
   emergencies lead to the establishment of evidence-based programmes.}},
Publisher = {{WORLD HEALTH ORGANIZATION}},
Address = {{MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Coninx, R (Reprint Author), Int Comm Red Cross, 29 Layards Rd, Colombo 05, Sri Lanka.
   Int Comm Red Cross, Colombo 05, Sri Lanka.}},
DOI = {{10.2471/BLT.06.037630}},
ISSN = {{0042-9686}},
Keywords-Plus = {{REFUGEE CAMP; MORTALITY; WAR; EPIDEMIOLOGY; PREVENTION; MANAGEMENT;
   CONFLICT; VIOLENCE; BORDER; IMPACT}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{rudiconinx@hotmail.com}},
Cited-References = {{Accorsi S, 2005, T ROY SOC TROP MED H, V99, P226, DOI 10.1016/j.trstmh.2004.09.008.
   Agutu WO, 1997, E AFR MED J, V74, P348.
   Biot M, 2003, TROP MED INT HEALTH, V8, P211, DOI 10.1046/j.1365-3156.2003.01025.x.
   Burkle FM, 1999, BRIT MED J, V319, P422.
   Coghlan B, 2006, LANCET, V367, P44, DOI 10.1016/S0140-6736(06)67923-3.
   Connolly MA, 2004, LANCET, V364, P1974, DOI 10.1016/S0140-6736(04)17481-3.
   CONNOLLY MA, 2006, WHOTB97221.
   Connolly MA, 2005, COMMUNICABLE DIS CON.
   Depoortere E, 2004, LANCET, V364, P1315, DOI 10.1016/S0140-6736(04)17187-0.
   Doveren RFC, 2001, INT J TUBERC LUNG D, V5, P486.
   Hehenkamp A, 2003, LANCET, V362, pS30, DOI 10.1016/S0140-6736(03)15066-0.
   Keus K, 2003, T ROY SOC TROP MED H, V97, P614, DOI 10.1016/S0035-9203(03)80048-2.
   Martins N, 2006, INT J TUBERC LUNG D, V10, P975.
   Martins N, 2006, PLOS MED, V3, P1765, DOI 10.1371/journal.pmed.0030383.
   MASTRO TD, 1988, TUBERCLE, V69, P95, DOI 10.1016/0041-3879(88)90071-2.
   {*}MED SANS FRONT, 1997, REF HKTH APPR EM SIT.
   MILES SH, 1984, AM REV RESPIR DIS, V130, P827.
   MUNIM A, 2005, SUMMARISED PROGR REP.
   Reid A, 2006, LANCET INFECT DIS, V6, P483, DOI 10.1016/S1473-3099(06)70549-7.
   RIEDER HL, 1985, TUBERCLE, V66, P179, DOI 10.1016/0041-3879(85)90034-0.
   Rodger AJ, 2002, B WORLD HEALTH ORGAN, V80, P451.
   Salama P, 2004, LANCET, V364, P1801, DOI 10.1016/S0140-6736(04)17405-9.
   The Sphere Project, 2004, HUM CHART MIN STAND.
   Spiegel PB, 2000, LANCET, V355, P2204, DOI 10.1016/S0140-6736(00)02404-1.
   Stop TB Partnership and World Health Organization, 2006, WHOHTMSTB200635.
   SUDRE P, 1993, EMTUB180ER593.
   TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296.
   TOOLE MJ, 1993, LANCET, V341, P1193, DOI 10.1016/0140-6736(93)91013-C.
   TOOLE MJ, 1995, LANCET, V345, P339.
   Tuberculosis Coalition for Technical Assistance, 2006, INT STAND TUB CAR.
   {*}UN, 1999, OCHA OR HDB COMPL EM.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.
   ZWI A, 1989, SOC SCI MED, V28, P633, DOI 10.1016/0277-9536(89)90210-4.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{Bull. World Health Organ.}},
Doc-Delivery-Number = {{199QK}},
Unique-ID = {{ISI:000248710100015}},
}

@article{ ISI:000248710100019,
Author = {Brands, Annemieke and Ottmani, Salah-Eddine and Loennroth, Knut and
   Blanc, Leopold J. and Rahman, Khalilur and Bettchera, Douglas W. and
   Raviglione, Mario},
Title = {{Reply to `Addressing smoking cessation in tuberculosis control'}},
Journal = {{BULLETIN OF THE WORLD HEALTH ORGANIZATION}},
Year = {{2007}},
Volume = {{85}},
Number = {{8}},
Pages = {{647-648}},
Month = {{AUG}},
Publisher = {{WORLD HEALTH ORGANIZATION}},
Address = {{MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Brands, A (Reprint Author), WHO, 11 Ave Appia, Geneva, Switzerland.
   WHO, Geneva, Switzerland.}},
ISSN = {{0042-9686}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{brandsa@who.int}},
ResearcherID-Numbers = {{Lonnroth, Knut/L-2339-2014}},
ORCID-Numbers = {{Lonnroth, Knut/0000-0001-5054-8240}},
Cited-References = {{Esson KM, 2004, MILLENNIUM DEV GOALS.
   Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442.
   WARREN CW, 2006, LANCET.
   World Health Organization, 2003, WHO FRAM CONV TOB CO.}},
Number-of-Cited-References = {{4}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Bull. World Health Organ.}},
Doc-Delivery-Number = {{199QK}},
Unique-ID = {{ISI:000248710100019}},
}

@article{ ISI:000248534700019,
Author = {Gagliardi, Maria Cristina and Lemassu, Anne and Teloni, Raffaela and
   Mariotti, Sabrina and Sargentini, Valeria and Pardini, Manuela and
   Daffe, Mamadou and Nisini, Roberto},
Title = {{Cell wall-associated alpha-glucan is instrumental for Mycobacterium
   tuberculosis to block CD1 molecule expression and disable the function
   of dendritic cell derived from infected monocyte}},
Journal = {{CELLULAR MICROBIOLOGY}},
Year = {{2007}},
Volume = {{9}},
Number = {{8}},
Pages = {{2081-2092}},
Month = {{AUG}},
Abstract = {{We previously described an escape mechanism exploited by Mycobacterium
   tuberculosis (Mtb) to prevent the generation of fully competent
   dendritic cells (DC). We have now tested the effect of isolated
   mycobacterial components on human monocyte differentiation into DC and
   demonstrated that cell wall (CW)-associated alpha-glucan induces
   monocytes to differentiate into DC (Glu-MoDC) with the same altered
   phenotype and functional behaviour of DC derived from Mtb-infected
   monocytes (Mt-MoDC). In fact, Glu-MoDC lack CD1 molecule expression,
   fail to upregulate CD80 and produce IL-10 but not IL-12. We also showed
   that Glu-MoDC are not able to prime effector T cells or present lipid
   antigens to CD1-restricted T-cell clones. Thus, we propose a mechanism
   of Mtb-monocyte interaction mediated by CW-associated alpha-glucan,
   which allows the bacterium to evade both innate and acquired immune
   responses.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Nisini, R (Reprint Author), Ist Super Sanita, Dipartimento Malattie Infett Parassitarie \& Immun, Viale Regina Elena 299, I-00161 Rome, Italy.
   Ist Super Sanita, Dipartimento Malattie Infett Parassitarie \& Immun, I-00161 Rome, Italy.
   CNRS, UMR 5089, Inst Pharmacol \& Biol Struct, Dept Mecan Mol Infect Mycobacteriennes, F-31077 Toulouse 04, France.
   Univ Toulouse 3, F-31077 Toulouse 04, France.}},
DOI = {{10.1111/j.1462-5822.2007.00940.x}},
ISSN = {{1462-5814}},
Keywords-Plus = {{BACILLUS-CALMETTE-GUERIN; COLONY-STIMULATING FACTOR; CD1-RESTRICTED
   T-CELLS; DC-SIGN; ACTIVE TUBERCULOSIS; IMMUNE-RESPONSES; PRESENTING
   CELLS; LIPID ANTIGENS; DIFFERENTIATION; CONTRIBUTE}},
Research-Areas = {{Cell Biology; Microbiology}},
Web-of-Science-Categories  = {{Cell Biology; Microbiology}},
Author-Email = {{roberto.nisini@iss.it}},
ResearcherID-Numbers = {{PARDINI, MANUELA/M-4365-2015
   MARIOTTI, SABRINA/M-4361-2015
   Nisini, Roberto/M-4363-2015
   }},
ORCID-Numbers = {{Nisini, Roberto/0000-0003-1077-423X
   Pardini, Manuela/0000-0002-3625-1309}},
Cited-References = {{BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333.
   Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131.
   De Libero G, 2005, NAT REV IMMUNOL, V5, P485, DOI 10.1038/nri1631.
   De Libero G, 2005, IMMUNITY, V22, P763, DOI 10.1016/j.immuni.2005.04.013.
   Dinadayala P, 2004, J BIOL CHEM, V279, P12369, DOI 10.1074/jbc.M308908200.
   Draper P., 1998, FRONT BIOSCI, V15, P1253.
   Flynn JL, 2003, CURR OPIN IMMUNOL, V15, P450, DOI 10.1016/S0952-7915(03)00075-X.
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93.
   Gagliardi MC, 2004, VACCINE, V22, P3848, DOI 10.1016/j.vaccine.2004.07.009.
   Gagliardi MC, 2005, J LEUKOCYTE BIOL, V78, P106, DOI 10.1189/jlb.0105037.
   Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229.
   Giacomini E, 2001, J IMMUNOL, V166, P7033.
   Gilleron M, 2004, J EXP MED, V199, P649, DOI 10.1084/jem.20031097.
   Goletti D, 2005, CLIN DIAGN LAB IMMUN, V12, P1311, DOI 10.1128/CDLI.12.11.1311-1316.2005.
   Goletti D, 2006, CLIN MICROBIOL INFEC, V12, P544, DOI 10.1111/j.1469-0691.2006.01391.x.
   Kaufmann SHE, 2003, J EXP MED, V197, P1, DOI 10.1084/jem.20021964.
   Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558.
   Kawashima T, 2003, J IMMUNOL, V170, P5345.
   Krutzik SR, 2003, NAT MED, V9, P525, DOI 10.1038/nm864.
   Lang ML, 2006, INFECT IMMUN, V74, P803, DOI 10.1128/IAI.74.2.803-809.2006.
   Leimane V, 2005, LANCET, V365, P318.
   Lemassu A, 1996, MICROBIOL-UK, V142, P1513.
   LEMASSU A, 1994, BIOCHEM J, V297, P351.
   Mariotti S, 2004, INFECT IMMUN, V72, P4385, DOI 10.1128/IAI.72.8.4385-4392.2004.
   Mariotti S, 2002, EUR J IMMUNOL, V32, P3050, DOI 10.1002/1521-4141(200211)32:11<3050::AID-IMMU3050>3.0.CO;2-K.
   Meyer BC, 2003, NEW ENGL J MED, V348, P1293.
   Moody DB, 2006, NAT IMMUNOL, V7, P811, DOI 10.1038/ni1368.
   Murray RA, 2007, J IMMUNOL, V178, P338.
   Nisini R, 1996, EUR J IMMUNOL, V26, P797, DOI 10.1002/eji.1830260411.
   Nisini R, 2001, INFECT IMMUN, V69, P3728, DOI 10.1128/IAI.69.6.3728-3736.2001.
   Onyebujoh P, 2004, NAT REV MICROBIOL, V2, P930, DOI 10.1038/nrmicro1050.
   ORTALOMAGNE A, 1995, MICROBIOL-UK, V141, P1609.
   Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746.
   Pathan AA, 2001, J IMMUNOL, V167, P5217.
   Prete SP, 2001, J CHEMOTHERAPY, V13, P52.
   Ravn P, 2004, SCAND J INFECT DIS, V36, P499, DOI 10.1080/00365540410015222.
   Rook GAW, 2005, NAT REV IMMUNOL, V5, P661, DOI 10.1038/nri1666.
   Roura-Mir C, 2005, J IMMUNOL, V175, P1758.
   SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109.
   Shamshiev A, 2002, J EXP MED, V195, P1013, DOI 10.1084/jem.20011963.
   Shen Y, 2004, J VIROL, V78, P14023, DOI 10.1128/JVI.78.24.14023-14032.2004.
   Sprent J, 2002, ANNU REV IMMUNOL, V20, P551, DOI 10.1146/annurev.immunol.20.100101.151926.
   Stenger S, 1998, J IMMUNOL, V161, P3582.
   Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468.
   Trajkovic V, 2004, MICROBES INFECT, V6, P513, DOI 10.1016/j.micinf.2003.12.015.
   Tufariello JM, 2003, LANCET INFECT DIS, V3, P578, DOI 10.1016/S1473-3099(03)00741-2.
   Ulrichs T, 2003, INFECT IMMUN, V71, P3076, DOI 10.1128/IAI.71.6.3076-3087.2003.
   Westermann J, 2001, IMMUNOL REV, V184, P20, DOI 10.1034/j.1600-065x.2001.1840103.x.}},
Number-of-Cited-References = {{48}},
Times-Cited = {{50}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Cell Microbiol.}},
Doc-Delivery-Number = {{197DR}},
Unique-ID = {{ISI:000248534700019}},
}

@article{ ISI:000248481000011,
Author = {Shahemabadi, A. S. and Hosseini, A. Zavaran and Shaghsempour, S. and
   Masjedi, M. R. and Rayani, M. and Pouramiri, M.},
Title = {{Evaluation of T cell immune responses in multi-drug-resistant
   tuberculosis (MDR-TB) patients to Mycobacterium tuberculosis total tipid
   antigens}},
Journal = {{CLINICAL AND EXPERIMENTAL IMMUNOLOGY}},
Year = {{2007}},
Volume = {{149}},
Number = {{2}},
Pages = {{285-294}},
Month = {{AUG}},
Abstract = {{Mycobacterium tuberculosis lipid antigens produce significant T cell
   responses in healthy tuberculin reactor {[}purified protein derivative
   (PPD-positive] individuals. In the present study, proliferation and
   interferon (IFN)-gamma/ interleukin (IL)-4 responses were analysed to M.
   tuberculosis total lipid antigens in T lymphocytes from 25 patients with
   multi-drug-resistant tuberculosis (MDR-TB). The obtained results were
   compared with those of 30 asymptomatic healthy PPD-positive and 30
   healthy tuberculin skin test negative (PPD-negative) subjects.
   Peripheral blood mononuclear cells (PBMCs) and T cells (CD4(+) and
   CD8(+)) were stimulated using autologous immature dendritic cells.
   Proliferation responses were assessed using
   3-\{4,5-dimethylthiazol-2-yl\}-2,5 diphenyl tetrazolium bromide (MTT).
   IFN-gamma/IL-4 concentrations in the supernatant of the CD4(+) and
   CD8(+)T cells were measured by enzyme-linked inummosorbent assay.
   Proliferation assay showed that the peripheral blood mononuclear cells
   and CD4(+) T cells from the MDR-TB patients responded significantly less
   to the M. tuberculosis total lipid antigens than to the CD4(+) T cells
   in the PPD-positive subjects. Total lipid antigen-specific proliferative
   responses in the CD8(+) T cells from the MDR-TB patients were minimally
   detected and the responses were similar to those of the PPD-positive
   subjects. IFN-gamma production by the CD4(+)T cells stimulated by total
   lipid antigens from the MDR-TB patients was decreased significantly
   compared with the PPD-positive individuals, whereas IL-4 production in
   the patients was elevated. IFN-gamma and IL-4 production in the CD8(+) T
   cells of the MDR-TB patients was similar to those of the PPD-positive
   subjects. In conclusion, it is suggested that stimulated CD4(+) T cells
   by M. tuberculosis total lipid antigens may be shifted to T helper 2
   responses in MDR-TB patients.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hosseini, AZ (Reprint Author), Tarbiat Modares Univ, Fac Med Sci, Dept Immunol, Jalale Ale Ahmad Ave,POB 14115-331, Tehran, Iran.
   Tarbiat Modares Univ, Fac Med Sci, Dept Immunol, Tehran, Iran.
   Shahid Beheshti Univ Med Sci, Natl Res Inst TB \& Lung Dis, Masih Daneshvari Hosp, Tehran, Iran.
   Shahid Beheshti Univ Med Sci, Mycobacteriol Res Ctr, Masih Daneshvari Hosp, NRITLD, Tehran, Iran.}},
DOI = {{10.1111/j.1365-2249.2007.03406.x}},
ISSN = {{0009-9104}},
Keywords = {{interferon-gamma; interleukin-4; multi-drug-resistant tuberculosis; T
   cells; total lipid antigens}},
Keywords-Plus = {{BLOOD MONONUCLEAR-CELLS; PULMONARY TUBERCULOSIS; GAMMA-INTERFERON;
   IFN-GAMMA; INFECTION; RECOGNITION; CD8(+); INTERLEUKIN-4; ACTIVATION;
   EXPRESSION}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{zavarana@modares.ac.ir}},
Cited-References = {{Bai XY, 2004, TUBERCULOSIS, V84, P375, DOI 10.1016/j.tube.2004.05.001.
   BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203.
   Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6.
   Dao DN, 2004, INFECT IMMUN, V72, P2067, DOI 10.1128/IAI.72.4.2067-2074.2004.
   Dascher CC, 2003, INT IMMUNOL, V15, P915, DOI 10.1093/intimm/dxg091.
   Dlugovitzky D, 2000, CLIN EXP IMMUNOL, V122, P343, DOI 10.1046/j.1365-2249.2000.01394.x.
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814.
   Feng CG, 1999, INFECT IMMUN, V67, P3242.
   Flynn JL, 2000, CURR OPIN IMMUNOL, V12, P432, DOI 10.1016/S0952-7915(00)00116-3.
   FOLCH J, 1957, J BIOL CHEM, V226, P497.
   Gumperz JE, 2001, CURR OPIN IMMUNOL, V13, P471, DOI 10.1016/S0952-7915(00)00243-0.
   Hirsch CS, 1999, J INFECT DIS, V179, P945, DOI 10.1086/314667.
   HOCHSTENBACH F, 1988, J EXP MED, V168, P761, DOI 10.1084/jem.168.2.761.
   ISEMAN MD, 1993, NEW ENGL J MED, V329, P784.
   Jo EK, 2000, SCAND J IMMUNOL, V51, P209.
   Kim J, 2001, J IMMUNOL, V167, P779.
   Lee JS, 2002, CLIN EXP IMMUNOL, V128, P516, DOI 10.1046/j.1365-2249.2002.01858.x.
   Manca C, 2004, INFECT IMMUN, V72, P5511, DOI 10.1128/IAI.72.9.5511-5514.2004.
   Mogues T, 2001, J EXP MED, V193, P271, DOI 10.1084/jem.193.3.271.
   Moody DB, 2000, J EXP MED, V192, P965, DOI 10.1084/jem.192.7.965.
   Moody DB, 2004, SCIENCE, V303, P527, DOI 10.1126/science.1089353.
   Moody DB, 2000, NATURE, V404, P884, DOI 10.1038/35009119.
   Porcelli SA, 1999, ANNU REV IMMUNOL, V17, P297, DOI 10.1146/annurev.immunol.17.1.297.
   ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83.
   SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109.
   Scanga CA, 2000, J EXP MED, V192, P347, DOI 10.1084/jem.192.3.347.
   Seah GT, 2000, J INFECT DIS, V181, P385, DOI 10.1086/315200.
   Seah GT, 2001, J IMMUNOL, V167, P1230.
   Sharma SK, 2004, INDIAN J MED RES, V120, P354.
   SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404.
   Smith SM, 2002, TUBERCULOSIS, V82, P7, DOI 10.1054/tube.2001.0317.
   Song CH, 2000, INFECT IMMUN, V68, P4477, DOI 10.1128/IAI.68.8.4477-4484.2000.
   Stenger S, 1998, J IMMUNOL, V161, P3582.
   Sugawara I, 2000, MICROBIOL IMMUNOL, V44, P971.
   Tascon RE, 1998, INFECT IMMUN, V66, P830.
   Ulrichs T, 2003, INFECT IMMUN, V71, P3076, DOI 10.1128/IAI.71.6.3076-3087.2003.
   Ulrichs T, 2000, Rev Immunogenet, V2, P416.
   van Crevel R, 2000, J INFECT DIS, V181, P1194, DOI 10.1086/315325.
   World Health Organization, 2004, WHOHTMTB2004330.
   ZHANG M, 1995, INFECT IMMUN, V63, P3231.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Clin. Exp. Immunol.}},
Doc-Delivery-Number = {{196KT}},
Unique-ID = {{ISI:000248481000011}},
}

@article{ ISI:000248481000023,
Author = {Jeevan, A. and Majorov, K. and Sawant, K. and Cho, H. and McMurray, D.
   N.},
Title = {{Lung macrophages from bacitte Calmette-Guerin-vaccinated guinea pigs
   suppress T cell proliferation but restrict intracellular growth of
   M-tuberculosis after recombinant guinea pig interferon-gamma activation}},
Journal = {{CLINICAL AND EXPERIMENTAL IMMUNOLOGY}},
Year = {{2007}},
Volume = {{149}},
Number = {{2}},
Pages = {{387-398}},
Month = {{AUG}},
Abstract = {{The guinea pig model of low-dose pulmonary tuberculosis has been used to
   study the pathogenesis of infection as well as the mechanisms of bacille
   Calmette-Guerin (BCG) vaccine-induced resistance. We investigated the
   function of lung cells from naive and BCG-vaccinated guinea pigs after
   enzymatic digestion of lung tissue with collagenase and DNase I. The
   total lung digest cells proliferated poorly to purified protein
   derivative (PPD) but comparatively better to ConA as assessed by
   {[}H-3]-thymidine uptake. However, the non-adherent population obtained
   after plastic adherence of lung digests showed an enhanced response to
   concanavalin A (ConA) and PPD. Therefore, proliferation to ConA and PPD
   of nylon wool-purified T cells co-cultured with peritoneal (PMos),
   alveolar (AMos) or lung macrophages (LMos) was assessed. Co-cultures of
   lung T cells and PMos showed maximum proliferation to PPD, whereas
   proliferation was suppressed significantly by the addition of AMos or
   LMos. The response of T cells to ConA was unaffected in co-cultures.
   Incubation of co-cultures with recombinant guinea pig interferon-gamma
   (rgpIFN-gamma) did not reverse the suppression. In contrast,
   rgpIFN-gamma-treated plastic adherent LMos that were non-specific
   esterase-positive were capable of reducing the intracellular growth of
   Mycobacterium tuberculosis. Similarly, total, non-adherent and adherent
   lung digest cells from BCG-vaccinated guinea pigs showed IFN-gamma and
   tumour necrosis factor (TNF)-alpha mRNA expression in response to ConA,
   lipopolysaccharide or PPD by reverse transcription-polymerase chain
   reaction followed by release of TNF protein but not IFN. These studies
   indicate that rgp-IFN-gamma-treated lung tissue macrophages from
   BCG-vaccinated guinea pigs are defective for inducing antigenspecific
   proliferation in T cells, but control the intracellular accumulation of
   virulent M. tuberculosis.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Jeevan, A (Reprint Author), Texas A\&M Univ, SHSC, Dept Microbial \& Mol Pathogenesis, 407 Reynolds Med Bldg, College Stn, TX 77843 USA.
   Texas A\&M Univ, SHSC, Dept Microbial \& Mol Pathogenesis, College Stn, TX 77843 USA.
   Cent Inst TB, Lab Immunogenet, Moscow, Russia.}},
DOI = {{10.1111/j.1365-2249.2007.03425.x}},
ISSN = {{0009-9104}},
Keywords = {{BCG; cytokine mRNA; guinea pig lung digest cells; rgpIFN-gamma; T cell
   proliferation}},
Keywords-Plus = {{TUMOR-NECROSIS-FACTOR; BOVIS BCG VACCINATION; HUMAN ALVEOLAR
   MACROPHAGES; MESSENGER-RNA EXPRESSION; FACTOR-ALPHA; PROTEIN-PRODUCTION;
   IFN-GAMMA; INFECTION; LYMPHOCYTES; INHIBITION}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{ajeevan@medicine.tamhsc.edu}},
ResearcherID-Numbers = {{Sawant, Kirti/L-1602-2013
   Sawant, Kirti/H-3778-2013}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}R01 AI15495, R01 AI015495]}},
Cited-References = {{Allen SS, 2003, INFECT IMMUN, V71, P4271, DOI 10.1128/IAI.71.8.4271-4277.2003.
   ANTONY VB, 1983, CHEST, V83, pS95, DOI 10.1378/chest.83.5\_Supplement.95S.
   Appleberg R., 1989, CLIN EXP IMMUNOL, V78, P478.
   BARNES PF, 1990, J IMMUNOL, V145, P149.
   BILYK N, 1993, J EXP MED, V177, P1773, DOI 10.1084/jem.177.6.1773.
   BILYK N, 1995, IMMUNOLOGY, V86, P31.
   Canetti G., 1955, TUBERCLE BACILLUS PU.
   Chackerian AA, 2001, INFECT IMMUN, V69, P2666, DOI 10.1128/IAI.69.4.2666-2674.2001.
   Cho H, 2005, INFECT IMMUN, V73, P1367, DOI 10.1128/IAI.73.3.1367-1376.2005.
   Cho HS, 2005, INFECT IMMUN, V73, P8437, DOI 10.1128/IAI.73.12.8437-8441.2005.
   COHEN MK, 1987, INFECT IMMUN, V55, P314.
   COMSTOCK GW, 1982, AM REV RESPIR DIS, V125, P8.
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243.
   Debout C, 1999, LEUKEMIA RES, V23, P137, DOI 10.1016/S0145-2126(98)00155-6.
   Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901.
   Fenton MJ, 1997, INFECT IMMUN, V65, P5149.
   FLESCH IEA, 1990, INFECT IMMUN, V58, P2675.
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249.
   FULTZ MJ, 1993, INT IMMUNOL, V5, P1383, DOI 10.1093/intimm/5.11.1383.
   Holscher C, 2001, J IMMUNOL, V167, P6957.
   HOLT PG, 1986, CLIN EXP IMMUNOL, V63, P261.
   HOLT PG, 1993, EUR RESPIR J, V6, P120.
   HOLT PG, 1980, CELL IMMUNOL, V50, P210, DOI 10.1016/0008-8749(80)90020-9.
   HOLT PG, 1979, IMMUNOLOGY, V37, P429.
   Jeevan A, 2006, INFECT IMMUN, V74, P213, DOI 10.1128/IAI.74.1.213-224.2006.
   Jeevan A, 2003, INFECT IMMUN, V71, P354, DOI 10.1128/IAI.71.1.354-364.2003.
   Jeevan A, 2002, INFECT IMMUN, V70, P1245, DOI 10.1128/IAI.70.3.1245-1253.2002.
   KAUFMANN S, 1987, MICROBIOL SCI, V4, P324.
   KEMIJO R, 1993, J EXP MED, V178, P1435.
   KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4.
   Lasco TM, 2005, TUBERCULOSIS, V85, P245, DOI 10.1016/j.tube.2005.01.001.
   Lasco TM, 2004, INFECT IMMUN, V72, P1147, DOI 10.1128/IAI.72.2.1147-1149.2004.
   Lasco TM, 2003, INFECT IMMUN, V71, P7035, DOI 10.1128/IAI.71.12.7035-7042.2003.
   Lyadova IV, 2000, J IMMUNOL, V165, P5921.
   Lyons MJ, 2004, TUBERCULOSIS, V84, P283, DOI 10.1016/j.tube.2003.09.003.
   Lyons MJ, 2002, INFECT IMMUN, V70, P5471, DOI 10.1128/IAI.70.10.5471-5478.2002.
   MACKANES.GB, 1968, AM REV RESPIR DIS, V97, P337.
   MCCOMBS CC, 1982, CHEST, V82, P266, DOI 10.1378/chest.82.3.266.
   ORME IM, 1992, J IMMUNOL, V148, P189.
   Pouliot N, 1996, INFLAMMATION, V20, P263, DOI 10.1007/BF01488203.
   Raqib R, 1996, EUR J IMMUNOL, V26, P1130, DOI 10.1002/eji.1830260526.
   ROCHE PW, 1995, TRENDS MICROBIOL, V3, P397, DOI 10.1016/S0966-842X(00)88986-6.
   Skwor TA, 2004, J LEUKOCYTE BIOL, V76, P1229, DOI 10.1189/jlb.0704414.
   SMITH D, 1979, J BIOL STAND, V7, P179, DOI 10.1016/S0092-1157(79)80021-9.
   Stewart GR, 2003, NAT REV MICROBIOL, V1, P97, DOI 10.1038/nrmicro749.
   Udani P. M., 1994, Indian Journal of Pediatrics, V61, P451, DOI 10.1007/BF02751703.
   Upham JW, 1997, THORAX, V52, P786.
   UPHAM JW, 1995, IMMUNOLOGY, V84, P142.
   Verreck FAW, 2004, P NATL ACAD SCI USA, V101, P4560, DOI 10.1073/pnas.0400983101.
   Wang J, 1999, J CLIN INVEST, V103, P1023, DOI 10.1172/JCI6224.
   YAM LT, 1971, AM J CLIN PATHOL, V55, P283.
   Yamamoto T, 2002, J INTERF CYTOK RES, V22, P793, DOI 10.1089/107999002320271387.
   YOUNG LS, 1986, REV INFECT DIS, V8, P1024.
   Zhang X., 1998, Tubercle and Lung Disease, V79, P119, DOI 10.1054/tuld.1998.0014.}},
Number-of-Cited-References = {{54}},
Times-Cited = {{12}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Clin. Exp. Immunol.}},
Doc-Delivery-Number = {{196KT}},
Unique-ID = {{ISI:000248481000023}},
}

@article{ ISI:000248465100014,
Author = {Silverman, M. S. and Reynolds, D. and Kavsak, P. A. and Garay, J. and
   Daly, A. and Davis, I.},
Title = {{Use of an interferon-gamma based assay to assess bladder cancer patients
   treated with intravesical BCG and exposed to tuberculosis}},
Journal = {{CLINICAL BIOCHEMISTRY}},
Year = {{2007}},
Volume = {{40}},
Number = {{12}},
Pages = {{913-915}},
Month = {{AUG}},
Abstract = {{Objective: Compare the QuantiFERON-TB Gold In-Tube (QFT) assay and the
   tuberculin skin test (TST) in bladder cancer patients receiving high
   dose BCG therapy (BCG patients).
   Design and methods: BCG patients and healthy visitors, both exposed to
   tuberculosis, were screened with a TST and QFT. Results: QFT-TST
   correlation was excellent in visitors, but poor in BCG patients. BCG
   therapy predicted a positive TST (p < 0.00 1) but not a positive QFT
   (p=0.35).
   Discussion: The management of BCG patients was impacted, by measuring
   the QFT. (c) 2007 The Canadian Society of Clinical Chemists. Published
   by Elsevier Inc. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Silverman, MS (Reprint Author), 1 Hosp Court, Oshawa, ON, Canada.
   Univ Toronto, Toronto, ON, Canada.
   Lakeridge Hlth, Oshawa, ON, Canada.
   Sanofi Pasteur Pharmaceut, Toronto, ON, Canada.
   McMaster Univ, Hamilton, ON, Canada.
   York Reg Hlth Dept, Newmarket, ON, Canada.
   Univ Calgary, Calgary, AB T2N 1N4, Canada.}},
DOI = {{10.1016/j.clinbiochem.2007.04.006}},
ISSN = {{0009-9120}},
Keywords = {{bladder cancer; bacillus Calmette-Guerin; tuberculin skin test;
   interferon-gamma}},
Keywords-Plus = {{BACILLUS-CALMETTE-GUERIN; SKIN-TEST}},
Research-Areas = {{Medical Laboratory Technology}},
Web-of-Science-Categories  = {{Medical Laboratory Technology}},
Author-Email = {{msilverman@rogers.com}},
ResearcherID-Numbers = {{Silverman, Michael/J-3776-2014}},
ORCID-Numbers = {{Silverman, Michael/0000-0002-0389-7656}},
Cited-References = {{Bilen CY, 2003, J UROLOGY, V169, P1702, DOI 10.1097/01.ju.0000059681.67567.12.
   Brock Iinger, 2004, American Journal of Respiratory and Critical Care Medicine, V170, P65, DOI 10.1164/rccm.200402-232OC.
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968.
   KAVSAK P, 2005, CLIN CHEM, V51, pD65.
   LAMM DL, 1985, J UROLOGY, V134, P40.
   LONG R, 2000, CANADIAN TUBERCULOSI.
   Menzies D, 1999, CAN MED ASSOC J, V161, P717.
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC.
   Wang L, 2002, THORAX, V57, P804, DOI 10.1136/thorax.57.9.804.}},
Number-of-Cited-References = {{9}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Clin. Biochem.}},
Doc-Delivery-Number = {{196ES}},
Unique-ID = {{ISI:000248465100014}},
}

@article{ ISI:000247621100008,
Author = {Detjen, A. K. and Keil, T. and Roll, S. and Hauer, B. and Mauch, H. and
   Wahn, U. and Magdorf, K.},
Title = {{Interferon-gamma release assays improve the diagnosis of tuberculosis
   and nontuberculous mycobacterial disease in children in a country with a
   low incidence of tuberculosis}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{45}},
Number = {{3}},
Pages = {{322-328}},
Month = {{AUG 1}},
Abstract = {{Background. Diagnosis of childhood tuberculosis ( TB) is challenging.
   The widely used tuberculin skin test (TST) may produce-positive results
   because of cross-reactivity with nontuberculous mycobacteria or bacille
   Calmette-Guerin vaccination, resulting in unnecessary treatment. Two
   recently developed interferon-gamma release assays (IGRAs) show good
   diagnostic accuracy for active TB in adults; pediatric data are limited,
   particularly in areas with a low incidence of TB. We assessed the
   diagnostic accuracy of IGRAs for TB in children in an area with a low
   incidence of TB.
   Methods. In a hospital-based study, the diagnostic accuracy of the TST
   and 2 IGRAs (T SPOT-TB {[}T-SPOT; Oxford Immunotec] and QuantiFERON-TB
   Gold In-Tube {[}QFT-IT; Cellestis]) were assessed in a cohort of 73
   children ( median age, 39 months); 28 children with bacteriologically
   confirmed TB were compared with children without TB ( 23 with
   bacteriologically confirmed nontuberculous mycobacterial lymphadenitis
   and 22 with other nonmycobacterial respiratory tract infections).
   Results. The specificity for TB of QFT-IT was 100\% (95\% confidence
   interval {[}CI], 91\%-100\%), and the specificity of T-SPOT was 98\%
   (95\% CI, 87\%-100\%), both of which were considerably higher than the
   specificity of TST (58\%; 95\% CI, 42\%-73\%). The specificity of the
   TST was 10.5\% (95\% CI, 1\%-33\%) in children with nontuberculous
   mycobacterial lymphadenitis and was 100\% (95\% CI, 83\%-100\%) in
   children with other nonmycobacterial respiratory tract infections. The
   sensitivity of both QFT-IT and T-SPOT was 93\% (95\% CI, 77\%-99\%), and
   the sensitivity of the TST was 100\% (95\% CI, 88\%-100\%). Agreement
   between the IGRAs was 95.6\% (kappa = 0.91); 6.8\% of the IGRAs showed
   indeterminate results.
   Conclusions. Both IGRAs showed high diagnostic value in
   bacteriologically confirmed childhood TB. Their advantage in this study,
   when performed in addition to the TST, was the ability to
   distinguish-positive TST results caused by nontuberculous mycobacterial
   disease, thereby reducing overdiagnosis of TB and guiding clinical
   management.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Detjen, AK (Reprint Author), Dept Pediat Pneumol \& Immunol, Charite Campus Virchow Kli,Augustenburger Platz 1, D-13353 Berlin, Germany.
   Dept Pediat Pneumol \& Immunol, D-13353 Berlin, Germany.
   Charite Univ Med Berlin, Ctr Med, Inst Social Med, Berlin, Germany.
   Charite Univ Med Berlin, Ctr Med, Dept Pediat Pneumol \& Allergy, Berlin, Germany.
   German Cent Comm TB, Dept Hecheshorn, Berlin, Germany.}},
DOI = {{10.1086/519266}},
ISSN = {{1058-4838}},
Keywords-Plus = {{ENZYME-LINKED IMMUNOSPOT; LATENT TUBERCULOSIS; SKIN-TEST;
   CLINICAL-PRACTICE; RURAL INDIA; INFECTION; TESTS; RESPONSES; PROTEIN;
   RISK}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{anne.detjen@charite.de}},
Cited-References = {{American Thoracic Society, 2000, AM J RESP CRIT CARE, V161, P221.
   Arend SM, 2007, AM J RESP CRIT CARE, V175, P618, DOI 10.1164/rccm.200608-1099OC.
   Connell TG, 2006, THORAX, V61, P616, DOI 10.1136/thx.2005.048033.
   DIEL R, 2007, PNEUMOLOGIE.
   Dogra S, 2007, J INFECTION, V54, P267, DOI 10.1016/j.jinf.2006.04.007.
   Doherty TM, 2005, J IMMUNOL METHODS, V298, P129, DOI 10.1016/j.jim.2005.01.013.
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6.
   Franken WPJ, 2007, CLIN VACCINE IMMUNOL, V14, P477, DOI 10.1128/CVI.00463-06.
   Haimi-Cohen Y, 2001, CLIN INFECT DIS, V33, P1786.
   Harboe M, 1996, INFECT IMMUN, V64, P16.
   Haverkamp MH, 2004, CLIN INFECT DIS, V39, P450, DOI 10.1086/422319.
   Hill PC, 2006, PEDIATRICS, V117, P1542, DOI 10.1542/peds.2005-2095.
   KHANG YA, 2005, JAMA-J AM MED ASSOC, V293, P2756.
   Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824.
   Lee JY, 2006, EUR RESPIR J, V28, P24, DOI 10.1183/09031936.06.00016906.
   Liebeschuetz S, 2004, LANCET, V364, P2196, DOI 10.1016/S0140-6736(04)17592-2.
   Mazurek Gerald H., 2005, Morbidity and Mortality Weekly Report, V54, P49.
   Meier T, 2005, EUR J CLIN MICROBIOL, V24, P529, DOI 10.1007/s10096-005-1377-8.
   Menzies D, 2007, ANN INTERN MED, V146, P340.
   Nakaoka H, 2006, EMERG INFECT DIS, V12, P1383.
   Nicol MP, 2005, CLIN INFECT DIS, V40, P1301, DOI 10.1086/429245.
   {*}NIH CLIN EX, 2006, TUB CLIN DIAGN MAN T.
   {*}OXF IMM, T SPOT TB TEST MAN I.
   Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746.
   PAI M, 2007, CLIN INFECT DIS, V4, P74.
   Pai M, 2006, EXPERT REV MOL DIAGN, V6, P413, DOI 10.1586/14737159.6.3.413.
   Piana F, 2006, EUR RESPIR J, V28, P31, DOI 10.1183/09031936.06.00110205.
   Porsa E, 2006, CLIN VACCINE IMMUNOL, V13, P53, DOI 10.1128/CVI.13.1.53-58.2006.
   {*}ROB KOCH I, 2007, BER EP TUB DTSCH 200, P35.
   Romanus V, 1995, Scand J Infect Dis Suppl, V98, P15.
   Shams H, 2005, AM J RESP CRIT CARE, V172, P1161, DOI 10.1164/rccm.200505-748OC.
   Starke JR, 2006, PEDIATR INFECT DIS J, V25, P941, DOI 10.1097/01.inf.0000239685.49999.d3.
   Tsiouris SJ, 2006, INT J TUBERC LUNG D, V10, P939.
   Vu Thien-Tuong-Vi, 2005, J Otolaryngol, V34 Suppl 1, pS40.
   Wang JY, 2007, EMERG INFECT DIS, V13, P553.
   WIESEPOSSELT M, 2005, MONATSSCHR KINDERH, V152, P797.
   CELLESTIS.}},
Number-of-Cited-References = {{37}},
Times-Cited = {{169}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{184DK}},
Unique-ID = {{ISI:000247621100008}},
}

@article{ ISI:000247621100010,
Author = {Hamilton, Carol Dukes and Sterling, Timothy R. and Blumberg, Henry M.
   and Leonard, Michael and McAuley, James and Schlossberg, David and
   Stout, Jason and Huitt, Gwen},
Title = {{Extensively drug-resistant tuberculosis: Are we learning from history or
   repeating it?}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{45}},
Number = {{3}},
Pages = {{338-342}},
Month = {{AUG 1}},
Abstract = {{Tuberculosis (TB) is an enormous global public health problem. Cases of
   extensively drug-resistant TB (XDR-TB) are being reported in increasing
   numbers across the globe. A large outbreak of XDR-TB associated with
   rapid and nearly universal mortality has been reported among patients
   with human immunodeficiency virus infection or acquired immunodeficiency
   disease in South Africa who have been receiving standard TB therapy and
   antiretrovirals. Epidemiologic features of this outbreak make it highly
   suspicious for health care-associated transmission. We urge the
   Infectious Diseases Society of America and its members to increase
   involvement in ongoing international TB prevention and treatment efforts
   and to develop a registry of experts in infection control and laboratory
   and disease management. We urge advocacy for increased funding for
   domestic and global TB control programs, including expanded access to
   sputum culture and drug susceptibility testing, as well as funding for
   TB clinical trials and research capacity. We believe that substandard TB
   diagnostic tests are not acceptable for TB control in resource-poor
   countries. We urge the development of shorter, less toxic TB treatment
   and prevention regimens. Funding of TB control and research should be
   reassessed to prevent budget cuts at a time when the disease is killing
   as many as 2 million people a year.}},
Publisher = {{OXFORD UNIV PRESS INC}},
Address = {{JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Hamilton, CD (Reprint Author), Duke Univ, Med Ctr, Box 3306, Durham, NC 27710 USA.
   Duke Univ, Sch Med, Durham, NC USA.
   N Carolina TB Control Program, Raleigh, NC USA.
   Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA.
   Rush Univ, Med Ctr, Chicago, IL 60612 USA.
   Dept Hlth, TB Control Program, Philadelphia, PA USA.
   Temple Univ, Sch Med, Philadelphia, PA USA.
   Univ Colorado, Sch Med, Denver, CO 80202 USA.
   Univ Colorado, Natl Jewish Resp Ctr, Denver, CO 80202 USA.}},
DOI = {{10.1086/519292}},
ISSN = {{1058-4838}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; MYCOBACTERIUM; EPIDEMIOLOGY; DIAGNOSIS;
   COUNTRIES; OUTCOMES; DOTS}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{dukes002@mc.duke.edu}},
ORCID-Numbers = {{Stout, Jason/0000-0002-6698-8176}},
Cited-References = {{Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753.
   Apers L, 2003, INT J TUBERC LUNG D, V7, P376.
   Badri M, 2001, INT J TUBERC LUNG D, V5, P225.
   Burman WJ, 2006, AM J RESP CRIT CARE, V174, P331, DOI 10.1164/rccm.200603-360OC.
   Centers for Disease Control and Prevention, 2006, MMWR-MORBID MORTAL W, V55, P1176.
   Centers for Disease Control Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P305.
   Centers for Disease Control and Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P301.
   COMSTOCK GW, 1972, ARCH ENVIRON HEALTH, V25, P333.
   DRIVER CR, 1994, PUBLIC HEALTH REP, V109, P632.
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0.
   ENARSON DA, 1978, CAN MED ASSOC J, V118, P1520.
   Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537.
   Falzon D, 2007, CLIN INFECT DIS, V44, P1261, DOI 10.1086/514343.
   Farmer P, 2001, ANN NY ACAD SCI, V953, P165, DOI 10.1111/j.1749-6632.2001.tb11375.x.
   Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Glickman SW, 2006, SCIENCE, V311, P1246, DOI 10.1126/science.1119299.
   GRZYBOWSKI S, 1971, AM REV RESPIR DIS, V104, P605.
   Hopewell PC, 2006, LANCET INFECT DIS, V6, P710, DOI 10.1016/S1473-3099(06)70628-4.
   Kochi A, 1997, WORLD HEALTH FORUM, V18, P225.
   Menzies D, 2001, AM J RESP CRIT CARE, V164, P914.
   Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524.
   Peterson EM, 1999, J CLIN MICROBIOL, V37, P3564.
   ROSENTHAL IM, 2006, P AM THORAC SOC, V3, pA744.
   Shah NS, 2007, EMERG INFECT DIS, V13, P380.
   {*}TREATM ACT GROUP, TB HIV PROJ.
   Volmink J., 2006, COCHRANE DB SYST REV, V2.
   Whalen CC, 2000, AIDS, V14, P1219, DOI 10.1097/00002030-200006160-00020.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{17}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{184DK}},
Unique-ID = {{ISI:000247621100010}},
}

@article{ ISI:000247664900002,
Author = {Palomino, J. C. and Martin, A. and Portaels, F.},
Title = {{Rapid drug resistance detection in Mycobacterium tuberculosis: a review
   of colourimetric methods}},
Journal = {{CLINICAL MICROBIOLOGY AND INFECTION}},
Year = {{2007}},
Volume = {{13}},
Number = {{8}},
Pages = {{754-762}},
Month = {{AUG}},
Abstract = {{Several new methods to detect drug resistance in Mycobacterium
   tuberculosis have been proposed in recent years. Colourimetric methods
   that use redox indicators or the nitrate reduction assay have received
   increasing attention because of their simplicity and the absence of any
   requirement for sophisticated equipment or highly trained personnel.
   Several studies have evaluated their accuracy and performance in
   comparison with reference standard methods, particularly for the
   detection of resistance to rifampicin and isoniazid, which are the two
   most important drugs used for the treatment of tuberculosis. This review
   describes the development, evaluation and implementation of these
   methods as rapid alternative tests for the detection of multidrug
   resistance in M. tuberculosis. Based on published evidence and the high
   accuracy of colourimetric methods for detecting drug resistance in M.
   tuberculosis, these methods seem to be appropriate for implementation in
   high-burden low-resource countries.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Palomino, JC (Reprint Author), Inst Trop Med, Mycobacteriol Unit, Nationalestr 155, B-2000 Antwerp, Belgium.
   Inst Trop Med, Mycobacteriol Unit, B-2000 Antwerp, Belgium.}},
DOI = {{10.1111/j.1469-0691.2007.01698.x}},
ISSN = {{1198-743X}},
Keywords = {{antimicrobial resistance; colourimetric methods; detection;
   Mycobacterium tuberculosis; review; susceptibility testing}},
Keywords-Plus = {{NITRATE REDUCTASE ASSAY; RESAZURIN MICROTITER ASSAY; ALAMAR BLUE ASSAY;
   3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5-DIPHENYL TETRAZOLIUM BROMIDE; GROWTH
   INDICATOR TUBE; COLORIMETRIC METHOD; ANTIMYCOBACTERIAL ACTIVITY; TESTING
   SUSCEPTIBILITY; RIFAMPICIN RESISTANCE; ANTIMICROBIAL AGENTS}},
Research-Areas = {{Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology}},
Author-Email = {{jcpalomino@itg.be}},
Cited-References = {{Abate G, 2004, J CLIN MICROBIOL, V42, P871, DOI 10.1128/JCM.42.2.871-873.2004.
   Abate G, 1998, INT J TUBERC LUNG D, V2, P1011.
   AHMED SA, 1994, J IMMUNOL METHODS, V170, P211.
   Akihisa T, 2005, BIOL PHARM BULL, V28, P158, DOI 10.1248/bpb.28.158.
   Angeby KAK, 2002, J CLIN MICROBIOL, V40, P553, DOI 10.1128/JCM.40.2.553-555.2002.
   Banfi E, 2003, J ANTIMICROB CHEMOTH, V52, P796, DOI 10.1093/jac/dkg439.
   Barnes PF, 2002, INFECT DIS CLIN N AM, V16, P107, DOI 10.1016/S0891-5520(03)00048-5.
   Bastian I, 2001, ANTIMICROB AGENTS CH, V45, P1934, DOI 10.1128/AAC.45.6.1934-1936.2001.
   Carter RA, 1998, ARCH ANDROLOGY, V40, P59.
   Caviedes L, 2002, J CLIN MICROBIOL, V40, P1873, DOI 10.1128/JCM.40.5.1873-1874.2002.
   Centers for Disease Control and Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P301.
   Coban AY, 2006, J CHEMOTHERAPY, V18, P140.
   Collins LA, 1997, ANTIMICROB AGENTS CH, V41, P1004.
   De Logu A, 2003, INT J ANTIMICROB AG, V21, P244, DOI 10.1016/S0924-8579(02)00350-3.
   De Logu A, 2001, EUR J CLIN MICROBIOL, V20, P33, DOI 10.1007/PL00011234.
   De Logu Alessandro, 2003, Clin Lab, V49, P357.
   Garcia de Viedma D, 2003, CLIN MICROBIOL INFEC, V9, P349, DOI DOI 10.1046/J.1469-0691.2003.00695.X.
   Farnia P, 2004, MICROBES INFECT, V6, P972, DOI 10.1016/j.micinf.2004.04.017.
   Foongladda S, 2002, INT J TUBERC LUNG D, V6, P1118.
   Franzblau SG, 1998, J CLIN MICROBIOL, V36, P362.
   Johansen IS, 2004, DIAGN MICR INFEC DIS, V50, P103, DOI 10.1016/j.diagmicrobio.2004.04.001.
   Kent T. K., 1985, PUBLIC HLTH MYCOBACT.
   Kumar M, 2005, INT J TUBERC LUNG D, V9, P939.
   Laszlo A, 2002, INT J TUBERC LUNG D, V6, P748.
   Lemus D, 2004, J ANTIMICROB CHEMOTH, V54, P130, DOI 10.1093/jac/dkh320.
   Mann CM, 1998, J APPL MICROBIOL, V84, P538, DOI 10.1046/j.1365-2672.1998.00379.x.
   Martin A, 2005, J MICROBIOL METH, V63, P145, DOI 10.1016/j.mimet.2005.03.004.
   Martin A, 2005, J CLIN MICROBIOL, V43, P1612, DOI 10.1128/JCM.43.4.1612-1616.2005.
   Martin A, 2003, ANTIMICROB AGENTS CH, V47, P3616, DOI 10.1128/AAC.47.11.3616-3619.2003.
   Martin A, 2005, INT J TUBERC LUNG D, V9, P901.
   Martin A, 2006, J ANTIMICROB CHEMOTH, V58, P327, DOI 10.1093/jac/dkl231.
   Masjedi MR, 2006, CLIN INFECT DIS, V43, P841, DOI 10.1086/507542.
   Montoro E, 2005, J ANTIMICROB CHEMOTH, V55, P500, DOI 10.1093/jac/dki023.
   Morcillo N, 2004, INT J TUBERC LUNG D, V8, P253.
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4.
   Mshana RN, 1998, J CLIN MICROBIOL, V36, P1214.
   Musa HR, 2005, J CLIN MICROBIOL, V43, P3159, DOI 10.1128/JCM.43.7.3159-3161.2005.
   Nateche F, 2006, J MED MICROBIOL, V55, P857, DOI 10.1099/jmm.0.46513-0.
   NOVAK SM, 1993, J CLIN MICROBIOL, V31, P3056.
   O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x.
   Palomino JC, 1999, EUR J CLIN MICROBIOL, V18, P380, DOI 10.1007/PL00015025.
   Palomino JC, 2002, ANTIMICROB AGENTS CH, V46, P2720, DOI 10.1128/AAC.46.8.2720-2722.2002.
   Palomino JC, 1999, INT J TUBERC LUNG D, V3, P344.
   Palomino JC, 2006, CURR OPIN PULM MED, V12, P172, DOI 10.1097/01.mcp.0000219265.50310.9b.
   PFALLER MA, 1994, J CLIN MICROBIOL, V32, P1992.
   Pracharktam Roongnapa, 2001, Journal of the Medical Association of Thailand, V84, P1241.
   ROBERTS GD, 1983, J CLIN MICROBIOL, V18, P689.
   Shawar RM, 1997, ANTIMICROB AGENTS CH, V41, P570.
   Small PM, 2000, LANCET, V356, P1048, DOI 10.1016/S0140-6736(00)02724-0.
   Smith CF, 1999, J FOOD PROTECT, V62, P1404.
   Solis LA, 2005, INT J TUBERC LUNG D, V9, P760.
   Sriram D, 2005, BIOORG MED CHEM LETT, V15, P4502, DOI 10.1016/j.bmcl.2005.07.011.
   Syre H, 2006, J ANTIMICROB CHEMOTH, V57, P987, DOI 10.1093/jac/dk1054.
   Syre H, 2003, J CLIN MICROBIOL, V41, P5173, DOI 10.1128/JCM.41.11.5173-5177.2003.
   {*}TDR DIAGN EV EXP, 2006, NAT REV MICROBIOL, V4, P521.
   Umubyeyi AN, 2006, INT J TUBERC LUNG D, V10, P808.
   VANDERSCHOUW YT, 1995, INVEST RADIOL, V30, P334, DOI 10.1097/00004424-199506000-00002.
   WAYNE LG, 1974, AM REV RESPIR DIS, V109, P147.
   World Health Organization, 2004, WHOHTMTB2004343.
   World Health Organization, 2006, WHOHTMTB2006362.
   YAJKO DM, 1995, J CLIN MICROBIOL, V33, P2324.}},
Number-of-Cited-References = {{61}},
Times-Cited = {{29}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{Clin. Microbiol. Infect.}},
Doc-Delivery-Number = {{184TK}},
Unique-ID = {{ISI:000247664900002}},
}

@article{ ISI:000247664900016,
Author = {Sun, Y.-J. and Lee, A. S. G. and Wong, S.-Y. and Paton, N. I.},
Title = {{Analysis of the role of Mycobacterium tuberculosis kasA gene mutations
   in isoniazid resistance}},
Journal = {{CLINICAL MICROBIOLOGY AND INFECTION}},
Year = {{2007}},
Volume = {{13}},
Number = {{8}},
Pages = {{833-835}},
Month = {{AUG}},
Abstract = {{Previous studies have suggested that Mycobacterium tuberculosis kasA
   G312S and G269S gene mutations may represent sequence polymorphisms of
   the M. tuberculosis East-African-Indian (EAI) and T families,
   respectively, rather than relating to isoniazid resistance. The present
   study examined polymorphisms of these two codons in 98 drug-susceptible
   M. tuberculosis isolates (68 EAI and 30 T isolates). Twenty-eight
   isolates belonging to a sub-lineage of the EAI family had the kasA G312S
   mutation, but none of the 30 T isolates had the G269S mutation. The data
   suggest that the kasA G312S mutation is not related to isoniazid
   resistance, but represents a sequence polymorphism in a sub-lineage of
   the EAI family.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Sun, YJ (Reprint Author), Tan Tock Seng Hosp, Infect Dis Res Lab, TTSH Med Ctr, Dept Infect Dis, Level 2,11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
   Tan Tock Seng Hosp, Infect Dis Res Lab, TTSH Med Ctr, Dept Infect Dis, Singapore 308433, Singapore.
   Natl Canc Ctr, Div Med Sci, Singapore, Singapore.}},
DOI = {{10.1111/j.1469-0691.2007.01752.x}},
ISSN = {{1198-743X}},
Keywords = {{drug resistance; isoniazid; kasA gene; mutation; Mycobacterium
   tuberculosis; sequence polymorphism}},
Keywords-Plus = {{NUCLEOTIDE POLYMORPHISMS; POPULATION-GENETICS; SINGAPORE}},
Research-Areas = {{Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology}},
Author-Email = {{yong\_jiang\_sun@ttsh.com.sg}},
Cited-References = {{Baker L, 2004, EMERG INFECT DIS, V10, P1568.
   Brudey K, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-23.
   Cardoso RF, 2004, ANTIMICROB AGENTS CH, V48, P3373, DOI 10.1128/AAC.48.9.3373-3381.2004.
   Chen Xi, 2005, Zhonghua Jiehe He Huxi Zazhi, V28, P250.
   Filliol I, 2002, EMERG INFECT DIS, V8, P1347.
   Hazbon MH, 2006, ANTIMICROB AGENTS CH, V50, P2640, DOI 10.1128/AAC.00112-06.
   Hillemann D, 2005, ANTIMICROB AGENTS CH, V49, P1229, DOI 10.1128/AAC.49.3.1229-1231.2005.
   Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200.
   Lee ASG, 1999, ANTIMICROB AGENTS CH, V43, P2087.
   Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607.
   Piatek AS, 2000, ANTIMICROB AGENTS CH, V44, P103.
   Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002.
   Ramaswamy SV, 2003, ANTIMICROB AGENTS CH, V47, P1241, DOI 10.1128/AAC.47.4.1241-1250.2003.
   Sun YJ, 2007, INT J TUBERC LUNG D, V11, P436.
   Victor TC, 2001, J CLIN MICROBIOL, V39, P4184, DOI 10.1128/JCM.39.11.4184-4186.2001.
   Zhang M, 2005, J CLIN MICROBIOL, V43, P5477, DOI 10.1128/JCM.43.11.5477-5482.2005.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Clin. Microbiol. Infect.}},
Doc-Delivery-Number = {{184TK}},
Unique-ID = {{ISI:000247664900016}},
}

@article{ ISI:000247664900017,
Author = {Tuuminen, T. and Sorva, S. and Liippo, K. and Vasankari, T. and Soini,
   H. and Eriksen-Neuman, B. and Miettinen, A. and Seppala, I. J.},
Title = {{Feasibility of commercial interferon-gamma-based methods for the
   diagnosis of latent Mycobacterium tuberculosis infection in Finland, a
   country of low incidence and high bacille Calmette-Guerin vaccination
   coverage}},
Journal = {{CLINICAL MICROBIOLOGY AND INFECTION}},
Year = {{2007}},
Volume = {{13}},
Number = {{8}},
Pages = {{836-838}},
Month = {{AUG}},
Abstract = {{The performances of the QuantiFERON-TB Gold in Tubes (QFGT), T SPOT-TB
   (ELISPOT) and the Mantoux test were compared for the diagnosis of latent
   tuberculosis infection in Finland, a country of low tuberculosis
   incidence. In Cohort A (16 students), freshly isolated peripheral blood
   mononuclear cells (PBMCs), and in Cohort B (21 school children),
   cryopreserved PBMCs, were used for the ELISPOT assay. Cryopreservation
   of cells in fetal calf serum, but not in serum-free medium, produced
   false-positive results. Discrepancies between the results of the assays
   were observed. It was concluded that the accuracy of these ex-vivo
   methods needs additional evaluation.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tuuminen, T (Reprint Author), Univ Helsinki Hosp, Dept Immunol, Div Clin Microbiol, HUSLAB, Haartmaninkatu 3,POB 400, Helsinki, Finland.
   Univ Helsinki Hosp, Dept Immunol, Div Clin Microbiol, HUSLAB, Helsinki, Finland.
   Haartman Inst, Helsinki, Finland.
   Univ Helsinki, Dept Appl Chem \& Microbiol, Helsinki, Finland.
   Turku Univ Hosp, Dept Pulm Dis, Paimio Hosp, Preitila, Finland.
   Natl Publ Hlth Inst, Mycobacterial Reference Lab, Turku, Finland.
   Vasa Cent Hosp, Dept Infect Dis, Vaasa, Finland.}},
DOI = {{10.1111/j.1469-0691.2007.01750.x}},
ISSN = {{1198-743X}},
Keywords = {{diagnosis; ELISPOT; Mantoux test; Mycobacterium tuberculosis;
   QuantiFERON test; tuberculosis}},
Keywords-Plus = {{ASSAY; CELLS}},
Research-Areas = {{Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology}},
Author-Email = {{Tamara.Tuuminen@Helsinki.Fi}},
Cited-References = {{Dheda K, 2005, CURR OPIN PULM MED, V11, P195, DOI 10.1097/01.mcp.0000158726.13159.5e.
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6.
   Kreher CR, 2003, J IMMUNOL METHODS, V278, P79, DOI 10.1016/S0022-1759(03)00226-6.
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081.
   Leyten EMS, 2006, J CLIN MICROBIOL, V44, P1197, DOI 10.1128/JCM.44.3.1197-1201.2006.
   Liebeschuetz S, 2004, LANCET, V364, P2196, DOI 10.1016/S0140-6736(04)17592-2.
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.
   Richeldi L, 2006, CLIN MICROBIOL INFEC, V12, P34, DOI 10.1111/j.1469-0691.2006.01655.x.
   Rothman Stanley, 2005, FORUM, V3.}},
Number-of-Cited-References = {{9}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Clin. Microbiol. Infect.}},
Doc-Delivery-Number = {{184TK}},
Unique-ID = {{ISI:000247664900017}},
}

@article{ ISI:000248669300004,
Author = {Key, J. Albert and Brand, Richard A. and Peltier, Leonard F.},
Title = {{Positive pressure in arthrodesis for tuberculosis of the knee joint}},
Journal = {{CLINICAL ORTHOPAEDICS AND RELATED RESEARCH}},
Year = {{2007}},
Number = {{461}},
Pages = {{6-8}},
Month = {{AUG}},
Abstract = {{John Albert Key (1890-1955; Fig. 1) was a junior medical student when he
   volunteered to go overseas with the Johns Hopkins Unit \#18 during World
   War I. This decision affected his later career in two important ways. It
   was in France that he met the American nurse affiliated with the
   hospital who became Mrs. Key, and, it was in France that he finished his
   medical school education and began working with patients with skeletal
   injuries. Following his return to the United States, he continued his
   postgraduate education at Massachusett's General Hospital and the
   Children's Hospital in Boston. His first academic position was as an
   instructor in applied physiology at the Harvard School of Medicine.
   After a short experience as an instructor of orthopedic surgery at the
   University of Maryland, he became the Director of Research at the
   Shriner's Hospital in St. Louis. This hospital and the Washington
   University Medical School became the axis about which his professional
   life revolved the rest of his life.
   J. Albert Key belonged to all of the important surgical and orthopedic
   societies and was president of the American Orthopaedic Association. He
   presided over the first session of the Orthopaedic Section of the
   Surgical Forum of the American College of Surgeons. He was a surgical
   scientist of the first rank and is remembered for his critical
   discussions at meetings.
   His paper describing positive pressure arthrodesis is typical of his
   style. It is clear and concise, and without redundancy. The operation
   was based on the belief that `other things being equal, two bones will
   most readily unite if they are placed in contact and absolutely
   immobilized until union by bone has occurred.' Some of his scepticism
   and his reliance upon an investigative approach is revealed when he
   says: `Whether or not the positive pressure also stimulates osteogenesis
   and union between the bones I do not know. I have attempted to answer
   this question in the experimental laboratory, but as yet the results are
   inconclusive.'}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Reprint}},
Language = {{English}},
Affiliation = {{Brand, RA (Reprint Author), Univ City, Ctr Sci, Clin Orthopaed \& Related Res, 3550 Market St,Suite 220, Philadelphia, PA 19104 USA.
   Univ City, Ctr Sci, Clin Orthopaed \& Related Res, Philadelphia, PA 19104 USA.}},
DOI = {{10.1097/BLO.0b013e318123eb6e}},
ISSN = {{0009-921X}},
Research-Areas = {{Orthopedics; Surgery}},
Web-of-Science-Categories  = {{Orthopedics; Surgery}},
Author-Email = {{dick.brand@clinorthop.org}},
Number-of-Cited-References = {{0}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Clin. Orthop. Rel. Res.}},
Doc-Delivery-Number = {{199AT}},
Unique-ID = {{ISI:000248669300004}},
}

@article{ ISI:000249425000190,
Author = {Azevedo, L. G. and Muccillo-Baisch, A. L. and Filgueira, V, D. and
   Ramos, D. F. and Soares, A. D. and Lerner, C. and Silva, P. A. and
   Trindade, G. S.},
Title = {{Investigation of the cytotoxic and anti-tuberculosis effects of Aplysina
   caissara marine sponge crude extracts}},
Journal = {{COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR \& INTEGRATIVE
   PHYSIOLOGY}},
Year = {{2007}},
Volume = {{148}},
Number = {{1}},
Pages = {{S77-S78}},
Month = {{AUG}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
DOI = {{10.1016/j.cbpa.2007.06.201}},
ISSN = {{1095-6433}},
Research-Areas = {{Biochemistry \& Molecular Biology; Physiology; Zoology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Physiology; Zoology}},
Author-Email = {{daza@vetorial.net}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Comp. Biochem. Physiol. A-Mol. Integr. Physiol.}},
Doc-Delivery-Number = {{209YX}},
Unique-ID = {{ISI:000249425000190}},
}

@article{ ISI:000249368700011,
Author = {Cooper, Andrea M. and Solache, Alejandra and Khader, Shabaana A.},
Title = {{Interleukin-12 and tuberculosis: an old story revisited}},
Journal = {{CURRENT OPINION IN IMMUNOLOGY}},
Year = {{2007}},
Volume = {{19}},
Number = {{4}},
Pages = {{441-447}},
Month = {{AUG}},
Abstract = {{Our understanding of the role of interleukin (IL)-12 in controlling
   tuberculosis has expanded because of increased interest in other members
   of the IL-12 family of cytokines. Recent data show that IL-12, IL-23 and
   IL-27 have specific roles in the initiation, expansion and control of
   the cellular response to tuberculosis. Specifically, IL-12, and to a
   lesser degree IL-23, generates protective cellular responses and
   promotes survival, whereas IL-27 moderates the inflammatory response and
   is required for long-term survival. Paradoxically, IL-27 also limits
   bacterial control, suggesting that a balance between bacterial killing
   and tissue damage is required for survival. Understanding the balance
   between IL-12, IL-23 and IL-27 is crucial to the development of immune
   intervention in tuberculosis.}},
Publisher = {{CURRENT BIOLOGY LTD}},
Address = {{84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Cooper, AM (Reprint Author), Trudeau Inst Inc, 154 Algonquin Ave, Saranac Lake, NY 12983 USA.
   Trudeau Inst Inc, Saranac Lake, NY 12983 USA.
   Millipore Corp, Temecula, CA 92590 USA.}},
DOI = {{10.1016/j.coi.2007.07.004}},
ISSN = {{0952-7915}},
Keywords-Plus = {{T-CELL RESPONSES; CALMETTE-GUERIN INFECTION; MYCOBACTERIUM-TUBERCULOSIS;
   PROTECTIVE EFFICACY; IL-12 PRODUCTION; AUTOIMMUNE ENCEPHALOMYELITIS;
   CHRONIC INFLAMMATION; IMMUNE-RESPONSE; MICE DISPLAY; DNA VACCINE}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{acooper@trudeauinstitute.org}},
ORCID-Numbers = {{Cooper, Andrea/0000-0001-6050-3863}},
Funding-Acknowledgement = {{NIA NIH HHS {[}R21 AG028878, R21 AG028878-01, R21 AG028878-02,
   AG028878]; NIAID NIH HHS {[}AI067723, AI46530, P01 AI046530, P01
   AI046530-050004, R01 AI067723, R01 AI067723-01A1, R01 AI067723-02]}},
Cited-References = {{Aliberti J, 2002, J EXP MED, V196, P1253, DOI 10.1084/jem.20021183.
   Bafica A, 2005, J EXP MED, V202, P1715, DOI 10.1081/jem.20051782.
   Bafica A, 2005, J CLIN INVEST, V115, P1601, DOI 10.1172/JCI23949.
   Batten M, 2007, J MOL MED-JMM, V85, P661, DOI 10.1007/s00109-007-0164-7.
   Batten M, 2006, NAT IMMUNOL, V7, P929, DOI 10.1038/ni1375.
   Bosticardo M, 2004, MOL THER, V9, P895, DOI 10.1016/j.ymthe.2004.02.024.
   Bustamante J, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.043406.
   Chackerian AA, 2006, INFECT IMMUN, V74, P6092, DOI 10.1128/IAI.00621-06.
   CLEARY A, 2002, J IMMUNOL, V170, P597.
   Cooper AM, 2002, J IMMUNOL, V168, P1322.
   Cooper AM, 2007, TRENDS IMMUNOL, V28, P33, DOI 10.1016/j.it.2006.11.002.
   Cruz A, 2006, J IMMUNOL, V177, P1416.
   DSouza CD, 1997, J IMMUNOL, V158, P1217.
   Feinberg J, 2004, EUR J IMMUNOL, V34, P3276, DOI 10.1002/eji.200425221.
   Feng CG, 2005, J IMMUNOL, V174, P4185.
   Filipe-Santos O, 2006, SEMIN IMMUNOL, V18, P347, DOI 10.1016/j.smim.2006.07.010.
   Filipe-Santos O, 2006, J EXP MED, V203, P1745, DOI 10.1084/jem.20050085.
   Flores-Villanueva PO, 2005, J EXP MED, V202, P1649, DOI 10.1084/jem20050216.
   Fremond CM, 2004, J CLIN INVEST, V114, P1790, DOI 10.1172/JCI200421027.
   Ha SJ, 2006, INFECT IMMUN, V74, P4954, DOI 10.1128/IAI.01781-05.
   Happel KI, 2005, INFECT IMMUN, V73, P5782, DOI 10.1128/IAI.73.9.5782-5788.2005.
   Holscher C, 2005, J IMMUNOL, V174, P3534.
   Holscher C, 2001, J IMMUNOL, V167, P6957.
   Khader SA, 2005, J IMMUNOL, V175, P788.
   Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449.
   Khader SA, 2006, J EXP MED, V203, P1805, DOI 10.1084/jem.20052545.
   Li H, 2006, VACCINE, V24, P1315, DOI 10.1016/j.vaccine.2005.09.025.
   Lindblad EB, 1997, INFECT IMMUN, V65, P623.
   Lockhart E, 2006, J IMMUNOL, V177, P4662.
   NAKANO N, 2007, BLOOD.
   OKADA M, 2007, VACCINE, V85, P661.
   Pathak SK, 2005, J BIOL CHEM, V280, P42794, DOI 10.1074/jbc.M506471200.
   Pearl JE, 2004, J IMMUNOL, V173, P7490.
   Pecora ND, 2006, J IMMUNOL, V177, P422.
   Reinhardt RL, 2006, J IMMUNOL, V177, P1618.
   Rosas LE, 2006, AM J PATHOL, V168, P158, DOI 10.2353/ajpath.2006.050013.
   Scanga CA, 2004, INFECT IMMUN, V72, P2400, DOI 10.1128/IAI.72.4.2400-2404.2004.
   Stobie L, 2000, P NATL ACAD SCI USA, V97, P8427, DOI 10.1073/pnas.160197797.
   Stumhofer JS, 2006, NAT IMMUNOL, V7, P937, DOI 10.1038/ni1376.
   Trinchieri G, 2003, IMMUNITY, V19, P641, DOI 10.1016/S1074-7613(03)00296-6.
   Ulrichs T, 2005, EUR J PEDIATR, V164, P166, DOI 10.1007/s00431-004-1599-2.
   Umemura M, 2007, J IMMUNOL, V178, P3786.
   Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001.
   Veldhoen M, 2006, NAT IMMUNOL, V7, P1151, DOI 10.1038/ni1391.
   Wozniak TM, 2006, J IMMUNOL, V177, P8684.
   Wozniak TM, 2006, INFECT IMMUN, V74, P557, DOI 10.1128/IAI.74.1.557-565.2006.
   Yoshida S, 2006, VACCINE, V24, P1191, DOI 10.1016/j.vaccine.2005.08.103.}},
Number-of-Cited-References = {{47}},
Times-Cited = {{64}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{Curr. Opin. Immunol.}},
Doc-Delivery-Number = {{209DH}},
Unique-ID = {{ISI:000249368700011}},
}

@article{ ISI:000248747100005,
Author = {Holton, Simon J. and Weiss, Manfred S. and Tucker, Paul A. and Wilmanns,
   Matthias},
Title = {{Structure-based approaches to drug discovery against tuberculosis}},
Journal = {{CURRENT PROTEIN \& PEPTIDE SCIENCE}},
Year = {{2007}},
Volume = {{8}},
Number = {{4}},
Pages = {{365-375}},
Month = {{AUG}},
Abstract = {{Tuberculosis has become one of the deadliest global emergencies due to
   the widespread existence of multiple drug resistance strains of
   Mycobacterium tuberculosis and the increase of immuno-compromised
   populations in large parts of the world. Although the complete genome of
   M. tuberculosis became available in 1998, opening unprecedented
   opportunities for target-specific drug development, the progress since
   then has been slow, mainly due to a lack of a sufficiently strong
   interest by pharmaceutical and biotechnology industries. One of the most
   promising tools for future drug discovery lies in the elucidation of the
   molecular structures of potential drug targets from the M. tuberculosis
   proteome. During the last five years, the structures of about 200 unique
   targets have already been determined, which comprise about 5\% of the
   entire M. tuberculosis proteome. As an example, we present the approach
   and some of the key achievements of the X-MTB consortium based in
   Germany. We summarize and discuss some recent highlights of potential
   drug targets of M. tuberculosis involved in lipid metabolism, protein
   phosphorylation/dephosphorylation and amino acid biosynthesis. The
   achievements of several structural genomics consortia that focus on
   targets from the M. tuberculosis proteome are now providing a solid
   framework to support coordinated international approaches for future
   structure-based drug discovery programs at the interface between
   industrial enterprises and academic research. One of the objectives will
   be to focus on target complexes, in addition to single targets that
   dominate the present repository of structures from the M. tuberculosis
   proteome.}},
Publisher = {{BENTHAM SCIENCE PUBL LTD}},
Address = {{EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Wilmanns, M (Reprint Author), DESY, European Mol Biol Lab, Notkestr 85, D-22603 Hamburg, Germany.
   DESY, European Mol Biol Lab, D-22603 Hamburg, Germany.}},
ISSN = {{1389-2037}},
Keywords-Plus = {{RAY DIFFRACTION ANALYSIS; ACYL CARRIER PROTEIN; PYRUVATE-DEHYDROGENASE
   COMPLEX; SIGNAL-TRANSDUCTION SYSTEM; PEDANT GENOME DATABASE; GROWTH
   IN-VIVO; MYCOBACTERIUM-TUBERCULOSIS; CRYSTAL-STRUCTURE; ACID
   BIOSYNTHESIS; TYROSINE PHOSPHATASES}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{wilmanns@embl-hamburg.de}},
ResearcherID-Numbers = {{Weiss, Manfred/B-6857-2013
   }},
ORCID-Numbers = {{Wilmanns, Matthias/0000-0002-4643-5435}},
Cited-References = {{Alangaden GJ, 1997, CLIN INFECT DIS, V25, P1213, DOI 10.1086/516116.
   Alifano P, 1996, MICROBIOL REV, V60, P44.
   Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018.
   Anderson DH, 2001, J MOL BIOL, V307, P671, DOI 10.1006/jmbi.2001.4461.
   Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753.
   Anishetty S, 2005, COMPUT BIOL CHEM, V29, P368, DOI 10.1016/j.compbiolchem.2005.07.001.
   Anstrom DM, 2006, PROTEIN SCI, V15, P2002, DOI 10.1110/ps.062300206.
   Arcus VL, 2006, DRUG DISCOV TODAY, V11, P28, DOI 10.1016/S1359-6446(05)03667-6.
   Av-Gay Y, 2000, TRENDS MICROBIOL, V8, P238, DOI 10.1016/S0966-842X(00)01734-0.
   Bagchi G, 2005, MICROBIOL-SGM, V151, P4045, DOI 10.1099/mic.0.28333-0.
   Barona-Gomez F, 2003, EMBO REP, V4, P296, DOI 10.1038/sj.embor.embor771.
   Blundell TL, 2002, NAT REV DRUG DISCOV, V1, P45, DOI 10.1038/nrd706.
   Boitel B, 2003, MOL MICROBIOL, V49, P1493, DOI 10.1046/j.1365-2958.2003.03657.x.
   Boshoff HIM, 2005, NAT REV MICROBIOL, V3, P70, DOI 10.1038/nrmicro1065.
   Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6.
   Camus JC, 2002, MICROBIOL-SGM, V148, P2967.
   Chaudhuri BN, 2003, STRUCTURE, V11, P753, DOI 10.1016/S0969-2126(03)00106-0.
   Cho Y, 2003, J BIOL CHEM, V278, P8333, DOI 10.1074/jbc.M212124200.
   Chua J, 2004, CURR OPIN MICROBIOL, V7, P71, DOI 10.1016/j.mib.2003.12.011.
   Cirilli M, 2003, BIOCHEMISTRY-US, V42, P10644, DOI 10.1021/bi030044v.
   Coggins JR, 2003, BIOCHEM SOC T, V31, P548, DOI 10.1042/BST0310548.
   Cohen J, 2006, SCIENCE, V313, P1554.
   Cohen-Gonsaud M, 2005, NAT STRUCT MOL BIOL, V12, P270, DOI 10.1038/nsmb905.
   Cohen-Gonsaud M, 2002, J MOL BIOL, V320, P249, DOI 10.1016/S0022-2836(02)00463-1.
   Cole ST, 1998, NATURE, V393, P537.
   Cox JS, 1999, NATURE, V402, P79.
   Cozzone AJ, 2005, J MOL MICROB BIOTECH, V9, P198, DOI 10.1159/000089648.
   Cronan JE, 2002, PROG LIPID RES, V41, P407, DOI 10.1016/S0163-7827(02)00007-3.
   Daugelat S, 2003, MICROBES INFECT, V5, P1082, DOI 10.1016/S1286-4579(03)00205-3.
   Deretic V, 2006, CELL MICROBIOL, V8, P719, DOI 10.1111/j.1462-5822.2006.00705.x.
   Diacovich L, 2004, BIOCHEMISTRY-US, V43, P14027, DOI 10.1021/bi049065v.
   Diacovich L, 2002, J BIOL CHEM, V277, P31228, DOI 10.1074/jbc.M203263200.
   Dias MVB, 2006, J STRUCT BIOL, V154, P130, DOI 10.1016/j.jsb.2005.12.008.
   Diaz R, 2006, TUBERCULOSIS, V86, P314, DOI 10.1016/j.tube.2006.01.002.
   Douglas JD, 2002, MICROBIOL-SGM, V148, P3101.
   Downing KJ, 2005, INFECT IMMUN, V73, P3038, DOI 10.1128/IAI.73.5.3038-3043.2005.
   Duncan K, 2004, CURR PHARM DESIGN, V10, P3185, DOI 10.2174/1381612043383223.
   Dyer DH, 2005, PROTEIN SCI, V14, P1508, DOI 10.1110/ps.041288005.
   Eswaran J, 2006, BIOCHEM J, V395, P483, DOI 10.1042/BJ20051931.
   Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002.
   Franzblau SG, 1998, J CLIN MICROBIOL, V36, P362.
   Frieden TR, 2005, CLIN CHEST MED, V26, P197, DOI 10.1016/j.ccm.2005.02.001.
   Frishman D, 2003, NUCLEIC ACIDS RES, V31, P207, DOI 10.1093/nar/gkg005.
   Fuchs TM, 2000, J BACTERIOL, V182, P3626, DOI 10.1128/JB.182.13.3626-3631.2000.
   Gan JH, 2006, BIOCHEMISTRY-US, V45, P8539, DOI 10.1021/bi0606290.
   Gande R, 2004, J BIOL CHEM, V279, P44847, DOI 10.1074/jbc.M408648200.
   Gay LM, 2006, J MOL BIOL, V360, P409, DOI 10.1016/j.jmb.2006.05.015.
   Geerlof A, 2006, ACTA CRYSTALLOGR D, V62, P1125, DOI 10.1107/S0907444906030307.
   Glynn JR, 2002, EMERG INFECT DIS, V8, P843.
   Gokulan K, 2003, J BIOL CHEM, V278, P18588, DOI 10.1074/jbc.M301549200.
   Gopalan G, 2006, PROTEINS, V65, P796, DOI 10.1002/prot.21126.
   Gordhan BG, 2002, INFECT IMMUN, V70, P3080, DOI 10.1128/IAI.70.6.3080-3084.2002.
   Gould TA, 2006, MOL MICROBIOL, V61, P940, DOI 10.1111/j.1365-2958.2006.05297.x.
   Goulding CW, 2003, BIOPHYS CHEM, V105, P361, DOI 10.1016/S0301-4622(03)00101-7.
   Greenstein AE, 2005, J MOL MICROB BIOTECH, V9, P167, DOI 10.1159/000089645.
   Grundner C, 2005, STRUCTURE, V13, P1625, DOI 10.1016/j.str.2005.07.017.
   Gu YJ, 2002, J MOL BIOL, V319, P779, DOI 10.1016/S0022-2836(02)00339-X.
   Hall PR, 2003, EMBO J, V22, P2334, DOI 10.1093/emboj/cdg244.
   Hartmann MD, 2006, J MOL BIOL, V364, P411, DOI 10.1016/j.jmb.2006.09.001.
   Haydel SE, 2004, FEMS MICROBIOL LETT, V236, P341, DOI 10.1016/j.femsle.2004.06.010.
   Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1.
   Hegde SS, 2005, SCIENCE, V308, P1480, DOI 10.1126/science.1110699.
   Hisert KB, 2004, INFECT IMMUN, V72, P5315, DOI 10.1128/IAI.72.9.5315-5321.2004.
   Holton SJ, 2006, FEBS LETT, V580, P6898, DOI 10.1016/j.febslet.2006.11.054.
   Hondalus MK, 2000, INFECT IMMUN, V68, P2888, DOI 10.1128/IAI.68.5.2888-2898.2000.
   Hu YM, 2006, INFECT IMMUN, V74, P861, DOI 10.1128/IAI.74.2.861-868.2006.
   Huang CC, 2002, J BIOL CHEM, V277, P11559, DOI 10.1074/jbc.M111698200.
   Hutton CA, 2003, MINI-REV MED CHEM, V3, P115, DOI 10.2174/1389557033405359.
   Johnson R, 2006, CURR ISSUES MOL BIOL, V8, P97.
   Jones DD, 2000, BIOCHEMISTRY-US, V39, P8448, DOI 10.1021/bi992978i.
   Jordan SW, 1997, J BIOL CHEM, V272, P17903, DOI 10.1074/jbc.272.29.17903.
   Kanehisa M., 2004, NUCLEIC ACIDS RES, V32, P277.
   Kantardjieff K, 2004, CURR PHARM DESIGN, V10, P3195, DOI 10.2174/1381612043383205.
   Kaufmann SHE, 2005, NAT IMMUNOL, V6, P1063, DOI 10.1038/ni1105-1063.
   Kaufmann SHE, 2005, CURR OPIN IMMUNOL, V17, P79, DOI 10.1016/j.coi.2004.12.004.
   Keep NH, 2006, TRENDS MICROBIOL, V14, P271, DOI 10.1016/j.tim.2006.04.003.
   Kefala G, 2005, ACTA CRYSTALLOGR F, V61, P718, DOI 10.1107/S074430910501938X.
   Kefala G, 2005, ACTA CRYSTALLOGR F, V61, P782, DOI 10.1107/S1744309105022839.
   Kefala G, 2006, ACTA CRYSTALLOGR F, V62, P1116, DOI 10.1107/S1744309106039844.
   Kim P, 2006, J MED CHEM, V49, P159, DOI 10.1021/jm050825p.
   Koon N, 2004, P NATL ACAD SCI USA, V101, P8295, DOI 10.1073/pnas.0400820101.
   Koul A, 2004, NAT REV MICROBIOL, V2, P189, DOI 10.1038/nrmicro840.
   Koul A, 2000, J BACTERIOL, V182, P5425, DOI 10.1128/JB.182.19.5425-5432.2000.
   Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200.
   Kuper J, 2005, EMBO REP, V6, P134, DOI 10.1038/sj.embor.7400330.
   Lawn SD, 2006, BRIT MED J, V333, P559, DOI 10.1136/bmj.38971.587222.AB.
   Leonardi R, 2005, PROG LIPID RES, V44, P125, DOI 10.1016/j.plipres.2005.04.001.
   Leyten EMS, 2006, MICROBES INFECT, V8, P2052, DOI 10.1016/j.micinf.2006.03.018.
   Lin TW, 2006, P NATL ACAD SCI USA, V103, P3072, DOI 10.1073/pnas.0510580103.
   Ma QJ, 2006, P NATL ACAD SCI USA, V103, P8662, DOI 10.1073/pnas.0510436103.
   Malhotra V, 2004, FEMS MICROBIOL LETT, V231, P237, DOI 10.1016/S0378-1097(04)00002-3.
   Manabe YC, 2000, NAT MED, V6, P1327, DOI 10.1038/82139.
   Manger M, 2005, CHEMBIOCHEM, V6, P1749, DOI 10.1002/cbic.200500171.
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762.
   Marri PR, 2006, FEMS MICROBIOL REV, V30, P906, DOI 10.1111/j.1574-6976.2006.00041.x.
   Mattow J, 2003, ELECTROPHORESIS, V24, P3405, DOI 10.1002/elps.200305601.
   McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074.
   Mdluli K, 2006, CURR OPIN PHARMACOL, V6, P459, DOI 10.1016/j.coph.2006.06.004.
   Mira A, 2001, TRENDS GENET, V17, P589, DOI 10.1016/S0168-9525(01)02447-7.
   Mollenkopf HJ, 2004, INFECT IMMUN, V72, P6471, DOI 10.1128/IAI.72.11.6471-6479.2004.
   Mollenkopf HJ, 2002, METHOD ENZYMOL, V358, P242.
   Montero C, 2001, ANTIMICROB AGENTS CH, V45, P3387, DOI 10.1128/AAC.45.12.3387-3392.2001.
   Morth JP, 2004, STRUCTURE, V12, P1595, DOI 10.1016/j.str.2004.06.018.
   Morton J, 2005, CURR OPIN PHARMACOL, V5, P79, DOI 10.1016/j.coph.2004.08.007.
   Muller D, 2006, J MED CHEM, V49, P4871, DOI 10.1021/jm060327w.
   Mueller-Dieckmann J, 2006, ACTA CRYSTALLOGR D, V62, P1446, DOI 10.1107/S0907444906038121.
   Mukamolova GV, 2002, MOL MICROBIOL, V46, P611, DOI 10.1046/j.1365-2958.2002.03183.x.
   Munoz-Elias EJ, 2005, NAT MED, V11, P638, DOI 10.1038/nm1252.
   Musayev F, 2005, J MOL BIOL, V346, P1313, DOI 10.1016/j.jmb.2004.12.044.
   Nayyar A, 2005, CURR MED CHEM, V12, P1873, DOI 10.2174/0929867054546654.
   Nguyen L, 2005, TRENDS CELL BIOL, V15, P269, DOI 10.1016/j.tcb.2005.03.009.
   Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920.
   Norman RA, 2002, STRUCTURE, V10, P393, DOI 10.1016/S0969-2126(02)00718-9.
   Nowak E, 2006, J BIOL CHEM, V281, P9659, DOI 10.1074/jbc.M512004200.
   Nowak E, 2006, STRUCTURE, V14, P275, DOI 10.1016/j.str.2005.10.006.
   Nuermberger EL, 2004, AM J RESP CRIT CARE, V170, P1131, DOI 10.1164/rccm.200407-885SOC.
   Ortiz-Lombardia M, 2003, J BIOL CHEM, V278, P13094, DOI 10.1074/jbc.M300660200.
   Pai RK, 2003, J IMMUNOL, V171, P175.
   Parish T, 2002, MICROBIOL-SGM, V148, P3069.
   Parish T, 1999, MICROBIOL-UK, V145, P3497.
   Parish T, 2003, MICROBIOL-SGM, V149, P1423, DOI 10.1099/mic.0.26245-0.
   Park HD, 2003, MOL MICROBIOL, V48, P833, DOI 10.1046/j.1365-2958.2003.03474.x.
   Patzel V, 2005, NAT BIOTECHNOL, V23, P1440, DOI 10.1038/nbt1151.
   Pavelka MS, 2003, INFECT IMMUN, V71, P4190, DOI 10.1128/IAI.71.7.4190-4192.2003.
   Perez E, 2004, J BIOL CHEM, V279, P42584, DOI 10.1074/jbc.M406134200.
   Perez E, 2001, MOL MICROBIOL, V41, P179, DOI 10.1046/j.1365-2958.2001.02500.x.
   Portevin D, 2005, J BIOL CHEM, V280, P8862, DOI 10.1074/jbc.M408578200.
   Rachman H, 2006, MICROBES INFECT, V8, P747, DOI 10.1016/j.micinf.2005.09.011.
   Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837.
   Renshaw PS, 2005, EMBO J, V24, P2491, DOI 10.1038/sj.emboj.7600732.
   Rickman L, 2004, BIOCHEM BIOPH RES CO, V314, P259, DOI 10.1016/j.bbrc.2003.12.082.
   Riley ML, 2005, NUCLEIC ACIDS RES, V33, pD308, DOI 10.1093/nar/gki019.
   Roberts CW, 2002, J INFECT DIS, V185, pS25, DOI 10.1086/338004.
   Roberts DM, 2004, J BIOL CHEM, V279, P23082, DOI 10.1074/jbc.M401230200.
   Ronning DR, 2004, J BIOL CHEM, V279, P36771, DOI 10.1074/jbc.M400811200.
   Roy E, 2006, IMMUNOL LETT, V103, P196, DOI 10.1016/j.imlet.2005.10.011.
   Rozwarski DA, 1999, J BIOL CHEM, V274, P15582, DOI 10.1074/jbc.274.22.15582.
   Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034.
   Russell RJ, 2006, NATURE, V443, P45, DOI 10.1038/nature05114.
   Salgame P, 2005, CURR OPIN IMMUNOL, V17, P374, DOI 10.1016/j.coi.2005.06.006.
   Sambandamurthy VK, 2005, MICROBES INFECT, V7, P955, DOI 10.1016/j.micinf.2005.04.001.
   Sambandamurthy VK, 2005, INFECT IMMUN, V73, P1196, DOI 10.1128/IAI.73.2.1196-1203.2005.
   Sambandamurthy VK, 2002, NAT MED, V8, P1171, DOI 10.1038/nm765.
   Sankaranarayanan R, 2004, NAT STRUCT MOL BIOL, V11, P894, DOI 10.1038/nsmb809.
   Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100.
   Scarsdale JN, 2001, J BIOL CHEM, V276, P20516, DOI 10.1074/jbc.M010762200.
   Schade M, 2005, CURR OPIN DRUG DISC, V8, P365.
   Schmidt F, 2004, MOL CELL PROTEOMICS, V3, P24, DOI 10.1074/mcp.M300074-MCP200.
   Schroeder E. K., 2002, Current Pharmaceutical Biotechnology, V3, P197, DOI 10.2174/1389201023378328.
   Sharma SK, 2006, CHEST, V130, P261, DOI 10.1378/chest.130.1.261.
   Sharma V, 2000, NAT STRUCT BIOL, V7, P663, DOI 10.1038/77964.
   Singh RK, 2005, J MOL BIOL, V346, P1, DOI 10.1016/j.jmb.2004.11.059.
   Slayden RA, 2000, MOL MICROBIOL, V38, P514, DOI 10.1046/j.1365-2958.2000.02145.x.
   Smith CV, 2003, CURR OPIN STRUC BIOL, V13, P658, DOI 10.1016/j.sbi.2003.10.004.
   Smith CV, 2004, TUBERCULOSIS, V84, P45, DOI 10.1016/j.tube.2003.08.019.
   Smith DA, 2001, INFECT IMMUN, V69, P1142, DOI 10.1128/IAI.69.2.1442-1150.2001.
   Strong Michael, 2006, Methods Biochem Anal, V49, P245.
   Sulzenbacher G, 2006, EMBO J, V25, P1436, DOI 10.1038/sj.emboj.7601048.
   Surleraux DLNG, 2005, J MED CHEM, V48, P1965, DOI 10.1021/jm049454m.
   Sutcliffe IC, 2004, FEMS MICROBIOL REV, V28, P645, DOI 10.1016/j.femsre.2004.06.002.
   Takayama K, 2005, CLIN MICROBIOL REV, V18, P81, DOI 10.1128/CMR.18.1.81-101.2005.
   Terwilliger TC, 2003, TUBERCULOSIS, V83, P223, DOI 10.1016/S1472-9792(03)00051-9.
   Tong L, 2005, CELL MOL LIFE SCI, V62, P1784, DOI 10.1007/s00018-005-5121-4.
   Trivedi OA, 2004, NATURE, V428, P441, DOI 10.1038/nature02384.
   Tyagi JS, 2004, MICROBIOL-SGM, V150, P4, DOI 10.1009/mic.0.26863-0.
   Vega MC, 2005, MOL MICROBIOL, V55, P675, DOI 10.1111/j.1365-2958.2004.04422.x.
   Vergne I, 2005, P NATL ACAD SCI USA, V102, P4033, DOI 10.1073/pnas.0409716102.
   Veyron-Churlet R, 2004, MOL MICROBIOL, V54, P1161, DOI 10.1111/j.1365-2958.2004.04334.x.
   Vilcheze C, 2006, NAT MED, V12, P1027, DOI 10.1038/nm1466.
   VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0.
   Walburger A, 2004, SCIENCE, V304, P1800, DOI 10.1126/science.1099384.
   Wang F, 2006, ANTIMICROB AGENTS CH, V50, P2762, DOI 10.1128/AAC.00320-06.
   Wang SS, 2003, PROTEIN SCI, V12, P1097, DOI 10.1110/ps.0241803.
   Watkins HA, 2006, J BACTERIOL, V188, P3589, DOI 10.1128/JB.188.10.3589-3599.2006.
   Webby CJ, 2005, J MOL BIOL, V354, P927, DOI 10.1016/j.jmb.2005.09.
   Wehenkel A, 2006, FEBS LETT, V580, P3018, DOI 10.1016/j.febslet.2006.04.046.
   Weyand S, 2007, J MOL BIOL, V367, P825, DOI 10.1016/j.jmb.2007.01.023.
   Weyand S, 2006, ACTA CRYSTALLOGR F, V62, P794, DOI 10.1107/S1744309106026753.
   World Health Organization, 1993, SOZ PRAVENTIVMED, V38, P251, DOI DOI 10.1007/BF01624546.
   Williams SP, 2005, CURR OPIN CHEM BIOL, V9, P371, DOI 10.1016/j.cbpa.2005.06.007.
   Wilson Michael, 1999, Proceedings of the National Academy of Sciences of the United States of America, V96, P12833, DOI 10.1073/pnas.96.22.12833.
   Wisedchaisri G, 2005, J MOL BIOL, V354, P630, DOI 10.1016/j.jmb.2005.09.048.
   Wong HC, 2002, J BIOL CHEM, V277, P15874, DOI 10.1074/jbc.M112300200.
   Young D, 2002, NAT IMMUNOL, V3, P1026, DOI 10.1038/ni1102-1026.
   Young TA, 2003, NAT STRUCT BIOL, V10, P168, DOI 10.1038/nsb897.
   Zahrt TC, 2001, P NATL ACAD SCI USA, V98, P12706, DOI 10.1073/pnas.221272198.
   Zhang HL, 2003, SCIENCE, V299, P2064, DOI 10.1126/science.1081366.
   Zhang L, 2006, J HYDROL ENG, V11, P21, DOI 10.1061/(ASCE)1084-0699(2006)11:1(21).
   Zhang Y, 2002, CURR DRUG TARGETS, V3, P131, DOI 10.2174/1389450024605391.
   Zheng RJ, 2004, BIOCHEMISTRY-US, V43, P7171, DOI 10.1021/bi049676n.}},
Number-of-Cited-References = {{190}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Curr. Protein Pept. Sci.}},
Doc-Delivery-Number = {{200EQ}},
Unique-ID = {{ISI:000248747100005}},
}

@article{ ISI:000248937500016,
Author = {Ursavas, Ahmet and Ege, Ercuement and Bilgen, Oemer Faruk and Tasdelen,
   Ismet and Coskun, Funda and Soenmez, Sevginar and Goezue, R. Oktay},
Title = {{Breast and osteoarticular tuberculosis in a male patient}},
Journal = {{DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE}},
Year = {{2007}},
Volume = {{58}},
Number = {{4}},
Pages = {{477-479}},
Month = {{AUG}},
Abstract = {{Breast tuberculosis is an uncommon illness. It is predominant in young
   women. To our knowledge, only 7 cases of tuberculous mastitis in men
   have been reported in the English literature since 1945. Furthermore,
   there are no male patients who have breast and osteoarticular
   tuberculosis in the literature. We presented a 4 1 -year-old man who was
   admitted with a fixed tender mass in the right retromammary region and
   pain in the right hip. Mycobacterium tuberculosis colonies were isolated
   from the semisolid mass of breast. Histopathologic examination revealed
   caseous granulomatous infection in the right hip synovial tissue. He was
   treated successfully with only antituberculous drugs. (C) 2007 Elsevier
   Inc. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ursavas, A (Reprint Author), Uludag Univ, Tip Fak, TR-16059 Gorukle, Bursa, Turkey.
   Univ Uludag, Sch Med, Dept Pulm Med, Bursa, Turkey.
   Univ Uludag, Sch Med, Dept Orthopaed, Bursa, Turkey.
   Univ Uludag, Sch Med, Dept Gen Surg, Bursa, Turkey.}},
DOI = {{10.1016/j.diagmicrobio.2007.03.010}},
ISSN = {{0732-8893}},
Keywords = {{breast tuberculosis; male; osteoarticular tuberculosis}},
Keywords-Plus = {{MAMMARY TUBERCULOSIS}},
Research-Areas = {{Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology}},
Author-Email = {{ahmetursavas@gmail.com}},
Cited-References = {{Bani-Hani KE, 2005, INT J TUBERC LUNG D, V9, P920.
   Bodur Hurrem, 2003, Ann Clin Microbiol Antimicrob, V2, P6, DOI 10.1186/1476-0711-2-6.
   Engin G, 2000, RADIOGRAPHICS, V20, P471.
   FUKUOLA K, 1995, KEKKAKU, V2, P111.
   Gonzalez-Gay MA, 1999, CLIN EXP RHEUMATOL, V17, P663.
   HAAGENSEN CD, 1971, DIS BREAST, P335.
   HAMIT HF, 1982, J ROY SOC MED, V75, P764.
   Kakkar S, 2000, ACTA CYTOL, V44, P292.
   Khanna R, 2002, POSTGRAD MED J, V78, P422, DOI 10.1136/pmj.78.921.422.
   LUNA A, 2004, BREAST, P58.
   SHINDE SR, 1995, WORLD J SURG, V19, P379.
   Tewari M, 2005, INDIAN J MED RES, V122, P103.
   Verfaillie Guy, 2004, Breast J, V10, P60, DOI 10.1111/j.1524-4741.2004.09621.x.
   Winzer KJ, 2005, INT J INFECT DIS, V9, P176, DOI 10.1016/j.ijid.2004.07.007.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Diagn. Microbiol. Infect. Dis.}},
Doc-Delivery-Number = {{202XJ}},
Unique-ID = {{ISI:000248937500016}},
}

@article{ ISI:000248530900009,
Author = {den Boon, Saskia and van Lill, Schalk W. P. and Borgdorff, Martien W.
   and Enarson, Donald A. and Verver, Suzanne and Bateman, Eric D. and
   Irusen, Elvis and Lombard, Carl J. and White, Neil W. and de Villiers,
   Christine and Beyers, Nulda},
Title = {{High prevalence of tuberculosis in previously treated patients, Cape
   Town, South Africa}},
Journal = {{EMERGING INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{13}},
Number = {{8}},
Pages = {{1189-1194}},
Month = {{AUG}},
Abstract = {{The tuberculosis (TB) notification rate is high and increasing in 2
   communities in Cape Town, South Africa. In 2002, we conducted a
   prevalence survey among adults >= 15 years of age to determine the TB
   prevalence rate; 15\% of households in these communities were randomly
   sampled. All persons living in sampled households were eligible for
   chest radiography and sputum examination. Of the 3,483 adults who
   completed a questionnaire, 2,608 underwent chest radiography and sputum
   examination. We detected 26 bacteriologically confirmed TB cases and a
   prevalence of 10.0/1,000 (95\% confidence interval {[}Cl] 6.2-13.8 per
   1,000). We found 18 patients with smear-positive TB, of whom 8 were new
   patients (3.1/1,000, 95\% Cl 0.9-5.1/1,000). More than half of patients
   with smear-positive TB (10, 56\%) had previously been treated. Such
   patients may contribute to transmission of Mycobacterium tuberculosis
   and the high TB prevalence rate. Successful treatment of TB patients
   must be a priority.}},
Publisher = {{CENTER DISEASE CONTROL}},
Address = {{ATLANTA, GA 30333 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{den Boon, S (Reprint Author), KNCV TB Fdn, POB 146, NL-2501 CC The Hague, Netherlands.
   KNCV TB Fdn, NL-2501 CC The Hague, Netherlands.
   Univ Stellenbosch, Cape Town, South Africa.
   Acad Med Ctr, Amsterdam, Netherlands.
   Int Union TB \& Lung Dis, Paris, France.
   Univ Cape Town, ZA-7925 Cape Town, South Africa.
   MRC, Cape Town, South Africa.
   City Cape Town Hlth Dept, Cape Town, South Africa.}},
ISSN = {{1080-6040}},
Keywords-Plus = {{DRUG-RESISTANT TUBERCULOSIS; TRIBAL POPULATION; WESTERN CAPE;
   REINFECTION; PROGRAM; INDIA}},
Research-Areas = {{Immunology; Infectious Diseases}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases}},
Author-Email = {{denboons@kncvtbc.nl}},
Cited-References = {{Carroll NM, 2002, CLIN CHEM LAB MED, V40, P888, DOI 10.1515/CCLM.2002.157.
   Chen XY, 2004, LANCET, V364, P417.
   {*}CIT CAP TOWN METR, 2002, PARTN PROV ADM W CAP.
   Corbett EL, 2004, AM J RESP CRIT CARE, V170, P673, DOI 10.1164/rccm.200405-590OC.
   Datta M, 2001, INT J TUBERC LUNG D, V5, P240.
   Den Boon S, 2005, INT J TUBERC LUNG D, V9, P1088.
   Department of Health, 2005, NAT HIV SYPH ANT SER.
   Enarson D, 2000, MANAGEMENT TUBERCULO.
   Enarson DA, 1998, INT J TUBERC LUNG D, V2, pS16.
   Gopi PG, 2003, INT J TUBERC LUNG D, V7, P1154.
   GRZYBOWSKI S, 1972, ARCH ENVIRON HEALTH, V25, P329.
   Hong YP, 1998, INT J TUBERC LUNG D, V2, P27.
   HOUGH A, 1996, PHYSIOTHERAPY RESP C, P134.
   Murhekar MV, 2004, B WORLD HEALTH ORGAN, V82, P836.
   National Tuberculosis Control Program South Africa, 2002, MOB TUB S AFR PLAN T.
   Okutan O, 2003, YONSEI MED J, V44, P242.
   Schaaf HS, 2006, ACTA PAEDIATR, V95, P523, DOI 10.1080/08035250600675741.
   Schaaf HS, 2000, INT J TUBERC LUNG D, V4, P1149.
   StataCorp, 2003, STAT STAT SOFTW REL.
   {*}STAT S AFR, 2001, STAT SUPP INF.
   Tupasi TE, 1999, INT J TUBERC LUNG D, V3, P471.
   Van Deun A, 2004, INT J TUBERC LUNG D, V8, P816.
   Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602.
   Verver S, 2005, AM J RESP CRIT CARE, V171, P1430, DOI 10.1164/rccm.200409-1200OC.
   {*}W CAP TUB PROGR, 2001, HLTH FAC REP UITS CL.
   WEYER K, 1995, S AFR MED J, V85, P499.
   World Health Organization, 2005, WHOHTMTB2005349.}},
Number-of-Cited-References = {{27}},
Times-Cited = {{41}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Emerg. Infect. Dis}},
Doc-Delivery-Number = {{197CK}},
Unique-ID = {{ISI:000248530900009}},
}

@article{ ISI:000248865500111,
Author = {Park, S-H and Hart, L. and Cao, W.},
Title = {{Screening mycobacterium tuberculosis genome for genes involved in
   cellular response to nitrosative stress.}},
Journal = {{ENVIRONMENTAL AND MOLECULAR MUTAGENESIS}},
Year = {{2007}},
Volume = {{48}},
Number = {{7}},
Pages = {{567-568}},
Month = {{AUG}},
Note = {{38th Annual Meeting of the Environmental-Mutagen-Society, Atlanta, GA,
   OCT 20-24, 2007}},
Organization = {{Environm Mutagen Soc}},
Publisher = {{WILEY-LISS}},
Address = {{DIV JOHN WILEY \& SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Clemson Univ, S Carolina Expt Stn, Dept Genet \& Biochem, Clemson, SC USA.}},
ISSN = {{0893-6692}},
Research-Areas = {{Environmental Sciences \& Ecology; Genetics \& Heredity; Toxicology}},
Web-of-Science-Categories  = {{Environmental Sciences; Genetics \& Heredity; Toxicology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Environ. Mol. Mutagen.}},
Doc-Delivery-Number = {{201XI}},
Unique-ID = {{ISI:000248865500111}},
}

@article{ ISI:000249150500020,
Author = {van Hest, N. A. H. and Smit, F. and Baars, H. W. M. and De Vries, G. and
   De Haas, P. E. W. and Westenend, P. J. and Nagelkerke, N. J. D. and
   Richardus, J. H.},
Title = {{Completeness of notification of tuberculosis in The Netherlands: how
   reliable is record-linkage and capture-recapture analysis?}},
Journal = {{EPIDEMIOLOGY AND INFECTION}},
Year = {{2007}},
Volume = {{135}},
Number = {{6}},
Pages = {{1021-1029}},
Month = {{AUG}},
Abstract = {{The aim of this study was to describe a systematic process of
   record-linkage, cross-validation, case-ascertainment and
   capture-recapture analysis to assess the quality of tuberculosis
   registers and to estimate the completeness of notification of incident
   tuberculosis cases in The Netherlands in 1998. After record-linkage and
   cross-validation 1499 tuberculosis patients were identified, of whom
   1298 were notified, resulting in an observed under-notification of
   13.4\%. After adjustment for possible imperfect record-linkage and
   remaining false-positive hospital cases observed under-notification was
   7.3\%. Log-linear capture-recapture analysis initially estimated a total
   number of 2053 (95\% CI 1871-2443) tuberculosis cases, resulting in an
   estimated under-notification of 36.8\%. After adjustment for possible
   imperfect record-linkage and remaining false-positive hospital cases
   various capture-recapture models estimated under-notification at 13.6\%.
   One of the reasons for the higher than expected estimated
   under-notification in a country with a well-organized system of
   tuberculosis control might be that some tuberculosis cases, e.g.
   extrapulmonary tuberculosis, are managed by clinicians less familiar
   with notification of infectious diseases. This study demonstrates the
   possible impact of violation of assumptions underlying capture-recapture
   analysis, especially the perfect record-linkage, perfect positive
   predictive value and absent three-way interaction assumptions.}},
Publisher = {{CAMBRIDGE UNIV PRESS}},
Address = {{32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{van Hest, NAH (Reprint Author), Dept Infect Dis Control, Rotterdam Publ Hlth Serv, Tuberculosis Control Sect, PO Box 70032, NL-3000 LP Rotterdam, Netherlands.
   Dept Infect Dis Control, Publ Hlth Serv, Rotterdam, Netherlands.
   Erasmus Univ, Ctr Med, Dept Publ Hlth, Rotterdam, Netherlands.
   Inst Mental Hlth \& Addict, Trimbos Inst, Utrecht, Netherlands.
   Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands.
   Natl Inst Publ Hlth \& Environm, Mycobacteria Ref Unit, Diagnost Lab Infect Dis \& Prenatal Screening, NL-3720 BA Bilthoven, Netherlands.
   Pathol Lab, Dordrecht, Netherlands.
   United Arab Emirates Univ, Fac Med \& Hlth Sci, Dept Commun Med, Al Ain, U Arab Emirates.}},
DOI = {{10.1017/S0950268806007540}},
ISSN = {{0950-2688}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; SYSTEMS ESTIMATION; POPULATION-SIZE; FREQUENCY
   DATA; EPIDEMIOLOGY; LIMITATIONS; PREVALENCE; NUMBER; VALIDITY; PROVINCE}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Author-Email = {{vanhestr@ggd.rotterdam.nl}},
ORCID-Numbers = {{Westenend, Pieter/0000-0002-5509-920X}},
Cited-References = {{Baussano I, 2006, INT J TUBERC LUNG D, V10, P415.
   Bishop Yvonne M. M., 1975, DISCRETE MULTIVARIAT.
   Bohning D, 2004, EUR J EPIDEMIOL, V19, P1075, DOI 10.1007/s10654-004-3006-8.
   BRENNER H, 1995, EPIDEMIOLOGY, V6, P42, DOI 10.1097/00001648-199501000-00009.
   Cailhol J, 2005, INT J TUBERC LUNG D, V9, P803.
   CHAO A, 1989, BIOMETRICS, V45, P427, DOI 10.2307/2531487.
   CHAO A, 1987, BIOMETRICS, V43, P783, DOI 10.2307/2531532.
   CHAO A, 1988, J WILDLIFE MANAGE, V52, P295, DOI 10.2307/3801237.
   Cormack RM, 1999, J CLIN EPIDEMIOL, V52, P909.
   Cortes JMM, 2001, EUR J EPIDEMIOL, V17, P737.
   DESENCLOS JC, 1994, INT J EPIDEMIOL, V23, P1322, DOI 10.1093/ije/23.6.1322.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   FIENBERG SE, 1972, BIOMETRIKA, V59, P591, DOI 10.2307/2334810.
   Hay G, 2003, ADDICT RES THEORY, V11, P235, DOI 10.1080/1606635031000135622.
   Hook EB, 2000, AM J EPIDEMIOL, V152, P771, DOI 10.1093/aje/152.8.771.
   Hook EB, 1995, EPIDEMIOL REV, V17, P243.
   HOOK EB, 1982, AM J EPIDEMIOL, V116, P168.
   Jarvis S N, 2000, Inj Prev, V6, P46, DOI 10.1136/ip.6.1.46.
   Klein S, 2005, Euro Surveill, V10, P244.
   {*}KNCV TUB FDN, 2005, IND TUB 2001 2002 NE.
   MIGLIORI GB, 1995, EUR RESPIR J, V8, P1252, DOI 10.1183/09031936.95.08081252.
   Mukerjee A K, 1999, Commun Dis Public Health, V2, P143.
   Papoz L, 1996, INT J EPIDEMIOL, V25, P474, DOI 10.1093/ije/25.3.474.
   Regal RR, 1998, STAT MED, V17, P69, DOI 10.1002/(SICI)1097-0258(19980115)17:1<69::AID-SIM729>3.0.CO;2-Q.
   Sanghavi DM, 1998, AM J EPIDEMIOL, V148, P384.
   Seber GAF, 2000, BIOMETRICS, V56, P1227, DOI 10.1111/j.0006-341X.2000.01227.x.
   Smit F, 2002, EVAL PROGRAM PLANN, V25, P101, DOI 10.1016/S0149-7189(02)00002-2.
   SMIT F, 1997, PROJECT METHODOLOGIC, P47.
   Tilling K, 2001, INT J EPIDEMIOL, V30, P12, DOI 10.1093/ije/30.1.12.
   Tocque K, 2001, Commun Dis Public Health, V4, P141.
   Van Hest NAH, 2002, EPIDEMIOL INFECT, V129, P371, DOI 10.1017/S0950268802007306.
   van Loenhout-Rooyackers JH, 2001, INT J TUBERC LUNG D, V5, P1156.
   World Health Organization (WHO), 2004, 2004 WHO.
   WILSON RM, 1992, BIOMETRIKA, V79, P543, DOI 10.1093/biomet/79.3.543.
   YIP PSF, 1995, AM J EPIDEMIOL, V142, P1059.
   YIP PSF, 1995, AM J EPIDEMIOL, V142, P1047.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{31}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Epidemiol. Infect.}},
Doc-Delivery-Number = {{205YG}},
Unique-ID = {{ISI:000249150500020}},
}

@article{ ISI:000248327200011,
Author = {Bartu, V.},
Title = {{Multidrug-resistant tuberculosis in the Czech Republic: strategy and
   therapeutic outcomes}},
Journal = {{EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY \& INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{26}},
Number = {{8}},
Pages = {{603-605}},
Month = {{AUG}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING STREET, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bartu, V (Reprint Author), Charles Univ Prague, Sch Med 1, Dept Resp Dis, Thomayer Fac Hosp, Prague, Czech Republic.
   Charles Univ Prague, Sch Med 1, Dept Resp Dis, Thomayer Fac Hosp, Prague, Czech Republic.}},
DOI = {{10.1007/s10096-007-0332-2}},
ISSN = {{0934-9723}},
Research-Areas = {{Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology}},
Author-Email = {{vaclava.bartu@ftn.cz}},
Cited-References = {{Caminero JA, 2005, EUR RESPIR J, V25, P928, DOI 10.1183/09031936.05.00103004.
   Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706.
   ISEMAN MD, 1993, NEW ENGL J MED, V329, P784.
   Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928.
   MOHAPATRA PR, 2004, AM J RESP CRIT CARE, V169, P920.
   Sbarbaro JA, 1997, CHEST, V111, P1149, DOI 10.1378/chest.111.5.1149.
   Schachter EN, 2004, CHEST, V126, P1724, DOI 10.1378/chest.126.6.1724.
   van Rie A, 2005, AM J RESP CRIT CARE, V172, P636, DOI 10.1164/rccm.200503-449OC.
   World Health Organization, 2004, PUBL WHO.}},
Number-of-Cited-References = {{9}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Eur. J. Clin. Microbiol. Infect. Dis.}},
Doc-Delivery-Number = {{194EN}},
Unique-ID = {{ISI:000248327200011}},
}

@article{ ISI:000248327200012,
Author = {Neonakis, I. K. and Gitti, Z. and Baritaki, M. and Kourbeti, I. S. and
   Baritaki, S. and Petinaki, E. and Maraki, S. and Krambovitis, E. and
   Spandidos, D. A.},
Title = {{Resistance status of Mycobacterium tuberculosis on the island of Crete,
   Greece}},
Journal = {{EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY \& INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{26}},
Number = {{8}},
Pages = {{607-609}},
Month = {{AUG}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING STREET, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Neonakis, IK (Reprint Author), Univ Hosp Heraklion, Mycobacteriol Lab, Dept Clin Bacteriol Parasitol Zoonoses \& Geog Med, Iraklion 71201, Crete, Greece.
   Univ Hosp Heraklion, Mycobacteriol Lab, Dept Clin Bacteriol Parasitol Zoonoses \& Geog Med, Iraklion 71201, Crete, Greece.
   Univ Hosp Heraklion, Dept Internal Med, Iraklion 71201, Crete, Greece.
   Univ Crete, Sch Med, Dept Lab Med, Iraklion, Greece.
   Univ Thessaly, Sch Med, Dept Microbiol, Larisa, Greece.
   Univ Thessaly, Sch Hlth Sci, Dept Vet Med, Microbiol \& Parasitol Lab, Larisa, Greece.}},
DOI = {{10.1007/s10096-007-0341-1}},
ISSN = {{0934-9723}},
Keywords-Plus = {{INVITRO; ASSAY}},
Research-Areas = {{Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology}},
Author-Email = {{ineonakis@gmail.com}},
ORCID-Numbers = {{Gitti, Zoe/0000-0003-0997-9385}},
Cited-References = {{Hillemann D, 2005, J CLIN MICROBIOL, V43, P3699, DOI 10.1128/JCM.43.8.3699-3703.2005.
   Kanavaki S, 2006, INT J TUBERC LUNG D, V10, P559.
   Neonakis IK, 2007, EUR J CLIN MICROBIOL, V26, P151, DOI 10.1007/s10096-007-0255-y.
   TEXIERMAUGEIN J, 1987, EUR J CLIN MICROBIOL, V6, P584, DOI 10.1007/BF02014255.
   Trakada G, 2004, Monaldi Arch Chest Dis, V61, P65.
   TRUFFOTPERNOT C, 1991, TUBERCLE, V72, P57, DOI 10.1016/0041-3879(91)90025-N.
   {*}WHO, 2004, DRUG RES WORLD WHO I.
   2006, WKLY EPIDEMIOL REC, V10, P430.}},
Number-of-Cited-References = {{8}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Eur. J. Clin. Microbiol. Infect. Dis.}},
Doc-Delivery-Number = {{194EN}},
Unique-ID = {{ISI:000248327200012}},
}

@article{ ISI:000249197600008,
Author = {Gupta, Revathi A. and Gupta, Arun K. and Soni, Love K. and Kaskhedikar,
   S. G.},
Title = {{Rationalization of physicochemical characters of oxazolyl
   thiosemicarbazone analogs towards multi-drug resistant tuberculosis: A
   QSAR approach}},
Journal = {{EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY}},
Year = {{2007}},
Volume = {{42}},
Number = {{8}},
Pages = {{1109-1116}},
Month = {{AUG}},
Abstract = {{The emergence of multi-drug resistant (MDR) strains of Mycobacterium
   tuberculosis and the continuing pandemic of tuberculosis emphasizes the
   urgent need for the development of new and potent anti-tubercular
   agents. In an effort to develop new and more effective agents to treat
   tuberculosis emphasis was focused on quantification of
   structure-activity relationship of oxazolyl thiosernicarbazone
   derivatives. The de novo analysis gave insight to some important
   structural features i.e. nitro group on phenyl ring at R, position is
   optimal for the activity and might be responsible for electronic
   interaction, while phenyl ring at R position interact with the
   hydrophobic pocket more effectively as compared to unsubstituted or
   methyl substituted analogs. Hansch approach offered the understanding
   and parameterization of interactions of the inhibitor with receptor.
   Similarly QSAR analysis gave some important physicochemical properties,
   i.e. empirical aromatic index (ARR) and 3D-MoRSE code value of
   scattering angle at 8A(-1). These two physicochemical properties shall
   be helpful in the development of more potent analogs. (c) 2007 Elsevier
   Masson SAS. All rights reserved.}},
Publisher = {{ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER}},
Address = {{23 RUE LINOIS, 75724 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kaskhedikar, SG (Reprint Author), Shri GS Inst Technol \& Sci, Dept Pharm, CADD Lab, Mol Modelling Study Grp, 23 Pk Rd, Indore 452003, Madhya Pradesh, India.
   Shri GS Inst Technol \& Sci, Dept Pharm, CADD Lab, Mol Modelling Study Grp, Indore 452003, Madhya Pradesh, India.}},
DOI = {{10.1016/j.ejmech.2007.01.018}},
ISSN = {{0223-5234}},
Keywords = {{QSAR; oxazolyl thiosemicarbazone analogs; tuberculosis}},
Keywords-Plus = {{INFECTION; DISCOVERY}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Chemistry, Medicinal}},
Author-Email = {{arunkg\_73@hotmail.com}},
Cited-References = {{ABRAHAM MH, 1993, CHEM SOC REV, V22, P73, DOI 10.1039/cs9932200073.
   Abraham MH, 2001, J ENVIRON MONITOR, V3, P377, DOI 10.1039/b103318m.
   Agerton TB, 1999, CLIN INFECT DIS, V29, P85, DOI 10.1086/520187.
   Arcus VL, 2006, DRUG DISCOV TODAY, V11, P28, DOI 10.1016/S1359-6446(05)03667-6.
   Bentrup KHZ, 2001, TRENDS MICROBIOL, V9, P597, DOI 10.1016/S0966-842X(01)02238-7.
   {*}CS CHEM OFF, VERS 8 0 CAMBR SOFT, P452.
   Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814.
   Gasteiger J, 1996, J CHEM INF COMP SCI, V36, P1030, DOI 10.1021/ci960343+.
   Gupta AK, 2004, INDIAN J PHARM SCI, V66, P396.
   Hansch C, 1979, SUBSTITUENT CONSTANT.
   Havlir DV, 1999, NEW ENGL J MED, V340, P367, DOI 10.1056/NEJM199902043400507.
   Schaper KJ, 1999, QUANT STRUCT-ACT REL, V18, P354, DOI 10.1002/(SICI)1521-3838(199910)18:4<354::AID-QSAR354>3.0.CO;2-2.
   Schuur J, 1997, ANAL CHEM, V69, P2398, DOI 10.1021/ac9611071.
   Schuur JH, 1996, J CHEM INF COMP SCI, V36, P334, DOI 10.1021/ci950164c.
   SKAGERBERG B, 1989, QUANT STRUCT-ACT REL, V8, P32, DOI 10.1002/qsar.19890080105.
   Sonnenberg P, 2005, J INFECT DIS, V191, P150, DOI 10.1086/426827.
   Sriram D, 2006, J MED CHEM, V49, P3448, DOI 10.1021/jm060339h.
   Todeschini R., 2000, HDB MOL DESCRIPTORS.
   Todeschini R, 2001, DRAGON SOFTWARE CALC.
   Wold S., 1995, CHEMOMETRIC METHODS.
   WOLFF ME, 1994, MED CHEM DRUG DISCOV.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{12}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Eur. J. Med. Chem.}},
Doc-Delivery-Number = {{206QI}},
Unique-ID = {{ISI:000249197600008}},
}

@article{ ISI:000250519300394,
Author = {Locatelli, P. and Ngonga, G. and Matteelli, A. and Carosi, G. and
   Padovani, A.},
Title = {{A case of severe cerebral tuberculosis infection in an HIV positive
   patient}},
Journal = {{EUROPEAN JOURNAL OF NEUROLOGY}},
Year = {{2007}},
Volume = {{14}},
Number = {{1}},
Pages = {{120}},
Month = {{AUG}},
Note = {{11th Congress of the European-Federation-of-Neurological-Societies,
   Brussels, BELGIUM, AUG 25-28, 2007}},
Organization = {{European Federat Neurol Soc}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Locatelli, P.; Ngonga, G.; Padovani, A., Univ Brescia, Dept Infect Dis, Brescia, Italy.
   Matteelli, A.; Carosi, G., Univ Brescia, Spedali Civili, Dept Neurol, Brescia, Italy.}},
ISSN = {{1351-5101}},
Research-Areas = {{Neurosciences \& Neurology}},
Web-of-Science-Categories  = {{Clinical Neurology; Neurosciences}},
ResearcherID-Numbers = {{Matteelli, Alberto/M-8784-2015}},
ORCID-Numbers = {{Matteelli, Alberto/0000-0001-5109-9248}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Eur. J. Neurol.}},
Doc-Delivery-Number = {{225LL}},
Unique-ID = {{ISI:000250519300394}},
}

@article{ ISI:000250519300396,
Author = {Aichenbaum, S. R. and Klein, C. and Zandbank, I. and Rothman, Z. and
   Leonov, Y. and Karplus, R. and Pojevsky, A. and Rabey, J. M.},
Title = {{Central nervous system tuberculosis: A clinico-pathological presentation}},
Journal = {{EUROPEAN JOURNAL OF NEUROLOGY}},
Year = {{2007}},
Volume = {{14}},
Number = {{1}},
Pages = {{121}},
Month = {{AUG}},
Note = {{11th Congress of the European-Federation-of-Neurological-Societies,
   Brussels, BELGIUM, AUG 25-28, 2007}},
Organization = {{European Federat Neurol Soc}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Aichenbaum, S. R.; Klein, C.; Zandbank, I.; Rabey, J. M., Tel Aviv Univ, Dept Neurol, Tel Aviv, Israel.
   Rothman, Z., Tel Aviv Univ, Dept Pathol, Tel Aviv, Israel.
   Leonov, Y., Tel Aviv Univ, Neurosurg Unit, Tel Aviv, Israel.
   Karplus, R., Tel Aviv Univ, Intens Care Unit, Tel Aviv, Israel.
   Pojevsky, A., Tel Aviv Univ, Dept Infect Dis, Tel Aviv, Israel.
   Tel Aviv Univ, Affiliated Sackler Sch Med, Assaf Harofeh Med Ctr, Dept Radiol, Tel Aviv, Israel.}},
ISSN = {{1351-5101}},
Research-Areas = {{Neurosciences \& Neurology}},
Web-of-Science-Categories  = {{Clinical Neurology; Neurosciences}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Eur. J. Neurol.}},
Doc-Delivery-Number = {{225LL}},
Unique-ID = {{ISI:000250519300396}},
}

@article{ ISI:000250519300402,
Author = {Duarte, S. and Aguas, M. J. and Aleixo, M. J.},
Title = {{Tuberculous meningitis in HIV-infected patients during anti-tuberculosis
   treatment with poor CNS penetration}},
Journal = {{EUROPEAN JOURNAL OF NEUROLOGY}},
Year = {{2007}},
Volume = {{14}},
Number = {{1}},
Pages = {{122-123}},
Month = {{AUG}},
Note = {{11th Congress of the European-Federation-of-Neurological-Societies,
   Brussels, BELGIUM, AUG 25-28, 2007}},
Organization = {{European Federat Neurol Soc}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Duarte, S., Garcia Orta Hosp, Dept Neurol, Almada, Portugal.
   Aguas, M. J.; Aleixo, M. J., Garcia Orta Hosp, Dept Infect Dis, Almada, Portugal.}},
ISSN = {{1351-5101}},
Research-Areas = {{Neurosciences \& Neurology}},
Web-of-Science-Categories  = {{Clinical Neurology; Neurosciences}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Eur. J. Neurol.}},
Doc-Delivery-Number = {{225LL}},
Unique-ID = {{ISI:000250519300402}},
}

@article{ ISI:000250519300854,
Author = {Ivashynka, A. V. and Likhachev, S. A.},
Title = {{Risk factors in polyneuropathy onset in patients with primary pulmonary
   tuberculosis}},
Journal = {{EUROPEAN JOURNAL OF NEUROLOGY}},
Year = {{2007}},
Volume = {{14}},
Number = {{1}},
Pages = {{261}},
Month = {{AUG}},
Note = {{11th Congress of the European-Federation-of-Neurological-Societies,
   Brussels, BELGIUM, AUG 25-28, 2007}},
Organization = {{European Federat Neurol Soc}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Ivashynka, A. V., Natl Res \& Clin Ctr Neurol \& Neurosurg, Dept Neurol, Minsk, Byelarus.
   Likhachev, S. A., Natl Res \& Clin Ctr Neurol \& Neurosurg, Minsk, Byelarus.}},
ISSN = {{1351-5101}},
Research-Areas = {{Neurosciences \& Neurology}},
Web-of-Science-Categories  = {{Clinical Neurology; Neurosciences}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Eur. J. Neurol.}},
Doc-Delivery-Number = {{225LL}},
Unique-ID = {{ISI:000250519300854}},
}

@article{ ISI:000248613500019,
Author = {Diel, R. and Wrighton-Smith, P. and Zellweger, J-P.},
Title = {{Cost-effectiveness of interferon-gamma release assay testing for the
   treatment of latent tuberculosis}},
Journal = {{EUROPEAN RESPIRATORY JOURNAL}},
Year = {{2007}},
Volume = {{30}},
Number = {{2}},
Pages = {{321-332}},
Month = {{AUG}},
Abstract = {{The aim of the present study was to assess the cost-effectiveness of the
   new T-SPOT.TB assay versus the tuberculin skin test (TST) for screening
   contacts for latent tuberculosis (TB) infection in Switzerland.
   Health and economic outcomes of isoniazid treatment of 20- and 40-yr-old
   close contacts were compared in a Markov model over a 20-yr period
   following screening with TST only (at three cutoff values) and T-SPOT.TB
   alone or in combination with the TST.
   T-SPOT.TB-based treatment was cost-effective at epsilon 11,621 and
   epsilon 23,692 per life-year-gained (LYG) in the younger and older age
   group, respectively. No TST-based programmes were cost-effective, except
   at a 15-mm cut-off in the younger group only, where the
   cost-effectiveness (epsilon 26,451 center dot LYG(-1)) fell just below
   the willing ness-to-pay threshold. Combination of the TST with T-SPOT.TB
   slightly reduced the total cost compared with the T-SPOT.TB alone by 4.4
   and 5.0\% in the younger and older groups respectively. The number of
   contacts treated to avoid one case of TB decreased from 50 (95\%
   confidence interval 32-106) with the TST (10-mm cut-off) to 18 (95\%CI
   11-43) if T-SPOT.TB was used.
   Using T-SPOT.TB alone or in combination with the tuberculin skin test
   for screening of close contacts before latent tuberculosis infection
   treatment is highly cost-effective in reducing the disease burden of
   tuberculosis.}},
Publisher = {{EUROPEAN RESPIRATORY SOC JOURNALS LTD}},
Address = {{146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Diel, R (Reprint Author), Univ Dusseldorf, Sch Publ Hlth, Inst Med Sociol, Post Box 101007, D-40001 Dusseldorf, Germany.
   Univ Dusseldorf, Sch Publ Hlth, D-4000 Dusseldorf, Germany.
   Oxford Immunotec, Oxford, England.
   Univ Lausanne, Med Policlin, Lausanne, Switzerland.}},
DOI = {{10.1183/09031936.00145906}},
ISSN = {{0903-1936}},
Keywords = {{cost-effectiveness; interferon-gamma release assay; latent tuberculosis
   infection; latent tuberculosis infection treatment; tuberculosis}},
Keywords-Plus = {{ENZYME-LINKED IMMUNOSPOT; CELL-BASED TEST; MYCOBACTERIUM-TUBERCULOSIS;
   T-CELLS; CLINICAL-PRACTICE; RAPID DETECTION; CLOSE CONTACTS; SKIN-TEST;
   INFECTION; HIV}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Author-Email = {{Roland.Diel@uni-duesseldorf.de}},
Cited-References = {{Broekmans JF, 2002, EUR RESPIR J, V19, P765, DOI 10.1183/09031936.02.00261402.
   Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008.
   Diel R, 2006, EUR RESPIR J, V28, P16, DOI 10.1183/09031936.06.00107005.
   Diel R, 2005, EUR RESPIR J, V26, P465, DOI 10.1183/09031936.05.00047805.
   Diel R, 2006, EUR RESPIR J, V28, P35, DOI 10.1183/09031936.06.00011806.
   Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002.
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9.
   Fallab-Stubi CL, 1998, INT J TUBERC LUNG D, V2, P525.
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6.
   Harries AD, 2006, LANCET, V367, P1817, DOI 10.1016/S0140-6736(06)68799-0.
   Horsburgh CR, 2004, NEW ENGL J MED, V350, P2060, DOI 10.1056/NEJMsa031667.
   Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824.
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081.
   Lee JY, 2006, EUR RESPIR J, V28, P24, DOI 10.1183/09031936.06.00016906.
   Meier T, 2005, EUR J CLIN MICROBIOL, V24, P529, DOI 10.1007/s10096-005-1377-8.
   Mugisha B, 2006, INT J TUBERC LUNG D, V10, P761.
   NICOLET G, 2003, SCHWEIZ MED FORUM, V22, P506.
   Nunn P, 2005, NAT REV IMMUNOL, V5, P819, DOI 10.1038/nri1704.
   Owens DK, 1998, J GEN INTERN MED, V13, P716.
   Pathan AA, 2001, J IMMUNOL, V167, P5217.
   Piana F, 2006, EUR RESPIR J, V28, P31, DOI 10.1183/09031936.06.00110205.
   Richeldi L, 2004, AM J RESP CRIT CARE, V170, P288, DOI 10.1164/rccm.200403-307OC.
   Schoffski O, 1999, DEUT MED WOCHENSCHR, V124, P1503.
   Shams H, 2005, AM J RESP CRIT CARE, V172, P1161, DOI 10.1164/rccm.200505-748OC.
   Shrestha RK, 2006, INT J TUBERC LUNG D, V10, P656.
   {*}SWISS FED OFF PUB, 2006, 2006 B, P428.
   {*}SWISS FED STAT OF, 2005, MORT TABL SWISS 1998.
   {*}SWISS FED STAT OF, IND ASS.
   {*}SWISS FED STAT OF, 2006, STAT DAT SWITZ 2006, P8.
   {*}SWISS FED STAT OF, 2007, SAL EARN IND.
   {*}SWISS LUNG LEAG, 2005, DET TUB INF BLOOD TE.
   {*}SWISS LUNG LEAG S, 2003, SCHWEIZ MED FORUM, V3, P487.
   Woldehanna S, 2004, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD000171.PUB2.
   Wrighton-Smith P, 2006, EUR RESPIR J, V28, P45, DOI 10.1183/09031936.06.00005906.
   Zellweger JP, 2005, INT J TUBERC LUNG D, V9, P1242.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{48}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Eur. Resp. J.}},
Doc-Delivery-Number = {{198FX}},
Unique-ID = {{ISI:000248613500019}},
}

@article{ ISI:000248613500020,
Author = {Cacho, J. and Perez Meixeira, A. and Cano, I. and Soria, T. and Martos,
   A. Ramos and Sanchez Concheiro, M. and Samper, S. and Gavin, P. and
   Martin, C.},
Title = {{Recurrent tuberculosis from 1992 to 2004 in a metropolitan area}},
Journal = {{EUROPEAN RESPIRATORY JOURNAL}},
Year = {{2007}},
Volume = {{30}},
Number = {{2}},
Pages = {{333-337}},
Month = {{AUG}},
Abstract = {{The proportion of recurrent tuberculosis (TB) cases caused by
   re-infection has varied widely in previous studies. The aim of the
   present study was to determine the relative frequency of relapse and
   exogenous re-infection in patients with second episodes of TB, using DNA
   fingerprinting.
   A population-based retrospective longitudinal descriptive study was
   conducted in Madrid (Spain) during 1992-2004. The study consisted of 645
   patients with culture-confirmed TB. Of these, 20 (3.1 \%) were retained
   because they presented with a second isolate of Mycobacterium
   tuberculosis. Finally, 12 of these cases were excluded because they did
   not complete the full treatment prescribed. All strains were typed by
   restriction fragment length polymorphism analysis and some by
   mycobacterial interspersed repetitive unit-variable number of tandem
   repeats analysis. The patients with recurrent TB were compared with
   those without recurrent TB.
   For seven out of the eight patients, the restriction fragment length
   polymorphism patterns of the Mycobacterium tuberculosis strains from the
   episodes of recurrent disease showed identical initial and final
   genotypes, indicating relapse; the remaining recurrent case showed
   different genotypes, suggesting exogenous re-infection.
   Re-infection is possible among people in developed countries, but the
   rates are lower than those occurring in high-risk areas. The risk
   factors for recurrent tuberculosis should be taken into account in the
   follow-up of treatment and tuberculosis control strategies.}},
Publisher = {{EUROPEAN RESPIRATORY SOC JOURNALS LTD}},
Address = {{146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Cacho, J (Reprint Author), Univ Hosp Getafe, Dept Microbiol, Ctra Toledo Km 12,5, Madrid 28905, Spain.
   Univ Hosp Getafe, Dept Microbiol, Madrid 28905, Spain.
   Univ Hosp Getafe, Dept Pulmonol, Madrid, Spain.
   Autonomous Community Madrid, Dept Publ Hlth, Madrid, Spain.
   Univ Saragossa, Mycobacteria Genet Grp \& CIBER Resp Dis, Zaragoza, Spain.}},
DOI = {{10.1183/09031936.00005107}},
ISSN = {{0903-1936}},
Keywords = {{epidemiology; recurrence; re-infection; relapse; restriction fragment
   length polymorphism; tuberculosis}},
Keywords-Plus = {{RESISTANT MYCOBACTERIUM-TUBERCULOSIS; EXOGENOUS REINFECTION; PULMONARY
   TUBERCULOSIS; MIXED INFECTION; POPULATION; RELAPSE; STRAIN}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Author-Email = {{jcacho.hugf@salud.madrid.org}},
ResearcherID-Numbers = {{Martin, Carlos/A-7283-2008}},
ORCID-Numbers = {{Martin, Carlos/0000-0003-2993-5478}},
Cited-References = {{Bandera A, 2001, J CLIN MICROBIOL, V39, P2213, DOI 10.1128/JCM.39.6.2213-2218.2001.
   Calvo JC, 2005, INT J TUBERC LUNG D, V9, P1236.
   Caminero JA, 2001, AM J RESP CRIT CARE, V163, P717.
   Chaves F, 1999, AIDS, V13, P615, DOI 10.1097/00002030-199904010-00011.
   Chiang CY, 2005, LANCET INFECT DIS, V5, P629, DOI 10.1016/S1473-3099(05)70240-1.
   DAS S, 1993, TUBERCLE LUNG DIS, V74, P47, DOI 10.1016/0962-8479(93)90068-9.
   DEVIEDMA DG, 2002, ARCH INTERN MED, V162, P1873, DOI 10.1001/archinte.162.16.1873.
   El Sahly HM, 2004, INT J TUBERC LUNG D, V8, P333.
   Fine PEM, 1999, NEW ENGL J MED, V341, P1226, DOI 10.1056/NEJM199910143411609.
   Jasmer RM, 2004, AM J RESP CRIT CARE, V170, P1360, DOI 10.1164/rccm.200408-10810C.
   Kremer K, 1999, J CLIN MICROBIOL, V37, P2607.
   Lambert ML, 2003, LANCET INFECT DIS, V3, P282, DOI 10.1016/S1473-3099(03)00607-8.
   NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502.
   Rivero A, 2001, CLIN INFECT DIS, V32, P159, DOI 10.1086/317547.
   SAHADEVAN R, 1995, J CLIN MICROBIOL, V33, P3037.
   Shafer RW, 1995, TUBERCLE LUNG DIS, V76, P575, DOI 10.1016/0962-8479(95)90537-5.
   SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601.
   Sonnenberg P, 2001, LANCET, V358, P1687, DOI 10.1016/S0140-6736(01)06712-5.
   Supply P, 2006, J CLIN MICROBIOL, V44, P4498, DOI 10.1128/JCM.01392-06.
   Turett GS, 1997, CLIN INFECT DIS, V24, P513.
   van Rie A, 2005, AM J RESP CRIT CARE, V172, P636, DOI 10.1164/rccm.200503-449OC.
   Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.
   Verver S, 2005, AM J RESP CRIT CARE, V171, P1430, DOI 10.1164/rccm.200409-1200OC.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{17}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Eur. Resp. J.}},
Doc-Delivery-Number = {{198FX}},
Unique-ID = {{ISI:000248613500020}},
}

@article{ ISI:000248866800016,
Author = {Xing, Zhou and Carters, Thomas James},
Title = {{Heterologous boost vaccines for bacillus Calmette-Guerin prime
   immunization against tuberculosis}},
Journal = {{EXPERT REVIEW OF VACCINES}},
Year = {{2007}},
Volume = {{6}},
Number = {{4}},
Pages = {{539-546}},
Month = {{AUG}},
Abstract = {{The current tuberculosis (TB) epidemic continues to call for the
   development of effective vaccination strategies. The initial TB vaccine
   research effort mostly focused on the search for a vaccine that might be
   better than, and thus could replace, the current bacillus
   Calmette-Guerin (BCG) vaccine. It has increasingly been realized that
   BCG or an improved BCG will continue to be used as a prime TB vaccine
   and there is a need to develop effective boost vaccines that could
   enhance and prolong the protective immunity of BCG prime immunization.
   Mounting experimental evidence suggests that recombinant vaccines,
   including both recombinant protein and genetic vector vaccines, are
   effective in boosting immune activation and protection by BCG
   vaccination. This review will discuss recent advances and the authors'
   views in the development of there boost vaccines.}},
Publisher = {{FUTURE DRUGS LTD}},
Address = {{UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Xing, Z (Reprint Author), McMaster Univ, Div Infect Dis, Ctr Gene Therapeut, Dept Pathol \& Mol Med,Room 4012 MDCL, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.
   McMaster Univ, Div Infect Dis, Ctr Gene Therapeut, Dept Pathol \& Mol Med,Room 4012 MDCL, Hamilton, ON L8N 3Z5, Canada.}},
DOI = {{10.1586/1470584.6.4.539}},
ISSN = {{1476-0584}},
Keywords = {{BCG; mucosal immunization; prime-boost; tuberculosis; vaccines; viral
   vector}},
Keywords-Plus = {{MYCOBACTERIUM-BOVIS BCG; PULMONARY TUBERCULOSIS; PROTECTIVE EFFICACY;
   PUBLISHED LITERATURE; ADENOVIRAL VECTORS; SUBUNIT VACCINE; DNA VACCINES;
   GUINEA-PIGS; GM-CSF; IMMUNITY}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{xingz@mcmaster.ca}},
Cited-References = {{Agger EM, 2001, VACCINE, V19, P2298, DOI 10.1016/S0264-410X(00)00519-3.
   Andersen CS, 2007, INFECT IMMUN, V75, P408, DOI 10.1128/IAI.01290-06.
   Aronson NE, 2004, JAMA-J AM MED ASSOC, V291, P2086, DOI 10.1001/jama.291.17.2086.
   Brandt L, 2004, INFECT IMMUN, V72, P6622, DOI 10.1128/IAI.72.11.6622-6632.2004.
   Brandt L, 2002, INFECT IMMUN, V70, P672, DOI 10.1128/IAI.70.2.672-678.2002.
   Brewer TF, 2000, CLIN INFECT DIS, V31, pS64, DOI 10.1086/314072.
   Brooks JV, 2001, INFECT IMMUN, V69, P2714, DOI 10.1128/IAI.69.4.2714-2717.2001.
   Buddle BM, 2003, INFECT IMMUN, V71, P6411, DOI 10.1128/IAI.71.11.6411-6419.2003.
   Casimiro DR, 2003, J VIROL, V77, P6305, DOI 10.1128/JVI.77.11.6305-6313.2003.
   Catanzaro AT, 2006, J INFECT DIS, V194, P1638, DOI 10.1086/509258.
   COLDITZ GA, 1995, PEDIATRICS, V96, P29.
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698.
   Corner LAL, 2002, VET MICROBIOL, V84, P327, DOI 10.1016/S0378-1135(01)00461-8.
   D'Souza S, 2002, INFECT IMMUN, V70, P3681, DOI 10.1128/IAI.70.7.3681-3688.2002.
   Derrick SC, 2004, VACCINE, V23, P780, DOI 10.1016/j.vaccine.2004.07.036.
   Dietrich J, 2006, J IMMUNOL, V177, P6353.
   Feng CG, 2001, INFECT IMMUN, V69, P4174, DOI 10.1128/IAI.69.6.4174-4176.2001.
   Fine PEM, 1996, LANCET, V348, P17.
   Ghosh SS, 2006, APPL BIOCHEM BIOTECH, V133, P9, DOI 10.1385/ABAB:133:1:9.
   Hannan P, 2002, AM J HEALTH PROMOT, V17, P1, DOI 10.1093/heapro/17.1.1.
   Horwitz MA, 2005, INFECT IMMUN, V73, P4676, DOI 10.1128/IAI.73.8.4676-4683.2005.
   Horwitz MA, 2003, INFECT IMMUN, V71, P1672, DOI 10.1128/IAI.71.4.1672-1679.2003.
   Huygen K, 2003, INFECT IMMUN, V71, P1613, DOI 10.1128/IAI.71.4.1613-1621.2003.
   Kallenius G, 2007, TUBERCULOSIS, V87, P257, DOI 10.1016/j.tube.2006.12.006.
   Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558.
   Kubit S, 1983, Pediatr Pol, V58, P775.
   Lugosi L, 1987, Bull Int Union Tuberc Lung Dis, V62, P15.
   Majlessi L, 2006, INFECT IMMUN, V74, P2128, DOI 10.1128/IAI.74.4.2128-2137.2006.
   Majlessi L, 2005, J IMMUNOL, V174, P3570.
   McMurray DN, 2001, SCAND J INFECT DIS, V33, P175, DOI 10.1080/00365540151060743.
   McShane H, 2005, TUBERCULOSIS, V85, P47, DOI 10.1016/j.tube.2004.09.015.
   McShane H, 2005, MICROBES INFECT, V7, P962, DOI 10.1016/j.micinf.2005.03.009.
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128.
   Mollenkopf HJ, 2004, INFECT IMMUN, V72, P6471, DOI 10.1128/IAI.72.11.6471-6479.2004.
   Orme IM, 2005, DRUGS, V65, P2437, DOI 10.2165/00003495-200565170-00002.
   Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859.
   Reed S, 2005, MICROBES INFECT, V7, P922, DOI 10.1016/j.micinf.2005.03.011.
   Rodrigues LC, 2005, LANCET, V366, P1290, DOI 10.1016/S0140-6736(05)67145-0.
   Romano M, 2006, VACCINE, V24, P3353, DOI 10.1016/j.vaccine.2005.12.066.
   Santosuosso M, 2005, VIRAL IMMUNOL, V18, P283, DOI 10.1089/vim.2005.18.283.
   Santosuosso M, 2005, J IMMUNOL, V174, P7986.
   Santosuosso M, 2007, J IMMUNOL, V178, P2387.
   Santosuosso M, 2006, INFECT IMMUN, V74, P4634, DOI 10.1128/IAI.00517-06.
   Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419.
   Sterne JAC, 1998, INT J TUBERC LUNG D, V2, P200.
   Tala-Heikkila MM, 1998, AM J RESP CRIT CARE, V157, P1324.
   Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013.
   Vordermeier HM, 2004, IMMUNOLOGY, V112, P461, DOI 10.1046/j.1365-2567.2004.01903.x.
   Vordermeier HM, 2006, INFECT IMMUN, V74, P1416, DOI 10.1128/IAI.74.2.1416-1418.2006.
   Wang J, 2004, J IMMUNOL, V173, P6357.
   Wang Jun, 2002, Expert Rev Vaccines, V1, P341, DOI 10.1586/14760584.1.3.341.
   Wedlock DN, 2005, INFECT IMMUN, V73, P3540, DOI 10.1128/IAI.73.6.3540-3546.2005.
   World Health Organization, 2007, GLOB TUB CONTR SURV.
   Williams A, 2005, INFECT IMMUN, V73, P3814, DOI 10.1128/IAI.73.6.3814-3816.2005.
   Williams A, 2005, TUBERCULOSIS, V85, P29, DOI 10.1016/j.tube.2004.09.009.
   Xing Z, 2005, CURR GENE THER, V5, P485, DOI 10.2174/156652305774329230.
   Xing Z, 1996, J LEUKOCYTE BIOL, V59, P481.
   Zhang XZ, 2007, VACCINE, V25, P1342, DOI 10.1016/j.vaccine.2006.09.089.}},
Number-of-Cited-References = {{58}},
Times-Cited = {{30}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Expert Rev. Vaccines}},
Doc-Delivery-Number = {{201XV}},
Unique-ID = {{ISI:000248866800016}},
}

@article{ ISI:000247817800004,
Author = {Natarajan, Palaniappan and Narayanan, Sujatha},
Title = {{Mycobacterium tuberculosis H37Rv induces monocytic release of
   interleukin-6 via activation of mitogen-activated protein kinases:
   inhibition by N-acetyl-L-cysteine}},
Journal = {{FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{50}},
Number = {{3}},
Pages = {{309-318}},
Month = {{AUG}},
Abstract = {{The release of proinflammatory cytokines after mycobacterial infection
   is a host immune response that may be propitious or deleterious to the
   host. Elevated levels of interleukin (IL)-6 are present in plasma of
   patients with active tuberculosis infection. The aim of this study was
   to investigate the role of mitogen-activated protein kinases in the
   secretion of interleukin-6 in THP-1 cells and human primary monocytes
   that were infected with Mycobacterium tuberculosis H37Rv, and its
   regulation by N-acetyl-L-cysteine, a potential antimycobacterial agent.
   Exposure of THP-1 human monocytes to M. tuberculosis H37Rv induced
   rapidly, in a time-dependent manner, the phosphorylation of
   mitogen-activated protein kinase kinase 3/6 and p38 mitogen-activated
   protein kinase, accompanied by an upregulation of interleukin-6. Using
   highly specific inhibitors of mitogen-activated protein kinase kinase-1,
   p38 mitogen-activated protein kinase and nuclear factor-kappa B, we
   found that extracellular-signal regulated kinase 1/2, p38
   mitogen-activated protein kinase and nuclear factor-kappa B were
   essential for M. tuberculosis H37Rv-induced interleukin-6 production in
   human primary monocytes. Pretreatment with N-acetyl-L-cysteine reduced,
   in a dose-dependent manner, M. tuberculosis H37Rv-induced activation of
   mitogen-activated protein kinase kinase 3/6 and interleukin-6 production
   in THP-1 cells.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Narayanan, S (Reprint Author), TB Res Ctr, Dept Immunol, Mayor VR Ramanathan Rd, Madras 600031, Tamil Nadu, India.
   TB Res Ctr, Dept Immunol, Madras 600031, Tamil Nadu, India.}},
DOI = {{10.1111/j.1574-695X.2007.00256.x}},
ISSN = {{0928-8244}},
Keywords = {{mitogen-activated protein kinases; N-acetyl-L-cysteine (NAC);
   mycobacterium tuberculosis}},
Keywords-Plus = {{NECROSIS-FACTOR-ALPHA; KAPPA-B; SIGNALING PATHWAYS; GENE-EXPRESSION;
   HUMAN MACROPHAGES; TNF-ALPHA; INFECTION; IMMUNITY; LIPOARABINOMANNAN;
   INDUCTION}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{sujatha.sujatha36@gmail.com}},
Cited-References = {{Ameixa C, 2002, INFECT IMMUN, V70, P4743, DOI 10.1128/IAI.70.8.4743-4746.2002.
   Bhattacharyya A, 2002, FEMS IMMUNOL MED MIC, V34, P73, DOI 10.1111/j.1574-695X.2002.tb00605.x.
   BLUEMENTHAL A, 2002, INFECT IMMUN, V70, P4961.
   Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858.
   Chan ED, 2001, INFECT IMMUN, V69, P2001, DOI 10.1128/IAI.69.4.2001-2010.2001.
   Cheung BKW, 2005, J IMMUNOL, V175, P7218.
   Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220.
   Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199.
   ElAhmady O, 1997, ANN CLIN BIOCHEM, V34, P160.
   Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486.
   HADDAD JJ, 2001, INT ARCH BIOSCI, P1001.
   Jung SB, 2006, INFECT IMMUN, V74, P2686, DOI 10.1128/IAI.74.5.2686-2696.2006.
   Koul A, 2004, NAT REV MICROBIOL, V2, P189, DOI 10.1038/nrmicro840.
   LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0.
   Maiti D, 2001, J BIOL CHEM, V276, P329.
   Mendez-Samperio P, 2004, J INFECTION, V48, P66, DOI 10.1016/j.jinf.2003.08.009.
   Mendez-Samperio P, 2001, CELL IMMUNOL, V211, P113, DOI 10.1006/cimm.2001.1816.
   MORUGUCHI T, 1996, J BIOL CHEM, V271, P13675.
   Nagabhushanam V, 2003, J IMMUNOL, V171, P4750.
   NEWMAN GW, 1991, J IMMUNOL, V147, P3942.
   OGAWA T, 1991, INFECT IMMUN, V59, P3021.
   Orme IM, 1999, IMMUNOL TODAY, V20, P307, DOI 10.1016/S0167-5699(98)01438-8.
   Rao KMK, 2001, J LEUKOCYTE BIOL, V69, P3.
   Reiling N, 2001, J IMMUNOL, V167, P3339.
   Riendeau CJ, 2003, INFECT IMMUN, V71, P254, DOI 10.1128/IAI.71.1.254-259.2003.
   Roach SK, 2002, INFECT IMMUN, V70, P3040, DOI 10.1128/IAI.70.6.3040-3052.2002.
   Schorey JS, 2003, CELL MICROBIOL, V5, P133, DOI 10.1046/j.1462-5822.2003.00263.x.
   Song CH, 2003, J CLIN IMMUNOL, V23, P194, DOI 10.1023/A:1023309928879.
   Tse HM, 2002, J IMMUNOL, V168, P825.
   Tsuji F, 1999, CLIN EXP IMMUNOL, V115, P26.
   van Crevel R, 2002, CLIN MICROBIOL REV, V15, P294, DOI 10.1128/CMR.15.2.294-309.2002.
   Venketaraman Vishwanath, 2006, AIDS Res Ther, V3, P5, DOI 10.1186/1742-6405-3-5.
   YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008.
   ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{FEMS Immunol. Med. Microbiol.}},
Doc-Delivery-Number = {{186ZT}},
Unique-ID = {{ISI:000247817800004}},
}

@article{ ISI:000249390500001,
Author = {Steingart, Karen R. and Curry, Francis J. and Ramsay, Andrew and Pai,
   Madhukar},
Title = {{Commercial serological tests for the diagnosis of tuberculosis: do they
   work?}},
Journal = {{FUTURE MICROBIOLOGY}},
Year = {{2007}},
Volume = {{2}},
Number = {{4}},
Pages = {{355-359}},
Month = {{AUG}},
Publisher = {{FUTURE MEDICINE LTD}},
Address = {{UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Steingart, KR (Reprint Author), McGill Univ, Dept Epidemiol \& Biostat \& Occupat Hlth, Montreal, PQ, Canada.
   McGill Univ, Dept Epidemiol \& Biostat \& Occupat Hlth, Montreal, PQ, Canada.
   Montreal Chest Inst, Resp Epidemiol \& Clin Res Unit, Montreal, PQ, Canada.}},
DOI = {{10.2217/17460913.2.4.355}},
ISSN = {{1746-0913}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; MICROSCOPY; INFECTION; AUTOPSY}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{karenst@u.washington.edu
   ramsaya@who.int
   madhukar.pai@mcgill.ca}},
Cited-References = {{{*}CDCP, 2005, REP TUB US.
   CUNNINGHAM J, RAPID SEROLOGICAL BA.
   DINNES J, 2007, SYSTEMATIC REV RAPID, P1.
   {*}HLTH PROT EG, EP DAT TABL FIG.
   HOPEWELL PC, 2005, MURRAY NADELS TXB RE, P984.
   Johnson JL, 1998, INT J TUBERC LUNG D, V2, P397.
   Marais BJ, 2007, ARCH DIS CHILD, V92, P446, DOI 10.1136/adc.2006.104976.
   MAS SR, 2007, INT J TUBERC LUND DI, V11, P485.
   McConkey SJ, 2002, INT J TUBERC LUNG D, V6, P246.
   Menzies D, 2007, ANN INTERN MED, V146, P340.
   Monforte AD, 1996, EUR J CLIN MICROBIOL, V15, P453, DOI 10.1007/BF01691311.
   Pai M, 2006, EXPERT REV MOL DIAGN, V6, P509, DOI 10.1586/14737159.6.4.509.
   Rana FS, 2000, J ACQ IMMUN DEF SYND, V24, P23.
   Samanich K, 2001, INFECT IMMUN, V69, P4600, DOI 10.1128/IAI.69.7.4600-4609.2001.
   Sartain MJ, 2006, MOL CELL PROTEOMICS, V5, P2102, DOI 10.1074/mcp.M600089-MCP200.
   Singh KK, 2001, INFECT IMMUN, V69, P4185, DOI 10.1128/IAI.69.6.4185-4191.2001.
   Squire SB, 2005, INT J TUBERC LUNG D, V9, P25.
   Steingart KR, 2007, EXPERT REV ANTI-INFE, V5, P327, DOI 10.1586/14787210.5.3.327.
   Steingart KR, 2007, PLOS MED, V4, P1041, DOI 10.1371/journal.pmed.0040202.
   Steingart KR, 2006, LANCET INFECT DIS, V6, P664, DOI 10.1016/S1473-3099(06)70602-8.
   STEINGART KR, 2007, IN PRESS THORAC.
   URBANCZIK R, 1985, ZBL BAKT-INT J MED M, V260, P81.
   World Health Organization Special Programme for Research and Training in Tropical Diseases Foundation for Innovative New Diagnostics, 2006, DIAGN TUB GLOB DEM M, P49.
   World Health Organization, 2007, GLOB TUB CONTR SURV.
   {*}WHO, TB EP SURV WORKSH.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Future Microbiol.}},
Doc-Delivery-Number = {{209LR}},
Unique-ID = {{ISI:000249390500001}},
}

@article{ ISI:000250480500010,
Author = {Diel, R. and Forssbohm, M. and Loytved, G. and Haas, W. and Hauer, B.
   and Maffei, D. and Magdorf, K. and Nienhaus, A. and Rieder, H. L. and
   Schaberg, T. and Zellweger, J.-P. and Loddenkernper, R.},
Title = {{Recommendations for environmetal contact tracing in tuberculosis -
   German central commitee against tuberculosis}},
Journal = {{GESUNDHEITSWESEN}},
Year = {{2007}},
Volume = {{69}},
Number = {{8-9}},
Pages = {{488-503}},
Month = {{AUG-SEP}},
Publisher = {{GEORG THIEME VERLAG KG}},
Address = {{RUDIGERSTR 14, D-70469 STUTTGART, GERMANY}},
Type = {{Review}},
Language = {{German}},
Affiliation = {{Loddenkernper, R (Reprint Author), HELIOS Klinikum Emil von Behring, Lungenklin Heckeshorn, Deutsch Zentralkomitee Bekampfung Tuberkulose, Walterhoferstr 11, D-14165 Berlin, Germany.
   HELIOS Klinikum Emil von Behring, Lungenklin Heckeshorn, Deutsch Zentralkomitee Bekampfung Tuberkulose, D-14165 Berlin, Germany.}},
DOI = {{10.1055/s-2007-980089}},
ISSN = {{0941-3790}},
Keywords-Plus = {{LINKED IMMUNOSPOT ASSAY; INTERFERON-GAMMA ASSAY;
   MYCOBACTERIUM-TUBERCULOSIS; LATENT TUBERCULOSIS; SKIN-TEST;
   RHEUMATOID-ARTHRITIS; CLINICAL-PRACTICE; BLOOD-TEST; INFECTION;
   TRANSMISSION}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{rloddenkemper@dzk-tuberkulose.de}},
Cited-References = {{ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403.
   American Thoracic Society, 2000, AM J RESP CRIT CARE, V161, P221.
   {*}ATS, 1992, AM REV RESPIR DIS, V118, P1623.
   BALES S, 2000, KOMMENTAR ZUM INFEKT.
   Behr MA, 1999, LANCET, V353, P444, DOI 10.1016/S0140-6736(98)03406-0.
   Behr MA, 1998, AM J RESP CRIT CARE, V158, P465.
   Braden CR, 1997, J INFECT DIS, V175, P1446.
   {*}BRIT THOR ASS, 1978, TUBERCLE, V59, P245.
   Brodhun B, 2006, PNEUMOLOGE, V3, P257, DOI 10.1007/s10405-006-0100-5.
   Cole ST, 1998, NATURE, V396, P190, DOI 10.1038/24206.
   COMSTOCK G, 1975, AM REV RESPIR DIS, V111, P5763.
   COMSTOCK GW, 1988, AM REV RESPIR DIS, V138, P479.
   Curtis AB, 1999, NEW ENGL J MED, V341, P1491, DOI 10.1056/NEJM199911113412002.
   de Leon DP, 2005, ANN RHEUM DIS, V64, P1360, DOI 10.1136/ard.2004.029041.
   Detjen A, 2006, MONATSSCHR KINDERH, V154, P152, DOI 10.1007/s00112-005-1288-x.
   DEWAN PK, 2006, BMC INFECT DIS, V15, P6.
   Diel R, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-77.
   Diel R, 2006, EUR RESPIR J, V28, P16, DOI 10.1183/09031936.06.00107005.
   Diel R, 2002, J CLIN MICROBIOL, V40, P532, DOI 10.1128/JCM.40.2.532-539.2002.
   Diel R, 2004, INT J TUBERC LUNG D, V8, P855.
   Diel R, 2006, EUR RESPIR J, V28, P35, DOI 10.1183/09031936.06.00011806.
   Diel R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-35.
   DIEL R, 2004, EUR J HLTH EC, V5, P278.
   {*}DIN, 2000, 589437 DIN.
   Dogra S, 2007, J INFECTION, V54, P267, DOI 10.1016/j.jinf.2006.04.007.
   {*}DZK, 2001, PNEUMOLOGIE, V55, P57.
   {*}DZK, 1996, GESUNDHEITSWESEN, V58, P657.
   {*}DZK, 1996, ARZTEBL, V93, P1199.
   Efthimiou P, 2007, ANN RHEUM DIS, V66, P276, DOI 10.1136/ard.2006.061184.
   Elwood RK, 2005, INT J TUBERC LUNG D, V9, P49.
   ERDLE H, 2000, INFEKTIONSSCHUTZGEST.
   Ferebee S H, 1970, ADV TUBERC RES, V17, P28.
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6.
   GRONAUER W, 2004, BEMERKENSWERTE TUBER, V58, P9.
   Hauer B, 2006, UNTERSUCHUNGEN TUBER.
   HAUER B, 2006, PNEUMOLOGE, V3, P277, DOI 10.1007/s10405-006-0102-3.
   Hill PC, 2006, PEDIATRICS, V117, P1542, DOI 10.1542/peds.2005-2095.
   Horsburgh CR, 2004, NEW ENGL J MED, V350, P2060, DOI 10.1056/NEJMsa031667.
   Tuberculosis Coalition for Technical Assistance, 2006, TUB COAL TECHN ASS.
   Kang YA, 2005, JAMA-J AM MED ASSOC, V293, P2756, DOI 10.1001/jama.293.22.2756.
   KAUFMANN SHE, 1999, IMMUNANTWORT GEGEN T.
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110.
   Kendig N, 1998, INT J TUBERC LUNG D, V2, pS57.
   Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501.
   KHAN EA, 1995, EMERG INFECT DIS, V1, P115.
   Kohler H, 1973, Z Urol Nephrol, V66, P207.
   KOLLECKER S, 2003, TUBERKULOSE BERUFSKR.
   Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824.
   Lange C, 2006, DEUT MED WOCHENSCHR, V131, P341, DOI 10.1055/s-2006-932523.
   Liebeschuetz S, 2004, LANCET, V364, P2196, DOI 10.1016/S0140-6736(04)17592-2.
   LOUDON RG, 1967, AM REV RESPIR DIS, V95, P435.
   LOUDON RG, 1969, AM REV RESPIR DIS, V99, P109.
   LOYTVED G, 2004, TUBERKULINTESTUNG FR.
   {*}LUNG SCHW, 2007, HDB TUB.
   MAGDORF K, 2003, DTSCH GES PADIAT INF.
   Marks GB, 2000, AM J RESP CRIT CARE, V162, P1851.
   Meier T, 2005, EUR J CLIN MICROBIOL, V24, P529, DOI 10.1007/s10096-005-1377-8.
   Menzies D, 1999, AM J RESP CRIT CARE, V159, P15.
   Meyer M, 2003, CHEST, V124, P1824, DOI 10.1378/chest.124.5.1824.
   MORGENROTH K, 1999, STUTTGART.
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC.
   NAKAOKA H, 2006, EMERG INFECT DIS, V12, P1283.
   {*}NATL TUB CONTR AS, 2005, MMWR-MORBID MORTAL W, V54, P1.
   Neumann G, 1985, Offentl Gesundheitswes, V47, P98.
   {*}NICE, 2006, TUB NATL CLIN GUID D.
   Nienhaus A, 2007, Pneumologie, V61, P219, DOI 10.1055/s-2007-959161.
   Pai M, 2006, EXPERT REV MOL DIAGN, V6, P413, DOI 10.1586/14737159.6.3.413.
   Passalent L, 2007, CLIN J AM SOC NEPHRO, V2, P68, DOI 10.2215/CJN.01280406.
   Piana F, 2006, EUR RESPIR J, V28, P31, DOI 10.1183/09031936.06.00110205.
   Poulsen A, 1950, ACTA TUBERC SCAND, V24, P311.
   Rangaka MX, 2007, AM J RESP CRIT CARE, V175, P514, DOI 10.1164/rccm.200610-1439OC.
   {*}REC NATL TUB CONT, 2005, MMWR-MORBID MORTAL W, V54, P1.
   Richeldi L, 2006, AM J RESP CRIT CARE, V174, P736, DOI 10.1164/rccm.200509-1516PP.
   RILEY RL, 1983, SCHWEIZ MED WSCHR, V113, P75.
   {*}RKI, 2001, EPID B, V41, P25.
   {*}RKI, 2007, FALLD ROB KOCH I.
   {*}RKI, 2004, EPID B, V44, P377.
   {*}RKI, 2004, EP B, V44, P378.
   {*}RKI, 2001, ERSTV BUND GES GES, V44, P830.
   {*}ROB KOCH I, 2006, BER EP TUB DTSCH.
   Schaberg T, 2004, Pneumologie, V58, P255.
   Sebek M, 2000, INT J TUBERC LUNG D, V4, pS45.
   SEIDLER A, 2003, TUBERKULOSE BERUFSKR.
   SELBY CD, 1989, RESP MED, V83, P353, DOI 10.1016/S0954-6111(89)80212-4.
   Simon K, 1988, Prax Klin Pneumol, V42, P423.
   Singh D, 2002, CHEST, V122, P1299, DOI 10.1378/chest.122.4.1299.
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402.
   SOOLINGEN D, 1999, J INFECT DIS, V180, P726.
   SULTAN L, 1960, AM REV RESPIR DIS, V82, P358.
   Sutherland I, 1976, Adv Tuberc Res, V19, P1.
   TEMPLETON GL, 1995, ANN INTERN MED, V122, P922.
   Tissot F, 2005, CLIN INFECT DIS, V40, P211, DOI 10.1086/426434.
   Tufariello JM, 2003, LANCET INFECT DIS, V3, P578, DOI 10.1016/S1473-3099(03)00741-2.
   vanDeutekom H, 1997, CLIN INFECT DIS, V25, P1071, DOI 10.1086/516072.
   VEEN J, 1992, TUBERCLE LUNG DIS, V73, P73, DOI 10.1016/0962-8479(92)90058-R.
   WALLGREN A, 1948, TIME TABLE TUBERCULO, V29, P250.
   Weis SE, 2002, AM J RESP CRIT CARE, V166, P36, DOI 10.1164/rccm.2109089.
   {*}WHO, 2006, GUID NATL TUB PROGR.
   World Health Organization, 2006, TUB AIR TRAV GUID PR.
   Wrighton-Smith P, 2006, EUR RESPIR J, V28, P45, DOI 10.1183/09031936.06.00005906.
   Youssef E, 2005, CAN MED ASSOC J, V173, P34, DOI 10.1503/cmaj.050710.
   2002, VERORDNUNG ANDERUNG, P1869.
   2006, CONS STAT WOLF KNCV.
   1999, VERORDNUNG UMSETZUNG, P50.
   1959, VERSR, V10, P353.
   1987, VERORDNUNG SCHUTZ SC, P114.}},
Number-of-Cited-References = {{106}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Gesundheitswesen}},
Doc-Delivery-Number = {{224XA}},
Unique-ID = {{ISI:000250480500010}},
}

@article{ ISI:000247755900003,
Author = {Motta, Adriana and Schmitz, Carla and Rodrigues, Luiz and Ribeiro,
   Flavia and Teixeira, Cesar and Detanico, Thiago and Bonan, Carla and
   Zwickey, Heather and Bonorino, Cristina},
Title = {{Mycobacterium tuberculosis heat-shock protein 70 impairs maturation of
   dendritic cells from bone marrow precursors, induces interleukin-10
   production and inhibits T-cell proliferation in vitro}},
Journal = {{IMMUNOLOGY}},
Year = {{2007}},
Volume = {{121}},
Number = {{4}},
Pages = {{462-472}},
Month = {{AUG}},
Abstract = {{In different inflammatory disease models, heat-shock proteins (hsp) and
   hsp-derived peptides have been demonstrated to possess anti-inflammatory
   properties. While some studies have shown that hsp can directly interact
   with antigen-presenting cells, others report that bacterial hsp can
   induce specific T cells with regulatory phenotypes. Effective
   characterization of the immunomodulatory effects of hsp 70, however, has
   historically been confounded by lipopolysaccharide (LPS) contamination.
   In this study, we compared the effects of LPS-free Mycobacterial
   tuberculosis hsp 70 (TBhsp70) and its possible contaminants on dendritic
   cells (DC). We demonstrate herein that LPS-free TBhsp70 inhibits murine
   DC maturation in vitro, while LPS-contaminated TBhsp70 induces DC
   maturation. Mock recombinant preparations have no effect. In contrast to
   LPS, TBhsp70 does not induce tumour necrosis factor-alpha production by
   DC, but interleukin-10. In vivo, only LPS-contaminated TBhsp70 induces
   up-regulation of CD86 in splenic mature DC. Finally, TBhsp70 inhibited
   phytohaemagglutinin-induced T-cell proliferation. Our results support
   the hypothesis that TBhsp70 does not have inflammatory potential, but
   rather has immunosuppressive properties.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bonorino, C (Reprint Author), Inst Biomed Res, Dept Microbiol, Ave Ipiranga 6690 20 Andar, BR-90680 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Inst Pesquisas Biomed, Fac Biosci, Porto Alegre, RS, Brazil.
   Natl Jewish Res Ctr, Denver, CO USA.
   Natl Coll Nat Med, Portland, OR USA.}},
DOI = {{10.1111/j.1365-2567.2007.02564.x}},
ISSN = {{0019-2805}},
Keywords = {{cytokines; dendritic cells; heat-shock protein 70; Mycobacterium
   tuberculosis; T-cell proliferation}},
Keywords-Plus = {{HEAT-SHOCK-PROTEIN; TOLL-LIKE RECEPTORS; ANTIGEN-PRESENTING CELLS;
   EXPERIMENTAL ARTHRITIS; RHEUMATOID-ARTHRITIS; ADJUVANT ARTHRITIS; TH2
   RESPONSES; HSP70; INDUCTION; PEPTIDE}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{cbonorino@pucrs.br}},
ResearcherID-Numbers = {{Bonan, Carla/J-7899-2015
   Rodrigues Junior, Luiz /A-2302-2016}},
ORCID-Numbers = {{Bonan, Carla/0000-0001-9715-6244
   Rodrigues Junior, Luiz /0000-0002-5380-8930}},
Cited-References = {{ADAM O, 1995, ANAL BIOCHEM, V225, P321, DOI 10.1006/abio.1995.1161.
   AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U.
   ANDERSON SL, 1994, J EXP MED, V180, P1565, DOI 10.1084/jem.180.4.1565.
   ARNOLD D, 1995, J EXP MED, V182, P885, DOI 10.1084/jem.182.3.885.
   Asea A, 2000, NAT MED, V6, P435.
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588.
   BARRIOS C, 1994, CLIN EXP IMMUNOL, V98, P229.
   Barthel TK, 2001, J BACTERIOL, V183, P5482, DOI 10.1128/JB.183.19.5482-5490.2001.
   Bausinger H, 2002, TRENDS IMMUNOL, V23, P342, DOI 10.1016/S1471-4906(02)02249-4.
   Bodman-Smith MD, 2003, RHEUMATOLOGY, V42, P637, DOI 10.1093/rheumatology/keg204.
   Bonorino C, 1998, J IMMUNOL, V161, P5210.
   BOORSTEIN WR, 1994, J MOL EVOL, V38, P1.
   Chandawarkar RY, 1999, J EXP MED, V189, P1437, DOI 10.1084/jem.189.9.1437.
   Chandawarkar RY, 2004, INT IMMUNOL, V16, P615, DOI 10.1093/intimm/dxh063.
   Corrigall VM, 2001, J IMMUNOL, V166, P1492.
   Cortez-Herrera E, 2001, EXP PARASITOL, V97, P215, DOI 10.1006/expr.2001.4605.
   DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413.
   Detanico T, 2004, CLIN EXP IMMUNOL, V135, P336, DOI 10.1046/j.1365-2249.2003.02351.x.
   Dillon S, 2004, J IMMUNOL, V172, P4733.
   FISCHER HP, 1992, EUR J IMMUNOL, V22, P1667, DOI 10.1002/eji.1830220651.
   Gao BC, 2004, BIOCHEM BIOPH RES CO, V317, P1149, DOI 10.1016/j.bbrc.2004.03.160.
   Huang Bo, 2002, Zhonghua Zhongliu Zazhi, V24, P421.
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693.
   Ishii T, 1999, J IMMUNOL, V162, P1303.
   Itano AA, 2003, IMMUNITY, V19, P47, DOI 10.1016/S1074-7613(03)00175-4.
   Khoruts A, 2004, EUR J IMMUNOL, V34, P1085, DOI 10.1002/eji.200324170.
   Kimura Y, 1998, INT IMMUNOL, V10, P117, DOI 10.1093/intimm/10.2.117.
   Kingston AE, 1996, CLIN EXP IMMUNOL, V103, P77, DOI 10.1046/j.1365-2249.1996.929628.x.
   Langelaar MFM, 2005, SCAND J IMMUNOL, V61, P242, DOI 10.1111/j.1365-3083.2005.01559.x.
   Laouini D, 2003, J CLIN INVEST, V112, P1058, DOI 10.1172/JCI200318246.
   LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443.
   Liu SG, 1997, CLIN BIOCHEM, V30, P455, DOI 10.1016/S0009-9120(97)00049-0.
   MacAry PA, 2004, IMMUNITY, V20, P95, DOI 10.1016/S1074-7613(03)00357-1.
   Mainali ES, 2004, CELL IMMUNOL, V232, P127, DOI 10.1016/j.cellimm.2005.03.002.
   Manickasingham SR, 2003, EUR J IMMUNOL, V33, P101, DOI 10.1002/immu.200390001.
   Matasic R, 1999, J LEUKOCYTE BIOL, V66, P909.
   MEHLERT A, 1989, MOL MICROBIOL, V3, P125, DOI 10.1111/j.1365-2958.1989.tb01801.x.
   Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200.
   Morelli AE, 2001, BLOOD, V98, P1512, DOI 10.1182/blood.V98.5.1512.
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4.
   Nussbaum G, 2006, INT IMMUNOL, V18, P1413, DOI 10.1093/intimm/dxl074.
   Palma JP, 2002, J IMMUNOL, V168, P4221.
   Panayi GS, 2006, AUTOIMMUN REV, V5, P140, DOI 10.1016/j.autrev.2005.08.006.
   Pedersen AE, 2004, IMMUNOL LETT, V91, P63, DOI 10.1016/j.imlet.2003.11.004.
   Pockley AG, 2003, HYPERTENSION, V42, P235, DOI 10.1161/01.HYP.0000086522.13672.23.
   Prakken BJ, 2001, J IMMUNOL, V167, P4147.
   Quintana FJ, 2004, ARTHRITIS RHEUM, V50, P3712, DOI 10.1002/art.20635.
   Rico EP, 2003, LIFE SCI, V73, P2071, DOI 10.1016/S0024-3205(03)00596-4.
   Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712.
   Steinman RM, 2003, APMIS, V111, P675, DOI 10.1034/j.1600-0463.2003.11107802.x.
   SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1.
   SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313.
   Suzue K, 1996, J IMMUNOL, V156, P873.
   Tanaka S, 1999, J IMMUNOL, V163, P5560.
   Tobian AAR, 2004, J IMMUNOL, V172, P5277.
   Triantafilou K, 2001, J CELL SCI, V114, P2535.
   Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127.
   VANEDEN W, 1988, NATURE, V331, P171.
   Wang YF, 2002, J IMMUNOL, V169, P2422.
   Wang YF, 2001, IMMUNITY, V15, P971, DOI 10.1016/S1074-7613(01)00242-4.
   Woltman AM, 2002, J IMMUNOL, V168, P6181.
   Xing NZ, 2002, BIOCHEM BIOPH RES CO, V297, P645, DOI 10.1016/S0006-291X(02)02262-3.
   Zanin-Zhorov A, 2006, J CLIN INVEST, V116, P2022, DOI 10.1172/JCI28423.
   Zhu JH, 2003, ARTERIOSCL THROM VAS, V23, P1055, DOI 10.1161/01.ATV.0000074899.60898.FD.}},
Number-of-Cited-References = {{64}},
Times-Cited = {{40}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Immunology}},
Doc-Delivery-Number = {{186CE}},
Unique-ID = {{ISI:000247755900003}},
}

@article{ ISI:000247755900007,
Author = {da Fonseca, Denise Morais and Silva, Celio Lopes and Paula, Marina
   Oliveira e and Soares, Edson Garcia and Marchal, Gilles and Horn,
   Cynthia and Deperon Bonato, Vania Luiza},
Title = {{Increased levels of interferon-gamma primed by culture filtrate proteins
   antigen and CpG-ODN immunization do not confer significant protection
   against Mycobacterium tuberculosis infection}},
Journal = {{IMMUNOLOGY}},
Year = {{2007}},
Volume = {{121}},
Number = {{4}},
Pages = {{508-517}},
Month = {{AUG}},
Abstract = {{The results of various animal model studies of tuberculosis (TB) suggest
   that culture filtrate proteins (CFPs), which are antigens secreted by
   Mycobacterium tuberculosis, are largely responsible for improvements in
   TB vaccines. The great obstacle to developing protein subunit vaccines
   is that adjuvants are required in order to stimulate relevant protective
   immune responses. Acting as immune adjuvants, CpG-oligodeoxynucleotides
   (CpG-ODNs) promote the activation of Th1 cells and of pro-inflammatory
   cytokines. To evaluate the adjuvant role of CpG-ODNs in conferring
   enhanced immunogenic capacity and protection against M. tuberculosis, we
   immunized mice with CFP antigen combined with synthetic CpG-ODNs
   (CFP/CpG) or with incomplete Freund's adjuvant (IFA) (CFP/IFA).
   Immunization with CFP/CpG induced a T helper 1 (Th1)-biased response
   accompanied by a higher immunoglobulin G2a (IgG2a) antibody/IgG1
   antibody ratio, elevated production of interferon-gamma (IFN-gamma) by
   spleen cells and in lungs. However, CFP/IFA-immunized mice presented
   higher levels of IgG1 antibodies, as well as increased production of
   IFN-gamma, interleukin (IL)-5, and IL-10 by spleen cells, together with
   lower levels of IFN-gamma in the lungs. Despite the stronger Th1
   response seen in both groups, believed to be necessary for protection
   against TB, only mice immunized with CFP/IFA were protected after M.
   tuberculosis infection. Lung histology revealed that lung parenchyma
   were better preserved in CFP/IFA-immunized mice, which also presented
   intense lymphocyte recruitment to the lesion, whereas CFP/CpG-immunized
   mice presented severe pulmonary injury accompanied by necrosis. Based on
   the data presented, we discuss the widely accepted paradigm that high
   levels of IFN-gamma are directly correlated with protection against
   experimental TB.}},
Publisher = {{WILEY-BLACKWELL}},
Address = {{111 RIVER ST, HOBOKEN 07030-5774, NJ USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bonato, VLD (Reprint Author), Univ Sao Paulo, Ribeirao Preto Sch Med, Tuberculosis Res Ctr, Dept Biochem \& Immunol, Avenida Bandeirantes,3900, BR-14049900 Ribeirao Preto, Brazil.
   Univ Sao Paulo, Ribeirao Preto Sch Med, Tuberculosis Res Ctr, Dept Biochem \& Immunol, BR-14049900 Ribeirao Preto, Brazil.
   Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Pathol, BR-05508 Sao Paulo, Brazil.
   Inst Pasteur, Lab Reference Mycobacteries, Paris, France.
   Fiocruz MS, Oswaldo Cruz Inst Fdn, BR-21045900 Rio De Janeiro, Brazil.}},
DOI = {{10.1111/j.1365-2567.2007.02597.x}},
ISSN = {{0019-2805}},
EISSN = {{1365-2567}},
Keywords = {{tuberculosis; culture filtrate proteins; CpG oligodeoxynucleotides;
   vaccine, adjuvant}},
Keywords-Plus = {{GUINEA-PIG MODEL; IMMUNE-RESPONSES; SUBUNIT VACCINE; PULMONARY
   TUBERCULOSIS; BACTERIAL-DNA; FUSION PROTEIN; BALB/C MICE; EFFICACY; BCG;
   OLIGODEOXYNUCLEOTIDES}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{vlbonato@fmrp.usp.br}},
ResearcherID-Numbers = {{Silva, Celio/C-4639-2012
   Fonseca, Denise/E-7419-2012}},
ORCID-Numbers = {{Fonseca, Denise/0000-0001-8310-0186}},
Cited-References = {{Al-Mariri A, 2001, INFECT IMMUN, V69, P4816, DOI 10.1128/IAI.69.8.4816-4822.2001.
   Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211.
   ANDERSEN P, 1994, INFECT IMMUN, V62, P2536.
   ANDERSEN P, 1993, INFECT IMMUN, V61, P844.
   ANDERSEN P, 1991, INFECT IMMUN, V59, P1905.
   ANDERSEN P, 1991, INFECT IMMUN, V59, P665.
   Ballas ZK, 1996, J IMMUNOL, V157, P1840.
   Bloom Barry R., 1994, P531.
   Bonato VLD, 2004, IMMUNOLOGY, V113, P130, DOI 10.1046/j.1365-2567.2004.01931.x.
   Bonato VLD, 2001, SCAND J IMMUNOL, V54, P564, DOI 10.1046/j.1365-3083.2001.00996.x.
   Brandt L, 2004, INFECT IMMUN, V72, P6622, DOI 10.1128/IAI.72.11.6622-6632.2004.
   Cole ST, 1998, NATURE, V393, P537.
   Degen Winfried G J, 2003, Expert Rev Vaccines, V2, P327, DOI 10.1586/14760584.2.2.327.
   Freidag BL, 2000, INFECT IMMUN, V68, P2948, DOI 10.1128/IAI.68.5.2948-2953.2000.
   Gramzinski RA, 2001, INFECT IMMUN, V69, P1643, DOI 10.1128/IAI.69.3.1643-1649.2001.
   Grode L, 2005, J CLIN INVEST, V115, P2472, DOI 10.1172/JCI24617.
   HAVLIR DV, 1991, INFECT IMMUN, V59, P665.
   Hernandez-Pando R, 2004, EUR J IMMUNOL, V34, P174, DOI 10.1002/eji.200324253.
   HernandezPando R, 1997, INFECT IMMUN, V65, P3317.
   HERNANDEZPANDO R, 1994, IMMUNOLOGY, V70, P2100.
   Hogarth PJ, 2003, VACCINE, V21, P977, DOI 10.1016/S0264-410X(02)00548-0.
   Horwitz MA, 2000, P NATL ACAD SCI USA, V97, P13853, DOI 10.1073/pnas.250480397.
   Hovav AH, 2003, INFECT IMMUN, V71, P3146, DOI 10.1128/IAI.71.6.3146-3154.2003.
   Hsieh MJ, 2004, VACCINE, V22, P655, DOI 10.1016/j.vaccine.2003.08.035.
   HUBBARD RD, 1992, CLIN EXP IMMUNOL, V87, P94.
   Juffermans NP, 2002, INFECT IMMUN, V70, P147, DOI 10.1128/IAI.70.1.147-152.2002.
   Klinman DM, 2004, IMMUNOL REV, V199, P201, DOI 10.1111/j.0105-2896.2004.00148.x.
   Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879.
   KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0.
   Kumar S, 2004, INFECT IMMUN, V72, P949, DOI 10.1128/IAI.72.2.949-957.2004.
   Langermans JAM, 2005, VACCINE, V23, P2740, DOI 10.1016/j.vaccine.2004.11.051.
   Lindblad EB, 1997, INFECT IMMUN, V65, P623.
   Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326.
   Majlessi L, 2006, INFECT IMMUN, V74, P2128, DOI 10.1128/IAI.74.4.2128-2137.2006.
   MCDONOUGH KA, 1995, INFECT IMMUN, V63, P4802.
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128.
   Olsen AW, 2001, INFECT IMMUN, V69, P2773, DOI 10.1128/IAI.69.5.2773-2778.2001.
   Olsen AW, 2004, INFECT IMMUN, V72, P6148, DOI 10.1128/IAI.72.10.6148-6150.2004.
   PAL PG, 1992, INFECT IMMUN, V60, P4781.
   Pashine A, 2005, NAT MED, V11, pS63, DOI 10.1038/nm1210.
   Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.1440-1711.2004.01272.x.
   Rao V, 2005, SCAND J IMMUNOL, V61, P410, DOI 10.1111/j.1365-3083.2005.01569.x.
   ROBERTS AD, 1995, IMMUNOLOGY, V85, P502.
   Rook GAW, 2005, NAT REV IMMUNOL, V5, P661, DOI 10.1038/nri1666.
   Rook GAW, 2005, VACCINE, V23, P2115, DOI 10.1016/j.vaccine.2005.01.069.
   Rook GAW, 2004, TRENDS IMMUNOL, V25, P483, DOI 10.1016/j.it.2004.06.005.
   Sable SB, 2005, VACCINE, V23, P4175, DOI 10.1016/j.vaccine.2005.03.040.
   SEAH GT, 2000, J INFECT DIS, V181, P685.
   SHEIKY YAW, 2006, NAT REV MICROBIOL, V4, P469.
   Skeiky YAW, 2004, J IMMUNOL, V172, P7618.
   van Crevel R, 2000, J INFECT DIS, V181, P1194, DOI 10.1086/315325.
   Wongratanacheewin S, 2004, INFECT IMMUN, V72, P4494, DOI 10.1128/IAI.72.8.4494-4502.2004.}},
Number-of-Cited-References = {{52}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Immunology}},
Doc-Delivery-Number = {{186CE}},
Unique-ID = {{ISI:000247755900007}},
}

@article{ ISI:000250455600012,
Author = {Anand, S. Prabhu and Selvaraj, P. and Jawahar, M. S. and Adhilakshmi, A.
   R. and Narayanan, P. R.},
Title = {{Interleukin-12B \& interleukin-10 gene polymorphisms in pulmonary
   tuberculosis}},
Journal = {{INDIAN JOURNAL OF MEDICAL RESEARCH}},
Year = {{2007}},
Volume = {{126}},
Number = {{2}},
Pages = {{135-138}},
Month = {{AUG}},
Abstract = {{Background \& objectives: Cytokines play an important role in
   anti-tuberculosis immune response. Skewing of immunity from protective
   to pathogenic may involve a shift in Th1-Th2 paradigm. Cytokine gene
   polymorphism is known to be associated with functional differences in
   cytokine regulation and altered clinical performance in a variety of
   diseases. The aim of this study was to know whether Interleukin-12B 3'
   UTR (Taq1) (A/C) and Interleukin-10 (-1082 G/A) gene polymorphisms were
   associated with susceptibility to pulmonary tuberculosis.
   Methods: IL -10 (-1,082 G/A) and IL-12B gene polymorphisms were studied
   in132 pulmonary TB (PTB) patients and 143 normal healthy subjects (NHS),
   using DNA based polymerase chain reaction (PCR) with sequence specific
   primers and restriction digestion. Results: The allelic as well as
   genotypic frequencies of Interleukin -10 (-1082) and Interleukin -12B
   (3'UTR Taq 1) did not differ significantly between the patients and
   controls.
   Interpretation \& conclusion: Our findings suggested that IL -10 (-1082
   G/A) and IL -12B 3'UTR (Taq 1) (A/C) gene polymorphisms were not
   associated either with susceptibility or resistance to pulmonary
   tuberculosis in the south Indian population.}},
Publisher = {{INDIAN COUNCIL MEDICAL RES}},
Address = {{PO BOX 4911 ANSARI NAGAR, NEW DELHI 110029, INDIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Selvaraj, P (Reprint Author), TB Res Ctr, Dept Immunol, Mayor VR Ramanathan Rd, Madras 600031, Tamil Nadu, India.
   TB Res Ctr, Dept Immunol, Madras 600031, Tamil Nadu, India.}},
ISSN = {{0971-5916}},
Keywords = {{IL; 10; IL; 12B; polymorphism}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; SUSCEPTIBILITY; ASSOCIATIONS; LYMPHOCYTES;
   AFRICANS}},
Research-Areas = {{Immunology; General \& Internal Medicine; Research \& Experimental
   Medicine}},
Web-of-Science-Categories  = {{Immunology; Medicine, General \& Internal; Medicine, Research \&
   Experimental}},
Author-Email = {{psraj2l@hotmail.com}},
Cited-References = {{Akahoshi M, 2003, HUM GENET, V112, P237, DOI 10.1007/s00439-002-0873-5.
   ANDERSEN P, 1993, INFECT IMMUN, V61, P844.
   Bellamy R, 2000, CLIN SCI, V98, P245, DOI 10.1042/CS19990228.
   Bellamy R., 1998, Tubercle and Lung Disease, V79, P83, DOI 10.1054/tuld.1998.0009.
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002.
   Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P7.
   Delgado JC, 2002, J INFECT DIS, V186, P1463, DOI 10.1086/344891.
   FLYNN J, 2002, ANNU REV IMMUNOL, V22, P345.
   HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X.
   Huang D, 2000, GENES IMMUN, V1, P515, DOI 10.1038/sj.gene.6363720.
   Lopez-Maderuelo D, 2003, AM J RESP CRIT CARE, V167, P970, DOI 10.1164/rccm.200205-438BC.
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215.
   ORME IM, 1993, J IMMUNOL, V151, P518.
   PAK S, 1998, STAT HUMAN GENETICS, P39.
   Selvaraj P., 1999, Tubercle and Lung Disease, V79, P221, DOI 10.1054/tuld.1999.0204.
   Selvaraj P, 2003, CURR SCI INDIA, V84, P1564.
   TOM HM, 2005, TUBERCULOSIS, V85, P53.
   Torres M, 1998, INFECT IMMUN, V66, P176.
   Tso HW, 2004, J INFECT DIS, V190, P913, DOI 10.1086/422693.
   UMA S, 2001, INDIAN J MED RES, V113, P117.
   van Crevel R, 2002, CLIN MICROBIOL REV, V15, P294, DOI 10.1128/CMR.15.2.294-309.2002.
   {*}WHO, 2006, 104 TUB FACT SHEET.
   XIN MA, 2003, J INTECT DIS, V188, P1116.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{17}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Indian J. Med. Res.}},
Doc-Delivery-Number = {{224OF}},
Unique-ID = {{ISI:000250455600012}},
}

@article{ ISI:000250486400011,
Author = {Akhila, K. and Mahadevan, S. and Adhisivam, B.},
Title = {{Qualitative evaluation of tuberculin test responses in childhood
   tuberculosis (Vol 74, Pg 641, 2007)}},
Journal = {{INDIAN JOURNAL OF PEDIATRICS}},
Year = {{2007}},
Volume = {{74}},
Number = {{8}},
Pages = {{770}},
Month = {{AUG}},
Publisher = {{ALL INDIA INST MEDICAL SCIENCES}},
Address = {{ANSARI NAGAR, NEW DELHI 110 029, INDIA}},
Type = {{Correction}},
Language = {{English}},
ISSN = {{0019-5456}},
Research-Areas = {{Pediatrics}},
Web-of-Science-Categories  = {{Pediatrics}},
Cited-References = {{Akhila K, 2007, INDIAN J PEDIATR, V74, P641, DOI 10.1007/s12098-007-0114-y.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Indian J. Pediatr.}},
Doc-Delivery-Number = {{224ZH}},
Unique-ID = {{ISI:000250486400011}},
}

@article{ ISI:000249046400013,
Author = {Singh, Meenu and Kothur, Kavitha},
Title = {{Pulmonary sarcoidosis masquerading as tuberculosis}},
Journal = {{INDIAN PEDIATRICS}},
Year = {{2007}},
Volume = {{44}},
Number = {{8}},
Pages = {{615-617}},
Month = {{AUG}},
Abstract = {{Pulmonary manifestations of sarcoidosis are common and may be initially
   confused with other common diseases like tuberculosis. We report an 11
   yr old girl who presented with chronic cough, low grade fever, recent
   exposure to tuberculosis and hilar lymphadenopathy. She was
   provisionally diagnosed as pulmonary tuberculosis and treated
   accordingly. As she had poor response to anti tubercular therapy,
   diagnosis was subsequently revised to sarcoidosis by lung biopsy.
   Treatment with steroids resulted in significant clinical improvement.}},
Publisher = {{INDIAN ACAD PEDIATRICS}},
Address = {{MAULANA AZAD MEDICAL COLLEGE, DEPT PEDIATRICS, NEW DELHI, 110 002, INDIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Singh, M (Reprint Author), Postgrad Inst Med Educ \& Res, Adv Pediat Ctr, Pediat Pulmonol Unit, Chandigarh 160012, India.
   Postgrad Inst Med Educ \& Res, Adv Pediat Ctr, Pediat Pulmonol Unit, Chandigarh 160012, India.}},
ISSN = {{0019-6061}},
Keywords = {{pulmonary sarcoidosis}},
Keywords-Plus = {{CLINICAL-FEATURES; CHILDREN}},
Research-Areas = {{Pediatrics}},
Web-of-Science-Categories  = {{Pediatrics}},
Author-Email = {{meenusingh4@rediffmail.com}},
Cited-References = {{Baughman RP, 2004, CLIN CHEST MED, V25, P521, DOI 10.1016/j.ccm.2004.04.006.
   BRAUNER MW, 1989, RADIOLOGY, V172, P467.
   Clark S K, 1987, Pediatr Dermatol, V4, P291, DOI 10.1111/j.1525-1470.1987.tb00796.x.
   Gupta Samir Kumar, 2001, Indian Journal of Pediatrics, V68, P931, DOI 10.1007/BF02722586.
   Hoffmann AL, 2004, ACTA PAEDIATR, V93, P30, DOI 10.1080/08035250310007213.
   Kabra S K, 1995, Indian Pediatr, V32, P577.
   Milman N, 1998, ACTA PAEDIATR, V87, P871, DOI 10.1080/080352598750013662.
   Paramothayan S, 2002, JAMA-J AM MED ASSOC, V287, P1301, DOI 10.1001/jama.287.10.1301.
   Shetty A K, 2000, Curr Probl Pediatr, V30, P149.
   {[}Anonymous], 1997, INDIAN PEDIAT, V34, P1093.}},
Number-of-Cited-References = {{10}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Indian Pediatrics}},
Doc-Delivery-Number = {{204LW}},
Unique-ID = {{ISI:000249046400013}},
}

@article{ ISI:000249046400017,
Author = {John, T. Jacob},
Title = {{Tuberculosis infection in BCG vaccinated and non-vaccinated children}},
Journal = {{INDIAN PEDIATRICS}},
Year = {{2007}},
Volume = {{44}},
Number = {{8}},
Pages = {{624-625}},
Month = {{AUG}},
Publisher = {{INDIAN ACAD PEDIATRICS}},
Address = {{MAULANA AZAD MEDICAL COLLEGE, DEPT PEDIATRICS, NEW DELHI, 110 002, INDIA}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{John, TJ (Reprint Author), 439 Civil Supplies Godown Lane,Kamalakshipuram, Vellore 632002, Tamil Nadu, India.}},
ISSN = {{0019-6061}},
Keywords-Plus = {{SOUTH-INDIA}},
Research-Areas = {{Pediatrics}},
Web-of-Science-Categories  = {{Pediatrics}},
Author-Email = {{vlr\_tjjohn@sancharnet.in}},
Cited-References = {{Chadha V. K., 2004, Indian Journal of Pediatrics, V71, P1063, DOI 10.1007/BF02829815.
   CHADHA VK, 2000, INDIAN J TUBERC, V47, P139.
   Gopi PG, 2006, INDIAN J MED RES, V124, P71.
   John TJ, 2007, INDIAN J MED RES, V125, P95.
   Pulickal AS, 2007, INDIAN PEDIATR, V44, P344.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Indian Pediatrics}},
Doc-Delivery-Number = {{204LW}},
Unique-ID = {{ISI:000249046400017}},
}

@article{ ISI:000248355200047,
Author = {Radosevic, Katarina and Wieland, Catharina W. and Rodriguez, Ariane and
   Weverling, Gerrit Jan and Mintardjo, Ratna and Gillissen, Gert and
   Vogels, Ronald and Skeiky, Yasir A. W. and Hone, David M. and Sadoff,
   Jerald C. and van der Poll, Tom and Havenga, Menzo and Goudsmit, Jaap},
Title = {{Protective immune responses to a recombinant adenovirus type 35
   tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope
   mapping and role of gamma interferon}},
Journal = {{INFECTION AND IMMUNITY}},
Year = {{2007}},
Volume = {{75}},
Number = {{8}},
Pages = {{4105-4115}},
Month = {{AUG}},
Abstract = {{There is an urgent need for an efficacious vaccine against tuberculosis
   (TB). Cellular immune responses are key to an effective protective
   response against TB. Recombinant adenovirus (rAd) vectors are especially
   suited to the induction of strong T-cell immunity and thus represent
   promising vaccine vehicles for the prevention of TB. We have previously
   reported on rAd vector serotype 35, the serotype of choice due to low
   preexisting immunity worldwide, which expresses a unique fusion protein
   of Mycobacterium tuberculosis antigens Ag85A, Ag85B, and TB10.4
   (Ad35-TBS). Here, we demonstrate that Ad35-TBS confers protection
   against M. tuberculosis when administered to mice through either an
   intranasal or an intramuscular route. Histological evaluation of lung
   tissue corroborated the protection and, in addition, demonstrated
   differences between two mouse strains, with diffuse inflammation in
   BALB/c mice and distinct granuloma formation in C57BL/6 mice. Epitope
   mapping analysis in these mouse strains showed that the major T-cell
   epitopes are conserved in the artificial fusion protein, while three
   novel CD8 peptides were discovered. Using a defined set of T-cell
   epitopes, we reveal differences between the two mouse strains in the
   type of protective immune response, demonstrating that different
   antigen-specific gamma interferon (IFN-gamma)-producing T cells can
   provide protection against M. tuberculosis challenge. While in BALB/c
   (H-2(d)) mice, a dominant CD8 T-cell response was detected, in C57BL/6
   (H-2(b)) mice, more balanced CD4/CD8 T-cell responses were observed,
   with a more pronounced CD4 response in the lungs. These results unify
   conflicting reports on the relative importance of CD4 versus CD8 T-cell
   responses in protection and emphasize the key role of IFN-gamma.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Radosevic, K (Reprint Author), Crucell Holland BV, Archimedesweg 4-6, NL-2333 CN Leiden, Netherlands.
   Crucell Holland BV, NL-2333 CN Leiden, Netherlands.
   Crucell Holland BV, NL-2301 CA Leiden, Netherlands.
   Univ Amsterdam, Amsterdam Med Ctr, Ctr Infect \& Immun, NL-1105 AZ Amsterdam, Netherlands.
   Aeras Global TB Vaccine Fdn, Rockville, MD 20850 USA.}},
DOI = {{10.1128/IAI.00004-07}},
ISSN = {{0019-9567}},
EISSN = {{1098-5522}},
Keywords-Plus = {{REPLICATION-DEFECTIVE ADENOVIRUS; IMMUNODEFICIENCY-VIRUS TYPE-1;
   PREEXISTING ANTI-AD5 IMMUNITY; VECTOR-BASED VACCINES;
   MYCOBACTERIUM-TUBERCULOSIS; DNA VACCINE; PULMONARY TUBERCULOSIS;
   NONHUMAN-PRIMATES; RHESUS-MONKEYS; ESAT-6 FAMILY}},
Research-Areas = {{Immunology; Infectious Diseases}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases}},
Author-Email = {{katarina.radosevic@crucell.com}},
Cited-References = {{Barouch DH, 2005, HUM GENE THER, V16, P149, DOI 10.1089/hum.2005.16.149.
   Barouch DH, 2004, J IMMUNOL, V172, P6290.
   Baumann S, 2006, CURR OPIN IMMUNOL, V18, P438, DOI 10.1016/j.coi.2006.05.016.
   Brooks JV, 2001, INFECT IMMUN, V69, P2714, DOI 10.1128/IAI.69.4.2714-2717.2001.
   Capone S, 2006, J VIROL, V80, P1688, DOI 10.1128/JVI.80.4.1688-1699.2006.
   Casimiro DR, 2004, J VIROL, V78, P11434, DOI 10.1128/JVI.78.20.11434-11438.2004.
   Casimiro DR, 2003, J VIROL, V77, P6305, DOI 10.1128/JVI.77.11.6305-6313.2003.
   D'Souza S, 2000, EUR J IMMUNOL, V30, P2455, DOI 10.1002/1521-4141(200009)30:9<2455::AID-IMMU2455>3.0.CO;2-2.
   D'Souza S, 2003, INFECT IMMUN, V71, P483, DOI 10.1128/IAI.71.1.483-493.2003.
   DEL VM, 1991, CELL, V66, P1145.
   Denis O, 1998, INFECT IMMUN, V66, P1527.
   Derrick SC, 2004, INFECT IMMUN, V72, P1685, DOI 10.1128/IAI.72.3.1685-1692.2004.
   Dietrich J, 2005, J IMMUNOL, V174, P6332.
   Eddine AN, 2005, MICROBES INFECT, V7, P939, DOI 10.1016/j.micinf.2005.03.012.
   Fallaux FJ, 1998, HUM GENE THER, V9, P1909, DOI 10.1089/hum.1998.9.13-1909.
   Hadeler KP, 2004, MATH BIOSCI, V188, P63, DOI 10.1016/j.mbs.2003.08.007.
   Havenga M, 2006, J GEN VIROL, V87, P2135, DOI 10.1099/vir.0.81956-0.
   Hervas-Stubbs S, 2006, INFECT IMMUN, V74, P3396, DOI 10.1128/IAI.02086-05.
   Hess J, 1998, P NATL ACAD SCI USA, V95, P5299, DOI 10.1073/pnas.95.9.5299.
   Hoffmeister B, 2003, METHODS, V29, P270, DOI 10.1016/S1046-2023(02)00349-3.
   Horwitz MA, 2000, P NATL ACAD SCI USA, V97, P13853, DOI 10.1073/pnas.250480397.
   HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530.
   Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893.
   Kaufmann SHE, 2005, NAT MED, V11, pS33, DOI 10.1038/nm1221.
   Kostense S, 2004, AIDS, V18, P1213, DOI 10.1097/00002030-200405210-00019.
   Leemans JC, 2003, J CLIN INVEST, V111, P681, DOI 10.1172/JCI200316936.
   Lemckert AAC, 2005, J VIROL, V79, P9694, DOI 10.1128/JVI.79.15.9694-9701.2005.
   Majlessi L, 2003, INFECT IMMUN, V71, P7173, DOI 10.1128/IAI.71.12.7173-7177.2003.
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128.
   Nanda A, 2005, J VIROL, V79, P14161, DOI 10.1128/JVI.79.22.14161-14168.2005.
   Ngai P, 2007, INFECT IMMUN, V75, P2244, DOI 10.1128/IAI.00024-07.
   North RJ, 2004, ANNU REV IMMUNOL, V22, P599, DOI 10.1146/annurev.immunol.22.012703.104635.
   Ophorst OJAE, 2006, INFECT IMMUN, V74, P313, DOI 10.1128/IAI.74.1.313-320.2006.
   Santra S, 2005, J VIROL, V79, P6516, DOI 10.1128/JVI.79.10.6516-6522.2005.
   Shiver JW, 2004, ANNU REV MED, V55, P355, DOI 10.1146/annurev.med.55.091902.104344.
   Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419.
   Skjot RLV, 2002, INFECT IMMUN, V70, P5446, DOI 10.1128/IAI.70.10.5446-5453.2002.
   Skjot RLV, 2000, INFECT IMMUN, V68, P214.
   Sullivan NJ, 2003, NATURE, V424, P681, DOI 10.1038/nature01876.
   Sumida SM, 2005, J IMMUNOL, V174, P7179.
   Tanghe A, 2001, INFECT IMMUN, V69, P3041, DOI 10.1128/IAI.69.5.3041-3047.2001.
   Tascon RE, 1998, INFECT IMMUN, V66, P830.
   Thorner AR, 2006, J CLIN MICROBIOL, V44, P3781, DOI 10.1128/JCM.01249-06.
   Tobery TW, 2001, J IMMUNOL METHODS, V254, P59, DOI 10.1016/S0022-1759(01)00397-0.
   Vogels R, 2003, J VIROL, V77, P8263, DOI 10.1128/JVI.77.15.8263-8271.2003.
   Wang DH, 2006, VACCINE, V24, P2975, DOI 10.1016/j.vaccine.2005.11.046.
   Wang J, 2004, J IMMUNOL, V173, P6357.
   Wang J, 2004, J IMMUNOL, V173, P4590.
   Wieland CW, 2005, INT IMMUNOL, V17, P1399, DOI 10.1093/intimm/dxh317.
   Williams A, 2005, TUBERCULOSIS, V85, P29, DOI 10.1016/j.tube.2004.09.009.
   Xing Z, 2005, CURR GENE THER, V5, P485, DOI 10.2174/156652305774329230.
   Yanagisawa S, 1997, INT IMMUNOL, V9, P227, DOI 10.1093/intimm/9.2.227.}},
Number-of-Cited-References = {{52}},
Times-Cited = {{130}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{Infect. Immun.}},
Doc-Delivery-Number = {{194PB}},
Unique-ID = {{ISI:000248355200047}},
}

@article{ ISI:000248730600027,
Author = {Mahajan, Vikram K. and Sharma, Nand Lal and Sharma, Vikas C. and Sarin,
   Sandip and Sharma, Ramesh Chander and Sood, Bhrigu},
Title = {{Acquired generalized lipodystrophy (panniculitis variety) triggered by
   pulmonary tuberculosis}},
Journal = {{INTERNATIONAL JOURNAL OF DERMATOLOGY}},
Year = {{2007}},
Volume = {{46}},
Number = {{8}},
Pages = {{886-888}},
Month = {{AUG}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Letter}},
Language = {{English}},
DOI = {{10.1111/j.1365-4632.2007.03302.x}},
ISSN = {{0011-9059}},
Research-Areas = {{Dermatology}},
Web-of-Science-Categories  = {{Dermatology}},
Cited-References = {{BILLINGS JK, 1987, ARCH DERMATOL, V123, P1662, DOI 10.1001/archderm.123.12.1662.
   CHANDALIA M, 1995, J CLIN ENDOCR METAB, V80, P3077, DOI 10.1210/jc.80.10.3077.
   Foster DW, 1998, HARRISONS PRINCIPLES, P2209.
   GARG A, 1992, J CLIN ENDOCR METAB, V75, P358, DOI 10.1210/jc.75.2.358.
   Hubler A, 1998, EXP CLIN ENDOCR DIAB, V106, P79.
   Misra A, 2003, MEDICINE, V82, P129, DOI 10.1097/00005792-200303000-00007.
   Westvik J, 1996, Acta Paediatr Suppl, V413, P44.}},
Number-of-Cited-References = {{7}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Dermatol.}},
Doc-Delivery-Number = {{199YH}},
Unique-ID = {{ISI:000248730600027}},
}

@article{ ISI:000249069100009,
Author = {Sylla, Laurie and Bruce, R. Douglas and Kamarulzaman, Adeeba and Altice,
   Frederick L.},
Title = {{Integration and co-location of HIV/AIDS, tuberculosis and drug treatment
   services}},
Journal = {{INTERNATIONAL JOURNAL OF DRUG POLICY}},
Year = {{2007}},
Volume = {{18}},
Number = {{4}},
Pages = {{306-312}},
Month = {{AUG}},
Abstract = {{Injection drug use (IDU) plays a critical role in the HIV epidemic in
   several countries throughout the world. In these countries, injection
   drug users are at significant risk for both HIV and tuberculosis, and
   active IDU negatively impacts treatment access, adherence and retention.
   Comprehensive strategies are therefore needed to effectively deliver
   preventive, diagnostic and curative services to these complex patient
   populations. We propose that developing co-located integrated care
   delivery systems should become the focus of national programmes as they
   continue to scale-up access to antiretroviral medications for drug
   users. Existing data suggest that such a programme will expand services
   for each of these diseases; increase detection of tuberculosis (TB) and
   HIV; improve medication adherence; increase entry into substance use
   treatment; decrease the likelihood of adverse drug events; and improve
   the effectiveness of prevention interventions. Key aspects of
   integration programmes include: co-location of services convenient to
   the patient; provision of effective substance use treatment, including
   pharmacotherapies; cross-training of generalist and specialist care
   providers; and provision of enhanced monitoring of drug-drug
   interactions and adverse side effects. Central to implementing this
   agenda will be fostering the political will to fund infrastructure and
   service delivery, expanding street-level outreach to IDUs, and training
   community health workers capable of cost effectively delivering these
   services. (C) 2007 Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Altice, FL (Reprint Author), Yale Univ, AIDS Program, 135 Coll St,Suite323, New Haven, CT 06510 USA.
   Yale Univ, AIDS Program, New Haven, CT 06510 USA.
   Univ Malaya, Kuala Lumpur, Malaysia.}},
DOI = {{10.1016/j.drugpo.2007.03.001}},
ISSN = {{0955-3959}},
Keywords = {{HIV; AIDS; injection drug use; substance use; tuberculosis; health care
   integration; health services; prevention}},
Keywords-Plus = {{REPORTED ANTIRETROVIRAL THERAPY; HIV-INFECTED PATIENTS; OPIOID
   DEPENDENCE; USERS; CARE; BUPRENORPHINE; HEPATITIS; EPIDEMIC; DISEASE; TB}},
Research-Areas = {{Substance Abuse}},
Web-of-Science-Categories  = {{Substance Abuse}},
Author-Email = {{raltice@aol.com}},
ResearcherID-Numbers = {{KAMARULZAMAN, ADEEBA/B-5216-2010}},
Funding-Acknowledgement = {{CSAT SAMHSA HHS {[}H79 TI 15767]; NIDA NIH HHS {[}K24 DA017072-05, K23
   DA022143, K23 DA022143-01, K23 DA022143-02, K23-DA 022143, K24 DA017072,
   K24-DA 017072]}},
Cited-References = {{Abdool-Karim Salim S, 2004, AIDS, V18, P975.
   Aceijas C, 2004, AIDS, V18, P2295, DOI 10.1097/00002030-200411190-00010.
   Alaei K, 2002, East Mediterr Health J, V8, P754.
   Aliyu MH, 2003, WIEN KLIN WOCHENSCHR, V115, P685.
   Altarac D, 1995, J Public Health Manag Pract, V1, P40.
   Altice FL, 2005, J URBAN HEALTH, V82, P151, DOI 10.1093/jurban/jti016.
   Altice FL, 2003, J URBAN HEALTH, V80, P416, DOI 10.1093/jurban/jtg053.
   Altice FL, 2006, CLIN INFECT DIS, V43, pS178, DOI 10.1086/508181.
   Basu S, 2006, CLIN INFECT DIS, V42, P716, DOI 10.1086/500200.
   Brassard P, 2004, INT J TUBERC LUNG D, V8, P988.
   Broadhead RS, 2002, SOC SCI MED, V55, P235, DOI 10.1016/S0277-9536(01)00167-8.
   Bruce RD, 2007, INT J DRUG POLICY, V18, P326, DOI 10.1016/j.drugpo.2006.12.011.
   Bruce R Douglas, 2003, AIDS Read, V13, P378.
   BRUCE RD, 2006, J ACQUIRED IMMUNE DE, V41.
   Carrieri MP, 2003, DRUG ALCOHOL DEPEN, V72, P13, DOI 10.1016/S0376-8716(03)00189-3.
   Celentano DD, 1998, JAMA-J AM MED ASSOC, V280, P544, DOI 10.1001/jama.280.6.544.
   Celentano DD, 2001, AIDS, V15, P1707, DOI 10.1097/00002030-200109070-00015.
   Coetzee D, 2004, TROP MED INT HEALTH, V9, pA11, DOI 10.1111/j.1365-3156.2004.01259.x.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Currie CSM, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-130.
   Dworkin MS, 2005, JAIDS-J ACQ IMM DEF, V39, P464, DOI 10.1097/01.qai.0000152400.36723.85.
   FitzGerald JM, 1999, INT J TUBERC LUNG D, V3, P153.
   Foisy MM, 2004, ANN PHARMACOTHER, V38, P550, DOI 10.1345/aph.1D444.
   Grusky O, 2006, INT J STD AIDS, V17, P354, DOI 10.1258/095646206776790196.
   Gunn RA, 2005, AM J PREV MED, V29, P27, DOI 10.1016/j.amepre.2005.03.010.
   Hunt N., 2005, REDUCING DRUG RELATE.
   Klein A., 2004, DRUG POLICY HIV PAND.
   Kourbatova EV, 2006, INT J TUBERC LUNG D, V10, P1224.
   Lally MA, 2005, AIDS PATIENT CARE ST, V19, P298, DOI 10.1089/apc.2005.19.298.
   Lee SS, 2006, AIDS, V20, P1349, DOI 10.1097/01.aids.0000232254.12275.fc.
   Liebman J, 2002, PUBLIC HEALTH NURS, V19, P345, DOI 10.1046/j.1525-1446.2002.19504.x.
   Loughlin A, 2004, AIDS CARE, V16, P485, DOI 10.1080/09540120410001683411.
   Lucas GM, 2001, J ACQ IMMUN DEF SYND, V27, P251.
   Lucas Gregory M, 2004, Hopkins HIV Rep, V16, P5.
   McShane H, 2005, INT J STD AIDS, V16, P95, DOI 10.1258/0956462053057576.
   Moore RD, 2004, JAIDS-J ACQ IMM DEF, V35, P46, DOI 10.1097/00126334-200401010-00006.
   Mosam A, 2005, AIDS, V19, P441, DOI 10.1097/01.aids.0000161775.36652.85.
   Mur-Veeman I, 2003, HEALTH POLICY, V65, P227, DOI 10.1016/S0168-8510(02)00215-4.
   Narita M, 1998, AM J RESP CRIT CARE, V158, P157.
   Nunn P, 2005, NAT REV IMMUNOL, V5, P819, DOI 10.1038/nri1704.
   Ouellet D, 1998, ANTIMICROB AGENTS CH, V42, P3107.
   Paltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088.
   Price P, 2001, J CLIN VIROL, V22, P279, DOI 10.1016/S1386-6532(01)00200-1.
   Rompalo AM, 2001, J ACQ IMMUN DEF SYND, V28, P28.
   Sharma SK, 2005, INDIAN J MED RES, V121, P550.
   Smith-Rohrberg D, 2006, JAIDS-J ACQ IMM DEF, V43, pS48, DOI 10.1097/01.qai.0000248338.74943.85.
   Snyder DC, 1999, AM J RESP CRIT CARE, V160, P178.
   Solomon S, 2004, AIDS EDUC PREV, V16, P155, DOI 10.1521/aeap.16.3.5.155.35534.
   Strathdee SA, 1998, JAMA-J AM MED ASSOC, V280, P547, DOI 10.1001/jama.280.6.547.
   Sullivan LE, 2005, CLIN INFECT DIS, V41, P891, DOI 10.1086/432888.
   Sullivan LE, 2005, ADDICTION, V100, P150, DOI 10.1111/j.1360-0443.2004.00963.x.
   WALDROPVALVERDE D, 2006, AIDS BEHAV.
   Walensky Rochelle P, 2005, Am J Med, V118, P292, DOI 10.1016/j.amjmed.2004.07.055.
   {*}WHO, 2005, WHOHIV200506.}},
Number-of-Cited-References = {{54}},
Times-Cited = {{51}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{10}},
Journal-ISO = {{Int. J. Drug Policy}},
Doc-Delivery-Number = {{204UI}},
Unique-ID = {{ISI:000249069100009}},
}

@article{ ISI:000248835500005,
Author = {Vissandjee, Bilkis and Pai, Madhukar},
Title = {{The socio-cultural challenge in public health interventions: the case of
   tuberculosis in India}},
Journal = {{INTERNATIONAL JOURNAL OF PUBLIC HEALTH}},
Year = {{2007}},
Volume = {{52}},
Number = {{4}},
Pages = {{199-201}},
Month = {{AUG}},
Publisher = {{BIRKHAUSER VERLAG AG}},
Address = {{VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Vissandjee, B (Reprint Author), Univ Montreal, Sch Nursing, POB 6128, Montreal, PQ H3C 3J7, Canada.
   Univ Montreal, Sch Nursing, Montreal, PQ H3C 3J7, Canada.
   McGill Univ, Montreal, PQ, Canada.}},
DOI = {{10.1007/s00038-007-0218-1}},
ISSN = {{1661-8556}},
Keywords-Plus = {{SOCIAL DETERMINANTS; GENDER; POPULATION; AFRICA; FOCUS}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{bilkis.vissandjee@umontreal.ca}},
Cited-References = {{Anderson J., 2000, NURS INQ, V7, P220, DOI 10.1046/j.1440-1800.2000.00074.x.
   Atre SR, 2004, TROP MED INT HEALTH, V9, P1228, DOI 10.1111/j.1365-3156.2004.01321.x.
   Balasubramanian R, 2004, INT J TUBERC LUNG D, V8, P323.
   Caburnay C A, 2001, J Public Health Manag Pract, V7, P81.
   Eastwood SV, 2004, INT J TUBERC LUNG D, V8, P70.
   Frohlich K, 2007, INT J PUBLIC HEALTH, V52, P2, DOI 10.1007/s00038-006-6101-7.
   Graham H, 2004, MILBANK Q, V82, P101, DOI 10.1111/j.0887-378X.2004.00303.x.
   GREEN L, 2002, HLTH PROMOTION HLTH, P321.
   Green LW, 2001, AM J PUBLIC HEALTH, V91, P1926, DOI 10.2105/AJPH.91.12.1926.
   Holmes CB, 1998, INT J TUBERC LUNG D, V2, P96.
   MacQueen KM, 2001, AM J PUBLIC HEALTH, V91, P1929, DOI 10.2105/AJPH.91.12.1929.
   Marmot M, 2005, LANCET, V365, P1099, DOI 10.1016/S0140-6736(05)71146-6.
   Marmot M., 2000, SOCIAL EPIDEMIOLOGY.
   MCLAREN J, 2000, EVALUATING PROGRAMS.
   MCMURRAY A, 2007, COMMUNITY HLTH WELLN, P279.
   Narayanan PR, 2003, TUBERCULOSIS, V83, P135, DOI 10.1016/S1472-9792(02)00068-9.
   Needham DM, 2001, TROP MED INT HEALTH, V6, P256, DOI 10.1046/j.1365-3156.2001.00709.x.
   Potvin L, 2005, AM J PUBLIC HEALTH, V95, P591, DOI 10.2105/AJPH.2004.048017.
   RICHARDSON W, 2002, CRITICAL ISSUES GLOB, P375.
   Sen A, 2001, INT J HEALTH SERV, V31, P469.
   Sen G, 2002, ENGENDERING INT HLTH, P281.
   Uplekar MW, 2001, INT J TUBERC LUNG D, V5, P220.
   Vissandjee B, 2002, QUAL HEALTH RES, V12, P826, DOI 10.1177/10432302012006009.
   Vlassoff C, 2000, SOC SCI MED, V50, P1353, DOI 10.1016/S0277-9536(99)00389-5.
   Vlassoff C, 2002, SOC SCI MED, V54, P1713, DOI 10.1016/S0277-9536(01)00339-2.
   Weiss M., 2001, ANTHROPOL MED, V8, P5, DOI DOI 10.1080/13648470120070980.
   World Health Organization, 2002, INT GEND HIV AIDS PR.
   {*}WHO, 2006, GEND TUB CROSS SIT A.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Public Health}},
Doc-Delivery-Number = {{201MJ}},
Unique-ID = {{ISI:000248835500005}},
}

@article{ ISI:000250998000002,
Author = {Panjabi, R. and Comstock, G. W. and Golub, J. E.},
Title = {{Recurrent tuberculosis and its risk factors: adequately treated patients
   are still at high risk}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{828-837}},
Month = {{AUG}},
Abstract = {{Recurrent tuberculosis (TB) poses significant threats, including drug
   resistance, to TB control programs. However, recurrence and its causes,
   particularly in the era of epidemic human immunodeficiency virus (HIV),
   have not been well described. We systematically searched published
   material for studies reporting on recurrent TB following completion of
   standard treatment regimens to provide data on the issue. A total of 32
   studies were reviewed. Among controlled trials, the overall recurrence
   rates (per 100 000 person-years) were respectively 3010 (95\%CI
   2230-3970) and 2290 (95\%CI 1730-2940) at 6 and 12 months after
   treatment completion. Recurrence rates were higher among observational
   studies compared to controlled trials and in countries with high versus
   low background TB incidence. TB recurrence (\%) was higher among
   HIV-infected (6.7, 95\%CI 5.9-7.6) than non-HIV-infected individuals
   (3.3, 95\%CI 2.8-3.9). Factors independently associated with recurrence
   in the literature included residual cavitation, greater area of involved
   lung tissue, positive sputum culture at 2 months of treatment and HIV
   infection. Among those with HIV infection, recurrent TB was associated
   with a low initial CD4 count and receiving less than 37 weeks of
   anti-tuberculosis treatment. We argue that adequately treated patients
   are still at high risk for recurrent disease and should be considered in
   case-finding strategies. Moreover, those with multiple risk factors may
   benefit from modification of standard treatment.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Panjabi, R (Reprint Author), Univ N Carolina, Sch Med, 2304 Gordon Rd,High Point, Chapel Hill, NC 27515 USA.
   Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA.
   Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.}},
ISSN = {{1027-3719}},
Keywords = {{pulmonary tuberculosis; recurrence; risk factors}},
Keywords-Plus = {{HUMAN-IMMUNODEFICIENCY-VIRUS; AFRICAN GOLD MINERS; DIAGNOSED PULMONARY
   TUBERCULOSIS; DRUG-RESISTANT TUBERCULOSIS; HIV-INFECTED PATIENTS;
   EXOGENOUS REINFECTION; CLINICAL-TRIAL; CONTINUATION PHASE; FOLLOW-UP;
   RELAPSE}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{rajesh\_panjabi@med.unc.edu}},
Cited-References = {{ABER V R, 1978, Bulletin of the International Union Against Tuberculosis, V53, P260.
   Bandera A, 2001, J CLIN MICROBIOL, V39, P2213, DOI 10.1128/JCM.39.6.2213-2218.2001.
   Benator D, 2002, LANCET, V360, P528.
   British Thoracic Association, 1982, AM REV RESPIR DIS, V126, P460.
   Cao JP, 1998, INT J TUBERC LUNG D, V2, P360.
   Chaisson RE, 1996, AM J RESP CRIT CARE, V154, P1034.
   CHANG KC, 2006, J RESP CRIT CARE MED, V174, P1153.
   Chiang CY, 2005, LANCET INFECT DIS, V5, P629, DOI 10.1016/S1473-3099(05)70240-1.
   COMBS DL, 1990, ANN INTERN MED, V112, P397.
   Connolly C, 1999, AIDS, V13, P1543, DOI 10.1097/00002030-199908200-00015.
   Corbett EL, 1999, AM J RESP CRIT CARE, V159, P94.
   COWIE RL, 1989, AM REV RESPIR DIS, V139, P1086.
   Den Boon S, 2005, INT J TUBERC LUNG D, V9, P1088.
   Driver CR, 2001, CLIN INFECT DIS, V33, P1762, DOI 10.1086/323784.
   East African/British Medical Research Council, 1972, LANCET, Vi, P1079.
   El-Sadr WM, 1998, CLIN INFECT DIS, V26, P1148.
   Fitzgerald DW, 2000, LANCET, V356, P1470, DOI 10.1016/S0140-6736(00)02870-1.
   Fitzpatrick LK, 2002, INT J TUBERC LUNG D, V6, P550.
   Fujiwara PI, 1997, ARCH INTERN MED, V157, P531, DOI 10.1001/archinte.157.5.531.
   Garcia-Garcia MD, 2000, ARCH INTERN MED, V160, P630, DOI 10.1001/archinte.160.5.630.
   Gilks CF, 1997, AIDS, V11, P911, DOI 10.1097/00002030-199707000-00011.
   GIRLING DJ, 1991, AM REV RESPIR DIS, V143, P262.
   GIRLING DJ, 1988, AM REV RESPIR DIS, V137, P1147.
   GONZALEZMONTANER LJ, 1994, TUBERCLE LUNG DIS, V75, P341, DOI 10.1016/0962-8479(94)90079-5.
   Hong Kong Chest Service / British Medical Research Council, 1991, AM REV RESPIR DIS, V143, P700.
   Hong Kong Chest Service/British Medical Research Council, 1987, AM REV RESPIR DIS, V136, P1339.
   Jasmer RM, 2004, AM J RESP CRIT CARE, V170, P1360, DOI 10.1164/rccm.200408-10810C.
   Johnson Jasmin, 2003, Indian J Chest Dis Allied Sci, V45, P105.
   Johnson JL, 1997, INT J TUBERC LUNG D, V1, P446.
   Kennedy N, 1996, CLIN INFECT DIS, V22, P827.
   Lambert ML, 2003, LANCET INFECT DIS, V3, P282, DOI 10.1016/S1473-3099(03)00607-8.
   Lawn SD, 2005, AIDS, V19, P2109, DOI 10.1097/01.aids.0000194808.20035.c1.
   Malkin JE, 1997, INT J TUBERC LUNG D, V1, P68.
   Mallory KF, 2000, INT J TUBERC LUNG D, V4, P455.
   Mathew R, 1997, INT J TUBERC LUNG D, V1, P509.
   Murray J, 1999, AM J RESP CRIT CARE, V159, P733.
   Nettles RE, 2004, CLIN INFECT DIS, V38, P731, DOI 10.1086/381675.
   Okwera A, 2006, INT J TUBERC LUNG D, V10, P39.
   OYAMA T, 1955, AM REV TUBERC PULM, V72, P613.
   PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204.
   Pulido F, 1997, ARCH INTERN MED, V157, P227, DOI 10.1001/archinte.157.2.227.
   Selassie AW, 2005, ANN EPIDEMIOL, V15, P519, DOI 10.1016/j.annepidem.2005.03.002.
   Singapore Tuberculosis Service/ British Medical Research Council, 1979, AM REV RESPIR DIS, V119, P579.
   Singapore Tuberculosis Service/British Medical Research Council, 1991, AM REV RESPIR DIS, V143, P707.
   SLUTKIN G, 1988, AM REV RESPIR DIS, V138, P1622.
   SNIDER DE, 1984, AM REV RESPIR DIS, V130, P1091.
   Sonnenberg P, 2001, LANCET, V358, P1687, DOI 10.1016/S0140-6736(01)06712-5.
   Sterling TR, 1999, AIDS, V13, P1899, DOI 10.1097/00002030-199910010-00012.
   Tam CM, 2002, INT J TUBERC LUNG D, V6, P3.
   Thomas A, 2005, INT J TUBERC LUNG D, V9, P556.
   TRIPATHY SP, 1981, INDIAN J TUBERC, V28, P45.
   Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602.
   Vernon A, 1999, LANCET, V353, P1843, DOI 10.1016/S0140-6736(98)11467-8.
   World Health Organization, 2003, WHOCDSTB2003313.
   World Health Organization, 2006, WHOHTMTB2006362.
   Wilkinson D, 1998, INT J TUBERC LUNG D, V2, P52.
   Wood R, 2000, J ACQ IMMUN DEF SYND, V23, P75.}},
Number-of-Cited-References = {{57}},
Times-Cited = {{54}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000002}},
}

@article{ ISI:000250998000003,
Author = {Enarson, D. A. and Slarna, K. and Chiang, C. -Y.},
Title = {{Providing and monitoring quality service for smoking cessation in
   tuberculosis care}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{838-847}},
Month = {{AUG}},
Abstract = {{All tobacco smokers should be identified and provided with a smoking
   cessation intervention (SCI) during tuberculosis (TB) treatment. To
   ensure that this occurs, the intervention process should be recorded and
   monitored. Monitoring is the best guarantee that care is standardised
   and offered equitably to all patients. It allows for evaluation of
   processes and outcomes so that population needs can be identified and
   appropriate techniques added or updated. In this article we propose
   steps for brief intervention as a part of the monitoring process, using
   model forms and suggested procedures for filling them in. The suggested
   forms are a modified TB treatment card that includes information about
   tobacco use, an SCI patient card to be added to the patient's TB
   treatment folder, SCI registers and SCI quarterly report forms and a
   tobacco use questionnaire for evaluation of services.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Slarna, K (Reprint Author), Int Union Against TB \& Lung Dis, 68 Bd St Michel, F-75006 Paris, France.
   Int Union Against TB \& Lung Dis, F-75006 Paris, France.}},
ISSN = {{1027-3719}},
Keywords = {{tobacco cessation; monitoring; TB case management}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{kslama@iuatld.org}},
Number-of-Cited-References = {{0}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000003}},
}

@article{ ISI:000250998000004,
Author = {Zachariah, R. and Fitzgerald, M. and Massaquoi, M. and Acabu, A. and
   Chilomo, D. and Salaniponi, F. M. L. and Harries, A. D.},
Title = {{Does antiretroviral treatment reduce case fatality among HIV-positive
   patients with tuberculosis in Malawi?}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{848-853}},
Month = {{AUG}},
Abstract = {{SETTING: Thvolo district, Malawi.
   OBJECTIVES: To report on 1) case fatality among human immunodeficiency
   virus (HIV) positive tuberculosis (TB) patients while on
   anti-tuberculosis treatment and 2) whether antiretroviral treatment
   (ART) initiated during the continuation phase of TB treatment reduces
   case fatality.
   DESIGN: Retrospective cohort analysis.
   METHODS: Comparative analysis of treatment outcomes for TB patients
   registered between January and December 2004.
   RESULTS: Of 983 newly registered TB patients receiving diagnostic HIV
   testing, 658 (67\%) were HIV-positive. A total of 132 (20\%) patients
   died during the 8-month course of anti-tuberculosis treatment, of whom
   82 (62\%) died within the first 2 months of treatment when ART was not
   provided (cumulative incidence 3.0, 95 \%CI 2.5-3.6 per 100
   person-years). A total of 576 TB patients started the continuation phase
   of anti-tuberculosis treatment, 180 (31\%) of whom were started on ART.
   The case-fatality rate per 100 person-years was not significantly
   different for patients on ART (1.0, 95\%CI 0.6-1.7) and those without
   ART (1.2, 95\%CI 0.9-1.7, adjusted hazard ratio 0.86, 95\%CI 0.4-1.6, P
   = 0.6).
   CONCLUSIONS: ART provided in the continuation phase of TB treatment does
   not have a significant impact on reducing case fatality. Reasons for
   this and possible measures to reduce high case fatality in the initial
   phase of TB treatment are discussed.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Zachariah, R (Reprint Author), Brussels Operat Ctr, Dept Med, Med Frontiers, 68 Rue Gadperich, L-1617 Luxembourg, Luxembourg.
   Brussels Operat Ctr, Dept Med, Med Frontiers, L-1617 Luxembourg, Luxembourg.
   Med Frontiers, Lilongwe, Malawi.
   Natl TB Control Program, Minist Educ, Lilongwe, Malawi.
   HIV Care \& Support, Minist Hlth, Lilongwe, Malawi.
   London Sch Hyg \& Trop Med, London, England.}},
ISSN = {{1027-3719}},
Keywords = {{Malawi; HIV/AIDS; TB; ART; case fatality}},
Keywords-Plus = {{SUB-SAHARAN AFRICA; THERAPY; MORTALITY; OUTCOMES; BACTEREMIA; ADULTS;
   ERA; TB}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{zachariah@internet.lu}},
Cited-References = {{ALZEER AH, 1993, TUBERCLE LUNG DIS, V74, P6, DOI 10.1016/0962-8479(93)90060-B.
   Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/01.aids.0000125925.87797.38.
   Colebunders R, 2006, INT J TUBERC LUNG D, V10, P946.
   Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4.
   ELLIS ME, 1983, LANCET, V1, P655.
   GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z.
   Gordon MA, 2001, J INFECTION, V42, P44, DOI 10.1053/jinf.2000.0779.
   Harries AD, 2006, INT J TUBERC LUNG D, V10, P1306.
   Harries AD, 2006, LANCET, V367, P944, DOI 10.1016/S0140-6736(06)68387-6.
   Hung CC, 2003, AIDS, V17, P2615, DOI 10.1097/01.aids.0000088220.77946.19.
   Kang'ombe CT, 2004, INT J TUBERC LUNG D, V8, P829.
   Kelly PM, 1999, T ROY SOC TROP MED H, V93, P287, DOI 10.1016/S0035-9203(99)90025-1.
   Libamba E, 2005, INT J TUBERC LUNG D, V9, P1062.
   {*}MIN HLTH POP, 2002, MAN NAT TUB CONTR PR.
   Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2.
   Mukadi YD, 2001, AIDS, V15, P143, DOI 10.1097/00002030-200101260-00002.
   Raviglione M, 2006, INT J TUBERC LUNG D, V10, P1185.
   Sungkanuparph S, 2006, J INFECTION, V52, P188, DOI 10.1016/j.jinf.2005.05.010.
   {*}WHO, 2005, SCAL ANT THER RES LI.
   World Health Organization, 2006, IMPR DIAGN TREATM SM.
   World Health Organization, 2003, TREATM TUB GUID NAT.
   Zachariah R, 2002, T ROY SOC TROP MED H, V96, P291, DOI 10.1016/S0035-9203(02)90103-3.
   Zachariah R, 2003, AIDS, V17, P1053, DOI 10.1097/01.aids.0000060355.78202.b7.
   Zachariah R, 2005, INT J TUBERC LUNG D, V9, P238.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{21}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000004}},
}

@article{ ISI:000250998000006,
Author = {Umubyeyi, A. N. and Shamputa, I. C. and Rigouts, L. and Dediste, A. and
   Karita, E. and Struelens, M. J. and Portaels, F.},
Title = {{Molecular investigation of recurrent tuberculosis in patients from
   Rwanda}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{860-867}},
Month = {{AUG}},
Abstract = {{SETTING: Pulmonary tuberculosis (TB) patients enrolled in four provinces
   of Rwanda.
   OBJECTIVE: To determine the cause of recurrent TB.
   DESIGN: Serial Mycobacterium tuberculosis isolates obtained from
   patients with recurrent TB from January 2002 to September 2005 were
   genotyped by spoligotyping and mycobacterial interspersed repetitive
   unit-variable number of tandem repeat (MIRU-VNTR) typing. Drug
   resistance was determined by phenotypic susceptibility testing and
   sequencing of rpoB, katG, inhA and embB genes.
   RESULTS: Among 710 culture-positive TB patients enrolled in the study,
   initial drug susceptibility testing results were available for 638.
   Sixty-nine of these had multidrug-resistant (MDR) TB and 569 were
   non-MDR-TB. Among the MDR-TB patients, 22 had follow-up isolates after
   cure (n = 12) or chronic infection (n = 10). The DNA patterns of
   sequential isolates from 4 of the 12 previously cured MDR-TB patients
   were different, indicating re-infection. DNA patterns of isolates from
   the remaining 8 previously cured and 10 chronic MDR-TB patients were
   identical, suggesting reactivation and treatment failure, respectively.
   Among the non-MDR-TB patients, disease recurrence was observed in one
   case; this was determined to be due to reactivation after initial mixed
   infection.
   CONCLUSION: These results document a high treatment failure/reactivation
   rate for MDR-TB and suggest that re-infection within 2 years may not be
   a common cause of recurrent TB in this setting.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Umubyeyi, AN (Reprint Author), Inst Trop Med, Unit Mycobacteriol, B-2000 Antwerp, Belgium.
   Inst Trop Med, Unit Mycobacteriol, B-2000 Antwerp, Belgium.
   CHU St Pierre, Dept Microbiol, Brussels, Belgium.
   Trop Dis Res Ctr, Microbiol Unit, Ndola, Zambia.
   Emory Univ, Project San Francisco, Kigali, Rwanda.
   Univ Libre Bruxelles, Erasme Hosp, Dept Microbiol, Brussels, Belgium.}},
ISSN = {{1027-3719}},
Keywords = {{DNA fingerprinting; M. tuberculosis; reactivation; recurrence;
   re-infection}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; EXOGENOUS REINFECTION; PULMONARY
   TUBERCULOSIS; DRUG-RESISTANCE; MIXED INFECTION; EPIDEMIOLOGY; STRAIN;
   SWITZERLAND; COHORT}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{alainenyaruhirira@hotmail.com}},
Cited-References = {{Bandera A, 2001, J CLIN MICROBIOL, V39, P2213, DOI 10.1128/JCM.39.6.2213-2218.2001.
   Caminero JA, 2001, AM J RESP CRIT CARE, V163, P717.
   Chaves F, 1999, AIDS, V13, P615, DOI 10.1097/00002030-199904010-00011.
   DEVIEDMA DG, 2002, ARCH INTERN MED, V162, P1873, DOI 10.1001/archinte.162.16.1873.
   Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706.
   Fitzpatrick LK, 2002, INT J TUBERC LUNG D, V6, P550.
   Glynn JR, 2004, J INFECT DIS, V190, P1158, DOI 10.1086/423144.
   HEWLETT D, 1995, JAMA-J AM MED ASSOC, V273, P916, DOI 10.1001/jama.273.12.916.
   Iseman M., 2000, DRUG RESISTANT TUBER.
   Jasmer RM, 2004, AM J RESP CRIT CARE, V170, P1360, DOI 10.1164/rccm.200408-10810C.
   Johnson JL, 2000, INT J TUBERC LUNG D, V4, P1032.
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907.
   KLEEBERG HH, 1980, BAKTERIOL ORIG A, V207, P58.
   LEVYFREBAULT VV, 1992, INT J SYST BACTERIOL, V42, P315.
   March F, 1997, CLIN INFECT DIS, V25, P1044, DOI 10.1086/516065.
   {*}MIN SANT, 2002, RAPP ANN 2002 PROGR.
   NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502.
   Shamputa IC, 2004, J CLIN MICROBIOL, V42, P5528, DOI 10.1128/JCM.42.12.5528-5536.2004.
   Shamputa IC, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-99.
   Siddiqi SH., 1996, BACTEC 460 TB SYSTEM.
   SRINAND S, 1996, ANTIMICROB AGENTS CH, V40, P1024.
   Strassle A, 1997, J CLIN MICROBIOL, V35, P374.
   Sudre P, 1999, INFECTION, V27, P323, DOI 10.1007/s150100050037.
   Supply P, 2000, MOL MICROBIOL, V36, P762, DOI 10.1046/j.1365-2958.2000.01905.x.
   Telenti A, 1997, J CLIN MICROBIOL, V35, P719.
   THEISEN A, 1995, LANCET, V345, P1512, DOI 10.1016/S0140-6736(95)91073-5.
   Van Rie A, 2001, J CLIN MICROBIOL, V39, P636, DOI 10.1128/JCM.39.2.636-641.2001.
   Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602.
   Verver S, 2005, AM J RESP CRIT CARE, V171, P1430, DOI 10.1164/rccm.200409-1200OC.
   {[}Anonymous], 1997, WHOTB97229.
   World Health Organization, 2004, WHOHTMTB2004343.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000006}},
}

@article{ ISI:000250998000007,
Author = {Marra, F. and Marra, C. A. and Bruchet, N. and Richardson, K. and
   Moadebi, S. and Elwood, R. K. and FitzGerald, J. M.},
Title = {{Adverse drug reactions associated with first-line anti-tuberculosis drug
   regimens}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{868-875}},
Month = {{AUG}},
Abstract = {{BACKGROUND: Standard treatment of active tuberculosis (TB) consists of
   Isoniazid (INH), rifampin (RMP), pyrazinamide (PZA) and ethambutol
   (EMB). Although this regimen is effective in treating active TB, it is
   associated with many adverse drug reactions (ADRs) and poses a
   significant challenge to completion of treatment. OBJECTIVES: To examine
   the incidence of major ADRs and risk factors associated with first-line
   anti-tuberculosis medications.
   METHODS: This study evaluated patients receiving treatment for active TB
   from a population-based database (2000-2005). The nature of the ADRs,
   likelihood of association with the study medications and severity were
   evaluated.
   RESULTS: A total of 1061 patients received treatment, of whom 318 (30\%)
   had at least one major ADR. The overall incidence of all major ADRs was
   7.3 events per 100 person-months (95\%CI 7.2-7.5): 23.3 (95\%CI
   23.0-23.7) when on all four first-line drugs, 13.6 (95\%CI 13.3-14.0)
   when on RMP, INH and PZA, and 2.4 (95\%CI 2.3-2.6) when on INH and RMP.
   Adjusted hazard ratio (HR) revealed that combination regimens containing
   PZA, females, subjects aged 35-59 and >= 60 years, baseline aspartate
   aminotransferase >= 80 U/1 and drug resistance were associated with any
   major event.
   CONCLUSIONS: First-line anti-tuberculosis drugs are associated with
   significant ADRs. There are several risk factors associated with the
   development of ADRs, including exposure to regimens containing PZA.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Marra, CA (Reprint Author), Univ British Columbia, St Pauls Hosp, Ctr Hlth Evaluat \& Outcome Sci, Fac Pharmaceut Sci, 620-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
   Univ British Columbia, Vancouver, BC V6Z 1Y6, Canada.
   BC Ctr Dis Control, Vancouver, BC, Canada.
   Ctr Hlth Evaluat \& Outcome Sci, Vancouver, BC, Canada.}},
ISSN = {{1027-3719}},
Keywords = {{first-line medications; tuberculosis; adverse events}},
Keywords-Plus = {{HEPATITIS-B; PULMONARY TUBERCULOSIS; ACTIVE TUBERCULOSIS; CHEMOTHERAPY;
   HEPATOTOXICITY; PYRAZINAMIDE; INFECTION; MODEL; RISK}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{carlo.marra@ubc.ca}},
Cited-References = {{American Thoracic Society/Centers for Disease Control and Prevention/Infectious Disease Society of America, 2003, AM J RESP CRIT CARE, V167, P603.
   ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976.
   CAMPAGNA M, 1954, AM REV TUBERC PULM, V69, P334.
   Centers for Disease Control and Prevention, 2001, MMWR-MORBID MORTAL W, V50, P289.
   COMBS DL, 1990, ANN INTERN MED, V112, P397.
   Essebag Vidal, 2005, BMC Med Res Methodol, V5, P5, DOI 10.1186/1471-2288-5-5.
   Forget EJ, 2006, EXPERT OPIN DRUG SAF, V5, P231, DOI 10.1517/14740338.5.2.231.
   Horsburgh CR, 2004, NEW ENGL J MED, V350, P2060, DOI 10.1056/NEJMsa031667.
   Hosmer DW, 1999, APPL SURVIVAL ANAL R.
   Hwang SJ, 1997, J GASTROEN HEPATOL, V12, P87, DOI 10.1111/j.1440-1746.1997.tb00353.x.
   Jindani A, 2004, LANCET, V364, P1244, DOI 10.1016/S0140-6736(04)17141-9.
   Lee BH, 2005, CHEST, V127, P1304, DOI 10.1378/chest.127.4.1304.
   LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085.
   LONG R, 2000, CANADIAN TUBERCULOSI.
   Marra F, 2005, CHEST, V128, P1406, DOI 10.1378/chest.128.3.1406.
   MCDERMOTT W, 1954, AM REV TUBERC PULM, V69, P319.
   Pan L, 2005, WORLD J GASTROENTERO, V11, P2518.
   Schaberg T, 1996, EUR RESPIR J, V9, P2026, DOI 10.1183/09031936.96.09102026.
   Ungo JR, 1998, AM J RESP CRIT CARE, V157, P1871.
   Wong WM, 2000, HEPATOLOGY, V31, P201, DOI 10.1002/hep.510310129.
   Yee D, 2003, AM J RESP CRIT CARE, V167, P1472, DOI 10.1164/rccm.200206-626OC.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{37}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000007}},
}

@article{ ISI:000250998000008,
Author = {Chiang, C-Y. and Luh, K-T. and Enarson, D. A. and Yang, S-L. and Wu,
   Y-C. and Lin, T-P.},
Title = {{Accuracy of classification of notified tuberculosis cases in Taiwan}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{876-881}},
Month = {{AUG}},
Abstract = {{SETTING: Tuberculosis (TB) suspects and cases reported in 2003 in
   Taiwan.
   OBJECTIVES: To evaluate the accuracy of the classification of notified
   TB cases in Taiwan.
   DESIGN: A list of all TB cases reported in 2003 in Taiwan was obtained
   from the Taiwan Center for Disease Control, along with their
   classification. TB cases residing in Taipei City were investigated by
   consulting their medical charts. RESULTS: Of 1973 patients, 782 (39.6\%)
   were bacteriologically confirmed, 1024 (52\%) were not bacteriologically
   confirmed (indeterminate) and 167 (9\%) were not TB cases (in whom
   non-tuberculosis mycobacteria {[}NTM] was isolated). Of the 1973 cases,
   1716 (87\%) had been treated with anti-tuberculosis drugs, while 257
   (13\%) had not been treated. Of the 782 bacteriologically confirmed
   cases, 68 (8.7\%) were misclassified as non-notifiable (32 {[}4.1\%] had
   their diagnosis changed by a clinician and 36 {[}4.6\%] by
   administrative coding). Of the 167 cases in whom NTM were isolated, 72
   (43.1 \%) were misclassified as TB cases. Of the 257 untreated suspects,
   31 (12.1\%) did not have any evidence of TB (20 indeterminate and I I
   NTM cases) and were questionably classified as newly diagnosed cases.
   CONCLUSION: There was substantial misclassification of notified TB cases
   in Taiwan.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Chiang, CY (Reprint Author), No 26-2,Lane 46,Guang-Fu S Rd, Taipei, Taiwan.
   Int Union Against TB \& Lung Dis, Paris, France.
   Natl TB Assoc, Taipei, Taiwan.
   Ctr Dis Control, Taipei, Taiwan.}},
ISSN = {{1027-3719}},
Keywords = {{tuberculosis; notification; Taipei}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{cychiang@iuatld.org}},
Cited-References = {{{*}CDC DEP HLTH, 2004, STAT COMM DIS SURV R, P124.
   {*}CDC DEP HLTH, 2002, TUB ANN REP 2000.
   {*}CDC DEP HLTH, 2005, STAT COMM DIS SURV R, P121.
   Chiang CY, 2002, INT J TUBERC LUNG D, V6, P974.
   Chiang CY, 2005, J FORMOS MED ASSOC, V104, P502.
   {*}CHRON DIS CONTR B, 1998, TB STAT 1997.
   Enarson D, 2000, MANAGEMENT TUBERCULO.
   Mori T, 2000, EMERG INFECT DIS, V6, P566.
   Rieder HL, 1996, EUR RESPIR J, V9, P1097, DOI 10.1183/09031936.96.09051097.
   World Health Organization, 2003, WHOCDSTB2003313.
   WHO/UNICEF/ICCIDD, 1994, WHOTB94179, P1.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000008}},
}

@article{ ISI:000250998000009,
Author = {Masjedi, M. R. and Fadaizadeh, L. and Asl, R. Taghizadeh},
Title = {{Notification of patients with tuberculosis detected in the private
   sector, Tehran, Iran}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{882-886}},
Month = {{AUG}},
Abstract = {{OBJECTIVE: To determine the case notification rate of patients with
   tuberculosis (TB) detected by private laboratories, in Tehran, Iran.
   STUDY DESIGN: Cross-sectional study.
   METHOD: All confirmed TB cases among suspected cases referred to private
   laboratories for acid-fast bacilli (AFB) examination in 2002-2003 were
   enrolled in the study. All AFB-positive cases were followed up for
   notification to the Iranian Ministry of Health (MOH) National
   Tuberculosis Programme (NTP).
   RESULTS: Of the total number of cases referred to private laboratories,
   646 AFB-positive cases were followed up. Of these, 317 (49.1\%) cases
   were female and 328 (50.8\%) were male; the mean age was 52.2 years (SD
   +/- 21.7). Patients were contacted either at their residence or by
   telephone: 82 were found to be registered with the MOH while 564
   (87.3\%) could not be traced. A positive correlation was detected
   between physician advice for patient referral to health centres and case
   registration by the MOH (Fisher's Exact test 0.000).
   CONCLUSION: The private sector in Tehran plays a significant role in TB
   detection, but there are major gaps in the collaboration between the
   private and public health systems.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Fadaizadeh, L (Reprint Author), Natl Res Inst TB \& Lung Dis, Shahid Bahonar Ave, Tehran 1955841452, Iran.
   Shaheed Beheshti Univ Med Sci, Res Ctr Mycobacteriol, Natl Res Inst TB \& Lung Dis, Tehran, Iran.}},
ISSN = {{1027-3719}},
Keywords = {{tuberculosis; private sector; notification; laboratories}},
Keywords-Plus = {{CHI-MINH CITY; PULMONARY TUBERCULOSIS; KATHMANDU VALLEY; INDIA; NEPAL;
   PARTNERSHIP; CULTURE; VIETNAM; CLINICS}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{lfadaizadeh@nritld.ac.ir}},
ResearcherID-Numbers = {{fadaizadeh, lida/G-4351-2017
   }},
ORCID-Numbers = {{fadaizadeh, lida/0000-0002-0736-2130
   Masjedi, Mohammadreza/0000-0003-4964-3851}},
Cited-References = {{Brugha R, 1998, HEALTH POLICY PLANN, V13, P107, DOI 10.1093/heapol/13.2.107.
   Chakravorty S, 2005, J CLIN MICROBIOL, V43, P2703, DOI 10.1128/JCM.6.2703-2708.2004.
   Corless JA, 2000, EUR RESPIR J, V16, P976, DOI 10.1183/09031936.00.16597600.
   Hong YP, 1999, INT J TUBERC LUNG D, V3, P695.
   Hurtig AK, 1999, INT J TUBERC LUNG D, V3, P1009.
   Hurtig AK, 2002, HEALTH POLICY PLANN, V17, P78, DOI 10.1093/heapol/17.1.78.
   Khan JA, 2003, TROP DOCT, V33, P94.
   Lonnroth K, 2003, INT J TUBERC LUNG D, V7, P165.
   Lonnroth K, 2001, SOC SCI MED, V52, P935, DOI 10.1016/S0277-9536(00)00195-7.
   McNabb SJN, 2002, BMC PUBLIC HEALTH, V2, DOI 10.1186/1471-2458-2-2.
   Mills A, 2002, WORLD HOSP HLTH SERV, V38, P41.
   Mills Anne, 2002, World Hosp Health Serv, V38, P24.
   Murthy KJR, 2001, INT J TUBERC LUNG D, V5, P354.
   Newell JN, 2004, B WORLD HEALTH ORGAN, V82, P92.
   NSHUTS L, 2001, INT J TUBERC LUNG D, V4, P1006.
   Rangan SG, 2004, INT J TUBERC LUNG D, V8, P552.
   Rangan Sheela, 2003, J Indian Med Assoc, V101, P161.
   Uplekar M, 1998, INT J TUBERC LUNG D, V2, P324.
   Vyas RM, 2003, INT J TUBERC LUNG D, V7, P543.
   World Health Organization, 2003, WHOCDSTB2003316.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{11}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000009}},
}

@article{ ISI:000250998000010,
Author = {Muniyandi, M. and Rajeswari, R. and Balasubramanian, R. and Nirupa, C.
   and Gopi, P. G. and Jaggarajamma, K. and Sheela, F. and Narayanan, P. R.},
Title = {{Evaluation of post-treatment health-related quality of life (HRQoL)
   among tuberculosis patients}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{887-892}},
Month = {{AUG}},
Abstract = {{BACKGROUND: Health-related quality of life (HRQoL) measures the impact
   of a disease by assessing the health status of patients.
   OBJECTIVE: To assess the HRQoL of tuberculosis (TB) patients one year
   after treatment completion.
   METHODS: Patients registered under the TB control programme from July
   2002 to June 2003 in a TB Unit in south India were interviewed one year
   after successful completion of treatment. Data on HRQoL were collected
   using the SF-36 questionnaire, which covers physical, mental and social
   well-being components. Data on economic well-being were also collected.
   Scores were given for all domains.
   RESULT: Of 436 TB patients interviewed, the mean scores for social,
   physical, mental and economic well-being were respectively 84, 74, 68
   and 62 on a scale of 100. The well-being scores were significantly
   related to age, sex, education, employment and persistent symptoms.
   There was a significant association between economic and social
   well-being.
   CONCLUSION: This study suggests that the HRQoL of TB patients one year
   after successful completion of treatment under the TB control programme
   was normal for most of the domains studied and was associated with age,
   literacy and employment, income, smoking, alcoholism and persistence of
   symptoms.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Narayanan, PR (Reprint Author), TB Res Ctr, Indian Council Med Res, Mayor VR Ramanathan Rd, Madras 600031, Tamil Nadu, India.
   TB Res Ctr, Indian Council Med Res, Madras 600031, Tamil Nadu, India.}},
ISSN = {{1027-3719}},
Keywords = {{tuberculosis; DOTS; SF-36; HRQoL; long-term follow-up; India}},
Keywords-Plus = {{WHITEHALL-II; SOUTH-INDIA; SF-36; QUESTIONNAIRE; CARE}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{prnarayanan@trcchennai.in}},
Cited-References = {{ARORA VK, 1992, INDIAN J TUBERC, V39, P181.
   BRAZIER JE, 1992, BRIT MED J, V305, P160.
   Chamla D, 2004, INT J TUBERC LUNG D, V8, P1100.
   {*}CTR TB DIV DIR GE, 2006, TB IND RNTCP STAT RE.
   Dion MJ, 2004, QUAL LIFE RES, V13, P653, DOI 10.1023/B:QURE.0000021320.89524.64.
   FITZPATRICK R, 1992, BRIT MED J, V305, P1074.
   Harper R, 1997, THORAX, V52, P879.
   Hemingway H, 1997, AM J PUBLIC HEALTH, V87, P1484, DOI 10.2105/AJPH.87.9.1484.
   Hemingway H, 1997, BMJ-BRIT MED J, V315, P1273.
   JENKINSON C, 1995, QUAL LIFE RES, V4, P47, DOI 10.1007/BF00434383.
   Jenkinson C, 1999, J PUBLIC HEALTH MED, V21, P372, DOI 10.1093/pubmed/21.4.372.
   KUYKEN W, 1995, SOC SCI MED, V41, P1403.
   Murray C J, 1991, Bull Int Union Tuberc Lung Dis, V66, P149.
   Needham DM, 1996, LANCET, V348, P134, DOI 10.1016/S0140-6736(05)64654-5.
   {*}QUAL METR INC, 1990, SF 36 SCOR US NORM D.
   Rajeswari R, 2005, SOC SCI MED, V60, P1845, DOI 10.1016/j.socscimed.2004.08.024.
   RAO KVK, 1999, P NAT C PULM DIS NAP.
   STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907.
   Thomas A, 2005, INT J TUBERC LUNG D, V9, P556.
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{20}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000010}},
}

@article{ ISI:000250998000011,
Author = {Sharma, A. K. and Sharma, R.},
Title = {{Impact of mass media on knowledge about tuberculosis control among
   homemakers in Delhi}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{893-897}},
Month = {{AUG}},
Abstract = {{SETTING: Homes in Delhi, India.
   OBJECTIVE: To study the reach of mass media campaigns and their impact
   on awareness about tuberculosis (TB) control among
   homemakers/housewives.
   DESIGN: A community-based cross-sectional survey among homemakers
   residing in Delhi for more than 6 months.
   RESULTS: Of a total of 920 women interviewed, about 74.2\% had seen
   specific TB-related health messages in one or more of the mass media.
   The maximum number of subjects could recall having seen billboards or
   television campaigns. The percentage of respondents who had correct
   information about various aspects of the disease was higher among those
   who had seen TB campaigns on any of the mass media. The effectiveness of
   radio and newsprint in communicating TB messages was found to be more
   limited than that of television and billboards.
   CONCLUSION: The mass media can be effective in getting messages about TB
   across to the community of women who are homemakers, especially in
   developing countries. In view of our findings, it may be recommended
   that television and billboards be used as tools for reaching out to them
   with specific campaigns regarding TB control, and that the use of these
   media should be strengthened further.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Sharma, R (Reprint Author), Univ Coll Med Sci, GTB Hosp Complex, Dept Community Med, Delhi 110095, India.
   Univ Coll Med Sci, Dept Community Med, Delhi, India.}},
ISSN = {{1027-3719}},
Keywords = {{mass media; tuberculosis; impact}},
Keywords-Plus = {{INDIA}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{aayrash@yahoo.com}},
Cited-References = {{Ali SS, 2003, INT J TUBERC LUNG D, V7, P1052.
   Arora V K, 2000, Indian J Chest Dis Allied Sci, V42, P21.
   Chakraborty AK, 2004, INDIAN J MED RES, V120, P248.
   Cheriyan C S, 1984, Indian J Lepr, V56, P151.
   {*}IIPS, 2002, ORC MACR NAT FAM HLT.
   Jaramillo E, 2001, HEALTH POLICY PLANN, V16, P68, DOI 10.1093/heapol/16.1.68.
   Malhotra R, 2002, IND J COMM MED, V27, P62.
   MEHROTRA ML, 1998, INDIAN J TUBERCULOSI, V45, P191.
   Noar SM, 2006, J HEALTH COMMUN, V11, P21, DOI 10.1080/10810730500461059.
   Sharma N, 2005, INT J TUBERC LUNG D, V9, P1259.
   World Health Organization, 2006, WHOHTMTB2006362.
   WHO, 2004, WORLD HLTH REP 2004.}},
Number-of-Cited-References = {{12}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000011}},
}

@article{ ISI:000250998000013,
Author = {Kiraz, N. and Et, L. and Akgun, Y. and Kasifoglu, N. and Kiremitci, A.},
Title = {{Rapid detection of Mycobacterium tuberculosis from sputum specimens
   using the FASTPlaqueTB test}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{904-908}},
Month = {{AUG}},
Abstract = {{OBJECTIVES: To determine the performance of the FASTPlaqueTB test, based
   on bacterlophage amplification technology, by comparison with the BACTEC
   460 TB culture system, the Lowenstein-Jensen (LJ) medium culture method
   and Ziehl-Neelsen (ZN) staining.
   METHODS: Of 400 sputum specimens studied in our laboratory, 19 were
   excluded due to contaminant growth. The FASTPlaqueTB test was performed
   according to the manufacturer's instructions.
   RESULTS: Only 42 of the 381 specimens examined were positive on at least
   one test: 30 were positive with ZN staining, 34 with LJ medium, 36 with
   the FASTPlaqueTB test and 39 with BACTEC 460 TB. The combination of
   BACTEC 460 TB and LJ medium culture was considered the gold standard.
   The sensitivity and specificity were 70.7\% and 99.7\% for ZN staining,
   87.8\% and 100\% for the FASTPlaqueTB test, 82.9\% and 100\% for LJ, and
   95.1\% and 100\% for BACTEC 460 TB.
   CONCLUSIONS: The FASTPlaqueTB testis useful in the rapid diagnosis of
   TB.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kiraz, N (Reprint Author), Eskisehir Osmangazi Univ, Fac Med, Dept Microbiol, TR-26480 Eskisehir, Turkey.
   Eskisehir Osmangazi Univ, Fac Med, Dept Microbiol, TR-26480 Eskisehir, Turkey.
   Iskenderun State Hosp, Microbiol Lab, Iskenderun, Turkey.}},
ISSN = {{1027-3719}},
Keywords = {{FASTPlaqueTB test; Mycobacterium tuberculosis; sputum}},
Keywords-Plus = {{SYSTEM; ASSAY}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{nkiraz@ogu.edu.tr}},
Cited-References = {{Albay A, 2003, DIAGN MICR INFEC DIS, V46, P211, DOI 10.1016/S0732-8893(03)00048-8.
   Albert H, 2002, INT J TUBERC LUNG D, V6, P529.
   CAVUSOGLU C, 2002, TURK J MED SCI, V32, P487.
   Della Latta P., 2004, CLIN MICROBIOLOGY PR, V2, P7111.
   Eltringham IJ, 1999, J CLIN MICROBIOL, V37, P3528.
   Metchock B.G., 1999, MANUAL CLIN MICROBIO, P399.
   Muzaffar R, 2002, INT J TUBERC LUNG D, V6, P635.
   Oh EJ, 2001, J MICROBIOL METH, V46, P29, DOI 10.1016/S0167-7012(01)00254-8.
   Palacios JJ, 1999, EUR J CLIN MICROBIOL, V18, P265.
   Shenai S, 2002, Indian J Med Microbiol, V20, P194.}},
Number-of-Cited-References = {{10}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000013}},
}

@article{ ISI:000250998000017,
Author = {Al-Hammady, A. and Ohkado, A. and Masui, T. and Al-Absi, A.},
Title = {{A survey on the referral of tuberculosis patients at the National
   Tuberculosis Institute, Yemen}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{928-930}},
Month = {{AUG}},
Abstract = {{The study alms to determine whether the tuberculosis (TB) patients
   referred from the National Tuberculosis Institute (NTI), Sana'a City,
   actually present themselves, are registered and initiate treatment at
   the health facilities to which they are referred. In 2004, 591
   smear-positive TB cases were diagnosed, 481 cases were referred back to
   health centres, 75 cases were registered at the NTI and 35 cases could
   not be retrieved. Among the 481 referred cases, 427 cases actually
   presented themselves and were registered at the health centres (88.8\%).
   The average number of days between the day of referral and that of
   registration was 2.5 days (median 1 day).}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ohkado, A (Reprint Author), Japan Anti TB Assoc, Res Inst TB, Matsuyama 3-1-24, Tokyo 2048533, Japan.
   Japan Anti TB Assoc, Res Inst TB, Tokyo 2048533, Japan.
   Minist Publ Hlth \& Populat, Natl TB Control Program, Sanaa, Yemen.
   Aichi Prefectural Inst Publ Hlth, Nagoya, Aichi, Japan.}},
ISSN = {{1027-3719}},
Keywords = {{tuberculosis; referral; survey; Yemen}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{ohkadoa@jata.or.jp}},
Cited-References = {{MASUI T, 2005, MISSION REPORT TUBER.
   {*}NAT TB CONTR PROG, 1996, MAN NAT TUB CONTR PR.
   {*}UNFPA, 2004, PREL RES YEM 2004 PO.
   World Health Organization, 1994, WHOTB94179.}},
Number-of-Cited-References = {{4}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000017}},
}

@article{ ISI:000250998000018,
Author = {Tavil, Betul and Caliskan, Umran and Unal, Sule and Gumruk, Fatma},
Title = {{Pulmonary tuberculosis presenting with pancytopaenia, haemophagocytosis
   and foamy histiocytes in an infant}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{931-932}},
Month = {{AUG}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Gumruk, F (Reprint Author), Univ Hacettepe, Fac Med, Paediat Haematol Unit, Ankara, Turkey.
   Univ Hacettepe, Fac Med, Paediat Haematol Unit, Ankara, Turkey.}},
ISSN = {{1027-3719}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{fgumruk@hacettepe.edu.tr}},
Cited-References = {{EZEKOWITZ RAB, 2003, NATHAN OSKIS HEMATOL, P1776.
   Gurgey A, 2005, PEDIATR INFECT DIS J, V24, P1116, DOI 10.1097/01.inf.0000190043.48182.31.
   Kumar PV, 2005, J PEDIAT HEMATOL ONC, V27, P97, DOI 10.1097/01.mph.0000153957.95486.8b.
   MAARTENS G, 1990, AM J MED, V89, P291, DOI 10.1016/0002-9343(90)90340-J.
   Shaw PH, 2000, PEDIATR INFECT DIS J, V19, P475, DOI 10.1097/00006454-200005000-00018.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000018}},
}

@article{ ISI:000250998000025,
Author = {Bastos, L. G. V. and Fonseca, L. S. and Mello, F. C. Q. and
   Ruffino-Netto, A. and Golub, J. E. and Conde, M. B.},
Title = {{Pulmonary tuberculosis prevalence among respiratory symptomatic subjects
   in an out-patient primary health unit (vol 11, pg 156, 2007)}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{936}},
Month = {{AUG}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Correction}},
Language = {{English}},
ISSN = {{1027-3719}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
ResearcherID-Numbers = {{Mello, Fernanda /I-2957-2013
   Conde, Marcus/A-2501-2013}},
Cited-References = {{Bastos LGV, 2007, INT J TUBERC LUNG D, V11, P156.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000025}},
}

@article{ ISI:000250998000027,
Author = {Chiang, C-Y. and Slama, K. and Enarson, D. A.},
Title = {{`Associations between tobacco and tuberculosis' (vol 11, pg 258, 2007)}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{936}},
Month = {{AUG}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Correction}},
Language = {{English}},
ISSN = {{1027-3719}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Cited-References = {{Chiang CY, 2007, INT J TUBERC LUNG D, V11, P258.
   NISAR M, 1993, THORAX, V48, P1257, DOI 10.1136/thx.48.12.1257.}},
Number-of-Cited-References = {{2}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000027}},
}

@article{ ISI:000250998000024,
Author = {Umubyeyi, A. N. and Vandebriel, G. and Gasana, M.},
Title = {{Results of a national survey on drug resistance among pulmonary
   tuberculosis patients in Rwanda (vol 11, pg 189, 2007)}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2007}},
Volume = {{11}},
Number = {{8}},
Pages = {{936}},
Month = {{AUG}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Correction}},
Language = {{English}},
ISSN = {{1027-3719}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Cited-References = {{Umubyeyi AN, 2007, INT J TUBERC LUNG D, V11, P189.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{232DI}},
Unique-ID = {{ISI:000250998000024}},
}

@article{ ISI:000207991900003,
Author = {Rajpal, Sanjay and Mittal, Anshu and Dhingra, V. K. and Malhotra, Rahul
   and Gupta, Rajni and Malhotra, Chetna and Taneja, D. K.},
Title = {{KNOWLEDGE, ATTITUDE AND PRACTICES REGARDING TUBERCULOSIS AND DOTS AMONG
   INTERNS IN DELHI, INDIA}},
Journal = {{JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN}},
Year = {{2007}},
Volume = {{17}},
Number = {{8}},
Pages = {{457-461}},
Month = {{AUG}},
Abstract = {{Objective: To assess the knowledge, attitude and practices regarding
   tuberculosis (TB) and DOTS among young medical graduates (interns).
   Design: Cross-sectional study.
   Place and Duration of Study: Lady Hardinge Medical College and Maulana
   Azad Medical College, New Delhi, India, during November and December
   2002, simultaneously.
   Subjects and Methods: A pre-tested semi-structured questionnaire
   consisting of 30 items was administered to the young medical
   graduates/interns posted in different departments. The questions covered
   mode of transmission, symptoms of pulmonary TB, investigations, short
   course chemotherapy including DOTS as well as conventional
   anti-tubercular treatment, special situations, health education and
   chemoprophylaxis.
   Results: A total of 287 interns were surveyed. Majority of the study
   subjects (92.7\%) ranked DOTS strategy as more successful for treating
   tuberculosis in comparison to self-administered therapy. However, a mere
   4.2\% study subjects were aware of all modes of transmission. One
   hundred and eighty-nine (65.9\%) correctly chose sputum examination for
   acid fast bacilli as the single most confirmatory test for diagnosing
   pulmonary TB. The rest either gave incorrect responses (including
   ELISA-17.0\%, PCR-9.8\%, X-ray chest-4.2\%, ESR-1.7\%) or did not
   respond (1.4\%). Only 2.1\% marked pyrazinamide and rifampicin as the
   agents to be avoided in patients with liver disease. One hundred and
   forty-one different treatment regimens were mentioned in the responses
   received and of those only 11(7.8\%) were scientifically acceptable.
   Conclusion: TB is a major health problem in South East Asian countries.
   There is a need for appropriate changes to be made in the undergraduate
   medical teaching/training curriculum in the concerned countries with
   regard to TB.}},
Publisher = {{COLL PHYSICIANS \& SURGEONS PAKISTAN}},
Address = {{SEVENTH CENTRAL ST, DEFENCE HOUSING AUTHORITY, KARACHI, 75500, PAKISTAN}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mittal, A (Reprint Author), New Delhi TB Ctr, Dept Epidemiol, Jawaharlal Nehru Marg, New Delhi 110002, India.
   Rajpal, Sanjay; Mittal, Anshu; Dhingra, V. K., New Delhi TB Ctr, Dept Epidemiol, New Delhi 110002, India.
   Malhotra, Rahul; Gupta, Rajni; Malhotra, Chetna; Taneja, D. K., Maulana Azad Med Coll, Dept Community Med, New Delhi, India.}},
ISSN = {{1022-386X}},
Keywords = {{Tuberculosis; Knowledge; Interns; Management; Diagnosis}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{navyaanshu@yahoo.com}},
Cited-References = {{AZEEM R, MANAGEMENT PULMONARY.
   Bhalla A, 2001, CHEST, V119, P1288, DOI 10.1378/chest.119.4.1288.
   Cirit M, 2003, INT J TUBERC LUNG D, V7, P243.
   Deveci S Erhan, 2003, Tuberk Toraks, V51, P40.
   Emili J, 2001, MED EDUC, V35, P530, DOI 10.1046/j.1365-2923.2001.00918.x.
   Frieden T., 2004, TOMANS TUBERCULOSIS.
   HONG YP, 1995, TUBERCLE LUNG DIS, V76, P431, DOI 10.1016/0962-8479(95)90010-1.
   Khan J, 2003, East Mediterr Health J, V9, P769.
   Khan JA, 2005, TROP DOCT, V35, P144, DOI 10.1258/0049475054620770.
   Kilicaslan Z, 2003, INT J TUBERC LUNG D, V7, P159.
   Liu ZY, 1998, CHEST, V113, P1446, DOI 10.1378/chest.113.6.1446.
   LoBue PA, 2001, INT J TUBERC LUNG D, V5, P933.
   {*}MED COUNC IND, 2006, LIST REC MED COLL IN.
   Olle-Goig JE, 1999, INT J TUBERC LUNG D, V3, P74.
   Prasad R, 2002, INT J TUBERC LUNG D, V6, P895.
   Rao SN, 2000, CHEST, V117, P734, DOI 10.1378/chest.117.3.734.
   Rizvi N, 2001, J Pak Med Assoc, V51, P333.
   Singla N, 1998, INT J TUBERC LUNG D, V2, P384.
   Suleiman B A, 2003, East Mediterr Health J, V9, P789.
   Sumartojo EM, 1997, AM J PUBLIC HEALTH, V87, P2008, DOI 10.2105/AJPH.87.12.2008.
   UPLEKAR MW, 1993, TUBERCLE LUNG DIS, V74, P332, DOI 10.1016/0962-8479(93)90108-A.
   World Health Organization, 2005, WHOHTMTB2005349.
   WHO, 1997, TREATM TUB GUID NAT.
   {*}WHO, 1997, REP WHO WORKSH ROM I.
   Yu CT, 2002, PHILIPP J MICROBIOL, V31, P1.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{JCPSP-J. Coll. Physicians Surg.}},
Doc-Delivery-Number = {{V18FY}},
Unique-ID = {{ISI:000207991900003}},
}

@article{ ISI:000248737900011,
Author = {Settas, Lucas D. and Tsimirikas, George and Vosvotekas, George and
   Triantafyllidou, Eva and Nicolaides, Paul},
Title = {{Reactivation of pulmonary tuberculosis in a patient with rheumatoid
   arthritis during treatment with IL-1 receptor antagonists (Anakinra)}},
Journal = {{JCR-JOURNAL OF CLINICAL RHEUMATOLOGY}},
Year = {{2007}},
Volume = {{13}},
Number = {{4}},
Pages = {{219-220}},
Month = {{AUG}},
Abstract = {{This single case report describes reactivation of previous pulmonary
   tuberculosis (TBC) after 23 months of treatment with the IL-I receptor
   antagonist anakinra. This patient had severe acute rheumatoid arthritis
   (Disease Activity Score >6). Initially, he received treatment with 10 mg
   prednisolone daily along with oral methotrexate 15 mg weekly.
   Methotrexate was discontinued after 3 months because of repeated liver
   enzyme elevation. After the disease became more active. lie was treated
   with the IL-I receptor antagonist along with 10 mg prednisolone daily.
   One month later, the patient improved significantly, and prednisolone
   was decreased to 5 ing on alternate days and discontinued after another
   3 months. After 23 months of anakinra monotherapy, the patient developed
   pulmonary TBC and was put on quadruple anti-TBC treatment, which
   resulted in excellent recovery. Six years before, the patient had
   pulmonary TBC and received triple anti-TBC treatment for 9 months with
   complete clinical and radiologic remission. We believe this is the first
   reported case of TBC reactivation during anakinra treatment.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Settas, LD (Reprint Author), Univ Thessaloniki, AHEPA Hosp, Rheumatol Unit, 1 Stilp Kiriakidi Str, GR-54006 Thessaloniki, Greece.
   Univ Thessaloniki, AHEPA Hosp, Rheumatol Unit, GR-54006 Thessaloniki, Greece.
   Univ Thessaloniki, AHEPA Hosp, Infect Dis Unit, Dept Med 1, GR-54006 Thessaloniki, Greece.}},
DOI = {{10.1097/RHU.0b013e31812e00a1}},
ISSN = {{1076-1608}},
Keywords = {{pulmonary mberculosis; IL-1 antagonist; anakinra}},
Keywords-Plus = {{TUMOR-NECROSIS-FACTOR; BLOCKING-AGENTS; FACTOR-ALPHA; INFECTIONS;
   DISEASES; SAFETY}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Author-Email = {{lsettas@the.forthnet.gr}},
Cited-References = {{{*}AMG, 2002, KIN SUMM PROD CHAR, P1.
   Botsios C, 2005, AUTOIMMUN REV, V4, P162, DOI 10.1016/j.autrev.2004.09.001.
   Ehlers S, 2005, CLIN INFECT DIS, V41, pS199, DOI 10.1086/429998.
   Fleishmann RM, 2002, CLIN EXP RHEUMATOL, V20, pS35.
   Furst DE, 2005, ANN RHEUM DIS, V64, P2, DOI 10.1136/ard.2005.044941.
   Keane J, 2005, RHEUMATOLOGY, V44, P714, DOI 10.1093/rheumatology/keh567.
   Ledingham J, 2005, RHEUMATOLOGY, V44, P1205, DOI 10.1093/rheumatology/kei103.
   Winthrop KL, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2005.042390.}},
Number-of-Cited-References = {{8}},
Times-Cited = {{23}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{JCR-J. Clin. Rheumatol.}},
Doc-Delivery-Number = {{200BC}},
Unique-ID = {{ISI:000248737900011}},
}

@article{ ISI:000248986500011,
Author = {Taneja, Neetu Kumra and Tyagi, Jaya Sivaswami},
Title = {{Resazurin reduction assays for screening of anti-tubercular compounds
   against dormant and actively growing Mycobacterium tuberculosis,
   Mycobacterium bovis BCG and Mycobacterium smegmatis}},
Journal = {{JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY}},
Year = {{2007}},
Volume = {{60}},
Number = {{2}},
Pages = {{288-293}},
Month = {{AUG}},
Abstract = {{Objectives: To develop simple, rapid, low-cost and robust assays for
   screening drugs against dormant and actively growing mycobacteria.
   Methods: Actively growing aerobic and hypoxia-adapted dormant cultures
   of Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium
   smegmatis were tested for susceptibility to standard antimicrobial drugs
   by resazurin reduction assay. The visual and fluorimetric MICs were
   compared with those obtained by the standard cfu assay.
   Results: Drug MICs for M. tuberculosis and M. bovis BCG were determined
   by the aerobic resazurin microplate assay (REMA) and correlated well
   with those obtained by the cfu assay. Metronidazole and nitrofurans
   showed comparable bactericidal activity in the hypoxic resazurin
   reduction assay (HyRRA). The HyRRA assay was noted to be superior to the
   cfu assay in that it distinguished between metabolically active dormant
   bacteria and non-viable organisms, unlike the cfu assay that could not
   differentiate between these two populations. The HyRRA assay performed
   with good concordance in both fluorimetric and visual formats to
   distinguish between bactericidal and bacteriostatic effects of a drug.
   Conclusions: The REMA and HyRRA assays will be useful for
   anti-tubercular anti-dormancy compound screening and drug susceptibility
   testing in a safe, reliable, easy and cost-effective manner particularly
   in low resource countries. The application of the assays in M. smegmatis
   or M. bovis BCG offers the distinct advantage of rapidly and safely
   screening anti-tubercular compounds in a high-throughput format.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tyagi, JS (Reprint Author), All India Inst Med Sci, Dept Biotechnol, Ansari Nagar, New Delhi 110029, India.
   All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, India.}},
DOI = {{10.1093/jac/dkm207}},
ISSN = {{0305-7453}},
Keywords = {{M. tuberculosis; M. bovis BCG; M. smegmatis; dormancy; REMA; HyRRA}},
Keywords-Plus = {{DEPLETION-INDUCED DORMANCY; ALAMAR BLUE ASSAY; ISONIAZID RESISTANCE;
   INEXPENSIVE METHOD; DRUG-RESISTANCE; PLATE; AHPC}},
Research-Areas = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Author-Email = {{jstyagi@aiims.ac.in}},
Cited-References = {{Mayuri Bagchi G, 2002, FEMS MICROBIOL LETT, V211, P231.
   Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215.
   Collins LA, 1998, ANTIMICROB AGENTS CH, V42, P344.
   Collins LA, 1997, ANTIMICROB AGENTS CH, V41, P1004.
   Dhillon J, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-51.
   Dick T, 1998, FEMS MICROBIOL LETT, V163, P159, DOI 10.1016/S0378-1097(98)00166-9.
   Franzblau SG, 1998, J CLIN MICROBIOL, V36, P362.
   Heym B, 1997, INFECT IMMUN, V65, P1395.
   LEVIN ME, 1993, MOL MICROBIOL, V8, P277, DOI 10.1111/j.1365-2958.1993.tb01572.x.
   Lim A, 1999, J BACTERIOL, V181, P2252.
   Martin A, 2005, J CLIN MICROBIOL, V43, P1612, DOI 10.1128/JCM.43.4.1612-1616.2005.
   Martin A, 2003, ANTIMICROB AGENTS CH, V47, P3616, DOI 10.1128/AAC.47.11.3616-3619.2003.
   Montoro E, 2005, J ANTIMICROB CHEMOTH, V55, P500, DOI 10.1093/jac/dki023.
   Murugasu-Oei B, 2000, J ANTIMICROB CHEMOTH, V46, P917, DOI 10.1093/jac/46.6.917.
   Palomino JC, 2002, ANTIMICROB AGENTS CH, V46, P2720, DOI 10.1128/AAC.46.8.2720-2722.2002.
   WAYNE LG, 1994, ANTIMICROB AGENTS CH, V38, P2054.
   Wayne LG, 1996, INFECT IMMUN, V64, P2062.
   WAYNE LG, 1994, EUR J CLIN MICROBIOL, V13, P908, DOI 10.1007/BF02111491.
   Wilson TM, 1996, MOL MICROBIOL, V19, P1025, DOI 10.1046/j.1365-2958.1996.449980.x.
   YAJKO DM, 1995, J CLIN MICROBIOL, V33, P2324.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{58}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{18}},
Journal-ISO = {{J. Antimicrob. Chemother.}},
Doc-Delivery-Number = {{203PM}},
Unique-ID = {{ISI:000248986500011}},
}

@article{ ISI:000248986500031,
Author = {Banaiee, Niaz and Jacobs, William R. and Ernst, Joel D.},
Title = {{LspA-independent action of globomycin on Mycobacterium tuberculosis}},
Journal = {{JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY}},
Year = {{2007}},
Volume = {{60}},
Number = {{2}},
Pages = {{414-416}},
Month = {{AUG}},
Abstract = {{Objectives: The objective of this study was to investigate the
   antimicrobial activity and specificity of globomycin, an inhibitor of
   lipoprotein signal peptidase II (LspA), against Mycobacterium
   tuberculosis.
   Methods: The mycobactericidal and mycobacterlostatic activity of
   globomycin was determined by optical density and cfu plating. The
   specificity of globomycin was determined by western immunoblotting using
   anti-MPT83 antibody.
   Results: Globomycin is mycobactericidal at concentrations >= 40 mg/L.
   However, at 80 mg/L, the processing of the lipoprotein MPT-83 is
   unaffected and growth-inhibitory effect of globomycin is unchanged in an
   IspA null mutant (Delta IspA::IspA(mut)) lacking the putative drug
   target.
   Conclusions: Globomycin kills M. tuberculosis through a mechanism that
   is independent of LspA.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Banaiee, N (Reprint Author), Stanford Univ, Sch Med, Dept Pathol, 3375 Hillview Ave,Room 1602, Palo Alto, CA 94304 USA.
   Stanford Univ, Sch Med, Dept Pathol, Palo Alto, CA 94304 USA.
   NYU, Sch Med, Dept Med, Div Infect Dis, New York, NY 10016 USA.
   Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA.
   Albert Einstein Coll Med, Dept Microbiol \& Immunol, Bronx, NY 10461 USA.
   NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.}},
DOI = {{10.1093/jac/dkm223}},
ISSN = {{0305-7453}},
Keywords = {{lipoproteins; lipoprotein signal peptidase; lipoprotein processing;
   antimycobacterials}},
Keywords-Plus = {{DRUG-RESISTANT TUBERCULOSIS; SIGNAL PEPTIDASE; INHIBITION}},
Research-Areas = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Author-Email = {{nbanaiee@stanford.edu}},
ORCID-Numbers = {{Ernst, Joel/0000-0001-9951-6207}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}K08 AI061105, K08 AI061105-05, L30 AI061958-01, L30
   AI061958-02, R01 AI46097]}},
Cited-References = {{Banaiee N, 2006, J IMMUNOL, V176, P3019.
   DeRiemer K, 2005, LANCET, V365, P1239, DOI 10.1016/S0140-6736(05)74812-1.
   DEV IK, 1985, J BIOL CHEM, V260, P5891.
   Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537.
   INUKAI M, 1978, J ANTIBIOT, V31, P421.
   Kiho T, 2004, BIOORGAN MED CHEM, V12, P337, DOI 10.1016/j.bmc.2003.10.055.
   Kim JY, 2003, TUBERCULOSIS, V83, P59, DOI 10.1016/S1472-9792(02)00078-1.
   Raviglione MC, 2003, TUBERCULOSIS, V83, P4, DOI 10.1016/S1472-9792(02)00071-9.
   Sander P, 2004, MOL MICROBIOL, V52, P1543, DOI 10.1111/j.1365-2958.2004.04041.x.
   Tjalsma H, 1999, J BIOL CHEM, V274, P28191, DOI 10.1074/jbc.274.40.28191.}},
Number-of-Cited-References = {{10}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{J. Antimicrob. Chemother.}},
Doc-Delivery-Number = {{203PM}},
Unique-ID = {{ISI:000248986500031}},
}

@article{ ISI:000248986500035,
Author = {Cynamon, Michael and Sklaney, Mary R. and Shoen, Carolyn},
Title = {{Gatiffoxacin in combination with rifampicin in a murine tuberculosis
   model}},
Journal = {{JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY}},
Year = {{2007}},
Volume = {{60}},
Number = {{2}},
Pages = {{429-432}},
Month = {{AUG}},
Abstract = {{Objectives: Gatifloxacin previously demonstrated good in vitro and in
   vivo activities against Mycobacterium tuberculosis. Several regimens of
   gatifloxacin in combination with rifampicin were compared with isoniazid
   plus rifampicin in a mouse tuberculosis model.
   Methods: C57BL/6 mice were infected intranasally with similar to 10(6)
   viable M. tuberculosis organisms. Treatment with various regimens of
   gatifloxacin plus rifampicin was started 1 week post-infection and was
   administered for 4-12 weeks. Mice were euthanized at the end of therapy
   and their right lungs were removed and cell counts were determined.
   Results: Gatifloxacin 100 mg/kg plus rifampicin 10 mg/kg has activity
   similar to that of isoniazid plus rifampicin in the 12 week treatment
   model. Gatifloxacin 300 mg/kg plus rifampicin 20 mg/kg yields a
   non-cultivatable state after 12 weeks of therapy and approaches but does
   not achieve a durable cure.
   Conclusions: Gatifloxacin in combination with rifampicin is a promising
   combination for potential evaluation in human clinical trials.
   Gatifloxacin plus rifampicin regimens had activities similar to or
   better than isoniazid plus rifampicin. A quinolone plus rifampicin
   combination may provide the foundation for shorter course regimens than
   the current isoniazid plus rifampicin-based regimen.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Cynamon, M (Reprint Author), Vet Affairs Med Ctr, 800 Irving Ave, Syracuse, NY 13210 USA.
   Vet Affairs Med Ctr, Syracuse, NY 13210 USA.}},
DOI = {{10.1093/jac/dkm200}},
ISSN = {{0305-7453}},
Keywords = {{mycobacterium tuberculosis; mycobacteria; TB; pulmonary;
   antimycobacterial agents}},
Keywords-Plus = {{IN-VIVO ACTIVITIES; MYCOBACTERIUM-TUBERCULOSIS; MOXIFLOXACIN;
   GATIFLOXACIN; REGIMENS; VITRO}},
Research-Areas = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Author-Email = {{michael.cynamon@med.va.gov}},
Cited-References = {{Alvirez-Freites EJ, 2002, ANTIMICROB AGENTS CH, V46, P1022, DOI 10.1128/AAC.46.4.1022-1025.2002.
   Cynamon MH, 2003, ANTIMICROB AGENTS CH, V47, P2442, DOI 10.1128/AAC.47.8.2442-2444.2003.
   Gillespie SH, 1999, J ANTIMICROB CHEMOTH, V44, P393, DOI 10.1093/jac/44.3.393.
   Hu YM, 2003, ANTIMICROB AGENTS CH, V47, P653, DOI 10.1128/AAC.47.2.653-657.2003.
   Ji BH, 1998, ANTIMICROB AGENTS CH, V42, P2066.
   KIRK RE, 1986, EXPT DESIGNS PROCEDU.
   Lenaerts AMJA, 1999, ANTIMICROB AGENTS CH, V43, P2356.
   Malik M, 2006, ANTIMICROB AGENTS CH, V50, P2842, DOI 10.1128/AAC.00250-06.
   Nuermberger EL, 2004, AM J RESP CRIT CARE, V170, P1131, DOI 10.1164/rccm.200407-885SOC.
   Nuermberger EL, 2004, AM J RESP CRIT CARE, V169, P421, DOI 10.1164/rccm.200310-1380OC.
   Zimmerli W, 2004, NEW ENGL J MED, V351, P1645, DOI 10.1056/NEJMra040181.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Antimicrob. Chemother.}},
Doc-Delivery-Number = {{203PM}},
Unique-ID = {{ISI:000248986500035}},
}

@article{ ISI:000248584800014,
Author = {Titgemeyer, Fritz and Amon, Johannes and Parche, Stephan and Mahfoud,
   Maysa and Bail, Johannes and Schlicht, Maximilian and Rehm, Nadine and
   Hillmann, Dietmar and Stephan, Joachim and Walter, Britta and Burkovski,
   Andreas and Niederweis, Michael},
Title = {{A genomic view of sugar transport in Mycobacterium smegmatis and
   Mycobacterium tuberculosis}},
Journal = {{JOURNAL OF BACTERIOLOGY}},
Year = {{2007}},
Volume = {{189}},
Number = {{16}},
Pages = {{5903-5915}},
Month = {{AUG}},
Abstract = {{We present a comprehensive analysis of carbohydrate uptake systems of
   the soil bacterium Mycobacterium smegmatis and the human pathogen
   Mycobacterium tuberculosis. Our results show that M. smegmatis has 28
   putative carbohydrate transporters. The majority of sugar transport
   systems (19/28) in M. smegmatis belong to the ATP-binding cassette (ABC)
   transporter family. In contrast to previous reports, we identified genes
   encoding all components of the phosphotransferase system (PTS),
   including permeases for fructose, glucose, and dihydroxyacetone, in M.
   smegmatis. It is anticipated that the PTS of M. smegmatis plays an
   important role in the global control of carbon metabolism similar to
   those of other bacteria. M. smegmatis further possesses one putative
   glycerol facilitator of the major intrinsic protein family, four sugar
   permeases of the major facilitator superfamily, one of which was
   assigned as a glucose transporter, and one galactose permease of the
   sodium solute superfamily. Our predictions were validated by gene
   expression, growth, and sugar transport analyses. Strikingly, we
   detected only five sugar permeases in the slow-growing species M.
   tuberculosis, two of which occur in M. smegmatis. Genes for a PTS are
   missing in M. tuberculosis. Our analysis thus brings the diversity of
   carbohydrate uptake systems of fast- and a slow-growing mycobacteria to
   light, which reflects the lifestyles of M. smegmatis and M. tuberculosis
   in their natural habitats, the soil and the human body, respectively.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Titgemeyer, F (Reprint Author), Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, Staudtstr 5, D-91058 Erlangen, Germany.
   Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany.
   Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA.}},
DOI = {{10.1128/JB.00257-07}},
ISSN = {{0021-9193}},
Keywords-Plus = {{STREPTOMYCES-COELICOLOR A3(2); CARBON CATABOLITE REPRESSION;
   ESCHERICHIA-COLI K-12; PHOSPHOTRANSFERASE SYSTEM; BACILLUS-SUBTILIS;
   BINDING-PROTEIN; RECEPTOR PROTEIN; L-ARABINOSE;
   CORYNEBACTERIUM-GLUTAMICUM; NUCLEOTIDE-SEQUENCE}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{fritz.titgemeyer@googlemail.com
   mnieder@uab.edu}},
ORCID-Numbers = {{Niederweis, Michael/0000-0003-4068-8092}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI 06432]}},
Cited-References = {{Alvarez-Anorve LI, 2005, J BACTERIOL, V187, P2974, DOI 10.1128/JB.187.9.2974-2982.2005.
   Bai GC, 2005, J BACTERIOL, V187, P7795, DOI 10.1128/JB.187.22.7795-7804.2005.
   BELL AW, 1986, J BIOL CHEM, V261, P7652.
   Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028.
   Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a.
   Bertram R, 2004, J BACTERIOL, V186, P1362, DOI 10.1128/JB.186.5.1362-1373.2004.
   Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453.
   Borich SM, 2000, MICROBIOS, V102, P7.
   Braibant M, 2000, FEMS MICROBIOL REV, V24, P449, DOI 10.1111/j.1574-6976.2000.tb00550.x.
   BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333.
   Brinkkotter A, 2000, MOL MICROBIOL, V37, P125, DOI 10.1046/j.1365-2958.2000.01969.x.
   Bruckner R, 2002, FEMS MICROBIOL LETT, V209, P141.
   Cole ST, 1998, NATURE, V393, P537.
   Connell Nancy D., 1994, P333.
   Content J, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P379.
   Crick D. C., 2001, GLYCOBIOLOGY, V11, p107R.
   Daley DO, 2005, SCIENCE, V308, P1321, DOI 10.1126/science.1109730.
   Derouaux A, 2004, J BACTERIOL, V186, P1893, DOI 10.1128/JB.186.6.1893-1897.2004.
   DUPLAY P, 1984, J BIOL CHEM, V259, P606.
   EDSON NL, 1951, BACTERIOL REV, V15, P147.
   Erni B, 2006, CELL MOL LIFE SCI, V63, P890, DOI 10.1007/s00018-005-5518-0.
   EZE MO, 1981, J GEN MICROBIOL, V124, P299.
   Franke W., 1944, BIOCHEM Z, V319, P3130.
   Frey PA, 1996, FASEB J, V10, P461.
   Gutknecht R, 2001, EMBO J, V20, P2480, DOI 10.1093/emboj/20.10.2480.
   HINDLE Z, 1994, MOL MICROBIOL, V12, P737, DOI 10.1111/j.1365-2958.1994.tb01061.x.
   HURTUBISE Y, 1995, MOL MICROBIOL, V17, P367, DOI 10.1111/j.1365-2958.1995.mmi\_17020367.x.
   IZUMORI K, 1976, J BACTERIOL, V128, P587.
   IZUMORI K, 1978, J BACTERIOL, V133, P413.
   Kamionka A, 2002, EUR J BIOCHEM, V269, P2143, DOI 10.1046/j.1432-1033.2002.02864.x.
   Kawaguchi H, 2006, APPL ENVIRON MICROB, V72, P3418, DOI 10.1128/AEM.72.5.3418-3128.2006.
   Koch R, 1882, BERL KLIN WOCHENSCHR, V19, P221.
   LAWLIS VB, 1984, APPL ENVIRON MICROB, V47, P15.
   MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0.
   McCue LA, 2000, GENOME RES, V10, P204, DOI 10.1101/gr.10.2.204.
   McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074.
   Monedero V, 2007, J MOL MICROB BIOTECH, V12, P20, DOI 10.1159/000096456.
   Montero-Moran GM, 2001, BIOCHEMISTRY-US, V40, P10187, DOI 10.1021/bi0105835.
   Moon MW, 2007, J MOL MICROB BIOTECH, V12, P43, DOI 10.1159/000096458.
   Mota LJ, 1999, MOL MICROBIOL, V33, P476, DOI 10.1046/j.1365-2958.1999.01484.x.
   Munoz-Elias EJ, 2005, NAT MED, V11, P638, DOI 10.1038/nm1252.
   Murphy HN, 2005, J BIOL CHEM, V280, P14524, DOI 10.1074/jbc.M414232200.
   Nobelmann B, 1996, J BACTERIOL, V178, P6790.
   Nothaft H, 2003, J BACTERIOL, V185, P7019, DOI 10.1128/JB.185.23.7019-7023.2003.
   Nothaft H, 2003, J BACTERIOL, V185, P929, DOI 10.1128/JB.185.3.929-937.2003.
   Pan F, 2001, J BACTERIOL, V183, P3991, DOI 10.1128/JB.183.13.3991-3998.2001.
   Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1.
   Parche S, 2000, ANTON LEEUW INT J G, V78, P243, DOI 10.1023/A:1010274317363.
   Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120.
   Paula S, 1996, BIOPHYS J, V70, P339.
   Perez-Rueda E, 2000, NUCLEIC ACIDS RES, V28, P1838, DOI 10.1093/nar/28.8.1838.
   POSTMA PW, 1993, MICROBIOL REV, V57, P543.
   RAMAKRISHNAN T, 1972, BACTERIOL REV, V36, P65.
   Ratledge C., 1982, BIOL MYCOBACTERIA, P186.
   REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5.
   Reizer J, 1998, MOL MICROBIOL, V27, P1157, DOI 10.1046/j.1365-2958.1998.00747.x.
   RICHARDSON HB, 1931, T NAT TUBERC ASS, V27, P205.
   RIMMELE M, 1994, J BACTERIOL, V176, P5654.
   ROMANO AH, 1970, J BACTERIOL, V104, P808.
   SaNogueira I, 1997, MICROBIOL-SGM, V143, P957.
   Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100.
   Schlosser A, 1999, APPL ENVIRON MICROB, V65, P2636.
   Schlosser A, 1996, EUR J BIOCHEM, V242, P332, DOI 10.1111/j.1432-1033.1996.0332r.x.
   Schonert S, 1999, RES MICROBIOL, V150, P167, DOI 10.1016/S0923-2508(99)80033-3.
   Smeulders MJ, 1999, J BACTERIOL, V181, P270.
   SOERENSEN KI, 1996, J BACTERIOL, V178, P1003.
   Stahl C, 2001, MOL MICROBIOL, V40, P451, DOI 10.1046/j.1365-2958.2001.02394.x.
   Stephan J, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-45.
   Stephan J, 2005, MOL MICROBIOL, V58, P714, DOI 10.1111/j.1365-2958.2005.04878.x.
   SUMIYA M, 1995, RECEPTOR CHANNEL, V3, P117.
   TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493.
   Tobisch S, 1997, J BACTERIOL, V179, P496.
   van Wezel GP, 2005, MOL MICROBIOL, V55, P624, DOI 10.1111/j.1365-2958.2004.04413.x.
   Woodruff PJ, 2004, J BIOL CHEM, V279, P28835, DOI 10.1074/jbc.M313103200.
   WOODSON K, 1994, MICROBIOL-UK, V140, P1829.
   WU LF, 1990, J MOL BIOL, V213, P687, DOI 10.1016/S0022-2836(05)80256-6.
   ZHANG CC, 1989, MOL MICROBIOL, V3, P1221, DOI 10.1111/j.1365-2958.1989.tb00272.x.}},
Number-of-Cited-References = {{77}},
Times-Cited = {{49}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{J. Bacteriol.}},
Doc-Delivery-Number = {{197VO}},
Unique-ID = {{ISI:000248584800014}},
}

@article{ ISI:000248584800026,
Author = {de Jonge, Marien I. and Pehau-Arnaudet, Grard and Fretz, Marjan M. and
   Romain, Felix and Bottai, Daria and Brodin, Priscille and Honore, Nadine
   and Marchal, Gilles and Jiskoot, Wim and England, Patrick and Cole,
   Stewart T. and Brosch, Roland},
Title = {{ESAT-6 from Mycobacterium tuberculosis dissociates from its putative
   chaperone CFP-10 under acidic conditions and exhibits membrane-lysing
   activity}},
Journal = {{JOURNAL OF BACTERIOLOGY}},
Year = {{2007}},
Volume = {{189}},
Number = {{16}},
Pages = {{6028-6034}},
Month = {{AUG}},
Abstract = {{The 6-kDa early secreted antigenic target ESAT-6 and the 10-kDa culture
   filtrate protein CFP-10 of Mycobacterium tuberculosis are secreted by
   the ESX-1 system into the host cell and thereby contribute to
   pathogenicity. Although different studies performed at the organismal
   and cellular levels have helped to explain ESX-1-associated phenomena,
   not much is known about how ESAT-6 and CFP-10 contribute to pathogenesis
   at the molecular level. In this study we describe the interaction of
   both proteins with lipid bilayers, using biologically relevant liposomal
   preparations containing dimyristoylphosphatidylcholine (DMPC),
   dimyristoylphosphatidylglycerol, and cholesterol. Using floatation
   gradient centrifugation, we demonstrate that ESAT-6 showed strong
   association with liposomes, and in particular with preparations
   containing DMPC and cholesterol, whereas the interaction of CFP-10 with
   membranes appeared to be weaker and less specific. Most importantly,
   binding to the biomembranes no longer occurred when the proteins were
   present as a 1:1 ESAT-6 . CFP-10 complex. However, lowering of the pH
   resulted in dissociation of the protein complex and subsequent
   protein-liposome interaction. Finally, cryoelectron microscopy revealed
   that ESAT-6 destabilized and lysed liposomes, whereas CFP-10 did not. In
   conclusion, we propose that one of the main features of ESAT-6 in the
   infection process of M. tuberculosis is the interaction with
   biomembranes that occurs after dissociation from its putative chaperone
   CFP-10 under acidic conditions typically encountered in the phagosome.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Brosch, R (Reprint Author), Inst Pasteur, Unite Genet Mol Bacterienne, Paris, France.
   Inst Pasteur, Unite Genet Mol Bacterienne, Paris, France.
   Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, NL-3508 TC Utrecht, Netherlands.
   Inst Pasteur, Unite Postulante Dynam Struct Macromol, Paris, France.
   Inst Pasteur, Lab Immunothe, Paris, France.
   Inst Pasteur, Plate Forme Biophys Macromol \& Leurs Interact, Paris, France.
   Inst Pasteur, Plate Forme Cryomicroscopie Mol, Paris, France.}},
DOI = {{10.1128/JB.00469-07}},
ISSN = {{0021-9193}},
Keywords-Plus = {{BACILLE CALMETTE-GUERIN; SECRETION SYSTEM; ESAT-6-CFP-10 COMPLEX;
   PATHOGENIC MYCOBACTERIA; CONTAINING PHAGOSOMES; HUMAN MACROPHAGES; BOVIS
   BCG; VIRULENCE; RD1; CHOLESTEROL}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{rbrosch@pasteur.fr}},
ResearcherID-Numbers = {{de Jonge, Marien/P-5869-2015
   Jiskoot, Wim/A-6877-2016
   Brodin, Priscille/E-5802-2014
   }},
ORCID-Numbers = {{de Jonge, Marien/0000-0003-2812-5895
   Jiskoot, Wim/0000-0002-1012-3456
   Brodin, Priscille/0000-0003-0991-7344
   Brosch, Roland /0000-0003-2587-3863}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}HHSN266200400091C]}},
Cited-References = {{Abdallah AM, 2006, MOL MICROBIOL, V62, P667, DOI 10.1111/j.1365-2958.2006.05409.x.
   Bonev BB, 2001, J BIOL CHEM, V276, P5714, DOI 10.1074/jbc.M005126200.
   Brodin P, 2006, INFECT IMMUN, V74, P88, DOI 10.1128/IAI.74.1.88-98.2006.
   Brodin P, 2005, J BIOL CHEM, V280, P33953, DOI 10.1074/jbc.M503515200.
   Brodin P, 2002, INFECT IMMUN, V70, P5568, DOI 10.1128/IAI.70.10.5568-5578.2002.
   Brosch R, 2007, P NATL ACAD SCI USA, V104, P5596, DOI 10.1073/pnas.0700869104.
   Champion PAD, 2006, SCIENCE, V313, P1632, DOI 10.1126/science.1131167.
   Collins DM, 2005, INFECT IMMUN, V73, P2379, DOI 10.1128/IAI.73.4.2379-2386.2005.
   Converse SE, 2005, J BACTERIOL, V187, P1238, DOI 10.1128/JB.187.4.1238-1245.2005.
   DERRICK SC, CELL MICROBIOL, V9, P1547.
   Flint JL, 2004, P NATL ACAD SCI USA, V101, P12598, DOI 10.1073/pnes.040482101.
   Gao LY, 2004, MOL MICROBIOL, V53, P1677, DOI 10.1111/j.1365-2958.2004.04261.x.
   Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647.
   Guinn KM, 2004, MOL MICROBIOL, V51, P359, DOI 10.1046/j.1365-2958.2003.03844.x.
   Hodel A, 2001, BIOCHEM J, V356, P843, DOI 10.1042/0264-6021:3560843.
   Howe D, 2006, CELL MICROBIOL, V8, P496, DOI 10.1111/j.1462-5822.2005.00641.x.
   Hsu T, 2003, P NATL ACAD SCI USA, V100, P12420, DOI 10.1073/pnas.1635213100.
   Junqueira-Kipnis AP, 2006, IMMUNOLOGY, V119, P224, DOI 10.1111/j.1365-2567.2006.02427.x.
   Killian JA, 2003, FEBS LETT, V555, P134, DOI 10.1016/S0014-5793(03)01154-2.
   Kusner DJ, 2001, J IMMUNOL, V167, P3308.
   Lafont F, 2005, MOL MICROBIOL, V56, P575, DOI 10.1111/j.1365-2958.2005.04570.x.
   Lewis KN, 2003, J INFECT DIS, V187, P117, DOI 10.1086/345862.
   Mahairas GG, 1996, J BACTERIOL, V178, P1274.
   Majlessi L, 2005, J IMMUNOL, V174, P3570.
   Marei A, 2005, INT IMMUNOL, V17, P1439, DOI 10.1093/intimm/dxh322.
   Marmiesse M, 2004, MICROBIOL-SGM, V150, P483, DOI 10.1099/mic.0.26662-0.
   MCDONOUGH KA, 1993, INFECT IMMUN, V61, P2763.
   Meher AK, 2006, FEBS J, V273, P1445, DOI 10.1111/j.1742-4658.2006.05166.x.
   Nguyen L, 2005, TRENDS CELL BIOL, V15, P269, DOI 10.1016/j.tcb.2005.03.009.
   Okkels LM, 2004, PROTEOMICS, V4, P2954, DOI 10.1002/pmic.200400906.
   Pallen MJ, 2002, TRENDS MICROBIOL, V10, P209, DOI 10.1016/S0966-842X(02)02345-4.
   Pathak SK, 2007, NAT IMMUNOL, V8, P610, DOI 10.1038/ni1468.
   Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859.
   Pym AS, 2002, MOL MICROBIOL, V46, P709, DOI 10.1046/j.1365-2958.2002.03237.x.
   Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200.
   Renshaw PS, 2005, EMBO J, V24, P2491, DOI 10.1038/sj.emboj.7600732.
   ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316.
   Russell DG, 2003, NAT CELL BIOL, V5, P776, DOI 10.1038/ncb0903-776.
   Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100.
   Schaible UE, 1998, J IMMUNOL, V160, P1290.
   Schumann G, 2006, CENT EUR J BIOL, V1, P183, DOI 10.2478/s11535-006-0018-2.
   Seelig J, 2004, BBA-BIOMEMBRANES, V1666, P40, DOI 10.1016/j.bbamem.2004.08.004.
   Stamm LM, 2003, J EXP MED, V198, P1361, DOI 10.1084/jem.20031072.
   Stanley SA, 2003, P NATL ACAD SCI USA, V100, P13001, DOI 10.1073/pnas.2235593100.
   Stanley SA, 2007, J IMMUNOL, V178, P3143.
   Stober CB, 2001, J IMMUNOL, V166, P6276.
   Strong M, 2006, P NATL ACAD SCI USA, V103, P8060, DOI 10.1073/pnas.0602606103.
   Tan T, 2006, CELL MICROBIOL, V8, P1417, DOI 10.1111/j.1462-5822.2006.00721.x.
   Tekaia F., 1999, Tubercle and Lung Disease, V79, P329, DOI 10.1054/tuld.1999.0220.
   van der Wel N, 2007, CELL, V129, P1287, DOI 10.1016/j.cell.2007.05.059.
   Gamieldien J, 2001, GENOME BIOL, V2, DOI DOI 10.1186/GB-2001-2-10-RESEARCH0044.
   Veldhuizen R, 1998, BBA-MOL BASIS DIS, V1408, P90, DOI 10.1016/S0925-4439(98)00061-1.
   Volkman HE, 2004, PLOS BIOL, V2, P1946, DOI 10.1371/journal.pbio.0020367.}},
Number-of-Cited-References = {{53}},
Times-Cited = {{132}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{J. Bacteriol.}},
Doc-Delivery-Number = {{197VO}},
Unique-ID = {{ISI:000248584800026}},
}

@article{ ISI:000248478100036,
Author = {Hinchey, Joseph and Lee, Sunhee and Jeon, Bo Y. and Basaraba, Randall J.
   and Venkataswamy, Manjunatha M. and Chen, Bing and Chan, John and
   Braunstein, Miriam and Orme, Ian M. and Derrick, Steven C. and Morris,
   Sheldon L. and Jacobs, Jr., William R. and Porcelli, Steven A.},
Title = {{Enhanced priming of adaptive immunity by a proapoptotic mutant of
   Mycobacterium tuberculosis}},
Journal = {{JOURNAL OF CLINICAL INVESTIGATION}},
Year = {{2007}},
Volume = {{117}},
Number = {{8}},
Pages = {{2279-2288}},
Month = {{AUG}},
Abstract = {{The inhibition of apoptosis of infected host cells is a well-known but
   poorly understood function of pathogenic mycobacteria. We show that
   inactivation of the secA2 gene in Mycobacterium tuberculosis, which
   encodes a component of a virulence-associated protein secretion system,
   enhanced the apoptosis of infected macrophages by diminishing secretion
   of mycobacterial superoxide dismutase. Deletion of secA2 markedly
   increased priming of antigen-specific CD8(+) T cells in vivo, and
   vaccination of mice and guinea pigs with a secA2 mutant significantly
   increased resistance to M. tuberculosis challenge compared with standard
   M. bovis bacille Calmette-Guerin vaccination. Our results define a
   mechanism for a key immune evasion strategy of M. tuberculosis and
   provide what we believe to be a novel approach for improving
   mycobacterial vaccines.}},
Publisher = {{AMER SOC CLINICAL INVESTIGATION INC}},
Address = {{35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Jacobs, WR (Reprint Author), Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, 1300 Morris Pk Ave, Bronx, NY 10461 USA.
   Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA.
   Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol \& Immunol, Bronx, NY 10461 USA.
   US FDA, Ctr Biol Evaluat \& Res, Bethesda, MD 20014 USA.
   Colorado State Univ, Dept Microbiol Immunol \& Pathol, Ft Collins, CO 80523 USA.
   Albert Einstein Coll Med, Dept Med, New York, NY USA.
   Univ N Carolina, Dept Microbiol, Chapel Hill, NC USA.}},
DOI = {{10.1172/JCI31947}},
ISSN = {{0021-9738}},
Keywords-Plus = {{CD8 T-CELLS; BACILLUS-CALMETTE-GUERIN; SUPEROXIDE-DISMUTASE; PATHOGENIC
   MYCOBACTERIA; PANTOTHENATE AUXOTROPH; ANTIMICROBIAL ACTIVITY; MACROPHAGE
   APOPTOSIS; DNA VACCINE; INFECTION; EXPRESSION}},
Research-Areas = {{Research \& Experimental Medicine}},
Web-of-Science-Categories  = {{Medicine, Research \& Experimental}},
Author-Email = {{jacobs@aecom.yu.edu
   porcelli@aecom.yu.edu}},
Funding-Acknowledgement = {{NCI NIH HHS {[}CA 13330, P30 CA013330]; NIAID NIH HHS {[}AI063537, AI
   051519, AI054697, AI54540, HHSN266200400091C, P01 AI063537, P30
   AI051519, R01 AI054540, R01 AI054697]; PHS HHS {[}HHSN266200400091C]}},
Cited-References = {{Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211.
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444.
   Behar SM, 1999, J EXP MED, V189, P1973, DOI 10.1084/jem.189.12.1973.
   Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009.
   Braunstein M, 2003, MOL MICROBIOL, V48, P453, DOI 10.1046/j.1365-2958.2003.03438.x.
   Braunstein M, 2002, METHOD ENZYMOL, V358, P67.
   CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111.
   Cho S, 2000, P NATL ACAD SCI USA, V97, P12210, DOI 10.1073/pnas.210391497.
   Danelishvili L, 2003, CELL MICROBIOL, V5, P649, DOI 10.1046/j.1462-5822.2003-00312.x.
   DeGroote MA, 1997, P NATL ACAD SCI USA, V94, P13997, DOI 10.1073/pnas.94.25.13997.
   Derrick SC, 2005, INFECT IMMUN, V73, P7727, DOI 10.1128/IAI.73.11.7727-7735.2005.
   Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767.
   Edwards KM, 2001, AM J RESP CRIT CARE, V164, P2213, DOI 10.1164/rccm2106093.
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93.
   Gillet G, 1996, TRENDS MICROBIOL, V4, P312, DOI 10.1016/0966-842X(96)10047-0.
   Grode L, 2005, J CLIN INVEST, V115, P2472, DOI 10.1172/JCI24617.
   Harth G, 1999, J BIOL CHEM, V274, P4281, DOI 10.1074/jbc.274.7.4281.
   HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4.
   Houben ENG, 2006, CURR OPIN MICROBIOL, V9, P76, DOI 10.1016/j.mib.2005.12.014.
   Hsu T, 2003, P NATL ACAD SCI USA, V100, P12420, DOI 10.1073/pnas.1635213100.
   Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893.
   Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009.
   Kahl R, 2004, DRUG METAB REV, V36, P747, DOI 10.1081/DMR-200033488.
   Kaufmann SHE, 2005, MICROBES INFECT, V7, P897, DOI 10.1016/j.micinf.2005.03.006.
   Keane J, 2000, J IMMUNOL, V164, P2016.
   Keane J, 2002, TUBERCULOSIS, V82, P55, DOI 10.1054/tube.322.
   Kurtz S, 2006, INFECT IMMUN, V74, P6855, DOI 10.1128/IAI.01022-06.
   Lee J, 2006, J IMMUNOL, V176, P4267.
   Manca C, 2005, J INTERF CYTOK RES, V25, P694, DOI 10.1089/jir.2005.25.694.
   Marzo AL, 2005, NAT IMMUNOL, V6, P793, DOI 10.1038/ni1227.
   Menaker RJ, 2003, MICROBES INFECT, V5, P1149, DOI 10.1016/J.MICINF.2003.08.001.
   Mogues T, 2001, J EXP MED, V193, P271, DOI 10.1084/jem.193.3.271.
   MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499.
   Navarre WW, 2000, CELL MICROBIOL, V2, P265, DOI 10.1046/j.1462-5822.2000.00056.x.
   Perskvist N, 2002, J IMMUNOL, V168, P6358.
   Riendeau CJ, 2003, INFECT IMMUN, V71, P254, DOI 10.1128/IAI.71.1.254-259.2003.
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702.
   Sambandamurthy VK, 2005, INFECT IMMUN, V73, P1196, DOI 10.1128/IAI.73.2.1196-1203.2005.
   Sambandamurthy VK, 2002, NAT MED, V8, P1171, DOI 10.1038/nm765.
   Schaible UE, 2003, NAT MED, V9, P1039, DOI 10.1038/nm906.
   Sly LM, 2003, J IMMUNOL, V170, P430.
   Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121.
   STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0.
   Winau F, 2006, IMMUNITY, V24, P105, DOI 10.1016/j.immuni.2005.12.001.
   Winau F, 2005, APOPTOSIS, V10, P707, DOI 10.1007/s10495-005-2940-6.
   Yanagisawa S, 1997, INT IMMUNOL, V9, P227, DOI 10.1093/intimm/9.2.227.
   Yrlid U, 2000, J EXP MED, V191, P613, DOI 10.1084/jem.191.4.613.}},
Number-of-Cited-References = {{47}},
Times-Cited = {{185}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Clin. Invest.}},
Doc-Delivery-Number = {{196JS}},
Unique-ID = {{ISI:000248478100036}},
}

@article{ ISI:000248793300008,
Author = {Sawyer, J. and Mealing, D. and Dalley, D. and Dave, D. and Lesellier, S.
   and Palmer, S. and Bowen-Davies, J. and Crawshaw, T. R. and Chambers, M.
   A.},
Title = {{Development and evaluation of a test for tuberculosis in live European
   badgers (Meles meles) based on measurement of gamma interferon mRNA by
   real-time PCR}},
Journal = {{JOURNAL OF CLINICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{45}},
Number = {{8}},
Pages = {{2398-2403}},
Month = {{AUG}},
Abstract = {{A real-time PCR assay for the measurement of gamma interferon
   (IFN-gamma) mRNA in European badger (Meles meles) blood cultures was
   developed. The levels of IFN-gamma mRNA in blood cultures stimulated
   with either bovine or avian tuberculin or specific mycobacterial
   antigens were compared with those in a nonstimulated control blood
   culture as the basis for determining the tuberculosis (TB) status of
   live badgers. The assay was validated by testing 247 animals for which
   there were matching data from postmortem examination and culture of
   tissues. Relative changes in the levels of IFN-gamma mRNA in response to
   bovine tuberculin and specific antigens were found to be greater among
   badgers with tissues positive for TB on culture. The test was at its
   most accurate (87\% of test results were correct) by using blood
   cultures containing bovine tuberculin as the antigen and when the
   response to avian tuberculin was taken into account by subtracting the
   avian tuberculin response from the bovine tuberculin response. At a
   specificity of 90.7\%, the test was 70.6\% sensitive. At the same
   specificity, the current serological enzyme-linked immunosorbent assay
   for TB in badgers was only 53\% sensitive. This work demonstrates that
   measurement of IFN-gamma mRNA by real-time PCR is a valid method for the
   detection of TB in live badgers and may provide an alternative to the
   current serological methods of diagnosis, the Brock test. The testing
   procedure can be completed within 5 h of receipt of the blood culture
   samples. In addition, the use of a molecular biology-based test offers
   the potential to fully automate the testing procedure through the use of
   robotics.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Chambers, MA (Reprint Author), Vet Labs Agcy Weybridge, Dept Statutory \& Exot Bacteria, TB Res Grp, Addlestone KT15 3NB, Surrey, England.
   Vet Labs Agcy Weybridge, Dept Statutory \& Exot Bacteria, TB Res Grp, Addlestone KT15 3NB, Surrey, England.
   Vet Labs Agcy Weybridge, Dept Biotechnol, Technol Transfer Unit, Addlestone KT15 3NB, Surrey, England.
   TBD Wildlife Unit, Stroud GL6 8GA, Glos, England.
   Vet Labs Agcy Starcross, Exeter EX6 8PE, Devon, England.}},
DOI = {{10.1128/JCM.00292-07}},
ISSN = {{0095-1137}},
Keywords-Plus = {{MYCOBACTERIUM-BOVIS INFECTION; QUANTITATIVE PCR; DIAGNOSTIC-TESTS;
   ASSAY; CATTLE; ELISA; RESPONSES}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{m.a.chambers@vla.defra.gsi.gov.uk}},
ResearcherID-Numbers = {{Sawyer, Jason/C-3197-2011
   Lesellier, Sandrine/C-9508-2011
   Dalley, Deanna/D-8830-2011
   Dave, Dipesh/D-9566-2011
   Crawshaw, Tim/D-6101-2011
   APHA, Staff publications/E-6082-2010
   Chambers, Mark/C-9470-2009}},
ORCID-Numbers = {{Dave, Dipesh/0000-0003-1691-8185
   Crawshaw, Tim/0000-0001-6709-6578
   Chambers, Mark/0000-0002-8073-8069}},
Cited-References = {{Chambers MA, 2002, VET MICROBIOL, V86, P183, DOI 10.1016/S0378-1135(02)00012-3.
   CLIFTONHADLEY RS, 1995, VET REC, V137, P555.
   Collins J. D., 2002, Cattle Practice, V10, P223.
   CORNER LA, 1994, VET MICROBIOL, V40, P53, DOI 10.1016/0378-1135(94)90046-9.
   Dalley D, 1999, VET IMMUNOL IMMUNOP, V70, P85, DOI 10.1016/S0165-2427(99)00072-0.
   Dalley DJ, 2004, VET IMMUNOL IMMUNOP, V101, P19, DOI 10.1016/j.vetimm.2004.04.010.
   Doherty TM, 2005, J IMMUNOL METHODS, V298, P129, DOI 10.1016/j.jim.2005.01.013.
   Donnelly CA, 2006, NATURE, V439, P843, DOI 10.1038/nature04454.
   Donnelly CA, 2003, NATURE, V426, P834, DOI 10.1038/nature02192.
   Durr PA, 2000, REV SCI TECH OIE, V19, P675.
   Fujiwara S, 2003, VET IMMUNOL IMMUNOP, V93, P9, DOI 10.1016/S0165-2427(03)00049-7.
   GOODGER J, 1994, VET REC, V135, P82.
   Greenwald R, 2003, DIAGN MICR INFEC DIS, V46, P197, DOI 10.1016/S0732-8893(03)00046-4.
   Greiner M, 2000, PREV VET MED, V45, P23, DOI 10.1016/S0167-5877(00)00115-X.
   Jackson R, 1995, NEW ZEAL VET J, V43, P306, DOI 10.1080/00480169./1995.35911.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   ROTHEL JS, 1992, AUST VET J, V69, P1, DOI 10.1111/j.1751-0813.1992.tb09848.x.
   Welsh MD, 2005, IMMUNOLOGY, V114, P101, DOI 10.1111/j.1365-2567.2004.02003.x.
   WHIPPLE DL, 1995, AM J VET RES, V56, P415.
   WOOD PR, 1990, RES VET SCI, V49, P46.
   WOOD PR, 1991, AUST VET J, V68, P286, DOI 10.1111/j.1751-0813.1991.tb03254.x.
   WOOD PR, 1992, VET MICROBIOL, V31, P71, DOI 10.1016/0378-1135(92)90142-G.
   2005, ANIMAL HLTH 2004 REP.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{14}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{J. Clin. Microbiol.}},
Doc-Delivery-Number = {{200WK}},
Unique-ID = {{ISI:000248793300008}},
}

@article{ ISI:000248793300018,
Author = {Al-Hajoj, Sahal A. M. and Zozio, Thierry and Al-Rabiah, Fahad and
   Mohammad, Viquar and Al-Nasser, Maryam and Sola, Christophe and Rastogi,
   Nalin},
Title = {{First insight into the population structure of Mycobacterium
   tuberculosis in Saudi Arabia}},
Journal = {{JOURNAL OF CLINICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{45}},
Number = {{8}},
Pages = {{2467-2473}},
Month = {{AUG}},
Abstract = {{This study constitutes a first attempt to describe the genetic
   population structure and drug resistance of the tubercle bacilli
   circulating in Saudi Arabia. A total of 1,505 clinical isolates of M.
   tuberculosis, isolated between 2002 and 2005 from seven regions of Saudi
   Arabia, were studied. The sample studied showed a male-to-female sex
   ratio of 1.27, with half of the cases among foreign-born individuals and
   47\% within the 21- to 40-year-old age group; a total resistance rate of
   19.7\%; and multiple drug resistance of 4.5\%. Upon spoligotyping, a
   total of 387 individual patterns were obtained (clustering rate, 86.4\%;
   182 clusters containing between 2 and 130 isolates per cluster). A total
   of 94\% of the strains matched the spoligotype patterns in an
   international database. Nearly 81\% of the isolates in this study
   belonged to established phylogeographic clades: Central Asian (CAS),
   22.5\%; ill-defined T clade, 19.5\%; East African-Indian (EAI), 13.5\%;
   Haarlem, 7.5\%; Latin American-Mediterranean, 7.2\%; Beijing, 4.4\%;
   Mann, 2.7\%; X, 0.9\%; and Bovis, 0.9\%. Two clonal complexes with
   unique spoligotyping signatures (octal codes 703777707770371 and
   467777377413771) specific to Saudi Arabia were identified. These
   belonged to the CAS and EAI clades, respectively, as confirmed upon
   secondary typing using mycobacterial interspersed repetitive units
   (MIRUs). The results obtained underline the predominance of historic
   clones of principal genetic group 1, which are responsible for roughly
   45\% of all tuberculosis cases in Saudi Arabia. The high rate of
   clustering observed might be an indication of rapid ongoing transmission
   within certain communities and/or subpopulations in Saudi Arabia;
   nonetheless, spoligotyping is known to overestimate clustering, and only
   a systematic second-line typing, such as MIRUs, coupled with a better
   tuberculosis registry and epidemiological investigations would allow us
   to know the exact rate of ongoing transmission and associated risk
   factors in Saudi Arabia.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rastogi, N (Reprint Author), King Faisal Specialist Hosp \& Res Ctr, Dept Comparat Med, MBC 03,POB 3354, Riyadh 11211, Saudi Arabia.
   King Faisal Specialist Hosp \& Res Ctr, Dept Comparat Med, Riyadh 11211, Saudi Arabia.
   King Faisal Specialist Hosp \& Res Ctr, Dept Med, Riyadh 11211, Saudi Arabia.
   Inst Pasteur Guadeloupe, Unite Tuberculose \& Mycobacteries, Abymes, Guadeloupe.}},
DOI = {{10.1128/JCM.02293-06}},
ISSN = {{0095-1137}},
Keywords-Plus = {{EPIDEMIOLOGY; COMPLEX; PHYLOGENY; STRAINS; POLYMORPHISM; REGION; IS6110;
   VNTR}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{nrastogi@pasteur-guadeloupe.fr}},
ORCID-Numbers = {{Rastogi, Nalin/0000-0002-7199-7747
   SOLA, Christophe Noel/0000-0003-4672-2140}},
Cited-References = {{Al-Hajjaj M S, 2001, Respirology, V6, P317, DOI 10.1046/j.1440-1843.2001.00344.x.
   Al-Hajoj SA, 2004, SAUDI MED J, V25, P1545.
   ALKASSIMI FA, 1993, TUBERCLE LUNG DIS, V74, P254, DOI 10.1016/0962-8479(93)90051-X.
   AlMazrou YY, 1997, SCAND J INFECT DIS, V29, P323, DOI 10.3109/00365549709019056.
   Alrajhi AA, 2002, SAUDI MED J, V23, P305.
   Alzeer A, 1998, J INFECTION, V36, P303, DOI 10.1016/S0163-4453(98)94315-8.
   Brudey K, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-23.
   Dale JW, 2003, J BACTERIOL, V185, P2555, DOI 10.1128/JB.185.8.2555-2562.2003.
   Filliol I, 2006, J BACTERIOL, V188, P3162, DOI 10.1128/JB.188.8.3162-3163.2006.
   Filliol I, 2006, J BACTERIOL, V188, P759, DOI 10.1128/JB.188.2.759-772.2006.
   Filliol I, 2002, EMERG INFECT DIS, V8, P1347.
   Huard RC, 2006, J BACTERIOL, V188, P4271, DOI 10.1128/JB.01783-05.
   Kam KM, 2005, J CLIN MICROBIOL, V43, P306, DOI 10.1128/JCM.43.1.306-313.2005.
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907.
   Kanduma E, 2003, J APPL MICROBIOL, V94, P781, DOI 10.1046/j.1365-2672.2003.01918.x.
   Kovalev SY, 2005, INT J TUBERC LUNG D, V9, P746.
   Kremer K, 1999, J CLIN MICROBIOL, V37, P2607.
   Kulkarni S, 2005, RES MICROBIOL, V156, P588, DOI 10.1016/j.resmic.2005.01.005.
   MILAAT MA, 1994, SAUDI MED J, V15, P133.
   SCHIOTT CR, 1984, LAEGER, V146, P4024.
   Sola C, 2001, J MOL EVOL, V53, P680, DOI 10.1007/s002390010255.
   Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869.
   Supply P, 2001, J CLIN MICROBIOL, V39, P3563, DOI 10.1128/JCM.39.10.3563-3571.2001.
   van Soolingen D, 2001, J INTERN MED, V249, P1, DOI 10.1046/j.1365-2796.2001.00772.x.
   VANSOOLINGEN D, 1994, METHOD ENZYMOL, V235, P196.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{28}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{J. Clin. Microbiol.}},
Doc-Delivery-Number = {{200WK}},
Unique-ID = {{ISI:000248793300018}},
}

@article{ ISI:000248793300040,
Author = {Hillemann, Doris and Ruesch-Gerdes, Sabine and Richter, Elvira},
Title = {{Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid
   susceptibility testing of Mycobacterium tuberculosis strains and
   clinical specimens}},
Journal = {{JOURNAL OF CLINICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{45}},
Number = {{8}},
Pages = {{2635-2640}},
Month = {{AUG}},
Abstract = {{The new GenoType MTBDRplus assay (Hain Lifescience GmbH, Nehren,
   Germany) was tested with 125 clinical isolates and directly with 72
   smear-positive sputum specimens for its ability to detect rifampin (RMP)
   and isoniazid (INH) resistance in Mycobacterium tuberculosis complex
   (MTBC) strains. In total, 106 RMPr/ INHr, 10 RMPs/INHr, and 80 RMPs/INHs
   MTBC strains were comparatively analyzed with the new and the old MTBDR
   assays. Besides the detection of mutations within the 81-bp hot spot
   region of rpoB and katG codon 315, the GenoType MTBDRplus assay is
   designed to detect mutations in the regulatory region of inhA. The
   applicability of the new assay directly to specimens was shown, since 71
   of 72 results for smear-positive sputa and all 125 results for clinical
   isolates were interpretable and no discrepancies compared with the
   results of real-time PCR or DNA sequencing were obtained. In comparison
   to conventional drug susceptibility testing, both assays were able to
   identify RMP resistance correctly in 74 of 75 strains (98.7\%) and 30 of
   31 specimens (96.8\%). The misidentification of RMP resistance was
   obtained for two strains containing rpoB P533L mutations. Compared to
   the old MTBDR assay, the new GenoType MTBDRplus assay enhanced the rate
   of detection of INH resistance from 66 (88.0\%) to 69 (92.0\%) among the
   75 INH-resistant strains and 36 (87.8\%) to 37 (90.2\%) among the 41
   specimens containing INH-resistant strains. Thus, the new GenoType
   MTBDRplus assay represents a reliable and upgraded tool for the
   detection of INH and RMP resistance in strains or directly from
   smear-positive specimens.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hillemann, D (Reprint Author), Natl Referenzzentrum Mykobakterien, Forschungszentrum Borstel, Parkallee 18, D-23845 Borstel, Germany.
   Natl Referenzzentrum Mykobakterien, Forschungszentrum Borstel, D-23845 Borstel, Germany.}},
DOI = {{10.1128/JCM.00521-07}},
ISSN = {{0095-1137}},
Keywords-Plus = {{MOLECULAR CHARACTERIZATION; RPOB GENE; RESISTANCE MUTATIONS; RAPID
   DETECTION; COMPLEX; DNA; CHINA; KATG; REGION; INHA}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{dhillemann@fz-borstel.de}},
Cited-References = {{Bang D, 2006, J CLIN MICROBIOL, V44, P2605, DOI 10.1128/JCM.00752-06.
   Bartfai Z, 2001, J CLIN MICROBIOL, V39, P3736, DOI 10.1128/JCM.39.10.3736-3739.2001.
   CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21.
   Cavusoglu C, 2006, J CLIN MICROBIOL, V44, P2338, DOI 10.1128/JCM.00425-06.
   {*}DTSCH I NORM, 1986, MED MICR DIAGN TU 32.
   Deutsches Institut fur Normung, 1986, MED MICR DIAGN TUB 3.
   Espinal MA, 2003, TUBERCULOSIS, V83, P44, DOI 10.1016/S1472-9792(02)00058-6.
   GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802.
   Hazbon MH, 2006, ANTIMICROB AGENTS CH, V50, P2640, DOI 10.1128/AAC.00112-06.
   Heep M, 2001, J CLIN MICROBIOL, V39, P107, DOI 10.1128/JCM.39.1.107-110.2001.
   Hillemann D, 2005, ANTIMICROB AGENTS CH, V49, P1229, DOI 10.1128/AAC.49.3.1229-1231.2005.
   Hillemann D, 2006, INT J TUBERC LUNG D, V10, P1057.
   Hillemann D, 2005, J CLIN MICROBIOL, V43, P3699, DOI 10.1128/JCM.43.8.3699-3703.2005.
   Kelley CL, 1997, ANTIMICROB AGENTS CH, V41, P2057.
   Kent PT, 1985, PUBLIC HLTH MYCOBACT.
   Ma X, 2006, J CLIN MICROBIOL, V44, P3409, DOI 10.1128/JCM.00515-06.
   Makinen J, 2006, J CLIN MICROBIOL, V44, P350, DOI 10.1128/JCM.44.2.350-352.2006.
   Miotto P, 2006, J CLIN MICROBIOL, V44, P2485, DOI 10.1128/JCM.00083-06.
   Mokrousov I, 2002, ANTIMICROB AGENTS CH, V46, P1417, DOI 10.1128/AAC.46.5.1417-1424.2002.
   Morlock GP, 2003, ANTIMICROB AGENTS CH, V47, P3799, DOI 10.1128/AAC.47.12.3799-3805.2003.
   Musser JM, 1996, J INFECT DIS, V173, P196.
   Ohno H, 1996, ANTIMICROB AGENTS CH, V40, P1053.
   Piatek AS, 2000, ANTIMICROB AGENTS CH, V44, P103.
   Piersimoni C, 2006, J CLIN MICROBIOL, V44, P20, DOI 10.1128/JCM.44.1.20-28.2006.
   Sajduda A, 2004, J CLIN MICROBIOL, V42, P2425, DOI 10.1128/JCM.42.6.2425-2431.2004.
   Somoskovi A, 2006, J CLIN MICROBIOL, V44, P4459, DOI 10.1128/JCM.01506-06.
   Sreevatsan S, 1997, ANTIMICROB AGENTS CH, V41, P600.
   Taniguchi H, 1996, FEMS MICROBIOL LETT, V144, P103, DOI 10.1111/j.1574-6968.1996.tb08515.x.
   Telenti A, 1997, J CLIN MICROBIOL, V35, P719.
   Traore H, 2006, J CLIN MICROBIOL, V44, P4384, DOI 10.1128/JCM.01332-06.
   Yue J, 2003, J CLIN MICROBIOL, V41, P2209, DOI 10.1128/JCM.41.5.2209-2212.2003.
   Zhang M, 2005, J CLIN MICROBIOL, V43, P5477, DOI 10.1128/JCM.43.11.5477-5482.2005.}},
Number-of-Cited-References = {{32}},
Times-Cited = {{203}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{9}},
Journal-ISO = {{J. Clin. Microbiol.}},
Doc-Delivery-Number = {{200WK}},
Unique-ID = {{ISI:000248793300040}},
}

@article{ ISI:000248793300044,
Author = {van Klingeren, Bert and Dessens-Kroon, Mirjam and van der Laan, Tridia
   and Kremer, Kristin and van Soolingen, Dick},
Title = {{Drug susceptibility testing of Mycobacterium tuberculosis complex by use
   of a high-throughput, reproducible, absolute concentration method}},
Journal = {{JOURNAL OF CLINICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{45}},
Number = {{8}},
Pages = {{2662-2668}},
Month = {{AUG}},
Abstract = {{Accurate drug susceptibility testing (DST) for Mycobacterium
   tuberculosis is highly important for both therapy guidance and
   surveillance of drug resistance. Although liquid medium DST methods are
   used increasingly and seem most efficient and fast, the high costs
   hamper widespread implementation. In addition, an inability to check the
   colony morphology of the growing bacteria is a disadvantage of these
   methods. Moreover, these methods discriminate only between
   susceptibility and resistance and do not determine the MIC. In this
   paper, we describe a low-cost, reproducible, high-throughput,
   proportional absolute concentration DST method. The method uses a
   concentration series of antituberculosis drugs, including pyrazinamide
   in 71110 medium, distributed semiautomatically in 25-well plates. The
   performance of this 25-well DST method was evaluated by the World Health
   Organization and the International Union against Tuberculosis and Lung
   Disease in 10 rounds of proficiency testing regarding sensitivity,
   specificity, efficiency, reproducibility, and predictive value for
   resistance and susceptibility. The performance of the method for these
   characteristics was 100\% for isoniazid and from 96 to 100\% for
   rifampin, 91 to 100\% for streptomycin, and 85 to 100\% for ethambutol.
   The method was 100\% reproducible for all four drugs. The levels of drug
   resistance and the MIC distributions for the first-line antituberculosis
   drugs were determined for all 7,956 M. tuberculosis strains isolated in
   The Netherlands from 1998 to 200 and amounted to 7.5\% for isoniazid,
   1.4\% for rifampin, 8.5\% for streptomycin, and 1.0\% for ethambutol.
   Pyrazinamide testing was successful for 7,026 (88.3\%) of the isolates
   and showed a resistance level of 0.8\%.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{van Soolingen, D (Reprint Author), Natl Inst Publ Hlth \& Environm RIVM, Ctr Infect Dis Control, Mycobacteriol Reference Lab Pb 22, POB 1,LIS,Pb 22, NL-3720 BA Bilthoven, Netherlands.
   Natl Inst Publ Hlth \& Environm RIVM, Ctr Infect Dis Control, Mycobacteriol Reference Lab Pb 22, NL-3720 BA Bilthoven, Netherlands.}},
DOI = {{10.1128/JCM.00244-07}},
ISSN = {{0095-1137}},
Keywords-Plus = {{QUALITY ASSURANCE PROGRAM; LABORATORY NETWORK; RADIOMETRIC METHOD;
   GENETIC-MARKERS; PYRAZINAMIDE; EPIDEMIOLOGY; STREPTOMYCIN; NETHERLANDS;
   ETHAMBUTOL; DIAGNOSIS}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{d.van.soolingen@rivm.nl}},
Cited-References = {{Aziz M, 2007, INT J TUBERC LUNG D, V11, P247.
   Berner P., 2002, J CLIN MICROBIOL, V40, P150.
   CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21.
   de Vries G, 2005, Ned Tijdschr Geneeskd, V149, P1921.
   DELPORTILLO P, 1991, J CLIN MICROBIOL, V29, P2163.
   Franzblau SG, 1998, J CLIN MICROBIOL, V36, P362.
   Hazbon M H, 2000, J Clin Microbiol, V38, P4599.
   HEILMEYER L, 1957, DEUT MED WOCHENSCHR, V82, P941.
   Laszlo A, 1997, INT J TUBERC LUNG D, V1, P231.
   Laszlo A, 2002, INT J TUBERC LUNG D, V6, P748.
   MCDERMOTT W, 1954, AM REV TUBERC PULM, V70, P748.
   Palomino JC, 1999, INT J TUBERC LUNG D, V3, P344.
   Rusch-Gerdes S, 2006, J CLIN MICROBIOL, V44, P688, DOI 10.1128/JCM.44.3.688-692.2006.
   Scarparo C, 2004, J CLIN MICROBIOL, V42, P1109, DOI 10.1128/JCM.42.3.1109-1114.2004.
   SIDDIQI SH, 1981, J CLIN MICROBIOL, V13, P908.
   SIDDIQI SH, 1995, BECKTON DICKINSON MI.
   STOTTMEIER KD, 1967, AM REV RESPIR DIS, V96, P1072.
   Tortoli E, 2002, J CLIN MICROBIOL, V40, P607, DOI 10.1128/JCM.40.2.607-610.2002.
   TRIPATHY S P, 1970, Tubercle, V51, P375, DOI 10.1016/0041-3879(70)90003-6.
   van Soolingen D, 1999, J INFECT DIS, V180, P726, DOI 10.1086/314930.
   van Soolingen D, 1998, J CLIN MICROBIOL, V36, P1840.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.
   VANSOOLINGEN D, 1992, J CLIN MICROBIOL, V30, P1772.
   VANSOOLINGEN D, 1994, J CLIN MICROBIOL, V32, P2425.
   vanSoolingen D, 1997, INT J SYST BACTERIOL, V47, P1236.
   VANWEEZENBEEK CSL, 2003, INT J TUBERC LUNG D, V7, pS463.
   Wanger A, 1996, J CLIN MICROBIOL, V34, P1672.
   WAYNE LG, 1966, AM J CLIN PATHOL, V45, P769.
   World Health Organization, 2004, 3 WHO.
   WOODLEY CL, 1988, ANTIMICROB AGENTS CH, V32, P125.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{57}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Clin. Microbiol.}},
Doc-Delivery-Number = {{200WK}},
Unique-ID = {{ISI:000248793300044}},
}

@article{ ISI:000248509000010,
Author = {Carvalho, Anna C. C. and Pezzoli, Maria Chiara and El-Hamad, Issa and
   Arce, Patricia and Bigoni, Sara and Scarcella, Carmelo and Indelicato,
   Anna Maria and Scolari, Carla and Carosi, Giampiero and Matteelli,
   Alberto},
Title = {{QuantiFERON (R)-TB Gold test in the identification of latent
   tuberculosis infection in immigrants}},
Journal = {{JOURNAL OF INFECTION}},
Year = {{2007}},
Volume = {{55}},
Number = {{2}},
Pages = {{164-168}},
Month = {{AUG}},
Abstract = {{Background: The identification and treatment of latent tuberculosis
   infection (LTBI) among immigrants are an effective strategy for TB
   control in developed countries. A new test for LTBI identification that
   uses more specific antigens of Mycobacterium tuberculosis is now
   commercially available under the brand name of QuantiFERON (R)-TB Gold
   test.
   Objective: To compare QuantiFERON (R)-TB Gold test to tuberculin skin
   testing (TST) for the detection of LTBI among immigrants from high
   endemic TB areas. Patients and methods: Undocumented immigrants
   attending a district medical center were enrolled if they originated
   from high endemic TB areas, the time of arrival in Italy was <= 5 years,
   had neither active TB disease nor known immunodeficiency status. The TST
   was applied according to standards and QuantiFERON (R)-TB Gold test was
   performed following the manufacturer's instructions.
   Results: Hundred subjects were included in the comparative analysis. TST
   was positive in 44\% of subjects; 15\% had a positive QuantiFERON (R)-TB
   Gold test result. The total agreement between TST and QuantiFERON (R)-TB
   Gold test was 71\%, for a k statistics of 0.37; agreement was 100\% for
   TST negative results, but only 34\% for TST positive ones. In the
   multivariate logistic regression analysis, previous BCG vaccination was
   independently associated with a tower chance of disagreement between the
   tests.
   Conclusion: The prevalence of LTBI among immigrants was lower when
   determined by QuantiFERON (R)-TB Gold; this may be a consequence of more
   specific MTB antigens used. Our results suggest that QuantiFERON (R)-TB
   Gold may be used as confirmatory test for TST positive immigrants
   candidate to preventive therapy. (c) 2007 The British Infection Society.
   Published by Elsevier Ltd. All rights reserved.}},
Publisher = {{W B SAUNDERS CO LTD}},
Address = {{32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Carvalho, ACC (Reprint Author), Univ Brescia, Inst Infect \& Trop Dis, Piazza Spedali Civili 1, I-25125 Brescia, Italy.
   Univ Brescia, Inst Infect \& Trop Dis, I-25125 Brescia, Italy.
   Dist Hlth Dept, Brescia, Italy.}},
DOI = {{10.1016/j.jinf.2007.02.004}},
ISSN = {{0163-4453}},
Keywords = {{QuantiFERON((R))-TB gold; ESAT-6; CFP 10; immigrants; latent
   tuberculosis infection}},
Keywords-Plus = {{INTERFERON-GAMMA ASSAY; CALMETTE-GUERIN VACCINATION; SKIN-TEST;
   DIAGNOSIS; RESPONSES; CHILDREN; ANTIGENS; BURDEN}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{a.carvalho@libero.it}},
ResearcherID-Numbers = {{Matteelli, Alberto/M-8784-2015}},
ORCID-Numbers = {{Matteelli, Alberto/0000-0001-5109-9248}},
Cited-References = {{Arend SM, 2002, J INFECT DIS, V186, P1797, DOI 10.1086/345760.
   {[}Anonymous], 2000, AM J RESP CRIT CARE, V161, pS221.
   Black GF, 2001, J INFECT DIS, V184, P322, DOI 10.1086/322042.
   Brock Iinger, 2004, American Journal of Respiratory and Critical Care Medicine, V170, P65, DOI 10.1164/rccm.200402-232OC.
   Broekmans JF, 2002, EUR RESPIR J, V19, P765, DOI 10.1183/09031936.02.00261402.
   Carvalho ACC, 2005, EPIDEMIOL INFECT, V133, P179, DOI 10.1017/S0950268804003061.
   Carvalho ACC, 2001, INT J TUBERC LUNG D, V5, P297.
   {*}CDC, 2005, MMWR-MORBID MORTAL W, V54, P245.
   Centis R, 2002, Monaldi Arch Chest Dis, V57, P297.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Faggiano F, 2004, INT J TUBERC LUNG D, V8, P171.
   Ferrara G, 2005, AM J RESP CRIT CARE, V172, P631, DOI 10.1164/rccm.200502-196OC.
   Kang YA, 2005, JAMA-J AM MED ASSOC, V293, P2756, DOI 10.1001/jama.293.22.2756.
   Kimura M, 1999, J INFECT DIS, V179, P1297, DOI 10.1086/314707.
   Matteelli A, 2000, AM J RESP CRIT CARE, V162, P1653.
   Mazurek GH, 2001, JAMA-J AM MED ASSOC, V286, P1740, DOI 10.1001/jama.286.14.1740.
   Menzies D, 1999, AM J RESP CRIT CARE, V159, P15.
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC.
   Mudido PM, 1999, INT J TUBERC LUNG D, V3, P891.
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.
   Pottumarthy S, 1999, J CLIN MICROBIOL, V37, P3229.
   RIEDER HL, 1995, TUBERCLE LUNG DIS, V76, P114, DOI 10.1016/0962-8479(95)90552-9.
   {*}US FDA CTR DEV RA, QUANTIFERON TB P01 2.
   Wang L, 2002, THORAX, V57, P804, DOI 10.1136/thorax.57.9.804.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{33}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{J. Infect.}},
Doc-Delivery-Number = {{196UZ}},
Unique-ID = {{ISI:000248509000010}},
}

@article{ ISI:000248509000011,
Author = {Dheda, K. and Pooran, A. and Pai, M. and Miller, R. F. and Lesley, K.
   and Booth, H. L. and Scott, G. M. and Akbar, A. N. and Zumla, A. and
   Rook, G. A.},
Title = {{Interpretation of Mycobacterium tuberculosis antigen-specific IFN-gamma
   release assays (T-SPOT.TB) and factors that may modulate test results}},
Journal = {{JOURNAL OF INFECTION}},
Year = {{2007}},
Volume = {{55}},
Number = {{2}},
Pages = {{169-173}},
Month = {{AUG}},
Abstract = {{Background: Data about T cell antigen-specific (ESAT-6 and CFP-10)
   IFN-gamma release assays (IGRAs) during and after completion of
   anti-tuberculous (TB) treatment are limited and highly discordant. Thus,
   the utility of IGRAs as a surrogate marker of mycobacterial burden
   remain unclear.
   Methods: To investigate factors that modulate IGRA responses during
   anti-TB treatment we used a standardised assay (T-SPOT.TB) in 33
   patients with culture positive tuberculosis.
   Results: Significantly more patients in the early (<= 4 months of
   anti-TB treatment) rather than the late phase (>4 months or completed
   anti-TB treatment) had positive IGRA responses {[}10/12 (83\%) vs 4/21
   (19\%); p <= 0.01]. Thus, 17/21 (81\%) in the late phase or who had
   completed treatment (mean duration of treatment = 8.7 months) were IGRA
   negative, despite having robust antigen-specific recall proliferative
   responses. In these 17 patients prolonged incubation (5 days vs
   overnight), use of different antigen preparations (protein vs peptide)
   and addition of endotoxin, failed to elicit positive responses.
   Conclusions: In treated TB patients the discordant IGRA data remain
   unexplained by variation in laboratory protocols and are more likely due
   to host or environmental factors. In a low burden setting IGRAs may be a
   promising surrogate marker of mycobacterial disease burden. (c) 2007
   Published by Elsevier Ltd on behalf of The British Infection Society.}},
Publisher = {{W B SAUNDERS CO LTD}},
Address = {{32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Dheda, K (Reprint Author), UCL Royal Free \& Univ Coll Med Sch, Ctr Infect Dis \& Int Hlth, Div Infect \& Immun, Wind Eyer Bldg,46 Cleveland St, London, England.
   UCL Royal Free \& Univ Coll Med Sch, Ctr Infect Dis \& Int Hlth, Div Infect \& Immun, London, England.
   Univ Cape Town, Dept Med, Div Pulm, ZA-7700 Rondebosch, South Africa.
   UCL Royal Free \& Univ Coll Med Sch, Div Infect \& Immun, Dept Immunol \& Mol Pathol, London, England.
   McGill Univ, Dept Epidemiol Biostat \& Occupat Hlth, Montreal, PQ, Canada.}},
DOI = {{10.1016/j.jinf.2007.02.005}},
ISSN = {{0163-4453}},
Keywords = {{ESAT-6; CFP-10; human; tuberculosis; IFN-gamma}},
Keywords-Plus = {{BLOOD MONONUCLEAR-CELLS; RESPONSES; ESAT-6; INFECTION; CHEMOTHERAPY;
   INDIVIDUALS; CONTACTS}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{k.dheda@ucl.ac.uk}},
ORCID-Numbers = {{Rook, Graham/0000-0002-8041-8110
   Zumla, Alimuddin/0000-0002-5111-5735}},
Cited-References = {{Aiken AM, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-66.
   Al-Attiyah R, 2003, FEMS IMMUNOL MED MIC, V38, P249, DOI 10.1016/S0928-8244(03)00166-4.
   Arend SM, 2000, INFECT IMMUN, V68, P3314, DOI 10.1128/IAI.68.6.3314-3321.2000.
   Carrara S, 2004, CLIN INFECT DIS, V38, P754, DOI 10.1086/381754.
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977.
   Dheda K, 2005, LANCET INFECT DIS, V5, P324, DOI 10.1016/S1473-3099(05)70119-5.
   Dheda K, 2005, CURR OPIN PULM MED, V11, P195, DOI 10.1097/01.mcp.0000158726.13159.5e.
   Dogra S, 2007, J INFECTION, V54, P267, DOI 10.1016/j.jinf.2006.04.007.
   Ferrand RA, 2005, INT J TUBERC LUNG D, V9, P1034.
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6.
   Harari A, 2005, J IMMUNOL, V174, P1037.
   Hsu T, 2003, P NATL ACAD SCI USA, V100, P12420, DOI 10.1073/pnas.1635213100.
   Jansky L, 2003, PHYSIOL RES, V52, P593.
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778.
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081.
   Pai Madhukar, 2006, J Occup Med Toxicol, V1, P7, DOI 10.1186/1745-6673-1-7.
   Pathan AA, 2001, J IMMUNOL, V167, P5217.
   Ulrichs T, 2000, INT J TUBERC LUNG D, V4, P1181.
   Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001.
   Wu-Hsieh BA, 2001, CLIN INFECT DIS, V33, P1336, DOI 10.1086/323044.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{46}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Infect.}},
Doc-Delivery-Number = {{196UZ}},
Unique-ID = {{ISI:000248509000011}},
}

@article{ ISI:000249178300016,
Author = {Choi, Jae Choi and Lim, Song Yong and Suh, Gee Young and Chung, Man Pyo
   and Kim, Hojoong and Kwon, Jung and Lee, Nam Yong and Park, Young Kil
   and Bai, Gil Han and Koh, Won-Jung},
Title = {{Drug resistance rates of Mycobacterium tuberculosis at a private
   referral center in Korea}},
Journal = {{JOURNAL OF KOREAN MEDICAL SCIENCE}},
Year = {{2007}},
Volume = {{22}},
Number = {{4}},
Pages = {{677-681}},
Month = {{AUG}},
Abstract = {{The goals of this study were to identify first-line drug resistance in
   new and previously treated tuberculosis (TB) cases and to determine risk
   factors for multidrug-resistant TB (MDR-TB) at a private referral center
   in Korea. All patients with culture-confirmed pulmonary TB over a 2-yr
   period between July 2002 and June 2004 were prospectively included in
   this study. In total, 637 patients were included; 512 (80.4\%) were new
   cases, and 125 (19.6\%) were previously treated cases. Resistance to at
   least one first-line drug was identified in 11.7\% of new cases and
   41.6\% of previously treated cases. MDR-TB was detected in 3.9\% of new
   cases and 27.2\% of previously treated cases. The proportion of
   extensively drug-resistant TB among MDR-TB patients was 16.7\% (9/54).
   Factors associated with MDR-TB included age under 45 yr, previous TB
   treatment, and the presence of cavitation on chest radiography. Rates of
   first-line drug resistance are high, particularly in previously treated
   patients, in the private sector in Korea. This underscores the need for
   an improved control program, coupled with early diagnosis of MDR-TB, to
   reduce the spread and development of resistance.}},
Publisher = {{KOREAN ACAD MEDICAL SCIENCES}},
Address = {{302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Koh, WJ (Reprint Author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Pulm \& Crit Care Med, 50 Irwon-dong, Seoul 135710, South Korea.
   Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Pulm \& Crit Care Med, Seoul 135710, South Korea.
   Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Internal Med,Div Pulm \& Crit Care Med, Seoul, South Korea.
   Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med \& Lab Med,Div Pulm \& Crit Care Med, Seoul, South Korea.
   Korean Natl TB Assoc, Inst TB, Seoul, South Korea.}},
ISSN = {{1011-8934}},
Keywords = {{Mycobacterium tuberculosis; Korea; drug resistance; isoniazid; rifampin}},
Keywords-Plus = {{RISK-FACTORS; SOUTH-KOREA}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{wjkoh@skku.edu}},
ResearcherID-Numbers = {{Koh, Won Jung/C-9595-2011}},
Cited-References = {{Arevalo M, 1996, EUR RESPIR J, V9, P274, DOI 10.1183/09031936.96.09020274.
   Bai GH, 2007, INT J TUBERC LUNG D, V11, P571.
   Centers for Disease Control and Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P301.
   Colebunders R, 2004, LANCET, V363, P1240, DOI 10.1016/S0140-6736(04)15970-9.
   Djuretic T, 2002, THORAX, V57, P477, DOI 10.1136/thorax.57.6.477.
   Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376.
   Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537.
   Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706.
   Espinal MA, 2001, INT J TUBERC LUNG D, V5, P887.
   Faustini A, 2006, THORAX, V61, P158, DOI 10.1136/thx.2005.045963.
   Ferrara G, 2005, INT J TUBERC LUNG D, V9, P507.
   Harrow EM, 1998, CHEST, V113, P1452, DOI 10.1378/chest.113.6.1452.
   Hong YP, 1998, INT J TUBERC LUNG D, V2, P27.
   Kang YA, 2006, RESPIROLOGY, V11, P793, DOI 10.1111/j.1400-1843.2006.00948.x.
   Kim DK, 2005, TUBER RESP DIS, V58, P243.
   KIM JH, 1995, TUBER RESP DIS, V42, P831.
   Kim SJ, 1997, INT J TUBERC LUNG D, V1, P302.
   Kim Sun Young, 1999, Korean Journal of Internal Medicine, V14, P27.
   {*}KOR CDCP, 2006, ANN REP NOT TUB PAT.
   Kordy FNS, 2004, INT J TUBERC LUNG D, V8, P1007.
   Lee Jin Hwa, 2001, Korean Journal of Internal Medicine, V16, P173.
   Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301.
   Ruddy M, 2005, THORAX, V60, P130, DOI 10.1136/thx.2004.026922.
   Seung KJ, 2003, INT J TUBERC LUNG D, V7, P912.
   Sharma SK, 2003, INFECT GENET EVOL, V3, P183, DOI 10.1016/S1567-1348(03)00086-8.
   Timperi R, 2005, INT J TUBERC LUNG D, V9, P175.
   Torun T, 2005, INT J TUBERC LUNG D, V9, P1373.
   {*}WHO, 2006, REP M WHO GLOB TASK.
   World Health Organization, 2003, TREATM TUB GUID NAT.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{18}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{J. Korean Med. Sci.}},
Doc-Delivery-Number = {{206IY}},
Unique-ID = {{ISI:000249178300016}},
}

@article{ ISI:000248821300007,
Author = {Byrne, Sean T. and Denkin, Steven M. and Gu, Peihua and Nuermberger,
   Eric and Zhang, Ying},
Title = {{Activity of ketoconazole against Mycobacterium tuberculosis in vitro and
   in the mouse model}},
Journal = {{JOURNAL OF MEDICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{56}},
Number = {{8}},
Pages = {{1047-1051}},
Month = {{AUG}},
Abstract = {{There is an urgent need for the development of new drugs that are active
   against drug-resistant Mycobacterium tuberculosis strains and can
   shorten tuberculosis (TB) therapy. It has previously been reported that
   the azole class of antifungals has anti-TB activity in vitro. This study
   evaluated ketoconazole (KTC) for activity against M. tuberculosis. The
   MIC of KTC for different M. tuberculosis strains ranged from 8 to 16 mu
   g ml(-1) under both acidic and neutral conditions, with the minimum
   bactericidal concentration being about twofold higher than the MIC. KTC
   had enhanced activity against old, non-growing bacilli in vitro when
   combined with pyrazinamide (PZA) and rifampicin (RIF). A single oral
   dose of KTC at 75 mg kg(-1) led to an inhibitory serum concentration 2
   In after administration. The in vivo activity of KTC was evaluated in
   established pulmonary TB in the murine model, compared alone and in
   combination with isoniazid (INH), PZA and RIF. KTC alone exhibited
   little effect after short-term treatment, with a borderline
   bacteriostatic effect on spleen colony counts but not on lung counts.
   KTC, when added in combination with INH, PZA and RIF, significantly
   improved the treatment outcome in the lungs (compared with treatment
   with INH, PZA and RIF). The lowest numbers of bacilli in lungs were
   found in mice treated with KTC, PZA and RIF. Further investigation is
   necessary to determine the role of KTC in the treatment of TB.}},
Publisher = {{SOC GENERAL MICROBIOLOGY}},
Address = {{MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Zhang, Y (Reprint Author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol \& Immunol, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol \& Immunol, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Med, Ctr TB Res, Baltimore, MD 21231 USA.}},
DOI = {{10.1099/jmm.0.47058-0}},
ISSN = {{0022-2615}},
Keywords-Plus = {{RIFAMPIN; PYRAZINAMIDE; INHIBITORS}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{yzhang@jhsph.edu}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI44063, AI49485, K08 AI058993]}},
Cited-References = {{American Thoracic Society Centre for Disease Control and Infectious Diseases Society of America, 2003, MMWR RECOMM REP, V52, P1.
   Boshoff HIM, 2004, J BIOL CHEM, V279, P40174, DOI 10.1074/jbc.M406796200.
   ENGELHARD D, 1984, NEW ENGL J MED, V311, P1681, DOI 10.1056/NEJM198412273112606.
   Finch CK, 2002, ARCH INTERN MED, V162, P985, DOI 10.1001/archinte.162.9.985.
   GROSSET J, 1992, ANTIMICROB AGENTS CH, V36, P548.
   MCCUNE R, 1957, AM REV TUBERC PULM, V76, P1106.
   McLean KJ, 2002, MICROBIOL-SGM, V148, P2937.
   {*}NCCLS, 1999, METH SER BACT TEST A.
   Nuermberger EL, 2004, AM J RESP CRIT CARE, V169, P421, DOI 10.1164/rccm.200310-1380OC.
   Sun Z., 1999, Tubercle and Lung Disease, V79, P319, DOI 10.1054/tuld.1999.0212.
   Zhang Y, 2002, J MED MICROBIOL, V51, P42.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{21}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Med. Microbiol.}},
Doc-Delivery-Number = {{201HE}},
Unique-ID = {{ISI:000248821300007}},
}

@article{ ISI:000248821300008,
Author = {Wada, Takayuki and Maeda, Shinji and Hase, Atsushi and Kobayashi, Kazuo},
Title = {{Evaluation of variable numbers of tandem repeat as molecular
   epidemiological markers of Mycobacterium tuberculosis in Japan}},
Journal = {{JOURNAL OF MEDICAL MICROBIOLOGY}},
Year = {{2007}},
Volume = {{56}},
Number = {{8}},
Pages = {{1052-1057}},
Month = {{AUG}},
Abstract = {{Using 243 Mycobacterium tuberculosis isolates obtained in 2001 in Osaka
   City, Japan, the discriminatory power of variable numbers of tandem
   repeats (VNTRs) of 12 standard mycobacterial interspersed repetitive
   units (MIRUs) was assessed. The biggest cluster defined by MIRU-VNTRs
   consisted of 57 (23.5\%) isolates and they belonged to the Beijing
   family based on spoligotyping. When additional VNTR loci were included
   in the MIRU-VNTR analysis, the 57 originally clustered strains were
   further differentiated by the addition of Queen's University Belfast
   (QUB)-VNTRs, but not exact tandem repeat-VNTR. The allelic diversity of
   additional VNTR loci such as VNTR 3232 (QUB-3232), VNTR 2163a (QUB-1 1
   a), VNTR 2163b (QUB-11b) and VNTR 1982 (QUB-18) was high in the 57
   strains. When the 243 M. tuberculosis isolates were analysed using
   16-locus VNTR (the 12 standard MIRUs and the 4 QUB loci) and IS61 10
   RFLP, the respective Hunter-Gaston discriminatory indexes were 0.9966
   and 0.9971. The discrimination power of 16-locus VNTR was equal to that
   of IS61 10 RFLP analysis, If appropriate loci are added to the standard
   MIRU analysis, VNTR genotyping could be a valuable tool for strain
   typing and epidemiological research of M. tuberculosis in Japan.}},
Publisher = {{SOC GENERAL MICROBIOLOGY}},
Address = {{MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Wada, T (Reprint Author), Osaka City Inst Publ Hlth \& Environm Sci, Dept Microbiol, Tennoji Ku, 8-34 Tojo Cho, Osaka 5430026, Japan.
   Osaka City Inst Publ Hlth \& Environm Sci, Dept Microbiol, Tennoji Ku, Osaka 5430026, Japan.
   Mol Epidemiol \& Genet Identificat Mycobacterium, Res Inst TB, Tokyo 2048533, Japan.
   Natl Inst Infect Dis, Dept Immunol, Tokyo 1628640, Japan.}},
DOI = {{10.1099/jmm.0.46990-0}},
ISSN = {{0022-2615}},
Keywords-Plus = {{FRAGMENT-LENGTH-POLYMORPHISM; W-BEIJING FAMILY; STRAIN DIFFERENTIATION;
   DISCRIMINATORY POWER; GENETIC DIVERSITY; COMPLEX BACTERIA; VNTR LOCI;
   HONG-KONG; IS6110; REPRODUCIBILITY}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{taka-wada@city.osaka.lg.jp}},
Cited-References = {{Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6.
   Blackwood KS, 2004, J CLIN MICROBIOL, V42, P5001, DOI 10.1128/JCM.42.11.5001-5006.2004.
   CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q.
   {*}CDC, 2004, HDB TB CONTR EP LAB.
   Chan MY, 2001, EPIDEMIOL INFECT, V127, P169.
   Cowan LS, 2005, J CLIN MICROBIOL, V43, P688, DOI 10.1128/JCM.43.2.688-695.2005.
   Frothingham R, 1998, MICROBIOL-UK, V144, P1189.
   Glynn JR, 2002, EMERG INFECT DIS, V8, P843.
   HUNTER PR, 1988, J CLIN MICROBIOL, V26, P2465.
   Kam KM, 2006, FEMS MICROBIOL LETT, V256, P258, DOI 10.1111/j.1574-6968.2006.00126.x.
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907.
   Kremer K, 2005, J CLIN MICROBIOL, V43, P5628, DOI 10.1128/JCM.43.11.5628-5638.2005.
   Kremer K, 2005, J CLIN MICROBIOL, V43, P314, DOI 10.1128/JCM.43.1.314-320.2005.
   Kremer K, 2004, J CLIN MICROBIOL, V42, P4040, DOI 10.1128/JCM.42.9.4040-4049.2004.
   Kremer K, 1999, J CLIN MICROBIOL, V37, P2607.
   Le Fleche P, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-37.
   Mazars E, 2001, P NATL ACAD SCI USA, V98, P1901, DOI 10.1073/pnas.98.4.1901.
   Molhuizen HOF, 1998, METH MOL B, V101, P381, DOI 10.1385/0-89603-471-2:381.
   Nikolayevskyy V, 2006, EMERG INFECT DIS, V12, P1406.
   OELEMANN MC, 2006, J CLIN MICROBIOL, V45, P691.
   Roring S, 2004, VET MICROBIOL, V101, P65, DOI 10.1016/j.vetmic.2004.02.013.
   Roring S, 2002, J CLIN MICROBIOL, V40, P2126, DOI 10.1128/JCM.40.6.2126-2133.2002.
   Skuce RA, 2002, MICROBIOL-SGM, V148, P519.
   Smittipat N, 2005, J CLIN MICROBIOL, V43, P5034, DOI 10.1128/JCM.43.10.5034-5043.2005.
   Sun YJ, 2004, J CLIN MICROBIOL, V42, P1986, DOI 10.1128/JCM.42.5.1986-1993.2004.
   Supply P, 2000, MOL MICROBIOL, V36, P762, DOI 10.1046/j.1365-2958.2000.01905.x.
   Supply P, 2001, J CLIN MICROBIOL, V39, P3563, DOI 10.1128/JCM.39.10.3563-3571.2001.
   Supply P, 2006, J CLIN MICROBIOL, V44, P4498, DOI 10.1128/JCM.01392-06.
   Surikova OV, 2005, EUR J EPIDEMIOL, V20, P963, DOI 10.1007/s10654-005-3636-5.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.
   VANSOOLINGEN D, 1995, J CLIN MICROBIOL, V33, P3234.
   Warren RM, 2004, J CLIN MICROBIOL, V42, P5774, DOI 10.1128/JCM.42.12.5774-5782.2004.}},
Number-of-Cited-References = {{32}},
Times-Cited = {{25}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{J. Med. Microbiol.}},
Doc-Delivery-Number = {{201HE}},
Unique-ID = {{ISI:000248821300008}},
}

@article{ ISI:000248523900010,
Author = {Cheng, Xiaodong and Zhang, Jianfang and Yang, Liu and Xu, Xiuli and Liu,
   Jianyun and Yu, Wenbin and Su, Mingquan and Hao, Xiaoke},
Title = {{A new multi-PCR-SSCP assay for simultaneous detection of isoniazid and
   rifampin resistance in Mycobacterium tuberculosis}},
Journal = {{JOURNAL OF MICROBIOLOGICAL METHODS}},
Year = {{2007}},
Volume = {{70}},
Number = {{2}},
Pages = {{301-305}},
Month = {{AUG}},
Abstract = {{Prompt detection of drug resistance in Mycobacterium tuberculosis is
   essential for effective control of tuberculosis (TB). We developed a
   Multi-PCR-SSCP method that detects more than 80\% commonly observed
   isoniazid (INH) and rifampin (RIF) resistance M tuberculosis in a single
   assay. The usefulness of the newly developed method was evaluated with
   It 6 clinical isolates of M. tuberculosis. Distinct SSCP patterns were
   observed for different mutations and the correlation between
   Multi-PCR-SSCP results and DNA sequencing data was strong. Using the
   culture-based phenotypic drug susceptibility testing as a reference, the
   sensitivity of the newly developed Multi-PCR-SSCP assay was determined
   to be 80\% and 81.8\% for INH and RIF, respectively. The specificity of
   the assay was 100\% and 92\%, for INH and RIF, respectively.
   Multi-PCR-SSCP provides a rapid and potentially more cost-effective
   method of detecting multidrug-resistant TB. (c) 2007 Published by
   Elsevier B.V.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hao, XK (Reprint Author), Fourth Mil Med Univ, Xijing Hosp, Dept Clin Lab, Xian 710032, Peoples R China.
   Fourth Mil Med Univ, Xijing Hosp, Dept Clin Lab, Xian 710032, Peoples R China.
   Fourth Mil Med Univ, Dept Microbiol, Xian 710032, Peoples R China.}},
DOI = {{10.1016/j.mimet.2007.05.002}},
ISSN = {{0167-7012}},
Keywords = {{multidrug resistant; tuberculosis; multiplex PCR; Single-Strand
   Conformational Polymorphism Analysis (SSCP)}},
Keywords-Plus = {{DRUG-RESISTANCE; MUTATIONS}},
Research-Areas = {{Biochemistry \& Molecular Biology; Microbiology}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Microbiology}},
Author-Email = {{haoxkg@fmmu.edu.cn}},
Cited-References = {{BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I.
   CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21.
   Cole ST, 1998, NATURE, V396, P190, DOI 10.1038/24206.
   Dye C, 2002, J INFECT DIS, V185, P1197, DOI 10.1086/339818.
   Laszlo A, 1997, INT J TUBERC LUNG D, V1, P231.
   LIBONATI JP, 1988, DIAGN MICR INFEC DIS, V10, P41, DOI 10.1016/0732-8893(88)90125-3.
   Lin SYG, 2004, J CLIN MICROBIOL, V42, P4204, DOI 10.1128/JCM.42.9.4204-4208.2004.
   Marin M, 2004, ANTIMICROB AGENTS CH, V48, P4293, DOI 10.1128/AAC.48.11.4293-4300.2004.
   Mokrousov I, 2004, J MICROBIOL METH, V57, P323, DOI 10.1016/j.mimet.2004.02.006.
   Schluger NW, 2000, INT J TUBERC LUNG D, V4, pS71.
   Schneider E, 2003, TUBERCULOSIS, V83, P21, DOI 10.1016/S1472-9792(02)00075-6.
   World Health Organization, 2000, 2 WHO.
   Yang ZH, 2005, DIAGN MICR INFEC DIS, V53, P201, DOI 10.1016/j.diagmicrobio.2005.06.007.}},
Number-of-Cited-References = {{13}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{J. Microbiol. Methods}},
Doc-Delivery-Number = {{197AB}},
Unique-ID = {{ISI:000248523900010}},
}

@article{ ISI:000250279200010,
Author = {Oudidi, Abellatif and Hachimi, Hicham and El Alami, Med Noutredine},
Title = {{Tuberculosis of the cavum}},
Journal = {{JOURNAL OF OTOLARYNGOLOGY}},
Year = {{2007}},
Volume = {{36}},
Number = {{4}},
Pages = {{253-255}},
Month = {{AUG}},
Publisher = {{B C DECKER INC}},
Address = {{50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO
   L8N 3K7, CANADA}},
Type = {{Article}},
Language = {{French}},
Affiliation = {{Oudidi, A (Reprint Author), BP 592 Poste Batha, Fes 30000, Morocco.
   CHU Hassan II, Serv Otorhinolaryngol, Fes, Morocco.}},
DOI = {{10.2310/7070.2007.0027}},
ISSN = {{0381-6605}},
Keywords-Plus = {{NASOPHARYNGEAL TUBERCULOSIS}},
Research-Areas = {{Otorhinolaryngology}},
Web-of-Science-Categories  = {{Otorhinolaryngology}},
Author-Email = {{otorhino@hotmail.com}},
Cited-References = {{AWAD M, 2001, AM J OTOLARYNG, V22, P236.
   Chan ABW, 2004, OTOLARYNG HEAD NECK, V130, P125, DOI 10.1016/j.otohns.2003.08.014.
   CHAULET P, 1995, TUBERCLE LUNG DIS, V76, P407, DOI 10.1016/0962-8479(95)90006-3.
   Chongkolwatana Cheerasook, 1998, Journal of the Medical Association of Thailand, V81, P329.
   HOLLANDER AR, 1964, LARYNGOSCOPE, V56, P282.
   Iriberri M, 2001, ARCH BRONCONEUMOL, V37, P216.
   LECOINTRE F, 1980, ANN OTO-LAR CHIR C-F, V97, P423.
   Percodani J, 1999, J LARYNGOL OTOL, V113, P928.
   Srirompotong S, 2004, OTOLARYNG HEAD NECK, V131, P762, DOI 10.1016/j.otohns.2004.02.052.
   Srirompotong S, 2003, J OTOLARYNGOL, V32, P230, DOI 10.2310/7070.2003.41716.
   Tse GMK, 2003, LARYNGOSCOPE, V113, P737, DOI 10.1097/00005537-200304000-00027.
   Unal M, 2002, J OTOLARYNGOL, V31, P186, DOI 10.2310/7070.2002.10927.
   YADAV SPS, 1992, TUBERCLE LUNG DIS, V73, P397, DOI 10.1016/0962-8479(92)90049-P.
   2004, MED MAL INFECT, V34, P364.
   2004, MED MAL INFECT, V34, P375.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Otolaryngol.}},
Doc-Delivery-Number = {{222EP}},
Unique-ID = {{ISI:000250279200010}},
}

@article{ ISI:000248391400013,
Author = {Qureshi, W. and Hassan, G. and Kadri, S. M. and Khan, G. Q. and Samuel,
   Bensson and Arshad, Ali},
Title = {{Hyperuricemia and arthralgias during pyrazinamide therapy in patients
   with pulmonary tuberculosis}},
Journal = {{LABMEDICINE}},
Year = {{2007}},
Volume = {{38}},
Number = {{8}},
Pages = {{495-497}},
Month = {{AUG}},
Abstract = {{Background: Pyrazinamide (PZA) is used frequently in monotherapy or in
   combination therapy with isoniazide and rifampicin in the management of
   patients with pulmonary tuberculosis (TB). However, hyperuricemia,
   arthralgia, or symptoms of gout may occur in patients treated long-term
   with PZA. Typically, aspirin therapy is instituted to reduce the
   inflammatory pain associated with arthralgia in patients being treated
   with PZA. The authors determined the incidence of hyperuricemia and
   arthralgias in TB patients treated with combination therapy and the
   effect of aspirin therapy on serum uric acid levels in these patients.
   Methods: The authors enrolled 50 patients categorized as having active
   pulmonary tuberculosis based on clinical history, physical exam
   findings, and related investigations Whole blood samples were obtained
   from these patients before, during, and after combination therapy,
   following discontinuation of combination therapy, and after
   administration of aspirin. Uric acid Was quantified in serum samples
   from all patients using the uricase method in the Hitachi 916 chemistry
   analyzer. The uric acid levels during and after discontinuation of
   combination therapy and after initiation of aspirin therapy were
   determined. In addition, the authors determined the incidence of
   hyperuricemia and arthralgia among these patients.
   Results: Combination therapy resulted in progressive hyperuricemia in
   about 50\% of the patients between the 6th and 8th week of treatment.
   Arthralgia occurred in. 22\%, of these cases. Discontinuation of
   combination therapy and institution of aspirin therapy for 2 weeks
   resulted in the return of uric acid levels to the pretreatment levels in
   these patients.
   Conclusion: Significant, hyperuricemia, with some arthralgia, can occur
   in TB patients treated with combination therapy. Pyrazinamide is the
   most likely component of combination therapy responsible for these
   effec. However, aspirin therapy is effective in controlling joint pain
   in these patients and in reducing their hyperuricemia to normouricemic
   levels. combination therapy remains a useful treatment in the
   managementof patients with pulmonary TB, despite the relatively minimal
   side effects caused by PZA.}},
Publisher = {{AMER SOC CLINICAL PATHOLOGY}},
Address = {{2100 W HARRISON ST, CHICAGO, IL 60612 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Qureshi, W (Reprint Author), SMHS Hosp, Srinagar, Jammu \& Kashmir, India.
   SMHS Hosp, Srinagar, Jammu \& Kashmir, India.
   Govt Med Coll, Dept Med, Srinagar, Jammu \& Kashmir, India.
   Directorate Hlth Serv, Reg Inst Hlth \& Family Welfare, Srinagar, Jammu \& Kashmir, India.
   Karol Marcinkowskeigo Univ Med, Poznan, Poland.}},
DOI = {{10.1309/7GBYQTY62PFEHDP1}},
ISSN = {{0007-5027}},
Keywords-Plus = {{URIC-ACID}},
Research-Areas = {{Medical Laboratory Technology}},
Web-of-Science-Categories  = {{Medical Laboratory Technology}},
Cited-References = {{CULLEN JH, 1956, AM REV TUBERC PULM, V74, P289.
   CULLEN JH, 1957, AM J MED, V23, P587, DOI 10.1016/0002-9343(57)90229-2.
   GUTMAN AB, 1969, AM J MED, V47, P575, DOI 10.1016/0002-9343(69)90188-0.
   Hong Kong Chest Service/British Medical Research Council, 1978, AM REV RESPIR DIS, V118, P219.
   HORSFALL PAL, 1979, TUBERCLE, V60, P13, DOI 10.1016/0041-3879(79)90051-5.
   IYER KN, 1987, INDIAN J TUBERC, V25, P197.
   KELLEY WN, 1975, ANNU REV PHARMACOL, V15, P327, DOI 10.1146/annurev.pa.15.040175.001551.
   KHANA BK, 1991, NIHON KOKYUKI GAKKAI, V38, P21.
   MANDELL GL, GOODMAN GILMANS PHAR, P1155.
   McDermott W., 1954, AM REV TUBERC, V70, P740.
   PETTY TL, 1964, ANN INTERN MED, V60, P898.
   RAGHUPATI SG, 1983, TUBERCLE, V64, P93.
   SHAPIRO M, 1957, AM J MED, V23, P596, DOI 10.1016/0002-9343(57)90230-9.
   Sharma T. N., 1981, INDIAN J TUBERCLE, V28, P92.
   {*}WHO, 2003, TREATM TUB GUID NAT, P87.
   ZIERSKI M, 1980, TUBERCLE, V60, P44.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Labmedicine}},
Doc-Delivery-Number = {{195CZ}},
Unique-ID = {{ISI:000248391400013}},
}

@article{ ISI:000248410200015,
Author = {Senior, Kathryn},
Title = {{Action needed now to prevent resistant tuberculosis}},
Journal = {{LANCET INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{7}},
Number = {{8}},
Pages = {{511}},
Month = {{AUG}},
Publisher = {{LANCET LTD}},
Address = {{84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND}},
Type = {{News Item}},
Language = {{English}},
DOI = {{10.1016/S1473-3099(07)70176-7}},
ISSN = {{1473-3099}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Lancet Infect. Dis.}},
Doc-Delivery-Number = {{195KD}},
Unique-ID = {{ISI:000248410200015}},
}

@article{ ISI:000248819700007,
Author = {Strassburg, Alan and Jafari, Claudia and Greinert, Ulf and Lange,
   Christoph},
Title = {{Clinical diagnostics of pulmonary tuberculosis}},
Journal = {{MEDIZINISCHE KLINIK}},
Year = {{2007}},
Volume = {{102}},
Number = {{8}},
Pages = {{665-675}},
Month = {{AUG}},
Publisher = {{URBAN \& VOGEL}},
Address = {{NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY}},
Type = {{Article}},
Language = {{German}},
Affiliation = {{Strassburg, A (Reprint Author), Forschungsinst Borstel, Med Klin, Christopher Lange Klin Infekt, D-23845 Borstel, Germany.
   Forschungsinst Borstel, Med Klin, Christopher Lange Klin Infekt, D-23845 Borstel, Germany.}},
DOI = {{10.1007/s00063-007-1083-7}},
ISSN = {{0723-5003}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; LATENT TUBERCULOSIS; RAPID DIAGNOSIS;
   INDUCED SPUTUM; INFECTION; SMEAR; TRANSMISSION; METAANALYSIS; UPDATE;
   ASSAY}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{clange@fz-borstel.de}},
ResearcherID-Numbers = {{Lange, Christoph/J-6289-2012}},
Cited-References = {{American Thoracic Society, 2000, MMWR RECOMM REP, V49, P1.
   Anderson ST, 2006, AM J RESP CRIT CARE, V173, P1038, DOI 10.1164/rccm.200509-1526OC.
   Bell D, 2003, J INFECTION, V47, P317, DOI 10.1016/S0163-4453(03)00093-8.
   CANETTI G, 1972, Bulletin of the International Union Against Tuberculosis, V47, P116.
   DANIEL TM, 1990, J LAB CLIN MED, V116, P277.
   Deichgraber K., 1982, PATIENTEN HIPPOKRATE.
   Diel R, 2006, EUR RESPIR J, V28, P35, DOI 10.1183/09031936.06.00011806.
   DIEL R, 2007, PNEUMOLOGIE, V62, P440.
   Ferebee SH, 1969, ADV TUBERC RES, V17, P29.
   Harries AD, 2000, INT J TUBERC LUNG D, V4, P36.
   Hernandez-Garduno E, 2004, THORAX, V59, P286, DOI 10.1136/thx.2003.011759.
   Jafari C, 2006, AM J RESP CRIT CARE, V174, P1048, DOI 10.1164/rccm.200604-465OC.
   Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558.
   KRAUSE AK, 1982, AM REV TUBERC, V18, P271.
   KUBICA T, 2004, DT ARZTBL, V101, pA906.
   Lange C, 2006, DEUT MED WOCHENSCHR, V131, P341, DOI 10.1055/s-2006-932523.
   Lee JY, 2006, EUR RESPIR J, V28, P24, DOI 10.1183/09031936.06.00016906.
   Menzies D, 2007, ANN INTERN MED, V146, P340.
   Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524.
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC.
   Richeldi L, 2006, AM J RESP CRIT CARE, V174, P736, DOI 10.1164/rccm.200509-1516PP.
   {*}ROB KOCH I, 2006, BER EP TUB DEUTSCHL.
   Roth A, 1997, EUR RESPIR J, V10, P1877, DOI 10.1183/09031936.97.10081877.
   Saglam L, 2005, J INT MED RES, V33, P260.
   Schaberg T, 2004, Pneumologie, V58, P255.
   Taylor GM, 2007, MICROBIOL-SGM, V153, P1243, DOI 10.1099/mic.0.2006/002154-0.
   Wang L, 2002, THORAX, V57, P804, DOI 10.1136/thorax.57.9.804.
   Warren JR, 2000, AM J RESP CRIT CARE, V161, P1559.
   White MY, 2006, LANCET, V368, P971, DOI 10.1016/S0140-6736(06)69379-3.
   World Health Organization, 2006, GLOB TUB CONTR SURV, P362.
   Wilkinson KA, 2005, CLIN INFECT DIS, V40, P184, DOI 10.1086/426139.
   WILLCOX PA, 1986, THORAX, V41, P681, DOI 10.1136/thx.41.9.681.
   Wrighton-Smith P, 2006, EUR RESPIR J, V28, P45, DOI 10.1183/09031936.06.00005906.
   Yew WW, 2007, AM J RESP CRIT CARE, V175, P541, DOI 10.1164/rccm.200611-1653UP.
   Zink AR, 2003, J CLIN MICROBIOL, V41, P359, DOI 10.1128/JCM.41.1.359-367.2003.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Med. Klin.}},
Doc-Delivery-Number = {{201GO}},
Unique-ID = {{ISI:000248819700007}},
}

@article{ ISI:000248917900016,
Author = {Nassar, A. F. C. and Miyashiro, S. and Oliveira, C. G. and Pacheco, W.
   A. and Ogata, R. A.},
Title = {{Isolation and identification of bovine tuberculosis in a Brazilian herd
   (Sao Paulo)}},
Journal = {{MEMORIAS DO INSTITUTO OSWALDO CRUZ}},
Year = {{2007}},
Volume = {{102}},
Number = {{5}},
Pages = {{639-642}},
Month = {{AUG}},
Abstract = {{Mycobacterium was verified in animals from a Brazilian dairy herd, a
   total of 42 samples from 30 cows were submitted to culture and the
   isolated strains were analyzed by two polymerase chain reaction ( PCR),
   the first specific for species belonging to the Mycobacterium complex (
   MTBC) and the other for differentiating M. tuberculosis from M. bovis.
   Twenty seven samples ( 64.3\%) from 18 animals ( 60\%) were positive for
   mycobacteria by culture, including samples from 15 retrofaryngeal
   lymphnodes ( 55.5\%), 9 prescapular lymphnodes ( 33.3\%), 2 lungs (
   7.4\%), and 1 liver ( 3.7\%). All isolated colonies were confirmed by
   PCR to contain MTBC organisms, and were identified as M. bovis by the
   same methodology.}},
Publisher = {{FUNDACO OSWALDO CRUZ}},
Address = {{AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Nassar, AFC (Reprint Author), Inst Biol, Av Conselheiro Rodrigues Alves 1252, BR-04014002 Sao Paulo, Brazil.
   Inst Biol, BR-04014002 Sao Paulo, Brazil.
   Coordenadoria Assistencia Tecn Integral, Sao Paulo, Brazil.
   Univ Sao Paulo, Sao Paulo, Brazil.}},
DOI = {{10.1590/S0074-02762007005000073}},
ISSN = {{0074-0276}},
Keywords = {{tuberculosis; bovine; Mycobacterium bovis; intradermal tuberculin test;
   isolation; polymerase chain reaction}},
Keywords-Plus = {{MYCOBACTERIUM-BOVIS; DIFFERENTIATION; PCR}},
Research-Areas = {{Parasitology; Tropical Medicine}},
Web-of-Science-Categories  = {{Parasitology; Tropical Medicine}},
Author-Email = {{nassar@biologico.sp.gov.br}},
ResearcherID-Numbers = {{Ogata, Renato Akio/D-8764-2013
   Nassar, Alessandra/D-8308-2013}},
Cited-References = {{Abrahao RMCM, 1999, ARCH VET SCI, V4, P5.
   Ahmed ASN, 1999, ANIM REPROD SCI, V57, P15, DOI 10.1016/S0378-4320(99)00053-6.
   Araujo Cristina Pires de, 2005, Mem Inst Oswaldo Cruz, V100, P749.
   BERMERMELCHIOR P, 1999, J CLIN MICROBIOL, V37, P2350.
   BOUVET E, 1993, AIDS, V7, P1453, DOI 10.1097/00002030-199311000-00008.
   de los Monteros LEE, 1998, J CLIN MICROBIOL, V36, P239.
   Haddad N, 2004, RES VET SCI, V76, P1, DOI 10.1016/S0034-5288(03)00078-X.
   Ritacco V, 1994, VET MICROBIOL, V40, P5.
   KANTOR IN, 1979, NOTA TECNICA, V11.
   Milian-Suazo F, 2000, AM J VET RES, V61, P86, DOI 10.2460/ajvr.2000.61.86.
   {*}MIN AGR, 2005, PROGR NAC CONTR ERR.
   MONAGHAN ML, 1994, VET MICROBIOL, V40, P111, DOI 10.1016/0378-1135(94)90050-7.
   Shah DH, 2002, FEMS MICROBIOL LETT, V214, P39, DOI 10.1016/S0378-1097(02)00844-3.
   Silva MR, 2006, MEM I OSWALDO CRUZ, V101, P391, DOI 10.1590/S0074-02762006000400008.
   Singh Sandeep Kumar, 2004, J Vet Sci, V5, P331.
   WARDS BJ, 1995, VET MICROBIOL, V43, P227, DOI 10.1016/0378-1135(94)00096-F.
   Zanini M.S., 2001, MEM I O CRUZ, V96, P1.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Mem. Inst. Oswaldo Cruz}},
Doc-Delivery-Number = {{202QK}},
Unique-ID = {{ISI:000248917900016}},
}

@article{ ISI:000249044900006,
Author = {Pouillot, Flavie and Fayolle, Corinne and Carniel, Elisabeth},
Title = {{A putative DNA adenine methyltransferase is involved in Yersinia pseudo
   tuberculosis pathogenicity}},
Journal = {{MICROBIOLOGY-SGM}},
Year = {{2007}},
Volume = {{153}},
Number = {{8}},
Pages = {{2426-2434}},
Month = {{AUG}},
Abstract = {{Some adenine methyltransferases have been shown not only to protect
   specific DNA restriction sites from cleavage by a restriction
   endonuclease, but also to play a role in various bacterial processes and
   sometimes in bacterial virulence. This study focused on a type I
   restriction-modification system (designated yrml) of Y.
   pseudotuberculosis. This system is composed of three adjacent genes
   which could potentially encode an N-6-adenine DNA methylase (YamA), an
   enzyme involved in site-specific recognition (YrsA) and a restriction
   endonuclease (YreA). Screening of 85 isolates of Y. pestis and Y.
   pseudotuberculosis indicated that the yrml system has been lost by Y.
   pestis and that yamA (but not yrsA or yreA) is present in all Y
   pseudotuberculosis strains tested, suggesting that it may be important
   at some stages of the epidemiological cycle of this species. To further
   investigate the role of yamA in Y pseudo tuberculosis survival,
   multiplication or virulence, a Delta yamA mutant of Y pseudotuberculosis
   IP32953 was constructed by allelic exchange with a kanamycin cassette.
   The fact that Delta yamA mutants were obtained indicated that this gene
   is not essential for Y pseudotuberculosis viability. The IP32953 Delta
   yamA mutant strain grew as well as the wild-type in a rich medium at
   both 28 degrees C and 37 degrees C. It also grew normally in a
   chemically defined medium at 28 degrees C, but exhibited a growth defect
   at 37 degrees C. In contrast to the Dam adenine methyltransferase, a
   mutation in yamA did not impair the functions of DNA repair or
   resistance to detergents. However, the Delta yamA mutant exhibited a
   virulence defect in a mouse model of intragastric infection. The in
   silico analysis indicated that the chromosomal region carrying the Y
   pseudotuberculosis yrml locus has been replaced in Y. pestis by a
   horizontally acquired region which potentially encodes another
   methyltransferase. YamA might thus be dispensable for Y. pestis growth
   and virulence because this species has acquired another gene fulfilling
   the same functions.}},
Publisher = {{SOC GENERAL MICROBIOLOGY}},
Address = {{MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Carniel, E (Reprint Author), Inst Pasteur, Yersinia Res Unit, 28 Rue Dr Roux, F-75724 Paris 15, France.
   Inst Pasteur, Yersinia Res Unit, F-75724 Paris 15, France.}},
DOI = {{10.1099/mic.0.2007/005736-0}},
ISSN = {{1350-0872}},
Keywords-Plus = {{RESTRICTION-MODIFICATION SYSTEMS; HELICOBACTER-PYLORI; ESCHERICHIA-COLI;
   DAM MUTANT; METHYLASE MUTANTS; PSEUDOTUBERCULOSIS; GENOME; PESTIS;
   EVOLUTION; SEQUENCE}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{carniel2@pasteur.fr}},
Cited-References = {{Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495.
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389.
   BARRAS F, 1989, TRENDS GENET, V5, P139, DOI 10.1016/0168-9525(89)90054-1.
   Bujnicki Janusz M., 1999, Acta Microbiologica Polonica, V48, P19.
   Chain PSG, 2004, P NATL ACAD SCI USA, V101, P13826, DOI 10.1073/pnas.0401412101.
   CONCHAS RF, 1990, GENE, V87, P133, DOI 10.1016/0378-1119(90)90505-L.
   Derbise A, 2003, FEMS IMMUNOL MED MIC, V38, P113, DOI 10.1016/S0928-8244(03)00181-0.
   Falker S, 2006, J BACTERIOL, V188, P7072, DOI 10.1128/JB.00583-06.
   Handa N, 2000, J BACTERIOL, V182, P2218, DOI 10.1128/JB.182.8.2218-2229.2000.
   Handa N, 1999, BIOCHIMIE, V81, P931.
   Handa N, 2001, MOL MICROBIOL, V40, P932, DOI 10.1046/j.1365-2958.2001.02436.x.
   Heithoff DM, 1999, SCIENCE, V284, P967, DOI 10.1126/science.284.5416.967.
   Heithoff DM, 2001, INFECT IMMUN, V69, P6725, DOI 10.1128/IAI.69.11.6725-6730.2001.
   Heitman J, 1993, Genet Eng (N Y), V15, P57.
   Heusipp G, 2007, INT J MED MICROBIOL, V297, P1, DOI 10.1016/j.ijmm.2006.10.002.
   Hinchliffe SJ, 2003, GENOME RES, V13, P2018, DOI 10.1101/gr.1507303.
   Ibanez M, 1997, GENE, V196, P145, DOI 10.1016/S0378-1119(97)00220-5.
   Jeltsch A, 1996, J MOL EVOL, V42, P91, DOI 10.1007/BF02198833.
   JELTSCH A, 1995, GENE, V160, P7, DOI 10.1016/0378-1119(95)00181-5.
   Jeltsch A, 2003, GENE, V317, P13, DOI 10.1016/S0378-1119(03)00652-8.
   Julio SM, 2002, INFECT IMMUN, V70, P1006, DOI 10.1128/IAI.70.2.1006-1009.2002.
   Julio SM, 2001, INFECT IMMUN, V69, P7610, DOI 10.1128/IAI.69.12.7610-7615.2001.
   KESSLER C, 1990, GENE, V92, P1, DOI 10.1016/0378-1119(90)90486-B.
   Kobayashi I, 2001, NUCLEIC ACIDS RES, V29, P3742, DOI 10.1093/nar/29.18.3742.
   Kong HM, 2000, NUCLEIC ACIDS RES, V28, P3216, DOI 10.1093/nar/28.17.3216.
   KUSANO K, 1995, P NATL ACAD SCI USA, V92, P11095, DOI 10.1073/pnas.92.24.11095.
   MESSER W, 1988, BIOCHIM BIOPHYS ACTA, V951, P351, DOI 10.1016/0167-4781(88)90106-6.
   Murray NE, 2002, MICROBIOL-SGM, V148, P3.
   NAITO T, 1995, SCIENCE, V267, P897, DOI 10.1126/science.7846533.
   Nobusato A, 2000, GENE, V259, P89, DOI 10.1016/S0378-1119(00)00455-8.
   Nobusato Ayaka, 2000, Gene (Amsterdam), V259, P99, DOI 10.1016/S0378-1119(00)00456-X.
   Noyer-Weidner M, 1993, EXS, V64, P39.
   Oshima T, 2002, MOL MICROBIOL, V45, P673, DOI 10.1046/j.1365-2958.2002.03037.x.
   Ostendorf T, 1999, J BACTERIOL, V181, P3880.
   Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083.
   Pouillot F, 2005, MICROBIOL-SGM, V151, P3759, DOI 10.1099/mic.0.28274-0.
   Pucciarelli MG, 2002, MICROBIOL-SGM, V148, P1171.
   REED L. J., 1938, AMER JOUR HYG, V27, P493.
   Roberts RJ, 1998, NUCLEIC ACIDS RES, V26, P338, DOI 10.1093/nar/26.1.338.
   Robinson VL, 2005, FEMS MICROBIOL LETT, V252, P251, DOI 10.1016/j.femsle.2005.09.001.
   Sistla S, 2004, CRIT REV BIOCHEM MOL, V39, P1, DOI 10.1080/10409230490440532.
   Taylor VL, 2005, MICROBIOL-SGM, V151, P1919, DOI 10.1099/mic0.27959-0.
   Tock MR, 2005, CURR OPIN MICROBIOL, V8, P466, DOI 10.1016/j.mib.2005.06.003.
   Wion D, 2006, NAT REV MICROBIOL, V4, P183, DOI 10.1038/nrmicro1350.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Microbiology-(UK)}},
Doc-Delivery-Number = {{204LI}},
Unique-ID = {{ISI:000249044900006}},
}

@article{ ISI:000253299000021,
Author = {Champion, M. and DiGiuseppe, P. and Cox, J.},
Title = {{Quantification of secreted proteins from Mycobacterium tuberculosis
   identifies alternative secretion pathways and elucidates molecular
   mechanisms of secretion}},
Journal = {{MOLECULAR \& CELLULAR PROTEOMICS}},
Year = {{2007}},
Volume = {{6}},
Number = {{8, S}},
Pages = {{22}},
Month = {{AUG}},
Publisher = {{AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Champion, M., Appl Biosyst Inc, Foster City, CA 94404 USA.
   DiGiuseppe, P.; Cox, J., Univ Calif San Francisco, Dept Microbiol \& Immunol, San Francisco, CA 94143 USA.}},
ISSN = {{1535-9476}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemical Research Methods}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Mol. Cell. Proteomics}},
Doc-Delivery-Number = {{264OX}},
Unique-ID = {{ISI:000253299000021}},
}

@article{ ISI:000248484000008,
Author = {Kendall, Sharon L. and Withers, Mike and Soffair, Catherine N. and
   Moreland, Nicole J. and Gurcha, Sudagar and Sidders, Ben and Frita,
   Rosangela and ten Bokum, Annemieke and Besra, Gurdyal S. and Lott, J.
   Shaun and Stoker, Neil G.},
Title = {{A highly conserved transcriptional repressor controls a large regulon
   involved in lipid degradation in Mycobacterium smegmatis and
   Mycobacterium tuberculosis}},
Journal = {{MOLECULAR MICROBIOLOGY}},
Year = {{2007}},
Volume = {{65}},
Number = {{3}},
Pages = {{684-699}},
Month = {{AUG}},
Abstract = {{The Mycobacterium tuberculosis TetR-type regulator Rv3574 has been
   implicated in pathogenesis as it is induced in vivo, and genome-wide
   essentiality studies show it is required for infection. As the gene is
   highly conserved in the mycobacteria, we deleted the Rv3574 orthologue
   in Mycobacterium smegmatis (MSMEG - 6042) and used real-time
   quantitative polymerase chain reaction and microarray analyses to show
   that it represses the transcription both of itself and of a large number
   of genes involved in lipid metabolism. We identified a conserved motif
   within its own promoter (TnnAACnnGTTnnA) and showed that it binds as a
   dimer to 29 bp probes containing the motif. We found 16 and 31 other
   instances of the motif in intergenic regions of M. tuberculosis and M.
   smegmatis respectively. Combining the results of the microarray studies
   with the motif analyses, we predict that Rv3574 directly controls the
   expression of 83 genes in M. smegmatis, and 74 in M. tuberculosis. Many
   of these genes are known to be induced by growth on cholesterol in
   rhodococci, and palmitate in M. tuberculosis. We conclude that this
   regulator, designated elsewhere as kstR, controls the expression of
   genes used for utilizing diverse lipids as energy sources, possibly
   imported through the mce4 system.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Stoker, NG (Reprint Author), Univ London Royal Vet Coll, Dept Pathol \& Infect Dis, Royal Coll St, London NW1 0TU, England.
   Univ London Royal Vet Coll, Dept Pathol \& Infect Dis, London NW1 0TU, England.
   Univ Auckland, Sch Biol Sci, Struct Biol Lab, Auckland 1, New Zealand.
   Univ Auckland, Sch Biol Sci, Maurice Wilkins Ctr Mol Biodivers, Auckland 1, New Zealand.
   Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.
   Univ London London Sch Hyg \& Trop Med, Dept Infect \& Trop Dis, London WC1E 7HT, England.}},
DOI = {{10.1111/j.1365-2958.2007.05827.x}},
ISSN = {{0950-382X}},
Keywords-Plus = {{ARYLAMINE N-ACETYLTRANSFERASE; SIGNAL-TRANSDUCTION SYSTEM; GENOME
   SEQUENCE; MYCOLIC ACIDS; BOVIS BCG; VIRULENCE; MICE; GENE; MACROPHAGES;
   EXPRESSION}},
Research-Areas = {{Biochemistry \& Molecular Biology; Microbiology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Microbiology}},
Author-Email = {{nstoker@rvc.ac.uk}},
ResearcherID-Numbers = {{Stoker, Neil/L-8812-2016
   ten Bokum, Annemieke/N-9097-2013
   }},
ORCID-Numbers = {{Stoker, Neil/0000-0001-7055-6184
   Sidders, Ben/0000-0003-2733-3078
   ten Bokum, Annemieke/0000-0002-7954-7337
   Besra, Gurdyal/0000-0002-5605-0395
   Moreland, Nicole/0000-0001-6548-637X
   Lott, Shaun/0000-0003-3660-452X}},
Funding-Acknowledgement = {{Wellcome Trust {[}073237, 081455]}},
Cited-References = {{Alderwick LJ, 2005, J BIOL CHEM, V280, P32362, DOI 10.1074/jbc.M506339200.
   Anderton MC, 2006, MOL MICROBIOL, V59, P181, DOI 10.1111/j.1365-2958.2005.04945.x.
   Ando M, 2003, INFECT IMMUN, V71, P7170, DOI 10.1128/IAI.71.12.7170-7172.2003.
   ARRUDA S, 1993, SCIENCE, V261, P1454, DOI 10.1126/science.8367727.
   Bailey T L, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P28.
   Bailey TL, 1998, BIOINFORMATICS, V14, P48, DOI 10.1093/bioinformatics/14.1.48.
   Baulard AR, 2000, J BIOL CHEM, V275, P28326.
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289.
   Bhakta S, 2004, J EXP MED, V199, P1191, DOI 10.1084/jem.20031956.
   Bishai W, 2000, NATURE, V406, P683, DOI 10.1038/35021159.
   Burguiere A, 2005, J BIOL CHEM, V280, P42124, DOI 10.1074/jbc.M507500200.
   Calamita H, 2005, CELL MICROBIOL, V7, P233, DOI 10.1111/j.1462-5822.2004.00454.x.
   Camus JC, 2002, MICROBIOL-SGM, V148, P2967.
   Carver TJ, 2005, BIOINFORMATICS, V21, P3422, DOI 10.1093/bioinformatics/bti553.
   Casali N, 2002, INFECT IMMUN, V70, P6846, DOI 10.1128/IAI.70.12.6846-6852.2002.
   CHANG JC, 2007, IN PRESS J INFECT DI.
   Chen P, 2000, INFECT IMMUN, V68, P5575, DOI 10.1128/IAI.68.10.5575-5580.2000.
   Cole ST, 1998, NATURE, V393, P537.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004.
   Dobson G., 1985, CHEM METHODS BACTERI, P237.
   Dover LG, 2004, J MOL BIOL, V340, P1095, DOI 10.1016/jmb.2004.06.003.
   Frenois F, 2004, MOL CELL, V16, P301, DOI 10.1016/j.molcel.2004.09.020.
   Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647.
   Gomez M, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P111.
   Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665.
   Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6.
   Joshi SM, 2006, P NATL ACAD SCI USA, V103, P11760, DOI 10.1073/pnas.0603179103.
   Kendall SL, 2004, TRENDS MICROBIOL, V12, P537, DOI 10.1016/j.tim.2004.10.005.
   Malhotra V, 2004, FEMS MICROBIOL LETT, V231, P237, DOI 10.1016/S0378-1097(04)00002-3.
   Martin C, 2006, VACCINE, V24, P3408, DOI 10.1016/j.vaccine.2006.03.017.
   McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074.
   Mitra D, 2005, TUBERCULOSIS, V85, P337, DOI 10.1016/j.tube.2005.08.010.
   Orth P, 2000, NAT STRUCT BIOL, V7, P215.
   Parish T, 2000, MICROBIOL-UK, V146, P1969.
   Parish T, 1998, METH MOL B, V101, P129, DOI 10.1385/0-89603-471-2:129.
   Parish T, 2003, MICROBIOL-SGM, V149, P1423, DOI 10.1099/mic.0.26245-0.
   Perez E, 2001, MOL MICROBIOL, V41, P179, DOI 10.1046/j.1365-2958.2001.02500.x.
   Ramos JL, 2005, MICROBIOL MOL BIOL R, V69, P326, DOI 10.1128/MMBR.69.2.326-356.2005.
   Rao V, 2006, J CLIN INVEST, V116, P1660, DOI 10.1172/JCI27335.
   Rengarajan J, 2005, P NATL ACAD SCI USA, V102, P8327, DOI 10.1073/pnas.0503272102.
   Reuter M, 1998, J BIOL CHEM, V273, P8294, DOI 10.1074/jbc.273.14.8294.
   Rickman L, 2004, BIOCHEM BIOPH RES CO, V314, P259, DOI 10.1016/j.bbrc.2003.12.082.
   Rosas-Magallanes V, 2007, INFECT IMMUN, V75, P504, DOI 10.1128/IAI.00058-06.
   Russell DG, 2002, J CELL BIOL, V158, P421, DOI 10.1083/jcb.200205034.
   Sandy J, 2002, J MOL BIOL, V318, P1071, DOI 10.1016/S0022-2836(02)00141-9.
   Santangelo MP, 2002, MICROBIOL-SGM, V148, P2997.
   Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100.
   Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846.
   Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020.
   SMYTH GK, 2005, BIOINFORMATICS COMPU, P397, DOI DOI 10.1007/0-387-29362-0\_23.
   SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x.
   Sun RG, 2004, MOL MICROBIOL, V52, P25, DOI 10.1111/j.1365-2958.2003.03958.x.
   Talaat AM, 2004, P NATL ACAD SCI USA, V101, P4602, DOI 10.1073/pnas.0306023101.
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673.
   Uchida Y, 2007, CELL MICROBIOL, V9, P1275, DOI 10.1111/j.1462-5822.2006.00870.x.
   Van der Geize R, 2007, P NATL ACAD SCI USA, V104, P1947, DOI 10.1073/pnas.0605728104.
   Walters SB, 2006, MOL MICROBIOL, V60, P312, DOI 10.1111/j.1365-2958.2006.05102.x.
   Wernisch L, 2003, BIOINFORMATICS, V19, P53, DOI 10.1093/bioinformatics/19.1.53.
   Zahrt TC, 2001, P NATL ACAD SCI USA, V98, P12706, DOI 10.1073/pnas.221272198.}},
Number-of-Cited-References = {{60}},
Times-Cited = {{107}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{9}},
Journal-ISO = {{Mol. Microbiol.}},
Doc-Delivery-Number = {{196LT}},
Unique-ID = {{ISI:000248484000008}},
}

@article{ ISI:000248674600018,
Author = {Stevens, Katherine},
Title = {{Tuberculosis on the run}},
Journal = {{NATURE MEDICINE}},
Year = {{2007}},
Volume = {{13}},
Number = {{8}},
Pages = {{911}},
Month = {{AUG}},
Publisher = {{NATURE PUBLISHING GROUP}},
Address = {{75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA}},
Type = {{News Item}},
Language = {{English}},
ISSN = {{1078-8956}},
Research-Areas = {{Biochemistry \& Molecular Biology; Cell Biology; Research \&
   Experimental Medicine}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Cell Biology; Medicine, Research \&
   Experimental}},
Cited-References = {{CELL, V128, P1287.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Nat. Med.}},
Doc-Delivery-Number = {{199CU}},
Unique-ID = {{ISI:000248674600018}},
}

@article{ ISI:000249612300014,
Author = {Roback, P. and Beard, J. and Baumann, D. and Gille, C. and Henry, K. and
   Krohn, S. and Wiste, H. and Voskuil, M. I. and Rainville, C. and
   Rutherford, R.},
Title = {{A predicted operon map for Mycobacterium tuberculosis}},
Journal = {{NUCLEIC ACIDS RESEARCH}},
Year = {{2007}},
Volume = {{35}},
Number = {{15}},
Pages = {{5085-5095}},
Month = {{AUG}},
Abstract = {{The prediction of operons in Mycobacterium tuberculosis (MTB) is a first
   step toward understanding the regulatory network of this pathogen. Here
   we apply a statistical model using logistic regression to predict
   operons in MTB. As predictors, our model incorporates intergenic
   distance and the correlation of gene expression calculated for adjacent
   gene pairs from over 474 microarray experiments with MTB RNA. We
   validate our findings with known examples from the literature and
   experimentation. From this model, we rank each potential operon pair by
   the strength of evidence for cotranscription, choose a classification
   threshold with a true positive rate of over 90\% at a false positive
   rate of 9.1\%, and use it to construct an operon map for the MTB genome.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rutherford, R (Reprint Author), Seattle Univ, Dept Biol, 901 12th Ave, Redmond, WA 98052 USA.
   Seattle Univ, Dept Biol, Redmond, WA 98052 USA.
   St Olaf Coll, Dept Math Stat \& Comp Sci, Northfield, MN 55057 USA.
   St Olaf Coll, Interdisciplinary Res Ctr, Northfield, MN 55057 USA.
   St Olaf Coll, Dept Biol, Northfield, MN 55057 USA.
   Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Aurora, CO 80045 USA.}},
DOI = {{10.1093/nar/gkm518}},
ISSN = {{0305-1048}},
Keywords-Plus = {{ESCHERICHIA-COLI; GENE-EXPRESSION; GENOME SEQUENCE; SIGMA-FACTORS; MCE3
   OPERON; IN-VIVO; VIRULENCE; TRANSCRIPTION; RESISTANCE; PROMOTERS}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{robertr@seattleu.edu}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}5R01AI061505-02, R01 AI061505]}},
Cited-References = {{AGRESTI A, 1990, CATAGORICAL DATA ANA.
   Ahmad S, 2005, SCAND J IMMUNOL, V62, P16, DOI 10.1111/j.1365-3083.2005.01639.x.
   Bagchi G, 2005, MICROBIOL-SGM, V151, P4045, DOI 10.1099/mic.0.28333-0.
   Banerjee A, 1998, MICROBIOL-SGM, V144, P2697.
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195.
   Bigi F, 2000, MICROBIOL-UK, V146, P1011.
   Bockhorst J, 2003, BIOINFORMATICS, V19, P1227, DOI 10.1093/bioinformatics/btg147.
   Brooks PC, 2001, J BACTERIOL, V183, P4459, DOI 10.1128/JB.183.15.4459-4467.2001.
   Camus JC, 2002, MICROBIOL-SGM, V148, P2967.
   Casali N, 2006, J BACTERIOL, V188, P441, DOI 10.1128/JB.188.2.441-449.2006.
   Cole ST, 1998, NATURE, V393, P537.
   Davis EO, 2002, MOL MICROBIOL, V46, P791, DOI 10.1046/j.1365-2958.2002.03199.x.
   De Hoon M J L, 2004, Pac Symp Biocomput, P276.
   de Hoon MJL, 2005, PLOS COMPUT BIOL, V1, P212, DOI 10.1371/journal.pcbi.0010025.
   Ermolaeva MD, 2001, NUCLEIC ACIDS RES, V29, P1216, DOI 10.1093/nar/29.5.1216.
   Gao LY, 2006, INFECT IMMUN, V74, P1757, DOI 10.1128/IAI.74.3.1757-1767.2006.
   Gardiner-Garden M, 2001, Brief Bioinform, V2, P143, DOI 10.1093/bib/2.2.143.
   Goh KS, 2005, J CLIN MICROBIOL, V43, P4010, DOI 10.1128/JCM.43.8.4010-4014.2005.
   Gomez JE, 1997, TUBERCLE LUNG DIS, V78, P175, DOI 10.1016/S0962-8479(97)90024-1.
   Gopaul KK, 2003, J BACTERIOL, V185, P6005, DOI 10.1128/JB.185.20.6005-6015.2003.
   Hosmer D. W., 2000, APPL LOGISTIC REGRES.
   Kutner MH, 2005, APPL LINEAR STAT MOD.
   LIANG E, 2006, GENOME BIOL, V7, pR46.
   Manganelli R, 2001, MOL MICROBIOL, V41, P423, DOI 10.1046/j.1365-2958.2001.02525.x.
   Manganelli R, 2004, J BACTERIOL, V186, P895, DOI 10.1128/JB.186.4.895-902.2004.
   Milano A, 2004, RES MICROBIOL, V155, P192, DOI 10.1016/j.resmic.2003.11.009.
   Parish T, 2003, MICROBIOL-SGM, V149, P1423, DOI 10.1099/mic.0.26245-0.
   Pasca MR, 2004, ANTIMICROB AGENTS CH, V48, P3175, DOI 10.1128/AAC.48.8.3175-3138.2004.
   Price MN, 2005, NUCLEIC ACIDS RES, V33, P880, DOI 10.1093/nar/gki232.
   Rodriguez GM, 2002, INFECT IMMUN, V70, P3371, DOI 10.1128/IAI.70.7.3371-3381.2002.
   Romero PR, 2004, BIOINFORMATICS, V20, P709, DOI 10.1093/bioinformatics/btg471.
   Rosas-Magallanes V, 2006, MOL BIOL EVOL, V23, P1129, DOI 10.1093/molbev/msj120.
   Sabatti C, 2002, NUCLEIC ACIDS RES, V30, P2886, DOI 10.1093/nar/gkf388.
   Salgado H, 2000, P NATL ACAD SCI USA, V97, P6652, DOI 10.1073/pnas.110147297.
   Salgado H, 2006, NUCLEIC ACIDS RES, V34, pD394, DOI 10.1093/nar/gkj156.
   Santangelo MP, 2002, MICROBIOL-SGM, V148, P2997.
   Sharma K, 2006, J BACTERIOL, V188, P2936, DOI 10.1128/JB.188.8.2936-2944.2006.
   Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498.
   Singh A, 2003, FEMS MICROBIOL LETT, V227, P53, DOI 10.1016/S0378-1097(03)00648-7.
   Torres A, 2001, MICROB PATHOGENESIS, V30, P289, DOI 10.1006/mpat.2001.0434.
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520.
   Tundup S, 2006, FEBS LETT, V580, P1285, DOI 10.1016/k.febslet.2006.01.042.
   Unniraman S, 2002, J BACTERIOL, V184, P5449, DOI 10.1128/JB.184.19.5449-5456.2002.
   Voskuil MI, 2004, TUBERCULOSIS, V84, P256, DOI 10.1016/j.tube.2003.12.014.
   Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{48}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Nucleic Acids Res.}},
Doc-Delivery-Number = {{212QQ}},
Unique-ID = {{ISI:000249612300014}},
}

@article{ ISI:000247971500008,
Author = {Griffith-Richards, Stephanie Barbara and Goussard, Pierre and
   Andronikou, Savvas and Gie, Robert P. and Przybojewski, Stefan J. and
   Strachan, Melanie and Vadachia, Yousuf and Kathan, David L.},
Title = {{Cavitating pulmonary tuberculosis in children: correlating radiology
   with pathogenesis}},
Journal = {{PEDIATRIC RADIOLOGY}},
Year = {{2007}},
Volume = {{37}},
Number = {{8}},
Pages = {{798-804}},
Month = {{AUG}},
Abstract = {{Background Cavitating pulmonary tuberculosis (PTB) is generally known as
   a disease of adults, with children typically having features of primary
   PTB.
   Objective To group children with PTB and cavities according to possible
   pathogenesis by evaluating the clinical and radiological findings.
   Materials and methods The clinical and radiological findings in ten
   randomly selected children with PTB and cavitations on chest radiographs
   were retrospectively reviewed and evaluated.
   Results Three groups emerged: group 1 (four children) had cavities,
   usually single and unilateral in the classic upper lobe distribution of
   postprimary PTB; group 2 (three children) developed progressive primary
   spread of disease with extensive and bilateral pulmonary cavities; and
   group 3 (three children) developed cavities secondary to airway
   obstruction by mediastinal lymph nodes with consequent distal collapse
   and consolidation. Children in group 1 responded well to treatment and
   had unremarkable recoveries. Children in group 2 were all below 2 years
   of age with complicated recoveries. Children in group 3 had frequent
   complications resulting in one fatality.
   Conclusion Cavities in PTB in children may arise by one of three
   possible mechanisms with a relatively equal incidence. A study is
   underway to determine the incidence of cavity formation associated with
   mediastinal lymphadenopathy and airway obstruction.}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING STREET, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Griffith-Richards, SB (Reprint Author), Tygerberg Hosp, Dept Radiol, POB 19063, ZA-7505 Tygerberg, South Africa.
   Tygerberg Hosp, Dept Radiol, ZA-7505 Tygerberg, South Africa.
   Univ Stellenbosch, ZA-7505 Tygerberg, South Africa.}},
DOI = {{10.1007/s00247-007-0496-z}},
ISSN = {{0301-0449}},
Keywords = {{lung; tuberculosis; cavitation; children}},
Keywords-Plus = {{CHILDHOOD; MANIFESTATIONS; FEATURES}},
Research-Areas = {{Pediatrics; Radiology, Nuclear Medicine \& Medical Imaging}},
Web-of-Science-Categories  = {{Pediatrics; Radiology, Nuclear Medicine \& Medical Imaging}},
Author-Email = {{drsteph21@hotmail.com}},
Cited-References = {{AGRONS GA, 1993, SEMIN ROENTGENOL, V28, P158, DOI 10.1016/S0037-198X(05)80105-1.
   CREMIN BJ, 1995, CHILDHOOD TUBERCULOS, P11.
   Goussard P, 2004, PEDIATR PULM, V38, P451, DOI 10.1002/ppul.20119.
   Kisembo HN, 2001, J TROP PEDIATRICS, V47, P276, DOI 10.1093/tropej/47.5.276.
   Koh DM, 2001, CLIN RADIOL, V56, P535, DOI 10.1053/crad.2001.0755.
   LAMONT AC, 1986, PEDIATR RADIOL, V16, P2, DOI 10.1007/BF02387495.
   LEUNG AN, 1992, RADIOLOGY, V182, P87.
   Marais BJ, 2006, INT J TUBERC LUNG D, V10, P259.
   Marais BJ, 2004, PEDIATR RADIOL, V34, P886, DOI 10.1007/s00247-004-1238-0.
   MCADAMS HP, 1995, RADIOL CLIN N AM, V33, P655.
   {*}S AFR DEP HLTH, 2000, S AFR TUB CONTR PROG, P32.
   Shewchuk JR, 2002, PEDIATR RADIOL, V32, P648, DOI 10.1007/s00247-002-0769-5.
   Weber HC, 2000, ANN TROP PAEDIATR, V20, P5, DOI 10.1080/02724930091995.}},
Number-of-Cited-References = {{13}},
Times-Cited = {{11}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Pediatr. Radiol.}},
Doc-Delivery-Number = {{189EF}},
Unique-ID = {{ISI:000247971500008}},
}

@article{ ISI:000249395900033,
Author = {Tosdemir, D. and Topaloglu, B. and Perozzo, R. and Brun, R. and O'Neill,
   R. and Corbolleiro, N. M. and Zhang, X. and Tonge, P. and Rueedi, P.},
Title = {{The first marine natural products from Agelas oroides inhibiting the
   Fabl enzymes from Plasmodium falciparum, Mycobacterium tuberculosis and
   Escherichia coli}},
Journal = {{PLANTA MEDICA}},
Year = {{2007}},
Volume = {{73}},
Number = {{9}},
Meeting = {{SL013}},
Pages = {{807-808}},
Month = {{AUG}},
Note = {{55th Annual Congress of the Society-for-Medicinal-Plant-Research, Karl
   Franzens Univ, Graz, AUSTRIA, SEP 02-06, 2007}},
Organization = {{Soc Med Plant Res}},
Publisher = {{GEORG THIEME VERLAG KG}},
Address = {{RUDIGERSTR 14, D-70469 STUTTGART, GERMANY}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Univ London, Sch Pharm, Ctr Pharmacognosy Phytotherapy, London WC1N 1AX, England.
   Univ Istanbul, Fac Fisheries, TR-34480 Istanbul, Turkey.
   Univ Geneva, Sch Pharmaceut Sci, CH-1211 Geneva, Switzerland.
   Swiss Trop Inst, CH-4002 Basel, Switzerland.
   Univ Puerto Rico, Dept Chem, Rio Piedras, PR 00931 USA.
   SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.
   Univ Zurich, Inst Organ Chem, CH-8006 Zurich, Switzerland.}},
ISSN = {{0032-0943}},
Research-Areas = {{Plant Sciences; Pharmacology \& Pharmacy; Integrative \& Complementary
   Medicine}},
Web-of-Science-Categories  = {{Plant Sciences; Chemistry, Medicinal; Integrative \& Complementary
   Medicine; Pharmacology \& Pharmacy}},
ResearcherID-Numbers = {{Tonge, Peter/A-7443-2009}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Planta Med.}},
Doc-Delivery-Number = {{209NS}},
Unique-ID = {{ISI:000249395900033}},
}

@article{ ISI:000249395900269,
Author = {McGaw, L. J. and Lall, N. and Hlokwe, T. and Michel, A. and Meyer, J. J.
   M. and Eloff, J. N.},
Title = {{Bovine tuberculosis: a zoonotic target for medicinal plants}},
Journal = {{PLANTA MEDICA}},
Year = {{2007}},
Volume = {{73}},
Number = {{9}},
Meeting = {{P 186}},
Pages = {{882}},
Month = {{AUG}},
Note = {{55th Annual Congress of the Society-for-Medicinal-Plant-Research, Karl
   Franzens Univ, Graz, AUSTRIA, SEP 02-06, 2007}},
Organization = {{Soc Med Plant Res}},
Publisher = {{GEORG THIEME VERLAG KG}},
Address = {{RUDIGERSTR 14, D-70469 STUTTGART, GERMANY}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Univ Pretoria, Fac Vet Sci, Dept Paraclin Sci, Phytomed Programme, ZA-0110 Onderstepoort, South Africa.
   Univ Pretoria, Dept Bot, ZA-0002 Pretoria, South Africa.
   ARC Onderstepoort Vet Inst, TB Lab, ZA-0110 Onderstepoort, South Africa.}},
ISSN = {{0032-0943}},
Research-Areas = {{Plant Sciences; Pharmacology \& Pharmacy; Integrative \& Complementary
   Medicine}},
Web-of-Science-Categories  = {{Plant Sciences; Chemistry, Medicinal; Integrative \& Complementary
   Medicine; Pharmacology \& Pharmacy}},
ResearcherID-Numbers = {{Meyer, Marion/E-3042-2010
   Eloff, Jacobus/E-6204-2012
   Michel, Anita/N-8996-2014}},
ORCID-Numbers = {{Michel, Anita/0000-0001-9240-2653}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Planta Med.}},
Doc-Delivery-Number = {{209NS}},
Unique-ID = {{ISI:000249395900269}},
}

@article{ ISI:000249395900275,
Author = {Hassouna, R. A. and Khalid, A. S. and Khalid, V, H.},
Title = {{Screening of some Sudanese plants against Mycobacterium tuberculosis}},
Journal = {{PLANTA MEDICA}},
Year = {{2007}},
Volume = {{73}},
Number = {{9}},
Meeting = {{P 192}},
Pages = {{884}},
Month = {{AUG}},
Note = {{55th Annual Congress of the Society-for-Medicinal-Plant-Research, Karl
   Franzens Univ, Graz, AUSTRIA, SEP 02-06, 2007}},
Organization = {{Soc Med Plant Res}},
Publisher = {{GEORG THIEME VERLAG KG}},
Address = {{RUDIGERSTR 14, D-70469 STUTTGART, GERMANY}},
Type = {{Meeting Abstract}},
Language = {{English}},
ISSN = {{0032-0943}},
Research-Areas = {{Plant Sciences; Pharmacology \& Pharmacy; Integrative \& Complementary
   Medicine}},
Web-of-Science-Categories  = {{Plant Sciences; Chemistry, Medicinal; Integrative \& Complementary
   Medicine; Pharmacology \& Pharmacy}},
Cited-References = {{Cruickshank R., 1975, MED MICROBIOLOGY, V2.
   KHALID EA, 2003, COMMUNICATION.}},
Number-of-Cited-References = {{2}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Planta Med.}},
Doc-Delivery-Number = {{209NS}},
Unique-ID = {{ISI:000249395900275}},
}

@article{ ISI:000249107900005,
Author = {Brennan, Michael J. and Fruth, Uli and Milstien, Julie and Tiernan,
   Rosemary and Nishioka, Sergio de Andrade and Chocarro, Liliana and
   Developing Countries Vaccine Regul and Ad Hoc Regulatory and TB Expert
   Panel},
Title = {{Development of new tuberculosis vaccines: A global perspective on
   regulatory issues}},
Journal = {{PLOS MEDICINE}},
Year = {{2007}},
Volume = {{4}},
Number = {{8}},
Pages = {{1299-1302}},
Month = {{AUG}},
Publisher = {{PUBLIC LIBRARY SCIENCE}},
Address = {{185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Brennan, MJ (Reprint Author), US FDA, Ctr Biol Evaluat \& Res, Off Vaccines Res \& Review, Rockville, MD 20857 USA.
   US FDA, Ctr Biol Evaluat \& Res, Off Vaccines Res \& Review, Rockville, MD 20857 USA.
   WHO, Initiat Vaccine Res, CH-1211 Geneva, Switzerland.
   Univ Maryland, Sch Med, Dept Geograph Med, Montpellier, France.
   US FDA, Ctr Biol Evaluat \& Res, Div Vaccines \& Related Prod Applicat, Rockville, MD USA.
   Natl Hlth Surveillance Agcy ANVISA, Ctr Surveillance Adverse Events \& Qual Deviat, Brasilia, DF, Brazil.
   WHO, CH-1211 Geneva, Switzerland.}},
DOI = {{10.1371/journal.pmed.0040252}},
Article-Number = {{e252}},
ISSN = {{1549-1277}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; CLINICAL-TRIALS; TB VACCINES; STRATEGIES;
   PROTEIN; PROTECTION; IMMUNITY; ESAT-6}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{Michael.Brennan@fda.hhs.gov}},
Cited-References = {{Andersen P, 2005, MICROBES INFECT, V7, P911, DOI 10.1016/j.micinf.2005.03.013.
   Brennan MJ, 2005, TUBERCULOSIS, V85, P7, DOI 10.1016/j.tube.2004.09.001.
   Brennan MJ, 2004, EXPERT OPIN BIOL TH, V4, P1493, DOI 10.1517/14712598.4.9.1493.
   Fruth U, 2004, INT J TUBERC LUNG D, V8, P151.
   Hess J, 1998, P NATL ACAD SCI USA, V95, P5299, DOI 10.1073/pnas.95.9.5299.
   Horwitz MA, 2000, P NATL ACAD SCI USA, V97, P13853, DOI 10.1073/pnas.250480397.
   Ibango HB, 2006, LANCET INFECT DIS, V6, P522, DOI 10.1016/S1473-3099(06)70552-7.
   Kamath AT, 2005, VACCINE, V23, P3753, DOI 10.1016/j.vaccine.2005.03.001.
   McShane H, 2005, MICROBES INFECT, V7, P962, DOI 10.1016/j.micinf.2005.03.009.
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128.
   Olsen AW, 2001, INFECT IMMUN, V69, P2773, DOI 10.1128/IAI.69.5.2773-2778.2001.
   Perez E, 2001, MOL MICROBIOL, V41, P179, DOI 10.1046/j.1365-2958.2001.02500.x.
   Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859.
   Rowland SS, 2005, TUBERCULOSIS, V85, P39, DOI 10.1016/j.tube.2004.09.012.
   Sambandamurthy VK, 2005, MICROBES INFECT, V7, P955, DOI 10.1016/j.micinf.2005.04.001.
   Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419.
   Skeiky YAW, 2004, J IMMUNOL, V172, P7618.
   World Health Organization, 2003, WHO GUID NONC EV VAC, V1.
   Young D, 2006, CELL, V124, P683, DOI 10.1016/j.cell.2006.02.013.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{34}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{PLos Med.}},
Doc-Delivery-Number = {{205IT}},
Unique-ID = {{ISI:000249107900005}},
}

@article{ ISI:000249107900019,
Author = {Steingart, Karen R. and Henry, Megan and Laal, Suman and Hopewell,
   Philip C. and Ramsay, Andrew and Menzies, Dick and Cunningham, Jane and
   Weldingh, Karin and Pai, Madhukar},
Title = {{Commercial serological antibody detection tests for the diagnosis of
   pulmonary tuberculosis: A systematic review (vol 4, art no e202, 2007)}},
Journal = {{PLOS MEDICINE}},
Year = {{2007}},
Volume = {{4}},
Number = {{8}},
Pages = {{1417}},
Month = {{AUG}},
Publisher = {{PUBLIC LIBRARY SCIENCE}},
Address = {{185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA}},
Type = {{Correction}},
Language = {{English}},
DOI = {{10.1371/journal.pmed.0040254}},
Article-Number = {{e254}},
ISSN = {{1549-1277}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{Steingart KR, 2007, PLOS MED, V4, P1041, DOI 10.1371/journal.pmed.0040202.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{PLos Med.}},
Doc-Delivery-Number = {{205IT}},
Unique-ID = {{ISI:000249107900019}},
}

@article{ ISI:000248360600011,
Author = {Kruh, Nicole A. and Rawat, Richa and Ruzsicska, Bela P. and Tonge, Peter
   J.},
Title = {{Probing mechanisms of resistance to the tuberculosis drug isoniazid:
   Conformational changes caused by inhibition of InhA, the enoyl reductase
   from Mycobacterium tuberculosis}},
Journal = {{PROTEIN SCIENCE}},
Year = {{2007}},
Volume = {{16}},
Number = {{8}},
Pages = {{1617-1627}},
Month = {{AUG}},
Abstract = {{The frontline tuberculosis drug isoniazid (INH) inhibits InhA, the
   NADH-dependent fatty acid biosynthesis (FAS-II) enoyl reductase from
   Mycobacterium tuberculosis (MTB), via formation of a covalent adduct
   with NAD(+) (the INH- NAD adduct). Resistance to INH can be correlated
   with many mutations in MTB, some of which are localized in the InhA
   cofactor binding site. While the InhA mutations cause a substantial
   decrease in the affinity of InhA for NADH, surprisingly the same
   mutations result in only a small impact on binding of the INH-NAD
   adduct. Based on the knowledge that InhA interacts in vivo with other
   components of the FAS-II pathway, we have initiated experiments to
   determine whether enzyme inhibition results in structural changes that
   could affect protein - protein interactions involving InhA and how these
   ligand-induced conformational changes are modulated in the InhA mutants.
   Significantly, while NADH binding to wild-type InhA is hyperbolic, the
   InhA mutants bind the cofactor with positive cooperativity, suggesting
   that the mutations permit access to a second conformational state of the
   protein. While cross-linking studies indicate that enzyme inhibition
   causes dissociation of the InhA tetramer into dimers, analytical
   ultracentrifugation and size exclusion chromatography reveal that ligand
   binding causes a conformational change in the protein that prevents
   cross-linking across one of the dimer - dimer interfaces in the InhA
   tetramer. Interestingly, a similar ligand-induced conformational change
   is also observed for the InhA mutants, indicating that the mutations
   modulate communication between the subunits without affecting the two
   conformational states of the protein that are present.}},
Publisher = {{COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT}},
Address = {{500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tonge, PJ (Reprint Author), SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.
   SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.
   SUNY Stony Brook, Grad Program Mol Genet \& Microbiol, Stony Brook, NY 11794 USA.
   SUNY Stony Brook, Inst Chem Biol \& Drug Discovery, Stony Brook, NY 11794 USA.}},
DOI = {{10.1110/ps.062749007}},
ISSN = {{0961-8368}},
Keywords = {{enoyl reductase; InhA; fatty acid synthesis; isoniazid; Mycobacterium
   tuberculosis}},
Keywords-Plus = {{PROTEIN-PROTEIN INTERACTIONS; ACID ELONGATION SYSTEM; ENZYMATIC
   CHARACTERIZATION; CRYSTAL-STRUCTURE; MYCOLIC ACIDS; ACP REDUCTASE; LAMM
   EQUATION; FAS-II; TARGET; SYNTHASE}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{peter.tonge@sunysb.edu}},
ResearcherID-Numbers = {{Tonge, Peter/A-7443-2009
   Kruh-Garcia, Nicole/D-5853-2017}},
ORCID-Numbers = {{Kruh-Garcia, Nicole/0000-0002-9896-8380}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}HHSN266200400091C, AI44639, T32 AI007539, R01 AI044639,
   R21 AI044639]; PHS HHS {[}HHSN266200400091C]}},
Cited-References = {{Argyrou A, 2006, NAT STRUCT MOL BIOL, V13, P408, DOI 10.1038/nsmb1089.
   BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673.
   Basso LA, 1998, J INFECT DIS, V178, P769.
   Dam J, 2004, METHOD ENZYMOL, V384, P185.
   DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450.
   Heymann DL, 2006, CELL, V124, P671, DOI 10.1016/j.cell.2006.02.009.
   Kremer L, 2003, J BIOL CHEM, V278, P20547, DOI 10.1074/jbc.M302435200.
   Larsen MH, 2002, MOL MICROBIOL, V46, P453, DOI 10.1046/j.1365-2958.2002.03162.x.
   Marrakchi H, 2000, MICROBIOL-UK, V146, P289.
   Marrakchi H, 2002, MICROBIOL-SGM, V148, P951.
   Mdluli K, 1996, J INFECT DIS, V174, P1085.
   Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607.
   MIDDLEBROOK G, 1952, AM REV TUBERC PULM, V65, P765.
   ODRIOZOLA JM, 1977, BIOCHIM BIOPHYS ACTA, V488, P207, DOI 10.1016/0005-2760(77)90178-3.
   Parikh S, 1999, BIOCHEMISTRY-US, V38, P13623, DOI 10.1021/bi990529c.
   QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004.
   Rawat R, 2003, P NATL ACAD SCI USA, V100, P13881, DOI 10.1073/pnas.2235848100.
   Rozwarski DA, 1999, J BIOL CHEM, V274, P15582, DOI 10.1074/jbc.274.22.15582.
   Savvides SN, 2003, EMBO J, V22, P1969, DOI 10.1093/emboj/cdg223.
   Schuck P, 1998, BIOPHYS J, V75, P1503.
   Schuck P, 2000, BIOPHYS J, V78, P1606.
   Slayden RA, 2000, MOL MICROBIOL, V38, P514, DOI 10.1046/j.1365-2958.2000.02145.x.
   TAKAYAMA K, 1975, J LIPID RES, V16, P308.
   Veyron-Churlet R, 2005, J MOL BIOL, V353, P847, DOI 10.1016/j.jmb.2005.09.016.
   Veyron-Churlet R, 2004, MOL MICROBIOL, V54, P1161, DOI 10.1111/j.1365-2958.2004.04334.x.
   Vilcheze C, 2000, J BACTERIOL, V182, P4059, DOI 10.1128/JB.182.14.4059-4067.2000.
   Vilcheze C, 2006, NAT MED, V12, P1027, DOI 10.1038/nm1466.
   {*}WHO, 2003, GLOB TB CONTR REP.
   ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{12}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{9}},
Journal-ISO = {{Protein Sci.}},
Doc-Delivery-Number = {{194RD}},
Unique-ID = {{ISI:000248360600011}},
}

@article{ ISI:000248360600019,
Author = {Sousa, Eduardo Henrique Silva and Tuckerman, Jason Robert and Gonzalez,
   Gonzalo and Gilles-Gonzalez, Marie-Alda},
Title = {{DosT and DevS are oxygen-switched kinases in Mycobacterium tuberculosis}},
Journal = {{PROTEIN SCIENCE}},
Year = {{2007}},
Volume = {{16}},
Number = {{8}},
Pages = {{1708-1719}},
Month = {{AUG}},
Abstract = {{Exposure of Mycobacterium tuberculosis to hypoxia is known to alter the
   expression of many genes, including ones thought to be involved in
   latency, via the transcription factor DevR (also called DosR). Two
   sensory kinases, DosT and DevS (also called DosS), control the activity
   of DevR. We show that, like DevS, DosT contains a heme cofactor within
   an N-terminal GAF domain. For full-length DosT and DevS, we determined
   the ligand- binding parameters and the rates of ATP reaction with the
   liganded and unliganded states. In both proteins, the heme state was
   coupled to the kinase such that the unliganded, CO-bound, and NO-bound
   forms were active, but the O-2-bound form was inactive. Oxygen-bound
   DosT was unusually inert to oxidation to the ferric state ( half life in
   air > 60 h). Though the kinase activity of DosT was unaffected by NO,
   this ligand bound 5000 times more avidly than O-2 to DosT (K-d {[}NO]
   similar to 5 nM versus K-d {[}O-2] = 26 mu M). These results demonstrate
   direct and specific O-2 sensing by proteins in M. tuberculosis and
   identify for the first time a signal ligand for a sensory kinase from
   this organism. They also explain why exposure of M. tuberculosis to NO
   donors under aerobic conditions can give results identical to hypoxia,
   i.e., NO saturates DosT, preventing O-2 binding and yielding an active
   kinase.}},
Publisher = {{WILEY-BLACKWELL}},
Address = {{111 RIVER ST, HOBOKEN 07030-5774, NJ USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Gilles-Gonzalez, MA (Reprint Author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA.}},
DOI = {{10.1110/ps.072897707}},
ISSN = {{0961-8368}},
EISSN = {{1469-896X}},
Keywords = {{FixL; GAF domain; heme-based sensor; histidine-protein kinase;
   host-microbe interactions; oxygen sensor; sensor kinase; response
   regulator; signal transduction}},
Keywords-Plus = {{SPERM-WHALE MYOGLOBIN; HEME-BASED SENSORS; 2-COMPONENT SYSTEM;
   RHIZOBIUM-MELILOTI; HYPOXIC RESPONSE; GENE-EXPRESSION; LIGAND-BINDING;
   NITRIC-OXIDE; NONREPLICATING PERSISTENCE; SIGNAL-TRANSDUCTION}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{marie-alda.gilles-gonzalez@utsouthwestern.edu}},
ResearcherID-Numbers = {{Sousa, Eduardo/J-8167-2014}},
ORCID-Numbers = {{Sousa, Eduardo/0000-0002-0007-8452}},
Cited-References = {{Appleby C. A., 1980, Methods for evaluating biological nitrogen fixation., P315.
   Bagchi G, 2005, MICROBIOL-SGM, V151, P4045, DOI 10.1099/mic.0.28333-0.
   BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995.
   Brencic A, 2005, MICROBIOL MOL BIOL R, V69, P155, DOI 10.1128/MMBR.69.1.155-194.2005.
   Cevallos MA, 1996, J BACTERIOL, V178, P1646.
   Chan ED, 2001, AM J RESP CELL MOL, V25, P606.
   Chan J, 2004, CLIN IMMUNOL, V110, P2, DOI 10.1016/S1521-6616(03)00210-9.
   Cole ST, 1998, NATURE, V393, P537.
   Da Re S, 1999, MOL MICROBIOL, V34, P504, DOI 10.1046/j.1365-2958.1999.01614.x.
   Dasgupta N, 2000, TUBERCLE LUNG DIS, V80, P141, DOI 10.1054/tuld.2000.0240.
   DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6.
   Dixon R, 2004, NAT REV MICROBIOL, V2, P621, DOI 10.1038/nrmicro954.
   Dunham CM, 2003, BIOCHEMISTRY-US, V42, P7701, DOI 10.1021/bi0343370.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   FISCHER HM, 1994, MICROBIOL REV, V58, P352.
   Florczyk MA, 2003, INFECT IMMUN, V71, P5332, DOI 10.1128/IAI.71.9.5332-5343.2003.
   Flynn JL, 2005, TRENDS MICROBIOL, V13, P98, DOI 10.1016/j.tim.2005.01.005.
   Gilles-Gonzalez MA, 2005, J INORG BIOCHEM, V99, P1, DOI 10.1016/j.jinorgbio.2004.11.006.
   GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011.
   GILLESGONZALEZ MA, 1995, BIOCHEMISTRY-US, V34, P232, DOI 10.1021/bi00001a027.
   GILLESGONZALEZ MA, 1993, J BIOL CHEM, V268, P16293.
   GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0.
   Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177.
   Gonzalez G, 1998, BIOCHEMISTRY-US, V37, P10188, DOI 10.1021/bi980529x.
   HAAPANEN JH, 1959, AM REV RESPIR DIS, V80, P1.
   Ioanoviciu A, 2007, BIOCHEMISTRY-US, V46, P4250, DOI 10.1021/bi602422p.
   Kohler S, 2002, P NATL ACAD SCI USA, V99, P15711, DOI 10.1073/pnas.232454299.
   Kwon O. Jung, 1997, Journal of Korean Medical Science, V12, P481.
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0.
   Malhotra V, 2004, FEMS MICROBIOL LETT, V231, P237, DOI 10.1016/S0378-1097(04)00002-3.
   Matsoso LG, 2005, J BACTERIOL, V187, P6300, DOI 10.1128/JB.187.18.6300-6308.2005.
   Muttucumaru DGN, 2004, TUBERCULOSIS, V84, P239, DOI 10.1016/j.tube.2003.12.006.
   Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841.
   Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169.
   Parish T, 2003, INFECT IMMUN, V71, P1134, DOI 10.1128/IAI.71.3.1134-1140.2003.
   Park HD, 2003, MOL MICROBIOL, V48, P833, DOI 10.1046/j.1365-2958.2003.03474.x.
   QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569.
   Reed MB, 2007, J BACTERIOL, V189, P2583, DOI 10.1128/JB.01670-06.
   Roberts DM, 2004, J BIOL CHEM, V279, P23082, DOI 10.1074/jbc.M401230200.
   ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168.
   Saini DK, 2004, FEBS LETT, V565, P75, DOI 10.1016/j.febslet.2004.02.092.
   Saini DK, 2004, MICROBIOL-SGM, V150, P865, DOI 10.1099/mic.0.26218-0.
   Saini DK, 2002, PROTEIN EXPRES PURIF, V25, P203, DOI 10.1006/prep.2002.1628.
   Sardiwal S, 2005, J MOL BIOL, V353, P929, DOI 10.1016/j.jmb.2005.09.011.
   Schnappinger D, 2006, MICROBES INFECT, V8, P1132, DOI 10.1016/j.micinf.2005.10.027.
   SCHNAPPINGER D, 2003, J BACTERIOL, V185, P693.
   Sharma D, 2006, FEMS IMMUNOL MED MIC, V48, P329, DOI 10.1111/j.1574-695X.2006.00160.x.
   Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498.
   Shiloh MU, 2000, CURR OPIN MICROBIOL, V3, P35, DOI 10.1016/S1369-5274(99)00048-X.
   Singh A, 2006, P NATL ACAD SCI USA, V103, P11346, DOI 10.1073/pnas.0602817103.
   Sohaskey CD, 2005, MICROBIOL-SGM, V151, P3803, DOI 10.1099/mic.0.28263-0.
   Sousa EHS, 2007, BIOCHEMISTRY-US, V46, P6249, DOI 10.1021/bi7003334.
   Sousa EHS, 2005, BIOCHEMISTRY-US, V44, P15359, DOI 10.1021/bi051661h.
   TALAAT AM, 2007, P NATL ACAD SCI USA, V46, P6249.
   Timm J, 2003, P NATL ACAD SCI USA, V100, P14321, DOI 10.1073/pnas.2436197100.
   Tuckerman JR, 2002, BIOCHEMISTRY-US, V41, P6170, DOI 10.1021/bi025628w.
   Voskuil MI, 2004, TUBERCULOSIS, V84, P218, DOI 10.1016/j.tube.2004.02.003.
   Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205.
   Wayne LG, 1996, INFECT IMMUN, V64, P2062.
   Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139.}},
Number-of-Cited-References = {{60}},
Times-Cited = {{84}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{Protein Sci.}},
Doc-Delivery-Number = {{194RD}},
Unique-ID = {{ISI:000248360600019}},
}

@article{ ISI:000247451700009,
Author = {Corner, L. A. L. and Costello, E. and Lesellier, S. and O'Meara, D. and
   Sleeman, D. P. and Gormley, E.},
Title = {{Experimental tuberculosis in the European, badger (Meles meles) after
   endobronchial inoculation of Mycobacterium bovis: I. Pathology and
   bacteriology}},
Journal = {{RESEARCH IN VETERINARY SCIENCE}},
Year = {{2007}},
Volume = {{83}},
Number = {{1}},
Pages = {{53-62}},
Month = {{AUG}},
Abstract = {{The aim was to develop an endobronchial infection procedure for the
   study of Mycobacterium bovis infection in badgers. The badgers were
   anaesthetised and a cannula was passed per os to the tracheal
   bifurcation. When in place 1 ml of M. bovis suspension was inoculated.
   Three concentrations of M. bovis suspension were used; < 10 colony
   forming units (cfu), similar to 10(2) cfu and similar to 3 x 10(3) cfu.
   The badgers were examined at three weekly intervals for clinical signs
   of disease and a tracheal aspirate was collected at each examination.
   The badgers were euthanased 17 weeks post infection (pi) and at the post
   mortem examination a wide range of tissues were examined for gross and
   histopathological lesions of tuberculosis and cultured for M. bovis. A
   sample of bronchial alveolar lavage (BAL) fluid was collected at post
   mortem for culture.
   At post mortem examination 17 weeks after infection, gross and
   histopathological lesions of tuberculosis were observed in all badgers
   inoculated with the high and medium dose and 1/3 inoculated with the low
   dose. M. bovis was recovered from all inoculated badgers. Infection in
   the high dose group was more widely disseminated than in the other
   groups. The number of sites with gross and histopathological lesions
   increased with increasing dose of M. bovis. All tracheal aspirates were
   negative on culture and only one BAL, collected from a badger of the
   high dose group, was positive on culture. No clinical signs due to the
   experimental infection were observed.
   The endobronchial route of inoculation is an effective route for
   establishing experimental infection, and could be used for studies of
   tuberculosis pathogenesis, immunology of M. bovis infection in badgers
   and for challenging badgers in vaccine protection studies. Badgers
   appeared to be very susceptible to infection by this procedure even with
   a dose of < 10 cfu but appear to control and limit the resulting
   infection. (c) 2006 Elsevier Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Corner, LAL (Reprint Author), Univ Coll Dublin, Sch Agr Food Sci \& Vet Med, Large Anim Clin Studies, Stillorgan Rd, Dublin 2, Ireland.
   Univ Coll Dublin, Sch Agr Food Sci \& Vet Med, Large Anim Clin Studies, Dublin 2, Ireland.
   Cent Vet Res Labs, Dept Agr \& Food, Dublin, Ireland.
   Univ Coll Cork, Dept Zool Ecol \& Plant Sci, Cork, Ireland.}},
DOI = {{10.1016/j.rvse.2006.10.016}},
ISSN = {{0034-5288}},
Keywords = {{badger; tuberculosis; Mycobacterium bovis; endobronchial infection;
   experimental infection; pathogenesis}},
Keywords-Plus = {{ORAL VACCINATION; POPULATION; CATTLE; BCG; PROTECTION; CHALLENGE;
   INFECTION; IRELAND; PROGRAM; POSSUMS}},
Research-Areas = {{Veterinary Sciences}},
Web-of-Science-Categories  = {{Veterinary Sciences}},
Author-Email = {{leigh.corner@ucd.ie}},
ResearcherID-Numbers = {{Lesellier, Sandrine/C-9508-2011}},
Cited-References = {{Aldwell FE, 1995, NEW ZEAL VET J, V43, P356, DOI 10.1080/00480169./1995.35920.
   Aldwell FE, 2003, VACCINE, V22, P70, DOI 10.1016/S0264-410X(03)00539-5.
   BUDDLE BM, 1995, RES VET SCI, V59, P10, DOI 10.1016/0034-5288(95)90023-3.
   CLIFTONHADLEY RS, 1993, EPIDEMIOL INFECT, V111, P9.
   COLLINS CH, 1997, CULTURAL METHODS TUB.
   Dean GS, 2005, INFECT IMMUN, V73, P6467, DOI 10.1128/IAI.73.10.6467-6471.2005.
   DELISLE GW, 1983, NEW ZEAL VET J, V31, P213, DOI 10.1080/00480169.1983.35037.
   Dolan L.A., 1993, P108.
   GALLAGHER J, 1976, VET REC, V98, P9.
   Gallagher J, 1998, VET REC, V142, P710.
   GALLAGHER J, 1977, J HYG-CAMBRIDGE, V79, P155.
   Gallagher J, 2000, RES VET SCI, V69, P203, DOI 10.1053/rvsc.2000.0422.
   Gavier-Widen D, 2001, VET REC, V148, P299.
   Gormley E, 2000, TUBERCLE LUNG DIS, V80, P229, DOI 10.1021/tuld.2000.0250.
   GRIFFIN JM, 2005, PREVENTIVE VET MED.
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907.
   LITTLE TWA, 1982, VET REC, V111, P550.
   MAHMOOD KH, 1987, EPIDEMIOL INFECT, V98, P155.
   NOLAN A, 1994, VET MICROBIOL, V40, P179, DOI 10.1016/0378-1135(94)90054-X.
   O Mairtin D, 1998, PREV VET MED, V35, P79, DOI 10.1016/S0167-5877(98)00056-7.
   O Mairtin D, 1998, PREV VET MED, V34, P47.
   OBOYLE I, 2002, SELECTED PAPERS 2000, P19.
   Palmer MV, 2001, AM J VET RES, V62, P692, DOI 10.2460/ajvr.2001.62.692.
   PFEFFER A, 1994, J COMP PATHOL, V111, P353, DOI 10.1016/S0021-9975(05)80094-5.
   Qureshi T, 1999, INT J TUBERC LUNG D, V3, P1025.
   Wilkinson D, 2000, J ZOOL, V250, P389, DOI 10.1017/S0952836900003113.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{36}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Res. Vet. Sci.}},
Doc-Delivery-Number = {{181QR}},
Unique-ID = {{ISI:000247451700009}},
}

@article{ ISI:000248406900027,
Author = {Raimondi, Gianfranco and Contini, Silvia and Legramante, Jacopo Maria
   and Bocchino, Marialuisa and Sacco, Sergio and Pallante, Marco and
   Cazzola, Mario and Saltini, Cesare},
Title = {{Autonomic nervous system dysfunction in the course of active pulmonary
   tuberculosis}},
Journal = {{RESPIRATORY MEDICINE}},
Year = {{2007}},
Volume = {{101}},
Number = {{8}},
Pages = {{1804-1808}},
Month = {{AUG}},
Abstract = {{Background: Functional alterations of the autonomic nervous system have
   been described in relation to chronic hypoxemia in chronic obstructive
   pulmonary diseases. Aim of the present study was to investigate the
   occurrence of neuro-vegetative dysfunction during active tuberculosis in
   the absence of hypoxemia.
   Materials and methods: Fifteen patients affected by pulmonary
   tuberculosis under standard therapy and 17 matched controls were
   enrolled. Activation of the sympathetic system was induced by the
   tilt-up test. Systolic and diastolic arterial pressures and the R-R
   interval were monitored for 15 min by Finapres and ECG. The baroreflex
   sensitivity was evaluated by the spontaneous sequences method.
   Results: Systolic and diastolic pressures were significantly higher at
   basal conditions and showed a less increase during the tilt test in
   tuberculosis patients compared to healthy controls. The basal R-R
   interval was shorter and its reduction during the tilt test was less
   evident in patients. The baroreflex sensitivity was decreased in
   patients at basal conditions and its reduction during the tilt test was
   less evident than in controls.
   Conclusions: Our preliminary results suggest the presence in
   tuberculosis patients of an altered autonomic cardiovascular regulation,
   which is a reduced function of the baroreflex control of-the sinus node.
   (c) 2007 Elsevier Ltd. All rights reserved.}},
Publisher = {{W B SAUNDERS CO LTD}},
Address = {{32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Cazzola, M (Reprint Author), Univ Roma Tor Vergata, Dept Internal Med, Unit Resp Dis, Via Montpellier 1, I-00133 Rome, Italy.
   Univ Roma Tor Vergata, Dept Internal Med, Unit Resp Dis, I-00133 Rome, Italy.
   Univ Roma Tor Vergata, Postgrad Sch Resp Med, I-00133 Rome, Italy.
   Univ Naples Federico 2, Sch Biotechnol, Dept Clin \& Expt Med, Naples, Italy.}},
DOI = {{10.1016/j.rmed.2007.02.008}},
ISSN = {{0954-6111}},
Keywords = {{autonomic nervous system; baroreflex sensitivity; pulmonary tuberculosis}},
Keywords-Plus = {{HEART-RATE-VARIABILITY; BAROREFLEX SENSITIVITY; CIRCULATING LEPTIN;
   PLASMA LEPTIN; DISEASE; COPD; OXYGEN; REST}},
Research-Areas = {{Cardiovascular System \& Cardiology; Respiratory System}},
Web-of-Science-Categories  = {{Cardiac \& Cardiovascular Systems; Respiratory System}},
Author-Email = {{mario.cazzola@uniroma2.it}},
ResearcherID-Numbers = {{Cazzola, Mario/G-9397-2012}},
Cited-References = {{Bartels MN, 2000, CHEST, V118, P691, DOI 10.1378/chest.118.3.691.
   Bertinieri G., 1988, AM J PHYSIOL, V254, P377.
   Broekhuizen R, 2005, RESP MED, V99, P70, DOI 10.1016/j.rmed.2004.03.029.
   Bruno A, 2005, EUR RESPIR J, V26, P398, DOI 10.1183/09031936.05.00092404.
   CHEN WL, 2006, RESPIR MED, P17.
   Garan AR, 2005, J CARDIOVASC ELECTR, V16, P433, DOI 10.1046/j.1540-8167.2005.40664.x.
   Grassi G, 2004, CURR HYPERTENS REP, V6, P236, DOI 10.1007/s11906-004-0075-8.
   Iellamo F, 1996, J HYPERTENS, V14, P1099.
   La Rovere MT, 1998, LANCET, V351, P478.
   Legramante JM, 2001, CIRCULATION, V103, P1250.
   lellamo F, 2000, CIRCULATION, V102, P2588, DOI DOI 10.1161/01.CIR.102.21.
   LELLAMO F, 1997, AM J PHYSIOL, V272, pH1157.
   NIKOLAEVA OD, 2003, SIDE EFFECTS CHEMOTH, P74.
   PARATI G, 1989, HYPERTENSION, V13, P647.
   Scalvini S, 1999, EUR RESPIR J, V13, P119, DOI 10.1183/09031936.99.13111999.
   Schols AMWJ, 1999, AM J RESP CRIT CARE, V160, P1220.
   Takabatake N, 1999, AM J RESP CRIT CARE, V159, P1215.
   Takabatake N, 2001, AM J RESP CRIT CARE, V163, P1314.
   van Crevel R, 2002, J CLIN ENDOCR METAB, V87, P758, DOI 10.1210/jc.87.2.758.
   VOLTERRANI M, 1994, CHEST, V106, P1432, DOI 10.1378/chest.106.5.1432.
   WATANABE E, 1981, JPN J MED, V20, P180.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Respir. Med.}},
Doc-Delivery-Number = {{195IW}},
Unique-ID = {{ISI:000248406900027}},
}

@article{ ISI:000254581400004,
Author = {de Benedetti, M. Eleno Z. and Barbara Carranza, L. and Eduordo Gotuzzo,
   H. and Isaias Rolondo, C.},
Title = {{Ocular tuberculosis}},
Journal = {{REVISTA CHILENA DE INFECTOLOGIA}},
Year = {{2007}},
Volume = {{24}},
Number = {{4}},
Pages = {{284-295}},
Month = {{AUG}},
Abstract = {{Tuberculosis (TB) is considered a public health problem in several
   countries. This disease is classified as either pulmonary or
   extrapulmonary. Within the extrapulmonary disease, ocular involvement is
   uncommon but it is important to recognize it because its incidence has
   been reported up to 1\%. Ocular TB cases can be divided in primary and
   secondary. These manifestations can be caused by an active infection
   that invades the eye or by an immunologic reaction of delayed
   hypersensitivity in absence of the infectious agent. The most common
   clinical presentations are: chronic anterior uveitis, choroiditis and
   sclerokeratitis. Despite the existence of highly sensitive molecular
   diagnostic techniques, the diagnosis of ocular tuberculosis continues to
   be presumptive, based upon clinical presentation, systemic evaluation
   and response to treatment. For the treatment we use four drugs during a
   two month period (isoniazid, rifampin, pyrazinamide and ethambutol) and
   two drugs for four additional months.}},
Publisher = {{SOC CHILENA INFECTOLOGIA}},
Address = {{BERNARDA MORIN 488, 2 PISO, PROVIDENCIA, SANTIAGO 00000, CHILE}},
Type = {{Article}},
Language = {{Spanish}},
Affiliation = {{Gotuzzo, HE (Reprint Author), Univ Peruana Cayetano Heredia, Inst Med Trop Alexander Von Humboldt, Lima, Peru.
   Barbara Carranza, L.; Eduordo Gotuzzo, H.; Isaias Rolondo, C., Univ Peruana Cayetano Heredia, Inst Med Trop Alexander Von Humboldt, Lima, Peru.
   Eduordo Gotuzzo, H.; Isaias Rolondo, C., Univ Peruana Cayetano Heredia, Hosp Nacl Cayetano Heredia, Lima, Peru.}},
ISSN = {{0716-1018}},
Keywords = {{ocular tuberculosis; ocular manifestations; choroidal tubercles;
   uveitis; diagnosis}},
Keywords-Plus = {{POLYMERASE-CHAIN-REACTION; PRESUMED INTRAOCULAR TUBERCULOSIS;
   MYCOBACTERIUM-TUBERCULOSIS; EALES-DISEASE; PULMONARY TUBERCULOSIS;
   CHOROIDAL TUBERCULOSIS; MILIARY TUBERCULOSIS; UVEITIS; MANAGEMENT; EYE}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{egotuzzo@gotuzzos.com}},
Cited-References = {{ABRAMS J, 1982, AM J OPHTHALMOL, V94, P511.
   Arora S. K., 1999, Tubercle and Lung Disease, V79, P229, DOI 10.1054/tuld.1999.0210.
   Biswas J, 1999, BRIT J OPHTHALMOL, V83, P994, DOI 10.1136/bjo.83.8.994.
   Bodaghi B, 2000, Curr Opin Ophthalmol, V11, P443, DOI 10.1097/00055735-200012000-00010.
   Bonfioli Adriana A, 2005, Semin Ophthalmol, V20, P169, DOI 10.1080/08820530500231912.
   Bouza E, 1997, MEDICINE, V76, P53, DOI 10.1097/00005792-199701000-00005.
   Bowyer JD, 1999, OPHTHALMOLOGY, V106, P290, DOI 10.1016/S0161-6420(99)90068-4.
   CALDERON P, 1987, UVEITIS ASPECTOS CLI.
   CERRATE A, 2006, ADENOSINA DEAMINASA.
   Chawla R, 2004, MED SCI MONITOR, V10, pCS57.
   Cunningham ET, 2001, BRIT J OPHTHALMOL, V85, P127, DOI 10.1136/bjo.85.2.127.
   Das S, 1995, TUBERCLE LUNG DIS, V76, P550, DOI 10.1016/0962-8479(95)90533-2.
   Demirci H, 2004, SURV OPHTHALMOL, V49, P78, DOI 10.1016/j.survophthal.2003.10.009.
   DONAHUE HC, 1967, AM J OPHTHALMOL, V64, P742.
   DoucetPopulaire F, 1996, TUBERCLE LUNG DIS, V77, P358, DOI 10.1016/S0962-8479(96)90102-1.
   Grewal A, 1998, ARCH OPHTHALMOL-CHIC, V116, P953.
   Grosse V, 2002, LANCET, V360, P922, DOI 10.1016/S0140-6736(02)11029-4.
   Gupta Amit, 2003, Indian Journal of Ophthalmology, V51, P347.
   Gupta V, 2006, OCUL IMMUNOL INFLAMM, V14, P35, DOI 10.1080/09273940500269939.
   Gupta V, 1998, ACTA OPHTHALMOL SCAN, V76, P679, DOI 10.1034/j.1600-0420.1998.760609.x.
   Gupta V, 2003, OPHTHALMOLOGY, V110, P1744, DOI 10.1016/S0161-6420(03)00619-5.
   GUPTA V, 2005, AM J OPHTHALMOL, V149, P310.
   Heifets L, 2000, CHEST, V118, P4, DOI 10.1378/chest.118.1.4.
   HELM CJ, 1993, SURV OPHTHALMOL, V38, P229, DOI 10.1016/0039-6257(93)90076-J.
   Islam SMM, 2002, OPHTHALMIC EPIDEMIOL, V9, P239, DOI 10.1076/opep.9.4.239.1507.
   API Consensus Expert Committee, 2006, J ASSOC PHYSICIAN I, V54, P219.
   Kuruvilla A, 2003, LANCET, V361, P260, DOI 10.1016/S0140-6736(03)12295-7.
   Levecq LJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P864, DOI 10.1001/archopht.123.6.864.
   Lobo A, 2003, OPHTHALMOLOGY, V110, P595, DOI 10.1016/S0161-6420(02)01895-X.
   Madhavan HN, 2000, INVEST OPHTH VIS SCI, V41, P822.
   Martínez M, 2004, RFM, V27, P157.
   Mehta S, 2004, OCUL IMMUNOL INFLAMM, V12, P311, DOI 10.1080/092739490500354.
   Moldow B, 2003, ACTA OPHTHALMOL SCAN, V81, P304, DOI 10.1034/j.1600-0420.2003.00059.x.
   Morimura Y, 2002, OPHTHALMOLOGY, V109, P851, DOI 10.1016/S0161-6420(02)00973-9.
   Nahid Payam, 2006, Proc Am Thorac Soc, V3, P103, DOI 10.1513/pats.200511-119JH.
   NANDA M, 1989, AM J OPHTHALMOL, V108, P736.
   NARITA M, 1992, ACTA PAEDIATR, V81, P997, DOI 10.1111/j.1651-2227.1992.tb12162.x.
   Okada AA, 2000, ARCH OPHTHALMOL-CHIC, V118, P116.
   {*}PAN AM HLTH ORG, 2005, HLTH SIT AM BAS IND.
   Raina UK, 2000, AM J OPHTHALMOL, V130, P843, DOI 10.1016/S0002-9394(00)00646-2.
   Rodriguez A, 1996, ARCH OPHTHALMOL-CHIC, V114, P593.
   RODRIGUEZ R, 1959, BUENOS AIRES EDITORI, P216.
   Rohatgi J, 2000, JPN J OPHTHALMOL, V44, P146, DOI 10.1016/S0021-5155(99)00185-9.
   Romero Aroca P, 2004, Arch Soc Esp Oftalmol, V79, P81.
   SAHU G, 1998, IND J TUB, V45, P153.
   Sakai J, 2001, BRIT J OPHTHALMOL, V85, P130, DOI 10.1136/bjo.85.2.130.
   Salman A, 2003, RETINA-J RET VIT DIS, V23, P796, DOI 10.1097/00006982-200312000-00009.
   Sarvananthan N, 1998, ARCH OPHTHALMOL-CHIC, V116, P1386.
   SHAH SM, 1988, J ROY SOC MED, V81, P232.
   Shanmugam MP, 2004, SURV OPHTHALMOL, V49, P619, DOI 10.1016/j.survophthal.2004.08.013.
   Sharma PM, 2003, RETINA-J RET VIT DIS, V23, P101, DOI 10.1097/00006982-200302000-00018.
   Sheu SJ, 2001, OPHTHALMOLOGY, V108, P1580, DOI 10.1016/S0161-6420(01)00693-5.
   Shields JA, 2002, ARCH OPHTHALMOL-CHIC, V120, P311.
   Shome D, 2006, OPHTHAL PLAST RECONS, V22, P219, DOI 10.1097/01.iop.0000214528.96858.ad.
   Singh Ramandeep, 2004, Indian Journal of Ophthalmology, V52, P121.
   Tanaka MM, 2000, P NATL ACAD SCI USA, V97, P3532, DOI 10.1073/pnas.060564997.
   Therese KL, 2005, INDIAN J MED RES, V122, P165.
   Torres RM, 2004, AM J OPHTHALMOL, V138, P1048, DOI 10.1016/j.ajo.2004.06.020.
   Varma D, 2006, EYE, V20, P1068, DOI 10.1038/sj.eye.6702093.
   {*}WHO TB COUNTR PRO, 2006, WHO REP 2006 GLOB TU.}},
Number-of-Cited-References = {{60}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Rev. Chil. Infectol.}},
Doc-Delivery-Number = {{282QD}},
Unique-ID = {{ISI:000254581400004}},
}

@article{ ISI:000249496600012,
Author = {Dempers, Johan J. and Bezuidenhout, Juanita and Schneider, Johann W. and
   van Rensburg, Michle Janse},
Title = {{Tuberculosis and phrenic nerve destruction}},
Journal = {{SAMJ SOUTH AFRICAN MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{97}},
Number = {{8}},
Pages = {{572-573}},
Month = {{AUG}},
Publisher = {{SA MEDICAL ASSOC}},
Address = {{BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Dempers, JJ (Reprint Author), Univ Stellenbosch, Dept Forens Med \& Pathol, ZA-7600 Stellenbosch, South Africa.
   Univ Stellenbosch, Dept Forens Med \& Pathol, ZA-7600 Stellenbosch, South Africa.
   Natl Hlth Lab Serv, Tygerberg, South Africa.
   Univ Stellenbosch, Tygerberg Coastal Branch, ZA-7600 Stellenbosch, South Africa.
   Univ Stellenbosch, Dept Anat \& Pathol, ZA-7600 Stellenbosch, South Africa.}},
ISSN = {{0256-9574}},
Keywords-Plus = {{DIAPHRAGM; PALSY; PLICATION}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{jd2@snn.ac.za}},
ResearcherID-Numbers = {{Schneider, Johann/P-7534-2016}},
ORCID-Numbers = {{Schneider, Johann/0000-0001-5187-6756}},
Cited-References = {{Aggarwal S, 2000, PEDIATR NEPHROL, V14, P203.
   COOVADIA HM, 1998, PAEDIAT CHILD HLTH, P321.
   Gie R P, 2004, Paediatr Respir Rev, V5 Suppl A, pS139, DOI 10.1016/S1526-0542(04)90026-7.
   LANGER JC, 1988, J PEDIATR SURG, V23, P749, DOI 10.1016/S0022-3468(88)80417-2.
   MOHAN B, 1985, Indian Pediatrics, V22, P468.
   RAINE J, 1992, BRIT HEART J, V67, P308.
   Simansky DA, 2002, THORAX, V57, P613, DOI 10.1136/thorax.57.7.613.
   STONE KS, 1987, ANN THORAC SURG, V44, P62.}},
Number-of-Cited-References = {{8}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{SAMJ S. Afr. Med. J.}},
Doc-Delivery-Number = {{211AL}},
Unique-ID = {{ISI:000249496600012}},
}

@article{ ISI:000248504100010,
Author = {Bottasso, O. and Bay, M. L. and Besedovsky, H. and del Rey, A.},
Title = {{The immuno-endocrine component in the pathogenesis of tuberculosis}},
Journal = {{SCANDINAVIAN JOURNAL OF IMMUNOLOGY}},
Year = {{2007}},
Volume = {{66}},
Number = {{2-3}},
Pages = {{166-175}},
Month = {{AUG-SEP}},
Abstract = {{Tuberculosis (TB) may be regarded as a disease in which the immune
   response to Mycobacterium tuberculosis, its etiologic agent, is engaged
   both in protection and pathology. Different T-lymphocyte subsets are
   involved in the immune response against M. tuberculosis, but production
   of interferon-gamma (IFN-gamma) by T cells seems to be fundamental for
   disease control. Th1-type cytokine responses predominate in patients
   with mild or moderate forms of pulmonary TB, whereas the production of
   Th2-type cytokines prevails in the severe disease. Since the immune
   response fails to definitely eradicate the pathogen, a chronic infection
   is established, and it is likely that a broad range of regulatory
   mechanisms operate in this situation. Cytokines released during the
   course of an immune response activate the hypothalamus-pituitary-adrenal
   axis leading to the production of glucocorticoids and
   dehydroepiandrosterone (DHEA), with known immunomodulatory effects. TB
   patients exhibit increased concentrations of interleukin-6 and cortisol
   in plasma, reduced DHEA and testosterone levels, together with
   remarkably increased growth hormone concentrations that were not
   accompanied by an expected raise in insulin-like growth factor-1.
   Significant increases in estradiol, prolactin, and thyroid hormone
   concentrations were also detected in patients. Cortisol inhibits the
   mycobacterial antigen-driven proliferation and IFN-gamma production,
   whereas DHEA suppresses transforming growth factor beta production by
   lymphoid cells from TB patients with advanced disease. Furthermore,
   supernatants from cultures of M. tuberculosis-stimulated mononuclear
   cells of TB patients inhibit DHEA secretion by a human adrenal cell
   line. This type of immunoendocrine interactions may affect the control
   of tissue damage and the development of protective immune responses,
   partly accounting for disease aggravation.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Bottasso, O (Reprint Author), Univ Nacl Rosario, Fac Ciencias Med, Inst Inmunol, RA-2000 Rosario, Santa Fe, Argentina.
   Univ Nacl Rosario, Fac Ciencias Med, Inst Inmunol, RA-2000 Rosario, Santa Fe, Argentina.
   Inst Normale \& Pathol Physiol, Marburg, Germany.}},
DOI = {{10.1111/j.1365-3083.2007.01962.x}},
ISSN = {{0300-9475}},
Keywords-Plus = {{TUMOR-NECROSIS-FACTOR; BLOOD MONONUCLEAR-CELLS; GROWTH-FACTOR-BETA;
   ACTIVE PULMONARY TUBERCULOSIS; PITUITARY-ADRENAL AXIS; REGULATORY
   T-CELLS; MYCOBACTERIUM-TUBERCULOSIS; INTERFERON-GAMMA; IN-VITRO;
   FACTOR-ALPHA}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{bottasso@uolsinectis.com.ar}},
Funding-Acknowledgement = {{FIC NIH HHS {[}5D43 TW0010137]}},
Cited-References = {{Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0.
   Actor JK, 2000, COMB CHEM HIGH T SCR, V3, P343.
   Altare F, 1998, CURR OPIN IMMUNOL, V10, P413, DOI 10.1016/S0952-7915(98)80114-3.
   Baker RW, 2000, AM J RESP CRIT CARE, V162, P1641.
   Baliko Z, 1998, FEMS IMMUNOL MED MIC, V22, P199, DOI 10.1111/j.1574-695X.1998.tb01207.x.
   Baumann S, 2006, CURR OPIN IMMUNOL, V18, P438, DOI 10.1016/j.coi.2006.05.016.
   Bekker LG, 2000, INFECT IMMUN, V68, P6954, DOI 10.1128/IAI.68.12.6954-6961.2000.
   Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181.
   Besedovsky HO, 1996, ENDOCR REV, V17, P64, DOI 10.1210/er.17.1.64.
   Bonecini-Almeida MG, 2004, INFECT IMMUN, V72, P2628, DOI 10.1128/IAI.72.5.2628-2634.2004.
   Bonecini-Almeida MG, 1998, J IMMUNOL, V160, P4490.
   Bonifachich E, 2006, VACCINE, V24, P2894, DOI 10.1016/j.vaccine.2005.12.044.
   Boom WH, 1996, INFECT AGENT DIS, V5, P73.
   Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918.
   Bulat-Kardum L, 2006, SCAND J IMMUNOL, V63, P142, DOI 10.1111/j.1365-3083.2005.01694.x.
   CADRANEL J, 1990, CLIN EXP IMMUNOL, V81, P319.
   Casarini M, 1999, AM J RESP CRIT CARE, V159, P143.
   CHAN J, 1995, CLIN INFECT DIS   S2, V21, P162.
   CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351.
   Condos R, 1998, AM J RESP CRIT CARE, V157, P729.
   Condos R, 1997, LANCET, V349, P1513, DOI 10.1016/S0140-6736(96)12273-X.
   Cutolo M, 2003, CLIN EXP RHEUMATOL, V21, P687.
   De La Barrera S, 2004, CLIN EXP IMMUNOL, V138, P128, DOI 10.1111/j.1365-2249.2004.02577.x.
   del Rey A, 2007, BRAIN BEHAV IMMUN, V21, P171, DOI 10.1016/j.bbi.2006.06.005.
   DENIS M, 1991, CLIN EXP IMMUNOL, V84, P200.
   Dheda K, 2005, J INFECT DIS, V192, P1201, DOI 10.1086/444545.
   DLUGOVITZKY D, 1995, BRAZ J MED BIOL RES, V28, P331.
   Dlugovitzky D, 2000, CLIN EXP IMMUNOL, V122, P343, DOI 10.1046/j.1365-2249.2000.01394.x.
   Dlugovitzky D, 1999, SCAND J IMMUNOL, V49, P210, DOI 10.1046/j.1365-3083.1999.00492.x.
   Dlugovitzky D, 1997, FEMS IMMUNOL MED MIC, V18, P203, DOI 10.1016/S0928-8244(97)00040-0.
   Doffinger R, 2005, CURR OPIN RHEUMATOL, V17, P440, DOI 10.1097/01.bor.0000166387.70475.dd.
   Dorshkind K, 2000, ENDOCR REV, V21, P292, DOI 10.1210/er.21.3.292.
   ELLIS ME, 1986, BRIT J DIS CHEST, V80, P7, DOI 10.1016/0007-0971(86)90003-3.
   FAREBEE SH, 1970, ADV TUBER RES, V7, P29.
   FILLEY EA, 1992, IMMUNOLOGY, V77, P505.
   Flynn JL, 2004, TUBERCULOSIS, V84, P93, DOI 10.1016/j.tube.2003.08.010.
   FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2.
   Fortes A, 2005, CLIN EXP IMMUNOL, V141, P541, DOI 10.1111/j.1365-2249.2005.02872.x.
   Foster MP, 2000, CLIN IMMUNOL, V96, P140, DOI 10.1006/clim.2000.4889.
   Gennari R, 1997, CRIT CARE MED, V25, P1207, DOI 10.1097/00003246-199707000-00024.
   Gomez-Reino JJ, 2003, ARTHRITIS RHEUM, V48, P2122, DOI 10.1002/art.11137.
   Gong JH, 1996, INFECT IMMUN, V64, P913.
   Guyot-Revol V, 2006, AM J RESP CRIT CARE, V173, P803, DOI 10.1164/rccm.200508-1294OC.
   Helke KL, 2006, TUBERCULOSIS, V86, P337, DOI 10.1016/j.tube.2005.09.001.
   Hernandez-Pando R, 2000, LANCET, V356, P2133, DOI 10.1016/S0140-6736(00)03493-0.
   Hernandez-Pando R, 1998, IMMUNOLOGY, V95, P234.
   HIRSCH CS, 1994, J INFECT DIS, V170, P1229.
   Howard AD, 1999, CLIN EXP IMMUNOL, V115, P428.
   HUYGEN K, 1988, SCAND J IMMUNOL, V27, P187, DOI 10.1111/j.1365-3083.1988.tb02338.x.
   Imrich Richard, 2002, Endocr Regul, V36, P95.
   Kanda N, 1999, ARTHRITIS RHEUM, V42, P328, DOI 10.1002/1529-0131(199902)42:2<328::AID-ANR16>3.0.CO;2-\#.
   Kelestimur F, 2000, J ENDOCRINOL INVEST, V23, P235.
   Keven K, 1998, INT J TUBERC LUNG D, V2, P419.
   Kooijman R, 1996, ADV IMMUNOL, V63, P377.
   Kroboth PD, 1999, J CLIN PHARMACOL, V39, P327, DOI 10.1177/00912709922007903.
   Law K, 1996, AM J RESP CRIT CARE, V153, P799.
   LEBRETHON MC, 1994, J CLIN ENDOCR METAB, V79, P1033, DOI 10.1210/jc.79.4.1033.
   Lienhardt C, 2002, EUR J IMMUNOL, V32, P1605, DOI 10.1002/1521-4141(200206)32:6<1605::AID-IMMU1605>3.0.CO;2-6.
   Lillebaek T, 2002, J INFECT DIS, V185, P401, DOI 10.1086/338342.
   Mahuad C, 2004, SCAND J IMMUNOL, V60, P639, DOI 10.1111/j.0300-9475.2004.01514.x.
   Malkin CJ, 2004, J CLIN ENDOCR METAB, V89, P3313, DOI 10.1210/jc.2003-031069.
   Mazzarella G, 2003, CLIN EXP IMMUNOL, V132, P283, DOI 10.1046/j.1365-2249.2003.02121.x.
   Miyaura H, 2002, J IMMUNOL, V168, P1087.
   MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165.
   Moreira AL, 2000, MICROB PATHOGENESIS, V29, P175, DOI 10.1006/mpat.2000.0382.
   Murray PJ, 1999, INFECT IMMUN, V67, P3087.
   Olobo JO, 2001, SCAND J IMMUNOL, V53, P85, DOI 10.1046/j.1365-3083.2001.00844.x.
   ORME IM, 1993, CURR OPIN IMMUNOL, V5, P497, DOI 10.1016/0952-7915(93)90029-R.
   Othieno C, 1999, INFECT IMMUN, V67, P5730.
   Ottenhoff THM, 2005, TUBERCULOSIS, V85, P53, DOI 10.1016/j.tube.2004.09.011.
   Padgett DA, 1995, ANN NY ACAD SCI, V774, P323.
   Pathan AA, 2001, J IMMUNOL, V167, P5217.
   Ramirez F, 1996, J IMMUNOL, V156, P2406.
   Ribeiro-Rodrigues R, 2006, CLIN EXP IMMUNOL, V144, P25, DOI 10.1111/j.1365-2249.2006.03027.x.
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P154.
   ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303.
   Rook G A, 2001, Curr Opin Pulm Med, V7, P116, DOI 10.1097/00063198-200105000-00002.
   Rook GAW, 1996, QJM-INT J MED, V89, P333.
   Rook GAW, 2004, TRENDS IMMUNOL, V25, P483, DOI 10.1016/j.it.2004.06.005.
   ROOK GAW, 1986, IMMUNOLOGY, V57, P159.
   SANCHEZ FO, 1994, INFECT IMMUN, V62, P5673.
   SHAUF V, 1993, J INFECT DIS, V168, P1056.
   SKINSNES OK, 1968, ANN NY ACAD SCI, V54, P19.
   Small PM, 2001, NEW ENGL J MED, V345, P189, DOI 10.1056/NEJM200107193450307.
   Smith SM, 2002, TUBERCULOSIS, V82, P7, DOI 10.1054/tube.2001.0317.
   Sodhi A, 1997, CLIN INFECT DIS, V25, P617, DOI 10.1086/513769.
   Straub RH, 2003, ARTHRITIS RHEUM, V48, P1504, DOI 10.1002/art.11036.
   SURCEL HM, 1994, IMMUNOLOGY, V81, P171.
   SWAIN SL, 1991, J IMMUNOL, V147, P2991.
   Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817.
   Tomioka H, 1995, J LEUKOCYTE BIOL, V58, P704.
   TOOSSI Z, 1986, J EXP MED, V163, P1162, DOI 10.1084/jem.163.5.1162.
   Toossi Z, 1998, CLIN IMMUNOL IMMUNOP, V87, P107, DOI 10.1006/clin.1998.4528.
   TORRES M, 1994, CLIN EXP IMMUNOL, V96, P75.
   Turnbull AV, 1999, PHYSIOL REV, V79, P1.
   Turner J, 2002, J IMMUNOL, V169, P6343.
   van Crevel R, 2000, J INFECT DIS, V181, P1194, DOI 10.1086/315325.
   Van den Berghe G, 2003, ENDOCRIN METAB CLIN, V32, P385, DOI 10.1016/S0889-8529(03)00005-7.
   Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602.
   Verbon A, 1999, CLIN EXP IMMUNOL, V115, P110.
   Verreck FAW, 2004, P NATL ACAD SCI USA, V101, P4560, DOI 10.1073/pnas.0400983101.
   Visser J, 1998, BLOOD, V91, P4255.
   WARWICKDAVIES J, 1995, J IMMUNOL, V155, P3186.
   World Health Organization, GLOB TUB CONTR SURV.
   Wilckens T, 1997, IMMUNOL TODAY, V18, P418, DOI 10.1016/S0167-5699(97)01111-0.
   WILDER RL, 1995, ANNU REV IMMUNOL, V13, P307.
   Zhang M, 1999, J IMMUNOL, V162, P2441.
   ZHANG M, 1995, INFECT IMMUN, V63, P3231.}},
Number-of-Cited-References = {{108}},
Times-Cited = {{23}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Scand. J. Immunol.}},
Doc-Delivery-Number = {{196TC}},
Unique-ID = {{ISI:000248504100010}},
}

@article{ ISI:000248504100011,
Author = {Abebe, F. and Holm-Hansen, C. and Wiker, H. G. and Bjune, G.},
Title = {{Progress in serodiagnosis of Mycobacterium tuberculosis infection}},
Journal = {{SCANDINAVIAN JOURNAL OF IMMUNOLOGY}},
Year = {{2007}},
Volume = {{66}},
Number = {{2-3}},
Pages = {{176-191}},
Month = {{AUG-SEP}},
Abstract = {{One-third of the world population is estimated to have Mycobacterium
   tuberculosis infection. Accurate and timely identification of infected
   individuals is critical for treatment and control. The current
   diagnostic methods lack the desired sensitivity and specificity, require
   sophisticated equipment and skilled workforce or take weeks to yield
   results. Diagnosis of extrapulmonary TB, TB-HIV co-infection, childhood
   TB and sputum smear-negative pulmonary TB pose serious challenges.
   Interest in developing serodiagnostic methods is increasing because
   detection of antibody is rapid, simple and relatively inexpensive, and
   does not require a living cell for detection. Three types of tests,
   namely screening tests to overcome diagnostic delay, specific tests for
   diagnosis of extrapulmonary TB and other bacteriologically negative
   cases, and rests for vaccine-induced immunity need critical
   consideration. Several factors must be considered to develop
   serodiagnostic methods for TB. Antigen recognition by infected
   individuals is highly heterogeneous due to stage of disease, differences
   in HLA types, strain of the bacilli, health of the patient and bacillary
   load. With advances in molecular biological techniques, a number of
   novel antigens have been identified. Some of these antigens have proven
   valuable in detecting specific antibodies in some of the most
   challenging TB patients. The best example is a fusion protein containing
   several M. tuberculosis proteins (e.g. CFP-10, MTB8, MTB48, MTB81 and
   the 38-kDa protein) which showed encouraging results in detecting
   antibodies in sera of patients, including TB-HIV co-infection. This
   review presents progress made in the serodiagnosis of TB during the last
   decade.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Abebe, F (Reprint Author), Univ Oslo, Inst Gen Practice \& Community Med, Sect Int Hlth, Oslo, Norway.
   Univ Oslo, Inst Gen Practice \& Community Med, Sect Int Hlth, Oslo, Norway.
   Norwegian Inst Publ Hlth, Oslo, Norway.
   Univ Bergen, Gade Inst, Microbiol \& Immunol Sect, Bergen, Norway.
   Haukeland Hosp, Dept Microbiol \& Immunol, N-5021 Bergen, Norway.}},
DOI = {{10.1111/j.1365-3083.2007.01978.x}},
ISSN = {{0300-9475}},
Keywords-Plus = {{HEPARIN-BINDING HEMAGGLUTININ; HUMAN-IMMUNODEFICIENCY-VIRUS;
   LINKED-IMMUNOSORBENT-ASSAY; CULTURE FILTRATE ANTIGENS; DOT-IMMUNOBINDING
   ASSAY; 38 KDA ANTIGEN; PULMONARY TUBERCULOSIS; T-CELL; HUMORAL RESPONSE;
   BOVIS BCG}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{fekadu.abebe@medisin.uio.no}},
ResearcherID-Numbers = {{Wiker, Harald/A-7798-2008}},
Cited-References = {{ABOUZEID C, 1991, INFECT IMMUN, V59, P2712.
   Adjei AA, 2003, JPN J INFECT DIS, V56, P161.
   Alifano M, 1998, THORAX, V53, P377.
   Andersen MJ, 2000, J BIOLAW BUS, V3, P56.
   ANDERSEN P, 1995, J IMMUNOL, V154, P3359.
   Araujo Z, 2004, MEM I OSWALDO CRUZ, V99, P517, DOI 10.1590/S0074-02762004000500011.
   Attallah AM, 2005, CLIN CHIM ACTA, V356, P58, DOI 10.1016/j.cccn.2004.11.036.
   BARNES PF, 1991, NEW ENGL J MED, V324, P1644.
   Barnes PF, 2004, AM J RESP CRIT CARE, V170, P5, DOI 10.1164/rccm.2404004.
   BARRERA L, 1989, PEDIATR INFECT DIS J, V8, P763, DOI 10.1097/00006454-198911000-00007.
   Beck ST, 2005, BRAZ J MED BIOL RES, V38, P587, DOI 10.1590/S0100-879X2005000400013.
   Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420.
   BOTHAMLEY GH, 1992, THORAX, V47, P270, DOI 10.1136/thx.47.4.270.
   BOTHAMLEY GH, 1992, J INFECT DIS, V166, P182.
   Brock I, 2001, INT J TUBERC LUNG D, V5, P462.
   Brodin P, 2004, TRENDS MICROBIOL, V12, P500, DOI 10.1016/j.tim.2004.09.007.
   Chan ED, 2000, TUBERCLE LUNG DIS, V80, P131, DOI 10.1054/tuld.2000.0243.
   CHANDRAMUKI A, 1989, J CLIN MICROBIOL, V27, P821.
   Chang ZY, 1996, J BIOL CHEM, V271, P7218.
   Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008.
   Chaudhary VK, 2005, PROTEIN EXPRES PURIF, V40, P169, DOI 10.1016/j.pep.2004.10.016.
   Cherian Thomas, 2000, Indian Journal of Pediatrics, V67, pS47.
   Chiang IH, 1997, AM J RESP CRIT CARE, V156, P906.
   Chierakul N, 2001, INT J TUBERC LUNG D, V5, P968.
   Choudhary RK, 2004, PROTEIN EXPRES PURIF, V36, P249, DOI 10.1016/j.pep.2004.03.016.
   Colangeli R, 2000, INFECT IMMUN, V68, P990, DOI 10.1128/IAI.68.2.990-993.2000.
   Cole RA, 1996, TUBERCLE LUNG DIS, V77, P363, DOI 10.1016/S0962-8479(96)90103-3.
   Cole ST, 1998, NATURE, V396, P190, DOI 10.1038/24206.
   Cole ST, 1998, NATURE, V393, P537.
   DANIEL TM, 1986, AM REV RESPIR DIS, V134, P662.
   DANIEL TM, 1994, TUBERCLE LUNG DIS, V75, P33, DOI 10.1016/0962-8479(94)90099-X.
   DANIEL TM, 1987, AM REV RESPIR DIS, V135, P1137.
   Del Pezzo M, 1996, New Microbiol, V19, P363.
   Delogu G, 2001, INFECT IMMUN, V69, P5606, DOI 10.1128/IAI.69.9.5606-5611.2001.
   Demissie A, 2006, CLIN VACCINE IMMUNOL, V13, P179, DOI 10.1128/CVI.13.2.179-186.2006.
   Demkow U, 2004, J Physiol Pharmacol, V55 Suppl 3, P57.
   Demkow U, 2002, INT J TUBERC LUNG D, V6, P1023.
   Devi KRU, 2003, DIAGN MICR INFEC DIS, V46, P205, DOI 10.1016/S0732-8893(03)00047-6.
   Escamilla L, 1996, AM J RESP CRIT CARE, V154, P1864.
   Espitia C, 1999, MICROBIOL-UK, V145, P3487.
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9.
   Foulds J, 1998, INT J TUBERC LUNG D, V2, P778.
   Garg SK, 2003, J CLIN LAB ANAL, V17, P155, DOI 10.1002/jcla.10086.
   Ghelani D R, 1999, J Assoc Physicians India, V47, P787.
   Ghoshal Ujjala, 2003, Indian J Pathol Microbiol, V46, P530.
   Greenaway C, 2005, INT J TUBERC LUNG D, V9, P1112.
   GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x.
   Grubek-Jaworska H, 1997, INT J TUBERC LUNG D, V1, P556.
   HARBOE M, 1977, BRIT MED J, V2, P430.
   HARBOE M, 1981, AM REV RESPIR DIS, V124, P80.
   HARBOE M, 1992, J INFECT DIS, V166, P874.
   Harboe M, 1998, SCAND J IMMUNOL, V48, P577.
   Harboe M, 1996, INFECT IMMUN, V64, P16.
   Hendrickson RC, 2000, J CLIN MICROBIOL, V38, P2354.
   Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030.
   Houghton RL, 2002, CLIN DIAGN LAB IMMUN, V9, P883, DOI 10.1128/CDLI.9.4.883-891.2002.
   Imaz MS, 2000, INT J TUBERC LUNG D, V4, P562.
   Imaz MS, 2001, INT J TUBERC LUNG D, V5, P1036.
   JACKETT PS, 1988, J CLIN MICROBIOL, V26, P2313.
   Julian E, 2002, J CLIN MICROBIOL, V40, P3782, DOI 10.1128/JCM.40.10.3782-3788.2002.
   KADIVAL GV, 1994, ZBL BAKT-INT J MED M, V281, P95.
   Kaisermann MC, 2005, INT J TUBERC LUNG D, V9, P461.
   Kanaujia GV, 2005, INT J TUBERC LUNG D, V9, P1120.
   Kanaujia GV, 2003, COMPARATIVE MED, V53, P602.
   KIM TC, 1984, AM REV RESPIR DIS, V129, P264.
   Kulshrestha A, 2005, PROTEIN EXPRES PURIF, V44, P75, DOI 10.1016/j.pep.2005.04.014.
   Kunter E, 2003, CLIN MICROBIOL INFEC, V9, P212, DOI 10.1046/j.1469-0691.2003.00536.x.
   Laal S, 1997, J INFECT DIS, V176, P133, DOI 10.1086/514015.
   Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1.
   Lalvani A, 2007, CURR OPIN INFECT DIS, V20, P264, DOI 10.1097/QCO.0b013e32813e3fd8.
   Lathigra R, 1996, RES MICROBIOL, V147, P237, DOI 10.1016/0923-2508(96)81384-2.
   Lawn SD, 1998, INT J TUBERC LUNG D, V2, P635.
   Li L F, 1998, Changgeng Yi Xue Za Zhi, V21, P258.
   Lim JH, 1999, INFECT IMMUN, V67, P6187.
   Lodes MJ, 2001, J CLIN MICROBIOL, V39, P2485, DOI 10.1128/JCM.39.7.2485-2493.2001.
   Lopez-Vidal Y, 2004, ARCH MED RES, V35, P308, DOI 10.1016/j.arcmed.2004.04.008.
   Luh K T, 1996, Respirology, V1, P145, DOI 10.1111/j.1440-1843.1996.tb00024.x.
   Lyashchenko K, 1998, INFECT IMMUN, V66, P3936.
   Mahenthiralingam E, 1998, INFECT IMMUN, V66, P3626.
   Maheshwari Alok, 2000, Journal of Communicable Diseases, V32, P54.
   Malen H, 2007, PROTEOMICS, V7, P1702, DOI 10.1002/pmic.200600853.
   Masungi C, 2002, J INFECT DIS, V185, P513, DOI 10.1086/338833.
   Mattow J, 2003, ELECTROPHORESIS, V24, P3405, DOI 10.1002/elps.200305601.
   MCDONOUGH JA, 1992, J LAB CLIN MED, V120, P318.
   Menozzi FD, 1996, J EXP MED, V184, P993, DOI 10.1084/jem.184.3.993.
   Moran AJ, 2001, FEMS MICROBIOL LETT, V198, P31, DOI 10.1016/S0378-1097(01)00115-X.
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC.
   Mukherjee P, 2007, CLIN MICROBIOL INFEC, V13, P146, DOI 10.1111/j.1469-0691.2006.01660.x.
   Mukherjee S, 2004, CLIN DIAGN LAB IMMUN, V11, P280, DOI 10.1128/CDLI.11.2.280-286.2004.
   MURRAY CJL, 1990, LANCET, V335, P1043, DOI 10.1016/0140-6736(90)91114-P.
   Mustafa T, 2006, MODERN PATHOL, V19, P1606, DOI 10.1038/modpathol.3800697.
   NAGAI S, 1991, INFECT IMMUN, V59, P372.
   Neu N, 1999, PEDIATR INFECT DIS J, V18, P122, DOI 10.1097/00006454-199902000-00008.
   Noss EH, 2001, J IMMUNOL, V167, P910.
   O'Toole R, 2003, J BACTERIOL, V185, P1543, DOI 10.1128/JB.185.5.1543-1554.2003.
   Okkels LM, 2003, INFECT IMMUN, V71, P6116, DOI 10.1128/IAI.71.11.6116-6123.2003.
   Patil SA, 1996, CLIN IMMUNOL IMMUNOP, V81, P35, DOI 10.1006/clin.1996.0154.
   Pethe K, 2002, P NATL ACAD SCI USA, V99, P10759, DOI 10.1073/pnas.162246899.
   Pethe K, 2001, NATURE, V412, P190, DOI 10.1038/35084083.
   Pethe K, 2001, MOL MICROBIOL, V39, P89, DOI 10.1046/j.1365-2958.2001.02206.x.
   Preneta R, 2004, MICROBIOL-SGM, V150, P2135, DOI 10.1099/mic.0.26789-0.
   Raja A, 2004, DIAGN MICR INFEC DIS, V50, P253, DOI 10.1016/j.diagmicrobio.2004.08.010.
   Raja A, 2001, PEDIATR INFECT DIS J, V20, P1161, DOI 10.1097/00006454-200112000-00013.
   Raja A, 2002, CLIN DIAGN LAB IMMUN, V9, P308, DOI 10.1128/CDLI.9.2.308-312.2002.
   Ramakrishnan L, 2000, SCIENCE, V288, P1436, DOI 10.1126/science.288.5470.1436.
   Ramalingam B, 2004, PROTEIN EXPRES PURIF, V36, P53, DOI 10.1016/j.pep.2004.01.016.
   Ramalingam B, 2003, SCAND J INFECT DIS, V35, P234, DOI 10.1080/00365540310000292.
   Ramalingam B, 2002, J TROP PEDIATRICS, V48, P188, DOI 10.1093/tropej/48.3.188.
   Rasolofo V, 1999, J CLIN MICROBIOL, V37, P4201.
   RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297.
   Ravn P, 2005, CLIN DIAGN LAB IMMUN, V12, P491, DOI 10.1128/CDLI.12.4.491-496.2005.
   ROSEN EU, 1990, TUBERCLE, V71, P127, DOI 10.1016/0041-3879(90)90008-V.
   Rosenkrands I, 2000, ELECTROPHORESIS, V21, P935, DOI 10.1002/(SICI)1522-2683(20000301)21:5<935::AID-ELPS935>3.3.CO;2-G.
   Samanich KM, 1998, J INFECT DIS, V178, P1534, DOI 10.1086/314438.
   Samanich KM, 2000, CLIN DIAGN LAB IMMUN, V7, P662, DOI 10.1128/CDLI.7.4.662-668.2000.
   Shafer RW, 1996, CLIN INFECT DIS, V22, P683.
   Sharma S K, 2000, Indian J Chest Dis Allied Sci, V42, P77.
   Siddiqi K, 2003, LANCET INFECT DIS, V3, P288, DOI 10.1016/S1473-3099(03)00609-1.
   Silva VMC, 2003, INT J TUBERC LUNG D, V7, P478.
   Singh KK, 2005, INFECT IMMUN, V73, P5004, DOI 10.1128/IAI.73.8.5004-501.4.2005.
   Singh KK, 2005, CLIN DIAGN LAB IMMUN, V12, P354, DOI 10.1128/CDLI.12.2.354-358.2005.
   Singh KK, 2001, INFECT IMMUN, V69, P4185, DOI 10.1128/IAI.69.6.4185-4191.2001.
   SLUTSKER L, 1993, CLIN INFECT DIS, V16, P513.
   Smith KC, 1996, PEDIATRICS, V97, P155.
   Sonnenberg MG, 1997, INFECT IMMUN, V65, P4515.
   SORENSEN AL, 1995, INFECT IMMUN, V63, P1710.
   SPENCE DPS, 1993, BRIT MED J, V307, P759.
   STEELE BA, 1991, AM REV RESPIR DIS, V143, P713.
   Sumi MG, 1999, J CLIN MICROBIOL, V37, P3925.
   Sumi MG, 2000, ACTA NEUROL SCAND, V101, P61, DOI 10.1034/j.1600-0404.2000.00012.x.
   Swaminathan Soumya, 1999, Indian Journal of Pediatrics, V66, P837, DOI 10.1007/BF02723848.
   Tanghe A, 2001, INFECT IMMUN, V69, P5403, DOI 10.1128/IAI.69.9.5403-5411.2001.
   Temmerman S, 2004, NAT MED, V10, P935, DOI 10.1038/nm1090.
   Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544.
   THYBO S, 1995, TUBERCLE LUNG DIS, V76, P149, DOI 10.1016/0962-8479(95)90558-8.
   VIKERFORS T, 1993, INT J LEPROSY, V61, P571.
   WAYNE LG, 1994, EUR J CLIN MICROBIOL, V13, P908, DOI 10.1007/BF02111491.
   Weldingh K, 2005, J CLIN MICROBIOL, V43, P57, DOI 10.1128/JCM.43.1.57-65.2005.
   {[}Anonymous], 2007, WHO REP 2007 GLOB TU.
   {*}WHO, 1997, WHO TUB DIAGN WORKSH.
   WIKER HG, 1992, SCAND J IMMUNOL, V36, P307, DOI 10.1111/j.1365-3083.1992.tb03104.x.
   WIKER HG, 1992, MICROBIOL REV, V56, P648.
   WIKER HG, 1988, SCAND J IMMUNOL, V27, P223, DOI 10.1111/j.1365-3083.1988.tb02342.x.
   WILKINS EGL, 1990, LANCET, V336, P641, DOI 10.1016/0140-6736(90)92144-7.
   Wilkinson RJ, 1997, J CLIN MICROBIOL, V35, P553.
   Yeremeev VV, 2000, CLIN EXP IMMUNOL, V120, P274, DOI 10.1046/j.1365-2249.2000.01212.x.
   Yeremeev VV, 2000, TUBERCLE LUNG DIS, V80, P243, DOI 10.1054/tuld.2000.0252.
   Yuan Y, 1998, P NATL ACAD SCI USA, V95, P9578, DOI 10.1073/pnas.95.16.9578.
   Yuan Ying, 1996, Journal of Bacteriology, V178, P4484.
   Yuce A, 2001, CLIN MICROBIOL INFEC, V7, P372, DOI 10.1046/j.1198-743x.2001.00263.x.
   Zanetti S, 2005, CLIN DIAGN LAB IMMUN, V12, P1135, DOI 10.1128/CDLI.12.9.1135-1138.2005.
   ZOU YL, 1994, CLIN INFECT DIS, V19, P1084.}},
Number-of-Cited-References = {{152}},
Times-Cited = {{83}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Scand. J. Immunol.}},
Doc-Delivery-Number = {{196TC}},
Unique-ID = {{ISI:000248504100011}},
}

@article{ ISI:000249088700008,
Author = {Pronyk, Paul M. and Kahn, Kathleen and Tollman, Stephen M.},
Title = {{Using health and demographic surveillance to understand the burden of
   disease in populations: The case of tuberculosis in rural South Africa}},
Journal = {{SCANDINAVIAN JOURNAL OF PUBLIC HEALTH}},
Year = {{2007}},
Volume = {{35}},
Number = {{69}},
Pages = {{45-51}},
Month = {{AUG}},
Abstract = {{Aims: To utilize the Agincourt health and demographic surveillance
   system (HDSS) platform to assess the burden of pulmonary tuberculosis
   (PTB) in a rural South African sub-district. Methods: During 1999, data
   from three sources were combined to estimate disease prevalence amongst
   a non-migrant adult population: (1) passive case-finding (PCF) through
   hospital register data, (2) active case finding (ACF) using a systematic
   household assessment of chronic coughers; and (3) verbal autopsy (VA)
   data on cause of death. Results: Of 66,840 residents, 38,251 permanent
   adult residents were included in the analysis. A total of 102 cases of
   PTB were detected through PCF. ACF sweep detected 366 chronic coughers
   with 6 cases of confirmed PTB. Among 28 PTB deaths detected by VA, 13
   (46\%) were not previously identified by the health service. The total
   PTB prevalence was 157/100,000; 110/100,000 of prevalent cases were
   detected by PCF. Among undetected cases, 24/ 100,000 were identified
   through ACF, while 23/100,000 were detected by the VA process.
   Conclusions: Amongst prevalent PTB cases in the permanent adult
   population, 70\% were detected by the health service; 15\% of cases were
   undiagnosed in the community, while an equal proportion died of PTB
   prior to diagnosis. The latter groups contributed disproportionately to
   infectiousness in the community through prolonged duration of symptoms.
   As most of these cases presented to the health service on a number of
   occasions, strengthening early case detection should remain the
   cornerstone of TB control efforts. Strategies to strengthen the
   application of health \& demographic surveillance systems to disease
   surveillance are discussed.}},
Publisher = {{TAYLOR \& FRANCIS AS}},
Address = {{PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Pronyk, PM (Reprint Author), Univ Witwatersrand, RADAR, POB 2, ZA-1360 Acornhoek, South Africa.
   Univ Witwatersrand, RADAR, ZA-1360 Acornhoek, South Africa.
   London Sch Hyg \& Trop Med, Dept Infect \& Trop Dis, Climat Res Unit, London, England.
   Univ Witwatersrand, Sch Publ Hlth, MRC, Wits Rural Publ Hlth \& Hlth Transit Res Unit, ZA-2050 Wits, South Africa.}},
DOI = {{10.1080/14034950701355767}},
ISSN = {{1403-4948}},
Keywords = {{active-case finding; demographic surveillance system; epidemioloy; South
   Africa; tuberculosis; tuberculosis surveillance; verbal autopsy}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{pronyk@soft.co.za}},
Cited-References = {{CORMICAN MG, 1992, J CLIN PATHOL, V45, P601, DOI 10.1136/jcp.45.7.601.
   DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213.
   GARENNE M, 1997, PROSPECTIVE COMMUNIT, P297.
   Grange JM, 1999, TUBERCULOSIS INTERDI, P3, DOI 10.1142/9781848160552\_0001.
   {*}HLTH SYST TRUST, 2001, S AFR HLTH REV.
   Kahn K, 1999, TROP MED INT HEALTH, V4, P433, DOI 10.1046/j.1365-3156.1999.00415.x.
   Kahn K, 2000, TROP MED INT HEALTH, V5, P824, DOI 10.1046/j.1365-3156.2000.00638.x.
   Murray C, 1993, DIS CONTROL PRIORITI, P233.
   Pronyk PM, 2004, INT J TUBERC LUNG D, V8, P796.
   Pronyk PM, 2001, INT J TUBERC LUNG D, V5, P619.
   SANDIFORD P, 1992, SOC SCI MED, V34, P1077, DOI 10.1016/0277-9536(92)90281-T.
   Sankoh OA, 2002, POPULATION HLTH DEV, V1.
   STYBLO K, 1968, SCAND J RESPIR DIS, V49, P236.
   STYBLO K, 1969, B INT UNION TUBERC L, V42, P95.
   Tollman SM, 1999, S AFR MED J, V89, P853.
   WHO, 1991, 44 WORLD HLTH ASS.
   {*}WHO, 1998, WHOTB1998.
   WHO, 2005, GLOB TUB CONTR.
   World Health Organization, 2001, GLOB TUB CONTR.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{Scand. J. Public Health}},
Doc-Delivery-Number = {{205BT}},
Unique-ID = {{ISI:000249088700008}},
}

@article{ ISI:000248692200028,
Author = {Luzzati, Roberto and Giacomazzi, Donatella and Franchi, Fabio and
   Barcobello, Monica and Vento, Sandro},
Title = {{Life-threatening, multiple hypersensitivity reactions induced by
   rifampicin in one patient with pulmonary tuberculosis}},
Journal = {{SOUTHERN MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{100}},
Number = {{8}},
Pages = {{854-856}},
Month = {{AUG}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Univ Hosp Trieste, Transfus Ctr, Trieste, Italy.
   Hosp Azienda Ospedaliera Cosenza, Infect Dis Unit Annunziata, Cosenza, Italy.}},
ISSN = {{0038-4348}},
Keywords-Plus = {{ACUTE-RENAL-FAILURE}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
ResearcherID-Numbers = {{Vento, Sandro/I-1662-2017}},
Cited-References = {{De Vriese AS, 1998, AM J KIDNEY DIS, V31, P108, DOI 10.1053/ajkd.1998.v31.pm9428460.
   Grosset J., 1983, REV INFECT DIS S, V5, P440.
   Martinez E, 1999, MEDICINE, V78, P361, DOI 10.1097/00005792-199911000-00001.
   Muthukumar T, 2002, AM J KIDNEY DIS, V40, P690, DOI 10.1053/ajkd.2002.35675.
   PETZ LD, 1985, METHODS HEMATOLOGY I, P47.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{South.Med.J.}},
Doc-Delivery-Number = {{199JO}},
Unique-ID = {{ISI:000248692200028}},
}

@article{ ISI:000248689800007,
Author = {Story, A. and Murad, S. and Roberts, W. and Verheyen, M. and Hayward, A.
   C. and London Tuberculosis Nurses Network},
Title = {{Tuberculosis in London: The importance of homelessness, problem drug use
   and prison}},
Journal = {{THORAX}},
Year = {{2007}},
Volume = {{62}},
Number = {{8}},
Pages = {{667-671}},
Month = {{AUG}},
Abstract = {{Background: The control of tuberculosis (TB) is founded on early case
   detection and complete treatment of disease. In the UK, TB is
   concentrated in subgroups of the population in large urban centres. The
   impact of homelessness, imprisonment and problem drug use on TB control
   in London is reviewed.
   Methods: A cohort study was undertaken of all patients with TB in
   Greater London to determine the point prevalence of disease in different
   groups and to examine risk factors for smear positivity, drug
   resistance, treatment adherence, loss to follow-up and use of directly
   observed therapy (DOT).
   Results: Data were collected on 97\% (1941/1995) of eligible patients.
   The overall prevalence of TB was 27 per 100 000. An extremely high
   prevalence of TB was seen in homeless people (788/100 000), problem drug
   users (354/100 000) and prisoners (208/100 000). Multivariate analysis
   showed that problem drug use was associated with smear positive disease
   (OR 2.2, p<0.001), being part of a known outbreak of drug resistant TB
   (OR 3.5, p = 0.001) and loss to follow-up (OR 2.7, p<0.001).
   Imprisonment was associated with being part of the outbreak (OR 10.3,
   p<0.001) and poor adherence (OR 3.9, p<0.001). Homelessness was
   associated with infectious TB (OR 1.6, p = 0.05), multidrug resistance
   (OR 2.1, p = 0.03), poor adherence (OR 2.5, p<0.001) and loss to
   follow-up (OR 3.8, p<0.001). In London, homeless people, prisoners and
   problem drug users collectively comprise 17\% of TB cases, 44\% of smear
   positive drug resistant cases, 38\% of poorly compliant cases and 44\%
   of cases lost to follow-up. 15\% of these patients start treatment on
   DOT but 46\% end up on DOT.
   Conclusions: High levels of infectious and drug resistant disease, poor
   adherence and loss to follow-up care indicate that TB is not effectively
   controlled among homeless people, prisoners and problem drug users in
   London.}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Story, A (Reprint Author), Hlth Protect Agcy, Ctr Infect, TB Sect, Dept Resp Dis, 61 Colindale Ave, London NW9 5EQ, England.
   Hlth Protect Agcy, Ctr Infect, TB Sect, Dept Resp Dis, London NW9 5EQ, England.
   UCL, Ctr Infect Dis Epidemiol, Dept Primary Care \& Populat Sci, Camden Primary Care Trust, London, England.
   NE London TB Network, London, England.}},
DOI = {{10.1136/thx.2006.065409}},
ISSN = {{0040-6376}},
Keywords-Plus = {{DIRECTLY OBSERVED THERAPY; ADHERENCE; PREVALENCE; PROSPECTS; PROGRAM}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Author-Email = {{alistair.story@hpa.org.uk}},
ResearcherID-Numbers = {{Hayward, Andrew/C-3268-2013}},
ORCID-Numbers = {{Hayward, Andrew/0000-0002-3549-6232}},
Cited-References = {{Anderson R., 1991, INFECT DIS HUMANS DY.
   Bock NN, 2001, INT J TUBERC LUNG D, V5, P96.
   Burman WJ, 1997, CHEST, V111, P1168, DOI 10.1378/chest.111.5.1168.
   Chaves F, 1997, AM J RESP CRIT CARE, V155, P719.
   {*}DEP HLTH, STOPP TUB ENGL ACT P.
   DEVRIES G, 2005, EUR J PUBLIC HEALTH, V17, P1101.
   Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767.
   {*}EUR MON CTR DRUG, ANN REP 2003 STAT DR.
   Golub JE, 2005, INT J TUBERC LUNG D, V9, P1183.
   Haddad MB, 2005, JAMA-J AM MED ASSOC, V293, P2762, DOI 10.1001/jama.293.22.2762.
   {*}HLTL PROT AG, 2006, FOC TUB ANN SURV REP.
   Huber P. J., 1967, P 5 BERK S MATH STAT, V1, P221, DOI DOI 10.3238/ARZTEBL.2011.0523A.
   Kumar D, 1995, J EPIDEMIOL COMMUN H, V49, P629, DOI 10.1136/jech.49.6.629.
   LoBue PA, 1999, CHEST, V115, P218, DOI 10.1378/chest.115.1.218.
   Moss AR, 2000, AM J RESP CRIT CARE, V162, P460.
   {*}NAT STAT, PRIS STAT ENGL WAL 2.
   {*}NIH, 2006, CLIN EXC NICE TUB CL.
   {*}OFF NAT STAT, MN OFF NAT STAT, V28.
   {*}OFF NATL STAT, 2003, NAT STAT 2001 CENS I.
   Ormerod P, 1998, THORAX, V53, P536.
   PablosMendez A, 1997, AM J MED, V102, P164.
   Ruddy MC, 2004, THORAX, V59, P279, DOI 10.1136/thx.2003.010405.
   Salomon N, 2000, INT J TUBERC LUNG D, V4, P47.
   Southern A, 1999, INT J TUBERC LUNG D, V3, P1001.
   SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311.
   SYCAMORE R, 2002, OVERVIEW HOMELESSNES.
   Volmink J, 2000, LANCET, V355, P1345, DOI 10.1016/S0140-6736(00)02124-3.
   Volmink J., 2006, COCHRANE DB SYST REV, V19.
   WHITE H, 1982, ECONOMETRICA, V50, P1, DOI 10.2307/1912526.
   WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934.
   2003, GREATER LONDON ALCOH.
   {[}Anonymous], 2006, CDR WEEKLY, V16.}},
Number-of-Cited-References = {{32}},
Times-Cited = {{94}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{18}},
Journal-ISO = {{Thorax}},
Doc-Delivery-Number = {{199IQ}},
Unique-ID = {{ISI:000248689800007}},
}

@article{ ISI:000248689800008,
Author = {Ahmed, Aliko B. and Abubakar, Ibrahim and Delpech, Valerie and Lipman,
   Marc and Boccia, Delia and Forde, Josh and Antoine, Delphine and Watson,
   John M.},
Title = {{The growing impact of HIV infection on the epidemiology of tuberculosis
   in England and Wales: 1999-2003}},
Journal = {{THORAX}},
Year = {{2007}},
Volume = {{62}},
Number = {{8}},
Pages = {{672-676}},
Month = {{AUG}},
Abstract = {{Background: Previous studies have estimated the prevalence of
   tuberculosis and HIV infection in population subgroups in the UK. This
   study was undertaken to describe recent trends in the proportion of
   individuals with HIV infection among reported cases of tuberculosis in
   England and Wales, and to review the implications for clinical and
   public health care.
   Methods: A population-based matching study using national surveillance
   databases was used to investigate all persons aged 15 years and over
   reported with a diagnosis of tuberculosis to the Health Protection
   Agency in England and Wales in 1999-2003. Record linkage was used to
   match the national tuberculosis and HIV/ AIDS surveillance databases to
   identify all cases of tuberculosis and determine the proportion of
   patients with tuberculosis co-infected with HIV. The distribution and
   characteristics of the cases were determined and the trend examined by
   year.
   Results: Of 30 670 cases of tuberculosis reported in England and Wales
   between 1999 and 2003, an estimated 1743 (5.7\%) were co-infected with
   HIV. There was a year on year increase in the proportion from 3.1\%
   (169/5388) in 1999 to 8.3\% (548/6584) in 2003 (p for trend <0.0001).
   Co-infected patients contributed to almost a third of the increase in
   the number of cases of tuberculosis during the 5 year period. Patients
   co-infected with HIV were predominantly those born abroad. 18.5\% (n =
   323) of co-infected patients had not been reported as active cases of
   tuberculosis on the national tuberculosis database.
   Conclusion: The proportion of patients with tuberculosis co-infected
   with HIV in England and Wales is increasing, with the greatest impact on
   those born abroad regardless of their ethnic origin. With HIV infection
   contributing substantially to the increase in the number of cases of
   tuberculosis, close cooperation in the clinical management and accurate
   notification of patients is vital if appropriate care and public health
   action is to be achieved.}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Watson, JM (Reprint Author), Hlth Protect Agcy, Dept Resp Dis, Ctr Infect, London NW9 5EQ, England.
   Hlth Protect Agcy, Dept Resp Dis, Ctr Infect, London NW9 5EQ, England.
   Univ E Anglia, Sch Med Hlth Policy \& Practice, Norwich NR4 7TJ, Norfolk, England.
   Royal Free Hosp, London NW3 2QG, England.}},
DOI = {{10.1136/thx.2006.072611}},
ISSN = {{0040-6376}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; INNER LONDON; SEROPREVALENCE; COINFECTION}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Author-Email = {{john.watson@hpa.org.uk}},
ORCID-Numbers = {{Abubakar, Ibrahim/0000-0002-0370-1430}},
Cited-References = {{{*}BHIVA, 2005, MAN TUB COINF, P405.
   Bowen EF, 2000, LANCET, V356, P1488, DOI 10.1016/S0140-6736(00)02876-2.
   Coates TJ, 2000, LANCET, V356, P103.
   {*}CTR DIS CONTR PRE, 2000, REP TUB US 1999.
   Dart S, 2006, THORAX, V61, P271, DOI 10.1136/thx.2005.048066.
   Dougan S, 2003, Commun Dis Public Health, V6, P147.
   Hayward AC, 2002, EPIDEMIOL INFECT, V128, P175, DOI 10.1017/S0950268801006690.
   {*}HLTH PROT AG, 2002, HIV AIDS UK 2001 UPD.
   {*}HLTH PROT AG CTR, 2005, ANN REP TUB CAS REP.
   Kumar D, 1997, THORAX, V52, P1060.
   Lienhardt C, 1997, INT J TUBERC LUNG D, V1, P196.
   Marshall BG, 1999, J INFECTION, V38, P162, DOI 10.1016/S0163-4453(99)90244-X.
   Martin V, 2000, INT J TUBERC LUNG D, V4, P41.
   Mortimer J, 1995, COMMUNICAB DIS REP, V5, P183.
   {*}NATL COLL CTR CHR, 2006, TUB CLIN DIAGN MAN T.
   Ormerod P, 1998, THORAX, V53, P536.
   Pozniak AL, 2005, HIV MED, V6, P62, DOI 10.1111/j.1468-1293.2005.00293.x.
   Rose AMC, 2002, THORAX, V57, P442, DOI 10.1136/thorax.57.5.442.
   Smith DK, 2000, AIDS, V14, P1237, DOI 10.1097/00002030-200006160-00022.
   UK Collaborative Group for HIV and STI Surveillance, 2004, FOC PREV HIV OTH SEX.
   WATSON JM, 1993, THORAX, V48, P199, DOI 10.1136/thx.48.3.199.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{33}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Thorax}},
Doc-Delivery-Number = {{199IQ}},
Unique-ID = {{ISI:000248689800008}},
}

@article{ ISI:000248689800025,
Author = {Somocurcio, J. G. and Sotomayor, A. and Shin, S.},
Title = {{Surgery for patients with drug-resistant tuberculosis: Report of 121
   cases receiving community-based treatment in Lima, Peru}},
Journal = {{THORAX}},
Year = {{2007}},
Volume = {{62}},
Number = {{8}},
Pages = {{743}},
Month = {{AUG}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Correction}},
Language = {{English}},
ISSN = {{0040-6376}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Cited-References = {{SOMOCURCIO, 2007, SURGERY, V62, P416.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Thorax}},
Doc-Delivery-Number = {{199IQ}},
Unique-ID = {{ISI:000248689800025}},
}

@article{ ISI:000257676900010,
Author = {Ozlen, Burcu and Ozdemir, Levent and Yoruk, Yener and Altiay, Gundeniz
   and Tabakoglu, Erhan and Hatipoglu, Osman Nuri},
Title = {{A case of ruptured hydatid cyst with upper lobe localization that
   imitated active lung tuberculosis}},
Journal = {{TRAKYA UNIVERSITESI TIP FAKULTESI DERGISI}},
Year = {{2007}},
Volume = {{24}},
Number = {{2}},
Pages = {{146-149}},
Month = {{AUG}},
Note = {{27th Annual Congress of TUSAD, Antalya, TURKEY, OCT 19-23, 2005}},
Abstract = {{Hydatid cyst is a parasitic infestation caused by Echinococcus
   granulosus. Although liver is the most common site of infection, lungs
   may also be affected in 10 to 30 \% of cases. The cyst is usually
   located in the lower lobes. of the lungs. A 49-year-old male patient
   with a cavitary lesion in the posterior segment of the right upper lobe,
   was admitted to the tuberculosis ward with a preliminary diagnosis of
   lung tuberculosis (TB), and anti-TB treatment was started empirically.
   Bronchoscopy was performed after three different sputum examinations
   with negative results for acid-fast bacilli (AFB). Bronchoalveolar
   lavage examination was also negative for AFB. High resolution computed
   tomography showed findings of a ruptured hydatid cyst, rather than TB. A
   cysctotomy was performed to the patient whose indirect hemagglutination
   test result was negative for hydatid cyst.}},
Publisher = {{AVES YAYINCILIK, IBRAHIM KARA}},
Address = {{KIZILELMA CAD 5-3, FINDIKZADE, ISTANBUL, 34096, TURKEY}},
Type = {{Article; Proceedings Paper}},
Language = {{Turkish}},
Affiliation = {{Ozlen, B (Reprint Author), Trakya Univ, Tip Fak Gogus Hastaliklari Anabilim Dali, Edirne 22030, Turkey.
   Trakya Univ, Tip Fak Gogus Hastaliklari Anabilim Dali, Edirne 22030, Turkey.}},
ISSN = {{1301-3149}},
Keywords = {{echinococcosis; pulmonary/radiography; computed tomography; X-ray;
   tuberculosis; pulmonary}},
Keywords-Plus = {{DISEASE}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{burcu\_ozlen@hotmail.com}},
Cited-References = {{AYTAC A, 1977, ANN THORAC SURG, V23, P145.
   DOGANAY A, 1998, TURKIYE KLINIKLERI C, V139, P171.
   Halezeroglu S, 1997, J THORAC CARDIOV SUR, V113, P712, DOI 10.1016/S0022-5223(97)70228-9.
   Kokturk O, 2002, TORAKS, V3, P1.
   Kuru C, 1999, TURKIYE PARAZITOL DE, V23, P251.
   MAHMOUD AAF, 1997, PARASITIC LUNG DIS L, V101.
   MERDIVENCI A, 1976, TURKIYE KIST HIDATIK, P111.
   SAKSOUK FA, 1986, J COMPUT ASSIST TOMO, V10, P226, DOI 10.1097/00004728-198603000-00011.
   TUNCEL E, 1989, KLIN RADIODIAGNOSTIK, V1, P107.
   WATTAL C, 1986, J CLIN MICROBIOL, V24, P41.
   YALAV E, 1977, AKCIGER KIST HIDATIK, P64.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Trak. Univ. Tip. Fak. Derg.}},
Doc-Delivery-Number = {{326RP}},
Unique-ID = {{ISI:000257676900010}},
}

@article{ ISI:000248965300002,
Author = {Rhodes, Shelley G. and De Leij, Frans A. A. M. and Dale, Jeremy W.},
Title = {{Protozoa as an environmental reservoir of bovine tuberculosis}},
Journal = {{TRENDS IN MICROBIOLOGY}},
Year = {{2007}},
Volume = {{15}},
Number = {{8}},
Pages = {{338-339}},
Month = {{AUG}},
Publisher = {{ELSEVIER SCIENCE LONDON}},
Address = {{84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Rhodes, SG (Reprint Author), Univ Surrey, Sch Biomed \& Mol Sci, Microbial Sci Grp, Surrey GU2 7XH, England.
   Univ Surrey, Sch Biomed \& Mol Sci, Microbial Sci Grp, Surrey GU2 7XH, England.
   Vet Labs Agcy, TB Res Grp, Surrey KT15 3NB, England.}},
DOI = {{10.1016/j.tim.2007.06.001}},
ISSN = {{0966-842X}},
Keywords-Plus = {{MYCOBACTERIUM-AVIUM; ACANTHAMOEBA-CASTELLANII; AMEBAS; INFECTION;
   VIRULENCE; SURVIVAL}},
Research-Areas = {{Biochemistry \& Molecular Biology; Microbiology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Microbiology}},
ResearcherID-Numbers = {{Rhodes, Shelley/D-9877-2011
   APHA, Staff publications/E-6082-2010}},
Cited-References = {{BARKER J, 1994, MICROBIOL-UK, V140, P1253.
   Bermudez LE, 1997, INFECT IMMUN, V65, P1916.
   Bruggemann H, 2006, CELL MICROBIOL, V8, P1228, DOI 10.1111/j.1462-5822.2006.00703.x.
   Cirillo JD, 1997, INFECT IMMUN, V65, P3759.
   Courtenay O, 2006, BIOL LETT-UK, V2, P460, DOI 10.1098/rsbl.2006.0468.
   Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x.
   Greub G, 2004, CLIN MICROBIOL REV, V17, P413, DOI 10.1128/CMR.17.2.413-433.2004.
   Taylor SJ, 2003, APPL ENVIRON MICROB, V69, P4316, DOI 10.1128/AEM.69.7.4316-4319.2003.
   Tenant R, 2006, CURR MICROBIOL, V52, P128, DOI 10.1007/s00284-005-0218-4.
   Thomas V, 2006, APPL ENVIRON MICROB, V72, P2428, DOI 10.1128/AEM.72.4.2428-2438.2006.
   Wint GRW, 2002, TRENDS MICROBIOL, V10, P441, DOI 10.1016/S0966-842X(02)02444-7.
   Woodroffe R, 2006, P NATL ACAD SCI USA, V103, P14713, DOI 10.1073/pnas.0606251103.}},
Number-of-Cited-References = {{12}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Trends Microbiol.}},
Doc-Delivery-Number = {{203HI}},
Unique-ID = {{ISI:000248965300002}},
}

@article{ ISI:000249888400005,
Author = {Cho, Sang-Nae and Brennan, Patrick J.},
Title = {{Tuberculosis: Diagnostics}},
Journal = {{TUBERCULOSIS}},
Year = {{2007}},
Volume = {{87}},
Number = {{1}},
Pages = {{S14-S17}},
Month = {{AUG}},
Note = {{10th International Conference on Emerging Infectious Diseases in the
   Pacific Rim, kyoto, JAPAN, DEC 07-10, 2004}},
Organization = {{US-Japan Cooperat Med Sci Program}},
Abstract = {{While microscopy and culture are still the major backbone for laboratory
   diagnosis of tuberculosis (TB), new methods including molecular
   diagnostic tests have evolved over the Last two decades. The majority of
   molecular tests have been focused on: (i) detection of nucleic acids
   both DNA and RNA, which are specific to Mycobacterium tuberculosis, by
   amplification techniques such as polymerase chain reaction (PCR); and
   (ii) detection of mutations in the genes which are associated with
   resistance to anti-tuberculosis drugs by sequencing or nucleic acid
   hybridization. In the session of the conference on diagnosis of TB,
   there were two presentations: one on the development of new diagnostic
   tools for drug resistant M. tuberculosis, and the other on issues
   involved in the application of new diagnostic toots for multidrug
   resistant (MDR)-TB, pediatric TB and HIV-TB. (c) 2007 Elsevier Ltd. All
   rights reserved.}},
Publisher = {{CHURCHILL LIVINGSTONE}},
Address = {{JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Cho, SN (Reprint Author), Yonsei Univ, Coll Med, Dept Microbiol, 134 Shinchon Dong, Seoul 120752, South Korea.
   Yonsei Univ, Coll Med, Dept Microbiol, Seoul 120752, South Korea.
   Colorado State Univ, Dept Microbiol Immunol \& Pathol, Ft Collins, CO 80523 USA.}},
DOI = {{10.1016/j.tube.2007.05.001}},
ISSN = {{1472-9792}},
Keywords = {{tuberculosis; molecular diagnosis; immunodiagnosis}},
Keywords-Plus = {{RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HUMAN-IMMUNODEFICIENCY-VIRUS;
   CATALASE-PEROXIDASE GENE; SUB-SAHARAN AFRICA; LINE PROBE ASSAY;
   NEW-YORK-CITY; DRUG-RESISTANCE; STREPTOMYCIN RESISTANCE; CHILDHOOD
   TUBERCULOSIS; PULMONARY TUBERCULOSIS}},
Research-Areas = {{Immunology; Microbiology; Respiratory System}},
Web-of-Science-Categories  = {{Immunology; Microbiology; Respiratory System}},
Author-Email = {{raycho@yumc.yonsei.ac.kr}},
Cited-References = {{Alangaden GJ, 1998, ANTIMICROB AGENTS CH, V42, P1295.
   BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673.
   Bonington A, 1998, J CLIN MICROBIOL, V36, P1251.
   Brock I, 2001, INT J TUBERC LUNG D, V5, P462.
   Chan ED, 2000, TUBERCLE LUNG DIS, V80, P131, DOI 10.1054/tuld.2000.0243.
   Cooksey RC, 1997, J CLIN MICROBIOL, V35, P1281.
   Cooksey RC, 1996, ANTIMICROB AGENTS CH, V40, P1186.
   Davidson RN, 2000, T ROY SOC TROP MED H, V94, P5, DOI 10.1016/S0035-9203(00)90415-2.
   DERETIC V, 1995, MOL MICROBIOL, V17, P889, DOI 10.1111/j.1365-2958.1995.mmi\_17050889.x.
   Diel R, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-77.
   FINKEN M, 1993, MOL MICROBIOL, V9, P1239, DOI 10.1111/j.1365-2958.1993.tb01253.x.
   Giannoni F, 2005, ANTIMICROB AGENTS CH, V49, P2928, DOI 10.1128/AAC.49.7.2928-2933.2005.
   Gryadunov D, 2005, CLIN MICROBIOL INFEC, V11, P531, DOI 10.1111/j.1469-0691.2005.01183.x.
   HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2.
   Holmes CB, 2003, CLIN INFECT DIS, V36, P652, DOI 10.1086/367655.
   Jones D, 2002, CLIN CHEST MED, V23, P665, DOI 10.1016/S0272-5231(02)00015-1.
   Kambashi B, 2001, INT J TUBERC LUNG D, V5, P364.
   Kang YA, 2005, JAMA-J AM MED ASSOC, V293, P2756, DOI 10.1001/jama.293.22.2756.
   KATOMAEDA M, 2006, INFECTIONS, P388.
   Katsukawa C., 1997, Journal of Applied Microbiology, V83, P634, DOI 10.1046/j.1365-2672.1997.00279.x.
   Kivihya-Ndugga L, 2004, J CLIN MICROBIOL, V42, P1012, DOI 10.1128/JCM.42.3.1012-1015.2004.
   Lee ASG, 1999, ANTIMICROB AGENTS CH, V43, P2087.
   Lee H, 2003, J CLIN MICROBIOL, V41, P2213, DOI 10.1128/JCM.41.5.2213-2218.2003.
   Lee H, 1998, INT J TUBERC LUNG D, V2, P585.
   Lyashchenko K, 1998, INFECT IMMUN, V66, P3936.
   Meier T, 2005, EUR J CLIN MICROBIOL, V24, P529, DOI 10.1007/s10096-005-1377-8.
   Mokrousov I, 2004, J MICROBIOL METH, V57, P323, DOI 10.1016/j.mimet.2004.02.006.
   Montenegro SH, 2003, CLIN INFECT DIS, V36, P16, DOI 10.1086/344900.
   Musser JM, 1996, J INFECT DIS, V173, P196.
   Nelson LJ, 2004, INT J TUBERC LUNG D, V8, P636.
   Pahwa R, 2005, J MED MICROBIOL, V54, P873, DOI 10.1099/jmm.0.45904-0.
   Palmieri F, 2002, INFECTION, V30, P68, DOI 10.1007/s15010-002-2062-9.
   Park H, 2006, J CLIN MICROBIOL, V44, P1619, DOI 10.1128/JCM.44.5.1619-1624.2006.
   Piatek AS, 1998, NAT BIOTECHNOL, V16, P359, DOI 10.1038/nbt0498-359.
   Pitaksajjakul Pannamthip, 2005, Southeast Asian J Trop Med Public Health, V36 Suppl 4, P228.
   Pretorius GS, 1996, S AFR MED J, V86, P50.
   Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002.
   Ramaswamy SV, 2000, ANTIMICROB AGENTS CH, V44, P326, DOI 10.1128/AAC.44.2.326-336.2000.
   Rengarajan J, 2004, MOL MICROBIOL, V53, P275, DOI 10.1111/j.1365-2958.2004.04120.x.
   Scorpio A, 1996, NAT MED, V2, P662, DOI 10.1038/nm0696-662.
   Scorpio A, 1997, ANTIMICROB AGENTS CH, V41, P540.
   STARKE JR, 2000, TUBERCULOSIS NONTUBE, P365.
   Suzuki Y, 2002, J CLIN MICROBIOL, V40, P501, DOI 10.1128/JCM.40.2.501-507.2002.
   Suzuki Y, 1998, J CLIN MICROBIOL, V36, P1220.
   TAKIFF HE, 1994, ANTIMICROB AGENTS CH, V38, P773.
   Tang X, 2005, J MICROBIOL METH, V63, P318, DOI 10.1016/j.mimet.2005.04.026.
   TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F.
   Telenti A, 1997, NAT MED, V3, P567, DOI 10.1038/nm0597-567.
   Victor T. C., 1999, Tubercle and Lung Disease, V79, P343, DOI 10.1054/tuld.1999.0222.
   Victor TC, 2002, CLIN CHEM LAB MED, V40, P876, DOI 10.1515/CCLM.2002.155.
   WILLIAMS DL, 1994, ANTIMICROB AGENTS CH, V38, P2380.
   ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0.
   Zhang Y, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P235.}},
Number-of-Cited-References = {{53}},
Times-Cited = {{18}},
Usage-Count-Last-180-days = {{4}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{Tuberculosis}},
Doc-Delivery-Number = {{216OR}},
Unique-ID = {{ISI:000249888400005}},
}

@article{ ISI:000249888400004,
Author = {Mitsuyama, Masao and McMurray, David N.},
Title = {{Tuberculosis: Vaccine and drug development}},
Journal = {{TUBERCULOSIS}},
Year = {{2007}},
Volume = {{87}},
Number = {{1}},
Pages = {{S10-S13}},
Month = {{AUG}},
Note = {{10th International Conference on Emerging Infectious Diseases in the
   Pacific Rim, kyoto, JAPAN, DEC 07-10, 2004}},
Organization = {{US-Japan Cooperat Med Sci Program}},
Publisher = {{CHURCHILL LIVINGSTONE}},
Address = {{JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{McMurray, DN (Reprint Author), Texas A\&M Univ, Coll Med, Hlth Sci Ctr, College Stn, TX 77843 USA.
   Texas A\&M Univ, Coll Med, Hlth Sci Ctr, College Stn, TX 77843 USA.
   Kyoto Univ, Grad Sch Med, Kyoto, Japan.}},
DOI = {{10.1016/j.tube.2007.05.006}},
ISSN = {{1472-9792}},
Keywords-Plus = {{MYCOBACTERIUM-BOVIS BCG; SUBUNIT VACCINE; RECOMBINANT BCG; CONFERS
   PROTECTION; IMMUNE-RESPONSES; CLINICAL-TRIALS; GUINEA-PIGS; MICE;
   IMMUNOGENICITY; EFFICACY}},
Research-Areas = {{Immunology; Microbiology; Respiratory System}},
Web-of-Science-Categories  = {{Immunology; Microbiology; Respiratory System}},
Author-Email = {{mcmurray@medicine.tamhsc.edu}},
Cited-References = {{Aguilar LD, 2006, VACCINE, V24, P2333, DOI 10.1016/j.vaccine.2005.11.051.
   Aldwell FE, 2005, INFECT IMMUN, V73, P1903, DOI 10.1128/IAI.73.3.1903-1905.2005.
   Andersen CS, 2007, INFECT IMMUN, V75, P408, DOI 10.1128/IAI.01290-06.
   Andersen P, 2007, TRENDS MICROBIOL, V15, P7, DOI 10.1016/j.tim.2006.11.008.
   Brennan MJ, 2005, TUBERCULOSIS, V85, P7, DOI 10.1016/j.tube.2004.09.001.
   Cai H, 2005, VACCINE, V23, P4167, DOI 10.1016/j.vaccine.2005.03.024.
   Dietrich J, 2005, J IMMUNOL, V174, P6332.
   Dietrich J, 2007, J IMMUNOL, V178, P3721.
   Eddine AN, 2005, MICROBES INFECT, V7, P939, DOI 10.1016/j.micinf.2005.03.012.
   Gilbert SC, 2006, VACCINE, V24, P4554, DOI 10.1016/j.vaccine.2005.08.048.
   Horwitz MA, 2005, MICROBES INFECT, V7, P947, DOI 10.1016/j.micinf.2005.04.002.
   Ibango HB, 2006, LANCET INFECT DIS, V6, P522, DOI 10.1016/S1473-3099(06)70552-7.
   Izzo A, 2005, TUBERCULOSIS, V85, P25, DOI 10.1016/j.tube.2004.09.008.
   Kaufmann SHE, 2006, INT J TUBERC LUNG D, V10, P1068.
   Kaufmann S. H., 2005, NAT MED, V11, P33.
   Khera A, 2005, VACCINE, V23, P5655, DOI 10.1016/j.vaccine.2005.03.056.
   Kita Y, 2005, VACCINE, V23, P2132, DOI 10.1016/j.vaccine.2005.01.057.
   Langermans JAM, 2005, VACCINE, V23, P4935, DOI 10.1016/j.vaccine.2005.05.036.
   Li H, 2006, VACCINE, V24, P1315, DOI 10.1016/j.vaccine.2005.09.025.
   Martin C, 2006, VACCINE, V24, P3408, DOI 10.1016/j.vaccine.2006.03.017.
   Matsumoto S, 2005, J IMMUNOL, V175, P441.
   McShane H, 2005, TUBERCULOSIS, V85, P47, DOI 10.1016/j.tube.2004.09.015.
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128.
   Nagelkerke NJD, 2006, TUBERCULOSIS, V86, P41, DOI 10.1016/j.tube.2005.06.001.
   Orme IM, 2006, TUBERCULOSIS, V86, P68, DOI 10.1016/j.tube.2005.07.002.
   Orme IM, 2005, TUBERCULOSIS, V85, P13, DOI 10.1016/j.tube.2004.08.001.
   Reed S, 2005, MICROBES INFECT, V7, P922, DOI 10.1016/j.micinf.2005.03.011.
   Romano M, 2006, VACCINE, V24, P3353, DOI 10.1016/j.vaccine.2005.12.066.
   Rook GAW, 2005, NAT REV IMMUNOL, V5, P661, DOI 10.1038/nri1666.
   Sadoff JC, 2005, MICROBES INFECT, V7, P899, DOI 10.1016/j.micinf.2005.03.015.
   Sambandamurthy VK, 2005, MICROBES INFECT, V7, P955, DOI 10.1016/j.micinf.2005.04.001.
   Sander C, 2007, CLIN EXP IMMUNOL, V147, P401, DOI 10.1111/j.1365-2249.2006.03306.x.
   Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419.
   Williams A, 2005, INFECT IMMUN, V73, P3814, DOI 10.1128/IAI.73.6.3814-3816.2005.
   Yoshida S, 2006, VACCINE, V24, P1191, DOI 10.1016/j.vaccine.2005.08.103.
   Young D, 2006, CELL, V124, P683, DOI 10.1016/j.cell.2006.02.013.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Tuberculosis}},
Doc-Delivery-Number = {{216OR}},
Unique-ID = {{ISI:000249888400004}},
}

@article{ ISI:000249888400006,
Author = {Vermund, Sten H. and Yamamoto, Naoki},
Title = {{Co-infection with human immunodeficiency virus and tuberculosis in Asia}},
Journal = {{TUBERCULOSIS}},
Year = {{2007}},
Volume = {{87}},
Number = {{1}},
Pages = {{S18-S25}},
Month = {{AUG}},
Note = {{10th International Conference on Emerging Infectious Diseases in the
   Pacific Rim, Kyoto, JAPAN, DEC 07-10, 2004}},
Organization = {{US-Japan Cooperat Med Sci Program}},
Abstract = {{Asia has the highest numbers of tuberculosis cases (60\% of the global
   total) and has experienced a marked rise in HIV seroprevalence (22\% of
   the global total) in key subpopulations of these highly populous
   nations. Thus, co-infected patients are a challenge for practitioners
   and public health workers alike. The U.S.-Japan Cooperative Medical
   Science Program is spearheading interdisciplinary collaborations in Asia
   to address the many outstanding research priorities for HIV-tuberculosis
   co-infection. There is an urgency to this agenda for many reasons,
   including the frequency with which tuberculosis accounts for the death
   of HIV-infected persons in Asia, and the continued rise of multiple
   drug-resistant Mycobacterium tuberculosis. We review briefly the public
   health situation in Asia, highlighting research questions from
   US-Japan-Asian partner joint meetings, and cite salient studies to
   indicate trends and challenges. (c) 2007 Elsevier Ltd. All rights
   reserved.}},
Publisher = {{CHURCHILL LIVINGSTONE}},
Address = {{JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Vermund, SH (Reprint Author), Vanderbilt Univ, Sch Med, Inst Global Hlth, 2215 Garland Ave,319 Light Hall, Nashville, TN 37323 USA.
   Vanderbilt Univ, Sch Med, Inst Global Hlth, Nashville, TN 37323 USA.
   Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37323 USA.
   Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan.}},
DOI = {{10.1016/j.tube.2007.05.008}},
ISSN = {{1472-9792}},
Keywords = {{tuberculosis; HIV; AIDS; Asia; epidemiology; immune reconstitution
   syndrome; co-infection}},
Keywords-Plus = {{SEXUALLY-TRANSMITTED-DISEASES; ACTIVE ANTIRETROVIRAL THERAPY;
   DRUG-SUSCEPTIBILITY ASSAY; SUB-SAHARAN AFRICA; MULTIDRUG-RESISTANT
   TUBERCULOSIS; NEGATIVE PULMONARY TUBERCULOSIS; COST-EFFECTIVENESS
   ANALYSIS; MIDDLE-INCOME COUNTRIES; HIV-INFECTED PATIENTS; LATENT TB
   INFECTION}},
Research-Areas = {{Immunology; Microbiology; Respiratory System}},
Web-of-Science-Categories  = {{Immunology; Microbiology; Respiratory System}},
Author-Email = {{sten.vermund@vanderbilt.edu
   nyama@nih.go.jp}},
ORCID-Numbers = {{Vermund, Sten/0000-0001-7289-8698}},
Funding-Acknowledgement = {{FIC NIH HHS {[}R25 TW007766, R25 TW007766-02]; NIAID NIH HHS {[}P30
   AI054999, P30 AI054999-04]}},
Cited-References = {{Amornwichet P, 2002, JAMA-J AM MED ASSOC, V288, P245, DOI 10.1001/jama.288.2.245.
   Balasubramanian R, 2004, INT J TUBERC LUNG D, V8, P323.
   Baltussen R, 2005, BRIT MED J, V331, P1364, DOI 10.1136/bmj.38645.660093.68.
   Baumann S, 2006, CURR OPIN IMMUNOL, V18, P438, DOI 10.1016/j.coi.2006.05.016.
   Beyrer C, 2005, AIDS, V19, P1535, DOI 10.1097/01.aids.0000183122.01583.c7.
   Beyrer C, 2003, AIDS BEHAV, V7, P153, DOI 10.1023/A:1023946324822.
   Beyrer C, 2006, PLOS MED, V3, P1733, DOI 10.1371/journal.pmed.0030393.
   Biava M., 2006, Infectious Disorders - Drug Targets, V6, P159, DOI 10.2174/187152606784112173.
   Bonnet MMB, 2006, AIDS, V20, P1275, DOI 10.1097/01.aids.0000232235.26630.ee.
   Borgdorff MW, 2002, B WORLD HEALTH ORGAN, V80, P217.
   CALENTANO DD, 2000, ARCH INTERN MED, V160, P535.
   CARVELL ALM, 1990, BRIT MED J, V300, P1383.
   Centers for Disease Control Prevention, 2005, MMWR-MORBID MORTAL W, V54, P1177.
   Chadha VK, 2005, INT J TUBERC LUNG D, V9, P1072.
   Chandrasekaran P, 2006, LANCET INFECT DIS, V6, P508, DOI 10.1016/S1473-3099(06)70551-5.
   Chee CBE, 2005, INT J TUBERC LUNG D, V9, P1248.
   Chee CBE, 2004, INT J TUBERC LUNG D, V8, P226.
   Cheng Yingkai, 2006, Harm Reduct J, V3, P10, DOI 10.1186/1477-7517-3-10.
   Chiao C, 2006, SUBST USE MISUSE, V41, P1509, DOI 10.1080/10826080600846284.
   Choi KH, 2006, AIDS EDUC PREV, V18, P33, DOI 10.1521/aeap.2006.18.1.33.
   Citterio P, 2007, EXPERT OPIN INV DRUG, V16, P11, DOI 10.1517/13543784.16.1.11.
   CLOTTEY C, 1993, INFECT DIS CLIN N AM, V7, P753.
   Cohen MS, 2002, CURR CLIN TOPICS INF, V22, P214.
   Cohen Myron S, 2004, Top HIV Med, V12, P104.
   Colebunders R, 2000, INT J TUBERC LUNG D, V4, P97.
   Coninx R, 2000, BRIT MED J, V320, P440, DOI 10.1136/bmj.320.7232.440.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Dandona L, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-31.
   Dandona L, 2005, AIDS, V19, P611, DOI 10.1097/01.aids.0000163938.01188.e4.
   Davies PDO, 2006, T ROY SOC TROP MED H, V100, P291, DOI 10.1016/j.trstmh.2005.06.034.
   Di Perri Giovanni, 2005, Expert Opin Drug Saf, V4, P821, DOI 10.1517/14740338.4.5.821.
   Dimitrova B, 2006, HEALTH POLICY PLANN, V21, P265, DOI 10.1093/heapol/czl014.
   Dolan K, 2007, LANCET INFECT DIS, V7, P32, DOI 10.1016/S1473-3099(06)70685-5.
   Drobniewski FA, 2004, INT J STD AIDS, V15, P641, DOI 10.1258/0956462041944303.
   Duerr A, 2006, CLIN INFECT DIS, V43, P500, DOI 10.1086/505979.
   ELLNER JJ, 1993, J INFECT DIS, V168, P537.
   Fang CT, 2004, J INFECT DIS, V190, P879, DOI 10.1086/422601.
   Fideli Ulgen Semaye, 2001, AIDS Research and Human Retroviruses, V17, P901, DOI 10.1089/088922201750290023.
   Fiscus SA, 2007, J INFECT DIS, V195, P416, DOI 10.1086/510755.
   Fleming DT, 1999, SEX TRANSM INFECT, V75, P3.
   Fletcher Helen, 2006, Expert Opin Emerg Drugs, V11, P207, DOI 10.1517/14728214.11.2.207.
   Floyd K, 2006, B WORLD HEALTH ORGAN, V84, P437, DOI 10.2471/BLT.05.024109.
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4.
   Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794.
   Gandhi Neel R, 2006, Lancet, V368, P1575.
   Go VF, 2006, JAIDS-J ACQ IMM DEF, V42, P108, DOI 10.1097/01.qai.0000199354.88607.2f.
   Godfrey-Faussett P, 2002, B WORLD HEALTH ORGAN, V80, P939.
   Gupta A, 2006, JAIDS-J ACQ IMM DEF, V43, P483.
   Gupta S B, 2006, J Assoc Physicians India, V54, P57.
   Harries AD, 1998, B WORLD HEALTH ORGAN, V76, P651.
   He Q, 2006, AIDS BEHAV, V10, pS17, DOI 10.1007/s10461-006-9125-3.
   Hernandez AL, 2006, AIDS BEHAV, V10, pS5, DOI 10.1007/s10461-006-9129-z.
   Hidaka Y, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-239.
   Inoue Y, 2006, AIDS PATIENT CARE ST, V20, P792, DOI 10.1089/apc.2006.20.792.
   Islam MA, 2002, B WORLD HEALTH ORGAN, V80, P445.
   Jack C, 2004, JAIDS-J ACQ IMM DEF, V36, P929, DOI 10.1097/00126334-200408010-00006.
   Jiang J, 2006, SEX TRANSM DIS, V33, P118, DOI 10.1097/01.olq.0000199763.14766.2b.
   Kaljee LM, 2005, HEALTH EDUC RES, V20, P71, DOI 10.1093/her/cyg096.
   Kaufmann SHE, 2006, INT J TUBERC LUNG D, V10, P1068.
   Kawichai S, 2006, JAIDS-J ACQ IMM DEF, V41, P186, DOI 10.1097/01.qai.0000179431.42284.3e.
   Khan MA, 2005, HEALTH POLICY PLANN, V20, P354, DOI 10.1093/heapol/czi047.
   Khan SI, 2005, CULT HEALTH SEX, V7, P159, DOI 10.1080/13691050412331321258.
   Kizuki M, 2006, J EPIDEMIOL, V16, P167, DOI 10.2188/jea.16.167.
   Ko NY, 2006, SEX TRANSM DIS, V33, P467, DOI 10.1097/01.olq.0000204512.15297.5f.
   Kwara A, 2005, INT J TUBERC LUNG D, V9, P248.
   Letvin NL, 2006, NAT REV IMMUNOL, V6, P930, DOI 10.1038/nri1959.
   Lin DH, 2005, DRUG ALCOHOL DEPEN, V79, P103, DOI 10.1016/j.drugalcdep.2005.01.003.
   Liu A, 2006, INT FAM PLAN PERSPEC, V32, P126, DOI 10.1363/3212606.
   Madhivanan P, 2005, SEX TRANSM DIS, V32, P685, DOI 10.1097/01.olq.0000175405.36124.3b.
   Manosuthi W, 2006, JAIDS-J ACQ IMM DEF, V43, P42, DOI 10.1097/01.qai.0000230521.86964.86.
   Manosuthi W, 2006, J INFECTION, V53, P357, DOI 10.1016/j.jinf.2006.01.002.
   Mansergh G, 2006, AIDS BEHAV, V10, P743, DOI 10.1007/s10461-006-9108-4.
   Michailidis C, 2005, ANTIVIR THER, V10, P417.
   Moore DAJ, 2004, J CLIN MICROBIOL, V42, P4432, DOI 10.1128/JCM.42.10.4432-4437.2004.
   Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524.
   Moore DAJ, 2006, DIAGN MICR INFEC DIS, V56, P35, DOI 10.1016/j.diagmicrobio.2006.03.009.
   Nakamura Y, 2004, INTERNAL MED, V43, P263, DOI 10.2169/internalmedicine.43.263.
   Narain JP, 2004, INDIAN J MED RES, V120, P277.
   Ngamvithayapong J, 2001, INT J TUBERC LUNG D, V5, P741.
   Niveau G, 2006, PUBLIC HEALTH, V120, P33, DOI 10.1016/j.puhe.2005.03.017.
   Ono S, 2006, JPN J INFECT DIS, V59, P168.
   Over M, 2006, SEX TRANSM DIS, V33, pS145, DOI 10.1097/01.olq.0000238457.93426.0d.
   Pai M, 2006, EXPERT REV MOL DIAGN, V6, P423, DOI 10.1586/14737159.6.3.423.
   Pai M, 2006, EXPERT REV MOL DIAGN, V6, P413, DOI 10.1586/14737159.6.3.413.
   Park WG, 2002, J CLIN MICROBIOL, V40, P4750, DOI 10.1128/JCM.40.12.4740-4752.2002.
   Perlman D C, 1999, Semin Respir Infect, V14, P344.
   Pilcher CD, 2002, JAMA-J AM MED ASSOC, V288, P216, DOI 10.1001/jama.288.2.216.
   Punpanich W, 2004, AIDS EDUC PREV, V16, P119, DOI 10.1521/aeap.16.3.5.119.35520.
   Puthanakit T, 2005, CLIN INFECT DIS, V41, P100, DOI 10.1086/430714.
   Qian ZH, 2005, SEX TRANSM INFECT, V81, P442, DOI 10.1136/sti.2004.014258.
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303.
   Rahman M, 1998, J Epidemiol, V8, P123.
   Reid SE, 2004, INT J STD AIDS, V15, P713, DOI 10.1258/0956462042395195.
   Reyes H, 1997, BRIT MED J, V315, P1447.
   Risbud A, 2005, INDIAN J MED RES, V121, P369.
   Rodger AJ, 2002, B WORLD HEALTH ORGAN, V80, P451.
   Safren SA, 2006, AIDS BEHAV, V10, P443, DOI 10.1007/s10461-006-9094-6.
   Schneider R F, 1996, Curr Opin Pulm Med, V2, P246, DOI 10.1097/00063198-199605000-00013.
   Schwartzman K, 2005, NEW ENGL J MED, V353, P1008, DOI 10.1056/NEJMsa043194.
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901.
   Setia Maninder Singh, 2006, Indian J Dermatol Venereol Leprol, V72, P425.
   Shafer RW, 1996, CLIN INFECT DIS, V22, P683.
   Sharma SK, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-52.
   Sharma SK, 2005, INDIAN J MED RES, V121, P550.
   Shetty N, 2006, INT J TUBERC LUNG D, V10, P80.
   SHIFERAW G, 2007, J CLIN MIRCROBIOL.
   SINGH S, 1993, AIDS CARE, V5, P273, DOI 10.1080/09540129308258610.
   Sivaram S, 2004, AIDS EDUC PREV, V16, P137, DOI 10.1521/aeap.16.2.137.29393.
   Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419.
   Stachowiak JA, 2006, DRUG ALCOHOL DEPEN, V82, pS7, DOI 10.1016/S0376-8716(06)80002-5.
   STEAD WW, 1989, CLIN CHEST MED, V10, P397.
   Sterjovski J, 2006, CURR HIV RES, V4, P387, DOI 10.2174/157016206778560081.
   Suggaravetsiri P, 2003, INT J TUBERC LUNG D, V7, pS424.
   Sungkanuparph S, 2006, J INFECTION, V52, P188, DOI 10.1016/j.jinf.2005.05.010.
   Sutthent R, 2005, J CLIN VIROL, V34, P272, DOI 10.1016/j.jcv.2005.02.014.
   Swaminathan S, 2006, TROP DOCT, V36, P73, DOI 10.1258/004947506776593387.
   Thanprasertsuk S, 2005, AIDS, V19, P1932, DOI 10.1097/01.aids.0000189845.96783.17.
   Thanprasertsuk Sombat, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P83.
   Tomioka H, 2006, CURR PHARM DESIGN, V12, P4047, DOI 10.2174/138161206778743646.
   Tornee Songpol, 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P331.
   Tornee Songpol, 2004, Southeast Asian Journal of Tropical Medicine and Public Health, V35, P375.
   Tupasi TE, 2006, PLOS MED, V3, P1587, DOI 10.1371/journal.pmed.0030352.
   Umenai T, 1997, J ACQ IMMUN DEF SYND, V14, pS58, DOI 10.1097/00042560-199700002-00011.
   Vajpayee M, 2004, AIDS PATIENT CARE ST, V18, P209, DOI 10.1089/108729104323038883.
   van Dam C J, 1994, J Indian Med Assoc, V92, P8.
   van Griensven F, 2005, AIDS, V19, P521, DOI 10.1097/01.aids.0000162341.50933.e8.
   Vermund SH, 2003, CLIN INFECT DIS, V37, pS4, DOI 10.1086/375367.
   Vermund Sten H, 2006, J Pak Med Assoc, V56, pS1.
   Vernazza PL, 2000, AIDS, V14, P117, DOI 10.1097/00002030-200001280-00006.
   Villacian JS, 2005, J INFECTION, V51, P408, DOI 10.1016/j.jinf.2004.11.011.
   Watkins RE, 2004, INT J TUBERC LUNG D, V8, P218.
   Wendel KA, 2001, CHEST, V120, P193, DOI 10.1378/chest.120.1.193.
   Wiker HG, 2006, SCAND J IMMUNOL, V64, P243, DOI 10.1111/j.1365-3083.2006.01815.x.
   Williams BG, 2005, P NATL ACAD SCI USA, V102, P9619, DOI 10.1073/pnas.0501615102.
   Wong WCW, 2006, SEX TRANSM INFECT, V82, P127, DOI 10.1136/sti.2005.016790.
   Zar HJ, 2003, INT J TUBERC LUNG D, V7, P820.
   Zhang BC, 2005, CELL RES, V15, P858, DOI 10.1038/sj.cr.7290359.
   Zhang FJ, 2005, CELL RES, V15, P877, DOI 10.1038/sj.cr.7290362.
   Zhou YQR, 2006, CULT HEALTH SEX, V8, P487, DOI 10.1080/13691050600847455.
   Zulu I, 2004, JAIDS-J ACQ IMM DEF, V36, P831, DOI 10.1097/00126334-200407010-00010.
   Zumla A, 2000, POSTGRAD MED J, V76, P259, DOI 10.1136/pmj.76.895.259.}},
Number-of-Cited-References = {{141}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{Tuberculosis}},
Doc-Delivery-Number = {{216OR}},
Unique-ID = {{ISI:000249888400006}},
}

@article{ ISI:000248297900001,
Author = {Shitaye, J. E. and Tsegaye, W. and Pavlik, I.},
Title = {{Bovine tuberculosis infection in animal and human populations in
   Ethiopia: a review}},
Journal = {{VETERINARNI MEDICINA}},
Year = {{2007}},
Volume = {{52}},
Number = {{8}},
Pages = {{317-332}},
Month = {{AUG}},
Abstract = {{Ethiopia is one among the nations that possesses the largest number of
   livestock population in the African continent estimated to be 33 million
   cattle, 24 million sheep and 18 million goats. In contrast to the huge
   livestock resource, the livestock productivity is however, found to be
   very low. The major biological and socio-economical factors attributing
   to the low productivity includes: the low genetic potential and
   performance, poor nutrition ( in quality and quantity terms), the
   prevailing of different diseases, traditional way of husbandry systems
   and inadequate skilled manpower, among others. Ethiopia is one of the
   African countries where tuberculosis is wide spread in both humans and
   cattle and the endemic nature of tuberculosis in humans and cattle has
   long been documented. The disease is considered as one of the major
   livestock diseases that results in high morbidity and mortality,
   although the current status on the actual prevalence rate of bovine
   tuberculosis (BTB) at a national level is yet unknown. Detection of BTB
   in Ethiopia is carried out most commonly on the basis of tuberculin skin
   testing, abattoir meat inspection and very rarely on bacteriological
   techniques. Recently undertaken studies indicated the prevalence rate of
   BTB with a range of 3.4\% (in small holder production system) to 50\%
   (in intensive dairy productions) and a range of 3.5\% to 5.2\% in
   slaughterhouses in various places of the country. BTB in cattle remains
   to be a great concern due to the susceptibility of humans to the
   disease. The infections mainly take place by drinking raw milk and occur
   in the extra-pulmonary form, in the cervical lymphadenitis form in
   particular. The aim of this paper is to review the status of BTB in
   Ethiopia in relation with the existing animal husbandry systems and
   abattoir meat inspection surveillances. Control measures, economic
   impacts and the zoonotic aspect of the disease are also briefly
   addressed.}},
Publisher = {{VETERINARY RESEARCH INST}},
Address = {{HUDCOVA 70, BRNO, 621 32, CZECH REPUBLIC}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Pavlik, I (Reprint Author), Vet Res Inst, Hudcova 70, CS-62132 Brno, Czech Republic.
   Vet Res Inst, CS-62132 Brno, Czech Republic.
   Univ Vet \& Pharmaceut Sci, Brno, Czech Republic.
   Addis Ababa Urban Agr Off, Shola Vet Clin, Addis Ababa, Ethiopia.
   Addis Ababa Urban Agr Off, Shola Vet Lab, Addis Ababa, Ethiopia.}},
ISSN = {{0375-8427}},
Keywords = {{Mycobacterium bovis; pastoral production; pasteurisation; zoonosis; food
   safety; test-and-slaughter}},
Keywords-Plus = {{CENTRAL-EUROPEAN COUNTRIES; MYCOBACTERIUM-BOVIS; CATTLE; EPIDEMIOLOGY;
   INSPECTION; ABATTOIR; LESIONS}},
Research-Areas = {{Veterinary Sciences}},
Web-of-Science-Categories  = {{Veterinary Sciences}},
Author-Email = {{pavlik@vri.cz}},
ResearcherID-Numbers = {{Pavlik, Ivo/P-5887-2014}},
ORCID-Numbers = {{Pavlik, Ivo/0000-0002-5771-3381}},
Cited-References = {{ABDO J, 1993, THESIS U EDINBURGH.
   ABEL, 1989, SURVEY ABATTOIR INSP.
   ALEMAYEHU M, 2003, COUNTRY PASTURE FORA, P1.
   ALEMU T, 1992, THESIS U EDINBURGH.
   Amanfu W, 2006, TUBERCULOSIS, V86, P330, DOI 10.1016/j.tube.2006.01.007.
   Ameni G., 2003, International Journal of Applied Research in Veterinary Medicine, V1, P17.
   Ameni G., 2003, Bulletin of Animal Health and Production in Africa, V51, P125.
   Ameni G, 1996, THESIS ADDIS ABABA U.
   Ameni G., 2003, INT J APPL RES VET M, V1, P85.
   Ameni G, 2001, ETHIOPIAN J ANIM PRO, V1, P55.
   Ameni G, 1998, P 12 ANN C ETH VET A, P13.
   Ameni G, 2006, CLIN VACCINE IMMUNOL, V13, P1030, DOI 10.1128/CVI.00134-06.
   Ashford DA, 2001, REV SCI TECH OIE, V20, P325.
   Asseged B, 2004, TROP ANIM HEALTH PRO, V36, P537, DOI 10.1023/B:TROP.0000040934.32330.44.
   ASSEGED B, 2001, B ANIMAL HLTH PRODUC, V48, P71.
   Ayele WY, 2004, INT J TUBERC LUNG D, V8, P924.
   BAYWATER JEC, 1962, VET REC, V74, P1414.
   COLLINS CH, 1985, ORG PRACTICE TUBERCO.
   COLLINS CH, 1983, J APPL BACTERIOL, V5, P3.
   COLLINS FM, 1994, VET MICROBIOL, V40, P95, DOI 10.1016/0378-1135(94)90049-3.
   Cosivi O, 1998, EMERG INFECT DIS, V4, P1.
   COSIVI O, 1995, OIE SCI TECH REV, V14, P733.
   DABORN CJ, 1996, J APPL BACTERIOL, V81, P275.
   {*}FAO, 1972, REP GOV ETH.
   {*}FAO, 1967, REP GOV ETH.
   {*}FAO STAT, 2003, FAO STAT DAT WORLD W.
   GEMTA MB, 2000, TEHSSI ADDIS ABABA.
   GEZAHEGNE L, 1991, EC ASPECT CONDEMNED.
   GORDEN CG, 1968, GUIDE TUBERCULOSIS E.
   GRANGE JM, 1994, VET MICROBIOL, V40, P137, DOI 10.1016/0378-1135(94)90052-3.
   GRANGE JM, 1994, EUR RESPIR J, V7, P1564, DOI 10.1183/09031936.94.07091564.
   GRANGE JM, 1995, MYCOBACTERIUM BOVIS, P29.
   Hailemariam S., 1975, BRIEF ANAL ACTIVITIE.
   Jaumally M. R., 1983, Tropical Veterinary Journal, V1, P20.
   Kazwala RR, 1998, TROP ANIM HEALTH PRO, V30, P233, DOI 10.1023/A:1005075112393.
   Kidane D, 2002, J CLIN MICROBIOL, V40, P4230, DOI 10.1128/JCM.40.11.4230-4234.2002.
   KINFE G, 1987, P 1 NAT LIV IMPR C I.
   KIROS T, 1998, THESIS U FREIE U BER.
   Kleeberg H. H., 1984, Revue Scientifique et Technique, Office International des Epizooties, V3, P11.
   KONHYA LD, 1980, HDB SERIES ZOONOSE A, V2, P147.
   Kriek NP, 2006, MYCOBACTERIUM BOVIS, P238, DOI 10.1002/9780470344538.ch22.
   LISS GM, 1994, CAN J PUBLIC HEALTH, V85, P326.
   Macallan DC, 1999, DIAGN MICR INFEC DIS, V34, P153, DOI 10.1016/S0732-8893(99)00007-3.
   {*}MIN HLTH, 2004, HLTH HLTH REL IND YE.
   {*}MIN HLTH, 1978, ANN REP TUB INF.
   {*}MIN HLTH, 2002, AIDS ETH.
   {*}MIN HLTHY, 1993, GUID NAT GTUB ONTR.
   {*}MOA, 1984, LIV SECT REV ANN, V1.
   {*}MOA, 1973, MEAT INSP QUAR SERV.
   {*}MOA, 2001, PAST AGR PAST AR EXT.
   OCTAPODA A, 1963, ETHIOPIAN MED J, V2, P13.
   OREILLY LM, 1995, TUBERCLE LUNG DIS, V76, P1, DOI 10.1016/0962-8479(95)90591-X.
   Pavlik I, 2003, VET MED-CZECH, V48, P90.
   Pavlik I, 2002, VET MED-CZECH, V47, P45.
   Radostits O.M., 2000, VET MED TXB DIS CATT, P909.
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220.
   REDI N, 2003, THESIS ADDIS ABABA U.
   REGASSA A, 1999, THESIS ADDIS ABABA U.
   REGASSA A, 2005, THESIS ADDIS ABABA U.
   REGASSA F, 2001, THESIS ADDIS ABABA U.
   SCHWABE CW, 1984, VET MD HUMAN HLTH.
   Shitaye JE, 2006, VET MED-CZECH, V51, P512.
   TADELE AD, 1998, THESIS ADDIS ABABA U.
   Teklu A, 2004, REV SCI TECH OIE, V23, P957.
   TESHOME M, 1986, BOVINE TUBERCULSIS.
   TESHOME Y, 1995, MYCOBACTERIUM BOVIS, P273.
   TESHOME Y, 1993, THESIS GIESSEN.
   THOEN CO, 2006, MYCOBACTERUM BOVIS I.
   THOEN CO, 1995, MYCOBACTERIUM BOVIS, P167.
   TOWER DR, 1968, J AM VET MED ASSOC, V17, P266.
   TWEDDLE NE, 1994, VET MICROBIOL, V40, P23, DOI 10.1016/0378-1135(94)90044-2.
   WHO, 1994, B WORLD HEALTH ORGAN, V72, P851.
   World Health Organization (WHO), 2005, GLOB TUB CONTR SURV.
   {*}WHO, 1993, REP WHO M ZOON TUB, P93.
   WILIAMSON GA, 1978, INTRO ANIMAL HUSBAND.
   Thoen CO, 2006, MYCOBACTERIUM BOVIS, P199, DOI 10.1002/9780470344538.ch19.
   Zinsstag J., 2006, MYCOBACTERIUM BOVIS, P68, DOI 10.1002/9780470344538.ch9.
   {[}Anonymous], 2003, PROJECT APPRAISAL DO.
   1999, DAIRY DEV ENTERPRISE.}},
Number-of-Cited-References = {{79}},
Times-Cited = {{31}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{Vet. Med.}},
Doc-Delivery-Number = {{193TO}},
Unique-ID = {{ISI:000248297900001}},
}

@article{ ISI:000249454600153,
Author = {Sagindikova, Gulmira and Kogan, Evguenija},
Title = {{Role of the matrix metalloproteinases in the pathogenesis and
   morphogenesis of the chronic cavitary pulmonary tuberculosis of the
   persons who has been living in radioactive-contaminated zones of the
   semipalatinsk region of Kazakhstan}},
Journal = {{VIRCHOWS ARCHIV}},
Year = {{2007}},
Volume = {{451}},
Number = {{2}},
Pages = {{166}},
Month = {{AUG}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING STREET, NEW YORK, NY 10013 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Moscow Med Acad, Moscow, Russia.}},
ISSN = {{0945-6317}},
Research-Areas = {{Pathology}},
Web-of-Science-Categories  = {{Pathology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Virchows Arch.}},
Doc-Delivery-Number = {{210KH}},
Unique-ID = {{ISI:000249454600153}},
}

@article{ ISI:000249454600957,
Author = {Enache, Alexandra and Chatzinikolaou, Fotios and Vladika, Natalia and
   Moisidis, Ioannis},
Title = {{Sudden death cases due to tuberculosis}},
Journal = {{VIRCHOWS ARCHIV}},
Year = {{2007}},
Volume = {{451}},
Number = {{2}},
Pages = {{426}},
Month = {{AUG}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING STREET, NEW YORK, NY 10013 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Univ Timisoara, Dept Forens Med, Timisoara, Romania.
   Canc Hosp, Theageneio, Dept Pathol, Thessaloniki, Greece.}},
ISSN = {{0945-6317}},
Research-Areas = {{Pathology}},
Web-of-Science-Categories  = {{Pathology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Virchows Arch.}},
Doc-Delivery-Number = {{210KH}},
Unique-ID = {{ISI:000249454600957}},
}

@article{ ISI:000249454601261,
Author = {Kosjerina, Zdravko},
Title = {{Intensity of luminal alveolitis in pulmonary tuberculosis}},
Journal = {{VIRCHOWS ARCHIV}},
Year = {{2007}},
Volume = {{451}},
Number = {{2}},
Pages = {{523-524}},
Month = {{AUG}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING STREET, NEW YORK, NY 10013 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
ISSN = {{0945-6317}},
Research-Areas = {{Pathology}},
Web-of-Science-Categories  = {{Pathology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Virchows Arch.}},
Doc-Delivery-Number = {{210KH}},
Unique-ID = {{ISI:000249454601261}},
}

@article{ ISI:000249454601265,
Author = {Janos, Fillinger and Zoltan, Heiler},
Title = {{Coexisting pulmonary tuberculosis and multifocal pulmonary carcinoid in
   the same lobe: A case report}},
Journal = {{VIRCHOWS ARCHIV}},
Year = {{2007}},
Volume = {{451}},
Number = {{2}},
Pages = {{525}},
Month = {{AUG}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING ST, NEW YORK, NY 10013 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Koranyi Natl Inst Lund Dis Hosp, Budapest, Hungary.
   Semmelweis Univ, H-1085 Budapest, Hungary.}},
ISSN = {{0945-6317}},
Research-Areas = {{Pathology}},
Web-of-Science-Categories  = {{Pathology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Virchows Arch.}},
Doc-Delivery-Number = {{210KH}},
Unique-ID = {{ISI:000249454601265}},
}

@article{ ISI:000249454601443,
Author = {Kazachkov, Eugene and Tselischeva, Polina},
Title = {{Patogenetic variants of caseous pneumonia from the pointof view of
   teaching about pathomorphism of tuberculosis}},
Journal = {{VIRCHOWS ARCHIV}},
Year = {{2007}},
Volume = {{451}},
Number = {{2}},
Pages = {{582}},
Month = {{AUG}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING STREET, NEW YORK, NY 10013 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{State Med Acad, Chelyabinsk, Russia.}},
ISSN = {{0945-6317}},
Research-Areas = {{Pathology}},
Web-of-Science-Categories  = {{Pathology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Virchows Arch.}},
Doc-Delivery-Number = {{210KH}},
Unique-ID = {{ISI:000249454601443}},
}

@article{ ISI:000248672100005,
Author = {Gartner, Tatiana and Baeten, Martijn and Otieno, Samuel and Revets,
   Hilde and De Baetselier, Patrick and Huygen, Kris},
Title = {{Mucosal prime-boost vaccination for tuberculosis based on TLR triggering
   OprI lipoprotein from Pseudomonas aeruginosa fused to
   mycolyl-transferase Ag85A}},
Journal = {{IMMUNOLOGY LETTERS}},
Year = {{2007}},
Volume = {{111}},
Number = {{1}},
Pages = {{26-35}},
Month = {{JUL 31}},
Abstract = {{Toll-like receptor (TLR) triggering is an important step in the
   induction of T helper (Th) type I T cells which are key players in
   protection against the intracellular pathogen Mycobacterium (M.)
   tuberculosis. Here we report on the construction of a fusion protein
   consisting of a tuberculosis vaccine candidate mycolyl-transferase
   antigen 85A (Ag85A, Rv3804c) coupled to the outer membrane lipoprotein I
   (OprI) from Pseudomonas (P.) aeruginosa, a documented TLR2/TLR4 trigger.
   Subcutaneous boosting with this fusion protein in the absence of
   adjuvant increased significantly the Ag85A-specific humoral but not
   cellular immune responses of Ag85A-DNA vaccinated mice. Intranasal
   priming of C57BL/6 mice with live, attenuated Mycobacterium bovis
   bacille Calmette-Guerin (BCG) vaccine, followed by intranasal boosting
   with OprI-Ag85A increased systemic and local antigen-specific interferon
   (IFN)-gamma and interleukin (IL)-2 responses in spleen, draining
   cervical and mediastinal lymph nodes and particularly in lung tissue, as
   compared to responses in mice only vaccinated with BCG vaccine. Despite
   enhanced immune responses, boosting with OprI-Ag85A did not increase
   protective efficacy against M. tuberculosis of either plasmid DNA or BCG
   vaccine in this experimental setting. (c) 2007 Elsevier B.V. All rights
   reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Huygen, K (Reprint Author), WIV Pasteur Inst Brussels, Engelandstr 642, B-1180 Brussels, Belgium.
   WIV Pasteur Inst Brussels, B-1180 Brussels, Belgium.
   VIB, Dept Mol \& Cell Interact, Brussels, Belgium.
   Vrije Univ Brussels, Lab Cellular \& Mol Immunol, B-1050 Brussels, Belgium.}},
DOI = {{10.1016/j.imlet.2007.04.010}},
ISSN = {{0165-2478}},
Keywords = {{tuberculosis; OprI; Ag85A}},
Keywords-Plus = {{MYCOBACTERIUM-BOVIS BCG; BACILLE CALMETTE-GUERIN; VACCINIA VIRUS ANKARA;
   T-CELL EPITOPES; PROTECTIVE EFFICACY; PULMONARY TUBERCULOSIS; ANTIGEN
   85A; IMMUNE-RESPONSES; FUSION PROTEINS; DNA VACCINE}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{khuygen@pasteur.be}},
ResearcherID-Numbers = {{De Baetselier, Patrick/D-3866-2014}},
Cited-References = {{Abolhassani M, 2000, INFECT IMMUN, V68, P5657.
   ANDERSEN CS, 2006, INFECT IMMUN.
   Baldwin SL, 1998, INFECT IMMUN, V66, P2951.
   Borsutzky S, 2005, J IMMUNOL, V174, P6308.
   Brandt L, 2004, INFECT IMMUN, V72, P6622, DOI 10.1128/IAI.72.11.6622-6632.2004.
   Brooks JV, 2001, INFECT IMMUN, V69, P2714, DOI 10.1128/IAI.69.4.2714-2717.2001.
   Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851.
   Chen LH, 2004, INFECT IMMUN, V72, P238, DOI 10.1128/IAI.72.1.238-246.2004.
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243.
   CORNELIS P, 1989, MOL MICROBIOL, V3, P421, DOI 10.1111/j.1365-2958.1989.tb00187.x.
   Cornelis P, 1996, BIO-TECHNOL, V14, P203, DOI 10.1038/nbt0296-203.
   Cote-Sierra J, 1998, GENE, V221, P25, DOI 10.1016/S0378-1119(98)00437-5.
   Cote-Sierra J, 2002, INFECT IMMUN, V70, P240, DOI 10.1128/IAI.70.1.240-248.2002.
   D'Souza S, 2003, INFECT IMMUN, V71, P483, DOI 10.1128/IAI.71.1.483-493.2003.
   DEBRUYN J, 1987, MICROB PATHOGENESIS, V2, P351, DOI 10.1016/0882-4010(87)90077-5.
   Denis O, 1998, INFECT IMMUN, V66, P1527.
   Dietrich J, 2006, J IMMUNOL, V177, P6353.
   Doherty TM, 2004, J INFECT DIS, V190, P2146, DOI 10.1086/425931.
   Feng CG, 2001, INFECT IMMUN, V69, P4174, DOI 10.1128/IAI.69.6.4174-4176.2001.
   Freytag LC, 2005, VACCINE, V23, P1804, DOI 10.1016/j.vaccine.2004.11.010.
   GIRI PK, 2006, J INFECT.
   Goonetilleke NP, 2003, J IMMUNOL, V171, P1602.
   Hayashi EA, 2005, J IMMUNOL, V174, P6639.
   HUYGEN K, 1992, INFECT IMMUN, V60, P2880.
   Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893.
   HUYGEN K, 1994, INFECT IMMUN, V62, P363.
   Kaufmann SHE, 2006, NAT REV IMMUNOL, V6, P699, DOI 10.1038/nri1920.
   Kipnis A, 2005, INFECT IMMUN, V73, P7759, DOI 10.1128/IAI.73.11.7759-7764.2005.
   Lagranderie M, 2000, VACCINE, V18, P1186, DOI 10.1016/S0264-410X(99)00386-2.
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128.
   Rau H, 2006, VACCINE, V24, P4757, DOI 10.1016/j.vaccine.2006.03.028.
   Revets H, 2005, J IMMUNOL, V174, P1097.
   Romano M, 2006, VACCINE, V24, P3353, DOI 10.1016/j.vaccine.2005.12.066.
   Ronning DR, 2000, NAT STRUCT BIOL, V7, P141.
   Santosuosso M, 2005, J IMMUNOL, V174, P7986.
   Santosuosso M, 2006, INFECT IMMUN, V74, P4634, DOI 10.1128/IAI.00517-06.
   Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419.
   Swain SL, 2003, MICROBES INFECT, V5, P213, DOI 10.1016/S1286-4579(03)00013-3.
   Tanghe A, 2001, INFECT IMMUN, V69, P3041, DOI 10.1128/IAI.69.5.3041-3047.2001.
   Tanghe A, 1999, J IMMUNOL, V162, P1113.
   Tiruviluamala P, 2002, ANNU REV PUBL HEALTH, V23, P403, DOI 10.1146/annurev.publhealth.23.100901.140519.
   Tree JA, 2004, CLIN EXP IMMUNOL, V138, P405, DOI 10.1111/j.1365-2249.2004.02648.x.
   Wang J, 2004, J IMMUNOL, V173, P6357.
   WIKER HG, 1992, MICROBIOL REV, V56, P648.
   Wu CY, 2002, NAT IMMUNOL, V3, P852, DOI 10.1038/ni832.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Immunol. Lett.}},
Doc-Delivery-Number = {{199BV}},
Unique-ID = {{ISI:000248672100005}},
}

@article{ ISI:000249688500001,
Author = {Martin, Ana and Herranz, Marta and Serrano, Maria Jesus Ruiz and Bouza,
   Emilio and de Viedma, Dario Garcia},
Title = {{Rapid clonal analysis of recurrent tuberculosis by direct MIRU-VNTR
   typing on stored isolates}},
Journal = {{BMC MICROBIOLOGY}},
Year = {{2007}},
Volume = {{7}},
Month = {{JUL 30}},
Abstract = {{Background: The application of molecular tools to the analysis of
   tuberculosis has revealed examples of clonal complexity, such as
   exogenous reinfection, coinfection, microevolution or
   compartmentalization. The detection of clonal heterogeneity by standard
   genotyping approaches is laborious and often requires expertise. This
   restricts the rapid availability of Mycobacterium tuberculosis (MTB)
   genotypes for clinical or therapeutic decision-making. A new PCR-based
   technique, MIRU-VNTR, has made it possible to genotype MTB in a time
   frame close to real-time fingerprinting. Our purpose was to evaluate the
   capacity of this technique to provide clinicians with a rapid
   discrimination between reactivation and exogenous reinfection and
   whether MIRU-VNTR makes it possible to obtain data directly from stored
   MTB isolates from recurrent episodes.
   Results: We detected differences, between the MIRUtypes of recurrent
   isolates in 38.5\% (5/13) of the cases studied. These included cases of
   i) exogenous reinfection, often with more resistant strains, ii) likely
   examples of microevolution, leading to the appearance of new clonal
   variants and iii) a combination of microevolution, coinfection and
   competition.
   Conclusion: MIRU-VNTR rapidly obtained clinically useful genotyping data
   in a challenging situation, directly from stored MTB isolates without
   subculturing them or purifying their DNA. Our results also mean that
   MIRU-VNTR could be applied for easy, rapid and affordable massive
   screening of collections of stored MTB isolates, which could establish
   the real dimension of clonal heterogeneity in MTB infection.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{de Viedma, DG (Reprint Author), Univ Complutense, CIBERES, Hosp Gen Univ Gregorio Maranon, Serv Microbiol \& Enfermedades Infecciosas, E-28040 Madrid, Spain.
   Univ Complutense, CIBERES, Hosp Gen Univ Gregorio Maranon, Serv Microbiol \& Enfermedades Infecciosas, E-28040 Madrid, Spain.}},
DOI = {{10.1186/1471-2180-7-73}},
Article-Number = {{73}},
ISSN = {{1471-2180}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; EXOGENOUS REINFECTION; MIXED INFECTION;
   EPIDEMIOLOGY; STRAIN; POLYMORPHISM}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{anamartsan@yahoo.es
   m\_herranz01@hotmail.com
   mruiz@hgugm.salud.madrid.org
   ebouza@microb.net
   dgviedma@microb.net}},
ResearcherID-Numbers = {{Bouza, Emilio/D-8661-2014
   Herranz, Maria Angeles/K-1742-2014}},
ORCID-Numbers = {{Bouza, Emilio/0000-0001-6967-9267
   Herranz, Maria Angeles/0000-0001-9155-134X}},
Cited-References = {{Allix C, 2004, CLIN INFECT DIS, V39, P783, DOI 10.1086/423383.
   Allix C, 2006, J CLIN MICROBIOL, V44, P1951, DOI 10.1128/JCM.01775-05.
   Bandera A, 2001, J CLIN MICROBIOL, V39, P2213, DOI 10.1128/JCM.39.6.2213-2218.2001.
   Caminero JA, 2001, AM J RESP CRIT CARE, V163, P717.
   Chaves F, 1999, AIDS, V13, P615, DOI 10.1097/00002030-199904010-00011.
   Cowan LS, 2005, J CLIN MICROBIOL, V43, P688, DOI 10.1128/JCM.43.2.688-695.2005.
   Garcia de Viedma D., 2006, PEDIATR INFECT DIS J, V25, P457, DOI DOI 10.1097/01.INF.0000217473.90673.00.
   DEVIEDMA DG, 2002, ARCH INTERN MED, V162, P1873, DOI 10.1001/archinte.162.16.1873.
   Garcia de Viedma D, 2004, J CLIN MICROBIOL, V42, P3415, DOI 10.1128/JCM.42.8.3415-3418.2004.
   Lorenzo G., 2005, J INFECT DIS, V192, P2059, DOI DOI 10.1086/498245.PUBMED:16288368.
   Garcia de Viedma D., 2005, J CLIN MICROBIOL, V43, P5660, DOI DOI 10.1128/JCM.43.11.5660-5664.2005.
   Garcia de Viedma D, 2003, J INFECT DIS, V187, P695.
   Glynn JR, 2004, J INFECT DIS, V190, P1158, DOI 10.1086/423144.
   HORN DL, 1994, ANN INTERN MED, V121, P115.
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907.
   Kaplan G, 2003, INFECT IMMUN, V71, P7099, DOI 10.1128/IAI.71.12.7099-7108.2003.
   Post FA, 2004, J INFECT DIS, V190, P99, DOI 10.1086/421501.
   Savine E, 2002, J CLIN MICROBIOL, V40, P4561, DOI 10.1128/JCM.40.12.4561-4566.2002.
   Shamputa IC, 2004, J CLIN MICROBIOL, V42, P5528, DOI 10.1128/JCM.42.12.5528-5536.2004.
   Shamputa IC, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-99.
   Shen GM, 2006, EMERG INFECT DIS, V12, P1776.
   Supply P, 2001, J CLIN MICROBIOL, V39, P3563, DOI 10.1128/JCM.39.10.3563-3571.2001.
   Supply P, 2006, J CLIN MICROBIOL, V44, P4498, DOI 10.1128/JCM.01392-06.
   Turett GS, 1997, CLIN INFECT DIS, V24, P513.
   Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.
   Warren RM, 2004, AM J RESP CRIT CARE, V169, P610, DOI 10.1164/rccm.200305-714OC.}},
Number-of-Cited-References = {{27}},
Times-Cited = {{18}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{BMC Microbiol.}},
Doc-Delivery-Number = {{213SX}},
Unique-ID = {{ISI:000249688500001}},
}

@article{ ISI:000248950600001,
Author = {Krishnan, Manju Y. and Radhakrishnan, Indulakshmi and Joseph, Biljo V.
   and Gk, Madhavi Latha and Ajay, Kumar R. and Mundayoor, Sathish},
Title = {{Combined use of amplified fragment length polymorphism and IS6110-RFLP
   in fingerprinting clinical isolates of Mycobacterium tuberculosis from
   kerala, South India}},
Journal = {{BMC INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{7}},
Month = {{JUL 28}},
Abstract = {{Background: DNA fingerprinting by IS6110- RFLP has shown a high
   incidence of Mycobacterium tuberculosis isolates having no and low
   copies of the insertion sequence in Kerala, South India. Amplified
   Fragment Length Polymorphism (AFLP) would scan the entire genome rather
   than a few repetitive elements, we thought that this technique would
   help us in differentiating the large reservoir of isolates from an
   endemic region. Here we evaluate the ability of Amplified Fragment
   Length Polymorphism (AFLP) to type clinical isolates.
   Methods: Fifty clinical isolates of M. tuberculosis were analysed by
   conventional radioactive AFLP and IS6110- RFLP. M. bovis, M. bovis BCG
   and two non tuberculous mycobacteria were also analysed to see species
   specific differences generated by AFLP. Cluster analysis was performed
   using the AFLP profile that showed the maximum polymorphism within M.
   tuberculosis and this was compared to the number of copies of IS6110
   insertions.
   Results: For AFLP, out of ten primer pairs tested, the EO/MC pair
   generated maximum polymorphism among the clinical isolates of M.
   tuberculosis. The similarity between the isolates ranged between 88 and
   99.5\%. Majority ( nearly 85\%) of the `low copy' IS6110 isolates
   clustered together, while the rest clustered irrespective of the copy
   numbers. AFLP could show rare differences between isolates of M.
   tuberculosis, M. bovis and M. bovis BCG. The AFLP profiles for
   non-tuberculous mycobacteria were highly different from those of M.
   tuberculosis.
   Conclusion: Polymorphism generated by AFLP within the M. tuberculosis
   species is limited and hence AFLP alone seems to have limited use in
   fingerprinting the isolates in Kerala. The combined use of AFLP and
   IS6110- RFLP showed relatively better differentiation of ` high copy'
   IS6110 isolates, but failed to differentiate the ` low copy' isolates.
   However, the technique may be efficient in inter-species
   differentiation, and hence potentially useful in identifying and
   developing species- specific markers.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mundayoor, S (Reprint Author), Rajiv Gandhi Ctr Biotechnol, Thiruvananthapuram 695014, Kerala, India.
   Rajiv Gandhi Ctr Biotechnol, Thiruvananthapuram 695014, Kerala, India.}},
DOI = {{10.1186/1471-2334-7-86}},
Article-Number = {{86}},
ISSN = {{1471-2334}},
Keywords-Plus = {{IDENTIFICATION; GENOME; DIFFERENTIATION; REGIONS; AFLP}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{manjuyk@yahoo.com
   indulax@gmail.com
   biljojoseph@yahoo.com
   lata\_rgcb@yahoo.co.in
   ajay.rgcb@gmail.com
   mundayoor\_s@yahoo.com}},
ResearcherID-Numbers = {{Krishnan, Manju/B-7195-2009}},
Cited-References = {{Das S, 1995, TUBERCLE LUNG DIS, V76, P550, DOI 10.1016/0962-8479(95)90533-2.
   delaSalmoniere YOG, 1997, J CLIN MICROBIOL, V35, P2210.
   Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x.
   Goulding JN, 2000, J CLIN MICROBIOL, V38, P1121.
   Goyal M, 1997, J CLIN MICROBIOL, V35, P647.
   Huys G, 2000, J CLIN MICROBIOL, V38, P3675.
   KUBICA GP, 1973, AM REV RESPIR DIS, V107, P9.
   O'Shea B, 2004, J CLIN MICROBIOL, V42, P3600, DOI 10.1128/jcm.42.8.3600-3606.2004.
   RADHAKRISHNA G, 2003, NTI B, V39, P19.
   Radhakrishnan I, 2001, J CLIN MICROBIOL, V39, P1683, DOI 10.1128/JCM.39.4.1683.2001.
   Savelkoul PHM, 1999, J CLIN MICROBIOL, V37, P3083.
   Supply P, 2000, MOL MICROBIOL, V36, P762, DOI 10.1046/j.1365-2958.2000.01905.x.
   Supply P, 1997, MOL MICROBIOL, V26, P991, DOI 10.1046/j.1365-2958.1997.6361999.x.
   van den Braak N, 2004, J MICROBIOL METH, V56, P49, DOI 10.1016/j.mimet.2003.09.018.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.
   VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407.
   YUEN LKW, 1993, J CLIN MICROBIOL, V31, P1615.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{BMC Infect. Dis.}},
Doc-Delivery-Number = {{203BR}},
Unique-ID = {{ISI:000248950600001}},
}

@article{ ISI:000248662200024,
Author = {Tanne, Janice Hopkins},
Title = {{Patient with tuberculosis who flew internationally is being sued}},
Journal = {{BRITISH MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{335}},
Number = {{7612}},
Pages = {{177}},
Month = {{JUL 28}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{News Item}},
Language = {{English}},
DOI = {{10.1136/bmj.39286.532199.BD}},
ISSN = {{0959-8146}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{2007, BRIT MED J, V334, P1242.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Br. Med. J.}},
Doc-Delivery-Number = {{198YA}},
Unique-ID = {{ISI:000248662200024}},
}

@article{ ISI:000249343700001,
Author = {Martinez, Valerie and Carcelain, Guislaine and Badell, Edgar and Jouan,
   Marc and Mauger, Isabelle and Sellier, Pierre and Truffot, Chantal and
   Bricaire, Francois and Arend, Sandra M. and Ottenhoff, Tom and Autran,
   Brigitte and Gicquel, Brigitte},
Title = {{T-cell and serological responses to Erp, an exported Mycobacterium
   tuberculosis protein, in tuberculosis patients and healthy individuals}},
Journal = {{BMC INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{7}},
Month = {{JUL 26}},
Abstract = {{Background: The identification of antigens able to differentiate
   tuberculosis (TB) disease from TB infection would be valuable. Cellular
   and humoral immune responses to Erp (Exported repetitive protein)-a
   recently identified M. tuberculosis protein-have not yet been
   investigated in humans and may contribute to this aim.
   Methods: We analyzed the cellular and humoral immune responses to Erp,
   ESAT-6, Ag85B and PPD in TB patients, in BCG(+) individuals without
   infection, BCG+ individuals with latent TB infection (LTBI) and
   BCG-controls. We used lymphoproliferation, ELISpot IFN-gamma, cytokine
   production assays and detection of specific human antibodies against
   recombinant M. tuberculosis proteins.
   Results: We included 22 TB patients, 9 BCG+ individuals without TB
   infection, 7 LTBI and 7 BCG-controls. Erp-specific T cell counts were
   higher in LTBI than in the other groups. Erp-specific T cell counts were
   higher in LTBI subjects than TB patients (median positive frequency of
   211 SFC/10(6) PBMC (range 118-2000) for LTBI subjects compared to 80
   SFC/10(6) PBMC (range 50-191), p = 0.019); responses to PPD and ESAT-6
   antigens did not differ between these groups. IFN-gamma secretion after
   Erp stimulation differed between TB patients and LTBI subjects (p =
   0.02). Moreover, LTBI subjects but not TB patients or healthy subjects
   produced IgG3 against Erp.
   Conclusion: The frequencies of IFN-gamma-producing specific T cells, the
   IFN-gamma. secretion and the production of IgG3 after Erp stimulation
   are higher in LTBI subjects than in TB patients, whereas PPD and ESAT-6
   are not.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Martinez, V (Reprint Author), Hop La Pitie Salpetriere, INSERM, U543, Cellular Immunol Lab, 47-83 Blvd Hop, F-75651 Paris 13, France.
   Hop La Pitie Salpetriere, INSERM, U543, Cellular Immunol Lab, F-75651 Paris 13, France.
   Inst Pasteur, Unite Genet Mycobacter, F-75015 Paris, France.
   Hop Lariboisiere, Serv Med Interne, F-75010 Paris, France.
   Hop La Pitie Salpetriere, Bacteriol Lab, F-75651 Paris 13, France.
   Hop La Pitie Salpetriere, Serv Malad Infect \& Trop, F-75651 Paris, France.
   Leiden Univ, Med Ctr, Dept Infect Dis, Leiden, Netherlands.
   Leiden Univ, Med Ctr, Dept Immunohematol \& Blood Transfus, Leiden, Netherlands.}},
DOI = {{10.1186/1471-2334-7-83}},
Article-Number = {{83}},
ISSN = {{1471-2334}},
Keywords-Plus = {{PHOA GENE FUSIONS; ACTIVE TUBERCULOSIS; ESAT-6 ANTIGEN; IMMUNOGLOBULIN
   G3; IMMUNE-RESPONSES; B-CELLS; INFECTION; ANTIBODIES; MALARIA; DIAGNOSIS}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{valerie.martinez@psl.aphp.fr
   guislaine.carcelain@psl.aphp.fr
   ebadell@pasteur.fr
   mjouan@pasteur.fr
   isa.mauger@wanadoo.fr
   pierre.sellier@lrb.aphp.fr
   chantal.truffot@psl.aphp.fr
   francois.bricaire@psl.aphp.fr
   m.arend@lumc.nl
   h.m.ottenhoff@lumc.nl
   brigitte.autran@psl.aphp.fr
   bgicquel@pasteur.fr}},
Cited-References = {{Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2.
   ANDERSEN P, 1995, J IMMUNOL, V154, P3359.
   Arend SM, 2000, INFECT IMMUN, V68, P3314, DOI 10.1128/IAI.68.6.3314-3321.2000.
   Arend SM, 2000, J INFECT DIS, V181, P1850, DOI 10.1086/315448.
   Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520.
   Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420.
   Bentley-Hibbert SI, 1999, INFECT IMMUN, V67, P581.
   BERTHET FX, 1995, MICROBIOL-UK, V141, P2123.
   Berthet FX, 1998, SCIENCE, V282, P759, DOI 10.1126/science.282.5389.759.
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195.
   BIGI F, 1995, INFECT IMMUN, V63, P2581.
   BOUHAROUNTAYOUN H, 1995, J EXP MED, V182, P409, DOI 10.1084/jem.182.2.409.
   Bourgarit A, 2006, AIDS, V20, pF1, DOI 10.1097/01.aids.0000202648.18526.bf.
   Brandt L, 2000, INFECT IMMUN, V68, P791, DOI 10.1128/IAI.68.2.791-795.2000.
   BRIERE F, 1994, J EXP MED, V179, P757, DOI 10.1084/jem.179.2.757.
   Cardoso FLL, 2002, INFECT IMMUN, V70, P6707, DOI 10.1128/IAI.70.12.6707-6714.2002.
   Chan J, 2004, CLIN IMMUNOL, V110, P2, DOI 10.1016/S1521-6616(03)00210-9.
   CHERAYIL BJ, 1988, J IMMUNOL, V141, P4370.
   de Mendonca-Lima L, 2001, MICROBIOL-SGM, V147, P2315.
   Denis O, 1998, INFECT IMMUN, V66, P1527.
   DHANDAYUTHAPANI S, 1992, CLIN EXP IMMUNOL, V88, P253.
   Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93.
   GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747.
   Harboe M, 1996, INFECT IMMUN, V64, P16.
   HAVLIR DV, 1991, INFECT IMMUN, V59, P665.
   HUSSAIN R, 1995, INFECT IMMUN, V63, P410.
   HUYGEN K, 1988, SCAND J IMMUNOL, V27, P187, DOI 10.1111/j.1365-3083.1988.tb02338.x.
   Jo EK, 2000, SCAND J IMMUNOL, V51, P209.
   Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558.
   KITANI A, 1993, J IMMUNOL, V151, P3478.
   Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824.
   Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1.
   LIM EM, 1995, J BACTERIOL, V177, P59.
   Masungi C, 2002, J INFECT DIS, V185, P513, DOI 10.1086/338833.
   Mustafa AS, 1998, SCAND J IMMUNOL, V48, P535.
   Mustafa AS, 2000, CLIN INFECT DIS, V30, pS201, DOI 10.1086/313862.
   Oeuvray C, 2000, INFECT IMMUN, V68, P2617, DOI 10.1128/IAI.68.5.2617-2620.2000.
   OEUVRAY C, 1994, BLOOD, V84, P1594.
   Ohara N, 1997, INFECT IMMUN, V65, P3680.
   Perlmann P, 1997, INFECT IMMUN, V65, P116.
   Pollock JM, 1997, J INFECT DIS, V175, P1251.
   Ravn P, 1999, J INFECT DIS, V179, P637, DOI 10.1086/314640.
   Rzepczyk CM, 1997, INFECT IMMUN, V65, P1098.
   Sarthou JL, 1997, INFECT IMMUN, V65, P3271.
   Schwander SK, 2000, J IMMUNOL, V165, P1479.
   Skjot RLV, 2000, INFECT IMMUN, V68, P214.
   Song CH, 2000, INFECT IMMUN, V68, P4477, DOI 10.1128/IAI.68.8.4477-4484.2000.
   SORENSEN AL, 1995, INFECT IMMUN, V63, P1710.
   Stavnezer J, 1996, CURR OPIN IMMUNOL, V8, P199, DOI 10.1016/S0952-7915(96)80058-6.
   Tanghe A, 2001, INFECT IMMUN, V69, P3041, DOI 10.1128/IAI.69.5.3041-3047.2001.
   TIMM J, 1994, MOL MICROBIOL, V12, P491, DOI 10.1111/j.1365-2958.1994.tb01037.x.
   Ulrichs T, 1998, EUR J IMMUNOL, V28, P3949, DOI 10.1002/(SICI)1521-4141(199812)28:12<3949::AID-IMMU3949>3.3.CO;2-W.
   van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000.
   WIKER HG, 1992, MICROBIOL REV, V56, P648.}},
Number-of-Cited-References = {{56}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{BMC Infect. Dis.}},
Doc-Delivery-Number = {{208UC}},
Unique-ID = {{ISI:000249343700001}},
}

@article{ ISI:000248950400001,
Author = {Murphy, Dennis J. and Brown, James R.},
Title = {{Identification of gene targets against dormant phase Mycobacterium
   tuberculosis infections}},
Journal = {{BMC INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{7}},
Month = {{JUL 26}},
Abstract = {{Background: Mycobacterium tuberculosis, the causative agent of
   tuberculosis ( TB), infects approximately 2 billion people worldwide and
   is the leading cause of mortality due to infectious disease. Current TB
   therapy involves a regimen of four antibiotics taken over a six month
   period. Patient compliance, cost of drugs and increasing incidence of
   drug resistant M. tuberculosis strains have added urgency to the
   development of novel TB therapies. Eradication of TB is affected by the
   ability of the bacterium to survive up to decades in a dormant state
   primarily in hypoxic granulomas in the lung and to cause recurrent
   infections.
   Methods: The availability of M. tuberculosis genome- wide DNA
   microarrays has lead to the publication of several gene expression
   studies under simulated dormancy conditions. However, no single model
   best replicates the conditions of human pathogenicity. In order to
   identify novel TB drug targets, we performed a meta- analysis of
   multiple published datasets from gene expression DNA microarray
   experiments that modeled infection leading to and including the dormant
   state, along with data from genome- wide insertional mutagenesis that
   examined gene essentiality.
   Results: Based on the analysis of these data sets following
   normalization, several genome wide trends were identified and used to
   guide the selection of targets for therapeutic development. The trends
   included the significant up- regulation of genes controlled by devR,
   down- regulation of protein and ATP synthesis, and the adaptation of
   two- carbon metabolism to the hypoxic and nutrient limited environment
   of the granuloma. Promising targets for drug discovery were several
   regulatory elements ( devR/ devS, relA, mprAB), enzymes involved in
   redox balance and respiration, sulfur transport and fixation,
   pantothenate, isoprene, and NAD biosynthesis. The advantages and
   liabilities of each target are discussed in the context of enzymology,
   bacterial pathways, target tractability, and drug development.
   Conclusion: Based on our bioinformatics analysis and additional
   discussion of in- depth biological rationale, several novel anti- TB
   targets have been proposed as potential opportunities to improve present
   therapeutic treatments for this disease.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Brown, JR (Reprint Author), GlaxoSmithKline Inc, Informat Mol Discovery Res, 1250 S Collegeville Rd,UP1345,POB 5089, Collegeville, PA 19426 USA.
   GlaxoSmithKline Inc, Informat Mol Discovery Res, Collegeville, PA 19426 USA.
   GlaxoSmithKline Inc, Dept Biochem, Cardiovasc \& Urogenital CEDD, UW2523, King Of Prussia, PA 19406 USA.}},
DOI = {{10.1186/1471-2334-7-84}},
Article-Number = {{7}},
ISSN = {{1471-2334}},
Keywords-Plus = {{2-COMPONENT SIGNAL-TRANSDUCTION; UNIVERSAL STRESS-PROTEIN;
   SULFATE-ACTIVATING COMPLEX; RESPONSE REGULATOR; ESCHERICHIA-COLI;
   ALPHA-CRYSTALLIN; STATIONARY-PHASE; ALANINE DEHYDROGENASE; HYPOXIC
   RESPONSE; NITRIC-OXIDE}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{Dennis.6.Murphy@gsk.com
   James.R.Brown@gsk.com}},
Cited-References = {{Andries K, 2005, SCIENCE, V307, P223, DOI 10.1126/science.1106753.
   Avarbock D, 1999, GENE, V233, P261, DOI 10.1016/S0378-1119(99)00114-6.
   Barrett JF, 1998, ANTIMICROB AGENTS CH, V42, P1529.
   Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x.
   Boon C, 2002, J BACTERIOL, V184, P6760, DOI 10.1128/JB.184.24.6760-6767.2002.
   Boshoff HI, 2006, DRUG DISCOV TODAY DI, V3, P237, DOI 10.1016/j.ddmec.2006.06.002.
   Boshoff HIM, 2005, NAT REV MICROBIOL, V3, P70, DOI 10.1038/nrmicro1065.
   Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6.
   CAPPELLI G, 2006, RES MICROBIOL.
   Cho SH, 2006, TUBERCULOSIS, V86, P445, DOI 10.1016/j.tube.2005.10.002.
   Choudhry AE, 2003, ANTIMICROB AGENTS CH, V47, P2051, DOI 10.1128/AAC.47.6.2051-2055.2003.
   Cole ST, 1998, NATURE, V393, P537.
   Crick DC, 2001, GLYCOBIOLOGY, V11, p107R, DOI 10.1093/glycob/11.9.107R.
   Dahl JL, 2003, P NATL ACAD SCI USA, V100, P10026, DOI 10.1073/pnas.1631248100.
   Daniel J, 2004, J BACTERIOL, V186, P5017, DOI 10.1128/jb.186.15.5017-5030.2004.
   Darwin KH, 2005, INFECT IMMUN, V73, P4581, DOI 10.1128/IAI.73.8.4581-4587.2005.
   Dawes SS, 2003, INFECT IMMUN, V71, P6124, DOI 10.1128/IAI.71.11.6124-6131.2003.
   DeMaio J, 1997, TUBERCLE LUNG DIS, V78, P3, DOI 10.1016/S0962-8479(97)90010-1.
   DeMaio J, 1996, P NATL ACAD SCI USA, V93, P2790, DOI 10.1073/pnas.93.7.2790.
   Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767.
   Erickson MG, 2005, J BIOMOL SCREEN, V10, P270, DOI 10.1177/1087057104273930.
   Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068.
   Freestone P, 1997, J MOL BIOL, V274, P318, DOI 10.1006/jmbi.1997.1397.
   Freestone P, 1998, J MOL BIOL, V279, P1045, DOI 10.1006/jmbi.1998.1836.
   GROSSET J, 1982, PATHOL BIOL, V30, P444.
   Hampshire T, 2004, TUBERCULOSIS, V84, P228, DOI 10.1016/j.tube.2003.12.010.
   Hasan S, 2006, PLOS COMPUT BIOL, V2, P539, DOI 10.1371/journal.pcbi.0020061.
   He HJ, 2006, J BACTERIOL, V188, P2134, DOI 10.1128/JB.188.6.2134-2143.2006.
   Hu YM, 2006, INFECT IMMUN, V74, P861, DOI 10.1128/IAI.74.2.861-868.2006.
   Hu YM, 1998, FEMS MICROBIOL LETT, V158, P139.
   HURFORD J. V., 1957, TUBERCLE, V38, P194, DOI 10.1016/S0041-3879(57)80086-5.
   Hutter B, 1998, FEMS MICROBIOL LETT, V167, P7, DOI 10.1016/S0378-1097(98)00360-7.
   Hutter B, 1999, BIOCHEM J, V343, P669, DOI 10.1042/0264-6021:3430669.
   Jain V, 2006, PROTEIN SCI, V15, P1449, DOI 10.1110/ps.062117006.
   Jindani A, 2003, AM J RESP CRIT CARE, V167, P1348, DOI 10.1164/rccm.200210-1125OC.
   Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42.
   Kaplan G, 2003, INFECT IMMUN, V71, P7099, DOI 10.1128/IAI.71.12.7099-7108.2003.
   Karakousis PC, 2004, J EXP MED, V200, P647, DOI 10.1084/jem.20040646.
   Kendall SL, 2004, TUBERCULOSIS, V84, P247, DOI 10.1016/j.tube.2003.12.007.
   Kvint K, 2003, CURR OPIN MICROBIOL, V6, P140, DOI 10.1016/S1369-5274(03)00025-0.
   Lamichhane G, 2005, INFECT IMMUN, V73, P2533, DOI 10.1128/IAI.73.4.2533-2540.2005.
   Li JM, 2005, OLIGONUCLEOTIDES, V15, P215, DOI 10.1089/oli.2005.15.215.
   Lillebaek T, 2003, J INFECT DIS, V188, P1032, DOI 10.1086/378240.
   LOOMIS WF, 1948, J BIOL CHEM, V173, P807.
   Macielag MJ, 2000, EXPERT OPIN INV DRUG, V9, P2351, DOI 10.1517/13543784.9.10.2351.
   MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243.
   Makinoshima H, 2005, NATURE, V436, P406, DOI 10.1038/nature03713.
   Malhotra V, 2004, FEMS MICROBIOL LETT, V231, P237, DOI 10.1016/S0378-1097(04)00002-3.
   MARAGOS WF, 2004, J NEUROCHEM, V91, P527.
   Marchler B. A., 2004, NUCLEIC ACIDS RES, V32, P327, DOI DOI 10.1093/NAR/GKH454.
   McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074.
   Mitchison DA, 2005, AM J RESP CRIT CARE, V171, P699, DOI 10.1164/rccm.200411-1603OE.
   Mitchison DA, 2004, SEM RESP CRIT CARE M, V25, P307, DOI 10.1055/s-2004-829503.
   Mitchison DA, 2004, FRONT BIOSCI, V9, P1059, DOI 10.2741/1293.
   Munoz-Elias EJ, 2006, CELL MICROBIOL, V8, P10, DOI 10.1111/j.1462-5822.2005.00648.x.
   Munoz-Elias EJ, 2005, NAT MED, V11, P638, DOI 10.1038/nm1252.
   Muttucumaru DGN, 2004, TUBERCULOSIS, V84, P239, DOI 10.1016/j.tube.2003.12.006.
   Nystrom T, 1996, J BACTERIOL, V178, P927.
   NYSTROM T, 1993, J BACTERIOL, V175, P3949.
   O'Toole R, 2003, RES MICROBIOL, V154, P387, DOI 10.1016/S0923-2508(03)00081-0.
   Ohno H, 2003, CELL MICROBIOL, V5, P637, DOI 10.1046/j.1462-5822.2003.00307.x.
   PABST MJ, 1988, J IMMUNOL, V140, P634.
   Park HD, 2003, MOL MICROBIOL, V48, P833, DOI 10.1046/j.1365-2958.2003.03474.x.
   PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443.
   Payne DJ, 2007, NAT REV DRUG DISCOV, V6, P29, DOI 10.1038/nrd2201.
   Pinto R, 2004, MICROBIOL-SGM, V150, P1681, DOI 10.1099/mic.0.26894-0.
   Primm TP, 2000, J BACTERIOL, V182, P4889, DOI 10.1128/JB.182.17.4889-4898.2000.
   Qamra R, 2004, J BACTERIOL, V186, P8105, DOI 10.1128/jb.186.23.8105-8113.2004.
   Rachman H, 2006, INFECT IMMUN, V74, P1233, DOI 10.1128/IAI.74.2.1223-1242.2006.
   RACHMAN H, 2006, MICROBES INFECT.
   Rengarajan J, 2005, P NATL ACAD SCI USA, V102, P8327, DOI 10.1073/pnas.0503272102.
   Rhoades ER, 1997, TUBERCLE LUNG DIS, V78, P57, DOI 10.1016/S0962-8479(97)90016-2.
   Roberts DM, 2004, J BIOL CHEM, V279, P23082, DOI 10.1074/jbc.M401230200.
   Rodrigue S, 2006, FEMS MICROBIOL REV, V30, P926, DOI 10.1111/j.1574-6976.2006.00040.x.
   Saini DK, 2005, J BIOMOL SCREEN, V10, P215, DOI 10.1177/1087057104272090.
   Saini DK, 2004, FEBS LETT, V565, P75, DOI 10.1016/j.febslet.2004.02.092.
   Saini DK, 2004, MICROBIOL-SGM, V150, P865, DOI 10.1099/mic.0.26218-0.
   SALKIN D, 1956, Am Rev Tuberc, V74, P376.
   Sambandamurthy VK, 2002, NAT MED, V8, P1171, DOI 10.1038/nm765.
   Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100.
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x.
   Schelle MW, 2006, CHEMBIOCHEM, V7, P1516, DOI 10.1002/cbic.200600224.
   Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846.
   Sharma V, 2000, NAT STRUCT BIOL, V7, P663, DOI 10.1038/77964.
   Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498.
   Shi LB, 2005, P NATL ACAD SCI USA, V102, P15629, DOI 10.1073/pnas.0507850102.
   Sohaskey CD, 2005, MICROBIOL-SGM, V151, P3803, DOI 10.1099/mic.0.28263-0.
   Sohaskey CD, 2003, J BACTERIOL, V185, P7247, DOI 10.1128/JB.185.24.7247-7256.2003.
   Starck J, 2004, MICROBIOL-SGM, V150, P3821, DOI 10.1099/mic.0.27284-0.
   Stewart GR, 2005, MOL MICROBIOL, V55, P1127, DOI 10.1111/j.1365-2958.2004.04450.x.
   Stewart JN, 2006, MICROBIOL-SGM, V152, P233, DOI 10.1099/mic.0.28275-0.
   Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183.
   Sun MH, 2005, J BIOL CHEM, V280, P7861, DOI 10.1074/jbc.M409613200.
   Talaat AM, 2004, P NATL ACAD SCI USA, V101, P4602, DOI 10.1073/pnas.0306023101.
   Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631.
   Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41.
   Tripathi SM, 2006, J MOL BIOL, V362, P877, DOI 10.1016/j.jmb.2006.08.019.
   Usha V, 2002, CAN J MICROBIOL, V48, P7, DOI 10.1139/W01-026.
   van Helden Paul D, 2006, Expert Rev Anti Infect Ther, V4, P759, DOI 10.1586/14787210.4.5.759.
   Voskuil MI, 2004, TUBERCULOSIS, V84, P218, DOI 10.1016/j.tube.2004.02.003.
   Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205.
   Warner DF, 2006, CLIN MICROBIOL REV, V19, P558, DOI 10.1128/CMR.00060-05.
   WAYNE LG, 1994, ANTIMICROB AGENTS CH, V38, P2054.
   WAYNE LG, 1977, INFECT IMMUN, V17, P528.
   Wayne LG, 1996, INFECT IMMUN, V64, P2062.
   Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139.
   Weber I, 2000, MOL MICROBIOL, V35, P1017, DOI 10.1046/j.1365-2958.2000.01794.x.
   Weinstein EA, 2005, P NATL ACAD SCI USA, V102, P4548, DOI 10.1073/pnas.0500469102.
   Wheeler PR, 2005, J BIOL CHEM, V280, P8069, DOI 10.1074/jbc.M412540200.
   Williams SJ, 2002, J BIOL CHEM, V277, P32606, DOI 10.1074/jbc.M204613200.
   Wisedchaisri G, 2005, J MOL BIOL, V354, P630, DOI 10.1016/j.jmb.2005.09.048.
   Wooff E, 2002, MOL MICROBIOL, V43, P653, DOI 10.1046/j.1365-2958.2002.02771.x.
   Xie ZF, 2005, ANTIMICROB AGENTS CH, V49, P4778, DOI 10.1128/AAC.49.11.4778-4780.2005.
   Zahrt TC, 2003, INFECT IMMUN, V71, P6962, DOI 10.1128/IAI.71.12.6962-6970.2003.
   Zahrt TC, 2001, P NATL ACAD SCI USA, V98, P12706, DOI 10.1073/pnas.221272198.
   Zarembinski TI, 1998, P NATL ACAD SCI USA, V95, P15189, DOI 10.1073/pnas.95.26.15189.
   Zhang L, 2006, J HYDROL ENG, V11, P21, DOI 10.1061/(ASCE)1084-0699(2006)11:1(21).
   Zhang Y, 2004, FRONT BIOSCI, V9, P1136, DOI 10.2741/1291.
   Zhang Ying, 2005, Annu Rev Pharmacol Toxicol, V45, P529, DOI 10.1146/annurev.pharmtox.45.120403.100120.}},
Number-of-Cited-References = {{119}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{14}},
Journal-ISO = {{BMC Infect. Dis.}},
Doc-Delivery-Number = {{203BP}},
Unique-ID = {{ISI:000248950400001}},
}

@article{ ISI:000248121300032,
Author = {Johar, Monika and Manning, Tracey and Tse, Christopher and Desroches,
   Nancy and Agrawal, B. and Kunimoto, Dennis Y. and Kumar, Rakesh},
Title = {{Growth inhibition of Mycobacterium bovis, Mycobacterium tuberculosis and
   Mycobacterium avium in vitro: Effect of 1-beta-D-2 `-Arabinofuranosyl
   and 1-(2 `-Deoxy-2 `-fluoro-beta-D-2 `-ribofuranosyl) pyrimidine
   nucleoside analogs}},
Journal = {{JOURNAL OF MEDICINAL CHEMISTRY}},
Year = {{2007}},
Volume = {{50}},
Number = {{15}},
Pages = {{3696-3705}},
Month = {{JUL 26}},
Abstract = {{The resurgence of tuberculosis and the emergence of
   multiple-drug-resistant strains of Mycobacteria necessitate the search
   for new classes of antimycobacterial agents. We synthesized a series of
   1-beta-D-2'-arabinofuranosyl and
   1-(2'-deoxy-2'-fluoro-beta-D-ribofuranosyl) pyrimidine nucleosides
   possessing diverse sets of alkynyl, alkenyl, alkyl, and halo
   substituents at the C-5 position of the uracil and investigated their
   effect on activity against M. tuberculosis, M. bovis, and M. avium.
   Among these molecules, 5-alkynyl-substituted derivatives emerged as
   potent inhibitors of M. bovis, M. tuberculosis, and M. avium.
   Nucleosides 1-beta-D-2'-arabinofuranosyl-5-dodecynyluracil (5),
   1-(2'-deoxy-2'-fluoro-beta-D-ribofuranosyl)-5-dodecynyluracil (24), and
   1-(2'-deoxy-2'-fluoro-beta-D-ribofuranosyl)-5-tetradecynyluracil (25)
   showed the highest antimycobacterial potency against M. bovis and M.
   tuberculosis. The MIC90 exhibited by compounds 5,24, and 25 was similar
   or close to that of the reference drug rifampicin. The most active
   compounds 5, 24, and 25 were also found to retain sensitivity against a
   rifampicin-resistant strain of M. tuberculosis H37Rv at similar
   concentrations. Some of these analogs also revealed in vitro
   antimicrobial effect against several other gram-positive pathogens.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kumar, R (Reprint Author), Univ Alberta, Dept Lab Med \& Pathol, Fac Med \& Dent, 1-71 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.
   Univ Alberta, Dept Lab Med \& Pathol, Fac Med \& Dent, Edmonton, AB T6G 2H7, Canada.
   Univ Alberta, Dept Med, Fac Med \& Dent, Edmonton, AB T6G 2H7, Canada.
   Univ Alberta, Dept Surg, Fac Med \& Dent, Edmonton, AB T6G 2H7, Canada.}},
DOI = {{10.1021/jm0703901}},
ISSN = {{0022-2623}},
EISSN = {{1520-4804}},
Keywords-Plus = {{ALAMAR BLUE ASSAY; INFECTION; RESISTANT; DRUG; DERIVATIVES;
   EPIDEMIOLOGY; DISEASE; AGENTS; TB}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Chemistry, Medicinal}},
Author-Email = {{rakesh.kumar@ualberta.ca}},
Cited-References = {{BERES J, 1986, J MED CHEM, V29, P494, DOI 10.1021/jm00154a012.
   Cohen J, 2006, SCIENCE, V313, P1554.
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698.
   Cole ST, 1998, NATURE, V393, P537.
   Collins LA, 1997, ANTIMICROB AGENTS CH, V41, P1004.
   DAUTZENBERG B, 1994, RES MICROBIOL, V145, P197, DOI 10.1016/0923-2508(94)90018-3.
   ELLNER JJ, 1991, J INFECT DIS, V163, P1326.
   Espinal MA, 2003, TUBERCULOSIS, V83, P44, DOI 10.1016/S1472-9792(02)00058-6.
   Falkinham JO, 1996, CLIN MICROBIOL REV, V9, P177.
   Fillastre JP, 1996, J ANTIMICROB CHEMOTH, V37, P965, DOI 10.1093/jac/37.5.965.
   Franzblau SG, 1998, J CLIN MICROBIOL, V36, P362.
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4.
   Frieden TR, 2005, CLIN CHEST MED, V26, P197, DOI 10.1016/j.ccm.2005.02.001.
   Gordin FM, 1996, AM J RESP CRIT CARE, V154, P1478.
   Guerrero A, 1997, LANCET, V350, P1738, DOI 10.1016/S0140-6736(97)07567-3.
   Guerrin-Tran E, 2006, EUR J EPIDEMIOL, V21, P783, DOI 10.1007/s10654-006-9069-y.
   HERDEWIJN PAMM, 1994, ANTIVIR CHEM CHEMOTH, V5, P131.
   INDERLIED CB, 1993, CLIN MICROBIOL REV, V6, P266.
   Johar M, 2005, BIOORGAN MED CHEM, V13, P6663, DOI 10.1016/j.bmc.2005.07.046.
   KOEHLER CSW, 2002, DRUG DISCOVERY, P47.
   KUMAR R, 1993, NUCLEOS NUCLEOT, V12, P537, DOI 10.1080/07328319308021221.
   KUMAR R, 1989, J MED CHEM, V32, P941, DOI 10.1021/jm00125a003.
   Kumar R, 2003, J ENZYM INHIB MED CH, V18, P273, DOI 10.1080/1475636031000073115.
   Kumar R, 1992, Drug Des Discov, V8, P179.
   KUMAR R, 1994, CAN J CHEM, V72, P2005, DOI 10.1139/v94-256.
   KUMAR R, 1990, J MED CHEM, V33, P717, DOI 10.1021/jm00164a039.
   Lancet Editorial, 2006, LANCET, V368, P964.
   MACHIDA H, 1995, BIOCHEM PHARMACOL, V49, P763, DOI 10.1016/0006-2952(94)00543-U.
   Maher D., 2005, CLIN CHEST, V26, P168.
   MENDEZ AP, 1998, NEW ENGL J MED, V338, P1641.
   MERCER JR, 1987, J MED CHEM, V30, P670, DOI 10.1021/jm00387a015.
   Moss AR, 1997, INT J TUBERC LUNG D, V1, P115.
   Murray JF, 1998, RESPIRATION, V65, P335, DOI 10.1159/000029291.
   {*}NAT SURV TUB ENGL, 1998, COMM DIS REP WEEKL, V8, P209.
   Nayyar A, 2005, CURR MED CHEM, V12, P1873, DOI 10.2174/0929867054546654.
   NEUGEBAUER JM, 1990, METHOD ENZYMOL, V182, P239.
   PELOQUIN CA, 1994, ANN PHARMACOTHER, V28, P72.
   Pilheu JA, 1998, INT J TUBERC LUNG D, V2, P696.
   Pozniak Anton, 2002, J HIV Ther, V7, P13.
   Rai D, 2005, J MED CHEM, V48, P7012, DOI 10.1021/jm058167w.
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220.
   Ryan AJ, 2003, J MED CHEM, V46, P3448, DOI 10.1021/jm0340896.
   Valadas E, 2005, EUR J RADIOL, V55, P154, DOI 10.1016/j.ejrad.2005.04.013.
   VINCENT P, 1981, TETRAHEDRON LETT, V22, P945, DOI 10.1016/0040-4039(81)89015-6.
   {[}Anonymous], 2004, GLOB TUB CONTR SURV.
   {*}WHO, 2002, TUB WHO REP.
   {*}WHO, 2004, 104 WHO INF RES CTR.
   Willcox P A, 2000, Curr Opin Pulm Med, V6, P198, DOI 10.1097/00063198-200005000-00006.
   Wrigbt A., 2006, Morbidity and Mortality Weekly Report, V55, P301.
   Zhang Ying, 2005, Annu Rev Pharmacol Toxicol, V45, P529, DOI 10.1146/annurev.pharmtox.45.120403.100120.}},
Number-of-Cited-References = {{50}},
Times-Cited = {{24}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Med. Chem.}},
Doc-Delivery-Number = {{191HD}},
Unique-ID = {{ISI:000248121300032}},
}

@article{ ISI:000248588200007,
Author = {McNair, J. and Welsh, M. D. and Pollock, J. M.},
Title = {{The immunology of bovine tuberculosis and progression toward improved
   disease control strategies}},
Journal = {{VACCINE}},
Year = {{2007}},
Volume = {{25}},
Number = {{30, SI}},
Pages = {{5504-5511}},
Month = {{JUL 26}},
Note = {{4th International Veterinary Vaccines and Diagnostics Conference, Oslo,
   NORWAY, JUN 25-29, 2006}},
Abstract = {{Failure to remove cattle diseased with Mycobacterium bovis has immense
   financial implications for disease control, animal health and
   agricultural trade as well as the zoonotic risk to human health. Current
   disease control strategies based on DTH skin testing fail to detect all
   diseased cattle and additional measures are urgently needed to improve
   detection of disease and to prevent naive animals becoming exposed to
   infection. Experimental models of bovine TB traditionally based on
   intra-nasal instillation, intra-tracheal inoculation or placed
   in-contact with infected cattle, have been further developed using
   aerosolised bacteria delivered to the respiratory tract, allowing
   field-like bovine TB to be recreated under controlled, experimental
   conditions. Experimental infection models have already been used to
   improve diagnostic tests. Specificity of DTH skin testing can be
   improved under experimental conditions, using recombinant ESAT-6, while
   laboratory assays such as IFN-gamma release have benefited from the use
   of defined proteins to improve assay specificity. In combination,
   antigen cocktails may also improve test sensitivity. There is a
   concerted international effort to evaluate vaccines for use in cattle
   populations and to define vaccination strategies which will eliminate
   disease from infected herds. DNA, protein and genetically modified
   vaccines inoculated in a single dose, given as prime-boost or injected
   concurrently, will elicit significant protection against challenge with
   M. bovis under controlled conditions. However, vaccines and vaccination
   strategies require evaluation under field conditions. Furthermore,
   complementary strategies are under development to differentiate immune
   responses that follow vaccination from those following disease. This
   paper describes those recent advances which may lead to the introduction
   of improved disease control strategies. (c) 2007 Elsevier Ltd. All
   rights reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{McNair, J (Reprint Author), Agrifood \& Biosci Inst, Vet Sci Div, Stoney Rd, Belfast BT4 3SD, Antrim, North Ireland.
   Agrifood \& Biosci Inst, Vet Sci Div, Belfast BT4 3SD, Antrim, North Ireland.}},
DOI = {{10.1016/j.vaccine.2007.02.037}},
ISSN = {{0264-410X}},
Keywords = {{Mycobacterium bovis; immunology; vaccines; disease control}},
Keywords-Plus = {{VIRULENT MYCOBACTERIUM-BOVIS; GAMMA-INTERFERON ASSAY; BCG VACCINATED
   CATTLE; TEST-REACTOR CATTLE; DELTA T-CELLS; SUBUNIT VACCINE; INFECTED
   CATTLE; ANTIGEN 85B; PROTECTIVE EFFICACY; IMMUNE-RESPONSES}},
Research-Areas = {{Immunology; Research \& Experimental Medicine}},
Web-of-Science-Categories  = {{Immunology; Medicine, Research \& Experimental}},
Author-Email = {{jim.mcnair@afbini.gov.uk}},
Cited-References = {{Aagaard C, 2006, J CLIN MICROBIOL, V44, P4326, DOI 10.1128/JCM.01184-06.
   Abernethy DA, 2006, VET MICROBIOL, V112, P231, DOI 10.1016/j.vetmic.2005.11.023.
   Ameni G, 2000, TROP ANIM HEALTH PRO, V32, P267, DOI 10.1023/A:1005271421976.
   Andersen Ase Bengard, 1994, P307.
   BERGGREN SA, 1977, BRIT VET J, V133, P490.
   BERGGREN SA, 1981, BRIT VET J, V137, P88.
   Boom WH, 1996, INFECT AGENT DIS, V5, P73.
   BOVINE FJ, 1947, TUBERCULOSIS INCLUDI.
   Buddle BM, 1999, CLIN DIAGN LAB IMMUN, V6, P1.
   BUDDLE BM, 1995, VACCINE, V13, P1123, DOI 10.1016/0264-410X(94)00055-R.
   Buddle BM, 2006, VET MICROBIOL, V112, P191, DOI 10.1016/j.vetmic.2005.11.027.
   Buddle BM, 2005, TUBERCULOSIS, V85, P19, DOI 10.1016/j.tube.2004.09.003.
   Buddle BM, 2003, INT J PARASITOL, V33, P555, DOI 10.1016/S0020-7519(03)00060-2.
   Buddle BM, 2002, VACCINE, V20, P1126, DOI 10.1016/S0264-410X(01)00436-4.
   BUXTON J. B., 1939, JOUR COMP PATH AND THERAP, V52, P47.
   CALMETTE A., 1911, ANN I PASTEUR, V25, P625.
   Calmette A, 1920, ANN I PASTEUR, V34, P553.
   Cassidy JP, 2001, J COMP PATHOL, V124, P46, DOI 10.1053/jcpa.2000.0427.
   Cassidy JP, 1998, J COMP PATHOL, V119, P27, DOI 10.1016/S0021-9975(98)80069-8.
   Cockle PJ, 2002, INFECT IMMUN, V70, P6996, DOI 10.1128/IAI.70.12.6996-7003.2002.
   CORNER LA, 1994, VET MICROBIOL, V40, P53, DOI 10.1016/0378-1135(94)90046-9.
   Corner LAL, 2006, VET MICROBIOL, V112, P303, DOI 10.1016/j.vetmic.2005.11.015.
   DABORN CJ, 1993, BRIT VET J, V149, P405.
   DELARUADOMENECH R, 2006, RES VET SCI, V190, P210.
   Dietrich J, 2006, VET MICROBIOL, V112, P163, DOI 10.1016/j.vetmic.2005.11.030.
   Dietrich J, 2005, J IMMUNOL, V174, P6332.
   DONDO A, 1993, VET ITALIANA, V28, P14.
   Feng CG, 2001, INFECT IMMUN, V69, P4174, DOI 10.1128/IAI.69.6.4174-4176.2001.
   FRANCIS J, 1978, VET REC, V103, P420.
   GLOVER R. E., 1953, BRIT VET JOUR, V109, P411.
   GODFOID J, 2006, VET MICROBIOL, V112, P387.
   Gonzalez-Kirchner JP, 1999, FOLIA PRIMATOL, V70, P55, DOI 10.1159/000021676.
   HARRING CM, 1930, HILGARDIA, V4, P307.
   Hines N, 2006, J VET DIAGN INVEST, V18, P243.
   Hope JC, 2005, CLIN EXP IMMUNOL, V139, P48, DOI 10.1111/j.1365-2249.2004.02668.x.
   Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893.
   Johnson L, 2006, VET IMMUNOL IMMUNOP, V111, P219, DOI 10.1016/j.vetimm.2006.01.016.
   Johnson L, 2007, TUBERCULOSIS, V87, P71, DOI 10.1016/j.tube.2006.04.002.
   Kamath AT, 1999, INFECT IMMUN, V67, P1702.
   Kennedy HE, 2002, INFECT IMMUN, V70, P1488, DOI 10.1128/IAI.70.3.1488-1500.2002.
   Langermans JAM, 2005, VACCINE, V23, P2740, DOI 10.1016/j.vaccine.2004.11.051.
   Lightbody KA, 2000, VET MICROBIOL, V75, P177, DOI 10.1016/S0378-1135(00)00215-7.
   Lightbody KA, 1998, VET REC, V142, P295.
   LYASHCHENKO KP, 2006, VET MICROBIOL, V112, P387.
   Maue AC, 2004, VACCINE, V23, P769, DOI 10.1016/j.vaccine.2004.07.019.
   McCorry T, 2005, VET REC, V157, P613.
   McNair J, 2001, SCAND J IMMUNOL, V53, P365, DOI 10.1046/j.1365-3083.2001.00874.x.
   MCNAIR J, UNPUB.
   Monaghan M, 1997, IRISH VET J, V50, P229.
   MONAGHAN ML, 1994, VET MICROBIOL, V40, P111, DOI 10.1016/0378-1135(94)90050-7.
   Mustafa AS, 2000, INFECT IMMUN, V68, P3933, DOI 10.1128/IAI.68.7.3933-3940.2000.
   NEILL S, 1995, TUBERCULOSIS WILDLIF, P300.
   NEILL SD, 1994, VET MICROBIOL, V40, P41, DOI 10.1016/0378-1135(94)90045-0.
   Olsen AW, 2001, INFECT IMMUN, V69, P2773, DOI 10.1128/IAI.69.5.2773-2778.2001.
   Olsen AW, 2004, INFECT IMMUN, V72, P6148, DOI 10.1128/IAI.72.10.6148-6150.2004.
   Olsen I, 2005, INFECT IMMUN, V73, P5628, DOI 10.1128/IAI.73.9.5628-5635.2005.
   ONuallain EM, 1997, VET IMMUNOL IMMUNOP, V56, P65, DOI 10.1016/S0165-2427(96)05734-0.
   Palmer MV, 2006, VET MICROBIOL, V112, P181, DOI 10.1016/j.vetmic.2005.11.028.
   Palmer MV, 2002, TUBERCULOSIS, V82, P275, DOI 10.1054/tube.2002.0341.
   PALMER MV, 2006, CLIN VACCINE IMMUNOL, V3, P387.
   Phillips CJC, 2003, RES VET SCI, V74, P1, DOI 10.1016/S0034-5288(02)00145-5.
   Pollock JM, 2006, VET MICROBIOL, V112, P141, DOI 10.1016/j.vetmic.2005.11.032.
   Pollock JM, 1996, IMMUNOLOGY, V87, P236, DOI 10.1046/j.1365-2567.1996.457538.x.
   POLLOCK JM, 1994, IMMUNOLOGY, V82, P9.
   Pollock JM, 2003, J CLIN MICROBIOL, V41, P1856, DOI 10.1128/JCM.41.5.1856.1860.2003.
   Pollock JM, 2001, TUBERCULOSIS, V81, P103, DOI 10.1054/tube.2000.0258.
   Pollock JM, 2002, VET IMMUNOL IMMUNOP, V89, P105, DOI 10.1016/S0165-2427(02)00200-3.
   Pollock JM, 2000, VET REC, V146, P659.
   PRITCHARD DG, 1988, J COMP PATHOL, V99, P357, DOI 10.1016/0021-9975(88)90058-8.
   RODGERS JD, UNPUB TUBERCULOSIS.
   Rolle M, 1956, VET B, V27, P105.
   ROTH W, 1990, PERSONNEL, V67, P4.
   Saleem IY, 2005, J CONTROL RELEASE, V102, P551, DOI 10.1016/j.jconrel.2004.10.034.
   Schellner H, 1955, VET B, V26, P183.
   SIBGATULLIN RS, 1982, VET B, V53, P731.
   Skinner MA, 2003, INFECT IMMUN, V71, P4901, DOI 10.1128/IAI.71.9.4901-4907.2003.
   Skinner MA, 2001, REV SCI TECH OIE, V20, P112.
   Smyth AJ, 2001, INFECT IMMUN, V69, P89, DOI 10.1128/IAI.69.1.89-96.2001.
   THOEN CO, 1980, COMP IMMUNOL MICROB, V3, P355, DOI 10.1016/0147-9571(80)90012-0.
   TZEKHNOVITZER M., 1927, ANN INST PASTEUR, V41, P322.
   van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000.
   Vordermeier HM, 1999, CLIN DIAGN LAB IMMUN, V6, P675.
   Vordermeier HM, 2001, CLIN DIAGN LAB IMMUN, V8, P571, DOI 10.1128/CDLI.8.3.571-578.2001.
   VORDERMEIER M, 2006, VET MICROBIOL, V112, P387.
   WADDINGTON FG, 1972, BRIT VET J, V128, P541.
   Waters WR, 2006, CLIN VACCINE IMMUNOL, V13, P611, DOI 10.1128/CVI.00054-06.
   Watson EA, 1928, J AM VET MED ASSOC, V73, P799.
   Wedlock DN, 2005, INFECT IMMUN, V73, P3540, DOI 10.1128/IAI.73.6.3540-3546.2005.
   Wedlock DN, 2003, TUBERCULOSIS, V83, P339, DOI 10.1016/S1472-9792(03)00055-6.
   WHIPPLE DL, 1995, AM J VET RES, V56, P415.
   WOOD PR, 1992, VET MICROBIOL, V31, P71, DOI 10.1016/0378-1135(92)90142-G.}},
Number-of-Cited-References = {{91}},
Times-Cited = {{22}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{16}},
Journal-ISO = {{Vaccine}},
Doc-Delivery-Number = {{197WV}},
Unique-ID = {{ISI:000248588200007}},
}

@article{ ISI:000248472100037,
Author = {Mittruecker, Hans-Willi and Steinhoff, Ulrich and Koehler, Anne and
   Krause, Marion and Lazar, Doris and Mex, Peggy and Miekley, Delia and
   Kaufmann, Stefan H. E.},
Title = {{Poor correlation between BCG vaccination-induced T cell responses and
   protection against tuberculosis}},
Journal = {{PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA}},
Year = {{2007}},
Volume = {{104}},
Number = {{30}},
Pages = {{12434-12439}},
Month = {{JUL 24}},
Abstract = {{Mycobacterium bovis bacille Calmette-Guerin (BCG) is the most widely
   used live bacterial vaccine. However, limited information is available
   correlating route and dose of vaccination and induction of specific T
   cell responses with protection against tuberculosis. We compared
   efficacy of oral and systemic vaccination and correlated vaccine-induced
   T cell responses with protection in experimental tuberculosis of mice.
   After oral and systemic vaccination, we observed profound differences in
   persistence and dissemination of BCG and frequencies and location of
   specific IFN-gamma-secreting CD4(+) and CD8(+) T cells. Yet, both
   vaccination routes caused comparable levels of protection against
   aerosol challenge with Mycobacterium tuberculosis. Protection correlated
   best with rapid accumulation of specific CD8+ T cells in infected
   tissues of challenged mice. In contrast, specific IFN-gamma production
   by CD4(+) T cells reflected the load of M. tuberculosis rather than the
   strength of protection. Our data question the measurement of IFN-gamma
   secretion by CD4(+) T cells and emphasize the need for new biomarkers
   for evaluation of tuberculosis vaccine efficacies.}},
Publisher = {{NATL ACAD SCIENCES}},
Address = {{2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mittrucker, HW (Reprint Author), Max Planck Inst Infect Biol, Dept Immunol, Caritepl 1, D-10117 Berlin, Germany.
   Max Planck Inst Infect Biol, Dept Immunol, D-10117 Berlin, Germany.
   Univ Hamburg, Med Ctr, Inst Immunol, D-20246 Hamburg, Germany.}},
DOI = {{10.1073/pnas.0703510104}},
ISSN = {{0027-8424}},
Keywords = {{Mycobacterium tuberculosis; protective immunity}},
Keywords-Plus = {{MYCOBACTERIUM-BOVIS BCG; PULMONARY TUBERCULOSIS; LISTERIA-MONOCYTOGENES;
   EARLY EMERGENCE; INFECTION; MICE; RESISTANCE; MEMORY; IMMUNIZATION;
   LYMPHOCYTES}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Author-Email = {{h.mittruecker@uke.uni-hamburg.de}},
ResearcherID-Numbers = {{Kaufmann, Stefan HE/I-5454-2014}},
ORCID-Numbers = {{Kaufmann, Stefan HE/0000-0001-9866-8268}},
Cited-References = {{Abolhassani M, 2000, INFECT IMMUN, V68, P5657.
   Berg RE, 2003, J EXP MED, V198, P1583, DOI 10.1084/jem.20031051.
   Brigl M, 2003, NAT IMMUNOL, V4, P1230, DOI 10.1038/ni1002.
   CALMETTE A., 1924, ANN I PASTEUR, V38, P371.
   Chackerian AA, 2001, INFECT IMMUN, V69, P2666, DOI 10.1128/IAI.69.4.2666-2674.2001.
   D'Souza S, 2003, INFECT IMMUN, V71, P483, DOI 10.1128/IAI.71.1.483-493.2003.
   Fine PEM, 2001, SCAND J INFECT DIS, V33, P243, DOI 10.1080/003655401300077144.
   FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013.
   Foulds KE, 2006, IMMUNOL REV, V211, P58, DOI 10.1111/j.0105-2896.2006.00400.x.
   Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292.
   Goter-Robinson C, 2006, VACCINE, V24, P3522, DOI 10.1016/j.vaccine.2006.02.005.
   Gruppo V, 2002, TUBERCULOSIS, V82, P267, DOI 10.1054/tube.2002.0340.
   HORWITZ MA, 2005, VACCINE, V24, P443.
   Irwin SM, 2005, INFECT IMMUN, V73, P5809, DOI 10.1128/IAI.73.9.5809-5816.2005.
   IZUMI T, 1971, J EXP MED, V133, P376, DOI 10.1084/jem.133.2.376.
   Jacobsen M, 2007, J MOL MED-JMM, V85, P613, DOI 10.1007/s00109-007-0157-6.
   Jung YJ, 2005, J EXP MED, V201, P1915, DOI 10.1084/jem.20050265.
   Kamath AB, 2004, J EXP MED, V200, P1479, DOI 10.1084/jem.20041690.
   Kamath A, 2006, J IMMUNOL, V177, P6361.
   Kamath AT, 2000, CLIN EXP IMMUNOL, V120, P476, DOI 10.1046/j.1365-2249.2000.01240.x.
   Kaufmann SHE, 2006, IMMUNITY, V24, P351, DOI 10.1016/j.immuni.2006.04.003.
   Kaufmann SHE, 2006, NAT REV IMMUNOL, V6, P699, DOI 10.1038/nri1920.
   Kursar M, 2002, J IMMUNOL, V168, P6382.
   Lagranderie M, 2000, VACCINE, V18, P1186, DOI 10.1016/S0264-410X(99)00386-2.
   Lazarevic V, 2005, INFECT IMMUN, V73, P2910, DOI 10.1128/IAI.73.5.2910-2922.2005.
   LEFFORD MJ, 1980, INFECT IMMUN, V28, P508.
   Lertmemongkolchai G, 2001, J IMMUNOL, V166, P1097.
   Majlessi L, 2006, INFECT IMMUN, V74, P2128, DOI 10.1128/IAI.74.4.2128-2137.2006.
   Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867.
   Mogues T, 2001, J EXP MED, V193, P271, DOI 10.1084/jem.193.3.271.
   Palendira U, 2002, INFECT IMMUN, V70, P1410, DOI 10.1102/IAI.70.3.1410.1416.2002.
   Rolph MS, 2001, EUR J IMMUNOL, V31, P1944, DOI 10.1002/1521-4141(200106)31:6<1944::AID-IMMU1944>3.0.CO;2-R.
   Saunders BM, 2002, CELL IMMUNOL, V216, P65, DOI 10.1016/S0008-8749(02)00510-5.
   Serbina NV, 1999, INFECT IMMUN, V67, P3980.
   Serbina NV, 2001, INFECT IMMUN, V69, P4320, DOI 10.1128/IAI.69.7.4320-4328.2001.
   {*}WHO, 2006, 104 WHO.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{163}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Proc. Natl. Acad. Sci. U. S. A.}},
Doc-Delivery-Number = {{196HK}},
Unique-ID = {{ISI:000248472100037}},
}

@article{ ISI:000248403900003,
Author = {Wang Li-mei and Shi Chang-hong and Fan Xiong-lin and Ying, Xue and Bai
   Yin-lai and Xu Zhi-kai},
Title = {{Expression and immunogenicity of recombinant Mycobacterium bovis
   Bacillus Calmette-Guerin strains secreting the antigen ESAT-6 from
   Mycobacterium tuberculosis in mice}},
Journal = {{CHINESE MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{120}},
Number = {{14}},
Pages = {{1220-1225}},
Month = {{JUL 20}},
Abstract = {{Background Tuberculosis remains the leading cause of human death.
   Currently, Bacillus Calmette-Guerin (BCG) is the only available vaccine
   against tuberculosis but its efficacy is highly variable. Thus,
   developing new tuberculosis vaccines becomes an urgent task. In this
   study, we evaluated in BALB/c mice the humoral and cellular immune
   responses of recombinant BCG expressing the antigen ESAT-6 from
   Mycobacterium tuberculosis.
   Methods Escherichia coli-BCG shuttle plasmid named pDE22-esat-6 was
   constructed by inserting the BamHl/EcoRl digested esat-6 gene PCR
   product into the similarly digested parental plasmid pDE22. BCG cells
   were transformed with pDE22-esat-6, which was named recombinant BCG
   (rBCG). BALB/c mice were immunized subcutaneously on the back with 100
   mu l normal saline containing 10(6) CFU of BCG or rBCG. They were
   sacrificed after 4 weeks to detect their humoral and cellular responses.
   Results There was no any significant differences in the growth
   characteristics between the conventional BCG and rBCG. In immunized
   mice, the IgG antibody titres of rBCG group were as high as 1:8000,
   which was significantly higher than that in BCG group (1:1400, P <
   0.05). The elicited IFN-gamma level of rBCG group was (1993 +/- 106)
   pg/ml, which was also significantly higher than that in BCG group ((1463
   +/- 105) pg/ml, P < 0.05). The splenocyte proliferation index of rBCG
   group reached 4.34 +/- 0.3, which was higher than that of BCG group
   (3.79 +/- 0.24, P < 0.05).
   Conclusion rBCG secreted expressing antigen ESAT-6 stimulated stronger
   humoral and cellular immune responses than BCG did, and, therefore may
   be the better vaccine against mycobacterium tuberculosis.}},
Publisher = {{CHINESE MEDICAL ASSOC}},
Address = {{42 DONGSI XIDAJIE, BEIJING 100710, PEOPLES R CHINA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Xu, ZK (Reprint Author), Fourth Mil Med Univ, Dept Microbiol, Xian 710032, Peoples R China.
   Fourth Mil Med Univ, Dept Microbiol, Xian 710032, Peoples R China.
   Huazhong Univ Sci \& Technol, Tongji Med Coll, Dept Pathogen Biol, Wuhan 430030, Peoples R China.}},
ISSN = {{0366-6999}},
Keywords = {{Mycobacterium tuberculosis; Bacillus Calmette-Guerin; ESAT-6; vaccine}},
Keywords-Plus = {{T-CELL RESPONSES; PROTECTIVE IMMUNITY; BCG VACCINES; INFECTION; COMPLEX;
   INDUCTION; PROTEIN; RECALL; GAMMA}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{zhikaixu@fmmu.edu.cn}},
ResearcherID-Numbers = {{Fan, Xionglin/E-2747-2015}},
ORCID-Numbers = {{Fan, Xionglin/0000-0001-9754-372X}},
Cited-References = {{ANDERSEN P, 1991, INFECT IMMUN, V59, P1558.
   ANDERSEN P, 1995, J IMMUNOL, V154, P3359.
   Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520.
   Bonecini-Almeida MG, 1998, J IMMUNOL, V160, P4490.
   Brandt L, 2002, INFECT IMMUN, V70, P672, DOI 10.1128/IAI.70.2.672-678.2002.
   Brandt L, 1996, J IMMUNOL, V157, P3527.
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698.
   Collins DM, 2000, IMMUNOL CELL BIOL, V78, P342, DOI 10.1046/j.1440-1711.2000.00937.x.
   Dhar N, 2000, FEMS MICROBIOL LETT, V190, P309, DOI 10.1111/j.1574-6968.2000.tb09304.x.
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9.
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249.
   Girard MP, 2005, VACCINE, V23, P5725, DOI 10.1016/j.vaccine.2005.07.045.
   HANSON MS, 1995, ANN NY ACAD SCI, V754, P214, DOI 10.1111/j.1749-6632.1995.tb44453.x.
   Harboe M, 1996, INFECT IMMUN, V64, P16.
   Mahairas GG, 1996, J BACTERIOL, V178, P1274.
   Mustafa AS, 1998, SCAND J IMMUNOL, V48, P535.
   Ohara N, 2001, VACCINE, V19, P4089, DOI 10.1016/S0264-410X(01)00155-4.
   Parish Tanya, 1998, V101, P129.
   Pollock JM, 1997, INFECT IMMUN, V65, P2587.
   Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200.
   Sambrook J., 1989, MOL CLONING LAB MANU.
   {[}师长宏 Shi Changhong], 2005, {[}中华结核和呼吸杂志, Chinese Journal of Tuberculosis and Respiratiory Diseases], V28, P254.
   Shi J. H., 2000, J 4 MIL MED U, V21, P761.
   Skjot RLV, 2000, INFECT IMMUN, V68, P214.
   SORENSEN AL, 1995, INFECT IMMUN, V63, P1710.
   Ulrichs T, 1998, EUR J IMMUNOL, V28, P3949, DOI 10.1002/(SICI)1521-4141(199812)28:12<3949::AID-IMMU3949>3.3.CO;2-W.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{Chin. Med. J.}},
Doc-Delivery-Number = {{195HU}},
Unique-ID = {{ISI:000248403900003}},
}

@article{ ISI:000247994200033,
Author = {Bakshi, C. S. and Shah, D. H. and Verma, Rishendra and Singh, R. K. and
   Malik, Meenakshi},
Title = {{``Rapid differentiation of Mycobacterium bovis and Mycobacterium
   tuberculosis based on a 12.7-kb fragment by a single tube
   multiplex-PCR{''} (vol 109, pg 211, 2005)}},
Journal = {{VETERINARY MICROBIOLOGY}},
Year = {{2007}},
Volume = {{123}},
Number = {{1-3}},
Pages = {{282}},
Month = {{JUL 20}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Correction}},
Language = {{English}},
Affiliation = {{Verma, R (Reprint Author), Indian Vet Res Inst, Mycobacteria Lab, Div Biol Standardizat, Izatnagar 243122, Uttar Pradesh, India.
   Indian Vet Res Inst, Mycobacteria Lab, Div Biol Standardizat, Izatnagar 243122, Uttar Pradesh, India.
   Indian Vet Res Inst, Natl Biotechnol Ctr, Izatnagar 243122, Uttar Pradesh, India.}},
DOI = {{10.1016/j.vetmic.2007.02.005}},
ISSN = {{0378-1135}},
Research-Areas = {{Microbiology; Veterinary Sciences}},
Web-of-Science-Categories  = {{Microbiology; Veterinary Sciences}},
Author-Email = {{dhshah99@yahoo.com
   rishendra\_verma@yahoo.com}},
ResearcherID-Numbers = {{Malik, Meenakshi/F-1501-2015}},
ORCID-Numbers = {{Malik, Meenakshi/0000-0003-0051-4485}},
Cited-References = {{Bakshi CS, 2005, VET MICROBIOL, V109, P211, DOI 10.1016/j.vetmic.2005.05.015.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Vet. Microbiol.}},
Doc-Delivery-Number = {{189MY}},
Unique-ID = {{ISI:000247994200033}},
}

@article{ ISI:000247810400010,
Author = {Marshall, Geoffrey Brett and Babar, Judith Lynn and Mueller, Nestor Luiz},
Title = {{What's your call? Postprimary tuberculosis}},
Journal = {{CANADIAN MEDICAL ASSOCIATION JOURNAL}},
Year = {{2007}},
Volume = {{177}},
Number = {{2}},
Pages = {{148+}},
Month = {{JUL 17}},
Publisher = {{CMA MEDIA INC}},
Address = {{1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 3Y6, CANADA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Marshall, GB (Reprint Author), Univ British Columbia, Vancouver Gen Hosp, Dept Radiol, Vancouver, BC V5Z 1M9, Canada.
   Univ British Columbia, Vancouver Gen Hosp, Dept Radiol, Vancouver, BC V5Z 1M9, Canada.}},
DOI = {{10.1503/cmaj.070051}},
ISSN = {{0820-3946}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{Andreu J, 2004, EUR J RADIOL, V51, P139, DOI 10.1016/j.ejrad.2004.03.009.
   Van Dyck P, 2003, EUR RADIOL, V13, P1771, DOI 10.1007/s00330-002-1612-y.}},
Number-of-Cited-References = {{2}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Can. Med. Assoc. J.}},
Doc-Delivery-Number = {{186WX}},
Unique-ID = {{ISI:000247810400010}},
}

@article{ ISI:000247810400018,
Author = {Long, Richard and Boffa, Jody},
Title = {{Why internationally adopted children should be screened for tuberculosis}},
Journal = {{CANADIAN MEDICAL ASSOCIATION JOURNAL}},
Year = {{2007}},
Volume = {{177}},
Number = {{2}},
Pages = {{172-173}},
Month = {{JUL 17}},
Publisher = {{CMA MEDIA INC}},
Address = {{1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 3Y6, CANADA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Long, R (Reprint Author), Aberhart Hosp, Rm 8325,11402 Univ Ave, Edmonton, AB T6G 2J3, Canada.
   Univ Alberta, TB Program Evaluat \& Res Unit, Edmonton, AB, Canada.
   Alberta Hlth \& Wellness, Edmonton, AB, Canada.}},
DOI = {{10.1503/cmaj.070252}},
ISSN = {{0820-3946}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{richard.long@ualberta.ca}},
Cited-References = {{{*}ALB CHILDR SERV P, 2004, INT AD GUID ALB FAM.
   Barnett ED, 2005, PEDIATR CLIN N AM, V52, P1287, DOI 10.1016/j.pcl.2005.06.004.
   Canadian Paediatric Society, 1999, CHILDR YOUTH NEW CAN.
   {*}CIT IMM CAN, 2000, INT AD IMM PROC.
   Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192.
   HOSTETTER MK, 1991, NEW ENGL J MED, V325, P479, DOI 10.1056/NEJM199108153250706.
   Loeffler Ann M, 2003, Semin Respir Infect, V18, P272.
   Phypers Melissa, 2003, Can Commun Dis Rep, V29, P139.
   {*}PUBL HLTH AG CAN, TUB CAN ANN.
   Public Health Agency of Canada, 2007, CAN TUB STAND.
   Saiman L, 2001, PEDIATRICS, V108, P608, DOI 10.1542/peds.108.3.608.
   Staat MA, 2002, PEDIATR INFECT DIS J, V21, P257, DOI 10.1097/00006454-200203000-00019.
   YIP D, IN PRESS CAN J PUBLI.}},
Number-of-Cited-References = {{13}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Can. Med. Assoc. J.}},
Doc-Delivery-Number = {{186WX}},
Unique-ID = {{ISI:000247810400018}},
}

@article{ ISI:000248199200052,
Author = {Scherr, Nicole and Honnappa, Srinivas and Kunz, Gabriele and Mueller,
   Philipp and Jayachandran, Rajesh and Winkler, Fritz and Pieters, Jean
   and Steinmetz, Michel O.},
Title = {{Structural basis for the specific inhibition of protein kinase G, a
   virulence factor of Mycobacterium tuberculosis}},
Journal = {{PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA}},
Year = {{2007}},
Volume = {{104}},
Number = {{29}},
Pages = {{12151-12156}},
Month = {{JUL 17}},
Abstract = {{The pathogenicity of mycobacteria such as Mycobacterium tuberculosis is
   closely associated with their capacity to survive within host
   macrophages. A crucial virulence factor for intracellular mycobacterial
   survival is protein kinase G (PknG), a eukaryotic-like serine/threonine
   protein kinase expressed by pathogenic mycobacteria that blocks the
   intracellular degradation of mycobacteria in lysosomes. Inhibition of
   PknG with the highly selective lowmolecular-weight inhibitor AX20017
   results in mycobacterial transfer to lysosomes and killing of the
   mycobacteria. Here, we report the 2.4 angstrom x-ray crystal structure
   of PknG in complex with AX20017. The unique multidomain topology of PknG
   reveals a central kinase domain that is flanked by N- and C-terminal
   rubredoxin and tetratrico-pepticle repeat domains, respectively.
   Directed mutagenesis suggests that the rubredoxin domain functions as a
   regulator of PknG kinase activity. The structure of PknG-AX20017 further
   reveals that the inhibitor is buried deep within the adenosine-binding
   site, targeting an active conformation of the kinase domain. Remarkably,
   although the topology of the kinase domain is reminiscent of eukaryotic
   kinases, the AX20017-binding pocket is shaped by a unique set of amino
   acid side chains that are not found in any human kinase. Directed
   mutagenesis of the unique set of residues resulted in a drastic loss of
   the compound's inhibitory potency. Our results explain the specific mode
   of action of AX20017 and demonstrate that virulence factors highly
   homologous to host molecules can be successfully targeted to block the
   proliferation of M. tuberculosis.}},
Publisher = {{NATL ACAD SCIENCES}},
Address = {{2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Pieters, J (Reprint Author), Klingelbergstr 50, CH-4056 Basel, Switzerland.
   Univ Basel, Biozent, CH-4056 Basel, Switzerland.
   Paul Scherrer Inst, CH-5232 Villigen, Switzerland.}},
DOI = {{10.1073/pnas.0702842104}},
ISSN = {{0027-8424}},
Keywords = {{inhibitor; structure; serine-threonine protein kinases}},
Keywords-Plus = {{PATHOGENIC MYCOBACTERIA; CRYSTAL-STRUCTURE; MACROPHAGES; SURVIVAL;
   ACTIVATION}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Author-Email = {{jean.pieters@unibas.ch}},
Cited-References = {{Av-Gay Y, 2000, TRENDS MICROBIOL, V8, P238, DOI 10.1016/S0966-842X(00)01734-0.
   Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006.
   D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007.
   Ferrari G, 1999, CELL, V97, P435, DOI 10.1016/S0092-8674(00)80754-0.
   Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647.
   Goulding Celia W., 2002, Current Drug Targets - Infectious Disorders, V2, P121, DOI 10.2174/1568005023342551.
   Hamilton JA, 1997, MOL REPROD DEV, V46, P19, DOI 10.1002/(SICI)1098-2795(199701)46:1<19::AID-MRD4>3.0.CO;2-U.
   Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9.
   JAYACHANDRAN R, 2007, IN PRESS CELL.
   Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2.
   KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342.
   Koul A, 2004, NAT REV MICROBIOL, V2, P189, DOI 10.1038/nrmicro840.
   Lancet Editorial, 2006, LANCET, V368, P964.
   Leonard CJ, 1998, GENOME RES, V8, P1038.
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762.
   Masjedi MR, 2006, CLIN INFECT DIS, V43, P841, DOI 10.1086/507542.
   Nguyen L, 2005, J BACTERIOL, V187, P5852, DOI 10.1128/JB.187.16.5852-5856.2005.
   Nguyen L, 2005, TRENDS CELL BIOL, V15, P269, DOI 10.1016/j.tcb.2005.03.009.
   Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920.
   Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024.
   Ortiz-Lombardia M, 2003, J BIOL CHEM, V278, P13094, DOI 10.1074/jbc.M300660200.
   PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213.
   Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034.
   SIEKER LC, 1994, METHOD ENZYMOL, V243, P203.
   TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0.
   Vieira OV, 2002, BIOCHEM J, V366, P689, DOI 10.1042/BJ20020691.
   Walburger A, 2004, SCIENCE, V304, P1800, DOI 10.1126/science.1099384.
   Xaus J, 2001, IMMUNOBIOLOGY, V204, P543, DOI 10.1078/0171-2985-00091.
   Young TA, 2003, NAT STRUCT BIOL, V10, P168, DOI 10.1038/nsb897.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{80}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Proc. Natl. Acad. Sci. U. S. A.}},
Doc-Delivery-Number = {{192KA}},
Unique-ID = {{ISI:000248199200052}},
}

@article{ ISI:000246532600004,
Author = {Reilly, L. A. and Courtenay, O.},
Title = {{Husbandry practices, badger sett density and habitat composition as risk
   factors for transient and persistent bovine tuberculosis on UK cattle
   farms}},
Journal = {{PREVENTIVE VETERINARY MEDICINE}},
Year = {{2007}},
Volume = {{80}},
Number = {{2-3}},
Pages = {{129-142}},
Month = {{JUL 16}},
Abstract = {{Bovine tuberculosis (bTB) is a persistent problem in cattle herds in
   Great Britain and Ireland. Farm management and cattle husbandry
   practices can influence the risk of transmission of bTB and hence the
   likelihood of bTB breakdown (>= I reactor to the tuberculin skin test).
   Biological differences are expected in the transmission dynamics, and
   hence risk factors for bTB breakdown, on farms where infection persists
   in the herd compared to farms where infection is more sporadic or
   short-lived.
   Comparative case-control studies were performed to test farm management
   practices as potential risk factors for transient (under breakdown
   restrictions for <= 6 months) and persistent (under breakdown
   restrictions for >6 months) bTB breakdown over 5 years (1995-1999) on
   179 and 171 UK cattle farms, respectively. Farms were characterised for
   badger sett density and farm habitat composition by ground survey,
   farmers were questioned retrospectively on management practices, and
   cases and controls were identified from national tuberculin test
   records.
   Controlling for routine tuberculin testing interval, log-transformed
   herd size, regional location, badger sett density and farm habitat
   complexity, multivariable logistic regression identified increased odds
   of both transient and persistent breakdown on farms that bought-in cows
   (odds ratio (OR) >= 4.9; 95\% confidence interval (CI) >= 1.1;22.8). In
   addition, the purchase of >50 head of cattle (OR = 4.0, 95\% CI = 1.0;
   16.0) and the storage of manure for >6 months (OR = 4.4; 95\% CI = 1.3;
   15.4) were risk factors for transient breakdown, whereas the use of
   silage clamps (OR = 9. 1; 95\% CI = 2.0;40.8) increased the risk of
   persistent breakdown. Decreased odds of both transient and persistent
   breakdown were associated with higher stocking densities (>3 cattle/ha)
   (OR <= 0.2; 95\% CI < 0.1;0.9), and running mixed herd enterprises
   compared to only beef or dairy (OR = 0. 1; 95\% Cl = 0.0;0.7) was an
   additional protective factor against persistent breakdown. In these
   analyses, the covariates log herd size and tuberculin testing interval
   were significant predictors of both transient and persistent breakdown,
   whereas active badger sett density and regional location only affected
   the risk of persistent breakdown.
   The collective results suggest that the probability of transient
   breakdown is most strongly influenced by the purchase of cattle over
   other management variables and covariates, whereas the probability of
   persistent breakdown appears to be mostly affected by management factors
   relating to type of herd enterprise and silage storage in addition to
   the relative density of badgers. Implications for bTB management are
   discussed. (C) 2007 Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Courtenay, O (Reprint Author), Univ Warwick, Dept Biol Sci, Ecol \& Epidemiol Grp, Coventry CV4 7AL, W Midlands, England.
   Univ Warwick, Dept Biol Sci, Ecol \& Epidemiol Grp, Coventry CV4 7AL, W Midlands, England.}},
DOI = {{10.1016/j.prevetmed.2007.02.002}},
ISSN = {{0167-5877}},
Keywords = {{bovine tuberculosis; Mycobacterium bovis; case-control study; risk
   factor; epidemiology; cattle; farm management; badger}},
Keywords-Plus = {{REPUBLIC-OF-IRELAND; MYCOBACTERIUM-BOVIS; MELES-MELES; TRANSMISSION;
   ENGLAND; HERDS; ASSOCIATION; DISEASE; ENVIRONMENT; BREAKDOWNS}},
Research-Areas = {{Veterinary Sciences}},
Web-of-Science-Categories  = {{Veterinary Sciences}},
Author-Email = {{orin.courtenay@warwick.ac.uk}},
Cited-References = {{Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226.
   BENHAM PFJ, 1989, BRIT VET J, V145, P226.
   Rodriguez Delgado O, 2005, PATRIMONIO NATURAL I, P27.
   CORNER LA, 1994, VET MICROBIOL, V40, P53, DOI 10.1016/0378-1135(94)90046-9.
   Courtenay O, 2006, BIOL LETT-UK, V2, P460, DOI 10.1098/rsbl.2006.0468.
   COURTENAY O, UNPUB INTER INTRA RE.
   {*}DEFR, 2005, VET ADV METH RED LIK.
   {*}DEFR, 2005, GOV STR FRAM SUST CO.
   Denny GO, 1999, VET REC, V144, P305.
   Garnett BT, 2002, P ROY SOC B-BIOL SCI, V269, P1487, DOI 10.1098/rspb.2002.2072.
   Gilbert M, 2005, NATURE, V435, P491, DOI 10.1038/nature03548.
   Gopal R, 2006, VET REC, V159, P265.
   Green LE, 2005, PREV VET MED, V70, P293, DOI 10.1016/j.prevetmed.2005.05.005.
   Griffin JM, 1996, PREV VET MED, V27, P75, DOI 10.1016/0167-5877(95)00548-X.
   Griffin JM, 2005, PREV VET MED, V67, P237, DOI 10.1016/j.prevetmed.2004.10.009.
   GRIFFIN JM, 1993, PREV VET MED, V17, P145, DOI 10.1016/0167-5877(93)90025-O.
   Hutchings MR, 1997, VET J, V153, P149, DOI 10.1016/S1090-0233(97)80035-4.
   Johnston WT, 2005, BIOL LETT-UK, V1, P53, DOI 10.1098/rsbl.2004.0249.
   Krebs J, 1997, BOVINE TUBERCULOSIS.
   Kulldorff M, 1997, COMMUN STAT-THEOR M, V26, P1481, DOI 10.1080/03610929708831995.
   Marangon S, 1998, PREV VET MED, V34, P87, DOI 10.1016/S0167-5877(97)00087-1.
   Martin SW, 1997, PREV VET MED, V31, P113, DOI 10.1016/S0167-5877(96)01111-7.
   MONAGHAN ML, 1994, VET MICROBIOL, V40, P111, DOI 10.1016/0378-1135(94)90050-7.
   Moore N, 1999, J APPL ECOL, V36, P974, DOI 10.1046/j.1365-2664.1999.00454.x.
   Phillips CJC, 2003, RES VET SCI, V74, P1, DOI 10.1016/S0034-5288(02)00145-5.
   PHILLIPS CJC, 2000, ROLE CATTLE HUSBANDR.
   Scanlon MP, 2000, IRISH VET J, V53, P412.
   Scantlebury M, 2004, J DAIRY SCI, V87, P330.
   WHITE PCL, 1993, P ROY SOC B-BIOL SCI, V253, P277, DOI 10.1098/rspb.1993.0114.
   Woodroffe R, 2006, P NATL ACAD SCI USA, V103, P14713, DOI 10.1073/pnas.0606251103.
   2006, VET REC, V158, P222.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{51}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{18}},
Journal-ISO = {{Prev. Vet. Med.}},
Doc-Delivery-Number = {{168NZ}},
Unique-ID = {{ISI:000246532600004}},
}

@article{ ISI:000248138300017,
Author = {de Vries, Gerard and van Hest, Rob A. H. and Richardus, An H.},
Title = {{Impact of mobile radiographic screening on tuberculosis among drug users
   and homeless persons}},
Journal = {{AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE}},
Year = {{2007}},
Volume = {{176}},
Number = {{2}},
Pages = {{201-207}},
Month = {{JUL 15}},
Abstract = {{Rationale: In 2002, a mobile radiographic screening program was started
   in Rotterdam to respond to high rates of tuberculosis (TB) among illicit
   drug users and homeless persons.
   Objectives: We studied trends and characteristics of TB among these risk
   groups and assessed the impact of the screening program on transmission,
   using molecular typing.
   Methods: Description of trends, and of demographic and disease-related
   characteristics of tuberculosis cases among these risk groups between
   1993 and 2005. TB was considered to result from recent transmission if
   the mycobacterial DNA fingerprints of cases were identical to those of
   other cases in the risk groups in the previous 2 years.
   Measurements and Main Results: During the study period, 206 individuals
   with TB among illicit drug users and homeless persons were notified,
   representing 11.4\% of the total case load of 1,811 in Rotterdam. The
   annual number of tuberculosis cases declined from 24 at the start of the
   screening program to 11 cases in 2005. The screening program identified
   28 cases (a prevalence rate of 327 per 100,000 radiographs), of which 12
   were smear positive. In 19972002, more than 80\% of the illicit drug
   users or homeless persons with TB were infected with one of the
   Mycobacterium tuberculosis strains prevalent among these risk groups.
   After nearly 4 years of systematic radiographic screening this
   proportion declined to 45\% in 2005.
   Conclusions: DNA fingerprinting can be a useful tool to evaluate the
   impact of a TB screening program. We advocate that screening of illicit
   drug users and homeless persons should be continued to prevent a
   resurgence of TB.}},
Publisher = {{AMER THORACIC SOC}},
Address = {{1740 BROADWAY, NEW YORK, NY 10019-4374 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{de Vries, G (Reprint Author), Municipal Publ Hlth Serv Rotterdam Rijnmond, Dept TB Control, POB 70032, NL-3000 LP Rotterdam, Netherlands.
   Municipal Publ Hlth Serv Rotterdam Rijnmond, Dept TB Control, NL-3000 LP Rotterdam, Netherlands.
   Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands.
   Municipal Publ Hlth Serv Rotterdam Rijmond, Rotterdam, Netherlands.}},
DOI = {{10.1164/rccm.200612-1877OC}},
ISSN = {{1073-449X}},
Keywords = {{communicable disease control; DNA fingerprinting; molecular
   epidemiology; tuberculosis}},
Keywords-Plus = {{NEW-YORK-CITY; DIRECTLY OBSERVED THERAPY; MYCOBACTERIUM-TUBERCULOSIS;
   MOLECULAR EPIDEMIOLOGY; RESISTANT TUBERCULOSIS; URBAN HOMELESS;
   UNITED-STATES; OUTBREAK; TRANSMISSION; SHELTER}},
Research-Areas = {{General \& Internal Medicine; Respiratory System}},
Web-of-Science-Categories  = {{Critical Care Medicine; Respiratory System}},
Author-Email = {{devriesg@ggd.rotterdam.til}},
Cited-References = {{Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305.
   Barnes PF, 2003, NEW ENGL J MED, V349, P1149, DOI 10.1056/NEJMra021964.
   Borgdorff MW, 2005, EMERG INFECT DIS, V11, P597.
   Citron K, 1996, J EPIDEMIOL COMMUN H, V50, P382, DOI 10.1136/jech.50.3.382.
   Curtis AB, 2000, INT J TUBERC LUNG D, V4, P308.
   Davidson BL, 1998, CHEST, V114, P1239, DOI 10.1378/chest.114.5.1239.
   ERKENS CGM, 2006, EUR J PUBLIC HEALTH, V16, P133.
   Freeman R, 2005, J CLIN MICROBIOL, V43, P5550, DOI 10.1128/JCM.43.11.5550-5554.2005.
   Frieden TR, 1996, TUBERCLE LUNG DIS, V77, P407, DOI 10.1016/S0962-8479(96)90112-4.
   Friedman LN, 1996, NEW ENGL J MED, V334, P828, DOI 10.1056/NEJM199603283341304.
   FUJIWARA PI, 1996, TUBERCULOSIS, P99.
   Gasner MR, 1999, NEW ENGL J MED, V340, P359, DOI 10.1056/NEJM199902043400506.
   Glynn JR, 1999, INT J TUBERC LUNG D, V3, P1055.
   Haddad MB, 2005, JAMA-J AM MED ASSOC, V293, P2762, DOI 10.1001/jama.293.22.2762.
   Hayward AC, 2003, INT J TUBERC LUNG D, V7, P751.
   Jasmer RM, 1999, ANN INTERN MED, V130, P971.
   Keizer ST, 2000, J EPIDEMIOL COMMUN H, V54, P64, DOI 10.1136/jech.54.1.64.
   Kong PM, 2002, EMERG INFECT DIS, V8, P1280.
   Kumar D, 1995, J EPIDEMIOL COMMUN H, V49, P629, DOI 10.1136/jech.49.6.629.
   Lambregts-van Weezenbeek CSB, 2003, INT J TUBERC LUNG D, V7, pS463.
   Lofy KH, 2006, INT J TUBERC LUNG D, V10, P683.
   Lukacs J, 2004, J CLIN MICROBIOL, V42, P5931, DOI 10.1128/JCM.42.12.5931-5934.2004.
   McElroy PD, 2003, CLIN INFECT DIS, V36, P1305, DOI 10.1086/374836.
   Miller AC, 2002, INT J TUBERC LUNG D, V6, P872.
   MOOREGILLON J, 1998, CLIN TUBERCULOSIS, P383.
   Moss AR, 2000, AM J RESP CRIT CARE, V162, P460.
   Nolan CM, 1997, CHEST, V111, P1151, DOI 10.1378/chest.111.5.1151.
   PERLMAN DC, 1995, CLIN INFECT DIS, V21, P1253, DOI 10.1093/clinids/21.5.1253.
   REICHMAN LB, 1979, ARCH INTERN MED, V139, P337, DOI 10.1001/archinte.139.3.337.
   Rendleman NJ, 1999, AM J PREV MED, V17, P108, DOI 10.1016/S0749-3797(99)00052-5.
   Ruddy MC, 2004, THORAX, V59, P279, DOI 10.1136/thx.2003.010405.
   Solsona J, 2001, EUR J EPIDEMIOL, V17, P123, DOI 10.1023/A:1017580329538.
   SONNENBERG P, 2003, CLIN TUBERCULOSIS, P60.
   Southern A, 1999, INT J TUBERC LUNG D, V3, P1001.
   Story A, 2006, BRIT MED J, V333, P57, DOI 10.1136/bmj.333.7558.57.
   Tulsky JP, 2000, ARCH INTERN MED, V160, P697, DOI 10.1001/archinte.160.5.697.
   Valin N, 2005, INT J TUBERC LUNG D, V9, P528.
   van Deutekom H, 2004, AM J RESP CRIT CARE, V169, P806, DOI 10.1164/rccm.200306-856OC.
   van Hest N A, 2003, Ned Tijdschr Geneeskd, V147, P1825.
   van Soolingen D, 1999, J INFECT DIS, V180, P726, DOI 10.1086/314930.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.
   VANSOOLINGEN D, 1993, J CLIN MICROBIOL, V31, P1987.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{40}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Am. J. Respir. Crit. Care Med.}},
Doc-Delivery-Number = {{191NP}},
Unique-ID = {{ISI:000248138300017}},
}

@article{ ISI:000248138300019,
Author = {Antas, Paulo R. Z. and Sampaio, Elizabeth P.},
Title = {{Another round for the CD4(+)CD25(+) regulatory T cells in patients with
   tuberculosis}},
Journal = {{AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE}},
Year = {{2007}},
Volume = {{176}},
Number = {{2}},
Pages = {{214-215}},
Month = {{JUL 15}},
Publisher = {{AMER THORACIC SOC}},
Address = {{1740 BROADWAY, NEW YORK, NY 10019-4374 USA}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Antas, PRZ (Reprint Author), Vanderbilt Univ, Med Ctr, 221 Kirkland Hall, Nashville, TN 37240 USA.
   Vanderbilt Univ, Med Ctr, Nashville, TN 37240 USA.
   Fiocruz MS, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.}},
ISSN = {{1073-449X}},
Keywords-Plus = {{EXPRESSION; ANTIGENS}},
Research-Areas = {{General \& Internal Medicine; Respiratory System}},
Web-of-Science-Categories  = {{Critical Care Medicine; Respiratory System}},
Cited-References = {{Antas PRZ, 2002, MEM I OSWALDO CRUZ, V97, P1097, DOI 10.1590/S0074-02762002000800005.
   Arend SM, 2000, INFECT IMMUN, V68, P3314, DOI 10.1128/IAI.68.6.3314-3321.2000.
   Gazzola L, 2006, AM J RESP CRIT CARE, V174, P356.
   Guyot-Revol V, 2006, AM J RESP CRIT CARE, V173, P803, DOI 10.1164/rccm.200508-1294OC.
   Roncador G, 2005, EUR J IMMUNOL, V35, P1681, DOI 10.1002/eji.200526189.
   Rook GAW, 2004, SPRINGER SEMIN IMMUN, V25, P237, DOI 10.1007/s00281-003-0148-9.}},
Number-of-Cited-References = {{6}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Am. J. Respir. Crit. Care Med.}},
Doc-Delivery-Number = {{191NP}},
Unique-ID = {{ISI:000248138300019}},
}

@article{ ISI:000247343900016,
Author = {Gupta, Amita and Nayak, Uma and Ram, Malathi and Bhosale, Ramesh and
   Patil, Sandesh and Basavraj, Anita and Kakrani, Arjun and Philip, Sheeja
   and Desai, Dipali and Sastry, Jayagowri and Bollinger, Robert C. and
   Byramjee Jeejeebhoy Med},
Title = {{lPostpartum tuberculosis incidence and mortality among HIV-infected
   women and their infants in Pune, India, 2002-2005}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{45}},
Number = {{2}},
Pages = {{241-249}},
Month = {{JUL 15}},
Abstract = {{Background. In contrast with many other countries, isoniazid
   preventative therapy is not recommended in clinical care guidelines for
   human immunodeficiency virus ( HIV)-infected persons with latent
   tuberculosis ( TB) in India.
   Methods. Seven hundred fifteen HIV-infected mothers and their infants
   were prospectively followed up for 1 year after delivery at a public
   hospital in Pune, India. Women were evaluated for active TB during
   regular clinic visits, and tuberculin skin tests were performed. World
   Health Organization definitions for confirmed, probable, and presumed TB
   were used. Poisson regression was performed to determine correlates of
   incident TB, and adjusted probabilities of mortality were calculated.
   Results. Twenty-four of 715 HIV-infected women who were followed up for
   480 postpartum person-years developed TB, yielding a TB incidence of 5.0
   cases per 100 person-years ( 95\% confidence interval {[} CI], 3.2-7.4
   cases per 100 person-years). Predictors of incident TB included a
   baseline CD4 cell count < 200 cells/mm(3) ( adjusted incident rate ratio
   {[} IRR], 7.58; 95\% CI, 3.07-18.71), an HIV load 150,000 copies/mL (
   adjusted IRR, 3.92; 95\% CI, 1.69-9.11), and a positive tuberculin skin
   test result ( adjusted IRR, 3.08; 95\% CI, 1.27-7.47). Three ( 12.5\%)
   of 24 women with TB died, compared with 7 ( 1.0\%) of 691 women without
   TB ( IRR, 12.2; 95\% CI, 2.03-53.33). Among 23 viable infants with
   mothers with TB, 2 received a diagnosis of TB. Four infants with mothers
   with TB died, compared with 28 infants with mothers without TB ( IRR,
   4.71; 95\% CI, 1.19-13.57). Women with incident TB and their infants had
   a 2.2- and 3.4-fold increased probability of death, respectively,
   compared with women without active TB and their infants, controlling for
   factors independently associated with mortality ( adjusted IRR, 2.2 {[}
   95\% CI, 0.6-3.8] and 3.4 {[} 95\% CI, 1.22-10.59], respectively).
   Conclusions. Among Indian HIV-infected women, we found a high incidence
   of postpartum TB and associated postpartum maternal and infant death.
   Active screening and targeted use of isoniazid preventative therapy
   among HIV-infected women in India should be considered to prevent
   postpartum maternal TB and associated mother-to-child morbidity and
   mortality.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Gupta, A (Reprint Author), Ctr Clin Global Hlth Educ, Div Infect Dis, 600 N Wolfe St,Phipps 540B, Baltimore, MD 21287 USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   John Hopkins Univ Maternal Infant Transmiss Study, Byramjee Jeejeebhoy Med Coll, Pune, Maharashtra, India.}},
DOI = {{10.1086/518974}},
ISSN = {{1058-4838}},
Keywords-Plus = {{PRE-CHEMOTHERAPY ERA; MATERNAL MORTALITY; PULMONARY TUBERCULOSIS;
   PREVENTIVE THERAPY; SOUTH-AFRICA; RISK-FACTORS; TRANSMISSION; CHILDREN;
   PROGRAM; BURDEN}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{agupta25@jhmi.edu}},
Funding-Acknowledgement = {{FIC NIH HHS {[}2 D 43 TW000010-19-A]; NIAID NIH HHS {[}R01 AI45462]}},
Cited-References = {{Ahmed Y, 1999, INT J TUBERC LUNG D, V3, P675.
   ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143.
   Boggess KA, 2000, OBSTET GYNECOL, V96, P757, DOI 10.1016/S0029-7844(00)01039-5.
   Burnham K. P., 2002, MODEL SELECTION MULT.
   Day JH, 2004, J INFECT DIS, V190, P1677, DOI 10.1086/424851.
   Enarson RM, 2005, INT J TUBERC LUNG D, V9, P1299.
   FRANKS AL, 1989, PUBLIC HEALTH REP, V104, P151.
   GOLUB JE, IN PRESS AIDS.
   Grant AD, 2005, JAMA-J AM MED ASSOC, V293, P2719, DOI 10.1001/jama.293.22.2719.
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968.
   JUNEJA Y, 1994, INT J GYNECOL OBSTET, V46, P265, DOI 10.1016/0020-7292(94)90404-9.
   Kali PBN, 2006, JAIDS-J ACQ IMM DEF, V42, P379, DOI 10.1097/01.qai.0000218434.20404.9c.
   Khan M, 2000, ANN NY ACAD SCI, V918, P367.
   Lawn SD, 2005, AIDS, V19, P2109, DOI 10.1097/01.aids.0000194808.20035.c1.
   Lawn SD, 2006, AIDS, V20, P1605, DOI 10.1097/01.aids.0000238406.93249.cd.
   Marais BJ, 2004, INT J TUBERC LUNG D, V8, P278.
   Marais BJ, 2004, INT J TUBERC LUNG D, V8, P392.
   MOFENSON LM, 1995, ARCH INTERN MED, V155, P1066, DOI 10.1001/archinte.155.10.1066.
   Nachega J, 2003, AIDS, V17, P1398, DOI 10.1097/01.aids.0000060408.18106.d9.
   Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7.
   Padmapriyadarsini C, 2005, INDIAN J MED RES, V121, P415.
   Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746.
   Pillay T, 2004, LANCET INFECT DIS, V4, P155, DOI 10.1016/S1473-3099(04)00939-9.
   Pillay T, 2001, SAMJ S AFR MED J, V91, P983.
   Radhakrishna S, 2003, Int J Tuberc Lung Dis, V7, P1083.
   Robinson C A, 1996, Obstet Gynecol Surv, V51, P115, DOI 10.1097/00006254-199602000-00021.
   SARAIYA UB, 2001, PREGNANCY RISK CURRE, P132.
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901.
   Swaminathan S, 2000, INT J TUBERC LUNG D, V4, P839.
   {*}TB CONTR IND, TB IND 2006 RNTCP ST.
   {*}UN AIDS PROG R, 2006, 2006 REP GLOB AIDS E.
   Whalen CC, 2000, AIDS, V14, P1219, DOI 10.1097/00002030-200006160-00020.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.
   {*}WHO, 1998, WHO GLOB TUB PROGR P.
   {*}WHO, 2004, HIV TB CLIN MAN.
   Wolday D, 2003, Int J Tuberc Lung Dis, V7, P110.
   Woldehanna S, 2004, COCHRANE DB SYST REV, DOI {[}10.1002/14651858.CD000172.pub2, DOI 10.1002/14651858.CD000171.PUB2].
   YANCEY MK, 1992, OBSTET GYN CLIN N AM, V19, P413.
   Zar HJ, 2007, BRIT MED J, V334, P136, DOI 10.1136/bmj.39000.486400.55.
   {[}Anonymous], 2000, MMWR RECOMM REP, V49, P1.}},
Number-of-Cited-References = {{40}},
Times-Cited = {{64}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{180EC}},
Unique-ID = {{ISI:000247343900016}},
}

@article{ ISI:000247343900017,
Author = {Mofenson, Lynne M. and Laughon, Barbara E.},
Title = {{Human immunodeficiency virus, Mycobacterium tuberculosis, and pregnancy:
   A deadly combination}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{45}},
Number = {{2}},
Pages = {{250-253}},
Month = {{JUL 15}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Mofenson, LM (Reprint Author), NICHHD, NIH, Pediat Adolescent \& Maternal AIDS Branch, Ctr Res Mothers \& Children, 6100 Execut Blvd,Rm 4B11, Bethesda, MD 20892 USA.
   NICHHD, NIH, Pediat Adolescent \& Maternal AIDS Branch, Ctr Res Mothers \& Children, Bethesda, MD 20892 USA.
   NIAID, NIH, Complicat \& Coinfect Res Branch, Therapeut Res Program,Div AIDS, Bethesda, MD 20892 USA.}},
DOI = {{10.1086/518975}},
ISSN = {{1058-4838}},
Keywords-Plus = {{ACTIVE ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; MATERNAL MORTALITY;
   PREVENTIVE THERAPY; INFECTION; WOMEN; TRANSMISSION; DISEASE; RISK;
   COINFECTION}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{lm65d@nih.gov}},
ORCID-Numbers = {{Mofenson, Lynne/0000-0002-2818-9808}},
Cited-References = {{Adhikari M, 1997, PEDIATR INFECT DIS J, V16, P1108, DOI 10.1097/00006454-199712000-00003.
   Ahmed Y, 1999, INT J TUBERC LUNG D, V3, P675.
   ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439.
   Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3.
   Blumberg HM, 2005, JAMA-J AM MED ASSOC, V293, P2776, DOI 10.1001/jama.293.22.2776.
   Boggess KA, 2000, OBSTET GYNECOL, V96, P757, DOI 10.1016/S0029-7844(00)01039-5.
   Bucher HC, 1999, AIDS, V13, P501, DOI 10.1097/00002030-199903110-00009.
   Recommendations to prevent and control iron deficiency in the United States, 1998, MMWR-MORBID MORTAL W, V47, P1.
   Connell TG, 2006, EXPERT REV MOL DIAGN, V6, P663, DOI 10.1586/14737159.6.5.663.
   Connolly Maire, 1996, World Health Statistics Quarterly, V49, P115.
   Corbett EL, 2006, LANCET, V367, P926, DOI 10.1016/S0140-6736(06)68383-9.
   Diwan VK, 1999, LANCET, V353, P1000, DOI 10.1016/S0140-6736(99)01318-5.
   Drobac PC, 2005, CLIN INFECT DIS, V40, P1689, DOI 10.1086/430066.
   Elzi L, 2007, CLIN INFECT DIS, V44, P94, DOI 10.1086/510080.
   Espinal MA, 1996, J INFECT DIS, V173, P488.
   Figueroa-Damian R, 2001, ARCH MED RES, V32, P66, DOI 10.1016/S0188-4409(00)00266-6.
   FRANKS AL, 1989, PUBLIC HEALTH REP, V104, P151.
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4.
   Goletti D, 1996, J IMMUNOL, V157, P1271.
   Grant AD, 2005, JAMA-J AM MED ASSOC, V293, P2719, DOI 10.1001/jama.293.22.2719.
   Gupta A, 2007, CLIN INFECT DIS, V45, P241, DOI 10.1086/518974.
   Holmes CB, 1998, INT J TUBERC LUNG D, V2, P96.
   Jones JL, 2000, INT J TUBERC LUNG D, V4, P1026.
   Kali PBN, 2006, JAIDS-J ACQ IMM DEF, V42, P379, DOI 10.1097/01.qai.0000218434.20404.9c.
   Khan M, 2001, AIDS, V15, P1857, DOI 10.1097/00002030-200109280-00016.
   Lim HJ, 2006, HIV CLIN TRIALS, V7, P172, DOI 10.1310/hct0704-172.
   Lopez-Gatell H, 2007, AM J EPIDEMIOL, V165, P1134, DOI 10.1093/aje/kwm116.
   Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4.
   Nachega J, 2003, AIDS, V17, P1398, DOI 10.1097/01.aids.0000060408.18106.d9.
   Ormerod P, 2001, THORAX, V56, P494, DOI 10.1136/thorax.56.6.494.
   Pillay T, 2004, INT J TUBERC LUNG D, V8, P59.
   Pillay T, 2004, LANCET INFECT DIS, V4, P155, DOI 10.1016/S1473-3099(04)00939-9.
   Pillay T, 2001, SAMJ S AFR MED J, V91, P983.
   Sackoff JE, 2006, AM J OBSTET GYNECOL, V194, P451, DOI 10.1016/j.ajog.2005.07.054.
   Santoro-Lopes G, 2002, CLIN INFECT DIS, V34, P543, DOI 10.1086/338641.
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901.
   Skevaki Chrysanthi L, 2005, Paediatr Drugs, V7, P219, DOI 10.2165/00148581-200507040-00002.
   SNIDER DE, 1992, AM REV RESPIR DIS, V145, P494.
   Stop TB Partnership Childhood TB Subgroup: World Health Organization, 2007, INT J TUBERC LUNG D, V11, P12.
   Tripathy SN, 2003, INT J GYNECOL OBSTET, V80, P247, DOI 10.1016/S0020-7292(02)00393-4.
   {*}WHO, 2007, AIDS EP UPD DEC 2006.
   World Health Organization, 2004, TB HIV CLIN MAN.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{180EC}},
Unique-ID = {{ISI:000247343900017}},
}

@article{ ISI:000247752100056,
Author = {Fremond, Cecile M. and Togbe, Dieudonnee and Doz, Emilie and Rose,
   Stephanie and Vasseur, Virginie and Maillet, Isabelle and Jacobs,
   Muazzam and Ryffel, Bernhard and Quesniaux, Valerie F. J.},
Title = {{IL-1 receptor-mediated signal is an essential component of
   MyD88-dependent innate response to Mycobacterium tuberculosis infection}},
Journal = {{JOURNAL OF IMMUNOLOGY}},
Year = {{2007}},
Volume = {{179}},
Number = {{2}},
Pages = {{1178-1189}},
Month = {{JUL 15}},
Abstract = {{MyD88, the common adapter involved in TLR, IL-1, and IL-18 receptor
   signaling, is essential for the control of acute Mycobacterium
   tuberculosis (MTB) infection. Although TLR2, TLR4, and TLR9 have been
   implicated in the response to mycobacteria, gene disruption for these
   TLRs impairs only the long-term control of MTB infection. Here, we
   addressed the respective role of IL-I and EL-18 receptor pathways in the
   MyD88-dependent control of acute MTB infection. Mice deficient for
   IL-1R1, IL-18R, or Toll-IL-1R domain-containing adaptor protein (TIRAP)
   were compared with MyD88-deficient mice in an acute model of aerogenic
   MTB infection. Although primary MyD88-deficient macrophages and
   dendritic cells were defective in cytokine production in response to
   mycobacterial stimulation, IL-1R1-deficient macrophages exhibited (only
   a reduced IL-12p40 secretion with unaffected TNF, IL-6, and NO
   production and upregulation of costimulatory molecules CD40 and CD86.
   Aerogenic MTB infection of]IL-1R1-deficient mice was lethal within 4 wk
   with 2-log higher bacterial load in the lung and necrotic pneumonia but
   efficient pulmonary CD4 and CD8 T cell responses, as seen in
   MyD88-deficient mice. Mice deficient for IL-18R or TIRAP controlled
   acute MTB infection. These data demonstrate that absence of IL-1R signal
   leads to a dramatic defect of early control of MTB infection similar to
   that seen in the absence of MyD88, whereas IL-18R and TIRAP are
   dispensable, and that IL-1, together with IL-1-induced innate response,
   might account for most of MyD88-dependent host response to control acute
   MTB infection.}},
Publisher = {{AMER ASSOC IMMUNOLOGISTS}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ryffel, B (Reprint Author), Transgenose Inst, 3B Rue de la Ferollerie, F-45071 Orleans, France.
   Univ Orleans, Ctr Natl Rech Sci Mol Immunol \& Embryol, Orleans, France.
   Univ Cape Town, Fac Hlth Sci, Inst Infect Dis \& Mol Med, Div Immunol, ZA-7925 Cape Town, South Africa.}},
ISSN = {{0022-1767}},
Keywords-Plus = {{TOLL-LIKE RECEPTORS; BOVIS BCG INFECTION; TOXOPLASMA-GONDII INFECTION;
   BONE-MARROW-TRANSPLANTATION; ADAPTIVE IMMUNE-RESPONSE;
   BACILLUS-CALMETTE-GUERIN; NECROSIS-FACTOR-ALPHA; TNF-DEFICIENT MICE;
   DENDRITIC CELLS; CUTTING EDGE}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{bryffel@cnrs-orleans.fr
   quesniaux@cnrs-orleans.fr}},
Cited-References = {{Abel B, 2002, J IMMUNOL, V169, P3155.
   Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4.
   Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736.
   Amirzargar AA, 2006, EUR CYTOKINE NETW, V17, P84.
   Awomoyi AA, 2005, J ENDOTOXIN RES, V11, P281, DOI 10.1179/096805105X58706.
   Bafica A, 2005, J EXP MED, V202, P1715, DOI 10.1081/jem.20051782.
   Bean AGD, 1999, J IMMUNOL, V162, P3504.
   Botha T, 2003, J IMMUNOL, V171, P3110.
   Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2.
   Cooper AM, 2002, J IMMUNOL, V168, P1322.
   Drennan MB, 2004, AM J PATHOL, V164, P49, DOI 10.1016/S0002-9440(10)63095-7.
   Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814.
   Feng CG, 2004, J IMMUNOL, V172, P1163.
   Feng CG, 2003, J IMMUNOL, V171, P4758.
   Fleischmann RM, 2006, ANN RHEUM DIS, V65, P1006, DOI 10.1136/ard.2005.048371.
   Flynn JL, 2006, MICROBES INFECT, V8, P1179, DOI 10.1016/j.micinf.2005.10.033.
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93.
   FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2.
   Fremond CM, 2004, J CLIN INVEST, V114, P1790, DOI 10.1172/JCI200421027.
   Gamero AM, 2006, IMMUNITY, V24, P16, DOI 10.1016/j.immuni.2005.12.007.
   Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200.
   Gilleron M, 2006, CHEM BIOL, V13, P39, DOI 10.1016/j.chembiol.2005.10.013.
   Gomez LM, 2006, TISSUE ANTIGENS, V67, P290, DOI 10.1111/j.1399-0039.2006.00566.x.
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X.
   Guerardel Y, 2003, J BIOL CHEM, V278, P36637, DOI 10.1074/jbc.M305427200.
   Heldwein KA, 2003, J LEUKOCYTE BIOL, V74, P277, DOI 10.1189/jlb.0103026.
   Holscher C, 2001, J IMMUNOL, V167, P6957.
   Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180.
   Hoshino K, 1999, J IMMUNOL, V162, P3749.
   Hubeau C, 2003, CLIN EXP ALLERGY, V33, P386, DOI 10.1046/j.1365-2222.2003.01612.x.
   Jacobs M, 2000, CLIN IMMUNOL, V94, P192, DOI 10.1006/clim.2000.4835.
   Jacobs M, 2000, LAB INVEST, V80, P901.
   Juffermans NP, 2000, J INFECT DIS, V182, P902, DOI 10.1086/315771.
   Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2.
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110.
   Keane J, 2005, RHEUMATOLOGY, V44, P1205.
   Konttinen L, 2006, RHEUMATOL INT, V26, P916, DOI 10.1007/s00296-005-0097-9.
   Labow M, 1997, J IMMUNOL, V159, P2452.
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X.
   Lyadova IV, 2000, J IMMUNOL, V165, P5921.
   MacMicking JD, 2003, SCIENCE, V302, P654, DOI 10.1126/science.1088063.
   Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8.
   Means TK, 1999, J IMMUNOL, V163, P3920.
   Means TK, 2001, J IMMUNOL, V166, P4074.
   Mohan AK, 2004, CLIN INFECT DIS, V39, P295, DOI 10.1086/421494.
   Muller M, 1996, MOL MED, V2, P247.
   Mun HS, 2003, INT IMMUNOL, V15, P1081, DOI 10.1093/intimm/dxg108.
   Muraille E, 2003, J IMMUNOL, V170, P4237.
   Nicolle D, 2004, INFECT IMMUN, V72, P6994, DOI 10.1128/IAI.72.12.6994-7004.2004.
   Nicolle DM, 2004, LAB INVEST, V84, P1305, DOI 10.1038/labinvest.3700149.
   Pompei L, 2007, J IMMUNOL, V178, P5192.
   Quesniaux VJ, 2004, J IMMUNOL, V172, P4425.
   Reiling N, 2002, J IMMUNOL, V169, P3480.
   Riley LW, 2006, J CLIN INVEST, V116, P1475, DOI 10.1172/JC128734.
   Scanga CA, 2004, INFECT IMMUN, V72, P2400, DOI 10.1128/IAI.72.4.2400-2404.2004.
   Scanga CA, 2002, J IMMUNOL, V168, P5997.
   Schmitz N, 2003, EUR J IMMUNOL, V33, P991, DOI 10.1002/eji.200323801.
   Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712.
   Shi SP, 2005, J IMMUNOL, V175, P3318.
   Shim TS, 2003, TUBERCULOSIS, V83, P367, DOI 10.1016/S1472-9792(03)00071-4.
   Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577.
   Sugawara I, 1999, INFECT IMMUN, V67, P2585.
   Sugawara I, 2003, MICROBIOL IMMUNOL, V47, P327.
   Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468.
   Takeuchi O, 2002, J IMMUNOL, V169, P10.
   Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544.
   Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459.
   Yamada H, 2000, LAB INVEST, V80, P759.
   Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182.
   Zeisel MB, 2005, J IMMUNOL, V174, P7393.}},
Number-of-Cited-References = {{70}},
Times-Cited = {{182}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{J. Immunol.}},
Doc-Delivery-Number = {{186AS}},
Unique-ID = {{ISI:000247752100056}},
}

@article{ ISI:000247752100071,
Author = {Jacobsen, Marc and Detjen, Anne K. and Mueller, Henrik and Gutschmidt,
   Andrea and Leitner, Sandra and Wahn, Ulrich and Magdorft, Klaus and
   Kaufmann, Stefan H. E.},
Title = {{Clonal expansion of CD8(+) effector T cells in childhood tuberculosis}},
Journal = {{JOURNAL OF IMMUNOLOGY}},
Year = {{2007}},
Volume = {{179}},
Number = {{2}},
Pages = {{1331-1339}},
Month = {{JUL 15}},
Abstract = {{The role of CD8(+) T cells in human tuberculosis JB) remains elusive. We
   analyzed the T cell repertoire and phenotype in 1) children with active
   TB (:54 years), 2) healthy latently Mycobacterium tuberculosis -infected
   children, and 3) noninfected age-matched (tuberculin skin test-negative)
   controls. Ex vivo phenotyping of T cell subpopulations by flow cytometry
   revealed a significant increase in the proportion of
   CD8(+)CD45RO(-)CD62L(-)CD28(-)CD27(-) effector T cells (T-EF) in the
   peripherai blood of children with active TB (22.1 vs 9.5\% in latently
   M. tuberculosis -infected children, vs 8.5\% in tuberculin skin
   test-negative controls). Analyses of TCR variable beta-chains revealed
   markedly skewed repertoires in CD8(+) T-EF and effector memory T cells.
   Expansions were restricted to single TCR variable beta-chains in
   individual donors indicating clonal growth. CDR3 spectratyping and DNA
   sequencing verified clonal expansion as the cause for CD8(+) effector T
   cell enrichment in individual TB patients. The most prominent enrichment
   of highly similar T-EF clones (>70\% of CD8(+) T-EF) was found in two
   children with active severe TB. Therefore, clonal expansion of CD8(+)
   T-EF occurs in childhood TB with potential impact on course and severity
   of disease.}},
Publisher = {{AMER ASSOC IMMUNOLOGISTS}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Jacobsen, M (Reprint Author), Max Planck Inst Infect Biol, Dept Immunol, Chariteplatz 1, D-10117 Berlin, Germany.
   Univ Hosp Charite, Max Planck Inst Infect Biol, Dept Immunol, Berlin, Germany.
   Univ Hosp Charite, Dept Pediat Pneumol \& Immunol, Berlin, Germany.}},
ISSN = {{0022-1767}},
Keywords-Plus = {{EPSTEIN-BARR-VIRUS; ANTIGEN RECEPTOR; PERSISTENT INFECTION; MEMORY;
   SUBSETS; SELECTION; REPERTOIRES; RECOGNITION; LYMPHOCYTES; HLA-A2}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{jacobsen@mpiib-berlin.mpg.de}},
ResearcherID-Numbers = {{Kaufmann, Stefan HE/I-5454-2014}},
ORCID-Numbers = {{Kaufmann, Stefan HE/0000-0001-9866-8268}},
Cited-References = {{Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379.
   Arden Bernhard, 1995, Immunogenetics, V42, P455.
   ARGAET VP, 1994, J EXP MED, V180, P2335, DOI 10.1084/jem.180.6.2335.
   Boshoff HIM, 2005, NAT REV MICROBIOL, V3, P70, DOI 10.1038/nrmicro1065.
   Caccamo N, 2006, J IMMUNOL, V177, P1780.
   Carrol E D, 2001, Paediatr Respir Rev, V2, P113, DOI 10.1053/prrv.2000.0118.
   Cho S, 2000, P NATL ACAD SCI USA, V97, P12210, DOI 10.1073/pnas.210391497.
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243.
   DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0.
   DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213.
   FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0.
   FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013.
   GAMBONDEZA F, 1995, INFECT IMMUN, V63, P1235.
   Geginat J, 2003, BLOOD, V101, P4260, DOI 10.1182/blood-2002-11-3577.
   Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407.
   Hohn H, 2003, CLIN EXP IMMUNOL, V131, P102, DOI 10.1046/j.1365-2249.2003.02036.x.
   Jacobsen M, 2002, BRAIN, V125, P538, DOI 10.1093/brain/awf059.
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110.
   Kjer-Nielsen L, 2003, IMMUNITY, V18, P53, DOI 10.1016/S1074-7613(02)00513-7.
   Lalvani Ajit, 1998, Proceedings of the National Academy of Sciences of the United States of America, V95, P270, DOI 10.1073/pnas.95.1.270.
   Lewinsohn DM, 1998, J EXP MED, V187, P1633, DOI 10.1084/jem.187.10.1633.
   Miller F., 1963, TUBERCULOSIS CHILDRE.
   MOSS PAH, 1991, P NATL ACAD SCI USA, V88, P8987, DOI 10.1073/pnas.88.20.8987.
   ONWUBALILI JK, 1987, TUBERCLE, V68, P195, DOI 10.1016/0041-3879(87)90055-9.
   Price DA, 2004, IMMUNITY, V21, P793, DOI 10.1016/j.immuni.2004.10.010.
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702.
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385.
   Saule P, 2006, MECH AGEING DEV, V127, P274, DOI 10.1016/j.mad.2005.11.001.
   Silins SL, 1997, INT IMMUNOL, V9, P1745, DOI 10.1093/intimm/9.11.1745.
   Stenger S, 1997, SCIENCE, V276, P1684, DOI 10.1126/science.276.5319.1684.
   Tully G, 2005, J IMMUNOL, V174, P2174.
   van Leeuwen EMM, 2006, IMMUNOL REV, V211, P225, DOI 10.1111/j.0105-2896.2006.00379.x.
   Walls T, 2004, J INFECTION, V48, P13, DOI 10.1016/S0163-4453(03)00121-X.
   Walters G, 2004, J IMMUNOL METHODS, V294, P43, DOI 10.1016/j.jim.2004.08.015.
   Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{31}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Immunol.}},
Doc-Delivery-Number = {{186AS}},
Unique-ID = {{ISI:000247752100071}},
}

@article{ ISI:000247803100005,
Author = {Rook, Graham A. W. and Lowrie, Douglas B. and Hernandez-Pando, Rogelio},
Title = {{Immunotherapeutics for tuberculosis in experimental animals: Is there a
   common pathway activated by effective protocols?}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{2}},
Pages = {{191-198}},
Month = {{JUL 15}},
Note = {{Global XDR TB Task Force Meeting, Geneva, SWITZERLAND, JAN 28-31, 2007}},
Abstract = {{The increasing threat posed by drug- resistant strains of M.
   tuberculosis is leading to a reappraisal of the possibility of treating
   tuberculosis ( TB) by immunotherapy. We analyze 6 strategies that have
   been shown to be therapeutic in animal models of TB and identify a
   common pathway underlying the activity of the superficially different
   immunotherapeutic protocols. This pathway involves enhanced induction of
   CD8(+) cytotoxic T lymphocytes ( CTLs) and down- regulation of
   interleukin- 4 and transforming growth factor - beta, leading to further
   enhancement of the activity of CD8(+) CTLs and of other microbicidal
   pathways. This unifying analysis strengthens the rationale for future
   trials of immunotherapy in humans and points to surrogate markers that
   could be studied in such trials.}},
Publisher = {{OXFORD UNIV PRESS INC}},
Address = {{JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Rook, GAW (Reprint Author), Royal Free \& Univ Coll Med Sch, Ctr Infect Dis \& Int Hlth, Windeyer Inst Med Sci, 46 Cleveland St, London W1T 4JF, England.
   UCL, Ctr Infect Dis \& Int Hlth, London, England.
   Cardiff Univ, Dept Med Microbiol, Cardiff, Wales.
   Inst Nacl Ciencias Med \& Nutr Salvador Zubiran, Mexico City, DF, Mexico.}},
DOI = {{10.1086/518937}},
ISSN = {{1537-6613}},
Keywords-Plus = {{GROWTH-FACTOR-BETA; KILLED MYCOBACTERIUM-VACCAE; CD8(+) T-CELLS;
   PULMONARY TUBERCULOSIS; TGF-BETA; BALB/C MICE; INTERFERON-GAMMA;
   IN-VITRO; LATENT TUBERCULOSIS; ALLERGIC RESPONSE}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{g.rook@ucl.ac.uk}},
ResearcherID-Numbers = {{Lowrie, Douglas/B-8151-2013
   }},
ORCID-Numbers = {{Rook, Graham/0000-0002-8041-8110}},
Cited-References = {{AbouZeid C, 1997, INFECT IMMUN, V65, P1856.
   Adams VC, 2004, EUR J IMMUNOL, V34, P631, DOI 10.1002/eji.200324659.
   ANDERSON MC, 1891, LANCET, V1, P651.
   Aung H, 2005, SCAND J IMMUNOL, V61, P558, DOI 10.1111/j.1365-3083.2005.01623.x.
   Bonato VLD, 1998, INFECT IMMUN, V66, P169.
   Bonecini-Almeida MG, 2004, INFECT IMMUN, V72, P2628, DOI 10.1128/IAI.72.5.2628-2634.2004.
   Cardona PJ, 2006, TUBERCULOSIS, V86, P273, DOI 10.1016/j.tube.2006.01.024.
   Cardona PJ, 2005, VACCINE, V23, P1393, DOI 10.1016/j.vaccine.2004.09.008.
   Carranza C, 2006, AM J RESP CRIT CARE, V173, P238, DOI 10.1164/rccm.200503-411OC.
   Castro AZ, 2005, J INFECTION, V51, P318, DOI 10.1016/j.jinf.2004.08.035.
   Chattopadhyay S, 2005, HUM IMMUNOL, V66, P884, DOI 10.1016/j.humimm.2005.06.002.
   Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102.
   Converse PJ, 1998, CLIN DIAGN LAB IMMUN, V5, P871.
   Dahl KE, 1996, INFECT IMMUN, V64, P399.
   Dheda K, 2005, AM J RESP CRIT CARE, V172, P501, DOI 10.1164/rccm.200502-278OC.
   Dlugovitzky D, 1999, SCAND J IMMUNOL, V49, P210, DOI 10.1046/j.1365-3083.1999.00492.x.
   Dlugovitzky D, 2006, RESP MED, V100, P1079, DOI 10.1016/j.rmed.2005.09.026.
   Fiorenza G, 2005, IMMUNOL LETT, V98, P45, DOI 10.1016/j.imlet.2004.09.008.
   Flores-Villanueva PO, 2005, J EXP MED, V202, P1649, DOI 10.1084/jem20050216.
   Glatman-Freedman A, 2006, TUBERCULOSIS, V86, P191, DOI 10.1106/j.tube.2006.01.008.
   Grode L, 2005, J CLIN INVEST, V115, P2472, DOI 10.1172/JCI24617.
   Guirado E, 2006, MICROBES INFECT, V8, P1252, DOI 10.1016/j.micinf.2005.12.004.
   Hernandez-Garay M, 2003, ARCH MED RES, V34, P20, DOI 10.1016/S0188-4409(02)00463-0.
   Hernandez-Pando R, 2006, CLIN EXP IMMUNOL, V144, P264, DOI 10.1111/j.1365-2249.2006.03049.x.
   Hernandez-Pando R, 2005, J INFECT DIS, V191, P299, DOI 10.1086/426453.
   Hernandez-Pando R, 2004, EUR J IMMUNOL, V34, P174, DOI 10.1002/eji.200324253.
   Hernandez-Pando R, 2000, IMMUNOLOGY, V100, P391, DOI 10.1046/j.1365-2567.2000.00054.x.
   Hernandez-Pando R, 1998, IMMUNOLOGY, V95, P234.
   Hernandez-Pando R, 1998, QJM-MON J ASSOC PHYS, V91, P755, DOI 10.1093/qjmed/91.11.755.
   Hetzel C, 1998, INFECT IMMUN, V66, P3643.
   Hirsch CS, 2005, J CLIN IMMUNOL, V25, P353, DOI 10.1007/s10875-005-4841-4.
   HIRSCH CS, 1994, J INFECT DIS, V170, P1229.
   Hirsch CS, 1997, P NATL ACAD SCI USA, V94, P3926, DOI 10.1073/pnas.94.8.3926.
   Hopfenspirger MT, 2002, J IMMUNOL, V168, P2516.
   Hunt JRF, 2005, CLIN EXP ALLERGY, V35, P685, DOI 10.1111/j.1365-2222.2005.02239.x.
   JOUSSET A, 1942, TOXINE BACILLE KOCH.
   Kahnert A, 2006, EUR J IMMUNOL, V36, P631, DOI 10.1002/eji.200535496.
   KAUFMANN SHE, 1991, IMMUNOL REV, V121, P67, DOI 10.1111/j.1600-065X.1991.tb00823.x.
   Kaushal D, 2002, P NATL ACAD SCI USA, V99, P8330, DOI 10.1073/pnas.102055799.
   KHAZAIE K, 2006, CANC BIOL, V16, P124.
   Lacuesta K, 2006, J IMMUNOTHER, V29, P250, DOI 10.1097/01.cji.0000192104.24583.ca.
   LAMB JR, 1989, J AUTOIMMUN, V2, P93, DOI 10.1016/0896-8411(89)90120-0.
   Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809.
   Lewinsohn DM, 2001, J IMMUNOL, V166, P439.
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933.
   Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326.
   LOWRIE DB, 6 INT C PATH MYC INF.
   MACASSEY SLL, 1934, SPHLINGER CONTRA TUB.
   Malhotra I, 1999, J IMMUNOL, V162, P6843.
   Mendez-Samperio P, 2000, CELL IMMUNOL, V202, P103, DOI 10.1006/cimm.2000.1662.
   Moreira AL, 2002, INFECT IMMUN, V70, P2100, DOI 10.1128/IAI.70.4.2100-2107.2002.
   Nuermberger E, 2005, AM J RESP CRIT CARE, V172, P1452, DOI 10.1164/rccm.200507-1047OC.
   Olver S, 2006, CANCER RES, V66, P571, DOI 10.1158/0008-5472.CAN-05-1362.
   Ottenhoff THM, 2005, TUBERCULOSIS, V85, P53, DOI 10.1016/j.tube.2004.09.011.
   Reading C, 2006, CLIN MICROBIOL INFEC, V12, P1082, DOI 10.1111/j.1469-0691.2006.01520.x.
   Rook GAW, 2005, NAT REV IMMUNOL, V5, P661, DOI 10.1038/nri1666.
   Rook GAW, 2005, VACCINE, V23, P2115, DOI 10.1016/j.vaccine.2005.01.069.
   Rook GAW, 2004, TRENDS IMMUNOL, V25, P483, DOI 10.1016/j.it.2004.06.005.
   Rook GAW, 1996, ANNU REV MICROBIOL, V50, P259, DOI 10.1146/annurev.micro.50.1.259.
   Seah GT, 2000, J INFECT DIS, V181, P385, DOI 10.1086/315200.
   SILVA CL, 1994, IMMUNOLOGY, V83, P341.
   Silva CL, 2005, GENE THER, V12, P281, DOI 10.1038/sj.gt.3302418.
   Silva CL, 2000, INFECT IMMUN, V68, P3269, DOI 10.1128/IAI.68.6.3269-3274.2000.
   Skinner MA, 1997, INFECT IMMUN, V65, P4525.
   Skinner MA, 2001, IMMUNOLOGY, V102, P225, DOI 10.1046/j.1365-2567.2001.01174.x.
   Smit JJ, 2003, CLIN EXP ALLERGY, V33, P1083, DOI 10.1046/j.1365-2222.2003.01727.x.
   Stegelmann F, 2005, J IMMUNOL, V175, P7474.
   Szalai C, 2001, J ALLERGY CLIN IMMUN, V108, P375, DOI 10.1067/mai.2001.117930.
   TOOSSI Z, 1995, J IMMUNOL, V154, P465.
   Tully G, 2005, J IMMUNOL, V174, P2174.
   {*}US CDCP, 2006, MMWR-MORBID MORTAL W, V55, P301.
   van Crevel R, 2000, J INFECT DIS, V181, P1194, DOI 10.1086/315325.
   van Pinxteren LAH, 2000, EUR J IMMUNOL, V30, P3689, DOI 10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4.
   Wang CC, 1998, IMMUNOLOGY, V93, P307.
   WARWICKDAVIES J, 1995, J IMMUNOL, V155, P3186.
   Wilkinson KA, 2000, INFECT IMMUN, V68, P6505, DOI 10.1128/IAI.68.11.6505-6508.2000.
   Wilkinson RJ, 1998, IMMUNOLOGY, V95, P585.
   Woodworth JSM, 2006, CRIT REV IMMUNOL, V26, P317.
   Zhang Liqun, 2000, Zhonghua Jiehe He Huxi Zazhi, V23, P43.
   Zuany-Amorim C, 2002, J IMMUNOL, V169, P1492.
   Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625.
   Zugel U, 1997, INFECT IMMUN, V65, P3947.}},
Number-of-Cited-References = {{82}},
Times-Cited = {{38}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{186UF}},
Unique-ID = {{ISI:000247803100005}},
}

@article{ ISI:000247803100016,
Author = {Wang, Jann-Yuan and Lee, Li-Na and Lai, Hsin-Chih and Hsu, Hsiao-Leng
   and Liaw, Yuang-Shuang and Hsueh, Po-Ren and Yang, Pan-Chyr},
Title = {{Prediction of the tuberculosis reinfection proportion from the local
   incidence}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{2}},
Pages = {{281-288}},
Month = {{JUL 15}},
Abstract = {{Background. Reinfection is a major contributor to tuberculosis ( TB). It
   seems that the higher the local incidence, the higher the proportion of
   reinfection.
   Methods. Based on a systematic review of the literature, we established
   a regression model to predict the reinfection proportion from the local
   incidence. We then used our local data to verify the algorithm.
   Results. Of the 23 studies addressing reinfection in recurrent TB, 6
   were population based. The reinfection proportion was correlated with
   the local incidence ( reinfection proportion =-29.7 + 36.8 x
   log(Incidence)) (95\% confidence interval {[} CI] for coefficient, 15.3
   - 58.3;). The reinfection proportion in Taiwan ( incidence, 62.4/ 2 R
   p0.849 100,000 people) was estimated to be 36\% ( 95\% CI, 3\% - 69\%).
   Of our 49 recurrent patients, 51\% had reinfection. Patients with
   reactivation seemed more likely to have underlying diseases and less
   likely to be smear positive. The relapse isolates seemed more resistant
   than the initial isolates.
   Conclusions. The regression model could possibly predict the TB
   reinfection proportion from the local incidence. This algorithm is
   probably helpful in policy making for TB control programs. In areas
   where TB is endemic, reinfection might be responsible for > 50\% of TB
   cases, and aggressive surveillance to detect asymptomatic carriers could
   be an important strategy for controlling the disease.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hsueh, PR (Reprint Author), Natl Taiwan Univ Hosp, 7 Chung Shan S Rd, Taipei 100, Taiwan.
   Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei 10764, Taiwan.
   Natl Taiwan Univ, Coll Med, Lab Med, Taipei 10764, Taiwan.
   Natl Taiwan Univ, Coll Med, Clin Lab Sci \& Med Biotechnol, Taipei 10764, Taiwan.}},
DOI = {{10.1086/518898}},
ISSN = {{0022-1899}},
Keywords-Plus = {{RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HIV-RELATED TUBERCULOSIS;
   EXOGENOUS REINFECTION; PULMONARY TUBERCULOSIS; MOLECULAR EPIDEMIOLOGY;
   RECURRENT TUBERCULOSIS; BEIJING GENOTYPE; DRUG-RESISTANCE; MIXED
   INFECTION; UNITED-STATES}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{pcyang@ha.mc.ntu.edu.tw}},
ResearcherID-Numbers = {{Yang, Pan-Chyr /B-8808-2009
   }},
ORCID-Numbers = {{LEE, LI-NA/0000-0002-7654-2450
   HSUEH, PO-REN/0000-0002-7502-9225
   WANG, JANN-YUAN/0000-0003-3406-366X}},
Cited-References = {{Agerton TB, 1999, CLIN INFECT DIS, V29, P85, DOI 10.1086/520187.
   Agerton TB, 1999, CLIN INFECT DIS, V29, P93.
   Bandera A, 2001, J CLIN MICROBIOL, V39, P2213, DOI 10.1128/JCM.39.6.2213-2218.2001.
   Bifani PJ, 1999, JAMA-J AM MED ASSOC, V282, P2321, DOI 10.1001/jama.282.24.2321.
   Caminero JA, 2001, AM J RESP CRIT CARE, V164, P1165.
   Caminero JA, 2001, AM J RESP CRIT CARE, V163, P717.
   Centers for Disease Control (Taiwan), 2004, STAT COMM DIS SURV R.
   Chaves F, 1999, AIDS, V13, P615, DOI 10.1097/00002030-199904010-00011.
   DAS S, 1993, TUBERCLE LUNG DIS, V74, P47, DOI 10.1016/0962-8479(93)90068-9.
   Das S, 1995, TUBERCLE LUNG DIS, V76, P550, DOI 10.1016/0962-8479(95)90533-2.
   DAVIES BH, 1980, THORAX, V35, P481, DOI 10.1136/thx.35.7.481.
   De Boer AS, 2000, NEW ENGL J MED, V342, P1050.
   DEVIEDMA DG, 2002, ARCH INTERN MED, V162, P1873, DOI 10.1001/archinte.162.16.1873.
   El Sahly HM, 2004, INT J TUBERC LUNG D, V8, P333.
   El-Sadr WM, 1998, CLIN INFECT DIS, V26, P1148.
   Fitzpatrick LK, 2002, INT J TUBERC LUNG D, V6, P550.
   Fletcher H A, 2001, Curr Opin Pulm Med, V7, P154, DOI 10.1097/00063198-200105000-00007.
   GLASSROTH J, 1980, NEW ENGL J MED, V302, P1441, DOI 10.1056/NEJM198006263022603.
   GODFREYFAUSSETT P, 1994, TUBERCLE LUNG DIS, V75, P199, DOI 10.1016/0962-8479(94)90008-6.
   HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z.
   Jasmer RM, 2004, AM J RESP CRIT CARE, V170, P1360, DOI 10.1164/rccm.200408-10810C.
   Johnson JL, 2000, INT J TUBERC LUNG D, V4, P1032.
   Jou RW, 2005, J CLIN MICROBIOL, V43, P95, DOI 10.1128/JCM.43.1.95-100.2005.
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907.
   Lambert ML, 2003, LANCET INFECT DIS, V3, P282, DOI 10.1016/S1473-3099(03)00607-8.
   Lan NTN, 2003, EMERG INFECT DIS, V9, P1633.
   Lathan M, 2002, EMERG INFECT DIS, V8, P1249.
   Lourenco MCS, 2000, TROP MED INT HEALTH, V5, P488, DOI 10.1046/j.1365-3156.2000.00583.x.
   Mazars E, 2001, P NATL ACAD SCI USA, V98, P1901, DOI 10.1073/pnas.98.4.1901.
   McNabb SJN, 2002, EMERG INFECT DIS, V8, P1314.
   Miller AC, 2002, EMERG INFECT DIS, V8, P1285.
   Nikolayevskyy V, 2006, EMERG INFECT DIS, V12, P1406.
   Quy HTW, 2003, INT J TUBERC LUNG D, V7, P631.
   SAHADEVAN R, 1995, J CLIN MICROBIOL, V33, P3037.
   SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601.
   Sonnenberg P, 2001, LANCET, V358, P1687, DOI 10.1016/S0140-6736(01)06712-5.
   Sudre P, 1999, INFECTION, V27, P323, DOI 10.1007/s150100050037.
   Supply P, 2000, MOL MICROBIOL, V36, P762, DOI 10.1046/j.1365-2958.2000.01905.x.
   Toungoussova OS, 2003, CLIN INFECT DIS, V37, P665, DOI 10.1086/377205.
   Toungoussova OS, 2002, J CLIN MICROBIOL, V40, P1930, DOI 10.1128/JCM.40.6.1930-1937.2002.
   van Rie A, 2005, AM J RESP CRIT CARE, V172, P636, DOI 10.1164/rccm.200503-449OC.
   Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602.
   Vernon A, 1999, LANCET, V353, P1843, DOI 10.1016/S0140-6736(98)11467-8.
   Verver S, 2005, AM J RESP CRIT CARE, V171, P1430, DOI 10.1164/rccm.200409-1200OC.
   Wang JY, 2004, J CLIN MICROBIOL, V42, P4599, DOI 10.1128/JCM.42.10.4599-4603.2004.
   Warren RM, 2004, AM J RESP CRIT CARE, V169, P610, DOI 10.1164/rccm.200305-714OC.
   Lambregts-van Weezenbeek CSB, 2003, INT J TUBERC LUNG D, V7, pS463.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.}},
Number-of-Cited-References = {{48}},
Times-Cited = {{41}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{186UF}},
Unique-ID = {{ISI:000247803100016}},
}

@article{ ISI:000248426200006,
Author = {Wedlock, D. Neil and Denis, Michel and Vordermeier, H. Martin and
   Hewinson, R. Glyn and Buddle, Bryce M.},
Title = {{Vaccination of cattle with Danish and Pasteur strains of Mycobacterium
   bovis BCG induce different levels of IFN gamma post-vaccination, but
   induce similar levels of protection against bovine tuberculosis}},
Journal = {{VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY}},
Year = {{2007}},
Volume = {{118}},
Number = {{1-2}},
Pages = {{50-58}},
Month = {{JUL 15}},
Abstract = {{A number of studies have demonstrated significant protection of cattle
   against bovine tuberculosis following vaccination with the Pasteur
   strain of Mycobacterium bovis bacille Calmete-Guerin (BCG). However, it
   is unclear if other daughter strains of BCG are as effective, which is
   an important issue to resolve for a variety of regulatory compliance
   issues. This study compared the protective immune responses to bovine
   tuberculosis induced in cattle vaccinated with BCG Danish with those
   induced by BCG Pasteur. Groups of calves (n = 10) were vaccinated with
   10(6) colony forming units (CFU) BCG Pasteur prepared from a fresh
   liquid culture, 10(6) CFU BCG Danish prepared from a fresh liquid
   culture or 0.4 mg of reconstituted freeze-dried culture of BCG Danish.
   Another group (n = 10) served as non-vaccinated controls. BCG Pasteur
   induced significantly higher and more sustained levels of bovine
   purified protein derivative (PPD)-specific gamma interferon (IFN-gamma)
   in whole-blood cultures following vaccination compared to either fresh
   culture BCG Danish or freeze-dried BCG Danish. Vaccination with a fresh
   culture of BCG Pasteur, fresh culture BCG Danish and freeze-dried BCG
   Danish gave a significant enhancement in three, four and three
   pathological and microbiological parameters of protection, respectively,
   compared to the non-vaccinated group. These results demonstrate the
   Danish strain of BCG is a viable alternative to BCG Pasteur for
   vaccination of cattle as both strains had similar efficacy and there was
   little difference between freshly cultured and freeze-dried formulation
   of BCG Danish. The results also show that post-vaccination
   antigen-specific IFN-gamma levels in whole blood is not always a
   reliable indicator of protection against a subsequent virulent
   challenge. (c) 2007 Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Wedlock, DN (Reprint Author), AgResearch Ltd, Hopkirk Res Inst, Grassland Res Ctr, Private Bag 11008, Palmerston North, New Zealand.
   AgResearch, Wallaceville Anim Res Ctr, Upper Hutt, New Zealand.
   Vet Lab Agcy, Weybridge, Surrey, England.}},
DOI = {{10.1016/j.vetimm.2007.04.005}},
ISSN = {{0165-2427}},
Keywords = {{vaccine; M. bovis; BCG Pasteur; BCG Danish; cattle}},
Keywords-Plus = {{INTERFERON-GAMMA; VACCINES; INFECTION; CALVES; MACROPHAGES; RESPONSES;
   EFFICACY; PROGRESS; ABILITY; MODEL}},
Research-Areas = {{Immunology; Veterinary Sciences}},
Web-of-Science-Categories  = {{Immunology; Veterinary Sciences}},
Author-Email = {{neil.wedlock@agresearch.co.nz}},
ResearcherID-Numbers = {{denis, michel/A-9140-2008
   Hewinson, Glyn/F-7077-2010
   Hewinson, Glyn/J-1902-2014
   Vordermeier, H Martin/C-6936-2011
   APHA, Staff publications/E-6082-2010}},
Cited-References = {{Ameni G, 2002, J IMMUNOASS IMMUNOCH, V23, P245, DOI 10.1081/IAS-120003664.
   Behr MA, 2002, LANCET INFECT DIS, V2, P86, DOI 10.1016/S1473-3099(02)00182-2.
   Behr MA, 2001, SCAND J INFECT DIS, V33, P249, DOI 10.1080/003655401300077180.
   BUDDLE BM, 1995, RES VET SCI, V59, P10, DOI 10.1016/0034-5288(95)90023-3.
   BUDDLE BM, 1995, VACCINE, V13, P1123, DOI 10.1016/0264-410X(94)00055-R.
   Buddle BM, 2006, VET MICROBIOL, V112, P191, DOI 10.1016/j.vetmic.2005.11.027.
   Buddle BM, 2005, VET IMMUNOL IMMUNOP, V108, P45, DOI 10.1016/j.vetimm.2005.08.022.
   Buddle BM, 2003, INFECT IMMUN, V71, P6411, DOI 10.1128/IAI.71.11.6411-6419.2003.
   Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851.
   Castillo-Rodal AI, 2006, INFECT IMMUN, V74, P1718, DOI 10.1128/IAI.74.3.1718-1724.2006.
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243.
   Cosivi O, 1998, EMERG INFECT DIS, V4, P59.
   Denis M, 2004, CELL IMMUNOL, V232, P1, DOI 10.1016/j.cellimm.2005.01.003.
   Elias D, 2005, T ROY SOC TROP MED H, V99, P363, DOI 10.1019/j.trstmh.2004.08.006.
   Fine PEM, 2001, SCAND J INFECT DIS, V33, P243, DOI 10.1080/003655401300077144.
   GHEORGHIU M, 1993, ANN IMMUNOL PARIS C, V34, P125.
   Grode L, 2005, J CLIN INVEST, V115, P2472, DOI 10.1172/JCI24617.
   Kipnis A, 2005, INFECT IMMUN, V73, P7759, DOI 10.1128/IAI.73.11.7759-7764.2005.
   Langermans JAM, 2001, P NATL ACAD SCI USA, V98, P11497, DOI 10.1073/pnas.201404898.
   Logan KE, 2005, VACCINE, V23, P5526, DOI 10.1016/j.vaccine.2005.07.037.
   Mostowy S, 2003, VACCINE, V21, P4270, DOI 10.1016/S0264-410X(03)00484-5.
   Phillips CJC, 2003, RES VET SCI, V74, P1, DOI 10.1016/S0034-5288(02)00145-5.
   ROTHEL JS, 1990, AUST VET J, V67, P134, DOI 10.1111/j.1751-0813.1990.tb07730.x.
   Vordermeier HM, 2006, VET J, V171, P229, DOI 10.1016/j.tvjl.2004.11.001.
   Wedlock DN, 2005, INFECT IMMUN, V73, P3540, DOI 10.1128/IAI.73.6.3540-3546.2005.
   Wedlock DN, 1999, INFECT IMMUN, V67, P2172.
   Wedlock DN, 2003, TUBERCULOSIS, V83, P339, DOI 10.1016/S1472-9792(03)00055-6.
   Wedlock DN, 2000, INFECT IMMUN, V68, P5809, DOI 10.1128/IAI.68.10.5809-5815.2000.
   1994, WHOCDSVPH94138.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{41}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Vet. Immunol. Immunopathol.}},
Doc-Delivery-Number = {{195QH}},
Unique-ID = {{ISI:000248426200006}},
}

@article{ ISI:000248093600007,
Author = {Golub, Jonathan E. and Saraceni, Valeria and Cavalcante, Solange C. and
   Pacheco, Antonio G. and Moulton, Lawrence H. and King, Bonnie S. and
   Efron, Anne and Moore, Richard D. and Chaisson, Richard E. and Durovni,
   Betina},
Title = {{The impact of antiretroviral therapy and isoniazid preventive therapy on
   tuberculosis incidence in HIV-infected patients in Rio de Janeiro,
   Brazil}},
Journal = {{AIDS}},
Year = {{2007}},
Volume = {{21}},
Number = {{11}},
Pages = {{1441-1448}},
Month = {{JUL 11}},
Abstract = {{Background: Tuberculosis is a common complication and leading cause of
   death in HIV infection. Antiretroviral therapy (ART) lowers the risk of
   tuberculosis, but may not be sufficient to control HIV-related
   tuberculosis. Isoniazid preventive therapy (IPT) reduces tuberculosis
   incidence significantly, but is not widely used.
   Methods: We analysed tuberculosis incidence in 11026 HIV-infected
   patients receiving medical care at 29 public clinics in Rio de Janeiro,
   Brazil, between 1 September 2003 and 1 September 2005. Data were
   collected through a retrospective medical record review. We determined
   rates of tuberculosis in patients who received neither ART nor IPT, only
   ART, only IPT, or both ART and IPT.
   Results: The overall tuberculosis incidence was 2.2 8 cases/100 person
   -years (PY) {[}95 \% confidence interval (CI) 2.06-2.521. Among patients
   who received neither ART nor IPT, incidence was 4.01/100PY. Patients who
   received ART had an incidence of 1.90/ 100 PY (95\% Cl 1.66-2.17) and
   those treated with IPT had a rate of 1.27/100 FY (95\% CI 0.41 -2.95).
   The incidence among patients who received ART and IPT was 0.80/ 100 PY
   (95\% Cl 0.38-1.47). Multivariate Cox proportional hazards modeling
   revealed a 76\% reduction in tuberculosis risk among patients receiving
   both ART and IPT (adjusted relative hazard 0.24; P < 0.001) after
   adjusting for age, previous tuberculosis diagnosis, and CD4 cell counts
   at baseline.
   Conclusion: The use of both IPT and ART in HIV-infected patients is
   associated with significantly reduced tuberculosis incidence. In
   conjunction with expanded access to ART, the wider use of IPT in
   patients with HIV will improve tuberculosis control in high burden
   areas. (c) 2007 Lippincott Williams \& Wilkins.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Chaisson, RE (Reprint Author), Ctr Tuberculosis Res, 1550 Orleans St,1M08, Baltimore, MD 21231 USA.
   Johns Hopkins Univ, Ctr Tuberculosis Res, Dept Med, Baltimore, MD 21218 USA.
   Johns Hopkins Univ, Ctr Tuberculosis Res, Dept Int Hlth, Baltimore, MD 21218 USA.
   Municipal Hlth Secretariat, Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, FIOCRUZ, BR-21941 Rio De Janeiro, Brazil.}},
DOI = {{10.1097/QAD.0b013e328216f441}},
ISSN = {{0269-9370}},
Keywords = {{antiretroviral therapy; Brazil; HIV; isoniazid; tuberculosis}},
Keywords-Plus = {{HUMAN-IMMUNODEFICIENCY-VIRUS; CONTROLLED-TRIAL; RISK-FACTORS;
   RANDOMIZED-TRIAL; SOUTH-AFRICA; COHORT; RELAPSE; PROPHYLAXIS; ADULTS;
   CHEMOPROPHYLAXIS}},
Research-Areas = {{Immunology; Infectious Diseases; Virology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Virology}},
Author-Email = {{rchaiss@jhmi.edu}},
ResearcherID-Numbers = {{Pacheco, Antonio Guilherme/E-6378-2013
   }},
ORCID-Numbers = {{Pacheco, Antonio Guilherme/0000-0003-3095-1774
   Moulton, Lawrence/0000-0001-7041-7387}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI001637, AI066994, K01 AI066994, K01 AI066994-05, K24
   AI001637, K24 AI001637-10]}},
Cited-References = {{Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3.
   Balcells ME, 2006, EMERG INFECT DIS, V12, P744.
   Casado JL, 2002, CLIN INFECT DIS, V34, P386, DOI 10.1086/324746.
   Churchyard GJ, 2003, AIDS, V17, P2063, DOI 10.1097/01.aids.0000076319.42412.70.
   COMSTOCK GW, 1967, AM REV RESPIR DIS, V95, P935.
   Corbett EL, 2006, LANCET, V367, P926, DOI 10.1016/S0140-6736(06)68383-9.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Costagliola D, 2005, CLIN INFECT DIS, V41, P1772.
   Day JH, 2006, INT J TUBERC LUNG D, V10, P523.
   de Pinho AMF, 2001, AIDS, V15, P2129, DOI 10.1097/00002030-200111090-00008.
   Driver CR, 2001, CLIN INFECT DIS, V33, P1762, DOI 10.1086/323784.
   FEREBEE SH, 1963, AM REV RESPIR DIS, V88, P161.
   FILHO AC, 2004, J BRAS PNEUMOL S1, V30, pS62.
   Fitzgerald DW, 2000, LANCET, V356, P1470, DOI 10.1016/S0140-6736(00)02870-1.
   GETAHUN H, 2004, INTERIM POLICY COLLO.
   GODFREYFAUSSETT P, 2003, POLICY STATEMENT PRE.
   Gordin FM, 1997, NEW ENGL J MED, V337, P315, DOI 10.1056/NEJM199707313370505.
   Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X.
   Johnson JL, 2001, AIDS, V15, P2137, DOI 10.1097/00002030-200111090-00009.
   Jones JL, 2000, INT J TUBERC LUNG D, V4, P1026.
   Lawn SD, 2005, AIDS, V19, P2109, DOI 10.1097/01.aids.0000194808.20035.c1.
   Moore RD, 1998, J ACQ IMMUN DEF SYND, V17, pS38.
   Mosimaneotsile B, 2003, LANCET, V362, P1551, DOI 10.1016/S0140-6736(03)14745-9.
   Moulton LH, 2007, CLIN TRIALS, V4, P190, DOI 10.1177/1740774507076937.
   Mwinga A, 1998, AIDS, V12, P2447, DOI 10.1097/00002030-199818000-00014.
   Nettles RE, 2004, CLIN INFECT DIS, V38, P731, DOI 10.1086/381675.
   Okie S, 2006, NEW ENGL J MED, V354, P1977, DOI 10.1056/NEJMp068069.
   PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6.
   Pulido F, 1997, ARCH INTERN MED, V157, P227, DOI 10.1001/archinte.157.2.227.
   Quigley MA, 2001, AIDS, V15, P215, DOI 10.1097/00002030-200101260-00011.
   Reid A, 2006, LANCET INFECT DIS, V6, P483, DOI 10.1016/S1473-3099(06)70549-7.
   Santoro-Lopes G, 2002, CLIN INFECT DIS, V34, P543, DOI 10.1086/338641.
   Sonnenberg P, 2001, LANCET, V358, P1687, DOI 10.1016/S0140-6736(01)06712-5.
   Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{170}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Aids}},
Doc-Delivery-Number = {{190XI}},
Unique-ID = {{ISI:000248093600007}},
}

@article{ ISI:000258208800001,
Author = {Nunes, Carla},
Title = {{Tuberculosis incidence in Portugal: spatiotemporal clustering}},
Journal = {{INTERNATIONAL JOURNAL OF HEALTH GEOGRAPHICS}},
Year = {{2007}},
Volume = {{6}},
Month = {{JUL 11}},
Abstract = {{Background: The statistics of disease clustering is one of the most
   important tools for epidemiologists to detect and monitor public health
   disease patterns. Nowadays, tuberculosis (TB) - an infectious disease
   caused by the Mycobacterium tuberculosis - presents different
   (development in populations and antibiotics resistance) patterns and
   specialists are very concerned with it and its association to several
   other diseases and factors. Each year, tuberculosis kills about three
   million people in the world. In particular, it is responsible for the
   death of more than one-third of HIV-infected people, who prove
   particularly susceptible due to a decline in their immune defences. The
   purpose of this study is to determine if there are spatiotemporal
   tuberculosis incidence clusters in continental Portugal. The presented
   case study is based on the notification of new tuberculosis cases
   (disease incidence), between 2000 and 2004. In methodological terms, the
   spatial scan statistic, used to identify spatiotemporal clusters, was
   improved by including two new approaches: definition of window sizes in
   the cluster scanning processes considering empirical mean spatial
   semivariograms and an independent and posterior validation of identified
   clusters (based on geostatistical simulations).
   Results: Continental Portugal is organized in 18 districts with 278
   sub-districts. For this case study, the number of new notified cases of
   TB, per sub-district and per year (2000-2004) was available. TB
   incidence presents clear spatial patterns: a semivariogram consistent
   with 40\% of nugget effect and 60\% of spatial contribution, following
   an exponential model with a range of 143 kilometres. Temporal
   semivariograms were not conclusive, as only 5 years of data were
   available. The spatial and temporal persistence of clusters were
   analyzed considering different models. Significant high incidence rate
   space-time clusters were identified in three areas of Portugal (between
   2000 and 2004) and a purely temporal cluster was identified covering the
   whole country, during 2002.
   Conclusion: In terms of spatiotemporal clustering of tuberculosis
   disease, the proposed methodology allowed the identification of critical
   spatiotemporal areas. In Portugal there were 3 critical districts
   (Porto, Set bal and Lisbon) with high rates of notified incidences
   between 2000 and 2004. In methodological terms, semivariogram parameters
   were successfully applied to define spatiotemporal scan window sizes and
   shapes (ellipsoidal cylinders), showing very good results and
   performances in the case study. After defining the clusters, these were
   authenticated through a validation method, based on geostatistical
   simulations.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Nunes, C (Reprint Author), Natl Sch Publ Hlth, Epidemiol \& Stat Grp, Ave Padre Cruz, P-1600560 Lisbon, Portugal.
   Natl Sch Publ Hlth, Epidemiol \& Stat Grp, P-1600560 Lisbon, Portugal.}},
DOI = {{10.1186/1476-072X-6-30}},
ISSN = {{1476-072X}},
Keywords-Plus = {{INDIRECT STANDARDIZATION; CATTLE HERDS; DISEASE}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{cnunes@ensp.unl.pt}},
ResearcherID-Numbers = {{Nunes, Carla/H-1732-2011}},
ORCID-Numbers = {{Nunes, Carla/0000-0003-4562-1057}},
Cited-References = {{ANTUNES ML, 1996, EUROSURVEILLANCE, V1, P19.
   Berke O, 2004, INT J HEALTH GEOGR, V3, P18, DOI DOI 10.1186/1476-072X-3-18.
   BRIZ T, 2000 EUR C EP.
   CRESSIE N. A. C., 1991, STAT SPATIAL DATA.
   Elliot P, 1992, GEOGRAPHICAL ENV EPI.
   Frieden TR, 2002, INT J EPIDEMIOL, V31, P894, DOI 10.1093/ije/31.5.894.
   GOOVAERTS P, 1997, GEOSTATICS NATURAL R.
   Goovaerts Pierre, 2006, Int J Health Geogr, V5, P7, DOI 10.1186/1476-072X-5-7.
   Goovaerts Pierre, 2005, J Geogr Syst, V7, P137, DOI 10.1007/s10109-005-0154-7.
   HILLS M, 1989, J ROYAL STAT SOC A, V152, P307.
   HOWE GM, 1989, HIST EVOLUTION DIS M.
   Isaaks EH, 1989, INTRO APPL GEOSTATIS.
   IYENGAR V, 2005, MORBIDITY MORTALITY, V54.
   JACQUEZ GM, 1993, P WORKSH STAT COMP D.
   KADAFAR K, 2004, BRIEF EVALUATION STA.
   Klassen AC, 2005, INT J HEALTH GEOGR, V4, P1, DOI 10.1186/1476-072X-4-1.
   KLEINMAN JC, 1982, INT J EPIDEMIOL, V11, P146, DOI 10.1093/ije/11.2.146.
   KULDDORFF M, 2005, SATSCAN USER GUIDE V.
   Kulldorff M, 1997, COMMUN STAT-THEOR M, V26, P1481, DOI 10.1080/03610929708831995.
   KULLDORFF M, 1995, STAT MED, V14, P799, DOI 10.1002/sim.4780140809.
   MARSHALL RJ, 1991, J ROY STAT SOC A STA, V154, P421, DOI 10.2307/2983152.
   Matheron G, 1962, MEM BUREAU RECHERCHE, VI, P333.
   Moonan PK, 2004, INT J HEALTH GEOGR, V3, P23, DOI DOI 10.1186/1476-072X-3-23.
   Nkhoma ET, 2004, INT J HEALTH GEOGR, V3, P25, DOI 10.1186/1476-072X-3-25.
   Norstrom M, 2000, PREV VET MED, V47, P107, DOI 10.1016/S0167-5877(00)00159-8.
   Nunes C, 2005, Geostatistics for Environmental Applications, Proceedings, P185, DOI 10.1007/3-540-26535-X\_16.
   Ozonoff Al, 2005, Environ Health, V4, P19, DOI 10.1186/1476-069X-4-19.
   Porter JDH, 1999, TROP MED INT HEALTH, V4, P631, DOI 10.1046/j.1365-3156.1999.00475.x.
   Rodrigues AL, 2006, REV SAUDE PUBL, V40, P265, DOI 10.1590/S0034-89102006000200012.
   SERRA T, 1992, TUBERCLE LUNG DIS, V73, P345, DOI 10.1016/0962-8479(92)90038-L.
   Sheridan HA, 2005, CAN J VET RES, V69, P19.
   Song Changhong, 2003, Int J Health Geogr, V2, P9, DOI 10.1186/1476-072X-2-9.
   Tiwari Neeraj, 2006, Int J Health Geogr, V5, P33, DOI 10.1186/1476-072X-5-33.
   {*}WHO, 1997, GUID NAT PROGR.
   {*}WHO, 2002, DOTS EXP PLAN STOP T.
   WOLFENDEN H, 1962, POPULATION STUDIES, V16, P188, DOI 10.2307/2173125.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{29}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Int. J. Health Geogr.}},
Doc-Delivery-Number = {{334FX}},
Unique-ID = {{ISI:000258208800001}},
}

@article{ ISI:000248309300001,
Author = {Kashyap, Rajpal S. and Rajan, Anju N. and Ramteke, Sonali S. and
   Agrawal, Vijay S. and Kelkar, Sanjivani S. and Purohit, Hemant J. and
   Taori, Girdhar M. and Daginawala, Hatim F.},
Title = {{Diagnosis of tuberculosis in an Indian population by an indirect ELISA
   protocol based on detection of Antigen 85 complex: a prospective cohort
   study}},
Journal = {{BMC INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{7}},
Month = {{JUL 10}},
Abstract = {{Background: Diagnosis of tuberculosis (TB) remains problematic despite
   many new advanced diagnostic methods. A reliable and rapid diagnostic
   test, which could be performed in any standard pathology laboratory,
   would help to obtain definitive early diagnoses of TB. In the present
   study we describe a prospective evaluation for demonstrating Antigen
   (Ag) 85 complex in the sera from TB patients.
   Methods: Indirect ELISA, employing monoclonal antibodies (mAb) against
   the purified Ag 85 complex, was used to demonstrate Ag 85 complex in
   sera from TB patients. Serum samples were obtained from 197 different
   groups of patients: confirmed TB \{n = 24\}, clinically diagnosed TB \{n
   = 104\}, disease controls \{n = 49\} and healthy controls \{n = 20\}.
   Receiver operating curve (ROC) was used to calculate the cut off value
   and comparison between TB and non- TB groups were done by the chi-
   square test.
   Results: The indirect ELISA method, using an mAb against Ag 85 complex,
   yielded 82\% sensitivity (95\% confidence interval {[}CI] 67 to 93\%)
   and 86\% specificity (95\% CI, 57 to 98\%) for the diagnosis of TB. The
   serum positivities for Ag 85 complex in cases of confirmed and
   clinically diagnosed TB patients were 96\% (23/24) and 79\% (82/104)
   respectively, while the positivity for patients in the non- tuberculosis
   group was 14\% (10/69).
   Conclusion: The detection of Ag 85 complex in sera from TB patients by
   indirect ELISA using mAb against purified Ag 85 complex gives a reliable
   diagnosis and can be used to develop an immunodiagnostic assay with
   increased sensitivity and specificity.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Daginawala, HF (Reprint Author), Cent India Inst Med Sci, Biochem Res Lab, Nagpur 10, Maharashtra, India.
   Cent India Inst Med Sci, Biochem Res Lab, Nagpur 10, Maharashtra, India.
   Natl Environm Engn Res Inst, Environm Genom Unit, Nagpur 440020, Maharashtra, India.}},
DOI = {{10.1186/1471-2334-7-74}},
Article-Number = {{74}},
ISSN = {{1471-2334}},
Keywords-Plus = {{LINKED-IMMUNOSORBENT-ASSAY; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY
   TUBERCULOSIS; ACTIVE TUBERCULOSIS; SERODIAGNOSIS; ANTIBODIES; SPUTUM}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{raj\_ciims@rediffmail.com
   anju\_mudaliar@rediffmail.com
   sonaliramteke8@yahoo.co.in
   ciims\_ngp@sancharnet.in
   ciims\_ngp@sancharnet.in
   hemantdrd@hotmail.com
   taorigm\_ciims@yahoo.co.in
   hfd\_ciims@rediffmail.com}},
Cited-References = {{ABER VR, 1980, TUBERCLE, V61, P123, DOI 10.1016/0041-3879(80)90001-X.
   BEGI SS, 2006, INDIAN J MED RES, V124, P81.
   Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420.
   BENJAMIN RG, 1984, J MED MICROBIOL, V18, P309.
   Bentley-Hibbert SI, 1999, INFECT IMMUN, V67, P581.
   Chiang IH, 1997, AM J RESP CRIT CARE, V156, P906.
   DANIEL TM, 1987, AM REV RESPIR DIS, V135, P1137.
   Donald PR, 2002, CURR OPIN PULM MED, V8, P178, DOI 10.1097/00063198-200205000-00005.
   EDWARD WT, 2004, CLIN DIAGN LAB IMMUN, V11, P1089.
   Garg SK, 2003, J CLIN LAB ANAL, V17, P155, DOI 10.1002/jcla.10086.
   Kashyap Rajpal S, 2002, Med Sci Monit, V8, pMT95.
   Kashyap Rajpal S, 2003, Med Sci Monit, V9, pMT123.
   Kashyap RS, 2004, NEUROL INDIA, V52, P359.
   KASHYAP RS, 2001, CLIN DIAGN LAB IMMUN, V12, P752.
   Kashyap R, 2001, ANN INDIAN ACAD NEUR, V4, P197.
   Landowski CP, 2001, J CLIN MICROBIOL, V39, P2418, DOI 10.1128/JCM.39.7.2418-2424.2001.
   Lauzardo M, 2000, CHEST, V117, P1455, DOI 10.1378/chest.117.5.1455.
   Madhi SA, 2000, INT J TUBERC LUNG D, V4, P448.
   Maekura R, 2003, J CLIN MICROBIOL, V41, P1322, DOI 10.1128/JCM.41.3.1322-1325.2003.
   Narayanan PR, 2003, TUBERCULOSIS, V83, P135, DOI 10.1016/S1472-9792(02)00068-9.
   PARRY CM, 1993, TROP DOCT, V23, P145.
   Pessolani Maria Cristina V., 1992, Infection and Immunity, V60, P4452.
   Pottumarthy S, 2000, J CLIN MICROBIOL, V38, P2227.
   Ravn P, 2005, CLIN DIAGN LAB IMMUN, V12, P491, DOI 10.1128/CDLI.12.4.491-496.2005.
   SADA ED, 1990, J INFECT DIS, V162, P928.
   Sanchez-Rodriguez C, 2002, INT J TUBERC LUNG D, V6, P706.
   Wallis RS, 1998, J INFECT DIS, V178, P1115, DOI 10.1086/515701.
   {*}WHO, 2000, TUBERCULOSIS.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{26}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{BMC Infect. Dis.}},
Doc-Delivery-Number = {{193XU}},
Unique-ID = {{ISI:000248309300001}},
}

@article{ ISI:000248063400011,
Author = {Singh, Amit and Guidry, Loni and Narasimhulu, K. V. and Mai, Deborah and
   Trombley, John and Redding, Kevin E. and Giles, Gregory I. and
   Lancaster, Jr., Jack R. and Steyn, Adrie J. C.},
Title = {{Mycobacterium tuberculosis WhiB3 responds to O-2 and nitric oxide via
   its {[}4Fe-4S] cluster and is essential for nutrient starvation survival}},
Journal = {{PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA}},
Year = {{2007}},
Volume = {{104}},
Number = {{28}},
Pages = {{11562-11567}},
Month = {{JUL 10}},
Abstract = {{A fundamental challenge in the redox biology of Mycobacterium
   tuberculosis (Mtb) is to understand the mechanisms involved in sensing
   redox signals such as oxygen (O-2), nitric oxide (NO), and nutrient
   depletion, which are thought to play a crucial role in persistence. Here
   we show that Mtb WhiB3 responds to the dormancy signals NO and O-2
   through its iron-sulfur (Fe-S) cluster. To functionally assemble the
   WhiB3 Fe-S cluster, we identified and characterized the Mtb cysteine
   desulfurase (IscS; Rv3025c) and developed a native enzymatic
   reconstitution system for assembling Fe-S clusters in Mtb. EPR and
   UV-visible spectroscopy analysis of reduced WhiB3 is consistent with a
   one-electron reduction of EPR silent {[}4Fe-4S](2+) to EPR visible
   {[}4Fe-4S](+). Atmospheric O-2 gradually degrades the WhiB3
   {[}4Fe-4S]2(+) cluster to generate a {[}3Fe-4S](+) intermediate.
   Furthermore, EPR analysis demonstrates that NO forms a protein-bound
   dinitrosyl-iron-dithiol complex with the Fe-S cluster, indicating that
   NO specifically targets the WhiB3 Fe-S cluster. Our data suggest that
   the mechanism of WhiB3 4Fe-4S cluster degradation is similar to that of
   fumarate nitrate regulator. Importantly, Mtb Delta whiB3 shows enhanced
   growth on acetate medium, but a growth defect on media containing
   glucose, pyruvate, succinate, or fumarate as the sole carbon source. Our
   results implicate WhiB3 in metabolic switching and in sensing the
   physiologically relevant host signaling molecules NO and O-2 through its
   {[}4Fe-4S] cluster. Taken together, our results suggest that WhiB3 is an
   intracellular redox sensor that integrates environmental redox signals
   with core intermediary metabolism.}},
Publisher = {{NATL ACAD SCIENCES}},
Address = {{2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Steyn, AJC (Reprint Author), Univ Alabama, Dept Microbiol, 945 19th St S,308 BBRB, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Chem, Tuscaloosa, AL 35487 USA.
   Univ Alabama, Dept Anesthesiol, Ctr Free Radical Biol, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Physiol, Ctr Free Radical Biol, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Biophys, Ctr Free Radical Biol, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Environm Hlth Sci, Ctr Free Radical Physiol, Birmingham, AL 35294 USA.}},
DOI = {{10.1073/pnas.0700490104}},
ISSN = {{0027-8424}},
Keywords = {{dormancy; redox; metabolism; iron-sulfur}},
Keywords-Plus = {{IN-VIVO GROWTH; ESCHERICHIA-COLI; TRANSCRIPTION FACTOR; GENE-EXPRESSION;
   FNR; OXYGEN; PROTEIN; MACROPHAGES; PERSISTENCE; METABOLISM}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Author-Email = {{asteyn@uab.edu}},
ResearcherID-Numbers = {{Giles, Gregory/C-6368-2009
   }},
ORCID-Numbers = {{Singh, Amit/0000-0001-6761-1664}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}1T32AI55438, R01 AI058131, R01AI058131, T32 AI055438];
   NIGMS NIH HHS {[}T32 GM008111-19, T32 GM008111]}},
Cited-References = {{Agarwal N, 2006, MICROBIOL-SGM, V152, P2749, DOI 10.1099/mic.0.28924-0.
   Banaiee N, 2006, INFECT IMMUN, V74, P6449, DOI 10.1128/IAI.00190-06.
   Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x.
   Boshoff HIM, 2004, J BIOL CHEM, V279, P40174, DOI 10.1074/jbc.M406796200.
   Crack J, 2004, J BIOL CHEM, V279, P9278, DOI 10.1074/jbc.M309878200.
   Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339.
   Graham JE, 1999, P NATL ACAD SCI USA, V96, P11554, DOI 10.1073/pnas.96.20.11554.
   Green J, 2004, NAT REV MICROBIOL, V2, P954, DOI 10.1038/nrmicro1022.
   Heidenreich T, 2005, J BIOL CHEM, V280, P4213, DOI 10.1074/jbc.M411195200.
   Hutter B, 1999, RES MICROBIOL, V150, P295, DOI 10.1016/S0923-2508(99)80055-2.
   Jakimowicz P, 2005, J BIOL CHEM, V280, P8309, DOI 10.1074/jbc.M412622200.
   Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518.
   Kumar A, 2007, P NATL ACAD SCI USA, V104, P11568, DOI 10.1073/pnas.0705054104.
   Levanon SS, 2005, BIOTECHNOL BIOENG, V89, P556.
   Loebel RO, 1933, J BACTERIOL, V26, P167.
   Munoz-Elias EJ, 2005, NAT MED, V11, P638, DOI 10.1038/nm1252.
   NYSTROM T, 1994, MOL MICROBIOL, V12, P833, DOI 10.1111/j.1365-2958.1994.tb01069.x.
   Ohno H, 2003, CELL MICROBIOL, V5, P637, DOI 10.1046/j.1462-5822.2003.00307.x.
   Park HD, 2003, MOL MICROBIOL, V48, P833, DOI 10.1046/j.1365-2958.2003.03474.x.
   SEGAL W, 1956, J BACTERIOL, V72, P132.
   Shalel-Levanon S, 2005, BIOTECHNOL BIOENG, V92, P147, DOI 10.1002/bit.20583.
   Steyn AJC, 2002, P NATL ACAD SCI USA, V99, P3147, DOI 10.1073/pnas.052705399.
   Sutton VR, 2004, BIOCHEMISTRY-US, V43, P791, DOI 10.1021/bi0357053.
   TA DT, 1992, J BIOL CHEM, V267, P11120.
   Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479.
   Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205.
   Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139.}},
Number-of-Cited-References = {{27}},
Times-Cited = {{97}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{9}},
Journal-ISO = {{Proc. Natl. Acad. Sci. U. S. A.}},
Doc-Delivery-Number = {{190MQ}},
Unique-ID = {{ISI:000248063400011}},
}

@article{ ISI:000248063400012,
Author = {Kumar, Ashwani and Toledo, Jose C. and Patel, Rakesh P. and Lancaster,
   Jr., Jack R. and Steyn, Adrie J. C.},
Title = {{Mycobacterium tuberculosis DosS is a redox sensor and DosT is a hypoxia
   sensor}},
Journal = {{PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA}},
Year = {{2007}},
Volume = {{104}},
Number = {{28}},
Pages = {{11568-11573}},
Month = {{JUL 10}},
Abstract = {{A fundamental challenge to the study of oxidative stress responses of
   Mycobacterium tuberculosis (Mtb) is to understand how the protective
   host molecules are sensed and relayed to control bacilli gene
   expression. The genetic response of Mtb to hypoxia and NO is controlled
   by the sensor kinases DosS and DosT and the response regulator DosR
   through activation of the dormancy/NO (Dos) regulon. However, the
   regulatory ligands of DosS and DosT and the mechanism of signal sensing
   were unknown. Here, we show that both DosS and DosT bind heme as a
   prosthetic group and that DosS is rapidly autooxiclized to attain the
   met (Fe3+) form, whereas DosT exists in the O-2-bound (oxy) form. EPR
   and UV-visible spectroscopy analysis showed that O-2, NO, and CO are
   ligands of DosS and DosT. Importantly, we demonstrate that the oxidation
   or ligation state of the heme iron modulates DosS and DosT autokinase
   activity and that ferrous DosS, and deoxy DosT, show significantly
   increased autokinase activity compared with met DosS and oxy DosT. Our
   data provide direct proof that DosS functions as a redox sensor, whereas
   DosT functions as a hypoxia sensor, and that O-2, NO, and CO are
   modulatory ligands of DosS and DosT. Finally, we identified a third
   potential dormancy signal, CO, that induces the Mtb Dos regulon. We
   conclude that Mtb has evolved finely tuned redox and hypoxia-mediated
   sensing strategies for detecting O-2, NO, and CO. Data presented here
   establish a paradigm for understanding the mechanism of bacilli
   persistence.}},
Publisher = {{NATL ACAD SCIENCES}},
Address = {{2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Steyn, AJC (Reprint Author), Univ Alabama, Ctr Free Radical Biol, Birmingham, AL 35294 USA.
   Univ Alabama, Ctr Free Radical Biol, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Physiol \& Biophys, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Environm Hlth Sci, Birmingham, AL 35294 USA.}},
DOI = {{10.1073/pnas.0705054104}},
ISSN = {{0027-8424}},
Keywords = {{carbon monoxide; dormancy; nitric oxide; oxygen; persistence}},
Keywords-Plus = {{NITRIC-OXIDE SYNTHASE; HEME-BASED SENSORS; CARBON-MONOXIDE; RESPONSE
   REGULATOR; OXYGEN SENSOR; PROTEIN; EXPRESSION; BINDING; DEVR;
   IDENTIFICATION}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Author-Email = {{asteyn@uab.edu}},
ResearcherID-Numbers = {{Toledo Jr, Jose /J-4360-2015
   }},
ORCID-Numbers = {{Patel, Rakesh/0000-0002-1526-4303
   Kumar, Ashwani/0000-0002-6240-6810}},
Funding-Acknowledgement = {{NHLBI NIH HHS {[}HL074391, HL71189, R01 HL071189, R01 HL074391]; NIAID
   NIH HHS {[}R01 AI058131, AI058131, R56 AI058131]}},
Cited-References = {{Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727.
   Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989.
   Dasgupta N, 2000, TUBERCLE LUNG DIS, V80, P141, DOI 10.1054/tuld.2000.0240.
   Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s.
   Donnelly LE, 2001, AM J RESP CELL MOL, V24, P295.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   Gilles-Gonzalez MA, 2005, J INORG BIOCHEM, V99, P1, DOI 10.1016/j.jinorgbio.2004.11.006.
   GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011.
   GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0.
   Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570.
   Kim HP, 2006, ANNU REV PHARMACOL, V46, P411, DOI 10.1146/annurev.pharmtox.46.120604.141053.
   KINGER AK, 1993, GENE, V131, P113, DOI 10.1016/0378-1119(93)90678-V.
   MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243.
   Malhotra V, 2004, FEMS MICROBIOL LETT, V231, P237, DOI 10.1016/S0378-1097(04)00002-3.
   Martin E, 2006, J BIOL CHEM, V281, P27836, DOI 10.1074/jbc.M601078200.
   Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841.
   Ohno H, 2003, CELL MICROBIOL, V5, P637, DOI 10.1046/j.1462-5822.2003.00307.x.
   Park HD, 2003, MOL MICROBIOL, V48, P833, DOI 10.1046/j.1365-2958.2003.03474.x.
   Roberts DM, 2004, J BIOL CHEM, V279, P23082, DOI 10.1074/jbc.M401230200.
   ROMBERG RW, 1979, BIOCHEMISTRY-US, V18, P5387, DOI 10.1021/bi00591a020.
   Saini DK, 2004, FEBS LETT, V565, P75, DOI 10.1016/j.febslet.2004.02.092.
   Sardiwal S, 2005, J MOL BIOL, V353, P929, DOI 10.1016/j.jmb.2005.09.011.
   Singh A, 2007, P NATL ACAD SCI USA, V104, P11562, DOI 10.1073/pnas.0700490104.
   Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205.
   Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139.
   Weinberg JB, 1998, MOL MED, V4, P557.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{168}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{24}},
Journal-ISO = {{Proc. Natl. Acad. Sci. U. S. A.}},
Doc-Delivery-Number = {{190MQ}},
Unique-ID = {{ISI:000248063400012}},
}

@article{ ISI:000248105900002,
Author = {Tsenova, Liana and Harbacheuski, Ryhor and Sung, Nackmoon and Ellison,
   Evette and Fallows, Dorothy and Kaplan, Gilla},
Title = {{BCG vaccination confers poor protection against M-tuberculosis
   HN878-induced central nervous system disease}},
Journal = {{VACCINE}},
Year = {{2007}},
Volume = {{25}},
Number = {{28}},
Pages = {{5126-5132}},
Month = {{JUL 9}},
Abstract = {{Using a rabbit model of tuberculous meningitis (TBM), we compared the
   protective efficacy of Mycobacterium bovis bacillus Calmette-Guerin
   (BCG) vaccination against central nervous system infection with the
   virulent M. tuberculosis clinical isolate HN878 and the laboratory
   strain H37Rv. Although BCG clearly provided protection against infection
   with either challenge strain, protection against disease manifestations
   was significantly poorer in rabbits infected with HN878. BCG was less
   efficient in protecting against HN878 dissemination to the liver and
   spleen and against HN878-induced inflammation, loss of body weight, lung
   and brain pathology, and signs of disease. We suggest that the efficacy
   of newly developed vaccines should be tested in animal models not only
   against challenge with M. tuberculosis H37Rv but also with different
   clinical isolates including the highly virulent strains of the W-Beijing
   family. (c) 2006 Elsevier Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tsenova, L (Reprint Author), Publ Hlth Res Inst, Lab Mycobacteriol Immun \& Pathogenesis, 225 Warren St, Newark, NJ 07103 USA.
   Publ Hlth Res Inst, Lab Mycobacteriol Immun \& Pathogenesis, Newark, NJ 07103 USA.}},
DOI = {{10.1016/j.vaccine.2006.11.024}},
ISSN = {{0264-410X}},
Keywords = {{tuberculous meningitis; BCG vaccination; rabbits; M. tuberculosis
   strains; W-Beijing strains}},
Keywords-Plus = {{RABBIT MODEL; GLOBAL DISSEMINATION; POLYPROTEIN VACCINE;
   IMMUNE-RESPONSES; CLINICAL ISOLATE; STRAINS; MENINGITIS; MICE; EFFICACY;
   FAMILY}},
Research-Areas = {{Immunology; Research \& Experimental Medicine}},
Web-of-Science-Categories  = {{Immunology; Medicine, Research \& Experimental}},
Author-Email = {{tsenova@phri.org}},
ORCID-Numbers = {{waluyo, imam/0000-0002-1813-9487}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}R01 AI054338-04, R01 AI054338-06, R01 AI054338-03,
   AI054338, R01 AI054338]}},
Cited-References = {{Abebe F, 2006, CLIN EXP IMMUNOL, V145, P389, DOI 10.1111/j.1365-2249.2006.03162.x.
   Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520.
   Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6.
   Bifani PJ, 1999, JAMA-J AM MED ASSOC, V282, P2321, DOI 10.1001/jama.282.24.2321.
   Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452.
   Brandi ML, 2004, UROL INT, V72, P11, DOI 10.1159/000076584.
   BREWER TF, 1995, CLIN INFECT DIS, V20, P126.
   Castanon-Arreola M, 2005, TUBERCULOSIS, V85, P115, DOI 10.1016/j.tube.2004.10.004.
   Espinal MA, 2003, TUBERCULOSIS, V83, P44, DOI 10.1016/S1472-9792(02)00058-6.
   Fine PEM, 2001, SCAND J INFECT DIS, V33, P243, DOI 10.1080/003655401300077144.
   Ginsberg AM, 1998, PUBLIC HEALTH REP, V113, P128.
   Glynn JR, 2002, EMERG INFECT DIS, V8, P843.
   Grode L, 2005, J CLIN INVEST, V115, P2472, DOI 10.1172/JCI24617.
   Lagranderie MRR, 1996, INFECT IMMUN, V64, P1.
   Lopez B, 2003, CLIN EXP IMMUNOL, V133, P30, DOI 10.1046/j.1365-2249.2003.02171.x.
   Manabe YC, 2003, INFECT IMMUN, V71, P6004, DOI 10.1128/IAI.71.10.6004-6011.2003.
   Manca C, 1999, J IMMUNOL, V162, P6740.
   Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998.
   Mollenkopf HJ, 2004, J INFECT DIS, V190, P588, DOI 10.1086/422394.
   MORRIS SL, 2006, P 2 INT C TB VACC WO.
   Orme IM, 2001, J LEUKOCYTE BIOL, V70, P1.
   Orme IM, 2001, TRENDS MICROBIOL, V9, P115, DOI 10.1016/S0966-842X(00)01949-1.
   Pheiffer C, 2005, MICROBIOL-SGM, V151, P1139, DOI 10.1099/mic.0.27518-0.
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154.
   Sambandamurthy VK, 2006, VACCINE, V24, P6309, DOI 10.1016/j.vaccine.2006.05.097.
   Sampson SL, 2004, INFECT IMMUN, V72, P3031, DOI 10.1128/IAI.72.5.3031-3037.2004.
   Skeiky YAW, 2004, J IMMUNOL, V172, P7618.
   Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869.
   Tsenova L, 1998, J INFECT DIS, V177, P1563, DOI 10.1086/515327.
   Tsenova L, 2006, INFECT IMMUN, V74, P2392, DOI 10.1128/IAI.74.4.2392-2401.2006.
   Tsenova L, 2005, J INFECT DIS, V192, P98, DOI 10.1086/430614.
   Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001.
   VANSOOLINGEN D, 1995, J CLIN MICROBIOL, V33, P3234.
   World Health Organization Communicable Diseases Programme, 2000, GLOB TUB CONTR.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{36}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Vaccine}},
Doc-Delivery-Number = {{191BX}},
Unique-ID = {{ISI:000248105900002}},
}

@article{ ISI:000247862300024,
Author = {Jolobe, Oscar Mlungu},
Title = {{Anti-TNF alpha treatment and reactivation of latent tuberculosis}},
Journal = {{LANCET}},
Year = {{2007}},
Volume = {{370}},
Number = {{9581}},
Pages = {{27-28}},
Month = {{JUL 7}},
Publisher = {{LANCET LTD}},
Address = {{84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Jolobe, OM (Reprint Author), Manchester Med Soc, Manchester M13 9PP, Lancs, England.
   Manchester Med Soc, Manchester M13 9PP, Lancs, England.}},
DOI = {{10.1016/S0140-6736(07)61043-5}},
ISSN = {{0140-6736}},
Keywords-Plus = {{NECROSIS FACTOR; INFECTION}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{oscarjolobe@yahoo.co.uk}},
Cited-References = {{Braun J, 2007, LANCET, V369, P1379, DOI 10.1016/S0140-6736(07)60635-7.
   Fietta A, 2003, AM J INFECT CONTROL, V31, P347, DOI 10.1067/mic.2003.40.
   KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4.
   Mutlu GM, 2006, AM J MED, V119, P639, DOI 10.1016/j.amjmed.2006.01.015.}},
Number-of-Cited-References = {{4}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Lancet}},
Doc-Delivery-Number = {{187QE}},
Unique-ID = {{ISI:000247862300024}},
}

@article{ ISI:000247650600065,
Author = {Henriksson, Lena M. and Unge, Torsten and Carlsson, Jens and Aqvist,
   Johan and Mowbray, Sherry L. and Jones, T. Alwyn},
Title = {{Structures of Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate
   reductoisomerase provide new insights into catalysis}},
Journal = {{JOURNAL OF BIOLOGICAL CHEMISTRY}},
Year = {{2007}},
Volume = {{282}},
Number = {{27}},
Pages = {{19905-19916}},
Month = {{JUL 6}},
Abstract = {{Isopentenyl diphosphate is the precursor of various isoprenoids that are
   essential to all living organisms. It is produced by the mevalonate
   pathway in humans but by an alternate route in plants, protozoa, and
   many bacteria. 1-Deoxy-D-xylulose-5-phosphate reductoisomerase catalyzes
   the second step of this non-mevalonate pathway, which involves an
   NADPH-dependent rearrangement and reduction of 1-deoxy-D-xylulose
   5-phosphate to form 2-C-methyl-D-erythritol 4-phosphate. The use of
   different pathways, combined with the reported essentiality of the
   enzyme makes the reductoisomerase a highly promising target for drug
   design. Here we present several high resolution structures of the
   Mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate
   reductoisomerase, representing both wild type and mutant enzyme in
   various complexes with Mn2+, NADPH, and the known inhibitor
   fosmidomycin. The asymmetric unit corresponds to the biological
   homodimer. Although crystal contacts stabilize an open active site in
   the B molecule, the A molecule displays a closed conformation, with some
   differences depending on the ligands bound. An inhibition study with
   fosmidomycin resulted in an estimated IC50 value of 80 nM. The double
   mutant enzyme (D151N/E222Q) has lost its ability to bind the metal and,
   thereby, also its activity. Our structural information complemented with
   molecular dynamics simulations and free energy calculations provides the
   framework for the design of new inhibitors and gives new insights into
   the reaction mechanism. The conformation of fosmidomycin bound to the
   metal ion is different from that reported in a previously published
   structure and indicates that a rearrangement of the intermediate is not
   required during catalysis.}},
Publisher = {{AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Jones, TA (Reprint Author), Uppsala Univ, Biomed Ctr, Dept Mol \& Cell Biol, S-75124 Uppsala, Sweden.
   Uppsala Univ, Biomed Ctr, Dept Mol \& Cell Biol, S-75124 Uppsala, Sweden.
   Swedish Univ Agr Sci, Biomed Ctr, Dept Mol Biol, S-75124 Uppsala, Sweden.}},
DOI = {{10.1074/jbc.M701935200}},
ISSN = {{0021-9258}},
Keywords-Plus = {{NON-MEVALONATE PATHWAY; 5-PHOSPHATE REDUCTOISOMERASE; ISOPRENOID
   BIOSYNTHESIS; ISOPENTENYL DIPHOSPHATE; CRYSTAL-STRUCTURE; NONMEVALONATE
   PATHWAY; 2-C-METHYL-D-ERYTHRITOL 4-PHOSPHATE; TERPENOID BIOSYNTHESIS;
   ESCHERICHIA-COLI; DIFFRACTION DATA}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{Alwyn@xray.bmc.uu.se}},
ResearcherID-Numbers = {{Mowbray, Sherry/D-2141-2013
   }},
ORCID-Numbers = {{Carlsson, Jens/0000-0003-4623-2977}},
Cited-References = {{AQVIST J, 1993, CHEM REV, V93, P2523.
   AQVIST J, 1909, COMPUTATIONAL APPROA, P341.
   Argyrou A, 2004, BIOCHEMISTRY-US, V43, P4375, DOI 10.1021/bi049974k.
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004.
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235.
   Bjelic S, 2006, BIOCHEMISTRY-US, V45, P7709, DOI 10.1021/bi060131y.
   Boucher Y, 2000, MOL MICROBIOL, V37, P703, DOI 10.1046/j.1365-2958.2000.02004.x.
   Cole ST, 1998, NATURE, V393, P537.
   Collaborative Computational Project Number 4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112.
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002.
   Dhiman RK, 2005, J BACTERIOL, V187, P8395, DOI 10.1128/JB.187.24.8395-8402.2005.
   Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269.
   EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011.
   ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071.
   Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114.
   Haemers T, 2006, BIOORG MED CHEM LETT, V16, P1888, DOI 10.1016/j.bmcl.2005.12.082.
   Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697.
   Henriksson LM, 2006, ACTA CRYSTALLOGR D, V62, P807, DOI 10.1107/S0907444906019196.
   Hoeffler JF, 2002, EUR J BIOCHEM, V269, P4446, DOI 10.1046/j.1432-1033.2002.03150.x.
   Holmberg N, 1999, PROTEIN ENG, V12, P851, DOI 10.1093/protein/12.10.851.
   Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573.
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897.
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224.
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869.
   Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5.
   Kobayashi K, 2003, P NATL ACAD SCI USA, V100, P4678, DOI 10.1073/pnas.0730515100.
   Kuzuyama T, 2000, J BIOL CHEM, V275, P19928, DOI 10.1074/jbc.M001820200.
   Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P7913, DOI 10.1016/S0040-4039(98)01755-9.
   Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P4509, DOI 10.1016/S0040-4039(98)00802-8.
   LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886.
   Lell B, 2003, ANTIMICROB AGENTS CH, V47, P735, DOI 10.1128/AAC.47.2.735-738.2003.
   Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X.
   LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8.
   Lichtenthaler HK, 1999, ANNU REV PLANT PHYS, V50, P47, DOI 10.1146/annurev.arplant.50.1.47.
   Mac Sweeney A, 2005, J MOL BIOL, V345, P115, DOI 10.1016/j.jmb.2004.10.030.
   MACKERELL AD, 1995, J AM CHEM SOC, V117, P11946, DOI 10.1021/ja00153a017.
   Marelius J, 1998, J MOL GRAPH MODEL, V16, P213, DOI 10.1016/S1093-3263(99)00012-1.
   MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2.
   Missinou MA, 2002, LANCET, V360, P1941, DOI 10.1016/S0140-6736(02)11860-5.
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255.
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597.
   Proteau PJ, 1999, ORG LETT, V1, P921, DOI 10.1021/ol990839n.
   Radykewicz T, 2000, FEBS LETT, V465, P157, DOI 10.1016/S0014-5793(99)01743-3.
   READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622.
   Reuter K, 2002, J BIOL CHEM, V277, P5378, DOI 10.1074/jbc.M109500200.
   Ricagno S, 2004, BBA-PROTEINS PROTEOM, V1698, P37, DOI 10.1016/j.bbapap.2003.10.006.
   Rodriguez-Concepcion M, 2000, FEBS LETT, V473, P328, DOI 10.1016/S0014-5793(00)01552-0.
   Rohmer M, 1999, NAT PROD REP, V16, P565, DOI 10.1039/a709175c.
   ROHMER M, 1993, BIOCHEM J, V295, P517.
   Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788.
   Sem DS, 2004, CHEM BIOL, V11, P185, DOI 10.1016/j.chembio.2004.02.012.
   SHIGI Y, 1989, J ANTIMICROB CHEMOTH, V24, P131, DOI 10.1093/jac/24.2.131.
   Spurgeon SL, 1981, BIOSYNTHESIS ISOPREN, P1.
   Steinbacher S, 2003, J BIOL CHEM, V278, P18401, DOI 10.1074/jbc.M300993200.
   Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879.
   Warshel A., 1991, COMPUTER MODELING CH.
   Yajima S, 2004, J AM CHEM SOC, V126, P10824, DOI 10.1021/ja040126m.
   Yajima S, 2002, J BIOCHEM, V131, P313.
   Zeidler J, 1998, Z NATURFORSCH C, V53, P980.}},
Number-of-Cited-References = {{59}},
Times-Cited = {{57}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{J. Biol. Chem.}},
Doc-Delivery-Number = {{184OF}},
Unique-ID = {{ISI:000247650600065}},
}

@article{ ISI:000247721100024,
Author = {Markel, Howard and Gostin, Lawrence O. and Fidler, David P.},
Title = {{Extensively drug-resistant tuberculosis - An isolation order, public
   health powers, and a global crisis}},
Journal = {{JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION}},
Year = {{2007}},
Volume = {{298}},
Number = {{1}},
Pages = {{83-86}},
Month = {{JUL 4}},
Publisher = {{AMER MEDICAL ASSOC}},
Address = {{515 N STATE ST, CHICAGO, IL 60610-0946 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Markel, H (Reprint Author), Univ Michigan, Sch Med, Ctr Hist Med, 102 Observ,0725,100 SMI, Ann Arbor, MI 48109 USA.
   Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48109 USA.
   Georgetown Univ, Ctr Law, ONeill Inst Natl \& Global Hlth Law, Washington, DC USA.
   Indiana Univ, Sch Law, Bloomington, IN 47401 USA.}},
DOI = {{10.1001/jama.298.1.83}},
ISSN = {{0098-7484}},
Keywords-Plus = {{ACT}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{howard@umich.edu}},
Cited-References = {{BROWN D, 2007, WASHINGTON POST 0607, pA6.
   {*}CDC, 2007, EXT DRUG RES TUB XDR.
   {*}CDC, 1996, MMWR-MORBID MORTAL W, V45, P538.
   {*}COMM MEAS ENH EFF, 2006, QUAR STAT PORTS ENTR.
   Gostin LO, 2002, JAMA-J AM MED ASSOC, V288, P622, DOI 10.1001/jama.288.5.622.
   Hodge JG, 2006, J LAW MED ETHICS, V34, P77, DOI 10.1111/j.1748-720X.2006.00010.x.
   Markel Howard, 2005, GERMS TRAVEL 6 MAJOR.
   Markel H., 1999, QUARANTINE E EUROPEA.
   SCHARTZ J, 2007, NY TIMES        0602, pA1.
   Singh JA, 2007, PLOS MED, V4, P19, DOI 10.1371/journal.pmed.0040050.
   SPEAKER A, 2007, GOOD MORNING AM 0601.
   SPEAKER A, 2007, GOOD MORNING AM 0604.
   World Health Organization, 2007, WHO GUID HUM RIGHTS.
   2005, FED REG, V70, P71891.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{23}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{JAMA-J. Am. Med. Assoc.}},
Doc-Delivery-Number = {{185OU}},
Unique-ID = {{ISI:000247721100024}},
}

@article{ ISI:000247900000020,
Author = {Kumar, Pawan and Schelle, Michael W. and Jain, Madhulika and Lin, Fiona
   L. and Petzold, Christopher J. and Leavell, Michael D. and Leary, Julie
   A. and Cox, Jeffery S. and Bertozzi, Carolyn R.},
Title = {{PapA1and PapA2 are acyltransferases essential for the biosynthesis of
   the Mycobacterium tuberculosis virulence factor Sulfolipid-1}},
Journal = {{PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA}},
Year = {{2007}},
Volume = {{104}},
Number = {{27}},
Pages = {{11221-11226}},
Month = {{JUL 3}},
Abstract = {{Mycobacterium tuberculosis produces numerous exotic lipids that have
   been implicated as virulence determinants. One such glycolipid,
   Sulfolipid-1 (SL-1), consists of a trehalose-2-sulfate (US) core
   acylated with four lipid moieties. A diacylated intermediate in SL-1
   biosynthesis, SL1278, has been shown to activate the adaptive immune
   response in human patients. Although several proteins involved in SL-1
   biosynthesis have been identified, the enzymes that acylate the T2S core
   to form SL1278 and SL-1, and the biosynthetic order of these acylation
   reactions, are unknown. Here we demonstrate that PapA2 and PapAl are
   responsible for the sequential acylation of T2S to form SL1278 and are
   essential for SL-1 biosynthesis. In vitro, recombinant PapA2 converts
   T2S to 2'-palmitoyl T2S, and PapAl further elaborates this newly
   identified SL-1 intermediate to an analog of SL1278. Disruption of papA2
   and papA1 in M. tuberculosis confirmed their essential role in SL-1
   biosynthesis and their order of action. Finally, the Delta papA2 and
   Delta papAl mutants were screened for virulence defects in a mouse model
   of infection. The loss of SL-1 (and SL1278) did not appear to affect
   bacterial replication or trafficking, suggesting that the functions of
   SL-1 are specific to human infection.}},
Publisher = {{NATL ACAD SCIENCES}},
Address = {{2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bertozzi, CR (Reprint Author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.
   Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.
   Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.
   Univ Calif San Francisco, Dept Microbiol \& Immunol, San Francisco, CA 94143 USA.
   Univ Calif Davis, Dept Chem, Genome Ctr, Davis, CA 95606 USA.
   Univ Calif Davis, Div Mol \& Cellular Biol, Genome Ctr, Davis, CA 95606 USA.}},
DOI = {{10.1073/pnas.0611649104}},
ISSN = {{0027-8424}},
Keywords = {{pathogenesis; biochemistry; glycolipid; sulfation}},
Keywords-Plus = {{SYMBIOTIC HOST-SPECIFICITY; CELL-WALL; RHIZOBIUM-MELILOTI; LIPID
   ANTIGENS; GENES ENCODE; STRAIN H37RV; CORD FACTOR; T-CELLS; BIOGENESIS;
   SULFATIDE}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Author-Email = {{crb@berkeley.edu}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI51622, AI51667, R01 AI051622, R01 AI051667]}},
Cited-References = {{Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420.
   Bhatt K, 2007, MICROBIOL-SGM, V153, P513, DOI 10.1099/mic.0.2006/003103-0.
   Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6.
   Briken V, 2004, MOL MICROBIOL, V53, P391, DOI 10.1111/j.1365-2958.2004.04183.x.
   BROZNA JP, 1991, INFECT IMMUN, V59, P2542.
   Buglino J, 2004, J BIOL CHEM, V279, P30634, DOI 10.1074/jbc.M404011200.
   Cole ST, 1998, NATURE, V393, P537.
   Converse SE, 2003, P NATL ACAD SCI USA, V100, P6121, DOI 10.1073/pnas.1030024100.
   De Libero G, 2005, NAT REV IMMUNOL, V5, P485, DOI 10.1038/nri1631.
   Deretic V, 2006, CELL MICROBIOL, V8, P719, DOI 10.1111/j.1462-5822.2006.00705.x.
   Domenech P, 2004, J BIOL CHEM, V279, P21257, DOI 10.1074/jbc.M400324200.
   DUBOS RJ, 1948, AM REV TUBERC PULM, V58, P698.
   FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0.
   GANGADHARAM P R, 1963, Tubercle, V44, P452, DOI 10.1016/S0041-3879(63)80087-2.
   Gilleron M, 2004, J EXP MED, V199, P649, DOI 10.1084/jem.20031097.
   Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6.
   GOREN MB, 1970, BIOCHIM BIOPHYS ACTA, V210, P116, DOI 10.1016/0005-2760(70)90067-6.
   GOREN MB, 1970, BIOCHIM BIOPHYS ACTA, V210, P127, DOI 10.1016/0005-2760(70)90068-8.
   GOREN MB, 1976, BIOCHEMISTRY-US, V15, P2728, DOI 10.1021/bi00658a003.
   GOREN MB, 1971, BIOCHEMISTRY-US, V10, P72, DOI 10.1021/bi00777a012.
   Jain M, 2005, PLOS PATHOG, V1, P12, DOI 10.1371/journal.ppat.0010002.
   Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x.
   LANGSTON S, 1994, HELV CHIM ACTA, V77, P2341, DOI 10.1002/hlca.19940770821.
   LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0.
   MIDDLEBROOK G, 1959, P NATL ACAD SCI USA, V45, P1801, DOI 10.1073/pnas.45.12.1801.
   Minnikin DE, 2002, CHEM BIOL, V9, P545, DOI 10.1016/S1074-5521(02)00142-4.
   Moody DB, 2005, NAT REV IMMUNOL, V5, P387, DOI 10.1038/nri1605.
   Mougous JD, 2004, NAT STRUCT MOL BIOL, V11, P721, DOI 10.1038/nsmb802.
   Mougous JD, 2002, P NATL ACAD SCI USA, V99, P17037, DOI 10.1073/pnas.252514899.
   Okamoto Y, 2006, MICROB PATHOGENESIS, V40, P245, DOI 10.1016/j.micpath.2006.02.002.
   Onwueme KC, 2004, P NATL ACAD SCI USA, V101, P4608, DOI 10.1073/pnas.0306928101.
   PABST MJ, 1988, J IMMUNOL, V140, P634.
   ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F.
   Rousseau C, 2003, INFECT IMMUN, V71, P4684, DOI 10.1128/IAI.71.8.4684-4690.2003.
   Ryll R, 2001, MICROBIOL IMMUNOL, V45, P801.
   Sankaranarayanan R, 2004, NAT STRUCT MOL BIOL, V11, P894, DOI 10.1038/nsmb809.
   Schelle MW, 2006, CHEMBIOCHEM, V7, P1516, DOI 10.1002/cbic.200600224.
   Shen YW, 2002, MOL MICROBIOL, V44, P37, DOI 10.1046/j.1365-2958.2002.02862.x.
   Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200.
   Takayama K, 2005, CLIN MICROBIOL REV, V18, P81, DOI 10.1128/CMR.18.1.81-101.2005.
   Trivedi OA, 2005, MOL CELL, V17, P631, DOI 10.1016/j.molcel.2005.02.009.
   WALLACE PA, 1994, J CHEM SOC CHEM COMM, P329, DOI 10.1039/c39940000329.
   WALLACE PA, 1994, CARBOHYD RES, V263, P43, DOI 10.1016/0008-6215(94)00164-2.
   Wang CC, 2002, ANGEW CHEM INT EDIT, V41, P2360, DOI 10.1002/1521-3773(20020703)41:13<2360::AID-ANIE2360>3.0.CO;2-R.
   ZHANG L, 1991, J IMMUNOL, V146, P2730.
   ZHANG L, 1988, INFECT IMMUN, V56, P2876.
   ZHANG WW, 1994, CANCER GENE THER, V1, P1.}},
Number-of-Cited-References = {{47}},
Times-Cited = {{52}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Proc. Natl. Acad. Sci. U. S. A.}},
Doc-Delivery-Number = {{188DT}},
Unique-ID = {{ISI:000247900000020}},
}

@article{ ISI:000248163800002,
Author = {Vree, Marleen and Huong, Nguyen T. and Duong, Bui D. and Sy, Dinh N. and
   Van, Le N. and Co, Nguyen V. and Cobelens, Frank G. J. and Borgdorff,
   Martien W.},
Title = {{Mortality and failure among tuberculosis patients who did not complete
   treatment in Vietnam: a cohort study}},
Journal = {{BMC PUBLIC HEALTH}},
Year = {{2007}},
Volume = {{7}},
Month = {{JUL 2}},
Abstract = {{Background: Tuberculosis treatment failure and death rates are low in
   the Western Pacific Region, including Vietnam. However, failure or death
   may also occur among patients who did not complete treatment, i.e.
   reported as default or transfer-out. We aimed to assess the proportion
   failures and deaths among new smear-positive pulmonary tuberculosis
   patients with reported default or transfer-out.
   Treatment outcomes rates were 1.4\% default, 3.0\% transfer-out, 0.4\%
   failure and 2.6\% death in northern Vietnam in 2003.
   Methods: Tuberculosis patients in 32 randomly selected district
   tuberculosis units in northern Vietnam were followed up 1 to 3 years
   after treatment initiation for survival, recent treatment history and
   bacteriologically confirmed tuberculosis.
   Results: Included were 85 transferred patients and 42 who defaulted. No
   information was available of 41 (32\%), 28 (22\%) had died. Fifty-eight
   were available for follow-up (46\%); all had sputum smear results.
   Tuberculosis was recorded in 11 (13\%), including 6 (7\%) with positive
   sputum smears, 3 (3\%) with negative smears but positive culture and 2
   (2\%) who had started retreatment for bacteriologically confirmed
   tuberculosis. Fifteen (17\%, 95\% CI 10-27\%) had died within 8 months
   after treatment initiation. Of 86 patients with known study outcomes, 39
   (45\%, 95\% CI 35-56\%) had died or had bacteriologically confirmed
   tuberculosis. This was recorded for 29/53 ( 55\%, 95\% CI 40-68\%)
   transferred patients and 10/33 ( 30\%, 95\% CI 16-49\%) patients who
   defaulted.
   Conclusion: The total failure and death rates are 0.6\% and 0.8\% higher
   than based on routine reporting in northern Vietnam. Although this was a
   large proportion of treatment failures and deaths, failure and death
   rates were low. Defaulting and transfer carry a high risk of failure and
   in particular death.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Vree, M (Reprint Author), KNCV TB Fdn, The Hague, Netherlands.
   KNCV TB Fdn, The Hague, Netherlands.
   Univ Amsterdam, Acad Med Ctr, CINIMA, NL-1105 AZ Amsterdam, Netherlands.
   Natl TB Programme Vietnam, Hanoi, Vietnam.
   Natl Hosp TB Resp Dis, Hanoi, Vietnam.}},
DOI = {{10.1186/1471-2458-7-134}},
Article-Number = {{134}},
ISSN = {{1471-2458}},
Keywords-Plus = {{CONTROL PROGRAM; REINFECTION; RELAPSE}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{vreem@kncvtbc.nl
   Nthuong139@gmail.com
   Bdduong06@gmail.com
   ngocsy@bvlaobp.org
   vienlao@bvlaobp.org
   vienlao@bvlaobp.org
   cobelensf@kncvtbc.nl
   borgdorffm@kncvtbc.nl}},
Cited-References = {{Burman WJ, 1997, CHEST, V111, P1168, DOI 10.1378/chest.111.5.1168.
   Chee CBE, 2000, INT J TUBERC LUNG D, V4, P496.
   Garcia-Garcia MD, 2002, EMERG INFECT DIS, V8, P1327.
   Huong NT, 2005, INT J TUBERC LUNG D, V9, P151.
   Jindani A, 2004, LANCET, V364, P1244, DOI 10.1016/S0140-6736(04)17141-9.
   Lambert ML, 2003, LANCET INFECT DIS, V3, P282, DOI 10.1016/S1473-3099(03)00607-8.
   {*}NAT TUB CONTR PRO, 2005, 2004 ANN DAT.
   Nguyen Tran Hien, 2004, AIDS Educ Prev, V16, P137.
   Quy HT, 2006, INT J TUBERC LUNG D, V10, P45.
   Raviglione M, 2001, INT J TUBERC LUNG D, V5, P213.
   Verver S, 2005, AM J RESP CRIT CARE, V171, P1430, DOI 10.1164/rccm.200409-1200OC.
   Vree M, 2007, INT J TUBERC LUNG D, V11, P392.
   {*}WHO, 2005, GLOBAL TUBERCULOSIS.
   World Health Organization, 2003, GUID SURV DRUG RES T.
   {*}WHO, 1998, CULTURE.
   {*}WHO, 1998, ORG MAN, P10.
   {*}WHO, 2006, GLOBAL TUBERCULOSIS.
   {*}WHO UNAIDS UNICEF, 2006, EPIDEMIOLOGICAL FACT.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{16}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{BMC Public Health}},
Doc-Delivery-Number = {{191WX}},
Unique-ID = {{ISI:000248163800002}},
}

@article{ ISI:000248415600014,
Author = {Nohrstrom, Elina and Kentala, Erna and Kuusela, Pentti and Mattila,
   Petri S.},
Title = {{Tuberculosis of the head and neck in Finland}},
Journal = {{ACTA OTO-LARYNGOLOGICA}},
Year = {{2007}},
Volume = {{127}},
Number = {{7}},
Pages = {{770-774}},
Month = {{JUL}},
Abstract = {{Conclusion: Tuberculosis is a rare disease that can mimic a neck
   malignancy. It should be taken into consideration when evaluating a
   patient with a neck mass, especially when the patient has come from an
   area of high endemic incidence. Another risk group comprises older
   people with dormant tuberculosis. Objectives: We wanted to find out the
   incidence of head and neck tuberculosis in Finland and to define the
   factors that should make one suspect it. Patients and methods: This was
   a retrospective analysis of patients who were diagnosed with
   tuberculosis in the Department of Otolaryngology, Helsinki University
   Central Hospital (population base c.a. 1000 000) during 1996-2005. All
   the patients with culture- or PCR-positive tuberculosis were included.
   Results: During 1996-2005, 63 patients were diagnosed with head and neck
   tuberculosis, the average incidence being 0.6/100 000 per year. The age
   of the patients varied between 3 and 94 years (mean 47 years). The mean
   age of patients who were of Finnish extraction (37 patients) was 62
   years and that of immigrants (26 patients) was 27 years. Forty-four
   (70\%) patients were female and 19 (30\%) male. The majority of patients
   presented with a neck mass without symptoms of general infection such as
   fever or fatigue.}},
Publisher = {{TAYLOR \& FRANCIS AS}},
Address = {{PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mattila, PS (Reprint Author), Univ Helsinki, Cent Hosp, Dept Otorhinolaryngol, Haartmaninkatu 4 E,POB 220, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Otorhinolaryngol, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Div Clin Microbiol, Helsinki, Finland.}},
DOI = {{10.1080/00016480601002021}},
ISSN = {{0001-6489}},
Keywords = {{tuberculosis; head and neck mass; risk factors}},
Keywords-Plus = {{MYCOBACTERIAL CERVICAL LYMPHADENITIS; EXTRAPULMONARY TUBERCULOSIS;
   DIAGNOSIS; MANAGEMENT}},
Research-Areas = {{Otorhinolaryngology}},
Web-of-Science-Categories  = {{Otorhinolaryngology}},
Author-Email = {{petri.mattila@hus.fi}},
Cited-References = {{Al-Serhani AM, 2001, LARYNGOSCOPE, V111, P2012, DOI 10.1097/00005537-200111000-00027.
   ALLEVA M, 1988, LARYNGOSCOPE, V98, P855.
   Ammari FF, 2003, OTOLARYNG HEAD NECK, V128, P576, DOI 10.1016/mhn.2003.129.
   Cagatay AA, 2004, SCAND J INFECT DIS, V36, P799, DOI 10.1080/00365540410025339.
   Cailhol J, 2005, J CLIN EPIDEMIOL, V58, P1066, DOI 10.1016/j.jclinepi.2005.02.023.
   DANDAPAT MC, 1990, BRIT J SURG, V77, P911, DOI 10.1002/bjs.1800770823.
   Ebdrup L, 2003, SCAND J INFECT DIS, V35, P244, DOI 10.1080/00365540310000274.
   Golden MP, 2005, AM FAM PHYSICIAN, V72, P1761.
   Haas DW, 2000, PRINCIPLES PRACTICE, P2576.
   Ibekwe AO, 1997, AM J OTOLARYNG, V18, P202, DOI 10.1016/S0196-0709(97)90083-1.
   Jha BC, 2001, POSTGRAD MED J, V77, P185, DOI 10.1136/pmj.77.905.185.
   Kanlikama M, 1997, WORLD J SURG, V21, P516.
   Konishi K, 1998, ACTA OTO-LARYNGOL, P244.
   LIVONEN J, 2005, B132005 KTL NAT PUBL.
   MANOLIDIS S, 1993, OTOLARYNG HEAD NECK, V109, P427.
   Memish ZA, 2000, CLIN MICROBIOL INFEC, V6, P137, DOI 10.1046/j.1469-0691.2000.00033.x.
   Nalini B, 2006, AM J OTOLARYNG, V27, P39, DOI 10.1016/j.amjoto.2005.07.005.
   Penfold CN, 1996, BRIT J ORAL MAX SURG, V34, P508, DOI 10.1016/S0266-4356(96)90246-6.
   Weiler Z, 2000, J ORAL MAXIL SURG, V58, P477, DOI 10.1016/S0278-2391(00)90004-1.
   World Health Organization, 2006, GLOB PLAN STOP TB 20.
   Yang ZH, 2004, CLIN INFECT DIS, V38, P199, DOI 10.1086/380644.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Acta Oto-Laryngol.}},
Doc-Delivery-Number = {{195MF}},
Unique-ID = {{ISI:000248415600014}},
}

@article{ ISI:000249434900011,
Author = {Cohen, Gary M.},
Title = {{Access to diagnostics in support of HIV/AIDS and tuberculosis treatment
   in developing countries}},
Journal = {{AIDS}},
Year = {{2007}},
Volume = {{21}},
Number = {{4}},
Pages = {{S81-S87}},
Month = {{JUL}},
Note = {{Meeting on Sustaining Treatment Costs - Who Will Pay, Washington, DC,
   NOV 27-29, 2006}},
Organization = {{WHO; UNAIDS; World Bank}},
Abstract = {{Access to necessary diagnostic tests in support of HIV/AIDS and
   tuberculosis treatment, such as CD4 cell counts, viral load,
   tuberculosis culture, and susceptibility testing, has significantly
   lagged the provision of drug therapy in developing countries. This is an
   outcome of the fundamental limitations in overall access to basic health
   services in the developing world, particularly in sub-Saharan Africa.
   Among health services, laboratory capacity and access are particularly
   deficient, and often non-existent in rural settings. As such, treatment
   is commonly administered in the absence of diagnostic testing,
   potentially accelerating the incidence of drug-related toxicity and the
   onset of drug resistance if therapy results in incomplete viral
   suppression. Factors constraining the expansion of necessary diagnostic
   testing include a severe shortage of qualified laboratory personnel,
   limited access to training for specific diagnostic tests, and a lack of
   national standards and systems for laboratory accreditation, proficiency
   testing, quality control and logistics. Additional factors include
   insufficient funding for improvements in laboratory services, limited
   availability of technical support, and the cost of diagnostic
   instrumentation and consumables. As a result, laboratory tests that are
   routine and expected in the industrialized world are often not performed
   in developing countries, despite the massive scale-up in treatment
   access for HIV/AIDS. This results in unintended consequences such as
   higher levels of mortality among patients who have not been properly
   diagnosed, additional costs for providing ART to patients who may not
   yet require drug therapy, and earlier onset of resistance to first-line
   therapies among patients predisposed to drug resistance. (c) 2007
   Lippincott Williams \& Wilkins.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Cohen, GM (Reprint Author), Dick \& Co, 1 Becton Dr, Franklin Lakes, NJ 07417 USA.
   Dick \& Co, Franklin Lakes, NJ 07417 USA.}},
DOI = {{10.1097/01.aids.0000279710.47298.5c}},
ISSN = {{0269-9370}},
Keywords = {{antiretroviral treatment; CD4 cell count; flow cytometer; good
   laboratory practices; polymerase chain reaction; susceptibility testing}},
Keywords-Plus = {{TOTAL LYMPHOCYTE COUNT; ANTIRETROVIRAL THERAPY; HIV-INFECTION; SETTINGS;
   AFRICA}},
Research-Areas = {{Immunology; Infectious Diseases; Virology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Virology}},
Author-Email = {{gary\_m\_cohen@bd.com}},
Cited-References = {{{*}AIDS ED TRAIN CTR, 2007, CLIN MAN MAN HIV INF.
   {*}AIDS INF, CD4 FACT SHEET.
   Bagchi S, 2007, CLIN INFECT DIS, V44, P135, DOI 10.1086/510072.
   BISHAI D, 2007, IN PRESS AIDS, V21.
   DEGENNARO V, 2006, CHILDREN LEFT OUT GL.
   Erikstrup C, 2007, JAIDS-J ACQ IMM DEF, V44, P478, DOI 10.1097/QAI.0b013e318032bbcd.
   {*}GLOB HLTH IN, 2006, FUND ACT STRENGTH HE, P15.
   Goldie SJ, 2006, NEW ENGL J MED, V355, P1141, DOI 10.1056/NEJMsa060247.
   Harries AD, 2006, ANN TROP MED PARASIT, V100, P415, DOI 10.1179/136485906X91477.
   JANSSEN RS, 2007, HIV TESTING, V15, P6.
   {*}JOINT UN PROGR HI, 2006, DEC 06 AIDS EP UPD.
   Marks G, 2006, AIDS, V20, P1447, DOI 10.1097/01.aids.0000233579.79714.8d.
   MUGYENYI P, 2007, DIAGNOSTIC TESTING H.
   Murray JF, 1998, RESPIRATION, V65, P335, DOI 10.1159/000029291.
   {*}OARAC, 2006, GUID US ANT AG HIV 1.
   Petti CA, 2006, CLIN INFECT DIS, V42, P377, DOI 10.1086/499363.
   RAVIGLIONE MC, 1992, B WORLD HEALTH ORGAN, V70, P515.
   REVENGA A, 2006, EC EFFECTIVE AIDS EV.
   Schreibman T, 2004, CLIN INFECT DIS, V38, P257, DOI 10.1086/380792.
   Swan J, 2007, PEDIATRICS, V119, P838, DOI 10.1542/peds.2007-0273.
   TEMIVE EO, 2006, N NATL MED ASS, V98, P1252.
   van der Ryst E, 1998, J ACQ IMMUN DEF SYND, V19, P238.
   {*}WHO, 2006, 41 WHO, V81, P385.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.
   {*}WHO, 2006, WHOS CONTR UN ACC HI.
   {*}WHO, 2004, SCAL ANT THER RES LI.
   World Health Organization, 2006, DIAGN TUB GLOB DEM M.
   World Health Organization, 2006, GLOB PLAN STOP TB 20.
   {*}WHO, FREQU ASK QUEST XDR.
   {*}WHO, 2006, 104 WHO.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{33}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Aids}},
Doc-Delivery-Number = {{210CS}},
Unique-ID = {{ISI:000249434900011}},
}

@article{ ISI:000248020200012,
Author = {Ghosh, Anirban and Saha, Somnath and Bhattacharya, Basudeb and
   Chattopadhay, Sarbani},
Title = {{Primary tuberculosis of thyroid gland: a rare case report}},
Journal = {{AMERICAN JOURNAL OF OTOLARYNGOLOGY}},
Year = {{2007}},
Volume = {{28}},
Number = {{4}},
Pages = {{267-270}},
Month = {{JUL-AUG}},
Abstract = {{Tuberculosis of the thyroid gland is a rare entity, and primary
   tuberculosis of thyroid is even uncommon. At one time, it was believed
   that thyroid gland is relatively immune to tuberculosis. There are about
   200 cases of thyroid tuberculosis that had been reported in world
   literature. These include 156 cases reviewed by Goldfarb et al (Am J Med
   1965;38:825) and I each by Crompton et a] (Tubercle 1969;50:61-64),
   Johnson et at (Br J Surg 1973;60:668-669), Emry (J Laryngol Otol
   1980;94:553-558), and Kukreja and Sharma ML (Ind J Surg
   1982;44:190-192), and a histologic diagnosis by Das et al (Acta Cytol
   1992;36:517-522) and Mondal and Patra (J Laryngol Otol 1995;109:36-38).
   Almost all cases had primary foci elsewhere in the body. Isolated
   tuberculosis of the thyroid gland is extremely rare, with few reported
   cases; when it does occur, it may prove difficult to diagnose (J
   Laryngol Otol 1980;94:553-558). Among the different manifestations of
   tuberculous thyroiditis, abscess of the thyroid appears to be the rarest
   and the most dangerous (Tubercle 1969;50:61-64). Sachs et al (Am J Med
   1988;85:573-575) reported 4 cases of tuberculous thyroiditis that were
   diagnosed preoperatively, the rest of the cases were diagnosed either
   from surgical specimen or from autopsy. A case of primary tuberculosis
   of thyroid gland presenting as abscess and diagnosed preoperatively is
   reported here. (c) 2007 Published by Elsevier Inc.}},
Publisher = {{W B SAUNDERS CO-ELSEVIER INC}},
Address = {{1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Saha, S (Reprint Author), Sundaram Apartments,Barat,Lake Town, Kolkata 700089, W Bengal, India.
   Coll Med, Dept ENT, Kolkata, W Bengal, India.
   Dr BC Roy PG Inst Basic Med Sci, Dept Biochem \& Mol Biol, Kolkata, W Bengal, India.
   Coll Med, Dept Pathol, Kolkata, W Bengal, India.}},
DOI = {{10.1016/j.amjoto.2006.09.005}},
ISSN = {{0196-0709}},
EISSN = {{1532-818X}},
Keywords-Plus = {{NEEDLE ASPIRATION CYTOLOGY; POLYMERASE-CHAIN-REACTION; SUBACUTE
   THYROIDITIS; DIFFERENTIATION; DIAGNOSIS}},
Research-Areas = {{Otorhinolaryngology}},
Web-of-Science-Categories  = {{Otorhinolaryngology}},
Author-Email = {{sreekar\_saha@hotmail.com}},
Cited-References = {{Bhattacharya B, 2003, TROP MED INT HEALTH, V8, P150, DOI 10.1046/j.1365-3156.2003.01007.x.
   BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77.
   Crompton G K, 1969, Tubercle, V50, P61, DOI 10.1016/0041-3879(69)90008-7.
   DAS DK, 1992, ACTA CYTOL, V36, P517.
   GOLDFARB MD, 1965, AM J MED, V38, P825.
   GREENE JN, 1971, AM J MED, V51, P97, DOI 10.1016/0002-9343(71)90327-5.
   Herrera EA, 1996, J APPL BACTERIOL, V80, P596, DOI 10.1111/j.1365-2672.1996.tb03263.x.
   JOHNSON AG, 1973, BRIT J SURG, V60, P668, DOI 10.1002/bjs.1800600825.
   KARLISH AJ, 1970, LANCET, V2, P330.
   KUKREJA HK, 1982, INDIAN J SURG, V44, P190.
   LIOTE HA, 1987, TUBERCLE, V68, P229, DOI 10.1016/0041-3879(87)90060-2.
   MONDAL A, 1995, J LARYNGOL OTOL, V109, P36.
   Rankin FW, 1932, ANN SURG, V96, P625, DOI 10.1097/00000658-193210000-00013.
   SACHS MK, 1988, AM J MED, V85, P573.
   SYMMERS WST, 2006, SYSTEMIC PATHOLOGY, V4.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{18}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Am. J. Otolaryngol.}},
Doc-Delivery-Number = {{189WV}},
Unique-ID = {{ISI:000248020200012}},
}

@article{ ISI:000247672600002,
Author = {Schneider, Diana L. and Lobato, Mark N.},
Title = {{Tuberculosis control among people in US immigration and customs
   enforcement custody}},
Journal = {{AMERICAN JOURNAL OF PREVENTIVE MEDICINE}},
Year = {{2007}},
Volume = {{33}},
Number = {{1}},
Pages = {{9-14}},
Month = {{JUL}},
Abstract = {{Background: People detained by United States Immigration and Customs
   Enforcement (ICE) are a high-risk population for tuberculosis (TB).
   Detainees are screened for TB upon intake, and TB patients are reported
   to the Division of Immigration Health Services (DIHS).
   Methods: TB case reports were reviewed for ICE detainees reported to
   DIHS during 2004-2005. Case counts and frequency distributions are
   presented. Case counts are stratified by demographic characteristics,
   release status, laboratory and clinical findings, HIV/AIDS status, and
   drug resistance. Case rates were calculated for patients housed at
   facilities with DINS staffing. Duration of treatment and of ICE custody
   is provided. Analyses were conducted in 2006.
   Results: During 2004 and 2005, 76 and 142 TB patients were reported,
   respectively. The TB case rate was 82.6/100,000 in 2004 and
   121.5/100,000 in 2005. The culture-confirmed case rate of 55.8/100,000
   in 2005 was 2.5 times higher than the case rate in the U.S. foreign-born
   population. Of 218 patients, 127 (58.3\%) had Mycobacterium
   tuberculosis-positive sputum cultures, 70 (32.1\%) had acid-fast
   bacilli-positive sputum smears, and 36 (16.5\%) were symptomatic at
   diagnosis. Patients from Mexico, Honduras, Guatemala, and El Salvador
   accounted for 184 cases (84.4\%) and 184 patients (84.4\%) were
   repatriated. TB patients spent an average 82.6 days in treatment before
   release or repatriation.
   Conclusions: Screening at intake to ICE custody has helped DIHS staff in
   diagnosing TB and starting patients on treatment, but patients are
   usually deported before completing therapy. Because of deportation, and
   sometimes re-entry into the United States, unique collaborations are
   required to support completion of treatment.}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Schneider, DL (Reprint Author), US PHS, Div Immigrat Hlth Serv, 1220 L St NW,Suite 500, Washington, DC 20005 USA.
   US PHS, Div Immigrat Hlth Serv, Washington, DC 20005 USA.
   Ctr Dis Control \& Prevent, Div TB Eliminat, Atlanta, GA USA.}},
DOI = {{10.1016/j.amepre.2007.02.044}},
ISSN = {{0749-3797}},
Keywords-Plus = {{HEALTH}},
Research-Areas = {{Public, Environmental \& Occupational Health; General \& Internal
   Medicine}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Medicine, General \&
   Internal}},
Author-Email = {{Diana.Schneider@dhs.gov}},
Cited-References = {{AMERICAN THORACIC SOCIETY, 2000, AM J RESP CRIT CARE, V161, P1376, DOI {[}DOI 10.1164/AJRCCM.161.4.16141, 10.1164/ajrccm.161.4.16141].
   Asch S, 1998, AM J RESP CRIT CARE, V157, P1244.
   Recommendations to prevent and control iron deficiency in the United States, 1998, MMWR-MORBID MORTAL W, V47, P1.
   {*}CDCP, 2001, MORBIDITY MORTALITY, V50, P15.
   {*}CDCP, 2005, GLOB MIGR QUAR MED E.
   Centers for Disease Control and Prevention, 2003, MMWR-MORBID MORTAL W, V52, P438.
   Centers For Disease Control and Prevention, 2006, REP TUB US 2005.
   Goldberg SV, 2004, INT J TUBERC LUNG D, V8, P76.
   MacNeil JR, 2005, AM J PUBLIC HEALTH, V95, P1800, DOI 10.2105/AJPH.2004.055442.
   Moua M, 2002, J LAW MED ETHICS, V30, P189.
   Puisis M, 1996, PUBLIC HEALTH REP, V111, P330.
   Saunders DL, 2001, PUBLIC HEALTH REP, V116, P210.
   Schneider E, 2004, REV PANAM SALUD PUBL, V16, P23, DOI 10.1590/S1020-49892004000700004.
   Schwartzman K, 2005, NEW ENGL J MED, V353, P1008, DOI 10.1056/NEJMsa043194.
   {*}US DEP HOM SEC, 2006, PARTN DET OP MAN.
   {*}US DEP HOM SEC, 2006, ANN REP IMM ENF ACT.
   {*}US IMM CUST ENF, ICE FISC YEAR 2006.
   {*}US IMM CUST ENF, 2006, FACT SHEET ICE IMM E.
   {*}US IMM CUST ENF, 2007, PUBL INF.
   {*}WHO, 2006, WHO GLOB TB CONTR RE.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{11}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Am. J. Prev. Med.}},
Doc-Delivery-Number = {{184WF}},
Unique-ID = {{ISI:000247672600002}},
}

@article{ ISI:000247109900024,
Author = {Nayak, S. and Satish, R.},
Title = {{Genitourinary tuberculosis after renal transplantation - A report of
   three cases with a good clinical outcome}},
Journal = {{AMERICAN JOURNAL OF TRANSPLANTATION}},
Year = {{2007}},
Volume = {{7}},
Number = {{7}},
Pages = {{1862-1864}},
Month = {{JUL}},
Abstract = {{Tuberculosis (TB) continues to be a major opportunistic infection after
   renal transplantation especially in the tropical countries. The risk of
   TB in renal transplant recipients is reported to be 20-74 times higher
   than that in the general population. Genitourinary TB that occurs after
   renal transplantation in uncommon and appears to present differently
   than genitourinary TB in the non-transplant population. An increased
   risk of graft rejection and graft loss has been reported. We report
   three cases of genitourinary TB in renal transplant recipients, all of
   whom had a good clinical outcome and a review of published literature.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Nayak, S (Reprint Author), St Johns Med Coll Hosp, Sarjapur Rd, Bangalore 560034, Karnataka, India.
   St Johns Med Coll Hosp, Bangalore 560034, Karnataka, India.}},
DOI = {{10.1111/j.1600-6143.2007.01853.x}},
ISSN = {{1600-6135}},
Keywords = {{antituberculosis therapy; genitourinary tuberculosis; immunosuppression;
   renal transplant}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; RECIPIENTS; INFECTIONS}},
Research-Areas = {{Surgery; Transplantation}},
Web-of-Science-Categories  = {{Surgery; Transplantation}},
Author-Email = {{nayak\_shobhana@rediffmail.com}},
Cited-References = {{Aguado JM, 1997, TRANSPLANTATION, V63, P1278, DOI 10.1097/00007890-199705150-00015.
   Dowdy L, 2001, CLIN INFECT DIS, V32, P662, DOI 10.1086/318723.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   ERGON I, 2006, TRANSPL P, V38, P1344.
   John George T, 2002, Semin Respir Infect, V17, P274, DOI 10.1053/srin.2002.36445.
   KENNEDY DH, 1989, BIOL MYCOBACTERIA, V3, P245.
   LAKSHMINARYAN S, 1973, Tubercle, V54, P72, DOI 10.1016/0041-3879(73)90017-2.
   Lattes R, 1999, Transpl Infect Dis, V1, P98, DOI 10.1034/j.1399-3062.1999.010203.x.
   LICHTENSTEIN IH, 1983, REV INFECT DIS, V5, P216.
   LLOVERAS J, 1982, ARCH INTERN MED, V142, P888, DOI 10.1001/archinte.142.5.888.
   Mehta S, 2004, OCUL IMMUNOL INFLAMM, V12, P311, DOI 10.1080/092739490500354.
   MOURAD G, 1985, NEPHRON, V41, P82, DOI 10.1159/000183552.
   Munoz P, 2005, CLIN INFECT DIS, V40, P581, DOI 10.1086/427692.
   MUNOZ P, 1995, CLIN INFECT DIS, V21, P398.
   Sakhuja V, 1996, TRANSPLANTATION, V61, P211, DOI 10.1097/00007890-199601270-00008.
   SIMON HB, 1977, AM J MED, V63, P410, DOI 10.1016/0002-9343(77)90279-0.
   Singh N, 1998, CLIN INFECT DIS, V27, P1266, DOI 10.1086/514993.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Am. J. Transplant.}},
Doc-Delivery-Number = {{176UH}},
Unique-ID = {{ISI:000247109900024}},
}

@article{ ISI:000249559600017,
Author = {Nair, R. and Prabhash, K. and Sengar, M. and Bakshi, A. and Gujral, S.
   and Gupta, S. and Parikh, P.},
Title = {{The effect of short-term intensive chemotherapy on reactivation of
   tuberculosis}},
Journal = {{ANNALS OF ONCOLOGY}},
Year = {{2007}},
Volume = {{18}},
Number = {{7}},
Pages = {{1243-1245}},
Month = {{JUL}},
Note = {{31st Congress of the European-Society-for-Medical-Oncology, Istanbul,
   TURKEY, SEP 29-OCT 03, 2006}},
Organization = {{European Soc Med Oncol}},
Abstract = {{Background: Various malignancies and cytotoxic chemotherapy have been
   proposed to increase the risk of reactivation of tuberculosis. Available
   literature to support this observation is still conflicting. There is
   scarcity of data from countries with rampant tubercular infection, such
   as India, in this regard.
   Design and methods: In the present retrospective analysis, patients with
   high-grade non-Hodgkin's lymphoma with past history of tuberculosis and
   have had adequate antitubercular therapy were identified from a Lymphoma
   Group study. These patients were followed up during cytotoxic
   chemotherapy and later to assess the risk of reactivation.
   Results: A cohort of eight patients with past history of tuberculosis
   was selected from 141 patients of high-grade non-Hodgkin's lymphoma. The
   median age was 33.5 years (range, 24-53 years). Median duration between
   completion of antitubercular treatment and diagnosis of lymphoma was 5
   years (range, 1.5-10 years). All patients received cyclical cytotoxic
   chemotherapy. The median duration of follow up after completion of
   chemotherapy was 5 years (range, 10 months to 5 years). None of these
   patients developed reactivation of tuberculosis.
   Conclusion: Cyclical chemotherapy for non-Hodgkin's lymphoma does not
   lead to reactivation of tuberculosis.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Parikh, P (Reprint Author), Tata Mem Hosp, Dept Med Oncol, Bombay 400012, Maharashtra, India.
   Tata Mem Hosp, Dept Med Oncol, Bombay 400012, Maharashtra, India.
   Tata Mem Hosp, Dept Pathol, Bombay 400012, Maharashtra, India.}},
DOI = {{10.1093/annonc/mdm107}},
ISSN = {{0923-7534}},
Keywords = {{cyclical chemotherapy; cytotoxic chemotherapy; lymphoma treatment;
   non-Hodgkin's lymphoma; reactivation; tuberculosis}},
Keywords-Plus = {{PREVALENCE; MORTALITY; DISEASE; CANCER; INDIA}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{medicaloncology@tatahospital.org}},
Cited-References = {{CLIFFTON EE, 1970, NEW YORK STATE J MED, V70, P274.
   DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213.
   Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   FELD R, 1976, ARCH INTERN MED, V136, P67, DOI 10.1001/archinte.136.1.67.
   George B, 2001, BONE MARROW TRANSPL, V27, P973, DOI 10.1038/sj.bmt.1702993.
   GOPAL R, 2001, P AN M AM SOC CLIN, P20.
   Harakati S.E, 2001, KUWAIT MED J, V33, P325.
   Kamboj M, 2006, CLIN INFECT DIS, V42, P1592, DOI 10.1086/503917.
   KAPLAN MH, 1974, CANCER-AM CANCER SOC, V33, P850, DOI 10.1002/1097-0142(197403)33:3<850::AID-CNCR2820330334>3.0.CO;2-H.
   KARACHUNSKII MA, 2002, PROBL TUBERK, V12, P24.
   Kim DK, 2005, CHEST, V128, P2218, DOI 10.1378/chest.128.4.2218.
   Radhakrishna S, 2001, INT J TUBERC LUNG D, V5, P142.
   Verver S, 2005, AM J RESP CRIT CARE, V171, P1430, DOI 10.1164/rccm.200409-1200OC.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Oncol.}},
Doc-Delivery-Number = {{211YG}},
Unique-ID = {{ISI:000249559600017}},
}

@article{ ISI:000249469400012,
Author = {Alothman, Adel and Al Qahtani, Mohammed and Al-Khenaizan, Sultan},
Title = {{Erythema induratum: What is the role of Mycobacterium tuberculosis?}},
Journal = {{ANNALS OF SAUDI MEDICINE}},
Year = {{2007}},
Volume = {{27}},
Number = {{4}},
Pages = {{298-300}},
Month = {{JUL-AUG}},
Publisher = {{K FAISAL SPEC HOSP RES CENTRE}},
Address = {{PUBLICATIONS OFFICE PO BOX 3354, RIYADH 11211, SAUDI ARABIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Alothman, A (Reprint Author), King Abdulaziz Med City 1443, POB 22490, Riyadh 11426, Saudi Arabia.
   King Abdulaziz Med City 1443, Riyadh 11426, Saudi Arabia.
   King Abdul Aziz Med City, Dept Med, Riyadh, Saudi Arabia.}},
ISSN = {{0256-4947}},
Keywords-Plus = {{CUTANEOUS TUBERCULOSIS; BAZIN; DISEASE; VASCULITIS; PATIENT; DNA}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{alothman84@hotmail.com}},
Cited-References = {{ANDERSON SCL, 1970, ACTA DERM-VENER    S, V50, P65.
   AUDRY C, 1898, ANN DERMATOL SYPHIL, V29, P209.
   Baselga E, 1997, ARCH DERMATOL, V133, P457, DOI 10.1001/archderm.133.4.457.
   Bazin E, 1861, LECONS THEORIQUES CL, P146.
   Chang MW, 1999, PEDIATRICS, V103, P498, DOI 10.1542/peds.103.2.498.
   Cho K H, 1995, J Dermatol, V22, P143.
   DEGITZ K, 1993, LANCET, V341, P239, DOI 10.1016/0140-6736(93)90101-L.
   DESILVA HJ, 1988, POSTGRAD MED J, V64, P242.
   DISTLER O, 2000, J RHEUMATOL, V27, P307.
   FEIWEL M, 1965, BRIT MED J, V1, P1109.
   FERNANDEZ M, 1994, J AM ACAD DERMATOL, V31, P288.
   Heinemann C, 2003, J EUR ACAD DERMATOL, V17, P334, DOI 10.1046/j.1468-3083.2003.00689.x.
   JACINTO S, 2003, INT J DERMATOL, V421, P380.
   JORDAAN H, 2001, PEDIA DERMATOL, V17, P183.
   Koga T, 2001, EUR J DERMATOL, V11, P48.
   Lee YS, 2001, INT J DERMATOL, V40, P193, DOI 10.1046/j.1365-4362.2001.01138-2.x.
   MONTGOMERY H, 1945, JAMA-J AM MED ASSOC, V128, P335.
   OLLERT MW, 1993, ARCH DERMATOL, V129, P469, DOI 10.1001/archderm.129.4.469.
   PASIECZNY T, 1954, AMA ARCH DERM SYPH, V70, P514.
   RADEMAKER M, 1989, J AM ACAD DERMATOL, V21, P740, DOI 10.1016/S0190-9622(89)70248-6.
   Shafran SD, 2000, INFECT DIS CLIN PRAC, V9, P33, DOI 10.1097/00019048-200009010-00009.
   Shimizu A, 2003, DERMATOLOGY, V207, P426, DOI 10.1159/000074135.
   Tan SH, 1999, INT J DERMATOL, V38, P122, DOI 10.1046/j.1365-4362.1999.00576.x.
   Whitfield A, 1901, AM J MED SCI, V122, P828, DOI 10.1097/00000441-190112000-00016.
   YAGI M, 1994, ORLJ, V36, P291.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Ann. Saudi Med.}},
Doc-Delivery-Number = {{210PZ}},
Unique-ID = {{ISI:000249469400012}},
}

@article{ ISI:000253101100459,
Author = {Ling, P. L. and Klein, E. C. and Flynn, J. L.},
Title = {{Neutralization of TNIF in a non-human primate model of latent
   tuberculosis causes reactivation tuberculosis with extrapulmonary
   disease}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{144-145}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Ling, P. L., Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA USA.
   Klein, E. C., Univ Pittsburgh, Sch Med, Div Lab Anim Res, Pittsburgh, PA 15260 USA.
   Flynn, J. L., Univ Pittsburgh, Sch Med, Dept Mol Genet \& Biochem, Pittsburgh, PA 15260 USA.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101100459}},
}

@article{ ISI:000253101100474,
Author = {Plessner, H. and Ling, P. L. and Kohno, T. and Flynn, J.},
Title = {{Anti-TNF neutralizing agents differ in their ability to exacerbate
   chronic tuberculosis in a murine model}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{149}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Plessner, H.; Flynn, J., Univ Pittsburgh, Sch Med, Dept Mol Genet \& Biochem, Pittsburgh, PA 15260 USA.
   Ling, P. L., Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA.
   Kohno, T., Amgen Inc, Protein Sci, Thousand Oaks, CA USA.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101100474}},
}

@article{ ISI:000253101100517,
Author = {Birlik, M. and Akar, S. and Capar, S. and Ozmen, M. and Sari, I. and
   Can, G. and Onen, F. and Akkoc, N.},
Title = {{Effectiveness of national consensus recommendations in preventing
   reactivation of latent tuberculosis in patients treated with TNF
   inhibitors}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{161-162}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Capar, S., Dokuz Eylul Univ, Izmir, Turkey.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
ResearcherID-Numbers = {{Akar, Servet/G-2339-2012
   Sari, Ismail/E-1778-2011
   Capar, Sedat/H-9418-2014}},
ORCID-Numbers = {{Sari, Ismail/0000-0001-7737-4180
   Capar, Sedat/0000-0003-4741-4908}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101100517}},
}

@article{ ISI:000253101100520,
Author = {Askling, J. and ARTIS Study Grp},
Title = {{Increased long-term risk for tuberculosis following treatment with
   TNF-antagonists. The swedish experience 1999-2006}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{162-163}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Askling, J.; ARTIS Study Grp, Karolinska Univ Hosp, Stockholm, Sweden.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101100520}},
}

@article{ ISI:000253101100522,
Author = {Beevor, C. P. and Scrivener, S. and Fletcher, M. and Hull, R. and
   Thomas, A. and McCrae, F. and Thomas, L. and Shaban, M. and Min, S.
   Young and Ledingham, J.},
Title = {{Implementation of the tuberculosis screening tool as routine practice
   for nurses undertaking screening prior to anti-tumour necrosis factor
   (TNF) alpha treatment}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{163}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Beevor, C. P.; Fletcher, M.; Hull, R.; Thomas, A.; McCrae, F.; Thomas, L.; Shaban, M.; Min, S. Young; Ledingham, J., Dept Rheumatol, Portsmouth, Hants, England.
   Scrivener, S., Portsmouth Hosp NHS Trust, Resp Dept, Portsmouth, Hants, England.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Cited-References = {{Ormerod LP, 2005, THORAX, V60, P800, DOI 10.1136/thx.2005.046797.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101100522}},
}

@article{ ISI:000253101100532,
Author = {Dabbous, O. and Gilmer, K. and Tatsuki, Y. and Shane, P. and Togo, M.
   and Nogami, Y. and Tang, B. and Thompson, H. and Rahman, M.},
Title = {{Tuberculosis in Japanese patients with hheumatoid arthritis treated with
   infliximab: Findings from the post marketing surveillance trial}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{167}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Dabbous, O.; Tang, B.; Thompson, H.; Rahman, M., Centocor Inc, Horsham, Vic, Australia.
   Gilmer, K.; Shane, P., Centocor Inc, Malvern, PA USA.
   Tatsuki, Y.; Togo, M.; Nogami, Y., Tanabe Seiyaku Co Ltd, Osaka, Japan.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101100532}},
}

@article{ ISI:000253101100536,
Author = {Dinser, R. and Fousse, M. and Sester, U. and Albrecht, K. and Koehler,
   H. and Mueller-Ladner, U. and Sester, M.},
Title = {{Comparison of a flow-cytometric interferon gamma release assay with
   conventional screening for the diagnosis of latent tuberculosis
   infection of patients with inflammatory arthropathies evaluated for
   treatment with tumour necrosis factor-alpha blocking DR}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{168}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Dinser, R.; Albrecht, K.; Mueller-Ladner, U., Kerckhoff Clin, Bad Nauheim, Germany.
   Fousse, M.; Sester, U.; Koehler, H.; Sester, M., Univ Hosp Saarland, Homburg, Germany.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101100536}},
}

@article{ ISI:000253101100538,
Author = {Dudler, J. and Revaz, S. and Zellweger, J.},
Title = {{A prospective evaluation of interferon gamma release assays for
   tuberculosis infection screening before anti-TNF therapy}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{168-169}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Dudler, J.; Revaz, S., CHU Vaudois, CH-1011 Lausanne, Switzerland.
   Zellweger, J., Univ Med Policlin, Lausanne, Switzerland.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101100538}},
}

@article{ ISI:000253101100559,
Author = {Kalyoncu, U. and Cobanoglu, N. and Akdogan, A. and Karadag, O. and
   Kisacik, B. and Maras, Y. and Tufan, A. and Bilgen, S. Apras and
   Calguneri, M. and Ozcelik, U. and Kiraz, S. and Ertenli, I.},
Title = {{Using an interferon gamma assay for the diagnosis of tuberculosis
   infection before using tumor necrosis factor alpha blockers}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{175}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Kalyoncu, U.; Akdogan, A.; Karadag, O.; Kisacik, B.; Maras, Y.; Tufan, A.; Bilgen, S. Apras; Calguneri, M.; Kiraz, S.; Ertenli, I., Div Rheumatol, Ankara, Turkey.
   Cobanoglu, N.; Ozcelik, U., Univ Hacettepe, Pediat Pulm Dis Unit, TR-06100 Ankara, Turkey.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
ResearcherID-Numbers = {{Karadag, Omer/I-9042-2013
   TUFAN, ABDURRAHMAN/A-7613-2016}},
ORCID-Numbers = {{Karadag, Omer/0000-0002-3443-3117
   TUFAN, ABDURRAHMAN/0000-0001-6244-9362}},
Number-of-Cited-References = {{0}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101100559}},
}

@article{ ISI:000253101100596,
Author = {Sellam, J. and Hamdi, H. and Roy, C. and Puechal, X. and Breban, M. and
   Berenbaum, F. and Salmon, D. and Ravaud, P. and Emilie, D. and Mariette,
   X. and RATIO},
Title = {{Comparison of in vitro-specific blood tests with tuberculin skin test
   for diagnosis of latent tuberculosis before anti-TNF therapy}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{187}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Sellam, J.; Mariette, X., Hop Bicetre, Le Kremlin Bicetre, France.
   Hamdi, H.; Emilie, D., Hop Antoine Beclere, INSERM, UMR S764, Clamart, France.
   Roy, C.; Ravaud, P., Hop Xavier Bichat, INSERM, Rech Clin, U 738, Paris, France.
   Puechal, X., Le Mans Hosp, Le Mans, France.
   Breban, M., Hop Ambroise Pare, Boulogne, France.
   Salmon, D., Cochin Hosp, Paris, France.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101100596}},
}

@article{ ISI:000253101100615,
Author = {Vassilopoulos, D. and Stamoulis, N. and Hadziyannis, E. and
   Archimandritis, A. I.},
Title = {{Utility of an interferon-gamma elispot assay for mycubacterium
   tuberculosis (MTB) infection screening in rheumatic patients treated
   with anti-TNF agents}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{194}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Vassilopoulos, D.; Stamoulis, N.; Hadziyannis, E.; Archimandritis, A. I., Univ Athens, Hippokratio Gen Hosp, Sch Med, Dept Internal Med, Athens, Greece.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Cited-References = {{Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101100615}},
}

@article{ ISI:000253101100616,
Author = {Vencovsky, J. and Havelkova, M. and Forejtova, S. and Jarosova, K. and
   Putova, I.},
Title = {{Performance of quantiferon-TB gold test in screening for latent
   tuberculosis before and during anti-TNF treatment}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{194}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Vencovsky, J.; Putova, I., Inst Rheumatol, Res Dept, Prague, Czech Republic.
   Natl Inst Publ Hlth, Natl Reference Lab Mycobacteria, Mycobacteria Unit, Prague, Czech Republic.
   Forejtova, S.; Jarosova, K., Inst Rheumatol, Clin Dept, Prague, Czech Republic.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
ResearcherID-Numbers = {{Vencovsky, Jiri/G-6094-2017}},
ORCID-Numbers = {{Vencovsky, Jiri/0000-0002-0851-0713}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101100616}},
}

@article{ ISI:000253101100618,
Author = {Wajdula, J. and MacPeek, D. and Lin, S. and Hamza, S. and Fatenejad, S.},
Title = {{Incidence of tuberculosis is low in patients receiving etanercept
   therapy for the treatment of rheumatoid arthritis: Results from a
   combined analysis of us and ex-us double-blind trials and their open
   label extensions}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{195}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Wajdula, J.; MacPeek, D.; Fatenejad, S., Wyeth Res, Clin Res \& Dev, Collegeville, PA USA.
   Lin, S.; Hamza, S., Amgen Inc, Thousand Oaks, CA USA.}},
ISSN = {{0003-4967}},
Keywords-Plus = {{DISEASES}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Cited-References = {{Furst DE, 2006, ANN RHEUM DIS, V65, P2, DOI 10.1136/ard.2006.061937.
   Roach DR, 2002, J IMMUNOL, V168, P4620.
   Wallis RS, 2004, CLIN INFECT DIS, V38, P1261, DOI 10.1086/383317.
   Winthrop KL, 2005, ARTHRITIS RHEUM, V52, P2968, DOI 10.1002/art.21382.}},
Number-of-Cited-References = {{4}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101100618}},
}

@article{ ISI:000253101101401,
Author = {Carballido, C. Fernandez and Casano, V. Jovani and Diaz, I. Ibero and
   Valls, V. and Aviles, J. Colominas},
Title = {{Safety of latent tuberculosis treatment for patients treated with dmards}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{351}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Carballido, C. Fernandez; Casano, V. Jovani; Diaz, I. Ibero, Gen Hosp, Rheumatol Unit, Elda, Spain.
   Aviles, J. Colominas, Gen Hosp, Elda, Spain.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101101401}},
}

@article{ ISI:000253101101405,
Author = {Gogus, F. and Hizel, K. and Karakus, R. and Gunendi, Z. and Erdogan, Z.
   and Atalay, F. and Aybay, C.},
Title = {{Comparison of tuberculin skin test and antibody response to 38KDA, 16KDA
   proteins and lipoarabinomannan of mycobacterium tuberculosis in patients
   with rheumatoid arthritis}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{352}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Gogus, F.; Gunendi, Z.; Erdogan, Z.; Atalay, F., Gazi Univ, Div Rheumatol, Ankara, Turkey.
   Hizel, K., Gazi Univ, Div Infect Dis \& Clin Microbiol, Ankara, Turkey.
   Karakus, R.; Aybay, C., Gazi Univ, Div Immunol, Ankara, Turkey.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Cited-References = {{Eleftheriadis T, 2005, AM J KIDNEY DIS, V46, P706, DOI 10.1053/j.ajkd.2005.06.021.
   MARKUSSE HM, 1989, ANN RHEUM DIS, V48, P175, DOI 10.1136/ard.48.2.175-b.}},
Number-of-Cited-References = {{2}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101101405}},
}

@article{ ISI:000253101102244,
Author = {Barek, R. Ben M. and Sehli, H. and Cheour, E. and Mrabet, D. and
   Elleuch, M. and Meddeb, N. and Sellami, S.},
Title = {{Osteoarticular tuberculosis}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{535}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Barek, R. Ben M.; Sehli, H.; Cheour, E.; Mrabet, D.; Elleuch, M.; Meddeb, N.; Sellami, S., La Rabta Hosp, Dept Rheumatol, Tunis, Tunisia.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101102244}},
}

@article{ ISI:000253101102254,
Author = {Mateo, L. and Olive, A. and Ruiz, J. and Casares, E. Garcia and Melchor,
   E. Garcia and Minguez, S. and Holgado, S. and Perez, R. and Tena, X.},
Title = {{On bone and joint tuberculosis: Two decade study of 53 cases}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{538}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Mateo, L.; Olive, A.; Casares, E. Garcia; Melchor, E. Garcia; Minguez, S.; Holgado, S.; Tena, X., Hosp Badalona Germans Trias \& Pujol, Rheumatol Serv, Badalona, Spain.
   Ruiz, J.; Perez, R., Hosp Badalona Germans Trias \& Pujol, Badalona, Spain.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101102254}},
}

@article{ ISI:000253101102255,
Author = {Medina, F. and Perez-Saleme, L. and Fraga, A. and Jara, L. and Moreno,
   J.},
Title = {{Latent tuberculosis (TB) in connective tissue diseases (CTD). Comparison
   between 2 ``prophylactic{''} therapies}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{538}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Medina, F.; Moreno, J., Cent Med Nacl Siglo XXI, Auroimmune Dis Res Unit, Mexico City, DF, Mexico.
   Fraga, A., Cent Med Nacl Siglo XXI, IMSS, Mexico City, DF, Mexico.
   Jara, L., Cent Med La Raza, Mexico City, DF, Mexico.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101102255}},
}

@article{ ISI:000253101102267,
Author = {Timlin, H. and Beavil, K. and Stevens, R.},
Title = {{Audit on British thoracic society guidelines for assessing
   risk/management of mycobacterium tuberculosis prior to anti TNF therapy}},
Journal = {{ANNALS OF THE RHEUMATIC DISEASES}},
Year = {{2007}},
Volume = {{66}},
Number = {{2}},
Pages = {{542}},
Month = {{JUL}},
Note = {{Annual European Congress of Rheumatology (EULAR 2007), Barcelona, SPAIN,
   JUN 13-16, 2007}},
Organization = {{European League Against Rheumatism}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Timlin, H.; Beavil, K.; Stevens, R., Amersham Hosp, Amersham, England.}},
ISSN = {{0003-4967}},
Research-Areas = {{Rheumatology}},
Web-of-Science-Categories  = {{Rheumatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Rheum. Dis.}},
Doc-Delivery-Number = {{261SU}},
Unique-ID = {{ISI:000253101102267}},
}

@article{ ISI:000247665800020,
Author = {Ngo, Silvana C. and Zimhony, Oren and Chung, Woo Jin and Sayahi, Halimah
   and Jacobs, Jr., William R. and Welch, John T.},
Title = {{Inhibition of isolated mycobacterium tuberculosis fatty acid synthase I
   by pyrazinamide analogs}},
Journal = {{ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}},
Year = {{2007}},
Volume = {{51}},
Number = {{7}},
Pages = {{2430-2435}},
Month = {{JUL}},
Abstract = {{An analog of pyrazinamide (PZA), 5-chloropyrazinamide (5-Cl-PZA), has
   previously been shown to inhibit mycobacterial fatty acid synthase I
   (FASI). FASI has been purified from a recombinant strain of M. smegmatis
   (M. smegmatis Delta fas1 attB::M. tuberculosis fas1). Following
   purification, FASI activity and inhibition were assessed
   spectrophotometrically by monitoring NADPH oxidation. The observed
   inhibition was both concentration and structure dependent, being
   affected by both substitution at the 5 position of the pyrazine nucleus
   and the nature of the ester or N-alkyl group. Under the conditions
   studied, both 5-Cl-PZA and PZA exhibited concentration and substrate
   dependence consistent with competitive inhibition of FASI with K(i)s of
   55 to 59 mu M and 2,567 to 2,627 mu M, respectively. The results were
   validated utilizing a radiolabeled fatty acid synthesis assay. This
   assay showed that FASI was inhibited by PZA and pyrazinoic acid as well
   as by a series of PZA analogs.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Welch, JT (Reprint Author), SUNY Albany, Dept Chem, Albany, NY 12222 USA.
   SUNY Albany, Dept Chem, Albany, NY 12222 USA.
   Hebrew Univ Jerusalem, Kaplan Med Ctr, Div Infect Dis, Jerusalem, Israel.
   Albert Einstein Coll Med, Howard Hughes Med Inst, Dept Microbiol \& Immunol, Bronx, NY 10467 USA.}},
DOI = {{10.1128/AAC.01458-06}},
ISSN = {{0066-4804}},
Keywords-Plus = {{VITRO ANTIMYCOBACTERIAL ACTIVITY; PYRAZINOIC ACID; MULTIENZYME COMPLEX;
   POLYPEPTIDE-CHAINS; SYNTHETASE; BIOSYNTHESIS; SUSCEPTIBILITY; TARGET;
   ELONGATION; ESTERS}},
Research-Areas = {{Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Microbiology; Pharmacology \& Pharmacy}},
Author-Email = {{jwelch@uamail.albany.edu}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}R21 AI043268, AI052777-02, AI43268, R01 AI043268, R21
   AI052777]}},
Cited-References = {{BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359.
   Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919.
   Bloch K, 1975, Methods Enzymol, V35, P84, DOI 10.1016/0076-6879(75)35141-0.
   Boshoff HI, 2002, J BACTERIOL, V184, P2167, DOI 10.1128/JB.184.8.2167-2172.2002.
   Boshoff HIM, 2000, J BACTERIOL, V182, P5479, DOI 10.1128/JB.182.19.5479-5485.2000.
   BRINDLEY DN, 1969, NATURE, V224, P666, DOI 10.1038/224666a0.
   Burlingham BT, 2003, J CHEM EDUC, V80, P214.
   Cynamon MH, 1998, ANTIMICROB AGENTS CH, V42, P462.
   CYNAMON MH, 1995, J MED CHEM, V38, P3902, DOI 10.1021/jm00020a003.
   CYNAMON MH, 1992, J MED CHEM, V35, P1212, DOI 10.1021/jm00085a007.
   Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1.
   KAWAGUCHI A, 1977, P NATL ACAD SCI USA, V74, P3180, DOI 10.1073/pnas.74.8.3180.
   LINN TC, 1981, ARCH BIOCHEM BIOPHYS, V209, P613, DOI 10.1016/0003-9861(81)90320-9.
   Lynen F., 1969, METHOD ENZYMOL, V14, P17.
   Marrakchi H, 2000, MICROBIOL-UK, V146, P289.
   Nelson D.L., 2000, LEHNINGER PRINCIPLES.
   PRESCOTT DJ, 1972, ADV ENZYMOL RAMB, V36, P269.
   STEELE MA, 1988, CHEST, V94, P845, DOI 10.1378/chest.94.4.845.
   STOOPS JK, 1975, P NATL ACAD SCI USA, V72, P1940, DOI 10.1073/pnas.72.5.1940.
   Sun ZH, 1999, ANTIMICROB AGENTS CH, V43, P537.
   Sun ZH, 1997, MICROBIOL-SGM, V143, P3367.
   VOLPE JJ, 1973, ANNU REV BIOCHEM, V42, P21, DOI 10.1146/annurev.bi.42.070173.000321.
   WHEELER PR, 1990, J GEN MICROBIOL, V136, P211.
   {*}WHO, 2004, TUBERCULOSIS.
   WOOD WI, 1977, J BIOL CHEM, V252, P5745.
   WOOD WI, 1978, J BIOL CHEM, V253, P2650.
   Zhang Y, 2003, J ANTIMICROB CHEMOTH, V52, P790, DOI 10.1093/jac/dkg446.
   Zhang Y, 2003, INT J TUBERC LUNG D, V7, P6.
   Zhang Y, 2002, J MED MICROBIOL, V51, P42.
   Zhang Y, 1999, J BACTERIOL, V181, P2044.
   Zimhony O, 2000, NAT MED, V6, P1043.
   Zimhony O, 2004, J BACTERIOL, V186, P4051, DOI 10.1128/JB.186.13.4051-4055.2004.
   Zimhony O, 2007, ANTIMICROB AGENTS CH, V51, P752, DOI 10.1128/AAC.01369-06.
   DICK JD, 1995, Patent No. 9519706.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{39}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{17}},
Journal-ISO = {{Antimicrob. Agents Chemother.}},
Doc-Delivery-Number = {{184TS}},
Unique-ID = {{ISI:000247665800020}},
}

@article{ ISI:000247665800034,
Author = {Ruslami, Rovina and Nijland, Hanneke M. J. and Lisjahbana, Bachti A. and
   Parwati, Ida and van Crevel, Reinout and Aarnoutse, Rob E.},
Title = {{Pharmacokinetics and tolerability of a higher rifampin dose versus the
   standard dose in pulmonary tuberculosis patients}},
Journal = {{ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}},
Year = {{2007}},
Volume = {{51}},
Number = {{7}},
Pages = {{2546-2558}},
Month = {{JUL}},
Abstract = {{Rifampin is a key drug for tuberculosis (TB) treatment. The available
   data suggest that the currently applied 10-mg/kg of body weight dose of
   rifampin may be too low and that increasing the dose may shorten the
   treatment duration. A double-blind randomized phase II clinical trial
   was performed to investigate the effect of a higher dose of rifampin in
   terms of pharmacokinetics and tolerability. Fifty newly diagnosed adult
   Indonesian TB patients were randomized to receive a standard (450-mg,
   i.e., 10-mg/kg in Indonesian patients) or higher (600-mg) dose of
   rifampin in addition to other TB drugs. A full pharmacokinetic curve for
   rifampin, pyrazinamide, and ethambutol was recorded after 6 weeks of
   daily TB treatment. Tolerability was assessed during the 6-month
   treatment period. The geometric means of exposure to rifampin (area
   under the concentration-time curve from 0 to 24 h {[}AUC(0-24)]) were
   increased by 65\% (P < 0.001) in the higher-dose group (79.7 mg .
   h/liter) compared to the standard-dose group (48.5 mg . h/liter).
   Maximum rifampin concentrations (C-max) were 15.6 mg/liter versus 10.5
   mg/liter (49\% increase; P < 0.001). The percentage of patients for whom
   the rifampin C-max was >= 8 mg/liter was 96\% versus 79\% (P = 0.094).
   The pharmacokinetics of pyrazinamide and ethambutol were similar in both
   groups. Mild (grade 1 or 2) hepatotoxicity was more common in the
   higher-dose group (46 versus 20\%; P = 0.054), but no patient developed
   severe hepatotoxicity. Increasing the rifampin dose was associated with
   a more than dose-proportional increase in the mean AUC(0-24) and C-max
   of rifampin without affecting the incidence of serious adverse effects.
   Follow-up studies are warranted to assess whether high-dose rifampin may
   enable shortening of TB treatment.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Aarnoutse, RE (Reprint Author), Radboud Univ Nijmegen, Med Ctr, Dept Clin Pharm, NL-9101 HB Nijmegen, Netherlands.
   Padjadjaran State Univ, Fac Med, Dept Pharmacol, Bandung, Indonesia.
   Radboud Univ Nijmegen, Med Ctr, Dept Clin Pharm, Nijmegen, Netherlands.
   Padjadjaran State Univ, Hasan Sadikin Hosp, Fac Med, Dept Internal Med, Bandung, Indonesia.
   Padjadjaran State Univ, Hasan Sadikin Hosp, Fac Med, Dept Internal Med, Bandung, Indonesia.
   Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands.}},
DOI = {{10.1128/AAC.01550-06}},
ISSN = {{0066-4804}},
Keywords-Plus = {{ACYL-CARRIER PROTEIN; FATTY-ACID SYNTHASE; ENOYL-ACP REDUCTASE;
   PLASMODIUM-FALCIPARUM; ESCHERICHIA-COLI; TRICLOSAN-BINDING; DE-NOVO;
   BIOSYNTHESIS; INHIBITION; GLYCOSPHINGOLIPIDS}},
Research-Areas = {{Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Microbiology; Pharmacology \& Pharmacy}},
Author-Email = {{R.Aarnoutse@akf.umcn.nl}},
ResearcherID-Numbers = {{van Crevel, reinout/A-6636-2010
   Aarnoutse, R.E./L-4168-2015}},
Cited-References = {{Asturias FJ, 2005, NAT STRUCT MOL BIOL, V12, P225, DOI 10.1038/nsmb899.
   Chhibber M, 2006, BIOORGAN MED CHEM, V14, P8086, DOI 10.1016/j.bmc.2006.07.034.
   Couto AS, 2004, EUR J BIOCHEM, V271, P2204, DOI 10.1111/j.1432-1033.2004.04150.x.
   Crawford MJ, 2006, EMBO J, V25, P3214, DOI 10.1038/sj.emboj.7601189.
   Gerold P, 2001, MOL BIOCHEM PARASIT, V112, P29, DOI 10.1016/S0166-6851(00)00336-4.
   Hakomori S, 2003, CURR OPIN HEMATOL, V10, P16, DOI 10.1097/00062752-200301000-00004.
   HEATH RJ, 1995, J BIOL CHEM, V270, P26538.
   Heath RJ, 2002, APPL MICROBIOL BIOT, V58, P695, DOI 10.1007/s00253-001-0918-z.
   Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110.
   Jenni S, 2006, SCIENCE, V311, P1263, DOI 10.1126/science.1123251.
   KANNANGARA CG, 1971, BIOCHEM BIOPH RES CO, V44, P1544.
   Kapoor M, 2004, BIOCHEM J, V381, P735, DOI 10.1042/BJ20040302.
   Kapoor M, 2001, BIOCHEM BIOPH RES CO, V289, P832, DOI 10.1006/bbrc.2001.6061.
   Karmodiya K, 2006, FEBS J, V273, P4093, DOI 10.1111/j.1742-4658.2006.05412.x.
   Labaied M, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-49.
   Lack G, 2006, J BIOL CHEM, V281, P9538, DOI 10.1074/jbc.M509119200.
   LAMBALOT RH, 1995, J BIOL CHEM, V270, P24658.
   MAGNUSON K, 1993, MICROBIOL REV, V57, P522.
   Maier T, 2006, SCIENCE, V311, P1258, DOI 10.1126/science.1123248.
   Meadows ES, 2001, BIOCHEMISTRY-US, V40, P14855, DOI 10.1021/bi0113723.
   MIKOLAJCZYK S, 1990, EUR J BIOCHEM, V187, P431, DOI 10.1111/j.1432-1033.1990.tb15322.x.
   Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031.
   Pessi G, 2004, P NATL ACAD SCI USA, V101, P6206, DOI 10.1073/pnas.0307742101.
   Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200.
   Prigge ST, 2003, BIOCHEMISTRY-US, V42, P1160, DOI 10.1021/bi026847k.
   RAMYA TN, 2006, ANTIMICROB AGENTS CH, V51, P307.
   REVILL WP, 1991, J BACTERIOL, V173, P4379.
   Sharma S, 2003, ANTIMICROB AGENTS CH, V47, P3859, DOI 10.1128/AAC.47.12.3859-3866.2003.
   Sharma SK, 2007, J MED CHEM, V50, P765, DOI 10.1021/jm061154d.
   Sharma SK, 2005, BIOCHEM BIOPH RES CO, V330, P1019, DOI 10.1016/j.bbrc.2005.03.094.
   Sharma SK, 2003, J BIOL CHEM, V278, P45661, DOI 10.1074/jbc.M304283200.
   Slayden RA, 2000, MOL MICROBIOL, V38, P514, DOI 10.1046/j.1365-2958.2000.02145.x.
   Surolia A, 2004, BIOCHEM J, V383, P401, DOI 10.1042/BJ20041051.
   Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612.
   Tasdemir D, 2006, J MED CHEM, V49, P3345, DOI 10.1021/jm0600545.
   White SW, 2005, ANNU REV BIOCHEM, V74, P791, DOI 10.1146/annurev.biochem.74.082803.133524.
   World Health Organization, 2002, WORLD HLTH REP 2002.
   Yasuno R, 2004, J BIOL CHEM, V279, P8242, DOI 10.1074/jbc.M308894200.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{83}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Antimicrob. Agents Chemother.}},
Doc-Delivery-Number = {{184TS}},
Unique-ID = {{ISI:000247665800034}},
}

@article{ ISI:000247665800048,
Author = {Shen, Xin and Shen, Guo-miao and Wu, Jie and Gui, Xiao-hong and Li, Xia
   and Mei, Jian and DeRiemer, Kathryn and Gao, Qian},
Title = {{Association between embB codon 306 mutations and drug resistance in
   Mycobacterium tuberculosis}},
Journal = {{ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}},
Year = {{2007}},
Volume = {{51}},
Number = {{7}},
Pages = {{2618-2620}},
Month = {{JUL}},
Abstract = {{embB306 mutants were detected in both ethambutol (EMB)-resistant and
   EMB-susceptible strains of Mycobacterium tuberculosis.
   Multidrug-resistant (MDR) strains had a higher proportion of embB306
   mutants than non-MDR strains (odds ratio, 6.78; P < 0.001). The embB306
   locus is a candidate marker for rapid detection of MDR and extremely
   drug resistant tuberculosis.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Gao, Q (Reprint Author), Fudan Univ, Shanghai Med Coll, 138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.
   Shanghai Med Coll, Key Lab Med Mol Virol, Shanghai 200032, Peoples R China.
   Inst Med Microbiol, Shanghai 200032, Peoples R China.
   Inst Biomed Sci, Shanghai 200032, Peoples R China.
   Fudan Univ, Shanghai 200032, Peoples R China.
   Shanghai Municipal Ctr Dis Control \& Prevent, Dept TB Control, Shanghai, Peoples R China.
   Univ Calif Davis, Sch Med, Davis, CA 95616 USA.}},
DOI = {{10.1128/AAC.01516-06}},
ISSN = {{0066-4804}},
Keywords-Plus = {{ETHAMBUTOL RESISTANCE; GENE}},
Research-Areas = {{Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Microbiology; Pharmacology \& Pharmacy}},
Author-Email = {{qgao99@yahoo.com}},
ResearcherID-Numbers = {{SHEN, GUOMIAO/G-4518-2011
   }},
ORCID-Numbers = {{DeRiemer, Kathryn/0000-0002-8375-7505}},
Cited-References = {{Alcaide F, 1997, ANTIMICROB AGENTS CH, V41, P2270.
   Centers for Disease Control and Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P301.
   Chinese antituberculosis association, 1996, J CHINESE ANTITUBERC, V18, P28.
   Cohen J, 2006, SCIENCE, V313, P1554.
   DeRiemer K, 2005, LANCET, V365, P1239, DOI 10.1016/S0140-6736(05)74812-1.
   Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537.
   Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706.
   GAGNEUX S, 2006, PLOS PATHOG, V2, P1.
   Hazbon MH, 2005, ANTIMICROB AGENTS CH, V49, P3794, DOI 10.1128/AAC.49.9.3794-3802.2005.
   Isola D, 2005, J MICROBIOL METH, V62, P113, DOI 10.1016/j.mimet.2005.02.004.
   Johnson R, 2006, INT J TUBERC LUNG D, V10, P68.
   Kwara A, 2003, J CLIN MICROBIOL, V41, P2683, DOI 10.1128/JCM.41.6.2683-2685.2003.
   Lee ASG, 2004, ANTIMICROB AGENTS CH, V48, P4447, DOI 10.1128/AAC.48.11.4447-4449.2004.
   Lety MA, 1997, ANTIMICROB AGENTS CH, V41, P2629.
   Mokrousov I, 2002, J CLIN MICROBIOL, V40, P3810, DOI 10.1128/JCM.40.10.3810-3813.2002.
   Plinke C, 2006, ANTIMICROB AGENTS CH, V50, P1900, DOI 10.1128/AAC.50.5.1900-1902.2006.
   Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002.
   Ramaswamy SV, 2000, ANTIMICROB AGENTS CH, V44, P326, DOI 10.1128/AAC.44.2.326-336.2000.
   Sreevatsan S, 1997, ANTIMICROB AGENTS CH, V41, P1677.
   Telenti A, 1997, NAT MED, V3, P567, DOI 10.1038/nm0597-567.
   Van Rie A, 2001, J CLIN MICROBIOL, V39, P636, DOI 10.1128/JCM.39.2.636-641.2001.
   {*}WHO, 2004, ANTITUB DRUG RES WOR.
   Zhao JR, 2005, INT J TUBERC LUNG D, V9, P328.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{32}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Antimicrob. Agents Chemother.}},
Doc-Delivery-Number = {{184TS}},
Unique-ID = {{ISI:000247665800048}},
}

@article{ ISI:000247665800054,
Author = {Stickney, Dwight R. and Noveljic, Zoja and Garsd, Armando and Destiche,
   Daniel A. and Frincke, James M.},
Title = {{Safety and activity of the immune modulator HE2000 on the incidence of
   tuberculosis and other opportunistic infections in AIDS patients}},
Journal = {{ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}},
Year = {{2007}},
Volume = {{51}},
Number = {{7}},
Pages = {{2639-2641}},
Month = {{JUL}},
Abstract = {{Twenty-five AIDS patients were treated with HE2000, a synthetic adrenal
   hormone. The drug was well tolerated and safe and reduced both the
   incidence of tuberculosis coinfection by 42.2\% (P < 0.05) and the
   cumulative incidence of opportunistic infections (P < 0.05). These
   results warrant further clinical investigation of HE2000.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Stickney, DR (Reprint Author), Hollis Eden Pharmaceut Inc, 4435 Eastgate Mall,Suite 400, San Diego, CA 92121 USA.
   Hollis Eden Pharmaceut Inc, San Diego, CA 92121 USA.
   Karl Bremmer Hosp, Cape Town, South Africa.}},
DOI = {{10.1128/AAC.01446-06}},
ISSN = {{0066-4804}},
Keywords-Plus = {{INTERFERON-PRODUCING CELLS; 16-ALPHA-BROMOEPIANDROSTERONE;
   DEHYDROEPIANDROSTERONE; ANALOG; BLOOD}},
Research-Areas = {{Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Microbiology; Pharmacology \& Pharmacy}},
Author-Email = {{dstickney@holliseden.com}},
Cited-References = {{Ayi K, 2002, ANTIMICROB AGENTS CH, V46, P3180, DOI 10.1128/AAC.46.10.3180-3184.2002.
   Centers for Disease Control and Prevention, 1992, MMWR-MORBID MORTAL W, V41, P1.
   Cytel Inc, 2005, STATXACT 7 PROCS STA.
   Feldman S, 2001, CLIN IMMUNOL, V101, P201, DOI 10.1006/clim.2001.5111.
   FERBAS J, 1995, CLIN DIAGN LAB IMMUN, V2, P138.
   Freilich D, 2000, AM J TROP MED HYG, V63, P280.
   Frincke JM, 2007, AM J TROP MED HYG, V76, P232.
   Hernandez-Pando R, 2005, J INFECT DIS, V191, P299, DOI 10.1086/426453.
   Lin DY, 2000, J ROY STAT SOC B, V62, P711, DOI 10.1111/1467-9868.00259.
   Lin HJ, 1998, J CLIN MICROBIOL, V36, P835.
   NELSON WB, 2003, RECURRENT EVENTS DAT, P35.
   Pedersen NC, 2003, VET IMMUNOL IMMUNOP, V94, P133, DOI 10.1016/S0165-2427(03)00081-3.
   Reading C, 2006, CLIN MICROBIOL INFEC, V12, P1082, DOI 10.1111/j.1469-0691.2006.01520.x.
   SAS Institute Inc, 1999, SAS STAT US GUID VER.
   Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835.
   SIEGAL FP, 1986, J CLIN INVEST, V78, P115, DOI 10.1172/JCI112539.
   Soumelis V, 2001, BLOOD, V98, P906, DOI 10.1182/blood.V98.4.906.
   UNAIDS, 2005, AIDS EP UPD SPEC REP.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{11}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Antimicrob. Agents Chemother.}},
Doc-Delivery-Number = {{184TS}},
Unique-ID = {{ISI:000247665800054}},
}

@article{ ISI:000247555200008,
Author = {Fiorenza, Gladys and Farroni, Miguel A. and Bogue, Cristina and
   Selenscig, Dante and Lamas, Diego Martinel and Dlugovitzky, Diana},
Title = {{Functional characteristics of neutrophils and mononuclear cells from
   tuberculosis patients stimulated in vitro with heat killed
   M-tuberculosis}},
Journal = {{ARCHIVES OF MEDICAL RESEARCH}},
Year = {{2007}},
Volume = {{38}},
Number = {{5}},
Pages = {{526-533}},
Month = {{JUL}},
Abstract = {{Background. The major protective immune response against intracellular
   bacteria, such as Mycobacterium tuberculosis, is a cell-mediated
   immunity involving neutrophils (PMNs) and peripheral mononuclear cells
   (MCs), contributing to the clearance of this microorganism and the
   resolution of the infection. This study was addressed to evaluate PMNs
   and MCs for their bactericidal function.
   Methods. The sample comprised 14 tuberculosis (TB) inpatients (HIV-),
   and 10 healthy controls (HCo). Peripheral PMNs and MCs were separated by
   Ficoll-Hypaque and cultured in RPMI with or without heat-killed
   Mycobacterium tuberculosis (HK Mtb). Respiratory burst (RB), CD11b, IL-8
   and TNF alpha. receptor expression were assessed by flow cytometry in
   cells undergoing stimulation or not. Presence of IL-8 and TNF alpha in
   cell culture supernatants was determined by ELISA.
   Results. TB patients had a lower RB response than HCo for both cell
   types (MCs, p < 0.05, PMNs, p < 0.01) regardless of HK Mtb stimulation.
   Compared to HCo, PMNs and MCs from TB patients presented a reduced CD11b
   expression, with the two subject groups showing a decrease in this
   marker expression following HK. Mtb was added to both cell cultures.
   Whereas fewer IL-8 and TNF alpha receptors were found when studying MCs
   and PMNs from TB patients, antigen stimulation significantly raised the
   expression for both cytokine receptors. Culture supernatants from MCs
   and PNINs of TB patients contained increased amounts of IL-8 and TNF
   alpha.
   Conclusions. The present findings may provide some explanation as to the
   different roles played by PMNs and MCs in TB immunopathology. (c) 2007
   IMSS. Published by Elsevier Inc.}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Dlugovitzky, D (Reprint Author), Univ Nacl Rosario, Fac Ciencias Med, Secc Inmunol Catedra Microbiol, Rosario, Santa Fe, Argentina.
   Univ Nacl Rosario, Fac Ciencias Med, Secc Inmunol Catedra Microbiol, Rosario, Santa Fe, Argentina.
   Hosp 1, Dept Neumonol \& Tisiol, Carrasco, Argentina.}},
DOI = {{10.1016/j.arcmed.2007.01.011}},
ISSN = {{0188-4409}},
Keywords = {{CD11b; cytokine receptors; mononuclear cells; neutrophils; respiratory
   burst; tuberculosis}},
Keywords-Plus = {{PERIPHERAL-BLOOD NEUTROPHILS; TUMOR-NECROSIS-FACTOR; PULMONARY
   TUBERCULOSIS; OXIDATIVE BURST; GENE-EXPRESSION; APOPTOSIS; ACTIVATION;
   INFECTION; SEVERITY; IMMUNITY}},
Research-Areas = {{Research \& Experimental Medicine}},
Web-of-Science-Categories  = {{Medicine, Research \& Experimental}},
Author-Email = {{dianad@fmedic.unr.edu.ar}},
Cited-References = {{Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593.
   Aleman M, 2004, INFECT IMMUN, V72, P5150, DOI 10.1128/IAI.72.9.5150-5158.2004.
   Aleman M, 2002, AM J RESP CELL MOL, V27, P583, DOI 10.1165/rcmb.2002-0038OC.
   Aleman M, 2001, CLIN IMMUNOL, V100, P87, DOI 10.1006/clim.2001.5044.
   Barber EM, 2005, INFECT IMMUN, V73, P6322, DOI 10.1128/IAI.73.10.6322-6331.2005.
   Barr Erika L., 2005, Journal of Microbiology Immunology and Infection, V38, P244.
   Cardona PJ, 2003, TUBERCULOSIS, V83, P351, DOI 10.1016/S1472-9792(03)00056-8.
   Cooper AM, 2000, INFECT IMMUN, V68, P1231, DOI 10.1128/IAI.68.3.1231-1234.2000.
   COX G, 1995, AM J RESP CELL MOL, V12, P232.
   Das SD, 2004, FEMS IMMUNOL MED MIC, V41, P85, DOI 10.1016/j.femsim.2004.01.006.
   Dlugovitzky D, 2000, CLIN EXP IMMUNOL, V122, P343, DOI 10.1046/j.1365-2249.2000.01394.x.
   Dlugovitzky D, 1999, SCAND J IMMUNOL, V49, P210, DOI 10.1046/j.1365-3083.1999.00492.x.
   Dlugovitzky D, 2006, RESP MED, V100, P1079, DOI 10.1016/j.rmed.2005.09.026.
   Fiorenza G, 2005, IMMUNOL LETT, V98, P45, DOI 10.1016/j.imlet.2004.09.008.
   Fiorenza G, 2003, FEMS IMMUNOL MED MIC, V35, P159, DOI 10.1016/S0928-8244(03)00004-X.
   Kasahara K, 1998, J INFECT DIS, V178, P127.
   KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4.
   LECOANETHENCHOZ S, 1995, IMMUNITY, V3, P119, DOI 10.1016/1074-7613(95)90164-7.
   Meddows-Taylor S, 1998, J INFECT DIS, V177, P921.
   Mencacci A., 2000, Current Pharmaceutical Biotechnology, V1, P235, DOI 10.2174/1389201003378924.
   Orme IM, 1999, IMMUNOL TODAY, V20, P307, DOI 10.1016/S0167-5699(98)01438-8.
   Pereira CB, 2004, MICROBES INFECT, V6, P25, DOI 10.1016/j.micinf.2003.10.007.
   ROTHE G, 1994, METHOD ENZYMOL, V233, P539.
   SAMANTA AK, 1990, J BIOL CHEM, V265, P183.
   Sayles Peter C., 1996, Natural Immunity, V15, P249.
   Shalekoff S, 1998, CLIN DIAGN LAB IMMUN, V5, P41.
   Suttmann H, 2003, INFECT IMMUN, V71, P4647, DOI 10.1128/IAI.71.8.4647-4656.2003.
   Tsenova L, 1999, P NATL ACAD SCI USA, V96, P5657, DOI 10.1073/pnas.96.10.5657.
   van Crevel R, 2002, CLIN MICROBIOL REV, V15, P294, DOI 10.1128/CMR.15.2.294-309.2002.
   WILSON M, 2001, MYCOBACTERIUM TUBERC, P335.
   YASSIN RJ, 1994, CLIN EXP IMMUNOL, V97, P120.
   ZHANG YH, 1995, J CLIN INVEST, V95, P586, DOI 10.1172/JCI117702.}},
Number-of-Cited-References = {{32}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Arch. Med. Res.}},
Doc-Delivery-Number = {{183EJ}},
Unique-ID = {{ISI:000247555200008}},
}

@article{ ISI:000248325900007,
Author = {Kravchenko, T. B. and Platonov, M. E. and Vahrameeva, G. M. and Bannov,
   V. A. and Kudryavtseva, T. Ju. and Mokrievich, A. N. and Pavlov, V. M.},
Title = {{Cloning and expression of protective antigens of Mycobacterium
   tuberculosis Ag85B and ESAT-6 in Francisella tularensis 15/10}},
Journal = {{BIOCHEMISTRY-MOSCOW}},
Year = {{2007}},
Volume = {{72}},
Number = {{7}},
Pages = {{735-743}},
Month = {{JUL}},
Abstract = {{The possibility of expression of genes encoding mycobacterial antigens
   in Francisella tularensis 15/10 vaccine strain cells has been shown for
   the first time. To obtain stable and effective expression of
   mycobacterial antigens in the F. tularensis cells, the plasmid vector
   pPMC1 and hybrid genes consisting of the leader part FL of the F.
   tularensis membrane protein FopA and structural moieties of the mature
   protein Ag85B or the fused protein Ag85B-ESAT-6 were constructed.
   Recombinant strains F. tularensis RVp17 and RVp18 expressing protective
   mycobacterial antigens in the fused proteins FL-Ag85B and
   FL-Ag85B-ESAT-6, respectively, were obtained. Expression of the
   protective mycobacterial antigens in F. tularensis was analyzed using
   specific antisera to the recombinant proteins Ag85-(His)(6) and
   ESAT-6-(His)(6) isolated from Escherichia coli producer strains created
   on the basis of the pET23b(+) and pET24b(+) vectors. The expression of
   heterologous protective antigens in F. tularensis 15/10 is promising for
   creation of live recombinant anti-tuberculosis vaccines on the basis of
   the tularemia vaccine strain.}},
Publisher = {{MAIK NAUKA/INTERPERIODICA/SPRINGER}},
Address = {{233 SPRING ST, NEW YORK, NY 10013-1578 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kravchenko, TB (Reprint Author), State Res Ctr Appl Microbiol \& Biotechnol, Obolensk 142279, Moscow Region, Russia.
   State Res Ctr Appl Microbiol \& Biotechnol, Obolensk 142279, Moscow Region, Russia.}},
DOI = {{10.1134/S0006297907070073}},
ISSN = {{0006-2979}},
EISSN = {{0320-9725}},
Keywords = {{expression; Ag85B; ESAT-6; Mycobacterium tuberculosis; Francisella
   tularensis}},
Keywords-Plus = {{VACCINIA VIRUS ANKARA; IMMUNITY; PROTEINS; BCG; IMMUNOGENICITY;
   VACCINATION; EFFICACY; PROGRESS; VECTOR; SYSTEM}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{kravchenko@obolensk.org}},
ORCID-Numbers = {{Platonov, Mihail/0000-0003-3946-1755}},
Cited-References = {{Abomoelak B, 1999, INFECT IMMUN, V67, P5100.
   Agger EM, 2006, VACCINE, V24, P5452, DOI 10.1016/j.vaccine.2006.03.072.
   Andersen P, 2001, TRENDS IMMUNOL, V22, P160, DOI 10.1016/S1471-4906(01)01865-8.
   Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520.
   Brandt L, 2000, INFECT IMMUN, V68, P791, DOI 10.1128/IAI.68.2.791-795.2000.
   Dale JW, 1990, MOL BIOL MYCOBACTERI, P173.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   ERICSSON M, 1994, INFECT IMMUN, V62, P178.
   Fouts TR, 2003, FEMS IMMUNOL MED MIC, V37, P129, DOI 10.1016/S0928-8244(03)00067-1.
   Goonetilleke NP, 2003, J IMMUNOL, V171, P1602.
   HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530.
   Kamath AT, 1999, INFECT IMMUN, V67, P1702.
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0.
   Li ZM, 1999, INFECT IMMUN, V67, P4780.
   LOWRY OH, 1951, J BIOL CHEM, V193, P115.
   Lozes E, 1997, VACCINE, V15, P830, DOI 10.1016/S0264-410X(96)00274-5.
   Mahairas GG, 1996, J BACTERIOL, V178, P1274.
   MANIATIS T, 1984, METHODS GENE ENG MOL.
   MASHKO SV, 1990, GENE, V88, P121, DOI 10.1016/0378-1119(90)90069-4.
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128.
   Olsen AW, 2001, INFECT IMMUN, V69, P2773, DOI 10.1128/IAI.69.5.2773-2778.2001.
   PAVLOV VM, 1994, MOL GENET MIKROBIOL, V3, P39.
   PLATONOV M, 2003, 4 INT C TUL CIT BATH, P50.
   Pomerantsev AP, 2001, PLASMID, V46, P210, DOI 10.1006/plas.2001.1548.
   POMERANTSEV AP, 1991, MOL GENET MIKROBIOL, V9, P21.
   Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859.
   Skjot RLV, 2000, INFECT IMMUN, V68, P214.
   SORENSEN AL, 1995, INFECT IMMUN, V63, P1710.
   SPIRIN A S, 1957, Biokhimiia, V22, P744.
   TARNVIK A, 1989, REV INFECT DIS, V11, P440.
   Vogels R, 2003, J VIROL, V77, P8263, DOI 10.1128/JVI.77.15.8263-8271.2003.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Biochem.-Moscow}},
Doc-Delivery-Number = {{194EA}},
Unique-ID = {{ISI:000248325900007}},
}

@article{ ISI:000247360400021,
Author = {El-Hamamsy, Mervat H. R. I. and Smith, Anthony W. and Thompson, Andrew
   S. and Threadgill, Michael D.},
Title = {{Structure-based design, synthesis and preliminary evaluation of
   selective inhibitors of dihydrofolate reductase from Mycobacterium
   tuberculosis}},
Journal = {{BIOORGANIC \& MEDICINAL CHEMISTRY}},
Year = {{2007}},
Volume = {{15}},
Number = {{13}},
Pages = {{4552-4576}},
Month = {{JUL 1}},
Abstract = {{Tuberculosis is an increasing threat, owing to the spread of AIDS and to
   the development of resistance of the causative organism, Mycobacterium
   tuberculosis, to the currently available drugs. Dibydrofolate reductase
   (DHFR) is an important enzyme of the folate cycle; inhibition of DHFR
   inhibits growth and causes cell death. The crystal structure of M.
   tuberculosis DHFR revealed a glycerol tightly bound close to the binding
   site for the substrate dihydrofolate; this glycerol-binding motif is
   absent from the human enzyme. A series of pyrimidine-2,4-diamines was
   designed with a two-carbon tether between a glycerol-mimicking triol and
   the 6-position of the heterocycle; these compounds also carried aryl
   substituents at the 5-position. These, their diastereoisomers, analogues
   lacking two hydroxy groups and analogues lacking the two-carbon spacing
   linker were synthesised by acylation of the anions derived from
   phenylacetonitriles with ethyl
   (4S,5R)-4-benzyloxymethyl-2,2-dimethyl-1,3-dioxolane-4-propanoate, ethyl
   (4S,5s)4-benzyloxymethyl-2,2-dimethyl-1,3-dioxolane-4-propanoate,
   tetrahydrooxepin-2-one and 2,3-O-isopropylidene-D-erythronolactone,
   respectively, to give the corresponding alpha-acylphenylacetonitriles.
   Formation of the methyl enol ethers, condensation with guanidine and
   deprotection gave the pyrimidine-2,4-diamines. Preliminary assay of the
   abilities of these compounds to inhibit the growth of TB5 Saccharomyces
   cerevisiae carrying the DHFR genes from M. tuberculosis, human and yeast
   indicated that
   5-phenyl-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine
   selectively inhibited M. tuberculosis DHFR and had little effect on the
   human or yeast enzymes. (c) 2007 Elsevier Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Threadgill, MD (Reprint Author), Univ Bath, Dept Pharm \& Pharmacol, Claverton Down, Bath BA2 7AY, Avon, England.
   Univ Bath, Dept Pharm \& Pharmacol, Bath BA2 7AY, Avon, England.}},
DOI = {{10.1016/j.bmc.2007.04.011}},
ISSN = {{0968-0896}},
Keywords = {{Mycobacterium tuberculosis; dihydrofolate reductase;
   pyrimidine-2,4-diamine; glycerol; structure-based drug design}},
Keywords-Plus = {{SERINE HYDROXYMETHYLTRANSFERASE; BIOACTIVE COMPOUNDS;
   CRYSTAL-STRUCTURES; DRUG DISCOVERY; AVIUM COMPLEX; TARTARIC ACID;
   DERIVATIVES; PYRIMETHAMINE; SMEGMATIS; METOPRINE}},
Research-Areas = {{Biochemistry \& Molecular Biology; Pharmacology \& Pharmacy; Chemistry}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic}},
Author-Email = {{m.d.threadgill@bath.ac.uk}},
ResearcherID-Numbers = {{Threadgill, Michael/C-3925-2009}},
Cited-References = {{ACHMATOWICZ B, 1988, B POL ACAD SCI-CHEM, V36, P267.
   Arcus VL, 2006, DRUG DISCOV TODAY, V11, P28, DOI 10.1016/S1359-6446(05)03667-6.
   Argyrou A, 2006, NAT STRUCT MOL BIOL, V13, P408, DOI 10.1038/nsmb1089.
   BATTY D, 1992, J CHEM SOC PERK T 1, P3193, DOI 10.1039/p19920003193.
   BLANEY JM, 1984, CHEM REV, V84, P333, DOI 10.1021/cr00062a002.
   CARMACK M, 1968, J ORG CHEM, V33, P2171, DOI 10.1021/jo01269a123.
   Clough S, 2000, J CHEM SOC PERK T 1, P2475, DOI 10.1039/b001823f.
   Cody V, 1997, BIOCHEMISTRY-US, V36, P13897, DOI 10.1021/bi971711l.
   Cren S, 2004, ORG BIOMOL CHEM, V2, P2418, DOI 10.1039/B411554f.
   Crofton J, 1997, J PHARM PHARMACOL, V49, P3.
   da Cunha EFF, 2004, J BIOMOL STRUCT DYN, V22, P119.
   DAVIES JF, 1990, BIOCHEMISTRY-US, V29, P9467, DOI 10.1021/bi00492a021.
   De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457.
   DENNY BJ, 1992, J MED CHEM, V35, P2315, DOI 10.1021/jm00090a023.
   FALCO EA, 1951, J AM CHEM SOC, V73, P3753, DOI 10.1021/ja01152a058.
   Gerum AB, 2002, ANTIMICROB AGENTS CH, V46, P3362, DOI 10.1128/AAC.46.11.3362-3369.2002.
   GONZALEZ AH, 1989, J ANTIMICROB CHEMOTH, V24, P19, DOI 10.1093/jac/24.1.19.
   Haller L, 1999, CHEMOTHERAPY, V45, P452, DOI 10.1159/000007239.
   Haworth RD, 1934, J CHEM SOC, P1423, DOI 10.1039/jr9340001423.
   Hawser S, 2006, BIOCHEM PHARMACOL, V71, P941, DOI 10.1016/j.bcp.2005.10.052.
   Horton JR, 2005, J MOL BIOL, V353, P334, DOI 10.1016/j.jmb.2005.08.040.
   HUDLICKY T, 1990, J ORG CHEM, V55, P4683, DOI 10.1021/jo00302a037.
   HUNGERBUHLER E, 1981, HELV CHIM ACTA, V64, P687, DOI 10.1002/hlca.19810640311.
   Janin YL, 2007, BIOORGAN MED CHEM, V15, P2479, DOI 10.1016/j.bmc.2007.01.030.
   KATAKY R, 1990, J CHEM SOC PERK T 2, P321, DOI 10.1039/p29900000321.
   Kompis IM, 2005, CHEM REV, V105, P593, DOI 10.1021/cr0301144.
   LASZLO J, 1978, CANCER TREAT REP, V62, P341.
   Li RB, 2000, J MOL BIOL, V295, P307, DOI 10.1006/jmbi.1999.3328.
   LYNCH G, 1981, CANCER TREAT REP, V65, P127.
   Malik M, 2005, ANTIMICROB AGENTS CH, V49, P2008, DOI 10.1128/AAC.49.5.2008-2014.2005.
   MALIK NS, 1995, J ANDROL, V16, P169.
   McGuire JJ, 2003, CURR PHARM DESIGN, V9, P2593, DOI 10.2174/1381612033453712.
   Mdluli K, 1996, J INFECT DIS, V174, P1085.
   Mdluli K, 2006, CURR OPIN PHARMACOL, V6, P459, DOI 10.1016/j.coph.2006.06.004.
   MORIMOTO T, 1993, CHEM PHARM BULL, V41, P1149.
   PARK MH, 1987, TETRAHEDRON LETT, V28, P3823, DOI 10.1016/S0040-4039(00)96395-0.
   Quan SW, 1997, ANTIMICROB AGENTS CH, V41, P2456.
   Robson C, 1997, J MED CHEM, V40, P3040, DOI 10.1021/jm970055k.
   RUSSELL PB, 1951, J AM CHEM SOC, V73, P3763, DOI 10.1021/ja01152a060.
   SAKSENA AK, 1986, J ORG CHEM, V51, P5024, DOI 10.1021/jo00375a057.
   Sardarian A, 2003, ORG BIOMOL CHEM, V1, P960, DOI 10.1039/b211636g.
   Shah LM, 1996, ANTIMICROB AGENTS CH, V40, P2426.
   Sibley CH, 1997, METHODS, V13, P190, DOI 10.1006/meth.1997.0511.
   Srivastava R, 1997, BIOCHEM BIOPH RES CO, V235, P602, DOI 10.1006/bbrc.1997.6837.
   Suling WJ, 2000, ANTIMICROB AGENTS CH, V44, P2784, DOI 10.1128/AAC.44.10.2784-2793.2000.
   Suling WJ, 2005, ANTIMICROB AGENTS CH, V49, P4801, DOI 10.1128/AAC.49.11.4801-4801-4803.2005.
   TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493.
   Tarnchompoo B, 2002, J MED CHEM, V45, P1244, DOI 10.1021/jm010131q.
   TENDLER SJB, 1987, CANCER LETT, V36, P65, DOI 10.1016/0304-3835(87)90103-0.
   Then RL, 2004, J CHEMOTHERAPY, V16, P3.
   THREADGILL MD, 1987, J CHEM SOC PERK T 1, P2229, DOI 10.1039/p19870002229.
   Uwai K, 1999, TETRAHEDRON, V55, P9469, DOI 10.1016/S0040-4020(99)00520-7.
   White EL, 2004, FEMS MICROBIOL LETT, V232, P101, DOI 10.1016/S0378-1097(04)00038-2.
   WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328.
   Zanetti KA, 2003, J BIOL CHEM, V278, P10142, DOI 10.1074/jbc.M211569200.
   ZAWILSKA J, 1985, POL J PHARMACOL PHAR, V37, P821.
   Zhang Y, 2002, CURR DRUG TARGETS, V3, P131, DOI 10.2174/1389450024605391.}},
Number-of-Cited-References = {{57}},
Times-Cited = {{43}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{Bioorg. Med. Chem.}},
Doc-Delivery-Number = {{180JY}},
Unique-ID = {{ISI:000247360400021}},
}

@article{ ISI:000250175500004,
Author = {Cavalcanti, Hebe Rodrigues and Marques, Elizabeth and Fonseca, Leila de
   Souza and Feres Saad, Maria Helena},
Title = {{Do DNA extraction methods and Taq polimerase quality improve the double
   repetitive element (DRE) PCR typing method for Mycobacterium
   tuberculosis strains?}},
Journal = {{BRAZILIAN JOURNAL OF MICROBIOLOGY}},
Year = {{2007}},
Volume = {{38}},
Number = {{3}},
Pages = {{409-412}},
Month = {{JUL-SEP}},
Abstract = {{Double repetitive element (DRE) PCR amplification is a simple
   Mycobacterium tuberculosis typing method, however amplification failure
   or poor resolution of bands commit its efficacy. In order to verify if
   whether or not these features could be minimized by improving DNA
   extraction procedures or Taq polymerise quality, DRE-PCR was performed
   on 24 M. tuberculosis DNA samples extracted by heat-shock, mechanical
   and enzymatic methods applying conventional and hot start Taq pol. We
   demonstrated that when dealing with the Mycobacterium tuberculosis
   DRE-PCR typing method, Taq pol of better quality might be more important
   to improve amplification than the DNA extraction method.}},
Publisher = {{SOC BRASILEIRA MICROBIOLOGIA}},
Address = {{AV PROF LINEU PRESTES,1374, 05508 SAO PAULO, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Saad, MHF (Reprint Author), Fiocruz MS, Inst Oswaldo Cruz, Dept Micobacterioses, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
   Univ Estado Rio De Janeiro, Hosp Univ Pedro Ernesto, Rio De Janeiro, Brazil.
   Univ Estado Rio De Janeiro, Inst Microbiol, Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Dept Micobacterioses, Rio De Janeiro, Brazil.}},
DOI = {{10.1590/S1517-83822007000300004}},
ISSN = {{1517-8382}},
Keywords = {{Mycobacterium tuberculosis; PCR; Taq hot start; DRE-PCR}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{saad@ioc.fiocruz.br}},
Cited-References = {{ANJOS L, 2002, INT J TUBERC LUNG D, V6, P1.
   Cole ST, 1998, NATURE, V393, P537.
   FRIEDMAN CR, 1995, J CLIN MICROBIOL, V33, P1383.
   Gelfand DH, 1990, PCR PROTOCOLS GUIDE, P129.
   Kanduma E, 2003, J APPL MICROBIOL, V94, P781, DOI 10.1046/j.1365-2672.2003.01918.x.
   Kermekchiev MB, 2003, NUCLEIC ACIDS RES, V31, P6139, DOI 10.1093/nar/gkg813.
   KREMER K, 1999, J CLIN MICROBIOL, V37, P607.
   Montoro E, 1998, J CLIN MICROBIOL, V36, P3099.
   PLIKAYTIS BB, 1990, J CLIN MICROBIOL, V28, P1913.
   Raviglione MC, 2003, TUBERCULOSIS, V83, P4, DOI 10.1016/S1472-9792(02)00071-9.
   SOLA C, 1998, J CLIN MICROBIOL, V36, P122.
   Spurgiesz RS, 2003, J CLIN MICROBIOL, V41, P4224, DOI 10.1128/JCM.41.9.4224-4230.2003.
   van Soolingen D, 2001, J INTERN MED, V249, P1, DOI 10.1046/j.1365-2796.2001.00772.x.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Braz. J. Microbiol.}},
Doc-Delivery-Number = {{220RR}},
Unique-ID = {{ISI:000250175500004}},
}

@article{ ISI:000250175500007,
Author = {Almeida da Silva, Pedro Eduardo and Wiesel, Fernanda and Santos Boffo,
   Maria Marta and von Groll, Andrea and de Mattos, Ivo Gomes and Mejia,
   Gloria and Robledo, Jaime},
Title = {{Microcolony detection in thin layer culture as an alternative method for
   rapid detection of Mycobacterium tuberculosis in clinical samples}},
Journal = {{BRAZILIAN JOURNAL OF MICROBIOLOGY}},
Year = {{2007}},
Volume = {{38}},
Number = {{3}},
Pages = {{421-423}},
Month = {{JUL-SEP}},
Abstract = {{Tuberculosis remains one of the major causes of mortality worldwide. The
   early detection of new cases is an important goal in the program of
   tuberculosis control. Several methodologies for rapid and accurate
   laboratorial diagnosis have been developed, however, some of these
   techniques are expensive or cumbersome, making their implementation in
   low-income regions unfeasible. In this study, the thin layer culture
   method was compared with conventional culture method and it was observed
   that it provides earlier results and a presumptive species
   identification, being adequate alternative method for rapid laboratory
   diagnosis.}},
Publisher = {{SOC BRASILEIRA MICROBIOLOGIA}},
Address = {{AV PROF LINEU PRESTES,1374, 05508 SAO PAULO, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{da Silva, PEA (Reprint Author), Fundacao Univ Fed Rio Grande, Dept Patol, Rio Grande, RS, Brazil.
   Fundacao Univ Fed Rio Grande, Dept Patol, Rio Grande, RS, Brazil.
   UPB, Escuela Ciencias Salud, CIB, Corp Invest, Medellin, Colombia.}},
ISSN = {{1517-8382}},
Keywords = {{tuberculosis; rapid diagnosis; Mycobacterium tuberculosis}},
Keywords-Plus = {{DIAGNOSIS}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{pedre@furg.br.ou}},
Cited-References = {{ANJOS L, 2002, BRAZ J MICROBIOL, V33.
   Drobniewski FA, 2003, LANCET INFECT DIS, V3, P141, DOI 10.1016/S1473-3099(03)00544-9.
   IDIGORAS P, 1995, EUR J CLIN MICROBIOL, V14, P6, DOI 10.1007/BF02112611.
   Mejia GI, 1999, INT J TUBERC LUNG D, V3, P138.
   MEJIA GI, 1999, BIOMEDICA, V24, P52.
   {*}MIN SAUD, 1993, MAN BACT TUB OUTR MI.
   Palomino JC, 2005, EUR RESPIR J, V26, P1.
   Perkins MD, 2006, LANCET, V367, P942, DOI 10.1016/S0140-6736(06)68386-4.
   SUSEMIHL MAA, 1993, REV BRAS PATOL CLIN, V29, P51.
   Tanoue S, 2002, TUBERCULOSIS, V82, P63, DOI 10.1054/tube.323.
   {[}Anonymous], 2006, GLOB TUB CONTR SURV.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Braz. J. Microbiol.}},
Doc-Delivery-Number = {{220RR}},
Unique-ID = {{ISI:000250175500007}},
}

@article{ ISI:000250175500016,
Author = {Lilenbaum, Walter and Ferreira, Rachel and Marassi, Carla Dray and
   Ristow, Paula and Roland Oelemann, Walter Martins and Fonseca, Leila de
   Souza},
Title = {{Interference of tuberculosis on the performance of ELISAS used in the
   diagnosis of paratuberculosis in cattle}},
Journal = {{BRAZILIAN JOURNAL OF MICROBIOLOGY}},
Year = {{2007}},
Volume = {{38}},
Number = {{3}},
Pages = {{472-477}},
Month = {{JUL-SEP}},
Abstract = {{Forty-four cows from five herds infected with tuberculosis ( TB) and
   without paratuberculosis (PTB), and 21 cows from a herd without either
   infection were studied. The cattle presented concordant results in both
   the skin test and-interferon assay for TB and two commercial ELISAs for
   PTB. Animals were divided according to TB test results into Group A with
   28 TB-infected animals, Group B with 16 TB-negative animals from
   infected herds, and Group C with 21 TB-negative cows from a
   tuberculosis-free herd ( which were used as controls). Twenty of 28
   animals from Group A (71.4\%), 6/16 from Group B (37.5\%) and none from
   Group C were reactive to PTB ELISAs, suggesting that these commercial
   kits were unable to distinguish between PTB and TB. It is proposed that
   natural occurring TB strongly interferes in the diagnosis of PTB and
   that commercial ELISAs cannot be considered reliable tools in the
   diagnosis of paratuberculosis in tuberculosis-infected herds.}},
Publisher = {{SOC BRASILEIRA MICROBIOLOGIA}},
Address = {{AV PROF LINEU PRESTES,1374, 05508 SAO PAULO, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Lilenbaum, W (Reprint Author), Univ Fed Fluminense, Lab Bacteriol Vet, Rua Ernani Mello 101, BR-24210130 Niteroi, RJ, Brazil.
   Univ Fed Fluminense, Lab Bacteriol Vet, BR-24210130 Niteroi, RJ, Brazil.
   Univ Fed Rio de Janeiro, Microbiol Lab, Rio De Janeiro, Brazil.}},
DOI = {{10.1590/S1517-83822007000300016}},
ISSN = {{1517-8382}},
Keywords = {{paratuberculosis; tuberculosis; Mycobacterium bovis; Mycobacterium avium
   paratuberculosis}},
Keywords-Plus = {{AVIUM SUBSP PARATUBERCULOSIS; LINKED-IMMUNOSORBENT-ASSAY; BOVINE
   TUBERCULOSIS; INFECTIONS; ARGENTINA; ANTIGEN; TESTS}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{mipwalt@vm.uff.br}},
Cited-References = {{Buddle BM, 2003, VET REC, V153, P615.
   Collins MT, 2005, CLIN DIAGN LAB IMMUN, V12, P685, DOI 10.1128/CDLI.12.6.685-692.2005.
   COLLINS MT, 1993, J AM VET MED ASSOC, V203, P1456.
   ElZaatari FAK, 1997, J CLIN MICROBIOL, V35, P1794.
   HUNTLEY JFJ, 2005, BMC MICROBIOL, V5.
   Jorge MC, 2000, REV SCI TECH OIE, V19, P800.
   Kohler H, 2001, J VET MED B, V48, P185, DOI 10.1046/j.1439-0450.2001.00443.x.
   Lilenbaum W, 1999, J VET MED B, V46, P353.
   Manning EJB, 2001, REV SCI TECH OIE, V20, P133.
   Olsen I, 2001, CLIN DIAGN LAB IMMUN, V8, P797, DOI 10.1128/CDLI.08.4.797-801.2001.
   Paolicchi FA, 2003, J VET MED B, V50, P20, DOI 10.1046/j.1439-0450.2003.00606.x.
   Reichel MP, 1999, VET MICROBIOL, V66, P135, DOI 10.1016/S0378-1135(98)00311-3.
   RISTOW P, 2007, IN PRESS VET J.
   Vordermeier M., 2001, Tuberculosis (Edinburgh), V81, P177, DOI 10.1054/tube.2001.0283.
   Waters WR, 2004, CLIN DIAGN LAB IMMUN, V11, P729, DOI 10.1128/CDLI.11.4.729-735.2004.
   Wood PR, 2001, TUBERCULOSIS, V81, P147, DOI 10.1054/tube.2000.0272.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Braz. J. Microbiol.}},
Doc-Delivery-Number = {{220RR}},
Unique-ID = {{ISI:000250175500016}},
}

@article{ ISI:000248185200081,
Author = {Bunting, S. and Morris-Jones, R. and Bansal, S. and Fuller, L. C.},
Title = {{Cutaneous manifestations of congenital tuberculosis: case report and
   review of the literature}},
Journal = {{BRITISH JOURNAL OF DERMATOLOGY}},
Year = {{2007}},
Volume = {{157}},
Number = {{1}},
Pages = {{38}},
Month = {{JUL}},
Note = {{87th Annual Meeting of the British-Association-of-Dermatologists,
   Birmingham, ENGLAND, JUL 10-13, 2007}},
Organization = {{British Assco Dermatologists}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Kings Coll London, NHS Trust, London WC2R 2LS, England.}},
ISSN = {{0007-0963}},
Research-Areas = {{Dermatology}},
Web-of-Science-Categories  = {{Dermatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Br. J. Dermatol.}},
Doc-Delivery-Number = {{192FC}},
Unique-ID = {{ISI:000248185200081}},
}

@article{ ISI:000248185200083,
Author = {Vani, B. P. Amirtha and Frith, P. and Downes, S. M. and Burge, S. and
   Lewis, H. M.},
Title = {{Pulmonary tuberculosis and choroidal granuloma in a patient with severe
   chronic plaque psoriasis treated with infliximab}},
Journal = {{BRITISH JOURNAL OF DERMATOLOGY}},
Year = {{2007}},
Volume = {{157}},
Number = {{1}},
Pages = {{39}},
Month = {{JUL}},
Note = {{87th Annual Meeting of the British-Association-of-Dermatologists,
   Birmingham, ENGLAND, JUL 10-13, 2007}},
Organization = {{British Assco Dermatologists}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Univ Hosp Birmingham NHS Trust, Sellyoak Hosp, Birmingham, W Midlands, England.
   Oxford Eye Hosp, Oxford Radclivve Hosp NHS Trust, Oxford, England.
   Churchill Hosp, Oxford Radcliffe Hosp NHS Trust, Oxford OX3 7LJ, England.}},
ISSN = {{0007-0963}},
Research-Areas = {{Dermatology}},
Web-of-Science-Categories  = {{Dermatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Br. J. Dermatol.}},
Doc-Delivery-Number = {{192FC}},
Unique-ID = {{ISI:000248185200083}},
}

@article{ ISI:000248185200115,
Author = {Raste, Y. and Desai, N. and Cooke, N. and Harland, C. C.},
Title = {{Quantiferon gold testing for tuberculosis screening in psoriasis
   patients prior to anti-tumour necrosis factor therapy}},
Journal = {{BRITISH JOURNAL OF DERMATOLOGY}},
Year = {{2007}},
Volume = {{157}},
Number = {{1}},
Pages = {{53}},
Month = {{JUL}},
Note = {{87th Annual Meeting of the British-Association-of-Dermatologists,
   Birmingham, ENGLAND, JUL 10-13, 2007}},
Organization = {{British Assco Dermatologists}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{St Helier Hosp, Carshalton, Surrey, England.}},
ISSN = {{0007-0963}},
Research-Areas = {{Dermatology}},
Web-of-Science-Categories  = {{Dermatology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Br. J. Dermatol.}},
Doc-Delivery-Number = {{192FC}},
Unique-ID = {{ISI:000248185200115}},
}

@article{ ISI:000248180900018,
Author = {Liu, Y. M. and Satyadas, T. and Cheong, E. and Smith, S. and Sinclair,
   M. T. and Rae, D. M.},
Title = {{Tuberculosis of the peripancreatic lymph nodes in an immunocompetent
   patient}},
Journal = {{BRITISH JOURNAL OF HOSPITAL MEDICINE}},
Year = {{2007}},
Volume = {{68}},
Number = {{7}},
Pages = {{390-391}},
Month = {{JUL}},
Publisher = {{MA HEALTHCARE LTD}},
Address = {{ST JUDES CHURCH, DULWICH ROAD, LONDON SE24 0PB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Liu, YM (Reprint Author), Ipswich Hosp, Dept Gen Surg, Ipswich IP4 5PD, Suffolk, England.
   Ipswich Hosp, Dept Gen Surg, Ipswich IP4 5PD, Suffolk, England.
   Ipswich Hosp, Dept Radiol, Ipswich IP4 5PD, Suffolk, England.}},
ISSN = {{1750-8460}},
Keywords-Plus = {{PANCREAS}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{Babu R D, 2001, Trop Gastroenterol, V22, P213.
   Evans JD, 2000, DIGEST SURG, V17, P183, DOI 10.1159/000018828.
   SOZBILEN M, 1992, BRIT J SURG, V79, P802, DOI 10.1002/bjs.1800790831.
   STAMBLER JB, 1982, GASTROENTEROLOGY, V83, P922.
   Xia F, 2003, WORLD J GASTROENTERO, V9, P1361.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Br. J. Hosp. Med.}},
Doc-Delivery-Number = {{192DL}},
Unique-ID = {{ISI:000248180900018}},
}

@article{ ISI:000247347700038,
Author = {O'Hearn, Thomas M. and Fawzi, Amani and Esmaili, Daniel and Javaheri,
   Michael and Rao, Narsing A. and Lim, Jennifer I.},
Title = {{Presumed ocular tuberculosis presenting as a branch retinal vein
   occlusion in the absence of retinal vasculitis or uveitis}},
Journal = {{BRITISH JOURNAL OF OPHTHALMOLOGY}},
Year = {{2007}},
Volume = {{91}},
Number = {{7}},
Pages = {{981-982}},
Month = {{JUL}},
Publisher = {{B M J PUBLISHING GROUP}},
Address = {{BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Lim, JI (Reprint Author), Univ So Calif, Keck Sch Med, Doheny Eye Inst, 1450 San Pablo St,DEI Suite 3612, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.}},
DOI = {{10.1136/bjo.2006.100933}},
ISSN = {{0007-1161}},
Keywords-Plus = {{CAT-SCRATCH DISEASE}},
Research-Areas = {{Ophthalmology}},
Web-of-Science-Categories  = {{Ophthalmology}},
Author-Email = {{jennifil@usc.edu}},
Cited-References = {{DONAHUE HC, 1967, AM J OPHTHALMOL, V64, P742.
   Gupta A, 2001, RETINA-J RET VIT DIS, V21, P435, DOI 10.1097/00006982-200110000-00004.
   Sander A, 2001, EUR J CLIN MICROBIOL, V20, P392, DOI 10.1007/PL00011280.
   Solley WA, 1999, OPHTHALMOLOGY, V106, P1546, DOI 10.1016/S0161-6420(99)90452-9.}},
Number-of-Cited-References = {{4}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Br. J. Ophthalmol.}},
Doc-Delivery-Number = {{180FK}},
Unique-ID = {{ISI:000247347700038}},
}

@article{ ISI:000253805900008,
Author = {Pessoa Militao de Albuquerque, Maria de Fatima and de Alencar Ximenes,
   Ricardo Arraes and Lucena-Silva, Norma and de Souza, Wayner Vieira and
   Dantas, Andrea Tavares and Souza Dantas, Odimariles Maria and Rodrigues,
   Laura Cunha},
Title = {{Factors associated with treatment failure, dropout, and death in a
   cohort of tuberculosis patients in Recife, Pernambuco State, Brazil}},
Journal = {{CADERNOS DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{23}},
Number = {{7}},
Pages = {{1573-1582}},
Month = {{JUL}},
Abstract = {{A cohort of cases initiating tuberculosis treatment from May 2001 to
   July 2003 was followed in Recife, Pernambuco State, Brazil, to
   investigate biological, clinical, social, lifestyle, and healthcare
   access factors associated with three negative tuberculosis treatment
   outcomes (treatment failure, dropout, and death) separately and as a
   group. Treatment failure was associated with treatment delay,
   illiteracy, and alcohol consumption. Factors associated with dropout
   were age, prior TB treatment, and illiteracy. Death was associated with
   age, treatment delay, HIV co-infection, and head of family's income.
   Main factors associated with negative treatment outcomes as a whole were
   age, HIV co-infection, illiteracy, alcoholism, and prior TB treatment.
   We suggest the following strategies to increase cure rates: further
   training of the Family Health Program personnel in TB control,
   awareness-raising on the need to tailor their activities to special care
   for cases (e.g., literacy training); targeting use of directly observed
   therapy for higher risk groups; establishment of a flexible referral
   scheme to handle technical and psychosocial problems, including
   alcoholism; and increased collaboration with the HIV/AIDS program.}},
Publisher = {{CADERNOS SAUDE PUBLICA}},
Address = {{RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{de Albuquerque, MDPM (Reprint Author), Fundacao Oswaldo Cruz, Dept Estudos Saude Coletiva, Ctr Pesquisas Aggeu Magalhaes, Av Dezessete Agosto 1820,Apto 301, BR-52061540 Recife, PE, Brazil.
   Pessoa Militao de Albuquerque, Maria de Fatima; Lucena-Silva, Norma; de Souza, Wayner Vieira, Fundacao Oswaldo Cruz, Dept Estudos Saude Coletiva, Ctr Pesquisas Aggeu Magalhaes, BR-52061540 Recife, PE, Brazil.
   Pessoa Militao de Albuquerque, Maria de Fatima; de Alencar Ximenes, Ricardo Arraes; Souza Dantas, Odimariles Maria, Univ Fed Pernambuco, Dept Med, Recife, PE, Brazil.
   de Alencar Ximenes, Ricardo Arraes, Univ Fed Pernambuco, Dept Clin Med, Recife, PE, Brazil.
   Dantas, Andrea Tavares, Univ Fed Pernambuco, Hosp \& Clin, Recife, PE, Brazil.
   Rodrigues, Laura Cunha, London Sch Hyg \& Trop Med, London WC1, England.}},
ISSN = {{0102-311X}},
Keywords = {{tuberculosis; risk factors; treatment failure}},
Keywords-Plus = {{DIRECTLY OBSERVED THERAPY; HIV-INFECTION; RISK-FACTORS; FOLLOW-UP;
   COMMUNITY; DISTRICT; PROGRAM; DECENTRALIZATION; ADHERENCE; MALAWI}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{militao@cpqam.fiocruz.br}},
ORCID-Numbers = {{Rodrigues, Laura Cunha/0000-0001-9008-660X}},
Cited-References = {{Albuquerque M F, 2001, Rev Panam Salud Publica, V9, P368.
   Aliyu MH, 2003, WIEN KLIN WOCHENSCHR, V115, P340.
   Anibarro Luis, 2004, Gac Sanit, V18, P38, DOI 10.1157/13057976.
   Antunes JLF, 2001, SOC SCI MED, V52, P1071, DOI 10.1016/S0277-9536(00)00214-8.
   Borgdorff MW, 2000, EUR RESPIR J, V16, P209, DOI 10.1034/j.1399-3003.2000.16b05.x.
   Burman WJ, 1997, CHEST, V111, P1168, DOI 10.1378/chest.111.5.1168.
   Comolet TM, 1998, INT J TUBERC LUNG D, V2, P891.
   Connolly C, 1999, INT J TUBERC LUNG D, V3, P1081.
   Daucourt V, 2000, MED MALADIES INFECT, V30, P152, DOI 10.1016/S0399-077X(00)88805-8.
   DIASDACOSTA JS, 1998, CAD SAUDE PUBLICA, V14, P409.
   ELSONY AI, 2002, INT J TUBERC LUNG D, V6, P1052.
   Goncalves H, 1999, Cad Saude Publica, V15, P777, DOI 10.1590/S0102-311X1999000400012.
   Kang'ombe C, 2000, T ROY SOC TROP MED H, V94, P305, DOI 10.1016/S0035-9203(00)90335-3.
   Kangangi JK, 2003, INT J TUBERC LUNG D, V7, pS5.
   Liam CK, 1999, INT J TUBERC LUNG D, V3, P300.
   Marco A, 1998, EUR RESPIR J, V12, P967, DOI 10.1183/09031936.98.12040967.
   Menezes A, 1998, REV BRAS EPIDEMIOL, V1, P50, DOI 10.1590/S1415-790X1998000100006.
   Miti S, 2003, INT J TUBERC LUNG D, V7, pS92.
   Nyirenda TE, 2003, INT J TUBERC LUNG D, V7, pS21.
   OSCHERWITZ T, 1997, JAMA-J AM MED ASSOC, V278, P865.
   PAZ AM, 2004, 6 C BRAS EP RIO JAN.
   Rabahi Marcelo Fouad, 2002, Braz J Infect Dis, V6, P63, DOI 10.1590/S1413-86702002000200002.
   Rocha M, 2003, EUR RESPIR J, V21, P785, DOI 10.1183/09031936.03.00077302.
   RUFFINONETTO A, 2006, TUBERCULOSE IMPLANTA.
   Santos MAPS, 2005, BMC PUBLIC HEALTH, V5, P25, DOI DOI 10.1186/1471-2458-5-25.
   {*}SEC POL SAUD, 2002, MAN TECN CONTR TUB.
   SOUZA WV, 1998, THESIS.
   Tanguis HG, 2000, INT J TUBERC LUNG D, V4, P55.
   Uplekar MW, 2001, INT J TUBERC LUNG D, V5, P220.
   White MC, 1996, PUBLIC HEALTH, V110, P185, DOI 10.1016/S0033-3506(96)80074-6.
   {*}WHO, 2004, INT POL COL TB HIV A.
   Wobeser W, 1999, CAN MED ASSOC J, V160, P789.
   ZAFRAN N, 1994, TUBERCLE LUNG DIS, V75, P329, DOI 10.1016/0962-8479(94)90077-9.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{20}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Cad. Saude Publica}},
Doc-Delivery-Number = {{271RH}},
Unique-ID = {{ISI:000253805900008}},
}

@article{ ISI:000253805900026,
Author = {Levino, Antonio and de Oliveira, Roselene Martins},
Title = {{Tuberculosis among the Indian population in Sao Gabriel da Cachoeira,
   Amazonas State, Brazil}},
Journal = {{CADERNOS DE SAUDE PUBLICA}},
Year = {{2007}},
Volume = {{23}},
Number = {{7}},
Pages = {{1728-1732}},
Month = {{JUL}},
Abstract = {{This study describes the tuberculosis situation in Sao Gabriel da
   Cachoeira, Amazonas State, Brazil, from 1997 to 2002. The county, which
   has a predominantly Indian population, is a relevant tuberculosis area
   in Amazonas, since the infection rate is 2.4 to 4 times that of the
   overall State and national rates. The statistical analyses used to
   assess its association with age, gender, and clinical form showed
   differences in the endemic behavior, comparing the urban and rural
   incidence rates. Males had higher standardized incidence rates than
   females in both the urban and rural areas. The most heavily affected age
   group was greater than 50 years, but the rate among individuals under 15
   years was above the overall national rate, in addition to presenting
   different severity levels in the rural sub-areas that were studied. The
   situation can be explained mainly by inequalities in access to health
   services, which paradoxically appear to show lower case-resolving
   capacity in urban areas of the county.}},
Publisher = {{CADERNOS SAUDE PUBLICA}},
Address = {{RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL}},
Type = {{Article}},
Language = {{Portuguese}},
Affiliation = {{Levino, A (Reprint Author), Fundacao Oswaldo Cruz, Ctr Pesquisa Leonidas \& Maria Deane, Rua Teresina 476, Manaus, Amazonas, Brazil.
   Levino, Antonio, Fundacao Oswaldo Cruz, Ctr Pesquisa Leonidas \& Maria Deane, Manaus, Amazonas, Brazil.
   Levino, Antonio, Univ Fed Amazanos, Manaus, Amazonas, Brazil.
   de Oliveira, Roselene Martins, Univ Estado Amazonas, Manaus, Amazonas, Brazil.}},
DOI = {{10.1590/S0102-311X2007000700026}},
ISSN = {{0102-311X}},
Keywords = {{tuberculosis; South American Indians; health inequalities}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{antoniolevino@amazonia.fiocruz.br}},
Cited-References = {{Amarante JM, 2000, B PNEUMOLOGIA SANITA, V8, P5.
   Basta Paulo Cesar, 2004, Rev Soc Bras Med Trop, V37, P338, DOI 10.1590/S0037-86822004000400010.
   Escobar A L, 2001, Cad Saude Publica, V17, P285, DOI 10.1590/S0102-311X2001000200004.
   GARNELO L, 2002, THESIS U ESTADUAL CA.
   {*}I BRAS GEOGR EST, 2000, CENS DEM 2000 RES.
   {*}I SOC FED ORG IND, 1998, MAP LIVR POV IND ALT.
   {*}I SOC FED ORG IND, 1998, POV IND ALT MED NEGR.
   Ministerio da Saude. Fundacao Nacional de Saude. Centro de Referencia Prof. Helio Fraga. Sociedade Brasileira de Pneumologia e Tisiologia, 2002, CONTR TUB PROP INT E.
   Xavier MIM, 2007, CAD SAUDE PUBLICA, V23, P445, DOI 10.1590/S0102-311X2007000200021.
   Pereira MG., 1995, EPIDEMIOLOGIA TEORIA.
   Ramos Donatela Dourado, 2003, Cad Saude Publica, V19, P27, DOI 10.1590/S0102-311X2003000100004.
   {*}SEC EST SAUD AM, 2001, DAD SOBR TUB EST AM.
   {*}SEC VIG SAUD MIN, 2003, VIG SAUD DAD IND SEL.}},
Number-of-Cited-References = {{13}},
Times-Cited = {{12}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Cad. Saude Publica}},
Doc-Delivery-Number = {{271RH}},
Unique-ID = {{ISI:000253805900026}},
}

@article{ ISI:000249229900008,
Author = {Yip, David and Bhargava, Ravi and Yao, Yin and Sutherland, Karen and
   Manfreda, Jure and Long, Richard},
Title = {{Pediatric tuberculosis in Alberta - Epidemiology and case
   characteristics (1990-2004)}},
Journal = {{CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE}},
Year = {{2007}},
Volume = {{98}},
Number = {{4}},
Pages = {{276-280}},
Month = {{JUL-AUG}},
Abstract = {{Background: Pediatric tuberculosis (TB) is important medically and
   indicative of a public health problem. An understanding of the
   epidemiology and case characteristics of pediatric TB, in a province
   that accepts large numbers of immigrants, can inform TB elimination
   strategy.
   Methods: All cases of pediatric TB notified in Alberta between 1990 and
   2004 were identified in the TB Registry. Individual diagnostic criteria
   were reviewed and case patients were related to a population grid
   derived from Statistics Canada censuses and population estimates of
   Status Indians from the Department of Indian and Northern Affairs,
   Canada. Incidence rates were determined by ethnic group and gender.
   Clinical/mycobacteriologic case characteristics were compared by ethnic
   group and birth country.
   Results: Among 124 notified cases, 95 (96 episodes) met strict
   diagnostic criteria: 45 Status Indians, 30 Canadian-born `other' and 21
   foreign-born. Incidence rates were much higher in Status Indians and the
   foreign-born compared to the Canadian-born `other'; 10.7, 5.4, and 0.4
   per 100,000 person-years, respectively. Among Canadian-born `other'
   cases, 12 were Metis and 11 were Canadian-born children of foreign-born
   parents. Compared to foreign-born cases, Canadian-born cases were more
   likely to have a source case in Alberta, to be detected through contact
   tracing, to have primary pulmonary T13, and to have a rural address.
   Conclusion: Pediatric T13 in Alberta is mainly the result of ongoing
   transmission in Aboriginal peoples and immigration to Canada of persons
   with latent TB infection. The elimination of pediatric TB will require
   interruption of transmission in Aboriginal peoples and prevention of
   disease in immigrants.}},
Publisher = {{CANADIAN PUBLIC HEALTH ASSOC}},
Address = {{1565 CARLING AVE, SUITE 400, OTTAWA, ONTARIO K1Z 8R1, CANADA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Long, R (Reprint Author), Tuberculosis Program Evaluat \& Res Unit, Room 8325,Aberhart Ctr 1,11402 Univ Ave, Edmonton, AB T6G 2J3, Canada.
   Univ Alberta, Dept Med \& Radiol, Edmonton, AB, Canada.
   Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada.}},
ISSN = {{0008-4263}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; UNITED-STATES; FOREIGN-BORN; CHILDREN;
   CHILDHOOD; TRANSMISSION; INFECTION; CANADA}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{richard.long@ualberta.ca}},
Cited-References = {{American Thoracic Society/Centers for Disease Control and Prevention/Infectious Disease Society of America, 2003, AM J RESP CRIT CARE, V167, P603.
   {*}CDC, 2003, REP TUB US.
   Crockett M, 2004, CLIN INFECT DIS, V39, P1719, DOI 10.1086/425740.
   Feja K, 2005, CLIN CHEST MED, V26, P295, DOI 10.1016/j.ccm.2005.02.010.
   FROEHLICH H, 2001, PEDIATRICS, P107.
   GABRIEL PS, 2003, PUB HLTH REP, V118, P144, DOI 10.1016/S0033-3549(04)50229-7.
   GALBRAIT.JD, 1969, CAN MED ASSOC J, V100, P497.
   Heymann SJ, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.1.e1.
   Hoeppner V H, 2000, Can Respir J, V7, P141.
   JEREB JA, 1993, SEMIN PEDIAT INFECT, V4, P220.
   Kunimoto D, 2004, INT J TUBERC LUNG D, V8, P1213.
   LEUNG AN, 1992, RADIOLOGY, V182, P87.
   Loeffler Ann M, 2003, Semin Respir Infect, V18, P272.
   Long R, 2004, CAN J PUBLIC HEALTH, V95, P249.
   Long R, 2002, INT J TUBERC LUNG D, V6, P615.
   Mandalakas Anna M, 2005, Semin Pediatr Infect Dis, V16, P93, DOI 10.1053/j.spid.2005.01.001.
   Marais BJ, 2004, INT J TUBERC LUNG D, V8, P392.
   MENZIES D, 2000, CANADIAN TUBERCULOSI, P45.
   Nelson LJ, 2004, PEDIATRICS, V114, P333, DOI 10.1542/peds.114.2.333.
   Ozuah PO, 2001, JAMA-J AM MED ASSOC, V285, P451, DOI 10.1001/jama.285.4.451.
   Saiman L, 2001, PEDIATRICS, V107, P999, DOI 10.1542/peds.107.5.999.
   Schneider E, 2005, AM J PUBLIC HEALTH, V95, P873, DOI 10.2105/AJPH.2004.052456.
   Sen M, 2005, CAN MED ASSOC J, V172, P1453, DOI 10.1503/cmaj.1031052.
   SMUTS NA, 1994, PEDIATR RADIOL, V24, P478, DOI 10.1007/BF02015003.
   STEINER P, 1985, AM J DIS CHILD, V139, P780.
   Swingler GH, 2005, ARCH DIS CHILD, V90, P1153, DOI 10.1136/adc.2004.062315.
   Ussery XT, 1996, PEDIATR INFECT DIS J, V15, P697, DOI 10.1097/00006454-199608000-00013.
   Verver S, 2005, EUR RESPIR J, V26, P126, DOI 10.1183/09031936.05.00133204.
   2002, DRUG RESISTANT TUBER.
   2004, PEDIATRICS, V114, P1175.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Can. J. Public Health-Rev. Can. Sante Publ.}},
Doc-Delivery-Number = {{207CT}},
Unique-ID = {{ISI:000249229900008}},
}

@article{ ISI:000246790700032,
Author = {Lai-Cheong, J. E. and Perez, A. and Tang, V. and Martinez, A. and Hill,
   V. and Menage, H. du P.},
Title = {{Cutaneous manifestations of tuberculosis}},
Journal = {{CLINICAL AND EXPERIMENTAL DERMATOLOGY}},
Year = {{2007}},
Volume = {{32}},
Number = {{4}},
Pages = {{461-466}},
Month = {{JUL}},
Abstract = {{Cutaneous involvement is a rare manifestation of tuberculosis ( TB). The
   correct diagnosis is often significantly delayed because cutaneous TB is
   not routinely considered in the differential diagnosis or because
   investigations fail to reveal the presence of Mycobacterium
   tuberculosis. The clinical features of cutaneous TB are diverse, and
   result from exogenous and endogenous spread of M. tuberculosis and from
   immune-mediated mechanisms. The recognition of cutaneous TB is
   important, as the diagnosis is frequently overlooked resulting in
   delayed treatment.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Lai-Cheong, JE (Reprint Author), United Med \& Dent Sch Guys \& St Thomas Hosp, St Johns Inst Dermatol, London SE1 7EH, England.
   Univ London, Lewisham Hosp, Dept Dermatol, London, England.
   Univ London, Lewisham Hosp, Dept Pathol, London, England.}},
DOI = {{10.1111/j.1365-2230.2007.02352.x}},
ISSN = {{0307-6938}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; ERYTHEMA INDURATUM; LUPUS-VULGARIS; SKIN;
   SECONDARY; SERIES; DIAGNOSIS; ABSCESSES; PATIENT; NODOSUM}},
Research-Areas = {{Dermatology}},
Web-of-Science-Categories  = {{Dermatology}},
Author-Email = {{joey.lai-cheong@kcl.ac.uk}},
Cited-References = {{Almagro M, 2005, CLIN EXP DERMATOL, V30, P247, DOI 10.1111/j.1365-2230.2005.01728.x.
   Barbagallo Joseph, 2002, Am J Clin Dermatol, V3, P319, DOI 10.2165/00128071-200203050-00004.
   Bayer-Garner IB, 2005, J CUTAN PATHOL, V32, P220, DOI 10.1111/j.0303-6987.2005.00296.x.
   Connolly B, 1999, Am J Orthop (Belle Mead NJ), V28, P417.
   Daikos GL, 1998, CLIN INFECT DIS, V27, P205, DOI 10.1086/514608.
   Ekmekci TR, 2005, J EUR ACAD DERMATOL, V19, P511, DOI 10.1111/j.1468-3083.2004.01171.x.
   Gruber PC, 2002, CLIN EXP DERMATOL, V27, P188, DOI 10.1046/j.1365-2230.2002.00994.x.
   HORNEY DA, 1985, ARCH DERMATOL, V121, P648, DOI 10.1001/archderm.121.5.648.
   Inoue T, 2006, J DERMATOL, V33, P268, DOI 10.1111/j.1346-8138.2006.00065.x.
   Jacinto SS, 2003, CUTIS, V72, P373.
   Jordaan HF, 2000, PEDIATR DERMATOL, V17, P183, DOI 10.1046/j.1525-1470.2000.01748.x.
   Kivanc-Altunay I, 2003, INT J DERMATOL, V42, P197, DOI 10.1046/j.1365-4362.2003.01762.x.
   Mert A, 2004, SCAND J INFECT DIS, V36, P424, DOI 10.1080/00365540410027184.
   Mert A, 2004, J DERMATOL, V31, P66.
   Pandhi D, 2004, J EUR ACAD DERMATOL, V18, P546, DOI 10.1111/j.1468-3083.2004.00970.x.
   PREMALATHA S, 1987, INT J DERMATOL, V26, P600, DOI 10.1111/j.1365-4362.1987.tb02316.x.
   Ramam M, 2005, INT J DERMATOL, V44, P121, DOI 10.1111/j.1365-4632.2005.02063.x.
   RAMESH V, 1987, INT J DERMATOL, V26, P578, DOI 10.1111/j.1365-4362.1987.tb02309.x.
   RIEDMAN PC, 2005, J AM ACAD DERMATOL, V53, pS154.
   Saral Y, 2005, J CUTAN PATHOL, V32, P629, DOI 10.1111/j.0303-6987.2005.00348.x.
   Sehgal VN, 2005, INT J DERMATOL, V44, P521, DOI 10.1111/j.1365-4632.2005.02498.x.
   SEHGAL VN, 1994, DERMATOL CLIN, V12, P645.
   SEHGAL VN, 1990, INT J DERMATOL, V29, P237.
   Sehgal VN, 2001, INT J DERMATOL, V40, P205, DOI 10.1046/j.1365-4362.2001.01138-6.x.
   SEHGAL VN, 1994, INT J DERMATOL, V33, P97, DOI 10.1111/j.1365-4362.1994.tb01534.x.
   Tappeiner G, 1999, DERMATOLOGY GEN MED, P2274.
   Vieites B, 2005, BRIT J DERMATOL, V152, P1394, DOI 10.1111/j.1365-2133.2005.06650.x.
   VISSER AJ, 1993, CLIN EXP DERMATOL, V18, P507, DOI 10.1111/j.1365-2230.1993.tb01019.x.
   Wozniacka A, 2005, INT J DERMATOL, V44, P299, DOI 10.1111/j.1365-4632.2005.01976.x.
   Yates VM, 1997, BRIT J DERMATOL, V136, P483, DOI 10.1111/j.1365-2133.1997.tb02127.x.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{14}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Clin. Exp. Dermatol.}},
Doc-Delivery-Number = {{172FY}},
Unique-ID = {{ISI:000246790700032}},
}

@article{ ISI:000247113700016,
Author = {Burl, S. and Hill, P. C. and Jeffries, D. J. and Holland, M. J. and Fox,
   A. and Lugos, M. D. and Adegbola, R. A. and Rook, G. A. and Zumla, A.
   and McAdam, K. P. W. J. and Brookes, R. H.},
Title = {{FOXP3 gene expression in a tuberculosis case contact study}},
Journal = {{CLINICAL AND EXPERIMENTAL IMMUNOLOGY}},
Year = {{2007}},
Volume = {{149}},
Number = {{1}},
Pages = {{117-122}},
Month = {{JUL}},
Abstract = {{Regulatory T lymphocytes (T(regs)) that express FOXP3 are involved in
   the beneficial attenuation of immunopathology, but are also implicated
   in down-regulation of protective responses to infection. Their role in
   tuberculosis (TB) is unknown. We classified 1272 healthy TB contacts
   according to their tuberculin skin test (TST) and interferon (IFN)-gamma
   enzyme-linked immunospot (ELISPOT) results and 128 TB cases, and studied
   the expression of FOXP3 and interleukin (IL)-10 in blood samples.
   Compared to the uninfected contact group (TST(-), ELISPOT(-)), we
   observed higher levels of FOXP3 mRNA in blood from TB patients (<
   0.001), but IL-10 expression was slightly lower (P = 0.04). In contrast,
   FOXP3 expression levels were significantly lower (P = 0.001) in the
   recently infected contacts (TST(+), ELISPOT(+)) but there was no
   difference for IL-10 (P = 0.74). We hypothesize that during
   early/subclinical TB, most of which will become latent, FOXP3(+) T(regs)
   may be sequestered in the lungs, but when TB becomes progressive, FOXP3
   reappears at increased levels in the periphery. While these findings do
   not reveal the role, beneficial or harmful, of T(regs) in TB, they
   emphasize the probable importance of these cells.}},
Publisher = {{WILEY-BLACKWELL}},
Address = {{COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rook, GA (Reprint Author), UCL, Ctr Infect Dis \& Int Hlth, Windeyer Inst Med Sci, 46 Cleveland St, London W1T 4JF, England.
   UCL, Ctr Infect Dis \& Int Hlth, Windeyer Inst Med Sci, London W1T 4JF, England.
   London Sch Hyg \& Trop Med, Clin Res Unit, Dept Infect \& Trop Med, London WC1, England.
   Med Res Council UK Unit, Bacterial Dis Programme, TB Div, Banjul, Gambia.}},
DOI = {{10.1111/j.1365-2249.2007.03399.x}},
ISSN = {{0009-9104}},
Keywords = {{FOXP3; IL-10; T(regs); tuberculosis}},
Keywords-Plus = {{REGULATORY T-CELLS; LINKED IMMUNOSPOT ASSAY; PERIPHERAL-BLOOD;
   IMMUNE-RESPONSES; INFECTION; CD4(+); DIAGNOSIS; GAMBIA; RNA}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{g.rook@ucl.ac.uk}},
ORCID-Numbers = {{Rook, Graham/0000-0002-8041-8110
   Zumla, Alimuddin/0000-0002-5111-5735}},
Funding-Acknowledgement = {{Medical Research Council {[}MC\_U190071468]}},
Cited-References = {{Andersson J, 2005, J IMMUNOL, V174, P3143.
   Bisikirska B, 2005, J CLIN INVEST, V115, P2904, DOI 10.1172/JCI23961.
   Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918.
   Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047.
   Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116.
   Dheda K, 2004, BIOTECHNIQUES, V37, P112.
   Dheda K, 2004, BIOTECHNIQUES, V37, P116.
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904.
   GUYOTREVOL V, 2005, AM J RESP CRIT CARE, V173, P803.
   Hill PC, 2005, J CLIN MICROBIOL, V43, P2070, DOI 10.1128/JCM.43.5.2070-2074.2005.
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362.
   Hisaeda H, 2004, NAT MED, V10, P29, DOI 10.1038/nm975.
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490.
   Jarvis LB, 2005, EUR J IMMUNOL, V35, P2896, DOI 10.1002/eji.200526162.
   Jeffries DJ, 2004, INT J TUBERC LUNG D, V8, P1095.
   Ji JX, 2005, J IMMUNOL, V174, P7147.
   Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909.
   Kinter AL, 2004, J EXP MED, V200, P331, DOI 10.1084/jem.20032069.
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859.
   Morgan ME, 2005, HUM IMMUNOL, V66, P13, DOI 10.1016/j.humimm.2004.05.016.
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178.
   Soysal A, 2005, LANCET, V366, P1443, DOI 10.1016/S0140-6736(05)67534-4.
   Stassen M, 2004, EUR J IMMUNOL, V34, P1303, DOI 10.1002/eji.200324656.
   Stoop JN, 2005, HEPATOLOGY, V41, P771, DOI 10.1002/hep.20649.
   Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{34}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Clin. Exp. Immunol.}},
Doc-Delivery-Number = {{176VT}},
Unique-ID = {{ISI:000247113700016}},
}

@article{ ISI:000248074800005,
Author = {Connell, Tom G. and Shey, Muki S. and Seldon, Ronnett and Rangaka,
   Molebogeng X. and van Cutsem, Gilles and Simsova, Marcela and Marcekova,
   Zuzana and Sebo, Peter and Curtis, Nigel and Diwakar, Lavanya and
   Meintjes, Graeme A. and Leclerc, Claude and Wilkinson, Robert J. and
   Wilkinson, Katalin A.},
Title = {{Enhanced ex vivo stimulation of Mycobacterium tuberculosis-specific T
   cells in human immunodeficiency virus-infected persons via antigen
   delivery by the Bordetella pertussis adenylate cyclase vector}},
Journal = {{CLINICAL AND VACCINE IMMUNOLOGY}},
Year = {{2007}},
Volume = {{14}},
Number = {{7}},
Pages = {{847-854}},
Month = {{JUL}},
Abstract = {{The genetically detoxified Bordetella pertussis adenylate cyclase is a
   promising delivery system for immunodominant tuberculosis antigens in
   gamma interferon release assays. This system has not been evaluated in
   human immunodeficiency virus (HIV)-infected persons in high tuberculosis
   prevalence areas. A whole-blood gamma interferon release assay with
   Mycobacterium tuberculosis antigens (early-secreted antigenic target 6,
   culture filtrate protein 10, alpha-crystallin 2, and TB10.3) delivered
   by adenylate cyclase in addition to native tuberculosis antigens
   (without adenylate cyclase delivery) was evaluated in 119 adults in
   Khayelitsha Township, Cape Town, South Africa. Results were compared to
   tuberculin skin test results of 41 HIV-positive and 42 HIV-negative
   asymptomatic persons, in addition to 36 HIV-positive persons with
   recently diagnosed smear-or culture-positive pulmonary tuberculosis.
   Delivery of tuberculosis antigens by adenylate cyclase decreased by
   10-fold the amount of antigen required to restimulate T cells.
   Furthermore, the responses of HIV-positive persons with a low response
   to native tuberculosis antigens were enhanced when these antigens were
   delivered by adenylate cyclase. When gamma interferon responses to the
   tuberculosis antigens (with or without delivery by adenylate cyclase)
   were combined, a significantly higher number of patients were scored
   positive than by tuberculin skin testing. Ex vivo responses to
   tuberculosis antigens delivered by adenylate cyclase are maintained in
   the context of HIV infection. Our findings suggest that the majority of
   those in this population are infected with tuberculosis, which is of
   significant public health importance.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Wilkinson, KA (Reprint Author), Univ Cape Town, Fac Hlth Sci, Inst Infect Dis \& Mol Med, Anzio Rd, ZA-7700 Rondebosch, South Africa.
   Univ Cape Town, Fac Hlth Sci, Inst Infect Dis \& Mol Med, ZA-7700 Rondebosch, South Africa.
   Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Gen Med,Dept Paediat,Infect Dis Unit, Parkville, Vic 3052, Australia.
   Acad Sci Czech Republ, Inst Microbiol, Prague, Czech Republic.
   Inst Pasteur, INSERM, E352, Unit Regulat Immunitary \& Vaccinol, Paris, France.
   Univ London Imperial Coll Sci \& Technol, Wellcome Trust Ctr Res Clin Trop Med, Div Med, London, England.}},
DOI = {{10.1128/CVI.00041-07}},
ISSN = {{1556-6811}},
Keywords-Plus = {{ESAT-6 GENE FAMILY; SKIN-TEST; PRESENTATION PATHWAY; LATENT
   TUBERCULOSIS; SOUTH-AFRICA; GAMMA ASSAY; HIGH-RISK; DIAGNOSIS;
   INDIVIDUALS; CHILDREN}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{katalin.wilkinson@imperial.ac.uk}},
ResearcherID-Numbers = {{SEBO, Peter/F-7423-2011
   Curtis, Nigel/B-3491-2012
   Rangaka, Molebogeng/E-4116-2015
   Shey, Muki/M-1273-2016
   }},
ORCID-Numbers = {{SEBO, Peter/0000-0002-9755-7715
   Curtis, Nigel/0000-0003-3446-4594
   Shey, Muki/0000-0002-8776-4737
   Wilkinson, Robert/0000-0002-2753-1800
   Diwakar, Lavanya/0000-0003-4369-6637}},
Funding-Acknowledgement = {{Medical Research Council {[}MC\_U117588499]; Wellcome Trust {[}072070]}},
Cited-References = {{Anastos K, 1999, J ACQ IMMUN DEF SYND, V21, P141.
   Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2.
   Anderson ST, 2006, AM J RESP CRIT CARE, V173, P1038, DOI 10.1164/rccm.200509-1526OC.
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195.
   Brock I, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-56.
   Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008.
   Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/01.aids.0000125925.87797.38.
   Coetzee D, 2004, TROP MED INT HEALTH, V9, pA11, DOI 10.1111/j.1365-3156.2004.01259.x.
   Connell TG, 2006, EXPERT REV MOL DIAGN, V6, P663, DOI 10.1586/14737159.6.5.663.
   Converse PJ, 1997, J INFECT DIS, V176, P144, DOI 10.1086/514016.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Dheda K, 2005, AIDS, V19, P2038, DOI 10.1097/01.aids.0000191923.08938.5b.
   Guermonprez P, 1999, J IMMUNOL, V162, P1910.
   Guermonprez P, 2001, J EXP MED, V193, P1035, DOI 10.1084/jem.193.9.1035.
   Hogarth PJ, 2005, VACCINE, V23, P2557, DOI 10.1016/j.vaccine.2004.11.030.
   Johnson JL, 1998, AM J RESP CRIT CARE, V158, P1790.
   Liebeschuetz S, 2004, LANCET, V364, P2196, DOI 10.1016/S0140-6736(04)17592-2.
   Loucka J, 2002, INFECT IMMUN, V70, P1002.
   Mahairas GG, 1996, J BACTERIOL, V178, P1274.
   Mazurek Gerald H., 2005, Morbidity and Mortality Weekly Report, V54, P49.
   Rangaka MX, 2007, AM J RESP CRIT CARE, V175, P514, DOI 10.1164/rccm.200610-1439OC.
   Richeldi L, 2006, AM J RESP CRIT CARE, V174, P736, DOI 10.1164/rccm.200509-1516PP.
   Saron MF, 1997, P NATL ACAD SCI USA, V94, P3314, DOI 10.1073/pnas.94.7.3314.
   Schlecht G, 2004, J IMMUNOL, V173, P6089.
   Skjot RLV, 2002, INFECT IMMUN, V70, P5446, DOI 10.1128/IAI.70.10.5446-5453.2002.
   Tsiouris SJ, 2006, INT J TUBERC LUNG D, V10, P939.
   Vordermeier HM, 2004, INFECT IMMUN, V72, P6255, DOI 10.1128/IAI.72.11.6255-6261.2004.
   Wilkinson KA, 2005, INFECT IMMUN, V73, P2991, DOI 10.1128/IAI.73.5.2991-2998.2005.
   Wilkinson KA, 2005, J IMMUNOL, V174, P4237.
   2006, WKLY EPIDEMIOL REV, V81, P86.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{12}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Clin. Vaccine Immunol.}},
Doc-Delivery-Number = {{190QU}},
Unique-ID = {{ISI:000248074800005}},
}

@article{ ISI:000248074800010,
Author = {Leyten, Eliane M. S. and Arend, Sandra M. and Prins, Corine and
   Cobelens, Frank G. J. and Ottenhoff, Tom H. M. and van Dissel, Jaap T.},
Title = {{Discrenancy between Mycobacterium tuberculosis-specific gamma interferon
   release assays using short and prolonged in vitro incubation}},
Journal = {{CLINICAL AND VACCINE IMMUNOLOGY}},
Year = {{2007}},
Volume = {{14}},
Number = {{7}},
Pages = {{880-885}},
Month = {{JUL}},
Abstract = {{The sensitivities of various gamma interferon release assays (IGRAs) for
   the detection of past latent Mycobacterium tuberculosis infection are
   not known. In this study, we aimed to assess the effects of various IGRA
   formats and in vitro incubation periods on test outcome. The results of
   the tuberculin skin test (TST) were compared with those of the
   QuantiFERON-TB Gold in-tube (QFT-GIT) test, an overnight enzyme-linked
   immunospot assay (ELISPOT), and a 6-day lymphocyte stimulation test
   (LST) by using the same M. tuberculosis-specitic peptides and samples
   from 27 TST-positive persons with a history of exposure to M.
   tuberculosis, 4 patients cured of tuberculosis (TB), and 9 TST-negative
   controls. Among the TST-positive persons, the LST was more frequently
   positive (92\%; P < 0.01) than either the QFT-GIT test (33\%) or ELISPOT
   (46\%). While good agreement was observed between the QFT-GIT test and
   ELISPOT (kappa = 0.71) and between TST and LST (kappa = 0.78), the
   agreement between TST or LST, on the one hand, and the QFT-GIT test or
   ELISPOT, on the other, was poor. These data indicate that the QFT-GIT
   test and overnight ELISPOT are less sensitive for the detection of past
   latent TB than the 6-day LST. The observed discrepancies between these
   IGRAs are most likely related to differences in incubation periods.
   Whether TST-positive persons with positive LST results but negative
   QFT-GIT and ELISPOT results are at risk for the development of TB needs
   to be elucidated before short-incubation IGRAs can be used for the
   screening of individuals for latent TB before immunosuppressive
   treatment.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Arend, SM (Reprint Author), Medish Cent Haagladen, Dept Internal Med, Lijnbaan 32, NL-2512 VA The Hague, Netherlands.
   Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands.
   Leiden Univ, Med Ctr, Dept Immunohematol \& Blood Transfus, Leiden, Netherlands.
   KNCV Tuberculosis Fdn, The Hague, Netherlands.}},
DOI = {{10.1128/CVI.00132-07}},
ISSN = {{1556-6811}},
Keywords-Plus = {{T-CELL RESPONSES; ENZYME-LINKED IMMUNOSPOT; SKIN-TEST; WHOLE-BLOOD;
   INFECTION; DIAGNOSIS; ANTIGEN; ESAT-6; IMMUNODIAGNOSIS; POPULATION}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{S.M.Arend@LUMC.nl}},
Cited-References = {{Arend SM, 2007, AM J RESP CRIT CARE, V175, P618, DOI 10.1164/rccm.200608-1099OC.
   Arend SM, 2002, J INFECT DIS, V186, P1797, DOI 10.1086/345760.
   Arend SM, 2000, J INFECT DIS, V181, P1850, DOI 10.1086/315448.
   Brock I, 2004, J CLIN MICROBIOL, V42, P2379, DOI 10.1128/JCM.42.6.2379-2387.2004.
   Brock Iinger, 2004, American Journal of Respiratory and Critical Care Medicine, V170, P65, DOI 10.1164/rccm.200402-232OC.
   CHEE CB, 2006, AM J RESP CRIT CARE.
   Codecasa L R, 2005, Monaldi Arch Chest Dis, V63, P158.
   Codeluppi M, 2006, TRANSPLANT P, V38, P1083, DOI 10.1016/j.transproceed.2006.02.012.
   Diel R, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-77.
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9.
   Ewer K, 2006, AM J RESP CRIT CARE, V174, P831, DOI 10.1164/rccm.200511-1783OC.
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6.
   Godkin AJ, 2002, J IMMUNOL, V169, P2210.
   Goletti D, 2006, J INFECT DIS, V194, P984, DOI 10.1086/507427.
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362.
   Kang YA, 2005, JAMA-J AM MED ASSOC, V293, P2756, DOI 10.1001/jama.293.22.2756.
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110.
   Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1.
   LEYTEN EM, EUR RESP J.
   Mahomed H, 2006, INT J TUBERC LUNG D, V10, P310.
   Munk ME, 2001, J INFECT DIS, V183, P175, DOI 10.1086/317663.
   Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746.
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.
   Pai Madhukar, 2006, J Occup Med Toxicol, V1, P7, DOI 10.1186/1745-6673-1-7.
   Porsa E, 2006, CLIN VACCINE IMMUNOL, V13, P53, DOI 10.1128/CVI.13.1.53-58.2006.
   Rangaka MX, 2007, AM J RESP CRIT CARE, V175, P514, DOI 10.1164/rccm.200610-1439OC.
   Ravn P, 1999, J INFECT DIS, V179, P637, DOI 10.1086/314640.
   Scarpellini P, 2004, J CLIN MICROBIOL, V42, P3469, DOI 10.1128/JCM.42.8.3469-3474.2004.
   Scholvinck E, 2004, J CLIN MICROBIOL, V42, P829, DOI 10.1128/JCM.42.2.829-831.2004.
   Shams H, 2005, AM J RESP CRIT CARE, V172, P1161, DOI 10.1164/rccm.200505-748OC.
   Wilkinson KA, 2006, J INFECT DIS, V193, P354, DOI 10.1086/499311.
   Wu-Hsieh BA, 2001, CLIN INFECT DIS, V33, P1336, DOI 10.1086/323044.}},
Number-of-Cited-References = {{32}},
Times-Cited = {{71}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Clin. Vaccine Immunol.}},
Doc-Delivery-Number = {{190QU}},
Unique-ID = {{ISI:000248074800010}},
}

@article{ ISI:000248074800013,
Author = {Wang, Baolin and Henao-Tamayo, Marcela and Harton, Marisa and Ordway,
   Diane and Shanley, Crystal and Basaraba, Randall J. and Orme, Ian M.},
Title = {{A toll-like receptor-2-directed fusion protein vaccine against
   tuberculosis}},
Journal = {{CLINICAL AND VACCINE IMMUNOLOGY}},
Year = {{2007}},
Volume = {{14}},
Number = {{7}},
Pages = {{902-906}},
Month = {{JUL}},
Abstract = {{A fusion protein designated CSU-F36 was constructed that consisted of
   acylated Rv1411, a potent Toll-like receptor-2 agonist, fused to ESAT-6,
   a well-characterized immunogenic protein from Mycobacterium
   tuberculosis. The CSU-F36 fusion protein strongly induced interleukin 12
   secretion from macrophages and induced the increased accumulation of CD4
   T cells capable of secreting gamma interferon in the lungs of infected
   mice. These mice were significantly protected from low-dose aerosol
   challenge with M. tuberculosis, even with CSU-F36 delivered in a simple
   depot material. This ``natural adjuvant{''}-containing system could
   potentially bypass the need for more expensive TH1-inducing adjuvants
   and could be applied to many mycobacterial proteins to provide effective
   and cheap new vaccines against tuberculosis.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Orme, IM (Reprint Author), Colorado State Univ, Dept Microbiol Immunol \& Pathol, Ft Collins, CO 80523 USA.
   Colorado State Univ, Dept Microbiol Immunol \& Pathol, Ft Collins, CO 80523 USA.
   Colorado State Univ, Dept Microbiol Immunol \& Pathol, Mycobacteria Res Labs, Ft Collins, CO USA.}},
DOI = {{10.1128/CDLI.00077-07}},
ISSN = {{1556-6811}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; 27-KDA LIPOPROTEIN; TB VACCINES;
   GUINEA-PIGS; INFECTION; RECEPTORS; MTB72F; MICE}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{ian.orme@colostate.edu}},
ResearcherID-Numbers = {{Henao-Tamayo, Marcela/D-8189-2017
   Ordway, Diane/H-9732-2017}},
ORCID-Numbers = {{Henao-Tamayo, Marcela/0000-0002-4249-9650
   Ordway, Diane/0000-0003-0003-326X}},
Cited-References = {{Andersen P, 2001, TRENDS IMMUNOL, V22, P160, DOI 10.1016/S1471-4906(01)01865-8.
   Brandt L, 2004, INFECT IMMUN, V72, P6622, DOI 10.1128/IAI.72.11.6622-6632.2004.
   Brandt L, 2000, INFECT IMMUN, V68, P791, DOI 10.1128/IAI.68.2.791-795.2000.
   Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732.
   COOPER AM, 1995, INFECT IMMUN, V63, P3259.
   Dye C, 2002, J INFECT DIS, V185, P1197, DOI 10.1086/339818.
   Hovav AH, 2006, TUBERCULOSIS, V86, P225, DOI 10.1016/j.tube.2006.01.012.
   Hovav AH, 2003, INFECT IMMUN, V71, P3146, DOI 10.1128/IAI.71.6.3146-3154.2003.
   Hovav AH, 2006, MICROBES INFECT, V8, P1750, DOI 10.1016/j.micinf.2006.02.011.
   Kawahara M, 2002, INFECT IMMUN, V70, P6614, DOI 10.1128/IAI.70.12.6614-6620.2002.
   Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X.
   Orme IM, 2006, VACCINE, V24, P2, DOI 10.1016/j.vaccine.2005.07.078.
   Raviglione MC, 2003, TUBERCULOSIS, V83, P4, DOI 10.1016/S1472-9792(02)00071-9.
   Skeiky YAW, 2004, J IMMUNOL, V172, P7618.
   Stenger S, 2002, CURR OPIN IMMUNOL, V14, P452, DOI 10.1016/S0952-7915(02)00355-2.
   Turner J, 2004, INFECT IMMUN, V72, P3759, DOI 10.1128/IAI.72.7.3759-3768.2004.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{34}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Clin. Vaccine Immunol.}},
Doc-Delivery-Number = {{190QU}},
Unique-ID = {{ISI:000248074800013}},
}

@article{ ISI:000247029700023,
Author = {Singh, Akashdeep},
Title = {{Fluoroquinolones should not be the first-line antibiotics to treat
   community-acquired pneumonia in areas of tuberculosis endemicity}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{45}},
Number = {{1}},
Pages = {{133}},
Month = {{JUL 1}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Singh, A (Reprint Author), Christian Med Coll \& Hosp, 1521 Sector 32A,Chandigarh Rd, Ludhiana 141010, Punjab, India.
   Christian Med Coll \& Hosp, Ludhiana 141010, Punjab, India.}},
DOI = {{10.1086/520486}},
ISSN = {{1058-4838}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{drsinghakashdeep@gmail.com}},
Cited-References = {{Centers for Disease Control and Prevention (CDC), 2006, MMWR-MORBID MORTAL W, V55, P301.
   Dooley KE, 2002, CLIN INFECT DIS, V34, P1607, DOI 10.1086/340618.
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159.
   SULLIVAN EA, 1995, LANCET, V345, P1148, DOI 10.1016/S0140-6736(95)90980-X.
   UDWADIA ZF, 2003, EUR RESPIR J S45, V22, pS544.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{11}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{175RC}},
Unique-ID = {{ISI:000247029700023}},
}

@article{ ISI:000248076800001,
Author = {Jain, Anil K.},
Title = {{Tuberculosis of the spine - Editorial comment}},
Journal = {{CLINICAL ORTHOPAEDICS AND RELATED RESEARCH}},
Year = {{2007}},
Number = {{460}},
Pages = {{2-3}},
Month = {{JUL}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Jain, AK (Reprint Author), Univ Coll Med Sci, Delhi 110095, India.
   Univ Coll Med Sci, Delhi 110095, India.}},
DOI = {{10.1097/BLO.0b013e318073bd29}},
ISSN = {{0009-921X}},
Research-Areas = {{Orthopedics; Surgery}},
Web-of-Science-Categories  = {{Orthopedics; Surgery}},
Author-Email = {{dranilkjain@gmail.com}},
Cited-References = {{Jain AK, 2002, CLIN ORTHOP RELAT R, P75.
   Jain NK, 1992, IND J TUBERC, V92, P145.
   Luk KDK, 1999, EUR SPINE J, V8, P338, DOI 10.1007/s005860050185.
   Nolan CM, 1996, TUBERCLE LUNG DIS, V77, P293, DOI 10.1016/S0962-8479(96)90090-8.
   Rajasekaran S, 2001, J BONE JOINT SURG BR, V83B, P954, DOI 10.1302/0301-620X.83B7.12170.
   TULI SM, 1995, INT ORTHOP, V19, P327.}},
Number-of-Cited-References = {{6}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Clin. Orthop. Rel. Res.}},
Doc-Delivery-Number = {{190RN}},
Unique-ID = {{ISI:000248076800001}},
}

@article{ ISI:000248076800003,
Author = {Sherk, Henry H.},
Title = {{Tuberculosis of the spine - Comment on the classics}},
Journal = {{CLINICAL ORTHOPAEDICS AND RELATED RESEARCH}},
Year = {{2007}},
Number = {{460}},
Pages = {{10}},
Month = {{JUL}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING ST, NEW YORK, NY 10013 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Sherk, HH (Reprint Author), Drexel Univ, Coll Med, 245 N 15th St 7th Floor,MS420, Philadelphia, PA 19102 USA.
   Drexel Univ, Coll Med, Philadelphia, PA 19102 USA.}},
DOI = {{10.1097/BLO.0b013e318067b49c}},
ISSN = {{0009-921X}},
Research-Areas = {{Orthopedics; Surgery}},
Web-of-Science-Categories  = {{Orthopedics; Surgery}},
Author-Email = {{Henry.Sherk@DrexelMed.edu}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Clin. Orthop. Rel. Res.}},
Doc-Delivery-Number = {{190RN}},
Unique-ID = {{ISI:000248076800003}},
}

@article{ ISI:000248076800008,
Author = {Tuli, S. M.},
Title = {{Tuberculosis of the spine - A historical review}},
Journal = {{CLINICAL ORTHOPAEDICS AND RELATED RESEARCH}},
Year = {{2007}},
Number = {{460}},
Pages = {{29-38}},
Month = {{JUL}},
Abstract = {{Almost all ancient civilizations described tuberculous bacilli in their
   old scripts, and these bacteria have been found in prehistoric skeletal
   remains. The clinical availability of specific antitubercular drugs was
   the most important breakthrough in managing spinal tuberculosis. Any
   attempt at surgical excision of the disease prior to the antitubercular
   era met with serious complications, dissemination of disease and high
   mortality (nearly 50\%). Antitubercular drugs markedly improved the
   results of management by operative treatment. Excellent healing of
   disease was also observed in those patients who were treated
   nonoperatively. However, it took many years (1950-1970) for clinicians
   to appreciate the efficacy of antitubercular drugs. Operations for
   spinal tuberculosis are now indicated less for control of disease
   (5-10\% of all cases) than for complications, including nonresponding
   neural deficit (nearly 40\% of neural complications), prevention or
   correction of severe kyphotic deformity, and for tissue diagnosis
   (approximately 5\% of all cases). For a classic spondylodiscitis when
   surgery is required for debridement and decompression, an anterior
   approach through an extrapleural anterolateral route or through
   transpleural route is recommended. Healthy posterior elements should not
   be jeopardized by surgery. The real control of tuberculous disease
   requires a serious and sustained global effort to eliminate
   immunocompromised states, poverty, malnutrition, and overcrowding.}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING ST, NEW YORK, NY 10013 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Tuli, SM (Reprint Author), 72 Asiad Village, New Delhi 110049, India.}},
DOI = {{10.1097/BLO.0b013e318065b75e}},
ISSN = {{0009-921X}},
EISSN = {{1528-1132}},
Keywords-Plus = {{POTTS-DISEASE; JOINT TUBERCULOSIS; RADICAL TREATMENT; FOLLOW-UP;
   CONSERVATIVE TREATMENT; SKELETAL TUBERCULOSIS; AMBULANT TREATMENT;
   VERTEBRAL BODIES; CHEMOTHERAPY; FUSION}},
Research-Areas = {{Orthopedics; Surgery}},
Web-of-Science-Categories  = {{Orthopedics; Surgery}},
Author-Email = {{smohantuli@yahoo.co.in}},
Cited-References = {{Albee FH, 1930, J AMER MED ASSOC, V94, P1467.
   Albee FH, 1911, JAMA-J AM MED ASSOC, V57, P885.
   ALVIK I, 1949, ACTA CHIR SCAND    S, P141.
   ANDRE T, 1956, ACTA RADIOL, V46, P18.
   ARCT W, 1968, J BONE JOINT SURG AM, VA 50, P255.
   BARCLAY WR, 1953, JAMA-J AM MED ASSOC, V151, P1384.
   BARNES PF, 1991, NEW ENGL J MED, V324, P1644.
   BARNES PF, 1993, ANN INTERN MED, V119, P400.
   Bick KM, 1976, CLASSICS ORTHOPAEDIC.
   BOSWORTH DM, 1952, J BONE JOINT SURG AM, V34-A, P255.
   BOSWORTH DM, 1963, ANN NY ACAD SCI, V106, P98, DOI 10.1111/j.1749-6632.1963.tb16628.x.
   BRITTIAN HA, 1952, ARCHITECTURAL PRINCI.
   BUCHMAN J, 1961, NEW YORK STATE J MED, V61, P3657.
   Calot T, 1930, ACTA CHIR SCAND, V67, P206.
   CAMERON JAP, 1962, AM REV RESPIR DIS, V86, P76.
   CAUCHOIX J, 1961, Rev Chir Orthop Reparatrice Appar Mot, V47, P446.
   CHAHAL AS, 1980, INT ORTHOP, V4, P93.
   COMPERE E L, 1952, J Bone Joint Surg Am, V34-A, P288.
   DAVIES PDO, 1984, J BONE JOINT SURG BR, V66, P326.
   DEROY MS, 1952, J BONE JOINT SURG AM, V34-A, P299.
   DOBSON J, 1951, J BONE JOINT SURG BR, V33, P517.
   DONALDSON JR, 1965, IND J SURG, V27, P765.
   DURAISWAMI PK, 1971, CLIN ORTHOP RELAT R, P269.
   EVANS ET, 1952, J BONE JOINT SURG AM, V34-A, P267.
   FALK A, 1958, J BONE JOINT SURG AM, V40, P1161.
   FELLANDER M, 1952, Acta Tuberc Scand, V27, P176.
   FELLANDER M, 1955, Acta Orthop Scand Suppl, V19, P1.
   FOX W, 1962, LANCET, V2, P413.
   FOX W, 1964, BRIT MED J, V1, P135.
   FRIEDMAN B, 1973, CLIN ORTHOP RELAT R, P5.
   FRIEDMAN B, 1966, J BONE JOINT SURG AM, VA 48, P451.
   GIRDLESTEON GR, 1965, TUBERCULOSIS BONE JO.
   GIRDLESTEON GR, 1950, MODERN TRENDS ORTH 1.
   Grewal KS, 1956, INDIAN J SURG, V18, P394.
   Griffiths DL, 1952, TUBERCULOSIS BONES J, VII, P302.
   HANNGREN A, 1964, ACTA TUBERC PNEUM SC, V45, P14.
   HANNGREN A, 1959, ACTA RADIOL S175, V51, P1.
   HARRIS RI, 1952, J BONE JOINT SURG AM, V34-A, P279.
   Hibbs RA, 1912, J AMER MED ASSOC, V59, P433.
   Hibbs RA, 1918, J AMER MED ASSOC, V71, P1372.
   Hibbs RA, 1928, J BONE JOINT SURG, V10, P805.
   HOBBY GL, 1974, AM REV RESPIR DIS, V110, P96.
   HODGSON AR, 1960, BRIT J SURG, V48, P172, DOI 10.1002/bjs.18004820819.
   HODGSON AR, 1956, BRIT J SURG, V44, P266, DOI 10.1002/bjs.18004418508.
   HODGSON AR, 1969, RECENT ADV ORTHOPAED, P289.
   HODGSON AR, 1964, J WESTERN PACIFIC OR, V1, P3.
   Hodgson AR, 1960, J BONE JOINT SURG AM, V42, P1147.
   Jones R, 1923, ORTHOPAEDIC SURG.
   Kaplan CJ, 1959, TUBERCLE, V40, P335.
   Kemp H B, 1973, J Bone Joint Surg Br, V55, P715.
   KIRKALDYWILLIS WH, 1965, J BONE JOINT SURG AM, VA 47, P87.
   KOHLI S. B., 1967, J BONE JOINT SURG B BRIT, V49, P668.
   KONDO E, 1957, J BONE JOINT SURG AM, V39, P27.
   KONSTAM P G, 1963, Ann R Coll Surg Engl, V32, P99.
   KONSTAM PG, 1962, BRIT J SURG, V50, P26, DOI 10.1002/bjs.18005021908.
   KONSTAM PG, 1958, J BONE JOINT SURG BR, V40, P26.
   LAFOND EM, 1958, J BONE JOINT SURG AM, V40, P346.
   LAGENSKIOLD A, 1967, ACTA ORTHOP SCAND, V38, P181.
   LAKHANPAL VP, 1974, ACTA ORTHOP SCAND, V45, P36, DOI 10.3109/17453677408989119.
   LAKHANPAL VP, 1976, INDIAN J ORTHOP, V10, P13.
   Lichtor J, 1957, J BONE JOINT SURG AM, V39-A, P1938.
   Lindberg L, 1967, ACTA ORTHOP SCAND, P11.
   {*}MADR TUB CHEM CTR, 1959, B WORLD HEALTH ORGAN, V21, P51.
   Madras Tuberculosis Chemotherapy Centre, 1960, B WORLD HEALTH ORGAN, V23, P535.
   Martin N S, 1970, J Bone Joint Surg Br, V52, P613.
   Martini M, 1988, TUBERCULOSIS BONES J.
   {*}MED RES COUNC, 1985, J BONE JOINT SURG BR, V64, P393.
   Medical Research Council, 1985, J BONE JOINT SURG BR, V67B, P103.
   Medical Research Council Working Party on Tuberculosis of the Spine, 1978, J BONE JOINT SURG BR, V60, P163.
   MERCER WALTER, 1964, J ROY COLL SURG EDINB, V9, P243.
   MITCHISON DA, 1986, MUSCULOSKELETAL INFE, P186.
   MOON MS, 1987, INT ORTHOP, V11, P315, DOI 10.1007/BF00271307.
   Moon MS, 2002, CLIN ORTHOP RELAT R, P40.
   Moon MS, 1991, CURRENT ORTHOP, V5, P177, DOI 10.1016/0268-0890(91)90039-3.
   MUKOPADHAYA B, 1956, Ann R Coll Surg Engl, V18, P288.
   Mishra NK, 1957, INDIAN J SURG, V19, P59.
   ORELL S, 1951, ACTA CHIR SCAND, V102, P113.
   ORELL S, 1951, ACTA ORTHOP SCAND, V21, P109.
   OSTMAN P, 1951, Acta Orthop Scand, V21, P204, DOI 10.3109/17453675109024154.
   PATEL S, 1995, ANN RHEUM DIS, V54, P174, DOI 10.1136/ard.54.3.174.
   PAUS B, 1964, ACTA ORTHOP SCAND S, V72, P1.
   QIQIU W, 1971, CHIN MED J, V100, P819.
   Rajasekaran S, 2002, CLIN ORTHOP RELAT R, P85.
   Rajasekaran S, 1998, SPINE, V23, P1163, DOI 10.1097/00007632-199805150-00018.
   Reichman LB, 1997, INT J TUBERC LUNG D, V1, P3.
   RISKO T, 1963, J BONE JOINT SURG AM, V45, P53.
   ROAF R, 1958, J BONE JOINT SURG BR, V40, P3.
   ROAF R., 1959, SURG TREATMENT BONE.
   SCOTT JE, 1982, J BONE JOINT SURG BR, V64, P250.
   Seddon HJ, 1935, BRIT J SURG, V22, P769, DOI 10.1002/bjs.1800228813.
   SEDDON HJ, 1956, MODERN TRENDS ORTH 2, P230.
   SEVASTIKOGLOU J, 1953, Acta Orthop Scand, V23, P67.
   SEVERANCE RD, 1951, NEW YORK STATE J MED, V51, P2731.
   SHAW N E, 1963, Br Med J, V1, P162.
   SINHA BN, 1958, INDIAN J TUBERC, V5, P134.
   SKILVA JF, 1980, INT ORTHOP, V4, P79.
   SMITH AD, 1968, CLIN ORTHOP RELAT R, P171.
   SMITH GW, 1958, J BONE JOINT SURG AM, V40, P607.
   SOMERVILLE EW, 1965, GIRDLESTONES TUBERCU.
   STEVENSON F H, 1962, Tubercle, V43, P406.
   STOCK FE, 1962, AUST NZ J SURG, V43, P406.
   Sweany Henry C, 1943, AMER REV TUBERC, V48, P131.
   TULI SM, 1967, ACTA ORTHOP SCAND, V38, P445, DOI 10.3109/17453676708989653.
   TULI SM, 1975, J BONE JOINT SURG BR, VB 57, P13.
   TULI SM, 1977, ACTA ORTHOP SCAND, V48, P362.
   TULI SM, 1971, CLIN ORTHOP RELAT R, P56.
   TULI SM, 1974, J BONE JOINT SURG BR, VB 56, P551.
   TULI SM, 1979, INDIAN J ORTHOP, V13, P23.
   TULI SM, 1983, INDIAN J ORTHOP, V17, P14.
   Tuli SM, 2004, TUBERCULOSIS SKELETA.
   Vyaghreswarudu C, 1964, INDIAN J SURG, V26, P911.
   WEINBERG JA, 1957, J BONE JOINT SURG AM, V39, P17.
   WILKINSON MC, 1969, J BONE JOINT SURG AM, VA 51, P1331.
   WILKINSON MC, 1949, ANN ROY COLL SURG, V4, P168.
   WILKINSON MC, 1950, P ROY SOC MED, V43, P114.
   WILKINSON MC, 1955, J BONE JOINT SURG BR, V37, P382.
   YEAGER RL, 1963, ANN NY ACAD SCI, V106, P3, DOI 10.1111/j.1749-6632.1963.tb16614.x.
   Yilmaz C, 1999, J BONE JOINT SURG AM, V81A, P1261.
   1968, BMJ, V2, P638.}},
Number-of-Cited-References = {{119}},
Times-Cited = {{58}},
Usage-Count-Last-180-days = {{4}},
Usage-Count-Since-2013 = {{14}},
Journal-ISO = {{Clin. Orthop. Rel. Res.}},
Doc-Delivery-Number = {{190RN}},
Unique-ID = {{ISI:000248076800008}},
}

@article{ ISI:000248076800009,
Author = {Jain, Anil K. and Dhammi, Ish Kumar},
Title = {{Tuberculosis of the spine - A review}},
Journal = {{CLINICAL ORTHOPAEDICS AND RELATED RESEARCH}},
Year = {{2007}},
Number = {{460}},
Pages = {{39-49}},
Month = {{JUL}},
Abstract = {{We analyzed 124 papers published in the English language literature to
   define the indications and timing of surgery in spinal TB and to
   evaluate the outcome of various surgical procedures for kyphosis and
   neural outcome. Surgery in spinal tuberculosis is indicated for
   diagnostic dilemma, neural complications, and prevention of kyphosis
   progression. Up to 76\% canal encroachment is compatible with a normal
   neurologic state as the spinal cord tolerates gradually developing
   compression. Patients with relatively preserved cord size, but with
   edema/myelitis and predominantly fluid compression on MRI respond well
   to nonoperative treatment. We believe patients with extradural
   compression by granulation tissue with little fluid component
   compressing or constricting the cord circumferentially with cord
   edema/myelitis or myelomalacia need early surgical decompression.
   Transthoracic transpleural anterior decompression and extrapleural
   anterolateral decompression have similar results in the dorsal spine.
   Instrumented stabilization helps prevent graft-related complications
   when postdebridement defects exceed two disc spaces (4-5 cm).
   Progression of kyphosis may occur in a short-segment disease despite
   instrumented stabilization. Its outcome in a long-segment disease needs
   observation. The correction of healed kyphosis requires multistage
   surgery and is fraught with complications. Prospective studies are
   needed to define surgical approach, steps, stages, problems, and
   obstacles to correct severe kyphosis in spinal TB.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Jain, AK (Reprint Author), Univ Coll Med Sci, Delhi 110095, India.
   Univ Coll Med Sci, Delhi 110095, India.
   GTB Hosp, Dept Orthopaed, Delhi, India.}},
DOI = {{10.1097/BLO.0b013e318065b7c3}},
ISSN = {{0009-921X}},
Keywords-Plus = {{ANTERIOR INTERBODY FUSION; LOWER CERVICAL-SPINE; SHORT-COURSE
   CHEMOTHERAPY; SURGICAL-MANAGEMENT; POTTS PARAPLEGIA; POSTERIOR
   INSTRUMENTATION; RADICAL SURGERY; NEUROLOGICAL COMPLICATIONS;
   DEBRIDEMENT SURGERY; LUMBAR SPINE}},
Research-Areas = {{Orthopedics; Surgery}},
Web-of-Science-Categories  = {{Orthopedics; Surgery}},
Author-Email = {{draniljain@satyam.net.in}},
Cited-References = {{Adendorff J J, 1987, J R Coll Surg Edinb, V32, P152.
   ADENDORFF JJ, 1987, S AFR MED J, V71, P427.
   Al-Sebai MW, 2001, INT ORTHOP, V25, P322, DOI 10.1007/s002640100259.
   Alothman A, 2001, Spine (Phila Pa 1976), V26, pE565, DOI 10.1097/00007632-200112150-00020.
   Altman GT, 1996, CLIN ORTHOP RELAT R, P225.
   ALWALI AA, 2002, SAUDI ME DJ, V12, P1483.
   Azzam N I, 1988, Br J Neurosurg, V2, P85, DOI 10.3109/02688698808999663.
   Benli I. Teoman, 2004, Kobe Journal of Medical Sciences, V50, P167.
   Benli I. Teoman, 2000, Kobe Journal of Medical Sciences, V46, P39.
   Benli IT, 2003, EUR SPINE J, V12, P224, DOI 10.1007/s00586-002-0403-0.
   Bilsel N, 2000, SPINAL CORD, V38, P669, DOI 10.1038/sj.sc.3101082.
   Chacko AG, 2004, SPINE, V29, pE363, DOI 10.1097/01.brs.0000137063.64650.e1.
   CHAKIRGIL GS, 1991, ORTHOPEDICS, V14, P601.
   CHEN WJ, 1995, ACTA ORTHOP SCAND, V66, P137, DOI 10.3109/17453679508995507.
   Chen WJ, 2002, CLIN ORTHOP RELAT R, P50.
   Chen Yi-Cheng, 2003, J Chin Med Assoc, V66, P411.
   Christodoulou AG, 2006, CLIN ORTHOP RELAT R, P60, DOI 10.1097/01.blo.0000201175.87635.28.
   Dai LY, 2005, SPINE, V30, P2342, DOI 10.1097/01.brs.0000182109.36973.93.
   DARBYSHIRE J, 1993, J BONE JOINT SURG BR, V75, P240.
   Ekere A U, 2005, Niger J Med, V14, P386.
   FAM AG, 1994, J RHEUMATOL, V21, P1583.
   GARST RJ, 1992, J SPINAL DISORD, V5, P286.
   Ghadouane M, 1996, REV CHIR ORTHOP, V82, P620.
   Gong Suiliang, 2002, Zhonghua Jiehe He Huxi Zazhi, V25, P105.
   GOVENDER S, 1988, S AFR MED J, V74, P58.
   Govender S, 2001, J BONE JOINT SURG BR, V83B, P864, DOI 10.1302/0301-620X.83B6.11995.
   Govender S, 2003, INT ORTHOP, V27, P244, DOI 10.1007/s00264-003-0446-9.
   Govender S, 2002, CLIN ORTHOP RELAT R, P60.
   Govender S, 2001, J PEDIATR ORTHOPED, V21, P281, DOI 10.1097/00004694-200105000-00003.
   Govender S, 2001, J PEDIATR ORTHOPED, V21, P285, DOI 10.1097/00004694-200105000-00004.
   Govender S, 1999, J BONE JOINT SURG BR, V81B, P106, DOI 10.1302/0301-620X.81B1.9316.
   Griffiths DL, 1999, INT ORTHOP, V23, P73.
   GRUNTOVSKII T, 1998, PROBL TUBERK, V5, P34.
   Guo Lixin, 2002, Zhonghua Yi Xue Za Zhi, V82, P1121.
   GUVEN O, 1994, SPINE, V19, P1039.
   Guzey FK, 2005, J NEUROSURG-SPINE, V3, P450, DOI 10.3171/spi.2005.3.6.0450.
   Hassan MG, 2003, INT ORTHOP, V27, P73, DOI 10.1007/s00264-002-0400-2.
   HSU LCS, 1988, J BONE JOINT SURG BR, V70, P534.
   Huang TJ, 2000, CLIN ORTHOP RELAT R, P143.
   IKEM IC, 2001, NIGER POSTGRAD MED J, V18, P22.
   Jain AK, 2002, CLIN ORTHOP RELAT R, P75.
   Jain AK, 1999, SPINAL CORD, V37, P362, DOI 10.1038/sj.sc.3100833.
   Jain AK, 2000, NEUROL INDIA, V48, P132.
   Jain AK, 2005, SPINAL CORD, V43, P375, DOI 10.1038/sj.sc.3101718.
   Jain AK, 2004, J BONE JOINT SURG BR, V86B, P1027, DOI 10.1302/0301-620X.86B7.14546.
   Jain AK, 1999, INT ORTHOP, V23, P85, DOI 10.1007/s002640050313.
   JAIN AK, 2004, INT ORTHOP, V28, P10.
   Jalleh R D, 1991, Med J Malaysia, V46, P269.
   JANSSENS JP, 1990, CLIN ORTHOP RELAT R, P67.
   Jin D, 2000, Zhonghua Wai Ke Za Zhi, V38, P900.
   Jin D, 2001, Zhonghua Wai Ke Za Zhi, V39, P704.
   JIN D, 2000, ZHONGHUA WAI KE ZA Z, V38, P949.
   Jin DD, 2004, EUR SPINE J, V13, P114, DOI 10.1007/s00586-003-0661-5.
   Jutte PC, 2006, COCHRANE DB SYST REV, V1.
   Kapoor SK, 2005, SPINE, V30, pE605, DOI 10.1097/01.brs.0000182328.03082.e2.
   KIM DJ, 2001, SPINE, V29, pE275.
   Klockner C, 2003, SPINE, V28, P1036, DOI 10.1097/00007632-200305150-00016.
   Korkusuz F, 1997, WORLD J SURG, V21, P524.
   KORKUSUZ Z, 1989, ARCH ORTHOP TRAUM SU, V108, P349, DOI 10.1007/BF00932444.
   Kumar R, 2005, CHILD NERV SYST, V21, P19, DOI 10.1007/s00381-004-1029-9.
   Laheri VJ, 2001, SPINAL CORD, V39, P429, DOI 10.1038/sj.sc.3101185.
   LAVROV VN, 2000, PROBL TUBERK, V5, P44.
   Lee TC, 1999, J NEUROSURG, V91, P163, DOI 10.3171/spi.1999.91.2.0163.
   Lin Yu, 1998, Zhonghua Jiehe He Huxi Zazhi, V21, P620.
   Lin Yu, 1998, Zhonghua Jiehe He Huxi Zazhi, V21, P88.
   Linhardt O, 2004, Z ORTHOP GRENZGEB, V142, P73, DOI 10.1055/s-2004-818031.
   LOEMBE PM, 1988, NEUROCHIRURGIE, V34, P420.
   LOEMBE PM, 1995, PARAPLEGIA, V33, P579.
   LOEMBE PM, 1994, CAN J NEUROL SCI, V21, P339.
   LOEMBE PM, 1994, ACTA NEUROCHIR, V131, P125, DOI 10.1007/BF01401462.
   Loembe PM, 2000, NEUROCHIRURGIE, V46, P541.
   LOUW JA, 1990, J BONE JOINT SURG BR, V72, P686.
   Lu Chang, 2003, Hunan Yike Daxue Xuebao, V28, P162.
   Lu Ning, 2005, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V19, P420.
   Lukhele M, 1996, S AFR MED J, V86, P553.
   Medical Research Council Working Party on Tuberculosis of the Spine, 1986, TUBERCLE, V67, P243.
   Medical Research Council Working Party on Tuberculosis of the Spine, 1998, J BONE JOINT SURG BR, V80, P456.
   Mehta JS, 2001, J BONE JOINT SURG BR, V83B, P859, DOI 10.1302/0301-620X.83B6.11142.
   Moon MS, 1996, CLIN ORTHOP RELAT R, P122.
   MOON MS, 1987, INT ORTHOP, V11, P315, DOI 10.1007/BF00271307.
   Moon MS, 2003, SPINAL CORD, V41, P164, DOI 10.1038/sj.sc.3101366.
   MOON MS, 1995, SPINE, V20, P1910, DOI 10.1097/00007632-199509000-00013.
   Moon MS, 2002, CLIN ORTHOP RELAT R, P40.
   Moorthy RK, 2004, BRIT J NEUROSURG, V18, P584, DOI 10.1080/02688690400022839.
   Mukhtar AM, 2003, MED PRIN PRACT, V12, P92, DOI 10.1159/000069113.
   Mushkin AY, 1999, INT ORTHOP, V23, P210, DOI 10.1007/s002640050352.
   NAZIROV PKH, 2004, PROBL TUBERK BOLEZN, V12, P47.
   Nene Abhay, 2005, Spine J, V5, P79, DOI 10.1016/j.spinee.2004.05.255.
   NUSSBAUM ES, 1995, J NEUROSURG, V83, P243, DOI 10.3171/jns.1995.83.2.0243.
   OGA M, 1993, SPINE, V18, P1890, DOI 10.1097/00007632-199310000-00028.
   OMARI B, 1989, CHEST, V95, P145, DOI 10.1378/chest.95.1.145.
   Ozdemir HM, 2003, SPINE, V28, P474, DOI 10.1097/00007632-200303010-00012.
   Parthasarathy R, 1999, J BONE JOINT SURG BR, V81B, P464, DOI 10.1302/0301-620X.81B3.9043.
   PATTISSON PRM, 1986, PARAPLEGIA, V24, P77.
   Pertuiset E, 1999, MEDICINE, V78, P309, DOI 10.1097/00005792-199909000-00003.
   Qu Dong-bin, 2003, Zhonghua Yi Xue Za Zhi, V83, P110.
   RAJASEKARAN S, 1987, J BONE JOINT SURG AM, V69A, P503.
   RAJASEKARAN S, 1989, J BONE JOINT SURG AM, V71A, P1314.
   Rajasekaran S, 2001, J BONE JOINT SURG BR, V83B, P954, DOI 10.1302/0301-620X.83B7.12170.
   Ramani PS, 2005, NEUROL INDIA, V53, P83.
   RAND C, 1989, ANN ROY COLL SURG, V71, P105.
   Rasit A H, 2001, Med J Malaysia, V56, P143.
   REZAI AR, 1995, NEUROSURGERY, V36, P87.
   Schulitz KP, 1997, SPINE, V22, P1150, DOI 10.1097/00007632-199705150-00016.
   Sheng Wei-Bin, 2005, Zhonghua Wai Ke Za Zhi, V43, P205.
   Shi Pei-hua, 2003, Zhonghua Wai Ke Za Zhi, V41, P292.
   SOLOMON A, 1995, INT ORTHOP, V19, P110.
   Souidi A., 1996, Revue de Pneumologie Clinique, V52, P15.
   Sundararaj GD, 2003, J BONE JOINT SURG BR, V85B, P100, DOI 10.1302/0301-620X.85B1.13300.
   TULI SM, 1995, INT ORTHOP, V19, P327.
   Turgut M, 2001, NEUROSURG REV, V24, P8, DOI 10.1007/PL00011973.
   UPADHYAY SS, 1993, SPINE, V18, P1704, DOI 10.1097/00007632-199309000-00020.
   UPADHYAY SS, 1994, CLIN ORTHOP RELAT R, P173.
   UPADHYAY SS, 1994, SPINE, V19, P542, DOI 10.1097/00007632-199403000-00009.
   UPADHYAY SS, 1994, J BONE JOINT SURG BR, V76B, P91.
   Upadhyay SS, 1996, SPINE, V21, P1898, DOI 10.1097/00007632-199608150-00014.
   UPADHYAY SS, 1994, J BONE JOINT SURG AM, V76A, P701.
   Vidyasagar C, 1996, Natl Med J India, V9, P25.
   VIDYASAGAR C, 1994, ANN ROY COLL SURG, V76, P80.
   Wu Q Q, 1990, Zhonghua Jie He He Hu Xi Za Zhi, V13, P160.
   Yilmaz C, 1999, J BONE JOINT SURG AM, V81A, P1261.
   Yilmaz C, 2001, J BONE JOINT SURG AM, V83A, P463.
   Zhang Mingjian, 2004, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V18, P171.
   Zhao H, 1994, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V16, P206.
   Zhao H, 1994, Chin Med Sci J, V9, P179.}},
Number-of-Cited-References = {{125}},
Times-Cited = {{61}},
Usage-Count-Last-180-days = {{4}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{Clin. Orthop. Rel. Res.}},
Doc-Delivery-Number = {{190RN}},
Unique-ID = {{ISI:000248076800009}},
}

@article{ ISI:000248076800011,
Author = {Tyagi, Asha and Girotra, Gautam and Mohta, Medha and Bhardwaj, Rajesh
   and Sethi, Ashok Kumar},
Title = {{Autonomic dysfunction and adrenal insufficiency in thoracic spine
   tuberculosis}},
Journal = {{CLINICAL ORTHOPAEDICS AND RELATED RESEARCH}},
Year = {{2007}},
Number = {{460}},
Pages = {{56-61}},
Month = {{JUL}},
Abstract = {{While autonomic dysfunction has been reported in patients with spinal
   TB, little is known of the consequences. We matched 25 paraplegic
   patients with thoracic spine tuberculosis scheduled for spinal surgery
   (Group S) with 25 nontubercular American Society of Anesthesiologists
   Grade I patients scheduled for nonspinal surgeries (Group C) under
   identical operative conditions. All patients underwent four autonomic
   tests in the operating room, and a preoperative adrenocorticotropic
   hormone stimulation test was performed for patients in Group S. Compared
   to Group C, Group S had higher resting heart rate (103 +/- 20
   beats/minute versus 81 +/- 10 beats/minute), lower
   expiratory:inspiratory ratio (1.14 +/- 0.11 versus 1.22 +/- 0.10), and
   higher heart rate variability (20 +/- 12 beats/minute versus 14 7
   beats/minute), indicating probable parasympathetic dysfunction along
   with a relative sympathetic overactivity. Eight of the 17 patients who
   received an adrenocorticotropic hormone stimulation test had evidence of
   adrenal insufficiency. Incidence of hypotension in Group S and Group C
   was 100\% and 44\%, respectively. Mean systolic and diastolic blood
   pressure in Group S showed substantial decrease after induction and
   positioning of patients not associated with compensatory tachycardia.
   Coexisting pulmonary tuberculosis appears an important determinant of
   surgical approach as well as postoperative respiratory morbidity.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tyagi, A (Reprint Author), 103 Siddhartha Enclave, New Delhi 110014, India.
   Univ Coll Med Sci, Dept Anaesthesiol \& Crit Care, Delhi, India.
   GTB Hosp, Delhi, India.}},
DOI = {{10.1097/BLO.0b013e318073c228}},
ISSN = {{0009-921X}},
Research-Areas = {{Orthopedics; Surgery}},
Web-of-Science-Categories  = {{Orthopedics; Surgery}},
Author-Email = {{drashatyagi@gmail.com}},
Cited-References = {{BANNISTER R, 1992, AUTONOMIC FAILURE TX, P263.
   Byrne TN, 2004, NEUROLOGY CLIN PRACT, P351.
   Darmon P, 1999, EUR J ENDOCRINOL, V140, P51, DOI 10.1530/eje.0.1400051.
   KEHLET H, 1975, ACTA ANAESTH SCAND, V19, P260.
   LATSON TW, 1994, ANESTHESIOLOGY, V80, P326, DOI 10.1097/00000542-199402000-00013.
   Mathias CJ, 1997, NEW ENGL J MED, V336, P721, DOI 10.1056/NEJM199703063361010.
   Rivers EP, 2001, CHEST, V119, P889, DOI 10.1378/chest.119.3.889.
   Sharma SK, 2005, INDIAN J MED RES, V122, P127.
   Singh G, 2000, INDIAN J AGRON, V45, P470.
   Singh K. K., 1996, Indian Journal of Physiology and Pharmacology, V40, P145.
   Stewart PM., 2003, WILLIAMS TXB ENDOCRI, P491.
   Toyry JP, 1996, STROKE, V27, P1316.
   WEIMER LH, 2005, MERRITTS NEUROLOGY, P971.
   Widmer IE, 2005, J CLIN ENDOCR METAB, V90, P4579, DOI 10.1210/jc.2005-0354.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Clin. Orthop. Rel. Res.}},
Doc-Delivery-Number = {{190RN}},
Unique-ID = {{ISI:000248076800011}},
}

@article{ ISI:000248076800013,
Author = {Moon, Myung-Sang and Moon, Jeong-Lim and Kim, Sung-Sim and Moon,
   Young-Wan},
Title = {{Treatment of tuberculosis of the cervical spine - Operative versus
   nonoperative}},
Journal = {{CLINICAL ORTHOPAEDICS AND RELATED RESEARCH}},
Year = {{2007}},
Number = {{460}},
Pages = {{67-77}},
Month = {{JUL}},
Abstract = {{We retrospectively reviewed 15 children (four with paralysis) and 39
   adults (10 with paralysis) with tuberculosis of the cervical spine to
   assess the drug responses, disease arrest, and healing times. Ten
   children and 13 adults were treated nonoperatively, while anterior
   debridement was performed in five children (two with paralysis) and
   anterior radical surgery in 26 adults (10 with paralysis). Triple
   chemotherapy (isoniazid, rifampin, ethambutol for pyrazinamide for
   children]) was given to all patients for 12 months. The tuberculosis
   began to arrest after 3 months of chemotherapy and healed within 12
   months. Spontaneous fusion occurred in all adults but only two of the 10
   children. Surgical fusion was achieved within 12 to 16 weeks in adults.
   In nonoperated patients, an initial kyphosis of 12 degrees progressed to
   17 degrees at final followup in the children and an initial kyphosis of
   9 degrees progressed to 13 degrees in 13 adults. In operated patients,
   the initial kyphosis of 13 degrees in adults became 2 degrees at the
   time of the fusion, while the initial kyphosis of 14 degrees in the five
   children progressed to 18 degrees. Patients with paraplegia recovered
   completely within 14 days on average (range, 1-42 days) after treatment.
   Recovery was gradual in the nonoperative group, while it occurred within
   3 days in the operative group.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Moon, MS (Reprint Author), Sungkyunkwan Univ, Dept Orthoped Surg, Sch Med, Samsung Med Ctr, 50 Ilwon Dong, Seoul 135710, South Korea.
   Sungkyunkwan Univ, Dept Orthoped Surg, Sch Med, Samsung Med Ctr, Seoul 135710, South Korea.
   Sun Gen Hosp, Dept Orthoped Surg, Taejon, South Korea.
   Catholic Univ, Dept Rehabil Med, Seoul, South Korea.
   Moom Kims Inst Orthoped Res, Seoul, South Korea.}},
DOI = {{10.1097/BLO.0b013e31805470ba}},
ISSN = {{0009-921X}},
Keywords-Plus = {{CONSERVATIVE TREATMENT; ANTERIOR; DEFORMITY; KYPHOSIS; SURGERY; LUMBAR;
   FUSION; DEBRIDEMENT; CHILDREN; ADULTS}},
Research-Areas = {{Orthopedics; Surgery}},
Web-of-Science-Categories  = {{Orthopedics; Surgery}},
Author-Email = {{ywmoon@smc.samsung.co.kr}},
Cited-References = {{FOUNTAIN SS, 1975, J BONE JOINT SURG AM, V57, P1104.
   Frankel H L, 1969, Paraplegia, V7, P179.
   GURI JP, 1947, J BONE JOINT SURG, V29, P136.
   Hassan MG, 2003, INT ORTHOP, V27, P73, DOI 10.1007/s00264-002-0400-2.
   HSU LCS, 1984, J BONE JOINT SURG BR, V66, P1.
   Jain AK, 1999, SPINAL CORD, V37, P362, DOI 10.1038/sj.sc.3100833.
   KONSTAM PG, 1962, BRIT J SURG, V50, P26, DOI 10.1002/bjs.18005021908.
   LOEMBE PM, 1994, ACTA NEUROCHIR, V131, P125, DOI 10.1007/BF01401462.
   Lukhele M, 1996, S AFR MED J, V86, P553.
   Moon MS, 1996, CLIN ORTHOP RELAT R, P122.
   Moon MS, 1997, SPINE, V22, P1791, DOI 10.1097/00007632-199708010-00022.
   MOON MS, 1987, INT ORTHOP, V11, P315, DOI 10.1007/BF00271307.
   MOON MS, 1995, SPINE, V20, P1910, DOI 10.1097/00007632-199509000-00013.
   Moon MS, 2002, CLIN ORTHOP RELAT R, P40.
   MOON MS, 1971, J KOREA ORTHOP ASS, V6, P203.
   MOON MS, 1970, J KOREAN ORTHOP ASS, V5, P155.
   Moon MS, 1991, CURRENT ORTHOP, V5, P177, DOI 10.1016/0268-0890(91)90039-3.
   Rajasekaran S, 2002, CLIN ORTHOP RELAT R, P85.
   RATCLIFFE JF, 1985, ACTA RADIOL DIAGN, V26, P137.
   Schulitz KP, 1997, SPINE, V22, P1150, DOI 10.1097/00007632-199705150-00016.
   Sinha S, 2003, NEUROSURGERY, V52, P331, DOI 10.1227/01.NEU.0000043930.28934.FE.
   TULI SM, 1975, J BONE JOINT SURG BR, VB 57, P13.
   Tuli SM, 2004, TUBERCULOSIS SKELETA.
   Upadhyay SS, 1996, SPINE, V21, P2356, DOI 10.1097/00007632-199610150-00010.
   UPADHYAY SS, 1994, J BONE JOINT SURG BR, V76B, P91.
   YAU ACMC, 1974, J BONE JOINT SURG AM, VA 56, P1419.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{14}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Clin. Orthop. Rel. Res.}},
Doc-Delivery-Number = {{190RN}},
Unique-ID = {{ISI:000248076800013}},
}

@article{ ISI:000248076800014,
Author = {Govender, S. and Ramnarain, A. and Ortho, H. Dip and Danaviah, S.},
Title = {{Cervical spine tuberculosis in children}},
Journal = {{CLINICAL ORTHOPAEDICS AND RELATED RESEARCH}},
Year = {{2007}},
Number = {{460}},
Pages = {{78-85}},
Month = {{JUL}},
Abstract = {{The presentation and outcome of pediatric cervical spine tuberculosis
   are different from those of adult cervical spine tuberculosis. We
   retrospectively reviewed the clinical and radiographic outcome of 58
   children with cervical spine tuberculosis treated nonoperatively and
   operatively between 1996 and 2004. The mean age was 3.7 years (range,
   1.9-14 years). The cervicodorsal junction was affected in 27 children,
   the atlantoaxial complex in 19 children, and the midcervical spine in 12
   children. Multifocal noncontiguous spinal lesions were observed in 21
   patients. Surgery was performed in 25 children for: neurologic deficit
   (14); drainage of retropharyngeal abscesses (four); atlantoaxial fusion
   for late Cl-C2 instability (three); and progressive deformity and pain
   (four). Neurologic recovery occurred in all patients. Seven patients
   were lost to followup within 2 years. The minimum followup was 2.4 years
   (mean, 3.5 years; range, 2.4-10 years). We attributed the improved
   functional outcome after anti-TB chemotherapy alone to the remodeling
   potential of the pediatric cervical spine. Surgery was performed only
   for neurologic deficit, an atlantodental interval greater than 5 mm on
   flexion/extension view, and progressive deformity. Four patients
   developed superficial wound infection, two patients had graft
   repositioning for a slipped graft, and seven children developed a grade
   1 pressure sore over the scalp while on traction.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Govender, S (Reprint Author), Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Orthopaed Surg, 719 Umbilo Rd, ZA-4013 Congella, South Africa.
   Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Orthopaed Surg, ZA-4013 Congella, South Africa.
   Univ KwaZulu Natal, Mol Virol Lab, Africa Ctr Hlth \& Populat Studies, Congella, South Africa.}},
DOI = {{10.1097/BLO.0b013e31806a915f}},
ISSN = {{0009-921X}},
Keywords-Plus = {{RETROPHARYNGEAL APPROACH; SURGICAL-MANAGEMENT; JUNCTION}},
Research-Areas = {{Orthopedics; Surgery}},
Web-of-Science-Categories  = {{Orthopedics; Surgery}},
Author-Email = {{katia@ukzn.ac.za}},
Cited-References = {{BANKS GM, 1994, PEDIAT SPINE PRINCIP, P110.
   Behari S, 2003, NEUROSURGERY, V52, P72, DOI 10.1227/01.NEU.0000038740.08094.56.
   DOBSON J, 1951, J BONE JOINT SURG BR, V33, P517.
   Dogulu F, 2003, CHILD NERV SYST, V19, P192, DOI 10.1007/s00381-002-0694-9.
   FANG D, 1983, J BONE JOINT SURG BR, V65, P47.
   FANG HSY, 1962, J BONE JOINT SURG AM, V44, P1588.
   Frankel H L, 1969, Paraplegia, V7, P179.
   Govender S, 2001, J BONE JOINT SURG BR, V83B, P864, DOI 10.1302/0301-620X.83B6.11995.
   Govender S, 2001, J PEDIATR ORTHOPED, V21, P285, DOI 10.1097/00004694-200105000-00004.
   Govender S, 1999, J BONE JOINT SURG BR, V81B, P106, DOI 10.1302/0301-620X.81B1.9316.
   Govender S, 1991, NEURO-ORTHOPEDICS, V11, P101.
   HSU LCS, 1984, J BONE JOINT SURG BR, V66, P1.
   JANSSENS JP, 1990, CLIN ORTHOP RELAT R, P67.
   Kanaan IU, 1999, SURG NEUROL, V51, P21, DOI 10.1016/S0090-3019(97)00294-2.
   LIFESO R, 1987, J BONE JOINT SURG BR, V69, P183.
   Lindquist SW, 1997, PEDIATR INFECT DIS J, V16, P333, DOI 10.1097/00006454-199703000-00020.
   Lukhele M, 1996, S AFR MED J, V86, P553.
   Martin N S, 1970, J Bone Joint Surg Br, V52, P613.
   MCAFEE PC, 1987, J BONE JOINT SURG AM, V69A, P1371.
   OGA M, 1993, SPINE, V18, P1890, DOI 10.1097/00007632-199310000-00028.
   Rajasekaran S, 2002, CLIN ORTHOP RELAT R, P85.
   Rajasekaran S, 2001, J BONE JOINT SURG BR, V83B, P954, DOI 10.1302/0301-620X.83B7.12170.
   Sinha S, 2003, NEUROSURGERY, V52, P331, DOI 10.1227/01.NEU.0000043930.28934.FE.
   TULI SM, 1974, CLIN ORTHOP RELAT R, P209.
   Valaskatzis E, 1996, Eur Spine J, V5, P140, DOI 10.1007/BF00298397.
   WHITESIDES TE, 1978, ORTHOP CLIN N AM, V9, P1115.
   World Health Organization (WHO), WHO FACT SHEET.}},
Number-of-Cited-References = {{27}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Clin. Orthop. Rel. Res.}},
Doc-Delivery-Number = {{190RN}},
Unique-ID = {{ISI:000248076800014}},
}

@article{ ISI:000248076800015,
Author = {Rajasekaran, S.},
Title = {{Buckling collapse of the spine in childhood spinal tuberculosis}},
Journal = {{CLINICAL ORTHOPAEDICS AND RELATED RESEARCH}},
Year = {{2007}},
Number = {{460}},
Pages = {{86-92}},
Month = {{JUL}},
Abstract = {{We prospectively followed 61 children under 15 years of age at the time
   of diagnosis to identify the risk factors for deformity progression. The
   children had 63 lesions and a minimum of 15 years followup. All
   exhibited an increase in deformity during the active disease phase, but
   26 of 63 (41 \%) continued to progress during the quiescent phase until
   the growth was complete. In 21 of those 26, there was an increase in
   angular kyphosis with a final deformity < 90 degrees. In the other five,
   the deformity resembled a buckling collapse analogous to failure of an
   axially loaded slender column; the deformity was more than 100 degrees
   and associated with facet dislocation at multiple levels. These
   patients' vertebral segments above the level of destruction underwent
   severe sagittal rotation resulting in horizontal vertebrae with vertical
   growth plates, which resulted in longitudinal overgrowth of the
   vertebral segments. Risk factors for buckling collapse included an age
   of less than 7 years at the time of the disease, thoracolumbar
   involvement, loss of more than two vertebral bodies, and presence of
   radiographic spine-at-risk signs. Children at risk for buckling collapse
   must be carefully watched and the spine stabilized to avoid a massive
   increase in deformity.}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING ST, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rajasekaran, S (Reprint Author), Ganga Hosp, Dept Orthopaed \& Spine Surg, Swarnambika Layout, Coimbatore 641009, Tamil Nadu, India.
   Ganga Hosp, Dept Orthopaed \& Spine Surg, Coimbatore 641009, Tamil Nadu, India.}},
DOI = {{10.1097/BLO.0b013e31806a9172}},
ISSN = {{0009-921X}},
EISSN = {{1528-1132}},
Keywords-Plus = {{DEFORMITY; GROWTH; CHEMOTHERAPY; KYPHOSIS; CHILDREN; SURGERY}},
Research-Areas = {{Orthopedics; Surgery}},
Web-of-Science-Categories  = {{Orthopedics; Surgery}},
Author-Email = {{sr@gangahospital.com}},
Cited-References = {{GOODING CA, 1965, AMER J ROENTGENOL RA, V93, P388.
   HUTER C, 1865, FORMENTENWICKELUNG S.
   LEVENTHAL HR, 1960, J PEDIATR-US, V56, P447, DOI 10.1016/S0022-3476(60)80356-3.
   McGowan Dennis P., 1995, P27.
   Medical Research Council, 1985, J BONE JOINT SURG BR, V67B, P103.
   Medical Research Council Working Party on Tuberculosis of the Spine, 1982, J BONE JOINT SURG BR, V64, P393.
   Medical Research Council Working Party on Tuberculosis of the Spine, 1978, J BONE JOINT SURG BR, V60, P163.
   MOON MS, 1995, SPINE, V20, P1910, DOI 10.1097/00007632-199509000-00013.
   MOON MS, 1974, J W PAC ORTHOP ASS, V11, DOI UNSP 1Y16.
   Parthasarathy R, 1999, J BONE JOINT SURG BR, V81B, P464, DOI 10.1302/0301-620X.81B3.9043.
   RAJASEKARAN S, 1987, J BONE JOINT SURG AM, V69A, P503.
   Rajasekaran S, 2006, J PEDIATR ORTHOPED, V26, P716.
   Rajasekaran S, 2002, CLIN ORTHOP RELAT R, P85.
   Rajasekaran S, 2001, J BONE JOINT SURG BR, V83B, P954, DOI 10.1302/0301-620X.83B7.12170.
   SATYASRI S, 1993, PULMONARY EXTRAPULMO, P18.
   Schulitz KP, 1997, SPINE, V22, P1150, DOI 10.1097/00007632-199705150-00016.
   TIMOSHENKO SP, 1968, ELEMENTS STRENGHT MA, P68.
   TULI SM, 1995, INT ORTHOP, V19, P327.
   VONVOLKMANN R, 1862, CHIRURG ERFAHRUNGEN.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{22}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Clin. Orthop. Rel. Res.}},
Doc-Delivery-Number = {{190RN}},
Unique-ID = {{ISI:000248076800015}},
}

@article{ ISI:000248076800019,
Author = {Jain, Anil K. and Maheshwari, Aditya V. and Jena, Santosh},
Title = {{Kyphus correction in spinal tuberculosis}},
Journal = {{CLINICAL ORTHOPAEDICS AND RELATED RESEARCH}},
Year = {{2007}},
Number = {{460}},
Pages = {{117-123}},
Month = {{JUL}},
Abstract = {{Late-onset paraplegia is best avoided by correcting severe kyphosis in
   the active, healing, or healed stages of spinal tuberculosis. We report
   16 patients with dorsal or dorsolumbar spinal TB-nine with paraplegia,
   seven without paraplegia-who underwent kyphus correction. Nine patients
   had active, five partially treated, and two healed disease. The patients
   ranged in age from 3 to 38 years and had a mean kyphosis of 58.5 degrees
   (range, 35 degrees-76 degrees). Mean vertebral body involvement on
   computed tomography was 4.2 (2-9), and mean initial vertebral body loss
   was 1.76 (1-2.6). The sequential steps for kyphus correction were
   anterior corpectomy, shortening of the posterior column, posterior
   instrumentation and anterior gap grafting, and posterior fusion as a
   single-stage procedure by the extrapleural anterolateral
   (costotransversectomy) approach. Minimum followup was 3 months (range,
   3-36 months). All but one patient with neural deficit showed complete
   neural recovery. Mean kyphosis correction was 27.3 degrees (range, 9
   degrees-42 degrees). Mean correction loss on 1-year followup was 1.4
   degrees (range, 0 degrees-4 degrees).}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING ST, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Jain, AK (Reprint Author), A-10,Part B, Ghaziabad 201001, UP, India.
   Univ Coll Med Sci, Dept Orthopaed, Delhi, India.
   Guru Teg Bahadur Hosp, Delhi, India.}},
DOI = {{10.1097/BLO.0b013e3180514bfe}},
ISSN = {{0009-921X}},
EISSN = {{1528-1132}},
Keywords-Plus = {{ANTERIOR INTERBODY FUSION; POSTERIOR INSTRUMENTATION; POTTS PARAPLEGIA;
   LATE-ONSET; KYPHOSIS; DECOMPRESSION; DEFORMITY; DORSAL; ANGLE}},
Research-Areas = {{Orthopedics; Surgery}},
Web-of-Science-Categories  = {{Orthopedics; Surgery}},
Author-Email = {{dranilkjain@gmail.com}},
Cited-References = {{Bilsel N, 2000, SPINAL CORD, V38, P669, DOI 10.1038/sj.sc.3101082.
   GUVEN O, 1994, SPINE, V19, P1039.
   HSU LCS, 1988, J BONE JOINT SURG BR, V70, P534.
   Jain AK, 2002, CLIN ORTHOP RELAT R, P75.
   Jain AK, 2000, NEUROL INDIA, V48, P132.
   Jain AK, 2004, J BONE JOINT SURG BR, V86B, P1027, DOI 10.1302/0301-620X.86B7.14546.
   Jain AK, 2004, INT ORTHOP, V28, P110, DOI 10.1007/s00264-003-0516-z.
   Laheri VJ, 2001, SPINAL CORD, V39, P429, DOI 10.1038/sj.sc.3101185.
   LOUW JA, 1990, J BONE JOINT SURG BR, V72, P686.
   Luk KDK, 1999, EUR SPINE J, V8, P338, DOI 10.1007/s005860050185.
   Moon MS, 1997, SPINE, V22, P1791, DOI 10.1097/00007632-199708010-00022.
   MOON MS, 1995, SPINE, V20, P1910, DOI 10.1097/00007632-199509000-00013.
   RAJASEKARAN S, 1987, J BONE JOINT SURG AM, V69A, P503.
   Rajasekaran S, 2001, J BONE JOINT SURG BR, V83B, P954, DOI 10.1302/0301-620X.83B7.12170.
   Schulitz KP, 1997, SPINE, V22, P1150, DOI 10.1097/00007632-199705150-00016.
   TULI SM, 1995, INT ORTHOP, V19, P327.
   YAU ACMC, 1974, J BONE JOINT SURG AM, VA 56, P1419.
   Yilmaz C, 1999, J BONE JOINT SURG AM, V81A, P1261.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{21}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Clin. Orthop. Rel. Res.}},
Doc-Delivery-Number = {{190RN}},
Unique-ID = {{ISI:000248076800019}},
}

@article{ ISI:000248688400035,
Author = {Terada, Hiroshi},
Title = {{Phagocytosis of polymer microspheres by alveolar macrophages for
   overcoming tuberculosis}},
Journal = {{DRUGS OF THE FUTURE}},
Year = {{2007}},
Volume = {{32}},
Number = {{A}},
Pages = {{18}},
Month = {{JUL}},
Publisher = {{PROUS SCIENCE, SA}},
Address = {{PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Tokyo Univ Sci, Fac Pharmaceut Sci, Noda, Chiba 2788510, Japan.}},
ISSN = {{0377-8282}},
Keywords-Plus = {{RIFAMPICIN; DELIVERY}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Cited-References = {{HIROTA K, 2007, IN PRESS J CONTROL R.
   Makino K, 2004, COLLOID SURFACE B, V36, P35, DOI 10.1016/j.colsurfb.2004.018.
   Yoshida A, 2006, MICROBES INFECT, V8, P2484, DOI 10.1016/j.micinf.2006.06.004.}},
Number-of-Cited-References = {{3}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Drug Future}},
Doc-Delivery-Number = {{199IC}},
Unique-ID = {{ISI:000248688400035}},
}

@article{ ISI:000248688400043,
Author = {Ferreras, Julian A. and Ryu, Jag-Sang and Di Lello, Federico and Cisar,
   Justin S. and Wu, Nian and Tan, Derek S. and Quadri, Luis E. N.},
Title = {{Small-molecule inhibition of siderophore biosynthesis in Mycobacterium
   tuberculosis and Yersinia pestis}},
Journal = {{DRUGS OF THE FUTURE}},
Year = {{2007}},
Volume = {{32}},
Number = {{A}},
Pages = {{21-22}},
Month = {{JUL}},
Publisher = {{PROUS SCIENCE, SA}},
Address = {{PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{Cornell Univ, Weill Med Coll, Dept Microbiol \& Immunol, New York, NY 10021 USA.
   Cornell Univ, Med Ctr, Mem Sloan Kettering Canc Ctr, Mol Pharmacol \& Chem Program, New York, NY 10021 USA.
   Cornell Univ, Med Ctr, Mem Sloan Kettering Canc Ctr, Tri Institut Res Program, New York, NY 10021 USA.
   Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea.}},
ISSN = {{0377-8282}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
ResearcherID-Numbers = {{cisar, justin/C-4002-2012}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Drug Future}},
Doc-Delivery-Number = {{199IC}},
Unique-ID = {{ISI:000248688400043}},
}

@article{ ISI:000248688400282,
Author = {Bostanaba, Zaker S. and Bahrmand, A. R. and Titov, L. P.},
Title = {{Mutations in codons 526-531 of rpoB are associated with high-level
   resistance to rifampicine in M. tuberculosis in Belarusian and Iranian
   isolates}},
Journal = {{DRUGS OF THE FUTURE}},
Year = {{2007}},
Volume = {{32}},
Number = {{A}},
Pages = {{129}},
Month = {{JUL}},
Publisher = {{PROUS SCIENCE, SA}},
Address = {{PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN}},
Type = {{Meeting Abstract}},
Language = {{English}},
ISSN = {{0377-8282}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Drug Future}},
Doc-Delivery-Number = {{199IC}},
Unique-ID = {{ISI:000248688400282}},
}

@article{ ISI:000247758200006,
Author = {Akksilp, Somsak and Karnkawinpong, Opart and Wattanaamornkiat, Wanpen
   and Viriyakitja, Daranee and Monkongdee, Patarna and Sitti, Walya and
   Rienthong, Dhanida and Siraprapasiri, Taweesap and Wells, Charles D. and
   Tappero, Jordan W. and Varma, Jay K.},
Title = {{Antiretroviral therapy during tuberculosis treatment and marked
   reduction in death rate of HIV-infected patients, Thailand}},
Journal = {{EMERGING INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{13}},
Number = {{7}},
Pages = {{1001-1007}},
Month = {{JUL}},
Abstract = {{Antiretroviral therapy (ART) is lifesaving in patients with advanced HIV
   infection, but the magnitude of benefit in HIV-infected patients
   receiving tuberculosis (TB) treatment remains uncertain, and
   population-based data from developing countries are limited. We
   prospectively collected data about HIV-infected TB patients from
   February 2003 through January 2004 in Ubon-ratchathani, Thailand. During
   12 months, HIV was diagnosed in 329 (14\%) of 2,342 patients registered
   for TB treatment. Of patients with known outcomes, death during TB
   treatment occurred in 5 (7\%) of 71 who received ART and 94 (43\%) of
   219 who did not. Using multivariate analysis, we found a large reduction
   in the odds of death for patients receiving ART before or during TB
   treatment (odds ratio, 0.2; 95\% confidence interval, 0.1-0.5),
   adjusting for CD4 count, smear status, co-trimoxazole use, and treatment
   facility. ART is associated with a substantial reduction in deaths
   during TB treatment for HIV-infected TB patients in Thailand.}},
Publisher = {{CENTER DISEASE CONTROL}},
Address = {{ATLANTA, GA 30333 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Minist Publ Hlth, Ubon Ratchathani, Thailand.
   Minist Publ Hlth, Nonthaburi, Thailand.
   Ctr Dis Control \& Prevent, Thailand Minist Publ Hlth, Nonthaburi, Thailand.
   Ctr Dis Control \& Prevent, Atlanta, GA USA.}},
ISSN = {{1080-6040}},
Keywords-Plus = {{HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 LYMPHOCYTE COUNTS; COTE-DIVOIRE;
   AFRICAN PATIENTS; MORTALITY; SURVIVAL; ABIDJAN; COHORT; IMPACT; AIDS}},
Research-Areas = {{Immunology; Infectious Diseases}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases}},
Author-Email = {{jvarma@cdc.gov}},
Cited-References = {{Abouya L, 1998, AIDS, V12, P505, DOI 10.1097/00002030-199805000-00012.
   ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7.
   Breen RAM, 2006, J INFECT DIS, V193, P1437, DOI 10.1086/503437.
   Burman W, 2006, AM J RESP CRIT CARE, V173, P350, DOI 10.1164/rccm.200503-417OC.
   CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570.
   Dean GL, 2002, AIDS, V16, P75, DOI 10.1097/00002030-200201040-00010.
   Dheda K, 2004, J INFECT DIS, V190, P1670, DOI 10.1086/424676.
   ELLIOTT AM, 1995, T ROY SOC TROP MED H, V89, P78, DOI 10.1016/0035-9203(95)90668-1.
   Freudenberg N, 2006, AM J PUBLIC HEALTH, V96, P424, DOI 10.2105/AJPH.2005.063511.
   Joint United Nations Programme on HIV/AIDS (UNAIDS), 2006, REP GLOB AIDS EP.
   JONES BE, 1993, AM REV RESPIR DIS, V148, P1292.
   Kaplan JE, 2000, CLIN INFECT DIS   S1, V30, P5.
   Manosuthi W, 2006, JAIDS-J ACQ IMM DEF, V43, P42, DOI 10.1097/01.qai.0000230521.86964.86.
   MARTIN DJ, 1995, J ACQ IMMUN DEF SYND, V8, P386.
   Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0.
   Morris L, 2003, J INFECT DIS, V187, P1967, DOI 10.1086/375346.
   Mukadi YD, 2001, AIDS, V15, P143, DOI 10.1097/00002030-200101260-00002.
   NUNN P, 1992, AM REV RESPIR DIS, V146, P849.
   PALELLA EJ, 1998, NEW ENGL J MED, V338, P853.
   Tansuphasawadikul S, 1999, J ACQ IMMUN DEF SYND, V21, P326.
   Teck R, 2005, INT J TUBERC LUNG D, V9, P258.
   World Health Organization, 2004, WHOHTMTB2004330.
   World Health Organization, 2004, TB HIV CLIN MAN.
   World Health Organization, 2005, WHOHTMTB2005349.
   {*}WHO, 2005, P WHO HIV TB C MEK S.
   World Health Organization, 2003, TREATM TUB GUID NAT.
   Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0.
   Yu LM, 1997, INT J EPIDEMIOL, V26, P1367, DOI 10.1093/ije/26.6.1367.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{70}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Emerg. Infect. Dis}},
Doc-Delivery-Number = {{186DB}},
Unique-ID = {{ISI:000247758200006}},
}

@article{ ISI:000247758200027,
Author = {Rao, V. Bhargavi and Pelly, Tom F. and Gilman, Robert H. and Cabrera,
   Lilia and Delgado, Jose and Soto, Giselle and Friedland, Jon S. and
   Escombe, A. Roderick and Black, Robert E. and Evans, Carlton A.},
Title = {{Zinc cream and reliability of tuberculosis skin testing}},
Journal = {{EMERGING INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{13}},
Number = {{7}},
Pages = {{1101-1104}},
Month = {{JUL}},
Abstract = {{In 50 healthy Peruvian shantytown residents, zinc cream applied to
   tuberculosis skin-test sites caused a 32\% increase in induration
   compared with placebo cream. Persons with lower plasma zinc had smaller
   skin-test reactions and greater augmentation with zinc cream. Zinc
   deficiency caused false-negative skin-test results, and topical zinc
   supplementation augmented anti mycobacterial immune responses enough to
   improve diagnosis.}},
Publisher = {{CENTER DISEASE CONTROL}},
Address = {{ATLANTA, GA 30333 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Evans, CA (Reprint Author), Asociac Benefica Prisma, Av Carlos Gonzales Nro 251, Lima, Peru.
   Asociac Benefica Prisma, Lima, Peru.
   Univ London Imperial Coll Sci \& Technol, London, England.
   London Sch Hyg \& Trop Med, London WC1, England.
   Univ Peruana Cayetano Heredia, Lima, Peru.
   Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.}},
ISSN = {{1080-6040}},
Keywords-Plus = {{MALNUTRITION}},
Research-Areas = {{Immunology; Infectious Diseases}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases}},
Author-Email = {{carltonevans@yahoo.com}},
ORCID-Numbers = {{Black, Robert/0000-0001-9926-7984}},
Funding-Acknowledgement = {{Wellcome Trust}},
Cited-References = {{Cuevas LE, 2002, ANN TROP PAEDIATR, V22, P313, DOI 10.1179/027249302125001967.
   GOLDEN MHN, 1978, LANCET, V1, P1226.
   Karyadi E, 2002, AM J CLIN NUTR, V75, P720.
   LIN RY, 1985, ACTA DERM-VENEREOL, V65, P190.
   Pelly TF, 2005, INT J TUBERC LUNG D, V9, P977.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Emerg. Infect. Dis}},
Doc-Delivery-Number = {{186DB}},
Unique-ID = {{ISI:000247758200027}},
}

@article{ ISI:000248439200049,
Author = {Molnar, Thomas F. and Detterbeck, Frank and Batiko, Zoltan},
Title = {{Another perspective of the dysphagia due to tuberculosis}},
Journal = {{EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY}},
Year = {{2007}},
Volume = {{32}},
Number = {{1}},
Pages = {{184}},
Month = {{JUL}},
Publisher = {{OXFORD UNIV PRESS INC}},
Address = {{JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Molnar, TF (Reprint Author), Univ Pecs, Sch Med, Dept Surg, Ifjusag 12, H-7632 Pecs, Hungary.
   Univ Pecs, Sch Med, Dept Surg, H-7632 Pecs, Hungary.
   Yale Univ, Div Thorac Surg, New Haven, CT USA.
   Teaching Cty Hosp Pecs, Pecs, Hungary.}},
DOI = {{10.1016/j.ejcts.2007.03.005}},
ISSN = {{1010-7940}},
Keywords = {{dysphagia; medical humanities; tuberculosis; history}},
Research-Areas = {{Cardiovascular System \& Cardiology; Respiratory System; Surgery}},
Web-of-Science-Categories  = {{Cardiac \& Cardiovascular Systems; Respiratory System; Surgery}},
Author-Email = {{mft@iseb.pote.hu}},
Cited-References = {{Carter R, 1998, ANN THORAC SURG, V65, P578.
   GAENSLER EA, 1982, AM REV RESPIR DIS, V125, P73.
   MANN T, 1996, MAGIC MOUNTAIN ENGLI, P516.
   Rathinam S, 2006, EUR J CARDIO-THORAC, V30, P833, DOI 10.1016/j.ejcts.2006.09.025.}},
Number-of-Cited-References = {{4}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Eur. J. Cardio-Thorac. Surg.}},
Doc-Delivery-Number = {{195VC}},
Unique-ID = {{ISI:000248439200049}},
}

@article{ ISI:000248439200050,
Author = {Rathinam, Sridhar and Chandramohan, Servarayan M.},
Title = {{Another perspective of the dysphagia due to tuberculosis - Reply}},
Journal = {{EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY}},
Year = {{2007}},
Volume = {{32}},
Number = {{1}},
Pages = {{184}},
Month = {{JUL}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Chandramohan, SM (Reprint Author), Govt Royapettah Hosp, Dept Gasterointestinal Surg, Madras, Tamil Nadu, India.
   Govt Royapettah Hosp, Dept Gasterointestinal Surg, Madras, Tamil Nadu, India.
   Kilpauk Med Coll, Madras, Tamil Nadu, India.}},
DOI = {{10.1016/j.ejcts.2007.03.006}},
ISSN = {{1010-7940}},
Keywords = {{dysphagia; medical humanities; tuberculosis}},
Research-Areas = {{Cardiovascular System \& Cardiology; Respiratory System; Surgery}},
Web-of-Science-Categories  = {{Cardiac \& Cardiovascular Systems; Respiratory System; Surgery}},
Author-Email = {{smchandra@yahoo.com}},
Cited-References = {{Molnar TF, 2007, EUR J CARDIO-THORAC, V32, P184, DOI 10.1016/j.ejcts.2007.03.005.
   Rathinam S, 2006, EUR J CARDIO-THORAC, V30, P833, DOI 10.1016/j.ejcts.2006.09.025.
   World Health Organization, TUBERCULOSIS.}},
Number-of-Cited-References = {{3}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Eur. J. Cardio-Thorac. Surg.}},
Doc-Delivery-Number = {{195VC}},
Unique-ID = {{ISI:000248439200050}},
}

@article{ ISI:000254355800014,
Author = {Nakamura, Masanao and Niwa, Yasumasa and Ohmiya, Naoki and Arakawa,
   Daigo and Honda, Wataru and Miyahara, Ryoji and Matsuura, Tetsuo and
   Ando, Takafumi and Maeda, Osamu and Itoh, Akihiro and Hirooka, Yoshiki
   and Goto, Hidemi},
Title = {{Small bowel tuberculosis diagnosed by the combination of video capsule
   endoscopy and double balloon enteroscopy}},
Journal = {{EUROPEAN JOURNAL OF GASTROENTEROLOGY \& HEPATOLOGY}},
Year = {{2007}},
Volume = {{19}},
Number = {{7}},
Pages = {{595-598}},
Month = {{JUL}},
Abstract = {{Small bowel tuberculosis is sometimes encountered in oriental countries,
   and because its symptoms are vague and present a nonspecific pattern,
   confirmative diagnosis is difficult to achieve. In 2001, two new
   innovative endoscopic techniques for the small bowel, video capsule
   endoscopy and double balloon enteroscopy, were introduced, thus
   advancing the diagnostic technology for small bowel disorders. Our
   asymptomatic patient with small bowel tuberculosis was diagnosed
   definitively using the combination of video capsule endoscopy and double
   balloon enteroscopy. The number of such cases will increase when those
   procedures become more widely used. At present, the endoscopic view of
   small bowel tuberculosis is difficult to differentiate from Crohn's
   disease and drug-induced enteropathy, but from now on it will be
   possible to distinguish them utilizing endoscopic and fluoroscopic
   images. On the basis of the characteristics of small bowel tuberculosis
   with its endoscopic images, referring to our case report and previous
   literature, we report a topical diagnostic procedure, the combination of
   video capsule endoscopy and double balloon enteroscopy.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Niwa, Y (Reprint Author), Nagoya Univ, Grad Sch Med, Dept Gastroenterol, Showa Ku, 66 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.
   Nakamura, Masanao; Niwa, Yasumasa; Ohmiya, Naoki; Arakawa, Daigo; Honda, Wataru; Miyahara, Ryoji; Matsuura, Tetsuo; Ando, Takafumi; Maeda, Osamu; Itoh, Akihiro; Hirooka, Yoshiki; Goto, Hidemi, Nagoya Univ, Grad Sch Med, Dept Gastroenterol, Showa Ku, Nagoya, Aichi 4668550, Japan.}},
DOI = {{10.1097/MEG.0b013e3280ec544c}},
ISSN = {{0954-691X}},
Keywords = {{capsule endoscopy; double balloon enteroscopy; small bowel tuberculosis}},
Keywords-Plus = {{INTESTINAL TUBERCULOSIS}},
Research-Areas = {{Gastroenterology \& Hepatology}},
Web-of-Science-Categories  = {{Gastroenterology \& Hepatology}},
Author-Email = {{yniwa@med.nagoya-u.ac.jp}},
ResearcherID-Numbers = {{MAEDA, Osamu/Q-1016-2015
   Miyahara, Ryoji/I-7403-2014}},
ORCID-Numbers = {{Miyahara, Ryoji/0000-0001-7172-4602}},
Cited-References = {{Appleyard M, 2001, NEW ENGL J MED, V344, P232, DOI 10.1056/NEJM200101183440316.
   ELIAKIM R, 2005, ENDOSCOPY, V12, P1165.
   Ha HK, 1999, ABDOM IMAGING, V24, P32, DOI 10.1007/s002619900436.
   Iddan G, 2000, NATURE, V405, P417, DOI 10.1038/35013140.
   KUROMARU G, 1952, KEKKAKU, V12, P28.
   May A, 2003, ENDOSCOPY, V35, P985.
   Nagi B, 2004, ABDOM IMAGING, V29, P335, DOI 10.1007/s00261-003-0115-x.
   Ohmiya N, 2005, GASTROINTEST ENDOSC, V61, P140, DOI 10.1016/S0016-5107(04)02457-5.
   Patel N, 2004, J GASTROEN HEPATOL, V19, P1240, DOI 10.1111/j.1400-1746.2004.03485.x.
   PAUSTIAN FF, 1959, AM J MED, V27, P509, DOI 10.1016/0002-9343(59)90016-6.
   Pennazio M, 2004, GASTROENTEROLOGY, V126, P643, DOI 10.1053/j.gastro.2003.11.057.
   Reddy DN, 2003, ENDOSCOPY, V35, P99.
   SATHIRAVIKARN W, 2006, INDIAN J DERMATOL VE, V72, P276.
   Sato S, 2004, GASTROINTEST ENDOSC, V59, P362, DOI 10.1016/S0016-5107(03)02716-0.
   Yamamoto H, 2003, GASTROENTEROLOGY, V125, P1556, DOI 10.1053/S0016-5085(03)01405-7.
   Yamamoto H, 2004, CLIN GASTROENTEROL H, V2, P1010, DOI 10.1053/S1542-3565(04)00453-7.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Eur. J. Gastroenterol. Hepatol.}},
Doc-Delivery-Number = {{279LD}},
Unique-ID = {{ISI:000254355800014}},
}

@article{ ISI:000248191600031,
Author = {Janssens, J-P.},
Title = {{Interferon-gamma release assay tests to rule out active tuberculosis}},
Journal = {{EUROPEAN RESPIRATORY JOURNAL}},
Year = {{2007}},
Volume = {{30}},
Number = {{1}},
Pages = {{183-184}},
Month = {{JUL}},
Publisher = {{EUROPEAN RESPIRATORY SOC JOURNALS LTD}},
Address = {{146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Janssens, JP (Reprint Author), Univ Hosp Geneva, Geneva, Switzerland.
   Univ Hosp Geneva, Geneva, Switzerland.}},
DOI = {{10.1183/09031936.00042807}},
ISSN = {{0903-1936}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; LATENT TUBERCULOSIS; INFECTION; DIAGNOSIS}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Cited-References = {{Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008.
   Dewan PK, 2007, CLIN INFECT DIS, V44, P69, DOI 10.1086/509928.
   DYE C, 2007, WHO GLOBAL TUBERCULO, P277.
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6.
   Lee JY, 2006, EUR RESPIR J, V28, P24, DOI 10.1183/09031936.06.00016906.
   MAYER D, 2004, ESSENTIAL EVIDENCE B, P222.
   Mazurek Gerald H., 2005, Morbidity and Mortality Weekly Report, V54, P49.
   Nendaz MR, 2004, REV MAL RESPIR, V21, P394.
   Pai M, 2007, CLIN INFECT DIS, V44, P74, DOI 10.1086/509927.
   Pai M, 2006, EXPERT REV MOL DIAGN, V6, P413, DOI 10.1586/14737159.6.3.413.
   van Leeuwen RML, 2007, EUR RESPIR J, V29, P605, DOI 10.1183/09031936.00066506.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Eur. Resp. J.}},
Doc-Delivery-Number = {{192HM}},
Unique-ID = {{ISI:000248191600031}},
}

@article{ ISI:000248191600032,
Author = {van Leeuwen, R. M. and Bossink, A. W. J. and Thijsen, S. F. T.},
Title = {{Interferon-gamma release assay tests to rule out active tuberculosis}},
Journal = {{EUROPEAN RESPIRATORY JOURNAL}},
Year = {{2007}},
Volume = {{30}},
Number = {{1}},
Pages = {{184-185}},
Month = {{JUL}},
Publisher = {{EUROPEAN RESPIRATORY SOC JOURNALS LTD}},
Address = {{146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{van Leeuwen, RM (Reprint Author), Diakonessenhuis Utrecht, Dept Internal Med, Utrecht, Netherlands.
   Diakonessenhuis Utrecht, Dept Internal Med, Utrecht, Netherlands.
   Diakonessenhuis Utrecht, Dept Pulm \& TB, Utrecht, Netherlands.
   Diakonessenhuis Utrecht, Dept Med Microbiol \& Immunol, Utrecht, Netherlands.}},
DOI = {{10.1183/09031936.00051507}},
ISSN = {{0903-1936}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; INFECTION; DIAGNOSIS}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Cited-References = {{DIJKSTRA F, 2006, INFECT B, V11, P390.
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6.
   Hays W. L., 1994, STATISTICS.
   Richeldi L, 2004, ANN INTERN MED, V140, P709.
   van Leeuwen RML, 2007, EUR RESPIR J, V29, P605, DOI 10.1183/09031936.00066506.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Eur. Resp. J.}},
Doc-Delivery-Number = {{192HM}},
Unique-ID = {{ISI:000248191600032}},
}

@article{ ISI:000250759800002,
Author = {Steingart, Karen R. and Ramsay, Andrew and Pai, Madhukar},
Title = {{Optimizing sputum smear microscopy for the diagnosis of pulmonary
   tuberculosis}},
Journal = {{EXPERT REVIEW OF ANTI-INFECTIVE THERAPY}},
Year = {{2007}},
Volume = {{5}},
Number = {{3}},
Pages = {{327-331}},
Month = {{JUL}},
Abstract = {{`Sputum smear microscopy has high specificity in tuberculosis-endemic
   countries, but modest sensitivity that varies among laboratories,
   However, currently used microscopy methods can be optimized to generate
   higher sensitivity and yield.'}},
Publisher = {{FUTURE DRUGS LTD}},
Address = {{UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Pai, M (Reprint Author), McGill Univ, Montreal Chest Inst, Resp Epidemiol \& Clin Res Unit, Dept Biostat Epidemiol \& Occupat Hlth, 1020 Pine Ave W, Montreal, PQ H3A 1A2, Canada.
   McGill Univ, Montreal Chest Inst, Resp Epidemiol \& Clin Res Unit, Dept Biostat Epidemiol \& Occupat Hlth, Montreal, PQ H3A 1A2, Canada.
   Univ Calif San Francisco, San Francisco Gen Hosp, Div Pulm \& Crit Care Med, San Francisco, CA 94110 USA.
   Francis J Curry Natl TB Ctr, San Francisco, CA 94110 USA.
   WHO, Special Programme Res \& Training Trop Dis, UNICEF, UNDP,World Bank, CH-1211 Geneva 27, Switzerland.}},
DOI = {{10.1586/14787210.5.3.327}},
ISSN = {{1478-7210}},
Keywords-Plus = {{FLUORESCENCE MICROSCOPY; EMERGING TECHNOLOGIES; TOOLS; PREVALENCE;
   BACILLI}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Author-Email = {{karenst@u.washington.edu
   ramsaya@who.int
   madhukar.pai@mcgill.ca}},
Cited-References = {{Angeby KAK, 2004, INT J TUBERC LUNG D, V8, P806.
   Behr MA, 1999, LANCET, V353, P444, DOI 10.1016/S0140-6736(98)03406-0.
   BENNEDSEN J, 1966, SCAND J RESPIR DIS, V47, P114.
   Bruchfeld J, 2000, T ROY SOC TROP MED H, V94, P677, DOI 10.1016/S0035-9203(00)90230-X.
   Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767.
   GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90.
   Keeler Emmett, 2006, Nature, V444 Suppl 1, P49, DOI 10.1038/nature05446.
   Kivihya-Ndugga LEA, 2003, INT J TUBERC LUNG D, V7, P1163.
   Luelmo F., 2004, TOMANS TUBERCULOSIS, P7.
   Mase SR, 2007, INT J TUBERC LUNG D, V11, P485.
   NGUYEN VH, 2007, LANCET INFECT DIS, V7, P238.
   NGUYEN VH, 2007, LANCET INFECT DIS, V7, P239.
   Pai M, 2006, EXPERT REV MOL DIAGN, V6, P423, DOI 10.1586/14737159.6.3.423.
   Pai M, 2006, EXPERT REV MOL DIAGN, V6, P413, DOI 10.1586/14737159.6.3.413.
   Perkins MD, 2006, LANCET, V367, P942, DOI 10.1016/S0140-6736(06)68386-4.
   Perkins MD, 2000, INT J TUBERC LUNG D, V4, pS182.
   Prasanthi K, 2005, Indian J Med Microbiol, V23, P179.
   Steingart K, 2006, LANCET INFECT DIS, V6, P570, DOI 10.1016/S1473-3099(06)70578-3.
   SHAW JB, 1954, AM REV TUBERC PULM, V69, P724.
   SHINGADIA G, 2003, LANCET INFECT DIS, V3, P624.
   Squire SB, 2005, INT J TUBERC LUNG D, V9, P25.
   Steingart KR, 2007, LANCET INFECT DIS, V7, P239, DOI 10.1016/S1473-3099(07)70060-9.
   Steingart KR, 2006, LANCET INFECT DIS, V6, P664, DOI 10.1016/S1473-3099(06)70602-8.
   URBANCZIK R, 1985, ZBL BAKT-INT J MED M, V260, P81.
   Van Deun A, 2004, TOMANS TUBERCULOSIS, P35.
   WHO, 2007, GLOB SURV PREV CONTR, P1.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{60}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Expert Rev. Anti-Infect. Ther.}},
Doc-Delivery-Number = {{228VD}},
Unique-ID = {{ISI:000250759800002}},
}

@article{ ISI:000250759800015,
Author = {Pai, Madhukar and Mohan, Alladi and Dheda, Keertan and Leung, Chi Chiu
   and Yew, Wing Wai and Christopher, Devasahayam J. and Sharma, Surendra
   K.},
Title = {{Lethal interaction: the colliding epidemics of tobacco and tuberculosis}},
Journal = {{EXPERT REVIEW OF ANTI-INFECTIVE THERAPY}},
Year = {{2007}},
Volume = {{5}},
Number = {{3}},
Pages = {{385-391}},
Month = {{JUL}},
Abstract = {{Tobacco consumption ranks high among the leading health risks and
   tuberculosis (TB) is a major public health issue in countries where the
   smoking problem has reached epidemic proportions. Given that both
   smoking and TB are major health concerns and are widely prevalent in
   several countries, it is surprising that the association between smoking
   and TB is still a matter of debate and controversy. Although several
   studies have evaluated the effect of smoking on TB, the association has
   been largely overlooked by the TB and public health communities at
   large. Three recent reviews, including two meta-analyses, have
   summarized a large body of published literature on the association
   between smoking and various TB outcomes. These reviews show that there
   is considerable evidence that tobacco smoking is associated with TB. The
   evidence is strong for TB disease but less strong for TB infection and
   mortality. Even if the effect is relatively modest, the
   population-attributable risk is likely to be substantial due to the
   widespread nature of tobacco exposure. TB control programs must begin to
   address tobacco control as a potential preventive intervention. Since
   tobacco control will have multiple health benefits, it is likely to be a
   highly cost-effective intervention from a societal perspective.}},
Publisher = {{FUTURE DRUGS LTD}},
Address = {{UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Pai, M (Reprint Author), McGill Univ, Dept Biostat Epidemiol \& Occupat Hlth, 1020 Pine Ave W, Montreal, PQ H3A 1A2, Canada.
   McGill Univ, Dept Biostat Epidemiol \& Occupat Hlth, Montreal, PQ H3A 1A2, Canada.
   Sri Venkateswara Inst Med Sci, Dept Med, Div Pulm \& Crit Care Med, Tirupati 517507, Andhra Pradesh, India.
   Univ Cape Town, Groote Schuur Hosp Observ, Dept Med, Div Pulmonol, ZA-7925 Cape Town, South Africa.
   Ctr Hlth Protect, TB \& Chest Serv, Dept Hlth, Shaukeiwan, Hong Kong, Peoples R China.
   Grantham Hosp, TB \& Chest Unit, Hong Kong, Hong Kong, Peoples R China.
   Christian Med Coll \& Hosp, Dept Pulm Med, Vellore 632004, Tamil Nadu, India.
   All India Inst Med Sci, Dept Med, Div Pulm Crit Care \& Sleep Med, New Delhi 110029, India.}},
DOI = {{10.1586/14787210.5.3.385}},
ISSN = {{1478-7210}},
Keywords = {{mortality; smoking; tobacco; tuberculosis}},
Keywords-Plus = {{CIGARETTE-SMOKE; ALVEOLAR MACROPHAGES; HONG-KONG; INDIA; CELLS;
   INTERVENTIONS; ASSOCIATION; MORTALITY; INFECTION; EXPOSURE}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Author-Email = {{madhukar.pai@mcgill.ca
   alladimohan@rediffmail.com
   keertandheda@yahoo.co.uk
   cc\_leung@dh.gov.hk
   yewww@ha.org.hk
   djchris@cmcvellore.ac.in
   surensk@gmail.com}},
Cited-References = {{Anderson J.C., 2006, PUBLIC HLTH, V120, P1156, DOI DOI 10.1016/J.PUHE.2006.07.023.
   Avanzini MA, 2006, INT J IMMUNOPATH PH, V19, P609.
   Baris E, 2004, BRIT MED J, V329, P1090, DOI 10.1136/bmj.329.7474.1090.
   Bates MN, 2007, ARCH INTERN MED, V167, P335, DOI 10.1001/archinte.167.4.335.
   Borovikova LV, 2000, NATURE, V405, P458.
   Chiang CY, 2007, INT J TUBERC LUNG D, V11, P258.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Davies PDO, 2006, T ROY SOC TROP MED H, V100, P291, DOI 10.1016/j.trstmh.2005.06.034.
   Dheda K, 2005, J INFECT DIS, V192, P1201, DOI 10.1086/444545.
   Dheda K, 2004, AM J RESP CRIT CARE, V170, P821.
   Feldman Charles, 2005, Curr Opin Infect Dis, V18, P165, DOI 10.1097/01.qco.0000160907.79437.5a.
   Furber AS, 2007, SEX TRANSM INFECT, V83, P41, DOI 10.1136/sti.2005.019505.
   Gajalakshmi V, 2003, LANCET, V362, P507, DOI 10.1016/S0140-6736(03)14109-8.
   Gu DF, 2004, AM J PUBLIC HEALTH, V94, P1972, DOI 10.2105/AJPH.94.11.1972.
   Gupta PC, 2005, INT J EPIDEMIOL, V34, P1395, DOI 10.1093/ije/dyi196.
   Jha P, 2006, PLOS MED, V3, P191, DOI 10.1371/journal.pmed.0030018.
   Jha P, 2000, TOBACCO CONTROL DEV.
   Jha P, 2006, DRUG ALCOHOL REV, V25, P597, DOI 10.1080/09595230600944511.
   John RM, 2005, HEALTH POLICY, V71, P213, DOI 10.1016/j.healthpol.2004.08.008.
   Leung CC, 2004, AM J RESP CRIT CARE, V170, P1027, DOI 10.1164/rccm.200404-512oc.
   Leung CC, 2003, INT J TUBERC LUNG D, V7, P980.
   Lin HH, 2007, PLOS MED, V4, P173, DOI 10.1371/journal.pmed.0040020.
   Mackay J, 2002, TOBACCO ATLAS.
   Matsunaga K, 2002, J INFECT DIS, V185, P229, DOI 10.1086/338449.
   Maurya V, 2002, INT J TUBERC LUNG D, V6, P942.
   Nordskog BK, 2005, TOXICOLOGY, V212, P87, DOI 10.1016/j.tox.2005.04.005.
   Patel Nick, 2006, Clin Occup Environ Med, V5, P193.
   PEDNEKAR MS, 2007, PREV MED.
   Proulx LI, 2007, CANCER IMMUNOL IMMUN, V56, P831, DOI 10.1007/s00262-006-0243-6.
   Rani M, 2003, Tob Control, V12, pe4, DOI 10.1136/tc.12.4.e4.
   Robbins CS, 2004, AM J RESP CELL MOL, V30, P202, DOI 10.1165/rcmb.2003-0259OC.
   Rook GAW, 2005, NAT REV IMMUNOL, V5, P661, DOI 10.1038/nri1666.
   Tomita K, 2002, AM J RESP CRIT CARE, V166, P724, DOI 10.1164/rccm.2104010.
   World Health Organization, 2007, GLOB TUB CONTR SURV.
   Organization WH, 2002, WORLD HLTH REP 2002.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{39}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Expert Rev. Anti-Infect. Ther.}},
Doc-Delivery-Number = {{228VD}},
Unique-ID = {{ISI:000250759800015}},
}

@article{ ISI:000250759800022,
Author = {Achkar, Jacqueline M. and Casadevall, Arturo and Glatman-Freedman,
   Aharona},
Title = {{Immunological options for the treatment of tuberculosis: evaluation of
   novel therapeutic approaches}},
Journal = {{EXPERT REVIEW OF ANTI-INFECTIVE THERAPY}},
Year = {{2007}},
Volume = {{5}},
Number = {{3}},
Pages = {{461-474}},
Month = {{JUL}},
Abstract = {{The emergence of multidrug-resistant tuberculosis strains and the
   coinfection with HIV, together with advances in immunology, have led to
   renewed interest regarding ways to exploit the immune responses against
   Mycobacterium tuberculosis therapeutically. Here we review the
   fundamentals of tuberculosis therapy in view of the epidemiological and
   clinical challenges, and explore the experience with immune-based
   therapies for the treatment of active tuberculosis. These immune-based
   therapies are discussed here with the aim of assessing their potential
   use as adjuncts to chemotherapy.}},
Publisher = {{EXPERT REVIEWS}},
Address = {{UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Glatman-Freedman, A (Reprint Author), Albert Einstein Coll Med, Div Infect Dis, Dept Pediat, 1300 Morris Pk, Bronx, NY 10461 USA.
   Albert Einstein Coll Med, Div Infect Dis, Dept Pediat, Bronx, NY 10461 USA.
   Albert Einstein Coll Med, Dept Microbiol \& Immunol, Bronx, NY 10461 USA.
   Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA.
   Albert Einstein Coll Med, Div Infect Dis, Dept Med, Bronx, NY 10461 USA.}},
DOI = {{10.1586/14787210.5.3.461}},
ISSN = {{1478-7210}},
Keywords = {{antibodies; cytokines; immunotherapy; tuberculosis}},
Keywords-Plus = {{TUMOR-NECROSIS-FACTOR; RESISTANT PULMONARY TUBERCULOSIS;
   ANTIBODY-MEDIATED IMMUNITY; ADJUNCTIVE THALIDOMIDE THERAPY; CHRONIC
   GRANULOMATOUS-DISEASE; BACILLUS-CALMETTE-GUERIN; MYCOBACTERIUM-BOVIS
   BCG; INTERFERON-GAMMA; FACTOR-ALPHA; RECOMBINANT INTERLEUKIN-2}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Author-Email = {{jachkar@aecom.yu.edu
   casadeva@aecom.yu.edu
   afreedma@aecom.yu.edu}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI067665, U54-AI057158-LIPKIN]}},
Cited-References = {{AKUFFO H, 1990, J INFECT DIS, V161, P775.
   Algood HMS, 2004, J IMMUNOL, V172, P6846.
   Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211.
   Aung H, 1996, J CLIN INVEST, V98, P1261, DOI 10.1172/JCI118910.
   BARNES PF, 1990, J IMMUNOL, V145, P149.
   Bekker LG, 1998, J INFECT DIS, V178, P580.
   Bemiller LS, 1995, BLOOD CELL MOL DIS, V21, P239, DOI 10.1006/bcmd.1995.0028.
   Bermudez Luiz E., 1995, Trends in Microbiology, V3, P22, DOI 10.1016/S0966-842X(00)88864-2.
   BLANCHARD DK, 1992, ADV EXP MED BIOL, V319, P105.
   BLANCHARD DK, 1989, CELL IMMUNOL, V119, P402, DOI 10.1016/0008-8749(89)90254-2.
   Blumberg Henry M, 2003, Am J Respir Crit Care Med, V167, P603.
   Bouchonnet F, 2002, INFECT IMMUN, V70, P3020, DOI 10.1128/IAI.70.6.3020-3025.2002.
   Cardona PJ, 2005, VACCINE, V23, P1393, DOI 10.1016/j.vaccine.2004.09.008.
   Casadevall A, 2003, NAT REV MICROBIOL, V1, P17, DOI 10.1038/nrmicro732.
   Casadevall A, 1999, INFECT IMMUN, V67, P3703.
   {*}CDCP, 1993, JAMA-J AM MED ASSOC, V270, P694.
   Chambers MA, 2004, FEMS IMMUNOL MED MIC, V41, P93, DOI 10.1016/j.femsim.2004.01.004.
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698.
   Collins Kalonji R., 2002, AIDS Reviews, V4, P165.
   Condos R, 1997, LANCET, V349, P1513, DOI 10.1016/S0140-6736(96)12273-X.
   CONVERSE P, 1990, SCAND J IMMUNOL, V32, P83, DOI 10.1111/j.1365-3083.1990.tb02897.x.
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243.
   COOPER AM, 1995, IMMUNOLOGY, V84, P423.
   Cooper AM, 2002, J IMMUNOL, V168, P1322.
   Cooper AM, 1997, J EXP MED, V186, P39, DOI 10.1084/jem.186.1.39.
   Cooper AM, 2000, INFECT IMMUN, V68, P6879, DOI 10.1128/IAI.68.12.6879-6882.2000.
   DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300.
   DANNENBERG AM, 1989, REV INFECT DIS, V11, pS369.
   Dinarello CA, 2003, VACCINE, V21, P24.
   Doherty TM, 1997, J IMMUNOL, V158, P4822.
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0.
   EDWARDS CK, 1986, J IMMUNOL, V136, P1820.
   EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509.
   Falero-Diaz G, 2000, INT ARCH ALLERGY IMM, V122, P143, DOI 10.1159/000024370.
   Feng CG, 2005, J IMMUNOL, V174, P4185.
   FILLEY EA, 1991, INFECT IMMUN, V59, P2567.
   FILLEY EA, 1992, IMMUNOLOGY, V77, P505.
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249.
   FLYNN JL, 1995, J IMMUNOL, V155, P2515.
   FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2.
   GALLIN JI, 1995, ANN INTERN MED, V123, P216.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Gardam MA, 2003, LANCET INFECT DIS, V3, P148, DOI 10.1016/S1473-3099(03)00545-0.
   Gautier G, 2005, J EXP MED, V201, P1435, DOI 10.1081/jem.20011961.
   Giacomini E, 2001, J IMMUNOL, V166, P7033.
   Giosue S, 2000, EUR CYTOKINE NETW, V11, P99.
   GIRGIS NI, 1991, PEDIATR INFECT DIS J, V10, P179, DOI 10.1097/00006454-199103000-00002.
   Glatman-Freedman A, 2006, TUBERCULOSIS, V86, P191, DOI 10.1106/j.tube.2006.01.008.
   Glatman-Freedman A, 2003, FEMS IMMUNOL MED MIC, V39, P9, DOI 10.1016/S0928-8244(03)00172-X.
   Glatman-Freedman A, 1998, CLIN MICROBIOL REV, V11, P514.
   Glatman-Freedman A, 2000, INFECT IMMUN, V68, P335.
   GlatmanFreedman A, 1996, J CLIN MICROBIOL, V34, P2795.
   Greinert U, 2001, EUR RESPIR J, V17, P1049, DOI 10.1183/09031936.01.17510490.
   Guerin C, 1957, BCG VACCINATION TUBE, P48.
   Guirado E, 2006, MICROBES INFECT, V8, P1252, DOI 10.1016/j.micinf.2005.12.004.
   Ha SJ, 2006, INFECT IMMUN, V74, P4954, DOI 10.1128/IAI.01781-05.
   Hamasur B, 2004, CLIN EXP IMMUNOL, V138, P30, DOI 10.1111/j.1365-2249.2004.02593.x.
   HANCOCK GE, 1991, CELL IMMUNOL, V132, P277, DOI 10.1016/0008-8749(91)90027-9.
   Hill AR, 2002, MEDICINE, V81, P179, DOI 10.1097/00005792-200205000-00002.
   HIRSCH CS, 1994, J IMMUNOL, V152, P743.
   Holland S M, 2000, Adv Intern Med, V45, P431.
   HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904.
   JEEVAN A, 1988, INFECT IMMUN, V56, P660.
   Johnson BJ, 1997, TUBERCLE LUNG DIS, V78, P195, DOI 10.1016/S0962-8479(97)90026-5.
   JOHNSON BJ, 1995, CYTOKINES MOL THER, V1, P185.
   Johnson JL, 2003, AM J RESP CRIT CARE, V168, P185, DOI 10.1164/rccm.200211-1359OC.
   KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435.
   KAPLAN G, 1991, J EXP MED, V173, P993, DOI 10.1084/jem.173.4.993.
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110.
   Kim HJ, 2006, EUR RESPIR J, V28, P576, DOI 10.1183/09031936.06.00023006.
   KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4.
   Koh WJ, 2004, J KOREAN MED SCI, V19, P167.
   Kuchtey J, 2006, IMMUNOLOGY, V118, P39, DOI 10.1111/j.1365-2567.2006.02337.x.
   Lawn SD, 2001, T ROY SOC TROP MED H, V95, P449, DOI 10.1016/S0035-9203(01)90212-3.
   LEE CH, 1988, CHEST, V94, P1256, DOI 10.1378/chest.94.6.1256.
   Leonard JP, 1997, BLOOD, V90, P2541.
   Long R, 2003, CAN MED ASSOC J, V168, P1153.
   Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998.
   Mayanja-Kizza H, 2005, J INFECT DIS, V191, P856, DOI 10.1086/427995.
   Murray HW, 1996, INTENS CARE MED, V22, pS456, DOI 10.1007/BF01743724.
   Nolt D, 2004, INFECT IMMUN, V72, P2976, DOI 10.1128/IAI.72.5.2976.2988.2004.
   Okafor MC, 2003, PHARMACOTHERAPY, V23, P481, DOI 10.1592/phco.23.4.481.32115.
   Palmero D, 1999, INT J TUBERC LUNG D, V3, P214.
   Pethe K, 2001, NATURE, V412, P190, DOI 10.1038/35084083.
   Pinto LMD, 2002, BLOOD, V99, P1666.
   Pomerantz BJ, 2001, J THORAC CARDIOV SUR, V121, P448, DOI 10.1067/mtc.2001.112339.
   Reljic R, 2006, TUBERCULOSIS, V86, P179, DOI 10.1016/j.tube.2006.01.011.
   Reljic R, 2006, CLIN EXP IMMUNOL, V143, P467, DOI 10.1111/j.1365-2249.2006.03012.x.
   Remoli ME, 2002, J IMMUNOL, V169, P366.
   Ribeiro-Rodrigues R, 2002, CLIN DIAGN LAB IMMUN, V9, P818, DOI 10.1128/CDLI.9.4.818-823.2002.
   Roach DR, 2002, J IMMUNOL, V168, P4620.
   ROOK GAW, 1991, PATHOBIOLOGY, V59, P148, DOI 10.1159/000163633.
   Roy E, 2005, INFECT IMMUN, V73, P6101, DOI 10.1128/IAI.73.9.6101-6109.2005.
   Schoeman JF, 2006, J CHILD NEUROL, V21, P301, DOI 10.2310/7010.2006.00071.
   Schoeman JF, 2004, J CHILD NEUROL, V19, P250, DOI 10.1177/088307380401900402.
   Schoeman JF, 2000, J CHILD NEUROL, V15, P497, DOI 10.1177/088307380001500801.
   Schon T, 2003, EUR RESPIR J, V21, P483, DOI 10.1183/09031936.03.00090702.
   Schwebach JR, 2001, INFECT IMMUN, V69, P5671, DOI 10.1128/IAI.69.9.5671-5678.2001.
   Scott DL, 2006, NEW ENGL J MED, V355, P704, DOI 10.1056/NEJMct055183.
   SIBLEY LD, 1987, INFECT IMMUN, V55, P680.
   Skeiky YAW, 2006, NAT REV MICROBIOL, V4, P469, DOI 10.1038/nrmicro1419.
   Skomsvoll JF, 2007, NAT CLIN PRACT RHEUM, V3, P156, DOI 10.1038/ncprheum0426.
   SQUIRES KE, 1989, J INFECT DIS, V159, P599.
   Sterne JAC, 1998, INT J TUBERC LUNG D, V2, P200.
   STRANG JIG, 1988, LANCET, V2, P759.
   STRANG JIG, 1987, LANCET, V2, P1418.
   Suarez-Mendez R, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-44.
   TAKAHASHI S, 1991, CHEST, V99, P310, DOI 10.1378/chest.99.2.310.
   Takeda S, 2005, ANN THORAC SURG, V79, P959, DOI 10.1016/j.athoracsur.2004.09.007.
   Teitelbaum R, 1998, P NATL ACAD SCI USA, V95, P15688, DOI 10.1073/pnas.95.26.15688.
   TRAMONTANA JM, 1995, MOL MED, V1, P384.
   Triccas JA, 2002, IMMUNOL CELL BIOL, V80, P346, DOI 10.1046/j.1440-1711.2002.01087.x.
   Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001.
   Wallis RS, 2004, AIDS, V18, P257, DOI 10.1097/01.aids.0000104367.21567.d8.
   Wallis RS, 2005, CLIN INFECT DIS, V41, P201, DOI 10.1086/430914.
   WALLIS RS, 1990, P NATL ACAD SCI USA, V87, P3348, DOI 10.1073/pnas.87.9.3348.
   Wallis RS, 2001, ANTIMICROB AGENTS CH, V45, P1302, DOI 10.1128/AAC.45.4.1302-1304.2001.
   Williams A, 2004, IMMUNOLOGY, V111, P328, DOI 10.1111/j.1365-2567.2004.01809.x.
   Yi ZJ, 2007, VACCINE, V25, P638, DOI 10.1016/j.vaccine.2006.08.037.
   Zumla A, 2000, POSTGRAD MED J, V76, P259, DOI 10.1136/pmj.76.895.259.
   1996, MMWR MORBID MORTAL W, V45, P1.
   2006, MMWR MORBID MORTAL W, V5, P301.}},
Number-of-Cited-References = {{122}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Expert Rev. Anti-Infect. Ther.}},
Doc-Delivery-Number = {{228VD}},
Unique-ID = {{ISI:000250759800022}},
}

@article{ ISI:000250759800023,
Author = {Elias, Daniel and Britton, Sven and Kassu, Afework and Akuffo, Hannah},
Title = {{Chronic helminth infections may negatively influence immunity against
   tuberculosis and other diseases of public health importance}},
Journal = {{EXPERT REVIEW OF ANTI-INFECTIVE THERAPY}},
Year = {{2007}},
Volume = {{5}},
Number = {{3}},
Pages = {{475-484}},
Month = {{JUL}},
Abstract = {{Tuberculosis (TB) has once again become a major public health threat
   owing to the combined effects of deteriorating socioeconomic situations
   and the emergence of the HIV/AIDS pandemic. The only vaccine available
   against TB, although effective in reducing the burden of childhood TB,
   shows enormous variability in its efficacy against pulmonary TB, which
   is the most common form of the disease in adults. Most areas of high TB
   incidence and poor TB vaccine efficacy have a high prevalence of
   intestinal helminth infections. Such infections have been shown to cause
   a range of immunomodulation characterized by enhanced T helper 2-type
   cytokine profile, high immunoglobulin E levels and upregulated
   regulatory T-cell activity, as well as chronic immune activation. An
   altered background immune profile could have adverse effects on the
   outcome of subsequent infections and vaccinations. In support of this
   hypothesis, studies conducted in animals and humans living in
   worm-endemic areas have shown that helminths impair resistance against a
   number of infections of major public health importance, including TB,
   malaria and HIV/AIDS. Understanding such interactions could assist in
   the design of vaccines against these diseases.}},
Publisher = {{FUTURE DRUGS LTD}},
Address = {{UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Elias, D (Reprint Author), ACE Biosci, Unsbjergvej 2A, DK-5220 Odense SOE, Denmark.
   ACE Biosci, DK-5220 Odense SOE, Denmark.
   Ammaeur Hansen Res Inst, Addis Ababa, Ethiopia.
   Karolinska Inst, Dept Med, Infect Dis Unit, S-10401 Stockholm, Sweden.
   Karolinska Inst, Dept Microbiol Cell \& Tumor Biol, S-10401 Stockholm, Sweden.}},
DOI = {{10.1586/14787210.5.3.475}},
ISSN = {{1478-7210}},
Keywords = {{helminths; HIV; immune disorder; immunomodulation; tuberculosis}},
Keywords-Plus = {{BACILLE CALMETTE-GUERIN; HUMAN-IMMUNODEFICIENCY-VIRUS; REGULATORY
   T-CELLS; BLOOD MONONUCLEAR-CELLS; SCHISTOSOMA-MANSONI;
   MYCOBACTERIUM-TUBERCULOSIS; INTERFERON-GAMMA; INTESTINAL HELMINTHS; BCG
   VACCINATION; INCREASED SUSCEPTIBILITY}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Author-Email = {{elias@acebiosciences.com
   sven.britton@ki.se
   afeworkkassu@yahoo.com
   hannah.akuffo@sida.se}},
Cited-References = {{ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948.
   ACTOR JK, 1994, EUR J IMMUNOL, V24, P3050, DOI 10.1002/eji.1830241220.
   Altare F, 1998, J CLIN INVEST, V102, P2035, DOI 10.1172/JCI4950.
   Ayash-Rashkovsky M, 2002, VACCINE, V20, P2684, DOI 10.1016/S0264-410X(02)00202-5.
   Ayash-Rashkovsky M, 2001, BIOCHEM BIOPH RES CO, V282, P1169, DOI 10.1006/bbrc.2001.4698.
   Babu S, 2006, J IMMUNOL, V176, P3248.
   Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100.
   Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181.
   Bentwich Z, 1999, IMMUNOL TODAY, V20, P485, DOI 10.1016/S0167-5699(99)01499-1.
   Bentwich Z, 1996, CLIN EXP IMMUNOL, V103, P239, DOI 10.1046/j.1365-2249.1996.d01-612.x.
   Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4.
   BOGDAN C, 1994, J LEUKOCYTE BIOL, V55, P227.
   Boitelle A, 2003, J IMMUNOL, V171, P447.
   Borkow G, 2004, CLIN MICROBIOL REV, V17, P1012, DOI 10.1128/CMR.17.4.1012-1030.2004.
   Borkow G, 2001, SCAND J INFECT DIS, V33, P568, DOI 10.1080/00365540110026656.
   Borkow G, 2000, J CLIN INVEST, V106, P1053, DOI 10.1172/JCI10182.
   Bradley JE, 2004, PARASITE IMMUNOL, V26, P429, DOI 10.1111/j.0141-9838.2004.00730.x.
   Brown M, 2005, J INFECT DIS, V191, P1648, DOI 10.1086/429668.
   Brunet LR, 2002, TRENDS IMMUNOL, V23, P127, DOI 10.1016/S1471-4906(01)02166-4.
   Bundy D, 2000, PARASITOL TODAY, V16, P273, DOI 10.1016/S0169-4758(00)01689-6.
   Cancrini G., 2006, Parassitologia (Rome), V48, P53.
   Cappello M, 2004, PEDIATR INFECT DIS J, V23, P663, DOI 10.1097/01.inf.0000132228.00778.e4.
   Casati A, 1996, EUR J ANAESTH, V13, P498, DOI 10.1046/j.1365-2346.1996.d01-393.x.
   Chan MS, 1997, PARASITOL TODAY, V13, P438, DOI 10.1016/S0169-4758(97)01144-7.
   Chenine AL, 2005, AIDS, V19, P1793, DOI 10.1097/01.aids.0000189857.51935.0b.
   Chu D, 2004, INFECT IMMUN, V72, P2214, DOI 10.1128/IAI.72.4.2214-2221.2004.
   Cooper PJ, 2006, LANCET, V367, P1598, DOI 10.1016/S0140-6736(06)68697-2.
   Correale J, 2007, ANN NEUROL, V61, P97, DOI 10.1002/ana.21067.
   CURRY AJ, 1995, J EXP MED, V181, P769, DOI 10.1084/jem.181.2.769.
   Dieli F, 2004, EUR J IMMUNOL, V34, P3227, DOI 10.1002/eji.200425368.
   Diniz LM, 2001, AM J TROP MED HYG, V65, P852.
   Doetze A, 2000, INT IMMUNOL, V12, P623, DOI 10.1093/intimm/12.5.623.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   Elias D, 2006, TROP MED INT HEALTH, V11, P551, DOI 10.1111/j.1365-3156.2006.01578.x.
   Elias D, 2005, T ROY SOC TROP MED H, V99, P363, DOI 10.1019/j.trstmh.2004.08.006.
   Elias D, 2005, CLIN EXP IMMUNOL, V139, P398, DOI 10.1111/j.1365-2249.2005.02719.x.
   Elias D, 2005, VACCINE, V23, P1326, DOI 10.1016/j.vaccine.2004.09.03.
   Elias D, 2001, CLIN EXP IMMUNOL, V123, P219, DOI 10.1046/j.1365-2249.2001.01446.x.
   FELDMEIER H, 1985, CLIN EXP IMMUNOL, V60, P234.
   FINE PEM, 1995, CLIN INFECT DIS, V20, P11.
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9.
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249.
   Gallagher M, 2005, AIDS, V19, P1849, DOI 10.1097/01.aids.0000189846.90946.5d.
   Gonzalez-Juarrero M, 2001, INFECT IMMUN, V69, P1722, DOI 10.1128/IAI.69.3.1722-1728.2001.
   Gopinath R, 2000, J INFECT DIS, V182, P1804, DOI 10.1086/317623.
   Helmby H, 1998, INFECT IMMUN, V66, P5167.
   Hoerauf A, 2005, PARASITE IMMUNOL, V27, P417, DOI 10.1111/j.1365-3024.2005.00792.x.
   Hoft DF, 1998, J IMMUNOL, V161, P1045.
   Hori S, 2004, MICROBES INFECT, V6, P745, DOI 10.1016/j.micinf.2004.02.020.
   Hori S, 2003, ADV IMMUNOL, V81, P331, DOI 10.1016/S0065-2776(03)81008-8.
   Jaffar S, 2004, B WORLD HEALTH ORGAN, V82, P462.
   Jouanguy E, 1999, NAT GENET, V21, P370.
   Jouanguy E, 1999, CURR OPIN IMMUNOL, V11, P346, DOI 10.1016/S0952-7915(99)80055-7.
   Kalinkovich A, 1998, CLIN EXP IMMUNOL, V114, P414, DOI 10.1046/j.1365-2249.1998.00736.x.
   Kaufmann SHE, 2005, TRENDS IMMUNOL, V26, P660, DOI 10.1016/j.it.2005.09.012.
   Kaufmann SHE, 2002, ANN RHEUM DIS, V61, P54.
   Khuroo MS, 1996, GASTROENTEROL CLIN N, V25, P553, DOI 10.1016/S0889-8553(05)70263-6.
   King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4.
   KOCHI A, 1994, IMMUNOBIOLOGY, V191, P325.
   KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M.
   Lamhamedi S, 1998, INT J MOL MED, V1, P415.
   Lau SKP, 2007, J CLIN PATHOL, V60, P202, DOI 10.1136/jcp.2006.037267.
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128.
   Mekonnen Y, 2005, J INFECT DIS, V192, P739, DOI 10.1086/432545.
   Modjarrad K, 2005, J INFECT DIS, V192, P1277, DOI 10.1086/444543.
   Moreels TG, 2004, GUT, V53, P99, DOI 10.1136/gut.53.1.99.
   Mortimer K, 2006, AM J TROP MED HYG, V75, P914.
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602.
   Olsen AW, 2004, INFECT IMMUN, V72, P6148, DOI 10.1128/IAI.72.10.6148-6150.2004.
   PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4.
   ROMAGNANI S, 1991, INT J CLIN LAB RES, V21, P152.
   Rook GAW, 2005, NAT REV IMMUNOL, V5, P661, DOI 10.1038/nri1666.
   Rook GAW, 2005, VACCINE, V23, P2115, DOI 10.1016/j.vaccine.2005.01.069.
   Schonemeyer A, 2001, J IMMUNOL, V167, P3207.
   Selassie FG, 2000, CLIN EXP ALLERGY, V30, P356, DOI 10.1046/j.1365-2222.2000.00706.x.
   Serbina NV, 2001, INFECT IMMUN, V69, P4320, DOI 10.1128/IAI.69.7.4320-4328.2001.
   Sewell D, 2003, INT IMMUNOL, V15, P59, DOI 10.1093/intimm/dxg012.
   Sewell DL, 2002, IMMUNOL LETT, V82, P101, DOI 10.1016/S0165-2478(02)00025-1.
   Shams H, 2001, INFECT IMMUN, V69, P3497, DOI 10.1128/IAI.69.5.3497-3501.2001.
   Shapira-Nahor O, 1998, AIDS, V12, P1731.
   Shevach EM, 2001, J EXP MED, V193, pF41, DOI 10.1084/jem.193.11.F41.
   Skeiky YAW, 2004, J IMMUNOL, V172, P7618.
   STADECKER MJ, 1990, J IMMUNOL, V145, P2697.
   Stenger S, 1999, CURR OPIN MICROBIOL, V2, P89, DOI 10.1016/S1369-5274(99)80015-0.
   Stephenson LS, 2000, PARASITOLOGY, V121, pS23, DOI 10.1017/S0031182000006491.
   Stewart GR, 1999, CLIN EXP IMMUNOL, V117, P517.
   Strachan DP, 1996, ARCH DIS CHILD, V74, P422.
   STROMBERG BE, 1980, J IMMUNOL, V125, P833.
   Summers RW, 2003, AM J GASTROENTEROL, V98, P2034, DOI 10.1016/S0002-9270(03)00623-3.
   Tristao-Sa Ricardo, 2002, Rev Soc Bras Med Trop, V35, P533, DOI 10.1590/S0037-86822002000500020.
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3.
   van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2.
   Warren R, 1996, S AFR MED J, V86, P45.
   Weinstock JV, 2002, J LAB CLIN MED, V139, P334, DOI 10.1067/mlc.2002.124343.
   World Health Organization, 1993, SOZ PRAVENTIVMED, V38, P251, DOI DOI 10.1007/BF01624546.
   Wilson MS, 2004, CLIN REV ALLERG IMMU, V26, P35, DOI 10.1385/CRIAI:26:1:35.
   Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572.
   Wolday D, 2002, JAIDS, V31, P56, DOI 10.1097/01.QAI.0000026520.02173.F7.
   Wood Kathryn J, 2003, Novartis Found Symp, V252, P177.}},
Number-of-Cited-References = {{99}},
Times-Cited = {{42}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{14}},
Journal-ISO = {{Expert Rev. Anti-Infect. Ther.}},
Doc-Delivery-Number = {{228VD}},
Unique-ID = {{ISI:000250759800023}},
}

@article{ ISI:000247319500021,
Author = {Iwamoto, Tomotada and Yoshida, Shiomi and Suzuki, Katsuhiro and Tomita,
   Motohisa and Fujiyama, Riyo and Tanaka, Noriko and Kawakami, Yasuto and
   Ito, Masahiro},
Title = {{Hypervariable loci that enhance the discriminatory ability of newly
   proposed 15-loci and 24-loci variable-number tandem repeat typing method
   on Mycobacterium tuberculosis strains predominated by the Beijing family
   (vol 270, pg 67, 2007)}},
Journal = {{FEMS MICROBIOLOGY LETTERS}},
Year = {{2007}},
Volume = {{272}},
Number = {{2}},
Pages = {{282-283}},
Month = {{JUL}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Correction}},
Language = {{English}},
Affiliation = {{Iwamoto, T (Reprint Author), Kobe Inst Hlth, Dept Microbiol, Kobe, Hyogo, Japan.
   Kobe Inst Hlth, Dept Microbiol, Kobe, Hyogo, Japan.
   Natl Hosp Org, Kinki Chuo Chest Med Ctr, Osaka, Japan.
   Kobe City Publ Hlth Ctr, Kobe, Hyogo, Japan.}},
DOI = {{10.1111/jj.1574-6968.2007.00777.x}},
ISSN = {{0378-1097}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{kx2t-iwmt@asahi-net.or.jp}},
Cited-References = {{Iwamoto T, 2007, FEMS MICROBIOL LETT, V270, P67, DOI 10.1111/j.1574-6968.2007.00658.x.}},
Number-of-Cited-References = {{1}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{FEMS Microbiol. Lett.}},
Doc-Delivery-Number = {{179VY}},
Unique-ID = {{ISI:000247319500021}},
}

@article{ ISI:000247393200005,
Author = {Yan, Fei and Thomson, Rachael and Tang, Shenglan and Squire, Stephen
   Bertel and Wang, Wei and Liu, Xiaoyun and Gong, Youlong and Zhao,
   Fengzeng and Tolhurst, Rachel},
Title = {{Multiple perspectives on diagnosis delay for tuberculosis from key
   stakeholders in poor rural China: Case study in four provinces}},
Journal = {{HEALTH POLICY}},
Year = {{2007}},
Volume = {{82}},
Number = {{2}},
Pages = {{186-199}},
Month = {{JUL}},
Abstract = {{This study aims to understand the contextual barriers to accessing
   timely TB diagnosis after first seeking care, especially among the poor
   and vulnerable in rural China. Both quantitative and qualitative methods
   were used to elicit the experiences and perspectives of TB patients and
   suspected TB patients, community residents, health providers and policy
   makers in poor, rural areas of four provinces. Between 30 and 60\% of
   patients across the four provinces experienced a delay in receiving a
   diagnosis after first seeking care. Most patients had to visit health
   facilities more than once before diagnosis, with 17-30\% patients making
   more than 6 visits. These delays and multiple visits mainly occurred
   because of the limited capacity of health providers to recognize TB, and
   financial disincentives to refer patients to TB dispensaries, due to the
   pressures of the cost recovery system. Poverty and socio-economic
   disadvantage amongst patients also influenced their capability to seek
   further care to obtain a reliable diagnosis. Qualitative data showed
   that women and the elderly patients were likely to experience
   more,system' delay, and these findings were to some extent supported by
   the survey. The study concludes that `system' delay is a serious
   problem, which is influenced by the financing mechanisms for both TB
   control and general health services as well as poverty and disadvantage
   amongst patients. This requires a comprehensive strategy to shorten
   `system' delay in order to enable successful DOTS expansion, including
   developing appropriate financing mechanisms to improve general provider
   capacity and encourage referral, as well as measures to improve
   financial and social access to services for potential TB patients. (c)
   2006 Elsevier Ireland Ltd. All rights reserved.}},
Publisher = {{ELSEVIER IRELAND LTD}},
Address = {{ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Yan, F (Reprint Author), Fudan Univ, Sch Publ hlth, 138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.
   Fudan Univ, Sch Publ hlth, Shanghai 200032, Peoples R China.
   Univ Liverpool, Liverpool Sch Trop Med, EQUI TB Programme, Liverpool L3 5QA, Merseyside, England.
   Natl Ctr TB Council \& Prevent, Beijing 100051, Peoples R China.}},
DOI = {{10.1016/j.healthpol.2006.08.001}},
ISSN = {{0168-8510}},
Keywords = {{diagnosis delay; tuberculosis; poverty; multiple perspectives}},
Keywords-Plus = {{HEALTH-CARE SEEKING; PULMONARY TUBERCULOSIS; SYSTEM DELAYS; SERVICES;
   PATIENT; ACCESS; SHANDONG; VIETNAM; LESSONS; GENDER}},
Research-Areas = {{Health Care Sciences \& Services}},
Web-of-Science-Categories  = {{Health Care Sciences \& Services; Health Policy \& Services}},
Author-Email = {{fyan@shmu.edu.cn}},
Cited-References = {{Bustamante-Montes LP, 2000, INT J TUBERC LUNG D, V4, P208.
   Cambanis A, 2005, TROP MED INT HEALTH, V10, P330, DOI 10.1111/j.1365-3156.2005.01393.x.
   Chen XY, 2002, B WORLD HEALTH ORGAN, V80, P430.
   Cheng G, 2005, T ROY SOC TROP MED H, V99, P355, DOI 10.1016/j.trstmh.2004.07.005.
   {*}DEP DIS CONTR MIN, 2002, IMPL GUID TUB CONTR.
   Enarson DA, 2002, INT J TUBERC LUNG D, V6, P369.
   Gao J, 2001, HEALTH POLICY PLANN, V16, P302, DOI 10.1093/heapol/16.3.302.
   Lawn SD, 1998, INT J TUBERC LUNG D, V2, P635.
   Lienhardt C, 2001, INT J TUBERC LUNG D, V5, P233.
   Long NH, 1999, INT J TUBERC LUNG D, V3, P388.
   Meng QY, 2004, INT J HEALTH PLAN M, V19, pS45, DOI 10.1002/hpm.774.
   Ministry of Health China, 2002, REP NAT RAND SURV EP.
   {*}MIN HLTH CHIN, 2004, REP 3 NAT HLTH HOUS.
   Needham DM, 2001, TROP MED INT HEALTH, V6, P256, DOI 10.1046/j.1365-3156.2001.00709.x.
   Pirkis JE, 1996, TUBERCLE LUNG DIS, V77, P401, DOI 10.1016/S0962-8479(96)90111-2.
   PRONYK RM, 2001, INT J TUBERC LUNG D, V5, P61.
   Rajeswari R, 2002, INT J TUBERC LUNG D, V6, P789.
   Ritchie J., 2003, QUALITATIVE RES PRAC.
   Sherman LF, 1999, INT J TUBERC LUNG D, V3, P1088.
   Steen TW, 1998, INT J TUBERC LUNG D, V2, P627.
   Tang SL, 2005, HEALTH POLICY, V72, P93, DOI 10.1016/j.healthpol.2004.06.009.
   Thorson A, 2004, HEALTH POLICY, V68, P37, DOI 10.1016/j.healthpol.2003.07.010.
   Wandwalo ER, 2000, INT J TUBERC LUNG D, V4, P133.
   WANG L, 2002, INT J TUBERCULOSI S1, V6, pS96.
   Ward J, 2001, INT J TUBERC LUNG D, V5, P1021.
   WHO, 2002, COMM DIS.
   Xu B, 2004, HEALTH POLICY, V69, P139, DOI 10.1016/j.healthpol.2003.11.006.
   Yamasaki-Nakagawa M, 2001, INT J TUBERC LUNG D, V5, P24.
   Zhang XJ, 2004, J WUHAN UNIV TECHNOL, V19, P63.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{23}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Health Policy}},
Doc-Delivery-Number = {{180VB}},
Unique-ID = {{ISI:000247393200005}},
}

@article{ ISI:000254397000007,
Author = {Ramam, M. and Tejasvi, Trilokraj and Manchanda, Yashpal and Sharma,
   Sandeep and Miffal, Rashm},
Title = {{What is the appropriate duration of a therapeutic trial in cutaneous
   tuberculosis? Further observations}},
Journal = {{INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY \& LEPROLOGY}},
Year = {{2007}},
Volume = {{73}},
Number = {{4}},
Pages = {{243-246}},
Month = {{JUL-AUG}},
Abstract = {{Background: Laboratory tests for the diagnosis of cutaneous tuberculosis
   lack adequate sensitivity and specificity and a trial of therapy is
   often used as a diagnostic test in difficult cases. However, the
   duration for which the trial should be undertaken is not clearly
   defined. Our previous study indicated that one month of therapy was,
   adequate to detect a clinical response to treatment. However, about half
   the patients first reported after one month of treatment, some much
   later. Method: We therefore analysed the treatment records of 107
   patients who received four-drug, short course, antitubercular therapy
   for a diagnosis of cutaneous tuberculosis in our hospital and who were
   asked to return for follow-up at biweekly intervals in the first month
   of treatment. Result: Twenty-one patients did not return for any
   follow-up visit, nine patients did not respond to treatment and
   treatment was stopped in one patient. Of the remaining 76 patients, 72
   patients were recorded to have distinct clinical improvement within five
   weeks of starting treatment while only four patients showed improvement
   after 60-123 (8-17 weeks) days of therapy. Conclusion: These findings
   indicate that five weeks appears to be an adequate duration of a
   therapeutic trial in patients suspected to have cutaneous tuberculosis,
   with the exception of tuberculids and patients showing minimal clinical
   activity before treatment. Patients who have not responded by this time
   are unlikely to do so with further treatment and should have their
   diagnosis reviewed.}},
Publisher = {{MEDKNOW PUBLICATIONS}},
Address = {{A-108-109 KANARA BUSINESS CENTRE, GHAKTOPAR, MUMBAI, 400075, INDIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ramam, M (Reprint Author), All India Inst Med Sci, Dept Dermatol \& Venerol, New Delhi 110029, India.
   Ramam, M.; Tejasvi, Trilokraj; Manchanda, Yashpal; Sharma, Sandeep; Miffal, Rashm, All India Inst Med Sci, Dept Dermatol \& Venerol, New Delhi 110029, India.}},
ISSN = {{0378-6323}},
Keywords = {{diagnosis; lupus vulgaris; scrofuloderma}},
Keywords-Plus = {{POLYMERASE-CHAIN-REACTION; MYCOBACTERIUM-TUBERCULOSIS}},
Research-Areas = {{Dermatology}},
Web-of-Science-Categories  = {{Dermatology}},
Author-Email = {{mramam@hotmail.com}},
Cited-References = {{Arora SK, 2000, BRIT J DERMATOL, V142, P72, DOI 10.1046/j.1365-2133.2000.03244.x.
   Gopinathan R, 2001, Indian J Med Microbiol, V19, P193.
   Hsiao PF, 2003, INT J DERMATOL, V42, P281, DOI 10.1046/j.1365-4362.2003.01461.x.
   Kumar B, 2001, INT J DERMATOL, V40, P26, DOI 10.1046/j.1365-4362.2001.01165.x.
   MARGALL N, 1996, BRIT J DERMATOL, V135, P106.
   Padmavathy L, 2003, Indian J Dermatol Venereol Leprol, V69, P214.
   Pandhi D, 2004, J EUR ACAD DERMATOL, V18, P546, DOI 10.1111/j.1468-3083.2004.00970.x.
   PANDHI RK, 1977, INDIAN J DERMATOL, V22, P99.
   Ramam M, 2005, INT J DERMATOL, V44, P121, DOI 10.1111/j.1365-4632.2005.02063.x.
   RAMESH V, 1986, INT J DERMATOL, V22, P578.
   Sehgal VN, 2005, INT J DERMATOL, V44, P961, DOI 10.1111/j.1365-4632.2004.02327.x.
   SEHGAL VN, 1987, INT J DERMATOL, V26, P521, DOI 10.1111/j.1365-4362.1987.tb02294.x.
   SEHGAL VN, 1989, INT J DERMATOL, V28, P231, DOI 10.1111/j.1365-4362.1989.tb04810.x.
   SHARMA RC, 1975, TUBERCLE, V56, P324, DOI 10.1016/0041-3879(75)90088-4.
   Tan SH, 2001, ANN ACAD MED SINGAP, V30, P3.
   Thami GP, 2002, PEDIATR DERMATOL, V19, P122, DOI 10.1046/j.1525-1470.2002.00053.x.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Indian J. Dermatol. Venereol. Leprol.}},
Doc-Delivery-Number = {{280AJ}},
Unique-ID = {{ISI:000254397000007}},
}

@article{ ISI:000247845300003,
Author = {Upadhye, Vijay and Saha-Roy, Santa and Shende, Niraj and Kumar, Satish
   and Harinath, B. C.},
Title = {{Isolation of Mycobacterium tuberculosis protein antigens ES-31, ES-43
   and EST-6 of diagnostic interest from Tubercle Bacilli by affinity
   chromatography}},
Journal = {{INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY}},
Year = {{2007}},
Volume = {{45}},
Number = {{7}},
Pages = {{599-602}},
Month = {{JUL}},
Abstract = {{Immunodiagnostically useful M. tuberculosis H37Ra protein antigens
   ES-31, ES-43 and EST-6 were isolated from detergent soluble sonicate
   (DSS) antigen using monospecific antibodies by affinity chromatography
   and compared with similar antigens isolated from M. tuberculosis culture
   filtrate for seroreactivity in tuberculosis sera by Indirect Enzyme
   Linked Immunosorbent Assay. Recovery of affinity purified ES-31, ES-43
   and EST-6 antigen from DSS antigen was approximately 3, 3.5 and 4\%
   respectively, compared to 10, 9 and 6.3\% from culture filtrate.
   Affinity purified ES-31, ES-43 and EST-6 antigens from both culture
   filtrate as well as DSS antigen showed similar seroreactivity with
   overall sensitivity 85, 80 and 75\% respectively and specificity of 85\%
   at optimum concentration of 50 pg protein of each antigen. The results
   suggest that DSS antigen may be a promising antigen source for isolating
   antigens of diagnostic interest obviating the need for cumbersome,
   time-consuming culture techniques of mycobacteria.}},
Publisher = {{NATL INST SCIENCE COMMUNICATION}},
Address = {{DR K S KRISHNAN MARG, NEW DELHI 110 012, INDIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Harinath, BC (Reprint Author), Mahatma Gandhi Inst Med Sci, Jamnalal Bajaj Trop Dis Res Ctr, Sevagram 4422102, Wardha, India.
   Mahatma Gandhi Inst Med Sci, Jamnalal Bajaj Trop Dis Res Ctr, Sevagram 4422102, Wardha, India.
   Mahatma Gandhi Inst Med Sci, Dept Biochem, Sevagram 4422102, Wardha, India.}},
ISSN = {{0019-5189}},
Keywords = {{affinity chromatography; DSS antigens; ELISA; Mycobacterium
   tuberculosis; pulmonary tuberculosis}},
Keywords-Plus = {{SERODIAGNOSIS}},
Research-Areas = {{Life Sciences \& Biomedicine - Other Topics}},
Web-of-Science-Categories  = {{Biology}},
Author-Email = {{jbtdrc\_wda@sancharnet.in}},
Cited-References = {{AVINASH L, 1997, THESIS NAGPUR U NAGP.
   BANERJEE S, 2002, INT J TUBERC LUBG DI, V73, P278.
   Banerjee Swati, 2003, Indian J Pathol Microbiol, V46, P261.
   BASS JB, 1990, AM REV RESPIR DIS, V142, P725.
   Bisen PS, 2003, CLIN DIAGN LAB IMMUN, V10, P1051, DOI 10.1128/CDLI.10.6.1051-1058.2003.
   DANIEL TM, 1978, MICROBIOL REV, V42, P84.
   FITZGERALD D, 2005, PRINCIPLES PRACTICE, V2, P2852.
   GUPTA S, 2004, BIOMED RES, V15, P76.
   Harinath BC, 2006, DIAGN MICR INFEC DIS, V55, P65, DOI 10.1016/j.diagmicrobio.2005.10.021.
   Houghton RL, 2002, CLIN DIAGN LAB IMMUN, V9, P883, DOI 10.1128/CDLI.9.4.883-891.2002.
   Lodam AN, 1996, INDIAN J BIOCHEM BIO, V33, P66.
   Nair E R, 2001, Indian J Clin Biochem, V16, P132, DOI 10.1007/BF02867583.
   Nair E R, 2001, Indian J Chest Dis Allied Sci, V43, P81.
   Saha-Roy Santa, 2005, Indian Journal of Experimental Biology, V43, P1196.
   SONIKA G, 2004, THESIS NAGPUR U NAGP.
   {*}WHO, 2001, ANN REP STOP TB.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Indian J. Exp. Biol.}},
Doc-Delivery-Number = {{187KB}},
Unique-ID = {{ISI:000247845300003}},
}

@article{ ISI:000249736300018,
Author = {Singh, H. B. and Chauhan, D. S. and Faujdar, J. and Upadhyay, P. and
   Saxena, N. and Yadav, V. S. and Kumar, A. and Ahmed, I. and Katoch, V.
   M. and Sharma, V. D.},
Title = {{Tracing transmission of tuberculosis by random amplified polymorphic DNA
   (RAPD) analysis within same family \& neighbourhood}},
Journal = {{INDIAN JOURNAL OF MEDICAL RESEARCH}},
Year = {{2007}},
Volume = {{126}},
Number = {{1}},
Pages = {{82-84}},
Month = {{JUL}},
Publisher = {{INDIAN COUNCIL MEDICAL RES}},
Address = {{PO BOX 4911 ANSARI NAGAR, NEW DELHI 110029, INDIA}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Sharma, VD (Reprint Author), Meena Charitable Hosp, Natl JALMA Inst Leprosy, Dept Microbiol \& Mol Biol, Agra 282001, Uttar Pradesh, India.
   Meena Charitable Hosp, Natl JALMA Inst Leprosy, Dept Microbiol \& Mol Biol, Agra 282001, Uttar Pradesh, India.
   Meena Charitable Hosp, Natl JALMA Inst, Dept Biostat, Agra 282001, Uttar Pradesh, India.}},
ISSN = {{0971-5916}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; REPRODUCIBILITY; EPIDEMIOLOGY; STRAINS; CITY}},
Research-Areas = {{Immunology; General \& Internal Medicine; Research \& Experimental
   Medicine}},
Web-of-Science-Categories  = {{Immunology; Medicine, General \& Internal; Medicine, Research \&
   Experimental}},
Author-Email = {{jalma@sancharnet.in}},
Cited-References = {{ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403.
   COUTINHO HLC, 1993, LETT APPL MICROBIOL, V17, P282, DOI 10.1111/j.1472-765X.1993.tb01467.x.
   Frothingham R, 1998, MICROBIOL-UK, V144, P1189.
   Harn HJ, 1997, J CLIN PATHOL, V50, P505, DOI 10.1136/jcp.50.6.505.
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907.
   Katoch VM, 2000, MULTI-DRUG RESISTANCE IN EMERGING AND RE-EMERGING DISEASES, P87.
   Kremer K, 1999, J CLIN MICROBIOL, V37, P2607.
   LINTON CJ, 1994, J CLIN MICROBIOL, V32, P2169.
   PALITTAPONGARNPIM P, 1993, J INFECT DIS, V167, P975.
   Penner G A, 1993, PCR Methods Appl, V2, P341.
   SCHIERWATER B, 1993, NUCLEIC ACIDS RES, V21, P4647, DOI 10.1093/nar/21.19.4647.
   Singh H B, 2002, Indian J Med Microbiol, V20, P69.
   Supply P, 2001, J CLIN MICROBIOL, V39, P3563, DOI 10.1128/JCM.39.10.3563-3571.2001.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Indian J. Med. Res.}},
Doc-Delivery-Number = {{214KL}},
Unique-ID = {{ISI:000249736300018}},
}

@article{ ISI:000250486300006,
Author = {Akhila, K. and Mahadevan, S. and Adhisivam, B.},
Title = {{Qualitative evaluation of Tuberculin test responses in childhood
   Tuberculosis}},
Journal = {{INDIAN JOURNAL OF PEDIATRICS}},
Year = {{2007}},
Volume = {{74}},
Number = {{7}},
Pages = {{641-644}},
Month = {{JUL}},
Abstract = {{Objective. To study if different forms of clinical presentation of
   tuberculosis in children are associated with a different type of
   tuberculin reaction.
   Methods. This cross sectional study, describing Tuberculin skin testing
   (TST) responses in 268 children (134 cases and 134 controls) less than
   12 yr of age was carried out over a period of 18 months at JIPMER, a
   tertiary care referral hospital in Pondicherry, India. The qualitative
   and quantitative TST responses in various clinical forms of Tuberculosis
   were analysed.
   Results. Koch's and Listeria variants were more common in children with
   TB Lymphadenitis and Pulmonary TB respectively. 10\% of the study
   children with TB meningitis were tuberculin negative.
   Conclusion. Qualitative TST responses are non-homogeneous among the
   various clinical types of childhood tuberculosis. They are not a
   correlate of protective immunity with little or no prognostic
   significance.}},
Publisher = {{ALL INDIA INST MEDICAL SCIENCES}},
Address = {{ANSARI NAGAR, NEW DELHI 110 029, INDIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mahadevan, S (Reprint Author), JIPMER, Dept Pediat, Pondicherry 605006, India.
   JIPMER, Dept Pediat, Pondicherry 605006, India.}},
DOI = {{10.1007/s12098-007-0114-y}},
ISSN = {{0019-5456}},
Keywords = {{tuberculin test; TST responses; Tuberculosis}},
Research-Areas = {{Pediatrics}},
Web-of-Science-Categories  = {{Pediatrics}},
Author-Email = {{smaha1232@rediffmail.com}},
Cited-References = {{Fourie PB, 1998, INT J TUBERC LUNG D, V2, P116.
   OLIVEIRA HMV, 2000, J PEDIATR, V76, P115.
   Shastri ART, 2003, INT J TUBERC LUNG D, V7, P1092.
   STANFORD JL, 1983, TUBERCLE, V64, P275, DOI 10.1016/0041-3879(83)90024-7.
   VANEDEN W, 1983, CLIN EXP IMMUNOL, V52, P287.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Indian J. Pediatr.}},
Doc-Delivery-Number = {{224ZG}},
Unique-ID = {{ISI:000250486300006}},
}
